fluorouracil has been researched along with Adenocarcinoma, Basal Cell in 4932 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil, folinic acid and oxaliplatin) in patients with metastatic colorectal cancer (mCRC)." | 9.41 | Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). ( Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021) |
| "The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy." | 9.34 | Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. ( Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ, 2020) |
| " We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma." | 9.34 | Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. ( Attwood, K; Boland, PM; Fountzilas, C; Gosain, R; Iyer, R; Khushalani, N; Mukherjee, S; Tan, W, 2020) |
| "BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer." | 9.34 | Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020) |
| "Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)." | 9.34 | Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). ( Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H, 2020) |
| "5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for resectable gastric adenocarcinoma (RGA)." | 9.30 | Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). ( Bachet, JB; Cohen, R; Colin, D; de la Fouchardière, C; Ferraz, JM; Kim, S; Lefevre, M; Louvet, C; Meurisse, A; Svrcek, M; Tournigand, C; Watson, S, 2019) |
| "Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control." | 9.30 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019) |
| "Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)." | 9.27 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018) |
| "Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA)." | 9.27 | FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. ( Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH, 2018) |
| "Based upon preclinical data showing synergy with mTOR inhibition and platinum chemotherapy, this study explores the safety and tolerability of combining everolimus with mFOLFOX6 for patients with metastatic gastroesophageal adenocarcinoma." | 9.22 | Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C, 2016) |
| "The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint." | 9.20 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015) |
| " This study is to investigate the efficacy and tolerability of erlotinib plus capecitabine as first-line treatment in older Chinese patients (≥ 65 years) with lung adenocarcinoma." | 9.20 | Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. ( Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D, 2015) |
| "The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed." | 9.20 | Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015) |
| "This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 9.20 | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015) |
| "The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy." | 9.20 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| "Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is associated with significant toxicity." | 9.20 | Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. ( Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB, 2015) |
| "We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC)." | 9.19 | Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. ( Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014) |
| "This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma." | 9.19 | Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. ( Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N, 2014) |
| "To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma." | 9.19 | Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd ( André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M, 2014) |
| " We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." | 9.17 | A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. ( Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY, 2013) |
| "This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)." | 9.17 | Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013) |
| "The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer." | 9.17 | Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. ( Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M, 2013) |
| "To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)." | 9.17 | Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013) |
| "To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas." | 9.17 | Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. ( Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013) |
| "To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)." | 9.16 | Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012) |
| "We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy." | 9.16 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "The aims of this study is to determine the maximum tolerated dose of capecitabine and oxaliplatin (CAPOX) delivered concurrent with radiation therapy (RT) in the treatment of locally advanced pancreatic adenocarcinoma and to retrospectively compare outcomes with this regimen to concurrent 5-fluorouracil or capecitabine with RT (5FU-RT) or concurrent gemcitabine-based chemotherapy with RT (GEM-RT)." | 9.16 | Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. ( Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J, 2012) |
| "PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine." | 9.16 | A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012) |
| " From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily." | 9.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "Between October 2006 and December 2009, 36 patients with non-metastatic rectal adenocarcinoma were treated with chemoradiotherapy of irinotecan (50 mg/m(2) weekly), 5-fluorouracil (250 mg/m(2) for 5 days/week) and pelvic radiation (45 Gy/1." | 9.16 | Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2012) |
| " This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients." | 9.16 | A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. ( Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F, 2012) |
| "Capecitabine produces an objective response rate of up to 25% in anthracycline-treated, taxane-resistant metastatic breast cancer (MBC)." | 9.16 | A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). ( Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M, 2012) |
| "To determine the safety and efficacy of neoadjuvant gemcitabine/capecitabine followed by surgery for the treatment of locally advanced pancreatic adenocarcinoma (LAPC)." | 9.16 | Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. ( Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH, 2012) |
| "This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma." | 9.16 | Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. ( Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC, 2012) |
| "To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas." | 9.15 | Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. ( Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L, 2011) |
| "Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3." | 9.15 | Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese patients with unresectable advanced or metastatic colorectal cancer." | 9.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. ( Emi, Y; Fujita, F; Hasegawa, H; Inomata, M; Kakeji, Y; Kitazono, M; Maehara, Y; Morikita, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Samura, H; Shirabe, K; Shirouzu, K; Tanaka, T; Tokunaga, S; Yamamoto, M, 2011) |
| "The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 9.15 | Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K, 2011) |
| "The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial." | 9.15 | Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. ( Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA, 2011) |
| "This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer." | 9.15 | A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. ( Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer." | 9.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011) |
| "Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1." | 9.15 | S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. ( Benedetti, JK; Billingsley, KG; Blanke, CD; Bohanes, PO; Corless, CL; Danenberg, KD; Gold, PJ; Goldman, BH; Iqbal, S; Leichman, LP; Lenz, HJ; Thomas, CR, 2011) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 9.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward." | 9.14 | An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009) |
| "This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma." | 9.14 | Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. ( Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L, 2009) |
| "This Simon 2-stage phase II trial was designed to document antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer (CRC)." | 9.14 | Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. ( Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C, 2009) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 9.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 9.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
| "A randomized multicenter phase III study was conducted to compare the sequential docetaxel followed by epirubicin/cyclophosphamide combination with that of FEC regimen as adjuvant chemotherapy in women with axillary node-positive early breast cancer." | 9.14 | FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). ( Adamou, A; Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karvounis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N, 2010) |
| "Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression." | 9.14 | S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010) |
| "We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concurrent tamoxifen (CAFT)." | 9.14 | Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. ( Abeloff, MD; Albain, KS; Barlow, WE; Burton, GV; Cobau, CD; Farrar, WB; Green, SJ; Henderson, IC; Ingle, JN; Ketchel, SJ; Levine, EG; Lew, D; Lichter, AS; Livingston, RB; Martino, S; Muss, HB; Osborne, CK; Pritchard, KI; Ravdin, PM; Schneider, DJ, 2009) |
| "The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer." | 9.14 | Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 9.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "The Danish Breast Cancer Cooperative Group (DBCG) 77B trial examined the relative efficacy of levamisole, single-agent oral cyclophosphamide, and the classic combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) against no adjuvant systemic therapy in high-risk breast cancer patients." | 9.14 | Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. ( Andersen, J; Andersson, M; Ejlertsen, B; Jensen, MB; Kamby, C; Knoop, AS; Mouridsen, HT, 2010) |
| "To assess the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the treatment of advanced gastric adenocarcinoma." | 9.14 | [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial]. ( Liu, Y; Ma, T; Ye, ZB; Zhang, J; Zhu, ZG, 2010) |
| "The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma." | 9.14 | A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. ( Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H, 2010) |
| "In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer." | 9.14 | Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010) |
| "Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles." | 9.14 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010) |
| "The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients with metastatic colorectal cancer." | 9.14 | Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. ( Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E, 2010) |
| "Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer." | 9.14 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010) |
| "This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy." | 9.14 | Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. ( Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N, 2010) |
| "601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy." | 9.14 | Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010) |
| "Cyclophosphamide/methotrexate/fluorouracil (CMF) is a proven adjuvant option for patients with early-stage breast cancer." | 9.14 | Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. ( Atieh-Graham, D; D'Andrea, G; Drullinsky, P; Fornier, MN; Gilewski, T; Hudis, C; Lake, D; Mills, N; Norton, L; Patel, H; Patil, S; Seidman, AD; Sklarin, N; Sugarman, SM; Traina, T; Troso-Sandoval, T; Wasserheit-Lieblich, C; Yuan, J, 2010) |
| "The results indicate that the modified CAPOX regimen is safe and effective as salvage treatment in patients with advanced colorectal cancer who were previously treated with irinotecan-based frontline therapy." | 9.13 | Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. ( Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N, 2008) |
| "We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction." | 9.13 | Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. ( Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J, 2008) |
| "Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks." | 9.13 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008) |
| "We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer." | 9.13 | A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008) |
| "This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen." | 9.13 | Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008) |
| "XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)." | 9.13 | Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008) |
| "Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin." | 9.13 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008) |
| " A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer." | 9.13 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008) |
| "We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in terms of pathological (pCR) and objective responses of four courses of cisplatin containing chemotherapy (ECF, epirubicin, cisplatin, and fluorouracil as continuous infusion) followed by three courses of weekly paclitaxel." | 9.13 | Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. ( Balduzzi, A; Bottiglieri, L; Colleoni, M; Ghisini, R; Giovanardi, F; Goldhirsch, A; Luini, A; Orlando, L; Rocca, A; Torrisi, R; Veronesi, P; Viale, G, 2008) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 9.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas." | 9.13 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 9.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC)." | 9.13 | Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. ( Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M, 2008) |
| "Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil." | 9.13 | Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. ( Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA, 2008) |
| "Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP)." | 9.13 | Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Bokemeyer, C; Derigs, HG; Grossmann, J; Hartmann, JT; Hegewisch-Becker, S; Hofheinz, R; Hollerbach, S; Homann, N; Jäger, E; Knuth, A; Pauligk, C; Probst, S; Rethwisch, V; Schmalenberg, H; Schuch, G; Seipelt, G; Stoehlmacher, J; Wilhelm, G, 2008) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 9.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| "The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established." | 9.12 | Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ( Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D, 2006) |
| "Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia." | 9.12 | Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM, 2006) |
| "Oxaliplatin and 5-fluorouracil (5-FU) act synergistically in colorectal cancer." | 9.12 | Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ( Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006) |
| "Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction." | 9.12 | Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006) |
| "To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC)." | 9.12 | FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog ( Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N, 2006) |
| "To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer." | 9.12 | Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006) |
| "We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma." | 9.12 | A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. ( Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C, 2006) |
| "The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in patients after curative resection for pancreatic adenocarcinoma." | 9.12 | Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. ( Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T, 2006) |
| "The purpose of this study was to evaluate the antitumor activity and toxicity of fixed sequences of capecitabine/oxaliplatin followed by capecitabine/irinotecan in patients with previously untreated metastatic colorectal cancer." | 9.12 | Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. ( Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F, 2006) |
| "To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer." | 9.12 | [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006) |
| "PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial." | 9.12 | Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. ( Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A, 2007) |
| "In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer." | 9.12 | Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. ( Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX, 2006) |
| "Radiochemotherapy using gemcitabine followed by gemcitabine and capecitabine is an active regimen with manageable toxicity after resection of extrahepatic bile duct cancer but has significant toxicity in unresectable disease." | 9.12 | Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. ( Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H, 2006) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 9.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population." | 9.12 | A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. ( Bao, HY; Fang, WJ; Huang, S; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC, 2007) |
| "To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin." | 9.12 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007) |
| "The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU)/leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma." | 9.12 | Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. ( Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G, 2007) |
| "This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer." | 9.12 | A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. ( Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C, 2007) |
| "Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin." | 9.11 | A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 9.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 9.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 9.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
| "The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma." | 9.11 | First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004) |
| "The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 9.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| "To determine if the preoperative administration of tegafur and uracil (UFT) to patients with lung adenocarcinoma could induce apoptosis." | 9.11 | Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). ( Futagawa, T; Izumi, H; Konno, H; Miyamoto, H; Morio, A; Oh, T; Yamazaki, A, 2004) |
| "Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)." | 9.11 | Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004) |
| "A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer." | 9.11 | Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004) |
| "The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC)." | 9.11 | Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. ( Benson, A; Brandt, DS; Burger, B; Garay, CA; Gupta, S; Gurtler, J; Hallman, D; Hochster, H; Kemeny, N; Kennedy, P; Polikoff, J; Shumaker, G; Wertheim, M, 2004) |
| "The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC)." | 9.11 | Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. ( Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A, 2005) |
| "Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)." | 9.11 | Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. ( Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC, 2005) |
| "To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer." | 9.11 | Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. ( Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA, 2005) |
| "In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks." | 9.11 | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005) |
| "The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma." | 9.10 | A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ( Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M, 2002) |
| "We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas." | 9.10 | Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 9.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU." | 9.10 | Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002) |
| "Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)." | 9.10 | Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002) |
| "This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer." | 9.10 | Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. ( Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002) |
| " We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver." | 9.10 | Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003) |
| "This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer." | 9.10 | A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer. ( Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ, 2003) |
| "Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)." | 9.10 | Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003) |
| "In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57." | 9.10 | Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003) |
| "In breast cancer, chemotherapy regimens that include infusional 5-fluorouracil (5-FU) lead to high response rates, but require central venous access and pumps." | 9.10 | An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer. ( Atalay, G; Biganzoli, L; Bonnefoi, H; Cufer, T; Mauriac, L; Piccart, M; Schaefer, P, 2003) |
| "The purpose of the study was to determine the efficacy and safety of docetaxel plus continuous infusion of 5-fluorouracil (5-FU) in patients with metastatic breast cancer previously treated with anthracyclines." | 9.10 | Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer. ( Besson, D; Bougnoux, P; Bourgeois, H; Delozier, T; Gamelin, E; Lortholary, A; Lotz, V; Monnier, A; Riffaud, JCh; Tubiana-Mathieu, N, 2003) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer." | 9.10 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003) |
| "To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer." | 9.10 | Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003) |
| "The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer." | 9.10 | Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. ( Changchien, CR; Chen, JS; Chiang, JM; Hsieh, PS; Tang, R; Yang, TS; Yeh, CY, 2003) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 9.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| "Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas." | 9.10 | Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. ( Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F, 2003) |
| "To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens." | 9.10 | A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 9.10 | Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003) |
| ") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options." | 9.10 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002) |
| "Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine." | 9.10 | Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 9.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer." | 9.10 | Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002) |
| "To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients." | 9.10 | A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002) |
| " cerevisiae fusion protein) on the incidence, duration, and complications of neutropenia and thrombocytopenia after moderate-dose fluorouracil 600 mg/m(2), doxorubicin 60 mg/m(2), and cyclophosphamide 750 mg/m(2) (FAC) chemotherapy in patients with stage II and III breast cancer." | 9.09 | Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. ( Agura, E; Dimitrov, N; Duncan, L; Garrison, L; Hyman, W; Jones, SE; Khandelwal, P; Kirby, R; Lange, M; McIntyre, K; Mennel, R; Orr, D; Regan, D; Roque, T; Schuster, M, 1999) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer." | 9.09 | A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999) |
| "To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone." | 9.09 | Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. ( André, T; Beerblock, K; Bensmaine, MA; Bouché, O; Carola, E; de Gramont, A; Desseigne, F; Dupont-André, G; François, E; Louvet, C; Lucas, V; Merrouche, Y; Morvan, F, 1999) |
| "The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer." | 9.09 | Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). ( Abeloff, MD; Hochster, H; Kucuk, O; Pandya, KJ; Skeel, RT, 1999) |
| "Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil." | 9.09 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. ( Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000) |
| "It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure." | 9.09 | Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000) |
| "The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer." | 9.09 | Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000) |
| "In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen." | 9.09 | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 9.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| " This study was conducted to prospectively examine the tolerance and early efficacy of adjuvant gemcitabine following radiotherapy with concurrent 5-fluorouracil (5-FU) for nonmetastatic pancreatic adenocarcinoma." | 9.09 | Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. ( Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE, 2001) |
| "To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma." | 9.09 | Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. ( Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A, 2001) |
| "The goal of this work was to evaluate response rate, toxicity, and survival in treatment with intraarterial 5-fluorouracil (5-FU) and cisplatin in a neoadjuvant setting; this combination was administered to patients with locally advanced cervical adenocarcinoma." | 9.09 | Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma. ( Aoki, Y; Sasaki, M; Sato, T; Tanaka, K; Tsuneki, I; Watanabe, M, 2001) |
| "To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum." | 9.09 | Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001) |
| "Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma." | 9.09 | Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). ( André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F, 2001) |
| "Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV." | 9.09 | Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| "To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer." | 9.09 | Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. ( Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C, 2001) |
| " 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas." | 9.09 | A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001) |
| "Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)." | 9.09 | Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 9.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "Modulation of 5-fluorouracil (5-FU) is currently being investigated in advanced colorectal cancer." | 9.08 | Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. ( Astone, A; Barone, C; Cassano, A; Corsi, DC; Fontana, T; Noviello, MR; Pozzo, C, 1995) |
| "A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks." | 9.08 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 9.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer." | 9.08 | 5-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996) |
| "In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2." | 9.08 | Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996) |
| "Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer." | 9.08 | Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996) |
| "A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma." | 9.08 | A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program ( Armstead, B; Douglass, HO; Haller, DG; Holroyde, C; Meropol, NJ; Mintzer, D; Nuamah, I; Vaughn, DJ, 1997) |
| ") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma." | 9.08 | [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997) |
| "The aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients." | 9.08 | A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. ( Aschelter, AM; Franchi, F; Gallà, DA; Garufi, C; Giunta, S; Lévi, F; Narduzzi, C; Nisticò, C; Pace, R; Silecchia, GF; Terzoli, E, 1997) |
| "The objective of the study was to determine the response rate and associated toxicity of 5-fluorouracil and high-dose leucovorin in patients with recurrent adenocarcinoma of the cervix." | 9.08 | Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. ( Andersen, WA; Blessing, JA; Look, KY; Manetta, A; McGehee, R; Valea, FA; Webster, KD, 1997) |
| "Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)." | 9.08 | High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998) |
| "The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma." | 9.08 | The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. ( Crawley, C; Cunningham, D; Hill, A; Norman, A; Ross, P, 1998) |
| "To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)." | 9.08 | Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998) |
| "In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known." | 9.08 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. ( Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J, 1998) |
| "FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m2) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer." | 9.08 | Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. ( André, T; de Gramont, A; Louvet, C; Raymond, E; Tournigand, C, 1998) |
| "Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i." | 9.07 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994) |
| "We have studied a mitoxantrone, 5-fluorouracil (5-FU) and leucovorin chemotherapy regimen in metastatic breast cancer." | 9.07 | The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. ( Bélanger, K; Dionne, J; Gagné, L; Guévin, R; Jolivet, J; Latreille, J; Potvin, M; Rudinskas, L; Wilson, J; Yelle, L, 1994) |
| "Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m2, doxorubicin 50 mg/m2, and fluorouracil 500 mg/m2 (CAF) intravenously (IV) once every 3 weeks." | 9.07 | Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. ( Gelmon, KA; O'Reilly, SE; Onetto, N; Page, RA; Parente, J; Plenderleith, IH; Rubinger, M, 1993) |
| "We therefore initiated a Phase II study in which fluorouracil (370 mg/m2, day 1 through 5) plus folinic acid (200 mg/m2 day 1 through 5) was administered in a subset of 17 patients (median age, 57 years) affected by histologically diagnosed adenocarcinoma of unknown primary location characterized by liver metastases and elevated CEA of CA 19." | 9.07 | Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. ( Bajetta, E; Buzzoni, R; Colleoni, M; Nolè, F, 1993) |
| "A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer." | 9.07 | A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. ( Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993) |
| "In a randomized trial we compared single-agent epirubicin with the FEM (5-fluorouracil/epirubicin/mitomycin) combination in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas." | 9.07 | Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. ( Coombes, RC; Glees, J; Topham, C, 1993) |
| "5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas." | 9.07 | A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992) |
| "A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients." | 9.07 | Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU." | 9.07 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992) |
| "One hundred sixty consecutive patients with histologically confirmed colorectal cancer (advanced disease) without prior chemotherapy were entered in a randomized trial comparing 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion versus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU as described on days 2 to 6." | 9.07 | A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). ( Antón, A; Aranda, E; Belón, J; Carrato, A; Cruz-Hernández, J; Díaz-Rubio, E; Jimeno, J; Martin, M; Massuti, B; Sánchez, J, 1992) |
| "We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin." | 9.07 | Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991) |
| "Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide." | 9.07 | Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study. ( Coltman, CA; Ellis, GK; Green, S; Hynes, HE; Livingston, RB; Rivkin, S; Schulman, S, 1991) |
| "Forty-two previously untreated patients with advanced, measurable adenocarcinoma of the pancreas were treated with weekly fluorouracil (5-FU; 600 mg/m2 intravenous [IV]) and leucovorin 500 mg/m2 IV for 6 weeks followed by a 2-week rest." | 9.07 | Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. ( Arbuck, SG; DeCaprio, JA; Gonin, R; Mayer, RJ, 1991) |
| "To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes." | 9.07 | Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 9.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 9.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "Twenty-two patients with inoperable adenocarcinoma of the pancreas were treated with 5-fluorouracil (5-FU), mitomycin C (Mito-C), and 1(-2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)." | 9.06 | Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. ( Chapman, J; Chinn, B; Groshko, G; Maniscalco, B; Piper, D; Reznik, S; Vaughn, C; Ward, D, 1989) |
| "Seventy-seven patients with previously untreated, measurable, histologically confirmed, metastatic adenocarcinoma of the rectum or sigmoid were randomized to receive either epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i." | 9.06 | A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. ( Blum, RH; Lafleur, F; Molinaro, P, 1989) |
| "Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM)." | 9.06 | 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules. ( Ip, M; Kung, TM; Lam, WK; Sham, MK; So, SY, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma." | 9.06 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 9.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 9.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan." | 9.04 | Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978) |
| "One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide." | 9.04 | Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977) |
| "In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs." | 9.04 | Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. ( Baker, LH; Reed, ML; Seifert, P; Vaitkevicius, VK, 1975) |
| "The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)." | 8.95 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017) |
| ", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)." | 8.86 | Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010) |
| "A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy." | 8.77 | Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. ( Binsack, T; Mergenthaler, HG; Wilmanns, W, 1988) |
| "This case report describes a patient with cutaneous intestinal metaplasia with invasive adenocarcinoma treated successfully with intralesional fluorouracil." | 8.31 | Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil. ( Dahiya, M; Eilers, D; Joseph, MX; Tao, J; Vaudreuil, A, 2023) |
| "Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70's or they have comorbidities." | 8.31 | Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role? ( Aravantinos, G; Dessypris, N; Gkoura, S; Karampinos, K; Mauri, D; Miaris, N; Samantas, E; Sgouros, J; Spathas, N; Stamoulis, G; Theodoropoulos, I; Tzoudas, F; Visvikis, A, 2023) |
| "The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy." | 8.31 | The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. ( Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C, 2023) |
| "The primary mode of therapy for individuals with locally advanced esophageal adenocarcinoma (EAC) is neoadjuvant chemotherapy, commonly 5-Fluorouracil (5-FU)." | 8.31 | Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells. ( Chauhan, A; Cheng, L; Garrett, H; Idrovo, JP; Meguid, RA; Meng, X; Pratap, A; Qualman, A; The, E; Wani, S, 2023) |
| "Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist." | 8.12 | Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. ( Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S, 2022) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 8.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC), but they have not been directly compared in a clinical trial, and comparative clinical data analyses on their effectiveness are limited." | 8.12 | Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. ( Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G, 2022) |
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 8.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| "We report the case of a 74-years old patient with jejunum adenocarcinoma treated by capecitabine." | 8.12 | A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient. ( Botsen, D; Bouche, O; Gossery, C; Gratiaux, J; Rezzag-Mahcene, C; Slimano, F; Visseaux, L, 2022) |
| "The aim of this study was to investigate the antitumor effects of quercetin and luteolin combined with 5-Fluorouracil (5-FU) in HT-29 human colorectal cancer cells." | 8.12 | Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma ( Ağca, CA; Aşkın, H; Erdoğan, MK, 2022) |
| "In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019." | 7.96 | First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. ( Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K, 2020) |
| "The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)." | 7.91 | Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019) |
| "Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU." | 7.91 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019) |
| " We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations." | 7.91 | Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. ( Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019) |
| "Eighty-three patients were treated with locally advanced or metastatic adenocarcinoma of the pancreas with either FOLFIRINOX or nab-Paclitxel and Gemcitabine (nabPGem) as first- or second line therapy." | 7.91 | Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? ( Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T, 2019) |
| " Therefore, we examined the effects of flavones against CYR61-overexpressing human gastric adenocarcinoma AGS (AGS-cyr61) cells, which show remarkable resistance to 5-fluorouracil (5-FU), adriamycin (ADR), tamoxifen (TAM), paclitaxel (PAC), and docetaxel (DOC)." | 7.88 | Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( Cho, SK; Hyun, HB; Moon, JY, 2018) |
| "Lactoferrin nanoparticles demonstrated an attractive drug delivery module to manage the colon adenocarcinoma as it has improved the antiproliferative activity of 5-FU and Oxaliplatin against colon adenocarcinoma cells." | 7.88 | Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study. ( Ahmed, F; Kondapi, AK; Kumari, S, 2018) |
| "Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated." | 7.85 | 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. ( Cao, L; Du, C; Gu, J; Huang, D; Peng, Y; Wang, H; Yang, Y; Yao, Y; Zhao, Y; Zhu, WG, 2017) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 7.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer." | 7.83 | In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016) |
| " In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms." | 7.83 | Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. ( Li, F; Li, G; Liu, H; Ruan, Z; Wang, X; Wang, Y; Xie, X; Yu, H; Zhang, J; Zhou, Y, 2016) |
| "When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis." | 7.83 | Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. ( Abe, N; Fujinaga, A; Hayashi, H; Hirata, K; Ito, K; Komatsu, Y; Matsuda, K; Uchida, T, 2016) |
| "Two estrogen receptor (ER)-positive esophageal adenocarcinoma cell lines (OE-19 and OE-33) were treated with combinations of tamoxifen, cisplatin and 5-fluorouracil (5-FU)." | 7.83 | Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells. ( Astill, DS; Bastian, I; Ding, GQ; Due, SL; Hussey, DJ; Sukocheva, OA; Vat, L; Watson, DI, 2016) |
| "An aptamer (Apt) conjugated hyaluronan/chitosan nanoparticles (HACSNPs) were prepared as carrier for targeted delivery of 5-fluorouracil (5FU) to mucin1 (MUC1) overexpressing colorectal adenocarcinomas." | 7.81 | Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. ( Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Ghasemi, Z; Mottaghitalab, F; Sayari, E, 2015) |
| "The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma." | 7.81 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015) |
| "In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity." | 7.81 | Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. ( Candamio-Folgar, S; Lopez-Lopez, R; Martínez-Lago, N; Padin-Iruegas, ME; Vazquez-Rivera, F; Vidal-Insua, Y; Vieito-Villar, M, 2015) |
| "Hand-foot syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy." | 7.80 | Topical henna ameliorated capecitabine-induced hand-foot syndrome. ( Ilyas, S; Saif, MW; Wasif, K, 2014) |
| " The aim of this study is to evaluate the efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy in advanced gastric adenocarcinoma patients in China." | 7.80 | Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. ( Bai, L; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, RH; Yang, DJ; Zhang, DS; Zhou, YX, 2014) |
| "We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer." | 7.80 | The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014) |
| "We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer." | 7.80 | An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014) |
| "The aim of the present study was to evaluate the change of thymidine phosphorylase (TP) activity in gastric adenocarcinoma and adjacent tissue upon the intraarterial administration of 5-fluorouracil (5-FU)." | 7.80 | The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue. ( Dumanskiy, Y; Khomutov, E; Matviyenko, A; Stashkevych, M; Zinkovych, I, 2014) |
| "The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma." | 7.79 | Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. ( Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013) |
| " This study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the Bcl-2 gene would enhance the apoptosis and sensitivity of gastric adenocarcinoma SGC-7901 cell to 5-Fluorouracil." | 7.79 | Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. ( Liu, H; Liu, Y; Wu, FR; Xia, Q; Yu, DF, 2013) |
| "The efficacy of triple-drug combination regimens such as docetaxel, cisplatin and 5-fluorouracil (DCF), and epirubicin, oxaliplatin and capecitabine (EOX), is superior to standard cisplatin/5-fluorouracil in patients with upper gastrointestinal adenocarcinoma." | 7.79 | Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract. ( Asari, R; Ba-Ssalamah, A; Birner, P; Hejna, M; Ilhan-Mutlu, A; Pluschnig, U; Preusser, M; Püspök, A; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the first line treatment of advanced gastric adenocarcinoma." | 7.79 | Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma. ( Liu, Y; Ma, T; Shi, M; Xi, W; Yang, L; Ye, Z; Zhang, J; Zhu, Z, 2013) |
| "The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer." | 7.79 | Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013) |
| " In this study, we had investigated the synergistic effects of low dose fluorouracil (5-Fu) and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells and explored the potential mechanisms." | 7.79 | The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. ( He, J; Huang, M; Huang, Y; Ren, D; Yi, C; Zhao, F; Zhu, H, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 7.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| " This study sought to enrich cancer stem cells and explore cancer stem-like cell clones using 5-fluorouracil (5-FU) in the lung adenocarcinoma cell line, SPC." | 7.79 | Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC. ( Jia, XS; Li, X; Li, XL; Shi, MM; Wang, EH; Xiong, YL; Zhang, L, 2013) |
| " The aim of this study is to retrospectively evaluate the safety and efficacy of adjuvant epirubicin-based triplet chemotherapy and radiotherapy in the treatment of resected locally advanced stomach or gastroesophageal junction adenocarcinoma." | 7.79 | Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. ( Cai, G; Li, G; Ma, X; Zhang, Z; Zhu, J, 2013) |
| "A recent study showed that both 5-fluorouracil (5FU)-stimulated apoptosis and Fas-mediated apoptosis in human endometrial adenocarcinoma cells are enhanced by targeted knockdown of endogenous death-associated protein kinase (DAPK) with DAPK small-interfering RNAs." | 7.78 | Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells. ( Bai, T; Tanaka, J; Tanaka, T; Toujima, S; Utsunomiya, H; Utsunomiya, T; Yukawa, K, 2012) |
| "Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 7.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
| "To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts." | 7.78 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. ( Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 7.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "To assess whether early lung cancer prediction might be informed by an mRNA assay for 5-fluorouracil pathway genes in peripheral blood mononuclear cells (PBMNCs), we examined specimens taken from 51 adenocarcinoma patients and 38 controls (including six patients with benign tumors)." | 7.77 | A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma. ( Aida, S; Fujita, Y; Hasegawa, S; Hiroi, S; Kawai, T; Mio, T; Nakanishi, K; Ogata, S; Ozeki, Y; Takeuchi, K; Tanaka, F; Tominaga, S; Wada, H, 2011) |
| "Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities." | 7.77 | Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. ( Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 7.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "The aim of this retrospective study was to evaluate the efficacy and safety of weekly high-dose 5-fluorouracil (5-FU)/folinic acid (FA) as 24-h infusion (AIO regimen) plus irinotecan in patients with histologically proven metastatic gastroesophageal adenocarcinoma (UICC stage IV)." | 7.77 | Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b ( Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011) |
| "FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients." | 7.77 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "A retrospective analysis was carried out to evaluate toxicity and efficacy of the combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil (DCF) plus granulocyte colony-stimulating factor prophylaxis (G-CSF) in patients with metastatic gastric and gastroesophageal junction adenocarcinoma." | 7.77 | Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna. ( Ba-Ssalamah, A; Bojic, M; Datler, P; Hejna, M; Maresch, J; Pluschnig, U; Schoppmann, SF; Thallinger, CM; Zacherl, J, 2011) |
| "To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA)." | 7.77 | 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. ( Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M, 2011) |
| "To investigate anticancer effects of 5-fluorouracil (5-FU) combined with CL, extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma cell line (JEC)." | 7.77 | [Anticancer effect of 5-fluorouracil combined with extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma]. ( Dai, ZK; Yang, XS; Yu, LM, 2011) |
| "Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required." | 7.77 | Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993) |
| "To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo." | 7.76 | Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ( Jiang, Y; Luo, H; Yin, A; Zhang, X, 2010) |
| " We investigated whether p53 polymorphism and mutation were associated with in vitro sensitivity to 5-fluorouracil (5-FU) in patients with colorectal cancer." | 7.76 | Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. ( Higashiguchi, T; Hotta, T; Iwahashi, M; Matsuda, K; Nasu, T; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2010) |
| "The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX)." | 7.76 | Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. ( Cuilliere-Dartigues, P; de Gramont, A; Dumont, S; Duval, A; Fléjou, JF; Gayet, B; Guilloux, A; Louvet, C; Parc, Y; Praz, F; Tiret, E; Validire, P; Zaanan, A, 2010) |
| "The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX)." | 7.76 | EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. ( Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG, 2010) |
| "5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma." | 7.76 | A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma. ( Akboru, H; Bati, Y; Isikli, L; Unsal, M; Yoney, A, 2010) |
| "We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma." | 7.76 | [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. ( Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK, 2010) |
| "To investigate acquired 5-fluorouracil (5FU)-resistance in cancer cells, we established four monoclonal 5FU-resistant cell lines from human endometrial adenocarcinoma cells by long-term 5FU-exposure cultures and limiting dilution cultures." | 7.76 | Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma. ( Bai, T; Tanaka, T; Toujima, S, 2010) |
| "The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients." | 7.76 | Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010) |
| "A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas." | 7.75 | Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. ( Araki, O; Chida, M; Honma, K; Ishihama, H; Karube, Y; Masawa, N; Miyoshi, S; Seki, N; Tamura, M; Umezu, H, 2009) |
| "We report an elderly patient with esophageal adenocarcinoma in whom a complete response (CR) was obtained by chemoradiotherapy using daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU." | 7.75 | [A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation]. ( Furuta, T; Futami, H; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kodaira, C; Muramatsu, A; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Yamada, T; Yoshida, K, 2009) |
| "A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described." | 7.75 | A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. ( Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2009) |
| "The correlations between adenomatous polyposis coli (APC) mutations and 5-fluorouracil (5-FU) adjuvant chemotherapy and colorectal cancer (CRC) patients' prognosis are not well known." | 7.75 | Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Su, CC; Wu, CC, 2009) |
| "It is the aim of this study to assess the outcome of patients who received neoadjuvant 5-fluorouracil-cisplatin chemoradiation (CRT) for stage I/III pancreatic adenocarcinoma." | 7.75 | Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. ( de Chaisemartin, C; Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F, 2009) |
| " We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy." | 7.75 | Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. ( Mendiola, C; Vaz, MA, 2009) |
| "5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration." | 7.75 | Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. ( Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE, 2009) |
| " The aim of this study was to elucidate whether hyperoxia also enhances any actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes in the interstitium and extracellular matrix." | 7.75 | Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. ( Kolmannskog, O; Moen, I; Reed, RK; Salvesen, GS; Stuhr, LE; Tronstad, KJ, 2009) |
| "We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus." | 7.74 | Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. ( Fujii, Y; Fukui, I; Ishikawa, Y; Kawakami, S; Komai, Y; Okubo, Y; Takeshita, H; Tatokoro, M; Yamamoto, S; Yonese, J, 2008) |
| "To present our clinical experience of 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen administered as an adjuvant chemotherapy to 2 patients with advanced jejunal adenocarcinoma." | 7.74 | Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases. ( Chen, CW; Hsieh, JS; Su, YC; Wang, JY; Wang, WM; Wu, JY, 2008) |
| "We aimed at developing a more detailed understanding of cyclin D1 in early stage human breast cancer and defining the biologic profiles with different prognostic value correlating cyclin D1 gene amplification and chromosome 11 aneusomy with bio-pathologic variables of known clinical importance." | 7.74 | Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile. ( Buglioni, S; Cianciulli, A; Cognetti, F; Di Benedetto, A; Merola, R; Mottolese, M; Orlandi, G; Perracchio, L; Pinnarò, P; Sperduti, I; Venturo, I, 2007) |
| "To evaluate the efficacy and safety of a regimen using Irinotecan, 5FU and Leucovorin for patients with advanced or recurrent colorectal cancer." | 7.74 | Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. ( Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y, 2007) |
| "Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors." | 7.74 | Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? ( Barten, M; Ostwald, C; Prall, F; Schiffmann, L, 2007) |
| "Cetuximab (Erbitux) in combination with irinotecan is the most promising combination in heavily pretreated patients with advanced colorectal cancer." | 7.74 | Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. ( Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M, 2007) |
| "A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer." | 7.74 | Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007) |
| "Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas." | 7.74 | Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Ouchida, M; Soh, J; Suehisa, H; Takata, M; Toyooka, S; Uchida, A, 2007) |
| " Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer." | 7.74 | [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. ( Park, KG; Smith, TA; Suttie, SA, 2007) |
| "Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)." | 7.74 | Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. ( Diasio, RB; Han, HC; Iacopetta, B; Joseph, D; Ng, SS; Salto-Tellez, M; Shah, N; Soo, RA; Soong, R; Tai, BC; Tan, WL; Zeps, N, 2008) |
| "To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma." | 7.73 | Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. ( Adams, R; Jones, RS; Keene, KS; Penberthy, DR; Rich, TA; Shepard, RC, 2005) |
| "To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)." | 7.73 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006) |
| "We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy." | 7.73 | [Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005) |
| "We conducted a retrospective analysis of prognosis factors for survival in breast cancer patients with 1-3 axillary lymph node metastases and tried to identify a subset of patients with good prognosis suitable for cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy." | 7.73 | Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. ( Chang, HK; Chen, MF; Chen, SC; Hsueh, S; Hwang, TL; Lin, YC; Lo, YF; Tsai, CS, 2005) |
| "Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003." | 7.73 | Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. ( Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J, 2006) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 7.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| " For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil." | 7.72 | Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003) |
| "Four pancreatic adenocarcinoma cell lines were evaluated for their sensitivity to 5-fluorouracil (5-FU) and gemcitabine and two of these, Suit-2 and Panc-1, were chosen for combination experiments because they showed moderate and poor sensitivity, respectively, to 5-FU and gemcitabine." | 7.72 | 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. ( Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L, 2004) |
| "High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers." | 7.72 | Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004) |
| "Three dogs with advanced-stage adenocarcinoma of the gastrointestinal tract were treated by use of resection, adjuvant chemotherapy with cisplatin and 5-fluorouracil, and second-look laparotomy (SLL)." | 7.72 | Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. ( Gilson, SD; Stanclift, RM, 2004) |
| "The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials." | 7.71 | [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| "LSMs for 5-fluorouracil and 5-fluoro-5,6-dihydrouracil therapeutic monitoring have been developed in 80 patients with colorectal cancer (training set) given 5-fluorouracil, 370 mg/m(2) per day as an intravenous bolus, plus leucovorin, 100 mg/m(2) per day, for 5 days every 4 weeks." | 7.71 | Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. ( Amadori, D; Cionini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Mini, E; Vannozzi, F, 2002) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 7.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis." | 7.71 | Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001) |
| "To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy." | 7.71 | p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. ( Benevolo, M; Brenna, A; Buglioni, S; Cosimelli, M; D'Agnano, I; D'Angelo, C; Mottolese, M; Perrone Donnorso, R; Vasselli, S; Zupi, G, 2001) |
| "The aim of this study was to assess in patients with advanced colorectal cancer which factors were associated with short-term survival (6 months or less) and progression to first-line 5-fluorouracil (5-FU) chemotherapy." | 7.71 | Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. ( Cellerino, R; Lippe, P; Massacesi, C; Piga, A; Pistilli, B; Rocchi, MB; Valeri, M, 2002) |
| "We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy." | 7.71 | mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. ( Costa, A; De Lena, M; Lacava, J; Leone, A; Paradiso, A; Ranieri, G; Silvestris, N; Simone, G; Vallejo, C, 2002) |
| "This case can be considered the first documented Irinotecan-induced immune thrombocytopenia." | 7.70 | Irinotecan-induced immune thrombocytopenia. ( Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL, 1998) |
| "During a 4-year period we treated 20 patients with locally advanced adenocarcinoma of the rectum using a protocol of preoperative simultaneous pelvic irradiation (4,030-6,040 cGy) and infusion chemotherapy (5-fluorouracil 100 mg/m2 per day over 96 hours and mitomycin 10 mg/m2) followed by surgical resection." | 7.70 | Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. ( Burke, SJ; Knight, DC; Kwasnik, EM; Percarpio, BA, 1998) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 7.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "A selective inflammatory reaction involving actinic keratosis may occur in patients receiving systemic 5-fluorouracil as part of a chemotherapeutic protocol." | 7.70 | Selective inflammatory effect of systemic fluorouracil in actinic keratosis. ( Mehregan, D; Mohindra, R; Nabai, H, 1999) |
| "5-Fluorouracil combined with leucovorin and/or cisplatin has been used in the treatment of gastrointestinal adenocarcinoma and may be useful in primary adenocarcinoma of the bladder." | 7.70 | Intra-arterial infusion of 5-fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder. ( Awakura, Y; Fukuyama, T; Fukuzawa, S; Nonomura, M; Yamamoto, M, 1999) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 7.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer." | 7.70 | Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000) |
| "To report 5-fluorouracil in combination with folinic acid as a cause of severe nonischemic heart failure and to demonstrate the potential usefulness of an intra-aortic balloon pump." | 7.70 | Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. ( David, JS; Gaussorgues, P; Gueugniaud, PY; Hepp, A; Petit, P, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 7.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "To study the schedule-dependent reversion of cis-diamminedichloroplatinum (CDDP) resistance by 5-fluorouracil (5-Fu) in a CDDP resistant human lung adenocarcinoma cell line A549DDP." | 7.70 | Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. ( Liu, X; Zhan, M, 1999) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | 7.69 | [A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| "We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole." | 7.69 | Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995) |
| "To determine the effect of cellular proliferation and cell cycle stage on the ability of postirradiation 5-fluorouracil (5-FU) to radiosensitize cultured human colon adenocarcinoma Clone A cells." | 7.69 | 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. ( Buchholz, DJ; Lepek, KJ; Murray, D; Rich, TA, 1995) |
| "One hundred and seven previously untreated patients with measurable metastatic colorectal cancer who were treated with 5-fluorouracil (5FU) and leucovorin (LV) in two different maximum doses and schedules were retrospectively analyzed." | 7.69 | A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Bacoyannis, C; Basdanis, G; Foutzilas, G; Karvounis, N; Kosmidis, P; Markantonakis, P; Mylonakis, N; Sobolos, K; Tsavaris, N; Zisiadis, A, 1995) |
| "Exposure of the human colon adenocarcinoma HT29 cells to different concentrations of 5-fluorouracil (5FU) for 24 h resulted in a dose-dependent increase in the cellular glutathione (GSH) level which remained elevated up to 72 h following 5FU treatment." | 7.69 | Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells. ( Boyce, HW; Chen, LT; Chen, MF, 1995) |
| "The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of 5-fluorouracil (5-FU), used at different concentrations, in inhibiting the growth of gastric adenocarcinoma cells." | 7.69 | Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro. ( Brenner, RV; Buras, RR; Evans, SR; Nauta, RJ; Shabahang, M; Shchepotin, IB, 1994) |
| "We reported a case of successful treatment of disseminated breast cancer with epirubicin (EPI), 5-fluorouracil (5-FU), and medroxyprogesterone (MPA)." | 7.69 | [A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)]. ( Fujisawa, J; Satoh, Y; Uchino, J; Une, Y, 1994) |
| "We reviewed our results with chemotherapy for adenocarcinoma of the esophagus or gastroesophageal junction tumors in patients treated with 5-fluorouracil, Adriamycin, and mitomycin C (FAM) regimen as developed by MacDonald and colleagues for adenocarcinoma of the stomach." | 7.69 | 5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors. ( Allred, C; Khansur, T; Tavassoli, M, 1994) |
| "Several classes of plant polyphenols namely, flavonoids, chalcones and coumarins exhibited varying degrees of inhibition on the cell proliferation of human colon adenocarcinoma cell line 220." | 7.69 | Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. ( Das, NP; Yit, CC, 1994) |
| "To investigate the resistance against 5-fluorouracil (FU), thymidylate synthase (TS) mRNA level was measured by reverse transcription PCR (RT-PCR) technique and quantitated by a competitive-PCR method in human colon adenocarcinoma cell line, SNU-C1 and its FU resistant cell line, C1/FU." | 7.69 | [Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells]. ( Aiba, K; Horikoshi, N; Minowa, S; Shibata, H; Shibata, J, 1994) |
| "Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days." | 7.69 | Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994) |
| "Low-dose consecutive intra-arterial infusion therapy with cisplatin and 5-fluorouracil as neoadjuvant chemotherapy was performed on 3 cases of cervical adenocarcinoma (two stage IIb and one stage IIIb)." | 7.69 | [Three cases of uterine cervical adenocarcinoma successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)]. ( Narimatsu, A; Okada, O, 1996) |
| "Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)." | 7.69 | Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995) |
| "A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung." | 7.69 | [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996) |
| "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%." | 7.69 | Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995) |
| "After a loading dose of 4 x 90 mg folinic acid orally, a continuous infusion of 5-fluorouracil 500 mg/sqm/day for 5 days with concommitant folinic acid 6 x 60 mg/day orally, was administered to 29 consecutive patients with metastatic adenocarcinoma of the esophagus or esophagogastric junction area." | 7.69 | 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; van der Gaast, A, 1996) |
| "In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally." | 7.69 | Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. ( Kamm, YL; Punt, CJ; Wagener, DJ, 1997) |
| "5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone." | 7.69 | 5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997) |
| "Previous studies using cultured colon adenocarcinoma cells demonstrated that a mixture of the diastereoiosomers of the biologically active (6S) and inactive (6R) forms of (6RS) leucovorin or 5-formyl-H4PteGlu (LV) and recombinant human alpha2a-interferon (rIFN-alpha2a) in combination significantly increased the cytotoxicity of 5-fluorouracil (FUra) (by 10-14-fold) whereas FUra combined with single modulators was less potentiated (3-fold)." | 7.69 | Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. ( Cheshire, PJ; Houghton, JA; Morton, CL; Stewart, CF, 1995) |
| "We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer." | 7.68 | [Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. ( Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993) |
| "Our recent findings in vitro in the human colon adenocarcinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule." | 7.68 | Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. ( Aschele, C; Bertino, JR; Guglielmi, AP; Melioli, GG; Mori, AM; Rosso, R; Sobrero, AF, 1993) |
| " Thirteen patients with adenocarcinoma of the pancreas received weekly 5-fluorouracil by rapid intravenous infusion midway through a 2-h infusion of high dose leucovorin during external beam radiation therapy." | 7.68 | Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study. ( Dobelbower, RR; Howard, JM; Konski, AA; Merrick, HW; Schifeling, DJ; Skeel, RT, 1992) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | 7.68 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| "We have evaluated the effect of 5-fluorouracil 600 mg/m2, doxorubicin ('Adriamycin') 40 mg/m2, and Mitomycin-C 4 mg/m2 (FAM) in two groups of patients with adenocarcinoma of the oesophagus, as either a preoperative or primary treatment." | 7.68 | A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Matthews, HR; Steel, A; Walker, SJ, 1991) |
| "Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1." | 7.68 | [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991) |
| "We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)." | 7.68 | In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin. ( Atabek, U; Zirvi, KA, 1991) |
| "Fifteen patients with potentially resectable adenocarcinoma of the esophagus were treated with two cycles of preoperative chemotherapy with 5-fluorouracil (5-FU) and cisplatin (DDP)." | 7.68 | A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC, 1991) |
| "Exposure to dehydroepiandrosterone caused a concentration-dependent accumulation of HT-29 human colonic adenocarcinoma cells in S-phase and sensitization toward the cytotoxic effects of fluorouracil deoxyriboside but not 5-fluorouracil." | 7.68 | Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells. ( Holbrook, CT; Klann, RC; Nyce, J, 1990) |
| "A human colon adenocarcinoma cell line (GC3TK-) was selected for thymidine kinase (TK) deficiency from cloned parental cells (GC3C1) by exposure to 5-bromodeoxyuridine (BrdUrd)." | 7.68 | Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. ( Germain, G; Houghton, JA; Houghton, PJ; Pennington, J; Radparvar, S; Rahman, A, 1990) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 7.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| "The growth inhibitory effects of 5-fluorouracil (5-Fu) and the combination of 5-Fu and human leukocyte interferon (HuIFN-alpha) on the human salivary gland adenocarcinoma cell line HSG in culture were examined by measuring colony formation in the semi-solid agar medium and cell proliferation in the monolayer culture." | 7.67 | Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture. ( Hayashi, Y; Kobayashi, S; Nitta, T; Sato, M; Urata, M; Yanagawa, T; Yoshida, H; Yura, Y, 1984) |
| "The effect of 5-fluorouracil on the stability of DNA and the synthesis of DNA replication intermediates was analyzed in human colon adenocarcinoma cells." | 7.67 | Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. ( Lönn, S; Lönn, U, 1984) |
| "Twenty-one patients with adenocarcinoma of the cecum were treated in a pilot study between October, 1972 and June, 1982 by right hemicolectomy and received adjuvant postoperative irradiation (40-45 Gy/4-5 weeks) and 5-Fluorouracil (5-FU)." | 7.67 | Postoperative adjuvant irradiation and 5-fluorouracil for adenocarcinoma of the cecum. A pilot study. ( Cormier, WJ; Jazy, FK; Krause, RJ; Meyer, RL; Shehata, WM, 1984) |
| "Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen." | 7.67 | Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989) |
| "Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals." | 7.67 | Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989) |
| "Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma." | 7.67 | Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989) |
| "The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse." | 7.67 | Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989) |
| "A total of 23 patients with advanced gastric adenocarcinoma were treated with a combination of moderate-dose methotrexate (MDMTX), 250 mg/m2 i." | 7.67 | Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. ( Dickinson, R; Levi, J; Milliken, S; Presgrave, P; Woods, R, 1989) |
| "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1." | 7.67 | Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989) |
| "Sixty women with metastatic breast cancer refractory to at least one chemotherapeutic regimen were treated with fluorouracil (FUra) and high-dose continuous infusion folinic acid (leucovorin calcium)." | 7.67 | Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. ( Akman, S; Bertrand, M; Carr, B; Doroshow, JH; Flanagan, B; Goldberg, D; Leong, L; Margolin, K; Newman, E; Odujinrin, O, 1989) |
| "A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU." | 7.67 | Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. ( Creaven, PJ; Herrera, L; Madejewicz, S; Mittelman, A; Petrelli, NJ; Plager, J; Rustum, Y; Soloman, J, 1989) |
| "We report a case of recurrent adenocarcinoma of the bladder treated by intra-arterial infusion of 5-fluorouracil (5-FU)." | 7.67 | Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder. ( Fuchs, EF; Hatch, TR, 1989) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 7.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| "5-Fluorouracil (FUra) has been administered to mice bearing xenografts of human colon adenocarcinomas." | 7.67 | Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Torrance, PM; Weiss, KD; Williams, LG, 1986) |
| "Fifty-four patients with adenocarcinoma and large cell carcinoma of the lung, 16 with localized surgically resected disease and 38 with metastatic disease, were treated with 5-fluorouracil, doxorubicin, and mitomycin-C (FAM), in an attempt to prolong previously reported survival times in the patients." | 7.67 | 5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung. ( Shaw, MK; Shaw, MT, 1987) |
| "The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity." | 7.67 | Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine. ( Hoshi, A; Iigo, M; Kitagawa, H, 1986) |
| "When combined with bromovinyldeoxyuridine (BVdUrd), 5-fluorouracil (FUra) brought about a significant reduction in the growth of adenocarcinoma 755 tumors in mice, at doses at which either drug used alone (BVdUrd: 100 mg/kg) did not effect an appreciable antitumor activity." | 7.67 | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1987) |
| "A 64-year-old woman who was diagnosed as inoperable intrahepatic bile duct cancer with massive liver metastasis was treated with 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin-C (MMC)." | 7.67 | [A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy]. ( Hasegawa, H; Kozakai, M; Misu, Y; Saitoh, Y; Shikata, J; Takada, T; Tsuchiya, S; Uchiyama, K; Yasuda, H, 1988) |
| "An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion." | 7.67 | High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. ( Cady, J; De Gramont, A; Demuynck, B; Gonzalez-Canali, G; Grange, JD; Krulik, M; Lagadec, B; Loiseau, JP; Louvet, C; Maisani, JE, 1988) |
| "A marked inhibition of the growth of solid tumor adenocarcinoma 755 was achieved by the combination of 5-fluorouracil (5-FU) with bromovinyldeoxyuridine (BVDU)." | 7.67 | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. ( Araki, E; De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1988) |
| "The EORTC Gastrointestinal Group has conducted a phase II trial in 47 patients with locally advanced or metastatic adenocarcinoma of the pancreas with epirubicin 90 mg/m2 intravenously on day 1 in combination with 5-fluorouracil 500 mg/m2 in a 2 hr infusion day 1-4, every 4 weeks." | 7.67 | An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas. ( Bleiberg, H; Blijham, G; Dalesio, O; Duez, N; Planting, A; Splinter, T; Weber, W; Wils, J, 1987) |
| "Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX." | 7.67 | Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. ( Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma." | 7.67 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987) |
| "The effect of various guanine ribonucleotides on the antitumor activity of 5-fluorouracil (FUra) was investigated by its action on adenocarcinoma 755." | 7.67 | Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755. ( Hoshi, A; Iigo, M; Nishimura, S; Yamaizumi, Z, 1987) |
| "The combination of 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM) is often recommended for empiric management of patients with adenocarcinoma of unknown primary." | 7.67 | 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. ( Ahlgren, JD; Goldberg, RM; Schein, PS; Smith, FP; Ueno, W, 1986) |
| "Fifty-three patients with inoperable adenocarcinoma of the lung were treated with 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) in two dose schedules: schedule 1--5-FU 600 mg/m2 days 1, 8, 29, and 36 and Adriamycin 30 mg/m2 days 1 and 29 and mitomycin-C 10 mg/m2 day 1 repeated every 8 weeks." | 7.67 | 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung. ( Burkes, R; DeBoer, G; Evans, WK; Paul, K; Shepherd, FA, 1986) |
| "In order to determine the contribution of thymidine (dThd) salvage to intrinsic resistance to antimetabolites (5-fluoropyrimidines, antifolates) in the human colon adenocarcinoma xenograft, H X GC3, a subline deficient in thymidine kinase has been developed." | 7.67 | Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. ( Germain, G; Houghton, JA; Houghton, PJ; Torrance, PM, 1987) |
| "To delineate the efficacy of continuous intravenous 5-fluorouracil (5-FU) infusion therapy for advanced colorectal adenocarcinoma, a study of 36 patients with measurable metastatic disease was conducted." | 7.67 | Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. ( Ausman, R; Becker, T; Blake, D; Caballero, G; Hansen, R; Jenkins, D; Quebbeman, E; Ritch, P; Schulte, W; Tangen, L, 1985) |
| "Sequential methotrexate-5-fluorouracil (Mtx-5-Fu) reduces proliferation of human colon adenocarcinoma cells." | 7.67 | The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil. ( Lönn, S; Lönn, U, 1986) |
| "The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51 and 06/A." | 7.66 | In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. ( Corbett, TH; Heidelberger, C; Moran, RG; Shahinian, AH; Spears, CP, 1982) |
| "Sixty-three previously untreated patients with metastatic non-small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3 mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi)." | 7.66 | Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study. ( Carlin, DA; Grozea, PN; Miller, TP; Weick, JK, 1982) |
| "Because alpha-difluoromethylornithine (DFMO) reduces the incidence of experimental colon cancers, inhibits the growth of human lung cancer cells and human leukemia cells in culture, and in combination with methylglyoxal (bis)guanylhydrazone induces remission in children with leukemia, its effectiveness against a human colon adenocarcinoma cell line (Colo 205) was tested alone and in combination with 5-fluorouracil (5-FU)." | 7.66 | Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line. ( Diekema, KA; Kingsnorth, AN; Malt, RA; McCann, PP; Russell, WE, 1983) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 7.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 7.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer." | 7.66 | Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981) |
| "The anti-inflammatory drug indomethacin was tested for antitumor activity against transplantable mouse colon adenocarcinoma 38 (colon 38)." | 7.66 | Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. ( Goto, A; Narisawa, T; Sano, M; Sato, M; Takahashi, T, 1983) |
| "A series of four human colon adenocarcinomas, growing as xenografts in immune-deprived mice, have been used to evaluate the efficacy of 5-FU in combination with two purines, hypoxanthine (Hx) and allopurinol (HPP), which have reduced the toxicity of 5-FU in host mice." | 7.66 | Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. ( Houghton, JA; Houghton, PJ, 1982) |
| "After perioperative adjuvant chemotherapy of a sigma-adenocarcinoma with 400 mg peptichemio and 500 mg 5-fluorouracil a 61-year-old woman developed a severe intoxication: myelosuppression with pancytopenia, gastroenteritis and ulcerative proctitis, toxic hepato- and myocardiopathy, impaired renal function and alopecia." | 7.66 | [Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)]. ( Gasser, RW; Schmalzl, F, 1982) |
| "This study was designed to examine the possibilities for increasing the therapeutic index in the treatment of human colon adenocarcinomas maintained as xenografts in immune-deprived mice using combinations of methotrexate (MTX) that preceded 5-fluorouracil (FUra)." | 7.66 | The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Tice, AJ, 1982) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 7.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "Thirty patients with unresectable adenocarcinoma of the lung were treated with high doses of 5-fluorouracil, Adriamycin, and mitomycin-C (Hi-FAM)." | 7.66 | 5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung. ( Ali, M; Brown, B; Ewer, M; Nogeire, C; Rosi, DR; Samuels, M, 1981) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 7.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "28 patients with advanced adenocarcinomas were treated with combinations of 5-fluorouracil and mitomycin-C (FM, 21 patients) or of 5-fluorouracil, adriamycin and mitomycin-C (FAM, 7 patients)." | 7.66 | [Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas]. ( Hammer, B; Jungi, WF; Mayr, AC; Senn, HJ; Späti, B, 1980) |
| "Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM)." | 7.66 | 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. ( Hoth, DF; Karlin, DA; Levin, B; MacDonald, JS; Schein, PS; Smith, FP; Woolley, PV, 1980) |
| "The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma." | 7.66 | Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. ( Benz, C; Cadman, E, 1981) |
| "In two separate experiments, treatment of C3H/He mice bearing transplantable mammary adenocarcinomas (C3HBA) with a regimen of 6-propylthiouracil (PTUra) and 5-fluorouracil (FUra) plus chloroquine phosphate (CP) resulted in complete remissions of 77 and 65%, respectively." | 7.66 | Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. ( Dagher, RK; Shoemaker, JP, 1979) |
| "Twenty-five patients with advanced measurable adenocarcinoma of the lung were treated with combination chemotherapy consisting of 5-fluorouracil, adriamycin, and mitomycin-C (FAM)." | 7.66 | 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. ( Butler, TP; MacDonald, JS; Schein, PS; Smith, FP; Smith, LF; Woolley, PV, 1979) |
| "Metastasizing mammary adenocarcinoma 13762 in female Fischer rats has been used as a model for studying postoperative adjuvant chemotherapy, using methotrexate (Mtx) and 5-fluouracil (5FU) either singly or in combinations." | 7.65 | Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. ( Khwaja, TA; Lee, YT, 1977) |
| "Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate." | 7.65 | Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. ( Bruckner, HW; Deppe, G, 1977) |
| "For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy." | 7.01 | A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023) |
| "A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity." | 6.90 | Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 6.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients." | 6.82 | Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). ( Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I, 2016) |
| "With the changed dosing schedule, this regimen was very well tolerated." | 6.82 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. ( Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016) |
| " We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer." | 6.79 | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. ( Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M, 2014) |
| "4%) and renal adverse events (all grades: CS, 18." | 6.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a." | 6.78 | Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013) |
| "The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen." | 6.78 | Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. ( Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013) |
| " Toxic effects were graded according to NCI-CTC version 3." | 6.78 | The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. ( Abdel-Latif, RM; Anter, AH, 2013) |
| "Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU." | 6.77 | A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012) |
| "Gemcitabine dose was fixed at 750 mg/m² over 75 min, capecitabine was given twice daily and escalated from 500 to 650 mg/m² at DL2 and docetaxel increased from 30 to 36 mg/m² at DL3." | 6.76 | A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M, 2011) |
| "Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)." | 6.75 | A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010) |
| "Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent." | 6.74 | A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 6.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 6.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "Vorinostat was given orally twice daily for 1 week every 2 weeks." | 6.74 | A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. ( Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009) |
| "Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks." | 6.74 | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009) |
| "The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented." | 6.74 | Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. ( Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J, 2009) |
| "Capecitabine was given at 725 mg/m(2) orally twice daily Monday through Friday concurrently with RT." | 6.73 | Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. ( Andrews, C; Bullarddunn, K; Fakih, MG; Levea, C; Park, YM; Pendyala, L; Puthillath, A; Rajput, A; Ross, ME; Rustum, YM; Toth, K; Yang, GY, 2008) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | 6.73 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 6.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI." | 6.73 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008) |
| "Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities." | 6.73 | Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008) |
| "Pancreatic cancer is chemo-radiosensitive." | 6.72 | Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. ( Bossard, N; Ducreux, M; Girard, N; Mornex, F; Partensky, C; Rouanet, P; Roy, P; Scoazec, JY; Seitz, JF; Smith, D; Valette, PJ; Ychou, M, 2006) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 6.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "Capecitabine was administered to single-patient cohorts at escalating doses of 1500, 2000, and 2500 mg/m2/day in two equally divided doses for 14 of 21 days, beginning on day 1." | 6.71 | A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. ( Fehn, K; Landau, L; Makower, D; Mani, S; Sparano, JA; Versola, M; Wadler, S; Wissel, P, 2003) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 6.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever." | 6.71 | A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005) |
| "Patients (n=38) with colorectal cancer received IFN-alpha 5 MU/m(2) SC on days 1-6; on days 2-6, LV 200 mg/m(2) IV was given with 5-FU at initial doses of 370-425 mg/m(2)/h." | 6.71 | A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. ( Ernst, A; Grem, JL; Grogan, L; Grollman, F; Ismail, AS; Kao, V; Kirsch, IR; Parr, A; Quinn, MG; Wright, MA, 2005) |
| "Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay." | 6.69 | Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998) |
| " We then tested the effect of GM-CSF given with a more toxic regimen of 5-FU/LV/IFN-alpha (IFN alpha-2a)." | 6.69 | A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. ( Allegra, C; Behan, K; Chen, A; Flemming, D; Grem, JL; Grollman, F; Haller, D; Hamilton, JM; Harold, N; Johnston, PG; Lash, A; Liewehr, D; Monahan, B; Morrison, G; Quinn, M; Shapiro, JD; Steinberg, SM; Takimoto, C; Vaughn, D, 1999) |
| "Acute disseminated intravascular coagulation (DIC) is a rare but severe complication of gastric adenocarcinoma." | 6.69 | Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation. ( Chang, FY; Chao, Y; Chi, KH; Hung, HC; King, KL; Li, CP; Teng, HC; Yen, SH, 2000) |
| "Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7." | 6.69 | Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000) |
| " The dosage was as follows: group A received FA i." | 6.68 | Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996) |
| "Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1." | 6.68 | Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996) |
| " The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity." | 6.68 | A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. ( Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997) |
| "Two hundred patients with advanced colorectal cancer received PVI 5-FU 300 mg/m2/day for a maximum of 24 weeks and were randomised to PVI 5-FU alone or PVI 5-FU + MMC 10 mg/m2 (7 mg/m2 from June 1995) 6 weekly for 4 courses." | 6.68 | A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. ( Cunningham, D; Iveson, T; Massey, A; Norman, A; Oates, J; Padhani, A; Popescu, R; Prendiville, J; Ross, P; Watson, M; Webb, A, 1997) |
| " We were not able to increase 5FU weekly dosage above 700 mg/m2 due to the occurrence of grade 3-4 gastrointestinal toxicity." | 6.67 | Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. ( Buccellato, C; Cipolla, C; Comande, S; Curto, G; Gebbia, N; Gebbia, V; Latteri, M; Testa, A; Valenza, R, 1994) |
| "To determine the toxicities and potential for dose escalation of intravenous (IV) bolus fluorouracil (5-FU) given with 500 mg/m2/d leucovorin (LCV) and granulocyte-macrophage colony-stimulating factor (GM-CSF)." | 6.67 | Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. ( Arbuck, SG; Balis, F; Chen, A; Grem, JL; Hamilton, JM; Jordan, E; McAtee, N; Murphy, RF; Setser, A; Steinberg, S, 1994) |
| "Nine patients with advanced breast cancer received CAF (cyclophosphamide at 100 mg/m2/day p." | 6.67 | Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer. ( Dutcher, JP; Liebes, L; Robert, NJ; Schwartz, EL; Sparano, JA; Wadler, S, 1993) |
| " in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)." | 6.67 | Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). ( Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991) |
| "Treatment with capecitabine lead to clinical amelioration." | 6.44 | Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. ( Bergonzi, P; Fasola, G; Minisini, AM; Pauletto, G, 2007) |
| "Irinotecan or CPT11 is a topoisomerase 1 inhibitor." | 6.40 | [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998) |
| "Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10." | 6.40 | [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998) |
| "The purpose of this study was to evaluate the effectiveness of several new approaches designed to enhance the activity of fluorouracil (5-FU) in the management of advanced colorectal cancer." | 6.16 | Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. ( Cullinan, SA; Everson, LK; Krook, JE; Laurie, JA; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1989) |
| "5-Fluorouracil (5-FU) is a chemotherapy drug that treats several cancers; however, it causes severe adverse effects and multidrug resistance." | 5.91 | Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase. ( Ganesan, K; Gong, G; Tsim, KWK; Xiong, Q; Zheng, Y, 2023) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | 5.91 | In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| "A total of 554 patients with pancreatic cancer of all stages were screened, and 73 patients treated with Gem-Nab and 48 patients treated with Gem-Ox in the palliative first-line setting were identified and included in this analysis." | 5.91 | Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis. ( Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L, 2023) |
| "Folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or modified FOLFIRINOX (mFFX) is the first-line standard of care for metastatic pancreatic adenocarcinoma; effective and safe treatment strategies are needed as survival remains poor." | 5.69 | Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. ( Bai, X; Chen, Y; Fu, Q; Gao, S; Guo, C; Huang, D; Li, X; Liang, T; Que, R; Shen, Y; Wu, J; Xiao, W; Xue, X; Zhang, M; Zhang, Q; Zhang, X, 2023) |
| "In this prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma, patients did not derive clinical benefit from fluorouracil-based chemotherapy, given there were no objective responses, no difference in OS when treatment was delayed 6 months, and no difference in the rate of tumor growth while receiving chemotherapy." | 5.69 | Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. ( Beaty, KA; Eng, C; Foo, WC; Fournier, K; Hornstein, N; Lano, E; Mansfield, P; Matamoros, A; Overman, MJ; Rafeeq, S; Raghav, KP; Scally, C; Scofield, LC; Shen, JP; Taggart, M; Tidwell, RS; Uppal, A; Yousef, AM; Zeineddine, FA; Zeineddine, MA, 2023) |
| " This open-label randomized phase II trial (2:1) investigated the efficacy of combining pazopanib with FLO (5-fluorouracil, oxaliplatin) vs FLO alone (internal control arm) as first-line treatment in patients with advanced adenocarcinoma of the stomach and gastroesophageal junction (GEJ)." | 5.51 | Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510. ( Al-Batran, SE; Bartels, P; Breithaupt, K; Gläser, D; Hinke, A; Högner, A; Homann, N; Lorenz, M; Malfertheiner, P; Siveke, JT; Stein, A; Tamm, I; Thuss-Patience, P; Vogel, A, 2022) |
| "The objective of this study was to evaluate the efficacy and safety of induction chemotherapy (ICT), GOFL (gemcitabine, oxaliplatin plus fluorouracil (5-FU)/leucovorin) versus modified FOLFIRINOX (irinotecan, oxaliplatin plus 5-FU/leucovorin), followed by concurrent chemoradiotherapy (CCRT) in locally advanced pancreatic adenocarcinoma (LAPC)." | 5.51 | A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. ( Ch'ang, HJ; Chang, PY; Chen, LT; Chiang, NJ; Chiu, YF; Li, CP; Lin, J; Lin, SJ; Shan, YS; Su, YY; Yang, SH, 2022) |
| "The perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin plus docetaxel (FLOT) was recommended by the Chinese Society of Clinical Oncology Guidelines for gastric cancer (2018 edition) for patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (class IIA)." | 5.51 | Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. ( Jia, SJ; Liu, Q; Song, LY; Wang, C; Zeng, H; Zeng, X, 2022) |
| "Most patients had disease progression as the best response to treatment (75." | 5.51 | Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019) |
| "A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver." | 5.51 | Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019) |
| "Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon." | 5.51 | Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019) |
| "Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects." | 5.48 | Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( Bejarano, I; Espino, J; Pariente, JA; Pariente, R; Rodríguez, AB, 2018) |
| "All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively." | 5.48 | Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018) |
| "Blood examinations showed disseminated intravascular coagulation(DIC)at the end of the second-line chemotherapy." | 5.46 | Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation. ( Kichiraku, T; Kotanagi, H; Kotanagi, K; Kudoh, K; Masuda, A; Miyazawa, H; Munakata, M; Muto, O; Ouchi, S; Sakata, Y; Satoyoshi, R; Sawada, T; Yamagata, K, 2017) |
| "Peritoneal metastasis is common in gastric cancer." | 5.46 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | 5.46 | Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| " Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen." | 5.42 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. ( André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015) |
| " The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil, folinic acid and oxaliplatin) in patients with metastatic colorectal cancer (mCRC)." | 5.41 | Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). ( Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021) |
| " A phase I and Ib study of modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) with ADX revealed encouraging antitumor activity in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma." | 5.41 | Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). ( Ajani, JA; Bendell, J; Bhargava, P; Bodoky, G; Cunningham, D; He, J; Shah, MA; Starodub, A; Thai, D; Wainberg, ZA; Yip, D, 2021) |
| "Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic." | 5.40 | Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014) |
| " In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179." | 5.40 | Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ( Bose, A; Elyagoby, A; Wong, TW, 2014) |
| "Capecitabine is an oral prodrug to 5-fluorouracil and is commonly used in the treatment of advanced breast, colon and stomach cancer." | 5.40 | Capecitabine induced colitis. ( Grin, A; Grover, SC; Maggo, G, 2014) |
| "Capecitabine (CA) is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU and is one of the agents used instead of FU in such cases." | 5.39 | Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? ( Isikli, L; Yoney, A, 2013) |
| "5-Fluorouracil (5-FU) has a significant antineoplastic activity and has been used for the management of various malignant neoplasms." | 5.38 | Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. ( Çağdaş, M; Çalık, AN; Çeliker, E; Güzelburç, Ö; Velibey, Y, 2012) |
| " Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy." | 5.38 | Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. ( Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012) |
| "The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status." | 5.37 | Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. ( Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M, 2011) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 5.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen." | 5.36 | Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010) |
| "Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity." | 5.36 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010) |
| "Colorectal cancer is one of the leading malignancies in the world." | 5.36 | Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010) |
| "Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen." | 5.36 | [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010) |
| "Capecitabine (Xeloda) is an oral 5-fluorouracil pro-drug used in the treatment of two of the commonest cancers: breast and colorectal." | 5.35 | Capecitabine-associated coronary vasospasm: a case report. ( Papadopoulos, CA; Wilson, H, 2008) |
| "The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy." | 5.34 | Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. ( Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ, 2020) |
| " We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma." | 5.34 | Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. ( Attwood, K; Boland, PM; Fountzilas, C; Gosain, R; Iyer, R; Khushalani, N; Mukherjee, S; Tan, W, 2020) |
| "Using data from the 4-year follow-up results of an open, randomised, phase II study, this patient-based cost-effectiveness analysis compares mFOLFIRI (irinotecan, 5-fluorouracil and leucovorin, the IRI arm) with mFOLFOX7 (oxaliplatin, 5-fluorouracil and leucovorin, the OXA arm) as first-line treatments in patients with locally advanced gastric adenocarcinoma (GC)." | 5.34 | Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study. ( Bi, F; Chen, H; Li, Q; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K, 2020) |
| "BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer." | 5.34 | Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020) |
| "Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)." | 5.34 | Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). ( Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H, 2020) |
| "Previously published work has demonstrated that combining gemcitabine with irreversible electroporation (IRE) results in increased drug delivery to pancreatic adenocarcinoma cells in vivo." | 5.34 | Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. ( Bhutiani, N; Chen, Y; Li, Y; Martin, RCG; Pandit, H; Pulliam, ZR; Shi, X; Tan, M; Yu, Y; Zheng, Q, 2020) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 5.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| "Familial Mediterranean Fever is a chronic hereditary disease which is relatively prevalent in the Middle East and is associated with recurrent episodes of serosal, synovial or cutaneous inflammations." | 5.34 | Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. ( Brenner, B; Purim, O; Sulkes, A, 2007) |
| "5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells." | 5.33 | Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005) |
| "Capecitabine is an oral prodrug to 5-fluorouracil (5-FU)." | 5.33 | Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. ( Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN, 2005) |
| "Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity." | 5.33 | Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006) |
| "These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer." | 5.32 | Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003) |
| "Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%." | 5.31 | A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. ( Cheeseman, SL; Chester, JD; Dent, JT; Joel, SP; Richards, FJ; Seymour, MT; Wilson, G, 2002) |
| "Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)." | 5.31 | Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| "We investigated the expression patterns of Ki67 and p53 in metastatic pancreatic adenocarcinomas and analyzed their relationship with disease progression-free survival (PFS) and overall survival (OS) in the overall study population and in patients treated with a gemcitabine-containing chemotherapy versus FOLFIRINOX chemotherapy." | 5.30 | Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis. ( Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A, 2019) |
| "5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for resectable gastric adenocarcinoma (RGA)." | 5.30 | Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). ( Bachet, JB; Cohen, R; Colin, D; de la Fouchardière, C; Ferraz, JM; Kim, S; Lefevre, M; Louvet, C; Meurisse, A; Svrcek, M; Tournigand, C; Watson, S, 2019) |
| "Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control." | 5.30 | Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019) |
| " The mean total dosage was 6." | 5.30 | [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 5.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "5-Fluorouracil was given every 3 weeks by 5-day continuous chronomodulated venous infusion (CMVI) with peak 5-FU delivery at 4 a." | 5.29 | Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Itzhaki, M; Lévi, F; Misset, JL; Soussan, S, 1993) |
| "Irinotecan and etoposide were combined using the (d x 5)2 i." | 5.29 | Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. ( Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L, 1996) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 5.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells." | 5.28 | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989) |
| "Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy." | 5.27 | Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. ( Dochy, E; Lakomy, R; Macarulla, T; Magherini, E; Moiseyenko, VM; Papamichael, D; Prausova, J; Ruff, P; Soussan-Lazard, K; Van Cutsem, E; van Hazel, GA, 2018) |
| "Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)." | 5.27 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018) |
| "FOLFOXIRI (Fluorouracil, folinate, oxaliplatin, and irinotecan) plus bevacizumab improved progression-free survival (PFS) and overall survival in patients with metastatic colorectal cancer (mCRC), compared with FOLFIRI (fluorouracil, folinate, and irinotecan) plus bevacizumab, but significantly increased the incidences of adverse events." | 5.27 | A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. ( Bando, H; Emi, Y; Iwamoto, S; Kagawa, Y; Kanazawa, A; Kato, T; Kotaka, M; Muro, K; Nakamura, M; Nakayama, G; Oki, E; Sakisaka, H; Taniguchi, H; Touyama, T; Tsuji, A; Yamaguchi, T; Yamanaka, T; Yamazaki, K; Yoshino, T, 2018) |
| " Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine." | 5.27 | 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. ( Allan, K; Azzabi, A; Boyd, KA; Bridgewater, J; Briggs, A; Cassidy, J; Cunningham, D; Dhadda, AS; Ellis, R; Essapen, S; Falk, S; Farrugia, D; Glimelius, B; Gollins, S; Harkin, A; Harrison, M; Haydon, A; Hickish, T; Hollander, NH; Iveson, TJ; Kerr, RS; McQueen, J; Medley, L; Olesen, RK; Paul, J; Propper, D; Raouf, S; Rees, C; Saunders, MP; Scudder, C; Tabernero, J; Wasan, HS; Waterston, A; Weaver, A; Webb, A; Wilson, C, 2018) |
| "Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA)." | 5.27 | FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. ( Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH, 2018) |
| "Patients with metastatic adenocarcinoma of the pancreas or biliary tract, previously untreated or having received 1 cytotoxic regimen for advanced disease, were treated with gemcitabine 1000 mg/m intravenously (IV) over 100 minutes, cisplatin 35 mg/m IV over 30 minutes, and 5-FU 2400 mg/m IV over 48 hours on day 1 of a 14-day cycle." | 5.27 | A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. ( Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM, 2018) |
| "Laboratory experiments using breast cancer cells in long-term tissue culture revealed that tamoxifen is cytotoxic, estrogen stimulates the growth of ER-positive cells and can rescue cells from tamoxifen's effect, and sequential MTX/5-FU is synergistic in rapidly growing breast cancer cells." | 5.27 | Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer. ( Allegra, JC, 1983) |
| "The prognosis of bile duct cancer is still poor." | 5.27 | [Intraductal chemotherapy of bile duct cancer with 5-fluorouracil]. ( Arnold, W; Bartels, E; Schmeck, HJ; Viets, CH, 1986) |
| " Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs." | 5.27 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985) |
| "5-Fluorouracil treatments resulted in a dose-dependent inhibition of tumor growth under the two examined schedules (five daily doses and three doses every 4 days) when administered either i." | 5.27 | 5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice. ( Frei, E; Goldin, A; Mantel, N; VanWinkle, TJ; Zimmerman, RJ, 1986) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 5.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity." | 5.26 | A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer. ( Allegra, JC; Bland, KI; Richman, SP; Wittliff, JL; Woodcock, TM, 1982) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 5.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| "0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy." | 5.24 | Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. ( Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y, 2017) |
| "The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma." | 5.24 | Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. ( Al-Batran, SE; Arnold, D; Bechstein, W; Berkhoff, S; Egger, M; Fischbach, W; Grimm, K; Hartmann, JT; Höffkes, HG; Hofheinz, RD; Homann, N; Illerhaus, G; Jäger, E; Koenigsmann, M; Kraus, TW; Luley, KB; Martens, UM; Mayer, F; Messmann, H; Moehler, M; Mönig, S; Pauligk, C; Post, S; Prasnikar, N; Probst, S; Ronellenfitsch, U; Schmalenberg, H; Stoehlmacher, J, 2017) |
| "Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone." | 5.24 | Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). ( Alberts, SR; Berg, DJ; Bjarnason, GA; Ciombor, K; Dragovich, T; Enzinger, PC; Fuchs, CS; Goldberg, RM; Gunderson, LL; Haller, DG; Ilson, D; Mamon, HJ; Mayer, RJ; Meyerhardt, J; Niedzwiecki, D; O'Reilly, E; Swanson, RS; Tepper, JE; Venook, AP; Willett, CG; Ye, X, 2017) |
| "Patients with untreated metastatic adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus received mFOLFOX6 (leucovorin 400 mg/m, fluorouracil 400 mg/m bolus and 2400 mg/m continuous infusion over 46 h, oxaliplatin 85 mg/m) and bevacizumab (10 mg/kg) every 2 weeks until disease progression or intolerance." | 5.24 | Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma. ( Deng, Y; Doddamane, I; Fischbach, NA; Hochster, HS; Karimeddini, D; Kortmansky, JS; Lacy, J; Li, J; Stein, S; Yao, X; Zhang, Y, 2017) |
| "The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP)." | 5.22 | A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site. ( Bae, WK; Choi, YH; Chung, IJ; Kang, HJ; Kim, BS; Lee, HR; Na, II; Shim, HJ; Shin, DY; Song, EK; Yang, SH; Yuh, YJ, 2016) |
| "The HE6C/05 trial randomized 441 patients with stage II-III colorectal adenocarcinoma to adjuvant XELOX (capecitabine, oxaliplatin) or modified FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin)." | 5.22 | Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. ( Cohen, SA; Fountzilas, G; Gkakou, C; Gourgioti, G; Grady, WM; Kalogeras, KT; Karavasilis, V; Kotoula, V; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Raptou, G; Wirtz, R; Wu, C; Yu, M, 2016) |
| "Based upon preclinical data showing synergy with mTOR inhibition and platinum chemotherapy, this study explores the safety and tolerability of combining everolimus with mFOLFOX6 for patients with metastatic gastroesophageal adenocarcinoma." | 5.22 | Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C, 2016) |
| "Docetaxel is active in esophagogastric junction (EGJ) adenocarcinoma, and DCF (docetaxel/cisplatin/5-fluorouracil) has shown good results in the neoadjuvant setting." | 5.22 | A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. ( Al-Fakeeh, A; Al-Ruzug, I; Alcindor, T; Doerksen, T; Ferri, L; Mulla, N; Santos, F, 2016) |
| "We sought to assess the benefit-risk balance of FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic adenocarcinoma." | 5.22 | An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. ( Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M, 2016) |
| "Patients more than 18 years of age with gastric adenocarcinoma were randomized 1:1 to capecitabine-cisplatin plus either bevacizumab or placebo." | 5.20 | Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). ( Bu, L; Chen, L; Dai, G; Li, J; Liu, Y; Pan, H; Piao, Y; Qin, S; Shen, L; Shu, Y; Wang, J; Wang, L; Xu, J; Xu, R; Yang, Z; Yu, S, 2015) |
| "The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint." | 5.20 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015) |
| " This study is to investigate the efficacy and tolerability of erlotinib plus capecitabine as first-line treatment in older Chinese patients (≥ 65 years) with lung adenocarcinoma." | 5.20 | Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. ( Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D, 2015) |
| "Chemoradioimmunotherapy of patients with pancreatic adenocarcinoma from the CapRI trial did not show any benefit of interferon-α in addition to a 5-fluorouracil (5FU)-based treatment." | 5.20 | Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. ( Bazhin, AV; Harig, S; Hartwig, W; Jäger, D; Karakhanova, S; Mosl, B; Ryschich, E; Schmidt, J; Werner, J, 2015) |
| "The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed." | 5.20 | Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015) |
| "We performed a multicenter phase II study of sorafenib 200 mg orally twice daily along with oxaliplatin 85 mg/m(2) IV on days 1 and 15, followed by capecitabine 2250 mg/m(2) orally every 8 h for six doses starting on days 1 and 15 of a 28-day cycle in patients who had no more than one previous chemotherapy regimen for their pancreatic adenocarcinoma." | 5.20 | A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. ( Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM, 2015) |
| " This study was to compare the efficacy of TME with versus without preoperative concurrent chemoradiotherapy (CCRT) involving XELOX regimen (oxaliplatin plus capecitabine) in Chinese patients with stages II and III mid/low rectal adenocarcinoma." | 5.20 | Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial. ( Chen, G; Ding, PR; Fan, WH; Gao, YH; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zeng, ZF, 2015) |
| "In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3-4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m(2) on days 1-5 and 29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m(2) on days 1-5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m(2) on days 1-14 and 22-35) and oxaliplatin (50 mg/m(2) on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m(2) on days 1 and 15), leucovorin (400 mg/m(2) on days 1 and 15), and infusional fluorouracil (2400 mg/m(2) on days 1-2 and 15-16)." | 5.20 | Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. ( Arnold, D; Fietkau, R; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Hoffmanns, H; Hofheinz, RD; Hohenberger, W; Hothorn, T; Lang-Welzenbach, M; Liersch, T; Lindemann, F; Raab, HR; Rödel, C; Sauer, R; Schlenska-Lange, A; Staib, L; Ströbel, P; Wilhelm, M; Wittekind, C; Wolff, HA, 2015) |
| "This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 5.20 | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015) |
| "The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy." | 5.20 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| "The aim of the study was to compare efficacy and safety of first-line palliative chemotherapy with (EOX) epirubicin/oxaliplatin/capecitabine and (mDCF) docetaxel/cisplatin/5FU/leucovorin regimens for untreated advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma." | 5.20 | Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( Budzynski, A; Fijorek, K; Konopka, K; Krzemieniecki, K; Lazar, A; Matlok, M; Ochenduszko, S; Pedziwiatr, M; Puskulluoglu, M; Sinczak-Kuta, A; Urbanczyk, K, 2015) |
| "Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is associated with significant toxicity." | 5.20 | Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. ( Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB, 2015) |
| "In this phase I study, we sought to determine the feasibility and tolerability of neoadjuvant short course radiotherapy (SC-CRT) delivered with photon RT with concurrent capecitabine for resectable pancreatic adenocarcinoma." | 5.19 | Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. ( Ancukiewicz, M; Blaszkowsky, LS; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Lillemoe, KD; Mamon, HJ; Napolitano, BN; Ryan, DP; Swanson, RS; Tseng, YD; Wo, JY, 2014) |
| "Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection." | 5.19 | Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. ( Anthoney, A; Bassi, C; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Garner, E; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Jackson, R; Lacaine, F; Lamb, RF; Mackey, JR; Mayerle, J; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Scarpa, A; Shannon, J; Tebbutt, NC; Valle, JW, 2014) |
| "The purpose of this phase I study was to determine the safety, toxicity, maximum tolerated dose, and pharmacokinetics of capecitabine when administered concurrently with radiotherapy in patients with localised, inoperable pancreatic adenocarcinoma." | 5.19 | A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. ( Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L, 2014) |
| "We analyzed data from patients with stage III colon adenocarcinoma randomly assigned to groups given fluorouracil and leucovorin or IFL after surgery, from April 1999 through April 2001." | 5.19 | CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. ( Bertagnolli, MM; Dzieciatkowski, S; Emond, MJ; Foster, NR; Goldberg, RM; Grady, WM; Lao, VV; Luo, Y; Maizels, N; Monnat, RJ; Nam, E; Niedzwiecki, D; Renfro, LA; Saltz, LB; Shiovitz, S; Venook, A; Warren, RS, 2014) |
| "We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC)." | 5.19 | Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. ( Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014) |
| "This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma." | 5.19 | Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. ( Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N, 2014) |
| "To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma." | 5.19 | Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd ( André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M, 2014) |
| "The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs." | 5.19 | Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014) |
| " We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas." | 5.17 | A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. ( Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY, 2013) |
| "This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)." | 5.17 | Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013) |
| "The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer." | 5.17 | Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. ( Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M, 2013) |
| "To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)." | 5.17 | Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013) |
| "The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer." | 5.17 | FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013) |
| "To determine the maximum tolerated radiation dose (MTD) of an integrated boost to the tumor subvolume infiltrating vessels, delivered simultaneously with radical dose to the whole tumor and concomitant capecitabine in patients with pretreated advanced pancreatic adenocarcinoma." | 5.17 | Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. ( Balzano, G; Bettinardi, V; Calandrino, R; Castoldi, R; Cattaneo, GM; Cereda, S; Di Muzio, N; Gianolli, L; Gusmini, S; Longobardi, B; Passoni, P; Reni, M; Slim, N; Staudacher, C, 2013) |
| "To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas." | 5.17 | Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. ( Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013) |
| "Patients with localized, operable gastric or gastroesophageal adenocarcinoma received two cycles of induction chemotherapy of fluorouracil, docetaxel, and cisplatin (TPF) followed by 45 Gy of radiation and concurrent fluorouracil plus docetaxel then surgery for nonmetastatic patients." | 5.17 | Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome. ( Abd-Allah, D; El-Shazly, W; Khedr, G; Rostom, Y; Zaghloul, H, 2013) |
| "Patients with metastatic gastric, gastro-oesophageal junction, or distal oesophageal adenocarcinoma were randomized 1:1:1 to CX (cisplatin 80 mg/m(2) IV Q3W; capecitabine 1000 mg/m(2) P." | 5.17 | Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ( Adewoye, AH; Bampton, CL; Bass, MB; Bodoky, G; Eatock, MM; Nanayakkara, N; Strickland, AH; Sun, YN; Swieboda-Sadlej, A; Tebbutt, NC; Valladares-Ayerbes, M; Van Cutsem, E; Zhong, ZD, 2013) |
| "Ninety-nine consecutive patients with cT2-4N0-2M0 distal rectal adenocarcinoma were enrolled in a clinical trial (NCT00254683) and underwent baseline PET/CT followed by 54 Gy and 5-fluorouracil-based CRT." | 5.17 | Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation. ( Bailão Aguilar, P; Buchpiguel, CA; Gama-Rodrigues, J; Habr-Gama, A; Lynn, P; Nahas, SC; Ono, CR; Perez, RO; Proscurshim, I; São Julião, GP, 2013) |
| "Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions)." | 5.17 | Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. ( Anselmi, E; Ardizzoni, A; Bui, S; Camisa, R; Cascinu, S; Crafa, P; Dell'abate, P; Fontana, E; Galdy, S; Leonardi, F; Losardo, PL; Negri, FV; Pucci, F; Roncoroni, L, 2013) |
| "To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)." | 5.16 | Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012) |
| "We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy." | 5.16 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "The aims of this study is to determine the maximum tolerated dose of capecitabine and oxaliplatin (CAPOX) delivered concurrent with radiation therapy (RT) in the treatment of locally advanced pancreatic adenocarcinoma and to retrospectively compare outcomes with this regimen to concurrent 5-fluorouracil or capecitabine with RT (5FU-RT) or concurrent gemcitabine-based chemotherapy with RT (GEM-RT)." | 5.16 | Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. ( Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J, 2012) |
| "PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine." | 5.16 | A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012) |
| " From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily." | 5.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "Patients with T2-T4/N+ rectal adenocarcinoma were randomly assigned to arm A-preoperative CRT with 5-fluorouracil (5-FU) continuous infusion followed by surgery-or arm B-induction oxaliplatin, folinic acid and 5-FU followed by CRT and surgery." | 5.16 | Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. ( Delaunoit, T; Demetter, P; Demols, A; Franchimont, D; Hendlisz, A; Maréchal, R; Peeters, M; Polus, M; Van de Stadt, J; Van Houtte, P; Van Laethem, JL; Verset, G; Vos, B, 2012) |
| "Between October 2006 and December 2009, 36 patients with non-metastatic rectal adenocarcinoma were treated with chemoradiotherapy of irinotecan (50 mg/m(2) weekly), 5-fluorouracil (250 mg/m(2) for 5 days/week) and pelvic radiation (45 Gy/1." | 5.16 | Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2012) |
| "The AIO KRK-0306 trial compares the efficacy of infusional 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)." | 5.16 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. ( Decker, T; Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Heintges, T; Jäger, E; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Scheithauer, W; Stintzing, S; Stoll, C; Vehling-Kaiser, U, 2012) |
| "Therapy-naive patients, age 18-75 years, Karnofsky Performance Status (KPS)>60, gross total resection of stage IB-III pancreatic adenocarcinoma, stratified for center and surgical margins, were randomly assigned to receive either gemcitabine 1 g/m2 weekly on days 1, 8, and 15 (arm A) or the PEFG regimen (cisplatin and epirubicin 40 mg/m2, day 1; gemcitabine 600 mg/m2, days 1, 8; 5-fluorouracil 200 mg/m2 daily, days 1-28) (arm B)." | 5.16 | Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. ( Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A, 2012) |
| " This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients." | 5.16 | A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. ( Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F, 2012) |
| "This study aimed at assessing the efficacy and safety of biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX regimen) in patients with advanced small bowel adenocarcinoma (SBA)." | 5.16 | A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. ( Feng, M; Liu, YW; Qiu, F; Xiang, XJ; Xiong, JP; Yan, J; Yu, F; Zhan, ZY; Zhang, L; Zhao, JG, 2012) |
| "Capecitabine produces an objective response rate of up to 25% in anthracycline-treated, taxane-resistant metastatic breast cancer (MBC)." | 5.16 | A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). ( Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M, 2012) |
| "To determine the safety and efficacy of neoadjuvant gemcitabine/capecitabine followed by surgery for the treatment of locally advanced pancreatic adenocarcinoma (LAPC)." | 5.16 | Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. ( Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH, 2012) |
| "This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma." | 5.16 | Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. ( Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC, 2012) |
| " Given preclinical evidence of synergy when a fluoropyrimidine is added to gemcitabine plus a taxane in a sequence-specific schedule, we conducted a phase I study to evaluate the combination of nab-paclitaxel, gemcitabine, and capecitabine administered biweekly in patients with metastatic pancreatic adenocarcinoma." | 5.16 | A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. ( Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG, 2012) |
| "To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas." | 5.15 | Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. ( Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L, 2011) |
| "Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3." | 5.15 | Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese patients with unresectable advanced or metastatic colorectal cancer." | 5.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. ( Emi, Y; Fujita, F; Hasegawa, H; Inomata, M; Kakeji, Y; Kitazono, M; Maehara, Y; Morikita, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Samura, H; Shirabe, K; Shirouzu, K; Tanaka, T; Tokunaga, S; Yamamoto, M, 2011) |
| "The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 5.15 | Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K, 2011) |
| "Eighty patients with gastric adenocarcinoma after curative gastrectomy were randomized to receive a 2-h infusion of leucovorin (LV; 200mg/m(2)/d) followed by a 5-fluorouracil (5-FU) bolus (400mg/m(2)/d) and 22-h infusion (600 mg/m(2)/d) for 2 consecutive days every 2 weeks, either alone or together with oxaliplatin 85 mg/m(2) as a 2-h infusion on day 1 (FOLFOX4 regimen or LV5Fu2 regimen)." | 5.15 | Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. ( Ba, MC; Cui, SZ; Shi, HJ; Tang, YQ; Zhang, XL, 2011) |
| "The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial." | 5.15 | Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. ( Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA, 2011) |
| "This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer." | 5.15 | A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. ( Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS, 2011) |
| "An ancillary phase II study was conducted to study interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) in metastatic colorectal cancer patients cotreated with irinotecan and 5-fluorouracil." | 5.15 | Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ( Azzopardi, N; Boisdron-Celle, M; Gamelin, E; Gouilleux-Gruart, V; Lecomte, T; Morel, A; Paintaud, G; Piller, F; Ternant, D; Vignault-Desvignes, C; Watier, H, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer." | 5.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011) |
| "Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1." | 5.15 | S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. ( Benedetti, JK; Billingsley, KG; Blanke, CD; Bohanes, PO; Corless, CL; Danenberg, KD; Gold, PJ; Goldman, BH; Iqbal, S; Leichman, LP; Lenz, HJ; Thomas, CR, 2011) |
| "In this prospective pilot study, we assessed the efficacy and safety of the FOLFIRI regimen (irinotecan 180 mg/m², leucovorin 200 mg/m² d1 followed by bolus 400 mg/m² 5-fluorouracil (5-FU) and by a 46-h 2400 mg/m² 5-FU infusion, every 2 weeks) in patients with advanced esophageal or junctional adenocarcinoma." | 5.15 | FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study. ( Bourgeois, V; Ferte, C; Hebbar, M; Ladrat, L; Lindet, C; Mariette, C; Peugniez, C; Romano, O; Triboulet, JP, 2011) |
| "Oxaliplatin, irinotecan, and capecitabine given in a novel, weekly schedule does induce responses in advanced gastric and GEJ adenocarcinoma." | 5.14 | A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. ( Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I, 2009) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 5.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward." | 5.14 | An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009) |
| "This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma." | 5.14 | Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. ( Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L, 2009) |
| "A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule." | 5.14 | Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. ( Bellone, G; Bertetto, O; Chiappino, I; Ciuffreda, L; Giacobino, A; Milanesi, E; Novarino, A; Rahimi, F; Satolli, MA, 2009) |
| "This Simon 2-stage phase II trial was designed to document antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer (CRC)." | 5.14 | Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. ( Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C, 2009) |
| "The feasibility, safety, and efficacy of planned sequential administration of docetaxel and irinotecan with 5-fluorouracil (5-FU)/leucovorin in advanced upper gastrointestinal adenocarcinoma (UGIA) are unknown." | 5.14 | An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. ( Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D, 2010) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 5.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for colorectal cancer." | 5.14 | Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. ( Airoldi, M; Cattel, L; Drescher, A; Jaehde, U; Milla, P; Weber, G, 2009) |
| "This phase II trial investigated the efficacy and safety of oxaliplatin (O), 5-fluorouracil (5-FU), and folinic acid (FA) (OFF) as second-line treatment for patients with metastatic pancreatic adenocarcinoma after failure of first-line gemcitabine treatment." | 5.14 | Second-line therapy in refractory pancreatic cancer. results of a phase II study. ( Dörken, B; Hilbig, A; Oettle, H; Pelzer, U; Riess, H; Roll, L; Stieler, J, 2009) |
| "Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer." | 5.14 | Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009) |
| "Treatment-naive patients with stage III non-resectable pancreatic adenocarcinoma were treated with PEFG/PEXG (cisplatin, epirubicin, 5-fluorouracil (F)/capecitabine (X), gemcitabine) or PDXG (docetaxel substituting epirubicin) regimen for 6 months followed by radiotherapy (50-60 Gy) with concurrent F or X or G." | 5.14 | Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. ( Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A, 2009) |
| "A randomized multicenter phase III study was conducted to compare the sequential docetaxel followed by epirubicin/cyclophosphamide combination with that of FEC regimen as adjuvant chemotherapy in women with axillary node-positive early breast cancer." | 5.14 | FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). ( Adamou, A; Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karvounis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N, 2010) |
| "A subgroup analysis of oxaliplatin (LOHP)+irinotecan (CPT-11)+5-fluorouracil (5FU) and leucovorin (LV) (FOLFOXIRI regimen) versus irinotecan+5FU/LV (FOLFIRI regimen) as first-line treatment of patients >65 years old with metastatic colorectal cancer is presented." | 5.14 | Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). ( Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karampeazis, A; Kouroussis, Ch; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N, 2010) |
| "Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression." | 5.14 | S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010) |
| "This study compared chemotherapy discontinuation with maintenance therapy with leucovorin and fluorouracil after six cycles of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy in the first-line treatment of metastatic colorectal cancer." | 5.14 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. ( Afchain, P; André, T; Artru, P; Bennamoun, M; Carola, E; Chibaudel, B; Colin, P; de Gramont, A; Dupuis, O; Flesch, M; Larsen, AK; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Mineur, L; Tournigand, C, 2009) |
| " We enrolled patients aged 20-75 years or younger, who had histologically proven gastric adenocarcinoma, and randomly assigned them by minimisation to receive either: a continuous infusion of fluorouracil (800 mg/m(2) per day, on days 1-5) every 4 weeks (n=234); intravenous irinotecan (70 mg/m(2), on days 1 and 15) and cisplatin (80 mg/m(2), on day 1) every 4 weeks (n=236); or oral S-1 (40 mg/m(2), twice a day, on days 1-28) every 6 weeks (n=234)." | 5.14 | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. ( Boku, N; Doi, T; Fukuda, H; Koizumi, W; Nasu, J; Ohtsu, A; Saito, H; Sawaki, A; Shirao, K; Takiuchi, H; Yamaguchi, K; Yamamoto, S, 2009) |
| "A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic colorectal cancer." | 5.14 | Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Llédo, G; Rebischung, C; Ychou, M, 2010) |
| "We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concurrent tamoxifen (CAFT)." | 5.14 | Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. ( Abeloff, MD; Albain, KS; Barlow, WE; Burton, GV; Cobau, CD; Farrar, WB; Green, SJ; Henderson, IC; Ingle, JN; Ketchel, SJ; Levine, EG; Lew, D; Lichter, AS; Livingston, RB; Martino, S; Muss, HB; Osborne, CK; Pritchard, KI; Ravdin, PM; Schneider, DJ, 2009) |
| "The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer." | 5.14 | Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010) |
| "We compared 1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment; n=117) with no trastuzumab (118), in women with HER2-positive locally advanced or inflammatory breast cancer treated with a neoadjuvant chemotherapy regimen consisting of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and fluorouracil." | 5.14 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER ( Baronio, R; Barton, C; Baselga, J; Bozhok, A; Byakhow, M; Ciruelos, E; Climent, MA; Eiermann, W; Feyereislova, A; Gianni, L; Lichinitser, M; Lluch, A; Manikhas, A; Mansutti, M; Ojeda, B; Semiglazov, V; Tjulandin, S; Valagussa, P; Vazquez, F; Zambetti, M, 2010) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 5.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "The Danish Breast Cancer Cooperative Group (DBCG) 77B trial examined the relative efficacy of levamisole, single-agent oral cyclophosphamide, and the classic combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) against no adjuvant systemic therapy in high-risk breast cancer patients." | 5.14 | Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. ( Andersen, J; Andersson, M; Ejlertsen, B; Jensen, MB; Kamby, C; Knoop, AS; Mouridsen, HT, 2010) |
| "Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma." | 5.14 | A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. ( Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY, 2010) |
| "To assess the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the treatment of advanced gastric adenocarcinoma." | 5.14 | [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial]. ( Liu, Y; Ma, T; Ye, ZB; Zhang, J; Zhu, ZG, 2010) |
| "Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency." | 5.14 | A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. ( Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F, 2010) |
| "This phase II trial evaluated the efficacy and safety of cetuximab combined with FOLFOX6 (leucovorin [LV] 5-fluorouracil [5-FU]/oxaliplatin) in the first-line treatment of patients with advanced or metastatic colorectal cancer." | 5.14 | A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. ( Badarinath, S; Boccia, RV; Cosgriff, TM; Dakhil, SR; Headley, DL, 2010) |
| "The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma." | 5.14 | A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. ( Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H, 2010) |
| "Chemotherapy-naive patients with locally advanced or metastatic, histologically proven adenocarcinoma of the pancreas were treated with a 21-day regimen of gemcitabine [1000 mg/m² day (d) 1, d8], escalating doses of oxaliplatin (80-130 mg/m² d1) and capecitabine (650-800 mg/m² b." | 5.14 | Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. ( Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R, 2010) |
| "In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer." | 5.14 | Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010) |
| "Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles." | 5.14 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010) |
| "The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients with metastatic colorectal cancer." | 5.14 | Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. ( Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E, 2010) |
| "Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer." | 5.14 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010) |
| "Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma." | 5.14 | Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). ( Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M, 2010) |
| "This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy." | 5.14 | Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. ( Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N, 2010) |
| "601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy." | 5.14 | Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010) |
| "Cyclophosphamide/methotrexate/fluorouracil (CMF) is a proven adjuvant option for patients with early-stage breast cancer." | 5.14 | Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. ( Atieh-Graham, D; D'Andrea, G; Drullinsky, P; Fornier, MN; Gilewski, T; Hudis, C; Lake, D; Mills, N; Norton, L; Patel, H; Patil, S; Seidman, AD; Sklarin, N; Sugarman, SM; Traina, T; Troso-Sandoval, T; Wasserheit-Lieblich, C; Yuan, J, 2010) |
| " This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract." | 5.13 | Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ( Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS, 2008) |
| "Consenting operable patients with stage II or III adenocarcinoma of the rectum received capecitabine (825 mg/m2 PO BID, 5 days/wk x 5 weeks) and SIB-IMRT delivering 55 Gy (2." | 5.13 | Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. ( Ballonoff, A; Kane, M; Kavanagh, B; McCarter, M; Nash, R; Pearlman, N; Raben, D; Schefter, TE; Shah, RJ, 2008) |
| "The results indicate that the modified CAPOX regimen is safe and effective as salvage treatment in patients with advanced colorectal cancer who were previously treated with irinotecan-based frontline therapy." | 5.13 | Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. ( Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N, 2008) |
| "We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction." | 5.13 | Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. ( Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J, 2008) |
| "Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks." | 5.13 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008) |
| "To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer." | 5.13 | Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008) |
| "We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer." | 5.13 | A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008) |
| "This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen." | 5.13 | Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008) |
| "XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)." | 5.13 | Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008) |
| "Patients with localized, potentially resectable pancreatic adenocarcinoma were treated with 50 Gy irradiation combined with 5-fluorouracil by continuous infusion (300 mg ." | 5.13 | Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial. ( Le Scodan, R; Mercier, C; Mornex, F; Partensky, C; Roy, P; Scoazec, JY; Valette, PJ; Ychou, M, 2008) |
| "Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin." | 5.13 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008) |
| " A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer." | 5.13 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008) |
| "We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in terms of pathological (pCR) and objective responses of four courses of cisplatin containing chemotherapy (ECF, epirubicin, cisplatin, and fluorouracil as continuous infusion) followed by three courses of weekly paclitaxel." | 5.13 | Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. ( Balduzzi, A; Bottiglieri, L; Colleoni, M; Ghisini, R; Giovanardi, F; Goldhirsch, A; Luini, A; Orlando, L; Rocca, A; Torrisi, R; Veronesi, P; Viale, G, 2008) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 5.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "Patients with lymph node-positive breast cancer (n = 2887) were randomly assigned to one of four treatments: 1) sequential control (four cycles of doxorubicin at 75 mg/m2, followed by three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]); 2) concurrent control (four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF); 3) sequential docetaxel (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF); 4) concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2, followed by three cycles of CMF)." | 5.13 | Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. ( Andersson, M; Balil, A; Bendahmane, B; Buyse, M; Castiglione-Gertsch, M; Crown, J; Di Leo, A; Dolci, S; Francis, P; Gelber, RD; Goldhirsch, A; Gutiérrez, J; Jakesz, R; Jamin, S; Lang, I; Nordenskjöld, B; Piccart-Gebhart, M; van Hazel, G; Vorobiof, D, 2008) |
| "This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas." | 5.13 | Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008) |
| " Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil and radiation therapy with or without (32)P, followed by gemcitabine." | 5.13 | 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial. ( Al-Saadi, S; Black, T; Bloomston, M; Bowers, C; Briggs, J; Carey, L; Carroll, R; Chervenick, P; Chheda, H; Cooper, J; Goldin, S; Grundy, S; Kudryk, B; Luzardo, G; Rosemurgy, A; Zervos, E; Zwiebel, B, 2008) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 5.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC)." | 5.13 | Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. ( Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M, 2008) |
| "Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil." | 5.13 | Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. ( Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA, 2008) |
| "Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP)." | 5.13 | Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Bokemeyer, C; Derigs, HG; Grossmann, J; Hartmann, JT; Hegewisch-Becker, S; Hofheinz, R; Hollerbach, S; Homann, N; Jäger, E; Knuth, A; Pauligk, C; Probst, S; Rethwisch, V; Schmalenberg, H; Schuch, G; Seipelt, G; Stoehlmacher, J; Wilhelm, G, 2008) |
| "This multicentre phase II study evaluated the efficacy and safety of preoperative capecitabine plus oxaliplatin and radiotherapy (RT) in patients with locally advanced rectal cancer (T3/T4 rectal adenocarcinoma with or without nodal involvement)." | 5.13 | Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. ( Bieri, G; Burkhard, R; Heitzmann, F; Hess, V; Koeberle, D; Neuweiler, J; Ruhstaller, T; Rust, C; Terraciano, L; Toepfer, M; von Moos, R; Winterhalder, R, 2008) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 5.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| "The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established." | 5.12 | Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ( Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D, 2006) |
| "Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia." | 5.12 | Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM, 2006) |
| "Oxaliplatin and 5-fluorouracil (5-FU) act synergistically in colorectal cancer." | 5.12 | Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ( Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006) |
| "Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction." | 5.12 | Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006) |
| "To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC)." | 5.12 | FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog ( Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N, 2006) |
| "To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer." | 5.12 | Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006) |
| "We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma." | 5.12 | A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. ( Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C, 2006) |
| "A randomized phase II study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated advanced pancreatic adenocarcinoma has been conducted." | 5.12 | Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. ( Boige, V; Bouché, O; Breau, JL; Bugat, R; Cvitkovic, E; Ducreux, M; Etienne, PL; Mitry, E; Morvan, F; Ould-Kaci, M; Rougier, P; Seitz, JF; Tigaud, JM, 2006) |
| "The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in patients after curative resection for pancreatic adenocarcinoma." | 5.12 | Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. ( Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T, 2006) |
| "The purpose of this study was to evaluate the antitumor activity and toxicity of fixed sequences of capecitabine/oxaliplatin followed by capecitabine/irinotecan in patients with previously untreated metastatic colorectal cancer." | 5.12 | Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. ( Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F, 2006) |
| "Oxaliplatin (OXA), raltitrexed (RTX), 5-fluorouracil (FU) and folinic acid (FA) have shown activity in metastatic colorectal cancer, radioenhancing effect and synergism when combined." | 5.12 | Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. ( Avallone, A; Budillon, A; Cascini, LG; Comella, P; Delrio, P; Guida, C; Lastoria, S; Marone, P; Morrica, B; Parisi, V; Petrillo, A; Tatangelo, F, 2006) |
| "The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer." | 5.12 | Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. ( Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F, 2006) |
| "To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer." | 5.12 | [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006) |
| "PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial." | 5.12 | Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. ( Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A, 2007) |
| "A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma." | 5.12 | Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. ( Allum, WH; Chua, YJ; Cunningham, D; Falk, SJ; Iveson, TJ; Langley, RE; Lofts, FJ; Nicolson, M; Scarffe, JH; Smith, DB; Stenning, SP; Thompson, JN; Van de Velde, CJ; Verma, M; Weeden, S, 2006) |
| "From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401." | 5.12 | Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. ( Abbruzzese, JL; Cobb, PW; Doroshow, JH; Issell, BF; Macdonald, JS; McCoy, S; Patel, T; Yost, KJ, 2006) |
| "A phase III trial suggested that a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen might improve the outcome compared to gemcitabine in advanced pancreatic adenocarcinoma." | 5.12 | Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. ( Bonetto, E; Bordonaro, R; Cereda, S; Cordio, S; Di Carlo, V; Galli, L; Johnson, CD; Milandri, C; Passoni, P; Reni, M; Spreafico, A; Staudacher, C, 2006) |
| "In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer." | 5.12 | Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. ( Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX, 2006) |
| "Blood samples from 125 patients with primary adenocarcinoma of the mid-low rectum who received 5-fluorouracil-based chemotherapy and external beam radiotherapy (median dose 48." | 5.12 | A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. ( Agostini, M; Ambrosi, A; Friso, ML; Leon, A; Lise, M; Lisi, V; Nitti, D; Pasetto, LM; Pucciarelli, S; Terrazzino, S, 2006) |
| "Radiochemotherapy using gemcitabine followed by gemcitabine and capecitabine is an active regimen with manageable toxicity after resection of extrahepatic bile duct cancer but has significant toxicity in unresectable disease." | 5.12 | Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. ( Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H, 2006) |
| "Patients with squamous cell carcinoma or adenocarcinoma of the esophagus initially received capecitabine, carboplatin, and paclitaxel with RT (1." | 5.12 | A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. ( Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D, 2007) |
| "Patients with previously untreated metastatic colorectal cancer were enrolled in a phase II trial of infusional 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), bevacizumab and erlotinib." | 5.12 | Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. ( Battu, S; Bhargava, P; Blaszkowsky, L; Earle, CC; Enzinger, P; Fuchs, CS; Lawrence, C; Mayer, RJ; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX, 2007) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 5.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "After recovery from surgery for adenocarcinoma of the gastroesophageal junction or stomach, all patients were treated with capecitabine monotherapy, 1,000 mg/m2 twice daily for 2 weeks." | 5.12 | A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. ( Bartelink, H; Boot, H; Cats, A; Crosby, TD; Dubbelman, R; Jansen, EP; Saunders, MP; Verheij, M, 2007) |
| "The objective was to evaluate the efficacy and toxicity of leucovorin plus 5-fluorouracil combined with oxaliplatin (modified FOLFOX regimen) every 2 weeks on previously untreated advanced colorectal cancer patients in the Chinese population." | 5.12 | A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. ( Qiu, F; Tang, XM; Tao, QS; Xiang, XJ; Xiong, JP; Xu, J; Yu, F; Zhang, L; Zhong, LX, 2007) |
| "Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50." | 5.12 | A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. ( Ben-Josef, E; Desai, SP; El-Rayes, BF; Greenson, JK; Griffith, KA; Huang, EH; Knol, JA; McGinn, CJ; Philip, PA; Zalupski, MM, 2007) |
| "To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population." | 5.12 | A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. ( Bao, HY; Fang, WJ; Huang, S; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC, 2007) |
| "This phase III study compared the safety and efficacy of the following three different irinotecan-containing regimens in the first-line treatment of metastatic colorectal cancer: irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (mIFL), and irinotecan plus oral capecitabine (CapeIRI)." | 5.12 | Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. ( Barrueco, J; Fuchs, CS; Ganju, V; Jeffery, M; Marshall, J; Mitchell, E; Richards, D; Schulz, J; Soufi-Mahjoubi, R; Wang, B; Wierzbicki, R, 2007) |
| "Chinese patients with curatively resected Stage III colon adenocarcinoma, who received adjuvant capecitabine, were entered into a prospective database." | 5.12 | Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. ( Chau, KK; Choy, TS; Fu, YT; Law, CC; So, PF; Wong, KH, 2007) |
| "To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin." | 5.12 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007) |
| "The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU)/leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma." | 5.12 | Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. ( Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G, 2007) |
| "This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer." | 5.12 | A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. ( Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C, 2007) |
| "Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin." | 5.11 | A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004) |
| " In all, 18 patients with peritoneal and/or local metastases from colorectal adenocarcinoma underwent debulking surgery followed by 5-fluorouracil (5-FU) 550 mg m(-2) day(-1) i." | 5.11 | Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. ( Berglund, A; Glimelius, B; Graf, W; Hansson, J; Mahteme, H; Nygren, P; Påhlman, L, 2004) |
| "Patients with proven adenocarcinoma of the stomach were randomised to receive four courses of chemotherapy using 5-Fluorouracil, doxorubicin and methotrexate (FAMTX) prior to surgery or to undergo surgery alone." | 5.11 | Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. ( de Vries, JE; Hartgrink, HH; Kranenbarg, EK; Putter, H; Songun, I; Tesselaar, ME; van de Velde, CJ; van der Bijl, J; van Krieken, JH; Wils, JA, 2004) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 5.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 5.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 5.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
| "The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma." | 5.11 | First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004) |
| "The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 5.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| "To determine if the preoperative administration of tegafur and uracil (UFT) to patients with lung adenocarcinoma could induce apoptosis." | 5.11 | Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). ( Futagawa, T; Izumi, H; Konno, H; Miyamoto, H; Morio, A; Oh, T; Yamazaki, A, 2004) |
| "Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)." | 5.11 | Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004) |
| "To determine the efficacy and safety of a biweekly regimen of leucovorin (LV) plus fluorouracil (FU) alone or in combination with cisplatin or irinotecan in patients with previously untreated metastatic gastric adenocarcinoma and to select the best arm for a phase III study." | 5.11 | Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie ( Arsène, D; Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Etienne, PL; Giovannini, M; Guérin-Meyer, V; Kaminsky, MC; Lledo, G; Milan, C; Mitry, E; Paitel, JF; Raoul, JL; Rougier, P; Seitz, JF, 2004) |
| "A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer." | 5.11 | Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004) |
| " The authors evaluated 6-month survival, response, and toxicity associated with a combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA)." | 5.11 | Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. ( Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE, 2005) |
| "The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC)." | 5.11 | Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. ( Benson, A; Brandt, DS; Burger, B; Garay, CA; Gupta, S; Gurtler, J; Hallman, D; Hochster, H; Kemeny, N; Kennedy, P; Polikoff, J; Shumaker, G; Wertheim, M, 2004) |
| "The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC)." | 5.11 | Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. ( Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A, 2005) |
| "Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)." | 5.11 | Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. ( Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC, 2005) |
| "Gemcitabine is considered the gold standard treatment for unresectable pancreatic adenocarcinoma." | 5.11 | Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. ( Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D, 2004) |
| "We conducted a phase II study to assess the efficacy and tolerability of irinotecan and cisplatin as salvage chemotherapy in patients with advanced gastric adenocarcinoma, progressing after both 5-fluorouracil (5-FU)- and taxane-containing regimen." | 5.11 | Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. ( Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB, 2005) |
| "The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following relapse to Gemcitabine, in patients with advanced adenocarcinoma of the pancreas." | 5.11 | Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. ( Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A, 2005) |
| "Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin." | 5.11 | Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005) |
| "To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer." | 5.11 | Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. ( Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA, 2005) |
| "In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks." | 5.11 | Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005) |
| "5-fluorouracil (5-FU), irinotecan, and oxaliplatin are the most active drugs in advanced colorectal cancer (CRC), and survival is improved with patient exposure to all of them." | 5.11 | FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. ( Aparicio, J; Balcells, M; Busquier, I; Campos, JM; Fernandez-Martos, C; Llorca, C; Maestu, I; Perez-Enguix, D; Vincent, JM, 2005) |
| "In this study we evaluated the activity and toxicity of a combination of 5-fluorouracil continuous infusion and vinorelbine as second or third line chemotherapy in metastatic breast cancer (MBC)." | 5.11 | [Effectiveness of 5-fluoruracil and vinorelbine in patients who had received multi-treatments for metastatic breast cancer]. ( Brito Villanueva, WO; Cárdenas Estrada, E; González Guerrero, JF; González Vela, JL; Hernández Barajas, D; Sánchez Guillén, JM; Treviño Aguirre, SA, 2005) |
| "The aim of this study was to compare the longitudinal quality of life (QoL) between LV5FU2-irinotecan and LV5FU2 alone or LV5FU2-cisplatin in a randomized Phase II trial in patients with metastatic gastric adenocarcinoma." | 5.11 | Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. ( Arveux, P; Bedenne, L; Bonnetain, F; Bouché, O; Conroy, T; Etienne, PL; Giovannini, M; Girault, C; Mitry, E; Raoul, JL; Rougier, P; Seitz, JF, 2005) |
| "The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma." | 5.10 | A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ( Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M, 2002) |
| "We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas." | 5.10 | Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 5.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU." | 5.10 | Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002) |
| "Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)." | 5.10 | Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002) |
| "The purpose of this study was to evaluate the efficacy and tolerance of a combination of irinotecan, oxaliplatin, and 5-fluorouracil (5-FU)/leucovorin in advanced colorectal cancer (ACC)." | 5.10 | Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. ( Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J, 2002) |
| "This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer." | 5.10 | Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. ( Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002) |
| "Patients with previously untreated metastatic or unresectable measurable gastric adenocarcinoma received oral capecitabine 1250 mg/m(2) twice daily, days 1-14, and i." | 5.10 | Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. ( Ahn, JH; Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Yook, JH, 2002) |
| " We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver." | 5.10 | Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003) |
| "The aim of this study was to determine whether the efficacy of the combination of 5-fluorouracil (5-FU), leucovorin (LV) and radiation therapy (RT) could be improved by the addition of interferon-alpha2b (IFN-alpha) in patients who have had a 'curative' resection, for rectal adenocarcinoma (Dukes' B2/C; T3 N0, T4 N0, N1-3)." | 5.10 | Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-alpha2b. ( Andreadis, H; Androulakis, G; Batalis, T; Besbeas, S; Dardoufas, C; Gennatas, C; Hatzistylianos, G; Katsos, J; Komporozos, V; Legakis, N; Mallas, H; Mouratidou, D; Papadimitriou, J; Peros, G; Philippakis, M; Photopoulos, A; Pisiotis, C; Polymeneas, G; Pouli, A; Retalis, G; Samanidis, L; Smyrniotis, V; Stamatiadis, A; Tsavaris, N; Vasiliou, J; Voros, D, 2003) |
| "This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer." | 5.10 | A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer. ( Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ, 2003) |
| "Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)." | 5.10 | Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003) |
| "In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57." | 5.10 | Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003) |
| "In breast cancer, chemotherapy regimens that include infusional 5-fluorouracil (5-FU) lead to high response rates, but require central venous access and pumps." | 5.10 | An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer. ( Atalay, G; Biganzoli, L; Bonnefoi, H; Cufer, T; Mauriac, L; Piccart, M; Schaefer, P, 2003) |
| "The purpose of the study was to determine the efficacy and safety of docetaxel plus continuous infusion of 5-fluorouracil (5-FU) in patients with metastatic breast cancer previously treated with anthracyclines." | 5.10 | Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer. ( Besson, D; Bougnoux, P; Bourgeois, H; Delozier, T; Gamelin, E; Lortholary, A; Lotz, V; Monnier, A; Riffaud, JCh; Tubiana-Mathieu, N, 2003) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer." | 5.10 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003) |
| "To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer." | 5.10 | Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003) |
| "The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil." | 5.10 | Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. ( Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K, 2003) |
| "The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer." | 5.10 | Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. ( Changchien, CR; Chen, JS; Chiang, JM; Hsieh, PS; Tang, R; Yang, TS; Yeh, CY, 2003) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 5.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| "To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy." | 5.10 | Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003) |
| "Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas." | 5.10 | Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. ( Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F, 2003) |
| "To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens." | 5.10 | A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| " A total of 26 patients with adenocarcinoma of the stomach were treated with 3D-conformal radiation therapy to a dose of 45 Gy in 25 fractions with concurrent continuous infusional 5-fluorouracil (5-FU)." | 5.10 | Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. ( Foo, K; Leong, T; Lim Joon, D; Michael, M; Ngan, S; Thomas, R; Thompson, A; Weih, L; Zalcberg, J, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 5.10 | Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003) |
| "Gemcitabine is considered the golden standard treatment for unresectable pancreatic adenocarcinoma." | 5.10 | Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer. ( Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D, 2003) |
| ") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options." | 5.10 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002) |
| "Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine." | 5.10 | Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 5.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer." | 5.10 | Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002) |
| "The aim of this study was to evaluate the toxicity and efficacy of combination chemotherapy with weekly 24-h continuous infusion of 5-fluorouracil (5-FU)/folinic acid, weekly paclitaxel and 3-weekly cisplatin in patients with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.10 | Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Haag, C; Hartmann, JT; Hempel, V; Honecker, F; Kanz, L; Kollmannsberger, C; Quietzsch, D; Schroeder, M; Spott, C, 2002) |
| "Thirty-two consecutive patients with a palpable adenocarcinoma of the rectum received preoperative RT (45 Gy in 25 fractions over 5 weeks) plus continuous chemotherapy with doxifluridine and leucovorin or 5-fluorouracil by continuous intravenous infusion during RT." | 5.10 | Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. ( Andreola, S; Baratti, D; Bozzetti, F; Mariani, L; Spinelli, P; Stani, SC; Valvo, F, 2002) |
| "To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients." | 5.10 | A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002) |
| " Ten patients with unresectable adenocarcinoma of the pancreas received preoperative chemotherapy [5-fluorouracil (5-FU)], bypass surgery and postoperative chemotherapy (5-FU, doxorubicin and cisplatin) plus sandostatin and radiotherapy (45 Gy, 25 fractions, 5 days a week)." | 5.10 | Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma. ( Golematis, BC; Kouloulias, VE; Kouvaris, JR; Mystakidou, K; Nikita, KS; Uzunoglu, NK; Vlahos, LJ, 2002) |
| " cerevisiae fusion protein) on the incidence, duration, and complications of neutropenia and thrombocytopenia after moderate-dose fluorouracil 600 mg/m(2), doxorubicin 60 mg/m(2), and cyclophosphamide 750 mg/m(2) (FAC) chemotherapy in patients with stage II and III breast cancer." | 5.09 | Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. ( Agura, E; Dimitrov, N; Duncan, L; Garrison, L; Hyman, W; Jones, SE; Khandelwal, P; Kirby, R; Lange, M; McIntyre, K; Mennel, R; Orr, D; Regan, D; Roque, T; Schuster, M, 1999) |
| "To determine the maximum tolerable doses (MTDs) of irinotecan (CPT-11) and 5-fluorouracil (5-FU) plus levofolinic acid (LFA) administered together every two weeks, to define the toxicity profile of this regimen, and to have a preliminary evidence of its activity in the first-line management of advanced colorectal cancer patients." | 5.09 | Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. ( Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Comis, S; De Vita, F; Faranda, A; Gravina, A; Orditura, M; Petrillo, A, 1999) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer." | 5.09 | A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999) |
| "To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone." | 5.09 | Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. ( André, T; Beerblock, K; Bensmaine, MA; Bouché, O; Carola, E; de Gramont, A; Desseigne, F; Dupont-André, G; François, E; Louvet, C; Lucas, V; Merrouche, Y; Morvan, F, 1999) |
| "This prospective phase II clinical trial was performed to explore the activity and efficacy of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric adenocarcinoma." | 5.09 | Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. ( Aragao, BC; Cabral, LO; Guimaraes, RC; Murad, AM; Petroianu, A; Scalabrini-Neto, AO, 1999) |
| "The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer." | 5.09 | Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). ( Abeloff, MD; Hochster, H; Kucuk, O; Pandya, KJ; Skeel, RT, 1999) |
| "We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone." | 5.09 | Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. ( Bertino, JR; Blumgart, LH; Brennan, MF; Cohen, AM; Conti, JA; Fong, Y; Huang, Y; Kemeny, N; Shi, W; Stockman, J; Sullivan, D; Turnbull, AD, 1999) |
| "Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil." | 5.09 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. ( Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000) |
| "It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure." | 5.09 | Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000) |
| "Oxaliplatin is a novel platinum derivative, which, combined with 5-fluorouracil (5-FU), and folinic acid (FA), demonstrates synergistic activity in metastatic colorectal cancer (MCC)." | 5.09 | Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. ( Fountzilas, G; Janinis, J; Papagianopoulos, P; Papakostas, P; Samelis, G; Skarlos, D, 2000) |
| "The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer." | 5.09 | Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000) |
| "Biweekly intravenous infusions of low-dose cisplatin (CDDP) and 5-fluorouracil (5-FU) were evaluated in 80 patients with advanced or recurrent gastric, colorectal, pancreatic or gallbladder adenocarcinoma." | 5.09 | [Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma]. ( Kamata, T; Kanno, M; Koyasaki, N; Morita, A; Nakamoto, A; Onishi, I; Takeda, T, 2000) |
| " Those with locally invasive, unresectable, regional pancreatic adenocarcinoma initially were treated with simultaneous split-course RT plus 5-fluorouracil, streptozotocin, and cisplatin (RT-FSP) followed by selective surgery (Group 1)." | 5.09 | Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. ( Bruckner, H; Cooperman, A; Kiefer, L; Paradiso, J; Snady, H, 2000) |
| "In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen." | 5.09 | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000) |
| "To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma." | 5.09 | A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Clemens, M; Haag, C; Hartmann, JT; Hempel, V; Kanz, L; Kollmannsberger, C; Lingenfelser, T; Quietzsch, D; Schroeder, M, 2000) |
| "The aim of this study was to investigate the clinical pharmacokinetics of 5-fluorouracil (5-FU) and its major metabolite 5-fluoro-5,6-dihydrouracil (5-FDHU) in 20 colorectal cancer patients given two dose levels of 5-FU, 250 and 370 mg/m2, administered by i." | 5.09 | Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ( Allegrini, G; Barsanti, G; Battistoni, M; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, AD; Falcone, A; Innocenti, F; Melosi, A, 2000) |
| "Patients with stage IIIA or early stage IV gastric adenocarcinoma received neoadjuvant 5-fluorouracil, Leucovorin, Adriamycin, and Cisplatin and underwent gastrectomy or esophagogastrectomy with intraoperative radiotherapy (IORT; 1000 cGY) to the gastric bed and postoperative radiation therapy." | 5.09 | Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma. ( Fisher, SA; Harbison, SP; Henry, DH; Stiller, GD; Weese, JL, 2000) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 5.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "The purpose of this prospective study was to assess the efficacy, clinical benefit and safety of irinotecan (CPT-11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer (CRC)." | 5.09 | Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy. ( Jirajarus, M; Ratanatharathorn, V; Sirachainan, E; Sirilerttrakul, S, 2000) |
| "Chemotherapy-naïve patients with measurable advanced adenocarcinoma of the pancreas were treated with gemcitabine 1,000 mg/m(2) intravenously weekly x 3 followed by 1 week of rest every 4 weeks and 200 mg/m(2)/day CI fluorouracil until disease progression or limiting toxicity." | 5.09 | Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. ( Aebi, S; Borner, MM; Büchler, MW; Friess, H; Ludwig, CU; Maurer, CA; Pampallona, S; Rauch, DP, 2001) |
| " In this study 137 patients with gastric adenocarcinoma, all with positive nodes, were randomized after curative resection so that 69 received epidoxorubicin (EPI), leucovorin (LV) and 5-fluorouracil (5-FU) on days 1-3 every 3 weeks for 7 months, whereas the remaining 68 did not." | 5.09 | Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. ( Andreoli, F; Boffi, B; Cini, G; Francesconi, D; Mazzanti, R; Medi, F; Mercatelli, A; Moretti, R; Neri, B; Romano, S; Siliani, L; Tarquini, R, 2001) |
| " This study was conducted to prospectively examine the tolerance and early efficacy of adjuvant gemcitabine following radiotherapy with concurrent 5-fluorouracil (5-FU) for nonmetastatic pancreatic adenocarcinoma." | 5.09 | Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. ( Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE, 2001) |
| "A multicenter phase II trial was initiated in order to evaluate the weekly, high-dose 24-hour infusion of 5-fluorouracil (5-FU) plus folinic acid (FA) in patients with unresectable colorectal cancer hepatic metastases." | 5.09 | Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. ( Gassel, HJ; Heinrich, S; Junginger, T; Köhne, CH; Lorenz, M; Mattes, E; Mueller, HH; Saeger, HD; Schramm, H; Staib-Sebler, E; Vetter, G, 2001) |
| "We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)." | 5.09 | Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001) |
| "To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma." | 5.09 | Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. ( Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A, 2001) |
| "The goal of this work was to evaluate response rate, toxicity, and survival in treatment with intraarterial 5-fluorouracil (5-FU) and cisplatin in a neoadjuvant setting; this combination was administered to patients with locally advanced cervical adenocarcinoma." | 5.09 | Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma. ( Aoki, Y; Sasaki, M; Sato, T; Tanaka, K; Tsuneki, I; Watanabe, M, 2001) |
| " Thirty patients with poorly-differentiated carcinoma or poorly-differentiated adenocarcinoma (group A) received a combination of cisplatin and etoposide." | 5.09 | Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. ( Borel, C; Ducreux, M; Fizazi, K; Le Chevalier, T; Ruffié, P; Saghatchian, M; Théodore, C, 2001) |
| "To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum." | 5.09 | Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001) |
| "Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma." | 5.09 | Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). ( André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F, 2001) |
| "Forty-four patients with carcinoma of the esophagus or gastroesophageal junction were prospectively entered into a phase II trial of preoperative 5-fluorouracil, cisplatin, and interferon alfa with concurrent external beam radiotherapy before esophagectomy." | 5.09 | Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. ( Gooding, WE; Lew, JI; Posner, MC; Ribeiro, U; Safatle-Ribeiro, AV, 2001) |
| "Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV." | 5.09 | Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| " After radical resection of adenocarcinoma of the colon (pT1-4 pN>0 M0 and pT3-4 pN0 M0) and perioperative chemotherapy, patients were randomised to three treatment arms: observation only (A), 5-fluorouracil (5-FU) 450 mg/m(2) plus levamisol (B), or 5-FU 600 mg/m(2) (C)." | 5.09 | Response shift in the perception of health for utility evaluation. an explorative investigation. ( Bernhard, J; Hürny, C; Lowy, A; Maibach, R, 2001) |
| "To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer." | 5.09 | Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. ( Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C, 2001) |
| " 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas." | 5.09 | A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001) |
| "Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)." | 5.09 | Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001) |
| "To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma." | 5.09 | Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001) |
| "From August 1995 through March 1996, seven patients with unresectable adenocarcinoma of the pancreas underwent CS, with preoperative chemotherapy (5-fluorouracil [FU] for 96 h), plus 45-Gy external beam postoperative irradiation with a 6-MeV linear accelerator (1." | 5.09 | Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy. ( Golematis, VC; Kouloulias, VE; Kouvaris, JR; Nikita, KS; Papavasiliou, CG; Uzunoglu, NK; Vlahos, LJ, 2001) |
| "To compare the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) versus its inert vehicle in patients with unilateral nonmetastatic inflammatory breast cancer treated with fluorouracil, epirubicin, and cyclophosphamide high-dose (FEC-HD) neoadjuvant chemotherapy." | 5.08 | Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. ( Chevallier, B; Chollet, P; Fargeot, P; Fizames, C; Fumoleau, P; Genot, JY; Kerbrat, P; Merrouche, Y; Olivier, JP; Roche, H, 1995) |
| "Forty-nine patients with localized unresectable adenocarcinoma of the pancreas were treated in a multimodality program of initial IORT and perioperative chemotherapy (fluorouracil [5-FU]/leucovorin) followed by combined external-beam radiation (40 to 55 Gy) and continued chemotherapy." | 5.08 | Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. ( Barbot, D; Biermann, W; Cantor, R; Mohiuddin, M; Regine, WF; Rosato, F; Stevens, J, 1995) |
| "These studies demonstrate that the concurrent addition of modest dose cisplatin and infusional dose fluorouracil to radiation in the definitive, preoperative, and palliative settings contribute to high rates of durable dysphagia-free survival, with overall survival comparable to (and possibly better than) the chemoradiation arm of the recently reported Intergroup Study, but at the cost of less morbidity." | 5.08 | Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. ( Ackland, SP; Burmeister, BH; Denham, JW; Devitt, P; Gill, PG; Hamilton, CS; Jamieson, GG; Lamb, DS; O'Brien, M; Yeoh, E, 1995) |
| "Between 1966 and 1983 we selected 209 patients with colorectal adenocarcinomas, stage B (14%) and C (86%) of Dukes, treated with convenient surgery in 100% of cases, 5-fluorouracil in 85% and postoperative radiotherapy with telecobalt in 46." | 5.08 | [Is radiotherapy necessary in the control of colorectal cancer?]. ( Molina Esquivel, J; Rodríguez del Rincón, E; Vargas Sandoval, G; Velázquez López, J, 1995) |
| "Modulation of 5-fluorouracil (5-FU) is currently being investigated in advanced colorectal cancer." | 5.08 | Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. ( Astone, A; Barone, C; Cassano, A; Corsi, DC; Fontana, T; Noviello, MR; Pozzo, C, 1995) |
| "A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i." | 5.08 | 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas). ( Aschele, C; Bolli, E; Connio, M; Guglielmi, A; Ligas, B; Mondini, G; Mori, A; Rosso, R; Saccomanno, S; Sobrero, A, 1995) |
| "A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks." | 5.08 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995) |
| "From May 1988 to June 1992, 129 eligible patients suffering from measurable advanced colorectal cancer were enrolled in a randomized study comparing bolus fluorouracil plus leucovorin (FU-FA); continuous fluorouracil infusion (FU-cont); FUcont plus cyclophosphamide and mitomycin C (FUMIC)." | 5.08 | A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. ( Bonnel, C; Caudry, M; Caudry, Y; Dujols, JP; Floquet, A; Marsault, C; Maton, O; Pujol, J; Quétin, P; Skawinski, P, 1995) |
| "We tested the hypothesis that polymerase chain reaction (PCR) quantitation of the enzyme thymidylate synthase (TS) within a primary adenocarcinoma of the stomach, has an inverse relationship to response and survival for patients who receive fluorouracil (5FU)-based chemotherapy." | 5.08 | Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. ( Baranda, J; Cohen, H; Crookes, P; Danenberg, KD; Danenberg, PV; Garcia, Y; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Lenz, HJ; Li, J; Silberman, H, 1996) |
| "After curative resection for gastric adenocarcinoma, 103 patients, all with positive nodes, were randomised so that 48 received adjuvant chemotherapy of epidoxorubicin (EPI) 75 mg m-2 on day 1, leucovorin (LV) 200 mg m-2 on days 1-3 and 5-fluorouracil (5-FU) 450 mg m-2 on days 1-3, every 21 days for 7 months, whereas the remaining 55 did not." | 5.08 | Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. ( Andreoli, F; Borrelli, D; Bruno, L; Cini, G; de Leonardis, V; Fabbroni, S; Intini, C; Neri, B; Pernice, LM; Romano, S; Valeri, A, 1996) |
| "Fourteen patients with surgically resected periampullary adenocarcinoma were treated with adjuvant therapy consisting of prophylactic hepatic irradiation and pancreatic bed irradiation and concurrent infusional 5-fluorouracil and leucovorin (5-FU/LV)." | 5.08 | Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. ( Abrams, RA; Cameron, JL; Carducci, MA; Grochow, LB; Hruban, RH; Yeo, CJ; Zahurak, ML, 1996) |
| "The primary objective of this study was to determine the response rate of patients with metastatic colorectal cancer to combined therapy with 5-fluorouracil (5-FU), leucovorin, and intravenous azidothymidine (AZT), a thymidine nucleoside analog." | 5.08 | Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. ( Akerley, W; Beitz, J; Bigley, J; Browne, M; Clark, J; Cole, B; Cummings, F; Darnowski, J; Kennedy, T; Sikov, W; Wanebo, H; Weitberg, A, 1996) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 5.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer." | 5.08 | 5-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996) |
| "Evidence suggests that interferon-alpha (IFN-alpha) augments the antineoplastic activity of 5-fluorouracil (5-FU) in human adenocarcinoma cell lines in vitro and may enhance the efficacy of 5-FU in patients with advanced colorectal carcinoma." | 5.08 | Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. ( Benson, AB; Bushunow, PW; Dutcher, JP; Flynn, PJ; Hansen, R; Kirkwood, J; Lipsitz, S; Sparano, JA; Wadler, S, 1996) |
| "In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2." | 5.08 | Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996) |
| "Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer." | 5.08 | Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996) |
| "Fifty-nine patients with invasive primary gastric adenocarcinoma who were deemed resectable for cure entered a clinical trial that called for 2 cycles of protracted infusion 5-fluorouracil with weekly leucovorin and cisplatin chemotherapy followed by surgery." | 5.08 | Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. ( Baranda, J; Casagrande, Y; Crookes, P; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Silberman, H; Stain, S; Tan, M, 1997) |
| "The combination of radiation therapy with fluorouracil (5-FU)-based chemotherapy is generally accepted as appropriate postoperative therapy for patients with adenocarcinomas of the rectum that extend through the bowel wall or with lymph nodes positive for tumor." | 5.08 | Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. ( Benson, AB; Cooke, E; Cummings, B; Gunderson, LL; Hollis, D; Macdonald, JS; Martenson, JA; O'Connell, MJ; Petroni, GR; Tepper, JE, 1997) |
| "A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma." | 5.08 | A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program ( Armstead, B; Douglass, HO; Haller, DG; Holroyde, C; Meropol, NJ; Mintzer, D; Nuamah, I; Vaughn, DJ, 1997) |
| ") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma." | 5.08 | [Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997) |
| "The aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients." | 5.08 | A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. ( Aschelter, AM; Franchi, F; Gallà, DA; Garufi, C; Giunta, S; Lévi, F; Narduzzi, C; Nisticò, C; Pace, R; Silecchia, GF; Terzoli, E, 1997) |
| "Eighteen patients with esophageal carcinoma (16 adenocarcinoma, two squamous cell carcinoma) were treated with two cycles of induction chemotherapy consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 (3-hour infusion), cisplatin 20 mg/m2/d x 4 days, and 5-fluorouracil 1 g/m2/d (continuous infusion x 4 days) separated by a 28-day interval before surgical resection." | 5.08 | Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. ( Belani, CP; Day, R; Ferson, PF; Keenan, RJ; Kim, R; Landreaneau, RJ; Lembersky, B; Luketich, JD; Posner, M; Ramanathan, RK; Seeger, J, 1997) |
| "We have previously shown that relative thymidylate synthase (TS) mRNA levels in primary gastric adenocarcinomas treated with fluorouracil (5-FU) and cisplatin are inversely associated with response and survival." | 5.08 | ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. ( Baranda, J; Cohen, H; Crookes, P; Danenberg, KD; Danenberg, PV; Groshen, S; Hayashi, K; Konda, B; Laine, L; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Salonga, D; Silberman, H, 1998) |
| "The objective of the study was to determine the response rate and associated toxicity of 5-fluorouracil and high-dose leucovorin in patients with recurrent adenocarcinoma of the cervix." | 5.08 | Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. ( Andersen, WA; Blessing, JA; Look, KY; Manetta, A; McGehee, R; Valea, FA; Webster, KD, 1997) |
| "Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)." | 5.08 | High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998) |
| "The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma." | 5.08 | The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. ( Crawley, C; Cunningham, D; Hill, A; Norman, A; Ross, P, 1998) |
| "To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)." | 5.08 | Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998) |
| "In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known." | 5.08 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. ( Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J, 1998) |
| "FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m2) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer." | 5.08 | Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. ( André, T; de Gramont, A; Louvet, C; Raymond, E; Tournigand, C, 1998) |
| "Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus." | 5.08 | Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. ( Ajani, J; Estes, N; Ginsberg, R; Gunderson, L; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Pajak, TF; Roth, JA; Sheahan, DG, 1998) |
| "Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i." | 5.07 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994) |
| "Twenty-nine patients with adenocarcinomas of gastrointestinal or unknown primary, and three with advanced neuroendocrine tumours, were entered into a study of bolus plus infusional 5-fluorouracil (FUra) modulated with high-dose leucovorin (LV) and recombinant interferon alpha 2a (IFN-alpha)." | 5.07 | Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study. ( Hall, MR; Johnson, PW; Seymour, MT; Slevin, ML; Wrigley, PF, 1994) |
| "We have studied a mitoxantrone, 5-fluorouracil (5-FU) and leucovorin chemotherapy regimen in metastatic breast cancer." | 5.07 | The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. ( Bélanger, K; Dionne, J; Gagné, L; Guévin, R; Jolivet, J; Latreille, J; Potvin, M; Rudinskas, L; Wilson, J; Yelle, L, 1994) |
| "Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m2, doxorubicin 50 mg/m2, and fluorouracil 500 mg/m2 (CAF) intravenously (IV) once every 3 weeks." | 5.07 | Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. ( Gelmon, KA; O'Reilly, SE; Onetto, N; Page, RA; Parente, J; Plenderleith, IH; Rubinger, M, 1993) |
| "From April 1990 to April 1992, a comparative study was carried out in 46 patients with advanced breast cancer treated by CMxMF (Cyclophosphamide, mitoxantrone, methotrexate, 5-fluorouracil) and CAMF regimens (Cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil)." | 5.07 | [Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients]. ( Chen, JA, 1993) |
| "From December 1983 through December 1990, 27 patients with primary unresectable but localized pancreatic adenocarcinoma received high-dose (50 to 54 Gy) external beam irradiation with or without concomitant bolus 5-fluorouracil followed by surgical exploration and intraoperative electron beam irradiation (20 Gy) at the Mayo Clinic." | 5.07 | High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. ( Cha, SS; Donohue, JH; Garton, GR; Gunderson, LL; Martin, JK; McIlrath, DC; Nagorney, DM, 1993) |
| "We therefore initiated a Phase II study in which fluorouracil (370 mg/m2, day 1 through 5) plus folinic acid (200 mg/m2 day 1 through 5) was administered in a subset of 17 patients (median age, 57 years) affected by histologically diagnosed adenocarcinoma of unknown primary location characterized by liver metastases and elevated CEA of CA 19." | 5.07 | Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. ( Bajetta, E; Buzzoni, R; Colleoni, M; Nolè, F, 1993) |
| "Potentiation of the antitumor activity of 5-fluorouracil (5-FU) by folinic acid has been demonstrated in patients with colorectal adenocarcinoma." | 5.07 | 5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens. ( André, T; Goldschmidt, E; Grison, X; Hannoun, L; Lotz, JP; Machover, D; Marquet, J; Metzger, G; Richaud, J; Zittoun, J, 1993) |
| "A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer." | 5.07 | A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. ( Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993) |
| "In a randomized trial we compared single-agent epirubicin with the FEM (5-fluorouracil/epirubicin/mitomycin) combination in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas." | 5.07 | Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. ( Coombes, RC; Glees, J; Topham, C, 1993) |
| "5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas." | 5.07 | A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992) |
| "A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients." | 5.07 | Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "Thirty-eight patients with advanced colorectal adenocarcinoma were entered on a phase II trial of 5-fluorouracil (5-FU) in continuous infusion, using a portable pump." | 5.07 | Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma. ( Ammarguellat, H; Benhamed, M; Ghosn, M; Goldberg, J; Kac, J; Laplaige, P; Piot, G; Rougier, P; Theodore, C; Tigaud, JM, 1992) |
| "To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU." | 5.07 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992) |
| "One hundred sixty consecutive patients with histologically confirmed colorectal cancer (advanced disease) without prior chemotherapy were entered in a randomized trial comparing 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion versus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU as described on days 2 to 6." | 5.07 | A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). ( Antón, A; Aranda, E; Belón, J; Carrato, A; Cruz-Hernández, J; Díaz-Rubio, E; Jimeno, J; Martin, M; Massuti, B; Sánchez, J, 1992) |
| "This phase III prospective, randomized, and stratified trial was undertaken to evaluate the efficacy of four courses of combined fluorouracil (1000 mg per square meter of body-surface area daily for four days) and cisplatin (75 mg per square meter on the first day) plus 5000 cGy of radiation therapy, as compared with 6400 cGy of radiation therapy alone, in patients with squamous-cell carcinoma or adenocarcinoma of the thoracic esophagus." | 5.07 | Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. ( al-Sarraf, M; Brindle, J; Byhardt, R; Cooper, J; Davis, L; Emami, B; Herskovic, A; Leichman, L; Martz, K; Vaitkevicius, V, 1992) |
| "We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin." | 5.07 | Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991) |
| "Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide." | 5.07 | Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study. ( Coltman, CA; Ellis, GK; Green, S; Hynes, HE; Livingston, RB; Rivkin, S; Schulman, S, 1991) |
| "Forty-two previously untreated patients with advanced, measurable adenocarcinoma of the pancreas were treated with weekly fluorouracil (5-FU; 600 mg/m2 intravenous [IV]) and leucovorin 500 mg/m2 IV for 6 weeks followed by a 2-week rest." | 5.07 | Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. ( Arbuck, SG; DeCaprio, JA; Gonin, R; Mayer, RJ, 1991) |
| "To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes." | 5.07 | Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991) |
| "This study evaluated combined 5-fluorouracil (5FU) and doxorubicin as postoperative adjuvant chemotherapy for patients who had undergone potentially curative resection of a primary gastric adenocarcinoma." | 5.07 | A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. ( Beart, RW; Foley, JF; Krook, JE; Kugler, JW; Leigh, JE; O'Connell, MJ; Pfeifle, DM; Twito, DI; Wieand, HS, 1991) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 5.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "One hundred eighty-seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5-fluorouracil (5-FU) alone, to the Mallinson regimen (combined and sequential 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5-FU, doxorubicin, and cisplatin (FAP)." | 5.06 | A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. ( Barlow, JF; Cullinan, S; Foley, JF; Kardinal, CG; Krook, JE; Moertel, CG; Norris, BD; Schutt, AJ; Tschetter, LK; Wieand, HS, 1990) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 5.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "In preparation for a national Phase III study of dose and dose intensity in the treatment of node-positive, Stage II adenocarcinoma of the female breast, CALGB instituted a pilot study of intensive intravenous outpatient CAF (cyclophosphamide, Adriamycin, 5-fluorouracil) for four months." | 5.06 | A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443. ( Aisner, J; Budman, DR; Costanza, M; Korzun, AH; Rice, MA; Silver, R; Wood, W; Younger, J, 1990) |
| "We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion." | 5.06 | Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. ( Beart, RW; Fitzgibbons, RJ; Leigh, JE; Moertel, CG; van Heerden, JA; Wieand, HS; Windschitl, HE; Wolff, BG, 1990) |
| "Seventy-four previously untreated patients with metastatic colorectal adenocarcinoma were prospectively randomized into one of three treatment regimens: (1) 5-fluorouracil (5-FU) 450 mg/m2 as an intravenous (IV) bolus daily for five days or toxicity, then 200 mg/m2 IV bolus every other day for six doses; (2) methotrexate (MTX) 50 mg/m2 in normal saline by IV infusion over four hours followed by an IV bolus of 5-FU 600 mg/m2." | 5.06 | A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. ( Burke, P; Creaven, P; Emrich, LJ; Herrera, L; Mittelman, A; Petrelli, N; Rustum, Y; Stulc, J, 1987) |
| "Twenty-two patients with inoperable adenocarcinoma of the pancreas were treated with 5-fluorouracil (5-FU), mitomycin C (Mito-C), and 1(-2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)." | 5.06 | Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. ( Chapman, J; Chinn, B; Groshko, G; Maniscalco, B; Piper, D; Reznik, S; Vaughn, C; Ward, D, 1989) |
| "Seventy-seven patients with previously untreated, measurable, histologically confirmed, metastatic adenocarcinoma of the rectum or sigmoid were randomized to receive either epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i." | 5.06 | A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. ( Blum, RH; Lafleur, F; Molinaro, P, 1989) |
| "The effect of hepatic irradiation (RT) after intraarterial 5-fluorouracil (5-FU) was evaluated in 37 randomized patients with colorectal adenocarcinoma hepatic metastases." | 5.06 | Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study. ( Demets, D; Lee, JW; Ramirez, G; Stephenson, JA; Wiley, AL; Wirtanen, GW, 1989) |
| "One hundred thirty-three patients with advanced pancreatic adenocarcinoma and measurable disease were treated with 5-fluorouracil (5-FU) plus doxorubicin plus mitomycin C (FAM), streptozotocin plus mitomycin C plus 5-FU (SMF) in the regimen originally reported, and streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses." | 5.06 | Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. ( , 1986) |
| "Using a randomized prospective trial design, chemotherapy with 5-fluorouracil, vincristine, and mitomycin C (FOMi) was compared with cyclophosphamide, doxorubicin, and cisplatin (CAP) and with FOMi alternating with CAP (FOMi/CAP) in 452 eligible patients with metastatic large-cell undifferentiated and adenocarcinoma of the lung." | 5.06 | Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. ( Chen, TT; Coltman, CA; Fletcher, WS; Livingston, RB; Miller, TP; O'Bryan, RM; Stephens, RL; Vance, RB; Weiss, GB, 1986) |
| "In this prospective randomized study the effect of oral Ftorafur was compared with that of intravenous 5-fluorouracil in patients with advanced adenocarcinoma of the stomach, colon or rectum." | 5.06 | Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. ( Bjerkeset, T; Fjøsne, HE, 1986) |
| "Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM)." | 5.06 | 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules. ( Ip, M; Kung, TM; Lam, WK; Sham, MK; So, SY, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma." | 5.06 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986) |
| "A multi-institutional cooperative study of patients with locally advanced, recurrent, or metastatic gastric adenocarcinoma who had not previously received chemotherapy was conducted, prospectively randomizing patients to receive either doxorubicin or the three-drug combination, 5-fluorouracil (5-FU), doxorubicin (Adriamycin; Adria Laboratories, Columbus, Ohio), and BCNU (FAB)." | 5.06 | Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. ( Fox, RM; Gill, G; Levi, JA; Tattersall, MH; Thomson, D; Woods, RL, 1986) |
| "This prospective randomized study in nonhormonally responsive adenocarcinoma of the prostate shows that response rates to melphalan vs cyclophosphamide groups were virtually identical." | 5.06 | Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. ( Berry, WR; Cox, EB; Graham, SD; Laszlo, J; Paulson, DF; Walker, A, 1986) |
| "In patients with metastatic hormone-relapsed adenocarcinoma of the prostate, adriamycin was compared to 5-fluorouracil in a randomized trial in 99 patients and adriamycin alone was studied in an open trial in 48 patients." | 5.05 | A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. ( Begg, CB; Brodovsky, H; Creech, R; DeWys, WD; Khandekar, J, 1983) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 5.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "This prospective evaluation of 5-fluorouracil (5-FU) and methyl-CCNU administered in combination to patients with surgery for histologically proved gastric adenocarcinoma is based upon 312 patients randomized between August 1974 and May 1980." | 5.05 | Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. ( Amadeo, JH; Higgins, GA; Humphrey, EW; Keehn, RJ; Smith, DE, 1983) |
| "Between September 1976 and June 1982, 308 patients with operable breast cancer with 1-3 involved axillary nodes were stratified according to institution, type of mastectomy, and time from surgery to protocol entry, and then randomized to receive either six or 12 months of adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)." | 5.05 | Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience. ( Bartolucci, A; Ketcham, A; Liu, C; Marcial, V; Moore, M; Smalley, R; Velez-Garcia, E; Vogel, CL, 1983) |
| "Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB)." | 5.05 | 5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer. ( Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1984) |
| "Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, nine with SCC of other primary sites, 24 with colorectal, and five with gastric adenocarcinomas." | 5.05 | Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. ( Coates, AS; Fox, RM; Hedley, D; Raghavan, D; Swanson, C; Tattersall, MH, 1984) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 5.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "Two hundred forty-one patients with unresectable gastric adenocarcinoma were entered, between December 1978 and March 1981, into a prospectively randomized comparison of three chemotherapy regimens to identify therapeutic activity and determine patient tolerability: (1) 5-fluorouracil plus Adriamycin (FA); (2) FA plus methyl-CCNU (FAMe); and (3) FA plus mitomycin C (FAMi)." | 5.05 | Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group. ( , 1984) |
| "The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma." | 5.05 | Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. ( Athens, J; Chen, TT; Costanzi, JJ; Haas, C; Heilbrun, LK; McDonald, B; Oishi, N; Panettiere, FJ; Talley, RW, 1984) |
| "In a prospectively randomized trial, patients with advanced locally recurrent or metastatic gastric adenocarcinoma were randomized to receive 5-fluorouracil (5-FU) and methyl-CCNU; 5-FU, Adriamycin (Adria Laboratories, Columbus, Ohio), and methyl-CCNU; 5-FU, Adriamycin, and mitomycin C; or Adriamycin and mitomycin C alone." | 5.05 | An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). ( Douglass, HO; Goudsmit, A; Klaassen, DJ; Lavin, PT; Paul, AR, 1984) |
| "In a randomized, multicenter study, 168 evaluable patients with colorectal adenocarcinoma at B2, C1 or C2 stages of the Dukes, Astler and Coller classification, were treated after radical surgery with BCG and 5-fluorouracil alone (regimen A) or in combination with hydroxyurea, methyl-CCNU and mitomycin C (regimen B)." | 5.05 | Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma. ( De Vecchis, L; Lagomarsino Caprino, MC; Mazzei, T; Periti, P; Popoli, P, 1984) |
| "One hundred twenty-one patients with advanced measurable adenocarcinoma of the colon were randomized for treatment with intravenous 5-fluorouracil (IV 5-FU) alone, 15 mg/kg/week vs." | 5.05 | Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. ( Bateman, JR; Chlebowski, RT; Kardinal, C; Pajak, T; Silverberg, I; Weiner, J, 1980) |
| "One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU." | 5.05 | Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. ( Barkin, J; Bateman, J; Brooks, J; Chaffey, J; Childs, DS; Corson, JM; Douglas, HO; Frytak, S; Hahn, RG; Holbrook, MA; Kalser, M; Knowlton, A; Lavin, PT; Lessner, H; Livstone, E; Lokich, J; Mann-Kaplan, R; Moertel, CG; Nave, H; Novak, JW; O'Connell, MJ; Ramming, K; Reitemeier, RJ; Rubin, J; Schutt, AJ; Spiro, H; Thomas, P; Weiland, LH; Zamcheck, N, 1981) |
| "To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients)." | 5.05 | Prolongation of the disease-free interval in surgically treated rectal carcinoma. ( , 1985) |
| "After en bloc resection of gastric adenocarcinoma, 180 patients were randomized to 2 years of 5-fluorouracil (5-FU) + semustine (MeCCNU) chemotherapy or to observation only." | 5.05 | Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). ( Brunner, KW; Douglass, HO; Engstrom, PF; Lavin, PT, 1985) |
| "30 patients with advanced metastatic gastric adenocarcinoma, having a measurable indicator lesion, were randomized (1:2) to receive (intravenously) either weekly 5-fluorouracil alone (15 mg/kg) or combination treatment with cyclophosphamide (20 mg/kg) given on day 1 and 5-FU (15 mg/kg) given weekly on weeks 2-5, beginning on day 8." | 5.05 | Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma. ( Bateman, JR; Chlebowski, RT; Glass, A; Silverberg, I; Weiner, JM, 1985) |
| "From 1977 until 1980, 179 patients with newly diagnosed FIGO stages IIB, III or IV ovarian adenocarcinoma were randomized in a two-armed clinical trial: dihydroxybusulfan (B) 600 mg/m2 p." | 5.05 | A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. ( Aabo, K; Dombernowsky, P; Hald, I; Hansen, HH; Hørbov, S; Lundvall, F; Nielsen, NC; Sørensen, BL; Sørensen, HM, 1985) |
| "One hundred ninety-one patients with pathologically confirmed, locally unresectable adenocarcinoma of the stomach (57 patients) and pancreas (91 patients), were randomly allocated to therapy with 5-fluorouracil (5-FU) alone, 600 mg/m2 intravenously (IV) once weekly, or radiation therapy, 4,000 rad, plus adjuvant 5-FU, 600 mg/m2 IV, the first three days of radiotherapy, then follow-up maintenance 5-FU, 600 mg/m2, weekly." | 5.05 | Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. ( Catton, GE; Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Moertel, CG, 1985) |
| "Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan." | 5.04 | Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978) |
| "Thirty-one patients with carcinoma of the breast with metastases were treated by adrenalectomy-oophorectomy and randomized either for combined chemotherapy, vincristine, fluorouracil, methotrexate and thiotepa, beginning within one week after operation and continuing for three months or no chemotherapy." | 5.04 | Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases. ( Cady, B; Oberfield, RA; Pazianos, AG; Salzman, FA, 1979) |
| "One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide." | 5.04 | Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977) |
| "One hundred and thirty-two previously untreated patients with metastatic adenocarcinoma of the gastrointestinal (GI) tract were randomized to receive either a 120-hr infusion of 5-fluorouracil (5FU) with mitomycin-C or mitomycin-C alone." | 5.04 | Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas. ( Baker, LH; Buroker, TR; Kim, PN; Ratanatharathron, V; Vaitkevicius, VK; Wojtaszak, B, 1978) |
| "An adjuvant program of fluorouracil for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968." | 5.04 | Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report. ( Brown, PW; Horsley, JS; Lawrence, W; Romero, C; Terz, JJ, 1978) |
| "Eighteen previously untreated patients with advanced nonresectable adenocarcinoma of the stomach were treated with a four-drug regimen consisting of 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C." | 5.04 | 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer. ( Bunn, PA; Cohen, MH; Eddy, JL; Ihde, DC; Minna, JD; Nugent, JL, 1978) |
| "In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks." | 5.04 | Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2- ( Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978) |
| "Twenty-seven patients with a diagnosis of metastatic adenocarcinoma of the prostate were treated in a randomized, prospective trial with either Cyclophosphamide or a combination of Adriamycin, 5-Fluorouracil, and Cyclophosphamide." | 5.04 | Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. ( Bateman, JR; Chlebowski, RT; Hestorff, R; Sardoff, L; Weiner, J, 1978) |
| "In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups)." | 5.04 | [A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)]. ( Arnold, H; Drings, P; Geldmacher, J; Hartwich, G; Kredel, L; Mayer, M; Neidhardt, B; Queisser, W; Rösch, W; Schaefer, J; von Oldershausen, HF; Wahrendorf, J, 1979) |
| "Seventy-six patients with advanced gastric adenocarcinoma were studied in a prospecitive, randmoised, controlled trial using vincristine, methotrexate, cyclophosphamide, and 5-fluorouracil in an initiation course and mitomycin-C with 5-fluorouracil as maintenance therapy." | 5.04 | Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study. ( Cocking, JB; Cwynarski, MT; Diffey, BL; Fox, CA; Jackson, GA; Mallinson, CN; Rake, MO; Wass, VJ, 1979) |
| "A prospective randomized clinical trial of treatment with vincristine, cyclophosphamide, methotrexate and 5-fluorouracil after conventional curative treatment for stage II breast cancer is described." | 5.04 | Four drug combination cytotoxic chemotherapy following surgery for breast cancer. ( Bates, IS; Brinkley, D; Edelstyn, GA; MacRae, KD; Spittle, H; Wheeler, T, 1978) |
| "A combined intraoperative and postoperative adjuvant program of 5 minus Fluorouracil (5 FU) for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968." | 5.04 | Chemotherapy as an adjuvant to surgery for colorectal cancer. ( Brown, PW; Donaldson, M; Horsley, S; Lawrence, W; Lovett, WL; Regelson, W; Ruffner, BW; Terz, JJ, 1975) |
| "In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs." | 5.04 | Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. ( Baker, LH; Reed, ML; Seifert, P; Vaitkevicius, VK, 1975) |
| "The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)." | 4.95 | A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017) |
| " This review focuses on the development and establishment of the Dark Agouti rat mammary adenocarcinoma model by the Mucositis Research Group of the University of Adelaide over the past 20 years to characterize the mechanisms underlying methotrexate-, 5-fluorouracil-, and irinotecan-induced mucositis." | 4.91 | Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. ( Bateman, E; Keefe, D; Mayo, B; Stringer, A; Thorpe, D; Vanhoecke, B; Vanlancker, E, 2015) |
| "Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC)." | 4.90 | Role of solute carrier transporters in pancreatic cancer: a review. ( Lemstrová, R; Melichar, B; Mohelnikova-Duchonova, B; Souček, P, 2014) |
| "This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs." | 4.89 | Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody. ( Du, Z; He, X; Hu, Q; Li, M; Li, Q; Sang, Y; Tang, R; Wen, F; Zhang, P; Zhou, Y, 2013) |
| "We report on a case of a 65-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with capecitabine and oxaliplatin (XELOX) regimen." | 4.89 | Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma. ( Chang, SL; Chen, YN; Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Zhang, ZD; Zhao, Q; Zhao, XF, 2013) |
| "Metastatic pancreatic ductal adenocarcinoma has a grim prognosis and gemcitabine has been the reference treatment for 15 years." | 4.87 | Metastatic pancreatic cancer: old drugs, new paradigms. ( Adenis, A; Conroy, T; Gavoille, C, 2011) |
| ", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)." | 4.86 | Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010) |
| " In patients with metastatic or locally advanced/recurrent gastric or gastro-oesophageal junction adenocarcinoma, the median time to tumour progression was significantly prolonged with 3-week cycles of intravenous (IV) docetaxel plus cisplatin and fluorouracil (5-fluorouracil) compared with 4-week cycles of IV cisplatin plus IV fluorouracil (5." | 4.84 | Docetaxel: in gastric cancer. ( Deeks, ED; Scott, LJ, 2007) |
| "A patient with resected adenocarcinoma of the pancreas was treated with adjuvant radio-chemo-immunotherapy using a combination of low-dose Cisplatin, 5-Fluorouracil and Interferon alpha together with external beam radiation." | 4.83 | Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759]. ( Buchler, MW; Fritz, S; Hoffmann, K; Jager, D; Lindel, K; Marten, A; Schmidt, J, 2006) |
| "The addition of oxaliplatin and irinotecan to the armamentarium for the treatment of colorectal cancer (CRC) has resulted in significant improvements in response rates and survival." | 4.82 | The role of bevacizumab as first-line therapy for colon cancer. ( Marshall, J, 2005) |
| "Gemcitabine administered as a weekly 1,000 mg/m2 30 minutes infusion is considered as the standard treatment of non resectable pancreatic adenocarcinoma." | 4.81 | [Gemcitabine-based combinations in inoperable pancreatic cancers]. ( André, T; Artru, P; Louvet, C, 2002) |
| "The current standard therapy for metastatic pancreatic adenocarcinoma is the single-agent gemcitabine, by the increasingly used fixed rate infusion of 10 mg/m2/min." | 4.81 | Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review. ( Bruckner, HW; Evans, A; Kozuch, P; Petryk, M, 2001) |
| "The combination of cisplatin and continuous-infusion 5-fluorouracil is the standard regimen for the treatment of both squamous cell carcinoma and adenocarcinoma." | 4.81 | [Chemotherapy for the patients with esophageal cancer]. ( Ando, N; Shih, CH, 2002) |
| " Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine." | 4.81 | A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. ( Bruckner, HW; Kozuch, P; Petryk, M, 2002) |
| " Chemotherapy with fluorouracil (5FU) plus leucovorin remains a standard in the treatment of patients with metastatic colorectal cancer." | 4.80 | [Irinotecan in combination for colon cancer]. ( André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M, 1998) |
| "We report a patient who developed multifocal cerebral demyelination with the use of 5-fluorouracil, levamisole, and leucovorin as adjuvant treatment for intestinal adenocarcinoma." | 4.79 | Cerebral demyelination with 5-fluorouracil and levamisole. ( Fassas, AB; Gattani, AM; Morgello, S, 1994) |
| "For patients with localized pancreatic adenocarcinoma, the combination of radiation therapy and 5-fluorouracil has been shown to enhance patient survival." | 4.78 | Current approaches to multimodality management of advanced pancreatic cancer. ( Douglass, HO, 1993) |
| " From October 1985 to October 1987, 43 patients with local-regional esophageal cancer (adenocarcinoma in 21, squamous cell in 22) were treated with cisplatin, vinblastine, and 5-fluorouracil chemotherapy concurrent with 4,500 cGy radiation therapy for 21 days before transhiatal esophagectomy 3 weeks later." | 4.78 | Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma. ( Bromberg, J; Forastiere, AA; Orringer, MB; Perez-Tamayo, C; Takasugi, BJ; Urba, S, 1990) |
| "Growth of human adenocarcinomas of the colon and rectum in immunoincompetent mice has allowed for a greater understanding of the interaction of 5-fluorouracil, its metabolism, and mechanism(s) of cytotoxicity under conditions of tumor growth in situ." | 4.77 | Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy. ( Hazelton, BJ; Houghton, JA; Houghton, PJ; Radparvar, S, 1989) |
| "A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy." | 4.77 | Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. ( Binsack, T; Mergenthaler, HG; Wilmanns, W, 1988) |
| "There is limited real-world data on the efficacy of 2-weekly cycles of docetaxel, oxaliplatin, leucovorin, and fluorouracil (FLOT) compared to epirubicin, oxaliplatin, and capecitabine (EOX) as perioperative therapy in esophagogastric adenocarcinomas (EGAC)." | 4.31 | Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. ( Bhandare, M; Bhargava, P; Booma, N; Chaudhari, V; Chaugule, D; Das, S; Kannan, S; Kapoor, A; Mantri, A; Ostwal, V; Ramaswamy, A; Shrikhande, SV; Srinivas, S, 2023) |
| "This case report describes a patient with cutaneous intestinal metaplasia with invasive adenocarcinoma treated successfully with intralesional fluorouracil." | 4.31 | Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil. ( Dahiya, M; Eilers, D; Joseph, MX; Tao, J; Vaudreuil, A, 2023) |
| "Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70's or they have comorbidities." | 4.31 | Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role? ( Aravantinos, G; Dessypris, N; Gkoura, S; Karampinos, K; Mauri, D; Miaris, N; Samantas, E; Sgouros, J; Spathas, N; Stamoulis, G; Theodoropoulos, I; Tzoudas, F; Visvikis, A, 2023) |
| "Retrospective study included all resected patients with pancreatic adenocarcinoma who underwent neoadjuvant chemotherapy with FOLFIRINOX or gemcitabine/Abraxane." | 4.31 | Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer. ( Caron, M; Fitzgerald, TL; Nicolais, LM; Verdini, N, 2023) |
| "Chemotherapy using 5-fluorouracil (5-FU) is currently considered the most effective treatment for advanced colon adenocarcinoma (COAD)." | 4.31 | FOXM1/NCAPH activates glycolysis to promote colon adenocarcinoma stemness and 5-FU resistance. ( Chen, W; Lei, Y; Tian, X; Wang, D; Wei, J, 2023) |
| "The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy." | 4.31 | The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. ( Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C, 2023) |
| " This case report discusses the clinical trial treatment of a patient with rectal adenocarcinoma by a new ropidoxuridine-capecitabine-radiotherapy combination." | 4.31 | A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer. ( Collins, JM; Kinsella, TJ; Kunos, CA; Piekarz, R, 2023) |
| "The primary mode of therapy for individuals with locally advanced esophageal adenocarcinoma (EAC) is neoadjuvant chemotherapy, commonly 5-Fluorouracil (5-FU)." | 4.31 | Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells. ( Chauhan, A; Cheng, L; Garrett, H; Idrovo, JP; Meguid, RA; Meng, X; Pratap, A; Qualman, A; The, E; Wani, S, 2023) |
| "We hypothesized that perioperative FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) might be used as an alternative to standard FLOT (docetaxel, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with locally advanced oesogastric adenocarcinomas (OGA), particularly those with frailties." | 4.12 | Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma. ( Adenis, A; Khellaf, L; Mazard, T; Mourregot, A; Portales, F; Quesada, S; Samalin, E; Thezenas, S; Ychou, M, 2022) |
| "Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist." | 4.12 | Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. ( Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S, 2022) |
| "Large pragmatic studies of patients who received 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) as initial treatment for localized pancreatic ductal adenocarcinoma (PDAC) are lacking." | 4.12 | FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. ( Besselink, MG; Doppenberg, D; Groot Koerkamp, B; Janssen, QP; Jarnagin, WR; Katz, MHG; O' Reilly, EM; Paniccia, A; Prakash, LR; Tzeng, CD; van Dam, JL; van Eijck, CHJ; Wei, AC; Zureikat, AH, 2022) |
| "Recent studies have suggested the suboptimal efficacy of liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients previously treated with conventional irinotecan." | 4.12 | Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin. ( Bai, LY; Chan, DC; Chen, JS; Chen, LT; Chen, YY; Cheng, FM; Chiang, NJ; Chiu, SC; Chiu, TJ; Chou, WC; Chuang, SC; Hsueh, SW; Li, CP; Peng, CM; Shan, YS; Su, YY; Yang, SH; Yen, CJ, 2022) |
| "Perioperative FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) chemotherapy is a recent regimen used to treat resectable oesophagogastric (OG) adenocarcinoma, associated with improved overall survival versus earlier chemotherapy strategies." | 4.12 | Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. ( Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D, 2022) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 4.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC), but they have not been directly compared in a clinical trial, and comparative clinical data analyses on their effectiveness are limited." | 4.12 | Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. ( Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G, 2022) |
| "Nab -paclitaxel and gemcitabine (GnP) or FOLFIRINOX (a combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin [FFX]) is currently recognized as the standard first-line regimen for unresectable pancreatic ductal adenocarcinoma (PDAC)." | 4.12 | Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. ( Fujita, Y; Hayashi, K; Hirano, A; Hori, Y; Inoue, T; Kataoka, H; Kato, A; Kato, H; Miyabe, K; Naiki-Ito, A; Naitoh, I; Natsume, M; Nishi, Y; Okumura, F; Sano, H; Takada, H; Takahashi, S; Yoshida, M, 2022) |
| "To evaluate response rate, toxicity, and efficacy of the novel combination of nab-paclitaxel, oxaliplatin, 5-fluorouracil, and leucovorin [FOLFOX-A] in patients with advanced pancreatic ductal adenocarcinoma [PDAC]." | 4.12 | The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318. ( Almhanna, K; Beard, RE; Breakstone, R; Dionson, S; Dipetrillo, T; Kastura, M; Leonard, KL; Olszewski, A; Raufi, A; Renaud, J; Safran, H; Sturtevant, A; Wood, R, 2022) |
| "The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan, with or without dose modifications [(m)FOLFIRINOX], for patients with borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is uncertain." | 4.12 | Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. ( Besselink, MG; Crane, CH; Doppenberg, D; Ellsworth, SG; Groot Koerkamp, B; Janssen, QP; Jarnagin, WR; Katz, MHG; O'Reilly, EM; Paniccia, A; Prakash, LR; Reyngold, M; Tzeng, CD; van Dam, JL; van Eijck, CHJ; Wei, AC; Zureikat, AH, 2022) |
| "There is increased use of neoadjuvant fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in the management of localized pancreatic ductal adenocarcinoma (PDAC), yet there are few validated biomarkers of treatment response." | 4.12 | Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. ( Court, CM; D'Angelica, MI; Drebin, JA; Ecker, BL; Gonen, M; Janssen, QP; Jarnagin, WR; O'Reilly, EM; Tao, AJ; Wei, AC, 2022) |
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 4.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| "We report the case of a 74-years old patient with jejunum adenocarcinoma treated by capecitabine." | 4.12 | A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient. ( Botsen, D; Bouche, O; Gossery, C; Gratiaux, J; Rezzag-Mahcene, C; Slimano, F; Visseaux, L, 2022) |
| "The aim of this study was to investigate the antitumor effects of quercetin and luteolin combined with 5-Fluorouracil (5-FU) in HT-29 human colorectal cancer cells." | 4.12 | Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma ( Ağca, CA; Aşkın, H; Erdoğan, MK, 2022) |
| "Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone." | 4.02 | Results of the observational prospective RealFLOT study. ( Antonuzzo, L; Brugia, M; De Vita, F; Di Donato, S; Fancelli, S; Formica, V; Fornaro, L; Giommoni, E; Giovanardi, F; Iachetta, F; Lavacchi, D; Pecora, I; Pillozzi, S; Pompella, L; Pozzo, C; Prisciandaro, M; Puzzoni, M; Romagnani, A; Satolli, MA; Sisani, M; Spallanzani, A; Stragliotto, S; Strippoli, A; Tirino, G, 2021) |
| "Neoadjuvant folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) and chemoradiation have been used to downstage borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC)." | 4.02 | Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. ( Allen, JN; Cai, L; Clark, JW; Deshpande, V; Fernández-Del Castillo, C; Ferrone, CR; Ferrone, S; Hong, TS; Kontos, F; Kurokawa, T; Lillemoe, KD; Michelakos, T; Neyaz, A; Qadan, M; Ryan, DP; Sabbatino, F; Taylor, MS; Ting, DT; Villani, V; Warshaw, AL; Weekes, CD; Wo, JY; Yamada, T, 2021) |
| "FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab is the preferred first-line treatment for right-sided metastatic colorectal cancer with RAS mutation." | 4.02 | Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report. ( Aomatsu, N; Ikeda, K; Kurihara, S; Maeda, K; Matsutani, S; Miyamoto, H; Nishii, T; Okada, T; Tachimori, A; Takeuchi, K; Tsujio, G; Uchima, Y, 2021) |
| "The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma." | 4.02 | Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. ( Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D, 2021) |
| "A combination of nab-paclitaxel plus gemcitabine (N+G) has recently become a standard first-line treatment in patients with metastatic pancreatic adenocarcinoma (MPA), but there are currently no published data concerning second-line treatment after N+G." | 3.96 | Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. ( Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N, 2020) |
| "In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019." | 3.96 | First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. ( Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K, 2020) |
| "FOLFIRINOX [fluorouracil (5-FU), irinotecan, oxaliplatin] and gemcitabine plus nab-paclitaxel are standard treatments for patients with pancreatic ductal adenocarcinoma (PDAC)." | 3.96 | FOLFIRINOX ( Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF, 2020) |
| " In this study we aim to compare the efficacy and toxicity of two regimens FOLFOX (leucoverin, 5-fluorouracil and oxaliplatin) and modified DCF (mDCF) (docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced gastric adenocarcinoma." | 3.96 | Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma. ( Danandeh Mehr, A; Habibzadeh, A; Molaei, M; Pourghasemian, M, 2020) |
| "A 63-year-old Japanese male with stomach adenocarcinoma received oral 5-fluorouracil derivative, cisplatin and trastuzumab chemotherapy." | 3.96 | A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants. ( Fujiki, S; Hiratsuka, A; Ishiguro, M; Kawai, D; Ogura, K; Okada, H; Takeda, H; Takenaka, R; Tsugeno, H, 2020) |
| "We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC)." | 3.91 | Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. ( Abe, Y; Aiura, K; Endo, Y; Fukada, J; Hori, S; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Nakano, Y; Oshima, G; Shinoda, M; Yagi, H, 2019) |
| "The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)." | 3.91 | Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019) |
| " The aim of this study is to determine if SBRT with either chemotherapy (CMT) (Fluorouracil (5FU) or capecitabine) or Nelfinavir (NFV) to pancreatic adenocarcinoma induces lymphopenia to the same degree as CFRT with 5FU or capecitabine and how any associated difference affects patient survival outcomes." | 3.91 | Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. ( Baine, MJ; Li, S; Li, X; Lin, C; Wu, G; Zhao, N, 2019) |
| "Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU." | 3.91 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019) |
| " We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations." | 3.91 | Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. ( Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019) |
| "Eighty-three patients were treated with locally advanced or metastatic adenocarcinoma of the pancreas with either FOLFIRINOX or nab-Paclitxel and Gemcitabine (nabPGem) as first- or second line therapy." | 3.91 | Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? ( Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T, 2019) |
| "Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC)." | 3.91 | Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. ( Bono, P; Hänninen, UA; Karhunen, M; Lamminmäki, A; Osterlund, P; Soveri, LM, 2019) |
| "The objective is to investigate whether thymidylate synthase gene TS 5'-UTR polymorphism of peripheral blood mononuclear cells are associated with clinical outcomes of patients with stage II-III rectal adenocarcinoma treated with adjuvant 5-fluorouracil (5-FU) chemotherapy in Chinese population." | 3.91 | Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy. ( Chen, C; Li, S; Su, X; Wang, G; Xiao, H; Zhang, H, 2019) |
| " Therefore, we examined the effects of flavones against CYR61-overexpressing human gastric adenocarcinoma AGS (AGS-cyr61) cells, which show remarkable resistance to 5-fluorouracil (5-FU), adriamycin (ADR), tamoxifen (TAM), paclitaxel (PAC), and docetaxel (DOC)." | 3.88 | Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( Cho, SK; Hyun, HB; Moon, JY, 2018) |
| "Perioperative epirubicin, cisplatin and 5-FU or capecitabine (ECF/X) chemotherapy is recognised as a standard of care for patients with resectable gastroesophageal adenocarcinoma; however, there is limited evidence regarding its use in older patients." | 3.88 | Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma. ( Hepworth, R; Smith, E; Tin, AW; Wadd, N; Walker, J; Wilson, D, 2018) |
| "Lactoferrin nanoparticles demonstrated an attractive drug delivery module to manage the colon adenocarcinoma as it has improved the antiproliferative activity of 5-FU and Oxaliplatin against colon adenocarcinoma cells." | 3.88 | Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study. ( Ahmed, F; Kondapi, AK; Kumari, S, 2018) |
| "nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited." | 3.88 | Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. ( Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H, 2018) |
| "Improved outcomes with FOLFIRINOX or gemcitabine with nab-paclitaxel in the treatment of metastatic pancreatic adenocarcinoma (PDAC) have prompted incorporation of these regimens into neoadjuvant treatment of locally advanced unresectable PDAC." | 3.88 | Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. ( Allen, JN; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Keane, FK; Kwak, EL; Lillemoe, KD; Ryan, DP; Wo, JY, 2018) |
| "Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated." | 3.85 | 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. ( Cao, L; Du, C; Gu, J; Huang, D; Peng, Y; Wang, H; Yang, Y; Yao, Y; Zhao, Y; Zhu, WG, 2017) |
| " In this study, we chose human colorectal adenocarcinoma cell line HT-29 as the experimental model, and investigated the differential biological effects between 250 mGy single dose LDIR and 250 mGy intermittent LDIR pretreatments in high dose irradiation (HDIR) radiotherapy and 5-fluorouracil (5-FU) based chemotherapy." | 3.85 | Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( Li, Y; Wang, Y; Yang, L; Yin, D, 2017) |
| "Starting 7 days after transplantation of colonic adenocarcinoma colon-26 cells, STZ-treated and control mice were intraperitoneally administered oxaliplatin, fluorouracil, and levofolinate (FOLFOX) every 2 weeks." | 3.85 | Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil. ( Hashida, T; Ikemura, M, 2017) |
| " A 44-year-old male underwent right hemicolectomy followed by capecitabine for a moderately differentiated adenocarcinoma of the colon." | 3.85 | Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE. ( Azrumelashvili, T; Chikovani, T; Janikashvili, N; Kikodze, N; Mizandari, M; Paksashvili, N; Pantsulaia, I; Shanava, K, 2017) |
| "To assess anatomic changes on computed tomography (CT) after neoadjuvant FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) chemotherapy for secondary resected borderline resectable (BR) and locally advanced (LA) pancreatic adenocarcinoma and their accuracy to predict resectability and pathological response." | 3.85 | CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. ( Antunes, C; Bachet, JB; Cassinotto, C; Lucidarme, O; Pietrasz, D; Sa Cunha, A; Wagner, M; Zappa, M, 2017) |
| "To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy." | 3.83 | Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016) |
| "We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer." | 3.83 | In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016) |
| " We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal adenocarcinoma." | 3.83 | A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. ( Beumer, JH; Eads, JR; Holleran, JL; Meropol, NJ; Negrea, L; Strychor, S, 2016) |
| "Ten patients with histologically diagnosed peritoneal metastases of adenocarcinoma or pseudomyxoma peritonei underwent cytoreductive surgery and received HIPEC with 5-fluorouracil for 90 min, delivered via our modified system." | 3.83 | Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin. ( Cavazos, M; Cravioto-Villanueva, A; Esquivel, J; Luna-Perez, P; Martinez-Gomez, H; Montiel, H; Ramirez, ML; Solorzano, J, 2016) |
| " In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms." | 3.83 | Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. ( Li, F; Li, G; Liu, H; Ruan, Z; Wang, X; Wang, Y; Xie, X; Yu, H; Zhang, J; Zhou, Y, 2016) |
| "A 17 year-old male with metastatic pancreatic adenocarcinoma, under chemotherapy containing 5-fluorouracil, presented severe left ventricular dysfunction requiring mechanical ventilation and inotropes administration." | 3.83 | Transient global ventricular dysfunction in an adolescent affected by pancreatic adenocarcinoma. ( Chinali, M; De Pasquale, MD; De Sio, L; Giordano, U; Grimaldi, C; Mastronuzzi, A; Serra, A, 2016) |
| "When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis." | 3.83 | Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. ( Abe, N; Fujinaga, A; Hayashi, H; Hirata, K; Ito, K; Komatsu, Y; Matsuda, K; Uchida, T, 2016) |
| "Two estrogen receptor (ER)-positive esophageal adenocarcinoma cell lines (OE-19 and OE-33) were treated with combinations of tamoxifen, cisplatin and 5-fluorouracil (5-FU)." | 3.83 | Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells. ( Astill, DS; Bastian, I; Ding, GQ; Due, SL; Hussey, DJ; Sukocheva, OA; Vat, L; Watson, DI, 2016) |
| "Perioperative chemotherapy with 5-fluorouracil and cisplatin, with or without epirubicin, improves overall survival in resectable gastroesophageal junction and gastric adenocarcinoma." | 3.83 | Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. ( Afchain, P; Aparicio, T; Artru, P; Bachet, JB; Baumgaertner, I; Benallaoua, M; Boige, V; Boubaya, M; Coriat, R; des Guetz, G; Lecaille, C; Locher, C; Mary, F; Samalin, E; Tougeron, D; Zaanan, A, 2016) |
| "To compare the treatment outcomes of concurrent involved-field radiotherapy and XELOX (oxaliplatin and capecitabine) versus XELOX chemotherapy alone in gastric adenocarcinoma patients with locoregional recurrence." | 3.81 | Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. ( Huang, Y; Li, WH; Li, YQ; Liu, N; Liu, SG; Liu, XB; Liu, YH; Wang, FL; Yu, J; Yuan, ST; Zhang, JD; Zhang, Y, 2015) |
| "The MAGIC/UK Medical Research Council (MRC) trial set the standard of care for treatment of resectable gastric and junctional adenocarcinoma, demonstrating that perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (ECF) confers a survival benefit over surgery alone." | 3.81 | Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. ( Kalachand, R; King, S; Mongan, AM; Muldoon, C; O'Byrne, K; O'Farrell, NJ; Power, D; Ravi, N; Reynolds, JV, 2015) |
| "First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine." | 3.81 | FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. ( Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I, 2015) |
| " Here, we showed that miR-22 inhibited autophagy and promoted apoptosis to increase the sensitivity of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment both in vitro and in vivo." | 3.81 | MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. ( Kong, J; Lai, M; Li, C; Tang, J; Wang, J; Wu, Y; Xu, E; Zhang, H, 2015) |
| "Patients with locally advanced (cT3 or N+) esophageal and esophagogastric junction adenocarcinoma undergoing neoadjuvant TCF [Taxotere, cisplatin 5-fluorouracil (5-FU)], ECF (epirubicin, cisplatin, 5-FU), or FLOT (docetaxel, oxaliplatin, leucovorin, and 5-FU) at the McGill University Health Center from March 2007 to September 2012 were identified from a prospective database." | 3.81 | Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided? ( Alcindor, T; Asselah, J; Cools-Lartigue, J; Eckert, E; Ferri, LE; Jones, D; Rousseau, M; Spicer, J; Vanhuyse, M; Zourikian, T, 2015) |
| "An aptamer (Apt) conjugated hyaluronan/chitosan nanoparticles (HACSNPs) were prepared as carrier for targeted delivery of 5-fluorouracil (5FU) to mucin1 (MUC1) overexpressing colorectal adenocarcinomas." | 3.81 | Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. ( Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Ghasemi, Z; Mottaghitalab, F; Sayari, E, 2015) |
| "The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma." | 3.81 | Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015) |
| "Perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (5-FU) (ECF)-like regimens is the European standard for patients with adenocarcinoma of the gastroesophageal junction (GEJ) or gastric body (GaCa) stage UICC II/III (staged according to the Union for International Cancer Control)." | 3.81 | High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma. ( Bichev, D; Breithaupt, K; Daum, S; Dogan, Y; Schmidt, SC; Thuss-Patience, PC; Treese, C; von Winterfeld, M, 2015) |
| "In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity." | 3.81 | Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. ( Candamio-Folgar, S; Lopez-Lopez, R; Martínez-Lago, N; Padin-Iruegas, ME; Vazquez-Rivera, F; Vidal-Insua, Y; Vieito-Villar, M, 2015) |
| "The combination of 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX) is considered the first-line chemotherapy for fit patients with advanced pancreatic ductal adenocarcinoma (PDAC) but carries an unfavourable adverse event (AE) profile." | 3.81 | Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. ( Basu, B; Calder, J; Corrie, P; Ghorani, E; Hewitt, C; Wong, HH, 2015) |
| "Hand-foot syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy." | 3.80 | Topical henna ameliorated capecitabine-induced hand-foot syndrome. ( Ilyas, S; Saif, MW; Wasif, K, 2014) |
| " A 65-year-old man started chemotherapy for metastatic pancreatic adenocarcinoma with oxaliplatin-irinotecan-leucovorin-5-fluorouracil (FOLFIRINOX)." | 3.80 | A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria. ( Dasanu, CA; Joseph, R, 2014) |
| "Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse." | 3.80 | AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. ( Arthur, K; Blayney, JK; Dunne, PD; Greer, S; Johnston, PG; Kalimutho, M; Longley, DB; Loughrey, M; McArt, DG; Ong, CW; Redmond, K; Salto-Tellez, M; Srivastava, S; Van Schaeybroeck, S; Wang, T, 2014) |
| " In the present study, we evaluated ERCC1 expression levels in uterine cervical adenocarcinoma cell lines to assess whether they are affected by treatment with cisplatin with and without 5-fluorouracil (5-FU)." | 3.80 | ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. ( Fujii, T; Hasegawa, K; Kato, R; Minami, Y; Torii, Y; Udagawa, Y, 2014) |
| " The aim of this study is to evaluate the efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy in advanced gastric adenocarcinoma patients in China." | 3.80 | Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. ( Bai, L; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, RH; Yang, DJ; Zhang, DS; Zhou, YX, 2014) |
| "To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping." | 3.80 | FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. ( Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS, 2014) |
| "A 71-year-old patient receiving combination chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil (5-FU)) for metastatic pancreas cancer was admitted after her first cycle of chemotherapy with a severe and unexpectedly prolonged episode of neutropenic sepsis associated with pancytopenia and marked mucositis." | 3.80 | A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer. ( Gillmore, R; Suarez Martinez-Falero, B, 2014) |
| "We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer." | 3.80 | The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014) |
| "Current NCCN guidelines recommend epirubicin (E), cisplatin (C), and 5-fluorouracil (F) as a first-line therapeutic approach for operable gastric adenocarcinoma (GC)." | 3.80 | Molecular profiling in gastric cancer: examining potential targets for chemotherapy. ( Christians, KK; Eastwood, D; Gamblin, TC; George, B; Johnston, FM; Miura, JT; Thomas, J; Tsai, S; Turaga, KK, 2014) |
| "Our clinical study indicates esophageal adenocarcinoma patients on metformin had a better treatment response than those without metformin." | 3.80 | Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. ( Ajani, JA; Chen, Q; Honjo, S; Johnson, RL; Scott, AW; Skinner, HD; Song, S; Stroehlein, J, 2014) |
| "We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer." | 3.80 | An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014) |
| "The aim of this study was to investigate the antitumor effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling, combined with 5-fluorouracil treatment on CT-26 colorectal adenocarcinoma cells implanted into BALB/c mice." | 3.80 | The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells. ( Chang, GR; Chao, TH; Chen, PL; Chen, WY; Mao, FC, 2014) |
| "Patients with biopsy-proven adenocarcinoma of the rectum staged cT3-T4 by endoscopic ultrasound or magnetic resonance imaging received neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy." | 3.80 | Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. ( Ayuso-Colella, JR; Bombí, JA; Burkholder, I; Castells, A; Conill, C; Cuatrecasas, M; Delgado, S; Feliz, L; Fernández-Esparrach, G; Gallego, R; García-Albéniz, X; Ginés, A; Hochhaus, A; Hofheinz, RD; María de Lacy, A; Maurel, J; Miquel, R; Pagés, M; Pereira, V; Pineda, E; Reig, O; Sosa, A; Victoria, I, 2014) |
| "The aim of the present study was to evaluate the change of thymidine phosphorylase (TP) activity in gastric adenocarcinoma and adjacent tissue upon the intraarterial administration of 5-fluorouracil (5-FU)." | 3.80 | The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue. ( Dumanskiy, Y; Khomutov, E; Matviyenko, A; Stashkevych, M; Zinkovych, I, 2014) |
| "From March 2009 through April 2012, 22 patients were treated with proton therapy and concomitant capecitabine (1000 mg PO twice daily) for resected (n = 5); marginally resectable (n = 5); and unresectable/inoperable (n = 12) biopsy-proven pancreatic and ampullary adenocarcinoma." | 3.79 | Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. ( Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA, 2013) |
| "The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma." | 3.79 | Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. ( Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013) |
| " This study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the Bcl-2 gene would enhance the apoptosis and sensitivity of gastric adenocarcinoma SGC-7901 cell to 5-Fluorouracil." | 3.79 | Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. ( Liu, H; Liu, Y; Wu, FR; Xia, Q; Yu, DF, 2013) |
| "The efficacy of triple-drug combination regimens such as docetaxel, cisplatin and 5-fluorouracil (DCF), and epirubicin, oxaliplatin and capecitabine (EOX), is superior to standard cisplatin/5-fluorouracil in patients with upper gastrointestinal adenocarcinoma." | 3.79 | Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract. ( Asari, R; Ba-Ssalamah, A; Birner, P; Hejna, M; Ilhan-Mutlu, A; Pluschnig, U; Preusser, M; Püspök, A; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the first line treatment of advanced gastric adenocarcinoma." | 3.79 | Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma. ( Liu, Y; Ma, T; Shi, M; Xi, W; Yang, L; Ye, Z; Zhang, J; Zhu, Z, 2013) |
| "The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer." | 3.79 | Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013) |
| " In this study, we had investigated the synergistic effects of low dose fluorouracil (5-Fu) and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells and explored the potential mechanisms." | 3.79 | The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. ( He, J; Huang, M; Huang, Y; Ren, D; Yi, C; Zhao, F; Zhu, H, 2013) |
| " We aimed to investigate the effects of fish oil emulsion (FOE) rich in n-3 PUFA with the standard chemotherapeutic agents 5-fluorouracil (5-FU), oxaliplatin (OX) or irinotecan (IRI) on two human colorectal adenocarcinoma cells with different genetic backgrounds." | 3.79 | Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway. ( Cai, F; Clerc, A; Dupertuis, YM; Granci, V; Lecumberri, E; Pichard, C, 2013) |
| "The prognostic impact of CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) on the treatment outcome of colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) is unclear." | 3.79 | Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 3.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| " Surgery Division of Verona University, 155 consecutive patients with locally advanced esophageal cancers (90 SCC, 65 adenocarcinoma) were treated with a single protocol of neoadjuvant CRT (docetaxel, cisplatin, and 5-fluorouracil with 50." | 3.79 | Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. ( Casella, F; de Manzoni, G; Giacopuzzi, S; Pasini, F; Verlato, G; Weindelmayer, J; Zanoni, A; Zhao, E, 2013) |
| " This study sought to enrich cancer stem cells and explore cancer stem-like cell clones using 5-fluorouracil (5-FU) in the lung adenocarcinoma cell line, SPC." | 3.79 | Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC. ( Jia, XS; Li, X; Li, XL; Shi, MM; Wang, EH; Xiong, YL; Zhang, L, 2013) |
| " The aim of this study is to retrospectively evaluate the safety and efficacy of adjuvant epirubicin-based triplet chemotherapy and radiotherapy in the treatment of resected locally advanced stomach or gastroesophageal junction adenocarcinoma." | 3.79 | Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. ( Cai, G; Li, G; Ma, X; Zhang, Z; Zhu, J, 2013) |
| "Patients with Dukes' B colon cancer benefit from adjuvant chemotherapy and should be presented with this treatment option." | 3.79 | Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) ( Atkins, JN; Bear, HD; Jones, J; Mamounas, E; Rockette, H; Song, K; Wieand, S; Wolmark, N, 1999) |
| "The aim of this study was to determine the pathological complete remission (pCR) rate, and its relationship to clinical outcome, in patients with adenocarcinoma of the stomach or oesophagogastric junction receiving preoperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) every 2 weeks." | 3.78 | Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. ( Al-Batran, SE; Altmannsberger, HM; Atmaca, A; Bruch, HP; Homann, N; Jäger, E; Luley, K; Noack, F; Pauligk, C; Werner Kraus, T, 2012) |
| "Studies treating adenocarcinoma of the pancreas with gemcitabine alone or in combination with a doublet have demonstrated modest improvements in survival." | 3.78 | A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. ( Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L, 2012) |
| "FOLFOXIRI demonstrated higher efficacy compared to 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer." | 3.78 | Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. ( Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E, 2012) |
| "We assessed DNA repair efficiency over time, in vitro, in human colon adenocarcinoma HT-29 (wild-type KRAS) and HCT-116 (mutated KRAS) cell lines treated with Dbait in combination with 5-fluorouracil and/or camptothecin." | 3.78 | Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. ( Berger, F; Biau, J; Bousquet, G; Devun, F; Dutreix, M; Herbette, A; Robine, S; Roulin, C; Sun, JS, 2012) |
| "The patients with local advanced and metastatic colorectal cancer, receiving fluorouracil-based chemotherapy, and with an average plasma concentration of fluorouracil between 25 - 35 mg/L have a better prognosis, and lower incidence of adverse reactions such as bone marrow suppression, mucositis and diarrhea." | 3.78 | [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ( Cai, X; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2012) |
| "Human adenocarcinoma cells, colonic (Caco-2) and ovarian (59 M) cells, were incubated with 5-fluorouracil (1-300 µg·mL(-1) ) or paclitaxel (1-200 µg·mL(-1) ) in the presence or absence of platelets (1." | 3.78 | Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. ( Bazou, D; Inkielewicz-Stepniak, I; Jow, H; Medina, C; O'Driscoll, L; Radomski, A; Radomski, MW; Radziwon-Balicka, A; Treumann, A, 2012) |
| "A recent study showed that both 5-fluorouracil (5FU)-stimulated apoptosis and Fas-mediated apoptosis in human endometrial adenocarcinoma cells are enhanced by targeted knockdown of endogenous death-associated protein kinase (DAPK) with DAPK small-interfering RNAs." | 3.78 | Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells. ( Bai, T; Tanaka, J; Tanaka, T; Toujima, S; Utsunomiya, H; Utsunomiya, T; Yukawa, K, 2012) |
| "Capecitabine plus oxaliplatin combination (XELOX) is the first-line treatment in metastatic colorectal cancer." | 3.78 | Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. ( Alì, G; Calabrese, R; Lenzi, P; Moretti, P; Orsucci, D; Petrozzi, L; Pizzanelli, C; Ricci, G; Siciliano, G, 2012) |
| "Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 3.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
| "To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts." | 3.78 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. ( Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P, 2012) |
| " The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy." | 3.78 | Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012) |
| "Fourteen cases of metastatic brain tumors from lung cancer underwent biochemical modulation chemotherapy with daily administration of small doses of CDDP (5 or 10 mg/day) and continuous infusion of 5-FU (300 mg/day) for three tow six weeks." | 3.78 | [Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer]. ( Hagiwara, Y; Kanayama, T; Moriuchi, S; Nakagawa, H; Yamada, M, 1997) |
| "To assess whether early lung cancer prediction might be informed by an mRNA assay for 5-fluorouracil pathway genes in peripheral blood mononuclear cells (PBMNCs), we examined specimens taken from 51 adenocarcinoma patients and 38 controls (including six patients with benign tumors)." | 3.77 | A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma. ( Aida, S; Fujita, Y; Hasegawa, S; Hiroi, S; Kawai, T; Mio, T; Nakanishi, K; Ogata, S; Ozeki, Y; Takeuchi, K; Tanaka, F; Tominaga, S; Wada, H, 2011) |
| "Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities." | 3.77 | Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. ( Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S, 2011) |
| "Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed." | 3.77 | Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. ( Haier, J; Hummel, R; Hussey, DJ; Kist, J; Michael, MZ; Smith, C; Watson, DI, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 3.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "The aim of this retrospective study was to evaluate the efficacy and safety of weekly high-dose 5-fluorouracil (5-FU)/folinic acid (FA) as 24-h infusion (AIO regimen) plus irinotecan in patients with histologically proven metastatic gastroesophageal adenocarcinoma (UICC stage IV)." | 3.77 | Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b ( Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011) |
| " Here we show that ATP-binding cassette member B5 (ABCB5) identifies therapy-refractory tumor cells in colorectal cancer patients following fluorouracil (5-FU)-based chemoradiation therapy and provide evidence for a functional role of ABCB5 in colorectal cancer 5-FU resistance." | 3.77 | ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. ( Frank, MH; Frank, NY; Gasser, M; Gold, JS; Huang, Q; Ma, J; Murphy, GF; Saab, KR; Schanche, R; Schatton, T; Waaga-Gasser, AM; Wilson, BJ; Zhan, Q, 2011) |
| "FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients." | 3.77 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "Regimens containing bevacizumab and 5-fluorouracil have achieved substantial progress in the treatment of colorectal cancer." | 3.77 | Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. ( Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Matsuda, K; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "A retrospective analysis was carried out to evaluate toxicity and efficacy of the combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil (DCF) plus granulocyte colony-stimulating factor prophylaxis (G-CSF) in patients with metastatic gastric and gastroesophageal junction adenocarcinoma." | 3.77 | Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna. ( Ba-Ssalamah, A; Bojic, M; Datler, P; Hejna, M; Maresch, J; Pluschnig, U; Schoppmann, SF; Thallinger, CM; Zacherl, J, 2011) |
| "XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with metastatic colorectal cancer (MCRC)." | 3.77 | Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. ( Chau, J; Chua, DT; Lee, AW; Lee, V; McGhee, SM; Ng, WT; Tse, VC, 2011) |
| "To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA)." | 3.77 | 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. ( Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M, 2011) |
| "The aim of this study was to investigate efficacy and toxicity of a modified 5-fluorouracil (5-FU), folinic acid, oxaliplatin (mFOLFOX-4) regimen followed by infusional 5-FU concomitant with radiotherapy for curatively resected stage III rectum adenocarcinoma patients." | 3.77 | Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma. ( Aksoy, S; Babacan, NA; Cihan, Ş; Odabaş, H; Öksüzoğlu, B; Özdemir, N; Uncu, D; Zengin, N, 2011) |
| " Perioperative treatment with epirubicin, cisplatin, and 5-fluorouracil combination chemotherapy and surgery is considered the standard treatment of locally advanced gastric adenocarcinoma." | 3.77 | Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer. ( Amini, A; Sanati, H, 2011) |
| "To investigate anticancer effects of 5-fluorouracil (5-FU) combined with CL, extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma cell line (JEC)." | 3.77 | [Anticancer effect of 5-fluorouracil combined with extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma]. ( Dai, ZK; Yang, XS; Yu, LM, 2011) |
| "The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively." | 3.77 | Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. ( Cho, YB; Choi, SH; Chun, HK; Chung, HJ; Kim, HC; Lee, WY; Yun, SH, 2011) |
| "For a woman with poorly-differentiated anal canal adenocarcinoma in acknowledgment of metastasis to right inguinal lymph node, we gave radiotherapy combined with capecitabine as chemotherapy." | 3.77 | [Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node]. ( Ide, Y; Makino, S; Murata, K, 2011) |
| "5-fluorouracil was administered at a daily dose of 450 mg/m2 followed by folinic acid 200 mg/m2 for four consecutive days every four weeks." | 3.77 | Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature. ( Briassoulis, E; Klouvas, G; Nicolaides, C; Pavlidis, N, 1994) |
| "Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required." | 3.77 | Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993) |
| "Current and proposed trials in esophageal cancer have changed their focus accordingly to meet this new treatment challenge." | 3.77 | The use of mitomycin in esophageal cancer. ( Coia, LR, 1993) |
| "Mitomycin has also demonstrated efficacy when given in combination with doxorubicin and in the three-drug regimen FAM (5-fluorouracil/doxorubicin/mitomycin)." | 3.77 | Mitomycin therapy in gastric cancer. ( Macdonald, JS; Schnall, S, 1993) |
| "Levamisole is a synthetic, orally active agent that has antihelmintic and immunomodulatory properties." | 3.77 | Levamisole in the adjuvant treatment of colon cancer. ( Hutson, PR; Mutch, RS, 1991) |
| "To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo." | 3.76 | Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ( Jiang, Y; Luo, H; Yin, A; Zhang, X, 2010) |
| " We investigated whether p53 polymorphism and mutation were associated with in vitro sensitivity to 5-fluorouracil (5-FU) in patients with colorectal cancer." | 3.76 | Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. ( Higashiguchi, T; Hotta, T; Iwahashi, M; Matsuda, K; Nasu, T; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2010) |
| "The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX)." | 3.76 | Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. ( Cuilliere-Dartigues, P; de Gramont, A; Dumont, S; Duval, A; Fléjou, JF; Gayet, B; Guilloux, A; Louvet, C; Parc, Y; Praz, F; Tiret, E; Validire, P; Zaanan, A, 2010) |
| "The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX)." | 3.76 | EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. ( Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG, 2010) |
| "5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma." | 3.76 | A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma. ( Akboru, H; Bati, Y; Isikli, L; Unsal, M; Yoney, A, 2010) |
| "We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma." | 3.76 | [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. ( Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK, 2010) |
| "We examined the pre-treatment tumour biopsies (n=40) obtained from patients with rectal adenocarcinoma (clinical International Union Against Cancer stage ll/III) who were scheduled to receive neoadjuvant 5-fluorouracil-based chemoradiotherapy for EGFR, VEGF and HIF-1 expression by quantitative real-time polymerase chain reaction." | 3.76 | Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg ( Inoue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2010) |
| "A 78-year-old male with stage III colorectal adenocarcinoma was prescribed with weekly iv 5-fluorouracil and folinic acid (FU/FA)." | 3.76 | Do 5-fluorouracil therapies alter CYP2C19 metaboliser status? ( Helsby, NA; Laking, GR; Lo, WY; Thompson, P, 2010) |
| " In the first phase III study, the ToGA trial, HER2-positive patients with advanced gastroesophageal and gastric adenocarcinoma were randomized to receive 5-fluorouracil/capecitabine and cisplatin either alone or in combination with trastuzumab." | 3.76 | Targeted HER2 treatment in advanced gastric cancer. ( Jørgensen, JT, 2010) |
| "Survival and recurrence patterns of 91 patients with adenocarcinoma of the stomach who had received surgery followed by radiotherapy combined with fluorouracil and leucovorin (n = 5), capecitabine (n = 39), or capecitabine and cisplatin (n = 47) were analyzed and compared with survival and recurrence patterns of 694 patients from the DGCT (D1, n = 369; D2, n = 325)." | 3.76 | Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. ( Bakker, B; Boot, H; Cats, A; Dikken, JL; Hartgrink, HH; Jansen, EP; Kranenbarg, EM; Peeters, KC; Putter, H; van de Velde, CJ; Verheij, M, 2010) |
| " Using multiparameter cytometry we explored the effects of doxorubicin (DOX), cisplatin (CDDP) and 5-fluorouracil (5-FU) on four types of endometrioid adenocarcinoma cell lines (HEC-1A, HEC-1B, Ishikawa, KLE) correlating the drug-induced increases in phosphorylated H2AX (gammaH2AX) with cell cycle phase, induction of apoptosis and induction of cell senescence, the latter detected by analysis of beta-galactosidase." | 3.76 | DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. ( Darzynkiewicz, Z; Ikeda, M; Kurose, A; Sawai, T; Sugiyama, T; Takatori, E; Traganos, F, 2010) |
| " In this study, we examined the chemoresistance to 5-Fluorouracil (5-FU) using MCF-7 breast cancer MTS." | 3.76 | Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids. ( Jeon, HM; Jeong, EK; Kang, HS; Kim, CH; Lee, SY, 2010) |
| "Epirubicin, cisplatin or 5-fluorouracil was administered to severe combined immune-deficient mice bearing OE19 oesophageal adenocarcinoma xenografts." | 3.76 | Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. ( Appleyard, V; Baker, L; Exon, D; Kelly, P; Lamont, D; Murray, K; Paulin, F; Suttie, S; Thompson, A, 2010) |
| "The aim of this study was to determine whether pretherapeutic protein expression levels of the excision repair cross-complementing (ERCC1) enzyme, thymidylate synthetase (TS), multidrug-resistance protein 1 (MRP-1) and P-glycoprotein (P-gp) are associated with tumour response to cisplatin and fluorouracil (5-FU)-based neoadjuvant chemotherapy in oesophageal adenocarcinomas." | 3.76 | High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. ( Becker, K; Feith, M; Hofler, H; Langer, R; Lordick, F; Ott, K; Specht, K, 2010) |
| "To investigate acquired 5-fluorouracil (5FU)-resistance in cancer cells, we established four monoclonal 5FU-resistant cell lines from human endometrial adenocarcinoma cells by long-term 5FU-exposure cultures and limiting dilution cultures." | 3.76 | Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma. ( Bai, T; Tanaka, T; Toujima, S, 2010) |
| "Between January 2006 and November 2009, 17 patients (median age of 61 years) with advanced pancreatic adenocarcinoma, after receiving gemcitabine-containing chemotherapy as first-line median ECOG performance status 1 and with adequate organ function, were treated with either weekly docetaxel at 25 mg/m(2) or 3-weekly docetaxel regimen (docetaxel at 75 mg/m(2) or docetaxel-gemcitabine-capecitabine or docetaxel-gemcitabine) until progressive disease." | 3.76 | Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. ( Kaley, K; Penney, R; Saif, MW; Syrigos, K, 2010) |
| "One hundred fifty-six patients with locally advanced or metastatic esophageal adenocarcinoma received neoadjuvant chemotherapy with cisplatin, 5-fluorouracil, and leucovorin followed by resection." | 3.76 | Interleukin-10 and -12 predict chemotherapy-associated toxicity in esophageal adenocarcinoma. ( Friess, H; Holzmann, B; Knoefel, WT; Peiper, M; Schauer, MC; Theisen, J, 2010) |
| "The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients." | 3.76 | Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010) |
| "A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas." | 3.75 | Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. ( Araki, O; Chida, M; Honma, K; Ishihama, H; Karube, Y; Masawa, N; Miyoshi, S; Seki, N; Tamura, M; Umezu, H, 2009) |
| " In the present study we investigate the effects of HIF-1 modulation on the response of the human colon adenocarcinoma cell line HCT116 to 5-fluorouracil (5FU)." | 3.75 | Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. ( Gariboldi, MB; Marras, E; Molteni, R; Monti, E; Perletti, G; Ravizza, R, 2009) |
| "The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy." | 3.75 | Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. ( Choi, HJ; Kim, DC; Kim, HJ; Kim, SH; Kwon, HC; Lee, DM; Lee, JH; Lee, S; Oh, SY; Park, KJ; Roh, MS, 2009) |
| "We report an elderly patient with esophageal adenocarcinoma in whom a complete response (CR) was obtained by chemoradiotherapy using daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU." | 3.75 | [A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation]. ( Furuta, T; Futami, H; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kodaira, C; Muramatsu, A; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Yamada, T; Yoshida, K, 2009) |
| "A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described." | 3.75 | A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. ( Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2009) |
| "The correlations between adenomatous polyposis coli (APC) mutations and 5-fluorouracil (5-FU) adjuvant chemotherapy and colorectal cancer (CRC) patients' prognosis are not well known." | 3.75 | Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Su, CC; Wu, CC, 2009) |
| "Stage II-III colorectal cancer patients treated with adjuvant FOLFOX or fluorouracil/leucovorin (5-FU/LV) at Roswell Park Cancer Institute between 2002 and 2006 were identified." | 3.75 | Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. ( Angitapalli, R; Fakih, MG; Kumar, PR; Litwin, AM; Lombardo, J; Mashtare, T; Nasser, E; Wilding, GE, 2009) |
| "It is the aim of this study to assess the outcome of patients who received neoadjuvant 5-fluorouracil-cisplatin chemoradiation (CRT) for stage I/III pancreatic adenocarcinoma." | 3.75 | Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. ( de Chaisemartin, C; Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F, 2009) |
| "As surgery and chemotherapy may act as adjuvants providing antitumor immunity benefits, we ran phenotypical and functional immunomonitoring in patients with resectable pancreatic adenocarcinoma and advanced metastatic disease receiving combined treatment (cisplatin, gemcitabine, 5-FU)." | 3.75 | Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. ( Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B, 2009) |
| " The authors of this report reviewed their experience in a consecutive, unselected series of patients who received adjuvant 5-fluorouracil (5-FU) and radiation therapy (RT) for resected pancreatic adenocarcinoma." | 3.75 | Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. ( Hattangadi, JA; Hong, TS; Mamon, HJ; Yeap, BY, 2009) |
| " We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy." | 3.75 | Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. ( Mendiola, C; Vaz, MA, 2009) |
| "We studied 150 surgically resected colorectal adenocarcinoma patients who received postoperative 5-Fluorouracil (5-FU) chemotherapy." | 3.75 | Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. ( Bronner, MP; Chang, SJ; Cho, MY; Eom, M; Kim, IY; Kim, MD; Koh, SB; Ren, DN; Seong, SH; Yi, SY, 2009) |
| "One hundred and twenty-one MCRC patients with histologically proven adenocarcinoma and baseline ECOG performance status of < or =2 were treated with oxaplatin and (or) irinotecan-based chemotherapy regimens." | 3.75 | [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. ( An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH, 2009) |
| "5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration." | 3.75 | Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. ( Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE, 2009) |
| "5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma." | 3.75 | APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. ( Aly, E; Binnie, N; Collie-Duguid, ES; Gilbert, F; Loudon, M; MacDonald, G; McKinlay, A; Murray, GI; O'Kelly, T; Petty, RD; Samuel, LM; Semple, S; Wang, W, 2009) |
| " The aim of this study was to elucidate whether hyperoxia also enhances any actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes in the interstitium and extracellular matrix." | 3.75 | Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. ( Kolmannskog, O; Moen, I; Reed, RK; Salvesen, GS; Stuhr, LE; Tronstad, KJ, 2009) |
| "Human colorectal cancer cells were treated, individually and in combination, with Rosco, taxol, 5-Fluorouracil (5-FU), doxorubicine or vinblastine." | 3.74 | Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. ( Abaza, MS; Al-Attiyah, RJ; Bahman, AM, 2008) |
| "We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus." | 3.74 | Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. ( Fujii, Y; Fukui, I; Ishikawa, Y; Kawakami, S; Komai, Y; Okubo, Y; Takeshita, H; Tatokoro, M; Yamamoto, S; Yonese, J, 2008) |
| "Preoperative chemoradiation with 5-fluorouracil (5-FU) has improved local control and resectability in patients with locally advanced rectal adenocarcinoma." | 3.74 | Early clinical results from chemoradiation with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer. ( Kauh, J; Koshy, M; Landry, J; Lawson, JD; Staley, C, 2008) |
| "To compare the efficacy and tolerability of the regimen FOLFOX [1eucovorin (LV), 5-fluorouracil (5-Fu) and oxaliplatin] and the regimen PLF (Paclitaxel, leucovorin and 5-Fu) for treatment of advanced gastric adenocarcinoma." | 3.74 | [FOLFOX versus PLF regimen in treatment of advanced gastric adenocarcinoma]. ( Huang, Y; Lin, TY; Rong, J; Xiao, J; Ye, S; Zhai, LZ, 2008) |
| "To present our clinical experience of 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen administered as an adjuvant chemotherapy to 2 patients with advanced jejunal adenocarcinoma." | 3.74 | Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases. ( Chen, CW; Hsieh, JS; Su, YC; Wang, JY; Wang, WM; Wu, JY, 2008) |
| " This article presents the case of a 69-year-old African American man with a gastric adenocarcinoma status post gastrectomy who received 5-fluorouracil (5-FU) plus leucovorin for 5 days, to be followed by radiation plus capecitabine given 5 days per week for 5 weeks, and then 8 weeks of capecitabine monotherapy." | 3.74 | Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? ( Saif, MW; Sandoval, A, 2008) |
| "We have evaluated the 5-fluorouracil sensitivity of cancer cells from colorectal cancer patients using the collagen gel droplet embedded drug sensitivity test under multiple drug concentrations and contact durations." | 3.74 | Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis. ( Futagawa, S; Kitajima, M; Konishi, N; Nagaoka, I; Nishimura, K; Noguchi, H; Ochiai, T; Sato, G; Watanabe, T, 2007) |
| "We aimed at developing a more detailed understanding of cyclin D1 in early stage human breast cancer and defining the biologic profiles with different prognostic value correlating cyclin D1 gene amplification and chromosome 11 aneusomy with bio-pathologic variables of known clinical importance." | 3.74 | Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile. ( Buglioni, S; Cianciulli, A; Cognetti, F; Di Benedetto, A; Merola, R; Mottolese, M; Orlandi, G; Perracchio, L; Pinnarò, P; Sperduti, I; Venturo, I, 2007) |
| "Docetaxel, capecitabine and 5-fluorouracil have been shown to be active in the treatment of metastatic gastric adenocarcinoma." | 3.74 | Chemoimmunotherapy in the treatment of metastatic gastric cancer. ( Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G, 2007) |
| "To evaluate the efficacy and safety of a regimen using Irinotecan, 5FU and Leucovorin for patients with advanced or recurrent colorectal cancer." | 3.74 | Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. ( Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y, 2007) |
| "Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors." | 3.74 | Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? ( Barten, M; Ostwald, C; Prall, F; Schiffmann, L, 2007) |
| "Cetuximab (Erbitux) in combination with irinotecan is the most promising combination in heavily pretreated patients with advanced colorectal cancer." | 3.74 | Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. ( Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M, 2007) |
| "A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer." | 3.74 | Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007) |
| "Oxaliplatin, Irinotecan, 5-fluorouracil and leucovorin are commonly used to treat advanced colorectal cancer in Western countries." | 3.74 | Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer. ( Aso, M; Higashi, H; Imamura, S; Kakeji, Y; Katoh, H; Maehara, S; Maehara, Y; Makino, I; Saeki, H; Tanaka, J, 2007) |
| "We report a 59-year-old woman diagnosed with metastasic colorectal cancer who developed immune hemolytic anemia during FOLFOX chemotherapy (oxaliplatin/leucovorin/5-fluorouracil)." | 3.74 | Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. ( Albiol, S; Cobo, F; De Celis, G; Latorre, X; Pereira, A; Pujadas, J, 2007) |
| "Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas." | 3.74 | Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Ouchida, M; Soh, J; Suehisa, H; Takata, M; Toyooka, S; Uchida, A, 2007) |
| " Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer." | 3.74 | [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. ( Park, KG; Smith, TA; Suttie, SA, 2007) |
| "We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy." | 3.74 | Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. ( Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S, 2007) |
| " Therefore, we analyzed expression and prognostic significance of E2F-1 along with thymidylate synthase (TS) in R(0)-resected gastric adenocarcinoma patients, who underwent adjuvant chemoradiation therapy with 5-fluorouracil (5-FU) and leucovorin." | 3.74 | Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. ( Heo, JS; Kang, WK; Kim, KM; Kim, S; Lee, I; Lee, J; Lim, DH; Lim, HY; Lim, T; Noh, JH; Park, CK; Park, JO; Park, YS; Sohn, TS, 2008) |
| "Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)." | 3.74 | Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. ( Diasio, RB; Han, HC; Iacopetta, B; Joseph, D; Ng, SS; Salto-Tellez, M; Shah, N; Soo, RA; Soong, R; Tai, BC; Tan, WL; Zeps, N, 2008) |
| "Formalin fixed, paraffin embedded pre-therapeutical tumor biopsies (n = 22) and post-therapeutical resection specimens (n = 40) from patients with rectal adenocarcinoma (clinical UICC stage II/III) receiving standardized neoadjuvant 5-fluorouracil (5-FU) based chemoradiotherapy were studied for Ki67 and p53 expression by immunohistochemistry and correlated with TS mRNA expression by quantitative TaqMan real-time PCR after laser microdissection." | 3.74 | Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. ( Aust, DE; Baretton, GB; Becker, H; Jakob, C; Liersch, T; Meyer, W, 2008) |
| "The chemotherapy regimen suitable for advanced colorectal cancer patients previously treated with 5 fluorouracil (5FU); oxaliplatin and irinotecan remains an unresolved issue." | 3.74 | A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. ( Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E, 2008) |
| "To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma." | 3.73 | Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. ( Adams, R; Jones, RS; Keene, KS; Penberthy, DR; Rich, TA; Shepard, RC, 2005) |
| "To investigate the inhibitive effects of matrine and 5-fluorouracil (5-FU) on the growth of human gastric adenocarcinoma cell line SGC-7901 when transplanted into nude mice and to investigate the bone marrow toxicity of these compounds." | 3.73 | Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice. ( Fu, H; Hu, MJ; Qiao, MM; Wu, YL; Zeng, H; Zhang, S; Zhang, YP, 2005) |
| "To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)." | 3.73 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006) |
| "We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy." | 3.73 | [Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005) |
| "We conducted a retrospective analysis of prognosis factors for survival in breast cancer patients with 1-3 axillary lymph node metastases and tried to identify a subset of patients with good prognosis suitable for cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy." | 3.73 | Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. ( Chang, HK; Chen, MF; Chen, SC; Hsueh, S; Hwang, TL; Lin, YC; Lo, YF; Tsai, CS, 2005) |
| "To test the hypothesis that TS3'UTR polymorphisms predict outcomes in 146 Caucasian patients with esophageal adenocarcinoma treated with preoperative 5-fluorouracil-based chemoradiation." | 3.73 | Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. ( Ajani, JA; Correa, AM; Cox, JD; Komaki, R; Liao, Z; Liu, H; Roth, JA; Swisher, SG; Wang, L; Wei, Q; Wu, TT, 2006) |
| "To establish a 5-fluorouracil (5-FU)-resistant pancreatic adenocarcinoma (PAC) cell strain, and to investigate its biological characteristics." | 3.73 | [Establishment, characterization, and biological analysis of pancreatic adenocarcinoma cell strain SW1990/FU]. ( Chen, G; Guo, JC; Liao, Q; Zhang, LY; Zhao, YP, 2005) |
| "To assess the efficacy of 5-fluorouracil (5-FU) and either platinum compounds or irinotecan in patients with advanced small bowel adenocarcinoma (SBA), for whom data on the efficacy of chemotherapy are scarce." | 3.73 | Combination chemotherapy in advanced small bowel adenocarcinoma. ( Boige, V; Ducreux, M; Elias, D; Lasser, P; Lebray, P; Locher, C; Malka, D, 2005) |
| "The study comprised 141 rectal adenocarcinoma patients who underwent preoperative radiotherapy with 5-fluorouracil (FU) based chemotherapy, followed by radical surgery." | 3.73 | Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. ( Baik, SH; Cho, CW; Kim, NK; Lee, KY; Park, YA; Seong, J; Sohn, SK, 2006) |
| "A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen)." | 3.73 | Oxaliplatin-related acute myelogenous leukemia. ( Carneiro, BA; Eldibany, M; Kaminer, L; Kaul, K; Locker, GY; Sreekantaiah, C, 2006) |
| "Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003." | 3.73 | Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. ( Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J, 2006) |
| "Capecitabine is an oral prodrug of 5-fluorouracil used in the treatment of adenocarcinoma of the colon." | 3.73 | Capecitabine-induced cerebellar toxicity. ( Gill, S; Renouf, D, 2006) |
| "Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival." | 3.73 | Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. ( Gotlib, V; Khaled, S; Lapko, I; Mar, N; Saif, MW, 2006) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 3.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "Forty patients with advanced adenocarcinoma of the rectum underwent preoperative chemoradiation on a prospective trial with irinotecan (50 mg/m2), 5-fluorouracil (225 mg/m2), and concomitant external-beam radiation (45-54 Gy) followed by complete surgical resection of the tumor with total mesorectal excision." | 3.72 | Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. ( Anné, PR; Fry, RD; Goldstein, SD; Isenberg, GA; Mahmoud, NN; Mitchell, E; Rose, DG; Stein, DE, 2003) |
| "Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer." | 3.72 | Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. ( Batist, G; Cohen, V; Morin, I; Panet-Raymond, V; Rozen, R; Sabbaghian, N, 2003) |
| "Among the various pathophysiologic mechanisms proposed to explain the 5-fluorouracil cardiotoxicity, coronary vasospasm, occurring most frequently after the completion of the second or third dose of the cycle, has gained wide acceptance." | 3.72 | Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy. ( Giaccon, G; Mariani, G; Mastore, M, 2003) |
| " For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil." | 3.72 | Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003) |
| "Four pancreatic adenocarcinoma cell lines were evaluated for their sensitivity to 5-fluorouracil (5-FU) and gemcitabine and two of these, Suit-2 and Panc-1, were chosen for combination experiments because they showed moderate and poor sensitivity, respectively, to 5-FU and gemcitabine." | 3.72 | 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. ( Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L, 2004) |
| "High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers." | 3.72 | Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004) |
| "We pretreated cell lines derived from human melanomas, adenocarcinomas, and lymphomas with the PPIs omeprazole, esomeprazole, or pantoprazole and tested their response to cytotoxic drugs in cell death assays." | 3.72 | Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. ( Arancia, G; Belardelli, F; De Milito, A; Fais, S; Federici, C; Iessi, E; Logozzi, M; Lozupone, F; Luciani, F; Lugini, L; Marra, M; Molinari, A; Montinaro, A; Parmiani, G; Rivoltini, L; Spada, M, 2004) |
| "Three dogs with advanced-stage adenocarcinoma of the gastrointestinal tract were treated by use of resection, adjuvant chemotherapy with cisplatin and 5-fluorouracil, and second-look laparotomy (SLL)." | 3.72 | Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. ( Gilson, SD; Stanclift, RM, 2004) |
| " To evaluate the therapeutic effectiveness and safety of oxaliplatin combined with 5-fluorouracil and leucovorin on the patients with gastric carcinoma after palliative gastric resection, we analyzed all of the cases of gastric adenocarcinoma undergone palliative gastric resection in our Cancer Center in recent years." | 3.72 | [Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer]. ( Chen, YB; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ, 2004) |
| "A 60-year-old woman with a history of unresectable colon adenocarcinoma was treated by chemotherapy with a combination of oxaliplatin with leucovorin and fluorouracil." | 3.71 | Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. ( Carrie, E; Gagnadoux, F; Lebeau, B; Monnier-Cholley, L; Roiron, C, 2002) |
| "One hundred and three patients with recurrent adenocarcinoma of the rectum underwent reirradiation with concurrent 5-fluorouracil-based chemotherapy." | 3.71 | Long-term results of reirradiation for patients with recurrent rectal carcinoma. ( Marks, G; Marks, J; Mohiuddin, M, 2002) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials." | 3.71 | [Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002) |
| "The goal of this study was to ascertain the first cycle intolerability rate of the standard Mayo Clinic regimen, 5-fluorouracil (5-FU) 425 mg/m2 with low-dose folinic acid (FA) 20 mg/m2, as a rapid bolus intravenous injection (5-FU/FA) for 5 days every 4-5 weeks for advanced colorectal cancer chemotherapy." | 3.71 | Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose. ( Ho, C; Stitt, L; Tomiak, A; Vincent, M; Whiston, F; Winquist, E, 2002) |
| "One patient with pulmonary metastasis from colon cancer and one with para-aortic lymph node metastasis were treated with a combination of irinotecan and UFT." | 3.71 | [Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT]. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S, 2002) |
| "LSMs for 5-fluorouracil and 5-fluoro-5,6-dihydrouracil therapeutic monitoring have been developed in 80 patients with colorectal cancer (training set) given 5-fluorouracil, 370 mg/m(2) per day as an intravenous bolus, plus leucovorin, 100 mg/m(2) per day, for 5 days every 4 weeks." | 3.71 | Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. ( Amadori, D; Cionini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Mini, E; Vannozzi, F, 2002) |
| "A 62-year-old male patient who developed Philadelphia chromosome-positive chronic myeloid leukemia (CML) after cisplatin and 5-fluorouracil treatment for colon adenocarcinoma is reported." | 3.71 | Chronic myeloid leukemia in a patient with colon adenocarcinoma. ( Gokel, Y; Paydas, S, 2002) |
| "A retrospective chart review was performed on 141 consecutive patients who received neoadjuvant chemoradiation (5-fluorouracil +/- cisplatin and 4,500-5,040 cGy) for biopsy-proven locally advanced adenocarcinoma of the rectum." | 3.71 | Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. ( Anscher, MS; Clary, B; Hartwig, M; Hurwitz, H; Jowell, P; Lee, C; Ludwig, K; Mantyh, C; McGrath, K; Morse, M; Noone, RB; Onaitis, MW; Pappas, TN; Seigler, HF; Tyler , DS, 2001) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 3.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis." | 3.71 | Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001) |
| "To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy." | 3.71 | p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. ( Benevolo, M; Brenna, A; Buglioni, S; Cosimelli, M; D'Agnano, I; D'Angelo, C; Mottolese, M; Perrone Donnorso, R; Vasselli, S; Zupi, G, 2001) |
| "Resection specimens from 47 cases of oesophageal adenocarcinoma treated with preoperative 5-fluorouracil/cisplatin and radiotherapy were reviewed." | 3.71 | A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. ( Dunne, B; Griffin, M; Kelly, A; Mulligan, E; Reynolds, JV, 2001) |
| "Direct intraperitoneal chemotherapy with cisplatin or mitomycin prevents peritoneal carcinomatosis in experimental investigations." | 3.71 | Prophylaxis of peritoneal carcinomatosis in experimental investigations. ( Boltze, C; Halangk, W; Hribaschek, A; Kuhn, R; Lippert, H; Pross, M; Ridwelski, K, 2001) |
| "5-Fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR), a prodrug of 5-FU, are representative of the chemotherapeutic agents for colorectal adenocarcinomas." | 3.71 | Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo. ( Iwahashi, M; Nagata, T; Nakamori, M; Yamaue, H, 2002) |
| "The aim of this study was to assess in patients with advanced colorectal cancer which factors were associated with short-term survival (6 months or less) and progression to first-line 5-fluorouracil (5-FU) chemotherapy." | 3.71 | Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. ( Cellerino, R; Lippe, P; Massacesi, C; Piga, A; Pistilli, B; Rocchi, MB; Valeri, M, 2002) |
| "We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy." | 3.71 | mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. ( Costa, A; De Lena, M; Lacava, J; Leone, A; Paradiso, A; Ranieri, G; Silvestris, N; Simone, G; Vallejo, C, 2002) |
| "Sixteen patients with rectal adenocarcinoma up to 3 cm above the pectineal line with initial indications for abdominoperineal resection (APR) were submitted to a 5040-cGy (28 x 180 cGy) radiotherapy dose and chemotherapy during the first 3 and last 3 days of radiotherapy, using 425 mg/m2/day of 5-fluorouracil (5FU) and 20 mg/m2/day of folinic acid." | 3.70 | Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial. ( Filho, WD; Lopes, A; Nakagawa, WT; Novaes, PE; Rossi, BM, 1998) |
| "It has been observed previously that the pulmonary metastases of colorectal adenocarcinoma are less responsive to therapy with fluorouracil (FUra) as compared with other sites of metastasis (liver, local)." | 3.70 | Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. ( Banerjee, D; Bertino, JR; Danenberg, KD; Danenberg, PV; Fu, J; Gorlick, R; Jhanwar, S; Kemeny, N; Klimstra, D; Longo, GS; Metzger, R; Miles, JS; Salonga, D, 1998) |
| "This case can be considered the first documented Irinotecan-induced immune thrombocytopenia." | 3.70 | Irinotecan-induced immune thrombocytopenia. ( Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL, 1998) |
| "During a 4-year period we treated 20 patients with locally advanced adenocarcinoma of the rectum using a protocol of preoperative simultaneous pelvic irradiation (4,030-6,040 cGy) and infusion chemotherapy (5-fluorouracil 100 mg/m2 per day over 96 hours and mitomycin 10 mg/m2) followed by surgical resection." | 3.70 | Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. ( Burke, SJ; Knight, DC; Kwasnik, EM; Percarpio, BA, 1998) |
| "To determine the effect of combined treatment with 7-ethyl-10-hydroxycamptothecin (SN-38, the active metabolite of irinotecan) and 5-fluorouracil/ folinic acid (5FU/FA) in vitro using HCT-8 human intestinal adenocarcinoma cells." | 3.70 | Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. ( Erlichman, C; Kaufmann, SH; Mullany, S; Svingen, PA, 1998) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 3.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "Patients with radiographically resectable localized adenocarcinoma of the pancreatic head were entered onto a preoperative protocol that consisted of a 2-week course of fluorouracil (5-FU) 300 mg/m2 daily 5 days per week and concomitant rapid-fractionation radiation 30 Gy, 3 Gy daily 5 days per week." | 3.70 | Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. ( Abbruzzese, JL; Charnsangavej, C; Cleary, KR; Evans, DB; Goswitz, MS; Janjan, NA; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA, 1998) |
| " However, new chemotherapy, based on the synergistic antitumor activities of 5-fluorouracil (5-FU) and cisplatin (CDDP) producing biochemical modulation in solid cancers diagnosed as adenocarcinoma, has recently been reported to be effective." | 3.70 | Biochemical modulation therapy for pancreatic cancer. ( Denno, R; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takashima, T; Yamamitsu, S, 1998) |
| "The clonogenic hybrid spheroid assay has been used to determine the toxicity of 5-fluorouracil (5-FU), alone or in combination with indomethacin, in LoVo cells (a human colon adenocarcinoma line)." | 3.70 | Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids. ( Djordjevic, B; Lange, CS; Rotman, M; Schwartz, MS, 1998) |
| "A selective inflammatory reaction involving actinic keratosis may occur in patients receiving systemic 5-fluorouracil as part of a chemotherapeutic protocol." | 3.70 | Selective inflammatory effect of systemic fluorouracil in actinic keratosis. ( Mehregan, D; Mohindra, R; Nabai, H, 1999) |
| "Diarrhea and oral mucositis are the most frequently reported gastrointestinal side effects caused by 5-fluorouracil (5-FU)." | 3.70 | 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. ( Fata, F; Kelsen, DP; Kemeny, N; Klimstra, D; O'Reilly, E; Ron, IG, 1999) |
| "(1) The clinical file of gemcitabine in locally advanced metastatic adenocarcinoma of the pancreas mainly comprises one comparative trial versus 5 fluorouracil that shows the superiority of gemcitabine on a mixed end point (pain, functional capacities, weight)." | 3.70 | Gemcitabine and cancer of the pancreas: new preparation. Helpful or not? ( , 1999) |
| "5-Fluorouracil combined with leucovorin and/or cisplatin has been used in the treatment of gastrointestinal adenocarcinoma and may be useful in primary adenocarcinoma of the bladder." | 3.70 | Intra-arterial infusion of 5-fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder. ( Awakura, Y; Fukuyama, T; Fukuzawa, S; Nonomura, M; Yamamoto, M, 1999) |
| "Fifteen patients with rectal adenocarcinoma were endoscopically biopsied and given short-term [5 fluorouracil (5FU) (600 mg/m2) and Ca-Folinate (60 mg/m2) for two days] cytostatic therapy." | 3.70 | Changes in apoptotic and mitotic activity in rectal carcinoma after short-term cytostatic therapy as possible predictive factors. ( Benyó, I; Bodnár, Z; Farczádi, E; Kaszás, I; Szántó, J; Szende, B; Szlobodnyik, J, 1999) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 3.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "Epirubicin, cisplatin and continuous 5-fluorouracil (5-FU) infusion (ECF) has been reported to result in high clinical response rates in advanced gastro-oesophageal adenocarcinoma and is currently the 'gold standard' chemotherapy regimen for this tumour site." | 3.70 | Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. ( Banerji, U; Geh, JI; Glynne-Jones, R; Harrison, RA; Kwok, QS; Livingstone, JI; Mitchell, IC; Townsend, ER, 2000) |
| "The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer." | 3.70 | Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000) |
| "To report 5-fluorouracil in combination with folinic acid as a cause of severe nonischemic heart failure and to demonstrate the potential usefulness of an intra-aortic balloon pump." | 3.70 | Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. ( David, JS; Gaussorgues, P; Gueugniaud, PY; Hepp, A; Petit, P, 2000) |
| "(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy." | 3.70 | Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Donehower, RC; Grochow, LB; Hruban, RH; Hurwitz, H; Jaffee, EM; Korman, LT; Lillemoe, KD; O'Reilly, S; Yeo, CJ; Zahurek, ML, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 3.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "To study the schedule-dependent reversion of cis-diamminedichloroplatinum (CDDP) resistance by 5-fluorouracil (5-Fu) in a CDDP resistant human lung adenocarcinoma cell line A549DDP." | 3.70 | Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. ( Liu, X; Zhan, M, 1999) |
| "The relationship between augmentation of cytotoxic activity of 5-fluorouracil (FUra) by l-leucovorin (l-LV) and combination schedule was investigated using human colon adenocarcinoma KM 20 C cell line." | 3.69 | [Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil]. ( Okabe, H; Takeda, S; Toko, T; Unemi, N; Yuasa, C, 1995) |
| "We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin." | 3.69 | [A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995) |
| "125 stage III breast cancer patients, including 51 cases of inflammatory carcinoma, were treated with the following combined modality approach: three courses of primary 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) chemotherapy followed by locoregional treatment and subsequent adjuvant chemotherapy consisting of three courses of FAC alternating with three courses of cyclophosphamide, methotrexate, 5-fluorouracil (CMF)." | 3.69 | Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. ( Campora, E; Canavese, G; Catturich, A; Corvò, R; Gardin, G; Guenzi, M; Naso, C; Pronzato, P; Repetto, L; Rosso, R, 1995) |
| "We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole." | 3.69 | Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995) |
| "To determine the effect of cellular proliferation and cell cycle stage on the ability of postirradiation 5-fluorouracil (5-FU) to radiosensitize cultured human colon adenocarcinoma Clone A cells." | 3.69 | 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. ( Buchholz, DJ; Lepek, KJ; Murray, D; Rich, TA, 1995) |
| "One hundred and seven previously untreated patients with measurable metastatic colorectal cancer who were treated with 5-fluorouracil (5FU) and leucovorin (LV) in two different maximum doses and schedules were retrospectively analyzed." | 3.69 | A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Bacoyannis, C; Basdanis, G; Foutzilas, G; Karvounis, N; Kosmidis, P; Markantonakis, P; Mylonakis, N; Sobolos, K; Tsavaris, N; Zisiadis, A, 1995) |
| " Here we have examined human gastric/esophageal adenocarcinoma cell lines for p53 mutational status, chemosensitivity to 5-fluorouracil, mitomycin C, and cis-dichlorodiammineplatinum(II), alteration in p53 levels following exposure of cells to these drugs, and the mechanisms involved in regulating p53 levels." | 3.69 | The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. ( Albino, AP; Altorki, NK; Blundell, ML; de Oliveira, AR; Kelsen, DP; Lai, L; Loganzo, F; Maslak, P; Nabeya, Y; Schwartz, GK, 1995) |
| "Thirty-two patients with resectable (clinical stage IIa, n = 17; IIb, n = 1; III, n = 14) squamous cell cancer (n = 15) or adenocarcinoma (n = 17) were treated with neoadjuvant chemotherapy (cisplatin, 5-fluorouracil, leukovorin), resection, and postoperative chemoradiotherapy (hydroxyurea, 5-fluorouracil; 50-66 Gy)." | 3.69 | Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. ( Drinkard, LC; Ferguson, MK; Haraf, DJ; Hoffman, PC; Reeder, LB; Vokes, EE, 1995) |
| "Exposure of the human colon adenocarcinoma HT29 cells to different concentrations of 5-fluorouracil (5FU) for 24 h resulted in a dose-dependent increase in the cellular glutathione (GSH) level which remained elevated up to 72 h following 5FU treatment." | 3.69 | Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells. ( Boyce, HW; Chen, LT; Chen, MF, 1995) |
| "The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of 5-fluorouracil (5-FU), used at different concentrations, in inhibiting the growth of gastric adenocarcinoma cells." | 3.69 | Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro. ( Brenner, RV; Buras, RR; Evans, SR; Nauta, RJ; Shabahang, M; Shchepotin, IB, 1994) |
| "We reported a case of successful treatment of disseminated breast cancer with epirubicin (EPI), 5-fluorouracil (5-FU), and medroxyprogesterone (MPA)." | 3.69 | [A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)]. ( Fujisawa, J; Satoh, Y; Uchino, J; Une, Y, 1994) |
| "To examine if preferential retention of somatostatin analogues observed in some tumors might be used for modulation of effects of cancer drugs by co-treatment with long acting somatostatin analogues, the effects of somatostatin analogue octreotide on the kinetics of 5-fluorouracil (FUra) and 5-fluorouridine (FUrd) metabolism were studied by 19F NMR spectroscopy in multicell tumor spheroids comprised of human colon HT-29 adenocarcinoma cells." | 3.69 | Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids. ( Chen, TB; Huzak, M; Macura, S; Vuk-Pavlović, S, 1994) |
| "We reviewed our results with chemotherapy for adenocarcinoma of the esophagus or gastroesophageal junction tumors in patients treated with 5-fluorouracil, Adriamycin, and mitomycin C (FAM) regimen as developed by MacDonald and colleagues for adenocarcinoma of the stomach." | 3.69 | 5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors. ( Allred, C; Khansur, T; Tavassoli, M, 1994) |
| "Radiological and clinical evidence of acute necrosis in a meningioma following one cycle of chemotherapy with 5-fluorouracil, folinic acid, and levamisole was observed in a patient being treated for invasive rectal carcinoma." | 3.69 | Necrosis in a meningioma following systemic chemotherapy. Case report. ( Bernstein, M; Davidson, G; Erlichman, C; Villamil, A, 1994) |
| "Several classes of plant polyphenols namely, flavonoids, chalcones and coumarins exhibited varying degrees of inhibition on the cell proliferation of human colon adenocarcinoma cell line 220." | 3.69 | Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. ( Das, NP; Yit, CC, 1994) |
| " To improve local control and decrease metastases, a 7-month regimen was used with standard-dose radiotherapy (RT), cisplatin (DDP), and continuous infusion (CI) 5-fluorouracil (5-FU) in patients with locoregional squamous/adenocarcinoma of the esophagus." | 3.69 | Chemoradiotherapy of esophageal carcinoma. ( Cummings, G; Gaspar, LE; Herskovic, AM; Khanuja, PS; Kinzie, JL; Kraut, MJ; Lattin, PB; Poplin, EA; Steiger, Z; Vaitkevicius, VK, 1994) |
| "To investigate the resistance against 5-fluorouracil (FU), thymidylate synthase (TS) mRNA level was measured by reverse transcription PCR (RT-PCR) technique and quantitated by a competitive-PCR method in human colon adenocarcinoma cell line, SNU-C1 and its FU resistant cell line, C1/FU." | 3.69 | [Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells]. ( Aiba, K; Horikoshi, N; Minowa, S; Shibata, H; Shibata, J, 1994) |
| "Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days." | 3.69 | Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994) |
| "Low-dose consecutive intra-arterial infusion therapy with cisplatin and 5-fluorouracil as neoadjuvant chemotherapy was performed on 3 cases of cervical adenocarcinoma (two stage IIb and one stage IIIb)." | 3.69 | [Three cases of uterine cervical adenocarcinoma successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)]. ( Narimatsu, A; Okada, O, 1996) |
| "The use of 5-fluorouracil (5-FU) and levamisole in patients with Stage III adenocarcinoma of the colon has now become standard." | 3.69 | Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report. ( Gordon, J; Licho, R; Litofsky, NS; Ragland, R; Recht, L; Savarese, DM; Smith, TW, 1996) |
| "Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)." | 3.69 | Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995) |
| "A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung." | 3.69 | [5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996) |
| " The aim of this study was to define the toxicity (animal lethality) and the activity (growth delay assay, excision assay) of a bioreductive drug, tirapazamine, alone and combined with chemotherapy agents (5-FU, VP16, bleo, DTIC and c-DDP) on nude mice bearing xenografted human tumours: a rectal carcinoma (HRT18) and a melanoma (Na11+)." | 3.69 | The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. ( Guichard, M; Lartigau, E, 1996) |
| "Although intrahepatic infusion therapy with 5-fluorouracil for unresectable colorectal liver metastases may lead to improved overall survival for some patients, it is not clear why a response is not observed in others." | 3.69 | p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. ( Benhattar, J; Cerottini, JP; Givel, JC; Metthez, G; Saraga, E, 1996) |
| "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%." | 3.69 | Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995) |
| "Between 1977 and 1994, 173 patients (60 men, 113 women, aged 43-77 years [mean, 59 years]) with unresectable adenocarcinoma of the exocrine pancreas were treated, 106 with neutron irradiation alone and 67 with concomitant chemotherapy (fluorouracil [5-FU])." | 3.69 | Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy. ( Bennett, BR; Cohen, L; Hatcher, MA; Hendrickson, FR; Kroc, TK; Lennox, AJ, 1996) |
| " The objective of this study was to test the effect of tamoxifen and tamoxifen in combination with other agents [5-fluorouracil (5-FU) and interferon (IFN)] against experimental liver metastases of human colorectal tumor cells xenografted into nude mice." | 3.69 | Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon. ( Bender, E; Katoh, A; Mahaffey, W; Marrangoni, A; McKeating, J; Werner, A, 1996) |
| "After a loading dose of 4 x 90 mg folinic acid orally, a continuous infusion of 5-fluorouracil 500 mg/sqm/day for 5 days with concommitant folinic acid 6 x 60 mg/day orally, was administered to 29 consecutive patients with metastatic adenocarcinoma of the esophagus or esophagogastric junction area." | 3.69 | 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; van der Gaast, A, 1996) |
| " We report on a clinical deterioration, yet near-complete pathological and radiological response to a combination of cisplatin and fluorouracil in a patient with locally-advanced gastric adenocarcinoma." | 3.69 | Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma. ( Crellin, A; Guillou, PJ; Hassan, S; Macadam, R; Reynolds, JV; Sadek, SA; Somers, SS; Windsor, AC, 1995) |
| "A case of poorly differentiated adenocarcinoma of the small bowel with extensive lymph node metastases is herein presented, which responded to methotrexate/5-fluorouracil (MTX/5-FU) sequential therapy." | 3.69 | Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5-fluorouracil sequential therapy: report of a case. ( Imamura, M; Maetani, S; Nishitai, R; Onodera, H; Shimizu, K, 1997) |
| "We have investigated the effects of 5-fluorouracil (5-FU) on cell growth, DNA synthesis, morphological changes, DNA fragmentation and Fas antigen expression of cultured human uterine cervical carcinoma cells (OMC-1 squamous-cell carcinoma and OMC-4 adenocarcinoma)." | 3.69 | Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil. ( Inoki, C; Kumagai, K; Orino, I; Ueda, M; Ueki, K; Ueki, M, 1997) |
| " In this study, we characterized the growth-inhibitory effects of active metabolites of sulindac in cultured colon adenocarcinoma cells by determining the contribution of apoptosis and cell cycle arrest and the requirement for cyclooxygenase (COX) inhibition and p53 involvement and compared the effects of sulindac metabolites with the chemotherapeutic drug, 5-fluorouracil (5-FU)." | 3.69 | Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. ( Ahnen, DJ; Finn, TS; Fryer, BH; Li, H; Pamukcu, R; Piazza, GA; Rahm, AK; Stoumen, AL, 1997) |
| "In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally." | 3.69 | Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. ( Kamm, YL; Punt, CJ; Wagener, DJ, 1997) |
| " A high incidence of colorectal adenocarcinomas with varied grades of cell differentiation can be induced by 1,2-dimethylhydrazine (DMH) in rats." | 3.69 | Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. ( Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997) |
| "To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma." | 3.69 | Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. ( Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| "5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone." | 3.69 | 5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997) |
| "Previous studies using cultured colon adenocarcinoma cells demonstrated that a mixture of the diastereoiosomers of the biologically active (6S) and inactive (6R) forms of (6RS) leucovorin or 5-formyl-H4PteGlu (LV) and recombinant human alpha2a-interferon (rIFN-alpha2a) in combination significantly increased the cytotoxicity of 5-fluorouracil (FUra) (by 10-14-fold) whereas FUra combined with single modulators was less potentiated (3-fold)." | 3.69 | Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. ( Cheshire, PJ; Houghton, JA; Morton, CL; Stewart, CF, 1995) |
| "To explore an anti-tumor effect of indomethacin on human colon adenocarcinoma cell line HCT116, and its mechanism." | 3.69 | [Neoplasm-inhibiting effect and sensitivity-promoting effect of indomethacin in vitro]. ( Duan, C; Leng, A; Shi, J; Zhang, G, 1997) |
| "Based upon prior data suggesting that alpha-interferon possesses chemomodulatory activity, the Southwest Oncology Group conducted a study in which patients with hormone refractory, metastatic (stage D2) adenocarcinoma of the prostate were treated with 5-fluorouracil (5-FU) and Roferon-A." | 3.69 | Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study. ( Barnett, TC; Crawford, ED; Marshall, ME; O'Rourke, M; Wolf, M, 1996) |
| "In order to determine whether preresectional chemoradiotherapy (CTRT) would influence resectability, local control, and survival of patients with localized pancreatic adenocarcinoma, a 5 1/2-year prospective study of 39 patients treated with preoperative radiation therapy, 5-Fluorouracil (5-FU), and Mitomycin C has been performed." | 3.68 | A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. ( Agarwal, P; Eisenberg, BL; Engstrom, P; Hoffman, JP; Litwin, S; Paul, AR; Scher, R; Solin, LJ; Watts, P; Weese, JL, 1993) |
| "We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer." | 3.68 | [Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. ( Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993) |
| "Our recent findings in vitro in the human colon adenocarcinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule." | 3.68 | Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. ( Aschele, C; Bertino, JR; Guglielmi, AP; Melioli, GG; Mori, AM; Rosso, R; Sobrero, AF, 1993) |
| "Between December 1988 and August 1992, 68 patients with adenocarcinoma (n = 39) and squamous carcinoma (n = 29) of the esophagus were entered prospectively in a treatment protocol to receive two cycles of cisplatin, 5-fluorouracil, etoposide, leucovorin, and 3,000 cGy of radiation to the involved esophagus and adjacent mediastinum, followed by resection." | 3.68 | Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. ( Adkins, RB; Hoff, SJ; Johnson, DH; Merrill, WH; Murray, MJ; Sawyers, JL; Stewart, JR, 1993) |
| "A prospective trial was conducted involving 16 patients with colorectal adenocarcinoma using a regimen of continuous-infusion octreotide acetate (Sandostatin [octreotide acetate], Sandoz, East Hanover, NJ for the treatment of severe diarrhea induced by the weekly schedule of 5-fluorouracil (5-FU) in combination with leucovorin who were refractory to opiate therapy." | 3.68 | Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. ( Creaven, P; Herrera, L; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, Y, 1993) |
| "2-fold potentiation of 5-fluorouracil (FUra) cytotoxicity by recombinant human interferon-alpha 2a (rIFN-alpha 2a) in GC3/cl colon adenocarcinoma cells that was significantly enhanced to 14-fold when FUra was combined with rIFN-alpha 2a + a mixture of the diasteroisomers of the biologically active (6S) and inactive (6R) leucovorin or 5-formyl-H4PteGlu (LV), events that were reversible by thymidine (dThd)." | 3.68 | Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. ( Adkins, DA; Houghton, JA; Morton, CL; Rahman, A, 1993) |
| "Various factors, including thymidylate synthase, thymidine kinase, 5-fluorouracil phosphorylation and degradation pathways, folate concentrations, and the stability of ternary complex, which influence thymidylate synthase inhibition rate of fluoropyrimidines, were studied in 87 human adenocarcinoma tissues." | 3.68 | Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues. ( Dohden, K; Ohmura, K; Watanabe, Y, 1993) |
| "Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM), nine showed minor histological changes compared with 14 control cases." | 3.68 | Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. ( Allen, SM; Darnton, SJ; Edwards, CW; Matthews, HR, 1993) |
| "We report the fourth case of cerebral demyelinating disease associated with 5-fluorouracil and levamisole hydrochloride therapy for adenocarcinoma of the colon." | 3.68 | Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. ( Kimmel, DW; Schutt, AJ, 1993) |
| "Forty-three patients with locoregional squamous cell carcinoma or adenocarcinoma of the esophagus or cardia were treated with fluorouracil (5-FU), cisplatin, and bolus vinblastine concurrent with radiation administered over 21 days." | 3.68 | Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. ( Forastiere, AA; Orringer, MB; Perez-Tamayo, C; Urba, SG; Zahurak, M, 1993) |
| " Thirteen patients with adenocarcinoma of the pancreas received weekly 5-fluorouracil by rapid intravenous infusion midway through a 2-h infusion of high dose leucovorin during external beam radiation therapy." | 3.68 | Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study. ( Dobelbower, RR; Howard, JM; Konski, AA; Merrick, HW; Schifeling, DJ; Skeel, RT, 1992) |
| "Sequential therapy consisting of methotrexate (MTX) and 5-FU was performed together with the administration of heparin and FOY in 10 cases of gastric cancer with disseminated intravascular coagulation (DIC) causing systemic bone metastasis." | 3.68 | [Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation]. ( Ibuka, T; Imai, K; Ishiwata, J; Kobayashi, T; Monma, K; Ohno, T; Onozawa, Y; Sakaki, N; Sasaki, T; Tabata, I, 1992) |
| " Twenty-eight patients with cytologic or histologic proof of localized adenocarcinoma of the pancreatic head received preoperative chemoradiation (fluorouracil, 300 mg/m2 per day, and 50." | 3.68 | Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. ( Ames, FC; Byrd, DR; Charnsangavej, C; Cleary, KR; Connelly, JH; Evans, DB; Fenoglio, CJ; Levin, B; Rich, TA, 1992) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | 3.68 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| "A 63-year-old male had undergone combination chemotherapy including adriamycin, cisplatin, mitomycin C, 5-fluorouracil and vindesine for six months for double cancer of esophagus and stomach." | 3.68 | [Chemotherapy-associated hemolytic uremic syndrome--a case report]. ( Kanamaru, R; Kikuchi, H, 1992) |
| ") administration of 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FUdR) in BDF1 mice bearing murine mammary adenocarcinoma 755 and athymic mice bearing the transplantable human colon adenocarcinoma LS174T." | 3.68 | Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate. ( Hoshi, A; Iigo, M; Nakajima, Y, 1992) |
| " During a 12-month period seven patients with locally advanced adenocarcinoma of the rectum were treated preoperatively with simultaneous pelvic irradiation (4500-5040 cGy) and infusion chemotherapy (5-fluorouracil 1000 mg per m2 per day over 96 hours and mitomycin 10 mg per m2." | 3.68 | Combined modality preoperative therapy for unresectable rectal cancer. ( Alfano, F; Bitterman, J; Bowen, J; Percarpio, B; Ruszkowski, R; Sabbath, K, 1992) |
| "From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period." | 3.68 | Preoperative chemotherapy and radiotherapy for esophageal carcinoma. ( Andrus, CH; Baue, AE; Johnson, FE; Naunheim, KS; Petruska, P; Roy, TS; Schlueter, JM, 1992) |
| "Previous studies have demonstrated continuous-infusion 5-fluorouracil (CI 5-FU) to be an active single-agent treatment for breast cancer without significant myelotoxicity." | 3.68 | Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide: feasibility study. ( Carey, P; Saphner, T; Tormey, DC, 1992) |
| "A cerebral demyelinating disease developed in 3 patients during adjuvant therapy with 5-fluorouracil and levamisole for adenocarcinoma of the colon." | 3.68 | Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. ( Forsyth, PA; Hook, CC; Kimmel, DW; Kvols, LK; Moertel, CG; Rodriguez, M; Rubin, J; Scheithauer, BW, 1992) |
| "Between 2/87 and 2/91, 49 women with operable breast cancer involving greater than or equal to 10 axillary nodes were treated following mastectomy, with four cycles of Cyclophosphamide, Adriamycin, 5FU, followed by high doses of Cyclophosphamide, Cisplatin, Carmustine (HDCT) with autologous bone marrow transplant support." | 3.68 | Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. ( Halperin, EC; Marks, LB; Peters, W; Prosnitz, LR; Rosner, GL; Ross, M; Vredenburgh, JJ, 1992) |
| "To determine if fluorouracil (5-FU) plus high-dose leucovorin (LV) enhances local response in patients receiving preoperative radiation therapy (RT) for adenocarcinoma of the rectum, we compared the degree of downstaging in patients receiving preoperative RT with or without chemotherapy." | 3.68 | Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. ( Cohen, AM; Enker, WE; Frankel, J; Kelsen, DP; Kemeny, N; Minsky, BD; Reichman, B; Saltz, L; Sigurdson, ER, 1992) |
| "We have evaluated the effect of 5-fluorouracil 600 mg/m2, doxorubicin ('Adriamycin') 40 mg/m2, and Mitomycin-C 4 mg/m2 (FAM) in two groups of patients with adenocarcinoma of the oesophagus, as either a preoperative or primary treatment." | 3.68 | A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Matthews, HR; Steel, A; Walker, SJ, 1991) |
| "Eighty-seven colorectal adenocarcinomas from untreated patients were investigated by short term tumor cultures to test in vitro sensitivity to 5-fluorouracil and mitomycin C." | 3.68 | 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. ( Barone, C; Codacci-Pisanelli, G; Codacci-Pisanelli, M; Ferri, GM; Franchi, F; Garufi, C; Grieco, A; Pagani, V; Seminara, P, 1991) |
| "Juzen-taiho-to (JTT; [Shi-quan-da-bu-tang], a Japanese modified Chinese herbal prescription) in combination with an anticancer drug UFT (5-fluorouracil derivative) prevented the body weight loss and the induction of the colonic cancer in rats treated with a chemical carcinogen 1,2-dimethylhydrazine (DMH), and suppressed markedly the activity of thymidylate synthetase (TS) involved in the de novo pathway of pyrimidine synthesis in colonic cancer induced by DMH." | 3.68 | Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats. ( Kasahara, N; Kato, T; Kawasaki, T; Kudo, H; Kuwa, K; Nakayama, T; Okamoto, R; Sakamoto, S; Suzuki, S, 1991) |
| "Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1." | 3.68 | [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991) |
| "Because of conflicting reports of clinical synergy, we used the tetrazolium-based colorimetric (MTT) assay to test in vitro combination effects of methotrexate (MTX) plus 5-fluorouracil (FUra) in 4 schedules on 2 human non-small-cell lung cancer cell lines (adenocarcinoma, NC1-H23; bronchio-alveolar-cell carcinoma, NC1-H358), and 1 human colorectal adenocarcinoma cell line (SNU-C1)." | 3.68 | Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. ( Gazdar, AF; Kramer, BS; Perng, RP; Tsai, CM, 1991) |
| "We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)." | 3.68 | In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin. ( Atabek, U; Zirvi, KA, 1991) |
| "Experimental chemotherapy with 5-fluorouracil (5-FU; 60 mg/kg), 1-hexylcarbamoyl-5-fluorouracil (HCFU; 70 mg/kg), 3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxym ethyl-5- fluorouracil (BOF-A2; 30 mg/kg) and UFT (20 mg/kg as tegafur with uracil at a molar ratio of 1:4) was performed using human gastric (H-111) and colon (Co-4) carcinoma strains in nude mice." | 3.68 | Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. ( Abe, O; Arisawa, Y; Fujita, S; Ishibiki, K; Josui, K; Kodaira, S; Kubota, T; Mabuchi, K; Suto, A; Yamamoto, T, 1991) |
| "Thirty-one assessable patients with metastatic adenocarcinoma of the gastrointestinal tract were entered onto a pilot study designed to assess the impact of recombinant interferon alpha-2a (rIFN alpha-2a) on the toxicity and pharmacokinetics of fluorouracil (5-FU) and leucovorin (LV)." | 3.68 | A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. ( Balis, FM; Goldstein, LJ; Grem, JL; Hamilton, JM; Kramer, BS; McAtee, N; Murphy, RF; Sartor, O; Sorensen, JM; Steinberg, SM, 1991) |
| "We evaluated conventional pulse exposure versus continuous exposure models of 5-fluorouracil (5-FU) radiosensitization in HT-29 (human colon adenocarcinoma) and DU-145 (human prostate cancer adenocarcinoma) cell lines." | 3.68 | 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. ( Evans, RG; Kimler, BF; Smalley, SR, 1991) |
| "Fifteen patients with potentially resectable adenocarcinoma of the esophagus were treated with two cycles of preoperative chemotherapy with 5-fluorouracil (5-FU) and cisplatin (DDP)." | 3.68 | A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC, 1991) |
| "Fifty-six previously untreated patients with biopsy-proven, locally advanced or metastatic and measurable adenocarcinoma of the pancreas were treated with the combination of a protracted intravenous infusion of 5-fluorouracil (5-FU) and low dose weekly bolus cisplatin administered continuously for 10 weeks followed by a 2-week rest period." | 3.68 | Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. ( Ahlgren, J; Cantrell, JE; Difino, S; Fryer, J; Harvey, J; Lokich, J; Rothman, H, 1991) |
| "2,2'-Anhydro-5-ethyluridine (ANEUR), a potent inhibitor of uridine phosphorylase, markedly potentiated the antitumor activity of fluorouridine (FUR) against murine mammary adenocarcinoma 755 in BDF1 mice and human colon adenocarcinoma LS174T in athymic-nude mice." | 3.68 | Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine. ( De Clercq, E; Iigo, M; Nakajima, Y; Nishikata, K; Szabolcs, A; Szinai, I; Veres, Z, 1990) |
| "Peritoneal cells were derived from a patient (PK) with adenocarcinoma of the colon during the course of cisplatin/5-fluorouracil (5-FUra) treatment." | 3.68 | Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. ( Haedicke, K; Kashani-Sabet, M; Leong, L; Lu, Y; Scanlon, KJ, 1990) |
| "Exposure to dehydroepiandrosterone caused a concentration-dependent accumulation of HT-29 human colonic adenocarcinoma cells in S-phase and sensitization toward the cytotoxic effects of fluorouracil deoxyriboside but not 5-fluorouracil." | 3.68 | Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells. ( Holbrook, CT; Klann, RC; Nyce, J, 1990) |
| "Twenty-nine evaluable patients with colorectal adenocarcinoma were treated in a phase I-II trial of combination chemotherapy with a 72-h continuous infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU) with an infusion of VP-16 given at 24 and 48 h after the start of therapy." | 3.68 | A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. ( Browne, MJ; Calabresi, P; Clark, JW; Cummings, FJ; Curt, G; Posner, M; Slapak, CA; Urba, S; Weitberg, A; Wiemann, M, 1990) |
| "A human colon adenocarcinoma cell line (GC3TK-) was selected for thymidine kinase (TK) deficiency from cloned parental cells (GC3C1) by exposure to 5-bromodeoxyuridine (BrdUrd)." | 3.68 | Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. ( Germain, G; Houghton, JA; Houghton, PJ; Pennington, J; Radparvar, S; Rahman, A, 1990) |
| "Thirty-five consecutive patients with resectable adenocarcinoma of the esophagus or gastroesophageal junction were treated with two preoperative and three or four postoperative chemotherapy courses consisting of etoposide, fluorouracil, and cisplatin (EFP) to evaluate the rate of curative resection, clinical and pathologic response, toxic effects, and survival." | 3.68 | Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. ( Abbruzzese, JL; Ajani, JA; DeCaro, L; Jackson, DE; Levin, B; McMurtrey, M; Mountain, C; Rich, TA; Roth, JA; Ryan, B, 1990) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 3.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| "In a search for compounds related to flavoneacetic acid with activity against solid tumors, a series of methyl-, methoxy-, chloro-, nitro-, and hydroxy-substituted xanthenone-4-acetic acids have been synthesized and evaluated against subcutaneously implanted colon adenocarcinoma 38 in vivo, using a short-term histology assay as a primary screening system." | 3.67 | Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. ( Atwell, GJ; Baguley, BC; Calveley, SB; Denny, WA; Rewcastle, GW, 1989) |
| "Fifty-one patients with metastatic adenocarcinoma received Folinic Acid (FA) combined with 5-Fluorouracil (5FU) in a Phase I-II clinical trial." | 3.67 | 5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy. ( Budd, GT; Bukowski, RM; Cunningham, J; Purvis, J; Weick, JK, 1984) |
| "The growth inhibitory effects of 5-fluorouracil (5-Fu) and the combination of 5-Fu and human leukocyte interferon (HuIFN-alpha) on the human salivary gland adenocarcinoma cell line HSG in culture were examined by measuring colony formation in the semi-solid agar medium and cell proliferation in the monolayer culture." | 3.67 | Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture. ( Hayashi, Y; Kobayashi, S; Nitta, T; Sato, M; Urata, M; Yanagawa, T; Yoshida, H; Yura, Y, 1984) |
| "The effect of 5-fluorouracil on the stability of DNA and the synthesis of DNA replication intermediates was analyzed in human colon adenocarcinoma cells." | 3.67 | Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. ( Lönn, S; Lönn, U, 1984) |
| "Twenty-one patients with adenocarcinoma of the cecum were treated in a pilot study between October, 1972 and June, 1982 by right hemicolectomy and received adjuvant postoperative irradiation (40-45 Gy/4-5 weeks) and 5-Fluorouracil (5-FU)." | 3.67 | Postoperative adjuvant irradiation and 5-fluorouracil for adenocarcinoma of the cecum. A pilot study. ( Cormier, WJ; Jazy, FK; Krause, RJ; Meyer, RL; Shehata, WM, 1984) |
| "Twenty-two previously untreated patients with advanced gastric adenocarcinoma were treated with a modification of the original 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (FAM) combination chemotherapy." | 3.67 | Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM). ( Cohen, Y; Epelbaum, R; Haim, N; Robinson, E, 1984) |
| "A 68-year-old man was treated with FAM (5-fluorouracil, doxorubicin [Adriamycin], mitomycin-C) for metastic gastric adenocarcinoma." | 3.67 | Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. ( Kerwin, DM; Smith, FP; Tsou, E; Waldhorn, RE, 1984) |
| "5-Fluorouracil(5-FU)is a widely used antitumor agent for treating patients with adenocarcinoma of gastroenterial tract and breast following intravenous or oral administration." | 3.67 | [5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil]. ( Hashimoto, I; Kashi, Y; Mikami, J; Nakamura, T; Nakanishi, Y; Nishidai, H; Sawada, Y; Yoshimoto, M, 1984) |
| "Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil." | 3.67 | [Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate]. ( Akagi, T; Hara, M; Nanba, K; Obama, T; Ochi, J; Ozaki, Y; Saegusa, M; Tanahashi, T; Tsushima, T; Yoshimoto, J, 1987) |
| " Treatment regimens usually employed cis-diammine-dichloroplatinum (CDDP) plus peplomycin for squamous cell carcinoma, and CDDP plus vindesine for adenocarcinoma." | 3.67 | [Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion]. ( Inoue, F; Mimura, H; Miyake, M; Mori, T; Orita, K; Takeda, I; Tanaka, N, 1988) |
| "Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen." | 3.67 | Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989) |
| "Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals." | 3.67 | Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989) |
| "Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma." | 3.67 | Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989) |
| "Twenty-one consecutive patients with primarily non-resectable adenocarcinoma of the rectum were treated with preoperative split-course radiotherapy (40 Gy) and simultaneous sequential methotrexate + 5-fluorouracil + leucovorin (MFL)." | 3.67 | Preoperative irradiation with and without chemotherapy (MFL) in the treatment of primarily non-resectable adenocarcinoma of the rectum. Results from two consecutive studies. ( Frykholm, G; Glimelius, B; Påhlman, L, 1989) |
| "When given orally in combination with L-cysteine, 5'-deoxy-5-fluorouridine (DFUR) brought about a significant reduction in the growth of adenocarcinoma 755 and a significant prolongation of life-span in mice bearing Lewis lung carcinoma without increased toxicity to the host as compared with DFUR alone, though L-cysteine alone did not show an appreciable antitumor activity." | 3.67 | Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine. ( Araki, E; Hoshi, A; Iigo, M; Nakajima, Y, 1989) |
| "The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse." | 3.67 | Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989) |
| " A total of 37 patients with advanced measurable adenocarcinoma of the stomach were treated with Adriamycin, methotrexate, and 5-fluorouracil (AMF)." | 3.67 | Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. ( Abbruzzese, JL; Ajani, JA; Boman, BM; Faintuch, JS; Goudeau, P; Kanojia, MD; Levin, B, 1989) |
| "A total of 23 patients with advanced gastric adenocarcinoma were treated with a combination of moderate-dose methotrexate (MDMTX), 250 mg/m2 i." | 3.67 | Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. ( Dickinson, R; Levi, J; Milliken, S; Presgrave, P; Woods, R, 1989) |
| "Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1." | 3.67 | Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989) |
| "Two trials of leucovorin (LV) and 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer were done, both using a 3-day loading dose and then weekly doses to minimize toxicity." | 3.67 | Clinical experience with leucovorin and 5-fluorouracil. ( Brenckman, WD; Collier, M; Duch, DS; Ferone, R; Knick, VB; Laufman, LR; Morgan, ED; Mullin, R; Stydnicki, KA, 1989) |
| "Sixty women with metastatic breast cancer refractory to at least one chemotherapeutic regimen were treated with fluorouracil (FUra) and high-dose continuous infusion folinic acid (leucovorin calcium)." | 3.67 | Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. ( Akman, S; Bertrand, M; Carr, B; Doroshow, JH; Flanagan, B; Goldberg, D; Leong, L; Margolin, K; Newman, E; Odujinrin, O, 1989) |
| "Twelve patients with stage D2 adenocarcinoma of the prostate were treated with the combination chemotherapy of ifosfamide (2 g/body, i." | 3.67 | [Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer]. ( Andoh, M; Fukui, I; Higashi, Y; Horiuchi, S; Kihara, K; Kitahara, S; Oshima, H; Takeuchi, S, 1989) |
| "A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU." | 3.67 | Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. ( Creaven, PJ; Herrera, L; Madejewicz, S; Mittelman, A; Petrelli, NJ; Plager, J; Rustum, Y; Soloman, J, 1989) |
| "We report a case of recurrent adenocarcinoma of the bladder treated by intra-arterial infusion of 5-fluorouracil (5-FU)." | 3.67 | Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder. ( Fuchs, EF; Hatch, TR, 1989) |
| "Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma." | 3.67 | Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986) |
| "5-Fluorouracil (FUra) has been administered to mice bearing xenografts of human colon adenocarcinomas." | 3.67 | Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Torrance, PM; Weiss, KD; Williams, LG, 1986) |
| "Fifty-four patients with adenocarcinoma and large cell carcinoma of the lung, 16 with localized surgically resected disease and 38 with metastatic disease, were treated with 5-fluorouracil, doxorubicin, and mitomycin-C (FAM), in an attempt to prolong previously reported survival times in the patients." | 3.67 | 5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung. ( Shaw, MK; Shaw, MT, 1987) |
| "The combined effects of X-ray irradiation and 5-FU derivatives (5-FU, tegafur, HCFU) treatment were investigated in mouse adenocarcinoma-755." | 3.67 | [Combined effects of radiation and 5-FU derivatives]. ( Dokiya, T; Hashimoto, S; Kunieda, E; Miyamoto, H; Shigematsu, N; Tominaga, J, 1986) |
| "Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus." | 3.67 | Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986) |
| "The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity." | 3.67 | Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine. ( Hoshi, A; Iigo, M; Kitagawa, H, 1986) |
| "When combined with bromovinyldeoxyuridine (BVdUrd), 5-fluorouracil (FUra) brought about a significant reduction in the growth of adenocarcinoma 755 tumors in mice, at doses at which either drug used alone (BVdUrd: 100 mg/kg) did not effect an appreciable antitumor activity." | 3.67 | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1987) |
| "A 55-year-old female, in which an unresectable Borrmann II-type gastric cancer (moderately differentiated adenocarcinoma) extending from vicinity of the cardia to the lower portion of the corpus, with direct invasion into the pancreas and extensive lymph node metastases, confirmed by laparotomy, was treated postoperatively by 3 courses of chemotherapy with cisplatinum in combination with mitomycin C and 5-fluorouracil." | 3.67 | Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil. ( Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Sakata, K; Shimokawa, K; Suzuki, M; Tanemura, H, 1988) |
| "A 64-year-old woman who was diagnosed as inoperable intrahepatic bile duct cancer with massive liver metastasis was treated with 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin-C (MMC)." | 3.67 | [A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy]. ( Hasegawa, H; Kozakai, M; Misu, Y; Saitoh, Y; Shikata, J; Takada, T; Tsuchiya, S; Uchiyama, K; Yasuda, H, 1988) |
| "Twenty-two patients with disseminated adenocarcinoma of the large bowel received therapy with 5-fluorouracil 800-1000 mg/m2 as a 24 h infusion for 4 consecutive days with 60 mg/m2 intravenous folinic acid administered every 6 hours." | 3.67 | Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer. ( Higano, C; Mortimer, JE, 1988) |
| "An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion." | 3.67 | High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. ( Cady, J; De Gramont, A; Demuynck, B; Gonzalez-Canali, G; Grange, JD; Krulik, M; Lagadec, B; Loiseau, JP; Louvet, C; Maisani, JE, 1988) |
| "Between January 1981 and December 1986, 20 patients with adenocarcinoma of the esophagus and gastroesophageal junction were entered into a prospective study involving combined radiation therapy and chemotherapy (5-fluorouracil [5-FU] and mitomycin) as primary management." | 3.67 | Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. ( Coia, LR; Engstrom, PF; Paul, AR, 1988) |
| "A marked inhibition of the growth of solid tumor adenocarcinoma 755 was achieved by the combination of 5-fluorouracil (5-FU) with bromovinyldeoxyuridine (BVDU)." | 3.67 | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. ( Araki, E; De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1988) |
| "Fourteen patients with advanced gastric adenocarcinoma were treated with continuous 5-fluorouracil (5-FU) infusion, 300 mg/m2/day, through an indwelling central venous catheter; 13 were evaluable for response." | 3.67 | Continuous 5-fluorouracil infusion in advanced gastric carcinoma. ( Anderson, T; Ausman, R; Beatty, P; Chitambar, C; Hansen, R; Moynihan, T; Quebbeman, E; Ritch, P; Vukelich, M, 1988) |
| "The EORTC Gastrointestinal Group has conducted a phase II trial in 47 patients with locally advanced or metastatic adenocarcinoma of the pancreas with epirubicin 90 mg/m2 intravenously on day 1 in combination with 5-fluorouracil 500 mg/m2 in a 2 hr infusion day 1-4, every 4 weeks." | 3.67 | An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas. ( Bleiberg, H; Blijham, G; Dalesio, O; Duez, N; Planting, A; Splinter, T; Weber, W; Wils, J, 1987) |
| "Forty-four patients with locally recurrent or metastatic colorectal adenocarcinoma were treated with methotrexate (MTX) 100 mg/m2 i." | 3.67 | Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma. ( Anderson, T; Hansen, RM; Ritch, PS, 1986) |
| "Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX." | 3.67 | Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. ( Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma." | 3.67 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987) |
| "Forty patients with adenocarcinoma of the cecum who underwent right hemicolectomy received regional irradiation for 40-45 Gy/4-5 weeks and weekly 5-Fluorouracil (5-FU)." | 3.67 | Regional adjuvant irradiation for adenocarcinoma of the cecum. ( Cormier, WJ; Jazy, FK; Meyer, RL; Shehata, WM; Welling, RE, 1987) |
| "The effect of various guanine ribonucleotides on the antitumor activity of 5-fluorouracil (FUra) was investigated by its action on adenocarcinoma 755." | 3.67 | Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755. ( Hoshi, A; Iigo, M; Nishimura, S; Yamaizumi, Z, 1987) |
| "A 59-year-old man undergoing systemic 5-fluorouracil treatment for metastatic adenocarcinoma of the stomach developed ocular lesions consisting of bilateral conjunctival ulcers and ulcerative blepharitis leading to ankyloblepharon." | 3.67 | Ankyloblepharon associated with systemic 5-fluorouracil treatment. ( Helm, CJ; Insler, MS, 1987) |
| "Twenty-five patients with locally advanced but resectable adenocarcinoma of the stomach were given concomitant postoperative radiotherapy to the tumor bed and chemotherapy with 5-Fluorouracil (5-FU)." | 3.67 | Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma. ( Gez, E; Sulkes, A; Weshler, Z; Yablonsky-Peretz, T, 1986) |
| "The cytotoxic effects of three anticancer drugs, methotrexate (MTX), 5-fluorouracil (5-Fu) and oridonin (Rub A), were investigated using a human gastric adenocarcinoma cell line (MGc80-3) and a human esophageal cancer cell line (CaEs-17) by means of colony-forming assay, dye exclusion test, measurement of incorporation of 3H-thymidine into DNA and examination of mitotic index." | 3.67 | [Comparison of in vitro assays for the cytotoxic effect of anticancer drugs]. ( Li, PY; Li, XT; Lin, C, 1986) |
| "The combination of 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM) is often recommended for empiric management of patients with adenocarcinoma of unknown primary." | 3.67 | 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. ( Ahlgren, JD; Goldberg, RM; Schein, PS; Smith, FP; Ueno, W, 1986) |
| "Twelve patients with adenocarcinoma of the pancreas and two patients with carcinoma of the extrahepatic biliary tree received combined therapy with 125I implant, precision high-dose (PHD) photon external beam therapy, and systemic 5-fluorouracil (5-FU)." | 3.67 | 125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree. ( Ahuja, RK; Dobelbower, RR; Merrick, HW; Skeel, RT, 1986) |
| "Fifty-three patients with inoperable adenocarcinoma of the lung were treated with 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) in two dose schedules: schedule 1--5-FU 600 mg/m2 days 1, 8, 29, and 36 and Adriamycin 30 mg/m2 days 1 and 29 and mitomycin-C 10 mg/m2 day 1 repeated every 8 weeks." | 3.67 | 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung. ( Burkes, R; DeBoer, G; Evans, WK; Paul, K; Shepherd, FA, 1986) |
| "The adjuvant effect of calmodulin antagonists (W-5 and W-7) to 5-fluorouracil (5-FU) was studied by using two human cultured cell lines derived from ovarian adenocarcinoma." | 3.67 | Adjuvant effects of calmodulin antagonists to 5-fluorouracil on tumor cell proliferation and the mechanisms. ( Kato, K; Kikuchi, Y; Kizawa, I; Oomori, K, 1987) |
| "In order to determine the contribution of thymidine (dThd) salvage to intrinsic resistance to antimetabolites (5-fluoropyrimidines, antifolates) in the human colon adenocarcinoma xenograft, H X GC3, a subline deficient in thymidine kinase has been developed." | 3.67 | Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. ( Germain, G; Houghton, JA; Houghton, PJ; Torrance, PM, 1987) |
| "In order to test the possible cardiac-sparing effect of doxorubicin administered by six-hour intravenous infusion and to prospectively evaluate the role of resting left ventricular ejection fraction in monitoring these patients, 33 women with advanced breast cancer were treated with combination chemotherapy containing 5-fluorouracil, cyclophosphamide, and doxorubicin." | 3.67 | Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. ( Blum, RH; Dubin, N; Green, MD; Muggia, FM; Roses, D; Sanger, J; Speyer, JL; Wernz, JC, 1985) |
| "Bestatin enhanced the antitumor effects of mitomycin C, 5-fluorouracil and cis-dichlorodiammineplatinum against a syngeneic solid tumor of colon adenocarcinoma 26 in BALB/c mice." | 3.67 | Enhancement of antitumor effect of cytotoxic agents by bestatin. ( Abe, F; Ashizawa, J; Horinishi, H; Ishizuka, M; Matsuda, A; Shibuya, K; Takahashi, K; Takeuchi, T; Umezawa, H, 1985) |
| "To delineate the efficacy of continuous intravenous 5-fluorouracil (5-FU) infusion therapy for advanced colorectal adenocarcinoma, a study of 36 patients with measurable metastatic disease was conducted." | 3.67 | Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. ( Ausman, R; Becker, T; Blake, D; Caballero, G; Hansen, R; Jenkins, D; Quebbeman, E; Ritch, P; Schulte, W; Tangen, L, 1985) |
| "Sequential methotrexate-5-fluorouracil (Mtx-5-Fu) reduces proliferation of human colon adenocarcinoma cells." | 3.67 | The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil. ( Lönn, S; Lönn, U, 1986) |
| "During the past three years we have entered 54 patients with gastric adenocarcinoma into a clinical trial of oral administration of injectable 5-fluorouracil (5-Fu)." | 3.67 | Adjuvant chemotherapy of gastric carcinoma: a pilot study of oral administration of injectable 5-fluorouracil. ( Wu, YF, 1985) |
| "Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA." | 3.67 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985) |
| "Twenty patients (15 male, 5 female) with nonresectable gastric adenocarcinoma were treated with FAP (5-fluorouracil 300 mg/m2 IV on days 1-5, adriamycin 50 mg/m2 IV on day 1, cisplatin 20 mg/m2 IV on days 1-5)." | 3.67 | Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. ( Burghouts, JT; Hillen, HF; Hoogendoorn, GJ; Scheerder, H; van Dam, FE; van der Vegt, SG; Wagener, DJ; Wobbes, T; Yap, SH, 1985) |
| "Thirty-eight patients with advanced colorectal adenocarcinoma were treated with the following regimen: N5-10-methyltetrahydrofolate (MTHF) (200 mg/m2/day) and 5-fluorouracil (5-FU) (375 mg/m2/day) given concomitantly, consecutively for 5 days, every 4 weeks, in order to evaluate the potential advantage derived from the biochemical enhancement of cytotoxic activity of 5-FU by high-dose reduced folates." | 3.67 | Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. ( Bruzzone, M; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Tagarelli, G, 1985) |
| "Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)." | 3.67 | Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985) |
| "In a multicentre trial of adjuvant chemotherapy in gastric adenocarcinoma, a number of patients developed chronic haemolysis and renal failure following long-term treatment with 5-fluorouracil and mitomycin-C." | 3.66 | Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C. ( Brookes, VS; Fielding, JW; Howell, A; Jones, BG; Newman, CE, 1980) |
| "The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51 and 06/A." | 3.66 | In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. ( Corbett, TH; Heidelberger, C; Moran, RG; Shahinian, AH; Spears, CP, 1982) |
| "Nineteen patients with unresectable and metastatic adenocarcinoma of the pancreas and ampulla of Vater were treated with intermittent regional infusion of the celiac axis (CAI) with the combination of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S)." | 3.66 | Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. ( Bukowski, RM; Hewlett, JS; Livingston, RB; Theodors, A; Weick, JK, 1982) |
| "Twenty patients with advanced or recurrent endometrial adenocarcinoma were treated with combination chemotherapy consisting of Adriamycin, cyclophosphamide, 5-fluorouracil, and vincristine at three-week intervals." | 3.66 | Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels. ( Jänne, O; Kauppila, A; Kujansuu, E; Vihko, R, 1980) |
| "Sixty-three previously untreated patients with metastatic non-small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3 mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi)." | 3.66 | Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study. ( Carlin, DA; Grozea, PN; Miller, TP; Weick, JK, 1982) |
| "Following gastrectomy for locally advanced adenocarcinomas, three patients developed microangiopathic hemolytic anemia and renal failure shortly after completing courses of adjuvant chemotherapy with mitomycin and 5-FU." | 3.66 | Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome. ( Band, PR; Bettez, P; Giroux, L; Gruber, J; Jolivet, J; Laurin, S, 1983) |
| "Because alpha-difluoromethylornithine (DFMO) reduces the incidence of experimental colon cancers, inhibits the growth of human lung cancer cells and human leukemia cells in culture, and in combination with methylglyoxal (bis)guanylhydrazone induces remission in children with leukemia, its effectiveness against a human colon adenocarcinoma cell line (Colo 205) was tested alone and in combination with 5-fluorouracil (5-FU)." | 3.66 | Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line. ( Diekema, KA; Kingsnorth, AN; Malt, RA; McCann, PP; Russell, WE, 1983) |
| "Logothetis and von Eschenbach first 1981 reported encouraging preliminary results of the DMF regimen (Doxorubicine = Adriamycin, Mitomycin, 5 Fluorouracil) in hormone refractory adenocarcinoma of the prostate." | 3.66 | [Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study]. ( Burk, K; Gropp, C; Rodeck, G, 1983) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 3.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "Twenty-nine patients with advanced gastric adenocarcinoma were treated with 72-hour continuous intravenous infusion of 5-fluorouracil (30 mg/kg/24 hr) at 2-week intervals." | 3.66 | Chemotherapy of advanced gastric cancer with 72-hour continuous intravenous 5-fluorouracil infusion at 2-week intervals. ( MacDonald, WC; Shah, A, 1983) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 3.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| " Adenocarcinoma related to diethylstilbestrol exposure in utero is a recently recognized type of vaginal lesion, and melanoma and sarcoma occur rarely in the vagina." | 3.66 | Malignant tumors of the vagina. Classification and approach to treatment. ( Gerbie, MV, 1983) |
| "Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5-fluorouracil (5-FU) had renal impairment 6-11 months from the beginning of MMC therapy." | 3.66 | Renal disease after mitomycin C therapy. ( Hanna, WT; Krauss, S; Murphy, WM; Regester, RF, 1981) |
| "A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer." | 3.66 | Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981) |
| "A 72 year old man with rectal adenocarcinoma developed chronic renal failure when treated by surgery and subsequent chemotherapy (5-fluorouracil, Mitomycin C and Cytosine arabinoside) and immunotherapy." | 3.66 | Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs. ( Fornari, G; Mazzucco, G; Monga, G, 1982) |
| "The anti-inflammatory drug indomethacin was tested for antitumor activity against transplantable mouse colon adenocarcinoma 38 (colon 38)." | 3.66 | Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. ( Goto, A; Narisawa, T; Sano, M; Sato, M; Takahashi, T, 1983) |
| "Six patients with metastatic urothelial carcinoma--4 transitional cell carcinomas and 2 adenocarcinomas--were treated with cis-platinum (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU)." | 3.66 | [Chemotherapy of metastatic urothelial carcinoma]. ( Kawai, T; Kihara, K; Ogawa, M; Sakuramoto, T; Washizuka, M, 1982) |
| "A series of four human colon adenocarcinomas, growing as xenografts in immune-deprived mice, have been used to evaluate the efficacy of 5-FU in combination with two purines, hypoxanthine (Hx) and allopurinol (HPP), which have reduced the toxicity of 5-FU in host mice." | 3.66 | Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. ( Houghton, JA; Houghton, PJ, 1982) |
| " This ex vivo culture system was used to test the activity of 5-fluorouracil (5-FU) against four human colorectal adenocarcinoma cell lines (SW 403, SW 480, SW 620, and SW 707)." | 3.66 | Ex vivo hemodialysis culture system for assessing the activity of cancer chemotherapeutic agents. ( Leibovitz, A; Morris, NG; Quarles, JM, 1982) |
| "Twenty-one patients, presenting with metastases only to bone from a primary adenocarcinoma of the breast having previously undergone mastectomy, tolerated aggressive cytotoxic chemotherapy (CAF--cyclophosphamide 500 mg/m2, Adriamycin 50 mg/m2, 5-fluorouracil 500 mg/m2 q 3 weeks) without significant clinical morbidity." | 3.66 | Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases. ( Malmud, LS; Scogna, DM; Smalley, RV, 1982) |
| "After perioperative adjuvant chemotherapy of a sigma-adenocarcinoma with 400 mg peptichemio and 500 mg 5-fluorouracil a 61-year-old woman developed a severe intoxication: myelosuppression with pancytopenia, gastroenteritis and ulcerative proctitis, toxic hepato- and myocardiopathy, impaired renal function and alopecia." | 3.66 | [Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)]. ( Gasser, RW; Schmalzl, F, 1982) |
| "Twenty-five patients with advanced measurable adenocarcinoma of the colon were treated with 5-fluorouracil (FUra), 15 to 20 mg/kg/week i." | 3.66 | Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer. ( Bateman, JR; Block, JB; Chan, KK; Chlebowski, RT; Gota, CH; Weiner, JM, 1982) |
| "This study was designed to examine the possibilities for increasing the therapeutic index in the treatment of human colon adenocarcinomas maintained as xenografts in immune-deprived mice using combinations of methotrexate (MTX) that preceded 5-fluorouracil (FUra)." | 3.66 | The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Tice, AJ, 1982) |
| "Twenty-five patients with histologically proved adenocarcinoma of the prostate were divided into two groups and submitted to combination therapy with estramustine (Estracyt), cyclophosphamide (Cytoxan), 5-fluorouracil, and Cisplatin." | 3.66 | Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer. ( Beckley, S; Maeso, E; Murphy, G; Pontes, E; Wajsman, Z, 1981) |
| "The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system." | 3.66 | Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980) |
| "Consecutive studies were undertaken in advanced colorectal adenocarcinoma, comparing two different schedules of the combination methyl-CCNU, 6-thioguanine, and 5-fluorouracil in 89 patients." | 3.66 | Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer. ( Aroney, RS; Bell, DR; Chan, WK; Dalley, DN; Levi, JA, 1981) |
| "Thirty patients with unresectable adenocarcinoma of the lung were treated with high doses of 5-fluorouracil, Adriamycin, and mitomycin-C (Hi-FAM)." | 3.66 | 5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung. ( Ali, M; Brown, B; Ewer, M; Nogeire, C; Rosi, DR; Samuels, M, 1981) |
| "Antitumor activity of seven 5-fluorouracil derivatives having carbamoyl linkage with amino acid was examined against L-1210 leukemia, adenocarcinoma 755, ascites sarcoma 180, Ehrlich ascites carcinoma and Lewis lung carcinoma by oral administration." | 3.66 | Antitumor activity of 1-alkoxycarbonylalkylcarbamoyl-5-fluorouracil derivatives by oral administration. ( Ando, N; Hoshi, A; Iigo, M; Inomata, M; Kuretani, K, 1981) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma." | 3.66 | Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980) |
| "28 patients with advanced adenocarcinomas were treated with combinations of 5-fluorouracil and mitomycin-C (FM, 21 patients) or of 5-fluorouracil, adriamycin and mitomycin-C (FAM, 7 patients)." | 3.66 | [Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas]. ( Hammer, B; Jungi, WF; Mayr, AC; Senn, HJ; Späti, B, 1980) |
| "Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM)." | 3.66 | 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. ( Hoth, DF; Karlin, DA; Levin, B; MacDonald, JS; Schein, PS; Smith, FP; Woolley, PV, 1980) |
| "The effect of sequential methotrexate and 5-fluorouracil on the clonal growth of the human colon adenocarcinoma cell, HCT-8, and the hormone-dependent human breast carcinoma cell, 47-DN, was examined." | 3.66 | Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. ( Benz, C; Cadman, E; Choti, M; Schoenberg, M, 1980) |
| "The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma." | 3.66 | Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. ( Benz, C; Cadman, E, 1981) |
| "Twenty-two patients with adenocarcinoma metastatic to the liver were treated with rapid fractionation whole-liver irradiation (1350-2100 rads in 300-rad fractions) with simultaneous intrahepatic 5-fluorouracil (10-15 mg/kg/day) and intrahepatic Adriamycin 2." | 3.66 | Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study. ( Cassidy, M; Friedman, M; Levine, M; Phillips, T; Resser, KJ; Spivack, S, 1979) |
| "From May 1972 until May 1976, 105 patients were entered on Central Oncology Group protocol 7230 to compare the combination of streptozotocin, tubercidin, and 5-fluorouracil (5-FU) versus 5-FU alone in the treatment of adenocarcinoma and islet cell carcinoma of the pancreas." | 3.66 | 5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230. ( Aust, JB; Awrich, A; Fletcher, WS; Grage, TB; Hill, GJ; Klotz, JH; Minton, JP; Multhauf, PM, 1979) |
| "In two separate experiments, treatment of C3H/He mice bearing transplantable mammary adenocarcinomas (C3HBA) with a regimen of 6-propylthiouracil (PTUra) and 5-fluorouracil (FUra) plus chloroquine phosphate (CP) resulted in complete remissions of 77 and 65%, respectively." | 3.66 | Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. ( Dagher, RK; Shoemaker, JP, 1979) |
| "Twenty-five patients with advanced measurable adenocarcinoma of the lung were treated with combination chemotherapy consisting of 5-fluorouracil, adriamycin, and mitomycin-C (FAM)." | 3.66 | 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. ( Butler, TP; MacDonald, JS; Schein, PS; Smith, FP; Smith, LF; Woolley, PV, 1979) |
| "Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy." | 3.66 | Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. ( Ikard, M; Shippel, RM; Soloway, MS, 1979) |
| "Thirty-five patients with advanced-stage metastatic or unresectable gastric adenocarcinoma were given combination chemotherapy consisting of fluorouracil, doxorubicin, and 1,3-bis (2-chlorbethyl)-1-nitrosourea." | 3.66 | Improved combination chemotherapy in advanced gastric cancer. ( Aroney, RS; Dalley, DN; Levi, JA, 1979) |
| "Three distinct subpopulations of tumor cells derived from a single parent strain BALB/cfC3H mammary adenocarcinoma were tested in vivo for sensitivity to cyclophosphamide, methotrexate, and 5-fluorouracil." | 3.66 | Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. ( Calabresi, P; DeNucci, T; Dexter, DL; Heppner, GH; Miller, FR, 1978) |
| "Fifty-four patients with clinical evidence of residual colorectal adenocarcinoma following surgical removal of the primary tumor were treated with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside." | 3.66 | Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study. ( Davis, S; Park, YK, 1978) |
| "A number of chemotherapeutic agents, including L-asparaginase, actinomycin D, chloroethylcyclohexy-nitrosourea, 5-flourouracil, cyclophosphamide, hydroxyurea, cis-platinum, adriamycin and methotrexate, alone and in combination and at variable dose levels, were applied against the Dunning R3327 rat prostatic adenocarcinoma-subline G." | 3.66 | Further experience with chemotherapy in the Dunning prostatic adenocarcinoma. ( Block, NL; Camuzzi, F; Claflin, A; Politano, VA; Stover, B; Troner, M, 1978) |
| "Metastasizing mammary adenocarcinoma 13762 in female Fischer rats has been used as a model for studying postoperative adjuvant chemotherapy, using methotrexate (Mtx) and 5-fluouracil (5FU) either singly or in combinations." | 3.65 | Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. ( Khwaja, TA; Lee, YT, 1977) |
| "Arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation achieves a definite objective improvement in patients with estrogen-resistant adenocarcinoma of the prostate." | 3.65 | Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. ( Hoffman, AA; Nevin, JE, 1975) |
| "A carcinostatic substance (5-fluorouracil) was instilled into the mediastinal lymph nodes, the pleural cavity or the internal thoracic artery by continuous perfusion before operation on patients with bronchial carcinoma." | 3.65 | [Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)]. ( Inoguchi, T; Kita, T; Kuwano, K; Yamasaki, I; Yazuka, K, 1976) |
| " Following surgical removal of spontaneous mammary adenocarcinomas, phenylalanine mustard, adriamycin, and 5-fluorouracil (PAF) were administered at 4, 2, and 50 mg/kg, respectively, once a week for six injections." | 3.65 | Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. ( Anderson, JC; Fugmann, RA; Martin, DS; Stolfi, RL, 1977) |
| "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity." | 3.65 | Oculomotor disturbances associated with 5-fluorouracil chemotherapy. ( Bixenman, WW; Nicholls, JV; Warwick, OH, 1977) |
| "Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate." | 3.65 | Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. ( Bruckner, HW; Deppe, G, 1977) |
| " In squamous cell cancer of the lung 48 patients were administered methotrexate (90 mg per course), 18 patients with adenocarcinoma--5-fluoruracil, 29 patients with undifferentiated cancer-cyclophosphane (3 g of each substance)." | 3.65 | [Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)]. ( Abisatov, KhA; Khan, SV, 1976) |
| "In the present paper a test model was used to examine if human adenocarcinomas of the colon and the stomach are heterogenous as regards the sensitivity to cytosine arabinoside, melphalan, vinblastine sulphate, amethopterin and 5-fluorouracil in vitro." | 3.65 | Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs. ( Dencker, H; Håkansson, L; Tropé, C, 1975) |
| " 5-Fluorouracil (5 FU) is the first chemotherapeutic agent found to have a significant effect on gastrointestinal adenocarcinoma." | 3.64 | PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER. ( HART, GD, 1964) |
| " Secondary endpoints include the DFS of ctDNA positive patients versus ctDNA negative patients, the 2- and 3-year DFS rates, overall survival (OS), the impact of hallmark molecules on the treatment response, adverse events (AEs), and the impact of nutrition status or exercise on recurrence." | 3.30 | Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPL ( Chen, X; Chen, Y; Guo, F; Han, G; Li, W; Ma, L; Pan, L; Shu, Y; Tang, J; Tian, Y; Xie, L; Xu, H; Zhang, J; Zhang, X, 2023) |
| " Currently, no trials have investigated the impact of perioperative immunotherapy in combination with chemotherapy for resectable gastric or GEJ adenocarcinoma." | 3.11 | Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). ( Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB, 2022) |
| "For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy." | 3.01 | A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023) |
| "Hyperthermia was defined as feasible if 70% of patients received at least eight treatments." | 3.01 | Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. ( Bitzer, M; Fend, F; Gani, C; Gellermann, J; Heinrich, V; Königsrainer, A; Lamprecht, U; Moll, M; Wenz, S; Ziegler, A; Zips, D, 2021) |
| " We hypothesized that pelareorep in combination with pembrolizumab and chemotherapy in patients with PDAC would be safe and effective." | 2.94 | Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. ( Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B, 2020) |
| "This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic adenocarcinoma." | 2.94 | Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. ( Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C, 2020) |
| " Evaluation of pharmacogenomically dosed perioperative gFOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and UGT1A1 genotype-directed irinotecan) to optimize efficacy while limiting toxic effects may have value." | 2.94 | Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. ( Allen, K; Alpert, L; Catenacci, DVT; Chase, L; de Wilton Marsh, R; Ferguson, MK; Gordon, B; Hart, J; Karrison, T; Kindler, HL; Kipping-Johnson, K; Liao, CY; Lomnicki, S; Markevicius, U; Maron, SB; Moore, K; Narula, S; Peterson, B; Polite, BN; Posner, MC; Prachand, VN; Racette, C; Rampurwala, MM; Roggin, KK; Setia, N; Siddiqui, UD; Turaga, K; Xiao, SY, 2020) |
| "A total of 137 patients with advanced colorectal cancer were recruited." | 2.94 | The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer. ( Chang, L; Fu, X; Han, G; Han, Z; Hui, D; Jia, R; Li, Q; Li, Y; Liu, H; Liu, N; Zhang, H; Zhang, Y; Zhu, H, 2020) |
| " On the basis of preclinical data, sequential dosing was evaluated in cohort 4 (ipafricept day 1 followed nab-paclitaxel + gemcitabine day 3)." | 2.94 | Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ( Astsaturov, I; Brachmann, RK; Cardin, DB; Cohen, SJ; Denlinger, CS; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, W; O'Neil, B; Shahda, S; Stagg, RJ; Uttamsingh, S; Weekes, C, 2020) |
| " Adverse event data collection is recorded at every visit." | 2.94 | Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. ( Al Awabdeh, T; Al Darazi, M; Al Masri, M; Alqasem, K; Amarin, R; Charafeddine, M; Dabous, A; Daoud, F; Deeba, S; El Husseini, Z; Elkhaldi, M; Geara, F; Hushki, A; Jaber, O; Jamali, F; Kattan, J; Khalifeh, I; Kreidieh, M; Mohamad, I; Mukherji, D; Shamseddine, A; Temraz, S; Turfa, R; Zeidan, YH, 2020) |
| "A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity." | 2.90 | Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019) |
| "Patients affected with Stage IV colorectal cancer and unresectable metastases represent a heterogeneous group." | 2.90 | Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal Cancer: A Dilemma. ( Crocetti, D; DE Felice, F; DE Toma, G; Fiori, E; Lamazza, A; Mingoli, A; Sapienza, P; Sterpetti, AV; Tarallo, M, 2019) |
| "However, treatment for locally advanced pancreatic cancer is still controversial." | 2.90 | FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. ( Fukutomi, A; Kamei, K; Kobayashi, M; Kobayashi, S; Matsumoto, I; Matsuoka, H; Mizuno, N; Omae, K; Ozaka, M; Suzuki, S; Todaka, A; Ueno, H; Uesugi, K, 2019) |
| "A radical rectal cancer surgery was performed 6 to 8 weeks after the simultaneous chemoradiotherapy." | 2.90 | Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer. ( Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y, 2019) |
| " We included patients with rectal cancer who received 4 courses of modified FOLFOX6 (mFOLFOX6) before rectal surgery and examined the postoperative complication rate, the clinicopathological response, and the rate of chemotherapy-related adverse events (UMIN 000012559)." | 2.90 | Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study. ( Funakoshi, T; Hattori, M; Hirose, K; Homma, S; Ichikawa, N; Iijima, H; Ishikawa, T; Ishizu, H; Kamiizumi, Y; Kawamata, F; Koike, M; Kon, H; Kuraya, D; Minagawa, N; Murata, R; Nomura, M; Ohno, Y; Omori, K; Sato, M; Takahashi, N; Takeda, K; Taketomi, A; Yokota, R; Yoshida, T, 2019) |
| "Pancreatic cancer is a highly lethal disease predominantly affecting older patients." | 2.90 | Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. ( Blanc, JF; Chen, J; Chen, LT; de Jong, FA; Macarulla, T; Mirakhur, B; Siveke, JT; Wang-Gillam, A, 2019) |
| "The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study." | 2.90 | A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019) |
| "10-20% of patients with gastric cancer (GC) have HER2+ tumors." | 2.90 | EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden ( Caballero, C; Cats, A; Elme, A; Grabsch, HI; Kang, YK; Lordick, F; Marreaud, S; Martens, U; Mauer, M; Moehler, MH; Mueller, L; Rha, SY; Thuss-Patience, P; Tokunaga, M; Wagner, AD, 2019) |
| "9%) in arm B experienced grade 3/4 adverse events related to bevacizumab; the most frequent were 2 anastomotic fistulas (both in arm A) and abscesses (1 in arm A and 2 in arm B)." | 2.90 | Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. ( Adenis, A; André, T; Azria, D; Bachet, JB; Balosso, J; Ben Abdelghani, M; Borg, C; Boudghène, F; Conroy, T; Coudert, M; François, Y; Ghiringhelli, F; Ionescu-Goga, M; Lakkis, Z; Mantion, G; Mornex, F; Quero, L; Rio, E; Roullet, B; Spaëth, D; Tanang, A; Vendrely, V, 2019) |
| "The primary end point was the 10-month progression-free rate (PFR); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events." | 2.87 | Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. ( Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V, 2018) |
| " The objective of this study was to compare outcome measures, adverse effects, and cost of FOLFOX4 and FOLFIRINOX treatments in rectal cancer patients." | 2.87 | Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study. ( Chen, Y; Liu, J; Qi, F; Yan, Q; Zhang, G; Zheng, Z, 2018) |
| "3%), and 201 completed the treatment (early discontinuation was mainly due to intercurrent adverse events [AEs], 7." | 2.87 | Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. ( Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M, 2018) |
| "This phase I/II study was designed to determine the maximum tolerated dose of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors and to evaluate the safety and efficacy of this combination for patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach." | 2.84 | A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. ( Bendell, J; Flores, M; Hemphill, B; Kurkjian, C; Pant, S; Patel, M; Thompson, D, 2017) |
| " Patients received once-daily vandetanib (planned dosing levels of 100, 200, and 300 mg) with concomitant daily radiotherapy (1." | 2.84 | Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. ( Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ, 2017) |
| "To compare acute adverse events (AE) and postoperative complication rates in a randomized trial of short-course (SC) versus long-course (LC) preoperative radiotherapy." | 2.84 | Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). ( Ackland, S; Ansari, N; Burmeister, B; Fisher, RJ; Heriot, A; Joseph, D; Mackay, J; McClure, B; McLachlan, SA; Ngan, SY; Solomon, MJ, 2017) |
| "KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful." | 2.84 | Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. ( Al Baghdadi, T; Blanke, CD; Cardin, D; Chung, V; Doyle, LA; Dy, IA; Guthrie, KA; Hendifar, AE; Hochster, HS; Hui, L; Lowy, AM; McDonough, S; Philip, PA; Seery, TE; Tejani, MA; Wang-Gillam, A, 2017) |
| "Patients with resected stage III colon cancers were randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) chemotherapy with or without cetuximab (North Central Cancer Treatment Group N0147 trial) or adjuvant FOLFOX chemotherapy with or without bevacizumab (National Surgical Adjuvant Breast and Bowel Project C-08 trial)." | 2.84 | Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. ( Alberts, SR; Allegra, CJ; Goldberg, RM; Meyers, JP; Pogue-Geile, KL; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Thibodeau, SN; Yothers, G, 2017) |
| "Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al." | 2.84 | Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 2.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients." | 2.82 | Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). ( Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I, 2016) |
| "In the remaining seven (20%), the residual tumour clinically appeared benign." | 2.82 | Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign. ( Bujko, K; Malinowska, M; Mroz, A; Pietrzak, L; Rupinski, M; Rutkowski, A; Szczepkowski, M; Wyrwicz, L, 2016) |
| "With the changed dosing schedule, this regimen was very well tolerated." | 2.82 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. ( Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016) |
| "Patients with cT2-4 N0-2 M0 rectal cancer treated by standard CRT (54Gy and 2 cycles of 5FU-based chemotherapy) or extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy) underwent sequential PET/CT imaging at baseline, 6 weeks and 12 weeks from radiation completion." | 2.82 | Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. ( Buchpiguel, CA; Fernandez, LM; Figueiredo, MN; Gama-Rodrigues, J; Habr-Gama, A; Perez, RO; Proscurshim, I; São Julião, GP, 2016) |
| "Consecutive patients with distal rectal cancer undergoing neoadjuvant chemoradiation (50." | 2.82 | Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation. ( Fernandez, LM; Gama-Rodrigues, J; Habr-Gama, A; Jorge, JM; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2016) |
| "In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but limited tumor response." | 2.82 | Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. ( Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H, 2016) |
| "The rates of anastomotic leakage and stenosis were calculated for each treatment arm." | 2.82 | Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial. ( Deng, Y; Ma, T; Qin, Q; Wang, H; Wang, J; Wang, L; Zheng, J; Zhou, Z, 2016) |
| "Dutch Colorectal Cancer group, CKTO 2003-16, ISRCTN36266738." | 2.80 | Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. ( Berglund, Å; Breugom, AJ; Fokstuen, T; Gelderblom, H; Glimelius, B; Kapiteijn, E; Leer, JWH; Marijnen, CAM; Martijn, H; Meershoek-Klein Kranenbarg, E; Muller, EW; Nagtegaal, ID; Påhlman, L; Punt, CJA; Putter, H; Roodvoets, AGH; Rutten, HJT; Steup, WH; van de Velde, CJH; van den Broek, CBM; van Gijn, W, 2015) |
| "Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy." | 2.80 | Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015) |
| "Patients with locally advanced rectal cancer who achieve a pathological complete response to neoadjuvant chemoradiation have an improved prognosis." | 2.80 | Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. ( Avila, K; Cataldo, PA; Chow, OS; Coutsoftides, T; Dietz, DW; Fichera, A; Garcia-Aguilar, J; Herzig, DO; Hunt, SR; Kumar, AS; Marcet, JE; Oommen, S; Patil, S; Polite, BN; Smith, DD; Stamos, MJ; Ternent, CA; Varma, MG, 2015) |
| "1804 rectal cancer patients, staged cT3-4N0-2M0, participated in a multicenter study." | 2.80 | Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12. ( Baek, JY; Chie, EK; Cho, HM; Jang, HS; Jeong, BK; Jeong, JU; Kim, DY; Kim, JH; Kim, JS; Kim, K; Kim, SH; Kim, SY; Kim, TH; Lee, JH; Nam, TK; Oh, JH; Shim, BY; Yoon, MS, 2015) |
| "Stage II and III rectal cancer patients received, after total mesorectal excision, 2 cycles of XELOX regimen (oxaliplatin 130 mg/m(2) on day 1; capecitabine 1000 mg/m(2) bid on day 1 to 14, q21), followed by capecitabine (800 mg/m(2) bid daily; 20% dose at 12:00 AM and 80% dose at 12:00 PM) administered continuously during pelvic radiation (total 50." | 2.79 | Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. ( Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F, 2014) |
| "Capecitabine dose was increased from 650 mg/m(2) to 825 mg/m(2) orally twice daily on the days of radiation therapy; erlotinib dose was increased from 50 mg orally daily in weeks 1 to 3, to 50 mg daily in weeks 1 to 6, to 100 mg daily in weeks 1 to 6." | 2.79 | Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. ( Chang, GJ; Clemons, MV; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kopetz, SE; Krishnan, S; Maru, DM; Munsell, MF; Rodriguez-Bigas, MA; Shureiqi, I; Skibber, JM; You, YN, 2014) |
| "For resectable gastric cancer, both postoperative chemoradiotherapy and perioperative chemotherapy demonstrate high-level evidence for improved survival in Western populations." | 2.79 | Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308. ( Aparicio, T; Breysacher, G; Chapet, S; Dousset, B; Faroux, R; Jouve, JL; Maillard, E; Martel-Lafay, I; Michel, P; Mornex, F; Nguyen, S; Pere-Verge, D; Pezet, D; Seitz, JF; Sobhani, I, 2014) |
| "Capecitabine was administered twice daily on every radiotherapy treatment day in a dose-escalation schedule (mg/m²) of 625 (level I, n = 6), 700 (level II, n = 6), 800 (level III, n = 6), 900 (level IV, n = 0) and 1000 (level V, n = 0)." | 2.79 | Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. ( Fang, H; Jin, J; Li, YX; Liu, XF; Liu, YP; Ren, H; Song, YW; Wang, SL; Wang, WH; Wang, X; Yu, ZH, 2014) |
| " After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2." | 2.79 | Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014) |
| "A database of esophageal cancer was queried for nonmetastatic patients with adenocarcinoma treated between 2000 and 2011 with CRT." | 2.79 | Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. ( Almhanna, K; Freilich, J; Fulp, WJ; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Yue, B, 2014) |
| "Pancreatic cancer is one of the leading causes of cancer-related deaths worldwide." | 2.79 | Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. ( Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J, 2014) |
| " Predicted Cp [median and 90% prediction interval] was simulated using the population pharmacokinetic model established for other cancers (PPK model) and compared to observed Cp." | 2.79 | Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. ( Allison, DE; Han, K; Jin, J; Lowe, J; Maia, M; Sersch, MA, 2014) |
| "Gastric cancer is a heterogeneous disease, and the strategy of combining chemotherapy with HH inhibition may only be effective in tumors with high CD44 levels." | 2.79 | CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. ( Cohen, DJ; Janjigian, YY; Kim, TS; Lee, HJ; Park, DJ; Schmidt, B; Thomas, NJ; Yoon, C; Yoon, SS, 2014) |
| " We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer." | 2.79 | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. ( Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M, 2014) |
| "Brunch Regimen for locally advanced rectal cancer consisting of neoadjuvant chronomodulated capecitabine and concurrent radiation therapy is effective and well tolerated with good safety profile, particularly with regard to the occurrence of hand and foot syndrome, in patients with locally advanced rectal cancer." | 2.79 | Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. ( Akgun, Z; Balik, E; Cipe, G; Gural, Z; Kaytan-Saglam, E; Kilickap, S; Okyar, A; Saglam, S; Yildiz, S; Yucel, S, 2014) |
| "Capecitabine was administered on weekdays concurrently with pelvic radiotherapy at a daily dose of 1." | 2.79 | Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study. ( Hirakawa, K; Hosono, M; Maeda, K; Miki, Y; Nagahara, H; Shimatani, Y; Tsutsumi, S, 2014) |
| "Fluorouracil and cisplatin have been used most frequently as neoadjuvant therapy for esophageal cancer." | 2.79 | The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. ( Ba-Ssalamah, A; Hejna, M; Kandioler, D; Kappel, S; Kührer, I; Mittlböck, M; Pluschnig, U; Schoppmann, SF; Wolf, B; Wrba, F; Zacherl, J; Zwrtek, R, 2014) |
| "Patients (pts) with metastatic rectal cancer and symptomatic primary, require local and systemic control." | 2.79 | Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer. ( Bressel, M; Chander, S; Cooray, P; Heriot, A; Hicks, R; Jefford, M; Leong, T; MacKay, JR; McClure, B; McKendrick, J; Michael, M; Ngan, SY; Steel, M; Zalcberg, J, 2014) |
| "We consider that our observations in gastric cancer patients in our clinic can be useful in the future randomised trials to point the way to improved outcomes." | 2.79 | Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution. ( Coskun-Breuneval, M; Demirkasimoglu, T; Elgin, Y; Guney, Y; Kara, SP; Kucukpilakci, B; Misirlioglu, HC; Ozgen, A; Sanri, E; Ugur, VI, 2014) |
| "To explore the clinical effects of nimotuzumab combined with chemotherapy in the treatment of late gastric cancer." | 2.79 | Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer. ( Xu, CD, 2014) |
| "Patients with cT3 or cN1 and cM0 rectal cancer were eligible." | 2.79 | A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. ( Cubillo, A; De Vicente, E; García-García, E; Hernando-Requejo, O; Hidalgo, M; López, U; López-Ríos, F; Morelli, P; Muro, A; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Rubio, C, 2014) |
| " We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC." | 2.78 | A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. ( Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J, 2013) |
| "We compared the results of stage IV colorectal cancer patients treated within a large Dutch phase III trial (CAIRO), in which standard chemotherapy and standard safety eligibility criteria were used, to patients treated outside the trial during the trial accrual period in a representative selection of 29 Dutch hospitals." | 2.78 | Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. ( Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW, 2013) |
| "Adults with primary metastasized rectal cancer were enrolled." | 2.78 | Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. ( Beets, GL; Beukema, JC; de Jong, KP; Gelderblom, AJ; Havenga, K; Hospers, GA; Nagtegaal, ID; Rutten, HJ; Tamas, K; van de Velde, CJ; van Dijk, TH; Wiggers, T, 2013) |
| "Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options." | 2.78 | Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. ( Bodoky, G; Celik, I; Chung, HC; Gorbunova, V; Götte, H; Kang, YK; Kurteva, G; Lordick, F; Melezínková, H; Moehler, M; Moiseyenko, VM; Oh, SC; Park, JO; Salman, P; Sawaki, A; Volovat, C, 2013) |
| "An analysis of surgically resected esophageal cancer patients after nCRT was performed to determine an association between the number of LNs resected and survival." | 2.78 | Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. ( Almhanna, K; Chuong, MD; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Weber, JM, 2013) |
| "Metronidazole 10 g/m(2) was administered per rectum on days 8 and 15." | 2.78 | Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer. ( Barsukov, YA; Fedyanin, MY; Gordeyev, SS; Perevoshikov, AG; Tkachev, SI, 2013) |
| "4%) and renal adverse events (all grades: CS, 18." | 2.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "Squamous cell carcinoma is the most common malignant change." | 2.78 | Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution. ( Khemapech, N; Oranratanaphan, S, 2013) |
| "The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported." | 2.78 | HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. ( Cervantes, A; Chau, I; Cunningham, D; Eltahir, Z; Glimelius, B; Gonzalez de Castro, D; Oates, J; Peckitt, C; Roy, A; Sclafani, F; Tabernero, J; Wotherspoon, A, 2013) |
| " There was no evidence of a pharmacokinetic drug-drug interaction between sunitinib and 5-FU." | 2.78 | A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. ( Bellmunt, J; Gil-Martín, M; Gómez-Martín, C; Khosravan, R; Lechuga, MJ; Lin, X; Montagut, C; Núñez, JA; Puig, M; Salazar, R; Tursi, JM, 2013) |
| "Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a." | 2.78 | Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013) |
| "The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen." | 2.78 | Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. ( Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013) |
| "Seventy-three patients with cT3-4 rectal cancer were enrolled." | 2.78 | Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01). ( Baek, JY; Chang, HJ; Jang, HS; Kim, DY; Kim, JG; Kim, MJ; Kim, SY; Kim, TH; Lee, JH; Lee, MA; Nam, TK; Oh, JH; Park, JW; Yeo, SG, 2013) |
| " Toxic effects were graded according to NCI-CTC version 3." | 2.78 | The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. ( Abdel-Latif, RM; Anter, AH, 2013) |
| " However, because of decreased relative dose intensity during treatment, further study is warranted to determine optimal dosage and combination." | 2.77 | A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. ( Ahn, JY; Chung, HC; Hyung, WJ; Jeung, HC; Lee, SS; Noh, SH; Rha, SY, 2012) |
| "This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i." | 2.77 | A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ( Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G, 2012) |
| "pCR was achieved in 67% of squamous cell carcinoma." | 2.77 | Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. ( Balagué, C; Bellmunt, J; Conill, C; Gallego, R; Iglesias, M; Martín-Richard, M; Maurel, J; Momblan, D; Montagut, C; Pera, M; Pétriz, L; Reig, A, 2012) |
| "Patients with locally advanced or low rectal cancer were treated with capecitabine 825 mg/m(2) twice daily on days 1-14 and 22-35, oxaliplatin 50mg/m(2) on days 1, 8, 22 and 29, bevacizumab 5mg/kg on days 14, 1, 15 and 29, and radiation 50." | 2.77 | Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. ( Berry, S; Easaw, J; Hay, J; Kennecke, H; Post, J; Rao, S; Tankel, K; Wong, R; Zhou, C, 2012) |
| "Clinically staged T2N0 rectal cancer patients were treated with capecitabine and oxaliplatin during radiation followed by LE." | 2.77 | A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. ( Cataldo, P; Chan, E; Garcia-Aguilar, J; Marcet, J; Medich, D; Oommen, S; Pigazzi, A; Posner, MC; Shi, Q; Thomas, CR, 2012) |
| " The starting dosage of capecitabine was 2000 mg/m(2)/day (days 1-14, every 3 weeks)." | 2.77 | Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. ( Bang, SM; Chang, HJ; Kang, SB; Kim, DW; Kim, JH; Kim, YJ; Lee, JS; Lee, KW, 2012) |
| "Oral capecitabine is an effective alternative to bolus 5-FU/FA as adjuvant treatment of patients with stage III colon cancer with efficacy benefits maintained at 5 years and in older patients." | 2.77 | Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. ( Cassidy, J; Díaz-Rubio, E; Gilberg, F; McKendrick, J; Scheithauer, W; Seitz, JF; Twelves, C; Van Hazel, G; Wong, A, 2012) |
| "Patients with T3 to T4 and/or N+ rectal cancer received preoperative IMRT (47." | 2.77 | Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. ( Arbea, L; Aristu, J; Cambeiro, M; Chopitea, A; Díaz-González, JA; García-Foncillas, J; Gaztañaga, M; Hernández, JL; Martínez-Monge, R; Moreno, M; Nuñez, J; Ramos, LI; Rodríguez, J; Sola, JJ; Subtil, JC, 2012) |
| " The CCRT began 28 days after the first cycle of chemotherapy, and chemotherapy was given within the first four and last three days during the CCRT period, at a radiation dosage of 45 Gy/25 f, i." | 2.77 | Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. ( Li, T; Song, Y; Yu, C; Yu, R; Zhu, W, 2012) |
| "Patients with stage II-IIIB gastric cancer who had had curative D2 gastrectomy were randomly assigned to receive adjuvant chemotherapy of eight 3-week cycles of oral capecitabine (1000 mg/m(2) twice daily on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m(2) on day 1 of each cycle) for 6 months or surgery only." | 2.77 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. ( Bang, YJ; Button, P; Cho, JY; Chung, HC; Ji, J; Kim, YH; Kim, YW; Lee, KH; Lee, KW; Mok, YJ; Noh, SH; Noh, SI; Park, YK; Sirzén, F; Yang, HK; Yeh, TS, 2012) |
| " The aim of the study was to compare efficacy and safety, including response rate (RR), progression-free survival (PFS), overall survival, and grade ≥3 adverse events, between patients aged ≥65 years and patients aged <65 years." | 2.77 | Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. ( Bang, HY; Cho, YH; Hong Lee, M; Kim, SY; Lee, KY; Yoo, MW; Yoon, SY, 2012) |
| "Systemic chemotherapy for patients with gastric cancer has limited impact on overall survival." | 2.77 | Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. ( Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M, 2012) |
| "Patients with MSI-H (n=34) colon cancer presented with a significantly lower risk of relapse after 12 months of follow-up compared with MSS (n=189) colon cancer patients (5 year time to relapse: MSI-H 0." | 2.77 | Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. ( Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M, 2012) |
| "Capecitabine was administered at 825 t." | 2.77 | Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer. ( Alberola Candel, V; Alberola, A; Garde Noguera, J; Gasent Blesa, JM; Giner Bosch, V; Laforga Canales, JB; Peris Godoy, M; Provencio Pulla, M; Sanchez, JL; Soler Tortosa, M, 2012) |
| "New therapeutic options for metastatic pancreatic cancer are urgently needed." | 2.77 | Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. ( Bitzer, M; Boeck, S; Buechler, P; Endlicher, E; Geissler, M; Harder, J; Heinemann, V; Hofheinz, R; Ihorst, G; Kloeppel, G; Moehler, M; Reinacher-Schick, A; Röcken, C; Schmoor, C, 2012) |
| "Patients with stage II and III esophageal cancer were enrolled." | 2.77 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012) |
| "Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU." | 2.77 | A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012) |
| "Surgical resection of gastric cancer has produced suboptimal survival despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical procedures." | 2.77 | Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. ( Ajani, JA; Benedetti, JK; Blanke, CD; Estes, NC; Goldman, B; Gunderson, LL; Haller, DG; Hundahl, SA; Jessup, JM; Macdonald, JS; Martenson, JA; Smalley, SR; Stemmermann, GN, 2012) |
| " standard body-surface-area (BSA) dosing in a FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimen in metastatic colorectal cancer (mCRC)." | 2.77 | Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ( Asevoaia, A; Boisdron-Celle, M; Capitain, O; Gamelin, E; Morel, A; Poirier, AL, 2012) |
| "Despite substantial developments in gastric cancer treatment, the majority of patients relapse after definitive surgery." | 2.77 | Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. ( Hubert, A; Kadouri, L; Peretz, T; Rivkind, A; Rottenberg, Y; Sonnenblick, A; Vainer, GW; Wygoda, M, 2012) |
| "To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| "IGF-1 was associated with the number of metastases (p = 0." | 2.77 | Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. ( Camphausen, K; Graves, CA; Kim, HJ; Kim, SH; Kwon, HC; Lee, JH; Lee, S; Oh, SY, 2012) |
| "Chemo-naïve patients with metastatic gastric cancer were enrolled to receive 4 cycles of TCF-dd (docetaxel initially 85 mg/m(2) and cisplatin initially 75 mg/m(2) on day 1 [later modified due to toxicity: 70 and 60 mg/m(2) respectively], l-folinic acid 100 mg/m(2) on days 1 and 2, 5-fluorouracil 400 mg/m(2) bolus and then 600 mg/m(2) as a 22 h continuous infusion on day 1 and 2, every 14 days)." | 2.76 | Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial. ( Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G, 2011) |
| "Gemcitabine dose was fixed at 750 mg/m² over 75 min, capecitabine was given twice daily and escalated from 500 to 650 mg/m² at DL2 and docetaxel increased from 30 to 36 mg/m² at DL3." | 2.76 | A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M, 2011) |
| "Patients with clinical T3, T4, or N1-2 rectal cancer were subjected to a preoperative CCRT protocol with FOLFOX and bevacizumab (5 mg/kg) biweekly for 6 cycles followed by a standardized laparoscopic TME procedure, as detailed in the attached video." | 2.76 | Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. ( Cheng, KW; Lai, HS; Liang, JT, 2011) |
| "A total of 268 patients with stage II gastric cancer underwent D2 resection in our Cancer Center between January 1990 and December 2006 were recruited." | 2.76 | No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer. ( Chen, S; Chen, YB; Feng, XY; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ; Zhou, ZW, 2011) |
| "Patients (N = 207) with nonresectable rectal cancer were randomized to preoperative CRT or RT (2 Gy × 25 ± 5-fluorouracil/leucovorin)." | 2.76 | Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. ( Berglund, Å; Bruheim, K; Brændengen, M; Cvancarova, M; Glimelius, B; Tveit, KM, 2011) |
| "In patients with locally advanced rectal cancer (LARC), preoperative chemoradiation is known to improve local control, and down-staging of the tumor serves as a surrogate for survival." | 2.76 | Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study. ( Devries, AF; Eisterer, W; Fastner, G; Gnant, M; Greil, R; Jäger, R; Kapp, KS; Keil, F; Offner, F; Ofner, D; Rabl, H; Schaberl-Moser, R; Thaler, J; Tschmelitsch, J; Zitt, M, 2011) |
| "Patients with locally advanced rectal cancer (cT3, potentially resectable cT4 or N+) were randomly assigned to receive preoperative or postoperative CRT." | 2.76 | Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. ( Kim, JC; Kim, JH; Kim, TW; Park, JH; Yoon, SM; Yu, CS, 2011) |
| "Grade 3-4 toxicity during neoadjuvant treatment was diarrhea (38." | 2.76 | Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). ( Aprile, G; Aschele, C; Bardelli, A; Bochicchio, A; Di Fabio, F; Garufi, C; Giaquinta, S; Gion, M; Latiano, T; Maiello, E; Martoni, A; Pini, S; Pinto, C; Rosati, G; Torri, V, 2011) |
| "To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer." | 2.76 | [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. ( Chen, DY; Qi, Q; Zhao, WY, 2011) |
| "This phase II study is performed to evaluate the efficacy and safety of capecitabine combined with preoperative radiotherapy (RT) in Chinese patients with locally advanced rectal cancer (LARC)." | 2.76 | Preoperative radiotherapy combined with capecitabine chemotherapy in Chinese patients with locally advanced rectal cancer. ( Deng, J; Jin, J; Li, X; Lu, W; Meng, H; Wang, F; Xu, X; Xue, Z; Zhang, H; Zhou, G, 2011) |
| "To evaluate the safety and efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) in the treatment of HER2-positive advanced gastric cancer." | 2.76 | [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. ( Chen, QQ; Gao, XP; Li, W; Pan, SY; Sun, J, 2011) |
| "The prognosis of patients with advanced gastric cancer (AGC) remains poor, and no single chemotherapy regimen is recognized as a global standard." | 2.76 | Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. ( He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH, 2011) |
| "Patients with advanced pancreatic cancer who were refractory to prior gemcitabine- and 5-FU- based chemotherapy were enrolled in this study." | 2.75 | Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. ( Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2010) |
| "Patients with metastatic colorectal cancer received either FOLFOX-4 + bev or FOLFIRI + bev." | 2.75 | Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. ( Chin, K; Fujiwara, Y; Hatake, K; Ichimura, T; Kobayashi, K; Konishi, F; Kuboki, Y; Matsueda, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M, 2010) |
| " After two cycles, a 4-week outpatient treatment of gemcitabine (1000 mg/m(2)) on days 1 and 15 combined with 5-FU (500 mg/m(2)) and CDDP (7 mg/m(2)) on days 1 and 15 was commenced." | 2.75 | Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. ( Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y, 2010) |
| "Celecoxib dosage was fixed." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| "Preoperative treatment of rectal cancer with combined chemotherapy and radiation therapy has become a widely accepted strategy." | 2.75 | A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. ( Chang, M; George, TJ; Grobmyer, S; Hochwald, S; King, J; Larson, B; Marsh, Rde W; Mendenhall, WM; Siddiqui, T; Zlotecki, RA, 2010) |
| "The presence of residual tumour by conventional imaging, dichotomised as positive or negative, and the level of FDG uptake (standardised uptake values, SUV) were compared with histopathology, which served as the reference standard." | 2.75 | Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. ( Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C, 2010) |
| "Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)." | 2.75 | A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010) |
| "Patients with advanced gastric cancer (AGC), clinically unresectable because of local invasion or limited intra-abdominal metastasis in para-aortic lymph nodes and/or the peritoneum based on multidetector row computed tomography, were enrolled." | 2.75 | Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. ( Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH, 2010) |
| "Gemcitabine was given intravenously at a dose of 1000 mg/m(2) over 30 min on days 1, 8 and 15, repeated every 4 weeks." | 2.75 | Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. ( Boku, N; Fukuda, H; Fukutomi, A; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Nakamura, K; Ohkawa, S; Okusaka, T, 2010) |
| "Bortezomib was administered on days 1, 4, 8, and 11 every 21 days for 2 cycles with 5-fluorouracil at 225 mg/m2/day continuously and 50." | 2.75 | A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. ( Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE, 2010) |
| "Peritoneal carcinomatosis from colorectal cancer treated with chemotherapy alone results in median survival of 5 to 13 months, whereas CRS with HIPEC for early peritoneal carcinomatosis from colorectal cancer resulted in median survival of 48-63 months and 5 year survival of 51%." | 2.75 | Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. ( Avital, I; Davis, JL; Kemp, CD; Ripley, RT; Steinberg, SM; Toomey, MA, 2010) |
| "Forty two patients with advanced gastric cancer received neoadjuvant chemotherapy and subsequently 40 patients underwent standardized gastrectomy (2 patients with tumor progression had therapy limited to palliative chemotherapy without surgery)." | 2.75 | [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. ( Alakus, H; Baldus, S; Bollschweiler, E; Brabender, J; Dietlein, M; Hölscher, AH; Metzger, R; Mönig, SP; Schmidt, M; Schneider, PM; Vallböhmer, D, 2010) |
| "Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer." | 2.75 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. ( Aprile, G; Bang, YJ; Chung, HC; Feyereislova, A; Hill, J; Kang, YK; Kulikov, E; Lehle, M; Lordick, F; Ohtsu, A; Omuro, Y; Rüschoff, J; Satoh, T; Sawaki, A; Shen, L; Van Cutsem, E, 2010) |
| "The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada." | 2.75 | Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. ( Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN, 2010) |
| "Standard adjuvant chemoradiotherapy of rectal cancer still consists of 5-fluorouracil (5-FU) only." | 2.75 | Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α. ( Baumann, W; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Staib, L; Wiegel, T, 2010) |
| "Twenty-one patients with advanced gastric cancer who had failed first-line therapy received irinotecan on days 1 and 8 plus capecitabine on days 1-14 for a 21-day cycle." | 2.75 | [Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases]. ( Dong, CM; Kang, MF; Liu, Y; Luo, MQ, 2010) |
| "Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent." | 2.74 | A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009) |
| "Patients with histologically proven gastric cancer and measurable metastatic disease received capecitabine 825 mg/m(2) twice daily (1,650 mg/m(2) per day) on days 1-14 and paclitaxel 175 mg/m(2) by intravenous infusion on day 1 every 3 weeks until disease progression or unacceptable toxicities." | 2.74 | Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. ( Abakar-Mahamat, A; Baize, N; Berthier, F; Caroli-Bosc, FX; Mounier, N, 2009) |
| "Advanced or metastatic gastric cancer, which is one of the most common malignancies in Korea, is difficult to cure by surgery alone and generally requires combination chemotherapy." | 2.74 | Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. ( Ahn, JS; Jung, JY; Kim, HJ; Kim, I; Kim, JH; Kwon, JH; Lee, JA; Lee, KS; Park, YI; Song, HH; Zang, DY, 2009) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 2.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "The incidence of liver metastasis in group A was 34% which was lower than 50% in group B." | 2.74 | Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. ( Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ, 2009) |
| "However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs." | 2.74 | Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. ( Bjerkeset, O; Carlsen, E; Dahl, O; Eide, TJ; Fluge, Ø; Halvorsen, TB; Myrvold, HE; Podhorny, N; Tveit, KM; Vonen, B; Wiig, JN, 2009) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 2.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "Vorinostat was given orally twice daily for 1 week every 2 weeks." | 2.74 | A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. ( Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009) |
| "Of these, 50 patients had untreated gastric cancer, and 14 had received previous therapy with nonplatinum-based therapy." | 2.74 | Phase II study of capecitabine plus cisplatin in patients with gastric cancer. ( AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA, 2009) |
| "Between 1993 and 2003, 186 rectal cancer patients were enrolled." | 2.74 | Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection. ( Barbachano, Y; Chau, I; Chong, G; Cunningham, D; Watkins, D; Yau, T, 2009) |
| "Chinese drug ZW3 for the treatment of colonic cancer could improve the main clinical symptoms, improve the QOL, increase body weight and prolong the survival time of patients, showing a favorable integral effect." | 2.74 | Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine. ( Shan, ZZ; You, JL; Zhou, LY, 2009) |
| "Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks." | 2.74 | Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009) |
| "This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients." | 2.74 | [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. ( Lou, F; Pan, HM; Zhu, YH, 2009) |
| "The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented." | 2.74 | Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. ( Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J, 2009) |
| "Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy." | 2.74 | [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer]. ( Dai, H; Yan, D, 2009) |
| " This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients." | 2.74 | [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009) |
| "To investigate the efficiency, time to progression (TTP), overall survival (OS) and toxicity of epirubicin combined with DDP and 5-Fu (PELF regimen) for the treatment of advanced gastric cancer." | 2.74 | [Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD, 2009) |
| "Pancreatic cancer is an extremely aggressive malignancy." | 2.74 | An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinica ( Büchler, MW; Decker-Baumann, C; Harig, S; Jäger, D; Karapanagiotou-Schenkel, I; Märten, A; Ose, J; Rötzer, I; Schmidt, J; Wente, MN, 2009) |
| "This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC)." | 2.73 | Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. ( Chang, YF; Chao, TY; Chen, PM; Chiou, TJ; Chiu, CF; Chung, CY; Hwang, WS; Lin, SF, 2008) |
| "The treatment of peritoneal carcinomatosis is based on cytoreduction followed by hyperthermic intraperitoneal chemotherapy and combined with adjuvant chemotherapy." | 2.73 | 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. ( Boot, H; Bruin, S; van Slooten, G; van Tinteren, H; Verwaal, VJ, 2008) |
| "Capecitabine was given at 725 mg/m(2) orally twice daily Monday through Friday concurrently with RT." | 2.73 | Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. ( Andrews, C; Bullarddunn, K; Fakih, MG; Levea, C; Park, YM; Pendyala, L; Puthillath, A; Rajput, A; Ross, ME; Rustum, YM; Toth, K; Yang, GY, 2008) |
| "Paclitaxel was administered as a 1-h intravenous (i." | 2.73 | A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer. ( Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2008) |
| " Incidence of grade 3/4 treatment-related adverse events during the first 12 weeks of treatment were 59%, 36%, and 67% for mFOLFOX6, bFOL, and CapeOx, respectively, (TREE-1) and 59%, 51%, and 56% for the corresponding treatments plus bevacizumab (TREE-2; primary end point)." | 2.73 | Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. ( Abubakr, Y; Childs, BH; Cohn, AL; Fehrenbacher, L; Hainsworth, JD; Hart, LL; Hedrick, E; Hochster, HS; Ramanathan, RK; Saif, MW; Schwartzberg, L; Wong, L, 2008) |
| "2004, 285 patients with stage IIB-IIIB cervical cancer treated in Maternal and Child Health Hospital of Jiangxi Province were randomly assigned to receive radiotherapy alone or concurrent chemoradiotherapy." | 2.73 | [Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma]. ( Li, HP; Li, LY; Luo, B; Pan, M; Shu, KY; Zeng, SY, 2008) |
| "Capecitabine was given at an oral dosage of 825 mg/m(2)bid on each day of the radiotherapy period with the first daily dose applied 2 h before irradiation, followed by surgery 6 weeks later." | 2.73 | Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. ( Budach, W; Debus, J; Dunst, J; Hinke, A; Hoelscher, T; Mose, S; Reese, T; Roedel, C; Rudat, V; Wulf, J; Zuehlke, H, 2008) |
| "In patients with pancreatic cancer, CAI/RT had no significant effect on local recurrence (log-rank P = 0." | 2.73 | Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. ( Hermans, JJ; Hop, WC; Incrocci, L; Jeekel, J; Kazemier, G; Morak, MJ; van Dekken, H; van der Gaast, A; van Eijck, CH, 2008) |
| "The objective of this study was to evaluate the efficacy and safety of the POF regimen (biweekly 5-fluorouracil/leucovorin combined with paclitaxel and oxaliplatin) as first-line treatment for advanced gastric cancer (AGC)." | 2.73 | A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. ( Chen, L; Fan, NF; Guo, ZQ; Lin, RB; Liu, J; Wang, XJ, 2008) |
| "Celecoxib was given daily during CRT at one of five doses (200 mg bd to 600 mg bd)." | 2.73 | A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. ( Biagi, J; Dawson, SJ; Foo, KF; Hui, A; Jefford, M; Leong, T; Michael, M; Milner, AD; Ngan, SY; Thomas, RJ; Zalcberg, JR, 2007) |
| "The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma." | 2.73 | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). ( Berardi, R; Cascinu, S; Ceccarelli, C; Di Fabio, F; Funaioli, C; Giannetta, L; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL; Siena, S, 2007) |
| "We sought to evaluate the efficacy and safety data of a combination regimen using weekly irinotecan in combination with capecitabine and concurrent radiotherapy (CapIri-RT) as neoadjuvant treatment in rectal cancer in a phase-II trial." | 2.73 | A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. ( Grobholz, R; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Leitner, A; Post, S; Wenz, F; Willeke, F; Willer, A, 2007) |
| "Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included." | 2.73 | Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 2.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy." | 2.73 | Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K, 2007) |
| " In locally advanced rectal cancer, preoperative infusional chemotherapy combined with radiation was found to be less toxic than bolus chemotherapy and radiotherapy." | 2.73 | Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. ( Elsaleh, H; Joseph, D; Kaminski, A, 2007) |
| "In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone." | 2.73 | Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). ( Cartenì, G; Catalano, G; Ciardiello, F; Colucci, G; De Vita, F; Di Martino, N; Galizia, G; Gebbia, V; Giuliani, F; Maiello, E; Manzione, L; Montemurro, F; Orditura, M; Romito, S, 2007) |
| "Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone." | 2.73 | Combined modality chemoradiation in elderly oesophageal cancer patients. ( Anderson, SE; Bains, M; Hummer, A; Ilson, DH; Kelsen, D; Minsky, BD, 2007) |
| " This approach to treatment of locally advanced pancreatic cancer is safe and promising, with good local control for a substantial proportion of patients, and merits testing in a randomised trial." | 2.73 | Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. ( Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E, 2007) |
| "T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabine of 1000 mg/m(2) twice daily (days 1-14, 25-38) added to RT with 50." | 2.73 | Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. ( Cats, A; Havenga, K; Hospers, GA; Jansen, EP; Leer, JW; Marijnen, CA; Mulder, NH; Punt, CJ; Tesselaar, ME; Van de Velde, CJ; Van Krieken, HH; Wiggers, T, 2007) |
| "For patients with localized esophageal cancer, whether or not preoperative chemotherapy is administered, only an R0 resection results in substantial long-term survival." | 2.73 | Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. ( Ajani, JA; Estes, NC; Gunderson, LL; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Roth, JA; Willett, CG; Winter, KA, 2007) |
| "Eight patients had esophageal cancer and 9 had gastric cancer." | 2.73 | A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. ( Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H, 2007) |
| "We hypothesised that gastric cancer outcome could be improved with more effective and intensified postoperative chemoradiotherapy." | 2.73 | Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. ( Bartelink, H; Boot, H; Cats, A; Dubbelman, R; Jansen, EP; Verheij, M, 2007) |
| "Fifty-one patients with T3 or T4 gastric cancer received systemic 5-fluorouracil-based adjuvant chemotherapy, and intratumoral expression of TS and TP in 51 gastric cancer tissue samples was tested by real-time quantitative PCR." | 2.73 | Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. ( Deng, JZ; Hua, D; Huang, ZH; Mao, Y, 2007) |
| "Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only." | 2.73 | A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. ( Gnant, M; Greil, R; Herbst, F; Hofbauer, F; Jagoditsch, M; Jakesz, R; Rabl, H; Samonigg, H; Schaberl-Moser, R; Schippinger, W; Steger, GG; Thaler, J; Thödtmann, R; Tschmelitsch, J; Wohlmuth, P, 2007) |
| "Patients diagnosed with colorectal cancer (n=150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy." | 2.73 | Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. ( Elomaa, I; Joensuu, H; Korpela, R; Kouri, M; Ollus, A; Osterlund, P; Ruotsalainen, T; Saxelin, M; Valta, P, 2007) |
"These specimens were evaluated for DNA aneuploidy (DI | 2.73 | Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial. ( Crook, W; Eifel, PJ; Gaffney, DK; Grigsby, PW; Krishan, A; Lucci, JA; Markoe, AM; Morris, M; Winter, K; Wolfson, AH, 2008) | |
| " Patients in the treatment group (34 patients) received chemotherapy of DCF (docetaxel/cisplatin/5-fluorouracil) regimen combined with Chinese herbal medicine, and patients in the control group (32 patients) were treated with chemotherapy of the same regimen alone." | 2.73 | [Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction]. ( Gao, H; Wang, HB; Wang, HZ, 2007) |
| "50 patients with squamous cell carcinoma (90%) or adenocarcinoma and mostly advanced tumor stage were treated (82% T3/T4 and 70% N1)." | 2.73 | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. ( Brunner, TB; Grabenbauer, GG; Melzner, W; Rupp, A; Sauer, R, 2008) |
| "Data of 211 patients with advanced pancreatic cancer who underwent FLEC regimen were analyzed." | 2.73 | Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. ( Ballardini, M; Bassi, C; Cantore, M; Fiorentini, G; Guadagni, S; Iacono, C; Mambrini, A; Orlandi, M; Pacetti, P; Torri, T, 2008) |
| "To evaluate the therapeutic efficacy and adverse reaction of Aidi Injection (ADI) combined with FOLFOX4 regimen for treatment of patients with advanced colorectal cancer, and controlled with those of FOLFOX4 regimen alone." | 2.73 | [Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone]. ( Dong, L; Fu, SY; Li, HJ, 2007) |
| "Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI." | 2.73 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008) |
| "Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined." | 2.73 | Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. ( Baumann, W; Ette, C; Formentini, A; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Sander, S; Staib, L, 2008) |
| "PEFG regimen in gemcitabine refractory pancreatic cancer had an acceptable toxicity profile and interesting activity, and may constitute a treatment option in this setting." | 2.73 | PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. ( Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A, 2008) |
| "Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients." | 2.73 | Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. ( Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R, 2007) |
| "Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities." | 2.73 | Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008) |
| "Patients with clinically unresectable rectal cancer or for whom resection with histologically clear (R0) surgical margins was unlikely received continuous capecitabine (500-825 mg/m2 twice daily, 7 days/week), oxaliplatin 2-h intravenous infusion (130 mg/m2 days 1 and 29) and pelvic radiotherapy (Monday-Friday for 5 weeks, total dose 45 Gy in 25 daily 1." | 2.72 | A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. ( Falk, SJ; Glynne-Jones, R; Maughan, TS; McDonald, AC; Sebag-Montefiore, D, 2006) |
| " Seventy-seven patients were randomly assigned to receive paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on day 1, in combination with 5-FU 500 mg/m2 continuous infusion on days 1-5." | 2.72 | Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. ( Bang, SM; Cho, EK; Chung, M; Han, SH; Lee, JH; Lee, WK; Lee, Y; Park, SH; Shin, DB, 2006) |
| "Capecitabine and gefitinib were administered throughout the radiation course." | 2.72 | Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. ( Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D, 2006) |
| "Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated." | 2.72 | Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. ( Hirota, T; Kodaira, S; Mori, T; Ohashi, Y, 2006) |
| "Pancreatic cancer is chemo-radiosensitive." | 2.72 | Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. ( Bossard, N; Ducreux, M; Girard, N; Mornex, F; Partensky, C; Rouanet, P; Roy, P; Scoazec, JY; Seitz, JF; Smith, D; Valette, PJ; Ychou, M, 2006) |
| "Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions." | 2.72 | A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). ( Koizumi, W; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S, 2006) |
| "In patients with rectal cancer who receive preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival." | 2.72 | Chemotherapy with preoperative radiotherapy in rectal cancer. ( Bardet, E; Beny, A; Bosset, JF; Calais, G; Collette, L; Daban, A; Maingon, P; Mineur, L; Ollier, JC; Radosevic-Jelic, L, 2006) |
| "The 5-year incidence of local recurrence was lower with chemoradiotherapy (8." | 2.72 | Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. ( Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Chapet, O; Closon-Dejardin, MT; Conroy, T; Ducreux, M; Francois, E; Gérard, JP; Leduc, B; Mackiewicz, R; Maurel, J; Seitz, JF; Untereiner, M, 2006) |
| "Advanced gastric cancer patients were randomly assigned to docetaxel 75 mg/m2 and cisplatin 75 mg/m2 (day 1) plus fluorouracil 750 mg/m2/d (days 1 to 5) every 3 weeks or cisplatin 100 mg/m2 (day 1) plus fluorouracil 1,000 mg/m2/d (days 1 to 5) every 4 weeks." | 2.72 | Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. ( Ajani, JA; Boni, C; Chao, Y; Constenla, M; Fodor, M; Majlis, A; Moiseyenko, VM; Risse, ML; Rodrigues, A; Tjulandin, S; Van Cutsem, E; Voznyi, E, 2006) |
| "169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)." | 2.72 | Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006) |
| "Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials." | 2.71 | Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003) |
| "Multimodal treatment of esophageal cancer showed promising results, although not significant, in terms of survival and disease progression for patients achieving a complete pathologic response." | 2.71 | Preoperative chemoradiotherapy in cancer of the thoracic esophagus. ( Baccarani, U; Bresadola, F; Bresadola, V; Buffoli, A; Cartei, G; Cedolini, C; Fongione, S; Iop, A; Sacco, C; Signor, M; Terrosu, G; Uzzau, A; Vigevani, E, 2003) |
| "After curative resection of a stage III colon cancer, adjuvant treatment with 5-FU plus leucovorin is generally well tolerated." | 2.71 | 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. ( Arkenau, HT; Bermann, A; Porschen, R; Rettig, K; Strohmeyer, G, 2003) |
| "Metastatic gastric cancer is usually treated with cisplatin- and 5-FU-based chemotherapy regimens." | 2.71 | Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion. ( Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2003) |
| "Ninety-two patients with esophageal cancer (65 with adenocarcinoma and 27 with squamous cell carcinoma) were treated in two sequential protocols of preoperative chemoradiotherapy." | 2.71 | Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. ( Burtness, B; Forastiere, AA; Heath, EI; Heitmiller, R; Kleinberg, L; Knisely, JP; Salem, R; Zahurak, M, 2003) |
| "Capecitabine was administered to single-patient cohorts at escalating doses of 1500, 2000, and 2500 mg/m2/day in two equally divided doses for 14 of 21 days, beginning on day 1." | 2.71 | A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. ( Fehn, K; Landau, L; Makower, D; Mani, S; Sparano, JA; Versola, M; Wadler, S; Wissel, P, 2003) |
| " A Bayesian methodology was used to assess individual pharmacokinetic parameters using the NONMEM computer program." | 2.71 | Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ( Bressolle, F; Debrigode, C; Duffour, J; Gourgou, S; Kramar, A; Pinguet, F; Ychou, M, 2003) |
| "Ten patients with advanced or recurrent cancer of the cervix with no prior chemotherapy were entered in a phase II trial from October 2000 to November 2001." | 2.71 | First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study. ( Behtash, N; Ghaemmaghami, F; Khanafshar, N; Modares, M; Moosavi, A; Toogeh, G; Yarandi, F, 2003) |
| "Patients with gastric cancer staged IB to IV(M0) were treated with chemoradiotherapy after curative resection with extensive (D2) lymph node dissection." | 2.71 | Postoperative chemoradiotherapy for gastric cancer. ( Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, DY; Kim, K; Kim, S; Kim, WS; Kim, YI; Lee, KW; Lee, MH; Lim, DH; Noh, JH; Park, CH; Park, CK; Park, JO; Park, K; Park, SH; Sohn, TS, 2003) |
| "Attempted surgical salvage of rectal cancer recurrence is performed commonly in the United States." | 2.71 | Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. ( Cooke, E; Hollis, D; Mayer, RJ; Niedzwiecki, D; O'Connell, M; Tepper, JE, 2003) |
| "Patients with locally advanced gastric cancer (cT3, cT4, N+, M0) have a dismal prognosis, despite complete resection." | 2.71 | Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. ( Becker, K; Busch, R; Dittler, HJ; Fink, U; Helmberger, H; Kollmannsberger, C; Ott, K; Sendler, A; Siewert, JR, 2003) |
| "The aim of this study was to define the maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24 h-continuous infusion of 5-flourouracil (FU) plus folinic acid, and to assess the toxicity and activity in patients with previously treated colorectal and gastric cancer." | 2.71 | Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. ( Bokemeyer, C; Hartmann, JT; Hofheinz, RD; Honecker, F; Käfer, G; Kanz, L; Köhne, CH; Nehls, O; Oechsle, K; Quietzsch, D; Wein, A, 2003) |
| "In locally advanced pancreatic cancer, the utilization of chemotherapy and radiotherapy is increasing, although in view of the reported long-term results of several contemporary trials, further improvements are certainly needed." | 2.71 | Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. ( Adsay, V; Al-Sukhun, S; Ben-Josef, E; Forman, JD; Heilbrun, LK; Levin, K; Philip, PA; Shields, AF; Soulen, R; Vaitkevicius, VK; Weaver, D; Zalupski, MM, 2003) |
| "Treatment was given until disease progression or unacceptable toxicity." | 2.71 | A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. ( Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH, 2003) |
| "5-FU/irinotecan is a valuable regimen for second-line treatment in 5-FU/platinum-resistant O-G carcinoma." | 2.71 | Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ( Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS, 2004) |
| "Weight gain was observed in 12 of 33 (36%) patients." | 2.71 | Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. ( Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N, 2004) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 2.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "Four hundred three women with cervical cancer were randomly assigned to receive either EFRT or CTRT." | 2.71 | Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. ( Cooper, J; Eifel, PJ; Gershenson, D; Grigsby, PW; Levenback, C; Morris, M; Mutch, DG; Rotman, M; Winter, K, 2004) |
| "Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer." | 2.71 | Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. ( Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004) |
| "The median time to disease progression was 8 weeks, and the median overall survival was 15 weeks." | 2.71 | Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Gelibter, A; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E, 2004) |
| "For patients with resectable rectal cancer receiving concurrent, full dose radiotherapy, the recommended dose of capecitabine for further study is 1800 mg m(-2) day(-1) when given in this schedule." | 2.71 | A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. ( Leong, T; Lim Joon, D; Mackay, J; McKendrick, J; Michael, M; Ngan, SY; Zalcberg, JR, 2004) |
| "The paclitaxel dose was started at 75 mg/m(2) (n = 7) and escalated to 125 mg/m(2) (n = 5), at which point, dose-limiting toxicities occurred." | 2.71 | Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. ( Ancukiewicz, M; Choi, N; Donahue, D; Lynch, T; Mathisen, D; Park, SD; Wain, J; Wright, C, 2004) |
| "Gemcitabine was infused intravenously at a dose of 1000 mg once weekly for 3 consecutive weeks of every 4 weeks." | 2.71 | 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer. ( Chikamoto, A; Hiraoka, T; Ikeda, O; Imuta, M; Kanemitsu, K; Kudo, K; Nakahara, O; Takamori, H; Tanaka, H; Tsuji, T; Yamashita, Y, 2005) |
| " Patients in study arm A will be treated as outpatients with 5-Fluorouracil; Cisplatin and 3 million units Interferon alpha-2b for 5 1/2 weeks combined with external beam radiation." | 2.71 | Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]. ( Büchler, MW; Debus, J; Diehl, V; Fritz, S; Goldschmidt, H; Herrmann, T; Hoffmann, K; Knaebel, HP; Krempien, R; Lindel, K; Mansmann, U; Märten, A; Schmidt, J; Schmitz-Winnenthal, H; Seiler, C, 2005) |
| "To define the maximum-tolerated dose of oxaliplatin given with cisplatin, protacted 96-h infusion of fluorouracil, and radiotherapy for patients with advanced esophageal cancer." | 2.71 | Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. ( Cervantes, A; Chirivella, I; Conill, C; Gallego, R; Manzano, H; Marfa, X; Martin-Richard, M; Maurel, J; Pera, M; Salazar, R, 2005) |
| "Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever." | 2.71 | A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005) |
| "Patients (n=38) with colorectal cancer received IFN-alpha 5 MU/m(2) SC on days 1-6; on days 2-6, LV 200 mg/m(2) IV was given with 5-FU at initial doses of 370-425 mg/m(2)/h." | 2.71 | A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. ( Ernst, A; Grem, JL; Grogan, L; Grollman, F; Ismail, AS; Kao, V; Kirsch, IR; Parr, A; Quinn, MG; Wright, MA, 2005) |
| "5-Fluorouracil (5-FU) has two major mechanisms by which it exerts its anticancer activity." | 2.71 | Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients. ( Hoshino, S; Maekawa, T; Shirakusa, T; Yamashita, Y, 2005) |
| "In most cases, hyperbilirubinemia was associated with concomitant alterations in other hemolytic parameters." | 2.71 | Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. ( Cassidy, J; Filipovic-Ljeskovic, I; Jelic, S; Nikolic-Tomasevic, Z; Tomasevic, Z, 2005) |
| "Patients with either adenocarcinoma or squamous cell carcinoma of the esophagus could enroll; however, patients could not have received prior chemotherapy for metastatic disease." | 2.71 | A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. ( Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP, 2005) |
| "Forty patients with rectal cancer (T3-T4 and/or N+) received radiotherapy (1." | 2.71 | Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. ( Aydin, S; Baurain, JF; Canon, JL; Coche, JC; Coster, B; Duck, L; Gilbeau, L; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Octave-Prignot, M; Remouchamps, V; Scalliet, P; Sempoux, C; Van Maele, P, 2005) |
| "Fifteen patients with LA pancreatic cancer received three-dimensional conformal XRT to a dose of 50." | 2.71 | Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. ( Blanquicett, C; Carpenter, M; Diasio, RB; Eloubeidi, MA; Fiveash, J; Johnson, MR; Russo, S; Saif, MW; Steg, A; Thornton, J, 2005) |
| " Twenty four patients with advanced or metastatic biliary tumors were treated with epiadriamycin 50 mg/m2 and cisplatin 60 mg/m2 administered bolus in proper hepatic artery on day 1, combined with systemic continuous infusion of 5-fluorouracil 200 mg/m2/day, from day 1 to day 14, every 3 weeks." | 2.71 | Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study. ( Cantore, M; Carlone, N; Caudana, R; Fiorentini, G; Mambrini, A; Manni, A; Rabbi, C; Torri, T; Zamagni, D, 2003) |
| "Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| "33 had squamous carcinoma and 7 adenocarcinoma; 15 were male; the locoregional metastatic ratio was 1:39; median ECOG performance status was 2 (range 1-3)." | 2.70 | A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. ( Ajarim, D; Al Fadda, M; Bazarbashi, S; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, MA, 2002) |
| "Capecitabine was administered at escalating doses from 250 to 1,250 mg/m(2) bid (including weekends) for the duration of radiotherapy." | 2.70 | Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. ( Dunst, J; Frings, S; Hinke, A; Kölling-Schlebusch, K; Reese, T; Sutter, T; Zühlke, H, 2002) |
| "Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)." | 2.70 | Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002) |
| " 5-FU dosage was fixed at 1,600 mg/m2 while docetaxel was evaluated at weekly 1-hour infusion dosages of 30, 40 and 50 mg/m2 to determine the MTD." | 2.70 | A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. ( Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002) |
| " This phase I study was designed to find the maximum tolerated dose (MTD) of weekly cisplatin in combination with standard doses of gemcitabine (1,000 mg/m(2), 30 min) and 5-FU (750 mg/m(2), 24 h)/folinic acid (200 mg/m(2), 30 min)." | 2.70 | Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer. ( Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U, 2002) |
| " We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma." | 2.70 | Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
| " The current study was conducted to evaluate the efficacy and toxicity of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma." | 2.70 | Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. ( Ishikawa, O; Matsuno, S; Okada, S; Okusaka, T; Saisho, H; Sato, K; Sato, T; Tokuuye, K; Wakasugi, H, 2001) |
| " Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma." | 2.70 | Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. ( Chung, HC; Jeung, HC; Kim, BS; Min, JS; Noh, SH; Rha, SY, 2001) |
| "The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery." | 2.70 | Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001) |
| "Patients with stage II and III rectal cancer received weekly 2-hour infusions of FA 500 mg/m2 followed by continuous 24-hour infusions of 5-FU 2,600 mg/m2 postoperatively via a Port-A-Cath system." | 2.70 | Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of high-dose 5-fluorouracil and folinic acid: evaluation of feasibility. ( Bambach, M; Dencausse, Y; Dietzler, P; Edler, L; Hartung, G; Lindemann, H; Qeisser, W; Sturm, J; Wojatschek, C, 2001) |
| "The role of adjuvant treatment in pancreatic cancer remains uncertain." | 2.70 | Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. ( Almond, J; Bassi, C; Beger, H; Büchler, MW; Dervenis, C; Dunn, JA; Falconi, M; Fernandez-Cruz, L; Friess, H; Kerr, DJ; Lacaine, F; Link, K; Neoptolemos, JP; Pap, A; Pederzoli, P; Spooner, D; Stocken, DD, 2001) |
| "Inflammatory breast carcinoma (IBC) is a rare but aggressive form of breast carcinoma." | 2.70 | Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. ( Booser, D; Buzdar, AU; Cristofanilli, M; Hortobagyi, GN; Hunt, K; Ibrahim, N; McNeese, M; Murray, JL; Rivera, E; Singletary, ES; Smith, T; Sneige, N; Stelling, C; Strom, E; Ueno, N; Valero, V; Wasaff, B, 2001) |
| "Weight gain was observed in 48% of patients, and dysphagia improved in 76%." | 2.70 | Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. ( Artru, P; Baujat, B; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Maindrault, F; Taïeb, J; Tournigand, C, 2002) |
| " Both before and after the addition of OXA, the 5-FU dose was individually adjusted according to the pharmacokinetic follow-up (target steady-state plasma concentrations 2." | 2.70 | Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ( Boisdron-Celle, M; Brienza, S; Craipeau, C; Cvitkovic, E; Delva, R; Gamelin, E; Guérin-Meyer, V, 2002) |
| "To identify a dose and schedule of oxaliplatin (OXP) to be safely administered in combination with protracted-infusion (PI) fluorouracil (5-FU) and external-beam radiation therapy (XRT) for patients with primary esophageal carcinoma (EC)." | 2.70 | Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. ( Berdzik, J; Bodnar, L; Douglass, H; Greco, W; Khushalani, NI; Klippenstein, D; Leichman, CG; Leichman, L; Litwin, A; Nava, E; Nava, H; Pendyala, L; Proulx, G; Smith, J; Smith, P, 2002) |
| "Exclusive CRT approach is not safe to treat patients with low infiltrative rectal carcinoma." | 2.70 | Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? ( David Filho, WJ; de O Ferreira, F; Ferrigno, R; Lopes, A; Nakagawa, WT; Nishimoto, IN; Rossi, BM; Vieira, RA, 2002) |
| "Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay." | 2.69 | Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998) |
| " Toxicity was significant, with more than 50% of patients requiring treatment breaks and dosage reductions." | 2.69 | Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma. ( Flett, MQ; John, WJ, 1998) |
| " In a previous study with 5-FU stepwise dose escalation in a weekly regimen, and pharmacokinetic monitoring, we defined a therapeutic range for 5-FU plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 to 8 hours [AUC0-8], 16 to 24 mg x h/L)." | 2.69 | Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. ( Alleaume, C; Boisdron-Celle, M; Burtin, P; Cailleux, PE; Danquechin-Dorval, E; Delva, R; Dumesnil, Y; Fety, R; Gamelin, E; Geslin, J; Gesta, P; Goudier, MJ; Larra, F; Lortholary, A; Maigre, M; Maillart, P; Maillet, ML; Person-Joly, MC; Picon, L; Regimbeau, C; Robert, J; Sire, M, 1998) |
| "Paclitaxel is an important new agent in the treatment of esophageal carcinoma, and further evaluation of this agent in combination chemotherapy is warranted." | 2.69 | Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. ( Ajani, J; Bhalla, K; Donegan, J; Forastiere, A; Huang, Y; Ilson, DH; Kelsen, DP; Martin, L; Patel, P; Pazdur, R; Reed, C, 1998) |
| "Because of the poor response of pancreatic cancer to conventional therapy, the authors performed a phase II pilot study to evaluate whether beta-interferon and retinoids, added to active chemotherapeutic agents, could increase response rate and survival in a group of patients who had metastatic disease." | 2.69 | Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. ( Casucci, D; Frati, L; Gulino, A; Rea, S; Recchia, F; Sica, G, 1998) |
| "The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy." | 2.69 | [Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999) |
| "Nonresectable colorectal cancer metastases in the liver respond to chemotherapy in 20-25% only." | 2.69 | Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. ( Bangard, M; Bangard, N; Bender, H; Biersack, HJ; Metten, N; Mezger, J; Schomburg, A, 1999) |
| "Seventeen patients with stage II breast cancer were included." | 2.69 | The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy. ( Habbal, Z; Ibrahim, K; Kahwaji, S; Khalil, A; Medawar, W; Seoud, M; Shamseddine, A, 1998) |
| "Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (CR), but one died of pneumonia after 9 months while still in CR, and the other still in CR after more than 5 years." | 2.69 | Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. ( Bjarnason, GA; Cripps, C; Fields, AL; Goel, R; Hrincu, A; Jensen, JL; Kerr, IA; Khoo, KE; Warner, E, 1999) |
| "All patients had biopsy-proven invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix." | 2.69 | Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. ( Bundy, BN; Clarke-Pearson, DL; Fowler, WC; Hannigan, EV; Liao, SY; Malfetano, JH; Sause, W; Whitney, CW, 1999) |
| "5-fluorouracil (5-FU) has been widely used for the treatment of gastrointestinal cancers." | 2.69 | [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers]. ( Horimi, T; Morita, S; Shirasaka, T; Takahashi, I; Takasaki, M; Tsuji, A, 1999) |
| "A total of 99 patients with advanced colorectal cancer were treated with carboplatin (80 mg/m2, day 1-7), 5-FU (750 mg/m2, day 1-5), leucovorin (100 mg/m2, day 1-5) every 4 weeks." | 2.69 | The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category? ( Jelić, S; Nikolić-Tomasević, Z; Popov, I; Radosavljević, D, 1999) |
| "We examined whether patients with colon cancer undergoing surgery with or without adjuvant chemotherapy change the internal standards on which they base their quality-of-life (QL) estimation, and, if they do so, whether this reframing alters interpretation of QL findings." | 2.69 | Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK) ( Bernhard, J; Herrmann, R; Hürny, C; Laffer, U; Maibach, R, 1999) |
| "Early gastric cancer or cardia carcinoma were excluded." | 2.69 | Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). ( de Vries, JE; Hermans, J; Keizer, HJ; Klementschitsch, P; Songun, I; van de Velde, CJ; van der Bijl, J; van Krieken, JH; Wils, JA, 1999) |
| " We then tested the effect of GM-CSF given with a more toxic regimen of 5-FU/LV/IFN-alpha (IFN alpha-2a)." | 2.69 | A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. ( Allegra, C; Behan, K; Chen, A; Flemming, D; Grem, JL; Grollman, F; Haller, D; Hamilton, JM; Harold, N; Johnston, PG; Lash, A; Liewehr, D; Monahan, B; Morrison, G; Quinn, M; Shapiro, JD; Steinberg, SM; Takimoto, C; Vaughn, D, 1999) |
| "One hundred fourteen patients (55%) had pancreatic cancer (54 in the observation group and 60 in the treatment group)." | 2.69 | Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. ( Arnaud, JP; Couvreur, ML; de Wit, LT; Gonzalez, DG; Hennipman, A; Jeekel, J; Klinkenbijl, JH; Sahmoud, T; van Pel, R; Veenhof, CH; Wils, J, 1999) |
| "Median times to disease progression for the three treatment arms were as follows: 9." | 2.69 | Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000) |
| "Paclitaxel and cisplatin were administered as postoperative adjuvant therapy." | 2.69 | Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. ( Burtness, BA; Canto, MI; Forastiere, AA; Heath, EI; Heitmiller, RF; Kaufman, HS; Kleinberg, L; Knisely, JP; Olukayode, K; Salem, R; Talamini, MA; Topazian, M; Wu, TT; Yang, SC, 2000) |
| "From 1992 to 1998, 34 of 131 total esophageal cancer patients were designated stage III (16 T3N1, 9 T4N0, 9 T4N1) and medically fit to enter a combined modality protocol with continuous infusion 5-fluorouracil (CIS-FU, 300 to 600 mg/m2/day), high-dose external beam irradiation (60 Gy), and interval esophagectomy." | 2.69 | Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study. ( Alexander, EP; Harmon, J; Lipman, T; Wadleigh, R, 2000) |
| "Acute disseminated intravascular coagulation (DIC) is a rare but severe complication of gastric adenocarcinoma." | 2.69 | Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation. ( Chang, FY; Chao, Y; Chi, KH; Hung, HC; King, KL; Li, CP; Teng, HC; Yen, SH, 2000) |
| "For advanced irresectible gastric cancer, sequential high-dose methotrexate and 5-fluorouracil (both on day 1) combined with adriamycin on day 15 (FAMTX regimen), cycled every 28 days, is a fairly effective but toxic treatment, with a high incidence of neutropenic fever, dose reductions and dose delays." | 2.69 | Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. ( Boot, H; Craanen, M; Gerritsen, WR; Swart, M; Taal, BG; Westermann, AM, 2000) |
| "Five hundred patients with Dukes' C colon cancer were randomly assigned to adjuvant treatment for one year with 5-fluorouracil (450 mg/m2 i." | 2.69 | The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group. ( Bleeker, WA; Hermans, J; Mulder, NH; Otter, R; Plukker, JT, 2000) |
| "Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7." | 2.69 | Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000) |
| "To assess the effect and mechanism of composite Xiansu Capsule (CXSC) combined with chemotherapy in treating gastric carcinoma of mid-late stage." | 2.69 | [Clinical study on treatment of mid-late stage gastric carcinoma by composite xiansu capsule combined with chemotherapy]. ( Hua, B; Wang, A, 1999) |
| " However, in combination with radiation therapy, this regimen is tolerable when the primary goal is palliation of dysphagia near the end of life." | 2.68 | Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus. ( Turrisi, AT; Urba, SG, 1995) |
| "5-Fluorouracil has been reported to have modest antitumor activity in androgen independent prostate cancer." | 2.68 | The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. ( Daliani, DD; Eisenberg, PD; Fueger, R; Logothetis, CJ; Lord, R; Weems, J, 1995) |
| "Out of 213 consecutive cases of colorectal cancer patients, 39 patients had liver metastasis (31 synchronous metastases and 8 metachronous metastases)." | 2.68 | [Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer]. ( Ariga, T; Kinoshita, H; Maruyama, T; Ooshima, I; Ozaki, M; Shimada, H; Shouko, T; Takeda, A; Yoshimura, S, 1995) |
| "The histology was squamous cell carcinoma in 44 patients and adenocarcinoma in 3 patients with esophagus cancer." | 2.68 | Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update. ( Beattie, E; Malamud, S; Nussbaum, M; Vikram, B; Yu, L; Yudelman, I, 1995) |
| "40813) on adjuvant chemotherapy in gastric cancer, results obtained after administration of the FAM2 regimen (fluorouracil [5-FU], doxorubicin, and mitomycin) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval." | 2.68 | Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. ( Buyse, M; Dos Santos, JG; Duez, N; Fiorentino, M; Labianca, R; Lise, M; Marchet, A; Nitti, D; Rougier, P; Sahmoud, T, 1995) |
| "These findings suggest that colorectal cancer with aneuploidy and a DI above 1." | 2.68 | Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer. ( Hoshino, K; Kaibara, N; Kimura, O; Kurayoshi, K; Makino, M; Sugezawa, A, 1995) |
| " The Kaplan-Meier overall and cancer specific survival analysis estimates that the chronic administration of antimetabolites did not improve the cumulative 5-year survival in the SCC group." | 2.68 | [Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer]. ( Hirota, Y; Hongo, J; Iijima, Y; Inagaki, M; Koyama, M; Ozaki, M; Wada, K, 1995) |
| "Six patients (21%) had residual cancer in the resected specimen, either at the primary site or--more often--in adjacent lymph nodes." | 2.68 | Treating esophageal cancer with a combination of chemotherapy, radiation, and excision. ( Bates, DM; Clyde, JC; Garcia, JM; Girvin, GW; Lin, PH; Matsumoto, GH, 1995) |
| "Lymphatic metastasis is one of the most important problems in the treatment of gynecologic malignancy." | 2.68 | [Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report]. ( Cao, Z; You, Z; Zhou, S, 1995) |
| "There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer." | 2.68 | Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995) |
| "Twenty patients with non-resectable rectal cancer (Mason CS III-IV) have been irradiated from September 1989 through February 1994." | 2.68 | [Preoperative radiochemotherapy in primary non-resectable rectal cancer]. ( Dunst, J; Dworak, O; Keilholz, L; Köckerling, F; Sauer, R; Schwarz, B, 1995) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "Stomatitis was seen more in arm B and C than in arm A." | 2.68 | [A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group]. ( Akazawa, S; Konishi, T; Kumai, K; Kurihara, M; Ogawa, M; Ogawa, N; Ota, K; Sasaki, T; Taguchi, T; Tominaga, T, 1995) |
| "All patients had surgically documented minimal residual disease (1." | 2.68 | Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial. ( Averette, H; Berek, JS; Blessing, JA; Braly, PS; Homesley, HD, 1995) |
| " The dosage was as follows: group A received FA i." | 2.68 | Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996) |
| "We identified patients with gastric cancer at high risk for recurrence before therapy using endoscopic ultrasonography (EUS)." | 2.68 | Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. ( Botet, J; Brennan, M; Gerdes, H; Huang, Y; Karpeh, M; Kelsen, D; Klimstra, D; Lauers, G; Lightdale, C; Quan, V; Saltz, L; Schwartz, G, 1996) |
| "Mitomycin C was infused over 25 minutes followed by 5-FU over 10 minutes." | 2.68 | Regional chemotherapy for inoperable pancreatic carcinoma. ( George, WJ; Muchmore, JH; Preslan, JE, 1996) |
| "One hundred and three cases of advanced gastric cancer were randomly allocated into Group A (Me-CCNU, 5-Fu and ADM) and Group B (ACNU, 5-Fu and ADM)." | 2.68 | [ACNU and methyl-CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group]. ( Li, D; Xiao, S; Zhang, D, 1996) |
| "Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1." | 2.68 | Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996) |
| "Since 1984, 373 patients with oesophageal cancer have been treated on three prospective, but unrandomised, protocols involving radiation with concurrent cisplatin and infusional fluorouracil." | 2.68 | Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG) ( Burmeister, BH; Denham, JW; Hamilton, CS; Joseph, DJ; Lamb, DS; O'Brien, P; Spry, NA; Walker, QJ; Yeoh, E, 1996) |
| " The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity." | 2.68 | A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. ( Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997) |
| "Twenty-five patients with esophageal cancer were treated in a phase I pilot protocol consisting of initial esophagectomy with gastroesophagostomy and subsequent combined chemotherapy and radiation." | 2.68 | Integration of surgery in multimodality therapy for esophageal cancer. ( Doolas, A; Ebie, N; Griem, K; Hartsell, W; Kang, HJ; Millikan, K; Murthy, AK; Recine, DC; Taylor, S, 1997) |
| " However, the toxicities observed with this dosage schedule were considerable and further studies are needed to develop a less toxic regimen." | 2.68 | Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. ( Buzaid, AC; Cohen, N; Greenberg, BR; Slater, D; Sporn, JR, 1997) |
| "5-fluorouracil was given at a dose of 1000 mg/m2 for 5 consecutive days and cisplatin was given on day 2 at a dose of 100 mg/m2." | 2.68 | The French experience with infusional 5-FU in gastric and pancreatic cancer. ( Ducreux, M; Rougier, P, 1996) |
| "Patients with rectal cancer of stage dukes B and C were randomized into two groups." | 2.68 | [Preoperative intraluminal 5-FU osmosis chemotherapy as an adjuvant to radical resection for rectal cancer]. ( Liu, L; Lu, J; Zhao, L, 1996) |
| "In patients of 70 years and under with prostate cancer resistant to androgen-deprivation therapy and who still have good performance status, ECF chemotherapy can achieve useful remissions." | 2.68 | A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. ( Chao, D; Harland, SJ; von Schlippe, M, 1997) |
| "Forty patients with esophageal cancer were treated in a phase I and II trial of induction chemotherapy (cisplatin, 5-fluorouracil, and paclitaxel) at three dosage levels (75, 125, and 100 mg/m2) and concurrent hyperfractionated radiotherapy (45 Gy to the mediastinum, 58." | 2.68 | Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. ( Carey, RW; Choi, NC; Grillo, HC; Grossbard, ML; Lynch, TJ; Mathisen, DJ; Moncure, AC; Wain, JC; Wright, CD, 1997) |
| "Two hundred patients with advanced colorectal cancer received PVI 5-FU 300 mg/m2/day for a maximum of 24 weeks and were randomised to PVI 5-FU alone or PVI 5-FU + MMC 10 mg/m2 (7 mg/m2 from June 1995) 6 weekly for 4 courses." | 2.68 | A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. ( Cunningham, D; Iveson, T; Massey, A; Norman, A; Oates, J; Padhani, A; Popescu, R; Prendiville, J; Ross, P; Watson, M; Webb, A, 1997) |
| "The paclitaxel dose levels were 25 mg/m2 in four patients, 40 mg/m2 in five patients, 60 mg/m2 in nine patients, and paclitaxel 50 mg/m2 with 5-FU reduced to 200 mg/m2 in nine patients." | 2.68 | Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. ( Coia, LR; Colarusso, P; Dresler, C; Goldberg, M; Weiner, LM, 1997) |
| "We studied how gastric cancer tissues and cells changed as a result of preoperative chemotherapy." | 2.68 | [Influence of preoperative on gastric cancer tissues and cells]. ( Chen, Z; Li, G; Liu, F, 1997) |
| "Eighteen patients with gastric cancer with peritoneal metastasis were treated with methotrexate/5-fluorouracil sequential therapy." | 2.67 | [Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sejima, T; Sugaya, J; Takano, Y; Tomita, F, 1994) |
| " We were not able to increase 5FU weekly dosage above 700 mg/m2 due to the occurrence of grade 3-4 gastrointestinal toxicity." | 2.67 | Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. ( Buccellato, C; Cipolla, C; Comande, S; Curto, G; Gebbia, N; Gebbia, V; Latteri, M; Testa, A; Valenza, R, 1994) |
| " These results are consistent with either a dose-response effect or a threshold level of the dose or dose intensity." | 2.67 | Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. ( Budman, DR; Cooper, MR; Ellerton, JA; Ferree, CR; Hart, RD; Korzun, AH; Moore, A; Norton, L; Wood, WC; Younger, J, 1994) |
| "Chemoradiation for duodenal cancer has produced a complete pathologic response in all patients and survival has been excellent, suggesting efficacy of this regimen for duodenal cancer." | 2.67 | Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. ( Coia, L; Eisenberg, B; Hanks, G; Hoffman, J; Paul, A; Scher, R; Solin, L; Weese, J; Weiner, L, 1994) |
| " They were randomly assigned to receive one of the three drug combination regimens or to 5-FU alone administered by rapid injection in 5-day course." | 2.67 | Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. ( Cullinan, SA; Krook, JE; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1994) |
| "To determine the toxicities and potential for dose escalation of intravenous (IV) bolus fluorouracil (5-FU) given with 500 mg/m2/d leucovorin (LCV) and granulocyte-macrophage colony-stimulating factor (GM-CSF)." | 2.67 | Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. ( Arbuck, SG; Balis, F; Chen, A; Grem, JL; Hamilton, JM; Jordan, E; McAtee, N; Murphy, RF; Setser, A; Steinberg, S, 1994) |
| "A total of 23 advanced gastric cancer patients older than 65 years received 500 mg/m2 5-fluorouracil i." | 2.67 | Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. ( Cascinu, S; Catalano, G; Fedeli, A, 1994) |
| "FLEP is an active combination for oesophageal cancer, especially when used preoperatively in LAD." | 2.67 | 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. ( Achterrath, W; Berger, M; Berns, T; Fink, U; Harstrick, A; Knipp, H; Meyer, HJ; Preusser, P; Stahl, M; Wilke, H, 1994) |
| "Hycanthone was administered 60 mg/m2 intravenously within 2 to 4 hr during each day of the 5-day course of infusions during the first and fifth weeks of radiation therapy." | 2.67 | Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. ( Earle, JD; Foley, JF; Krook, JE; Kvols, LK; McKenna, PJ; Schutt, AJ; Tschetter, LK; Twito, DI; Wieand, HS, 1994) |
| "Grade 3 infections were seen in 9 cycles (5%)." | 2.67 | Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. ( Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H, 1993) |
| "Nine patients with advanced breast cancer received CAF (cyclophosphamide at 100 mg/m2/day p." | 2.67 | Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer. ( Dutcher, JP; Liebes, L; Robert, NJ; Schwartz, EL; Sparano, JA; Wadler, S, 1993) |
| "Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival." | 2.67 | Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study. ( Ackland, SP; Bonaventura, A; Cooper, SG; Denham, JW; Hamilton, CS; Joseph, DJ; Stewart, JF, 1993) |
| " The recommended dosage schedule with this technique is cisplatin 25 mg/m2 and FU 750 mg total dose IP with FU 500 mg/m2 as a continuous 24-hour infusion daily for days 1 to 4." | 2.67 | Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. ( Atiq, OT; Brennan, M; Kelsen, DP; Lin, S; Niedzwiecki, D; Saltz, L; Shiu, MH; Tong, W; Toomasi, F; Trochanowski, B, 1993) |
| "Thirteen patients had squamous cell carcinoma and 8 adenocarcinoma." | 2.67 | Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. ( Fell, S; Haynes, H; Kaleya, R; Katz, HJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1993) |
| "Mitomycin's role in anal cancer is being evaluated in a randomized clinical trial by the Radiation Therapy Oncology Group." | 2.67 | Mitomycin in anal canal carcinoma. ( Catton, CN; Cummings, BJ; Keane, TJ; O'Sullivan, B; Wong, CS, 1993) |
| "Hormone-refractory metastatic prostate cancer remains a therapeutic challenge." | 2.67 | Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. ( Blumenstein, BA; Boileau, M; Crawford, ED; Fletcher, WS; Rivkin, SE; Wozniak, AJ, 1993) |
| "In patients with colorectal cancer, we have done a multicentre, randomised controlled trial comparing five-year survival after intraportal infusion of fluorouracil (1 g per day) plus heparin (10,000 U per day) (130 patients) or heparin alone (123) during curative resection and for 7 days thereafter, or after resection alone (145)." | 2.67 | Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. ( Fielding, LP; Fry, JS; Grace, RH; Hittinger, R, 1992) |
| "A clinical trial for patients with gastric cancer amenable to curative resection was undertaken to determine feasibility and response to preoperative systemic chemotherapy followed by postoperative intraperitoneal (IP) chemotherapy." | 2.67 | Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. ( Kiyabu, M; Laine, L; Leichman, CG; Leichman, L; Muggia, FM; Radin, R; Ray, M; Silberman, H; Spears, CP; Stain, S, 1992) |
| "Histology was squamous cell carcinoma in 6 patients and undifferentiated carcinoma in the remaining 33 patients." | 2.67 | Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer. A retrospective analysis of 39 cases. ( Banis, K; Daniilidis, J; Dimitriadis, A; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Makrantonakis, P; Nicolaou, A; Sombolos, K; Sridhar, KS, 1991) |
| " The present study compared the pharmacokinetic profiles of intravenous and intra-hepatic arterial infusions of folinic acid in patients with colorectal liver metastases (n = 6) who were being treated with weekly regional infusions of 5-FU." | 2.67 | A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ( Anderson, JH; Cooke, TG; Kerr, DJ; McArdle, CS; Setanoians, A, 1992) |
| " in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)." | 2.67 | Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). ( Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991) |
| " Patients were treated with 5-fluorouracil given at a dosage of 4 gm/m2 over a 24-hour period every 2 weeks." | 2.67 | High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. ( Anthony, S; Atkins, JN; Brockschmidt, J; Case, D; Grote, TH; Muss, HB; O'Rourke, M; Schnell, FM; Stanley, V; West, JH, 1991) |
| "BACKGROUND Gastric cancer metastasis to the appendix is a rare condition that might present with symptoms of acute appendicitis or remain asymptomatic and be diagnosed incidentally." | 2.66 | Missed Gastric Cancer Metastasis to the Appendix: Case Report and Literature Review. ( Aburahmah, M; Alhadid, D; Almana, H; AlShammari, A, 2020) |
| "Choriocarcinoma is an aggressive malignancy of trophoblastic tissue, typically of gestational etiology." | 2.66 | Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of the literature. ( Boyce, J; Cole, JT; Tawagi, K, 2020) |
| "Thirty-two patients with untreated advanced colorectal carcinoma received high-dose methotrexate pretreatment followed sequentially by 5-fluorouracil (5-FU)." | 2.66 | High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. ( Ajani, JA; Bedikian, AY; Kanojia, MD, 1989) |
| " The LT 5-FU was given at a dosage of 750 mg/m2 every 2 weeks for 18 months or until progression." | 2.66 | Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. ( Bleiberg, H; Buyse, M; Dalesio, O; Gerard, A; Gignoux, M; Goffin, JC; Michel, J; Pector, JC; Roussel, A; Samana, G, 1989) |
| "Eighty-two patients with colo-rectal cancers (29 colon and 53 rectum) were admitted and underwent radical resection from January 1982 to June 1984." | 2.66 | [Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer--results of a randomized trial]. ( Wan, DS, 1988) |
| "Doxifluridine is an active agent in colorectal cancer." | 2.66 | A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. ( Alberto, P; Cavalli, F; Germano, G; Joss, R; Kaplan, S; Martz, G; Mermillod, B; Spati, B; Weber, W, 1988) |
| " During the past eleven years, we have used postoperative chemotherapy in three ways over three different periods: in the earliest period, short-term combined chemotherapy (STCC) was used, in the middle period, intermittent long-term combined chemotherapy (ILTCC) was used in combination with immunotherapy for a randomized group, and in the latest period, when continuous long-term combined chemotherapy (CLTCC) with immunotherapy was employed." | 2.66 | [Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy]. ( Hashizume, Y; Ichihashi, T; Iida, S; Kimoto, H; Kobayashi, H; Sato, H; Shimizu, J; Tsunamura, Y; Watanabe, Y; Yamada, T, 1985) |
| "Ten of the gastric cancer patients (29%) had partial responses." | 2.66 | Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. ( Ahmed, S; Alvarez, CA; Cazap, EL; Estevez, RA; Gisselbrecht, C; Hannois, A; Lagarde, C; Schein, PS; Smith, FP; Woolley, PV, 1986) |
| " Alpha-2 interferon, alone or in combination with 5-FU, is ineffective in advanced colorectal cancer." | 2.66 | Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. ( Blomgren, H; Cedermark, B; Clark, PI; Fallenius, A; Kurschel, E; Lundell, G; Niederle, N; Ohman, U; Reznek, RH; Slevin, ML, 1987) |
| " day 1, 2, 23 and 24) was applied with the same schedule and dosage of radiation." | 2.65 | The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer. ( Dujmović, I; Kolarić, K; Roth, A, 1984) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "In well differentiated squamous cell carcinoma, a marked positive effect was obtained in 48." | 2.65 | [Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer]. ( Bidiak, IP; Kiseleva, ES; Pitskhelauri, VG; Trakhtenberg, AKh; Zholkiver, KI, 1984) |
| "Three hundred and eleven cases of rectal cancer received treatment according to the protocol of a cooperative randomized study." | 2.65 | [Effectiveness of combined and complex treatment of patients with operable cancer of the rectum]. ( Aliev, BM; Barsukov, IuA; Bondar', GV; Dvoĭrin, VV; Knysh, VI, 1984) |
| "Although chemotherapy of pancreatic cancer is a developing field, clinically meaningful responses correlated with improved patient survival can be obtained with existing regimens." | 2.65 | Chemotherapy of pancreatic carcinoma. ( Schein, PS; Smith, FP; Zimmerman, SE, 1981) |
| "The Southeastern Cancer Study Group has evaluated 5-fluorouracil administered intravenously weekly at a dosage of 600 mg." | 2.65 | A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. ( Bartolucci, AA; Hemstreet, G; Hester, M; Smalley, RV, 1981) |
| " The polychemotherapy was given as a high dosage intermittent stosstherapy with 3 infusions at intervals of a week for 3 years." | 2.64 | [The combined treatment of bronchial carcinoma (author's transl)]. ( Karrer, K; Pridun, N, 1975) |
| "Ninety-two women with advanced breast cancer were allocated at random to receive either cytotoxic or endocrine treatment." | 2.64 | Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. ( Baum, M; Forbes, J; Jones, V; Priestman, T, 1977) |
| "originates in the stomach." | 2.64 | Gastric cancer: current status of treatment. ( Carter, SK; Comis, RL, 1977) |
| "route." | 2.64 | A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. ( Bruckner, HW; Hahn, RG; Moertel, CG; Schutt, AJ, 1975) |
| " A total dosage of 17-23 g." | 2.64 | [Use of ftorafur for the treatment of 3d-4th stage]. ( Gutman, EKh; Osman, VI; Plaude, RK; Purinia, IZh; Tabachnik, BI, 1975) |
| "Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501." | 2.58 | Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. ( Alberts, SR; Folprecht, G; Goldberg, RM; Julie, C; Laurent-Puig, P; Le Malicot, K; Meyers, JP; Mini, E; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Tabernero, J; Taieb, J; Van Laethem, JL; Zaanan, A; Zawadi, A, 2018) |
| "Locally advanced pancreatic cancer (LAPC) is an emerging entity lacking in level III evidence-based recommendations for its treatment." | 2.58 | Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? ( de Liguori Carino, N; McNamara, MG; O'Reilly, DA; Pihlak, R; Radhakrishna, G; Siriwardena, AK; Valle, JW, 2018) |
| "Gastric cancer has a fatality-to-case ratio of 0." | 2.55 | The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. ( Amlashi, FG; Blum Murphy, M; Bozkurt, M, 2017) |
| "The objective of the treatment of colorectal cancer patients with unresectable liver metastases should be clearly defined at the outset." | 2.53 | Unresectable liver metastases in colorectal cancer: review of current strategies. ( Pellerin, O; Pernot, S; Pointet, AL; Sueur, B; Taieb, J; Voron, T, 2016) |
| "Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related deaths." | 2.53 | Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. ( Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR, 2016) |
| "When paclitaxel plus platinum was compared with platinum plus 5-fluorouracil, the hazard ratios (95% CrI) in the entire, squamous cell carcinoma, and adenocarcinoma population were 0." | 2.52 | Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. ( Hsu, CH; Huang, TC; Lin, CC; Tu, YK, 2015) |
| "One of them was well differentiated tubular adenocarcinoma which occupied in mucosal layer." | 2.52 | Resection of a Submucosal Tumor-Like Superficial Carcinoma in Middle Thoracic Esophagus Concomitant with Mucosal Adenocarcinoma and Submucosal Squamous Cell Carcinoma: A Case Report and Review of Literature. ( Chino, O; Kazuno, A; Kumaki, N; Makuuchi, H; Ozawa, S; Sakai, I; Shimada, H; Tamayama, T; Yamamoto, S; Yasuda, S, 2015) |
| "Solitary adrenal metastasis of rectal cancer is comparatively rare condition and it is difficult to be diagnosed because it doesn't have any characteristic symptoms." | 2.52 | [A CASE OF SOLITARY ADRENAL TUMOR METASTASIZED FROM RECTAL CANCER]. ( Fukuda, H; Iida, S; Iizuka, J; Ikeda, T; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Toda, N, 2015) |
| "Sigmoid colon cancer was found on a pre-operative CT scan." | 2.52 | [A Case of Sigmoid Colon Cancer with Metastasis to the Uterus]. ( Arimitsu, H; Chibana, T; Chou, A; Ikeda, A; Kainuma, O; Kobayashi, R; Nabeya, N; Nagata, M; Souda, H; Takiguchi, N; Tokoro, Y; Tonooka, T; Yamamoto, H; Yanagibashi, H, 2015) |
| "Despite advances in the treatment of gastric cancer, it remains the world's second highest cause of cancer death." | 2.50 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives. ( Bilici, A, 2014) |
| "A 48-year-old man with colorectal cancer and right inguinal lymph node metastasis had previously undergone radiotherapy and chemotherapy (uracil/tegafur/leucovorin) after a colostomy in another hospital before being referred to us." | 2.50 | [Disappearance of a gastric lesion following modified FOLFOX6 chemotherapy in a patient with metastatic colorectal cancer: a case report and literature review]. ( Aihara, T; Fukuda, S; Iino, C; Mikami, T; Sakamoto, J; Sawaya, M; Tanaka, M; Tono, H; Yamagata, R; Yoshida, K, 2014) |
| "Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied." | 2.49 | Locally advanced pancreatic cancer. ( Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN, 2013) |
| "Metastatic pancreatic cancer is a rapidly fatal disease with few therapeutic options." | 2.49 | First-line treatment for advanced pancreatic cancer. ( Kim, R; Kothari, N; Saif, MW, 2013) |
| "Capecitabine is an orally administered prodrug that converts preferentially to 5-FU within tumors, resulting in enhanced concentrations of 5-FU in tumor tissue." | 2.49 | Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy. ( Endo, A; Nakashima, R; Takahashi, N; Tanabe, K; Yoshida, Y, 2013) |
| "What are the colorectal cancer prognostic factors which would guide the chemotherapy? TNM classification, number of examined lymph nodes, MSI status, and presence or not of a perforation or a perinervous, lymphatic or venous invasion is recognized prognostic factors." | 2.48 | [Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?]. ( Brezault, C; Chaussade, S; Coriat, R; Esch, A; Perkins, G, 2012) |
| "For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear." | 2.48 | Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. ( Brock, MV; Franco, N; Hooker, CM; How, R; Hulbert, A; Lee, S; Prevas, H; Shin, J; Yang, SC; Zhang, JQ, 2012) |
| "Capecitabine is a prodrug of 5-fluorouracil, more easily administered by mouth; its transformation in 5-fluorouracil is performed in the liver." | 2.47 | Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( Bagli, L; Drudi, F; Fantini, M; Gianni, L; Nicoletti, S; Possenti, C; Ravaioli, A; Sintini, M; Tamburini, E; Tassinari, D, 2011) |
| "Subacute cutaneous lupus erythematosus is an uncommon dermatosis characterised by a non-scarring, annular photo-distributed dermatosis associated with anti-Ro/SSA antibodies." | 2.47 | [Subacute cutaneous lupus erythematosus and cancer: two cases and literature review]. ( Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P, 2011) |
| "Gastric cancer is the fourth most common malignancy worldwide with Japan, Korea, Taiwan, China, Mongolia and many countries in South America and eastern Europe, as well as parts of the Middle East, contributing to the majority of cases." | 2.47 | A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. ( Ajani, JA; Blum, M; Suzuki, A, 2011) |
| "Keywords for the search were: "rectal cancer", "preoperative radiotherapy", "phase II-III", "preoperative chemotherapy", "adjuvant chemotherapy" and "surgery"." | 2.47 | [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies]. ( Bosset, JF; Créhange, G; Maingon, P, 2011) |
| "A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen." | 2.46 | Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. ( Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R, 2010) |
| "In colorectal cancer, increased response rates are achieved by cetuximab and panitumumab within standard chemotherapy schedules, but not in chemoradiation regimens." | 2.46 | Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? ( Glynne-Jones, R; Harrison, M; Mawdsley, S, 2010) |
| "We report a case of renal tubular acidosis (RTA) secondary to capecitabine, oxaliplatin, and cetuximab administration in a 63-year-old woman with liver metastasis from colon carcinoma who had partial treatment response." | 2.46 | Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. ( Meirovitz, A; Sonnenblick, A, 2010) |
| "Metastatic pancreatic cancer is often one of the most challenging malignancies a medical oncologist faces." | 2.46 | Palliative chemotherapy for pancreatic malignancies. ( Mehta, SP, 2010) |
| "A 47-year-old man who was diagnosed as Crohn's disease at the age of 27 became aware of a mass on the forehead." | 2.45 | [Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease]. ( Hayashi, N; Hayashi, Y; Hiramatsu, N; Iijima, H; Ito, H; Kondo, J; Nishida, T; Takehara, T; Tsuji, S; Tsujii, M; Tsutsui, S; Yamamoto, K, 2009) |
| "The median age at diagnosis of colorectal cancer is during the seventh decade, and the incidence of the disease increases continuously with age." | 2.45 | Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. ( Belda, C; Casado, E; Castro, JD; Feliu, J; González-Barón, M; Sereno, M, 2009) |
| "Pancreatic cancer is the fourth leading cause of cancer death in the United States." | 2.45 | Medical management of pancreatic adenocarcinoma. ( Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM, 2009) |
| "Data on colorectal cancer in HIV-positive patients are limited." | 2.44 | FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. ( Bearz, A; Berretta, M; Berretta, S; Del Ben, C; Di Benedetto, F; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U, 2008) |
| "Treatment with capecitabine lead to clinical amelioration." | 2.44 | Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. ( Bergonzi, P; Fasola, G; Minisini, AM; Pauletto, G, 2007) |
| "Pancreatic cancer is a devastating disease with a poor prognosis for most patients." | 2.44 | The case for routine use of adjuvant therapy in pancreatic cancer. ( Kennedy, EP; Yeo, CJ, 2007) |
| "Approximately 84% of patients with gastric cancer will have advanced disease and median survival of these patients without chemotherapy is only 3-4 months." | 2.44 | Chemotherapy of advanced gastric cancer. ( López-Brea, MF; Rivera, F; Vega-Villegas, ME, 2007) |
| "A new era in the treatment of advanced pancreatic cancer commenced a decade ago with the advent of gemcitabine as a standard of care." | 2.44 | Cytotoxic therapy for advanced pancreatic adenocarcinoma. ( Abou-Alfa, GK; O'Reilly, EM, 2007) |
| " Dosing of S-1 is different between Western and Asian populations due to differences in metabolism by CYP2A6." | 2.44 | Medical treatment for advanced gastroesophageal adenocarcinoma. ( Ajani, JA; Cen, P, 2007) |
| "Pancreatic cancer is one of the major causes of cancer death." | 2.44 | Neoadjuvant and adjuvant strategies for pancreatic cancer. ( Ghaneh, P; Neoptolemos, JP; Raraty, M; Smith, R; Tudor-Smith, C, 2008) |
| "Treatment of rectal cancer over the last two decades has evolved with changes in techniques of surgery and radiation based on national and international trials." | 2.44 | Total mesorectal excision and management of rectal cancer. ( Phang, PT; Pinsk, I, 2007) |
| "Gemcitabine has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil (5-FU)." | 2.44 | Pancreatic cancer--is the wall crumbling? ( Chua, YJ; Zalcberg, JR, 2008) |
| "If almost all colorectal cancers (CRC) correspond to the same histopathological type (adenocarcinoma), molecular biology allowed the identification of two different molecular mechanisms of colorectal carcinogenesis: chromosomal instability characterized by recurrent allelic losses on chromosomes 17, 5, 18, 8 and 22 that contribute to the inactivation of tumor suppressor genes, and genetic instability characterized by the instability of microsatellite loci due to an alteration of DNA mismatch repair leading to the accumulation of mutations in genes involved in the control of cell cycle and apoptosis." | 2.43 | [Molecular biology in clinical cancer research: the example of digestive cancers]. ( Laurent-Puig, P; Lièvre, A, 2005) |
| "We relate 2 cases reports about rectal cancer and pregnancy." | 2.43 | [Management of rectal cancer in pregnant women]. ( Benouna, J; Classe, JM; Dravet, F; Dupré, PF; Mahé, MA; Pigeau, H; Pioud, R, 2005) |
| "Capecitabine is an oral prodrug of 5-fluorouracil, which is converted to 5-fluorouracil by three sequential enzymatic reactions." | 2.43 | Capecitabine in carcinoma of the pancreas. ( Neoptolemos, JP; Smith, DB, 2006) |
| "Treatment of localized gastric cancer relies primarily on surgical intervention, although growing evidence suggests that the addition of chemoradiation may improve disease-free intervals and overall survival." | 2.43 | Molecular markers for gastric adenocarcinoma: an update. ( Anderson, C; Kim, J; Nijagal, A, 2006) |
| "The rare finding of heterotopic ossification in a case of primary rectal adenocarcinoma is described along with a review of the literature." | 2.42 | Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism. ( Gottfried, MR; Jones, R; Kypson, AP; Morphew, E; Seigler, HF, 2003) |
| "Assessment of response to therapy of pancreatic cancer has been a difficult challenge." | 2.42 | Developments in the systemic therapy of pancreatic cancer. ( el-Rayes, BF; Philip, PA; Shields, AF; Vaitkevicius, V, 2003) |
| "Selected patients with inflammatory breast cancer have the potential for long-term survival." | 2.42 | Ten-year outcome after combined modality therapy for inflammatory breast cancer. ( Bertsch, H; Fox, K; Glick, J; Harris, EE; Schultz, D; Solin, LJ, 2003) |
| "Gemcitabine has replaced 5-fluorouracil-based chemotherapy as the standard of care." | 2.42 | New perspectives in the management of pancreas cancer. ( Haller, DG, 2003) |
| "The late diagnosis of pancreatic cancer, at a locally advanced and metastatic stage explains in part its poor prognosis." | 2.41 | [Gemcitabine and pancreatic cancer]. ( Azria, D; Prost, P; Ychou, M, 2002) |
| "Gemcitabine is a new fluorine-substituted cytarabine compound." | 2.41 | Clinical update of gemcitabine in pancreas cancer. ( Au, E, 2000) |
| "Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects." | 2.41 | A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. ( Francini, G; Goldberg, RM; Haller, DG; Jacobson, SD; Labianca, R; Macdonald, JS; Sargent, DJ; Seitz, JF; Shepherd, LE, 2001) |
| "A case of AFP producing early gastric cancer successfully treated with a small dose of CDDP and 5-FU therapy administered intermittedly is reported with a review of the literature." | 2.41 | [A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy]. ( Aoki, T; Fujimitsu, Y; Koyanagi, Y; Moritani, M; Niido, T; Shinohara, M; Tsuchida, A, 2001) |
| "Most patients diagnosed with gastric cancer in the United States and the Western World will either present with advanced disease or have recurrence after surgery, requiring discussions of chemotherapy." | 2.41 | Chemotherapy options for gastric cancer. ( Fuchs, CS; Meyerhardt, JA, 2002) |
| "Pancreatic cancer is one of the deadliest malignancies and is fatal in more than 95% of affected individuals." | 2.41 | Management of locally advanced adenocarcinoma of the pancreas. ( Ryan, DP; Willett, CG, 2002) |
| "Advanced extramammary Paget's disease is also adenocarcinoma of the skin." | 2.40 | [Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature]. ( Yamazaki, N, 1997) |
| "Patients with advanced colorectal cancer can only benefit from these important advances, however, if a truly multidisciplinary approach to patient care is adopted which requires integration of the roles of the surgeon, medical oncologist and radiotherapist." | 2.40 | The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon. ( Neoptolemos, JP; Rougier, P, 1997) |
| "Irinotecan or CPT11 is a topoisomerase 1 inhibitor." | 2.40 | [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998) |
| "Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10." | 2.40 | [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998) |
| "Pancreatic cancer is widely regarded by medical personnel and the lay public as one of the most dreaded of all diagnoses." | 2.40 | Practical recommendations for the management of adenocarcinoma of the pancreas. ( Sporn, JR, 1999) |
| "Five-year survival rates were 57% for squamous cell carcinoma, 63% for adenocarcinoma, and 33% for melanoma." | 2.40 | Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. ( Klas, JV; Madoff, RD; Rothenberger, DA; Wong, WD, 1999) |
| "This article describes two cases of colorectal cancer in adolescents and reviews the literature regarding this rare condition." | 2.40 | Colorectal cancer in adolescents. ( Renaut, AJ; Shankar, A; Taylor, I; Whelan, J, 1999) |
| "Both gastric and pancreatic cancer remain leading causes of cancer death in the United States and worldwide." | 2.40 | Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer. ( Leach, SD; Lowy, AM, 1999) |
| "Locally advanced, fungating breast cancers pose particularly difficult management problems for which intra-arterial drug delivery may be appropriate in carefully, selected cases." | 2.39 | Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature. ( Bufill, JA; Grace, WR; Neff, R, 1994) |
| "Eighty percent of the patients had squamous cell carcinoma and 20% had adenocarcinoma." | 2.39 | Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. ( Bates, BA; Bernard, SA; Detterbeck, FC; Qaqish, BF; Tepper, JE, 1996) |
| " Thus, we should perform effective adjuvant therapies in combination with surgery, in order to completely prevent these two types of cancer relapse." | 2.39 | [Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas]. ( Furukawa, H; Imaoka, S; Ishikawa, O; Iwanaga, T; Kabuto, T; Matayoshi, Y; Nakaizumi, A; Ohigashi, H; Sasaki, Y; Uehara, H, 1996) |
| "The pharmacokinetic advantage of a novel system to noninvasively isolate the hepatic venous outflow and infuse high doses of chemotherapy (doxorubicin or 5-FU) is discussed and compared with intravenous infusion and intra-arterial infusion without hepatic venous detoxification." | 2.39 | Isolated liver perfusion for liver metastases: pharmacokinetic advantage? ( Dixon, K; Ravikumar, TS, 1996) |
| "5-Fluorouracil (5-FU) is a chemotherapy drug that treats several cancers; however, it causes severe adverse effects and multidrug resistance." | 1.91 | Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase. ( Ganesan, K; Gong, G; Tsim, KWK; Xiong, Q; Zheng, Y, 2023) |
| "Poorly cohesive cells-gastric cancer (PCC-GC) represents distinct features within the GC spectrum." | 1.91 | Clinical implications and chemo-sensitivity of adjuvant chemotherapy in patients with poorly cohesive cells-gastric cancer. ( Baek, JH; Cho, M; Kang, BW; Kang, H; Kim, JG; Kwon, OK; Park, JY; Park, KB; Seo, AN, 2023) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | 1.91 | In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| "A total of 554 patients with pancreatic cancer of all stages were screened, and 73 patients treated with Gem-Nab and 48 patients treated with Gem-Ox in the palliative first-line setting were identified and included in this analysis." | 1.91 | Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis. ( Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L, 2023) |
| "From 2016 to 2020, of 1551 pancreatic cancer patients, 615 received palliative-intent chemotherapy." | 1.72 | Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. ( Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R, 2022) |
| "Colorectal cancer is one of the most common cancers in the world." | 1.62 | Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report. ( Akkuş, E; Gürbüz, M; Utkan, G, 2021) |
| "• Margin-negative resection rate of pancreatic cancer following FOLFIRINOX therapy did not differ among each resectability (67-73%, p = 0." | 1.62 | CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. ( Byun, JH; Hong, SM; Jang, JK; Kang, JH; Kim, HJ; Kim, JH; Kim, KP; Kim, SC; Lee, MG; Lee, SS; Seo, DW; Son, JH; Yoo, C, 2021) |
| "Gemcitabine monotherapy was given to 13% (41/326) of patients and nab-paclitaxel/gemcitabine to 10% (33/326), with a median of two (IQR 3-5) and three (IQR 3-5) cycles respectively." | 1.62 | Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. ( Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW, 2021) |
| "Advanced, unresectable pancreatic cancer is often treated with either gemcitabine plus nab-paclitaxel (Gem/NabP) or FOLFIRINOX, although these regimens have never been compared in a head-to-head trial." | 1.62 | Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. ( Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M, 2021) |
| "KRas is frequently mutated in pancreatic cancers." | 1.62 | GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021) |
| "Pancreatic cancer is the 8th commonest cancer and the 5th commonest cause of cancer-related death in Australia, with a 9% average 5-year survival." | 1.62 | Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. ( Ashrafi-Zadeh, A; Chan, DL; Chua, TC; Clarke, S; Diakos, C; Gill, A; Hruby, G; Jamieson, NB; Kneebone, A; Maloney, S; Mittal, A; Nahm, CB; Pavlakis, N; Samra, JS; Wijetunga, AR, 2021) |
| "Patients with locally advanced pancreatic cancer (LAPC) are increasingly treated with FOLFIRINOX, resulting in improved survival and resection of tumors that were initially unresectable." | 1.62 | Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. ( Besselink, MG; Bosscha, K; Brada, LJH; Bruijnen, RC; Busch, OR; Daamen, LA; de Hingh, IH; de Meijer, VE; de Vries, JJJ; Festen, S; Liem, MLS; Los, M; Mohammad, NH; Patijn, GA; Polée, MB; Quintus Molenaar, I; Stommel, MWJ; van Dam, RM; van Lienden, KP; van Roessel, S; van Santvoort, HC; Walma, MS; Wessels, FJ; Wilmink, HW; Yung Nio, C, 2021) |
| "We obtained 93 pancreatic cancer specimens (tumor and adjacent nontumor tissues) from patients who underwent surgery and gemcitabine chemotherapy and analyzed them by immunohistochemistry." | 1.56 | ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. ( Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z, 2020) |
| "Niclosamide is an FDA‑approved anthelmintic drug, and may elicit antineoplastic effects through direct STAT3 inhibition, which has been revealed in numerous human cancer cells." | 1.56 | Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. ( Chen, YK; Hsu, YJ; Lee, MC; Lin, BR, 2020) |
| "We demonstrated in this study that dose escalation using IMRT in combination with platin-based chemotherapy as a definitive treatment for esophageal carcinoma is safe and results in higher loco-regional and control survival when compared to previously reported data." | 1.56 | Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. ( Carrère, N; Dalmasso, C; Guimbaud, R; Izar, F; Lusque, A; Modesto, A; Moyal, E; Rives, M; Vieillevigne, L, 2020) |
| "Cutaneous metastases from colorectal cancer are extremely rare and generally appear several years after diagnosis or resection of the primary colorectal tumor." | 1.56 | Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report. ( Cheng, Q; Liao, L; Pei, F; Ye, S; Zhu, G, 2020) |
| "The prognosis of patients with advanced gastric cancer remains unsatisfactory, highlighting the need for improved therapeutic strategies." | 1.56 | FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer. ( Cao, D; Du, T; Jiang, X; Li, H; Song, C; Sun, Q; Yan, D; Yang, Y; Yuan, B; Zhang, S, 2020) |
| " No toxic death was observed." | 1.56 | Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. ( Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J, 2020) |
| "Here, we report the case of a Lynch syndrome PDA patient with an exceptional response to a single cycle of pembrolizumab immunotherapy." | 1.56 | Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma. ( Khan, GN; Patil, NR, 2020) |
| "Esophageal cancer is increasingly common and carries a poor prognosis." | 1.56 | Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. ( Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC, 2020) |
| "Patients with PM from colorectal cancer and PCI >20 that were treated with CRS and HIPEC experience a one year longer and doubled overall survival compared with open-close/debulking patients." | 1.56 | Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( Artursson, S; Birgisson, H; Cashin, P; Enblad, M; Ghanipour, L; Graf, W, 2020) |
| "The patient had locally advanced rectal cancer with widespread contact with the sacrum, and preoperative radiochemotherapy (S-1 100 mg/day plus radiotherapy 50 Gy/25 Fr)was performed." | 1.56 | [A Case of Advanced Rectal Cancer Successfully Treated with Preoperative Radiochemotherapy]. ( Ichikawa, J; Koreeda, N; Nishiki, M; Noritomi, T; Okamoto, T; Ryu, S; Sannomiya, H; Sato, K; Shin, Y; Yamana, I; Yanagisawa, J; Yoshida, Y, 2020) |
| "Primary systemic therapy in resectable pancreatic cancer is currently under investigation." | 1.51 | Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer. ( Joseph, NE; Marsh, RW; Polish, A, 2019) |
| "Vulvar metastasis of colorectal cancer (CRC) and acquired resistance to cetuximab is a very rare phenomenon." | 1.51 | Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report. ( Ni, X; Qiang, W; Wu, Q; Zhang, C; Zhao, J, 2019) |
| "Most patients had disease progression as the best response to treatment (75." | 1.51 | Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019) |
| "From our established gastric cancer database, patients with pathological stage II and III gastric cancer who received adjuvant chemotherapy after D2 gastrectomy at Zhongshan Hospital of Fudan University were analyzed." | 1.51 | The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. ( Cheng, X; Cui, Y; Ji, Y; Jiang, H; Li, W; Liu, F; Liu, TS; Shen, Z; Sun, Y; Tang, C; Wang, X; Wang, Y; Yu, S; Yu, Y, 2019) |
| "Organoids were derived from resected gastric cancer tumors (huTGOs) or normal stomach tissue collected from sleeve gastrectomies (huFGOs)." | 1.51 | An Organoid-Based Preclinical Model of Human Gastric Cancer. ( Ahmad, S; Biesiada, J; Chakrabarti, J; Chang, J; Hawkins, J; Helmrath, M; Holokai, L; Mahe, M; Medvedovic, M; Nowacki, LM; Shroyer, N; Steele, NG; Sundaram, N; Wang, J; Zavros, Y, 2019) |
| "A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver." | 1.51 | Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019) |
| "Pathologists assess rectal cancers that have responded significantly to neoadjuvant therapy more thoroughly." | 1.51 | Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. ( Avila, K; Chow, OS; Chu, P; Garcia-Aguilar, J; Keskin, M; Patil, S; Shia, J; Smith, DD; Smith, JJ; Widmar, M, 2019) |
| "Distant metastasis still remained a major concern in pCR patients following nCRT and TME." | 1.51 | Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019) |
| "Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner." | 1.51 | Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer. ( Costache, M; Galateanu, B; Georgiana Nitu, S; Ginghina, O; Hudita, A; Iovu, H; Negrei, C; Radu, IC; Shtilman, M; Tanasa, EV; Tsatsakis, A; Velonia, K; Zaharia, C, 2019) |
| "Irinotecan was administered whenever initial serum bilirubin was <1." | 1.51 | Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. ( Almohamad, W; Biondani, P; Chebib, A; Gumus, Y; Haydar, M; Karaboué, A; Krimi, S; Morère, JF; Teyar, N; Ulusakarya, A, 2019) |
| "Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis." | 1.51 | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. ( Burnett, A; Cloutier, AS; Dubé, P; Gervais, MK; Lecompte, MA; Sideris, L; Trabulsi, N; Trilling, B, 2019) |
| "After few days, despite of this dose reduction, he experienced life-threatening adverse events such as mucositis G3, diarrhea G3, neutropenia G4, thrombocytopenia G4, and hyperbilirubinemia G3 according to Common Terminology Criteria for Adverse Events v 5." | 1.51 | A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. ( Ciardiello, D; Ciardiello, F; Conzo, G; Coppola, N; De Falco, V; De Vita, F; Giunta, EF; Marinaccio, A; Martinelli, E; Napolitano, S; Natalicchio, MI; Troiani, T; Vietri, MT; Vitale, P; Vitiello, PP; Zanaletti, N, 2019) |
| "Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon." | 1.51 | Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019) |
| "Sarcopenia was defined as SMI ≤38." | 1.51 | Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. ( Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L, 2019) |
| "But it is rare in adults." | 1.51 | [Intussusception Caused by Colon Cancer in Pregnancy]. ( Jung, YJ; Kim, CL; Kim, K; Kim, TO; Ko, M; Sim, HC, 2019) |
| "Adjuvant chemotherapy for gastric cancer, particularly stage III, improves survival after curative D2 gastrectomy." | 1.51 | Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, EC; Hwang, JE; Jeong, O; Kim, H; Park, YK; Ryu, SY; Shim, HJ, 2019) |
| "Atypical features of Posterior reversible encephalopathy syndrome (PRES) (diffusion restriction, involvement of corpus callosum & white matter tracts along posterior limbs of internal capsule) were seen in a patient after oxaliplatin administration (FOLFOX- 4 regimen)." | 1.51 | Atypical PRES with diffusion restriction or neurotoxicity- ? part of same spectrum-after oxaliplatin (FOLFOX-4 regimen) for colonic cancer. ( Jiji, V; Prahladan, A; Ramachandran, K; Roshni, S; Sen, A; Venugopal, M, 2019) |
| "Long-term outcomes of older esophageal cancer patients (70 y and above) selected for treatment with neoadjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy were comparable with the outcomes of their younger counterparts." | 1.48 | Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. ( Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM, 2018) |
| "Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects." | 1.48 | Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( Bejarano, I; Espino, J; Pariente, JA; Pariente, R; Rodríguez, AB, 2018) |
| "Data were analyzed from a prospective pancreatic cancer database." | 1.48 | Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. ( Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA, 2018) |
| "For advanced rectal cancer with involved or threatened mesorectal fascia (MRF), current standard is pre-operative long course chemoradiotherapy (PLCRT) with either capecitabine or 5-fluorouracil (5-FU)." | 1.48 | Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients. ( Chiang, CL; Lee, FAS; Lee, SF; Poon, CM; Tung, SY; Wong, FCS; Wong, YW, 2018) |
| "Mismatch repair status in pancreatic cancer patients is not only a prognostic indicator but also a potential guiding factor for the use of 5-fluorouracil-based adjuvant chemotherapy." | 1.48 | Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. ( Liang, C; Liang, D; Meng, Q; Ni, Q; Shi, S; Xu, J; Yu, X; Zhang, B, 2018) |
| " Dosing and completion of prescribed chemotherapy were assessed on the subset of patients who received all therapy at MSK." | 1.48 | Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. ( Cercek, A; Crane, CH; Garcia-Aguilar, J; Gollub, MJ; Gonen, M; Guillem, JG; Nash, GM; Paty, PB; Reidy, DL; Roxburgh, CSD; Saltz, LB; Segal, NH; Seier, K; Shia, J; Smith, JJ; Stadler, ZK; Strombom, P; Temple, LKF; Vakiani, E; Varghese, A; Weiser, MR; Wu, AJ; Yaeger, R, 2018) |
| "Colon cancer is common in the elderly, but owing to under representation in clinical trials, the benefit of standard therapies is uncertain in this age group." | 1.48 | Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. ( Aghmesheh, M; Brungs, D; Carolan, M; Clingan, P; de Souza, P; Ranson, M; Rose, J, 2018) |
| "All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively." | 1.48 | Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018) |
| "Indiana University Simon Cancer Center pancreatic cancer database was used to identify patients with metastatic PDAC, treated with FOLFIRINOX and had tissue available for DNA sequencing." | 1.48 | Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. ( Gbolahan, O; Hancock, BA; O'Neil, BH; Radovich, M; Sehdev, A; Shahda, S; Stanley, M; Wan, J; Wu, HH, 2018) |
| "The predictive role of biomarkers in colon cancer is still being defined." | 1.48 | The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer. ( Chouhan, H; Moore, JW; Sammour, T; Thomas, ML, 2018) |
| "Anal canal cancer occasionally accompanies extramammary Paget disease." | 1.48 | Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report. ( Hirose, S; Hyodo, I; Kawai, H; Moriwaki, T; Sato, M; Suganuma, D; Tajima, H; Uchida, Y; Watanabe, R; Yamada, T; Yamamoto, Y; Yamaura, M, 2018) |
| "MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy." | 1.48 | Acquired resistance to immunotherapy in MMR-D pancreatic cancer. ( Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD, 2018) |
| "Systemic EGFRi may increase dry eye signs as well as decrease CEBD and CNFD." | 1.48 | Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial. ( Adán, A; Castellà, C; Eixarch, A; Reguart, N; Saint-Jean, A; Sainz-de-la-Maza, M; Sánchez-Dalmau, B, 2018) |
| "Patients with rectal cancer treated with chemoradiotherapy and radical surgery from 2003 to 2015 (N = 222) were included." | 1.46 | Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy. ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Tanaka, T; Watanabe, T, 2017) |
| "Distal resection margin (≤5 vs >5 mm) did not show any significant difference in cumulative incidence of locoregional recurrence (P=." | 1.46 | Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis. ( Bae, JM; Jang, HS; Jeong, S; Kim, SH; Lee, JH; Lee, JW; Nam, TK; Song, JH; Sung, S, 2017) |
| "Of 216 stage IIIB cervical cancer patients, 114 of them had no LTI and 72 had LTI." | 1.46 | Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion. ( Katanyoo, K, 2017) |
| "Blood examinations showed disseminated intravascular coagulation(DIC)at the end of the second-line chemotherapy." | 1.46 | Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation. ( Kichiraku, T; Kotanagi, H; Kotanagi, K; Kudoh, K; Masuda, A; Miyazawa, H; Munakata, M; Muto, O; Ouchi, S; Sakata, Y; Satoyoshi, R; Sawada, T; Yamagata, K, 2017) |
| "We report a rare case of breast carcinoma metastatic to the left mandibular condyle in a 55-year-old Japanese woman, who visited our department for a dental check-up prior to chemotherapy." | 1.46 | Metastasis in the mandibular condyle: a case report. ( Dodo, M; Hirakawa, H; Kato, Y; Koseki, T; Kumagai, M, 2017) |
| "To investigate the association between polymorphisms of DNA repair genes and xenobiotic with acute adverse effects in locally advanced rectal cancer patients treated with neoadjuvant radiochemotherapy." | 1.46 | Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. ( Agolli, L; Borro, M; Bracci, S; De Sanctis, V; Di Nardo, F; Enrici, RM; Falco, T; Gentile, G; Maglio, M; Minniti, G; Nicosia, L; Osti, MF; Simmaco, M; Valeriani, M, 2017) |
| "The most common sites of metastases were liver (63%) and peritoneum (22%)." | 1.46 | Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. ( Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ, 2017) |
| "Perineural invasion (PNI) in colon cancer (CC) has been associated with poorer prognosis even in stage II disease (T3-4 N0 M0)." | 1.46 | Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer. ( Baixauli, J; Beorlegui, C; Cienfuegos, JA; Hernández-Lizoáin, JL; Martínez, P; Rodríguez, J; Rosenstone, S; Sola, JJ, 2017) |
| "Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed." | 1.46 | Usefulness of chemoradiotherapy for inoperable gastric cancer. ( Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K, 2017) |
| "Rectal cancer is a malignant disease requiring multidisciplinary management." | 1.46 | Management of rectal cancer: the 2016 French guidelines. ( Bridoux, V; Brouquet, A; de Chaisemartin, C; Kirzin, S; Lakkis, Z; Lefevre, JH; Maggiori, L; Manceau, G; Panis, Y, 2017) |
| "Locally advanced unresectable pancreatic cancer (LAPC) historically portends a poor prognosis." | 1.46 | Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? ( Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH, 2017) |
| "Peritoneal metastasis is common in gastric cancer." | 1.46 | Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017) |
| "Both patients presented with colorectal cancer with synchronous liver metastasis." | 1.46 | A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases. ( Aydin, N; Berber, E; Dural, C; Okoh, AK; Taskin, HE; Yazici, P; Yigitbas, H, 2017) |
| "For patients with operable esophagogastric cancer, peri-operative chemotherapy confers a significant overall survival benefit compared to surgery alone, however only 30-40% of patients demonstrate histopathological response." | 1.46 | The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. ( Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I, 2017) |
| "A total of 198 patients with rectal cancer underwent preoperative endoscopic assessments after chemoradiotherapy." | 1.46 | Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer. ( Fukayama, M; Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Watanabe, T, 2017) |
| "AFP-PGC patients had more liver metastases than non-AFP-PGC patients (p < 0." | 1.46 | The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma. ( Bozkaya, Y; Demirci, NS; Doğan, M; Erdem, GU; Yazıcı, O; Zengin, N, 2017) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | 1.46 | Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| "Pancreatic cancer has become the third leading cause of cancer death with minimal improvements in outcome for over 40 years." | 1.46 | BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. ( Bailey, P; Biankin, AV; Brody, JR; Chang, DK; Laheru, D; Pishvaian, MJ; Wolfgang, CL, 2017) |
| "Type of esophageal cancer was adenocarcinoma in 213 patients (80%) and squamous cell carcinoma in 46 patients (17%)." | 1.43 | Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience. ( Bhatia, S; Martenson, JA; Miller, RC; Quevedo, JF; Schomas, DA; Sio, TT; Stauder, MC; Wilson, ZC, 2016) |
| "Metastatic and refractory gastric cancer (GC) are associated with a poor prognosis; therefore, the identification of prognostic factors and chemosensitivity markers is extremely important." | 1.43 | Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients. ( Altan, B; Asao, T; Bai, T; Bao, P; Hara, K; Ide, M; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Nishiyama, M; Ogata, K; Oyama, T; Suzuki, M; Toyomasu, Y; Yokobori, T, 2016) |
| "RanBPM expression in human gastric cancer tissue samples was analyzed using real-time polymerase chain reaction." | 1.43 | Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance. ( Feng, YI; Gao, X; Ji, J; Ji, KE; Jia, Y; Jiang, WG; Satherley, LK; Shao, S; Sun, PH; Ye, L, 2016) |
| "Patients with resectable oesophageal cancer are treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery within 3-8 weeks." | 1.43 | Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. ( Creemers, GJ; Kathiravetpillai, N; Koëter, M; Luyer, MD; Nieuwenhuijzen, GA; Rutten, HJ; van der Sangen, MJ, 2016) |
| "The histological diagnosis was tubular adenocarcinoma (tub2-1), int, INF a, pMP, ly0, v0, pDM0, pPM0, R0." | 1.43 | [A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab]. ( Aomatsu, N; Dozaiku, T; Hanno, H; Hirakawa, T; Hirooka, T; Iwauchi, T; Kawamura, M; Morimoto, J; Nakazawa, K; Nishii, T; Takayanagi, S; Takeda, O; Takeuchi, K; Uchima, Y; Yukawa, Y, 2016) |
| "Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide." | 1.43 | Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer. ( Esmaeilpour, K; Haghighi, S; Kasbkar, H; Yasaei, M, 2016) |
| "Febrile neutropenia was not reported." | 1.43 | Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. ( Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C, 2016) |
| "For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared with gemcitabine but with significant toxicity, particularly in patients with a high tumor burden." | 1.42 | Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E, 2015) |
| "Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy." | 1.42 | Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. ( Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT, 2015) |
| " By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up." | 1.42 | A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. ( Bleecker, JD; Pauwels, W; Vandamme, M, 2015) |
| "For patients with locally advanced rectal cancer, higher radiation dose may contribute to the improvement of both LC and disease-free survival, without significantly increasing the incidence of acute and long-term complications compared with adjuvant chemoradiotherapy alone." | 1.42 | Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer. ( Fu, S; Huang, G; Li, P; Lu, JJ; Peng, L; Tey, J; Xiong, F; Yang, Z; Zhang, Q, 2015) |
| " Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen." | 1.42 | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. ( André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015) |
| " Most adverse events were mild (grade 1-2) (Common Terminology Criteria for Adverse Events, version 3." | 1.42 | Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ( Kumita, S; Mine, T; Murata, S; Onozawa, S; Sakamoto, A; Sugihara, F; Ueda, T; Yamaguchi, H; Yasui, D, 2015) |
| "In recent decades, the management of rectal cancer has been significantly improved by optimizing the surgical treatment with the total mesorectal excision and the development of neoadjuvant radiotherapy with or without chemotherapy." | 1.42 | [Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. ( Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B, 2015) |
| "025) in the toxic group (n = 12) compared to the non-toxic group (n = 19)." | 1.42 | Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. ( Bowen, JM; Game, PA; Hussey, DJ; Irvine, T; Karapetis, CS; Keefe, DM; Kristaly, K; Smith, L; Tan, H; Thompson, SK; Tsykin, A; Watson, DI; White, I, 2015) |
| "The bleak prognosis associated with pancreatic cancer (PDAC) drives the need for the development of novel treatment methodologies." | 1.42 | Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. ( Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A, 2015) |
| "In Europe, pancreatic cancer (PC) accounts for approximately 2." | 1.42 | Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. ( André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN, 2015) |
| "Metastasis of colorectal cancer (CRC) in an adrenal gland develops in 1." | 1.42 | [Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava]. ( Andreĭtseva, OI; Gritsiuta, AI; Kalinin, DV; Kharazov, AF; Vishnevskiĭ, AV; Zhavoronkova, OI, 2015) |
| "Patients with gastric cancer who undergo diagnostic laparoscopy, preoperative chemoradiation, and gastrectomy have a high frequency of obtaining an R0 resection and excellent OS rates." | 1.42 | Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. ( Ajani, J; Badgwell, B; Blum, M; Chiang, YJ; Das, P; Estrella, J; Fournier, K; Mansfield, P; Matamoros, A, 2015) |
| "The authors conclude that multiple synchronous neoplasms can be treated with individualized chemotherapeutic protocol with good efficacy and few adverse reactions." | 1.42 | [Individualized therapy of synchronous ovarian and colon cancers with lymph]. ( Bishr, AM; Deme, D; Nizar, J; Telekes, A, 2015) |
| "Stage III colon cancer is currently treated as an entity with a unified therapeutic principle." | 1.42 | A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. ( Deng, G; He, J; Ma, J; Pei, H; Shen, H; Wu, X; Zeng, S; Zhang, S; Zhang, Y, 2015) |
| "Colon cancer in pregnancy is uncommon." | 1.42 | Chemotherapeutic treatment of colorectal cancer in pregnancy: case report. ( Al-Khatani, K; Al-Mohaisen, F; Makoshi, Z; Perrott, C, 2015) |
| "Primary rectal cancer patients with synchronous distant metastases between September 2001 and August 2011 were enrolled." | 1.42 | Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2015) |
| "Stable disease and further disease progression were achieved in 36 and 14 patients, respectively." | 1.42 | Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. ( Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ, 2015) |
| "The human gastric cancer BGC-823 cells were infected with Cx43-IRES2-EGFP recombinant adenovirus vector." | 1.42 | Infection by Cx43 adenovirus increased chemotherapy sensitivity in human gastric cancer BGC-823 cells: not involving in induction of cell apoptosis. ( Hu, X; Li, Y; Liu, D; Liu, W; Shi, G; Sun, X; Wang, T; Wu, J; Yue, X; Zhang, X; Zhao, Y; Zhou, H, 2015) |
| "Pancreatic cancer is the fourth leading cause of cancer related death with median survival ranging from 3 to 6 months for metastatic disease." | 1.42 | Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. ( Jabbar, AA; Zahir, MN, 2015) |
| "Locally advanced rectum cancer patients experience good results with surgery and adjuvant concurrent chemoradiation." | 1.42 | Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand. ( Boonyawan, K; Chansriwong, P; Dangprasert, S; Darunikorn, P; Dhanachai, M; Jiarpinitnun, C; Pattaranutaporn, P; Puataweepong, P; Sitathanee, C; Swangsilpa, T, 2015) |
| "Colon cancer is a frequently occurring primary malignant tumor." | 1.42 | Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma. ( Cai, S; Hu, J; Xu, Y, 2015) |
| "The SCAN pancreatic cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for pancreatic adenocarcinoma in Singapore." | 1.42 | Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma. ( , 2015) |
| "After disease progression, a second line based on FOLFIRI-aflibercept was started achieving an initial partial response followed by a long-lasting disease stability with a good tolerability." | 1.42 | [Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case]. ( Aroldi, F; Zaniboni, A, 2015) |
| "Even in cases of peritoneal recurrence of colon cancer, aggressive resection may improve the prognosis in some cases." | 1.42 | [Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report]. ( Hakamada, K; Miura, T; Nakayama, Y, 2015) |
| "This was a rare case of rectal cancer with submucosal invasion that showed recurrence in the bone and lymph nodes 78 months after the additional resection." | 1.42 | [Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report]. ( Amikura, K; Asayama, M; Fukuda, T; Ishikawa, H; Kawashima, Y; Kazama, S; Kurozumi, M; Mori, Y; Nishimura, Y; Nishizawa, Y; Sakamoto, H; Takano, M; Takenoya, T; Tanaka, Y, 2015) |
| "Adverse events seen with chemotherapy consisted of grade 2 leukopenia in 1 patient, but there were no cases of delayed administration or dosage reduction due to grade 2 neurotoxicity." | 1.42 | Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery. ( Arimitsu, H; Hirano, A; Koda, K; Kosugi, C; Matsuo, K; Shiragami, R; Shuto, K; Suzuki, M; Tanaka, K; Yamazaki, M; Yasuda, H, 2015) |
| "Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic." | 1.40 | Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014) |
| "Case 1 was a 61-year-old man with squamous cell carcinoma of the urethra that directly invaded into the perineal skin." | 1.40 | Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. ( Arai, Y; Itoh, J; Kaiho, Y; Kimura, S; Mitsuzuka, K; Saito, H; Tanaka, T; Yamada, S; Yamamuro, T; Yamashita, S, 2014) |
| "After 4 weeks, dysphagia scores improved by at least 1 point in 67% of patients in group 1 versus 93% in group 2 (p=0." | 1.40 | Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. ( Archambeaud, I; Landi, B; Lepère, C; Lièvre, A; Mitry, E; Rougier, P; Touchefeu, Y, 2014) |
| "Knockdown of DAP3 was conducted in gastric cancer cell lines to investigate its impact on cell growth, migration, adhesion and invasion." | 1.40 | Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. ( Hargest, R; Ji, J; Ji, K; Jia, Y; Jiang, WG; Ye, L; Zhang, L, 2014) |
| "Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy." | 1.40 | Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma. ( Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS, 2014) |
| " Severe toxic reactions to 5-FU have been associated with decreased levels of dihydropyrimidine dehydrogenase (DPD) enzyme activity." | 1.40 | A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. ( Diasio, RB; Lee, AM; McConnell, K; Offer, SM; Relias, V; Saif, MW, 2014) |
| "However, the number of long-term esophageal cancer survivors has been increasing due to advances in early detection and therapy." | 1.40 | Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. ( Dasanu, CA; Nandy, N, 2014) |
| "The presented patient with stage IV rectal cancer and liver metastases was in a unique situation linked to its inclusion in a reversed treatment and the use of neoadjuvant chemotherapy alone." | 1.40 | Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer. ( Gervaz, P; Mentha, G; Morel, P; Naiken, SP; Roth, A; Rubbia-Brandt, L; Thomopoulos, T; Toso, C, 2014) |
| "The role of autophagy in pancreatic cancer is still not clear." | 1.40 | Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs. ( Bläuer, M; Hashimoto, D; Hirota, M; Ikonen, NH; Laukkarinen, J; Sand, J, 2014) |
| "Borderline resectable pancreatic cancer is best treated by multimodality therapy." | 1.40 | Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? ( Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L, 2014) |
| "Hepatic resection of metastatic colorectal cancer (CRC) has become the treatment of choice for patients after resection of the primary CRC." | 1.40 | Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases. ( Araki, K; Asao, T; Fujii, T; Kubo, N; Kuwano, H; Suzuki, H; Tsukagoshi, M; Tsutsumi, S; Wada, S; Watanabe, A, 2014) |
| " This treatment should be considered regardless of patients' age alone, but consideration should be given to the capacity of patients to tolerate adverse events." | 1.40 | Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. ( Bedenne, L; Bouvier, AM; Faivre, J; Hamza, S; Lepage, C; Rollot, F, 2014) |
| "Abdominal pain was the most frequent symptom (36." | 1.40 | Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients. ( Bai, L; Guo, XC; Mao, ZY; Su, D; Wang, LJ; Zhang, TT, 2014) |
| " In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179." | 1.40 | Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ( Bose, A; Elyagoby, A; Wong, TW, 2014) |
| "DCF has strong antitumor activity for esophageal cancer and may confer survival benefits when used as preoperative chemotherapy." | 1.40 | Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. ( Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N, 2014) |
| "Radiotherapy for advanced rectal cancer is an important treatment to reduce local recurrence." | 1.40 | Late complications after proctectomy in rectal cancer patients who underwent radiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2014) |
| "Patients with T3/T4 and or N+ rectal cancer (n = 65) were treated with preoperative concomitant boost radiotherapy (55 Gy/25 fractions) associated to concurrent chemotherapy with oral capecitabine." | 1.40 | Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients. ( Agolli, L; Bracci, S; De Sanctis, V; Falco, T; Masoni, L; Maurizi Enrici, R; Osti, MF; Valeriani, M, 2014) |
| "Secondary surgery of metastasized gastric cancer may be justified in selected cases without progression under induction chemotherapy." | 1.40 | Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. ( Friess, HM; Novotny, AR; Reim, D; Schuhmacher, C, 2014) |
| "Treatment of HCT-116 and Caco-2 colon cancer cells with the hypoxia mimic CoCl2 induced the formation of cells with larger cell and nuclear size (PGCCs), while the cells with normal morphology were selectively eliminated." | 1.40 | CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer. ( Aranda, E; De la Haba-Rodríguez, JR; Hernandez, V; Jimenez, C; Lopez-Pedrera, C; Lopez-Sánchez, LM; Martinez, A; Muñoz-Castañeda, JR; Peñarando, J; Rodriguez-Ariza, A; Valverde, A, 2014) |
| "Postoperative complications were graded according to the Clavien-Dindo classification." | 1.40 | Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer. ( Berkel, AE; Klaase, JM; van der Palen, J; Woutersen, DP, 2014) |
| "Capecitabine is an oral prodrug to 5-fluorouracil and is commonly used in the treatment of advanced breast, colon and stomach cancer." | 1.40 | Capecitabine induced colitis. ( Grin, A; Grover, SC; Maggo, G, 2014) |
| "Lung cancer is one of the leading causes of cancer-related death in developed countries." | 1.40 | SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. ( Feng, Y; Lu, W; Zhang, M; Zuo, Y, 2014) |
| "Pancreatic cancer is a lethal disease and its prognosis remains dismal." | 1.40 | First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward. ( Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN, 2014) |
| "Locally advanced rectal cancers are currently treated with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery, but stratification of risk and final outcomes remain suboptimal." | 1.40 | Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. ( Chen, TJ; Hsing, CH; Lee, SW; Lee, YY; Li, CF; Lin, CY; Lin, LC; Sheu, MJ; Wu, TF, 2014) |
| "However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011." | 1.40 | [A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy]. ( Kigawa, G; Matsubara, T; Matsumiya, A; Mizukami, H; Nemoto, H; Saito, M; Tanaka, J; Tate, G; Umemoto, T, 2014) |
| "Capecitabine is an established treatment alternative to intravenous 5-fluorouracil (5-FU) for patients with rectal cancer receiving chemoradiotherapy." | 1.40 | Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. ( Beijnen, JH; Cats, A; Dewit, L; Meulendijks, D; Schellens, JH; Tomasoa, NB; van Tinteren, H, 2014) |
| "We examined the outcomes of transanal endoscopic microsurgery excisions with entry into the peritoneal cavity and compared them with those that did not to address our hypothesis that entry is safe with no ill infectious or oncological consequences." | 1.40 | Transanal endoscopic microsurgery with entrance into the peritoneal cavity: is it safe? ( D'Andrea, AP; Frenkel, JL; Greenleaf, CE; Marks, JH, 2014) |
| "Radiotherapy (RT) planning of gastric cancer is important because of the low radiation tolerance of surrounding critical organs." | 1.40 | Comparison of 2-dimensional and 3-dimensional conformal treatment plans in gastric cancer radiotherapy. ( Adas, YG; Aktas, C; Akyurek, S; Andrieu, MN; Atakul, T; Dirican, B; Ergocen, S; Gokce, SC; Hicsonmez, A; Yilmaz, S, 2014) |
| "Computed tomography showed intussusception caused by a large tumor in the pelvis and absence of distant metastases." | 1.40 | Intussusception due to rectal adenocarcinoma in a young adult: a case report. ( Fujiwara, T; Inada, R; Kishimoto, H; Kondo, Y; Mori, Y; Nagasaka, T; Toshima, T, 2014) |
| "The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009." | 1.40 | Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014) |
| "Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer." | 1.40 | Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. ( Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O, 2014) |
| "Two patients presented with brain metastases, while one demonstrated lymphangitic spread to lungs." | 1.40 | A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. ( Calkins, SM; Cinar, P; Kelley, RK; Venook, AP, 2014) |
| "We report a case of rectal cancer, which was successfully treated with radical resection and neoadjuvant chemoradiotherapy." | 1.40 | [Efficiency of pre-operative chemoradiotherapy in treating a case of advanced rectal cancer]. ( Ami, K; Ando, M; Arai, K; Gokita, K; Hayasaka, J; Imai, K; Kitazume, A; Kondou, M; Okamoto, E; Shibayama, T; Takagi, K; Tamura, A; Tei, S; Watanabe, A, 2014) |
| "Herein, we present a case of advanced rectal cancer surgically resected after chemotherapy." | 1.40 | [Surgical resection after chemotherapy for advanced rectal cancer - report of a case]. ( Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nogami, H; Sakata, J; Shimada, Y; Suda, K; Wakai, T, 2014) |
| "The patient declined surgery for recurrence so radiotherapy was planned." | 1.40 | [Irradiation with carbon ions for locally recurrent rectal cancer]. ( Akita, H; Fujino, S; Fujiwara, Y; Fukata, T; Gotoh, K; Kishi, K; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2014) |
| "Metastatic gastric cancer is uncommon, and metastasis of colorectal cancer to the stomach is extremely rare." | 1.40 | [A case of metastatic gastric cancer originating from transverse colon cancer]. ( Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K, 2014) |
| "Six months after surgery, recurrence was detected in the para-aortic lymph node." | 1.40 | [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy]. ( Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N, 2014) |
| "The aim is to evaluate the preliminary efficacy and side effects of paclitaxel, 5-fluorouracil, and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) as postoperative adjuvant therapy for patients of locally advanced gastric cancer (GC) at high risk for recurrence after curative resection." | 1.40 | Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer. ( Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z, 2014) |
| "We examined 120 stage II colon cancer patients." | 1.39 | Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. ( Barbazza, R; Bonin, S; Donada, M; Pettirosso, D; Stanta, G, 2013) |
| "Borderline resectable pancreatic cancer remains an area that requires multi-disciplinary approach." | 1.39 | Advancements in the management of pancreatic cancer: 2013. ( Saif, MW, 2013) |
| "A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles); and Group III (>6 cycles)." | 1.39 | Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis. ( Bai, Y; Gao, J; Gong, YF; Jiang, B; Liu, F; Yuan, HH; Zhang, WJ; Zhang, WY, 2013) |
| "Ninety-five patients with esophageal cancer were retrospectively analyzed." | 1.39 | Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis. ( Domagk, D; Domschke, W; Heinzow, HS; Kucharzik, T; Meister, T; Seifert, H; Tsepetonidis, S; Wolters, H, 2013) |
| "The survival rates of esophageal cancer treated with DCRT in North West of Iran is poor; therefore, early detection and improved treatment methods, with clinical trials are a high priority." | 1.39 | Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran. ( Ghojazadeh, M; Jangjoo, AG; Mirinezhad, SK; Mohammadzadeh, M; Naseri, AR; Nasiri, B; Seyednezhad, F; Somi, MH, 2013) |
| "Almost all gastric cancers are adenocarcinomas, which have considerable heterogeneity among patients." | 1.39 | Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. ( Boussioutas, A; Chua, C; Das, K; Deng, N; Feng, Z; Flotow, H; Goh, LK; Guan, YK; Ivanova, T; Lee, M; Lei, Z; Lim, TK; Manesh, S; Ngo, A; Ooi, CH; Pattison, S; Rozen, SG; So, JB; Tan, E; Tan, IB; Tan, P; Teh, BT; Wu, J; Zhang, S; Zouridis, H, 2013) |
| "Postoperative complications have had occurred in 12." | 1.39 | [Immediate results of complex treatment of resectable rectal neoplasms of distal localization]. ( Basheev, VKh; Bondar', GV; Sovpel', IV; Sovpel', OV; Zolotukhin, SÉ, 2013) |
| "Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups." | 1.39 | Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. ( Huang, XE; Qian, YD; Wang, L; Xiang, J; Xu, HQ; Xu, X, 2013) |
| "Management of locally advanced rectal cancer is complex because curative treatment routinely involves administration of surgery, chemotherapy, and radiation." | 1.39 | Evolving role of neoadjuvant therapy in rectal cancer. ( Schrag, D, 2013) |
| " Simultaneous heterozygous UGT1A1 28 and UGT1A1 6 polymorphisms may produce higher exposure to SN-38 and a higher risk of adverse effects related to irinotecan." | 1.39 | Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. ( Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM, 2013) |
| "Because the gastric cancer was HER2-positive, she was treated with trastuzumab plus capecitabine plus cisplatin(XP)chemotherapy as third-line treatment." | 1.39 | [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment]. ( Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T, 2013) |
| "A total of 507 patients with rectal cancer underwent RT at HKL." | 1.39 | Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience. ( Lau, FN; Lee, WC; Phua, VC; Yusof, MM, 2013) |
| "Eighteen patients with rectal cancer and synchronous liver metastases, who had undergone laparoscopic colorectal resection and simultaneous treatment for liver metastases, were retrospectively reviewed." | 1.39 | The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy. ( Chen, F; Chen, K; Ding, XM; Hu, BS; Leng, JJ; Tan, HM; Tan, JW; Zhu, Z, 2013) |
| "DNA from 143 esophageal cancer patients, 63 receiving neoadjuvant therapy and 80 receiving primary surgery, was analyzed for the following polymorphisms: the GSTM1 null, GSTT1 null, and GSTP1 Ile105Val (rs16953) in glutathione S-transferase (GST) family, 2 in thymidylate synthase (TS) gene, and the ERCC1 Asn118Asn (rs11615), ERCC1 C8092A (rs3212986), XPD/ERCC2 Asp312Asn (rs1799793), and XPD/ERCC2 Lys751Gln (rs13181) of the nucleotide excision repair pathway." | 1.39 | ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. ( Alfieri, R; Amadori, A; Ancona, E; Basso, D; Boldrin, E; Cagol, M; Castoro, C; Cavallin, F; Rumiato, E; Ruol, A; Saggioro, D, 2013) |
| "Fecal incontinence was assessed by patient self-reported data without the use of a validated score." | 1.39 | Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer. ( Buchner, S; Dinnewitzer, A; Jäger, T; Nawara, C; Öfner, D; Wolfgang, H, 2013) |
| "Clinical data of 311 node-negative gastric cancer patients who underwent potentially curative gastrectomy with more than 15 lymph nodes resected, from January 2002 to December 2006, were analyzed retrospectively." | 1.39 | Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer. ( Deng, JY; Liang, H; Wang, XN; Xue, Q; Zhang, RP, 2013) |
| "Most (90%) patients with brain metastases were diagnosed within 24 months of surgery." | 1.39 | Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. ( Ajani, JA; Bhutani, MS; Blum, MA; Campagna, MC; Correa, AM; Hofstetter, WL; Komaki, R; Lee, JH; Maru, DM; Rice, DC; Skinner, H; Sudo, K; Swisher, S; Taketa, T; Wadhwa, R; Weston, B, 2013) |
| "MC was found in 12." | 1.39 | Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. ( de Hingh, IH; de Wilt, JH; Hugen, N; Lemmens, VE; Nagtegaal, ID; Pruijt, JF; Radema, SA; Verhoeven, RH, 2013) |
| "Of all patients operated for rectal cancer, 27." | 1.39 | Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications. ( Fietkau, R; Gock, M; Klar, E; Klautke, G; Prall, F; Rau, B; Schiffmann, L; Wedermann, N, 2013) |
| "Capecitabine (CA) is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU and is one of the agents used instead of FU in such cases." | 1.39 | Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? ( Isikli, L; Yoney, A, 2013) |
| "However, the role of Nrf2 in gastric cancer (GC) remains incompletely understood." | 1.39 | Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. ( Feng, XS; Gao, SG; Hu, XF; Peng, XQ; Wang, XS; Yang, YT; Yao, J, 2013) |
| "Time to recurrence (TTR) was the primary end point of the study, Kaplan-Meier curves and log-rank tests were used to assess the association between timing of the AC and TTR." | 1.39 | Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. ( Barzi, A; Lenz, HJ; Sadeghi, S; Senagore, A; Shabihkhani, M; Thara, E; Yang, D; Yu, S, 2013) |
| "The 3-year local recurrence and distant metastasis rates in the adjuvant chemotherapy group were 4." | 1.39 | [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy]. ( Chang, H; Chen, L; Du, XJ; Gao, YH; Liu, MZ; Peng, HH; Wen, BX; Xiao, L; You, KY; Zeng, ZF; Zhou, GQ, 2013) |
| "A 69-year-old man diagnosed with lower rectal cancer was referred to our hospital." | 1.39 | [A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer]. ( Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Marubashi, S; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Sueda, T; Takahashi, H; Tomita, Y; Yano, M, 2013) |
| "Synchronous gastric and pancreatic cancers represent a very rare association." | 1.39 | Double pancreatic and gastric adenocarcinomas: a rare association. ( Cuenod, CA; Dubreuil, O; Fabre, M; Kourie, HR; Landi, B; Markoutsaki, N; Palazzo, L; Rahmi, G; Rougier, P; Roussel, H; Taieb, J; Van der Stiegel, M, 2013) |
| "Twenty patients with esophageal cancer were treated with trimodal therapy (CRT plus surgery) and underwent [(18)F]FDG-PET/CT scans both before (pre-CRT) and after (post-CRT) CRT." | 1.39 | Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. ( Chen, W; D'Souza, WD; Feigenberg, S; Kim, G; Kligerman, S; Lu, M; Lu, W; Suntharalingam, M; Tan, S, 2013) |
| "Patients with small residual tumors (≤3 cm) radiologically staged ycT0-2N0 were treated by transanal endoscopic microsurgery." | 1.39 | Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. ( Bianchi, R; Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2013) |
| "We report on an 86-year-old woman with colon cancer with liver metastasis who was treated with 5-fluorouracil, folinic acid, and bevacizumab." | 1.39 | Cervical extravasation of bevacizumab. ( Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dréanic, J; Goldwasser, F; Mir, O; Perkins, G, 2013) |
| "To assess the outcome of esophageal cancer according to therapeutic strategy." | 1.39 | [Esophageal cancer: outcome according to therapeutic strategy]. ( Capitain, O; Cellier, P; Denis, F; Girault, S; Hamy, A; Mahé, MA; Mesgouez-Nebout, N; Paumier, A; Poirier, AL; Rousseau, D, 2013) |
| "Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008." | 1.39 | Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. ( Beukema, JC; Burgerhof, JG; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Muller, K; Paardekooper, G; Plukker, JT; Smit, JK; Timmer, PR; van Dijk, BA; Woutersen, D, 2013) |
| "A total of 93 Stage II-III rectal cancer patients were genotyped using peripheral blood samples." | 1.38 | X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. ( Anido, U; Balboa, E; Barros, F; Bernardez, B; Carracedo, A; Duran, G; Gomez, A; Lamas, MJ; Lopez, R; Rana-Diez, P, 2012) |
| "5-Fluorouracil (5-FU) has a significant antineoplastic activity and has been used for the management of various malignant neoplasms." | 1.38 | Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. ( Çağdaş, M; Çalık, AN; Çeliker, E; Güzelburç, Ö; Velibey, Y, 2012) |
| "Patients with resected pancreatic cancer (PC) have a poor prognosis." | 1.38 | Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience. ( Gill, S; Kim, C; Owen, D, 2012) |
| " SERMS are a safe and effective intervention in dysphagic patients undergoing neoadjuvant chemotherapy for esophageal cancer." | 1.38 | Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. ( Gilani, SQ; Jain, PK; Pellen, MG; Razack, A; Sabri, S, 2012) |
| "Patients with locally unresectable pancreatic cancer (AJCC stage III) have a median survival of 10-14 months." | 1.38 | Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. ( Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH, 2012) |
| "To study the efficacy of low-dose-rate californium-252 ((252)Cf) neutron intracavitary afterloading radiotherapy (RT) combined with external pelvic RT for treatment of cervical cancer." | 1.38 | Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer. ( Lin, S; Liu, JR; Pan, SD; Xu, HD; Yue, JH; Zhang, M, 2012) |
| "The prognosis of stage IVB cervical cancer is generally poor." | 1.38 | Outcomes and toxicities for the treatment of stage IVB cervical cancer. ( Hwang, JH; Kang, S; Kim, JY; Lim, MC; Park, SY; Seo, SS, 2012) |
| "Survival for patients with pancreatic cancer remains poor." | 1.38 | Intensity-modulated radiotherapy for pancreatic adenocarcinoma. ( Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC, 2012) |
| "ACA in locally advanced cervical cancer had poorer response rate from treatment and also used longer time to achieve CR than SCC." | 1.38 | Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. ( Katanyoo, K; Manusirivithaya, S; Sanguanrungsirikul, S, 2012) |
| "In spite of advances in rectal cancer surgery and the use of preoperative 5-fluorouracil-(5-FU) based chemoradiotherapy (CRT) in stage II and III disease distant metastases still occur in about 35-40% of the patients." | 1.38 | Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life. ( Brade, J; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kienle, P; Kripp, M; Post, S; Welzel, G; Wenz, F; Wieneke, J, 2012) |
| "One 67 gastric cancer patients with cT2-4 or TanyN1-3M0 between January 2006 and December 2007 were included." | 1.38 | Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. ( Dong, B; Du, H; Ji, J; Jia, Y; Liu, Y; Tang, L; Wu, A; Yuan, P, 2012) |
| "Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck." | 1.38 | Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ( Hurwitz, HI; McManus, TJ; Peer, CJ; Petros, WP, 2012) |
| "An analysis of 162 rectal cancer patients who underwent curative surgery between 2005 and 2010." | 1.38 | Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer. ( Contu, PC; Damin, DC; Ferreira, PR; Kliemann, LM; Rosito, MA; Schwartsmann, G; Tarta, C, 2012) |
| "Pancreatic cancer has a dismal prognosis." | 1.38 | Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. ( Dicheva, BM; Eggermont, AM; Hop, WC; Koning, GA; Seynhaeve, AL; Ten Hagen, TL; van Dekken, H; van der Zee, JA; van Eijck, CH, 2012) |
| "A 31-year-old man with sigmoid colon cancer with concomitant simultaneous multiple liver metastases had received FOLFIRI (leucovorin, fluorouracil and irinotecan) and FOLFOX6 (leucovorin, fluorouracil and oxaliplatin) after an ordinary sigmoidectomy." | 1.38 | Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. ( Kawahara, H; Kitamura, H; Onda, S; Saito, R; Toyama, Y; Ushigome, T; Watanabe, K; Yanaga, K; Yanagisawa, S; Yoshida, S, 2012) |
| "One hundred and twenty-eight advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine in Peking University Cancer Hospital from December 2006 to October 2010 were enrolled in the study." | 1.38 | Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. ( Gao, J; Li, Y; Lu, Z; Shen, L; Yu, J, 2012) |
| "After matching, only CEA and metastasectomy, but not CCRT, were independent prognostic factors." | 1.38 | Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer. ( Chang, SC; Chen, WS; Jiang, JK; Lan, YT; Lee, LK; Lin, CC; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH; Wang, HS; Yang, SH; Yen, CC, 2012) |
| "A total of 31 patients with advanced gastric cancer was included." | 1.38 | The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer. ( Bilici, A; Ercan, S; Gumus, M; Orcun, A; Seker, M; Ustaalioglu, BB; Yilmaz, BE, 2012) |
| "Irinotecan was given as a combined regimen for median 6 cycles (range, 3-12) and as a single agent for median 3 cycles (range, 1-10)." | 1.38 | Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. ( Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO, 2012) |
| "Unresectable pancreatic cancer (UPC) has low survival." | 1.38 | Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. ( Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ, 2012) |
| " Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy." | 1.38 | Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. ( Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012) |
| "Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection." | 1.38 | MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. ( Fabian, P; Gombosova, J; Kocakova, I; Nekvindova, J; Radova, L; Sana, J; Slaby, O; Svoboda, M; Vyzula, R, 2012) |
| "A 71 years old Italian man had type 3 gastric cancer of the greater curvature." | 1.38 | Local recurrence of gastric cancer after total gastrectomy: an unusual presentation. ( Amato, B; Cardin, F; Lorenzetti, R; Martella, B; Militello, C; Terranova, C, 2012) |
| "Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance." | 1.37 | Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. ( Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU, 2011) |
| "Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths." | 1.37 | Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. ( Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E, 2011) |
| "Between 1997 and 2007, 94 patients with esophageal cancer were treated with chemoradiation in our institute." | 1.37 | Chemoradiation for esophageal cancer: institutional experience with three different regimens. ( Aleman, BM; Boot, H; Cats, A; Courrech Staal, EF; Jansen, EP; van Coevorden, F; van Sandick, JW; van Velthuysen, ML, 2011) |
| "Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease." | 1.37 | Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011) |
| "Fatigue was a prominent long-lasting symptom in these patients." | 1.37 | Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. ( Aarstad, AK; Aarstad, HJ; Hjermstad, MJ; Hurmuzlu, M; Viste, A, 2011) |
| "Forty-four patients with rectal cancer treated with 5-FU-based preoperative CRT were prospectively enrolled in this study." | 1.37 | Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. ( Choi, J; Choi, SH; Hur, H; Kang, J; Keum, KC; Kim, H; Kim, NK; Lee, KY; Lee, MY; Min, BS; Shin, SJ, 2011) |
| "We studied 26 gastric cancer patients with lymph node metastasis who underwent gastric resection at the Korea University Guro Hospital from Feb 2007 to July 2008." | 1.37 | Metastatic lymph node targeted chemosensitivity test for gastric cancer. ( Jang, YJ; Kim, CS; Kim, JH; Kim, SJ; Mok, YJ; Park, SH; Park, SS, 2011) |
| "Human colon cancer HT-29 cells were transduced with a pLPCX expression retroviral vector containing green fluorescent protein and neomycin resistance genes." | 1.37 | A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumor. ( Ding, Y; Jin, H; Sun, Y; Wang, J; Yang, Z; Zhang, S, 2011) |
| "Patients with rectal cancer, candidates to receive pCRT, were enrolled in a multicenter prospective observational trial." | 1.37 | Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. ( Amato, A; Capirci, C; Cuicchi, D; De Paoli, A; Del Bianco, P; Efficace, F; Nitti, D; Pucciarelli, S; Serpentini, S, 2011) |
| "Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications." | 1.37 | Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011) |
| "Obesity is a risk factor for the development of esophageal malignancy." | 1.37 | Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity. ( Mathew, J; Odell, JA; Stauffer, JA, 2011) |
| "When capecitabine and melatonin were combined, a well-differentiated pancreatic adenocarcinoma was observed in 10% of animals." | 1.37 | Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. ( Arjona, A; Montilla, P; Muntané, J; Padillo, J; Perea, D; Ruiz-Rabelo, J; Túnez, I; Vázquez, R, 2011) |
| "Patients with locally advanced rectal cancer treated with neoadjuvant therapy can safely undergo laparoscopic proctectomy with a low rate of complications." | 1.37 | Laparoscopic proctectomy after neoadjuvant therapy: safety and long-term follow-up. ( Cone, MM; Diggs, BS; Herzig, DO; Lu, KC; Oommen, SC; Rea, JD, 2011) |
| "Adjuvant chemotherapy in rectal cancer is not well defined." | 1.37 | Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. ( Alfonso, R; Corona, J; Custodio, A; de las Heras, M; Dıaz-Rubio, E; Ortega, L; Puente, J; Rodriguez, L; Sanchez, JC; Sastre, J, 2011) |
| "Patients with metastatic colorectal cancers have poor outcomes." | 1.37 | Changing management and survival in patients with stage IV colorectal cancer. ( Ng, S; O'bichere, A; Platell, C; Tebbutt, N, 2011) |
| " The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group." | 1.37 | Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. ( Arai, T; Kobayashi, S; Koike, J; Koizumi, S; Makizumi, R; Miura, K; Miyajima, N; Nakano, H; Otsubo, T; Sakurai, J; Shimamura, T; Yamada, K, 2011) |
| "Patients with mucinous rectal cancer experienced a lower rate of T-downstaging after PCRT and had a poorer prognosis than did patients with nonmucinous cancer." | 1.37 | Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. ( Kim, CW; Kim, JC; Kim, JH; Kim, TW; Lim, SB; Shin, US; Yoon, SN; Yoon, YS; Yu, CS, 2011) |
| "Next, we showed that nine human colon cancer cell lines established from primary tumors or metastases expressed OX1R mRNA and underwent important apoptosis on orexin-A challenge." | 1.37 | Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis. ( Bedossa, P; Descatoire, V; El Firar, A; Fasseu, M; Henin, D; Laburthe, M; Lehy, T; Paradis, V; Rouyer-Fessard, C; Voisin, T; Walker, F, 2011) |
| "Pelvic schwannomas are rare; it is even more rare for a pelvic schwannoma to occur concurrently with a colon cancer." | 1.37 | Synchronous colonic adenocarcinoma and pelvic schwannoma. ( Bai, J; Kleyser-Sugrue, K; Nerenstone, SR; Welch, JP, 2011) |
| " Despite widespread concern about the successful performance of this procedure following neoadjuvant chemoradiotherapy (NACR) treatment, we hypothesized that safe and effective MIE could be performed in this setting." | 1.37 | Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy. ( Ben-David, K; Cendan, JC; Grobmyer, SR; Hochwald, SN; Rossidis, G; Sarosi, GA; Zlotecki, RA, 2011) |
| "We retrospectively evaluated 333 rectal cancer patients who received preoperative CRT followed by surgery with curative intent between January 2000 and December 2006." | 1.37 | Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. ( Kim, CW; Kim, JC; Kim, KH; Lim, SB; Yang, SS; Yoon, SN; Yoon, YS; Yu, CS, 2011) |
| "Patients with dMMR colon cancers have reduced rates of tumor recurrence, delayed TTR, and improved survival rates, compared with pMMR colon cancers." | 1.37 | DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. ( Allegra, C; Foster, NR; Gallinger, S; Kim, GP; Labianca, R; Marsoni, S; Monges, G; Moore, MJ; Sargent, DJ; Sinicrope, FA; Thibodeau, SN; Yothers, G, 2011) |
| "The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status." | 1.37 | Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. ( Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M, 2011) |
| "It is said that disseminated carcinomatosis of the bone marrow has a poor prognosis, but we were able to obtain a good response in this case by chemotherapy." | 1.37 | [Successful chemotherapy of carcinomatosis of the bone marrow with disseminated intravascular coagulation from a rectal carcinoma found by eosinophilia]. ( Abiko, S; Gotoh, J; Higashiyama, A; Kawamura, A; Kawamura, N; Kudo, M; Meguro, J; Nagasako, T; Takano, M; Tamaki, T; Tanino, M; Yamamoto, Y; Yonekawa, M, 2011) |
| "Metastatic colorectal cancer has a low cure rate." | 1.37 | Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer. ( Afonso, S; Afonso, V; Stefano, E; Viani, G, 2011) |
| "The finding that some rectal cancers respond to neoadjuvant chemoradiation is broadening new surgical options for the treatment of some of these tumors that, until now, required a total mesorectal excision." | 1.37 | Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? ( Arbea, L; Aristu, J; Baixauli, J; Beorlegui, C; Hernandez-Lizoain, JL; Pastor, C; Sola, J; Subtil, JC, 2011) |
| " In combination with gemcitabine, median survival was further prolonged." | 1.37 | An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. ( Bhattacharyya, M; Eddouadi, A; Francis, J; Halldén, G; Lemoine, NR, 2011) |
| "Gemcitabine alone was given to 60 (38%) patients, and gemcitabine with high-dose infusional fluorouracil (5-FU) with (n = 25) or without (n = 39) oxaliplatin was given to 64 (40%) patients." | 1.37 | Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. ( Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Kuo, YH; Tien, YW; Yang, SH, 2011) |
| "In two patients with locally invasive pancreatic cancer, the pancreatic blood supply was altered under angiographic guidance, and an intra-arterial catheter with a subcutaneous port was left in place for the administration of 5-fluorouracil (5-FU) 1,000 mg/m(2)." | 1.37 | Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer. ( Anai, H; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T, 2011) |
| "Two years later, he was diagnosed for rectal cancer and bilateral lung metastases by TBLB." | 1.37 | [A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Kurokawa, T; Nagahama, T; Nakamura, M; Okada, Y; Tei, S; Watayo, Y, 2011) |
| "A total of 107 patients with advanced gastric cancer treated in our hospital from December 2005 to November 2008 were included in this retrospective analysis." | 1.37 | [HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis]. ( Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH, 2011) |
| " Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases." | 1.36 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010) |
| "Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen." | 1.36 | Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010) |
| "Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity." | 1.36 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010) |
| "Patients with histologically proven gastric cancer and measurable metastatic disease received docetaxel 75 mg/m(2) as a 1-h intravenous infusion on day 1, and oral etoposide 50 mg/m(2) once daily on days 1-5, every 3 weeks until disease progression or unacceptable toxicities." | 1.36 | Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. ( Alici, S; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Dane, F; Gumus, M; Kalender, ME; Kaya, AO; Ozturk, B; Sevinc, A; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "Capecitabine was administrated 1,650 mg/m(2)/day, 7 days/week." | 1.36 | Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. ( Aygerinos, K; Baltatzis, G; Bamias, A; Beroukas, K; Boskos, CS; Dimopoulos, MA; Korkolis, D; Lamproglou, I; Liacos, C; Papasavvas, P; Stoupa, E; Terpos, E, 2010) |
| "The treatment of locally advanced pancreatic cancer varies enormously both within the UK and internationally." | 1.36 | Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment. ( Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S, 2010) |
| "Biopsied lung tumor was diagnosed as tubular adenocarcinoma, and CK7(+)/CK20(+)/Cdx-2(-)." | 1.36 | Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report. ( Arai, M; Asakage, M; Endo, J; Furukawa, Y; Muto, Y; Nozawa, H; Oka, T; Yamada, Y, 2010) |
| "Microsatellite instability was observed in all VCMsh2 strains and limited to the intestinal mucosa." | 1.36 | An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. ( Bronson, RT; Clark, AB; Edelmann, W; Fan, K; Hou, H; Jelicks, L; Kucherlapati, MH; Kucherlapati, R; Kunkel, TA; Lee, K; Li, H; Lipkin, M; Nguyen, AA; Rosulek, A; Yang, K, 2010) |
| "Of 100 patients with locally advanced rectal cancer, 32 were clinically staged as T3N0M0." | 1.36 | Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? ( Ceccarelli, C; Cola, B; Cuicchi, D; Di Fabio, F; Di Tullio, P; Iacopino, B; Lecce, F; Lombardi, R; Martoni, A; Minni, F; Neri, S; Pini, S; Pinto, C; Taffurelli, M; Tardio, ML; Ugolini, G, 2010) |
| "We established 2 HIF-1alpha knockdown gastric cancer cell lines in order to clarify the role of HIF-1alpha in chemo-resistance against 5-FU." | 1.36 | HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. ( Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Miyazaki, K; Nakamura, J; Noshiro, H, 2010) |
| "The BGC-823 gastric cancer cell line was incubated for 48 h with 0." | 1.36 | Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. ( Chen, XM; Huang, ZG; Wang, ZR; Zhang, DW; Zhang, X; Zhu, FS, 2010) |
| "Using a comprehensive esophageal cancer database, we identified patients who underwent esophagectomy between 1994 and 2008." | 1.36 | Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. ( Hoffe, S; Karl, R; Kelley, S; Marcovalerio, M; McLoughlin, J; Meredith, KL; Shah, N; Siegel, EM; Turaga, KK; Weber, JM, 2010) |
| "Borderline resectable pancreatic cancer is an emerging stage of disease defined by computed tomogrpahy criteria, patient (Katz type B), or disease characteristics (Katz type C)." | 1.36 | Management of borderline resectable pancreatic cancer. ( Christians, K; Evans, DB; Lal, A, 2010) |
| "Capecitabine is an anticancer agent, prodrug of 5 fluorouracil (5-FU) administered orally and with a narrow therapeutic index." | 1.36 | [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency]. ( Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C, 2010) |
| "Pre-operative chemoradiation in low rectal cancer is not associated with a higher incidence of peri-operative complications and its benefits may include reduction local recurrence." | 1.36 | Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers. ( Fan, JF; Law, WL; Lim, YK; Liu, R; Lo, OS; Poon, JT, 2010) |
| "In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy." | 1.36 | Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. ( Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L, 2010) |
| "The risk of venous thromboembolism has been reported to increase when receiving bevacizumab." | 1.36 | Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. ( Doi, T; Fuse, N; Ikematsu, H; Kaneko, K; Koike, K; Kojima, T; Minashi, K; Mochizuki, S; Ohtsu, A; Tahara, M; Yano, T; Yoshino, T, 2010) |
| "Adjuvant chemo-radiation for gastric cancer is a standard at our institution and has resulted in few relapses and an interesting median survival." | 1.36 | Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience. ( Aftimos, PG; Chahine, GY; El Helou, JA; Ghosn, MG; Nasr, DI; Nasr, EA; Nasr, FL; Noun, RJ, 2010) |
| "We report a case of acute interstitial pneumonitis and respiratory failure occurring in a 69-year-old, previously healthy patient receiving FOLFOX regimen plus cetuximab for colon cancer." | 1.36 | Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy. ( Chang, SC; Lai, JI; Lai, YC; Lin, PC; Wang, WS, 2010) |
| "298 patients with inoperable cancer of the esophagus were identified (16." | 1.36 | Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. ( Belka, C; Ganswindt, U; Haimerl, W; Hölzel, D; Niyazi, M; Schmidt, M; Wolf, M; Zehentmayr, F, 2010) |
| "Patients with locally advanced pancreatic cancer (LAPC) are most commonly managed with chemotherapy or concurrent chemoradiotherapy (CRT), which may or may not include non-involved regional lymph nodes in the clinical target volume." | 1.36 | Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. ( Dickinson, C; Green, MM; Jackson, AS; Jain, P; Price, PM; Saleem, A; Taylor, MB; Valle, J; Watkins, GR; Whitfield, GA, 2010) |
| "Colorectal cancer is one of the leading malignancies in the world." | 1.36 | Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010) |
| "To compare the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of FOLFOX6 and TLF regimens for advanced gastric cancer." | 1.36 | [Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer]. ( Deng, YM; Li, LL; Xian, HB; Yu, HB, 2010) |
| "Eighty five patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated." | 1.36 | [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy]. ( Jiang, J; Jiang, T; Li, QF; Liang, J; Lü, HY; Song, SA; Sun, YY; Yao, RY, 2010) |
| "Blood test showed severe disseminated intravascular coagulation (DIC)." | 1.36 | [mFOLFOX6 for treatment of anal canal cancer with disseminated carcinomatosis of bone marrow--a case report]. ( Doi, M; Okamoto, Y; Shinozaki, K; Yamauchi, M, 2010) |
| "Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen." | 1.36 | [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010) |
| "Goblet cell carcinoid of the large intestine is a rare neoplasm, usually located in ascending colon and rectum." | 1.36 | Perforated mixed carcinoid-adenocarcinoma in transverse colon and at gastroenterostomy site: case report. ( Erkasap, S; Ihtiyar, E; Karakaş, BR; Paşaoğlu, O; Yaşar, FN, 2010) |
| "Patients with nonmetastatic distal rectal cancer treated by neoadjuvant chemoradiation therapy, including 50." | 1.36 | Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. ( Gama-Rodrigues, J; Habr-Gama, A; Kessler, H; Marks, J; Perez, RO; Wynn, G, 2010) |
| " A protocol-defined prohibitive adverse event occurred in 4 patients (6%), including 2 treatment-associated deaths." | 1.36 | Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. ( Chen, HX; Christos, P; Hamilton, A; Horvath, L; Kindler, HL; Matulich, D; Ocean, AJ; Polite, B; Sparano, JA, 2010) |
| " Using the indwelling catheter-port system with the unification of the pancreatic blood supply, we initially conducted an arterial infusion of weekly high-dose 5-FU (1,000 mg/m2/qw) combined with systemic gemcitabine (1,000 mg/m2/qw)." | 1.36 | [Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report]. ( Anai, H; Hasegawa, M; Kichikawa, K; Maeda, S; Masada, T; Morimoto, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T; Yamamoto, K, 2010) |
| "It is important to understand that gastric cancer diagnosed poorly differentiated adenocarcinoma pathologically sometimes occurs duodenal invasion and obstructive jaundice." | 1.36 | [A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy]. ( Fukuda, S; Hiraki, S; Kawaoka, T; Matsukuma, S; Nagashima, A, 2010) |
| "A colonoscopy revealed primary rectal cancer." | 1.36 | [A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy]. ( Danno, K; Imaoka, S; Inatome, J; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Tsukao, Y; Watanabe, A, 2010) |
| "Colonoscopy detected an advanced rectal cancer." | 1.36 | [A case report of advanced rectal cancer showing a pathological complete response by neo-adjuvant FOLFOX chemotherapy]. ( Hirakawa, K; Inoue, T; Kubo, N; Maeda, K; Muguruma, K; Murata, A; Nagahara, H; Noda, E; Ohira, M; Tanaka, H; Yamada, N, 2010) |
| "Local therapy for early rectal cancer is a valid alternative to the classical radical operation, which has a higher morbidity and mortality rate." | 1.35 | Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience. ( Baldarelli, M; Bartolacci, S; Grillo Ruggeri, F; Guerrieri, M; Lezoche, E; Mantello, G; Organetti, L, 2008) |
| "However, G-CSF-producing colorectal cancer (CRC) has never been reported in the English literature." | 1.35 | Granulocyte-colony stimulating factor producing rectal cancer. ( Akamo, Y; Funahashi, H; Ochi, N; Sakamoto, M; Satoh, M; Sawai, H; Takahashi, H; Takayama, S; Takeyama, H; Wakasugi, T; Yasuda, A, 2008) |
| "Patients with localized esophageal cancer (LEC) have diverse outcomes (post-therapy pathologic response, disease-free survival [DFS], and overall survival [OS]) after preoperative chemoradiation (P-CTRT), dictated also by inherent molecular heterogeneity." | 1.35 | Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. ( Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG, 2008) |
| "In patients with metastatic colorectal cancer (mCRC), several prognostic factors such as performance status (PS), number of metastatic sites, carcinoembryonic antigen (CEA), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) have been reported." | 1.35 | Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. ( Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008) |
| "Locally advanced rectal cancer is frequently treated with neoadjuvant chemoradiotherapy to reduce local recurrence and possibly improve survival." | 1.35 | A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. ( Armstrong, J; Beddy, D; Fennelly, D; Gibbons, D; Hyland, JM; Lim, C; Moriarty, M; Sheahan, K; White, A; Winter, DC, 2008) |
| "Gemcitabine is a pyrimidine antimetabolite with activity in a number of cancers." | 1.35 | Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. ( Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K, 2008) |
| "We report a patient with pancreatic cancer, challenged with maintaining the international normalized ratio (INR) with gemcitabine-capecitabine combination, and later with gemcitabine monotherapy with concomitant warfarin, as well as, a brief review of the literature." | 1.35 | Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer. ( Saif, MW; Wasif, N, 2008) |
| "Two fatal cases of interstitial pneumonitis rapidly evolving to pulmonary fibrosis are reported here." | 1.35 | Fatal pneumonitis induced by oxaliplatin. ( Arévalo Lobera, S; Azkue Gabilondo, M; Basterretxea Badiola, L; Egaña Otaño, L; Elejoste Echeberría, I; La Casta Muñoa, A; Melé Olivé, M; Sagastibeltza Mariñelarena, N, 2008) |
| "Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licensed for the treatment of breast and gastrointestinal cancers." | 1.35 | Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. ( Kolluri, RB; Raouf, S; Tipples, K, 2009) |
| "While hiccups are usually benign, severe attacks may lead to exhaustion, eating difficulties, and affect quality of life." | 1.35 | Severe hiccups during chemotherapy: corticosteroids the likely culprit. ( Gilbar, P; McPherson, I, 2009) |
| "104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept." | 1.35 | [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD, 2009) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used in a number of solid malignancies, including colorectal cancer." | 1.35 | A case of 5-fluorouracil-induced acute psychosis. ( Alabsi, E; Fakih, M; Fora, A, 2009) |
| "Forty patients with rectal cancer underwent 5-fluorouracil based chemoradiotherapy followed by curative surgery." | 1.35 | Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues. ( Inoue, Y; Kusunoki, M; Miki, C; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| "Patients with locally advanced rectal cancer undergoing preoperative radiotherapy have disparity in pathological tumor regression." | 1.35 | [Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma]. ( Ding, PR; Lin, JZ; Pan, ZZ; Wan, DS; Zeng, ZF, 2009) |
| "Twenty-two specimens of colorectal cancer were collected." | 1.35 | [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues]. ( Chen, G; Fu, LW; Liang, YJ; Qiu, HB; Yuan, SQ; Zhang, LY; Zhou, ZW, 2009) |
| "We experienced this AFP-producing gastric cancer in which CR was possible by FLEP." | 1.35 | [Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case]. ( Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T, 2009) |
| "A clinical finding was Stage IV gastric cancer of poorly differentiated adenocarcinoma." | 1.35 | [A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy]. ( Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Yanagida, N, 2009) |
| " Administration of 30 mg/kg CS-706 from Day 7 combined with a single intravenous treatment of 10 mg/kg cisplatin on Day 7 completely regressed the tumors in all tumor-bearing mice examined, whereas only in 1 of 10 mice tumor was regressed with cisplatin treatment." | 1.35 | CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents. ( Fujiwara, K; Hanai, M; Inoue, S; Ishida, S; Kimura, T; Kurakata, S; Senzaki, M; Yada, A, 2008) |
| "Fifty-eight advanced gastric cancer patients with previous chemotherapy were enrolled into the study." | 1.35 | The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. ( Akbulut, H; Boruban, MC; Buyukcelik, A; Demirkazik, A; Icli, F; Onur, H; Sencan, O; Senler, FC; Yalcin, B, 2008) |
| "Therefore, ERUS-/MRI-staged T3N0 rectal cancer patients should continue to receive preoperative CMT." | 1.35 | cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. ( Aristu, JJ; Coco, C; Díaz-González, JA; Guillem, JG; Hernandez-Lizoain, JL; Jeong, SY; Leon, R; Minsky, BD; Nitti, D; Pucciarelli, S; Riedel, ER; Rodriguez-Bigas, MA; Valentini, V; Wong, WD, 2008) |
| "5-fluorouracil was given as continuous infusion 350 mg/m(2)/day five times weekly, and RHT (BSD-2000 system) was applied twice a week within 1 h after radiotherapy." | 1.35 | Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. ( Buecklein, V; Duehmke, E; Issels, RD; Milani, V; Pazos, M; Rahman, S; Schaffer, M; Schaffer, P; Tschoep, K; Wilkowski, R, 2008) |
| "The standard adjuvant therapy for rectal cancer is 5-fluorouracil (5-FU) often combined with radiotherapy." | 1.35 | A case of 5-fluorouracil-induced peripheral neuropathy. ( De Bleecker, JL; Pauwels, WJ; Werbrouck, BF, 2008) |
| " There was no toxic death, but 1 patient had long-term complications." | 1.35 | The toxicity and outcomes of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected high-risk gastric cancer: results of a single institute. ( Avraham, R; Ayala, H; Luna, K; Marc, W; Tamar, S; Yakir, R, 2008) |
| "The tumor caused rectosigmoid intussusception and then it prolapsed out through the anus." | 1.35 | Rectal prolapse as initial clinical manifestation of colon cancer. ( Chen, CW; Hsiao, CW; Jao, SW; Wu, CC, 2008) |
| "Capecitabine (Xeloda) is an oral 5-fluorouracil pro-drug used in the treatment of two of the commonest cancers: breast and colorectal." | 1.35 | Capecitabine-associated coronary vasospasm: a case report. ( Papadopoulos, CA; Wilson, H, 2008) |
| "Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced esophageal cancer." | 1.34 | Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. ( Baldus, SE; Bollschweiler, E; Dienes, HP; Hölscher, AH; Izbicki, JR; König, A; Mueller, RP; Prenzel, KL; Schneider, PM; Schnickmann, C; Schröder, W, 2007) |
| "Syndrome of DPD deficiency manifests as diarrhea, stomatitis, mucositis, and neurotoxicity and in some cases death." | 1.34 | DPYD*2A mutation: the most common mutation associated with DPD deficiency. ( Diasio, RB; Ezzeldin, H; Saif, MW; Sellers, S; Vance, K, 2007) |
| "Among the patients with T3/T4 gastric cancer, postoperative oral fluorouracil treatment was effective in those who were pAkt-positive." | 1.34 | Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. ( Ikeguchi, M; Katano, K; Murakami, D; Osaki, T; Saito, H; Tatebe, S; Tsujitani, S, 2007) |
| "Resection of locally recurrent rectal cancer (LRRC) after curative resection represents a difficult problem and a surgical challenge." | 1.34 | Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience. ( Asoglu, O; Emek, E; Igci, A; Kapran, Y; Karanlik, H; Kecer, M; Muslumanoglu, M; Ozmen, V; Parlak, M, 2007) |
| "50 patients diagnosed as advanced gastric cancer were administered continuous infusion of 5-FU (300 mg/m(2)/day, x 14 days) and intermittent infusion of CDDP (3 mg/m(2)/day, day 1-5 and 8-12) before surgery." | 1.34 | [Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer]. ( Koda, K; Miyazaki, M; Oda, K; Seike, K; Takano, S; Takiguchi, N, 2007) |
| "Here, we report the case of a sigmoid colon cancer patient with initially unresectable hepatic metastases showing a prolonged survival (6." | 1.34 | [A long survival case of sigmoid colon cancer patient with initially unresectable hepatic metastases]. ( Gega, M; Hashimoto, A; Ikeuchi, H; Kuno, T; Noda, M; Oshima, T; Tanaka, K; Tsukamoto, K; Yagyuu, T; Yamamura, T; Yanagi, H; Yoshikawa, R, 2007) |
| "Two human colon cancer cell lines (HCT-15 and HT-29) were treated with 5-FU and celecoxib, alone and in combination." | 1.34 | Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. ( Bae, YM; Chun, WJ; Lim, YJ; Rhee, JC, 2007) |
| "5-fluorouracil (5FU) has traditionally been the drug of choice in combination with radiation therapy." | 1.34 | Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma. ( Amichetti, M; Caraul, B; Casula, G; Deidda, MA; Dessì, M; Farci, D; Farigu, R; Lay, GC; Maxia, L; Murtas, R; Orrù, S, 2007) |
| "Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis." | 1.34 | [A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007) |
| "He was diagnosed as advanced sigmoid colon cancer which invaded the rectal colon (Ra) and prostate (SI, N 0, P 0, H 0, M (-), cStage IIIa)." | 1.34 | [A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery]. ( Maezawa, K; Mizukami, H; Nemoto, H; Sanada, Y; Sasaya, S; Yoshizawa, Y, 2007) |
| "After 10 years, second primary cancer (seven cases) became as important an issue as recurrence of primary gastric cancer (six cases)." | 1.34 | Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. ( Chung, HC; Jeung, HC; Kim, BS; Moon, YW; Noh, SH; Rha, SY; Roh, JK; Yoo, NC, 2007) |
| "To study the effects of two specific cyclooxygenase inhibitors (SCI), rofecoxib and celecoxib, combined with chemotherapeutic drugs 5-Fu, DDP and VP-16 on gastric cancer cell line BGC-823, and to evaluate whether specific cyclooxygenase inhibitors can be used as a synergetic agent in chemotherapy." | 1.34 | [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]. ( Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS, 2007) |
| "121 locally advanced middle-low rectal cancer patients were treated with preoperative radiotherapy or chemoradiotherapy followed by surgery after rest of 4 to 6 weeks." | 1.34 | [Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer]. ( Cao, WG; Che, JF; Jin, YN; Li, H; Ma, T; Xi, WQ; Xu, HP; Zhao, R, 2007) |
| " We have applied goshajinkigan (TJ 107) for a case of advanced colon cancer with mFOLFOX 6, and experienced a reduction in numbness, the adverse effect of LOHP." | 1.34 | [A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer]. ( Chisato, N; Ebisawa, Y; Kono, T; Mamiya, K; Mamiya, N; Satomi, M, 2007) |
| "Advanced pancreatic cancer has a poor prognosis." | 1.34 | [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer]. ( Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD, 2007) |
| "Colon cancer is c-kit positive and responsive to the specific tyrosine kinase inhibitor imatinib." | 1.34 | Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. ( Chalkiadakis, G; Kanakis, I; Karamanos, NK; Kletsas, D; Mavroudis, D; Roussidis, AE; Stahtea, XN; Tzanakakis, GN, 2007) |
| "Familial Mediterranean Fever is a chronic hereditary disease which is relatively prevalent in the Middle East and is associated with recurrent episodes of serosal, synovial or cutaneous inflammations." | 1.34 | Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. ( Brenner, B; Purim, O; Sulkes, A, 2007) |
| "101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging." | 1.34 | Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. ( Bischoff, A; Budach, V; Füller, J; Köhler, C; Marnitz, S; Roth, C; Schneider, A; Wendt, T, 2007) |
| "In order to develop a model of liver metastasis of human gastrointestinal cancer cells, we examined the potential of 10 human colon and stomach cancer cell lines (HT-29, WiDr, HCT-116, HCT-15, HCC-2998, MKN7, MKN28, MKN45, MKN74 and St-4) to form liver metastases in nude mice." | 1.34 | Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. ( Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T, 2007) |
| "The standard management of rectal cancer continues to be defined by the results of randomized, clinical trials exploring the optimal timing and use of adjuvant chemotherapy and radiation therapy in relation to surgery." | 1.34 | Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. ( Chao, M; Fong, A; Gibbs, P; Jones, IT; Kipp, D; Lim, L; McLaughlin, S; Millar, JL; Rezo, A; Shapiro, J, 2007) |
| "Treatment with capecitabine and erlotinib in gemcitabine-refractory patients was associated with an overall objective radiologic response rate of 10% and a median survival duration of 6." | 1.34 | Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. ( Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX, 2007) |
| "In one matched gastric cancer sample pair, the serial analysis of gene expression (SAGE) experiment was conducted to compare the gene expression profiles between cancerous and adjacent tissues." | 1.34 | Upregulated expression of S100A6 in human gastric cancer. ( Dong, H; Gao, HJ; Han, JS; Jiang, CL; Wu, JX; Wu, YL; Xiao, HS; Yang, YQ; Zhang, LJ; Zhang, QH; Zhu, ZG, 2007) |
| " The adverse effect included grade 3 or grade 4 leukopenia in 12." | 1.34 | [Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers]. ( Bai, P; Li, XG; Ma, SK; Wu, LY; Zhang, R; Zhang, WH, 2007) |
| " 60Co gamma-irradiation or 6MVX-ray with conventional fraction were used for radiotherapy with a total volume dosage of 55-70 Gy." | 1.34 | [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus]. ( Han, JQ; Li, XQ; Liang, RX; Liu, Q; Qu, FS; Sun, YH; Yan, TX, 2007) |
| "Capecitabine has shown efficacy in treatment of metastatic pancreatic cancer." | 1.34 | Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? ( Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A, 2007) |
| " The dosage of FOLFOX 4 was reduced after three courses due to neutropenia and diarrhea." | 1.34 | [A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy]. ( Fujisawa, M; Ishibiki, Y; Ishiyama, S; Kitabatake, T; Kojima, K; Machida, M; Nakayama, Y; Nitta, S; Ono, S; Shinjou, K; Urao, M, 2007) |
| "Surgery was performed for sigmoid colon cancer on September 29, 2004." | 1.34 | [A patient with recurrent sigmoid colon cancer in whom pleural effusion and ascites resolved after FOLFOX 4 therapy]. ( Akamatsu, M; Katamoto, T; Matsubara, S; Nakata, W; Ohata, K; Ohmae, T; Tsuji, Y, 2007) |
| "We report two cases of advanced low rectal cancer, with preoperative chemo-radiation therapy leading to a complete histological response." | 1.34 | [Two cases of advanced low rectal cancer, preoperative chemo-radiation therapy leading to complete histological response]. ( Fujita, H; Jida, M; Kubo, M; Maeda, H; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Waki, N, 2007) |
| "AI of human gastric cancer xenografts in nude mice was significantly increased to (9." | 1.34 | [Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA]. ( Gu, Y; Li, T; Tang, LD; Yang, JK; You, SF; Zhao, AG; Zhao, HL, 2007) |
| "For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life." | 1.34 | Inoperable pancreatic cancer: standard of care. ( Benson, AB; Small, W; Wahl, AO; Wisinski, KB, 2007) |
| "The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)." | 1.33 | Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005) |
| "3%), no toxic death, and only one grade 3 neutropenia (4." | 1.33 | Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients. ( Artru, P; Atlan, D; Bouché, O; Dahan, L; Lledo, G; Mitry, E; Nguyen, T; Richard, K; Ries, P; Rougier, P; Seitz, JF, 2005) |
| "Most patients (95%) had histology of squamous cell carcinoma." | 1.33 | Radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan. ( Inoue, T; Kawaguchi, A; Kodaira, T; Maebayashi, K; Mitsuhashi, N; Nakamura, K; Ogawa, K; Shinoda, A; Teshima, T; Toita, T; Uno, T, 2005) |
| " 5-FU serum concentrations were higher at night time and the peak concentration of 5-FU was obtained at 3 a." | 1.33 | [Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005) |
| "Patients with rectal cancer treated by preoperative chemoradiation showed a surprisingly low rate of micrometastasis detection (7%), even in high-risk patients (T3 and T4 tumors)." | 1.33 | Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. ( Coelho Siqueira, SA; Gama-Rodrigues, JJ; Habr-Gama, A; Kiss, DR; Nishida Arazawa, ST; Perez, RO; Rawet, V, 2005) |
| " After three cycles of chemotherapy over a 10-week period, the patient's dosage requirements returned to her baseline level (before treatment with 5-fluorouracil and leucovorin had started)." | 1.33 | Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy. ( Davis, DA; Fugate, SE, 2005) |
| "Complete response (no residual tumour, TRG 1) was seen in 7% of the patients (3/44) and total or major regression (TRG 1-3) in 73% of the patients (32/44) treated with 50-Gy chemoradiation." | 1.33 | Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. ( Jantunen, I; Juhola, M; Kairaluoma, M; Kellokumpu, I; Vironen, J, 2005) |
| "An HCT-8 colorectal cancer cell line was used and a high concentration of 5-Fluorouracid (5-FU) was introduced at the beginning to induce drug resistance, then the concentration of 5-FU was increased in gradients." | 1.33 | Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line. ( Bu, LM; Han, Y; Ji, X; Liu, CY; Wang, ZH, 2005) |
| "Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate." | 1.33 | Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. ( Abbruzzese, JL; Crane, CH; Delclos, ME; Evans, DB; Ho, L; Tamm, EP; Wolff, RA; Wong, AA; Xiong, HQ, 2005) |
| "5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells." | 1.33 | Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005) |
| "Male breast cancer is very rare, especially inflammatory breast cancer, which is an aggressive, rapidly proliferating manifestation of primary breast carcinoma." | 1.33 | Inflammatory breast cancer in a male. ( Choueiri, MB; El Saghir, NS; El-Hajj, II; Otrock, ZK; Tawil, AN, 2005) |
| "Intersphincteric resection of low rectal tumors is a surgical technique extending rectal resection into the intersphincteric space." | 1.33 | Technique and long-term results of intersphincteric resection for low rectal cancer. ( Feil, W; Hölbling, N; Holzer, B; Novi, G; Renner, K; Rosen, HR; Schiessel, R; Urban, M, 2005) |
| "We tested the hypothesis that rectal tumors are most responsive to neoadjuvant therapy if they possess p53 and/or caspase 8 activity." | 1.33 | Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. ( Coppola, D; Kelley, ST; Marcet, J; Yeatman, T, 2005) |
| "The use of chemoradiotherapy for pancreatic cancer has been advocated for its potential ability to downstage locally advanced tumors." | 1.33 | Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. ( Adhoute, X; Béllannée, G; Brunet, R; Collet, D; Laurent, C; Masson, B; Rault, A; Sa Cunha, A; Vendrely, V, 2005) |
| "Pseudomembranous colitis is frequently associated with antibiotics and more rarely with chemotherapeutic agents such as 5-fluorouracil." | 1.33 | Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. ( Aranda Aguilar, E; de la Haba Rodríguez, JR; Gómez España, MA; Méndez Vidal, MJ; Morales Chamorro, R; Rubio Pérez, MJ; Serrano Blanch, R, 2005) |
| "Twenty-two patients with localized esophageal cancer suitable for curative chemoradiation therapy and 24 patients suitable for palliative therapy were enrolled." | 1.33 | Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. ( Burmeister, BH; Burmeister, EA; Gotley, DC; Harvey, JA; Mark Smithers, B; Thomas, J; Thomson, DB; Walpole, ET, 2005) |
| "The role of second-line chemotherapy in gastric cancer is not yet established." | 1.33 | Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. ( Köster, W; Müller, C; Stahl, M; Wilke, H, 2005) |
| "HDRBT is safe and beneficial for local control in the radical treatment of patients with esophageal cancer." | 1.33 | The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. ( Burtin, P; Corns, R; David, M; Devic, S; Evans, M; Faria, S; Mayrand, S; Parent, J; Szego, P; Vuong, T, 2005) |
| "Capecitabine is an oral prodrug to 5-fluorouracil (5-FU)." | 1.33 | Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. ( Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN, 2005) |
| "To investigate the effect and feasibility of concurrent radiation and chemotherapy combined with endorectal brachytherapy in T3 rectal cancer with complete pathologic remission as end point." | 1.33 | Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. ( Bisgaard, C; Hansen, JW; Jakobsen, A; Lindebjerg, J; Mortensen, JP; Rafaelsen, SR, 2006) |
| "A 54-year-old woman who had ascending colon cancer with multiple liver and lung metastases underwent rt." | 1.33 | [A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11]. ( Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2005) |
| "She was diagnosed with advanced cecal cancer with simultaneous multiple liver metastases." | 1.33 | [A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy]. ( Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y, 2005) |
| "Patients who had rectal cancer with a distal margin within 6 cm of the anal verge had the anus included in the field of radiotherapy (Group A, n = 26)." | 1.33 | Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency. ( Chao, MW; Gibbs, P; Hiscock, R; Lim, JF; Tjandra, JJ, 2006) |
| " As adverse effects of the following systemic chemotherapy, three patients had grade 3 anemia and one had grade 3 leukopenia." | 1.33 | [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination]. ( Bamba, T; Hanyu, T; Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Makino, S; Ohashi, M; Sakamoto, K; Tanabe, T; Yajima, K, 2005) |
| " We dosed 6 cycles of FEC chemotherapy (CPA 800 mg, EPI 80 mg, 5-FU 750 mg/body x 1 cycle)." | 1.33 | [A case of breast cancer detected by MRI mammography after Hollywood syndrome]. ( Amano, S; Enomoto, K; Kitajima, A; Matsuo, S; Negishi, N; Nemoto, N; Oinuma, T; Sakurai, K, 2005) |
| "Twenty pretreatment biopsy samples from rectal cancer patients and their paired, post-CRT surgical specimens (n = 17) were analyzed." | 1.33 | Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. ( El-Hajjar, D; Geradts, J; Groth, J; Iyer, R; Javle, M; Lawrence, D; Watwe, V, 2005) |
| "The type of genomic instability could influence the prognosis of CRC, in particular in stages II and III." | 1.33 | Microsatellite instability and colorectal cancer prognosis. ( Barana, D; Benatti, P; Di Gregorio, C; Gafà, R; Guerzoni, L; Lanza, G; Losi, L; Maestri, I; Maffei, S; Marino, M; Menigatti, M; Oliani, C; Pedroni, M; Ponti, G; Ponz de Leon, M; Roncari, B; Roncucci, L; Rossi, G; Santini, A; Scarselli, A, 2005) |
| "Fifty-two patients with resectable esophageal cancers (cT2-4, Nx, and M0) received neoadjuvant radiochemotherapy (cisplatin, 5-5-fluorouracil, 36 Gy) followed by transthoracic en bloc esophagectomy." | 1.33 | High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. ( Baldus, SE; Bollschweiler, E; Brabender, J; Dienes, HP; Hoelscher, AH; Ling, FC; Metzger, R; Moenig, S; Mueller, RP; Neiss, S; Schneider, PM; Warnecke-Eberz, U; Xi, H, 2005) |
| "Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p." | 1.33 | Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. ( Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM, 2005) |
| "To evaluate the treatment outcome of radiotherapy combined with cis-diammine-glycolatoplatinum (nedaplatin) plus 5-fluorouracil (5-FU) for esophageal cancer." | 1.33 | Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study. ( Igaki, H; Nakagawa, K; Nakamura, N; Ohtomo, K; Sasano, N; Shiraishi, K; Tago, M; Yamashita, H, 2006) |
| "Patients with bilobar colorectal cancer metastases to the liver present a unique problem in terms of resection." | 1.33 | Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved. ( Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL, 2006) |
| "Progressive respiratory failure developed in a 68 year-old female who was treated with single-agent oxaliplatin for colorectal cancer." | 1.33 | Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. ( Colomer, R; Fabregat, MB; Merino, BQ; Puig, J; Soy, E; Yagüe, XH, 2005) |
| "This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and its application of pharmacogenetic analysis to multiple genes in each drug action pathway as a means of developing a more accurate and consistent risk prediction model." | 1.33 | Pharmacogenetics in esophageal cancer. ( Ajani, JA; Chiang, SS; Lu, C; Wu, X, 2005) |
| "One hundred fifteen patients with rectal cancer were treated with oral 5-fluorouracil or Tegafur with preoperative radiotherapy, surgery, and intraoperative electron beam radiation therapy to identify potential pre- and on-treatment characteristics that might be of prognostic value for disease outcome." | 1.33 | Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. ( Alvarez, E; Calvo, FA; Cortés, J; Del Valle, E; Díaz-González, JA; García-Sabrido, JL; Gómez-Espí, M; Muñoz-Jiménez, F, 2006) |
| "5-Fluorouracil is an antineoplastic antimetabolite responsible for a variety of cutaneous reactions." | 1.33 | Chronic cutaneous lupus flare induced by systemic 5-fluorouracil. ( Bessis, D; Guillot, B; Kluger, N, 2006) |
| "To describe oncocytic change in rectal cancers that have been treated with chemoradiation before surgery." | 1.33 | Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy. ( Chetty, R; Rouzbahman, M; Serra, S, 2006) |
| "We report here the case of a coma with a favorable outcome following 5FU chemotherapy." | 1.33 | [Coma following chemotherapy: is 5FU implicated? Discussion about on case-report]. ( Heluwaert, F; Hilleret, MN; Martin, C; Martin, D; Santre, C, 2006) |
| "Stage II-III rectal cancer patients received 2 cycles of bolus 5-FU (425 mg/m2) and leucovorin (LV) (20 mg/m2) on days 1-5 q3w followed by oral capecitabine (800 mg/m2 bid) continuously during pelvic radiotherapy (total 50." | 1.33 | Capecitabine chemoradiation for rectal cancer after curative surgery. ( Bajetta, E; Beretta, E; Buzzoni, R; Di Bartolomeo, M; Dognini, G; Ferrario, E; Mancin, M; Mariani, L; Valvo, F, 2006) |
| "Cyclin D1 ASODN could increase the chemosensitivity to 5-FU, MTX, CDDP in cells." | 1.33 | Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells. ( Chen, JH; Han, GX; Shuai, XM; Wang, GB, 2006) |
| "Adjuvant CRT for gastric cancer, even with conformal RT, is associated with significant toxicity." | 1.33 | Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. ( Brierley, J; Cummings, B; Kassam, Z; Kim, J; Knox, JJ; Lockwood, G; Moore, M; O'brien, C; Oza, A; Ringash, J; Siu, L; Swallow, C; Wong, R, 2006) |
| "The clinical diagnosis of multiple pyogenic granulomas was confirmed by histological examination." | 1.33 | Multiple periungual pyogenic granulomas following systemic 5-fluorouracil. ( Cooray, P; Curr, N; Gin, D; Murugasu, A; Saunders, H; Schwarz, M, 2006) |
| "Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity." | 1.33 | Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006) |
| "Seven patients with gastric cancer were treated with IMRT." | 1.33 | Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. ( Chmura, SJ; Farrey, K; Garofalo, MC; Heimann, R; Jani, AB; Milano, MT; Rash, C, 2006) |
| "Eligible patients had prostate cancer with clinical evidence of invasion through the prostatic capsule or into the seminal vesicles without evidence of nodal or distant metastasis." | 1.33 | Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. ( Crawford, ED; Faulkner, J; Noble, MJ; O'Rourke, TJ; Quick, DP; Smalley, SR; Stephens, RL; Swanson, GP; Thompson, IM; Weiss, GR, 2006) |
| "Twenty-five chemonaive patients with AGC have been treated with FOLFIRI regimen consisting of irinotecan 180 mg/m(2) over 30 min on day 1 combined with leucovorin 200 mg/m(2) over 2 h followed by 5-fluorouracil 400 mg/m(2) as bolus and 600 mg/m(2) as a 22-hour infusion on day 1 and 2." | 1.33 | Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. ( Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U, 2006) |
| "HCT116 colon cancer cells were treated with docetaxel, flavopiridol, and 5-FU in several different administrative schedules in vitro, either sequentially or simultaneously." | 1.33 | Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. ( Becerra, CR; Frenkel, EP; Fu, YC; Guo, J; Tripathy, D; Verma, UN; Zhou, AW, 2006) |
| "Human pancreatic cancer cells HPAF-II and Capan-1, and endothelial cells HMEC-1 and HUVEC were used in this study." | 1.33 | Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. ( Campbell, RB; Kalra, AV, 2006) |
| "Although patients with locally advanced pancreatic cancer (LAPC) have an extremely poor prognosis, they are a heterogeneous group." | 1.33 | Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. ( Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA, 2006) |
| " After that his general condition recovered, and two cycles of neoadjuvant chemotherapy (NAC) by irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) therapy were performed on an outpatient basis." | 1.33 | [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)]. ( Fukada, T; Hasegawa, A; Hashimoto, R; Hayashi, T; Kametaka, H; Kawano, H; Koyama, T; Seike, K; Tanaka, H; Yasuno, K, 2006) |
| "Forty-two patients with invasive breast carcinoma received 4 cycles of anthracycline based neoadjuvant chemotherapy." | 1.33 | Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. ( Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Manavoglu, O; Saraydaroglu, O; Ulukaya, EE, 2006) |
| "As leukopenia was seen after the first cycle, the administration doses were reduced and GTX has been continued for a total 13 cycles." | 1.33 | [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. ( Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H, 2006) |
| "An advanced colon cancer of the cecum was found with a colonoscopy." | 1.33 | [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. ( Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Miyake, Y; Oshima, K; Oshima, S; Yamamoto, H, 2006) |
| " Resection of liver metastases from SBA combined with neoadjuvant and adjuvant chemotherapy can result in extended disease-free survival and should undergo further investigation." | 1.33 | Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report. ( Eigenbrod, T; Klebl, F; Kullmann, F, 2006) |
| "In patients with locally advanced rectal cancer located 3-6 cm from anal verge who are traditionally treated with abdominoperineal resection, preservation of anal sphincter after preoperative chemoradiation therapy plus complete rectal excision with coloanal anastomosis is feasible and is associated with acceptable morbidity and no mortality." | 1.32 | Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis. ( Fernández, R; Gutiérrez De La Barrera, M; Hernández-Pacheco, F; Labastida, S; Luna-Pérez, P; Rodríguez-Ramírez, S, 2003) |
| "The prognosis and QOL of unresectable pancreatic cancer are very poor." | 1.32 | [A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1]. ( Endo, W; Fujito, T; Goda, F; Hojo, S; Maeura, Y; Matsuyama, J; Yamazaki, K; Yano, Y, 2003) |
| "A remission of lymph node metastasis was accurately shown by rES in 17/19 cases (90%) and by CT in 10/12 cases (83%)." | 1.32 | [Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?]. ( Becker, H; Füzesi, L; Ghadimi, BM; Jakob, C; Langer, C; Liersch, T; Markus, PM; Müller, D; Siemer, A, 2003) |
| "Adenocarcinoma of the female urethral diverticulum is rare and has been treated by surgery and/or radiation." | 1.32 | Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy. ( Awakura, Y; Fukuyama, T; Itoh, N; Maeno, A; Nonomura, M, 2003) |
| "Human esophageal cancer cells NEC and human lung adenocarcinoma cells GLC were cultured and then inoculated into the wells." | 1.32 | [The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells]. ( Huang, J; Jiao, SC; Lu, SX; Sun, Y, 2003) |
| "Drugs pharmacokinetic control is a usual practice in case of flat continuous infusions." | 1.32 | [Modeling 5-FU clearance during a chronomodulated infusion]. ( Chevalier, V; Chevrier, R; Chollet, P; Cure, H; Kwiatkowski, F; Richard, D, 2003) |
| "These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer." | 1.32 | Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003) |
| " At both institutions, concurrent chemotherapy consisted of a continuous infusion of 5-fluorouracil (5-FU) at a dosage of 1500 mg/m(2)/week." | 1.32 | The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. ( Birnbaum, EH; Chandra, A; Crane, CH; Delclos, ME; Feig, BW; Fleshman, JW; Janjan, NA; Kodner, IJ; Lin, EH; Lockett, MA; Myerson, RJ; Phan, T; Picus, J; Read, TE; Singh, AK; Skibber, JM; Thames, HD, 2003) |
| " Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)." | 1.32 | [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003) |
| " Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation." | 1.32 | [A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy]. ( Futamura, N; Matsutomo, M; Sakamoto, K; Tateyama, K; Yasumura, M, 2003) |
| "3R allele in colorectal cancer was subdivided into around half by the SNP, indicating its commonness among Japanese." | 1.32 | Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. ( Kawakami, K; Watanabe, G, 2003) |
| "Case 1 A 40-year-old female with gastric cancer located in the MULE area underwent total gastrectomy with D3 lymph node dissection on June 2, 1989." | 1.32 | [Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection]. ( Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T, 2003) |
| "We report a case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP." | 1.32 | [A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP]. ( Akiyama, N; Arai, F; Funakoshi, K; Inayoshi, J; Kato, T; Motoyama, H; Tasaki, A, 2003) |
| " After the operation, weekly bolus of 5-fluorouracil combined with levofolinate was carried out." | 1.32 | [A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil]. ( Inoue, M; Jingu, K; Nakajima, Y; Ochiai, T, 2004) |
| "Endoscope and CT scan revealed type 3 gastric cancer with paraaortic lymph nodal metastasis." | 1.32 | [A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU]. ( Fujita, K; Gotoh, M; Hirata, I; Hongo, H; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H, 2004) |
| "Under a diagnosis of advanced ileocecal colon cancer with metastases to Virchow's and the paraaortic lymph nodes, ileocecal resection was performed." | 1.32 | [A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy]. ( Kathou, T; Maruyama, H; Mio, H; Sekiya, M; Yamada, T, 2004) |
| "A 58-year-old man who had colon cancer with liver and multiple lung metastases underwent ileocecal resection on May 10, 2002." | 1.32 | [A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11]. ( Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T, 2004) |
| " He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11." | 1.32 | [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. ( Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004) |
| "Rare reports of intestinal obstruction have been confined to the stiff plastic and stainless-steel stents." | 1.32 | A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex). ( Ho, HS; Ong, HS, 2004) |
| "We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin." | 1.32 | [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy]. ( Aoki, T; Ichimiya, H; Kato, K; Katsumata, K; Okada, K; Wakana, Y, 2004) |
| "Human colon cancer cells were implanted s." | 1.32 | Comparison between triple therapy with octreotide, galanin and serotonin, 5-fluorouracil/leucovorin, and sequential treatment with both, on human colon cancer. ( El-Salhy, M, 2004) |
| "Capecitabine was given at 1,600 mg/m(2)/day in two divided doses, 5 days per week, concurrently with radiotherapy." | 1.32 | Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. ( Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V, 2004) |
| "Sigmoidectomy was performed for sigmoid colon cancer in 1991." | 1.32 | [A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy]. ( Beppu, T; Doi, K; Egami, H; Ishiko, T; Morinaga, H; Nakagawa, M; Sugiyama, S; Tanaka, H; Yamane, T, 2004) |
| "For synchronous liver metastases from rectal cancer, after extirpation of the primary lesion, a transcatheter arterial embolization was postoperatively performed 3 times at 6-month intervals." | 1.32 | [Long-term control of rectal liver metastases by hepatic arterial infusion chemotherapy of 5-fluorouracil and l-leucovorin--a case report]. ( Ishimaru, S; Kanayama, T, 2004) |
| "Mitomycin and cisplatin were highly effective to prevent peritoneal carcinomatosis (direct application immediately after tumor cell transfer - 1 (st) treatment group)." | 1.32 | [Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis]. ( Fenske, A; Hribaschek, A; Krüger, S; Lippert, H; Meyer, F; Pross, M; Ridwelski, K, 2004) |
| "Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy." | 1.32 | Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. ( Campos, FG; Gama-Rodrigues, J; Habr-Gama, A; Kiss, DR; Nadalin, W; Perez, RO; Ribeiro, U; Sabbaga, J; Silva e Sousa, AH, 2004) |
| "The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria)." | 1.32 | [Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics]. ( Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S, 2004) |
| "After surgical resection of colon cancer, he suffered a multiple liver metastasis." | 1.32 | [A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery]. ( Hayashi, T; Ishiwatari, H; Kato, J; Kogawa, T; Miyanishi, K; Niitsu, Y; Oku, T; Takada, K; Takahashi, M; Takanashi, K; Takayama, T, 2004) |
| "Human HCT116 colon cancer cells were stably transfected with the sense or antisense FPGS cDNA or blank (control)." | 1.32 | Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. ( Croxford, R; Kim, YI; Lucock, M; Moskovitz, DN; Novakovic, P; Smirnakis, F; Sohn, KJ; Yates, Z, 2004) |
| "We performed radio-frequency ablation (RFA) therapy combined with intra-arterial chemotherapy for a 71-year old female gastric cancer patient with liver metastasis." | 1.32 | [A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy]. ( Imaizumi, H; Kamei, K; Kosaka, T; Nakano, Y; Takashima, S; Ueno, K; Usami, K, 2004) |
| "Twenty patients with advanced gastric cancer received biweekly regimen of CF/5-FU/PTX (200 mg/m(2) of CF, intravenous infusion for 2 h, day 1; 500 mg/m(2) of 5-FU, intravenous injection, day 1; 1 500 mg/m(2) of 5-FU, intravenous infusion for 46 h, day 1, 2; 90 mg/m(2) of PTX, intravenous infusion for 3 h,day 1)." | 1.32 | [Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer]. ( Feng, JF; Lu, JW; Sun, XF, 2004) |
| "Surgical specimens were assessed for rectal cancer regression grade." | 1.32 | Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. ( Cunningham, C; Dodds, E; George, BD; Jones, AC; Mortensen, NJ; Warren, BF; Wheeler, JM, 2004) |
| "Drug resistance and toxic side effects are major limiting factors in the clinical use of antineoplastic chemotherapy." | 1.31 | Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. ( Aulmann, M; Dihlmann, S; Eisold, S; Linnebacher, M; Ridder, R; Ryschich, E; Schlehofer, JR; Schmidt, J; von Knebel Doeberitz, M, 2002) |
| "Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%." | 1.31 | A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. ( Cheeseman, SL; Chester, JD; Dent, JT; Joel, SP; Richards, FJ; Seymour, MT; Wilson, G, 2002) |
| "Capecitabine (Xeloda) is a new orally administered fluoropyrimidine carbamate that was rationally designed to exert its effect by tumor-selective activation." | 1.31 | Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. ( Cho, MJ; Kim, JS; Song, KS; Yoon, WH, 2002) |
| "This report shows a case of advanced gastric cancer that responded to low-dose 5-FU plus CDDP." | 1.31 | [A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP]. ( Baba, H; Endo, K; Ikeda, Y; Ishio, T; Kawamoto, K; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M, 2002) |
| "We report a case of inoperable gastric cancer with multiple liver metastases, which responded significantly to the short-term administration of TS-1 following intravenous FMP therapy." | 1.31 | [Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization]. ( Chinzei, T; Okada, Y; Tasaka, K; Tomofuji, Y, 2002) |
| "We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)." | 1.31 | [A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002) |
| "These results suggest that colon cancer cells with microsatellite instability are more sensitive to 5-FU, whereas more resistant to CDDP." | 1.31 | Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. ( Chen, XX; Huang, Q; Lai, MD; Zhang, YL, 2002) |
| " We examined the response of three human colon tumors to TRAIL alone and in combination with chemotherapy, using SCID mice engrafted with intact patient surgical specimens." | 1.31 | Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. ( Hylander, BL; Naka, T; Repasky, EA; Rustum, YM; Sugamura, K; Widmer, MB, 2002) |
| "Six patients with gastric cancer, stage IIIA to IV, received intraabdominal cisplatin (CDDP) at laporotomy." | 1.31 | [Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion]. ( Kagawa, R; Nakayama, N; Sakata, S; Tada, M; Yamaguchi, T, 2002) |
| " Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co." | 1.31 | [A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin]. ( Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002) |
| "Compared with adenocarcinoma, squamous cell carcinoma might be a favorable target for 5-FU-based chemotherapy in the treatment of nonsmall-cell lung cancer." | 1.31 | Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues. ( Koga, T; Ninomiya, S; Takeo, S; Yano, T, 2002) |
| "Ovarian metastasis is frequent." | 1.31 | Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. ( Blanchot, J; Boucher, E; Corbinais, S; Garin, L; Le Guilcher, P; Raoul, JL, 2002) |
| "Twenty-four patients with gastric cancers who underwent the intraoperative systemic chemotherapy were taken as controls." | 1.31 | [Clinical comparison between intraoperative local arterial infusion chemotherapy and systemic venous chemotherapy of gastric cancer]. ( Chen, D; Lai, Y; Peng, B; Xiao, Q; Zhang, S, 2001) |
| "112 cases of fresh human gastric cancer samples were obtained for drug sensitivity testing using MTT." | 1.31 | [Study on the chemosensitivity test of human gastric cancer using the MTT assay]. ( Chen, J; Chen, Z; Hu, J; Mao, Y; Yan, L; Zou, L, 2001) |
| "5-Fluorouracil (5-FU) is a drug of standard use in chemotherapy of colon carcinoma." | 1.31 | Role for alpha1,2-fucosyltransferase and histo-blood group antigen H type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil. ( Cordel, S; Goupille, C; Hallouin, F; Le Pendu, J; Meflah, K, 2000) |
| " Although various dosage regimens of FP therapy have been investigated, there has been a certain limit to the response rate achieved by this therapy, and new protocols have been explored." | 1.31 | [Two cases of recurrent gastric cancer for which combination chemotherapy with pirarubicin, cis-platinum and 5-fluorouracil were markedly effective]. ( Ashizawa, T; Katsumata, K; Koyanagi, Y; Majima, T; Mori, M; Murohashi, T; Nagashima, K; Sumi, T; Takahashi, S; Yamamoto, K; Yamashita, S, 2000) |
| "We report a case of unresectable rectal cancer in a 53-year-old male treated with chemoradiation." | 1.31 | [Long-term complete response in a case of unresectable rectal cancer following chemoradiation]. ( Musha, N; Oka, K; Saito, H; Sando, N; Sasaki, M; Setu, M; Setu, Y; Sunami, E, 2000) |
| "Preoperative chemoradiation for pancreatic cancer is associated with low rates of hepatic toxicity and biliary stent-related complications." | 1.31 | Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. ( Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA, 2000) |
| "It is possible to cure oesophageal cancer with chemo-radiotherapy and selective oesophagectomy, and achieve organ preservation in the majority of long term survivors." | 1.31 | Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation. ( Lim, JT; Wilson, KS, 2000) |
| "5-Fluorouracil (5-FU) was given as a bolus (500-1000 mg/m2/day) during the first and last weeks of RT in 22 patients, whereas continuous 5-FU (225 mg/m2/day) was given to 3 patients." | 1.31 | Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. ( Latona, C; Paulino, AC, 2000) |
| "5-fluorouracil (5-FU) was given 200 mg/day for 26 days orally." | 1.31 | [A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy]. ( Nashimoto, A; Tanaka, O; Yabusaki, H, 2000) |
| "Data on 45 patients with colorectal cancer were analyzed." | 1.31 | Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. ( Hinoshita, E; Kinukawa, N; Kuwano, M; Maehara, Y; Sugimachi, K; Taguchi, K; Tsuneyoshi, M; Uchiumi, T, 2000) |
| "Lymph node metastasis was not present." | 1.31 | [Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report]. ( Iesato, H; Morishita, Y; Nakagami, K; Ohwada, S; Ohya, T; Sasaki, T; Sugitani, K; Takahashi, T; Yokomori, T, 2000) |
| "In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr." | 1.31 | Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. ( Kim, GE; Kim, SN; Kim, SW; Park, TK; Suh, CO, 2000) |
| "We report a case of advanced rectal cancer accompanied by unresectable liver metastasis in which remission has been achieved for 7 years." | 1.31 | [A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective]. ( Baba, H; Kikunaga, H; Matsudo, A; Miura, H; Morisue, A; Nakai, H; Osakabe, Y; Sotome, K; Takao, M, 2000) |
| "Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)." | 1.31 | Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000) |
| "The oestrogen receptor positive breast cancer cell lines (MCF-7, T47D) demonstrated an increased level of HSP 27 and 70 expression compared with oestrogen receptor negative cell lines (BT20, HBL100)." | 1.31 | Heat shock protein expression in human tumours grown in severe combined immunodeficient mice. ( Katoh, M; Koninkx, J; Schumacher, U, 2000) |
| "A 67-year-old female with rectal cancer and multiple liver metastases underwent low anterior resection by total mesorectal excision (TME), cholecystectomy and hepatic arterial cannulation in June 1995." | 1.31 | [Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)]. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2001) |
| "Two patients were diagnosed with large rectal tumors and localized prostate cancer." | 1.31 | External beam radiotherapy for synchronous rectal and prostatic tumors. ( Kapp, DS; King, C; Siu, W; Terris, MK; Wren, SM, 2001) |
| "Preoperative chemoradiotherapy for gastric cancer can be delivered safely and is well tolerated." | 1.31 | A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. ( Ajani, JA; Feig, BW; Janjan, N; Lowy, AM; Mansfield, PF; Pisters, PW; Rich, TA, 2001) |
| " This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues." | 1.31 | Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. ( Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001) |
| " Because no data are available for patients with severe renal failure, the pharmacokinetic parameters of 5-FU and its catabolites were determined for a patient with colorectal carcinoma and end-stage renal disease on maintenance hemodialysis therapy." | 1.31 | Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. ( Bommer, J; Göggelmann, C; Hull, WE; Rengelshausen, J; Schwenger, V; Walter-Sack, I, 2002) |
| " We report three cases of advanced gastric cancer treated using TS-1 in combination with a low-dose of cisplatinum (CDDP) that well responded." | 1.31 | [Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum]. ( Gomi, T; Kanaya, S; Katayama, T; Momoi, H; Ohtoshi, M; Tamaki, N; Wada, Y, 2002) |
| "Human colon cancer cell lines LS174T and LiM6 were plated on plastic, on hepatocyte-derived ECM or on stromal ECM and in the presence of the antimetabolite 5-fluorouracil (5-FU)." | 1.31 | Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. ( Brill, S; Halpern, Z; Khaikin, M; Kouniavsky, G; Papa, M; Zippel, D; Zvibel, I, 2002) |
| "Ten patients with invasive distal rectal cancer (six T2, four T3) were treated with preoperative radiotherapy (3600-5040 cGy) with or without 5-fluorouracil based chemotherapy." | 1.31 | Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers. ( Cohen, AM; Guillem, JG; Minsky, BD; Paty, PB; Quan, SH; Ruo, L, 2002) |
| "A 59-year-old man with colon cancer was diagnosed as having a local recurrence of the disease, forming a huge intra pelvic tumor, accompanied by pulmonary metastasis 16 months after hemicolectomy." | 1.30 | [A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin]. ( Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Tabata, H; Takasaki, S, 1997) |
| "Advanced gastric cancer was found in 12 cases (operation performed in 9 cases and 7 cases resectable) and recurrent in 5 cases." | 1.30 | [Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer]. ( Katsumata, K; Kohno, M; Koyanagi, Y; Moriwaki, R; Ohno, M; Shibata, K; Tadatomo, H; Yamamoto, K; Yamashita, S, 1997) |
| "We reported two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil (5-FU), cisplatin (CDDP) and cytarabine (Ara-C), 5-FU (300-350 mg/body) was given by continuous intravenous infusion." | 1.30 | [Two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil, cisplatin and cytarabine]. ( Hizawa, Y; Itoh, J; Munakata, A; Saitoh, S; Satoh, T; Tamura, Y; Tsushima, K; Yamada, Y, 1997) |
| "Cranial dystonia is usually idiopathic but may be caused by trauma or medications." | 1.30 | Focal dystonia after chemotherapy: a case series. ( Brashear, A; Siemers, E, 1997) |
| " The mean total dosage was 6." | 1.30 | [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status." | 1.30 | Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. ( Bernard, SA; Detterbeck, FC; Egan, TM; Jones, DR; Parker, LA; Tepper, JE, 1997) |
| "Eighty-eight patients with cancer of the esophagus ineligible for surgery were entered in the study between 1986 and 1993." | 1.30 | Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients. ( Auperin, A; Dhermain, F; Ducreux, M; Elias, D; Girinsky, T; Kac, J; Marsiglia, H; Randrianarivelo, H; Rougier, P, 1997) |
| "About one-third of patients with gastric cancer are unresectable at the time of diagnosis." | 1.30 | Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. ( Cho, JY; Chung, HC; Kim, BS; Kim, CB; Kim, JH; Min, JS; Noh, SH; Park, JO; Rha, SY; Roh, JK; You, NC, 1997) |
| "This suggested that the therapy for a breast cancer patient with distant metastasis must be considered according to the region of recurrence." | 1.30 | [A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer]. ( Ayabe, H; Hara, S; Hashizume, S; Itoyanagi, N; Oka, T; Shinguu, H; Tagawa, Y; Tooyama, H; Tou, K; Tsuji, H; Yamamoto, S; Yamazumi, K, 1997) |
| "A 57-year-old man suffering from gastric cancer with esophageal invasion and liver and paraaortic lymph nodes metastases was treated with continuous 5-FU injection and intra-hepatic arterial infusion of low-dose cisplatin following non-curative surgery." | 1.30 | [A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin]. ( Oka, M; Ueno, T, 1997) |
| "Mitomycin C suppository was significantly less toxic compared with intravenous delivery, and higher rectal tissue concentrations were observed from 10 to 30 minutes (P < 0." | 1.30 | Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. ( Ackerman, D; Galandiuk, S; Hofmeister, A; LaRocca, R; Lewis, RK; Myers, SR; Paris, KJ; Pokorny, RM; Wrightson, WR, 1997) |
| "We reported a case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate (MTX) and 5-fluorouracil (5-FU) sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil." | 1.30 | [A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil]. ( Kamei, M; Kawabata, H; Matsuda, K; Nishioka, M; Sasahara, K; Uchida, Y, 1998) |
| "Twenty-nine patients with advanced colorectal cancer were divided into four groups, 3 days, 5 days, 7 days, and 10 days." | 1.30 | [Enhanced induction of apoptosis of human colorectal cancer cells after preoperative treatment with 5-fluorouracil its relationship to DNA ploidy pattern]. ( Kaibara, N; Kurayoshi, K; Makino, M; Taniguchi, T; Yamane, N, 1998) |
| "An advanced gastric cancer patient with T3N1M0 successfully underwent a curatively total gastrectomy combined with distal pancreatectomy and lymphnode dissection following ELF-P combined chemotherapy." | 1.30 | [Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case]. ( Kamiyama, H; Kawashima, K; Koike, N; Morishita, Y; Ogawa, T; Ohwada, S; Sato, Y; Takeyoshi, I, 1998) |
| "Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread." | 1.30 | [How I treat colorectal cancer. I. Prevention and adjuvant treatment]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "Then, 23 cases with local relapsed prostate cancer and two cases with endocrine-resistant prostate cancer received chemotherapy." | 1.30 | [Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer]. ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1998) |
| "The patient was diagnosed to have gastric cancer (T3 N3 M0 P3, Stage IV b)." | 1.30 | [Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival]. ( Horimi, T; Morita, S; Takahashi, I; Takamatsu, M; Takasaki, M; Tsuji, A, 1998) |
| " These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5." | 1.30 | Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ( Brown, N; Covington, W; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Pazdur, R, 1998) |
| "For advanced pancreatic cancer, there is no typical chemotherapy regimen non single chemotherapeutic agent." | 1.30 | [Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis]. ( Kobayashi, A; Yamaguchi, M, 1998) |
| "This study included seven cases of pancreatic cancer considered unresectable." | 1.30 | [Does neoadjuvant radiochemotherapy augment the resectability of pancreatic cancers?]. ( Alexandre, M; Bousquet, J; Chipponi, J; Cure, H; Pezet, D; Slim, K; Verrelle, P, 1998) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 1.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "In group 3, invasive squamous cell carcinoma and adenocarcinoma developed in one rat each." | 1.30 | Effect of 5-fluorouracil on gastrointestinal carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. ( Mori, M; Muto, T; Nagawa, H; Seto, Y; Tsuruo, T, 1999) |
| "An 80-year-old woman with metastatic bone cancer from ascending colon showed a remarkable response to combination therapy of 5-FU and radiation." | 1.30 | [Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report]. ( Masuda, M; Nakamura, N; Nakanishi, K; Okamoto, E; Satoh, M; Takeuchi, T; Tanihata, H; Terada, M; Ueno, Y; Yoshikawa, H, 1999) |
| "In stade II and III breast cancer, neoadjuvant chemotherapy with FEC-HD obtains an important histological response with an acceptable toxicity." | 1.30 | [Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer]. ( Arnoud, L; Belichard, C; Coudert, B; Darut-Jouve, A; Guerrin, J; Jolimoy, G, 1999) |
| "A total of 22 patients with primary colorectal cancer who underwent surgical treatment were examined for chemosensitivity with iable tumor samples using the Histoculture Drug Response Assay (HDRA)." | 1.30 | Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. ( Hayashi, H; Imaseki, H; Isono, K; Nakajima, K; Ochiai, T; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 1999) |
| "Invest, 101: 344-352, 1998) to suppress pancreatic cancer cell growth and increase cytotoxic actions of cisplatinum." | 1.30 | Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. ( Arber, N; Beger, HG; Danenberg, KD; Danenberg, PV; Korc, M; Kornmann, M, 1999) |
| " There were two EBRT dosage groups: Low EBRT, 23." | 1.30 | Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Grochow, LB; Haulk, TL; Hruban, RH; Lillemoe, KD; Ord, S; Pitt, HA; Sohn, TA; Yeo, CJ; Zahurak, ML, 1999) |
| "Fifty-three patients with localized esophageal cancer received concurrent chemoradiotherapy followed by brachytherapy." | 1.30 | High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. ( Dokiya, T; Oki, Y; Yorozu, A, 1999) |
| "Pancreatic cancer is one of the most common tumor of the gastrointestinal tract." | 1.30 | [Contribution of gemcitabine in the treatment of advanced pancreatic cancer]. ( Brunet, R; Fonck, M, 1999) |
| "The role in colorectal cancer is less clear, although there are some reports that suggest a benefit." | 1.30 | Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999) |
| "Local control of esophageal cancer is excellent following neoadjuvant chemotherapy and radiation therapy." | 1.30 | Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy. ( Adelstein, DJ; Becker, M; Chidel, MA; Kupelian, PA; Rice, TW; Suh, JH, 1999) |
| "The surgical treatment of colorectal cancer (CRC) in elderly patients (age 70 years or older) has improved, but data on adjuvant and palliative chemotherapy tolerability and benefits in this growing population remain scarce." | 1.30 | Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. ( Cunningham, D; Norman, A; Parikh, B; Popescu, RA; Ross, PJ, 1999) |
| "In contrast, in group B, 9 had tubular adenocarcinomas (well or moderately differentiated) and 3 non-solid or diffuse-type poorly differentiated adenocarcinomas and there was only one solid-type tumor." | 1.30 | Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. ( Ishihara, S; Kato, Y; Kitagawa, T; Nakajima, T; Ninomiya, Y; Yanagisawa, A, 1999) |
| "A 64-year-old man with unresectable esophageal cancer (A3, N1, M0) was treated with concurrent chemoradiotherapy." | 1.30 | [A case of stage IV (A3) cervical and upper thoracic esophageal adenocarcinoma successfully treated with concurrent chemoradiotherapy]. ( Inoue, H; Ise, H; Matsumoto, G; Matsuo, S; Suzuki, N, 1999) |
| "The prognosis of node negative breast cancer patients was mainly associated with tumor size." | 1.30 | [Prognosis and adjuvant chemotherapy of axillary node-negative breast cancer patients]. ( Han, Q; Shen, Z; Yu, L, 1997) |
| "The high sensitivity rate (HSR) of breast carcinoma cells to 5-fluorouracil (5-Fu), mitomycin (MMC), cisplatin (DDP), adriamycin(ADM), methotrexate(MTX), vincristin(VCR), vepesid(VP-16), taxol, and vindesine(VDS) were 57." | 1.30 | [Chemosensitivity test for 170 human breast carcinoma samples]. ( Chen, Z; Fei, H; He, Z; Liu, S; Shen, Z; Yuan, J, 1998) |
| "The another patient was 61 years old rectum cancer patient with lung and hepatic metastasis (stage V)." | 1.29 | [Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home]. ( Hayashi, K, 1994) |
| "We reported a case of gastric cancer with peritoneal dissemination, which was successfully treated by neoadjuvant chemotherapy and partial gastrectomy." | 1.29 | [Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy]. ( Ikeda, K; Shibata, N; Tamai, M, 1995) |
| " Low drug dosages (relative to the sensitivity of in vivo NMR) or rapid drug elimination create the additional problem of data sparsity where a pharmacokinetic model cannot be fitted individually." | 1.29 | Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach. ( Bachert, P; Port, RE; Schlemmer, HP, 1994) |
| "This report concerns four patients with brain metastases from breast carcinoma treated initially by systemic chemotherapy." | 1.29 | [Chemotherapy in the treatment of brain metastases of breast cancers]. ( Bastit, P; Chevallier, B; Couteau, C, 1994) |
| "In ten multiple metastatic brain tumors, three complete responses, two partial responses, one minor response and four non-responses were observed on MRI." | 1.29 | [Chemotherapy for metastatic brain tumors with CDDP and other agents: correlation between chemotherapeutic effects and the results of in vitro chemosensitivity tests using collagen gel-embedded culture combined with computerized image analysis in metastat ( Hagiwara, Y; Kanayama, T; Kobayashi, H; Koezuka, M; Miyawaki, Y; Nakagawa, H; Tokiyoshi, K; Tsuruzono, K; Yamada, M, 1994) |
| "A 67-year-old man with advanced gastric cancer with multiple liver metastases was treated by a new combination chemotherapy using 5-FU, THP and MMC (FTM)." | 1.29 | [A case of advanced gastric cancer with multiple liver metastases showing marked response to new combination chemotherapy using 5-FU, THP and MMC (FTM)]. ( Kusano, F; Maekawa, N; Sakai, Y; Sasaki, N; Tajiri, K; Tazawa, J; Yamamoto, C, 1994) |
| "We described a case of advanced gastric cancer with multiple liver metastases, who was placed on neoadjuvant chemotherapy using CDDP and 5-FU (FP therapy) with a marked reduction in tumor load." | 1.29 | [Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with multiple liver metastases]. ( Igarashi, S; Kurosu, Y; Mori, K; Niki, M; Nishimura, G; Oohara, M; Osada, H; Takamoto, Y; Tsuzuki, H; Ueda, H, 1994) |
| "levamisole/5-FU) treatment." | 1.29 | Enhancement of antitumor effects of combined chemoimmunotherapy. ( Fowler, WC; Gerçel-Taylor, C; Taylor, DD; Weese, JL, 1993) |
| "The second patient had advanced gastric cancer with carcinomatosis." | 1.29 | [Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports]. ( Furuya, Y; Hamabe, Y; Ku, Y; Nakamura, T; Saitoh, Y; Yamamoto, K, 1994) |
| "A 51-year-old female with inoperable gastric cancer and with infiltration of pancreatic tail diagnosed by abdominal CT was treated with leucovorin (LV) and 5-fluorouracil (5-FU)." | 1.29 | [Efficacy of the treatment of gastric cancer as neo-adjuvant chemotherapy of 48 hour continuous intravenous infusion of 5-fluorouracil (5-FU) with leucovorin (LV)]. ( Inamura, Y; Kanemitsu, T; Koike, A; Kojima, T; Matsumoto, K; Miwa, M; Nagata, H; Naruse, T; Ohiwa, Y; Suzumura, K, 1993) |
| "A 58-year-old woman with colon cancer, who had received oral 5-FU over 17 months after right hemicolectomy, was diagnosed as having a recurrence of the disease with multiple pulmonary metastasis." | 1.29 | [A case of pulmonary metastasis from colon cancer successfully treated by 5-FU combined with leucovorin and interferon alpha-2a]. ( Hirata, Y; Ichiki, Y; Kanaya, S; Nakamura, M; Nakano, S; Niho, Y, 1993) |
| "The energy metabolism of FM3A tumors in C3H mice following radiotherapy (20 Gy or 40 Gy), 5-fluorouracil compound (UFT) chemotherapy or radiotherapy (20 Gy) combined with UFT was investigated by in vivo 31P-MR spectroscopy on day 2 after treatment." | 1.29 | Changes of 31P-MR spectroscopy in experimental tumors following radiotherapy combined with 5-fluorouracil compound (UFT). ( Ohkubo, M, 1993) |
| "5-Fluorouracil was given every 3 weeks by 5-day continuous chronomodulated venous infusion (CMVI) with peak 5-FU delivery at 4 a." | 1.29 | Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Itzhaki, M; Lévi, F; Misset, JL; Soussan, S, 1993) |
| " A tolerable dosage regimen was radiation at 45 Gy with 4 days of 5-FU plus leucovorin during the first week and 3 days during the last week with postradiation chemotherapy." | 1.29 | Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. ( Burch, PA; Cha, SS; Gunderson, LL; Mailliard, JA; Martenson, JA; McKenna, PJ; Moertel, CG, 1994) |
| "A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with cis-diamminedichloroplatinum (CDDP) is reported." | 1.29 | [A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP]. ( Hayashi, H; Iwashita, R; Miyauchi, H; Miyoshi, H; Mochizuki, R; Nakagohri, T; Takeuchi, H; Tsunoda, Y; Ueda, K, 1994) |
| "Fifty-three patients with advanced colorectal cancer were given single oral doses of 5'-DFUR, 400 mg/body, preoperatively to assess the pharmacokinetics of 5'-DFUR in the patients with colorectal cancer and to investigate schedules for 5'-DFUR treatment." | 1.29 | [Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]. ( Hanyu, F; Hayashi, T; Igarashi, T; Suzuki, M; Watanabe, K; Yoshida, K, 1994) |
| " 5-Fluorouracil is given in a dosage of 1000 mg/m2/day as a continuous 24-hour infusion for 4 days." | 1.29 | Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer. ( Cellini, N; Coco, C; De Franco, A; Magistrelli, P; Mattana, C; Netri, G; Picciocchi, A; Roncolini, G; Valentini, V; Vecchio, FM, 1994) |
| "To evaluate the effect of the oral fluoropyrimidines, tegafur and uracil (UFT) and 5-fluorouracil (5-FU), a pharmacodynamic analysis was conducted using a nude mouse system and patients." | 1.29 | A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer. ( Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Kubota, T; Ogata, Y; Ozawa, I; Shimizu, H, 1993) |
| "A 59-year-old woman with advanced gastric cancer was treated with continuous 5-fluorouracil infusion for thirty-five days." | 1.29 | Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions. ( Kano, Y; Sasagawa, M; Seki, T; Suda, K, 1993) |
| "This case suggested that respiratory failure due to lymphangitis carcinomatosis can be a treatable condition." | 1.29 | Respiratory failure due to pulmonary lymphangitis carcinomatosis. ( Fujita, J; Kubo, A; Takahara, J; Takigawa, K; Yamagishi, Y; Yamaji, Y, 1993) |
| "An experience with an advanced gastric cancer patient with metastases to bilateral breasts, uterus, abdominal lymph nodes, bilateral axillary and supraclavicular lymph nodes, and bone marrow, responded extremely well to an FAP combined chemotherapy as reported here." | 1.29 | [A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy]. ( Azuma, T; Doihara, H; Kirihara, Y; Miyahara, E; Ohashi, R; Sakamoto, N; Soga, H; Takiyama, W; Tanada, M; Yokoyama, N, 1993) |
| "This metastatic model of human stomach cancer shows that locally growing and metastatic tumors may have different chemosensitivities, and provides the opportunity to test both with various treatment regimens." | 1.29 | Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Kuo, TH; Watanabe, M, 1993) |
| "In a 63-year-old male patient with gastric cancer having multiple liver metastases, the metastatic lesions responded well to postoperative staggered intraarterial infusion therapy with MTX and 5-FU." | 1.29 | [A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU]. ( Adachi, A; Nakano, Y; Ota, Y; Shirafuji, T; Yamaguchi, H; Yoshida, K, 1993) |
| "The patient was a 44-year-old male with gastric cancer accompanied by pancreatic invasion and metastasis to the periaortic lymph nodes." | 1.29 | [A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP]. ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Rino, Y; Sairenji, M, 1993) |
| "5-Fluorouracil was given concurrently by continuous infusion at a dose of 300 mg m-2 day-1." | 1.29 | Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. ( Abbruzzese, JL; Buchholz, DJ; Cleary, KR; Evans, OB; Lee, JE; Rich, TA, 1995) |
| "The palliative effects on dysphagia of radiotherapy (RT) and chemotherapy (CT) were evaluated retrospectively and compared with the effect of the self-expanding stent, evaluated in the prospective study." | 1.29 | Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. ( Albertsson, M; Cwikiel, M; Cwikiel, W, 1996) |
| "Patients with inflammatory breast cancer have a high risk of developing a local recurrence and/or distant metastases." | 1.29 | Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. ( Arriagada, R; Fontaine, F; Le Chevalier, T; Mouriesse, H; Spielmann, M; Thomas, F; Tursz, T, 1995) |
| "The proliferation of MCF-7, human breast cancer cell line, was stimulated by testosterone and estradiol." | 1.29 | Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell. ( Fujikura, T; Ideyama, Y; Kudoh, M; Mori, M; Nanya, T; Shikama, H; Susaki, Y, 1996) |
| "Three women with breast carcinoma were treated with combination chemotherapy, including cyclophosphamide, 5-fluorouracil, and methotrexate, after mastectomy." | 1.29 | Exacerbation of rheumatoid arthritis after termination of chemotherapy for breast carcinoma. ( Kramer, N; Leitner, SP; Michaelson, RA; Rosenstein, ED, 1996) |
| "Irinotecan and etoposide were combined using the (d x 5)2 i." | 1.29 | Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. ( Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L, 1996) |
| "We conclude that inoperable esophageal cancer can be treated successfully by radiotherapy with a curative intent." | 1.28 | [Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases]. ( Calais, G; Chauvet, B; Geara, F; Le Floch, O; Reynaud-Bougnoux, A, 1990) |
| "As a prerequisite four human breast cancer cell lines (MDA-MB-231, MCF-7, T-47-D and ZR-75-1) were characterized with regard to oestrogen and progesterone receptor content, modal chromosome number and proliferation kinetics depending on the number of passages in culture." | 1.28 | Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. ( Bernhardt, G; Birnböck, H; Reile, H; Schönenberger, H; Spruss, T, 1992) |
| "Thirty patients with advanced colorectal cancer were treated preoperatively by combined regional radiofrequency hyperthermia and 5-FU." | 1.28 | [Preoperative regional radiofrequency thermochemotherapy of colorectal cancer: clinical and pathological studies]. ( Wu, GR, 1992) |
| "Twenty patients with rectal cancer underwent the preoperative regimen that consisted of 3,000 cGy delivered in 10 fractions over 12 days with concomitant 5-fluorouracil and mitomycin-C." | 1.28 | Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma. ( Broadwater, JR; Gocio, JC; Hutchins, LF; Klimberg, VS; Lang, NP; Langston, JD; Maners, A; Westbrook, KC, 1992) |
| "Seven consecutive advanced ovarian cancer patients presented with massive ascites (5 with pleural effusion)." | 1.28 | [Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations]. ( Fujimoto, I; Hasumi, K; Masubuchi, K; Shimizu, Y; Tatsuki, Y; Yamauchi, K, 1992) |
| "Hypertriglyceridemia was maintained within acceptable levels, without adjusting the treatment plan, by an appropriate diet and gemfibrosil administration." | 1.28 | Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report. ( Berruti, A; Dogliotti, L; Gorzegno, G; Tampellini, M; Vitetta, G, 1992) |
| "A 60-year-old woman with gastric cancer had undergone partial gastrectomy in September 1989." | 1.28 | Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate. ( Hosokawa, T; Kajiwara, T; Ogawa, K; Otani, Y, 1992) |
| "A dosage form comprising 5-fluorouracil (5-FU, 25 mg/ml) adsorbed on a suspension of micronized charcoal (100 mg/ml) 2-5 microns in diameter, adsorbing 5-FU in aqueous solution was studied for intratumor treatment of mammary carcinoma in animal experiments." | 1.28 | Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles. ( Amdidouche, D; Bonhomme, L; Faure, E; Fredj, G; Guisteau, D; Mathieu, MC; Naveau, S, 1992) |
| "Mitomycin C was given on Day 1 (dose: 15 mg/m2 i." | 1.28 | Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer. ( Dobrowsky, W, 1992) |
| "We reported a case of metastatic liver cancer from rectal carcinoma, which was successfully treated by systemic continuous 5-Fluorouracil and intermittent Mitomycin C chemotherapy." | 1.28 | [A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy]. ( Noguchi, S; Shibata, N, 1992) |
| "Determined by clonogenic assay in human colon cancer HT-29 cells, the cell survivals for AZT, 10 microM, dipyridamole, 5 microM, and methotrexate (MTX), 0." | 1.28 | Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. ( Taniki, T; Weber, G; Zhen, YS, 1992) |
| "The records of patients with esophageal cancer who were treated with a combined modality therapy were reviewed to determine the effects of simultaneously administered chemotherapy and radiotherapy (RT) at sites of recurrence and the relationship between treatment outcome and clinicopathologic variables." | 1.28 | Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . ( Denham, JW; Devitt, PG; Gill, PG; Jamieson, GG; Olweny, C; Yeoh, E, 1992) |
| "A clone of human gastric cancer cells (AGS-6) and the parental line (AGS-P) from which it was isolated were used in cell survival studies to determine whether pretreatment for 24, 48 or 72h with alpha-difluoromethylornithine (DFMO, 5mM) would increase the cell's sensitivity to 5-Fluorouracil (5FU), Adriamycin (Adria), 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU), or Bleomycin (Bleo)." | 1.28 | Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro. ( Barranco, SC; Ford, PJ; Ho, BY; Koester, SK; Reumont, KJ; Townsend, CM, 1990) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 1.28 | Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991) |
| "Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5." | 1.28 | Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991) |
| "Radiation myelitis is a rare but serious complication of radiation therapy." | 1.28 | Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix. ( Berman, ML; Bloss, JD; DiSaia, PJ; Hyden, EC; Manetta, A; Mannel, RS; Walker, JL, 1991) |
| "A case of relapsing breast carcinoma presenting with acute visual loss secondary to choroidal metastases is described." | 1.28 | Choroidal metastases as a presenting sign after 24 years of a primary breast cancer. ( Baheti, D; Consul, S; Gupta, R, 1991) |
| "Presence of hepatomegaly emerged as the more significant (P = 0." | 1.28 | Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. ( Ducreux, M; Elias, D; Lasser, PH; Lumbroso, J; Pignon, JP; Rougier, P; Ruffie, P; Tigaud, JM, 1991) |
| "Eighty-three rats with isolated colon cancer underwent total colectomy; 40 of these rats with no metastases were randomized into two groups: surgery alone or surgery plus 5-FU (5 mg/kg body weight/day) for 5 days after surgery." | 1.28 | Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy. ( Ballet, F; Delelo, R; Herve, JP; Nordlinger, B; Panis, Y; Puts, JP, 1991) |
| "Feasibility of utilizing human gastric cancers as first transplant generation xenografts in nude mice for determining tumor sensitivity to chemotherapeutic agents was demonstrated by applying subrenal capsule (SRC) assay." | 1.28 | Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy. ( Akiyama, S; Ito, A; Ito, K; Kondo, K; Satta, T; Takagi, H; Watanabe, T; Yamauchi, M, 1991) |
| "A 55-year-old woman with gastric cancer underwent laparotomy and was found to have an unresectable tumor characterized by S3 (invasion of the pancreas), N3, P0 and H0." | 1.28 | [A long-term survival case of advanced gastric cancer undergoing radical gastrectomy by second-look operation after successful chemotherapy (CDDP, MMC, 5-FU)]. ( Azuma, S; Furuta, T; Kawata, R; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tanemura, H; Umemoto, T, 1991) |
| "Only two of them bore colonic cancer." | 1.28 | Disappearance of hyperplastic polyposis after resection of rectal cancer. Report of two cases. ( Fujita, S; Kusunoki, M; Sakanoue, Y; Shoji, Y; Utsunomiya, J; Yamamura, T; Yanagi, H, 1991) |
| "Pericarditis and cardiac arrhythmias developed, but the patient did not have cardiac tamponade." | 1.28 | Intrapericardial infusion of 5-fluorouracil. An unusual complication of a Hickman catheter. ( Cathcart-Rake, WF; Mowery, WE, 1991) |
| "Consequently, secondary biliary cirrhosis developed, requiring orthotopic liver transplantation." | 1.28 | [Ectasing cholangitis and secondary biliary cirrhosis following intra-arterial hepatic chemotherapy. Treatment by liver transplantation]. ( Chapuis, Y; Gaudric, M; Houssin, D; Louvel, A; Pitre, J; Vigouroux, C, 1991) |
| "Forty-four patients with advanced gastric cancer were treated with a combination including 5-fluorouracil, 4-epi-doxorubicin and mitomycin C." | 1.28 | Open phase II with 5-fluorouracil, 4-epi-doxorubicin and mitomycin C (FEM) in advanced gastric cancer. ( Kolarić, K; Luetić, J; Roth, A; Zupanc, D, 1990) |
| " This was deemed due to the small dosage and a short duration of 5'-DFUR." | 1.28 | [A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum]. ( Harada, T; Hirano, M; Kikkawa, H; Masuda, S; Matsu, T; Saito, H; Sakatoku, M; Tatsuzawa, T, 1990) |
| " The tumor pool of free 5FU in those human tumors that trapped 5FU was determined to have a half-life of 0." | 1.28 | Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. ( Albright, MJ; Atkinson, D; Barker, PB; el-Tahtawy, A; King, M; Ong, R; Presant, CA; Ring, R; Servis, KL; Wolf, W, 1990) |
| "The prognosis of unresectable advanced gastric cancer is extremely poor." | 1.28 | Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen. ( Chung, HC; Kim, BS; Lee, JT; Lee, KB; Lee, SI; Min, JS; Park, YJ; Roh, JK, 1990) |
| "Fourteen samples of epithelial ovarian cancer were studied; chemosensitivity in vitro was examined by clonogenic assay, and DNA content was measured by static cytometry." | 1.28 | Chemosensitivity and DNA content as prognostic factors in ovarian cancer: preliminary results. ( Carenza, L; Giovagnoli, MR; Prosperi Porta, R; Rulli, G, 1990) |
| "Of 25 patients with squamous cell carcinoma, 13 underwent esophagectomy." | 1.28 | Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma. ( Daniel, TM; Hahn, SS; Harkins, BJ; Stewart, FM, 1989) |
| "5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells." | 1.28 | Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989) |
| " 5-fluorouracil (5-FU) with a daily dosage of 1 g/m2/day was given continuously for 5 consecutive days at 3-week intervals." | 1.28 | Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy. ( Herrmann, R; Hohenberger, P; Räth, U; Schlag, P, 1989) |
| "Fluorouracil (Adrucil) has been used for more than 20 years to treat metastatic colorectal carcinoma and has provided significant palliation of symptoms to some patients." | 1.28 | Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil. ( Joseph, RR; Treat, J, 1989) |
| " Other adverse sequelae, such as abdominal pain, were manageable with medication." | 1.28 | Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study. ( Blessing, JA; Homesley, HD; Walton, LA, 1989) |
| "Retreatment of patients with colon cancer and liver metastases by hepatic arterial infusion of fluorodeoxyuridine and mitomycin C can result in significant prolongation of survival in patients with response to this treatment." | 1.27 | Effective retreatment of patients with colorectal cancer and liver metastases. ( Chuang, VP; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1983) |
| "Although both patients with hepatocellular cancer and the patient with a soft tissue sarcoma responded to the regimen, only 1 of 38 patients with adenocarcinoma had a favourable response." | 1.27 | Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer. ( Cedermark, BJ; Gunven, P; Hammarberg, C, 1983) |
| "Laboratory experiments using breast cancer cells in long-term tissue culture revealed that tamoxifen is cytotoxic, estrogen stimulates the growth of ER-positive cells and can rescue cells from tamoxifen's effect, and sequential MTX/5-FU is synergistic in rapidly growing breast cancer cells." | 1.27 | Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer. ( Allegra, JC, 1983) |
| "One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks." | 1.27 | [Clinical trial on the effect of tegafur (SF-SP)]. ( Akazawa, S; Futatsuki, K; Hattori, M; Ishibashi, I; Kanda, Y; Sendai, H; Shimada, S, 1984) |
| "Thirty patients with advanced gastric cancer were treated with a combination chemotherapy consisting of adriamycin 20-30 mg/m2 iv day 1 q3wks, mitomycin C 2." | 1.27 | [Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur]. ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Okada, Y; Usui, N, 1983) |
| "The sensitivity of two human pancreatic adenocarcinomas (Capan-1 and Capan-2) to heat and heat combined with chemotherapy was studied using xenografts of the tumors in the foot of athymic nude mice." | 1.27 | Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy. ( Cahan, A; Fogh, J; Fortner, JG; Shiu, MH, 1983) |
| "Tegafur was administered orally in two or three divided doses." | 1.27 | Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| "Three rectal cancer patients with partial response (PR) were obtained by oral administration of 800-1200 mg/day of SF-SP." | 1.27 | [The case studies on oral administration of tegafur encapsulated with slow releasing granule (SF-SP) for three rectal patients]. ( Endo, S; Furukawa, R; Katsumi, S; Mukae, S; Sato, T; Sekine, S; Watanabe, I; Watanabe, S, 1984) |
| "Spontaneous metastasis of highly metastatic variants, B16 melanoma BL-6 and colon adenocarcinoma 26 NL-22, was examined." | 1.27 | Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis. ( Iida, H; Kawabata, H; Naganuma, K; Oh-Hara, T; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "5-fluorouracil that was less active in the used therapeutic doses did not cause similar changes in the LSA levels." | 1.27 | [Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents]. ( Bassalyk, LS; Kozlov, AM; Novikov, AM; Sof'ina, ZP, 1984) |
| "Melphalan (L-PAM) was compared to (C) cyclophosphamide, (M) methotrexate, and (F) 5-fluorouracil (CMF) in 413 patients with advanced ovarian carcinoma." | 1.27 | Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer. ( Bauer, M; Brodovsky, HS; Elson, PJ; Horton, J, 1984) |
| "Eighty-four patients with advanced gastric cancer treated in four centres in Scotland between June 1980 and December 1982 were reviewed following treatment with 5-fluorouracil, adriamycin and mitomycin-C (FAM)." | 1.27 | Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. ( Allan, SG; Calman, KC; Carter, DC; Cunningham, D; Hutcheon, AW; Kaye, SB; McArdle, CS; Sangster, G; Smyth, JF; Soukop, M, 1984) |
| " Although the dosage of the anticancer chemotherapy was quite small, this treatment may have promoted the regression of the tumor in conjunction with activated antitumor immunity of the host." | 1.27 | [A case of advanced gastric cancer which disappeared histopathologically after short-time chemotherapy]. ( Furuta, K; Hara, K; Kiyomitsu, Y; Nakazaki, S; Shinoda, M; Watanabe, K; Yajima, K; Yasuda, S; Yokoyama, T, 1984) |
| "Tumor metastasis was examined after iv inoculation of highly metastatic variants of mouse tumors." | 1.27 | Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors. ( Hori, K; Kawabata, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "Twenty-one patients with advanced gastric cancer were treated with a combination chemotherapy of adriamycin and 5-fluorouracil (AF)." | 1.27 | [Co-administration of adriamycin and 5-fluorouracil for the treatment of advanced stomach cancer]. ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Usui, N, 1983) |
| "Chemoradiotherapy was recommended to 40 pancreatic cancer patients following exploratory and palliative operations." | 1.27 | [Chemoradiation treatment of pancreatic cancer]. ( Barkanov, AI; Itin, AB, 1985) |
| "The prognosis of bile duct cancer is still poor." | 1.27 | [Intraductal chemotherapy of bile duct cancer with 5-fluorouracil]. ( Arnold, W; Bartels, E; Schmeck, HJ; Viets, CH, 1986) |
| "Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2." | 1.27 | Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. ( Coia, LR; Engstrom, PF; Paul, A, 1987) |
| "The majority of patients (78%) had squamous cell carcinoma." | 1.27 | Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University. ( al-Sarraf, M; Cummings, G; Ensley, JF; Kelly, J; Kish, JA; LoRusso, P; Tapazoglou, E, 1988) |
| "The chemosensitivity of human colorectal cancer was studied in relation to the biological features of the tumor using a human tumor/nude mouse in-vivo system." | 1.27 | Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice. ( Yamada, K, 1987) |
| "For the response of advanced gastric cancer to chemotherapy in the National Cancer Center Hospital, the combined use of UFT and Mitomycin C gave the highest rate, 46%." | 1.27 | Radiation therapy for advanced gastric cancer. ( Akine, Y; Egawa, S; Hijikata, J; Kajiura, Y; Kitagawa, T; Ogino, T; Tsukiyama, I; Yamashita, K, 1988) |
| "All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls." | 1.27 | Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. ( Dakhil, SR; Housholder, DF; Marymont, JV; Travers, H, 1985) |
| "Nine patients had squamous cell carcinoma, two adenocarcinoma, and two large cell carcinoma." | 1.27 | [Postoperative chemotherapy of pathological stage I non-small cell carcinoma of the lung]. ( Kikuchi, K; Ogata, T, 1986) |
| " The drug sensitivity of the cultured cancer cells was investigated with a colony forming assay, and a dose-response curve was obtained for the time-dependent anticancer drug." | 1.27 | [Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment]. ( Maeda, T, 1986) |
| "A 55-year-old woman with gastric cancer underwent laparotomy and was found to have an unresectable tumor at the MC region, characterized by S3 (invasion into the pancreas), N3, P0, H0, Borrmann-II and moderately differentiated tubular adenocarcinoma." | 1.27 | [Successful treatment of advanced gastric cancer by combined cisplatinum, mitomycin C and 5-FU administration. A case report]. ( Ando, T; Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Shimokawa, K; Suzuki, M; Tanemura, H; Tsuya, H, 1987) |
| "Of the 77 patients who had squamous cell carcinoma, 62 received definitive treatment for disease confined to the esophagus and regional nodes." | 1.27 | Esophageal carcinoma: modest benefits from combined modality therapy. ( Carlson, RW; Goffinet, DR; Hancock, SL; Mark, JB, 1987) |
| "A 65-year-old man with gastric cancer showing multiple liver metastases was treated with recombinant interferon-gamma (KW-2202) and 5-fluorouracil (5-FU)." | 1.27 | [A case of gastric cancer with multiple liver metastases responding to combination therapy of recombinant interferon-gamma (KW-2202) and 5-FU]. ( Hisatsugu, T; Katano, M; Kitajima, Y; Sato, S; Uchida, Y; Yamamoto, H, 1987) |
| "A 75-year-old man with gastric cancer metastatic to the liver was treated by combined administration of Tegafur (800 mg/body/day), 5-fluorouracil (300 mg/body/day) and Mitomycin C (hepatic arterial infusion of 20 mg/body and intravenous infusion of 8 mg/body)." | 1.27 | [Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C]. ( Ito, T; Nehashi, Y; Sasaki, J; Sasaki, Y, 1988) |
| "Fluorodeoxyuridylate (FdUMP) was assayed by isotope dilution of [3H]FdUMP binding to bacterial TS; free and total TS was determined by [3H]FdUMP binding; and deoxyuridylate (dUMP) was assayed by conversion to [14C]thymidylate." | 1.27 | Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. ( Berne, M; Bernstein, L; Frösing, R; Gustavsson, BG; Hayes, AA; Spears, CP, 1988) |
| " At these dosage levels, diarrhea was not a limiting toxicity." | 1.27 | High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer. ( Arnold, DJ; Balcueva, EP; Dimitrov, NV; Scholnik, AP; Schwenke, P; Suhrland, LG; Walker, WS, 1988) |
| "However, it is unfortunate that colorectal cancer screening in young patients is difficult because of the low rates of precancerous states (4%)." | 1.27 | Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. ( Astre, C; Domergue, J; Ismail, M; Joyeux, H; Pujol, H; Saint-Aubert, B; Solassol, C, 1988) |
| "32 cases of colon cancer were given I/V 5-fluorouracil for at least one year." | 1.27 | Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital. ( Chia, KB; Chua, EJ; Khor, TH; Sethi, VK; Tan, BC; Tan, TM, 1987) |
| "Patients with metastatic breast carcinoma and similar presentations should be considered for prophylactic therapy with allopurinol and hydration before chemotherapy." | 1.27 | Fatal acute tumor lysis syndrome with metastatic breast carcinoma. ( Coonley, CJ; Dyer, MC; Stark, ME, 1987) |
| "In most cases of metastatic gastric cancer, treatment with cytostatic drugs seems to be justified." | 1.27 | [Chemotherapy of metastatic gastric cancer--x-ray follow-up]. ( Hofmann-Preiss, K; Theobaldy, S; Walter, M, 1987) |
| "Fifty-seven patients with esophageal cancer were treated with curative intent between January 1979 and June 1985." | 1.27 | Comparison of three treatment strategies for esophageal cancer within a single institution. ( Bae, Y; Burdakin, J; Jacobsen, G; Lewis, J; Richmond, J; Seydel, HG, 1987) |
| "Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| " Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs." | 1.27 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985) |
| "A 61-year-old man with double colon cancers and a solitary hepatic metastasis underwent right hemicolectomy and catheterization of the proper hepatic artery in April 1979." | 1.27 | [A long survival case of carcinoma of the colon with hepatic metastasis following intra-arterial infusion chemotherapy]. ( Itoh, J; Koyama, K; Masuda, T; Narisawa, T, 1985) |
| "At present hyperthermia shows great promise when combined with other modalities." | 1.27 | [Clinical application of local hyperthermia combined with antineoplastic agents]. ( Ishiwata, J; Iwamoto, S; Koike, M; Maeda, Y; Masuda, T; Sasaki, T; Takeshita, Y; Tanaka, Y, 1985) |
| "5-Fluorouracil treatments resulted in a dose-dependent inhibition of tumor growth under the two examined schedules (five daily doses and three doses every 4 days) when administered either i." | 1.27 | 5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice. ( Frei, E; Goldin, A; Mantel, N; VanWinkle, TJ; Zimmerman, RJ, 1986) |
| "The Southwest Oncology Group conducted a pilot study in patients who had had total clinical resection of cancer of the colon and had a high risk of recurrence (Duke's C); the purpose of the study was to determine the toxic effects of intra-arterial chemotherapy combined with hepatic radiotherapy, in anticipation of their potential use in an adjuvant groupwide protocol." | 1.27 | Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study. ( Boyer, C; Janaki, L; McCracken, JD; Oishi, N; Weatherall, TJ, 1985) |
| " This study demonstrates that sequential MTX and 5-FU in this dosage and schedule is ineffective in NSCCL." | 1.27 | Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung. ( Ponder, BA; Slevin, ML; Wood, CD; Wrigley, PF, 1985) |
| " The mean half-life of 5-FU in the isolated circuit was 18." | 1.27 | Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. ( Abramson, IS; Andrews, PA; Howell, SB; Murphy, MP; Stemmer, EA; Wile, AG, 1985) |
| "For stage I and II gastric cancer, radical gastrectomy and postoperative immunotherapy for 3 months would be the best treatment." | 1.27 | Immunochemosurgery for gastric cancer. ( Kim, JP, 1985) |
| "Patients with squamous cell carcinoma or good performance status were somewhat more likely to respond." | 1.27 | Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. ( Einstein, AB; Rudolph, RH; Weiden, PL, 1985) |
| "Phosphorylating activity in squamous cell carcinoma of the lung was similar to that in adenocarcinomas." | 1.26 | Metabolism of 5-fluorouracil in various human normal and tumor tissues. ( Fujii, S; Maehara, Y; Nagayama, S; Nakamura, H; Okazaki, H; Shirasaka, T, 1981) |
| "Other nonneoplastic gastrointestinal disorders showed an 18% abnormal CSAp titer frequency, of which more than half bordered the upper limit of normalcy." | 1.26 | Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer. ( Goldenberg, DM; Nelson, MO; Pant, KD; Shochat, D, 1982) |
| "Regional arterial infusion of high doses of anti-cancer drugs combined with direct hemoperfusion was done in 12 patients with malignancies of the urinary tract." | 1.26 | Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract. ( Harada, T; Nishizawa, O; Ohmura, H; Tsuchida, S, 1982) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 1.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "In the total 70 cases including those of undifferentiated carcinoma and adenocarcinoma, the 3-year and 5-year actual survival rates were 75." | 1.26 | Analysis of the results of our combined therapy for maxillary cancer. ( Inoue, S; Konno, A; Togawa, K, 1980) |
| "5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma." | 1.26 | Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982) |
| " Dose-response relationships of 3 triple-drug combinations and their component agents were explored, allowing the relative contributions of single agents in each combination to be assessed." | 1.26 | Experimental combination and single-agent chemotherapy in human lung-tumour xenografts. ( Jones, JM; Peckham, MJ; Shorthouse, AJ; Steel, GG, 1982) |
| "Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity." | 1.26 | A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer. ( Allegra, JC; Bland, KI; Richman, SP; Wittliff, JL; Woodcock, TM, 1982) |
| " The group of long term administration of FT-207 and CQ included many patients with good response." | 1.26 | [Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer]. ( Fukuda, O; Inoue, S; Maeyama, M; Nakayama, M; Tajima, C; Tokunaga, T, 1982) |
| "Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission." | 1.26 | Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982) |
| " Gastrointestinal and hematologic toxic effects were mild and infrequent." | 1.26 | High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule. ( Campbell, TN; House, BA; Howell, SB; Pfeifle, C, 1982) |
| "For the diffuse invasive type of gastric cancer, the changes in the X-ray finding such as stiffness and poor elasticity of gastric wall and malignant relief were also taken into consideration for the judgement." | 1.26 | [Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer]. ( Chin, F; Hirasawa, H; Isono, K; Kimura, M; Kouzu, T; Okuyama, K; Onoda, S; Ryu, M; Sato, H; Satoh, H; Tounosu, N; Yamamoto, Y, 1982) |
| "Pre-treatment with the anabolic steroid nandrolone decanoate (ND) increases the LD50 of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-Fluorouracil (FU) in NMRI mice." | 1.26 | Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours. ( Bibby, MC; Double, JA; Mughal, MA, 1981) |
| "Two patients with advanced rectal cancer, women aged 73 and 49 years, have survived more than nine years with chemotherapy only and no surgical removal of the disease foci." | 1.26 | Long-term survivors with nonresectable advanced carcinoma of the rectum. ( Fukuda, I; Iwanaga, T; Koyama, H; Otani, T; Taniguchi, H, 1981) |
| "A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin." | 1.26 | Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III. ( Drago, JR; Worgul, TJ, 1981) |
| " This route-dependent pharmacokinetic profile is consistent with the reported absence of myelosuppression in prolonged infusion and may be related to the resultant lower levels of 5-FUra achieved in bone marrow." | 1.26 | Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. ( Baker, LH; Buroker, TR; Fraile, RJ; Horwitz, J; Vaitkevicius, VK, 1980) |
| "After confirming the presence of gastric cancer, 1-n-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil, was given to the dogs orally as capsules at a daily dose of 5 or 10 mg/kg body weight." | 1.26 | Chemotherapeutic study on canine gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine. ( Aoyagi, M; Hirashima, T; Hirota, T; Kawachi, T; Matsukura, N; Sugimura, T; Takasugi, T; Uchida, E; Ushio, K; Yoshida, S, 1980) |
| "A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems." | 1.26 | [Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)]. ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976) |
| "Three patients with metastatic breast carcinoma who had untreated locally advanced primary tumors were treated initially with combination chemotherapy followed by hygienic mastectomy." | 1.26 | Mastectomy as an adjunct to combination chemotherapy. ( Aisner, J; Elias, EG; Morris, D; Wiernik, PH, 1978) |
| "Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2." | 1.26 | Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study. ( Buroker, T; Groppe, C; Guy, G; Heilbrun, L; Hoogstraten, B; McCracken, J; Padilla, F; Quagliana, J; Vaitkevicius, VK, 1979) |
| "Fifteen patients with advanced gastric cancer were treated with the combination of Ftorafur, Adriamycin and mitomycin-C (FAM II)." | 1.26 | A phase II trial of ftorafur: adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma. ( Haller, DG; Hoth, DF; MacDonald, JS; Rosenoff, S; Schein, PS; Smythe, T; Woolley, PV, 1979) |
| "Successful heterotransplantation of ovarian cancer in the mouse mutant, nude is described, with serial transmission, in one case to date." | 1.26 | Heterologous growth of human ovarian cancer. A new in vivo testing system. ( Davy, M; Johannessen, JV; Mossige, J, 1977) |
| "Cell free supernatants from human breast tumors produce less total phosphorylation than murine tumors and some specimens produce only monophosphates whereas others produce mono-, di and triphosphates." | 1.26 | Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors. ( Ardalan, B; Cooney, D; Macdonald, JS; Schein, PS, 1979) |
| "Two patients with generalized ovarian cancer may be cured." | 1.26 | Chemotherapy of ovarian cancer. ( Dimitriades, M; Midoulas, N; Panopoulos, C; Papadimitriou, GC; Razis, DV, 1978) |
| "Soft tissue metastases may be more responsive than bony lesions." | 1.26 | Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate. ( Bergreen, PW; Buell, GV; Saiers, JH; Saiki, JH, 1978) |
| "In additional 13 cases with gastric cancer, the active 5-FU concentrations in the regional lymph nodes were determined." | 1.26 | Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer. ( Cho, K; Fujita, Y; Majima, S; Morisawa, K; Nakao, E; Nishioka, B; Takahashi, T; Ueda, T; Watanabe, S, 1978) |
| "Two young women with cancer of the pancreas are described." | 1.26 | Cancer of the pancreas in young adults. ( Butterfield, D; Hobbs, JB; Kune, GA; Sali, A, 1978) |
| "A series of 156 patients with gastric cancer during a 15-year period were reviewed retrospectively to determine the effectiveness of combined surgery and adjuvant chemotherapy." | 1.26 | The treatment of gastric cancer with combined surgical resection and chemotherapy. ( Cruz, AB; Franz, JL, 1977) |
| "Seventeen patients with metastatic breast carcinoma were treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide and prednisone." | 1.25 | Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma. ( Blom, J; Stutz, FH; Tormey, DC, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 924 (18.73) | 18.7374 |
| 1990's | 900 (18.25) | 18.2507 |
| 2000's | 1421 (28.81) | 29.6817 |
| 2010's | 1466 (29.72) | 24.3611 |
| 2020's | 221 (4.48) | 2.80 |
| Authors | Studies |
|---|---|
| Rewcastle, GW | 1 |
| Atwell, GJ | 1 |
| Baguley, BC | 1 |
| Calveley, SB | 1 |
| Denny, WA | 1 |
| Nambaru, PK | 1 |
| Hübner, T | 1 |
| Köck, K | 1 |
| Mews, S | 1 |
| Grube, M | 1 |
| Payen, L | 1 |
| Guitton, J | 1 |
| Sendler, M | 1 |
| Jedlitschky, G | 1 |
| Rimmbach, C | 1 |
| Rosskopf, D | 1 |
| Kowalczyk, DW | 1 |
| Kroemer, HK | 1 |
| Weiss, FU | 1 |
| Mayerle, J | 4 |
| Lerch, MM | 3 |
| Ritter, CA | 1 |
| Lin, LW | 1 |
| Lai, PS | 1 |
| Chen, YY | 4 |
| Chen, CY | 2 |
| Hadj Bachir, E | 1 |
| Poiraud, C | 1 |
| Paget, S | 1 |
| Stoup, N | 1 |
| El Moghrabi, S | 1 |
| Duchêne, B | 1 |
| Jouy, N | 1 |
| Bongiovanni, A | 1 |
| Tardivel, M | 1 |
| Weiswald, LB | 2 |
| Vandepeutte, M | 1 |
| Beugniez, C | 1 |
| Escande, F | 1 |
| Leteurtre, E | 1 |
| Poulain, L | 2 |
| Lagadec, C | 1 |
| Pigny, P | 1 |
| Jonckheere, N | 1 |
| Renaud, F | 1 |
| Truant, S | 1 |
| Van Seuningen, I | 2 |
| Vincent, A | 1 |
| Catenacci, DVT | 2 |
| Othman, MS | 1 |
| Al-Bagawi, AH | 1 |
| Obeidat, ST | 1 |
| Fareid, MA | 1 |
| Habotta, OA | 1 |
| Moneim, AEA | 1 |
| Giommoni, E | 3 |
| Lavacchi, D | 1 |
| Tirino, G | 1 |
| Fornaro, L | 6 |
| Iachetta, F | 1 |
| Pozzo, C | 5 |
| Satolli, MA | 3 |
| Spallanzani, A | 1 |
| Puzzoni, M | 1 |
| Stragliotto, S | 1 |
| Sisani, M | 1 |
| Formica, V | 2 |
| Giovanardi, F | 2 |
| Strippoli, A | 1 |
| Prisciandaro, M | 1 |
| Di Donato, S | 1 |
| Pompella, L | 1 |
| Pecora, I | 1 |
| Romagnani, A | 1 |
| Fancelli, S | 1 |
| Brugia, M | 1 |
| Pillozzi, S | 1 |
| De Vita, F | 12 |
| Antonuzzo, L | 2 |
| Garnier, J | 2 |
| Magallon, C | 1 |
| Ewald, J | 3 |
| Palen, A | 1 |
| Marchese, U | 3 |
| Delpero, JR | 8 |
| Turrini, O | 6 |
| Högner, A | 1 |
| Al-Batran, SE | 17 |
| Siveke, JT | 5 |
| Lorenz, M | 6 |
| Bartels, P | 1 |
| Breithaupt, K | 4 |
| Malfertheiner, P | 1 |
| Homann, N | 10 |
| Stein, A | 2 |
| Gläser, D | 1 |
| Tamm, I | 1 |
| Hinke, A | 5 |
| Vogel, A | 1 |
| Thuss-Patience, P | 6 |
| Gebauer, F | 1 |
| Damanakis, AI | 1 |
| Popp, F | 1 |
| Quaas, A | 1 |
| Kütting, F | 2 |
| Lutz, K | 1 |
| Held, S | 1 |
| Deuß, B | 1 |
| Göser, T | 1 |
| Waldschmidt, D | 1 |
| Bruns, C | 1 |
| Assenat, E | 2 |
| de la Fouchardière, C | 7 |
| Portales, F | 4 |
| Ychou, M | 26 |
| Debourdeau, A | 1 |
| Desseigne, F | 8 |
| Iltache, S | 1 |
| Fiess, C | 1 |
| Mollevi, C | 3 |
| Mazard, T | 3 |
| Su, YY | 2 |
| Chiu, YF | 1 |
| Li, CP | 4 |
| Yang, SH | 9 |
| Lin, J | 2 |
| Lin, SJ | 1 |
| Chang, PY | 2 |
| Chiang, NJ | 3 |
| Shan, YS | 4 |
| Ch'ang, HJ | 1 |
| Chen, LT | 12 |
| Rogers, JE | 1 |
| Wang, X | 13 |
| Trail, A | 1 |
| Ajani, JA | 43 |
| Quesada, S | 1 |
| Samalin, E | 8 |
| Thezenas, S | 4 |
| Khellaf, L | 1 |
| Mourregot, A | 2 |
| Adenis, A | 9 |
| Yoshida, R | 1 |
| Mizuno, D | 1 |
| Suemori, K | 1 |
| Miyauchi, S | 3 |
| Iga, N | 1 |
| Uno, F | 2 |
| Kawai, H | 2 |
| Ishizaki, M | 2 |
| Nishi, H | 1 |
| Yamashita, K | 4 |
| Lalonde, CS | 1 |
| Wang, L | 16 |
| Quigley, B | 1 |
| Patel, P | 3 |
| Maithel, SK | 5 |
| El-Rayes, BF | 11 |
| Akce, M | 1 |
| Lee, LD | 1 |
| Pozios, I | 1 |
| Liu, V | 1 |
| Nachbichler, SB | 1 |
| Böhmer, D | 1 |
| Kamphues, C | 1 |
| Beyer, K | 1 |
| Bruns, CJ | 8 |
| Kreis, ME | 1 |
| Seeliger, H | 2 |
| Moore, JL | 1 |
| Kumar, S | 3 |
| Santaolalla, A | 1 |
| Patel, PH | 1 |
| Kapiris, M | 1 |
| Van Hemelrijck, M | 1 |
| Maisey, N | 2 |
| Hill, M | 5 |
| Lagergren, J | 1 |
| Gossage, JA | 4 |
| Kelly, M | 1 |
| Chaudry, A | 2 |
| Allum, WH | 10 |
| Baker, CR | 1 |
| Cunningham, D | 57 |
| Davies, AR | 1 |
| Zaibet, S | 1 |
| Hautefeuille, V | 4 |
| Auclin, E | 3 |
| Lièvre, A | 5 |
| Tougeron, D | 9 |
| Sarabi, M | 2 |
| Gilabert, M | 4 |
| Wasselin, J | 1 |
| Edeline, J | 3 |
| Artru, P | 12 |
| Bechade, D | 3 |
| Morin, C | 1 |
| Ducoulombier, A | 1 |
| Taieb, J | 22 |
| Pernot, S | 6 |
| Meneses-Medina, MI | 1 |
| Gervaso, L | 1 |
| Cella, CA | 1 |
| Pellicori, S | 1 |
| Gandini, S | 1 |
| Sousa, MJ | 1 |
| Fazio, N | 6 |
| Hochster, HS | 8 |
| Alexander, HR | 2 |
| Janssen, QP | 4 |
| van Dam, JL | 2 |
| Doppenberg, D | 2 |
| Prakash, LR | 3 |
| van Eijck, CHJ | 3 |
| Jarnagin, WR | 4 |
| O' Reilly, EM | 1 |
| Paniccia, A | 3 |
| Besselink, MG | 7 |
| Katz, MHG | 6 |
| Tzeng, CD | 3 |
| Wei, AC | 3 |
| Zureikat, AH | 5 |
| Groot Koerkamp, B | 3 |
| Chiu, TJ | 1 |
| Chiu, SC | 2 |
| Hsueh, SW | 1 |
| Bai, LY | 1 |
| Cheng, FM | 1 |
| Chuang, SC | 1 |
| Chan, DC | 1 |
| Yen, CJ | 2 |
| Peng, CM | 2 |
| Chen, JS | 5 |
| Chou, WC | 1 |
| Zheng, S | 2 |
| Hu, C | 1 |
| Lin, H | 2 |
| Li, G | 4 |
| Xia, R | 1 |
| Zhang, X | 12 |
| Su, D | 3 |
| Li, Z | 3 |
| Zhou, Q | 1 |
| Chen, R | 2 |
| Moussa, O | 1 |
| Bhogal, RH | 1 |
| Malietzis, G | 1 |
| Fribbens, C | 1 |
| Starling, N | 7 |
| Gerlinger, M | 1 |
| Watkins, D | 4 |
| Chau, I | 19 |
| Rao, S | 7 |
| Matsumura, K | 2 |
| Yamamura, K | 1 |
| Miyamoto, H | 7 |
| Hara, Y | 1 |
| Oda, E | 1 |
| Akahoshi, S | 1 |
| Yoshida, K | 11 |
| Yuki, H | 1 |
| Motohara, T | 2 |
| Sakamoto, K | 5 |
| Komohara, Y | 1 |
| Beppu, T | 3 |
| Elias, R | 1 |
| Cockrum, P | 3 |
| Surinach, A | 3 |
| Wang, S | 5 |
| Chul Chu, B | 1 |
| Shahrokni, A | 1 |
| Canton, C | 1 |
| Boussari, O | 1 |
| Boulin, M | 1 |
| Le Malicot, K | 7 |
| Dahan, L | 6 |
| Lopez, A | 1 |
| Lepage, C | 10 |
| Bachet, JB | 16 |
| Mehta, R | 1 |
| Frakes, J | 2 |
| Kim, J | 5 |
| Nixon, A | 1 |
| Liu, Y | 10 |
| Howard, L | 1 |
| Martinez Jimenez, ME | 1 |
| Carballido, E | 1 |
| Imanirad, I | 2 |
| Sanchez, J | 2 |
| Dessureault, S | 1 |
| Xie, H | 2 |
| Felder, S | 2 |
| Sahin, I | 2 |
| Hoffe, S | 4 |
| Malafa, M | 2 |
| Kim, R | 4 |
| Kim, G | 2 |
| Wainberg, Z | 2 |
| Temraz, S | 5 |
| Nassar, F | 1 |
| Hammoud, MS | 2 |
| Mukherji, D | 6 |
| O'Reilly, EM | 12 |
| Dbouk, H | 1 |
| Farhat, F | 2 |
| Charafeddine, M | 4 |
| Faraj, W | 3 |
| Khalifeh, MJ | 1 |
| Abou-Alfa, GK | 4 |
| Shamseddine, A | 8 |
| Kamposioras, K | 1 |
| Papaxoinis, G | 2 |
| Dawood, M | 1 |
| Appleyard, J | 1 |
| Collinson, F | 1 |
| Lamarca, A | 2 |
| Ahmad, U | 1 |
| Hubner, RA | 2 |
| Wright, F | 1 |
| Pihlak, R | 2 |
| Damyanova, I | 1 |
| Razzaq, B | 1 |
| Valle, JW | 8 |
| McNamara, MG | 2 |
| Anthoney, A | 7 |
| Ng, M | 1 |
| Chen, S | 5 |
| Ong, WS | 1 |
| Balachander, A | 1 |
| Seet, A | 1 |
| Yeong, J | 1 |
| Sutiman, N | 1 |
| Lim, TKH | 1 |
| Lee, B | 2 |
| Guo, YA | 1 |
| Leong, WF | 1 |
| Lee, SS | 5 |
| Lam, J | 1 |
| Choo, SP | 3 |
| Skanderup, AJ | 1 |
| Biswas, SK | 1 |
| Tai, D | 1 |
| Chowbay, B | 2 |
| Garcia-Aguilar, J | 7 |
| Patil, S | 4 |
| Gollub, MJ | 4 |
| Kim, JK | 1 |
| Yuval, JB | 1 |
| Thompson, HM | 1 |
| Verheij, FS | 1 |
| Omer, DM | 1 |
| Lee, M | 3 |
| Dunne, RF | 1 |
| Marcet, J | 4 |
| Cataldo, P | 3 |
| Polite, B | 2 |
| Herzig, DO | 3 |
| Liska, D | 1 |
| Oommen, S | 3 |
| Friel, CM | 2 |
| Ternent, C | 1 |
| Coveler, AL | 2 |
| Hunt, S | 2 |
| Gregory, A | 1 |
| Varma, MG | 2 |
| Bello, BL | 1 |
| Carmichael, JC | 1 |
| Krauss, J | 1 |
| Gleisner, A | 2 |
| Paty, PB | 10 |
| Weiser, MR | 5 |
| Nash, GM | 3 |
| Pappou, E | 1 |
| Guillem, JG | 10 |
| Temple, L | 1 |
| Wei, IH | 1 |
| Widmar, M | 2 |
| Lin, S | 4 |
| Segal, NH | 2 |
| Cercek, A | 3 |
| Yaeger, R | 2 |
| Smith, JJ | 4 |
| Goodman, KA | 6 |
| Wu, AJ | 4 |
| Saltz, LB | 6 |
| Campoverde, LE | 1 |
| Batalini, F | 1 |
| Bulushi, Y | 1 |
| Bullock, A | 1 |
| Shimano, R | 1 |
| Kotake, M | 2 |
| Ida, A | 1 |
| Hashimoto, M | 3 |
| Saito, H | 13 |
| Sawada, K | 1 |
| Oshima, M | 1 |
| Hada, M | 1 |
| Kato, Y | 6 |
| Oyama, K | 3 |
| Hara, T | 3 |
| Inaki, N | 1 |
| Janjigian, YY | 7 |
| Van Cutsem, E | 29 |
| Muro, K | 12 |
| Hyung, WJ | 3 |
| Molena, D | 1 |
| Marcovitz, M | 1 |
| Ruscica, D | 1 |
| Robbins, SH | 1 |
| Negro, A | 1 |
| Tabernero, J | 15 |
| Dos Santos, M | 1 |
| Lequesne, J | 1 |
| Leconte, A | 1 |
| Corbinais, S | 2 |
| Parzy, A | 1 |
| Guilloit, JM | 1 |
| Varatharajah, S | 1 |
| Brachet, PE | 1 |
| Dorbeau, M | 1 |
| Vaur, D | 1 |
| Le Gallic, C | 1 |
| Castera-Tellier, M | 1 |
| Galais, MP | 2 |
| Clarisse, B | 1 |
| Yu, KH | 3 |
| Park, J | 3 |
| Mittal, A | 2 |
| El Dika, I | 1 |
| Epstein, AS | 2 |
| Ilson, DH | 10 |
| Kelsen, DP | 20 |
| Ku, GY | 2 |
| Li, J | 20 |
| Park, W | 3 |
| Varghese, AM | 1 |
| Chou, JF | 2 |
| Capanu, M | 5 |
| Cooper, B | 1 |
| Bartlett, A | 1 |
| McCarthy, D | 1 |
| Sangar, V | 1 |
| McCarthy, B | 1 |
| Klein-Brill, A | 1 |
| Amar-Farkash, S | 1 |
| Lawrence, G | 1 |
| Collisson, EA | 1 |
| Aran, D | 1 |
| Kato, A | 1 |
| Naitoh, I | 1 |
| Naiki-Ito, A | 1 |
| Hayashi, K | 4 |
| Okumura, F | 1 |
| Fujita, Y | 5 |
| Sano, H | 1 |
| Nishi, Y | 1 |
| Miyabe, K | 1 |
| Inoue, T | 9 |
| Hirano, A | 2 |
| Takada, H | 1 |
| Yoshida, M | 4 |
| Hori, Y | 1 |
| Natsume, M | 1 |
| Kato, H | 9 |
| Takahashi, S | 6 |
| Kataoka, H | 2 |
| Breakstone, R | 1 |
| Almhanna, K | 4 |
| Raufi, A | 1 |
| Beard, RE | 1 |
| Leonard, KL | 1 |
| Renaud, J | 1 |
| Kastura, M | 1 |
| Dionson, S | 1 |
| Wood, R | 1 |
| Sturtevant, A | 1 |
| Dipetrillo, T | 4 |
| Olszewski, A | 1 |
| Safran, H | 11 |
| Möhring, C | 1 |
| Timotheou, A | 1 |
| Mańczak, A | 1 |
| Sadeghlar, F | 1 |
| Zhou, T | 3 |
| Mahn, R | 1 |
| Bartels, A | 1 |
| Monin, M | 1 |
| Toma, M | 1 |
| Feldmann, G | 1 |
| Brossart, P | 1 |
| Köksal, M | 1 |
| Sarria, GR | 1 |
| Giordano, FA | 1 |
| Lingohr, P | 1 |
| Jafari, A | 1 |
| Kalff, JC | 1 |
| Strassburg, CP | 1 |
| Gonzalez-Carmona, MA | 1 |
| Crane, CH | 17 |
| Ellsworth, SG | 2 |
| Reyngold, M | 2 |
| Shi, Q | 6 |
| Meyers, J | 1 |
| Herman, JM | 7 |
| Chuong, M | 1 |
| Wolpin, BM | 5 |
| Ahmad, S | 2 |
| Marsh, R | 1 |
| Schwartz, L | 1 |
| Behr, S | 1 |
| Frankel, WL | 2 |
| Collisson, E | 1 |
| Leenstra, J | 1 |
| Williams, TM | 3 |
| Vaccaro, G | 1 |
| Venook, A | 3 |
| Meyerhardt, JA | 10 |
| Ecker, BL | 2 |
| Court, CM | 1 |
| Tao, AJ | 1 |
| D'Angelica, MI | 2 |
| Drebin, JA | 2 |
| Gonen, M | 6 |
| Pan, H | 3 |
| Pan, J | 1 |
| Wu, J | 6 |
| Zhu, Z | 5 |
| Hou, Q | 1 |
| Wang, B | 5 |
| Li, C | 5 |
| Liu, L | 3 |
| Gong, W | 1 |
| Chai, J | 1 |
| Guo, H | 3 |
| Jia, Y | 5 |
| Santucci, J | 1 |
| Tacey, M | 1 |
| Thomson, B | 1 |
| Michael, M | 10 |
| Wong, R | 7 |
| Shapiro, J | 4 |
| Jennens, R | 1 |
| Clarke, K | 1 |
| Pattison, S | 2 |
| Burge, M | 2 |
| Zielinski, R | 1 |
| Nikfarjam, M | 1 |
| Ananda, S | 1 |
| Lipton, L | 1 |
| Gibbs, P | 5 |
| Marschner, N | 1 |
| Hegewisch-Becker, S | 5 |
| Reiser, M | 1 |
| von der Heyde, E | 1 |
| Bertram, M | 1 |
| Hollerbach, SH | 1 |
| Kreher, S | 1 |
| Wolf, T | 1 |
| Binninger, A | 1 |
| Chiabudini, M | 1 |
| Kaiser-Osterhues, A | 1 |
| Jänicke, M | 1 |
| Gong, J | 3 |
| Thomassian, S | 1 |
| Kim, S | 16 |
| Gresham, G | 1 |
| Moshayedi, N | 1 |
| Ye, JY | 1 |
| Yang, JC | 1 |
| Jacobs, JP | 1 |
| Lo, S | 1 |
| Nissen, N | 1 |
| Gaddam, S | 1 |
| Tighiouart, M | 1 |
| Osipov, A | 1 |
| Hendifar, A | 1 |
| Hamad, A | 2 |
| Crossnohere, N | 1 |
| Ejaz, A | 2 |
| Tsung, A | 1 |
| Pawlik, TM | 8 |
| Sarna, A | 1 |
| Santry, H | 1 |
| Wills, C | 2 |
| Cloyd, JM | 1 |
| Zhou, B | 1 |
| Mai, Z | 1 |
| Ye, Y | 3 |
| Song, Y | 2 |
| Zhang, M | 4 |
| Yang, X | 2 |
| Xia, W | 1 |
| Qiu, X | 1 |
| Aparicio, T | 13 |
| Bouché, O | 24 |
| Etienne, PL | 8 |
| Barbier, E | 3 |
| Mineur, L | 7 |
| Desgrippes, R | 2 |
| Guérin-Meyer, V | 3 |
| Hocine, F | 1 |
| Martin, J | 1 |
| Le Brun-Ly, V | 1 |
| Cretin, J | 2 |
| Desramé, J | 3 |
| Rinaldi, Y | 3 |
| Cany, L | 1 |
| Falandry, C | 2 |
| Lefevre, LB | 1 |
| Marous, M | 1 |
| Terrebonne, E | 6 |
| Mosser, L | 1 |
| Turpin, J | 1 |
| Turpin, A | 1 |
| Bauguion, L | 1 |
| Reichling, C | 1 |
| Van den Eynde, M | 2 |
| Carola, E | 10 |
| Hiret, S | 1 |
| Kroupová, J | 1 |
| Hanuš, J | 1 |
| Štěpánek, F | 1 |
| Sochacka-Ćwikła, A | 1 |
| Mączyński, M | 1 |
| Czyżnikowska, Ż | 1 |
| Wiatrak, B | 1 |
| Jęśkowiak, I | 1 |
| Czerski, A | 1 |
| Regiec, A | 1 |
| Ramaswamy, A | 1 |
| Bhargava, P | 3 |
| Srinivas, S | 1 |
| Kannan, S | 1 |
| Bhandare, M | 1 |
| Chaudhari, V | 1 |
| Mantri, A | 1 |
| Kapoor, A | 1 |
| Das, S | 1 |
| Booma, N | 1 |
| Chaugule, D | 1 |
| Shrikhande, SV | 1 |
| Ostwal, V | 1 |
| Tang, JL | 1 |
| Zhang, B | 6 |
| Xu, JP | 1 |
| Qi, L | 1 |
| Xin, D | 1 |
| Wang, BZ | 1 |
| Tian, YT | 1 |
| Li, Y | 20 |
| Huang, J | 4 |
| Zhou, R | 1 |
| Li, L | 5 |
| Xi, S | 1 |
| Zhang, Y | 10 |
| Liu, Z | 1 |
| Zeng, D | 1 |
| Sun, H | 2 |
| Shi, M | 3 |
| Bin, J | 1 |
| Liao, Y | 1 |
| Liao, W | 1 |
| Wang, T | 5 |
| Li, X | 10 |
| Zhai, J | 1 |
| Shen, L | 13 |
| Chen, Q | 2 |
| Cui, SP | 1 |
| Wang, D | 3 |
| Lang, R | 1 |
| Sarradin, V | 1 |
| Betrian, S | 1 |
| Chaltiel, L | 1 |
| Brac De La Perriere, C | 1 |
| Delord, JP | 2 |
| Zeng, H | 2 |
| Wang, C | 5 |
| Song, LY | 1 |
| Jia, SJ | 1 |
| Zeng, X | 1 |
| Liu, Q | 4 |
| Tao, J | 4 |
| Joseph, MX | 3 |
| Vaudreuil, A | 3 |
| Dahiya, M | 3 |
| Eilers, D | 3 |
| Gürler, F | 3 |
| Güven, DC | 3 |
| Aydemir, E | 3 |
| Sütçüoğlu, O | 3 |
| İnci, BK | 3 |
| Arık, Z | 3 |
| Yalçın, Ş | 9 |
| Özdemir, N | 6 |
| Özet, A | 3 |
| Yazıcı, O | 4 |
| Saif, A | 3 |
| Verbus, E | 3 |
| Erickson, B | 4 |
| Kamgar, M | 3 |
| Tsai, S | 5 |
| Evans, D | 4 |
| Hernandez, JM | 3 |
| Hall, WA | 3 |
| Chiang, CH | 3 |
| Chiu, JH | 1 |
| Ma, KS | 1 |
| Chen, BS | 1 |
| Luan, YZ | 1 |
| Cheng, TC | 1 |
| Hsieh, CL | 1 |
| Dayyani, F | 1 |
| Macarulla, T | 3 |
| Johnson, A | 1 |
| Wainberg, ZA | 4 |
| Fong, ZV | 1 |
| Verdugo, FL | 1 |
| Fernandez-Del Castillo, C | 7 |
| Ferrone, CR | 8 |
| Allen, JN | 6 |
| Blaszkowsky, LS | 8 |
| Clark, JW | 15 |
| Parikh, AR | 1 |
| Ryan, DP | 19 |
| Weekes, CD | 2 |
| Hong, TS | 11 |
| Wo, JY | 8 |
| Lillemoe, KD | 12 |
| Qadan, M | 3 |
| Sisic, L | 2 |
| Crnovrsanin, N | 1 |
| Nienhueser, H | 1 |
| Jung, JO | 1 |
| Schiefer, S | 1 |
| Haag, GM | 3 |
| Bruckner, T | 2 |
| Schneider, M | 2 |
| Müller-Stich, BP | 1 |
| Büchler, MW | 18 |
| Schmidt, T | 2 |
| Gong, G | 1 |
| Zheng, Y | 2 |
| Ganesan, K | 1 |
| Xiong, Q | 1 |
| Tsim, KWK | 1 |
| Goetze, TO | 1 |
| Hofheinz, RD | 18 |
| Gaiser, T | 2 |
| Schmalenberg, H | 7 |
| Strumberg, D | 4 |
| Goekkurt, E | 3 |
| Angermeier, S | 1 |
| Zander, T | 1 |
| Kopp, HG | 1 |
| Pink, D | 3 |
| Siegler, G | 1 |
| Schenk, M | 1 |
| Galizia, G | 5 |
| Maiello, E | 5 |
| Bechstein, WO | 2 |
| Elshafei, M | 1 |
| Loose, M | 1 |
| Sookthai, D | 1 |
| Brulin, T | 1 |
| Pauligk, C | 9 |
| Lamarre, N | 1 |
| Sgouros, J | 1 |
| Gkoura, S | 1 |
| Spathas, N | 1 |
| Tzoudas, F | 1 |
| Karampinos, K | 1 |
| Miaris, N | 1 |
| Visvikis, A | 2 |
| Dessypris, N | 1 |
| Mauri, D | 2 |
| Aravantinos, G | 5 |
| Theodoropoulos, I | 1 |
| Stamoulis, G | 1 |
| Samantas, E | 4 |
| Hingorani, M | 1 |
| Goody, R | 1 |
| Bozas, G | 1 |
| Zahid, K | 1 |
| Mitton, DJ | 1 |
| Jain, P | 3 |
| Wong, V | 1 |
| Roy, R | 3 |
| Fu, Q | 2 |
| Chen, Y | 11 |
| Huang, D | 3 |
| Guo, C | 1 |
| Xiao, W | 2 |
| Xue, X | 2 |
| Zhang, Q | 7 |
| Gao, S | 1 |
| Que, R | 1 |
| Shen, Y | 3 |
| Bai, X | 1 |
| Liang, T | 1 |
| Nicolais, LM | 1 |
| Caron, M | 1 |
| Verdini, N | 1 |
| Fitzgerald, TL | 1 |
| Lei, Y | 1 |
| Chen, W | 3 |
| Tian, X | 2 |
| Wei, J | 3 |
| Shen, JP | 1 |
| Yousef, AM | 1 |
| Zeineddine, FA | 1 |
| Zeineddine, MA | 1 |
| Tidwell, RS | 1 |
| Beaty, KA | 1 |
| Scofield, LC | 1 |
| Rafeeq, S | 1 |
| Hornstein, N | 1 |
| Lano, E | 1 |
| Eng, C | 6 |
| Matamoros, A | 2 |
| Foo, WC | 1 |
| Uppal, A | 1 |
| Scally, C | 1 |
| Mansfield, P | 2 |
| Taggart, M | 1 |
| Raghav, KP | 1 |
| Overman, MJ | 3 |
| Fournier, K | 2 |
| Procaccio, L | 1 |
| Merz, V | 3 |
| Fasano, M | 1 |
| Vaccaro, V | 1 |
| Pretta, A | 1 |
| Noventa, S | 1 |
| Giordano, G | 1 |
| Zichi, C | 1 |
| Pinto, C | 6 |
| Zecchetto, C | 2 |
| Barsotti, G | 1 |
| Milella, M | 4 |
| Scartozzi, M | 3 |
| Zaniboni, A | 4 |
| Spadi, R | 1 |
| Casalino, S | 1 |
| Bergamo, F | 3 |
| De Toni, C | 1 |
| Melisi, D | 4 |
| Lonardi, S | 6 |
| Xu, Y | 7 |
| Tang, Q | 1 |
| Ding, N | 1 |
| Zhang, T | 2 |
| Luo, H | 2 |
| Mangieri, CW | 1 |
| Valenzuela, CD | 1 |
| Solsky, IB | 1 |
| Erali, RA | 1 |
| Pardee, T | 1 |
| Lima, CMSR | 2 |
| Howerton, R | 1 |
| Clark, CJ | 1 |
| Shen, P | 2 |
| Kunos, CA | 1 |
| Piekarz, R | 1 |
| Collins, JM | 1 |
| Kinsella, TJ | 2 |
| Baek, JH | 7 |
| Kang, BW | 2 |
| Kang, H | 1 |
| Cho, M | 1 |
| Kwon, OK | 1 |
| Park, JY | 2 |
| Park, KB | 1 |
| Seo, AN | 1 |
| Kim, JG | 7 |
| Pratap, A | 1 |
| Qualman, A | 1 |
| Garrett, H | 1 |
| The, E | 1 |
| Chauhan, A | 1 |
| Idrovo, JP | 1 |
| Cheng, L | 1 |
| Wani, S | 1 |
| Meguid, RA | 1 |
| Meng, X | 1 |
| Susan, M | 1 |
| Macasoi, I | 1 |
| Pinzaru, I | 1 |
| Dehelean, C | 1 |
| Ilia, I | 1 |
| Susan, R | 1 |
| Ionita, I | 1 |
| Schlick, K | 1 |
| Gantschnigg, A | 1 |
| Seymer, A | 1 |
| Huemer, F | 1 |
| Greil, R | 4 |
| Weiss, L | 1 |
| Chi, XJ | 1 |
| Song, YB | 1 |
| Liu, DH | 1 |
| Wei, LQ | 1 |
| Zhao, AR | 1 |
| An, X | 4 |
| Feng, ZZ | 1 |
| Lan, XH | 1 |
| Lv, YM | 1 |
| Li, HJ | 2 |
| Lan, D | 1 |
| He, HM | 1 |
| Singhal, R | 1 |
| Rogers, SC | 1 |
| Lee, JH | 23 |
| Ramnaraign, B | 1 |
| Fabregas, JC | 1 |
| Thomas, RM | 1 |
| Hughes, SJ | 2 |
| Nassour, I | 1 |
| Hitchcock, K | 1 |
| Russell, K | 1 |
| Kayaleh, O | 1 |
| Turk, A | 1 |
| Zlotecki, R | 1 |
| DeRemer, DL | 1 |
| George, TJ | 3 |
| Pillarisetty, VG | 1 |
| Koh, WJ | 2 |
| Zhen, DB | 1 |
| Park, JO | 20 |
| King, GG | 1 |
| Sham, JG | 1 |
| Hannan, LM | 1 |
| Mann, GN | 1 |
| Baker, KK | 1 |
| Redman, MW | 1 |
| Swanson, PE | 2 |
| Chiorean, EG | 4 |
| Whiting, SH | 1 |
| Tasnim, S | 1 |
| Sudarshan, M | 2 |
| Zhang, J | 12 |
| Han, G | 3 |
| Tang, J | 2 |
| Guo, F | 1 |
| Li, W | 8 |
| Xie, L | 1 |
| Xu, H | 1 |
| Tian, Y | 3 |
| Pan, L | 1 |
| Shu, Y | 3 |
| Ma, L | 2 |
| Chen, X | 2 |
| Almeida Junior, JC | 1 |
| Helal-Neto, E | 1 |
| Pinto, SR | 1 |
| Dos Santos, SN | 1 |
| Bernardes, ES | 1 |
| Al-Qahtani, M | 1 |
| Nigro, F | 1 |
| Alencar, LMR | 1 |
| Ricci-Junior, E | 1 |
| Santos-Oliveira, R | 1 |
| Endo, Y | 3 |
| Kitago, M | 1 |
| Aiura, K | 1 |
| Shinoda, M | 3 |
| Yagi, H | 1 |
| Abe, Y | 1 |
| Oshima, G | 1 |
| Hori, S | 3 |
| Nakano, Y | 5 |
| Itano, O | 1 |
| Fukada, J | 1 |
| Masugi, Y | 1 |
| Kitagawa, Y | 1 |
| Jia, AY | 1 |
| Narang, A | 1 |
| Safar, B | 2 |
| Zaheer, A | 1 |
| Murphy, A | 1 |
| Azad, NS | 1 |
| Gearhart, S | 1 |
| Fang, S | 1 |
| Efron, J | 2 |
| Warczynski, T | 1 |
| Hacker-Prietz, A | 2 |
| Meyer, J | 2 |
| Sunde, B | 1 |
| Klevebro, F | 3 |
| Johar, A | 1 |
| Johnsen, G | 3 |
| Jacobsen, AB | 3 |
| Glenjen, NI | 2 |
| Friesland, S | 3 |
| Lindblad, M | 2 |
| Ajengui, A | 1 |
| Lundell, L | 3 |
| Lagergren, P | 1 |
| Nilsson, M | 3 |
| Sahu, KK | 1 |
| Pandey, D | 1 |
| Mishra, AK | 1 |
| O'Shea, J | 1 |
| McGregor, B | 1 |
| Tran, NH | 1 |
| Sahai, V | 1 |
| Griffith, KA | 5 |
| Nathan, H | 2 |
| Kaza, R | 1 |
| Cuneo, KC | 1 |
| Shi, J | 2 |
| Kim, E | 1 |
| Sonnenday, CJ | 1 |
| Cho, CS | 1 |
| Lawrence, TS | 3 |
| Zalupski, MM | 10 |
| Philip, PA | 15 |
| Buyse, ME | 1 |
| Alistar, AT | 1 |
| Rocha Lima, CM | 1 |
| Luther, S | 1 |
| Pardee, TS | 1 |
| Lin, C | 4 |
| Verma, V | 2 |
| Lazenby, A | 2 |
| Ly, QP | 2 |
| Berim, LD | 1 |
| Schwarz, JK | 2 |
| Madiyalakan, M | 1 |
| Nicodemus, CF | 1 |
| Hollingsworth, MA | 2 |
| Meza, JL | 2 |
| Are, C | 2 |
| Padussis, J | 1 |
| Grem, JL | 11 |
| Opattova, A | 1 |
| Horak, J | 1 |
| Vodenkova, S | 1 |
| Kostovcikova, K | 1 |
| Cumova, A | 1 |
| Macinga, P | 1 |
| Galanova, N | 1 |
| Rejhova, A | 1 |
| Vodickova, L | 1 |
| Kozics, K | 1 |
| Turnovcova, K | 1 |
| Hucl, T | 1 |
| Sliva, D | 1 |
| Vodicka, P | 2 |
| Borg, D | 1 |
| Sundberg, J | 1 |
| Brun, E | 1 |
| Kjellén, E | 2 |
| Petersson, K | 1 |
| Hermansson, M | 1 |
| Johansson, J | 1 |
| Eberhard, J | 1 |
| Johnsson, A | 5 |
| Polish, A | 1 |
| Joseph, NE | 1 |
| Marsh, RW | 1 |
| Gaszynski, R | 1 |
| Gray, A | 1 |
| Merrett, N | 1 |
| Pointet, AL | 3 |
| Pozet, A | 1 |
| Trouilloud, I | 5 |
| Lourenco, N | 2 |
| Locher, C | 5 |
| Williet, N | 2 |
| Soularue, E | 2 |
| Le Roy, B | 1 |
| Legué, LM | 1 |
| van Erning, FN | 1 |
| Bernards, N | 1 |
| Lemmens, VEPP | 1 |
| de Hingh, IHJT | 2 |
| Creemers, GJ | 6 |
| Wu, G | 1 |
| Baine, MJ | 1 |
| Zhao, N | 2 |
| Li, S | 4 |
| Sundar, R | 1 |
| Ng, A | 1 |
| Zouridis, H | 2 |
| Padmanabhan, N | 1 |
| Sheng, T | 1 |
| Zhang, S | 8 |
| Lee, MH | 3 |
| Ooi, WF | 1 |
| Qamra, A | 1 |
| Inam, I | 1 |
| Hewitt, LC | 1 |
| So, JB | 3 |
| Koh, V | 1 |
| Nankivell, MG | 1 |
| Langley, RE | 6 |
| Rozen, SG | 2 |
| Yong, WP | 3 |
| Grabsch, HI | 3 |
| Tan, P | 2 |
| Tsang, ES | 1 |
| Spratlin, J | 1 |
| Cheung, WY | 3 |
| Kim, CA | 2 |
| Kong, S | 1 |
| Gill, S | 4 |
| Mahalingam, D | 1 |
| Wilkinson, GA | 1 |
| Eng, KH | 1 |
| Fields, P | 1 |
| Raber, P | 1 |
| Moseley, JL | 1 |
| Cheetham, K | 1 |
| Coffey, M | 1 |
| Nuovo, G | 1 |
| Kalinski, P | 1 |
| Arora, SP | 1 |
| Fountzilas, C | 2 |
| Liu, M | 5 |
| Yang, J | 3 |
| Cui, X | 1 |
| Zhou, Z | 5 |
| Zhan, H | 1 |
| Ding, K | 1 |
| Yang, Z | 9 |
| Fung, KA | 1 |
| Edil, BH | 4 |
| Postier, RG | 1 |
| Bronze, MS | 1 |
| Fernandez-Zapico, ME | 1 |
| Stemmler, MP | 1 |
| Brabletz, T | 1 |
| Li, YP | 1 |
| Houchen, CW | 1 |
| Li, M | 4 |
| Igarashi, H | 1 |
| Taniguchi, H | 10 |
| Nosho, K | 1 |
| Ishigami, K | 1 |
| Koide, H | 1 |
| Mitsuhashi, K | 1 |
| Okita, K | 1 |
| Takemasa, I | 3 |
| Imai, K | 5 |
| Nakase, H | 1 |
| Jiang, Z | 2 |
| Hou, Z | 1 |
| Liu, W | 3 |
| Wang, H | 12 |
| Hammel, P | 6 |
| Fabienne, P | 1 |
| Metges, JP | 1 |
| Andre, T | 27 |
| Louvet, C | 35 |
| El Hajbi, F | 1 |
| Faroux, R | 3 |
| Guimbaud, R | 8 |
| Lecomte, T | 8 |
| Rebischung, C | 3 |
| Tournigand, C | 15 |
| Cros, J | 2 |
| Kay, R | 1 |
| Hamm, A | 1 |
| Gupta, A | 1 |
| El Hariry, I | 1 |
| Bang, YJ | 19 |
| Lee, KH | 11 |
| Chiu, CF | 2 |
| Kim, JS | 16 |
| Shim, HJ | 5 |
| Rau, KM | 1 |
| Choi, HJ | 5 |
| Oh, DY | 16 |
| Belanger, B | 1 |
| Mukherjee, S | 4 |
| Boland, PM | 2 |
| Gosain, R | 1 |
| Attwood, K | 1 |
| Tan, W | 1 |
| Khushalani, N | 2 |
| Iyer, R | 2 |
| Fiori, E | 1 |
| Crocetti, D | 1 |
| Lamazza, A | 1 |
| DE Felice, F | 3 |
| Tarallo, M | 1 |
| Sterpetti, AV | 1 |
| Mingoli, A | 1 |
| Sapienza, P | 1 |
| DE Toma, G | 1 |
| Wen, F | 2 |
| Zheng, H | 5 |
| Zhang, P | 2 |
| Zhou, J | 3 |
| Chen, H | 2 |
| Zhou, K | 1 |
| Li, Q | 5 |
| Bi, F | 1 |
| Farren, MR | 1 |
| Sayegh, L | 1 |
| Ware, MB | 1 |
| Chen, HR | 1 |
| Liang, Y | 1 |
| Krasinskas, A | 1 |
| Zaidi, M | 1 |
| Sarmiento, JM | 1 |
| Kooby, D | 1 |
| El-Rayes, B | 2 |
| Shaib, W | 2 |
| Lesinski, GB | 1 |
| Law, HC | 1 |
| Lagundžin, D | 1 |
| Clement, EJ | 1 |
| Qiao, F | 1 |
| Wagner, ZS | 1 |
| Krieger, KL | 1 |
| Costanzo-Garvey, D | 1 |
| Caffrey, TC | 1 |
| DiMaio, DJ | 1 |
| Grandgenett, PM | 1 |
| Cook, LM | 1 |
| Fisher, KW | 1 |
| Yu, F | 3 |
| Woods, NT | 1 |
| Lof, S | 1 |
| Korrel, M | 1 |
| van Hilst, J | 1 |
| Alseidi, A | 1 |
| Balzano, G | 12 |
| Boggi, U | 1 |
| Butturini, G | 3 |
| Casadei, R | 1 |
| Dokmak, S | 1 |
| Edwin, B | 1 |
| Falconi, M | 2 |
| Keck, T | 1 |
| Malleo, G | 4 |
| de Pastena, M | 1 |
| Tomazic, A | 1 |
| Wilmink, H | 1 |
| Zerbi, A | 9 |
| Abu Hilal, M | 1 |
| Qiang, W | 1 |
| Wu, Q | 2 |
| Ni, X | 1 |
| Zhang, C | 1 |
| Zhao, J | 2 |
| Brown, J | 1 |
| Liepa, AM | 1 |
| Bapat, B | 2 |
| Madhwani, S | 1 |
| Lorenzen, S | 9 |
| García-Foncillas, J | 3 |
| Candrilli, SD | 1 |
| Kaye, JA | 2 |
| Lee, MC | 1 |
| Chen, YK | 1 |
| Hsu, YJ | 1 |
| Lin, BR | 1 |
| Alhadid, D | 1 |
| AlShammari, A | 1 |
| Almana, H | 1 |
| Aburahmah, M | 1 |
| Jain, A | 2 |
| Roviello, G | 4 |
| Roviello, F | 2 |
| Mini, E | 8 |
| Wen, L | 1 |
| Yang, S | 3 |
| Li, P | 3 |
| Wang, Q | 2 |
| Kaspo, B | 1 |
| Fan, H | 1 |
| Hu, J | 5 |
| Rosati, G | 8 |
| Galli, F | 2 |
| Cantore, M | 8 |
| Banzi, M | 1 |
| Zampino, MG | 5 |
| Mattioli, R | 2 |
| Cardellino, GG | 2 |
| Ronzoni, M | 5 |
| Di Bartolomeo, M | 4 |
| Tamberi, S | 1 |
| Marchetti, P | 2 |
| Rimassa, L | 1 |
| Corsi, D | 1 |
| Bochicchio, AM | 3 |
| Artioli, F | 1 |
| Labianca, R | 11 |
| Rulli, E | 1 |
| Bilancia, D | 1 |
| Bregni, G | 1 |
| Lordick, F | 21 |
| Herrmann, K | 1 |
| Barbour, AP | 2 |
| Walpole, ET | 3 |
| Mai, GT | 1 |
| Barnes, EH | 1 |
| Watson, DI | 6 |
| Ackland, SP | 3 |
| Martin, JM | 1 |
| Finch, R | 1 |
| Karapetis, CS | 4 |
| Shannon, J | 2 |
| Nott, LM | 1 |
| Varma, S | 1 |
| Marx, G | 1 |
| Falk, GL | 2 |
| Gebski, V | 4 |
| Oostendorp, M | 1 |
| Wilson, K | 2 |
| Thomas, J | 7 |
| Lampe, G | 1 |
| Zalcberg, JR | 5 |
| Simes, J | 2 |
| Smithers, BM | 6 |
| Archid, R | 2 |
| Zieker, D | 2 |
| Weinreich, FJ | 1 |
| Hönes, F | 1 |
| Königsrainer, A | 5 |
| Quintanilla-Martínez, L | 1 |
| Reymond, MA | 1 |
| Solass, W | 1 |
| Nakajima, TE | 4 |
| Yamaguchi, K | 6 |
| Boku, N | 10 |
| Hyodo, I | 6 |
| Mizusawa, J | 1 |
| Hara, H | 3 |
| Nishina, T | 6 |
| Sakamoto, T | 3 |
| Shitara, K | 2 |
| Shinozaki, K | 4 |
| Katayama, H | 2 |
| Nakamura, S | 4 |
| Terashima, M | 1 |
| Ganschow, P | 1 |
| Hofmann, L | 1 |
| Stintzing, S | 4 |
| Heinemann, V | 11 |
| Angele, M | 2 |
| Werner, J | 4 |
| Schulz, C | 2 |
| Scherr, AL | 1 |
| Jassowicz, A | 1 |
| Pató, A | 1 |
| Elssner, C | 1 |
| Ismail, L | 1 |
| Schmitt, N | 1 |
| Hoffmeister, P | 1 |
| Neukirch, L | 1 |
| Gdynia, G | 1 |
| Goeppert, B | 1 |
| Schulze-Bergkamen, H | 2 |
| Jäger, D | 13 |
| Köhler, BC | 1 |
| Chase, L | 1 |
| Lomnicki, S | 1 |
| Karrison, T | 1 |
| de Wilton Marsh, R | 1 |
| Rampurwala, MM | 1 |
| Narula, S | 1 |
| Alpert, L | 1 |
| Setia, N | 1 |
| Xiao, SY | 1 |
| Hart, J | 1 |
| Siddiqui, UD | 1 |
| Peterson, B | 1 |
| Moore, K | 1 |
| Kipping-Johnson, K | 1 |
| Markevicius, U | 1 |
| Gordon, B | 2 |
| Allen, K | 1 |
| Racette, C | 1 |
| Maron, SB | 1 |
| Liao, CY | 1 |
| Polite, BN | 2 |
| Kindler, HL | 3 |
| Turaga, K | 1 |
| Prachand, VN | 1 |
| Roggin, KK | 1 |
| Ferguson, MK | 2 |
| Posner, MC | 3 |
| Wei, L | 1 |
| Chen, J | 8 |
| Wen, J | 1 |
| Wu, D | 2 |
| Ma, X | 2 |
| Chen, Z | 7 |
| Petito, LC | 1 |
| García-Albéniz, X | 3 |
| Logan, RW | 1 |
| Howlader, N | 1 |
| Mariotto, AB | 1 |
| Dahabreh, IJ | 1 |
| Hernán, MA | 1 |
| Modesto, A | 1 |
| Dalmasso, C | 1 |
| Lusque, A | 1 |
| Vieillevigne, L | 1 |
| Izar, F | 1 |
| Moyal, E | 1 |
| Carrère, N | 1 |
| Rives, M | 1 |
| Launay, S | 1 |
| Moureau-Zabotto, L | 4 |
| Poizat, F | 2 |
| Giovannini, M | 8 |
| Yamano, T | 1 |
| Kubo, S | 1 |
| Tomita, N | 1 |
| Kolla, BC | 1 |
| Petersen, A | 1 |
| Chengappa, M | 1 |
| Gummadi, T | 1 |
| Ganesan, C | 1 |
| Gaertner, WB | 1 |
| Blaes, A | 1 |
| Loi, M | 1 |
| Magallon-Baro, A | 1 |
| Suker, M | 2 |
| Van Eijck, C | 1 |
| Hoogeman, M | 1 |
| Nuyttens, JJ | 2 |
| Perri, G | 1 |
| Prakash, L | 1 |
| Caravati, A | 1 |
| Varadhachary, GR | 3 |
| Fogelman, D | 3 |
| Pant, S | 2 |
| Koay, EJ | 1 |
| Herman, J | 2 |
| Maggino, L | 2 |
| Kim, M | 1 |
| Ikoma, N | 2 |
| Tzeng, CW | 3 |
| Salvia, R | 3 |
| Lee, JE | 15 |
| Bassi, C | 9 |
| Golan, T | 2 |
| Barenboim, A | 2 |
| Lahat, G | 2 |
| Nachmany, I | 2 |
| Goykhman, Y | 2 |
| Shacham-Shmueli, E | 3 |
| Halpern, N | 2 |
| Brazowski, E | 2 |
| Geva, R | 2 |
| Wolf, I | 2 |
| Goldes, Y | 1 |
| Ben-Haim, M | 1 |
| Klausner, JM | 2 |
| Lubezky, N | 2 |
| Wu, S | 2 |
| Turner, JR | 2 |
| Blangero, Y | 1 |
| Rabilloud, M | 1 |
| Laurent-Puig, P | 7 |
| Ecochard, R | 1 |
| Subtil, F | 2 |
| Laurent-Badr, Q | 1 |
| Barbe, C | 1 |
| Brugel, M | 1 |
| Volet, J | 1 |
| Grelet, S | 1 |
| Desot, E | 1 |
| Botsen, D | 2 |
| Deguelte, S | 1 |
| Pitta, A | 1 |
| Abdelli, N | 1 |
| Brasseur, M | 1 |
| De Mestier, L | 1 |
| Neuzillet, C | 2 |
| Sugarbaker, PH | 6 |
| Nishikawa, Y | 1 |
| Hoshino, N | 1 |
| Horimatsu, T | 3 |
| Funakoshi, T | 2 |
| Hida, K | 1 |
| Sakai, Y | 4 |
| Muto, M | 3 |
| Nakayama, T | 4 |
| Probst, EA | 1 |
| Smith, AL | 1 |
| Abad, JD | 1 |
| Park, H | 2 |
| Jin, RU | 1 |
| Wang-Gillam, A | 10 |
| Suresh, R | 2 |
| Rigden, C | 1 |
| Amin, M | 1 |
| Tan, BR | 3 |
| Pedersen, KS | 1 |
| Lim, KH | 2 |
| Trikalinos, NA | 1 |
| Acharya, A | 1 |
| Copsey, ML | 1 |
| Navo, KA | 1 |
| Morton, AE | 1 |
| Gao, F | 2 |
| Lockhart, AC | 3 |
| Scarabel, L | 1 |
| Garziera, M | 1 |
| Fortuna, S | 1 |
| Asaro, F | 1 |
| Toffoli, G | 1 |
| Geremia, S | 1 |
| Liao, L | 1 |
| Cheng, Q | 1 |
| Zhu, G | 1 |
| Pei, F | 1 |
| Ye, S | 2 |
| Tintelnot, J | 1 |
| Binder, M | 1 |
| Knorrenschild, JR | 1 |
| Kretzschmar, A | 7 |
| Ettrich, T | 1 |
| Lindig, U | 2 |
| Jacobasch, L | 1 |
| Nilsson, S | 1 |
| Bokemeyer, C | 9 |
| Michelakos, T | 2 |
| Cai, L | 2 |
| Villani, V | 1 |
| Sabbatino, F | 2 |
| Kontos, F | 2 |
| Yamada, T | 13 |
| Neyaz, A | 1 |
| Taylor, MS | 2 |
| Deshpande, V | 3 |
| Kurokawa, T | 3 |
| Ting, DT | 3 |
| Warshaw, AL | 4 |
| Ferrone, S | 1 |
| Sakai, D | 1 |
| Sugimoto, N | 1 |
| Tamura, T | 4 |
| Esaki, T | 4 |
| Denda, T | 5 |
| Okuda, H | 2 |
| Satoh, T | 7 |
| Tsushima, T | 2 |
| Makiyama, A | 2 |
| Tsuda, T | 2 |
| Hosokawa, A | 5 |
| Kuramochi, H | 1 |
| Tokunaga, S | 5 |
| Moriwaki, T | 3 |
| Yasui, H | 4 |
| Ishida, H | 6 |
| Tsuji, A | 9 |
| Otsu, S | 1 |
| Shimokawa, H | 1 |
| Baba, E | 3 |
| Sato, M | 8 |
| Matsumoto, S | 5 |
| Ozaki, Y | 2 |
| Tamagawa, H | 1 |
| Goto, M | 4 |
| Kadowaki, S | 4 |
| Fujii, H | 1 |
| Koh, Y | 1 |
| Yamazaki, K | 7 |
| Hironaka, S | 3 |
| Kishimoto, J | 1 |
| Pan, CH | 1 |
| Otsuka, Y | 3 |
| Sridharan, B | 1 |
| Woo, M | 1 |
| Leiton, CV | 1 |
| Babu, S | 1 |
| Torrente Gonçalves, M | 1 |
| Kawalerski, RR | 1 |
| K Bai, JD | 1 |
| Chang, DK | 4 |
| Biankin, AV | 2 |
| Scampavia, L | 1 |
| Spicer, T | 1 |
| Escobar-Hoyos, LF | 1 |
| Shroyer, KR | 1 |
| Taghizadeh, H | 1 |
| Unseld, M | 1 |
| Schmiderer, A | 1 |
| Djanani, A | 1 |
| Wilthoner, K | 1 |
| Buchinger, D | 1 |
| Prager, GW | 1 |
| Frampton, JE | 1 |
| Taibi, A | 1 |
| Lo Dico, R | 1 |
| Kaci, R | 1 |
| Naneix, AL | 1 |
| Mathonnet, M | 1 |
| Pocard, M | 1 |
| Yan, D | 3 |
| Sun, Q | 1 |
| Du, T | 1 |
| Cao, D | 1 |
| Yang, Y | 4 |
| Yuan, B | 1 |
| Li, H | 7 |
| Jiang, X | 1 |
| Song, C | 1 |
| Colombo, PE | 1 |
| Quenet, F | 2 |
| Alric, P | 1 |
| Neron, M | 1 |
| Rouanet, P | 3 |
| Carrier, G | 1 |
| Wu, AA | 1 |
| Bever, KM | 1 |
| Ho, WJ | 1 |
| Fertig, EJ | 1 |
| Niu, N | 1 |
| Zheng, L | 3 |
| Parkinson, RM | 1 |
| Durham, JN | 1 |
| Onners, B | 1 |
| Ferguson, AK | 1 |
| Wilt, C | 1 |
| Ko, AH | 7 |
| Laheru, DA | 5 |
| Anders, RA | 1 |
| Thompson, ED | 1 |
| Sugar, EA | 2 |
| Jaffee, EM | 3 |
| Le, DT | 2 |
| Begg, SKS | 1 |
| Birnbaum, DJ | 1 |
| Mino-Kenudson, M | 1 |
| Wellner, UF | 1 |
| Schilling, O | 1 |
| Castillo, CF | 1 |
| Liss, AS | 1 |
| Fumet, JD | 1 |
| Vincent, J | 2 |
| Bengrine, L | 1 |
| Hennequin, A | 1 |
| Granconato, L | 1 |
| Palmier, R | 1 |
| Ghiringhelli, F | 4 |
| Cao, C | 2 |
| Parikh, P | 1 |
| Moezardalan, K | 1 |
| Anantharaman, A | 1 |
| Azarm, A | 1 |
| Lai, J | 1 |
| Khemissa Akouz, F | 1 |
| Wahiba, B | 1 |
| Louafi, S | 2 |
| Gratet, A | 1 |
| Miglianico, L | 1 |
| Laharie, H | 1 |
| Bouhier Leporrier, K | 1 |
| Thirot Bidault, A | 2 |
| Texereau, P | 1 |
| Coriat, R | 9 |
| Gouttebel, MC | 1 |
| Malka, D | 5 |
| Gürbüz, M | 1 |
| Akkuş, E | 1 |
| Utkan, G | 1 |
| Nicolle, R | 1 |
| Blum, Y | 1 |
| Duconseil, P | 1 |
| Vanbrugghe, C | 1 |
| Brandone, N | 1 |
| Roques, J | 1 |
| Bigonnet, M | 1 |
| Gayet, O | 1 |
| Rubis, M | 1 |
| Elarouci, N | 1 |
| Armenoult, L | 1 |
| Ayadi, M | 1 |
| de Reyniès, A | 1 |
| Grandval, P | 1 |
| Garcia, S | 1 |
| Canivet, C | 1 |
| Bournet, B | 1 |
| Buscail, L | 2 |
| Moutardier, V | 5 |
| Iovanna, J | 1 |
| Dusetti, N | 1 |
| Patil, NR | 1 |
| Khan, GN | 1 |
| Ye, L | 4 |
| Hines, OJ | 2 |
| Pishvaian, MJ | 3 |
| He, AR | 1 |
| Hwang, JJ | 1 |
| Smaglo, BG | 1 |
| Kim, SS | 3 |
| Weinberg, BA | 1 |
| Weiner, LM | 9 |
| Marshall, JL | 4 |
| Brody, JR | 2 |
| Fu, X | 2 |
| Chang, L | 1 |
| Hui, D | 1 |
| Jia, R | 1 |
| Liu, N | 3 |
| Zhang, H | 6 |
| Han, Z | 1 |
| Liu, H | 9 |
| Zhu, H | 2 |
| Bhutiani, N | 1 |
| Zheng, Q | 4 |
| Pandit, H | 1 |
| Shi, X | 1 |
| Yu, Y | 5 |
| Pulliam, ZR | 1 |
| Tan, M | 2 |
| Martin, RCG | 1 |
| Pazderová, N | 1 |
| Urbán, V | 1 |
| Makovník, M | 1 |
| Macák, D | 1 |
| Janega, P | 1 |
| Chovanec, M | 1 |
| Rejleková, K | 1 |
| Mardiak, J | 1 |
| Mego, M | 1 |
| Pucher, PH | 1 |
| Rahman, SA | 1 |
| Walker, RC | 1 |
| Grace, BL | 1 |
| Bateman, A | 2 |
| Iveson, T | 9 |
| Jackson, A | 1 |
| Rees, C | 2 |
| Byrne, JP | 3 |
| Kelly, JJ | 3 |
| Noble, F | 4 |
| Underwood, TJ | 4 |
| Dotan, E | 2 |
| Cardin, DB | 1 |
| Lenz, HJ | 14 |
| Messersmith, W | 1 |
| O'Neil, B | 1 |
| Cohen, SJ | 9 |
| Denlinger, CS | 2 |
| Shahda, S | 2 |
| Astsaturov, I | 1 |
| Kapoun, AM | 1 |
| Brachmann, RK | 1 |
| Uttamsingh, S | 1 |
| Stagg, RJ | 1 |
| Weekes, C | 1 |
| Tang, W | 1 |
| Ren, L | 2 |
| Liu, T | 3 |
| Ye, Q | 1 |
| Wei, Y | 3 |
| He, G | 1 |
| Lin, Q | 2 |
| Wang, M | 4 |
| Liang, F | 1 |
| Cui, Y | 2 |
| Xu, J | 11 |
| Kim, BH | 1 |
| Kim, K | 16 |
| Jang, JY | 9 |
| Kwon, W | 2 |
| Kim, H | 14 |
| Lee, KB | 6 |
| Chie, EK | 10 |
| Choi, YJ | 5 |
| Byun, Y | 1 |
| Kang, JS | 1 |
| Kim, HS | 8 |
| Han, Y | 4 |
| Paik, WH | 2 |
| Lee, SH | 11 |
| Ryu, JK | 2 |
| Kim, YT | 3 |
| Lee, K | 2 |
| Jang, JK | 1 |
| Byun, JH | 2 |
| Kang, JH | 5 |
| Son, JH | 1 |
| Kim, JH | 26 |
| Kim, HJ | 20 |
| Yoo, C | 1 |
| Kim, KP | 3 |
| Hong, SM | 1 |
| Seo, DW | 2 |
| Kim, SC | 3 |
| Lee, MG | 2 |
| Pourghasemian, M | 1 |
| Danandeh Mehr, A | 1 |
| Molaei, M | 1 |
| Habibzadeh, A | 1 |
| Zeidan, YH | 2 |
| Kreidieh, M | 2 |
| Khalifeh, I | 2 |
| Turfa, R | 2 |
| Kattan, J | 6 |
| Alqasem, K | 2 |
| Amarin, R | 2 |
| Al Awabdeh, T | 2 |
| Deeba, S | 2 |
| Jamali, F | 2 |
| Mohamad, I | 2 |
| Elkhaldi, M | 2 |
| Daoud, F | 2 |
| Al Masri, M | 2 |
| Dabous, A | 2 |
| Hushki, A | 2 |
| Jaber, O | 2 |
| Khoury, C | 1 |
| El Husseini, Z | 2 |
| Al Darazi, M | 2 |
| Geara, F | 3 |
| Birgisson, H | 1 |
| Enblad, M | 1 |
| Artursson, S | 1 |
| Ghanipour, L | 1 |
| Cashin, P | 1 |
| Graf, W | 5 |
| Ettrich, TJ | 1 |
| Perkhofer, L | 1 |
| Decker, T | 3 |
| Hoffmann, T | 1 |
| Hebart, HF | 1 |
| Herrmann, T | 4 |
| Hannig, CV | 1 |
| Büchner-Steudel, P | 1 |
| Güthle, M | 1 |
| Hermann, PC | 1 |
| Berger, AW | 1 |
| Seufferlein, T | 3 |
| Granata, V | 3 |
| Fusco, R | 3 |
| Palaia, R | 3 |
| Belli, A | 1 |
| Petrillo, A | 6 |
| Izzo, F | 3 |
| Koizumi, M | 3 |
| Shinji, S | 2 |
| Matsuda, A | 2 |
| Yokoyama, Y | 4 |
| Takahashi, G | 1 |
| Iwai, T | 2 |
| Takeda, K | 4 |
| Hara, K | 4 |
| Yoshida, H | 4 |
| Foster, L | 1 |
| Satyadas, T | 1 |
| Siriwardena, A | 1 |
| Song, J | 2 |
| Xu, B | 1 |
| Boyce, J | 1 |
| Tawagi, K | 1 |
| Cole, JT | 1 |
| Hagen, ER | 1 |
| Cleary, RK | 1 |
| Hue, JJ | 1 |
| Sugumar, K | 1 |
| Bingmer, K | 1 |
| Ammori, JB | 1 |
| Winter, JM | 3 |
| Hardacre, JM | 3 |
| Walma, MS | 2 |
| Brada, LJ | 1 |
| Patuleia, SIS | 1 |
| Blomjous, JG | 1 |
| Bollen, TL | 1 |
| Bosscha, K | 2 |
| Bruijnen, RC | 2 |
| Busch, OR | 3 |
| Daams, F | 1 |
| van Dam, R | 1 |
| Festen, S | 2 |
| Jan de Groot, D | 1 |
| Willem de Groot, J | 1 |
| Mohammad, NH | 3 |
| Hermans, JJ | 2 |
| de Hingh, IH | 4 |
| Kerver, ED | 1 |
| van Leeuwen, MS | 1 |
| van der Leij, C | 1 |
| Liem, MS | 1 |
| van Lienden, KP | 2 |
| Los, M | 3 |
| de Meijer, VE | 2 |
| Meijerink, MR | 1 |
| Mekenkamp, LJ | 1 |
| Nederend, J | 2 |
| Nio, CY | 1 |
| Patijn, GA | 2 |
| Polée, MB | 2 |
| Pruijt, JF | 2 |
| Renken, NS | 1 |
| Rombouts, SJ | 1 |
| Schouten, TJ | 1 |
| Stommel, MWJ | 2 |
| Verweij, ME | 1 |
| de Vos-Geelen, J | 2 |
| de Vries, JJJ | 2 |
| Vulink, A | 1 |
| Wessels, FJ | 2 |
| Wilmink, JW | 4 |
| van Santvoort, HC | 2 |
| Molenaar, IQ | 1 |
| Evrard, C | 1 |
| Hajbi, FE | 1 |
| Fiore, FD | 1 |
| Malicot, KL | 1 |
| Bibeau, F | 7 |
| Zaanan, A | 9 |
| Sokol, H | 1 |
| Chibaudel, B | 3 |
| Pierre, S | 1 |
| Gonzalez, D | 2 |
| Ishiguro, M | 1 |
| Takenaka, R | 1 |
| Ogura, K | 1 |
| Hiratsuka, A | 1 |
| Takeda, H | 3 |
| Kawai, D | 1 |
| Tsugeno, H | 1 |
| Fujiki, S | 1 |
| Okada, H | 1 |
| Sekigami, Y | 1 |
| Harrison, J | 1 |
| Catalano, O | 1 |
| Miwa, K | 3 |
| Oki, E | 5 |
| Enomoto, M | 1 |
| Ihara, K | 1 |
| Ando, K | 2 |
| Fujita, F | 4 |
| Tominaga, M | 2 |
| Mori, S | 1 |
| Nakayama, G | 2 |
| Shimokawa, M | 2 |
| Saeki, H | 5 |
| Baba, H | 10 |
| Mori, M | 15 |
| Akagi, Y | 1 |
| Runkel, M | 1 |
| Verst, R | 1 |
| Spiegelberg, J | 1 |
| Fichtner-Feigl, S | 2 |
| Hoeppner, J | 2 |
| Glatz, T | 2 |
| Nishiki, M | 1 |
| Yoshida, Y | 7 |
| Ryu, S | 1 |
| Ichikawa, J | 1 |
| Shin, Y | 1 |
| Sannomiya, H | 1 |
| Koreeda, N | 1 |
| Yamana, I | 1 |
| Sato, K | 4 |
| Okamoto, T | 3 |
| Yanagisawa, J | 1 |
| Noritomi, T | 1 |
| Dreyfuss, AD | 1 |
| Barsky, AR | 1 |
| Wileyto, EP | 1 |
| Eads, JR | 2 |
| Kucharczuk, JC | 1 |
| Williams, NN | 1 |
| Karasic, TB | 1 |
| Metz, JM | 4 |
| Ben-Josef, E | 7 |
| Plastaras, JP | 2 |
| Wojcieszynski, AP | 1 |
| Sohal, DPS | 2 |
| Duong, M | 1 |
| Ahmad, SA | 1 |
| Gandhi, NS | 1 |
| Beg, MS | 1 |
| Wade, JL | 1 |
| Guthrie, KA | 3 |
| Lowy, AM | 5 |
| Barrak, D | 1 |
| Desale, S | 1 |
| Yoon, JJ | 1 |
| Dugan, MM | 1 |
| Kodavanti, PP | 1 |
| Sampah, ME | 1 |
| Shah, MA | 9 |
| Bodoky, G | 9 |
| Starodub, A | 1 |
| Yip, D | 5 |
| Bendell, J | 2 |
| Thai, D | 1 |
| He, J | 3 |
| Bigness, A | 1 |
| Sahin, IH | 1 |
| Laskowitz, D | 1 |
| Sigel, K | 1 |
| Zhou, M | 1 |
| Park, YA | 4 |
| Mutetwa, T | 1 |
| Nadkarni, G | 1 |
| Yeh, C | 1 |
| Polak, P | 1 |
| Sigel, C | 1 |
| Conroy, T | 13 |
| Juzyna, B | 2 |
| Fojo, T | 1 |
| Wisnivesky, JP | 1 |
| Bates, SE | 2 |
| Gani, C | 2 |
| Lamprecht, U | 2 |
| Ziegler, A | 1 |
| Moll, M | 1 |
| Gellermann, J | 1 |
| Heinrich, V | 1 |
| Wenz, S | 1 |
| Fend, F | 1 |
| Bitzer, M | 3 |
| Zips, D | 1 |
| Mitachi, K | 1 |
| Ariake, K | 1 |
| Shima, H | 1 |
| Sato, S | 6 |
| Miura, T | 6 |
| Maeda, S | 3 |
| Ishida, M | 2 |
| Mizuma, M | 1 |
| Ohtsuka, H | 1 |
| Kamei, T | 1 |
| Igarashi, K | 1 |
| Unno, M | 1 |
| Marthey, L | 3 |
| Abdallah, R | 1 |
| Mas, L | 2 |
| Francois, E | 7 |
| Saint, A | 1 |
| Cunha, AS | 4 |
| Vienot, A | 1 |
| Ksontini, F | 1 |
| Forestier, J | 2 |
| Fabiano, E | 1 |
| Leroy, F | 1 |
| Li, K | 2 |
| He, X | 3 |
| Tong, S | 1 |
| Jooste, V | 1 |
| Bouvier, AM | 2 |
| Abrams, SL | 1 |
| Akula, SM | 1 |
| Meher, AK | 1 |
| Steelman, LS | 1 |
| Gizak, A | 1 |
| Duda, P | 1 |
| Rakus, D | 1 |
| Martelli, AM | 1 |
| Ratti, S | 1 |
| Cocco, L | 1 |
| Montalto, G | 1 |
| Cervello, M | 1 |
| Ruvolo, P | 1 |
| Libra, M | 1 |
| Falzone, L | 1 |
| Candido, S | 1 |
| McCubrey, JA | 1 |
| Wijetunga, AR | 1 |
| Chua, TC | 3 |
| Nahm, CB | 1 |
| Pavlakis, N | 2 |
| Clarke, S | 4 |
| Chan, DL | 1 |
| Diakos, C | 1 |
| Maloney, S | 1 |
| Ashrafi-Zadeh, A | 1 |
| Kneebone, A | 4 |
| Hruby, G | 1 |
| Jamieson, NB | 2 |
| Gill, A | 1 |
| Samra, JS | 1 |
| Fuchs, CS | 15 |
| Bhagia, P | 1 |
| Adelberg, D | 1 |
| Qin, SK | 2 |
| Zarkavelis, G | 1 |
| Koliou, GA | 1 |
| Papadopoulou, K | 1 |
| Batistatou, A | 1 |
| Pazarli, E | 1 |
| Tryfonopoulos, D | 1 |
| Tsipoura, A | 1 |
| Bobos, M | 1 |
| Psyrri, A | 2 |
| Makatsoris, T | 4 |
| Petraki, C | 1 |
| Pectasides, D | 4 |
| Fountzilas, G | 10 |
| Pentheroudakis, G | 6 |
| Aomatsu, N | 2 |
| Maeda, K | 7 |
| Uchima, Y | 2 |
| Matsutani, S | 1 |
| Tsujio, G | 1 |
| Okada, T | 1 |
| Kurihara, S | 1 |
| Nishii, T | 2 |
| Tachimori, A | 1 |
| Ikeda, K | 4 |
| Takeuchi, K | 5 |
| Rovers, KP | 1 |
| Bakkers, C | 1 |
| Nienhuijs, SW | 1 |
| Burger, JWA | 1 |
| Creemers, GM | 1 |
| Thijs, AMJ | 1 |
| Brandt-Kerkhof, ARM | 1 |
| Madsen, EVE | 1 |
| van Meerten, E | 1 |
| Tuynman, JB | 1 |
| Kusters, M | 2 |
| Versteeg, KS | 1 |
| Aalbers, AGJ | 1 |
| Kok, NFM | 1 |
| Buffart, TE | 1 |
| Wiezer, MJ | 1 |
| Boerma, D | 1 |
| de Reuver, PR | 1 |
| Bremers, AJA | 1 |
| Verheul, HMW | 1 |
| Kruijff, S | 1 |
| de Groot, DJA | 1 |
| Witkamp, AJ | 1 |
| van Grevenstein, WMU | 1 |
| Koopman, M | 4 |
| Lahaye, MJ | 1 |
| Kranenburg, O | 1 |
| Fijneman, RJA | 1 |
| van 't Erve, I | 1 |
| Snaebjornsson, P | 3 |
| Hemmer, PHJ | 1 |
| Dijkgraaf, MGW | 1 |
| Punt, CJA | 2 |
| Tanis, PJ | 1 |
| Le, VH | 1 |
| Franko, J | 1 |
| Paz, BI | 1 |
| Singh, G | 1 |
| Fakih, M | 3 |
| Chung, V | 4 |
| Abdel-Rahman, O | 1 |
| King, K | 1 |
| Scarfe, A | 2 |
| Ou, FS | 1 |
| Hall, NC | 1 |
| Bekaii-Saab, T | 9 |
| Fruth, B | 1 |
| Twohy, E | 1 |
| Meyers, MO | 1 |
| Boffa, DJ | 1 |
| Mitchell, K | 2 |
| Niedzwiecki, D | 14 |
| Noonan, A | 1 |
| Thurmes, PJ | 1 |
| Venook, AP | 7 |
| Park, SJ | 1 |
| Joo, I | 1 |
| Han, JK | 1 |
| Brada, LJH | 1 |
| Daamen, LA | 1 |
| van Roessel, S | 1 |
| van Dam, RM | 1 |
| Liem, MLS | 1 |
| Yung Nio, C | 1 |
| Wilmink, HW | 1 |
| Quintus Molenaar, I | 1 |
| Allen, CJ | 1 |
| Pointer, DT | 1 |
| Blumenthaler, AN | 1 |
| Mehta, RJ | 1 |
| Hoffe, SE | 4 |
| Minsky, BD | 22 |
| Smith, GL | 1 |
| Blum, M | 3 |
| Mansfield, PF | 7 |
| Das, P | 5 |
| Ajani, J | 6 |
| Dineen, SP | 1 |
| Fleming, JB | 5 |
| Badgwell, BD | 1 |
| Pimiento, JM | 1 |
| Machover, D | 7 |
| Almohamad, W | 2 |
| Castagné, V | 1 |
| Desterke, C | 1 |
| Gomez, L | 1 |
| Gaston-Mathé, Y | 1 |
| Boucheix, C | 1 |
| Goldschmidt, E | 7 |
| Gratiaux, J | 1 |
| Gossery, C | 1 |
| Rezzag-Mahcene, C | 1 |
| Visseaux, L | 1 |
| Slimano, F | 2 |
| Lutsyk, M | 1 |
| Awawda, M | 1 |
| Gourevich, K | 1 |
| Ben Yosef, R | 1 |
| Watts, K | 1 |
| Madi, A | 1 |
| Palles, C | 1 |
| Maughan, TS | 3 |
| Kaplan, R | 1 |
| Al-Tassan, NA | 1 |
| Kerr, R | 1 |
| Kerr, D | 4 |
| Gray, V | 1 |
| West, H | 1 |
| Houlston, RS | 1 |
| Escott-Price, V | 1 |
| Cheadle, JP | 1 |
| Shu, C | 1 |
| Wang, R | 1 |
| Wen, H | 1 |
| Tian, Z | 1 |
| Wu, X | 9 |
| Gou, G | 1 |
| Erdoğan, MK | 1 |
| Ağca, CA | 1 |
| Aşkın, H | 1 |
| Caron, B | 1 |
| Reimund, JM | 1 |
| Ben Abdelghani, M | 3 |
| Sondag, D | 1 |
| Noirclerc, M | 2 |
| Duclos, B | 1 |
| Kurtz, JE | 2 |
| Nguimpi-Tambou, M | 1 |
| Botta, GP | 1 |
| Kato, S | 4 |
| Patel, H | 2 |
| Fanta, P | 1 |
| Lee, S | 11 |
| Okamura, R | 1 |
| Kurzrock, R | 1 |
| Na, D | 1 |
| Chae, J | 1 |
| Cho, SY | 2 |
| Kang, W | 1 |
| Lee, A | 1 |
| Min, S | 1 |
| Kang, J | 3 |
| Kim, MJ | 3 |
| Choi, J | 2 |
| Lee, W | 1 |
| Shin, D | 1 |
| Min, A | 1 |
| Kim, YJ | 6 |
| Kim, TY | 16 |
| Suh, YS | 1 |
| Kong, SH | 1 |
| Lee, HJ | 4 |
| Kim, WH | 4 |
| Im, SA | 15 |
| Yang, HK | 4 |
| Lee, C | 5 |
| Kim, JI | 2 |
| Garza-Treviño, EN | 1 |
| Martínez-Rodríguez, HG | 1 |
| Delgado-González, P | 1 |
| Solís-Coronado, O | 1 |
| Ortíz-Lopez, R | 1 |
| Soto-Domínguez, A | 1 |
| Treviño, VM | 1 |
| Padilla-Rivas, GR | 1 |
| Islas-Cisneros, JF | 1 |
| Quiroz-Reyes, AG | 1 |
| Said-Fernández, SL | 1 |
| Sędłak, K | 1 |
| Rawicz-Pruszyński, K | 1 |
| Mlak, R | 1 |
| Gęca, K | 1 |
| Skórzewska, M | 2 |
| Pelc, Z | 1 |
| Małecka-Massalska, T | 1 |
| Polkowski, WP | 1 |
| Grieb, BC | 1 |
| Agarwal, R | 2 |
| Pijnappel, EN | 1 |
| Dijksterhuis, WPM | 1 |
| van der Geest, LG | 1 |
| de Groot, JWB | 1 |
| Homs, MYV | 2 |
| van Laarhoven, HWM | 1 |
| Makino, S | 4 |
| Takahashi, H | 6 |
| Haraguchi, N | 3 |
| Nishimura, J | 3 |
| Hata, T | 5 |
| Matsuda, C | 1 |
| Ikenaga, M | 3 |
| Murata, K | 5 |
| Yamamoto, H | 11 |
| Doki, Y | 7 |
| Mizushima, T | 5 |
| Leong, T | 7 |
| Haustermans, K | 3 |
| Miller, D | 1 |
| Zalcberg, J | 5 |
| Boussioutas, A | 2 |
| Findlay, M | 4 |
| O'Connell, RL | 1 |
| Verghis, J | 1 |
| Willis, D | 2 |
| Kron, T | 1 |
| Crain, M | 1 |
| Murray, WK | 1 |
| Swallow, C | 2 |
| Darling, G | 1 |
| Pelzer, U | 2 |
| Blanc, JF | 6 |
| Cubillo, A | 3 |
| Von Hoff, DD | 2 |
| Wan, Y | 1 |
| Solem, CT | 1 |
| Botteman, MF | 1 |
| de Jong, FA | 2 |
| Squire, T | 1 |
| Buchanan, G | 1 |
| Rangiah, D | 1 |
| Davis, I | 1 |
| Chua, YJ | 7 |
| Rich, T | 1 |
| Elsaleh, H | 4 |
| Ishihara, S | 7 |
| Kawai, K | 4 |
| Tanaka, T | 20 |
| Kiyomatsu, T | 3 |
| Hata, K | 5 |
| Nozawa, H | 6 |
| Morikawa, T | 2 |
| Watanabe, T | 10 |
| Lamb, YN | 1 |
| Scott, LJ | 2 |
| Bozkurt, M | 2 |
| Amlashi, FG | 1 |
| Blum Murphy, M | 1 |
| Sadahiro, S | 6 |
| Suzuki, T | 10 |
| Tanaka, A | 1 |
| Okada, K | 6 |
| Saito, G | 1 |
| Miyakita, H | 1 |
| Ogimi, T | 1 |
| Nagase, H | 1 |
| Illerhaus, G | 2 |
| Martens, UM | 1 |
| Stoehlmacher, J | 4 |
| Luley, KB | 1 |
| Prasnikar, N | 1 |
| Egger, M | 1 |
| Probst, S | 3 |
| Messmann, H | 1 |
| Moehler, M | 14 |
| Fischbach, W | 1 |
| Hartmann, JT | 15 |
| Mayer, F | 1 |
| Höffkes, HG | 1 |
| Koenigsmann, M | 1 |
| Arnold, D | 5 |
| Kraus, TW | 1 |
| Grimm, K | 1 |
| Berkhoff, S | 1 |
| Post, S | 5 |
| Jäger, E | 10 |
| Bechstein, W | 1 |
| Ronellenfitsch, U | 1 |
| Mönig, S | 1 |
| Du, C | 1 |
| Peng, Y | 1 |
| Yao, Y | 3 |
| Zhao, Y | 10 |
| Cao, L | 1 |
| Zhu, WG | 1 |
| Gu, J | 3 |
| Idasiak, A | 1 |
| Galwas-Kliber, K | 1 |
| Behrendt, K | 1 |
| Wziętek, I | 1 |
| Kryj, M | 1 |
| Stobiecka, E | 1 |
| Chmielik, E | 1 |
| Suwiński, R | 2 |
| Sanford, NN | 1 |
| Catalano, PJ | 6 |
| Enzinger, PC | 9 |
| King, BL | 1 |
| Bueno, R | 1 |
| Martin, NE | 1 |
| Mamon, HJ | 7 |
| Abrams, TA | 2 |
| Meyer, G | 2 |
| Schrag, D | 6 |
| Schröder, W | 3 |
| Antonios, A | 1 |
| Gharios, J | 1 |
| Tohme, C | 1 |
| Li, SS | 3 |
| Guan, QY | 1 |
| Meng, G | 1 |
| Chang, XF | 1 |
| Wei, JW | 1 |
| Wang, P | 3 |
| Kang, B | 1 |
| Xu, JJ | 1 |
| Chen, HY | 1 |
| Nakayama, N | 4 |
| Hirashima, Y | 5 |
| Fujita, M | 4 |
| Asayama, M | 2 |
| Moriyama, I | 1 |
| Nakashima, K | 1 |
| Kitamura, H | 2 |
| Yoshimura, K | 2 |
| Wang, Y | 14 |
| Yang, L | 8 |
| Yin, D | 1 |
| Sung, S | 1 |
| Kim, SH | 17 |
| Nam, TK | 3 |
| Jeong, S | 1 |
| Jang, HS | 3 |
| Song, JH | 1 |
| Lee, JW | 5 |
| Bae, JM | 4 |
| Takayoshi, K | 1 |
| Kusaba, H | 1 |
| Uenomachi, M | 1 |
| Mitsugi, K | 1 |
| Makiyama, C | 1 |
| Uchino, K | 1 |
| Shirakawa, T | 2 |
| Shibata, Y | 1 |
| Shinohara, Y | 1 |
| Inadomi, K | 1 |
| Tsuchihashi, K | 1 |
| Arita, S | 1 |
| Ariyama, H | 1 |
| Akashi, K | 1 |
| Park, JJ | 1 |
| Hajj, C | 1 |
| Shi, W | 2 |
| Zhang, Z | 8 |
| Cuaron, JJ | 1 |
| Lowery, MA | 2 |
| Patel, M | 3 |
| Kurkjian, C | 2 |
| Hemphill, B | 1 |
| Flores, M | 1 |
| Thompson, D | 1 |
| Hernandez-Aragues, I | 2 |
| Baniandrés-Rodríguez, O | 2 |
| Avilés-Izquierdo, JA | 1 |
| Vilas-Boas, PT | 2 |
| Oumrani, S | 1 |
| Guillaumot, MA | 1 |
| Brieau, B | 1 |
| Oudjit, A | 1 |
| Léandri, C | 1 |
| Brezault, C | 4 |
| Chaussade, S | 4 |
| Casadaban, L | 1 |
| Maker, AV | 1 |
| Cinar, P | 2 |
| Voncken, FEM | 1 |
| van der Kaaij, RT | 2 |
| Sikorska, K | 2 |
| van Werkhoven, E | 1 |
| van Dieren, JM | 2 |
| Grootscholten, C | 1 |
| van Sandick, JW | 4 |
| Aleman, BMP | 1 |
| Hirsch, D | 1 |
| Sasaki, T | 17 |
| Ito, Y | 7 |
| Ohue, M | 3 |
| Kanemitsu, Y | 1 |
| Kobatake, T | 1 |
| Ito, M | 2 |
| Moriya, Y | 1 |
| Saito, N | 2 |
| Ruff, P | 2 |
| Lakomy, R | 1 |
| Prausova, J | 2 |
| van Hazel, GA | 2 |
| Moiseyenko, VM | 6 |
| Soussan-Lazard, K | 1 |
| Dochy, E | 1 |
| Magherini, E | 1 |
| Papamichael, D | 4 |
| Davuluri, R | 1 |
| Jiang, W | 2 |
| Fang, P | 1 |
| Xu, C | 1 |
| Komaki, R | 11 |
| Gomez, DR | 1 |
| Welsh, J | 1 |
| Cox, JD | 5 |
| Hsu, CC | 3 |
| Lin, SH | 2 |
| Pariente, R | 1 |
| Bejarano, I | 1 |
| Rodríguez, AB | 1 |
| Pariente, JA | 1 |
| Espino, J | 1 |
| Bascoul-Mollevi, C | 3 |
| Gourgou, S | 2 |
| Raoul, JL | 13 |
| Douillard, JY | 7 |
| Bedenne, L | 12 |
| Francis, SR | 1 |
| Orton, A | 1 |
| Thorpe, C | 1 |
| Stoddard, G | 1 |
| Lloyd, S | 1 |
| Anker, CJ | 1 |
| Markovina, S | 1 |
| Youssef, F | 1 |
| Roy, A | 2 |
| Aggarwal, S | 2 |
| Khwaja, S | 2 |
| DeWees, T | 1 |
| Tan, B | 2 |
| Myerson, RJ | 5 |
| Chang, DT | 3 |
| Parikh, PJ | 3 |
| Olsen, JR | 2 |
| Kluger, MD | 1 |
| Rashid, MF | 1 |
| Rosario, VL | 1 |
| Schrope, BA | 1 |
| Steinman, JA | 1 |
| Hecht, EM | 1 |
| Chabot, JA | 3 |
| Mazzone, M | 1 |
| Finisguerra, V | 1 |
| Prenen, H | 4 |
| Abramov, M | 1 |
| Bondarenko, I | 1 |
| Shparyk, Y | 1 |
| Gorbunova, V | 5 |
| Hontsa, A | 1 |
| Otchenash, N | 1 |
| Alsina, M | 2 |
| Lazarev, S | 1 |
| Feliu, J | 4 |
| Elme, A | 2 |
| Esko, V | 1 |
| Abdalla, K | 1 |
| Verma, U | 1 |
| Benedetti, F | 1 |
| Aoyama, T | 3 |
| Mizuguchi, H | 2 |
| Makris, L | 1 |
| Payette, E | 1 |
| Sarker, S | 1 |
| Chalchal, H | 1 |
| Lloyd, MA | 1 |
| Turkington, R | 1 |
| Griffiths, E | 1 |
| O'Donovan, M | 1 |
| O'Neill, JR | 1 |
| Mercer, S | 1 |
| Parsons, SL | 5 |
| Fitzgerald, RC | 1 |
| Song, DJ | 1 |
| Xu, ZL | 1 |
| Xie, SP | 1 |
| Hu, JH | 1 |
| Tepper, JE | 10 |
| Ye, X | 3 |
| Swanson, RS | 3 |
| Haller, DG | 20 |
| Dragovich, T | 1 |
| Alberts, SR | 11 |
| Bjarnason, GA | 4 |
| Willett, CG | 17 |
| Gunderson, LL | 19 |
| Goldberg, RM | 20 |
| Ilson, D | 3 |
| O'Reilly, E | 3 |
| Ciombor, K | 1 |
| Berg, DJ | 1 |
| Meyerhardt, J | 1 |
| Mayer, RJ | 13 |
| Ikemura, M | 1 |
| Hashida, T | 1 |
| Meyers, JP | 2 |
| Smyrk, TC | 4 |
| Julie, C | 2 |
| Zawadi, A | 1 |
| Folprecht, G | 6 |
| Van Laethem, JL | 7 |
| Sargent, DJ | 8 |
| Sinicrope, FA | 6 |
| Lal, H | 1 |
| Yadav, P | 1 |
| Jena, R | 1 |
| Jain, M | 1 |
| Moussallem, T | 1 |
| Lim, C | 2 |
| Osseis, M | 1 |
| Esposito, F | 1 |
| Lahat, E | 1 |
| Fuentes, L | 1 |
| Salloum, C | 1 |
| Azoulay, D | 2 |
| Katanyoo, K | 2 |
| Mizandari, M | 1 |
| Paksashvili, N | 1 |
| Kikodze, N | 1 |
| Azrumelashvili, T | 1 |
| Pantsulaia, I | 1 |
| Shanava, K | 1 |
| Janikashvili, N | 1 |
| Chikovani, T | 1 |
| Muto, O | 1 |
| Munakata, M | 2 |
| Yamagata, K | 1 |
| Masuda, A | 1 |
| Kotanagi, K | 1 |
| Kichiraku, T | 1 |
| Satoyoshi, R | 1 |
| Kudoh, K | 1 |
| Sawada, T | 5 |
| Miyazawa, H | 1 |
| Ouchi, S | 1 |
| Kotanagi, H | 1 |
| Sakata, Y | 6 |
| Siena, S | 2 |
| Rivera, F | 5 |
| Peeters, M | 7 |
| Koukakis, R | 1 |
| Demonty, G | 1 |
| Köhne, CH | 13 |
| Lee, SF | 1 |
| Chiang, CL | 1 |
| Lee, FAS | 1 |
| Wong, YW | 1 |
| Poon, CM | 1 |
| Wong, FCS | 1 |
| Tung, SY | 1 |
| Dodo, M | 1 |
| Kumagai, M | 1 |
| Hirakawa, H | 1 |
| Koseki, T | 1 |
| Tseng, MSF | 1 |
| Ng, IWS | 1 |
| Leong, YH | 1 |
| Leong, CN | 1 |
| Cheong, WK | 1 |
| Tey, JCS | 1 |
| Sönnichsen, R | 1 |
| Hennig, L | 1 |
| Blaschke, V | 1 |
| Winter, K | 5 |
| Körfer, J | 1 |
| Hähnel, S | 1 |
| Monecke, A | 1 |
| Wittekind, C | 4 |
| Jansen-Winkeln, B | 1 |
| Thieme, R | 1 |
| Gockel, I | 1 |
| Grosser, K | 1 |
| Weimann, A | 1 |
| Kubick, C | 1 |
| Wiechmann, V | 1 |
| Aigner, A | 1 |
| Bechmann, I | 1 |
| Kallendrusch, S | 1 |
| Radyk, MD | 1 |
| Burclaff, J | 1 |
| Willet, SG | 1 |
| Mills, JC | 1 |
| Lund, K | 1 |
| Olsen, CE | 1 |
| Wong, JJW | 1 |
| Olsen, PA | 1 |
| Solberg, NT | 1 |
| Høgset, A | 1 |
| Krauss, S | 5 |
| Selbo, PK | 1 |
| Bruckner, HW | 15 |
| Gurell, D | 1 |
| Hirschfeld, A | 1 |
| Yamada, Y | 15 |
| Gamoh, M | 3 |
| Iwanaga, I | 2 |
| Yuki, S | 4 |
| Shimodaira, H | 2 |
| Nakamura, M | 9 |
| Yamaguchi, T | 16 |
| Ohori, H | 2 |
| Kobayashi, K | 8 |
| Tsuda, M | 3 |
| Kobayashi, Y | 3 |
| Miyamoto, Y | 2 |
| Shimada, K | 2 |
| Sato, A | 2 |
| Morita, S | 8 |
| Komatsu, Y | 8 |
| Ishioka, C | 4 |
| Conde-Montero, E | 1 |
| Suárez-Fernández, R | 1 |
| Liang, D | 1 |
| Shi, S | 1 |
| Liang, C | 1 |
| Meng, Q | 1 |
| Ni, Q | 1 |
| Yu, X | 1 |
| Hyun, HB | 1 |
| Moon, JY | 1 |
| Cho, SK | 1 |
| Park, Y | 1 |
| Paik, JH | 1 |
| Kim, SW | 8 |
| Watanabe, S | 3 |
| Kariya, K | 1 |
| Morita, A | 2 |
| Cremolini, C | 8 |
| Antoniotti, C | 2 |
| Aprile, G | 5 |
| Masi, G | 10 |
| Grande, R | 1 |
| Tonini, G | 5 |
| Mescoli, C | 3 |
| Coltelli, L | 1 |
| Salvatore, L | 8 |
| Corsi, DC | 3 |
| Lupi, C | 2 |
| Gemma, D | 1 |
| Dell'Aquila, E | 1 |
| Marmorino, F | 1 |
| Di Fabio, F | 5 |
| Mancini, ML | 1 |
| Marcucci, L | 1 |
| Fontanini, G | 2 |
| Zagonel, V | 1 |
| Boni, L | 2 |
| Falcone, A | 14 |
| Palmisano, A | 1 |
| Esposito, A | 2 |
| Di Chiara, A | 1 |
| Ambrosi, A | 4 |
| Passoni, P | 16 |
| Slim, N | 5 |
| Fiorino, C | 2 |
| Albarello, L | 1 |
| Di Muzio, N | 3 |
| Calandrino, R | 3 |
| Rosati, R | 1 |
| Del Maschio, A | 1 |
| De Cobelli, F | 1 |
| Chu, NS | 1 |
| Wu, IC | 1 |
| Chin, YY | 1 |
| Bonucci, M | 1 |
| Pastore, C | 1 |
| Ferrera, V | 1 |
| Fiorentini, C | 1 |
| Fabbri, A | 1 |
| Zykova, T | 1 |
| Zhu, F | 2 |
| Lim, DY | 1 |
| Yao, K | 1 |
| Roh, E | 1 |
| Yoon, SP | 1 |
| Kim, HG | 4 |
| Bae, KB | 1 |
| Wen, W | 1 |
| Shin, SH | 2 |
| Nadas, J | 1 |
| Ma, W | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Jin, Z | 3 |
| Hartgers, ML | 1 |
| Sanhueza, CT | 1 |
| Shubert, CR | 1 |
| Truty, MJ | 2 |
| Muppa, P | 1 |
| Nagorney, DM | 7 |
| Hassan, M | 1 |
| Mahipal, A | 2 |
| Kato, T | 16 |
| Bando, H | 1 |
| Yoshino, T | 3 |
| Kagawa, Y | 2 |
| Iwamoto, S | 3 |
| Emi, Y | 4 |
| Touyama, T | 1 |
| Kotaka, M | 1 |
| Sakisaka, H | 1 |
| Yamanaka, T | 1 |
| Kanazawa, A | 1 |
| Gouveia, HS | 1 |
| Lopes, SO | 1 |
| Faria, AL | 1 |
| Mayanagi, S | 1 |
| Kashiwabara, K | 1 |
| Honda, M | 1 |
| Oba, K | 3 |
| Kanda, M | 2 |
| Maeda, H | 5 |
| Hamada, C | 1 |
| Sakamoto, J | 5 |
| Saji, S | 6 |
| Yoshikawa, T | 3 |
| Roxburgh, CSD | 1 |
| Strombom, P | 1 |
| Temple, LKF | 1 |
| Stadler, ZK | 2 |
| Seier, K | 1 |
| Reidy, DL | 1 |
| Varghese, A | 1 |
| Shia, J | 7 |
| Vakiani, E | 2 |
| Kim, SM | 1 |
| An, JY | 1 |
| Lee, J | 17 |
| Sohn, TS | 6 |
| Antonoff, M | 1 |
| Jaramillo, S | 1 |
| Sagebiel, T | 1 |
| Murphy, MB | 1 |
| Iveson, TJ | 5 |
| Kerr, RS | 1 |
| Saunders, MP | 6 |
| Cassidy, J | 6 |
| Hollander, NH | 1 |
| Haydon, A | 1 |
| Glimelius, B | 26 |
| Harkin, A | 1 |
| Allan, K | 1 |
| McQueen, J | 1 |
| Scudder, C | 1 |
| Boyd, KA | 1 |
| Briggs, A | 1 |
| Waterston, A | 1 |
| Medley, L | 1 |
| Wilson, C | 2 |
| Ellis, R | 1 |
| Essapen, S | 2 |
| Dhadda, AS | 1 |
| Harrison, M | 7 |
| Falk, S | 9 |
| Raouf, S | 3 |
| Olesen, RK | 1 |
| Propper, D | 2 |
| Bridgewater, J | 4 |
| Azzabi, A | 1 |
| Farrugia, D | 1 |
| Webb, A | 6 |
| Hickish, T | 9 |
| Weaver, A | 1 |
| Gollins, S | 4 |
| Wasan, HS | 2 |
| Paul, J | 3 |
| Qi, F | 1 |
| Zheng, Z | 2 |
| Yan, Q | 1 |
| Liu, J | 8 |
| Zhang, G | 2 |
| Usón Junior, PLS | 1 |
| Rother, ET | 1 |
| Maluf, FC | 1 |
| Bugano, DDG | 1 |
| Kondoh, C | 1 |
| Komori, A | 1 |
| Narita, Y | 2 |
| Ura, T | 4 |
| Ando, M | 4 |
| Rombouts, AJM | 1 |
| Hugen, N | 2 |
| Verhoeven, RHA | 1 |
| Elferink, MAG | 1 |
| Poortmans, PMP | 1 |
| Nagtegaal, ID | 5 |
| de Wilt, JHW | 1 |
| Wawok, P | 1 |
| Polkowski, W | 2 |
| Richter, P | 1 |
| Szczepkowski, M | 3 |
| Olędzki, J | 2 |
| Wierzbicki, R | 4 |
| Gach, T | 1 |
| Rutkowski, A | 3 |
| Dziki, A | 1 |
| Kołodziejski, L | 1 |
| Sopyło, R | 2 |
| Pietrzak, L | 3 |
| Kryński, J | 2 |
| Wiśniowska, K | 2 |
| Spałek, M | 1 |
| Pawlewicz, K | 1 |
| Polkowski, M | 1 |
| Kowalska, T | 1 |
| Paprota, K | 2 |
| Jankiewicz, M | 2 |
| Radkowski, A | 1 |
| Chalubińska-Fendler, J | 1 |
| Michalski, W | 2 |
| Bujko, K | 4 |
| Walston, S | 1 |
| Salloum, J | 1 |
| Grieco, C | 1 |
| Wuthrick, E | 3 |
| Diaz, DA | 1 |
| Barney, C | 1 |
| Manilchuk, A | 1 |
| Schmidt, C | 2 |
| Dillhoff, M | 2 |
| MacGregor, TP | 1 |
| Carter, R | 5 |
| Gillies, RS | 1 |
| Findlay, JM | 1 |
| Kartsonaki, C | 1 |
| Castro-Giner, F | 1 |
| Sahgal, N | 1 |
| Wang, LM | 1 |
| Chetty, R | 3 |
| Maynard, ND | 1 |
| Cazier, JB | 1 |
| Buffa, F | 1 |
| McHugh, PJ | 1 |
| Tomlinson, I | 1 |
| Middleton, MR | 4 |
| Sharma, RA | 2 |
| Dhir, M | 1 |
| Zenati, MS | 2 |
| Singhi, AD | 1 |
| Bahary, N | 3 |
| Hogg, ME | 2 |
| Zeh, HJ | 2 |
| Petrioli, R | 6 |
| Nardone, V | 1 |
| Rosellini, P | 2 |
| Multari, AG | 2 |
| Conca, R | 3 |
| Aieta, M | 2 |
| Desai, GS | 1 |
| Pande, P | 1 |
| Shah, RC | 1 |
| Jagannath, P | 1 |
| Jones, CM | 1 |
| Adams, R | 3 |
| Downing, A | 1 |
| Glynne-Jones, R | 8 |
| Hawkins, M | 1 |
| Sebag-Montefiore, D | 3 |
| Gilbert, DC | 1 |
| Muirhead, R | 1 |
| Brungs, D | 1 |
| Aghmesheh, M | 1 |
| de Souza, P | 1 |
| Carolan, M | 1 |
| Clingan, P | 2 |
| Rose, J | 1 |
| Ranson, M | 2 |
| Jang, BS | 1 |
| Park, HJ | 3 |
| Huang, KW | 1 |
| Yang, PC | 1 |
| Pua, U | 1 |
| Kim, MD | 2 |
| Li, SP | 2 |
| Qiu, YD | 1 |
| Song, TQ | 1 |
| Liang, PC | 1 |
| Tin, AW | 1 |
| Smith, E | 1 |
| Hepworth, R | 1 |
| Walker, J | 1 |
| Wilson, D | 3 |
| Wadd, N | 2 |
| Pokorny, AMJ | 1 |
| Chin, VT | 1 |
| Nagrial, AM | 1 |
| Chantrill, LA | 1 |
| Cortellini, A | 1 |
| Cannita, K | 2 |
| Parisi, A | 1 |
| Venditti, O | 1 |
| Lanfiuti Baldi, P | 2 |
| De Berardis, B | 1 |
| Vicentini, R | 2 |
| Vicentini, V | 1 |
| Verna, L | 1 |
| Porzio, G | 1 |
| Ficorella, C | 2 |
| Erstad, DJ | 1 |
| Sojoodi, M | 1 |
| Ghoshal, S | 1 |
| Razavi, AA | 1 |
| Graham-O'Regan, KA | 1 |
| Bardeesy, N | 1 |
| Lanuti, M | 1 |
| Caravan, P | 1 |
| Tanabe, KK | 1 |
| Fuchs, BC | 1 |
| Cheng, X | 2 |
| Cui, YH | 1 |
| Hou, J | 2 |
| Ji, Y | 3 |
| Sun, YH | 3 |
| Shen, ZB | 2 |
| Liu, FL | 2 |
| Liu, TS | 3 |
| Álvarez-Gallego, R | 1 |
| Muñoz, M | 1 |
| Pond, G | 1 |
| Perea, S | 1 |
| Sánchez, G | 1 |
| Martin, M | 2 |
| Rodríguez-Pascual, J | 2 |
| Garralda, E | 1 |
| Vega, E | 1 |
| de Vicente, E | 2 |
| Quijano, Y | 2 |
| Muñoz, C | 1 |
| Ugidos, L | 1 |
| Toledo, RA | 1 |
| Hidalgo, M | 2 |
| Ahmed, F | 1 |
| Kumari, S | 1 |
| Kondapi, AK | 1 |
| Schwarz, L | 1 |
| Vernerey, D | 1 |
| Tuech, JJ | 1 |
| Michel, P | 7 |
| Mondaca, S | 1 |
| Margolis, M | 1 |
| Sanchez-Vega, F | 1 |
| Jonsson, P | 1 |
| Riches, JC | 1 |
| Hechtman, JF | 1 |
| Tuvy, Y | 1 |
| Berger, MF | 1 |
| Yu, K | 2 |
| Goldberg, Z | 1 |
| Desai, A | 1 |
| Solit, DB | 1 |
| Schultz, N | 1 |
| Sehdev, A | 2 |
| Gbolahan, O | 1 |
| Hancock, BA | 1 |
| Stanley, M | 1 |
| Wan, J | 1 |
| Wu, HH | 1 |
| Radovich, M | 1 |
| O'Neil, BH | 3 |
| Jiang, ZC | 1 |
| Chi, Y | 2 |
| Takada, S | 1 |
| Sagawa, T | 4 |
| Fujikawa, K | 1 |
| Tahatsu, K | 1 |
| Fukai, Y | 1 |
| Hashishita, H | 1 |
| Takahashi, Y | 3 |
| Endo, M | 3 |
| Nakache, R | 1 |
| Rosen, G | 1 |
| Isakov, O | 1 |
| de Liguori Carino, N | 1 |
| O'Reilly, DA | 1 |
| Siriwardena, AK | 1 |
| Radhakrishna, G | 1 |
| Kao, CT | 1 |
| Aziz, M | 1 |
| Kasi, A | 1 |
| Girardi, DM | 1 |
| Faria, LDBB | 1 |
| Teixeira, MC | 1 |
| Costa, FP | 1 |
| Hoff, PMG | 1 |
| Fernandes, GS | 1 |
| Tfayli, A | 2 |
| Assi, H | 1 |
| Makki, I | 1 |
| Nassif, S | 1 |
| Signorovitch, JE | 1 |
| Yang, H | 1 |
| Patterson-Lomba, O | 1 |
| Xiang, CQ | 1 |
| Ung, B | 1 |
| Parisi, M | 1 |
| Athauda, A | 1 |
| Mohammed, K | 1 |
| Tait, D | 6 |
| Aitken, K | 1 |
| Cao, Y | 1 |
| Yu, L | 4 |
| Lin, L | 4 |
| Kim, WR | 1 |
| Han, YD | 1 |
| Min, BS | 5 |
| Touchefeu, Y | 3 |
| Cohen, R | 3 |
| Gornet, JM | 5 |
| Nguyen, S | 5 |
| Azzedine, A | 3 |
| Phelip, JM | 4 |
| Chapelle, N | 1 |
| Sefrioui, D | 1 |
| Lucidarme, O | 2 |
| Levache, CB | 2 |
| Desauw, C | 1 |
| Brocard, F | 1 |
| Breysacher, G | 3 |
| Lagasse, JP | 1 |
| Di Fiore, F | 3 |
| Dupuis, OJM | 1 |
| Aleba, A | 1 |
| Singh, N | 2 |
| Wong, E | 1 |
| Riffat, F | 1 |
| Zambetti, M | 4 |
| Montemurro, F | 2 |
| Morandi, P | 1 |
| Zamagni, C | 1 |
| Brandes, AA | 1 |
| Bisagni, G | 4 |
| Cagossi, K | 1 |
| Bengala, C | 2 |
| Gori, S | 3 |
| Iannacone, C | 1 |
| Stell, A | 1 |
| Gianni, L | 3 |
| Chakrabarti, S | 1 |
| Sara, J | 1 |
| Lobo, R | 1 |
| Eiring, R | 1 |
| Finnes, H | 1 |
| Mitchell, J | 1 |
| Hartgers, M | 1 |
| Okano, A | 1 |
| Halfdanarson, T | 1 |
| Grothey, A | 1 |
| Chouhan, H | 1 |
| Sammour, T | 1 |
| Thomas, ML | 1 |
| Moore, JW | 1 |
| Rhoades, K | 1 |
| Smith, B | 1 |
| Honaker, MD | 1 |
| Druzhkova, I | 1 |
| Ignatova, N | 1 |
| Prodanets, N | 1 |
| Kiselev, N | 1 |
| Zhukov, I | 1 |
| Shirmanova, M | 1 |
| Zagainov, V | 1 |
| Zagaynova, E | 1 |
| Yu, S | 4 |
| Tang, C | 1 |
| Jiang, H | 1 |
| Sun, Y | 6 |
| Shen, Z | 3 |
| Liu, F | 7 |
| Lin, HY | 2 |
| Kuo, WT | 1 |
| Hsu, CW | 1 |
| Yamaura, M | 1 |
| Watanabe, R | 1 |
| Hirose, S | 3 |
| Tajima, H | 1 |
| Uchida, Y | 4 |
| Suganuma, D | 1 |
| Yamamoto, Y | 7 |
| Hu, ZI | 1 |
| Hellmann, MD | 1 |
| Wolchok, JD | 1 |
| Vyas, M | 1 |
| Diaz, LA | 2 |
| Saint-Jean, A | 1 |
| Reguart, N | 1 |
| Eixarch, A | 1 |
| Adán, A | 1 |
| Castellà, C | 1 |
| Sánchez-Dalmau, B | 1 |
| Sainz-de-la-Maza, M | 1 |
| Narjoux, G | 1 |
| Clarenne, J | 1 |
| Azzouz, B | 1 |
| Zeller, PS | 1 |
| Que, WC | 1 |
| Huang, YF | 1 |
| Lin, XY | 1 |
| Lan, YQ | 1 |
| Gao, XY | 1 |
| Wang, XL | 1 |
| Wu, RP | 1 |
| Du, B | 1 |
| Huang, XB | 1 |
| Qiu, HQ | 1 |
| Zhong, DT | 1 |
| Steele, NG | 1 |
| Chakrabarti, J | 1 |
| Wang, J | 12 |
| Biesiada, J | 1 |
| Holokai, L | 1 |
| Chang, J | 2 |
| Nowacki, LM | 1 |
| Hawkins, J | 1 |
| Mahe, M | 2 |
| Sundaram, N | 1 |
| Shroyer, N | 1 |
| Medvedovic, M | 1 |
| Helmrath, M | 1 |
| Zavros, Y | 1 |
| Watson, S | 1 |
| Ferraz, JM | 1 |
| Lefevre, M | 1 |
| Colin, D | 1 |
| Svrcek, M | 1 |
| Meurisse, A | 1 |
| Kim, TH | 8 |
| Lee, IJ | 1 |
| Lee, CG | 2 |
| Lee, YC | 3 |
| Kim, JW | 3 |
| Borelli, B | 1 |
| Pietrantonio, F | 2 |
| Maish, WN | 1 |
| Nguyen, LK | 1 |
| Ngu, C | 1 |
| Bennett, G | 1 |
| Pranavan, G | 1 |
| Vogl, UM | 1 |
| Andalibi, H | 1 |
| Klaus, A | 1 |
| Vormittag, L | 1 |
| Schima, W | 1 |
| Heinrich, B | 1 |
| Kafka, A | 1 |
| Winkler, T | 1 |
| Öhler, L | 1 |
| Raufi, AG | 1 |
| Manji, GA | 1 |
| Peng, T | 1 |
| Ouyang, Y | 1 |
| Tong, K | 1 |
| Soveri, LM | 1 |
| Lamminmäki, A | 1 |
| Hänninen, UA | 1 |
| Karhunen, M | 1 |
| Bono, P | 1 |
| Osterlund, P | 6 |
| Matsumoto, I | 2 |
| Kamei, K | 2 |
| Omae, K | 2 |
| Suzuki, S | 4 |
| Matsuoka, H | 3 |
| Mizuno, N | 1 |
| Ozaka, M | 2 |
| Ueno, H | 6 |
| Kobayashi, S | 5 |
| Uesugi, K | 1 |
| Kobayashi, M | 7 |
| Todaka, A | 1 |
| Fukutomi, A | 3 |
| Ito, A | 2 |
| Takata, R | 1 |
| Matsuo, T | 1 |
| Kimura, T | 3 |
| Otsuka, K | 1 |
| Ishii, S | 1 |
| Tokiwa, S | 1 |
| Tanji, S | 1 |
| Sugimura, J | 1 |
| Omori, S | 1 |
| Obara, W | 1 |
| Setola, SV | 1 |
| Albino, V | 1 |
| Piccirillo, M | 2 |
| Grimm, R | 1 |
| Paganini, G | 1 |
| Chiriacò, G | 1 |
| Aoto, K | 1 |
| Inoue, N | 1 |
| Kono, K | 2 |
| Margalit, O | 1 |
| Mamtani, R | 1 |
| Kopetz, S | 4 |
| Yang, YX | 2 |
| Lawrence, YR | 1 |
| Abu-Gazala, S | 1 |
| Reiss, KA | 1 |
| Aderka, D | 1 |
| Giantonio, B | 4 |
| Boursi, B | 1 |
| Chow, OS | 3 |
| Keskin, M | 1 |
| Smith, DD | 3 |
| Avila, K | 3 |
| Chu, P | 1 |
| Rezkallah, KNM | 1 |
| Ahmed, A | 1 |
| Patel, S | 3 |
| Kozma, K | 1 |
| Roca-Lema, D | 1 |
| Martinez-Iglesias, O | 1 |
| Fernández de Ana Portela, C | 1 |
| Rodríguez-Blanco, A | 1 |
| Valladares-Ayerbes, M | 3 |
| Díaz-Díaz, A | 1 |
| Casas-Pais, A | 1 |
| Prego, C | 1 |
| Figueroa, A | 1 |
| Jia, B | 1 |
| Du, X | 1 |
| Dai, G | 3 |
| Zeng, M | 1 |
| Wen, K | 1 |
| Zhu, Y | 5 |
| Feng, L | 1 |
| Ramanathan, RK | 7 |
| McDonough, SL | 1 |
| Hingorani, SR | 1 |
| Lacy, J | 4 |
| Kortmansky, JS | 3 |
| Thumar, J | 1 |
| Shields, AF | 9 |
| Behl, D | 1 |
| Mehan, PT | 1 |
| Gaur, R | 1 |
| Seery, T | 1 |
| Su, X | 1 |
| Xiao, H | 1 |
| Chen, C | 2 |
| Wang, G | 3 |
| Sasson, A | 1 |
| Hahn, SM | 1 |
| Kazlauskas, A | 1 |
| Darinskas, A | 1 |
| Meškys, R | 1 |
| Tamašauskas, A | 1 |
| Urbonavičius, J | 1 |
| Fan, Z | 2 |
| Song, N | 1 |
| Han, M | 1 |
| Yan, M | 1 |
| Guo, LH | 1 |
| Jihui, J | 1 |
| Liu, S | 2 |
| Ichikawa, N | 1 |
| Homma, S | 1 |
| Hattori, M | 2 |
| Kamiizumi, Y | 1 |
| Omori, K | 1 |
| Nomura, M | 3 |
| Yokota, R | 1 |
| Koike, M | 2 |
| Kon, H | 1 |
| Ishizu, H | 2 |
| Hirose, K | 1 |
| Kuraya, D | 1 |
| Ishikawa, T | 6 |
| Murata, R | 1 |
| Iijima, H | 2 |
| Kawamata, F | 1 |
| Yoshida, T | 4 |
| Ohno, Y | 1 |
| Minagawa, N | 1 |
| Takahashi, N | 4 |
| Taketomi, A | 3 |
| Mirakhur, B | 1 |
| Lu, X | 1 |
| Huang, Y | 11 |
| Chi, P | 1 |
| Radu, IC | 1 |
| Hudita, A | 2 |
| Zaharia, C | 1 |
| Galateanu, B | 2 |
| Iovu, H | 1 |
| Tanasa, EV | 1 |
| Georgiana Nitu, S | 1 |
| Ginghina, O | 2 |
| Negrei, C | 2 |
| Tsatsakis, A | 1 |
| Velonia, K | 1 |
| Shtilman, M | 1 |
| Costache, M | 2 |
| Massih, SA | 1 |
| Kanso, M | 1 |
| Renz, P | 1 |
| Wegner, RE | 1 |
| Hasan, S | 1 |
| Brookover, R | 1 |
| Finley, G | 1 |
| Monga, D | 1 |
| Raj, M | 1 |
| McCormick, J | 1 |
| Kirichenko, A | 1 |
| Cleary, JM | 1 |
| Horick, NK | 1 |
| McCleary, NJ | 1 |
| Yurgelun, MB | 1 |
| Azzoli, CG | 1 |
| Rubinson, DA | 1 |
| Brooks, GA | 1 |
| Chan, JA | 1 |
| Goyal, L | 2 |
| Ng, K | 1 |
| Savarese, DMF | 1 |
| Graham, C | 1 |
| Fitzpatrick, B | 1 |
| Gibb, KA | 1 |
| Boucher, Y | 1 |
| Duda, DG | 1 |
| Jain, RK | 1 |
| Rangelova, E | 1 |
| Wefer, A | 1 |
| Persson, S | 2 |
| Valente, R | 1 |
| Tanaka, K | 11 |
| Orsini, N | 1 |
| Segersvärd, R | 1 |
| Arnelo, U | 1 |
| Del Chiaro, M | 1 |
| Kang, YK | 17 |
| Cho, H | 1 |
| Lu, B | 2 |
| Lu, C | 3 |
| Sun, Z | 2 |
| Qu, C | 1 |
| Hua, Z | 1 |
| Tong, R | 1 |
| Ozaki, K | 1 |
| Hayashi, H | 7 |
| Ikuta, Y | 2 |
| Masuda, T | 4 |
| Akaboshi, S | 1 |
| Ogata, K | 2 |
| Matumoto, K | 1 |
| Ogawa, K | 6 |
| Kamio, T | 1 |
| Takamori, H | 2 |
| Pouypoudat, C | 1 |
| Buscail, E | 1 |
| Cossin, S | 1 |
| Cassinotto, C | 2 |
| Smith, D | 10 |
| Marty, M | 1 |
| Dupin, C | 1 |
| Laurent, C | 4 |
| Dabernat, S | 1 |
| Chiche, L | 1 |
| Vendrely, V | 6 |
| Ulusakarya, A | 1 |
| Teyar, N | 1 |
| Karaboué, A | 1 |
| Haydar, M | 1 |
| Krimi, S | 1 |
| Biondani, P | 2 |
| Gumus, Y | 1 |
| Chebib, A | 1 |
| Morère, JF | 2 |
| Bradley, CA | 1 |
| Kourie, H | 1 |
| Gaujoux, S | 1 |
| Bruzzi, M | 1 |
| Sauvanet, A | 1 |
| El-Hajjar, A | 1 |
| Vaillant, JC | 3 |
| Pietrasz, D | 3 |
| Han, C | 1 |
| Pang, Q | 1 |
| Sun, X | 3 |
| Zhang, W | 6 |
| Lin, Y | 1 |
| Ge, X | 1 |
| Ni, W | 1 |
| Chang, X | 1 |
| Liang, J | 4 |
| Deng, L | 1 |
| Wang, W | 3 |
| Xiao, Z | 1 |
| Buettner, S | 1 |
| Beumer, BR | 1 |
| Addeo, P | 2 |
| Bachellier, P | 2 |
| Bali, MA | 1 |
| Boone, BA | 1 |
| Frakes, JM | 1 |
| Grose, D | 1 |
| Hosein, PJ | 1 |
| Javed, AA | 1 |
| Khan, K | 2 |
| Margonis, GA | 1 |
| McCarter, MD | 1 |
| McKay, CJ | 2 |
| Mellon, EA | 1 |
| Moorcraft, SY | 2 |
| Okada, KI | 1 |
| Peters, NA | 1 |
| Rabl, H | 4 |
| Samra, J | 1 |
| Tinchon, C | 1 |
| van Tienhoven, G | 1 |
| van Veldhuisen, E | 1 |
| Weiss, MJ | 2 |
| Yamaue, H | 4 |
| Burnett, A | 1 |
| Lecompte, MA | 1 |
| Trabulsi, N | 1 |
| Dubé, P | 1 |
| Gervais, MK | 1 |
| Trilling, B | 1 |
| Cloutier, AS | 1 |
| Sideris, L | 1 |
| Xu, X | 6 |
| De Falco, V | 1 |
| Natalicchio, MI | 1 |
| Napolitano, S | 1 |
| Coppola, N | 1 |
| Conzo, G | 1 |
| Martinelli, E | 2 |
| Zanaletti, N | 1 |
| Vitale, P | 1 |
| Giunta, EF | 1 |
| Vietri, MT | 1 |
| Vitiello, PP | 1 |
| Ciardiello, D | 1 |
| Marinaccio, A | 1 |
| Ciardiello, F | 5 |
| Troiani, T | 1 |
| Wagner, AD | 3 |
| Mauer, M | 1 |
| Marreaud, S | 2 |
| Caballero, C | 1 |
| Mueller, L | 1 |
| Moehler, MH | 1 |
| Martens, U | 1 |
| Rha, SY | 14 |
| Cats, A | 11 |
| Tokunaga, M | 1 |
| Vollmer, CM | 1 |
| Behrman, SW | 1 |
| Allegrini, V | 1 |
| Aversa, J | 1 |
| Ball, CG | 1 |
| Barrows, CE | 1 |
| Berger, AC | 2 |
| Cagigas, MN | 1 |
| Christein, JD | 2 |
| Dixon, E | 2 |
| Fisher, WE | 1 |
| Freedman-Weiss, M | 1 |
| Guzman-Pruneda, F | 1 |
| Hollis, RH | 1 |
| House, MG | 1 |
| Kent, TS | 1 |
| Kowalsky, SJ | 1 |
| Salem, RR | 2 |
| Schmidt, CR | 1 |
| Seykora, TF | 1 |
| Zheng, R | 1 |
| Dickson, PV | 1 |
| Mochizuki, Y | 1 |
| Harada, H | 2 |
| Oyama, J | 1 |
| Michi, Y | 1 |
| Kuroshima, T | 1 |
| Kugimoto, T | 1 |
| Huffman, BM | 1 |
| Yadav, S | 1 |
| McWilliams, RR | 1 |
| Halfdanarson, TR | 1 |
| Das, M | 1 |
| Hajjar, AH | 1 |
| Eid, R | 1 |
| Haddad, FG | 1 |
| Kourie, HR | 3 |
| Kadakia, KC | 1 |
| Worrilow, WM | 1 |
| Coley, H | 1 |
| Salem, ME | 1 |
| Jin, X | 2 |
| Bai, Y | 4 |
| Gao, L | 3 |
| Vreeland, TJ | 1 |
| McAllister, F | 1 |
| Javadi, S | 1 |
| Fogelman, DR | 1 |
| Ho, L | 4 |
| Varadhachary, G | 4 |
| Aloia, TA | 3 |
| Vauthey, JN | 8 |
| Kim, MP | 1 |
| Vashi, PG | 1 |
| Gorsuch, K | 1 |
| Wan, L | 1 |
| Hill, D | 1 |
| Block, C | 1 |
| Gupta, D | 1 |
| Ko, M | 1 |
| Sim, HC | 1 |
| Kim, CL | 1 |
| Jung, YJ | 1 |
| Kim, TO | 1 |
| Hwang, JE | 1 |
| Bae, WK | 2 |
| Hwang, EC | 1 |
| Jeong, O | 1 |
| Ryu, SY | 1 |
| Park, YK | 3 |
| Cho, SH | 4 |
| Chung, IJ | 4 |
| Bala, A | 1 |
| Panditharadyula, SS | 1 |
| Borg, C | 5 |
| Mantion, G | 2 |
| Boudghène, F | 1 |
| Mornex, F | 10 |
| Azria, D | 5 |
| Balosso, J | 5 |
| François, Y | 1 |
| Rio, E | 1 |
| Roullet, B | 2 |
| Spaëth, D | 1 |
| Quero, L | 2 |
| Lakkis, Z | 4 |
| Coudert, M | 1 |
| Ionescu-Goga, M | 1 |
| Tanang, A | 1 |
| Sen, A | 1 |
| Jiji, V | 1 |
| Roshni, S | 1 |
| Prahladan, A | 1 |
| Venugopal, M | 1 |
| Ramachandran, K | 1 |
| Marchegiani, G | 2 |
| Viviani, E | 1 |
| Nessi, C | 1 |
| Ciprani, D | 1 |
| Landoni, L | 1 |
| Casetti, L | 1 |
| Tuveri, M | 1 |
| Paiella, S | 1 |
| Casciani, F | 1 |
| Sereni, E | 1 |
| Binco, A | 1 |
| Bonamini, D | 1 |
| Secchettin, E | 1 |
| Auriemma, A | 1 |
| Simionato, F | 1 |
| D'Onofrio, M | 1 |
| Huang, M | 3 |
| Cai, Y | 3 |
| Xiao, J | 3 |
| Lan, P | 3 |
| Hu, H | 1 |
| Ling, J | 1 |
| Peng, J | 3 |
| Chen, D | 3 |
| Kang, L | 1 |
| Ren, D | 3 |
| Lin, F | 1 |
| Zheng, J | 3 |
| Deng, Y | 5 |
| Neely, D | 1 |
| Ong, J | 1 |
| Patterson, J | 1 |
| Kirkpatrick, D | 1 |
| Skelly, R | 1 |
| Cabau, M | 1 |
| Luc, G | 2 |
| Belleanne, G | 1 |
| Sa Cunha, A | 3 |
| Collet, D | 3 |
| Bajetta, E | 10 |
| Buzzoni, R | 6 |
| Ferrario, E | 3 |
| Valvo, F | 3 |
| Mariani, L | 6 |
| Dotti, KF | 1 |
| Formisano, B | 1 |
| Gevorgyan, A | 2 |
| Grassi, P | 1 |
| Li, PF | 1 |
| Geng, M | 1 |
| Cao, YC | 1 |
| Yin, YC | 1 |
| Donada, M | 3 |
| Bonin, S | 3 |
| Barbazza, R | 1 |
| Pettirosso, D | 1 |
| Stanta, G | 3 |
| Kripp, M | 4 |
| Rosowski, J | 1 |
| Saif, MW | 28 |
| Oikonomopoulos, GM | 1 |
| Huber, KE | 1 |
| Syrigos, KN | 6 |
| Kothari, N | 1 |
| Skoura, E | 1 |
| Nichols, RC | 1 |
| Zaiden, RA | 1 |
| Awad, ZT | 1 |
| Asbun, HJ | 1 |
| Huh, S | 1 |
| Ho, MW | 1 |
| Mendenhall, NP | 1 |
| Morris, CG | 1 |
| Hoppe, BS | 1 |
| Pluschnig, U | 4 |
| Schoppmann, SF | 4 |
| Preusser, M | 2 |
| Datler, P | 2 |
| Asari, R | 2 |
| Ba-Ssalamah, A | 4 |
| Schwameis, K | 2 |
| Birner, P | 2 |
| Zacherl, J | 4 |
| Hejna, M | 5 |
| Uronis, HE | 2 |
| Bendell, JC | 7 |
| Altomare, I | 1 |
| Blobe, GC | 4 |
| Hsu, SD | 2 |
| Morse, MA | 7 |
| Pang, H | 2 |
| Zafar, SY | 1 |
| Conkling, P | 1 |
| Favaro, J | 1 |
| Arrowood, CC | 1 |
| Cushman, SM | 1 |
| Meadows, KL | 1 |
| Brady, JC | 1 |
| Nixon, AB | 1 |
| Hurwitz, HI | 8 |
| Vañó-Galván, S | 1 |
| Longo, F | 1 |
| Grillo, E | 1 |
| Jaén, P | 1 |
| Cohn, AL | 4 |
| Maurel, J | 6 |
| Nowara, E | 1 |
| Sastre, J | 4 |
| Chuah, BYS | 1 |
| Kopp, MV | 1 |
| Sakaeva, DD | 1 |
| Mitchell, EP | 2 |
| Dubey, S | 2 |
| Hei, YJ | 1 |
| Galimi, F | 1 |
| McCaffery, I | 2 |
| Pan, Y | 1 |
| Loberg, R | 1 |
| Cottrell, S | 1 |
| Mol, L | 1 |
| van Gils, CW | 1 |
| Ottevanger, PB | 1 |
| Punt, CJ | 7 |
| van Dijk, TH | 1 |
| Tamas, K | 2 |
| Beukema, JC | 2 |
| Beets, GL | 1 |
| Gelderblom, AJ | 1 |
| de Jong, KP | 1 |
| Rutten, HJ | 4 |
| van de Velde, CJ | 7 |
| Wiggers, T | 2 |
| Hospers, GA | 3 |
| Havenga, K | 2 |
| Gordon, MA | 1 |
| Gundacker, HM | 1 |
| Benedetti, J | 3 |
| Macdonald, JS | 41 |
| Baranda, JC | 1 |
| Levin, WJ | 1 |
| Blanke, CD | 9 |
| Elatre, W | 1 |
| Weng, P | 1 |
| Zhou, JY | 1 |
| Press, MF | 1 |
| Sohal, DP | 1 |
| Sun, W | 5 |
| Giantonio, BJ | 2 |
| Ginsberg, G | 1 |
| Kochman, ML | 1 |
| Teitelbaum, UR | 1 |
| Harlacker, K | 1 |
| Heitjan, DF | 1 |
| Feldman, MD | 1 |
| O'Dwyer, PJ | 10 |
| Garcia-Carbonero, R | 1 |
| Sobrero, A | 10 |
| Tejpar, S | 1 |
| Gladkov, O | 1 |
| Davidenko, I | 2 |
| Salazar, R | 5 |
| Vladimirova, L | 1 |
| Cheporov, S | 1 |
| Burdaeva, O | 1 |
| Samuel, L | 2 |
| Bulavina, I | 1 |
| Potter, V | 1 |
| Chang, YL | 1 |
| Lokker, NA | 1 |
| Zhang, WY | 1 |
| Zhang, WJ | 1 |
| Yuan, HH | 1 |
| Gao, J | 2 |
| Gong, YF | 1 |
| Jiang, B | 1 |
| Alici, S | 2 |
| Buyukberber, S | 5 |
| Alkis, N | 2 |
| Benekli, M | 4 |
| Ozkan, M | 4 |
| Bilici, A | 4 |
| Demirci, U | 2 |
| Karaca, H | 3 |
| Arpaci, E | 2 |
| Gumus, M | 5 |
| Altunbas, M | 1 |
| Dane, F | 4 |
| Turk, HM | 1 |
| Berindan-Neagoe, I | 1 |
| Braicu, C | 1 |
| Pileczki, V | 1 |
| Cojocneanu Petric, R | 1 |
| Miron, N | 1 |
| Balacescu, O | 1 |
| Iancu, D | 1 |
| Ciuleanu, T | 2 |
| Heinzow, HS | 1 |
| Seifert, H | 1 |
| Tsepetonidis, S | 1 |
| Wolters, H | 1 |
| Kucharzik, T | 1 |
| Domschke, W | 1 |
| Domagk, D | 1 |
| Meister, T | 1 |
| Iwasa, S | 2 |
| Mayahara, H | 2 |
| Brodowicz, T | 1 |
| Ciuleanu, TE | 1 |
| Radosavljevic, D | 2 |
| Vrbanec, D | 1 |
| Plate, S | 1 |
| Mrsic-Krmpotic, Z | 1 |
| Dank, M | 3 |
| Purkalne, G | 1 |
| Messinger, D | 1 |
| Zielinski, CC | 1 |
| Saridaki, Z | 1 |
| Lambrodimou, G | 1 |
| Kachris, S | 1 |
| Makrantonakis, P | 2 |
| Boukovinas, I | 2 |
| Polyzos, A | 9 |
| Anagnostopoulos, A | 1 |
| Athanasiadis, A | 6 |
| Stoltidis, D | 1 |
| Georgoulias, V | 9 |
| Souglakos, J | 6 |
| Nakai, T | 1 |
| Okuno, K | 1 |
| Kitaguchi, H | 1 |
| Ishikawa, H | 4 |
| Yamasaki, M | 4 |
| Carrato, A | 9 |
| Popov, I | 3 |
| Gaspà, L | 1 |
| Valladares, M | 1 |
| Rougier, P | 37 |
| Gog, C | 1 |
| Reichardt, P | 6 |
| Wils, J | 8 |
| Pignatti, F | 1 |
| Biertz, F | 1 |
| Hendlisz, A | 4 |
| Golfinopoulos, V | 1 |
| Deleporte, A | 1 |
| Paesmans, M | 3 |
| Mansy, HE | 1 |
| Garcia, C | 1 |
| Annemans, L | 1 |
| Vandeputte, C | 1 |
| Maetens, M | 1 |
| Borbath, I | 1 |
| Dresse, D | 1 |
| Houbiers, G | 1 |
| Fried, M | 1 |
| Awada, A | 1 |
| Piccart, M | 2 |
| Laethem, JL | 1 |
| Flamen, P | 2 |
| Rudek, MA | 1 |
| Connolly, RM | 1 |
| Hoskins, JM | 1 |
| Garrett-Mayer, E | 2 |
| Jeter, SC | 1 |
| Armstrong, DK | 1 |
| Fetting, JH | 1 |
| Stearns, V | 1 |
| Wright, LA | 1 |
| Zhao, M | 1 |
| Watkins, SP | 1 |
| McLeod, HL | 2 |
| Davidson, NE | 1 |
| Wolff, AC | 1 |
| Aichler, M | 2 |
| Elsner, M | 1 |
| Ludyga, N | 1 |
| Feuchtinger, A | 1 |
| Zangen, V | 1 |
| Maier, SK | 1 |
| Balluff, B | 1 |
| Schöne, C | 1 |
| Hierber, L | 1 |
| Braselmann, H | 1 |
| Meding, S | 1 |
| Rauser, S | 1 |
| Zischka, H | 1 |
| Aubele, M | 1 |
| Schmitt, M | 1 |
| Feith, M | 5 |
| Hauck, SM | 1 |
| Ueffing, M | 1 |
| Langer, R | 8 |
| Kuster, B | 1 |
| Zitzelsberger, H | 1 |
| Höfler, H | 6 |
| Walch, AK | 1 |
| Haller, B | 1 |
| Schuster, T | 2 |
| Luley, K | 2 |
| Bichev, D | 4 |
| Schumacher, G | 2 |
| Waddell, T | 1 |
| Okines, AF | 5 |
| Frances, A | 1 |
| Okines, C | 1 |
| Wotherspoon, A | 8 |
| Saffery, C | 3 |
| Middleton, G | 5 |
| Wadsley, J | 2 |
| Ferry, D | 3 |
| Mansoor, W | 1 |
| Crosby, T | 3 |
| Coxon, F | 3 |
| Waters, J | 2 |
| Slater, S | 2 |
| Peckitt, C | 4 |
| Barbachano, Y | 7 |
| Chung, HC | 17 |
| Salman, P | 1 |
| Oh, SC | 5 |
| Kurteva, G | 1 |
| Volovat, C | 2 |
| Sawaki, A | 4 |
| Celik, I | 2 |
| Götte, H | 1 |
| Melezínková, H | 1 |
| Xia, Q | 2 |
| Luo, R | 1 |
| Huang, P | 1 |
| Shi, Y | 1 |
| Yuan, ST | 1 |
| Wang, FL | 2 |
| Liu, YH | 2 |
| Liu, SG | 1 |
| Li, YQ | 1 |
| Liu, XB | 1 |
| Li, WH | 1 |
| Yu, J | 3 |
| Zhang, JD | 1 |
| de Amuriza-Chicharro, N | 1 |
| Gastalver-Martín, C | 1 |
| Cortijo-Cascajares, S | 1 |
| Ferrari-Piquero, JM | 1 |
| Hurt, CN | 1 |
| Staffurth, J | 1 |
| Ray, R | 1 |
| Bashir, N | 1 |
| Bridgewater, JA | 1 |
| Geh, JI | 2 |
| Blazeby, J | 1 |
| Maughan, T | 1 |
| Griffiths, G | 1 |
| Shridhar, R | 3 |
| Weber, JM | 2 |
| Chuong, MD | 1 |
| Karl, RC | 2 |
| Meredith, K | 2 |
| Ozerkan, T | 1 |
| Aydemir Sezer, U | 1 |
| Deliloglu Gurhan, İ | 1 |
| Gulce İz, S | 1 |
| Hasirci, N | 1 |
| Khanna, A | 1 |
| Reece-Smith, AM | 2 |
| Cunnell, M | 1 |
| Madhusudan, S | 4 |
| Thomas, A | 2 |
| Bowrey, DJ | 1 |
| Al-Tonbary, Y | 1 |
| Darwish, A | 1 |
| El-Hussein, A | 1 |
| Fouda, A | 1 |
| Barsukov, YA | 1 |
| Gordeyev, SS | 1 |
| Tkachev, SI | 1 |
| Fedyanin, MY | 2 |
| Perevoshikov, AG | 1 |
| Mirinezhad, SK | 2 |
| Somi, MH | 2 |
| Seyednezhad, F | 1 |
| Jangjoo, AG | 2 |
| Ghojazadeh, M | 2 |
| Mohammadzadeh, M | 2 |
| Naseri, AR | 2 |
| Nasiri, B | 2 |
| Wu, XY | 2 |
| Huang, XE | 3 |
| You, SX | 1 |
| Lu, YY | 2 |
| Cao, J | 2 |
| Yu, DF | 1 |
| Wu, FR | 1 |
| Lei, Z | 1 |
| Tan, IB | 2 |
| Das, K | 1 |
| Deng, N | 1 |
| Chua, C | 1 |
| Feng, Z | 1 |
| Guan, YK | 1 |
| Ooi, CH | 1 |
| Ivanova, T | 1 |
| Ngo, A | 1 |
| Manesh, S | 1 |
| Tan, E | 1 |
| Teh, BT | 1 |
| Goh, LK | 1 |
| Lim, TK | 1 |
| Flotow, H | 1 |
| Bondar', GV | 3 |
| Basheev, VKh | 1 |
| Zolotukhin, SÉ | 1 |
| Sovpel', IV | 1 |
| Sovpel', OV | 1 |
| Elezkurtaj, S | 1 |
| Moser, L | 1 |
| Budczies, J | 1 |
| Müller, AJ | 1 |
| Bläker, H | 1 |
| Buhr, HJ | 4 |
| Dietel, M | 1 |
| Kruschewski, M | 1 |
| Musio, D | 2 |
| Bulzonetti, N | 2 |
| Guarnaccia, R | 1 |
| Caiazzo, R | 2 |
| Bangrazi, C | 1 |
| Raffetto, N | 1 |
| Tombolini, V | 3 |
| Zhu, J | 5 |
| Gu, W | 2 |
| Lian, P | 3 |
| Sheng, W | 2 |
| Cai, G | 3 |
| Shi, D | 3 |
| Cai, S | 4 |
| Xu, HQ | 1 |
| Qian, YD | 1 |
| Xiang, J | 2 |
| Mitry, E | 12 |
| Dalban, C | 1 |
| Seitz, JF | 17 |
| Turki, H | 1 |
| Lepère, C | 3 |
| Vaillant, JN | 2 |
| Landi, B | 5 |
| El Bouzidi, L | 1 |
| Mahiou-Leddet, V | 1 |
| Bun, SS | 1 |
| Larhsini, M | 1 |
| Abbad, A | 1 |
| Markouk, M | 1 |
| Fathi, M | 1 |
| Boudon, M | 1 |
| Ollivier, E | 1 |
| Bekkouche, K | 1 |
| Todaro, M | 1 |
| Orlando, V | 1 |
| Cicero, G | 5 |
| Caccamo, N | 1 |
| Meraviglia, S | 1 |
| Stassi, G | 1 |
| Dieli, F | 1 |
| Cooper, AB | 2 |
| Katz, MH | 5 |
| Gerber, N | 1 |
| Bains, MS | 1 |
| Rizk, N | 1 |
| Rusch, VW | 1 |
| Trusilova, EV | 1 |
| Besova, NS | 2 |
| Bagrova, SG | 1 |
| Gorbunova, VA | 2 |
| Stilidi, IS | 1 |
| Nered, SN | 1 |
| Tang, R | 6 |
| Sang, Y | 1 |
| Hu, Q | 1 |
| Du, Z | 1 |
| Zhou, Y | 2 |
| Ahn, JS | 4 |
| Jeon, JR | 1 |
| Yoo, HS | 1 |
| Park, TK | 2 |
| Park, CK | 5 |
| Sinn, DH | 1 |
| Paik, SW | 1 |
| Miyata, H | 3 |
| Sugimura, K | 2 |
| Takahashi, T | 15 |
| Kurokawa, Y | 2 |
| Nakajima, K | 4 |
| Takiguchi, S | 3 |
| Xu, JM | 4 |
| Ge, FJ | 3 |
| Liu, ZY | 1 |
| Sharma, MR | 1 |
| Strimpakos, AS | 3 |
| Loupakis, F | 8 |
| Yang, D | 4 |
| Wakatsuki, T | 1 |
| Bohanes, P | 1 |
| Schirripa, M | 4 |
| Benhaim, L | 1 |
| Graziano, F | 4 |
| Ruzzo, A | 2 |
| Lucchesi, S | 1 |
| Murata, Y | 1 |
| Matsuura, T | 1 |
| Kanoshima, K | 1 |
| Kuwabara, H | 2 |
| Fuyuki, A | 1 |
| Tomeno, W | 1 |
| Taniguchi, R | 1 |
| Uchiyama, T | 1 |
| Kuriyama, H | 1 |
| Hata, Y | 1 |
| Oh, SY | 13 |
| Kim, MC | 3 |
| Kim, KH | 3 |
| Chen, SS | 1 |
| Yang, XC | 1 |
| Chi, F | 1 |
| Yu, WZ | 1 |
| Wang, ZB | 1 |
| Ning, FL | 1 |
| Yu, ZS | 1 |
| Hao, YZ | 1 |
| Li, ML | 1 |
| Wang, F | 7 |
| Geng, DZ | 1 |
| Liu, LH | 1 |
| Dong, XJ | 1 |
| Peng, XZ | 1 |
| Ji, CX | 1 |
| Lee, DW | 2 |
| Park, ST | 1 |
| Park, JS | 7 |
| Lee, HN | 2 |
| Shirmohamadi, M | 1 |
| Seyednejad, F | 1 |
| Lee, WC | 2 |
| Yusof, MM | 1 |
| Lau, FN | 1 |
| Phua, VC | 1 |
| Turner, ES | 1 |
| Ilhan-Mutlu, A | 1 |
| Püspök, A | 1 |
| Buyse, M | 10 |
| Lichinitser, M | 5 |
| Cascinu, S | 13 |
| Zaucha, R | 1 |
| Moiseyenko, V | 4 |
| Cai, Z | 1 |
| Ke, J | 1 |
| Yuan, R | 1 |
| Tan, JW | 1 |
| Tan, HM | 1 |
| Hu, BS | 1 |
| Chen, K | 1 |
| Ding, XM | 1 |
| Leng, JJ | 1 |
| Chen, F | 1 |
| Morita, M | 2 |
| Tsuda, Y | 1 |
| Hidaka, G | 1 |
| Kasagi, Y | 1 |
| Kawano, H | 2 |
| Otsu, H | 1 |
| Kimura, Y | 3 |
| Kusumoto, T | 1 |
| Maehara, Y | 9 |
| Murphy, CC | 1 |
| Incalcaterra, JR | 1 |
| Albright, HW | 1 |
| Correa, AM | 7 |
| Swisher, SG | 9 |
| Hofstetter, WL | 4 |
| Huddart, RA | 1 |
| Hall, E | 2 |
| Hussain, SA | 1 |
| Jenkins, P | 1 |
| Rawlings, C | 1 |
| Tremlett, J | 1 |
| Crundwell, M | 1 |
| Adab, FA | 1 |
| Sheehan, D | 1 |
| Syndikus, I | 1 |
| Hendron, C | 1 |
| Lewis, R | 1 |
| Waters, R | 1 |
| James, ND | 1 |
| Rumiato, E | 1 |
| Cavallin, F | 2 |
| Boldrin, E | 1 |
| Cagol, M | 2 |
| Alfieri, R | 2 |
| Basso, D | 1 |
| Castoro, C | 2 |
| Ancona, E | 3 |
| Amadori, A | 1 |
| Ruol, A | 3 |
| Saggioro, D | 1 |
| Shin, SJ | 8 |
| Russo, AL | 1 |
| Borger, DR | 2 |
| Szymonifka, J | 2 |
| Liang, WY | 1 |
| Kwak, EL | 6 |
| Zhu, AX | 8 |
| Berger, DL | 2 |
| Cusack, JC | 2 |
| Haigis, KM | 1 |
| Ilyas, S | 1 |
| Wasif, K | 1 |
| Bao, Q | 1 |
| Schwarz, B | 2 |
| Zhao, L | 3 |
| Mysliwietz, J | 2 |
| Ellwart, J | 1 |
| Renner, A | 2 |
| Hirner, H | 1 |
| Niess, H | 2 |
| Camaj, P | 3 |
| Gros, S | 1 |
| Izbicki, J | 1 |
| Jauch, KW | 4 |
| Nelson, PJ | 3 |
| Donnelly, ED | 1 |
| Refaat, T | 1 |
| Gentile, M | 1 |
| Herskovic, A | 7 |
| Boyle, J | 1 |
| Helenowski, I | 1 |
| Rademaker, A | 2 |
| Lurain, J | 1 |
| Schink, J | 1 |
| Singh, D | 1 |
| Strauss, JB | 1 |
| Small, W | 5 |
| Habr-Gama, A | 12 |
| Sabbaga, J | 3 |
| Gama-Rodrigues, J | 11 |
| São Julião, GP | 6 |
| Proscurshim, I | 5 |
| Bailão Aguilar, P | 2 |
| Nadalin, W | 5 |
| Perez, RO | 11 |
| Dinnewitzer, A | 1 |
| Jäger, T | 1 |
| Nawara, C | 1 |
| Buchner, S | 1 |
| Wolfgang, H | 1 |
| Öfner, D | 5 |
| Xue, Q | 1 |
| Wang, XN | 1 |
| Deng, JY | 1 |
| Zhang, RP | 1 |
| Liang, H | 1 |
| Gurzu, S | 1 |
| Jung, I | 3 |
| Comsulea, M | 1 |
| Kadar, Z | 1 |
| Azamfirei, L | 1 |
| Molnar, C | 1 |
| Kim, SE | 1 |
| Cole, PD | 1 |
| Cho, RC | 1 |
| Ly, A | 1 |
| Ishiguro, L | 1 |
| Sohn, KJ | 2 |
| Croxford, R | 2 |
| Kamen, BA | 1 |
| Kim, YI | 5 |
| Ky, V | 1 |
| Hav, M | 1 |
| Berrevoet, F | 2 |
| Troisi, RI | 2 |
| Ferdinande, L | 1 |
| Monsaert, E | 1 |
| Vanderstraeten, E | 1 |
| De Bosschere, K | 1 |
| Van Damme, N | 1 |
| Laurent, S | 2 |
| Geboes, K | 1 |
| Wadhwa, R | 2 |
| Taketa, T | 1 |
| Sudo, K | 2 |
| Campagna, MC | 1 |
| Blum, MA | 1 |
| Skinner, H | 1 |
| Bhutani, MS | 2 |
| Weston, B | 1 |
| Maru, DM | 2 |
| Rice, DC | 1 |
| Swisher, S | 4 |
| Kochi, M | 4 |
| Akiyama, Y | 2 |
| Aoki, T | 6 |
| Hagiwara, K | 1 |
| Hironaka, K | 1 |
| Teranishi, F | 1 |
| Osuka, F | 1 |
| Takeuchi, M | 1 |
| Fujii, M | 7 |
| Nakajima, T | 5 |
| Verhoeven, RH | 1 |
| Radema, SA | 1 |
| Lemmens, VE | 2 |
| de Wilt, JH | 1 |
| Schiffmann, L | 3 |
| Wedermann, N | 1 |
| Gock, M | 1 |
| Prall, F | 4 |
| Klautke, G | 3 |
| Fietkau, R | 10 |
| Rau, B | 1 |
| Klar, E | 1 |
| Oh, D | 1 |
| Huh, SJ | 2 |
| Nam, H | 1 |
| Choi, JY | 1 |
| Kim, BT | 1 |
| Hashash, JG | 1 |
| Proksell, S | 1 |
| Regueiro, MD | 1 |
| Martin-Richard, M | 3 |
| Gallego, R | 4 |
| Pericay, C | 4 |
| Garcia Foncillas, J | 1 |
| Queralt, B | 1 |
| Casado, E | 2 |
| Barriuso, J | 2 |
| Iranzo, V | 1 |
| Juez, I | 1 |
| Visa, L | 1 |
| Saigi, E | 3 |
| Barnadas, A | 4 |
| Oranratanaphan, S | 1 |
| Khemapech, N | 1 |
| Yao, Z | 1 |
| Yuan, Y | 3 |
| Yao, S | 1 |
| Fan, CW | 1 |
| Chen, T | 2 |
| Shang, YN | 1 |
| Gu, YZ | 1 |
| Zhang, SL | 2 |
| Lu, R | 1 |
| OuYang, SR | 1 |
| Zhou, X | 2 |
| Meng, WT | 1 |
| Hu, JK | 2 |
| Lu, Y | 3 |
| Sun, XF | 2 |
| Bu, H | 1 |
| Zhou, ZG | 2 |
| Mo, XM | 1 |
| Lee, KW | 6 |
| Park, SR | 4 |
| Park, YI | 3 |
| Khosravan, R | 2 |
| Lin, X | 3 |
| Lee, SY | 3 |
| Roh, EJ | 1 |
| Valota, O | 1 |
| Lechuga, MJ | 3 |
| Chao, D | 3 |
| Chen, WC | 1 |
| Thirkill, CE | 1 |
| Lee, AG | 1 |
| Joseph, R | 1 |
| Dasanu, CA | 4 |
| Madbouly, KM | 1 |
| Abbas, KS | 1 |
| Hussein, AM | 1 |
| Guindalini, RS | 1 |
| Mak, MP | 1 |
| Takahashi, TK | 1 |
| Testa, L | 1 |
| Dzik, C | 1 |
| Abdul-Jalil, KI | 1 |
| Sheehan, KM | 1 |
| Kehoe, J | 1 |
| Cummins, R | 1 |
| O'Grady, A | 1 |
| McNamara, DA | 1 |
| Deasy, J | 2 |
| Breathnach, O | 1 |
| Grogan, L | 2 |
| O'Neill, BD | 1 |
| Faul, C | 1 |
| Parker, I | 1 |
| Kay, EW | 1 |
| Hennessy, BT | 1 |
| Gillen, P | 1 |
| Kaira, K | 2 |
| Sunose, Y | 2 |
| Ohshima, Y | 1 |
| Ishioka, NS | 1 |
| Arakawa, K | 1 |
| Ogawa, T | 3 |
| Sunaga, N | 1 |
| Shimizu, K | 3 |
| Tominaga, H | 2 |
| Oriuchi, N | 1 |
| Itoh, H | 2 |
| Nagamori, S | 2 |
| Kanai, Y | 2 |
| Yamaguchi, A | 1 |
| Segawa, A | 1 |
| Ide, M | 3 |
| Oyama, T | 3 |
| Takeyoshi, I | 4 |
| Sclafani, F | 1 |
| Gonzalez de Castro, D | 2 |
| Cervantes, A | 7 |
| Eltahir, Z | 2 |
| Oates, J | 16 |
| Han, S | 1 |
| Lee, CW | 1 |
| Trevino, JG | 1 |
| Sarosi, GA | 2 |
| Ye, Z | 1 |
| Xi, W | 1 |
| Ma, T | 4 |
| Mahaseth, H | 1 |
| Brutcher, E | 1 |
| Kauh, J | 2 |
| Hawk, N | 1 |
| Kooby, DA | 2 |
| Landry, J | 4 |
| Mirza, A | 2 |
| Pritchard, S | 1 |
| Welch, I | 1 |
| Dunne, PD | 1 |
| McArt, DG | 1 |
| Blayney, JK | 1 |
| Kalimutho, M | 1 |
| Greer, S | 1 |
| Srivastava, S | 1 |
| Ong, CW | 2 |
| Arthur, K | 1 |
| Loughrey, M | 1 |
| Redmond, K | 1 |
| Longley, DB | 3 |
| Salto-Tellez, M | 3 |
| Johnston, PG | 5 |
| Van Schaeybroeck, S | 1 |
| Chang, W | 2 |
| Gao, X | 2 |
| Du, Y | 1 |
| Tan, X | 1 |
| Fan, X | 1 |
| Zhou, W | 1 |
| Fu, C | 1 |
| Cao, G | 1 |
| Yoney, A | 2 |
| Isikli, L | 2 |
| Hu, XF | 1 |
| Yao, J | 1 |
| Gao, SG | 1 |
| Wang, XS | 1 |
| Peng, XQ | 1 |
| Yang, YT | 1 |
| Feng, XS | 1 |
| Unal, OU | 3 |
| Oztop, I | 7 |
| Unek, IT | 3 |
| Yilmaz, AU | 1 |
| Shabihkhani, M | 1 |
| Thara, E | 1 |
| Senagore, A | 1 |
| Sadeghi, S | 1 |
| Barzi, A | 2 |
| Ueda, A | 2 |
| Yoshita, H | 2 |
| Mihara, H | 1 |
| Ando, T | 4 |
| Kajiura, S | 2 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Minemura, M | 1 |
| Terada, M | 2 |
| Kobayashi, T | 5 |
| Horikawa, N | 2 |
| Yabushita, K | 3 |
| Note, M | 2 |
| Sugiyama, T | 5 |
| Tseng, YD | 1 |
| Napolitano, BN | 1 |
| Ancukiewicz, M | 3 |
| Shimada, H | 5 |
| Nagata, M | 2 |
| Cho, A | 1 |
| Takiguchi, N | 3 |
| Kainuma, O | 2 |
| Soda, H | 1 |
| Ikeda, A | 2 |
| Nabeya, Y | 2 |
| Yajima, S | 1 |
| Itami, M | 1 |
| Tran Cao, HS | 1 |
| Pisters, PW | 13 |
| Wolff, RA | 15 |
| Abbruzzese, JL | 26 |
| Evans, DB | 20 |
| Abbott, DE | 1 |
| Curtis, NJ | 1 |
| Bailey, IS | 2 |
| Itoh, J | 3 |
| Mitsuzuka, K | 1 |
| Kimura, S | 1 |
| Yamamuro, T | 1 |
| Yamashita, S | 4 |
| Yamada, S | 4 |
| Kaiho, Y | 1 |
| Arai, Y | 4 |
| Wu, H | 2 |
| He, YL | 1 |
| Xu, JB | 1 |
| Cai, SR | 1 |
| Ma, JP | 1 |
| Chen, CQ | 1 |
| Zhang, XH | 1 |
| Zhan, WH | 1 |
| Reni, M | 15 |
| Cattaneo, GM | 2 |
| Cereda, S | 12 |
| Castoldi, R | 1 |
| Longobardi, B | 1 |
| Bettinardi, V | 1 |
| Gianolli, L | 1 |
| Gusmini, S | 1 |
| Staudacher, C | 7 |
| Archambeaud, I | 1 |
| Chen, KT | 2 |
| Devarajan, K | 1 |
| Milestone, BN | 1 |
| Cooper, HS | 3 |
| Denlinger, C | 1 |
| Meyer, JE | 2 |
| Hoffman, JP | 11 |
| Tatli, AM | 1 |
| Uysal, M | 1 |
| Goksu, SS | 1 |
| Gunduz, S | 1 |
| Arslan, D | 1 |
| Ozdogan, M | 1 |
| Hiraki, M | 2 |
| Ohtsuka, M | 1 |
| Shiomi, H | 1 |
| Uemura, M | 1 |
| Hayashi, T | 8 |
| Isohashi, F | 1 |
| Yoshioka, Y | 1 |
| Ji, K | 1 |
| Zhang, L | 9 |
| Hargest, R | 1 |
| Ji, J | 5 |
| Jiang, WG | 2 |
| Greenhalf, W | 4 |
| Ghaneh, P | 7 |
| Neoptolemos, JP | 13 |
| Palmer, DH | 3 |
| Cox, TF | 2 |
| Lamb, RF | 1 |
| Garner, E | 1 |
| Campbell, F | 2 |
| Mackey, JR | 1 |
| Costello, E | 4 |
| Moore, MJ | 9 |
| McDonald, AC | 5 |
| Tebbutt, NC | 6 |
| Goldstein, D | 9 |
| Dervenis, C | 8 |
| Deakin, M | 2 |
| Charnley, RM | 2 |
| Lacaine, F | 4 |
| Scarfe, AG | 2 |
| Halloran, CM | 3 |
| Oláh, A | 5 |
| Jackson, R | 2 |
| Rawcliffe, CL | 4 |
| Scarpa, A | 2 |
| Stiekema, J | 1 |
| Trip, AK | 1 |
| Jansen, EP | 7 |
| Boot, H | 9 |
| Ponz, OB | 1 |
| Verheij, M | 5 |
| Endo, A | 1 |
| Nakashima, R | 1 |
| Tanabe, K | 3 |
| Rodriguez-Bigas, MA | 4 |
| Chang, GJ | 1 |
| Skibber, JM | 3 |
| You, YN | 1 |
| Munsell, MF | 1 |
| Clemons, MV | 1 |
| Kopetz, SE | 1 |
| Garrett, CR | 1 |
| Shureiqi, I | 1 |
| Delclos, ME | 6 |
| Krishnan, S | 3 |
| Di Lauro, L | 4 |
| Vici, P | 2 |
| Belli, F | 1 |
| Tomao, S | 1 |
| Fattoruso, SI | 1 |
| Arena, MG | 1 |
| Pizzuti, L | 1 |
| Giannarelli, D | 1 |
| Paoletti, G | 2 |
| Barba, M | 1 |
| Sergi, D | 1 |
| Maugeri-Saccà, M | 1 |
| Zhao, F | 1 |
| Yi, C | 1 |
| You, KY | 1 |
| Peng, HH | 1 |
| Gao, YH | 3 |
| Chen, L | 5 |
| Zhou, GQ | 1 |
| Chang, H | 1 |
| Du, XJ | 1 |
| Xiao, L | 1 |
| Zeng, ZF | 4 |
| Wen, BX | 1 |
| Liu, MZ | 1 |
| Ubink, I | 1 |
| van der Sluis, P | 1 |
| Schipper, M | 1 |
| Reerink, O | 1 |
| Voest, E | 1 |
| Borel-Rinkes, I | 1 |
| Wijrdeman, H | 1 |
| Vleggaar, F | 1 |
| Agterof, M | 1 |
| Overkleeft, E | 1 |
| Siersema, P | 1 |
| van Hillegersberg, R | 2 |
| Lolkema, MP | 2 |
| Berger, AK | 1 |
| Weber, TF | 1 |
| Springfeld, C | 2 |
| Vasudev, E | 1 |
| Shellito, PC | 4 |
| Ajouz, H | 1 |
| Haydar, A | 1 |
| Yakan, AS | 1 |
| Saleh, A | 1 |
| Elias, E | 1 |
| Khalife, M | 1 |
| Zemelka, T | 1 |
| Barone, C | 8 |
| Schlichting, M | 1 |
| Heighway, J | 1 |
| Eggleton, SP | 1 |
| Srimuninnimit, V | 1 |
| Lee, AM | 1 |
| Offer, SM | 1 |
| McConnell, K | 1 |
| Relias, V | 1 |
| Diasio, RB | 8 |
| Kadota, T | 1 |
| Osuga, T | 1 |
| Ogawa, H | 1 |
| Kitami, M | 1 |
| Ishimura, M | 1 |
| Shigaki, Y | 1 |
| Nakajima, E | 1 |
| Nakata, S | 1 |
| Kadota, C | 1 |
| Hirano, S | 1 |
| Ikura, Y | 1 |
| Iwai, Y | 1 |
| Ueno, N | 3 |
| Ojima, E | 3 |
| Nakano, T | 7 |
| Kanamoto, A | 1 |
| Sasaki, S | 1 |
| Sueda, T | 1 |
| Noura, S | 2 |
| Shingai, T | 1 |
| Gotoh, K | 2 |
| Motoori, M | 2 |
| Kishi, K | 4 |
| Marubashi, S | 3 |
| Fujiwara, Y | 8 |
| Ohigashi, H | 4 |
| Yano, M | 3 |
| Tomita, Y | 2 |
| Ishikawa, O | 5 |
| Furukawa, H | 6 |
| Fukunaga, M | 1 |
| Munakata, S | 1 |
| Kawabata, R | 1 |
| Nakata, K | 2 |
| Yamamoto, T | 4 |
| Kawase, T | 2 |
| Ohzato, H | 1 |
| Torii, Y | 1 |
| Kato, R | 2 |
| Minami, Y | 1 |
| Hasegawa, K | 4 |
| Fujii, T | 5 |
| Udagawa, Y | 1 |
| Hirata, K | 11 |
| Nagata, N | 1 |
| Okuyama, Y | 1 |
| Andoh, H | 1 |
| Takahashi, K | 9 |
| Hazama, S | 3 |
| Mishima, H | 5 |
| Mochinaga, K | 1 |
| Tsuchiya, T | 2 |
| Nagasaki, T | 3 |
| Arai, J | 1 |
| Tominaga, T | 4 |
| Yamasaki, N | 2 |
| Matsumoto, K | 3 |
| Miyazaki, T | 4 |
| Nanashima, A | 2 |
| Tsukamoto, K | 2 |
| Nagayasu, T | 2 |
| Nolan, L | 1 |
| Bateman, AC | 1 |
| Sharland, DM | 1 |
| Rees, CN | 1 |
| Bateman, AR | 1 |
| Nandy, N | 1 |
| Palmer, D | 1 |
| Cox, T | 2 |
| Stocken, DD | 6 |
| O'Reilly, D | 1 |
| Robinson, BA | 1 |
| Karapetis, C | 2 |
| Sand, J | 2 |
| Izbicki, JR | 4 |
| Lind, PA | 4 |
| Sumpter, K | 4 |
| Hollywood, E | 1 |
| Reidy-Lagunes, DL | 1 |
| Temple, LK | 3 |
| Bichard, D | 1 |
| Limat, S | 2 |
| Lorgis, V | 2 |
| Berthou, J | 1 |
| Orry, D | 1 |
| Ortega-Deballon, P | 1 |
| Facy, O | 1 |
| Heyd, B | 1 |
| Rat, P | 1 |
| Nerich, V | 2 |
| Ladoire, S | 1 |
| Pere-Verge, D | 2 |
| Martel-Lafay, I | 1 |
| Chapet, S | 2 |
| Sobhani, I | 3 |
| Pezet, D | 4 |
| Dousset, B | 1 |
| Jouve, JL | 2 |
| Maillard, E | 3 |
| Gao, W | 1 |
| Zeng, F | 1 |
| Kong, LX | 1 |
| Naiken, SP | 1 |
| Toso, C | 1 |
| Rubbia-Brandt, L | 3 |
| Thomopoulos, T | 1 |
| Roth, A | 8 |
| Mentha, G | 3 |
| Morel, P | 3 |
| Gervaz, P | 4 |
| Chen, FW | 1 |
| Egbert, BM | 1 |
| Swetter, SM | 1 |
| Sarin, KY | 1 |
| Bosset, JF | 7 |
| Calais, G | 4 |
| Maingon, P | 4 |
| Stojanovic-Rundic, S | 1 |
| Bensadoun, RJ | 1 |
| Bardet, E | 2 |
| Beny, A | 2 |
| Ollier, JC | 2 |
| Bolla, M | 1 |
| Marchal, D | 1 |
| Klein, V | 1 |
| Giralt, J | 1 |
| Clavère, P | 1 |
| Glanzmann, C | 1 |
| Cellier, P | 2 |
| Collette, L | 3 |
| Alkhateeb, A | 1 |
| Zubritsky, L | 1 |
| Kinsman, B | 1 |
| Leitzel, K | 1 |
| Campbell-Baird, C | 1 |
| Ali, SM | 1 |
| Connor, J | 1 |
| Lipton, A | 1 |
| Akiyoshi, T | 1 |
| Ueno, M | 2 |
| Fukunaga, Y | 1 |
| Nagayama, S | 2 |
| Fujimoto, Y | 1 |
| Konishi, T | 4 |
| Kawabe, H | 1 |
| Tomizawa, G | 1 |
| Yabuhita, K | 1 |
| Ruf, C | 1 |
| Thomusch, O | 1 |
| Goos, M | 2 |
| Makowiec, F | 2 |
| Ruf, G | 2 |
| Hu, DL | 1 |
| Guo, XD | 1 |
| Sun, ZN | 1 |
| Zhao, YM | 1 |
| Yu, H | 2 |
| Lei, H | 1 |
| Xie, C | 1 |
| Zhong, Y | 2 |
| Chan, SL | 1 |
| Chan, ST | 1 |
| Chan, EH | 1 |
| He, ZX | 1 |
| Aoyama, F | 1 |
| Hiyoshi, M | 2 |
| Sawaguchi, A | 1 |
| Shoji, H | 2 |
| Morizane, C | 4 |
| Hiraoka, N | 1 |
| Kondo, S | 2 |
| Ohno, I | 1 |
| Shimizu, S | 3 |
| Mitsunaga, S | 1 |
| Ikeda, M | 8 |
| Okusaka, T | 9 |
| Barrueco, N | 1 |
| Such Díaz, A | 1 |
| Sáez de la Fuente, J | 1 |
| Escobar, I | 1 |
| Kim, GJ | 2 |
| Koshy, M | 2 |
| Hanlon, AL | 2 |
| Horiba, MN | 1 |
| Edelman, MJ | 1 |
| Burrows, WM | 1 |
| Battafarano, RJ | 1 |
| Suntharalingam, M | 2 |
| Hashimoto, D | 1 |
| Bläuer, M | 1 |
| Hirota, M | 1 |
| Ikonen, NH | 1 |
| Laukkarinen, J | 1 |
| Qiu, MZ | 5 |
| Wei, XL | 1 |
| Zhang, DS | 4 |
| Jin, Y | 2 |
| Zhou, YX | 1 |
| Wang, DS | 2 |
| Ren, C | 2 |
| Bai, L | 2 |
| Luo, HY | 4 |
| Wang, ZQ | 6 |
| Wang, FH | 6 |
| Li, YH | 11 |
| Yang, DJ | 1 |
| Xu, RH | 10 |
| Van Loon, K | 1 |
| Zhang, XT | 2 |
| Chu, YP | 1 |
| Gong, JF | 3 |
| Miranda, MB | 1 |
| Gencer, D | 2 |
| Hochhaus, A | 9 |
| Merx, K | 1 |
| Qin, S | 1 |
| Xu, R | 1 |
| Bu, L | 2 |
| Piao, Y | 1 |
| Babacan, T | 1 |
| Turkbeyler, IH | 1 |
| Dag, MS | 1 |
| Dilli, I | 1 |
| Balakan, O | 1 |
| Altundag, K | 4 |
| Petrelli, F | 1 |
| Coinu, A | 1 |
| Borgonovo, K | 1 |
| Cabiddu, M | 1 |
| Ghilardi, M | 1 |
| Barni, S | 3 |
| Christians, KK | 2 |
| Mahmoud, A | 1 |
| Ritch, P | 4 |
| Thomas, JP | 2 |
| Wiebe, L | 1 |
| Kelly, T | 1 |
| George, B | 2 |
| Jin, J | 4 |
| Li, YX | 1 |
| Ren, H | 2 |
| Fang, H | 1 |
| Wang, SL | 1 |
| Liu, YP | 2 |
| Wang, WH | 1 |
| Yu, ZH | 2 |
| Song, YW | 1 |
| Liu, XF | 1 |
| Kondratska, K | 1 |
| Kondratskyi, A | 1 |
| Yassine, M | 1 |
| Lemonnier, L | 1 |
| Lepage, G | 1 |
| Morabito, A | 1 |
| Skryma, R | 1 |
| Prevarskaya, N | 1 |
| Kojouharov, BM | 1 |
| Brackett, CM | 1 |
| Veith, JM | 1 |
| Johnson, CP | 1 |
| Gitlin, II | 1 |
| Toshkov, IA | 1 |
| Gleiberman, AS | 1 |
| Gudkov, AV | 1 |
| Burdelya, LG | 1 |
| Dirican, A | 4 |
| Kucukzeybek, Y | 4 |
| Alacacioglu, A | 4 |
| Varol, U | 3 |
| Aksun, S | 1 |
| Bayoglu, IV | 4 |
| Demir, L | 4 |
| Coban, E | 2 |
| Sutcu, R | 1 |
| Tarhan, MO | 4 |
| Esnaola, NF | 1 |
| Chaudhary, UB | 1 |
| O'Brien, P | 2 |
| Camp, ER | 1 |
| Thomas, MB | 1 |
| Cole, DJ | 1 |
| Montero, AJ | 2 |
| Hoffman, BJ | 1 |
| Romagnuolo, J | 1 |
| Orwat, KP | 1 |
| Marshall, DT | 1 |
| Karakhanova, S | 2 |
| Mosl, B | 2 |
| Harig, S | 5 |
| von Ahn, K | 1 |
| Fritz, J | 1 |
| Schmidt, J | 9 |
| Bazhin, AV | 2 |
| Faron, M | 1 |
| Chirica, M | 1 |
| Tranchard, H | 1 |
| Balladur, P | 1 |
| de Gramont, A | 26 |
| Afchain, P | 5 |
| Paye, F | 1 |
| Watkins, DJ | 1 |
| Webb, J | 2 |
| Brown, G | 5 |
| Suzuki, H | 5 |
| Asao, T | 6 |
| Tsutsumi, S | 5 |
| Wada, S | 1 |
| Araki, K | 2 |
| Kubo, N | 2 |
| Watanabe, A | 5 |
| Tsukagoshi, M | 1 |
| Kuwano, H | 10 |
| Patel, K | 1 |
| Iacobuzio-Donahue, CA | 1 |
| Gormley, PE | 1 |
| Kern, SE | 1 |
| Cunningham, SC | 2 |
| Marks, E | 2 |
| Yu, Z | 2 |
| Yu, JK | 1 |
| Fang, XF | 1 |
| Shen, H | 3 |
| Hamza, S | 1 |
| Rollot, F | 1 |
| Faivre, J | 1 |
| Yeh, YS | 1 |
| Huang, ML | 1 |
| Chang, SF | 1 |
| Chen, CF | 1 |
| Hu, HM | 1 |
| Wang, JY | 2 |
| Ma, ZJ | 1 |
| Guo, XC | 1 |
| Mao, ZY | 1 |
| Wang, LJ | 1 |
| Zhang, TT | 1 |
| Sonoda, H | 2 |
| Shimizu, T | 3 |
| Mekata, E | 1 |
| Tani, T | 3 |
| Tokuda, Y | 1 |
| Arakura, F | 1 |
| Uhara, H | 1 |
| Yoon, HH | 2 |
| Mahoney, MR | 2 |
| Nelson, GD | 1 |
| Nair, SG | 1 |
| Thibodeau, SN | 3 |
| Deng, W | 1 |
| Wang, QW | 1 |
| Lu, M | 5 |
| Lu, ZH | 4 |
| Suarez Martinez-Falero, B | 1 |
| Gillmore, R | 2 |
| Bose, A | 1 |
| Elyagoby, A | 1 |
| Wong, TW | 1 |
| Dorth, JA | 1 |
| Pura, JA | 1 |
| Palta, M | 1 |
| D'Amico, TA | 3 |
| Czito, BG | 5 |
| Watanabe, M | 8 |
| Baba, Y | 2 |
| Yoshida, N | 1 |
| Ishimoto, T | 1 |
| Nagai, Y | 2 |
| Iwatsuki, M | 1 |
| Iwagami, S | 1 |
| Dong, L | 2 |
| Lou, XP | 1 |
| Miao, JH | 1 |
| Lu, P | 1 |
| Chang, ZW | 1 |
| Han, ZF | 1 |
| Miyamoto, M | 1 |
| Kirii, Y | 1 |
| Takagi, H | 6 |
| Miyamoto, S | 3 |
| Li, T | 5 |
| Jia, X | 1 |
| Liu, B | 5 |
| Wan, X | 1 |
| Lang, J | 1 |
| Daniel, ES | 1 |
| Guerrieri, M | 2 |
| Faragher, I | 1 |
| Jung, SH | 3 |
| Etienne-Grimaldi, MC | 1 |
| Mahamat, A | 1 |
| Chazal, M | 1 |
| Olschwang, S | 1 |
| Gaub, MP | 1 |
| Formento, JL | 2 |
| Formento, P | 1 |
| Sudaka, A | 1 |
| Boige, V | 6 |
| Abderrahim-Ferkoune, A | 1 |
| Benchimol, D | 1 |
| Houry, S | 3 |
| Faucheron, JL | 1 |
| Letoublon, C | 2 |
| Gilly, FN | 1 |
| Lasser, P | 9 |
| Pradere, B | 1 |
| Penault-Llorca, F | 2 |
| Milano, G | 3 |
| Matsumoto, T | 2 |
| Hasegawa, S | 4 |
| Okoshi, K | 2 |
| Yamada, M | 5 |
| Kawada, K | 1 |
| Costa, C | 1 |
| Shen, J | 1 |
| Sanchez, JJ | 2 |
| Qian, X | 1 |
| Zou, Z | 1 |
| Gimenez-Capitan, A | 1 |
| Yue, G | 1 |
| Guan, W | 1 |
| Rosell, R | 4 |
| Hoshino, S | 2 |
| Aisu, N | 2 |
| Naito, M | 2 |
| Tanimura, S | 1 |
| Mogi, A | 1 |
| Tamura, K | 4 |
| Yamashita, Y | 9 |
| Cai, X | 2 |
| Fang, JM | 1 |
| Xue, P | 2 |
| Song, WF | 2 |
| Gu, HL | 2 |
| Yang, HY | 2 |
| Wang, LW | 4 |
| Hur, H | 4 |
| Kim, NK | 18 |
| Baik, SH | 5 |
| Lee, KY | 10 |
| Koom, WS | 4 |
| Ahn, JB | 9 |
| Roxburgh, P | 1 |
| Lumsden, GR | 1 |
| Harden, S | 1 |
| Sweeting, L | 1 |
| James, A | 1 |
| Crellin, A | 3 |
| Morrison, R | 2 |
| Evans, TR | 3 |
| Osti, MF | 2 |
| Agolli, L | 2 |
| Bracci, S | 2 |
| Masoni, L | 1 |
| Valeriani, M | 2 |
| Falco, T | 2 |
| De Sanctis, V | 2 |
| Maurizi Enrici, R | 1 |
| van Bunderen, CC | 1 |
| de Weger, VA | 1 |
| Griffioen-Keijzer, A | 1 |
| Ren, G | 1 |
| Xia, T | 1 |
| Miura, JT | 1 |
| Johnston, FM | 1 |
| Eastwood, D | 1 |
| Turaga, KK | 2 |
| Gamblin, TC | 1 |
| Freilich, J | 1 |
| Fulp, WJ | 1 |
| Yue, B | 1 |
| Holmes, HM | 1 |
| des Bordes, JK | 1 |
| Parker, NH | 1 |
| Shiovitz, S | 1 |
| Bertagnolli, MM | 1 |
| Renfro, LA | 1 |
| Nam, E | 1 |
| Foster, NR | 4 |
| Dzieciatkowski, S | 1 |
| Luo, Y | 1 |
| Lao, VV | 1 |
| Monnat, RJ | 1 |
| Emond, MJ | 1 |
| Maizels, N | 1 |
| Warren, RS | 1 |
| Grady, WM | 2 |
| Honjo, S | 1 |
| Scott, AW | 1 |
| Skinner, HD | 1 |
| Stroehlein, J | 1 |
| Johnson, RL | 1 |
| Song, S | 2 |
| Bozkurt, O | 2 |
| Ozaslan, E | 2 |
| Baldane, S | 1 |
| Berk, V | 3 |
| Inanc, M | 3 |
| Duran, AO | 2 |
| Dikilitas, M | 2 |
| Er, O | 1 |
| Luo, NQ | 1 |
| Zhang, ZH | 2 |
| Ma, Y | 2 |
| Mongan, AM | 1 |
| Kalachand, R | 1 |
| King, S | 1 |
| O'Farrell, NJ | 1 |
| Power, D | 2 |
| Ravi, N | 2 |
| Muldoon, C | 1 |
| O'Byrne, K | 1 |
| Reynolds, JV | 6 |
| Sio, TT | 1 |
| Wilson, ZC | 1 |
| Stauder, MC | 1 |
| Bhatia, S | 3 |
| Martenson, JA | 7 |
| Quevedo, JF | 1 |
| Schomas, DA | 1 |
| Miller, RC | 5 |
| Tashiro, J | 1 |
| Yamaguchi, S | 4 |
| Ishii, T | 1 |
| Suzuki, A | 4 |
| Kondo, H | 1 |
| Morita, Y | 2 |
| Koyama, I | 4 |
| Guo, Mg | 2 |
| zhong Di, J | 1 |
| Thind, G | 1 |
| Johal, B | 1 |
| Follwell, M | 1 |
| Kennecke, HF | 2 |
| Novotny, AR | 1 |
| Reim, D | 1 |
| Friess, HM | 1 |
| Schuhmacher, C | 3 |
| Senatore, FJ | 1 |
| Ynson, ML | 1 |
| Jiang, Y | 5 |
| Mackley, HB | 1 |
| Kimchi, ET | 1 |
| Gusani, N | 1 |
| Kaifi, J | 1 |
| Staveley-O'Carroll, KF | 1 |
| Belani, CP | 3 |
| Xie, S | 1 |
| He, L | 1 |
| Xu, W | 1 |
| Qin, Z | 1 |
| Combs, SE | 1 |
| Habermehl, D | 1 |
| Kessel, KA | 1 |
| Bergmann, F | 1 |
| Naumann, P | 1 |
| Debus, J | 5 |
| Okabe, T | 2 |
| Hoshino, K | 2 |
| Richter, I | 2 |
| Dvořák, J | 4 |
| Bartoš, J | 2 |
| Takada, T | 3 |
| Sutoh, T | 1 |
| Morita, H | 2 |
| Yajima, R | 2 |
| Thaler, J | 7 |
| Petersen, LN | 2 |
| Blons, H | 1 |
| Emile, JF | 4 |
| Lopez-Sánchez, LM | 1 |
| Jimenez, C | 1 |
| Valverde, A | 1 |
| Hernandez, V | 1 |
| Peñarando, J | 1 |
| Martinez, A | 2 |
| Lopez-Pedrera, C | 1 |
| Muñoz-Castañeda, JR | 1 |
| De la Haba-Rodríguez, JR | 1 |
| Aranda, E | 7 |
| Rodriguez-Ariza, A | 1 |
| Berkel, AE | 1 |
| Woutersen, DP | 1 |
| van der Palen, J | 2 |
| Klaase, JM | 1 |
| Han, K | 1 |
| Maia, M | 1 |
| Lowe, J | 1 |
| Sersch, MA | 1 |
| Allison, DE | 1 |
| Grey, A | 1 |
| Cooper, A | 1 |
| McNeil, C | 1 |
| O'Toole, S | 1 |
| Thompson, J | 4 |
| Grimison, P | 1 |
| Maggo, G | 1 |
| Grover, SC | 1 |
| Grin, A | 1 |
| Yoon, C | 2 |
| Park, DJ | 2 |
| Schmidt, B | 2 |
| Thomas, NJ | 1 |
| Kim, TS | 1 |
| Cohen, DJ | 2 |
| Yoon, SS | 1 |
| Ischenko, I | 1 |
| Krebs, S | 1 |
| Jäckel, C | 1 |
| Blum, H | 1 |
| Ellwart, JW | 1 |
| Silcocks, P | 1 |
| Valle, J | 4 |
| Ross, P | 4 |
| Roques, T | 1 |
| Corrie, P | 2 |
| Robinson, A | 2 |
| McAdam, K | 1 |
| Eatock, M | 2 |
| Evans, J | 1 |
| Archer, C | 2 |
| Garcia-Alonso, A | 1 |
| Nicolson, M | 8 |
| Steward, W | 2 |
| Shaw, V | 1 |
| Naisbitt, D | 1 |
| Rawcliffe, C | 1 |
| Nanson, G | 1 |
| Neoptolemos, J | 1 |
| Tassone, P | 1 |
| Yu, R | 2 |
| Szado, T | 1 |
| Garg, A | 1 |
| Donehower, RC | 5 |
| Tjulandin, S | 5 |
| Deptala, A | 1 |
| Nirni, S | 1 |
| Lakshmaiah, K | 1 |
| Zhu, M | 1 |
| Anderson, A | 1 |
| Oliner, KS | 1 |
| Loh, E | 1 |
| Takahashi, M | 5 |
| Niwa, K | 2 |
| Ishiyama, S | 2 |
| Sugimoto, K | 3 |
| Komiyama, H | 1 |
| Yaginuma, Y | 1 |
| Kojima, Y | 2 |
| Okuzawa, A | 1 |
| Tomiki, Y | 1 |
| Chao, TH | 1 |
| Chang, GR | 1 |
| Chen, WY | 1 |
| Chen, PL | 1 |
| Mao, FC | 1 |
| Vargas, GM | 1 |
| Parmar, AD | 1 |
| Sheffield, KM | 1 |
| Tamirisa, NP | 1 |
| Brown, KM | 1 |
| Riall, TS | 3 |
| Erten, C | 2 |
| Somali, I | 3 |
| Can, A | 2 |
| Akyol, M | 3 |
| Yildiz, Y | 2 |
| Koyuncu, B | 1 |
| Koca, D | 1 |
| Yılmaz, U | 5 |
| Swellengrebel, HA | 1 |
| Bosch, SL | 1 |
| Vincent, AD | 1 |
| Dewit, LG | 1 |
| Verwaal, VJ | 3 |
| Marijnen, CA | 2 |
| Alcindor, T | 5 |
| Ades, S | 3 |
| Aloraini, A | 1 |
| van Huyse, M | 1 |
| Asselah, J | 2 |
| David, M | 2 |
| Frechette, D | 1 |
| Brisson, S | 1 |
| Thirlwell, M | 1 |
| Ferri, L | 2 |
| Sa-Cunha, A | 1 |
| Gauthier, M | 3 |
| Cueff, A | 1 |
| Manfredi, S | 3 |
| Solub, D | 1 |
| Lécaille, C | 2 |
| Carbonnel, F | 1 |
| Rudloff, U | 1 |
| Langan, RC | 1 |
| Mullinax, JE | 1 |
| Beane, JD | 1 |
| Steinberg, SM | 6 |
| Beresnev, T | 1 |
| Webb, CC | 1 |
| Walker, M | 1 |
| Toomey, MA | 2 |
| Schrump, D | 1 |
| Pandalai, P | 1 |
| Stojadinovic, A | 1 |
| Avital, I | 2 |
| Nam, JK | 1 |
| Park, JK | 4 |
| Min, do S | 1 |
| Kuh, HJ | 2 |
| Lu, W | 3 |
| Zuo, Y | 1 |
| Feng, Y | 2 |
| Ishikawa, K | 4 |
| Nakamatsu, K | 1 |
| Shiraishi, O | 1 |
| Yasuda, T | 2 |
| Nishimura, Y | 4 |
| Ramfidis, VS | 1 |
| De Stefano, A | 1 |
| Moretto, R | 1 |
| Bucci, L | 1 |
| Pepe, S | 2 |
| Romano, FJ | 1 |
| Cella, AC | 1 |
| Attademo, L | 1 |
| Rosanova, M | 1 |
| De Falco, S | 1 |
| Fiore, G | 1 |
| Raimondo, L | 1 |
| De Placido, S | 4 |
| Carlomagno, C | 4 |
| Lemstrová, R | 1 |
| Souček, P | 1 |
| Melichar, B | 5 |
| Mohelnikova-Duchonova, B | 1 |
| Battisti, S | 1 |
| Guida, FM | 1 |
| Pagliara, E | 1 |
| Zobel, BB | 1 |
| Santini, D | 2 |
| Spratlin, JL | 1 |
| Armstrong, DE | 1 |
| Ghosh, S | 1 |
| Mulder, KE | 1 |
| Tejani, MA | 2 |
| ter Veer, A | 1 |
| Milne, D | 1 |
| Ottesen, R | 1 |
| Benson, AB | 15 |
| Shibata, S | 2 |
| Skibber, J | 3 |
| Weiser, M | 3 |
| Wilkinson, N | 1 |
| Lee, YY | 1 |
| Li, CF | 2 |
| Lin, CY | 3 |
| Lee, SW | 3 |
| Sheu, MJ | 2 |
| Lin, LC | 2 |
| Chen, TJ | 2 |
| Wu, TF | 1 |
| Hsing, CH | 2 |
| Akgun, Z | 1 |
| Saglam, S | 2 |
| Yucel, S | 2 |
| Gural, Z | 1 |
| Balik, E | 2 |
| Cipe, G | 1 |
| Yildiz, S | 1 |
| Kilickap, S | 1 |
| Okyar, A | 1 |
| Kaytan-Saglam, E | 1 |
| Shimada, Y | 10 |
| Sameshima, S | 2 |
| Ina, K | 3 |
| Sugihara, K | 5 |
| Fiteni, F | 2 |
| Jary, M | 2 |
| Monnien, F | 1 |
| Nguyen, T | 4 |
| Beohou, E | 1 |
| Demarchi, M | 1 |
| Dobi, E | 1 |
| Fein, F | 3 |
| Cleau, D | 2 |
| Fratté, S | 3 |
| Bonnetain, F | 10 |
| Pivot, X | 2 |
| Lv, F | 1 |
| Liu, X | 3 |
| Jin, M | 1 |
| Miki, Y | 3 |
| Hosono, M | 1 |
| Nagahara, H | 2 |
| Hirakawa, K | 4 |
| Shimatani, Y | 1 |
| Nemoto, H | 2 |
| Tate, G | 1 |
| Umemoto, T | 2 |
| Matsubara, T | 2 |
| Mizukami, H | 2 |
| Saito, M | 2 |
| Kigawa, G | 1 |
| Matsumiya, A | 1 |
| Tanaka, J | 6 |
| Donahue, TR | 1 |
| Nguyen, AH | 1 |
| Moughan, J | 2 |
| Tatishchev, S | 1 |
| Toste, P | 1 |
| Farrell, JJ | 1 |
| Kandioler, D | 1 |
| Zwrtek, R | 1 |
| Kappel, S | 1 |
| Wolf, B | 1 |
| Mittlböck, M | 1 |
| Kührer, I | 1 |
| Wrba, F | 1 |
| Kalikaki, A | 1 |
| Politaki, H | 1 |
| Apostolaki, S | 1 |
| Papadimitraki, E | 1 |
| Georgoulia, N | 1 |
| Tzardi, M | 2 |
| Mavroudis, D | 6 |
| Voutsina, A | 1 |
| Yao, X | 1 |
| Fischbach, NA | 1 |
| Stein, S | 1 |
| Doddamane, I | 1 |
| Karimeddini, D | 1 |
| Lambertz, A | 1 |
| Klink, CD | 1 |
| Schmitz, D | 1 |
| Pich, A | 1 |
| Feher, K | 1 |
| Bremus-Köbberling, E | 1 |
| Neumann, UP | 1 |
| Junge, K | 1 |
| Rose, PG | 1 |
| Java, JJ | 1 |
| Whitney, CW | 2 |
| Stehman, FB | 1 |
| Lanciano, R | 3 |
| Thomas, GM | 2 |
| Meulendijks, D | 1 |
| Dewit, L | 1 |
| Tomasoa, NB | 1 |
| van Tinteren, H | 3 |
| Beijnen, JH | 1 |
| Schellens, JH | 2 |
| McNamara, MJ | 1 |
| Adelstein, DJ | 10 |
| Bodmann, JW | 1 |
| Greskovich, JF | 1 |
| Ives, DI | 4 |
| Mason, DP | 3 |
| Murthy, SC | 4 |
| Rice, TW | 9 |
| Saxton, JP | 5 |
| Sohal, D | 1 |
| Stephans, K | 1 |
| Rodriguez, CP | 4 |
| Videtic, GM | 6 |
| Rybicki, LA | 5 |
| Lindner, K | 1 |
| Borchardt, C | 1 |
| Schöpp, M | 1 |
| Bürgers, A | 1 |
| Stock, C | 1 |
| Hussey, DJ | 5 |
| Haier, J | 3 |
| Hummel, R | 3 |
| Velut, G | 1 |
| Mary, F | 2 |
| Wind, P | 2 |
| Schwameis, M | 1 |
| Schober, A | 1 |
| Schörgenhofer, C | 1 |
| Kulinna-Cosentini, C | 1 |
| Laggner, A | 1 |
| Röggla, M | 1 |
| Jilma, B | 1 |
| Kaytan Saglam, E | 1 |
| Asoglu, O | 2 |
| Yamaner, S | 1 |
| Bugra, D | 1 |
| Oral, EN | 1 |
| Kizir, A | 1 |
| Kapran, Y | 2 |
| Sakar, B | 1 |
| Akyuz, A | 1 |
| Gulluoglu, M | 1 |
| Cienfuegos, JA | 2 |
| Rotellar, F | 1 |
| Baixauli, J | 6 |
| Beorlegui, C | 3 |
| Sola, JJ | 5 |
| Arbea, L | 4 |
| Pastor, C | 6 |
| Arredondo, J | 3 |
| Hernández-Lizoáin, JL | 7 |
| Marks, JH | 1 |
| Frenkel, JL | 1 |
| Greenleaf, CE | 1 |
| D'Andrea, AP | 1 |
| Chander, S | 2 |
| McKendrick, J | 6 |
| MacKay, JR | 2 |
| Steel, M | 1 |
| Hicks, R | 1 |
| Heriot, A | 2 |
| Cooray, P | 3 |
| Jefford, M | 2 |
| Bressel, M | 1 |
| McClure, B | 3 |
| Ngan, SY | 6 |
| Motschmann, M | 1 |
| Jütting, U | 1 |
| Luber, B | 1 |
| Becker, K | 11 |
| Ott, K | 8 |
| Siewert, JR | 10 |
| Walch, A | 1 |
| Fang, Y | 1 |
| Wang, XT | 1 |
| Dan, X | 1 |
| Sun, LL | 1 |
| Yildiz, I | 1 |
| Muslu, U | 1 |
| Cokmert, S | 1 |
| Karabulut, B | 2 |
| Uslu, R | 2 |
| Adas, YG | 1 |
| Andrieu, MN | 1 |
| Hicsonmez, A | 1 |
| Atakul, T | 1 |
| Dirican, B | 1 |
| Aktas, C | 1 |
| Yilmaz, S | 1 |
| Akyurek, S | 1 |
| Gokce, SC | 1 |
| Ergocen, S | 1 |
| Ahlgren, J | 2 |
| Patel, N | 1 |
| Simmens, S | 1 |
| Akin, E | 1 |
| Bishop, C | 1 |
| Kirkel, D | 1 |
| Siegel, P | 1 |
| Schuck, S | 1 |
| Guebre-Xabiher, H | 1 |
| Siegel, R | 1 |
| Dong, CX | 1 |
| Fu, JF | 1 |
| Ye, XY | 1 |
| Li, XF | 1 |
| Zhong, X | 1 |
| Abali, H | 3 |
| Vural, M | 1 |
| Oksuzoglu, B | 4 |
| Civelek, B | 1 |
| Oguz, D | 1 |
| Bostanci, B | 1 |
| Yalcin, B | 2 |
| Zengin, N | 5 |
| Xu, N | 4 |
| Schaeffer, DF | 1 |
| Yoshida, EM | 1 |
| Inada, R | 1 |
| Nagasaka, T | 2 |
| Toshima, T | 3 |
| Mori, Y | 2 |
| Kondo, Y | 1 |
| Kishimoto, H | 1 |
| Fujiwara, T | 3 |
| Ress, AL | 1 |
| Stiegelbauer, V | 1 |
| Schwarzenbacher, D | 1 |
| Deutsch, A | 1 |
| Perakis, S | 1 |
| Ling, H | 1 |
| Ivan, C | 1 |
| Calin, GA | 1 |
| Rinner, B | 1 |
| Gerger, A | 1 |
| Pichler, M | 2 |
| Yamahsita, S | 1 |
| Matsuda, Y | 1 |
| Kishino, T | 1 |
| Kushima, R | 1 |
| Kato, K | 10 |
| Igaki, H | 2 |
| Tachimori, Y | 1 |
| Osugi, H | 4 |
| Nagino, M | 3 |
| Ushijima, T | 2 |
| Iino, C | 1 |
| Mikami, T | 1 |
| Sawaya, M | 1 |
| Aihara, T | 2 |
| Yamagata, R | 1 |
| Tono, H | 1 |
| Tanaka, M | 5 |
| Fukuda, S | 3 |
| Ries, P | 3 |
| Boucher, E | 2 |
| Holck, S | 1 |
| Nielsen, HJ | 1 |
| Hammer, E | 1 |
| Christensen, IJ | 1 |
| Larsson, LI | 1 |
| Blüml, A | 1 |
| Cermáková, E | 1 |
| Urbanec, M | 1 |
| Sitorová, V | 1 |
| Ryška, A | 1 |
| Sirák, I | 2 |
| Buka, D | 1 |
| Ferko, A | 1 |
| Petera, J | 2 |
| Lunardi, G | 2 |
| Inno, A | 1 |
| Magarotto, R | 1 |
| Duranti, S | 1 |
| Messa, MG | 1 |
| Mucchino, C | 1 |
| Cirillo, M | 2 |
| Chen, HM | 1 |
| Lin, JK | 8 |
| Chen, WS | 3 |
| Jiang, JK | 5 |
| Lan, YT | 2 |
| Lin, CC | 4 |
| Teng, HW | 2 |
| Osawa, T | 2 |
| Sano, T | 3 |
| Shimizu, Y | 4 |
| Senda, Y | 1 |
| Yamaura, H | 1 |
| Inaba, Y | 3 |
| Larsen, AC | 1 |
| Holländer, C | 1 |
| Duval, L | 1 |
| Schønnemann, K | 1 |
| Achiam, M | 1 |
| Pfeiffer, P | 13 |
| Yilmaz, MK | 1 |
| Thorlacius-Ussing, O | 1 |
| Bæksgaard, L | 1 |
| Ladekarl, M | 1 |
| Sie, C | 1 |
| Ansar, A | 1 |
| Michael, MZ | 2 |
| Van der Hoek, M | 1 |
| Blazer, M | 2 |
| Wu, C | 3 |
| Phillips, G | 1 |
| Muscarella, P | 1 |
| Reardon, J | 3 |
| Ellison, EC | 1 |
| Bloomston, M | 4 |
| el Aziz, LM | 1 |
| Pardini, B | 1 |
| Rosa, F | 1 |
| Naccarati, A | 1 |
| Vymetalkova, V | 1 |
| di Gaetano, C | 1 |
| Buchler, T | 1 |
| Novotny, J | 1 |
| Matullo, G | 1 |
| Lee, SJ | 4 |
| Park, SH | 18 |
| Lim, DH | 6 |
| Park, YS | 18 |
| Lim, HY | 10 |
| Choi, MG | 1 |
| Kang, WK | 17 |
| Eisterer, W | 2 |
| De Vries, A | 2 |
| Koplmüller, R | 1 |
| Tschmelitsch, J | 3 |
| Schmid, R | 2 |
| Kapp, K | 1 |
| Lukas, P | 3 |
| Sedlmayer, F | 1 |
| Höfler, G | 1 |
| Gnant, M | 3 |
| Wang, CC | 1 |
| Liang, JT | 3 |
| Tsai, CL | 1 |
| Chen, YH | 1 |
| Lin, YL | 1 |
| Shun, CT | 2 |
| Cheng, JC | 2 |
| Perez, K | 3 |
| Sikov, W | 3 |
| Vrees, M | 2 |
| Klipfel, A | 2 |
| Shah, N | 3 |
| Schechter, S | 1 |
| Oldenburg, N | 1 |
| Pricolo, V | 2 |
| Rosati, K | 2 |
| Selcukbiricik, F | 1 |
| Demir, N | 1 |
| Oven Ustaalioglu, BB | 1 |
| Yildiz, O | 1 |
| Misirlioglu, HC | 1 |
| Coskun-Breuneval, M | 1 |
| Kucukpilakci, B | 1 |
| Ugur, VI | 1 |
| Elgin, Y | 1 |
| Demirkasimoglu, T | 1 |
| Kara, SP | 1 |
| Ozgen, A | 1 |
| Sanri, E | 1 |
| Guney, Y | 1 |
| Fernández-Esparrach, G | 1 |
| Ayuso-Colella, JR | 1 |
| Bombí, JA | 1 |
| Conill, C | 3 |
| Cuatrecasas, M | 1 |
| Delgado, S | 2 |
| Ginés, A | 2 |
| Miquel, R | 1 |
| Pagés, M | 2 |
| Pineda, E | 1 |
| Pereira, V | 1 |
| Sosa, A | 1 |
| Reig, O | 1 |
| Victoria, I | 1 |
| Feliz, L | 1 |
| María de Lacy, A | 1 |
| Castells, A | 1 |
| Burkholder, I | 1 |
| Boni, C | 7 |
| Massuti, B | 3 |
| Pimentel, FL | 1 |
| Cohn, A | 2 |
| Follana, P | 1 |
| Clemens, M | 2 |
| Richards, DA | 1 |
| Ecstein-Fraisse, E | 1 |
| Hitier, S | 1 |
| Lin, JZ | 3 |
| Luo, JL | 1 |
| Cai, MY | 1 |
| Cai, PQ | 1 |
| Kong, LH | 3 |
| Liu, GC | 1 |
| Tang, JH | 1 |
| Chen, G | 5 |
| Pan, ZZ | 7 |
| Ding, PR | 4 |
| Kong, J | 1 |
| Wu, Y | 3 |
| Xu, E | 1 |
| Lai, M | 1 |
| Dupont-Gossard, AC | 1 |
| Thirot-Bidault, A | 2 |
| Lobry, C | 1 |
| Asnacios, A | 1 |
| Manet-Lacombe, S | 1 |
| Dubreuil, O | 2 |
| Cools-Lartigue, J | 1 |
| Jones, D | 1 |
| Spicer, J | 1 |
| Zourikian, T | 1 |
| Rousseau, M | 1 |
| Eckert, E | 1 |
| Vanhuyse, M | 1 |
| Ferri, LE | 3 |
| Breugom, AJ | 1 |
| van Gijn, W | 1 |
| Muller, EW | 1 |
| Berglund, Å | 9 |
| van den Broek, CBM | 1 |
| Fokstuen, T | 4 |
| Gelderblom, H | 1 |
| Kapiteijn, E | 1 |
| Leer, JWH | 1 |
| Marijnen, CAM | 1 |
| Martijn, H | 2 |
| Meershoek-Klein Kranenbarg, E | 1 |
| Påhlman, L | 9 |
| Putter, H | 3 |
| Roodvoets, AGH | 1 |
| Rutten, HJT | 1 |
| Steup, WH | 1 |
| van de Velde, CJH | 1 |
| Sheen, YT | 1 |
| Lin, CP | 1 |
| Sheen, MC | 1 |
| Tan, BH | 1 |
| Brammer, K | 1 |
| Randhawa, N | 1 |
| Welch, NT | 1 |
| James, EJ | 1 |
| Catton, JA | 1 |
| Namikawa, T | 1 |
| Munekage, E | 1 |
| Kitagawa, H | 2 |
| Hanazaki, K | 1 |
| Calkins, SM | 1 |
| Kelley, RK | 1 |
| Vandamme, M | 1 |
| Pauwels, W | 1 |
| Bleecker, JD | 1 |
| Stashkevych, M | 1 |
| Khomutov, E | 1 |
| Dumanskiy, Y | 1 |
| Matviyenko, A | 1 |
| Zinkovych, I | 1 |
| Zhang, N | 1 |
| Derouet, MF | 1 |
| Liu, G | 3 |
| Darling, GE | 1 |
| Berdov, BA | 2 |
| Erygin, DV | 1 |
| Nevol'skikh, AA | 1 |
| Titova, LN | 1 |
| Zamulaeva, IA | 1 |
| Kondrashova, LM | 1 |
| Xu, CD | 1 |
| Neofytou, K | 2 |
| Giakoustidis, A | 1 |
| Smyth, EC | 2 |
| Mudan, S | 2 |
| Izumi, H | 2 |
| Touge, H | 1 |
| Igishi, T | 1 |
| Makino, H | 3 |
| Nishii-Ito, S | 1 |
| Takata, M | 2 |
| Nakazaki, H | 1 |
| Ueda, Y | 3 |
| Kodani, M | 1 |
| Kurai, J | 1 |
| Yanai, M | 1 |
| Tanaka, N | 14 |
| Nirodi, CS | 1 |
| Shimizu, E | 2 |
| Li, ZY | 2 |
| Li, ZW | 1 |
| Sun, YS | 1 |
| Ji, JF | 3 |
| Ferrandina, G | 1 |
| Gambacorta, A | 1 |
| Gallotta, V | 1 |
| Smaniotto, D | 1 |
| Fagotti, A | 1 |
| Tagliaferri, L | 1 |
| Foti, E | 1 |
| Fanfani, F | 1 |
| Autorino, R | 1 |
| Scambia, G | 1 |
| Valentini, V | 7 |
| Zhao, HY | 1 |
| Chen, GY | 2 |
| Li, XL | 2 |
| Feng, JF | 3 |
| Shi, MQ | 1 |
| Cheng, Y | 2 |
| Ma, LX | 1 |
| Zhang, YP | 2 |
| Gu, CP | 1 |
| Song, XQ | 1 |
| Zhou, D | 1 |
| Poulsen, LØ | 1 |
| Qvortrup, C | 4 |
| Yilmaz, M | 5 |
| Falkmer, U | 1 |
| Sorbye, H | 1 |
| Ritch, PS | 4 |
| Erickson, BA | 1 |
| McDonnell, EI | 1 |
| Santos, DD | 1 |
| Faris, JE | 1 |
| Murphy, JE | 1 |
| Kang, SY | 1 |
| Ahn, MS | 1 |
| Song, GW | 1 |
| Choi, YW | 1 |
| Lee, HW | 2 |
| Jeong, SH | 1 |
| Cho, YK | 2 |
| Han, SU | 2 |
| Sheen, SS | 1 |
| Han, JH | 1 |
| Choi, JH | 3 |
| Tey, J | 2 |
| Peng, L | 2 |
| Fu, S | 2 |
| Huang, G | 2 |
| Xiong, F | 2 |
| Lu, JJ | 2 |
| Okabe, H | 3 |
| Ihaya, T | 1 |
| Kichikawa, K | 3 |
| Ohashi, Y | 4 |
| Yuan, F | 1 |
| Shi, H | 1 |
| Cai, Q | 1 |
| Ghasemi, Z | 1 |
| Dinarvand, R | 1 |
| Mottaghitalab, F | 1 |
| Esfandyari-Manesh, M | 1 |
| Sayari, E | 1 |
| Atyabi, F | 1 |
| Strobel, O | 1 |
| Kozak, MM | 1 |
| von Eyben, R | 1 |
| Pai, J | 1 |
| Vossler, SR | 1 |
| Limaye, M | 1 |
| Jayachandran, P | 1 |
| Anderson, EM | 1 |
| Shaffer, JL | 1 |
| Longacre, T | 1 |
| Pai, RK | 1 |
| Koong, AC | 3 |
| Baba, K | 1 |
| Oshita, A | 1 |
| Kohyama, M | 1 |
| Inoue, S | 6 |
| Kuroo, Y | 2 |
| Nakamura, H | 4 |
| Sugiyama, Y | 4 |
| Tazaki, T | 2 |
| Sasaki, M | 5 |
| Imamura, Y | 2 |
| Daimaru, Y | 2 |
| Ohdan, H | 1 |
| Nakamitsu, A | 2 |
| Ojima, H | 1 |
| Fukuchi, M | 1 |
| Sakai, M | 1 |
| Sohda, M | 1 |
| Ieta, K | 1 |
| Saito, K | 2 |
| Sano, A | 1 |
| Yokobori, T | 2 |
| Inose, T | 1 |
| Nakajima, M | 2 |
| Riera Knorrenschild, J | 1 |
| Pohl, M | 1 |
| Bassermann, F | 2 |
| Helbig, U | 1 |
| Weißinger, F | 2 |
| Schnoy, E | 1 |
| Stocker, G | 2 |
| Rüschoff, J | 2 |
| Eisenmenger, A | 1 |
| Karapanagiotou-Schenkel, I | 2 |
| Rizvi, SM | 1 |
| Sarwani, N | 1 |
| El-Deiry, WS | 4 |
| Scheulen, ME | 1 |
| Jassem, J | 1 |
| Vynnychenko, I | 2 |
| Tamura, A | 2 |
| Ami, K | 2 |
| Hayasaka, J | 1 |
| Takagi, K | 1 |
| Okamoto, E | 2 |
| Kitazume, A | 1 |
| Kondou, M | 1 |
| Gokita, K | 1 |
| Tei, S | 2 |
| Arai, K | 8 |
| Shibayama, T | 1 |
| Suda, K | 2 |
| Kameyama, H | 1 |
| Sakata, J | 1 |
| Nogami, H | 1 |
| Minagawa, M | 1 |
| Kosugi, S | 2 |
| Koyama, Y | 3 |
| Wakai, T | 2 |
| Miyoshi, N | 1 |
| Fukata, T | 1 |
| Fujino, S | 1 |
| Akita, H | 1 |
| Sakon, M | 2 |
| Nushijima, Y | 2 |
| Nakano, K | 2 |
| Nakaguchi, K | 3 |
| Kan, K | 1 |
| Maruyama, H | 3 |
| Doi, S | 1 |
| Okamura, S | 4 |
| Tomihara, H | 1 |
| Hama, N | 2 |
| Wada, H | 2 |
| Tomokuni, A | 1 |
| Tomimaru, Y | 1 |
| Asaoka, T | 1 |
| Kawamoto, K | 2 |
| Eguchi, H | 1 |
| Nagano, H | 2 |
| Jeongho, M | 1 |
| Hatanaka, N | 1 |
| Odagiri, K | 1 |
| Honmyo, N | 1 |
| Inoue, M | 6 |
| Irei, T | 1 |
| Tanemura, M | 1 |
| Mihara, K | 1 |
| Yamashiro, N | 1 |
| Nishiya, S | 1 |
| Kemmochi, T | 1 |
| Egawa, T | 1 |
| Nagashima, A | 3 |
| Ryschich, E | 2 |
| Hartwig, W | 1 |
| Francini, E | 2 |
| Marrelli, D | 1 |
| Fiaschi, AI | 2 |
| Laera, L | 1 |
| Rossi, G | 3 |
| Bianco, V | 1 |
| Brozzetti, S | 1 |
| Hentic, O | 3 |
| Murata, S | 1 |
| Onozawa, S | 1 |
| Sugihara, F | 1 |
| Sakamoto, A | 1 |
| Ueda, T | 3 |
| Yamaguchi, H | 5 |
| Yasui, D | 1 |
| Mine, T | 1 |
| Kumita, S | 1 |
| Rosso, E | 1 |
| Fuchshuber, P | 2 |
| Oussoultzoglou, E | 1 |
| De Blasi, V | 1 |
| Simone, G | 2 |
| Belletier, C | 1 |
| Dufour, P | 2 |
| Lescut, N | 1 |
| Lepinoy, A | 1 |
| Schipman, B | 1 |
| Cerda, T | 1 |
| Guimas, V | 1 |
| Bednarek, C | 1 |
| Neumann, JH | 1 |
| Jung, A | 4 |
| Kirchner, T | 3 |
| McDonald, AM | 1 |
| Dulaney, CR | 1 |
| López-Araujo, J | 1 |
| Posey, JA | 1 |
| Keene, KS | 2 |
| Heslin, MJ | 1 |
| Wood, TE | 1 |
| Jacob, R | 1 |
| Rateesh, S | 1 |
| Shekar, K | 1 |
| Naidoo, R | 1 |
| Mittal, D | 1 |
| Bhaskar, B | 1 |
| Nicosia, L | 1 |
| Gentile, G | 1 |
| Di Nardo, F | 1 |
| Minniti, G | 1 |
| Maglio, M | 1 |
| Borro, M | 1 |
| Simmaco, M | 1 |
| Enrici, RM | 1 |
| Endo, S | 3 |
| Okuyama, M | 2 |
| Hiraoka, K | 1 |
| Konishi, K | 4 |
| Kim, C | 4 |
| Nakagawa, T | 2 |
| Nishikawa, K | 1 |
| Nishijima, J | 2 |
| Bowen, JM | 1 |
| White, I | 1 |
| Smith, L | 1 |
| Tsykin, A | 1 |
| Kristaly, K | 1 |
| Thompson, SK | 2 |
| Tan, H | 1 |
| Game, PA | 1 |
| Irvine, T | 1 |
| Keefe, DM | 1 |
| Argilés, G | 1 |
| Benson, A | 2 |
| Guillén Ponce, C | 1 |
| Macpherson, IR | 1 |
| Wagner, A | 1 |
| Luigi Garosi, V | 1 |
| Grunert, J | 1 |
| Kordes, S | 1 |
| Klümpen, HJ | 1 |
| Weterman, MJ | 1 |
| Richel, DJ | 1 |
| Treese, C | 1 |
| von Winterfeld, M | 1 |
| Dogan, Y | 2 |
| Schmidt, SC | 1 |
| Daum, S | 3 |
| Thuss-Patience, PC | 6 |
| Hassan, AS | 1 |
| Naicker, M | 1 |
| Yusof, KH | 1 |
| Wan Ishak, WZ | 1 |
| Hacibekiroglu, I | 1 |
| Kodaz, H | 1 |
| Erdogan, B | 1 |
| Turkmen, E | 1 |
| Esenkaya, A | 1 |
| Uzunoglu, S | 1 |
| Cicin, I | 1 |
| Gaduputi, V | 1 |
| Tariq, H | 1 |
| Ihimoyan, A | 1 |
| Guillen, KP | 1 |
| Restuccia, A | 1 |
| Harrison, RG | 1 |
| Smyth, EN | 1 |
| Ball, DE | 1 |
| Johnson, E | 1 |
| Viste, A | 3 |
| Myrnäs, T | 1 |
| Szabo, E | 1 |
| Tsai, JA | 2 |
| Vishnevskiĭ, AV | 1 |
| Andreĭtseva, OI | 1 |
| Kharazov, AF | 1 |
| Gritsiuta, AI | 1 |
| Kalinin, DV | 1 |
| Zhavoronkova, OI | 1 |
| Lastoria, S | 3 |
| Yhim, HY | 1 |
| Kim, SY | 12 |
| Cho, IS | 1 |
| Lee, KT | 3 |
| Lee, WS | 1 |
| Lee, SI | 4 |
| Park, MR | 1 |
| Park, SG | 1 |
| Han, HS | 2 |
| Choi, YS | 1 |
| Lee, NR | 1 |
| Song, EK | 3 |
| Yim, CY | 1 |
| Lopes-Ramos, C | 1 |
| Koyama, FC | 1 |
| Salim, AC | 1 |
| Bettoni, F | 1 |
| Asprino, PF | 1 |
| França, GS | 1 |
| Parmigiani, RB | 1 |
| Galante, PA | 1 |
| Camargo, AA | 1 |
| Illum, H | 1 |
| Wang, DH | 1 |
| Dowell, JE | 1 |
| Hittson, WJ | 1 |
| Torrisi, JR | 1 |
| Huerta, S | 1 |
| Vanhoecke, B | 1 |
| Bateman, E | 1 |
| Mayo, B | 1 |
| Vanlancker, E | 1 |
| Stringer, A | 1 |
| Thorpe, D | 1 |
| Keefe, D | 1 |
| Gakis, G | 1 |
| Morgan, TM | 1 |
| Daneshmand, S | 1 |
| Keegan, KA | 1 |
| Todenhöfer, T | 1 |
| Mischinger, J | 1 |
| Schubert, T | 1 |
| Zaid, HB | 1 |
| Hrbacek, J | 1 |
| Ali-El-Dein, B | 1 |
| Clayman, RH | 1 |
| Galland, S | 1 |
| Olugbade, K | 1 |
| Rink, M | 1 |
| Fritsche, HM | 1 |
| Burger, M | 1 |
| Chang, SS | 1 |
| Babjuk, M | 1 |
| Thalmann, GN | 1 |
| Stenzl, A | 1 |
| Efstathiou, JA | 1 |
| Yanai, H | 1 |
| Yahara, N | 1 |
| Furuya, T | 1 |
| Murakami, T | 1 |
| Shimokawa, Y | 1 |
| Sugihara, S | 1 |
| Gariboldi, MB | 2 |
| Taiana, E | 1 |
| Bonzi, MC | 1 |
| Craparotta, I | 1 |
| Giovannardi, S | 1 |
| Mancini, M | 1 |
| Monti, E | 2 |
| Teufel, A | 2 |
| Gerken, M | 1 |
| Hartl, J | 1 |
| Itzel, T | 1 |
| Stroszczynski, C | 1 |
| Schlitt, HJ | 2 |
| Hofstädter, F | 1 |
| Klinkhammer-Schalke, M | 1 |
| Zhao, Q | 3 |
| Qiao, X | 1 |
| Shi, G | 3 |
| Xu, Q | 3 |
| Li, R | 1 |
| Yang, P | 1 |
| Wiecha, C | 1 |
| Kunzmann, R | 1 |
| Heger, U | 1 |
| Weichert, W | 2 |
| Stange, A | 2 |
| Blank, S | 2 |
| Grenacher, L | 1 |
| Badgwell, B | 1 |
| Estrella, J | 1 |
| Chiang, YJ | 1 |
| Gronnier, C | 1 |
| Lebreton, G | 1 |
| Brigand, C | 1 |
| Mabrut, JY | 1 |
| Bail, JP | 1 |
| Meunier, B | 2 |
| Mariette, C | 7 |
| Korytova, LI | 1 |
| Sandalevskaya, AG | 1 |
| Krasnikoval, VG | 1 |
| Korytov, OV | 1 |
| Meshechkin, AV | 1 |
| Volovat, SR | 1 |
| Negru, SM | 1 |
| Danciu, M | 1 |
| Scripcariu, V | 1 |
| Deme, D | 1 |
| Bishr, AM | 1 |
| Nizar, J | 1 |
| Telekes, A | 1 |
| Wen, B | 1 |
| Huang, R | 1 |
| Peng, H | 1 |
| Dong, J | 1 |
| Zeng, Z | 1 |
| Gao, Y | 1 |
| Kim, ST | 7 |
| Marks, EI | 1 |
| Brennan, M | 4 |
| Lam, JY | 1 |
| McConnell, YJ | 2 |
| Rivard, JD | 1 |
| Temple, WJ | 2 |
| Mack, LA | 2 |
| Ma, J | 2 |
| Deng, G | 1 |
| Pei, H | 1 |
| Zeng, S | 1 |
| Makielski, RJ | 1 |
| Lubner, SJ | 1 |
| Mulkerin, DL | 1 |
| Traynor, AM | 1 |
| Groteluschen, D | 1 |
| Eickhoff, J | 1 |
| LoConte, NK | 1 |
| Park, IJ | 3 |
| Kim, DY | 10 |
| Kim, HC | 6 |
| Kim, HR | 4 |
| Kang, SB | 2 |
| Choi, GS | 3 |
| Oh, ST | 4 |
| Lim, SB | 8 |
| Kim, JC | 8 |
| Oh, JH | 7 |
| Lee, WY | 4 |
| Lee, JB | 1 |
| Yu, CS | 8 |
| Tseng, CL | 1 |
| Chen, JC | 1 |
| Wu, YC | 1 |
| Fang, HW | 1 |
| Lin, FH | 1 |
| Tang, TP | 1 |
| Makoshi, Z | 1 |
| Perrott, C | 1 |
| Al-Khatani, K | 1 |
| Al-Mohaisen, F | 1 |
| Nanda, RH | 1 |
| Van De Voorde, L | 1 |
| Janssen, L | 1 |
| Larue, R | 1 |
| Houben, R | 1 |
| Buijsen, J | 1 |
| Sosef, M | 1 |
| Vanneste, B | 1 |
| Schraepen, MC | 1 |
| Berbée, M | 1 |
| Lambin, P | 1 |
| Fan, WH | 1 |
| Li, LR | 2 |
| Wu, XJ | 4 |
| Wan, DS | 7 |
| Park, JM | 2 |
| Song, BJ | 1 |
| Badiyan, SN | 1 |
| Lee, AY | 1 |
| Menias, CO | 1 |
| Strasberg, SM | 1 |
| Hawkins, WG | 1 |
| Linehan, DC | 1 |
| Martínez-Lago, N | 1 |
| Vieito-Villar, M | 1 |
| Vidal-Insua, Y | 1 |
| Padin-Iruegas, ME | 1 |
| Vazquez-Rivera, F | 1 |
| Candamio-Folgar, S | 1 |
| Lopez-Lopez, R | 1 |
| Chang, KH | 1 |
| Kelly, NP | 1 |
| Duff, GP | 1 |
| Condon, ET | 1 |
| Waldron, D | 1 |
| Coffey, JC | 1 |
| Wu, Z | 1 |
| Ma, S | 1 |
| Jing, S | 1 |
| Deng, Q | 1 |
| Wu, K | 1 |
| Vargas, A | 2 |
| Montironi, C | 1 |
| Buxó, E | 2 |
| Ho, MY | 1 |
| Renouf, DJ | 1 |
| Lim, HJ | 1 |
| Messager, M | 2 |
| Chaudry, MA | 1 |
| Umemura, A | 1 |
| Nitta, H | 1 |
| Sasaki, A | 1 |
| Takahara, T | 2 |
| Hasegawa, Y | 1 |
| Wakabayashi, G | 1 |
| Marcet, JE | 1 |
| Cataldo, PA | 1 |
| Kumar, AS | 1 |
| Coutsoftides, T | 1 |
| Hunt, SR | 1 |
| Stamos, MJ | 1 |
| Ternent, CA | 1 |
| Fichera, A | 1 |
| Dietz, DW | 2 |
| Rödel, C | 3 |
| Graeven, U | 1 |
| Hohenberger, W | 8 |
| Hothorn, T | 1 |
| Ghadimi, M | 1 |
| Wolff, HA | 2 |
| Lang-Welzenbach, M | 1 |
| Raab, HR | 1 |
| Ströbel, P | 2 |
| Staib, L | 3 |
| Wilhelm, M | 1 |
| Grabenbauer, GG | 2 |
| Hoffmanns, H | 1 |
| Lindemann, F | 1 |
| Schlenska-Lange, A | 1 |
| Sauer, R | 7 |
| Liersch, T | 8 |
| Fleming, GF | 1 |
| Neureiter, D | 1 |
| Kemmerling, R | 1 |
| Folwaczny, M | 1 |
| Ning, Y | 1 |
| Sebio, A | 1 |
| Stremitzer, S | 1 |
| Sunakawa, Y | 1 |
| Matsusaka, S | 4 |
| Yamauchi, S | 1 |
| Ruffier-Loubière, A | 1 |
| Janoray, G | 1 |
| de Calan, L | 1 |
| Dumont, P | 4 |
| Dorval, É | 3 |
| Orain, I | 1 |
| De Divitiis, C | 1 |
| Cassata, A | 1 |
| Nasti, G | 1 |
| Ottaiano, A | 2 |
| Nappi, A | 1 |
| Barretta, ML | 1 |
| Iaffaioli, RV | 2 |
| Jiang, DM | 1 |
| Raissouni, S | 1 |
| Mercer, J | 1 |
| Kumar, A | 2 |
| Goodwin, R | 1 |
| Heng, DY | 1 |
| Tang, PA | 1 |
| Doll, C | 1 |
| MacLean, A | 1 |
| Powell, E | 1 |
| Price-Hiller, J | 1 |
| Monzon, J | 1 |
| Vickers, MM | 1 |
| Huang, TC | 1 |
| Hsu, CH | 4 |
| Tu, YK | 1 |
| Bronsert, P | 1 |
| Schäfer, M | 1 |
| Kulemann, B | 1 |
| Marjanovic, G | 1 |
| Sick, O | 1 |
| Hopt, UT | 1 |
| Zirlik, K | 1 |
| Osumi, H | 1 |
| Yoshio, T | 1 |
| Chin, K | 3 |
| Ogura, M | 2 |
| Kumekawa, Y | 1 |
| Suenaga, M | 3 |
| Shinozaki, E | 3 |
| Morishige, K | 1 |
| Ishiyama, A | 1 |
| Hirasawa, T | 1 |
| Tsuchida, T | 1 |
| Fujisaki, J | 1 |
| Igarashi, M | 1 |
| Mizunuma, N | 3 |
| Wagner, M | 2 |
| Regenet, N | 1 |
| Innominato, P | 1 |
| D'Haens, G | 2 |
| Bennouna, J | 3 |
| Ducreux, M | 22 |
| Latini, L | 1 |
| Staines, H | 1 |
| Oum'Hamed, Z | 1 |
| Dressler, H | 1 |
| Studeny, M | 1 |
| Capdevila, J | 2 |
| Piro, G | 1 |
| Giacopuzzi, S | 3 |
| Bencivenga, M | 1 |
| Carbone, C | 1 |
| Verlato, G | 3 |
| Frizziero, M | 1 |
| Zanotto, M | 1 |
| Mina, MM | 1 |
| Santoro, R | 1 |
| Zanoni, A | 3 |
| De Manzoni, G | 3 |
| Tortora, G | 1 |
| Schneider, CC | 1 |
| Fischer, N | 1 |
| Bühler, S | 1 |
| Venturelli, S | 1 |
| Berger, A | 1 |
| Burkard, M | 1 |
| Kirschniak, A | 1 |
| Bachmann, R | 1 |
| Glatzle, J | 1 |
| Cho, HM | 1 |
| Shim, BY | 1 |
| Baek, JY | 2 |
| Yoon, MS | 1 |
| Jeong, JU | 1 |
| Jeong, BK | 1 |
| Zhu, B | 1 |
| Wu, JR | 1 |
| Zhou, XP | 1 |
| Liu, D | 2 |
| Zhou, H | 1 |
| Yue, X | 1 |
| Hu, X | 3 |
| Zahir, MN | 1 |
| Jabbar, AA | 1 |
| Deniz, K | 1 |
| Nitsche, U | 1 |
| Wenzel, P | 1 |
| Braren, R | 1 |
| Holzapfel, K | 1 |
| Schlitter, AM | 1 |
| Stöß, C | 1 |
| Kong, B | 1 |
| Esposito, I | 1 |
| Erkan, M | 1 |
| Michalski, CW | 1 |
| Friess, H | 8 |
| Kleeff, J | 1 |
| Goto, R | 1 |
| Kurihara, M | 4 |
| Ochenduszko, S | 1 |
| Puskulluoglu, M | 1 |
| Konopka, K | 1 |
| Fijorek, K | 1 |
| Urbanczyk, K | 1 |
| Budzynski, A | 1 |
| Matlok, M | 1 |
| Lazar, A | 2 |
| Sinczak-Kuta, A | 1 |
| Pedziwiatr, M | 1 |
| Krzemieniecki, K | 1 |
| Yamamoto, S | 6 |
| Kumaki, N | 1 |
| Makuuchi, H | 4 |
| Ozawa, S | 1 |
| Chino, O | 1 |
| Kazuno, A | 1 |
| Yasuda, S | 5 |
| Tamayama, T | 1 |
| Sakai, I | 1 |
| Ghorani, E | 1 |
| Wong, HH | 1 |
| Hewitt, C | 1 |
| Calder, J | 1 |
| Basu, B | 1 |
| Serrano, JJ | 1 |
| Fernández, C | 2 |
| Ramirez, C | 1 |
| Ortega, L | 2 |
| García-Paredes, B | 1 |
| Corona, J | 2 |
| Alfonso, R | 2 |
| Córdoba, S | 2 |
| Díaz-Rubio, E | 7 |
| LoConte, N | 1 |
| Tempero, MA | 4 |
| Walker, EJ | 1 |
| Kate Kelley, R | 1 |
| Lewis, S | 1 |
| Chang, WC | 1 |
| Kantoff, E | 2 |
| Vannier, MW | 1 |
| Catenacci, DV | 1 |
| Mayer, B | 1 |
| Sander, S | 2 |
| Paschke, S | 1 |
| Henne-Bruns, D | 3 |
| Link, KH | 4 |
| Kornmann, M | 5 |
| Ikeda, T | 2 |
| Iida, S | 2 |
| Toda, N | 1 |
| Fukuda, H | 4 |
| Takagi, T | 4 |
| Iizuka, J | 1 |
| Kondo, T | 2 |
| Stoller, R | 1 |
| Kemeny, M | 1 |
| Krishnamurthi, S | 3 |
| Su, YB | 1 |
| Ocean, A | 1 |
| Mehrotra, B | 1 |
| Henderson, C | 1 |
| Sun, GP | 1 |
| Lu, HS | 1 |
| Zhong, MZ | 2 |
| Zhang, HL | 1 |
| Yu, SY | 1 |
| Hu, XH | 1 |
| Wang, JJ | 2 |
| Zhou, JT | 1 |
| Guo, ZQ | 3 |
| Guan, ZG | 1 |
| Zhu, D | 1 |
| Qin, C | 1 |
| Niu, W | 1 |
| Qin, X | 1 |
| Altan, B | 1 |
| Mochiki, E | 1 |
| Toyomasu, Y | 1 |
| Kogure, N | 1 |
| Kimura, A | 1 |
| Bai, T | 4 |
| Bao, P | 1 |
| Suzuki, M | 9 |
| Nishiyama, M | 4 |
| Lavau-Denes, S | 1 |
| Gargot, D | 2 |
| Gasmi, M | 2 |
| Adhoute, X | 2 |
| Khemissa, F | 1 |
| Provençal, J | 1 |
| Legoux, JL | 2 |
| Charneau, J | 1 |
| Chone, L | 1 |
| Serra-Aracil, X | 1 |
| Ocaña-Rojas, J | 1 |
| Mora-López, L | 1 |
| Dotor, E | 2 |
| Casalots, A | 2 |
| Pisa, A | 1 |
| Rupinski, M | 1 |
| Malinowska, M | 2 |
| Mroz, A | 1 |
| Wyrwicz, L | 2 |
| Kwon, HY | 1 |
| Kim, IK | 1 |
| Sohn, SK | 9 |
| Darunikorn, P | 1 |
| Puataweepong, P | 1 |
| Dhanachai, M | 1 |
| Dangprasert, S | 1 |
| Swangsilpa, T | 1 |
| Sitathanee, C | 1 |
| Jiarpinitnun, C | 1 |
| Pattaranutaporn, P | 1 |
| Boonyawan, K | 1 |
| Chansriwong, P | 1 |
| Charpentier, KP | 1 |
| Mantripragada, K | 1 |
| Miner, T | 3 |
| Kuritzky, B | 1 |
| Apor, E | 1 |
| Bishop, K | 1 |
| Luppe, D | 1 |
| Davis, EJ | 1 |
| Kim, EJ | 1 |
| Ruch, JM | 1 |
| McDonnell, KJ | 1 |
| Jung, M | 3 |
| Keum, KC | 3 |
| Lim, JS | 1 |
| Hong, SP | 1 |
| Kim, TI | 3 |
| Roh, JK | 11 |
| Oh, SK | 1 |
| Kim, HW | 1 |
| Kang, DH | 1 |
| Choi, CW | 3 |
| Choi, YY | 1 |
| Lim, HK | 1 |
| Goo, JJ | 1 |
| Choi, SY | 1 |
| Shin, DY | 1 |
| Choi, YH | 1 |
| Lee, HR | 4 |
| Na, II | 2 |
| Yuh, YJ | 1 |
| Kim, BS | 15 |
| Kang, HJ | 3 |
| Kuribara, T | 1 |
| Ichikawa, T | 1 |
| Kaneko, S | 1 |
| Osa, K | 1 |
| Ueda, M | 4 |
| Asanuma, K | 1 |
| Kishimoto, Y | 1 |
| Iai, A | 1 |
| Houssany, S | 1 |
| Renner, J | 1 |
| Boutonnet, M | 1 |
| Peigne, V | 1 |
| Soler, C | 1 |
| Sasaki, H | 4 |
| Kaneto, H | 1 |
| Iida, T | 1 |
| Naganawa, Y | 1 |
| Satoh, S | 2 |
| Shimizu, H | 2 |
| Sasaki, K | 9 |
| Konishi, Y | 1 |
| Kon, S | 1 |
| Bussolati, G | 1 |
| Nardon, E | 2 |
| Annaratone, L | 1 |
| Chiaravalli, AM | 1 |
| Capella, C | 1 |
| Hoefler, G | 1 |
| Beumer, JH | 1 |
| Negrea, L | 1 |
| Holleran, JL | 2 |
| Strychor, S | 1 |
| Meropol, NJ | 9 |
| Han, P | 1 |
| He, Y | 1 |
| Zhao, C | 1 |
| Yang, W | 2 |
| Shan, M | 1 |
| Yang, C | 1 |
| Weng, M | 1 |
| Cui, B | 1 |
| Shen, G | 1 |
| Vargo, CA | 1 |
| Gulati, M | 1 |
| Cohen, SA | 1 |
| Yu, M | 1 |
| Gourgioti, G | 1 |
| Wirtz, R | 2 |
| Raptou, G | 1 |
| Gkakou, C | 1 |
| Kotoula, V | 1 |
| Karavasilis, V | 1 |
| Kalogeras, KT | 1 |
| Cho, MS | 1 |
| Renehan, AG | 1 |
| Malcomson, L | 1 |
| Emsley, R | 1 |
| Maw, A | 1 |
| Myint, AS | 1 |
| Rooney, PS | 1 |
| Susnerwala, S | 2 |
| Blower, A | 1 |
| Wilson, MS | 1 |
| Scott, N | 2 |
| O'Dwyer, ST | 1 |
| Biffi, R | 3 |
| Maibach, R | 4 |
| Hayoz, S | 1 |
| Thierstein, S | 1 |
| Brauchli, P | 2 |
| Bernhard, J | 5 |
| Stupp, R | 3 |
| Andreoni, B | 1 |
| Renne, G | 1 |
| Crosta, C | 1 |
| Morant, R | 3 |
| Chiappa, A | 2 |
| Luca, F | 1 |
| Huber, O | 2 |
| Goldhirsch, A | 6 |
| de Braud, F | 6 |
| Roth, AD | 5 |
| Chae, YS | 2 |
| Park, SY | 3 |
| Li, TT | 1 |
| Li, FP | 1 |
| Hu, YF | 1 |
| Mou, TY | 1 |
| Lin, T | 1 |
| Li, GX | 1 |
| Li, D | 3 |
| Crane, C | 2 |
| Regine, WF | 8 |
| Abrams, RA | 9 |
| Liu, C | 3 |
| Chang, P | 1 |
| Freedman, GM | 1 |
| Winter, KA | 6 |
| Guha, C | 2 |
| Orlandi, A | 1 |
| Calegari, MA | 1 |
| Martini, M | 1 |
| Cocomazzi, A | 1 |
| Bagalà, C | 1 |
| Indellicati, G | 1 |
| Zurlo, V | 1 |
| Basso, M | 2 |
| Cassano, A | 3 |
| Larocca, LM | 1 |
| Cashin, PH | 1 |
| Mahteme, H | 3 |
| Spång, N | 1 |
| Syk, I | 1 |
| Frödin, JE | 3 |
| Torkzad, M | 1 |
| Aroldi, F | 1 |
| Alexandersson von Döbeln, G | 1 |
| Wang, N | 1 |
| Hatlevoll, I | 1 |
| Lind, P | 2 |
| Note, H | 1 |
| Ariga, T | 2 |
| Suzuki, K | 4 |
| Kobayashi, H | 5 |
| Sawada, N | 1 |
| Kanada, Y | 1 |
| Senba, Y | 1 |
| Yoshioka, T | 4 |
| Sato, Y | 7 |
| Miyazaki, A | 1 |
| Natsume, T | 2 |
| Matsuzaki, H | 1 |
| Tanaka, H | 9 |
| Maruyama, T | 3 |
| Nakayama, Y | 2 |
| Hakamada, K | 1 |
| Tokoro, Y | 1 |
| Tonooka, T | 1 |
| Souda, H | 1 |
| Chibana, T | 1 |
| Kobayashi, R | 1 |
| Arimitsu, H | 2 |
| Yanagibashi, H | 1 |
| Chou, A | 1 |
| Nabeya, N | 1 |
| Takenoya, T | 1 |
| Takano, M | 3 |
| Nishizawa, Y | 1 |
| Fukuda, T | 1 |
| Kazama, S | 1 |
| Amikura, K | 1 |
| Kurozumi, M | 1 |
| Kawashima, Y | 2 |
| Tanaka, Y | 4 |
| Sakamoto, H | 1 |
| Kakuta, S | 1 |
| Takayama, W | 2 |
| Kou, T | 1 |
| Satou, M | 1 |
| Sugaya, M | 1 |
| Cai, H | 1 |
| Zheng, W | 1 |
| Tong, M | 1 |
| Ao, L | 1 |
| Hong, G | 1 |
| Guan, Q | 1 |
| Guo, Z | 1 |
| Prithviraj, GK | 1 |
| Jiang, K | 2 |
| Zhao, X | 1 |
| Chen, DT | 1 |
| Strosberg, J | 1 |
| Campos, T | 1 |
| Shibata, D | 2 |
| Price, TJ | 2 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 4 |
| Sjoquist, KM | 1 |
| Strickland, A | 2 |
| Varma, SC | 1 |
| Young, R | 1 |
| Underhill, C | 4 |
| Shannon, JA | 2 |
| Ganju, V | 2 |
| Wild, AT | 1 |
| Dholakia, AS | 1 |
| Moningi, S | 1 |
| Rosati, LM | 1 |
| Assadi, RK | 1 |
| Saeed, AM | 1 |
| Tran, PT | 1 |
| Wolfgang, CL | 7 |
| Ford, E | 1 |
| Grossman, SA | 1 |
| Kosugi, C | 1 |
| Koda, K | 2 |
| Yamazaki, M | 2 |
| Shuto, K | 2 |
| Matsuo, K | 3 |
| Shiragami, R | 1 |
| Yasuda, H | 2 |
| Blum Murphy, MA | 1 |
| Qiao, W | 1 |
| Mewada, N | 1 |
| Elimova, E | 1 |
| Takashi, T | 1 |
| Phan, A | 1 |
| Baker, J | 1 |
| Fernandez, LM | 2 |
| Figueiredo, MN | 1 |
| Buchpiguel, CA | 2 |
| Geetha, P | 1 |
| Sivaram, AJ | 1 |
| Jayakumar, R | 1 |
| Gopi Mohan, C | 1 |
| Magnante, AL | 1 |
| Benevento, I | 1 |
| Nahas, SC | 3 |
| Rizkallah Nahas, CS | 1 |
| Sparapan Marques, CF | 1 |
| Ribeiro, U | 5 |
| Cotti, GC | 1 |
| Imperiale, AR | 1 |
| Capareli, FC | 1 |
| Chih Chen, AT | 1 |
| Hoff, PM | 6 |
| Cecconello, I | 1 |
| Lynn, PB | 2 |
| Jorge, JM | 1 |
| Hackert, T | 1 |
| Ulrich, A | 1 |
| Gao, K | 1 |
| Liang, Q | 1 |
| Zhao, ZH | 1 |
| Li, YF | 3 |
| Wang, SF | 1 |
| Shao, S | 1 |
| Sun, PH | 1 |
| Satherley, LK | 1 |
| Ji, KE | 1 |
| Feng, YI | 1 |
| Neuman, T | 1 |
| Olszanski, AJ | 1 |
| Davey, M | 1 |
| Cheng, JD | 2 |
| Lebenthal, A | 1 |
| Burtness, BA | 3 |
| Scott, WJ | 1 |
| Astsaturov, IA | 1 |
| Bupathi, M | 1 |
| Ahn, DH | 1 |
| Ciombor, KK | 1 |
| Stephens, JA | 1 |
| Goldstein, DA | 1 |
| Mazzola, R | 1 |
| Ferrera, G | 1 |
| Cucchiara, T | 1 |
| Figlia, V | 1 |
| Gueci, M | 1 |
| Sciumè, F | 1 |
| Di Paola, G | 1 |
| Scibetta, N | 1 |
| Lo Casto, A | 1 |
| Pappalardo, MP | 1 |
| Lagalla, R | 1 |
| Alongi, F | 1 |
| Stein, SM | 1 |
| James, ES | 1 |
| Cong, X | 1 |
| Staugaard, C | 1 |
| Indukala, D | 1 |
| Boustani, AM | 1 |
| Patel, V | 1 |
| Cha, CH | 1 |
| Chang, B | 1 |
| Ion, RM | 1 |
| Stan, M | 1 |
| Nikitovic, D | 1 |
| Hayes, AW | 1 |
| Spandidos, DA | 1 |
| Tsatsakis, AM | 1 |
| Ur Rehman, SS | 1 |
| Lim, K | 1 |
| Li, ZZ | 1 |
| Zhang, ZC | 1 |
| He, MM | 2 |
| Ren, J | 1 |
| Shao, JY | 1 |
| Frankel, P | 1 |
| Lim, D | 1 |
| Yeon, C | 1 |
| Leong, L | 7 |
| Chao, J | 1 |
| Ruel, N | 1 |
| Luevanos, E | 1 |
| Koehler, S | 1 |
| Chung, S | 1 |
| Lau, SC | 1 |
| Fakih, MG | 6 |
| Wang, ZX | 2 |
| Yang, XL | 1 |
| Zhou, ZW | 3 |
| Zhan, YQ | 3 |
| Yu, T | 1 |
| Cao, XL | 1 |
| Wu, GJ | 1 |
| Zhao, G | 1 |
| Jia, WW | 1 |
| Xiao, G | 1 |
| Kathiravetpillai, N | 1 |
| Koëter, M | 1 |
| van der Sangen, MJ | 2 |
| Luyer, MD | 1 |
| Nieuwenhuijzen, GA | 3 |
| Cravioto-Villanueva, A | 1 |
| Cavazos, M | 1 |
| Luna-Perez, P | 4 |
| Martinez-Gomez, H | 1 |
| Ramirez, ML | 1 |
| Solorzano, J | 1 |
| Montiel, H | 1 |
| Esquivel, J | 2 |
| Sinclair, R | 1 |
| Navidi, M | 1 |
| Griffin, SM | 1 |
| Osawa, H | 2 |
| Ohta, K | 1 |
| Chang, JY | 3 |
| Sainakham, M | 1 |
| Manosroi, A | 1 |
| Abe, M | 1 |
| Manosroi, W | 1 |
| Manosroi, J | 1 |
| Jung, SM | 1 |
| Kim, TW | 18 |
| Yoon, YS | 3 |
| Yukawa, Y | 1 |
| Kawamura, M | 1 |
| Takeda, O | 1 |
| Hanno, H | 1 |
| Takayanagi, S | 1 |
| Hirooka, T | 2 |
| Dozaiku, T | 1 |
| Hirakawa, T | 1 |
| Iwauchi, T | 1 |
| Morimoto, J | 1 |
| Nakazawa, K | 2 |
| Kouyama, M | 1 |
| Yabuta, Y | 1 |
| Shirai, A | 1 |
| Uzuhashi, K | 1 |
| Al-Fakeeh, A | 1 |
| Mulla, N | 1 |
| Doerksen, T | 1 |
| Al-Ruzug, I | 1 |
| Santos, F | 1 |
| Aydin, D | 1 |
| Sendur, MA | 1 |
| Kefeli, U | 1 |
| Ustaalioglu, BB | 2 |
| Aydin, O | 1 |
| Yildirim, E | 1 |
| Isik, D | 1 |
| Ozcelik, M | 1 |
| Surmeli, H | 1 |
| Oyman, A | 1 |
| Isik, S | 1 |
| Sener, N | 1 |
| Ercelep, O | 1 |
| Odabas, H | 2 |
| Aliustaoglu, M | 1 |
| Inukai, M | 1 |
| Tanioka, H | 1 |
| Nasu, J | 3 |
| Okajima, M | 1 |
| Yamaguchi, Y | 3 |
| Fassan, M | 1 |
| Lampis, A | 1 |
| Hahne, JC | 1 |
| Rugge, M | 2 |
| Nankivell, M | 1 |
| Langley, R | 1 |
| Ghidini, M | 3 |
| Braconi, C | 1 |
| Valeri, N | 1 |
| Xie, X | 1 |
| Ruan, Z | 1 |
| Li, F | 1 |
| Kalaitzakis, E | 1 |
| Havre, RF | 1 |
| Willemoe, GL | 1 |
| Meisner, S | 1 |
| Song, XL | 1 |
| Kang, HK | 1 |
| Jeong, GW | 1 |
| Ahn, KY | 1 |
| Jeong, YY | 1 |
| Kang, YJ | 1 |
| Cho, HJ | 1 |
| Moon, CM | 1 |
| Nagashima, K | 2 |
| Ikezawa, N | 1 |
| Hamaguchi, T | 6 |
| Honma, Y | 1 |
| Takashima, A | 4 |
| Okita, N | 1 |
| Daibo, K | 1 |
| Mera, T | 1 |
| Naito, K | 1 |
| Yasumoto, K | 1 |
| Kamigaki, T | 2 |
| Goto, S | 2 |
| Cramer, HM | 1 |
| Ibrahim, AA | 1 |
| Younger, AE | 1 |
| Murono, K | 1 |
| Yasuda, K | 2 |
| Otani, K | 1 |
| Nishikawa, T | 3 |
| Douglas, K | 1 |
| Villaflor, VM | 1 |
| Ahn, PH | 1 |
| Machtay, M | 1 |
| Anne, PR | 2 |
| Cognetti, D | 1 |
| Keane, WM | 1 |
| Dicker, AP | 2 |
| Axelrod, RS | 1 |
| Cho, JY | 5 |
| Kang, A | 1 |
| Shames, DS | 2 |
| Wang, Z | 4 |
| Hao, J | 1 |
| Paget-Bailly, S | 1 |
| Mathieu, P | 1 |
| Lamfichekh, N | 1 |
| Sakek, N | 1 |
| Jacquin, M | 1 |
| Foubert, A | 1 |
| Stanisavljević, L | 1 |
| Myklebust, MP | 1 |
| Leh, S | 1 |
| Dahl, O | 5 |
| De Pasquale, MD | 1 |
| Mastronuzzi, A | 1 |
| De Sio, L | 1 |
| Serra, A | 1 |
| Grimaldi, C | 1 |
| Chinali, M | 1 |
| Giordano, U | 1 |
| Nakakura, EK | 1 |
| Wang, ZJ | 1 |
| Kim, GE | 2 |
| Corvera, CU | 1 |
| Harris, HW | 1 |
| Kirkwood, KS | 1 |
| Hirose, R | 1 |
| Hecht, M | 1 |
| Büttner-Herold, M | 1 |
| Erlenbach-Wünsch, K | 1 |
| Haderlein, M | 1 |
| Croner, R | 1 |
| Grützmann, R | 1 |
| Hartmann, A | 1 |
| Distel, LV | 1 |
| Motton, M | 1 |
| Casella, F | 2 |
| Weindelmayer, J | 2 |
| Ambrosi, E | 1 |
| Di Leo, A | 2 |
| Vassiliadis, A | 1 |
| Ricci, F | 1 |
| Chopitea, A | 4 |
| González, I | 2 |
| A-Cienfuegos, J | 1 |
| Martínez, P | 2 |
| Rodriguez, J | 7 |
| Herbst, A | 1 |
| Kalinski, T | 1 |
| Qin, J | 1 |
| Benedix, F | 1 |
| Franke, S | 1 |
| Wartman, T | 1 |
| Halangk, W | 2 |
| Kolligs, FT | 1 |
| Haghighi, S | 1 |
| Kasbkar, H | 1 |
| Esmaeilpour, K | 1 |
| Yasaei, M | 1 |
| Supaadirek, C | 1 |
| Pesee, M | 1 |
| Thamronganantasakul, K | 1 |
| Thalangsri, P | 1 |
| Krusun, S | 1 |
| Supakalin, N | 1 |
| Uchida, T | 1 |
| Abe, N | 1 |
| Ito, K | 8 |
| Matsuda, K | 5 |
| Fujinaga, A | 1 |
| Martin-Romano, P | 1 |
| Diaz-Gonzalez, JA | 4 |
| Iragorri, Y | 1 |
| Martínez-Regueira, F | 1 |
| Ponz-Sarvise, M | 1 |
| Subtil, JC | 3 |
| Cano, D | 1 |
| Ceniceros, L | 1 |
| Legaspi, J | 1 |
| Hernandez, JL | 2 |
| Nasierowska-Guttmejer, A | 1 |
| Kosakowska, E | 1 |
| Zwoliński, J | 1 |
| Winiarek, M | 1 |
| Kuśnierz, J | 1 |
| Zając, L | 1 |
| Bednarczyk, M | 1 |
| Tarnowski, W | 1 |
| Paśnik, K | 1 |
| Radziszewski, J | 1 |
| Partycki, M | 1 |
| Bęczkowska, K | 1 |
| Styliński, R | 1 |
| Bury, P | 1 |
| Lewicka, M | 1 |
| Ciseł, B | 1 |
| Mielko, J | 1 |
| Danek, A | 1 |
| Nawrocki, G | 1 |
| Kępka, L | 1 |
| Due, SL | 1 |
| Bastian, I | 1 |
| Ding, GQ | 1 |
| Sukocheva, OA | 1 |
| Astill, DS | 1 |
| Vat, L | 1 |
| Gepfner-Tuma, I | 1 |
| Maderer, A | 1 |
| Ruessel, J | 1 |
| Wilke, H | 12 |
| Rafiyan, MR | 1 |
| Schmoll, HJ | 5 |
| Kullmann, F | 2 |
| von Weikersthal, LF | 2 |
| Weusmann, J | 1 |
| Kanzler, S | 2 |
| Schimanski, CC | 4 |
| Otte, M | 1 |
| Schollenberger, L | 1 |
| Koenig, J | 1 |
| Galle, PR | 8 |
| Zhuang, RY | 1 |
| Yu, YY | 1 |
| Shen, KT | 1 |
| Zhao, NQ | 1 |
| Qin, Q | 1 |
| Boubaya, M | 1 |
| Benallaoua, M | 1 |
| Baumgaertner, I | 2 |
| des Guetz, G | 2 |
| Rosenstone, S | 1 |
| Ansari, N | 1 |
| Solomon, MJ | 1 |
| Fisher, RJ | 1 |
| Mackay, J | 3 |
| Burmeister, B | 2 |
| Ackland, S | 2 |
| Joseph, D | 9 |
| McLachlan, SA | 2 |
| Taki, T | 1 |
| Hoya, Y | 1 |
| Nakayoshi, T | 1 |
| Sekine, H | 1 |
| Mitsumori, N | 1 |
| Yanaga, K | 2 |
| Hokuto, D | 1 |
| Nomi, T | 1 |
| Yamato, I | 1 |
| Obara, S | 1 |
| Kawaguchi, C | 2 |
| Kanehiro, H | 1 |
| Nakajima, Y | 12 |
| Pasquini, G | 1 |
| Vasile, E | 3 |
| Caparello, C | 1 |
| Vivaldi, C | 1 |
| Musettini, G | 1 |
| Lencioni, M | 3 |
| Petrini, I | 1 |
| Häussler, U | 1 |
| Bösmüller, H | 1 |
| Clasen, S | 1 |
| Götz, M | 1 |
| Malek, NP | 1 |
| Plentz, RR | 1 |
| Sueur, B | 1 |
| Pellerin, O | 1 |
| Voron, T | 1 |
| Gemici, C | 1 |
| Yaprak, G | 1 |
| Batirel, HF | 1 |
| Ilhan, M | 1 |
| Mayadagli, A | 1 |
| Keane, FK | 1 |
| Sánchez Cendra, C | 1 |
| Juez Martel, I | 1 |
| Gutierrez Abad, D | 1 |
| Braiteh, FS | 1 |
| Firdaus, I | 1 |
| Lewis, N | 1 |
| Anderson, DM | 1 |
| Arrowsmith, E | 2 |
| Schwartz, JD | 1 |
| Hsu, Y | 1 |
| Péron, J | 2 |
| Roy, P | 5 |
| Gourgou-Bourgade, S | 3 |
| Stanbury, T | 1 |
| Roche, L | 1 |
| Ozenne, B | 1 |
| Van Der Kraak, L | 1 |
| Goel, G | 2 |
| Ramanan, K | 1 |
| Kaltenmeier, C | 1 |
| Normolle, DP | 1 |
| Freeman, GJ | 1 |
| Tang, D | 1 |
| Nason, KS | 1 |
| Davison, JM | 1 |
| Luketich, JD | 3 |
| Dhupar, R | 1 |
| Lotze, MT | 1 |
| Fattouh, K | 1 |
| Collet-Benzaquen, D | 1 |
| Provensal, AM | 1 |
| Castillo, C | 2 |
| Combemale, P | 1 |
| de la Fouchardière, A | 1 |
| Manceau, G | 1 |
| Bridoux, V | 1 |
| Brouquet, A | 1 |
| Kirzin, S | 1 |
| Maggiori, L | 1 |
| de Chaisemartin, C | 2 |
| Lefevre, JH | 1 |
| Panis, Y | 3 |
| Bezborodova, OA | 1 |
| Nemtsova, ER | 1 |
| Gevorkov, AR | 1 |
| Boyko, AV | 1 |
| Venediktova, JB | 1 |
| Alekseenko, IV | 1 |
| Kostina, MB | 1 |
| Monastyrskaya, GS | 1 |
| Sverdlov, ED | 1 |
| Khmelevskiy, EV | 1 |
| Yakubovskaya, RI | 1 |
| Kalpande, S | 1 |
| Pandya, J | 1 |
| Sharma, T | 1 |
| Ghadban, T | 1 |
| Dibbern, JL | 1 |
| Reeh, M | 1 |
| Miro, JT | 1 |
| Tsui, TY | 1 |
| Wellner, U | 1 |
| Güngör, C | 1 |
| Vashist, YK | 1 |
| Ålgars, A | 1 |
| Sundström, J | 1 |
| Lintunen, M | 1 |
| Jokilehto, T | 1 |
| Kytölä, S | 1 |
| Kaare, M | 1 |
| Vainionpää, R | 1 |
| Orpana, A | 2 |
| Ristimäki, A | 1 |
| Carpen, O | 1 |
| Ristamäki, R | 2 |
| DeWitt, JM | 1 |
| Murthy, SK | 1 |
| Ardhanari, R | 1 |
| DuVall, GA | 1 |
| Wallner, G | 1 |
| Litka, P | 1 |
| Daugherty, C | 1 |
| Fowers, K | 1 |
| Antunes, C | 1 |
| Zappa, M | 1 |
| Bednar, F | 1 |
| Steve, J | 1 |
| Winters, S | 1 |
| Ocuin, LM | 1 |
| Chen, M | 1 |
| Hack, SP | 1 |
| Bruey, JM | 1 |
| Phan, S | 1 |
| Axilbund, J | 1 |
| Dalton, WB | 1 |
| Laheru, D | 6 |
| Watkins, S | 1 |
| Chu, D | 2 |
| Cravero, K | 1 |
| Button, B | 1 |
| Kyker-Snowman, K | 1 |
| Waters, I | 1 |
| Gocke, CD | 1 |
| Lauring, J | 1 |
| Park, BH | 1 |
| McDonough, S | 1 |
| Cardin, D | 1 |
| Hui, L | 1 |
| Seery, TE | 1 |
| Dy, IA | 1 |
| Al Baghdadi, T | 1 |
| Hendifar, AE | 1 |
| Doyle, LA | 1 |
| Chan, DY | 1 |
| Syn, NL | 1 |
| Yap, R | 1 |
| Phua, JN | 1 |
| Soh, TI | 1 |
| Chee, CE | 1 |
| Nga, ME | 1 |
| Shabbir, A | 1 |
| Allegra, CJ | 7 |
| Pogue-Geile, KL | 1 |
| Yothers, G | 4 |
| Sugiyama, K | 2 |
| Tajika, M | 1 |
| Ghosn, M | 6 |
| Ibrahim, T | 2 |
| Assi, T | 2 |
| El Rassy, E | 2 |
| Sánchez-Velázquez, P | 1 |
| Moosmann, N | 3 |
| Töpel, I | 1 |
| Piso, P | 2 |
| Clancy, TE | 1 |
| Mancias, JD | 1 |
| Rosenthal, MH | 1 |
| Balogoun, R | 1 |
| Mulot, C | 1 |
| Saban-Roche, L | 1 |
| Perkins, G | 3 |
| Luc Van Laethem, J | 1 |
| Laurent Puig, P | 1 |
| Hall, PS | 1 |
| Lord, SR | 1 |
| Collinson, M | 1 |
| Marshall, H | 1 |
| Jones, M | 1 |
| Lowe, C | 1 |
| Howard, H | 1 |
| Swinson, D | 1 |
| Velikova, G | 1 |
| Dent, J | 1 |
| Cheeseman, S | 1 |
| Last, K | 1 |
| Seymour, MT | 6 |
| Kondo, J | 2 |
| Maeda, Y | 6 |
| Nisimura, T | 1 |
| Nagashima, Y | 1 |
| Morita, K | 1 |
| Setoguchi, M | 1 |
| Sakata, K | 3 |
| Fujisaki, S | 1 |
| Takashina, M | 1 |
| Tomita, R | 1 |
| Sakurai, K | 2 |
| Takayama, T | 7 |
| Minoji, T | 1 |
| Kitahara, T | 1 |
| Hamano, R | 1 |
| Yanagisawa, T | 1 |
| Fukuchi, N | 2 |
| Ebisui, C | 2 |
| Yokouchi, H | 3 |
| Kinuta, M | 2 |
| Ohishi, K | 1 |
| Yigitbas, H | 1 |
| Yazici, P | 1 |
| Taskin, HE | 1 |
| Okoh, AK | 1 |
| Dural, C | 1 |
| Aydin, N | 1 |
| Berber, E | 2 |
| Nazim, UM | 1 |
| Rasheduzzaman, M | 1 |
| Lee, YJ | 3 |
| Seol, DW | 1 |
| Fernandez, E | 2 |
| Cacheux, W | 1 |
| Frossard, JL | 1 |
| Koessler, T | 1 |
| Abou, M | 1 |
| Moniez, M | 1 |
| Puppa, G | 1 |
| Staib, F | 1 |
| Göhler, T | 1 |
| Hebart, H | 1 |
| Heike, M | 4 |
| Neise, M | 1 |
| Rudi, J | 2 |
| Geer, T | 2 |
| Dingeldein, G | 1 |
| Lang, C | 1 |
| Ehscheidt, P | 1 |
| Flohr, T | 1 |
| Josten, KM | 1 |
| Karthaus, M | 1 |
| Schmittel, A | 1 |
| Wierecky, J | 1 |
| Boller, E | 1 |
| Indorf, M | 1 |
| Wörns, MA | 1 |
| El Karak, F | 1 |
| Zhang, F | 1 |
| Zhang, JG | 1 |
| Qu, J | 1 |
| Prasad, C | 1 |
| Wei, ZJ | 1 |
| Viaud, J | 1 |
| Brac, C | 1 |
| Le Pabic, E | 1 |
| Leconte, B | 2 |
| Bodère, A | 1 |
| Pracht, M | 1 |
| Le Sourd, S | 1 |
| Saunders, JH | 1 |
| Bowman, CR | 1 |
| Pang, V | 1 |
| Dorrington, MS | 1 |
| Mumtaz, E | 1 |
| Soomro, I | 1 |
| Kaye, P | 1 |
| Voncken, FE | 1 |
| Fukayama, M | 1 |
| Bozkaya, Y | 1 |
| Doğan, M | 1 |
| Erdem, GU | 1 |
| Demirci, NS | 1 |
| Del Rio, M | 4 |
| Vie, N | 2 |
| Selves, J | 1 |
| Roger, P | 1 |
| Gongora, C | 4 |
| Robert, J | 2 |
| Tubiana-Mathieu, N | 3 |
| Martineau, P | 4 |
| Bailey, P | 1 |
| Hu, S | 1 |
| Yue, J | 1 |
| Xue, L | 1 |
| Hwang, WS | 1 |
| Chao, TY | 2 |
| Lin, SF | 1 |
| Chung, CY | 1 |
| Chang, YF | 1 |
| Chen, PM | 5 |
| Chiou, TJ | 4 |
| Bruin, S | 1 |
| van Slooten, G | 1 |
| Becerra, CR | 3 |
| Verma, UN | 2 |
| Tran, HT | 1 |
| Tavana, D | 1 |
| Williams, NS | 1 |
| Frenkel, EP | 2 |
| Ballonoff, A | 1 |
| Kavanagh, B | 1 |
| McCarter, M | 1 |
| Kane, M | 1 |
| Pearlman, N | 1 |
| Nash, R | 1 |
| Shah, RJ | 1 |
| Raben, D | 1 |
| Schefter, TE | 1 |
| Greenberg, JA | 1 |
| Herndon, JE | 3 |
| Steele, GD | 1 |
| Mayer, R | 2 |
| Bleday, R | 1 |
| Agostini, M | 3 |
| Pasetto, LM | 2 |
| Pucciarelli, S | 8 |
| Terrazzino, S | 2 |
| Bedin, C | 2 |
| Galdi, F | 1 |
| Friso, ML | 7 |
| Urso, E | 4 |
| Leon, A | 2 |
| Lise, M | 9 |
| Nitti, D | 12 |
| Kakolyris, S | 5 |
| Ardavanis, A | 1 |
| Ziras, N | 7 |
| Varthalitis, I | 3 |
| Amarantidis, K | 2 |
| Tsousis, S | 2 |
| Vamvakas, L | 6 |
| Vardakis, N | 2 |
| Baldarelli, M | 1 |
| Organetti, L | 1 |
| Grillo Ruggeri, F | 1 |
| Mantello, G | 1 |
| Bartolacci, S | 1 |
| Lezoche, E | 1 |
| Lin, SS | 1 |
| Tai, CJ | 1 |
| Lee, WR | 1 |
| Chu, JS | 1 |
| Wang, KH | 1 |
| Jeung, HC | 11 |
| Yoo, NC | 3 |
| Noh, SH | 10 |
| Zaluski, J | 3 |
| Valvere, V | 3 |
| Peschel, C | 7 |
| Wenczl, M | 2 |
| Goker, E | 2 |
| Cisar, L | 1 |
| Wang, K | 1 |
| Bugat, R | 7 |
| Bullarddunn, K | 1 |
| Yang, GY | 1 |
| Pendyala, L | 4 |
| Toth, K | 3 |
| Andrews, C | 1 |
| Rustum, YM | 11 |
| Ross, ME | 2 |
| Levea, C | 1 |
| Puthillath, A | 1 |
| Park, YM | 1 |
| Rajput, A | 1 |
| Lindebjerg, J | 3 |
| Spindler, KL | 1 |
| Ploen, J | 3 |
| Jakobsen, A | 5 |
| Vikram, B | 2 |
| Fujita, T | 2 |
| Berretta, M | 2 |
| Di Benedetto, F | 1 |
| Bearz, A | 2 |
| Simonelli, C | 1 |
| Martellotta, F | 1 |
| Del Ben, C | 1 |
| Berretta, S | 2 |
| Spina, M | 1 |
| Tirelli, U | 2 |
| Yasuda, A | 1 |
| Ochi, N | 2 |
| Sakamoto, M | 2 |
| Takayama, S | 2 |
| Wakasugi, T | 1 |
| Funahashi, H | 1 |
| Sawai, H | 1 |
| Satoh, M | 2 |
| Akamo, Y | 2 |
| Takeyama, H | 2 |
| Izzo, L | 1 |
| Pietrasanta, D | 1 |
| Izzo, P | 1 |
| Caputo, M | 1 |
| Di Cello, P | 1 |
| Meloni, P | 1 |
| Bolognese, A | 1 |
| Ngeow, JY | 1 |
| Prakash, KM | 1 |
| Quek, ST | 1 |
| Ehrenberg, R | 1 |
| Hickmann, L | 1 |
| Vick, B | 1 |
| Urbanik, T | 1 |
| Berger, MR | 2 |
| Schad, A | 1 |
| Weber, A | 1 |
| Heeger, S | 2 |
| Woei Chung, L | 1 |
| Liao, YM | 1 |
| Hsieh, CY | 1 |
| Javeri, H | 1 |
| Arora, R | 1 |
| Liao, Z | 4 |
| McAleer, MF | 1 |
| Maru, D | 2 |
| Izzo, JG | 1 |
| Matsubara, J | 3 |
| Takahari, D | 5 |
| Okita, NT | 4 |
| Shirao, K | 6 |
| Gustafsson, SB | 1 |
| Lindgren, T | 1 |
| Jonsson, M | 1 |
| Jacobsson, SO | 1 |
| Warchoł, R | 1 |
| Szymański, L | 1 |
| Seichter, A | 1 |
| Kalofonos, HP | 5 |
| Bamias, A | 5 |
| Koutras, A | 1 |
| Papakostas, P | 3 |
| Basdanis, G | 3 |
| Karina, M | 1 |
| Misailidou, D | 1 |
| Pisanidis, N | 1 |
| Economopoulos, T | 2 |
| Papadimitriou, C | 2 |
| Skarlos, DV | 2 |
| Stavropoulos, M | 2 |
| Bafaloukos, D | 1 |
| Kardamakis, D | 2 |
| Karanikiotis, C | 1 |
| Vourli, G | 3 |
| Hart, LL | 1 |
| Childs, BH | 1 |
| Hainsworth, JD | 5 |
| Wong, L | 1 |
| Fehrenbacher, L | 1 |
| Abubakr, Y | 1 |
| Schwartzberg, L | 1 |
| Hedrick, E | 1 |
| Gosens, MJ | 1 |
| Moerland, E | 1 |
| Lemmens, VP | 1 |
| Rutten, HT | 1 |
| Tan-Go, I | 1 |
| van den Brule, AJ | 1 |
| Lee, JL | 6 |
| Zang, DY | 3 |
| Ryoo, BY | 5 |
| Shin, DB | 10 |
| Ryu, MH | 5 |
| Chang, HM | 9 |
| Min, YJ | 1 |
| Braendengen, M | 1 |
| Tveit, KM | 6 |
| Birkemeyer, E | 1 |
| Frykholm, G | 3 |
| Wiig, JN | 2 |
| Byström, P | 6 |
| Dietrich, D | 2 |
| Scheithauer, W | 16 |
| Gerber, D | 1 |
| Ruhstaller, T | 3 |
| Schüller, J | 2 |
| Saletti, P | 7 |
| Bauer, J | 2 |
| Figer, A | 3 |
| Pestalozzi, BC | 2 |
| Mingrone, W | 1 |
| Stemmer, SM | 1 |
| Kornek, GV | 7 |
| Koeberle, D | 3 |
| Herrmann, R | 7 |
| Hofheinz, R | 6 |
| Rethwisch, V | 2 |
| Clemens, MR | 1 |
| Mahlberg, R | 1 |
| Fritz, M | 1 |
| Seipelt, G | 3 |
| Sievert, M | 1 |
| Atmaca, A | 5 |
| Brell, JM | 1 |
| Krishnamurthi, SS | 1 |
| Javle, M | 4 |
| Saltzman, J | 1 |
| Wollner, I | 2 |
| Pelley, R | 1 |
| Dowlati, A | 1 |
| Kantharaj, BN | 1 |
| Schluchter, MD | 1 |
| Rath, L | 1 |
| Ivy, SP | 1 |
| Remick, SC | 1 |
| Frustaci, S | 2 |
| Talamini, R | 2 |
| Lombardi, D | 1 |
| Fratino, L | 1 |
| Lleshi, A | 1 |
| Bonanno, S | 1 |
| Spartà, D | 1 |
| Palmucci, S | 1 |
| Hizawa, K | 1 |
| Nagata, Y | 2 |
| Taniguchi, M | 2 |
| Nakamori, M | 2 |
| Iida, M | 1 |
| Sanz-Sánchez, T | 1 |
| Jiménez-Ayala, B | 1 |
| Borbujo, JM | 1 |
| Gartner, EM | 1 |
| Pan, Q | 1 |
| Brewer, GJ | 1 |
| Henja, GF | 1 |
| Merajver, SD | 2 |
| Button, MR | 1 |
| Morgan, CA | 1 |
| Croydon, ES | 1 |
| Roberts, SA | 3 |
| Crosby, TD | 4 |
| Comella, P | 8 |
| Massidda, B | 3 |
| Filippelli, G | 2 |
| Farris, A | 4 |
| Natale, D | 1 |
| Barberis, G | 1 |
| Maiorino, L | 4 |
| Palmeri, S | 4 |
| Cannone, M | 2 |
| Condemi, G | 1 |
| Rosenthal, DI | 2 |
| Landry, JC | 1 |
| Sigurdson, ER | 4 |
| Spitz, FR | 1 |
| Granci, V | 2 |
| Kramar, A | 3 |
| Boissière-Michot, F | 1 |
| Thirion, A | 1 |
| Hwang, J | 2 |
| Lee, SR | 1 |
| Yang, DH | 1 |
| Kim, YK | 1 |
| Lee, JJ | 4 |
| Trojan, J | 3 |
| Lubomierski, N | 1 |
| Lehnert, T | 1 |
| Engels, K | 1 |
| Zeuzem, S | 1 |
| Wen, S | 2 |
| Morris, J | 4 |
| Abaza, MS | 1 |
| Bahman, AM | 1 |
| Al-Attiyah, RJ | 1 |
| Tatokoro, M | 1 |
| Kawakami, S | 1 |
| Yonese, J | 1 |
| Fujii, Y | 2 |
| Okubo, Y | 1 |
| Takeshita, H | 1 |
| Komai, Y | 1 |
| Ishikawa, Y | 1 |
| Fukui, I | 2 |
| Wilson, PM | 1 |
| Fazzone, W | 1 |
| LaBonte, MJ | 1 |
| Deng, J | 2 |
| Neamati, N | 2 |
| Ladner, RD | 1 |
| Lawson, JD | 1 |
| Staley, C | 2 |
| Zeng, SY | 1 |
| Li, LY | 1 |
| Shu, KY | 1 |
| Pan, M | 1 |
| Li, HP | 1 |
| Luo, B | 1 |
| Caponigro, F | 2 |
| Lacombe, D | 1 |
| Twelves, C | 3 |
| Govaerts, AS | 1 |
| Milano, A | 2 |
| Rong, J | 1 |
| Lin, TY | 1 |
| Zhai, LZ | 1 |
| Chiarion-Sileni, V | 2 |
| Innocente, R | 2 |
| Cavina, R | 1 |
| Corti, L | 1 |
| Pigozzo, J | 1 |
| Del Bianco, P | 3 |
| Fumagalli, U | 1 |
| Santoro, A | 1 |
| Marti, JL | 1 |
| Hiotis, SP | 1 |
| Donahue, B | 2 |
| Ryan, T | 2 |
| Newman, E | 4 |
| Bollschweiler, E | 8 |
| Metzger, R | 10 |
| Drebber, U | 3 |
| Baldus, S | 2 |
| Vallböhmer, D | 6 |
| Kocher, M | 2 |
| Hölscher, AH | 7 |
| Chen, CW | 2 |
| Wang, WM | 1 |
| Su, YC | 2 |
| Wu, JY | 1 |
| Hsieh, JS | 1 |
| Seo, Y | 2 |
| Willis, J | 1 |
| Stellato, TA | 1 |
| Siegel, CT | 1 |
| Harpp, D | 1 |
| Willson, JK | 1 |
| Gibbons, J | 1 |
| Sanabria, JR | 1 |
| Schulak, JP | 1 |
| Kunoki, N | 1 |
| Nishiyama, R | 1 |
| Ryuzaki, H | 1 |
| Oonishi, M | 1 |
| Uno, A | 1 |
| Ogawa, M | 9 |
| Ogihara, A | 1 |
| Moriyama, M | 2 |
| Sou, K | 1 |
| Kinukawa, N | 2 |
| Machida, N | 1 |
| Onozawa, Y | 2 |
| Taku, K | 2 |
| Asaka, M | 3 |
| Recchia, F | 5 |
| Candeloro, G | 3 |
| Necozione, S | 3 |
| Bratta, M | 2 |
| Bisegna, R | 2 |
| Rea, S | 5 |
| Beddy, D | 1 |
| Hyland, JM | 1 |
| Winter, DC | 2 |
| White, A | 1 |
| Moriarty, M | 1 |
| Armstrong, J | 1 |
| Fennelly, D | 1 |
| Gibbons, D | 1 |
| Sheahan, K | 1 |
| Gu, Y | 2 |
| Haghighat, P | 1 |
| Conti, JA | 4 |
| Kendall, TJ | 1 |
| Armstrong, TA | 1 |
| Papa-Adams, A | 1 |
| Packham, G | 1 |
| Primrose, JN | 2 |
| Benyon, RC | 1 |
| Iredale, JP | 1 |
| Garrido, M | 1 |
| Bustos, M | 1 |
| Orellana, E | 1 |
| Madrid, J | 1 |
| Galindo, H | 1 |
| Sánchez, C | 1 |
| Pimentel, F | 1 |
| Guzmán, S | 1 |
| Ibáñez, L | 1 |
| Butte, JM | 1 |
| Alvarez, M | 1 |
| Besa, P | 1 |
| Wang, ZH | 3 |
| Guo, J | 2 |
| Li, CZ | 1 |
| Sheng, LJ | 1 |
| Zhou, DG | 1 |
| Wang, QC | 1 |
| Zhang, EN | 1 |
| Jurado, JM | 1 |
| Pajares, B | 1 |
| Olmos, D | 1 |
| Sevilla, I | 1 |
| Alba, E | 1 |
| Fisher, GA | 5 |
| Kuo, T | 3 |
| Ramsey, M | 1 |
| Schwartz, E | 1 |
| Rouse, RV | 1 |
| Cho, CD | 2 |
| Halsey, J | 2 |
| Sikic, BI | 2 |
| Lansigan, F | 1 |
| Cornfeld, D | 1 |
| Syrigos, K | 6 |
| Wasif, N | 1 |
| Almeyda, R | 1 |
| Capper, J | 1 |
| Seol, YM | 1 |
| Song, MK | 1 |
| Kim, GH | 1 |
| Shin, HJ | 2 |
| Song, GA | 1 |
| Chung, JS | 2 |
| Cho, GJ | 2 |
| Bertolini, F | 2 |
| Chiara, S | 1 |
| Antognoni, P | 1 |
| Dealis, C | 1 |
| Zironi, S | 7 |
| Malavasi, N | 2 |
| Scolaro, T | 1 |
| Depenni, R | 2 |
| Jovic, G | 1 |
| Sonaglio, C | 1 |
| Rossi, A | 2 |
| Luppi, G | 8 |
| Conte, PF | 5 |
| Konski, A | 5 |
| Sigurdson, E | 3 |
| Spies, S | 1 |
| Yu, JQ | 1 |
| Wahl, A | 1 |
| Stryker, S | 1 |
| Cheng, Z | 1 |
| Feng, CN | 1 |
| Sugae, T | 1 |
| Yaguchi, T | 1 |
| Kajikawa, M | 1 |
| Nakayama, S | 1 |
| Takase, T | 1 |
| Inokawa, Y | 1 |
| Tsushima, Y | 1 |
| Harada, A | 1 |
| Arévalo Lobera, S | 1 |
| Sagastibeltza Mariñelarena, N | 1 |
| Elejoste Echeberría, I | 1 |
| Melé Olivé, M | 1 |
| Egaña Otaño, L | 1 |
| Basterretxea Badiola, L | 1 |
| La Casta Muñoa, A | 1 |
| Azkue Gabilondo, M | 1 |
| Ishihama, H | 1 |
| Chida, M | 1 |
| Araki, O | 1 |
| Karube, Y | 1 |
| Seki, N | 1 |
| Tamura, M | 1 |
| Umezu, H | 1 |
| Honma, K | 1 |
| Masawa, N | 1 |
| Miyoshi, S | 1 |
| Hatlova, J | 1 |
| Vosmik, M | 1 |
| Zoul, Z | 1 |
| Tycova, V | 1 |
| Lesko, M | 1 |
| Hajduch, M | 1 |
| Dunst, J | 5 |
| Rudat, V | 1 |
| Wulf, J | 1 |
| Budach, W | 2 |
| Hoelscher, T | 1 |
| Reese, T | 3 |
| Mose, S | 1 |
| Roedel, C | 1 |
| Zuehlke, H | 1 |
| Chaput, U | 1 |
| Terris, B | 1 |
| Nobili, S | 2 |
| Checcacci, D | 1 |
| Filippelli, F | 1 |
| Del Buono, S | 1 |
| Mazzocchi, V | 1 |
| Mazzei, T | 3 |
| Twombly, R | 1 |
| Honda, T | 3 |
| Shimoda, T | 2 |
| Lorizzo, K | 1 |
| Radice, D | 1 |
| Boselli, S | 1 |
| Ariu, L | 1 |
| Nolè, F | 3 |
| Magni, E | 2 |
| Ardito, R | 1 |
| Minchella, I | 1 |
| Rocca, A | 2 |
| Di Meglio, G | 1 |
| Squadroni, M | 1 |
| Cartwright, T | 2 |
| Kuefler, P | 1 |
| Hyman, W | 2 |
| Berger, M | 2 |
| Richards, D | 3 |
| Vukelja, S | 1 |
| Nugent, JE | 1 |
| Ruxer, RL | 1 |
| Boehm, KA | 3 |
| Asmar, L | 3 |
| Sandoval, A | 1 |
| Lee, JT | 2 |
| Ahn, SJ | 1 |
| Lee, YL | 1 |
| Yoo, J | 1 |
| Ahn, BC | 1 |
| Ha, JH | 1 |
| Ota, K | 4 |
| Kurita, S | 1 |
| Nishimura, M | 2 |
| Kamei, Y | 1 |
| Ariyoshi, Y | 1 |
| Kataoka, K | 1 |
| Murakami, M | 1 |
| Oyama, A | 1 |
| Hoshino, A | 1 |
| Amo, H | 1 |
| Fanning, DM | 1 |
| Prichard, RS | 1 |
| Roche-Nagle, G | 1 |
| McNamara, D | 1 |
| Le Scodan, R | 3 |
| Partensky, C | 5 |
| Mercier, C | 3 |
| Valette, PJ | 4 |
| Scoazec, JY | 4 |
| Asiyanbola, B | 1 |
| Choti, MA | 2 |
| Swartz, M | 1 |
| Schulick, RD | 3 |
| Cameron, JL | 11 |
| Morak, MJ | 1 |
| van der Gaast, A | 4 |
| Incrocci, L | 2 |
| van Dekken, H | 2 |
| Jeekel, J | 4 |
| Hop, WC | 3 |
| Kazemier, G | 2 |
| van Eijck, CH | 3 |
| Minashi, K | 2 |
| Nihei, K | 2 |
| Kagami, Y | 3 |
| Gunnlaugsson, A | 2 |
| Anderson, H | 3 |
| Fernebro, E | 2 |
| Berglund, K | 1 |
| Ekelund, M | 1 |
| Holm, T | 1 |
| Kang, BM | 1 |
| Jun, SH | 1 |
| Hayashi, Y | 3 |
| Nishida, T | 4 |
| Yamamoto, K | 11 |
| Tsutsui, S | 1 |
| Hiramatsu, N | 1 |
| Tsujii, M | 1 |
| Tsuji, S | 1 |
| Ito, H | 4 |
| Takehara, T | 1 |
| Hayashi, N | 5 |
| Baize, N | 1 |
| Abakar-Mahamat, A | 1 |
| Mounier, N | 1 |
| Berthier, F | 1 |
| Caroli-Bosc, FX | 2 |
| Wolff, K | 2 |
| Wein, A | 9 |
| Reulbach, U | 3 |
| Männlein, G | 2 |
| Brückl, V | 1 |
| Meier, C | 1 |
| Ostermeier, N | 2 |
| Schwab, SA | 1 |
| Horbach, T | 1 |
| Hahn, EG | 4 |
| Boxberger, F | 4 |
| Lin, RB | 1 |
| Fan, NF | 1 |
| Wang, XJ | 1 |
| Oya, M | 1 |
| Muto, T | 6 |
| Konishi, F | 3 |
| Hatake, K | 2 |
| Jung, JY | 1 |
| Kwon, JH | 2 |
| Song, HH | 1 |
| Kim, I | 1 |
| Lee, KS | 7 |
| Lee, JA | 1 |
| Adinin, R | 1 |
| Lin, E | 5 |
| Morris, JS | 1 |
| Norman, AR | 7 |
| Hawkins, R | 1 |
| Harper, P | 4 |
| Seymour, M | 4 |
| Kortman, GA | 1 |
| Mekenkamp, L | 1 |
| Ligtenberg, MJ | 1 |
| Hoogerbrugge, N | 1 |
| Antonini, NF | 1 |
| van Krieken, JH | 3 |
| Ravizza, R | 1 |
| Molteni, R | 1 |
| Marras, E | 1 |
| Perletti, G | 1 |
| Gou, HY | 1 |
| Han, JS | 2 |
| Li, SM | 1 |
| Yang, R | 1 |
| Qiao, J | 1 |
| Lorusso, V | 3 |
| Casaretti, R | 3 |
| Putzu, C | 1 |
| Leo, S | 2 |
| Roselli, M | 1 |
| Mancarella, S | 3 |
| Greco, E | 2 |
| Vessia, G | 1 |
| Sandomenico, C | 2 |
| Franco, L | 1 |
| Kwon, HC | 10 |
| Lee, DM | 2 |
| Roh, MS | 2 |
| Kim, DC | 1 |
| Park, KJ | 2 |
| Novarino, A | 2 |
| Chiappino, I | 1 |
| Giacobino, A | 2 |
| Bellone, G | 2 |
| Rahimi, F | 1 |
| Milanesi, E | 1 |
| Bertetto, O | 1 |
| Ciuffreda, L | 2 |
| Chayahara, N | 1 |
| Yamamori, M | 1 |
| Kadowaki, Y | 1 |
| Okuno, T | 1 |
| Miki, I | 1 |
| Nishisaki, H | 2 |
| Maeda, T | 4 |
| Inoue, Y | 8 |
| Okumura, K | 1 |
| Azuma, T | 3 |
| Kasuga, M | 1 |
| Sakaeda, T | 1 |
| Hirai, M | 1 |
| Kozuch, P | 4 |
| Malamud, S | 3 |
| Wasserman, C | 1 |
| Homel, P | 2 |
| Mirzoyev, T | 2 |
| Grossbard, M | 2 |
| Yilmaz, G | 1 |
| Oztürk, B | 2 |
| Akyürek, N | 1 |
| Yildiz, R | 3 |
| Tonyali, O | 1 |
| Coşkun, U | 4 |
| Bitik, B | 1 |
| Kalpakci, Y | 1 |
| Altan, E | 1 |
| Dogan, E | 1 |
| Johansson, B | 2 |
| Nygren, P | 3 |
| Pedersen, D | 1 |
| Letocha, H | 1 |
| Fukui, T | 2 |
| Takano, J | 1 |
| Fujishima, S | 1 |
| Otake, S | 2 |
| Orii, T | 1 |
| Sato, T | 8 |
| Sasaki, Y | 8 |
| Nishise, S | 1 |
| Kawata, S | 1 |
| Takamura, H | 1 |
| Osawa, S | 1 |
| Iwaizumi, M | 1 |
| Hamaya, Y | 1 |
| Takagaki, K | 1 |
| Nishino, M | 1 |
| Kodaira, C | 1 |
| Muramatsu, A | 1 |
| Futami, H | 1 |
| Furuta, T | 4 |
| Ikuma, M | 1 |
| Kemeny, N | 13 |
| D'Angelica, M | 1 |
| Jarnagin, W | 1 |
| Haviland, D | 1 |
| Dematteo, R | 1 |
| Fong, Y | 3 |
| Jin, C | 1 |
| Yao, L | 1 |
| Long, J | 1 |
| Fu, DL | 1 |
| Yu, XJ | 1 |
| Yang, F | 1 |
| Ni, QX | 1 |
| Schønnemann, KR | 2 |
| Jensen, HA | 5 |
| Jensen, BY | 1 |
| Larsen, O | 1 |
| Benson, M | 2 |
| Lüpfert, C | 2 |
| Kurek, R | 2 |
| Baselga, J | 2 |
| Hill, A | 7 |
| Liu, JF | 1 |
| Jamieson, GG | 7 |
| Wu, TC | 1 |
| Zhu, GJ | 1 |
| Drew, PA | 1 |
| Fluge, Ø | 1 |
| Carlsen, E | 1 |
| Myrvold, HE | 1 |
| Vonen, B | 1 |
| Podhorny, N | 1 |
| Bjerkeset, O | 1 |
| Eide, TJ | 1 |
| Halvorsen, TB | 2 |
| Milicević, M | 2 |
| Radosević-Jelić, Lj | 2 |
| Pino, MS | 1 |
| Gelibter, A | 3 |
| Sperduti, I | 4 |
| De Marco, S | 2 |
| Nuzzo, C | 1 |
| Bria, E | 3 |
| Carpanese, L | 1 |
| Ruggeri, EM | 4 |
| Carlini, P | 5 |
| Cognetti, F | 7 |
| Saha, AK | 1 |
| Sutton, C | 1 |
| Rotimi, O | 1 |
| Dexter, S | 1 |
| Sue-Ling, H | 1 |
| Sarela, AI | 1 |
| Kim, MA | 2 |
| Kim, TM | 2 |
| Kim, DW | 7 |
| Heo, DS | 6 |
| Lee, KU | 2 |
| Choe, KJ | 2 |
| Tipples, K | 1 |
| Kolluri, RB | 1 |
| Gilbar, P | 1 |
| McPherson, I | 1 |
| Milla, P | 1 |
| Airoldi, M | 2 |
| Weber, G | 2 |
| Drescher, A | 1 |
| Jaehde, U | 1 |
| Cattel, L | 1 |
| Richter, SN | 1 |
| Nadai, M | 1 |
| Palumbo, M | 1 |
| Palù, G | 1 |
| Stieler, J | 2 |
| Roll, L | 1 |
| Hilbig, A | 1 |
| Dörken, B | 4 |
| Riess, H | 3 |
| Oettle, H | 4 |
| Martinez-Balibrea, E | 1 |
| Martínez-Cardús, A | 1 |
| Musulén, E | 1 |
| Manzano, JL | 1 |
| Plasencia, C | 1 |
| Abad, A | 6 |
| Gold, DG | 1 |
| Haddock, MG | 5 |
| Quevedo, F | 1 |
| Donohue, JH | 5 |
| Kobayashi, N | 2 |
| Hata, N | 1 |
| Yokoyama, S | 2 |
| Shinada, T | 1 |
| Shirakabe, A | 1 |
| Mizuno, K | 2 |
| Vaidya, KS | 1 |
| Kim, EL | 1 |
| Welch, DR | 1 |
| Chen, SP | 1 |
| Wu, CC | 2 |
| Lin, SZ | 1 |
| Kang, JC | 1 |
| Su, CC | 2 |
| Chen, YL | 1 |
| Lin, PC | 2 |
| Pang, CY | 1 |
| Harn, HJ | 1 |
| Angitapalli, R | 1 |
| Litwin, AM | 2 |
| Kumar, PR | 1 |
| Nasser, E | 1 |
| Lombardo, J | 1 |
| Mashtare, T | 1 |
| Wilding, GE | 1 |
| Mogck, U | 1 |
| Schuch, G | 2 |
| Kramer, M | 1 |
| Jaeger, E | 2 |
| Ehninger, G | 1 |
| Gómez Portilla, A | 1 |
| Cendoya, I | 1 |
| Olabarría, I | 1 |
| Martínez de Lecea, C | 1 |
| Gómez Martínez de Lecea, C | 1 |
| Gil, A | 1 |
| Martín, E | 1 |
| Muriel, J | 1 |
| Magrach, L | 1 |
| Romero, E | 1 |
| Lirola, A | 1 |
| Guede, N | 1 |
| Moraza, N | 1 |
| Kvadatze, M | 1 |
| Valdovinos, M | 1 |
| Larrabide, I | 1 |
| Ruiz de Alegría, N | 1 |
| Fernández, JL | 1 |
| Rua, O | 1 |
| Ulibarrena, MA | 1 |
| Dinter, D | 1 |
| Lukan, N | 1 |
| Sereno, M | 1 |
| Castro, JD | 1 |
| Belda, C | 1 |
| González-Barón, M | 2 |
| Dalzell, JR | 1 |
| Samuel, LM | 2 |
| Kim, BG | 2 |
| Rho, MH | 1 |
| Kim, YH | 10 |
| Rho, MS | 1 |
| Jeong, JS | 1 |
| Zouhairi, ME | 1 |
| Venner, A | 1 |
| Charabaty, A | 1 |
| Schuette, K | 1 |
| Link, H | 2 |
| Koehne, CH | 1 |
| Gruenwald, V | 1 |
| Stahl, M | 7 |
| Huebner, G | 1 |
| Bonfill, T | 1 |
| Darnell, A | 1 |
| Bombardó, J | 1 |
| Jhawer, M | 2 |
| Coit, D | 2 |
| Qin, LX | 1 |
| Klimstra, D | 4 |
| Tang, L | 3 |
| Rognone, A | 4 |
| Nicoletti, R | 9 |
| Mazza, E | 2 |
| Arcidiacono, PG | 2 |
| Di Carlo, V | 9 |
| Villa, E | 9 |
| Garajová, I | 1 |
| Svoboda, M | 2 |
| Slabý, O | 2 |
| Kocáková, I | 2 |
| Fabian, P | 2 |
| Kocák, I | 1 |
| Vyzula, R | 2 |
| Fetterly, G | 1 |
| Zwiebel, JA | 1 |
| Espinoza-Delgado, I | 1 |
| Litwin, A | 2 |
| Egorin, MJ | 2 |
| Hristov, B | 1 |
| Reddy, S | 3 |
| Hruban, RH | 8 |
| Swartz, MJ | 3 |
| Kemp, C | 1 |
| Markman, M | 2 |
| Brady, M | 1 |
| Hutson, A | 1 |
| Berek, JS | 2 |
| Salah-Eldin, MA | 1 |
| Ebrahim, MA | 1 |
| AL-Ashry, MS | 1 |
| Wexner, S | 2 |
| Zhao, R | 3 |
| Cruz-Correa, M | 1 |
| Berho, M | 3 |
| Yau, T | 1 |
| Chong, G | 1 |
| Viret, F | 4 |
| Guiramand, J | 2 |
| Lelong, B | 4 |
| Zhou, LY | 1 |
| Shan, ZZ | 1 |
| You, JL | 1 |
| Kim, DH | 6 |
| Wang-Chesebro, A | 1 |
| Weinberg, V | 1 |
| Pouliot, J | 1 |
| Chen, LM | 1 |
| Speight, J | 1 |
| Littell, R | 1 |
| Hsu, IC | 1 |
| Desai, S | 1 |
| Simeone, D | 1 |
| Greenson, JK | 2 |
| Francis, IR | 1 |
| Hampton, J | 1 |
| Colletti, L | 1 |
| Chang, AE | 1 |
| Yin, A | 1 |
| Freitas, D | 1 |
| Fernandes, Gdos S | 1 |
| Cunha, JE | 1 |
| Dembinski, JL | 1 |
| Vizio, B | 1 |
| Brondino, G | 1 |
| Addeo, A | 1 |
| Prati, A | 1 |
| Campra, D | 1 |
| Fronda, GR | 1 |
| Kabra, N | 1 |
| Li, B | 2 |
| Yeatman, T | 2 |
| Coppola, D | 2 |
| Okines, A | 1 |
| Allum, W | 1 |
| Riddell, A | 1 |
| Stavridi, F | 1 |
| Ashley, S | 3 |
| Iio, A | 1 |
| Nakagawa, Y | 2 |
| Naoe, T | 1 |
| Tanigawa, N | 2 |
| Akao, Y | 1 |
| Lee, GW | 2 |
| Jeong, CY | 1 |
| Pena Alvarez, C | 1 |
| Suh Oh, HJ | 1 |
| Sáenz de Miera Rodríguez, A | 1 |
| García Arroyo, FR | 1 |
| Covela Rúa, M | 1 |
| Salgado Boquete, L | 1 |
| López Clemente, PM | 1 |
| Constenla Figueiras, M | 1 |
| Lim, JY | 2 |
| Oh, KJ | 1 |
| Choi, SH | 9 |
| Tansley, S | 1 |
| Gibbons, S | 1 |
| Märten, A | 5 |
| Ose, J | 2 |
| Abel, U | 3 |
| Münter, MW | 2 |
| Adler, G | 2 |
| Gress, T | 1 |
| Lartigau, E | 2 |
| Chang, PA | 1 |
| Li, JJ | 1 |
| Pan, F | 1 |
| Bian, ZH | 1 |
| Zou, L | 2 |
| He, JM | 1 |
| Liang, HJ | 1 |
| Girard, N | 2 |
| Hattangadi, JA | 1 |
| Yeap, BY | 1 |
| Degirmenci, M | 1 |
| Karaca, B | 2 |
| Gorumlu, G | 1 |
| Durusoy, R | 1 |
| Demir Piskin, G | 1 |
| Bozkurt, MT | 1 |
| Cirak, Y | 1 |
| Tunali, D | 1 |
| Sanli, UA | 1 |
| Sica, G | 3 |
| Bonfili, P | 1 |
| Lou, F | 1 |
| Zhu, YH | 1 |
| Pan, HM | 1 |
| Yoshifuku, K | 1 |
| Deguchi, K | 1 |
| Kurono, Y | 1 |
| Sun, ZJ | 1 |
| Sun, MZ | 1 |
| Ai, CH | 1 |
| Lu, XL | 1 |
| Zheng, YF | 1 |
| Yang, BF | 2 |
| Dong, DL | 1 |
| Curran, D | 2 |
| Kimura, M | 4 |
| Takatsuka, Y | 3 |
| Toi, M | 1 |
| Abe, R | 2 |
| Koyama, H | 5 |
| Takashima, S | 5 |
| Nomura, Y | 4 |
| Miura, S | 1 |
| Kimijima, I | 1 |
| Tashiro, H | 1 |
| You, DD | 1 |
| Lee, HG | 2 |
| Heo, JS | 7 |
| Choi, DW | 3 |
| Huh, JW | 4 |
| Thiebot, T | 1 |
| Henno, S | 1 |
| Falize, L | 1 |
| Bretagne, JF | 2 |
| Koizumi, W | 4 |
| Tanabe, S | 3 |
| Azuma, M | 1 |
| Ishido, K | 1 |
| Nishimura, K | 3 |
| Nakatani, K | 1 |
| Higuchi, K | 2 |
| Katada, C | 2 |
| Geissler, M | 3 |
| Raedle, J | 1 |
| Ebert, MP | 2 |
| Flieger, D | 2 |
| Hoehler, T | 1 |
| Saltz, L | 11 |
| Dai, H | 1 |
| Xiao, Y | 1 |
| Zhang, XD | 4 |
| Chakrabarty, S | 1 |
| Dong, NN | 1 |
| Wang, MY | 1 |
| Liu, ZF | 1 |
| Jensen, BV | 3 |
| Nielsen, SE | 1 |
| Keldsen, N | 2 |
| Bjerregaard, B | 2 |
| Mejer, J | 1 |
| Larsen, FO | 1 |
| Teng, KY | 2 |
| Ruan, DY | 2 |
| Chen, XQ | 1 |
| He, YJ | 6 |
| Hyspler, R | 1 |
| Krcmová, L | 1 |
| Urbánek, L | 1 |
| Kalábová, H | 1 |
| Kasparová, M | 1 |
| Solichová, D | 1 |
| Fora, A | 1 |
| Alabsi, E | 1 |
| Grenader, T | 1 |
| Goldberg, A | 1 |
| Gabizon, A | 1 |
| Ozdemir, NY | 2 |
| Budakoglu, B | 2 |
| Uncu, D | 5 |
| Güler, T | 1 |
| Odabaşi, H | 1 |
| Malamos, N | 1 |
| Adamou, A | 1 |
| Kalbakis, K | 4 |
| Papakotoulas, P | 2 |
| Kouroussis, C | 1 |
| Karvounis, N | 2 |
| Christophyllakis, C | 1 |
| Farhat, FS | 1 |
| Chahine, GY | 2 |
| Younes, FC | 1 |
| Nasr, FL | 2 |
| Mroue, RM | 1 |
| Ghosn, MG | 2 |
| Tsikitis, VL | 1 |
| Larson, DW | 1 |
| Poola, VP | 1 |
| Nelson, H | 1 |
| Wolff, BG | 2 |
| Pemberton, JH | 1 |
| Cima, RR | 1 |
| Grimminger, P | 1 |
| Hoffmann, A | 1 |
| Schulte, C | 1 |
| Schneider, PM | 6 |
| Brabender, J | 6 |
| Kersting, S | 1 |
| Konopke, R | 1 |
| Dittert, D | 1 |
| Distler, M | 1 |
| Rückert, F | 1 |
| Gastmeier, J | 1 |
| Baretton, GB | 3 |
| Saeger, HD | 2 |
| Ponti, G | 2 |
| Mendiola, C | 1 |
| Vaz, MA | 1 |
| Hashmi, S | 1 |
| Bell, D | 1 |
| Tardío, JC | 1 |
| Nájera, L | 1 |
| Alemany, I | 1 |
| Martín, T | 1 |
| Castaño, A | 1 |
| Pérez-Regadera, JF | 1 |
| Fernández-Peralta, AM | 1 |
| Daimiel, L | 1 |
| Nejda, N | 1 |
| Iglesias, D | 1 |
| Medina Arana, V | 1 |
| González-Aguilera, JJ | 1 |
| Jansen, EPM | 1 |
| Dubbelman, R | 3 |
| Kuboki, Y | 1 |
| Ichimura, T | 1 |
| Matsueda, K | 1 |
| Ren, DN | 1 |
| Kim, IY | 1 |
| Koh, SB | 1 |
| Chang, SJ | 1 |
| Eom, M | 1 |
| Yi, SY | 1 |
| Seong, SH | 1 |
| Bronner, MP | 1 |
| Cho, MY | 1 |
| Yokoe, T | 2 |
| Saigusa, S | 2 |
| Toiyama, Y | 3 |
| Miki, C | 5 |
| Kusunoki, M | 8 |
| Feng, F | 3 |
| Jiang, WQ | 3 |
| Yuan, SQ | 1 |
| Liang, YJ | 1 |
| Fu, LW | 1 |
| Qiu, HB | 1 |
| Zhang, LY | 2 |
| Xiang, XJ | 4 |
| Karampeazis, A | 1 |
| Kouroussis, Ch | 2 |
| Iott, MJ | 1 |
| Corsini, MM | 2 |
| Zhong, B | 1 |
| Tucker, S | 1 |
| Cheng, J | 1 |
| Szynglarewicz, B | 1 |
| Matkowski, R | 1 |
| Halon, A | 1 |
| Lacko, A | 1 |
| Stepien, M | 1 |
| Forgacz, J | 1 |
| Pudelko, M | 1 |
| Kornafel, J | 1 |
| Itoh, S | 1 |
| Harimoto, N | 1 |
| Tsujita, E | 1 |
| Sugimachi, K | 4 |
| Gion, T | 1 |
| Stenning, SP | 3 |
| Bancewicz, J | 1 |
| Clark, PI | 2 |
| Chansky, K | 2 |
| Christman, KL | 1 |
| Hundahl, SA | 3 |
| Issell, BF | 3 |
| Van Veldhuizen, PJ | 1 |
| Budd, GT | 4 |
| Kim, SG | 2 |
| Kim, DK | 1 |
| Jang, JS | 1 |
| Maindrault-Goebel, F | 3 |
| Lledo, G | 8 |
| Bennamoun, M | 4 |
| Mabro, M | 6 |
| Flesch, M | 5 |
| Dupuis, O | 3 |
| Colin, P | 4 |
| Larsen, AK | 1 |
| Küronya, Z | 1 |
| Bodrogi, I | 1 |
| Lövey, J | 1 |
| Plótár, V | 1 |
| Manninger, S | 1 |
| Pápai, Z | 1 |
| Choi, M | 1 |
| Heilbrun, LK | 7 |
| Venkatramanamoorthy, R | 2 |
| Lawhorn-Crews, JM | 1 |
| Malik, I | 4 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 2 |
| Byrd, J | 2 |
| Garberoglio, C | 1 |
| Iwahashi, M | 2 |
| Takifuji, K | 1 |
| Hotta, T | 1 |
| Higashiguchi, T | 1 |
| Oku, Y | 1 |
| Nasu, T | 1 |
| Fareed, KR | 1 |
| Ilyas, M | 1 |
| Kaye, PV | 1 |
| Soomro, IN | 1 |
| Lobo, DN | 1 |
| Doi, T | 5 |
| Takiuchi, H | 3 |
| Ohtsu, A | 6 |
| Henningsen, N | 1 |
| Hapfelmeier, A | 1 |
| Hois, S | 1 |
| Plaschke, S | 1 |
| Keller, G | 2 |
| Marsh, Rde W | 1 |
| Siddiqui, T | 1 |
| Mendenhall, WM | 3 |
| Zlotecki, RA | 2 |
| Grobmyer, S | 1 |
| Hochwald, S | 1 |
| Chang, M | 1 |
| Larson, B | 1 |
| King, J | 1 |
| Sprenger, T | 3 |
| Rothe, H | 3 |
| Homayounfar, K | 2 |
| Beissbarth, T | 2 |
| Ghadimi, BM | 3 |
| Becker, H | 6 |
| Gounaris, I | 1 |
| Ahmad, A | 2 |
| Kalender, ME | 1 |
| Sevinc, A | 1 |
| Camci, C | 1 |
| Kaya, AO | 1 |
| Yaman, E | 1 |
| Cuilliere-Dartigues, P | 1 |
| Guilloux, A | 1 |
| Parc, Y | 1 |
| Tiret, E | 1 |
| Dumont, S | 1 |
| Gayet, B | 1 |
| Validire, P | 1 |
| Fléjou, JF | 1 |
| Duval, A | 1 |
| Praz, F | 1 |
| Nishigami, K | 1 |
| Kawami, H | 1 |
| Spindler, KG | 1 |
| Andersen, RF | 1 |
| Jensen, LH | 1 |
| Harper, PG | 7 |
| Dunn, J | 1 |
| Tudur-Smith, C | 1 |
| West, J | 1 |
| Adab, F | 1 |
| Leonard, P | 1 |
| Ostrowski, J | 1 |
| Boskos, CS | 1 |
| Liacos, C | 1 |
| Korkolis, D | 1 |
| Aygerinos, K | 1 |
| Lamproglou, I | 1 |
| Terpos, E | 1 |
| Stoupa, E | 1 |
| Baltatzis, G | 1 |
| Beroukas, K | 1 |
| Papasavvas, P | 1 |
| Dimopoulos, MA | 2 |
| Damast, S | 1 |
| Ho, AY | 1 |
| Montgomery, L | 1 |
| Fornier, MN | 2 |
| Ishill, N | 1 |
| Elkin, E | 1 |
| Beal, K | 1 |
| McCormick, B | 1 |
| Qin, H | 1 |
| Hudson, E | 1 |
| Hurt, C | 1 |
| Mort, D | 1 |
| Brewster, AE | 2 |
| Iqbal, N | 1 |
| Joseph, G | 1 |
| Lee, JK | 2 |
| Wilkowski, R | 3 |
| Boeck, S | 3 |
| Ostermaier, S | 1 |
| Herbst, M | 1 |
| Flentje, M | 2 |
| Miethe, S | 2 |
| Boettcher, HD | 1 |
| Scholten, T | 1 |
| Rau, HG | 1 |
| Buechner-Steudel, P | 2 |
| Behrens, R | 2 |
| Fahlke, J | 2 |
| Behl, S | 1 |
| Kuss, O | 2 |
| Kleber, G | 2 |
| Fleig, WE | 2 |
| Wang, TS | 1 |
| Ding, QQ | 1 |
| Guo, RH | 1 |
| Sun, J | 2 |
| Lu, KH | 1 |
| You, SH | 1 |
| Ge, HM | 1 |
| Shu, YQ | 1 |
| Liu, P | 1 |
| Kanamori, N | 1 |
| Kaiga, T | 1 |
| Funada, T | 1 |
| Natsuizaka, M | 1 |
| Tsuyuguchi, M | 1 |
| Nagasako, T | 2 |
| Kawamura, N | 2 |
| Kudo, M | 2 |
| Tsuda, I | 1 |
| Meguro, J | 2 |
| Dose-Schwarz, J | 1 |
| Tiling, R | 1 |
| Avril-Sassen, S | 1 |
| Mahner, S | 1 |
| Lebeau, A | 1 |
| Weber, C | 1 |
| Schwaiger, M | 1 |
| Jänicke, F | 1 |
| Untch, M | 1 |
| Avril, N | 1 |
| Hebbar, M | 3 |
| Kockler, L | 1 |
| Huang, C | 1 |
| Zhang, XM | 2 |
| Tavaluc, RT | 1 |
| Hart, LS | 2 |
| Dicker, DT | 2 |
| Muto, Y | 1 |
| Endo, J | 1 |
| Asakage, M | 1 |
| Oka, T | 2 |
| Furukawa, Y | 1 |
| Arai, M | 1 |
| Otrock, ZK | 2 |
| Barada, WM | 1 |
| Sawaya, RA | 1 |
| Saab, JF | 1 |
| Bazarbachi, AA | 1 |
| Kucherlapati, MH | 1 |
| Nguyen, AA | 1 |
| Clark, AB | 1 |
| Hou, H | 1 |
| Rosulek, A | 1 |
| Yang, K | 2 |
| Fan, K | 1 |
| Lipkin, M | 1 |
| Bronson, RT | 1 |
| Jelicks, L | 1 |
| Kunkel, TA | 1 |
| Kucherlapati, R | 1 |
| Edelmann, W | 1 |
| Paiva, CE | 1 |
| Paiva, BS | 1 |
| Garita, R | 1 |
| Michelin, OC | 1 |
| Sharma, S | 1 |
| Abhyankar, V | 1 |
| Burgess, RE | 1 |
| Infante, J | 1 |
| Trowbridge, RC | 1 |
| Tarazi, J | 1 |
| Tortorici, M | 1 |
| Robles, RL | 1 |
| Sym, SJ | 2 |
| Yook, JH | 3 |
| Collins, A | 1 |
| Robles-Jara, C | 1 |
| Robles-Medranda, C | 1 |
| Wente, MN | 2 |
| Rötzer, I | 1 |
| Decker-Baumann, C | 1 |
| Sala-Vila, A | 1 |
| Folkes, J | 1 |
| Calder, PC | 1 |
| Kim, JY | 3 |
| Rhee, PL | 2 |
| Kim, DS | 2 |
| Yun, H | 2 |
| Cho, YB | 3 |
| Yun, SH | 4 |
| Chun, HK | 3 |
| Ha, SW | 5 |
| Bati, Y | 1 |
| Akboru, H | 1 |
| Unsal, M | 1 |
| Rego, RL | 1 |
| Le, M | 1 |
| O'Connell, MJ | 17 |
| Windschitl, H | 1 |
| Petty, RD | 2 |
| Murray, GI | 1 |
| MacDonald, G | 1 |
| O'Kelly, T | 1 |
| Loudon, M | 1 |
| Binnie, N | 1 |
| Aly, E | 1 |
| McKinlay, A | 1 |
| Gilbert, F | 1 |
| Semple, S | 1 |
| Collie-Duguid, ES | 1 |
| Albain, KS | 1 |
| Barlow, WE | 1 |
| Ravdin, PM | 1 |
| Farrar, WB | 1 |
| Burton, GV | 1 |
| Ketchel, SJ | 1 |
| Cobau, CD | 1 |
| Levine, EG | 1 |
| Ingle, JN | 1 |
| Pritchard, KI | 1 |
| Lichter, AS | 1 |
| Schneider, DJ | 1 |
| Abeloff, MD | 2 |
| Henderson, IC | 2 |
| Muss, HB | 3 |
| Green, SJ | 1 |
| Lew, D | 1 |
| Livingston, RB | 6 |
| Martino, S | 1 |
| Osborne, CK | 1 |
| Lombardi, R | 1 |
| Cuicchi, D | 2 |
| Iacopino, B | 1 |
| Neri, S | 1 |
| Tardio, ML | 1 |
| Ceccarelli, C | 2 |
| Lecce, F | 1 |
| Ugolini, G | 1 |
| Pini, S | 2 |
| Di Tullio, P | 1 |
| Taffurelli, M | 1 |
| Minni, F | 1 |
| Martoni, A | 3 |
| Cola, B | 1 |
| Saunders, M | 2 |
| Uña, E | 1 |
| Bargagli, G | 1 |
| Lazzi, S | 1 |
| Pascucci, A | 1 |
| Bellan, C | 1 |
| Martellucci, I | 1 |
| Lorenzi, B | 1 |
| Francini, G | 5 |
| Moen, I | 1 |
| Tronstad, KJ | 1 |
| Kolmannskog, O | 1 |
| Salvesen, GS | 1 |
| Reed, RK | 1 |
| Stuhr, LE | 1 |
| Nakamura, J | 1 |
| Kitajima, Y | 3 |
| Kai, K | 1 |
| Hashiguchi, K | 1 |
| Noshiro, H | 1 |
| Miyazaki, K | 3 |
| Iida, A | 2 |
| Yoshidome, H | 1 |
| Kaneko, T | 2 |
| Mishima, T | 1 |
| Miyazaki, M | 4 |
| Miyamoto, A | 1 |
| Tsujie, M | 3 |
| Yasui, M | 1 |
| Hirao, M | 1 |
| Fujitani, K | 1 |
| Nakamori, S | 3 |
| Tsujinaka, T | 3 |
| Kita, K | 1 |
| Nakano, S | 6 |
| Akabane, H | 1 |
| Yanagida, N | 1 |
| Shomura, H | 1 |
| Hanamoto, T | 1 |
| Kuji, M | 1 |
| Oikawa, F | 1 |
| Miyagi, H | 1 |
| Takada, J | 1 |
| Kenno, S | 1 |
| Hamada, H | 4 |
| Katsuki, Y | 1 |
| Go, SI | 1 |
| Simianu, VV | 1 |
| Zyromski, NJ | 1 |
| Nakeeb, A | 1 |
| Kim, LG | 1 |
| Kong, HH | 1 |
| Low, LY | 1 |
| Iacopetta, B | 4 |
| Soong, R | 2 |
| Callister, MD | 1 |
| Farnell, MB | 1 |
| Kang, SH | 1 |
| Moon, HS | 1 |
| Sung, JK | 1 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Catania, C | 1 |
| Pelosi, G | 1 |
| Spitaleri, G | 1 |
| Noberasco, C | 1 |
| Maggioni, A | 1 |
| Trifirò, G | 1 |
| Toffalorio, F | 1 |
| Vigna, PD | 1 |
| De Pas, T | 1 |
| Orphanos, GS | 1 |
| Stavrou, NG | 1 |
| Picolos, MK | 1 |
| Kim, CW | 4 |
| Shin, US | 2 |
| Jung, KY | 1 |
| Yoon, SN | 3 |
| Eiermann, W | 1 |
| Semiglazov, V | 2 |
| Manikhas, A | 1 |
| Lluch, A | 1 |
| Vazquez, F | 1 |
| Byakhow, M | 1 |
| Climent, MA | 1 |
| Ciruelos, E | 1 |
| Ojeda, B | 1 |
| Mansutti, M | 1 |
| Bozhok, A | 1 |
| Baronio, R | 1 |
| Feyereislova, A | 3 |
| Barton, C | 1 |
| Valagussa, P | 3 |
| Okugawa, Y | 1 |
| Zhu, FS | 2 |
| Chen, XM | 2 |
| Huang, ZG | 1 |
| Wang, ZR | 1 |
| Zhang, DW | 1 |
| Njiaju, UO | 1 |
| Truica, CI | 1 |
| Meredith, KL | 1 |
| Siegel, EM | 1 |
| McLoughlin, J | 1 |
| Marcovalerio, M | 1 |
| Kelley, S | 1 |
| Karl, R | 1 |
| Manuyakorn, A | 1 |
| Paulus, R | 1 |
| Farrell, J | 1 |
| Dawson, NA | 1 |
| Tze, S | 1 |
| Cheung-Lau, G | 1 |
| Reber, H | 1 |
| Seligson, DB | 1 |
| Horvath, S | 1 |
| Kurdistani, SK | 1 |
| Dawson, DW | 1 |
| Dahlqvist, C | 1 |
| Fremault, A | 1 |
| Carrasco, J | 1 |
| Colinet, B | 1 |
| Kanagavel, D | 1 |
| Pokataev, IA | 1 |
| Tryakin, AA | 1 |
| Bazin, IS | 2 |
| Narimanov, MN | 1 |
| Yakovleva, ES | 1 |
| Garin, AM | 3 |
| Tjulandin, SA | 2 |
| García-Montesinos-De la Peña, M | 1 |
| Oteiza-López, L | 1 |
| Aldunate-Calvo, S | 1 |
| Gómez-Sánchez, MJ | 1 |
| Sáenz-Bañuelos, JJ | 1 |
| Tihista-Jiménez, JA | 1 |
| Lal, A | 1 |
| Christians, K | 1 |
| Rodriguez, W | 1 |
| Garin, A | 1 |
| Lang, I | 3 |
| Falcon, S | 1 |
| Helsby, NA | 1 |
| Lo, WY | 1 |
| Thompson, P | 3 |
| Laking, GR | 1 |
| Paczos, TA | 1 |
| Ackers, S | 1 |
| Odunsi, K | 1 |
| Lele, S | 2 |
| Mhawech-Fauceglia, P | 1 |
| Mawdsley, S | 3 |
| Ishii, H | 5 |
| Furuse, J | 2 |
| Ohkawa, S | 1 |
| Hamamoto, Y | 1 |
| Nakamura, K | 5 |
| Jørgensen, JT | 1 |
| Hongoh, S | 1 |
| Nomoto, T | 1 |
| Kawakami, M | 2 |
| Hanai, K | 1 |
| Inatsuchi, H | 1 |
| Terachi, T | 1 |
| Ejlertsen, B | 2 |
| Mouridsen, HT | 2 |
| Jensen, MB | 2 |
| Andersen, J | 2 |
| Andersson, M | 2 |
| Kamby, C | 2 |
| Knoop, AS | 1 |
| Viganò, MG | 3 |
| Aldrighetti, L | 2 |
| Vidaurreta, M | 1 |
| Sánchez-Muñoz, R | 1 |
| Veganzones, S | 1 |
| Rafael, S | 1 |
| Gutiérrez, M | 1 |
| de-la-Orden, V | 1 |
| Arroyo, M | 1 |
| Cerdán, FJ | 1 |
| Maestro de las Casas, ML | 1 |
| Seront, E | 1 |
| Marot, L | 1 |
| Coche, E | 1 |
| Gala, JL | 1 |
| Sempoux, C | 2 |
| Humblet, Y | 4 |
| Guo, JF | 1 |
| Wu, F | 1 |
| Xing, H | 1 |
| Zhu, GY | 1 |
| Nie, XY | 1 |
| Vilgelm, AE | 1 |
| Washington, MK | 1 |
| Prassolov, VS | 1 |
| Zaika, AI | 1 |
| Dalla Chiesa, M | 1 |
| Tomasello, G | 1 |
| Buti, S | 1 |
| Rovere, RK | 1 |
| Brighenti, M | 1 |
| Lazzarelli, S | 1 |
| Donati, G | 1 |
| Passalacqua, R | 3 |
| Rullier, A | 1 |
| Capdepont, M | 1 |
| Bioulac-Sage, P | 1 |
| Rullier, E | 2 |
| Sonnenblick, A | 2 |
| Meirovitz, A | 1 |
| Coursier, S | 1 |
| Martelet, S | 1 |
| Guillermet, A | 1 |
| Emptoz, J | 1 |
| Villier, C | 1 |
| Bontemps, H | 1 |
| Allegrini, G | 5 |
| Fontana, E | 2 |
| Granetto, C | 3 |
| Mentuccia, L | 1 |
| Andreuccetti, M | 2 |
| Cortesi, E | 3 |
| Merlano, M | 1 |
| Sogabe, S | 1 |
| Takano, H | 2 |
| Kawamoto, Y | 1 |
| Nakatsumi, H | 1 |
| Uehata, Y | 1 |
| Ye, ZB | 1 |
| Zhu, ZG | 2 |
| Lim, YK | 1 |
| Law, WL | 1 |
| Liu, R | 2 |
| Poon, JT | 1 |
| Fan, JF | 1 |
| Lo, OS | 1 |
| Spigel, DR | 2 |
| Greco, FA | 4 |
| Meluch, AA | 1 |
| Lane, CM | 1 |
| Farley, C | 1 |
| Gray, JR | 1 |
| Clark, BL | 1 |
| Burris, HA | 3 |
| Mehta, SP | 1 |
| Taura, M | 1 |
| Fukuda, R | 1 |
| Suico, MA | 1 |
| Eguma, A | 1 |
| Koga, T | 2 |
| Shuto, T | 2 |
| Morino-Koga, S | 1 |
| Kai, H | 1 |
| Dikken, JL | 1 |
| Bakker, B | 1 |
| Hartgrink, HH | 2 |
| Kranenbarg, EM | 1 |
| Peeters, KC | 1 |
| Kurose, A | 1 |
| Takatori, E | 1 |
| Traganos, F | 2 |
| Darzynkiewicz, Z | 1 |
| Sawai, T | 2 |
| McCollum, D | 1 |
| Hecht, JR | 5 |
| Pillai, M | 1 |
| Gollard, R | 1 |
| Heim, W | 1 |
| Swan, F | 1 |
| Patel, R | 2 |
| Dreiling, L | 1 |
| Mo, M | 1 |
| Boccia, RV | 1 |
| Cosgriff, TM | 1 |
| Headley, DL | 1 |
| Badarinath, S | 1 |
| Dakhil, SR | 3 |
| Raftery, L | 1 |
| Calvo, BF | 1 |
| Chakravarthy, AB | 1 |
| Ivanova, A | 1 |
| Myers, MO | 1 |
| Chan, E | 2 |
| Wise, PE | 1 |
| Caskey, LS | 1 |
| Bernard, SA | 4 |
| Sanoff, HK | 2 |
| Beretta, GD | 4 |
| Tondulli, L | 1 |
| De Pellegrin, A | 1 |
| Decorti, G | 1 |
| Jung, K | 1 |
| Christiansen, H | 1 |
| Conradi, LC | 2 |
| Lo, SS | 1 |
| Khorana, AA | 1 |
| Simon, S | 1 |
| Kiefer, G | 1 |
| Rajasenan, K | 1 |
| Hantel, A | 1 |
| Shayne, M | 1 |
| Schmotzer, A | 1 |
| Tran, B | 1 |
| Yovino, S | 1 |
| Poppe, M | 1 |
| Jabbour, S | 1 |
| David, V | 1 |
| Garofalo, M | 1 |
| Pandya, N | 1 |
| Alexander, R | 1 |
| Hanna, N | 2 |
| Andres, A | 2 |
| Majno, P | 1 |
| Promkan, M | 1 |
| Katopodis, O | 1 |
| Kentepozidis, N | 1 |
| Giassas, S | 1 |
| Rovithi, M | 1 |
| Bozionelou, V | 1 |
| Andersen, M | 1 |
| Vestermark, LW | 2 |
| Hess, V | 2 |
| Pratsch, S | 1 |
| Potthast, S | 1 |
| Lee, L | 1 |
| Winterhalder, R | 3 |
| Widmer, L | 3 |
| Cescato, C | 1 |
| Lohri, A | 1 |
| Jost, L | 1 |
| Stillhart, P | 1 |
| Pestalozzi, B | 1 |
| Trikudanathan, G | 1 |
| Uehara, K | 2 |
| Ishiguro, S | 2 |
| Nishio, H | 1 |
| Ebata, T | 1 |
| Kokuryo, T | 1 |
| Tsunoda, N | 1 |
| Igami, T | 1 |
| Sugawara, G | 1 |
| Fukaya, M | 1 |
| Hill, ME | 5 |
| Campbell, A | 1 |
| Culler, K | 1 |
| Zalupski, M | 2 |
| Hejna, G | 1 |
| Harris, W | 1 |
| Hoffman, J | 4 |
| Talamonti, M | 2 |
| Cooper, H | 3 |
| Avallone, A | 3 |
| Delrio, P | 2 |
| Pecori, B | 1 |
| Tatangelo, F | 2 |
| Marone, P | 2 |
| Aloi, L | 1 |
| Iaffaioli, VR | 1 |
| Scala, D | 1 |
| Iodice, G | 1 |
| Budillon, A | 2 |
| Joon, DL | 1 |
| Jayamoham, J | 1 |
| Spry, N | 3 |
| Harvey, J | 3 |
| Di Iulio, J | 1 |
| Milner, A | 1 |
| Mann, GB | 1 |
| Spanos, CP | 1 |
| Syrakos, T | 1 |
| Ogata, S | 1 |
| Ozeki, Y | 1 |
| Nakanishi, K | 2 |
| Tanaka, F | 2 |
| Mio, T | 1 |
| Hiroi, S | 1 |
| Tominaga, S | 1 |
| Aida, S | 1 |
| Kawai, T | 3 |
| Mochizuki, S | 1 |
| Kojima, T | 4 |
| Fuse, N | 2 |
| Ikematsu, H | 1 |
| Yano, T | 3 |
| Tahara, M | 2 |
| Kaneko, K | 2 |
| Koike, K | 2 |
| Gallagher, M | 2 |
| Whittington, R | 3 |
| Gilligan, D | 1 |
| Beadman, C | 1 |
| Ripley, RT | 1 |
| Davis, JL | 1 |
| Kemp, CD | 1 |
| Jeong, EK | 1 |
| Jeon, HM | 1 |
| Kim, CH | 1 |
| Kang, HS | 1 |
| Hurmuzlu, M | 2 |
| Øvrebø, K | 1 |
| Monge, OR | 1 |
| Smaaland, R | 1 |
| Wentzel-Larsen, T | 1 |
| Paduch, R | 1 |
| Kandefer-Szerszeń, M | 1 |
| Piersiak, T | 1 |
| Aftimos, PG | 1 |
| Nasr, EA | 1 |
| Nasr, DI | 1 |
| Noun, RJ | 1 |
| El Helou, JA | 1 |
| Lai, HS | 1 |
| Cheng, KW | 1 |
| Van Huysse, J | 1 |
| Vandenbossche, B | 1 |
| Sainz-Barriga, M | 1 |
| Vinci, A | 1 |
| Ricciardi, S | 1 |
| Bocchetti, T | 1 |
| Rogiers, X | 1 |
| de Hemptinne, B | 1 |
| Jauhri, M | 1 |
| Negi, A | 1 |
| Smyth, E | 1 |
| Lowery, M | 1 |
| Al-Olayan, A | 1 |
| Naghy, M | 1 |
| Saliba, T | 1 |
| Kelsen, D | 8 |
| Kelly, P | 1 |
| Appleyard, V | 1 |
| Murray, K | 1 |
| Paulin, F | 1 |
| Lamont, D | 1 |
| Baker, L | 2 |
| Suttie, S | 1 |
| Exon, D | 1 |
| Thompson, A | 2 |
| Lai, JI | 1 |
| Wang, WS | 3 |
| Lai, YC | 1 |
| Chang, SC | 2 |
| Schultheis, B | 1 |
| Riebeling, J | 1 |
| Allali, M | 1 |
| Bergmann, U | 1 |
| Kummer, G | 1 |
| Sendler, U | 1 |
| Tannapfel, A | 2 |
| Sendler, A | 3 |
| Napoli, C | 1 |
| Landini, I | 1 |
| Morganti, M | 1 |
| Cianchi, F | 1 |
| Valanzano, R | 1 |
| Tonelli, F | 1 |
| Cortesini, C | 1 |
| Courrech Staal, EF | 1 |
| Aleman, BM | 1 |
| van Velthuysen, ML | 1 |
| van Coevorden, F | 1 |
| Maleux, G | 1 |
| Lambert, B | 1 |
| Vannoote, J | 1 |
| De Keukeleire, K | 1 |
| Verslype, C | 2 |
| Defreyne, L | 1 |
| Delatte, P | 1 |
| Delaunoit, T | 3 |
| Personeni, N | 1 |
| Schneiders, FL | 1 |
| van den Berg, HP | 1 |
| Peters, GJ | 7 |
| Verheul, HM | 1 |
| van der Vliet, HJ | 1 |
| Engelman, JA | 1 |
| Sahani, DV | 1 |
| Lisovsky, M | 2 |
| Wolf, M | 2 |
| Zehentmayr, F | 1 |
| Niyazi, M | 1 |
| Ganswindt, U | 1 |
| Haimerl, W | 1 |
| Schmidt, M | 2 |
| Hölzel, D | 1 |
| Belka, C | 1 |
| Besch, S | 1 |
| Mönig, SP | 3 |
| Baldus, SE | 5 |
| Specht, K | 4 |
| Piperdi, M | 1 |
| McDade, TP | 1 |
| Shim, JK | 1 |
| Piperdi, B | 1 |
| Kadish, SP | 1 |
| Sullivan, ME | 1 |
| Whalen, GF | 1 |
| Tseng, JF | 1 |
| Li, HM | 1 |
| Chen, XF | 1 |
| Xie, KC | 1 |
| Huang, Q | 4 |
| Davies, L | 1 |
| Lewis, WG | 1 |
| Arnold, DT | 1 |
| Escofet, X | 1 |
| Blackshaw, G | 1 |
| Gwynne, S | 1 |
| Evans, M | 3 |
| Appadurai, I | 1 |
| Laurence, V | 1 |
| Tobias, J | 1 |
| Blackman, G | 1 |
| Meyer, T | 1 |
| Goodchild, K | 1 |
| Collis, C | 1 |
| Nonaka, K | 3 |
| Sha, S | 1 |
| Yamanaka, N | 1 |
| Son, JY | 1 |
| Shin, JW | 1 |
| Wang, JH | 2 |
| Raghavendran, HR | 1 |
| Son, CG | 1 |
| Astier, A | 1 |
| Takemura, M | 2 |
| Morimura, K | 1 |
| Kishida, S | 1 |
| Dietlein, M | 1 |
| Alakus, H | 2 |
| Jackson, AS | 1 |
| Watkins, GR | 1 |
| Whitfield, GA | 1 |
| Green, MM | 1 |
| Taylor, MB | 1 |
| Dickinson, C | 1 |
| Price, PM | 1 |
| Saleem, A | 1 |
| Tanoue, Y | 1 |
| Mounier-Boutoille, H | 1 |
| Boisdron-Celle, M | 6 |
| Cauchin, E | 1 |
| Galmiche, JP | 1 |
| Morel, A | 4 |
| Gamelin, E | 11 |
| Matysiak-Budnik, T | 1 |
| Unger, KR | 1 |
| Romney, DA | 1 |
| Koc, M | 2 |
| Moskaluk, CA | 1 |
| Foley, EF | 1 |
| Rich, TA | 21 |
| Kim, HK | 5 |
| Ko, BM | 1 |
| Hong, SJ | 1 |
| Moon, JH | 1 |
| Lee, JS | 12 |
| Lee, MS | 3 |
| Toujima, S | 2 |
| Ashley, SE | 1 |
| Turner, A | 1 |
| Redmond, KJ | 1 |
| Ahn, J | 1 |
| Penney, R | 1 |
| Kaley, K | 1 |
| Marshall, MB | 1 |
| Cupini, S | 2 |
| Ciarlo, A | 1 |
| Del Monte, F | 1 |
| Amoroso, D | 1 |
| Sensi, E | 1 |
| Bartholomeusz, D | 1 |
| Devitt, PG | 4 |
| Lamb, PJ | 1 |
| Ruszkiewicz, AR | 1 |
| Konings, IR | 1 |
| van der Wijk, LJ | 1 |
| de Jongh, FE | 1 |
| Eskens, FA | 1 |
| Sleijfer, S | 1 |
| Omuro, Y | 3 |
| Kulikov, E | 1 |
| Hill, J | 1 |
| Lehle, M | 1 |
| Ahn, JY | 1 |
| Stathopoulos, GP | 3 |
| Batziou, C | 1 |
| Trafalis, D | 1 |
| Koutantos, J | 1 |
| Batzios, S | 1 |
| Stathopoulos, J | 1 |
| Legakis, J | 1 |
| Armakolas, A | 1 |
| Savva-Bordalo, J | 1 |
| Ramalho-Carvalho, J | 1 |
| Pinheiro, M | 1 |
| Costa, VL | 1 |
| Rodrigues, A | 4 |
| Dias, PC | 1 |
| Veiga, I | 1 |
| Machado, M | 1 |
| Teixeira, MR | 1 |
| Henrique, R | 1 |
| Jerónimo, C | 1 |
| Aarstad, HJ | 1 |
| Aarstad, AK | 1 |
| Hjermstad, MJ | 1 |
| Gubanski, M | 1 |
| Kadar, L | 1 |
| Karlberg, I | 1 |
| Flygare, P | 1 |
| Padbury, R | 1 |
| Gallinger, S | 3 |
| Doi, R | 1 |
| Buckels, JA | 1 |
| Chen, YB | 2 |
| Sun, XW | 2 |
| Xu, DZ | 2 |
| Guan, YX | 2 |
| Feng, XY | 1 |
| Wolthuis, AM | 2 |
| Penninckx, F | 2 |
| Ectors, N | 1 |
| D'Hoore, A | 2 |
| Taylor, NJ | 1 |
| Makris, A | 2 |
| Ah-See, ML | 1 |
| Beresford, MJ | 1 |
| Stirling, JJ | 1 |
| d'Arcy, JA | 1 |
| Collins, DJ | 1 |
| Padhani, AR | 2 |
| Monjazeb, AM | 1 |
| Riedlinger, G | 1 |
| Aklilu, M | 1 |
| Geisinger, KR | 1 |
| Mishra, G | 1 |
| Isom, S | 1 |
| Clark, P | 1 |
| Levine, EA | 1 |
| Blackstock, AW | 2 |
| Wiegel, T | 2 |
| Kreuser, ED | 3 |
| Kron, M | 2 |
| Baumann, W | 2 |
| Shen, W | 1 |
| Tu, JK | 1 |
| Wang, XH | 1 |
| Fu, ZX | 1 |
| Yukawa, K | 2 |
| Schauer, MC | 1 |
| Holzmann, B | 1 |
| Peiper, M | 1 |
| Knoefel, WT | 1 |
| Theisen, J | 1 |
| Husein-ElAhmed, H | 1 |
| Aneiros-Fernandez, J | 1 |
| Arias-Santiago, S | 1 |
| Naranjo-Sintes, R | 1 |
| Hong, YS | 3 |
| Yun, T | 2 |
| Jeong, SY | 4 |
| Choi, HS | 3 |
| Chang, HJ | 6 |
| Jung, KH | 4 |
| Velenik, V | 4 |
| Oblak, I | 4 |
| Anderluh, F | 4 |
| Fantini, M | 1 |
| Tassinari, D | 1 |
| Nicoletti, S | 1 |
| Possenti, C | 1 |
| Drudi, F | 1 |
| Sintini, M | 1 |
| Bagli, L | 1 |
| Tamburini, E | 1 |
| Ravaioli, A | 1 |
| Atar, A | 1 |
| Korkmaz, ME | 1 |
| Ozin, B | 1 |
| Lee, MY | 2 |
| Brændengen, M | 1 |
| Bruheim, K | 1 |
| Cvancarova, M | 1 |
| Jang, YJ | 1 |
| Park, SS | 2 |
| Kim, SJ | 2 |
| Kim, CS | 1 |
| Mok, YJ | 3 |
| Lagares-Garcia, J | 1 |
| Cataldo, T | 1 |
| McNulty, B | 1 |
| Shipley, J | 1 |
| Anderson, E | 1 |
| Khurshid, H | 1 |
| Oconnor, B | 1 |
| Oldenburg, NB | 1 |
| Radie-Keane, K | 1 |
| Husain, S | 1 |
| Cattan, S | 2 |
| Chauffert, B | 4 |
| Yu, HB | 1 |
| Xian, HB | 1 |
| Deng, YM | 1 |
| Li, LL | 1 |
| Murad-Regadas, SM | 1 |
| Regadas, FS | 1 |
| Rodrigues, LV | 1 |
| Crispin, FJ | 1 |
| Kenmoti, VT | 1 |
| Fernandes, GO | 1 |
| Buchen, G | 1 |
| Monteiro, FC | 1 |
| Fischer von Weikersthal, L | 2 |
| Schalhorn, A | 3 |
| Stauch, M | 2 |
| Quietzsch, D | 5 |
| Maubach, PA | 1 |
| Lambertz, H | 1 |
| Oruzio, D | 2 |
| Schlag, R | 1 |
| Weigang-Köhler, K | 1 |
| Vehling-Kaiser, U | 3 |
| Schulze, M | 3 |
| Truckenbrodt, J | 1 |
| Goebeler, M | 1 |
| Mittermüller, J | 2 |
| Bosse, D | 1 |
| Szukics, B | 1 |
| Grundeis, M | 1 |
| Zwingers, T | 1 |
| Giessen, C | 2 |
| Chang, MH | 1 |
| Lee, IK | 1 |
| Si, Y | 1 |
| Woo, IS | 1 |
| Li, QF | 1 |
| Yao, RY | 1 |
| Lü, HY | 1 |
| Jiang, J | 1 |
| Sun, YY | 1 |
| Song, SA | 1 |
| Jiang, T | 1 |
| Ebara, T | 1 |
| Saito, J | 2 |
| Shioya, M | 3 |
| Sakurai, H | 3 |
| Xanthakis, I | 1 |
| Samelis, G | 2 |
| Xiros, N | 1 |
| Kosmidis, P | 4 |
| Christodoulou, C | 2 |
| Linardou, H | 1 |
| Skondra, M | 1 |
| Wernroth, L | 1 |
| Larsson, A | 1 |
| Einarsson, R | 1 |
| Tagawa, T | 1 |
| Honda, S | 1 |
| Hidaka, S | 1 |
| Baird, R | 1 |
| Biondo, A | 1 |
| Chhaya, V | 1 |
| McLachlan, J | 1 |
| Karpathakis, A | 1 |
| Rahman, S | 2 |
| Pantling, AZ | 1 |
| Mamidanna, R | 1 |
| Newman, G | 1 |
| Manifold, DK | 1 |
| Hale, PC | 1 |
| Burmeister, BH | 7 |
| Thomas, JM | 1 |
| Burmeister, EA | 2 |
| Harvey, JA | 2 |
| Thomson, DB | 2 |
| Gotley, DC | 3 |
| Yamauchi, M | 2 |
| Okamoto, Y | 2 |
| Doi, M | 1 |
| Jin, H | 1 |
| Ding, Y | 1 |
| Kang, MF | 1 |
| Luo, MQ | 1 |
| Dong, CM | 1 |
| Kang, EJ | 2 |
| Park, KH | 3 |
| Choi, IK | 4 |
| Seo, JH | 5 |
| Shin, SW | 4 |
| Xia, LP | 1 |
| Wu, PH | 1 |
| Xia, JC | 1 |
| Guan, ZZ | 1 |
| Guo, GF | 1 |
| Zeng, YX | 1 |
| Belli, C | 2 |
| Longoni, S | 2 |
| Fugazza, C | 3 |
| Brioschi, M | 1 |
| Madajewicz, S | 2 |
| Waterhouse, DM | 1 |
| Khan, MQ | 1 |
| Higby, DJ | 1 |
| Leichman, CG | 6 |
| Malik, SK | 1 |
| Hentschel, P | 1 |
| Gill, JF | 1 |
| Nicol, SJ | 1 |
| Ababneh, Y | 1 |
| Verpoort, K | 1 |
| Musch, R | 1 |
| Soeling, U | 1 |
| Maintz, C | 1 |
| Siebler, J | 4 |
| Efficace, F | 2 |
| Serpentini, S | 2 |
| Capirci, C | 1 |
| De Paoli, A | 2 |
| Amato, A | 1 |
| Thukral, A | 1 |
| Metz, J | 2 |
| Hwang, WT | 1 |
| O'Dwyer, P | 2 |
| Plastaras, J | 1 |
| Both, S | 1 |
| Bar-Ad, V | 1 |
| Ad, VB | 1 |
| Drullinsky, P | 1 |
| Sugarman, SM | 1 |
| D'Andrea, G | 1 |
| Gilewski, T | 1 |
| Lake, D | 1 |
| Traina, T | 1 |
| Wasserheit-Lieblich, C | 1 |
| Sklarin, N | 1 |
| Atieh-Graham, D | 1 |
| Mills, N | 1 |
| Troso-Sandoval, T | 1 |
| Seidman, AD | 1 |
| Yuan, J | 2 |
| Norton, L | 3 |
| Hudis, C | 3 |
| Paillas, S | 1 |
| Boissière, F | 1 |
| Denouel, A | 1 |
| Causse, A | 1 |
| Denis, V | 2 |
| Vezzio-Vié, N | 1 |
| Marzi, L | 1 |
| Cortijo, C | 1 |
| Ait-Arsa, I | 1 |
| Askari, N | 1 |
| Pourquier, P | 1 |
| Teke, Z | 1 |
| Nessar, G | 1 |
| Kiremitci, S | 1 |
| Aksoy, E | 1 |
| Elbir, OH | 1 |
| Abe, T | 3 |
| Hachiro, Y | 1 |
| Kunimoto, M | 1 |
| Liu, LJ | 2 |
| Zhao, CH | 2 |
| Liu, JZ | 2 |
| Li, ZQ | 1 |
| Stauffer, JA | 1 |
| Mathew, J | 1 |
| Odell, JA | 1 |
| Chi, KC | 1 |
| Lamas, MJ | 1 |
| Duran, G | 1 |
| Gomez, A | 1 |
| Balboa, E | 1 |
| Anido, U | 1 |
| Bernardez, B | 1 |
| Rana-Diez, P | 1 |
| Lopez, R | 1 |
| Carracedo, A | 1 |
| Barros, F | 1 |
| Ihtiyar, E | 1 |
| Paşaoğlu, O | 1 |
| Erkasap, S | 1 |
| Karakaş, BR | 1 |
| Yaşar, FN | 1 |
| Ruiz-Rabelo, J | 1 |
| Vázquez, R | 1 |
| Arjona, A | 1 |
| Perea, D | 1 |
| Montilla, P | 1 |
| Túnez, I | 1 |
| Muntané, J | 1 |
| Padillo, J | 1 |
| Wynn, G | 1 |
| Marks, J | 2 |
| Kessler, H | 1 |
| Cone, MM | 1 |
| Lu, KC | 1 |
| Rea, JD | 1 |
| Diggs, BS | 1 |
| Oommen, SC | 1 |
| Park, KS | 1 |
| Lefkowitz, RA | 1 |
| Robinson, E | 3 |
| Ogata, Y | 6 |
| Shirabe, K | 2 |
| Hasegawa, H | 4 |
| Sadanaga, N | 2 |
| Samura, H | 2 |
| Kitazono, M | 1 |
| Yamamoto, M | 6 |
| Morikita, T | 1 |
| Inomata, M | 3 |
| Kakeji, Y | 3 |
| Shirouzu, K | 2 |
| de Campos-Lobato, LF | 1 |
| Stocchi, L | 1 |
| da Luz Moreira, A | 1 |
| Geisler, D | 1 |
| Lavery, IC | 1 |
| Fazio, VW | 1 |
| Kalady, MF | 1 |
| Amonkar, SJ | 1 |
| Cain, HJ | 1 |
| Hughes, T | 1 |
| Hemming, JD | 1 |
| Browell, DA | 1 |
| Çalık, AN | 1 |
| Çeliker, E | 1 |
| Velibey, Y | 1 |
| Çağdaş, M | 1 |
| Güzelburç, Ö | 1 |
| Ocean, AJ | 1 |
| Christos, P | 1 |
| Horvath, L | 1 |
| Hamilton, A | 1 |
| Matulich, D | 1 |
| Chen, HX | 1 |
| Sparano, JA | 5 |
| Hirst, J | 1 |
| Barbour, A | 1 |
| Stokes, JB | 1 |
| Nolan, NJ | 1 |
| Stelow, EB | 1 |
| Walters, DM | 1 |
| Weiss, GR | 2 |
| de Lange, EE | 1 |
| Adams, RB | 1 |
| Bauer, TW | 1 |
| Custodio, A | 1 |
| Sanchez, JC | 1 |
| Rodriguez, L | 1 |
| Puente, J | 1 |
| de las Heras, M | 2 |
| Nishiofuku, H | 2 |
| Anai, H | 3 |
| Sueyoshi, S | 3 |
| Morimoto, K | 1 |
| Masada, T | 1 |
| Sho, M | 3 |
| Tamamoto, T | 2 |
| Hasegawa, M | 2 |
| Sakaguchi, H | 2 |
| Shimobayashi, T | 1 |
| Inatsugi, N | 1 |
| Yoshikawa, S | 1 |
| Uchida, H | 1 |
| Kuge, H | 1 |
| Yokotani, T | 1 |
| Yamaoka, K | 1 |
| Inagaki, M | 2 |
| Matsuoka, M | 1 |
| Tatsumi, K | 1 |
| Saraya, T | 1 |
| Otsuji, T | 1 |
| Yamochi, Y | 1 |
| Yamanishi, K | 1 |
| Enomoto, Y | 1 |
| Nonomura, A | 1 |
| Ota, T | 1 |
| Toma, T | 1 |
| Ohira, G | 1 |
| Uesato, M | 1 |
| Akutsu, Y | 1 |
| Kono, T | 2 |
| Matsubara, H | 1 |
| Kawaoka, T | 1 |
| Matsukuma, S | 1 |
| Hiraki, S | 1 |
| Kanoh, T | 1 |
| Ohnishi, T | 1 |
| Danno, K | 1 |
| Tsukao, Y | 1 |
| Inatome, J | 1 |
| Kagara, N | 1 |
| Tono, T | 1 |
| Monden, T | 1 |
| Imaoka, S | 4 |
| Murata, A | 2 |
| Noda, E | 1 |
| Muguruma, K | 2 |
| Yamada, N | 2 |
| Ohira, M | 1 |
| Okubo, K | 1 |
| Yoshioka, S | 1 |
| Asukai, K | 1 |
| Nakanishi, M | 1 |
| Maekawa, T | 2 |
| Kashiwazaki, M | 1 |
| Konishi, M | 2 |
| Yano, K | 1 |
| Fujimoto, T | 2 |
| Platell, C | 2 |
| Ng, S | 1 |
| O'bichere, A | 1 |
| Tebbutt, N | 1 |
| Luo, W | 1 |
| Liao, WJ | 2 |
| Huang, YT | 1 |
| Wen, Q | 1 |
| Zhou, MQ | 1 |
| Chai, H | 1 |
| Tian, R | 1 |
| Tang, H | 1 |
| Miura, K | 2 |
| Nakano, H | 2 |
| Sakurai, J | 1 |
| Koizumi, S | 2 |
| Arai, T | 5 |
| Shimamura, T | 1 |
| Makizumi, R | 1 |
| Yamada, K | 2 |
| Miyajima, N | 1 |
| Otsubo, T | 1 |
| Koike, J | 1 |
| Kidera, Y | 1 |
| Ueda, S | 2 |
| Okamoto, W | 1 |
| Okamoto, I | 1 |
| Fumita, S | 1 |
| Yonesaka, K | 1 |
| Makimura, C | 1 |
| Okamoto, K | 3 |
| Kiyota, H | 1 |
| Tsurutani, J | 1 |
| Yoshinaga, M | 1 |
| Fujiwara, K | 3 |
| Yamazoe, Y | 1 |
| Moriyama, K | 1 |
| Tsubaki, M | 2 |
| Chiba, Y | 2 |
| Nishida, S | 1 |
| Nakagawa, K | 5 |
| Hazard, L | 1 |
| Jones, K | 1 |
| Shaban, A | 1 |
| Anker, C | 1 |
| Scaife, C | 1 |
| Weis, J | 1 |
| Mulvihill, S | 1 |
| Gordon, VL | 1 |
| Harding, GA | 1 |
| Czaykowski, P | 1 |
| Smith, C | 1 |
| Kist, J | 1 |
| Sun Myint, A | 1 |
| Haylock, B | 1 |
| Wise, M | 1 |
| Neupane, R | 1 |
| Dougal, M | 2 |
| Lloyd, A | 1 |
| Topham, C | 3 |
| Devries, AF | 3 |
| Schaberl-Moser, R | 2 |
| Zitt, M | 1 |
| Kapp, KS | 1 |
| Fastner, G | 1 |
| Keil, F | 1 |
| Jäger, R | 1 |
| Offner, F | 1 |
| Chun, CL | 1 |
| Eisenstat, S | 1 |
| Dormady, S | 1 |
| Lombard, C | 1 |
| Triadafilopoulos, G | 1 |
| Advani, PP | 1 |
| Lustig, R | 1 |
| Konski, AA | 3 |
| Khan, A | 1 |
| Compton, S | 1 |
| Yeo, SG | 3 |
| Park, JW | 4 |
| Sohn, DK | 3 |
| Hass, HG | 3 |
| Dietzfelbinger, H | 1 |
| Klein, S | 1 |
| Zellmann, K | 1 |
| Abenhardt, W | 1 |
| Puchtler, G | 1 |
| Kappauf, H | 1 |
| Haberl, C | 2 |
| Adamo, V | 1 |
| Franchina, T | 1 |
| Minciullo, PL | 1 |
| Pace, E | 1 |
| Colonese, F | 1 |
| Ricciardi, GR | 1 |
| Saitta, S | 1 |
| Ferraro, M | 1 |
| Spatari, G | 1 |
| Gangemi, S | 1 |
| O'Donovan, TR | 1 |
| O'Sullivan, GC | 2 |
| McKenna, SL | 1 |
| Han, SW | 6 |
| Park, JH | 3 |
| Yoon, SM | 2 |
| Lee, YS | 2 |
| Park, EK | 1 |
| Miyashiro, I | 1 |
| Sasako, M | 3 |
| Nashimoto, A | 7 |
| Kinoshita, T | 2 |
| Kobayashi, O | 2 |
| Aksoy, S | 4 |
| Oksuzoglu, BC | 1 |
| Aslan, N | 1 |
| Bleckmann, A | 1 |
| Schirmer, M | 1 |
| Jo, P | 1 |
| Middel, P | 1 |
| Ghadimi, MB | 1 |
| Rachakonda, PS | 1 |
| Panzram, B | 1 |
| Buechler, M | 1 |
| Hemminki, K | 1 |
| Kumar, R | 2 |
| Yan, SK | 1 |
| Dai, WX | 1 |
| Liu, XR | 1 |
| Zhang, WD | 1 |
| Owen, D | 1 |
| Pohlen, U | 2 |
| Berger, G | 2 |
| Ritz, JP | 1 |
| Holmer, C | 1 |
| Coban, I | 1 |
| Kneuertz, PJ | 1 |
| Kauh, JS | 1 |
| Sarmiento, J | 1 |
| Staley, CA | 2 |
| Volkan Adsay, N | 1 |
| Renaud, S | 1 |
| Santelmo, N | 1 |
| Falcoz, PE | 1 |
| Massard, G | 1 |
| Choi, IJ | 4 |
| Kim, CG | 2 |
| Oshima, A | 1 |
| Michalowski, A | 1 |
| Green, JE | 1 |
| Precetti, FA | 1 |
| Prieto, Mde C | 1 |
| Pietrantonio, A | 1 |
| González, B | 1 |
| Latiano, T | 1 |
| Aschele, C | 9 |
| Garufi, C | 5 |
| Bochicchio, A | 1 |
| Giaquinta, S | 3 |
| Torri, V | 2 |
| Bardelli, A | 1 |
| Gion, M | 1 |
| Chang, BW | 1 |
| Bhangu, A | 1 |
| Tiramula, R | 1 |
| Fioravanti, A | 1 |
| Orlandi, P | 1 |
| Di Desidero, T | 1 |
| Canu, B | 1 |
| Frumento, P | 3 |
| Di Paolo, A | 3 |
| Danesi, R | 6 |
| Bocci, G | 2 |
| Zhang, XL | 1 |
| Shi, HJ | 1 |
| Cui, SZ | 1 |
| Tang, YQ | 1 |
| Ba, MC | 1 |
| Voisin, T | 1 |
| El Firar, A | 1 |
| Fasseu, M | 1 |
| Rouyer-Fessard, C | 1 |
| Descatoire, V | 1 |
| Walker, F | 1 |
| Paradis, V | 1 |
| Bedossa, P | 1 |
| Henin, D | 1 |
| Lehy, T | 1 |
| Laburthe, M | 1 |
| Enzo, MV | 1 |
| Briarava, M | 1 |
| Maretto, I | 1 |
| Toppan, P | 3 |
| Min, JJ | 1 |
| Eich, HT | 1 |
| Stepien, A | 1 |
| Zimmermann, C | 1 |
| Hellmich, M | 1 |
| Hölscher, A | 1 |
| Müller, RP | 2 |
| McCaffrey, R | 1 |
| Bahtiyar, M | 1 |
| Kohorn, EI | 1 |
| Chambers, JT | 1 |
| Schwartz, PE | 1 |
| Chambers, SK | 1 |
| Vázquez-Mazón, F | 1 |
| Ramos, FJ | 1 |
| Countouriotis, AM | 1 |
| Ruiz-Garcia, A | 1 |
| Wei, G | 1 |
| Tursi, JM | 2 |
| Guillen-Ponce, C | 3 |
| Moore, M | 4 |
| Germond, C | 1 |
| Berg, W | 2 |
| Chen, BL | 2 |
| Jalava, T | 2 |
| Lebwohl, D | 2 |
| Meinhardt, G | 2 |
| Laurent, D | 2 |
| Trarbach, T | 3 |
| Major, P | 1 |
| Lloyd-Salvant, K | 1 |
| Pendergrass, K | 1 |
| Nogué, M | 1 |
| Salud, A | 2 |
| Vicente, P | 1 |
| Arriví, A | 1 |
| Roca, JM | 1 |
| Losa, F | 1 |
| Ponce, J | 1 |
| Safont, MJ | 1 |
| Guasch, I | 1 |
| Moreno, I | 1 |
| Ruiz, A | 1 |
| Leibold, T | 1 |
| Akhurst, TJ | 1 |
| Chessin, DB | 2 |
| Yeung, HW | 1 |
| Macapinlac, H | 2 |
| Riedel, E | 1 |
| Mazumdar, M | 1 |
| Wong, WD | 4 |
| Larson, SM | 1 |
| Bai, J | 1 |
| Kleyser-Sugrue, K | 1 |
| Nerenstone, SR | 1 |
| Welch, JP | 1 |
| Ben-David, K | 1 |
| Rossidis, G | 1 |
| Grobmyer, SR | 1 |
| Cendan, JC | 1 |
| Hochwald, SN | 1 |
| Rodriguez, NA | 1 |
| Ascaso, FJ | 1 |
| Teo, M | 1 |
| Swan, NC | 1 |
| McDermott, RS | 1 |
| Abrams, R | 1 |
| Gavoille, C | 2 |
| Komaki, RU | 1 |
| Wu, TT | 7 |
| Strassburg, J | 1 |
| Ruppert, R | 1 |
| Ptok, H | 1 |
| Maurer, C | 1 |
| Junginger, T | 3 |
| Merkel, S | 2 |
| Hermanek, P | 1 |
| Hodul, P | 1 |
| Klapman, J | 1 |
| Centeno, B | 1 |
| Helm, J | 1 |
| Valone, T | 1 |
| Springett, G | 1 |
| Koucky, K | 1 |
| Konturek, PC | 1 |
| Albrecht, H | 1 |
| Busse, D | 1 |
| Golcher, H | 1 |
| Schildberg, C | 1 |
| Janka, R | 1 |
| Neurath, MF | 1 |
| Yang, SS | 1 |
| Scarpa, M | 1 |
| Zanchettin, G | 1 |
| Bécouarn, Y | 5 |
| Khemissa-Akouz, F | 1 |
| Delbaldo, C | 2 |
| Montoto-Grillot, C | 1 |
| Thompson, LC | 3 |
| Shepherd, SF | 1 |
| O'Mahony, MS | 1 |
| Parmar, M | 1 |
| Gantzer, A | 1 |
| Regnier, S | 1 |
| Cosnes, A | 1 |
| Ortonne, N | 1 |
| Wolkenstein, P | 1 |
| Bagot, M | 1 |
| Duong, TA | 1 |
| Negri, FV | 2 |
| Bozzetti, C | 1 |
| Ardizzoni, A | 4 |
| Lagrasta, C | 1 |
| Crafa, P | 2 |
| Silini, EM | 1 |
| Xie, T | 1 |
| Li, DR | 1 |
| Mao, NQ | 1 |
| Liu, DS | 1 |
| Zuo, CT | 1 |
| Huang, DM | 1 |
| Zhao, WY | 1 |
| Chen, DY | 1 |
| Qi, Q | 1 |
| Li, JH | 1 |
| Jiang, HR | 1 |
| Garant, A | 1 |
| Des Groseilliers, S | 1 |
| Martin, L | 2 |
| Ferland, É | 1 |
| Vuong, T | 2 |
| Mamon, H | 1 |
| Pellen, MG | 1 |
| Sabri, S | 1 |
| Razack, A | 1 |
| Gilani, SQ | 1 |
| Jain, PK | 1 |
| Marsoni, S | 2 |
| Monges, G | 3 |
| Kim, GP | 1 |
| Allegra, C | 4 |
| Hongo, K | 1 |
| Tsuno, NH | 1 |
| Shuno, Y | 1 |
| Kaneko, M | 1 |
| Sunami, E | 4 |
| Kitayama, J | 2 |
| Nagawa, H | 7 |
| Kim, BC | 1 |
| Cionini, L | 2 |
| Cordio, S | 4 |
| Artale, S | 1 |
| Tagliagambe, A | 1 |
| Ambrosini, G | 1 |
| Rosetti, P | 1 |
| Bonetti, A | 2 |
| Negru, ME | 1 |
| Tronconi, MC | 2 |
| Silvano, G | 1 |
| Chiaulon, G | 1 |
| Gallo, M | 1 |
| Norman, G | 1 |
| Rice, S | 1 |
| Spackman, E | 1 |
| Stirk, L | 1 |
| Danso-Appiah, A | 1 |
| Suh, D | 1 |
| Palmer, S | 1 |
| Eastwood, A | 1 |
| Werner Kraus, T | 1 |
| Bruch, HP | 1 |
| Noack, F | 1 |
| Altmannsberger, HM | 2 |
| Rezzonico, S | 1 |
| Cappio, S | 1 |
| Doglioni, C | 2 |
| Pederson, AW | 1 |
| Salama, JK | 1 |
| Witt, ME | 1 |
| Stenson, KM | 1 |
| Blair, EA | 1 |
| Vokes, EE | 3 |
| Haraf, DJ | 2 |
| Abbas, F | 1 |
| Romano, O | 2 |
| Mayes, PA | 1 |
| Dolloff, NG | 1 |
| Daniel, CJ | 1 |
| Liu, JJ | 1 |
| Kuribayashi, K | 1 |
| Allen, JE | 1 |
| Jee, DI | 1 |
| Dorsey, JF | 1 |
| Liu, YY | 1 |
| Brown, JM | 1 |
| Furth, EE | 1 |
| Klein, PS | 1 |
| Sears, RC | 1 |
| Nishihara, C | 1 |
| Kuratsukuri, K | 1 |
| Kawashima, H | 1 |
| Nakatani, T | 2 |
| Wilson, BJ | 1 |
| Schatton, T | 1 |
| Zhan, Q | 1 |
| Gasser, M | 1 |
| Saab, KR | 1 |
| Schanche, R | 1 |
| Waaga-Gasser, AM | 1 |
| Gold, JS | 1 |
| Murphy, GF | 1 |
| Frank, MH | 1 |
| Frank, NY | 1 |
| Pera, M | 2 |
| Montagut, C | 2 |
| Iglesias, M | 1 |
| Reig, A | 1 |
| Balagué, C | 1 |
| Pétriz, L | 1 |
| Momblan, D | 1 |
| Bellmunt, J | 2 |
| Hollis, D | 5 |
| Kennecke, H | 1 |
| Berry, S | 2 |
| Zhou, C | 1 |
| Tankel, K | 1 |
| Easaw, J | 1 |
| Post, J | 1 |
| Hay, J | 1 |
| Catalano, V | 3 |
| Galluccio, N | 1 |
| Canestrari, E | 1 |
| Vincenzi, B | 1 |
| Bencardino, K | 1 |
| Ricci, V | 2 |
| Manzoni, M | 1 |
| Danova, M | 1 |
| Magnani, M | 1 |
| Yoh, T | 1 |
| Yamamichi, K | 1 |
| Oishi, M | 2 |
| Iwaki, R | 1 |
| Motohiro, T | 1 |
| Kobunai, T | 2 |
| Nozawa, K | 2 |
| Iinuma, H | 2 |
| Horie, H | 1 |
| Ikeuchi, H | 3 |
| Eshima, K | 1 |
| Edden, Y | 1 |
| Wexner, SD | 2 |
| Wolff, R | 2 |
| von Gall, C | 1 |
| Weitz, J | 1 |
| Haberkorn, U | 2 |
| Zalinski, S | 1 |
| Farges, O | 1 |
| Kawashima, R | 1 |
| Abei, M | 2 |
| Fukuda, K | 4 |
| Murata, T | 3 |
| Wakayama, M | 2 |
| Seo, E | 2 |
| Hasegawa, N | 1 |
| Obata, Y | 1 |
| Yokoyama, KK | 2 |
| Jeanneret, LA | 1 |
| Schneider, MP | 1 |
| Troxler, S | 1 |
| Bugnon, O | 1 |
| Lüthi, F | 1 |
| Kuramitsu, Y | 1 |
| Murakami, K | 5 |
| Ryozawa, S | 1 |
| Taba, K | 1 |
| Kaino, S | 1 |
| Sakaida, I | 1 |
| Bojic, M | 1 |
| Thallinger, CM | 1 |
| Maresch, J | 1 |
| Higashiyama, A | 1 |
| Abiko, S | 1 |
| Gotoh, J | 1 |
| Tamaki, T | 1 |
| Yonekawa, M | 1 |
| Kawamura, A | 1 |
| Tanino, M | 1 |
| Tse, VC | 1 |
| Ng, WT | 2 |
| Lee, V | 1 |
| Lee, AW | 1 |
| Chua, DT | 1 |
| Chau, J | 1 |
| McGhee, SM | 1 |
| Zhang, D | 2 |
| Takigawa, N | 1 |
| Tanimoto, Y | 1 |
| Ichihara, E | 1 |
| Hotta, K | 2 |
| Tabata, M | 1 |
| Tanimoto, M | 1 |
| Kiura, K | 3 |
| Thomas, CR | 5 |
| Medich, D | 2 |
| Pigazzi, A | 1 |
| Kang, MK | 2 |
| Kim, MS | 1 |
| Leite, D | 1 |
| Kater, FR | 1 |
| Afonso, S | 2 |
| Viani, G | 1 |
| Afonso, V | 1 |
| Stefano, E | 1 |
| Iqbal, S | 2 |
| Chang, RY | 1 |
| Potmesil, M | 1 |
| Chandra, A | 2 |
| Utate, M | 1 |
| Hiotis, S | 1 |
| Pachter, LH | 1 |
| Hochster, H | 4 |
| Muggia, F | 2 |
| Assaf, E | 1 |
| Verlinde-Carvalho, M | 1 |
| Grenier, J | 1 |
| Sellam, Z | 1 |
| Pouessel, D | 1 |
| Bouaita, L | 1 |
| Tayar, C | 1 |
| Paul, M | 1 |
| Culine, S | 1 |
| Cihan, Ş | 1 |
| Babacan, NA | 1 |
| Rothmann, F | 1 |
| Blau, I | 1 |
| Schwaner, I | 1 |
| Grothoff, M | 1 |
| Grieser, C | 1 |
| Martijnse, IS | 1 |
| Dudink, RL | 1 |
| Vermeer, TA | 1 |
| West, NP | 1 |
| van Lijnschoten, I | 1 |
| Quirke, P | 1 |
| Meng, H | 1 |
| Zhou, G | 1 |
| Xue, Z | 1 |
| De Jesus-Acosta, A | 1 |
| Oliver, GR | 1 |
| Blackford, A | 1 |
| Kinsman, K | 1 |
| Flores, EI | 1 |
| Wilfong, LS | 1 |
| Cosgrove, D | 1 |
| Chung, K | 2 |
| Créhange, G | 3 |
| Sakamoto, E | 1 |
| Maeda, A | 1 |
| Tojima, Y | 1 |
| Omiya, N | 1 |
| Ishizuka, N | 1 |
| Nakao, A | 2 |
| Goto, H | 1 |
| Xenidis, N | 1 |
| Chelis, L | 1 |
| Chamalidou, E | 1 |
| Dimopoulos, P | 1 |
| Michailidis, P | 1 |
| Tentes, A | 1 |
| Deftereos, S | 1 |
| Karanikas, M | 1 |
| Karayiannakis, A | 1 |
| Lin, LS | 1 |
| DiCarlo, B | 1 |
| Dao, KM | 1 |
| Wang, HJ | 1 |
| Elashoff, R | 1 |
| Ryba, N | 1 |
| Bang, SM | 7 |
| Amini, A | 1 |
| Sanati, H | 1 |
| Sola, J | 1 |
| Aristu, J | 3 |
| Rai, K | 1 |
| Tsushima, M | 1 |
| Kudo, K | 2 |
| Mizuta, M | 2 |
| Yonei, T | 1 |
| Yamadori, I | 1 |
| Bhattacharyya, M | 1 |
| Francis, J | 1 |
| Eddouadi, A | 1 |
| Lemoine, NR | 1 |
| Halldén, G | 1 |
| Verhage, RJ | 1 |
| van der Horst, S | 1 |
| van der Sluis, PC | 1 |
| McCleod, M | 1 |
| Shipley, DL | 1 |
| Barnes, EK | 1 |
| Infante, JR | 1 |
| Mohammed, TA | 1 |
| Dennie, T | 1 |
| Holen, KD | 2 |
| Serra, S | 2 |
| Kennedy, E | 1 |
| Gujral, DM | 1 |
| Hawkins, MA | 1 |
| Leonulli, BG | 1 |
| Shumaker, GC | 1 |
| Khandelwal, P | 2 |
| Smith, DA | 1 |
| Neubauer, MA | 3 |
| Mehta, N | 1 |
| Watkins, DL | 1 |
| Zhang, K | 1 |
| Yassine, MR | 1 |
| Ferrarotto, R | 1 |
| Pathak, P | 1 |
| Agarwal, A | 1 |
| Overman, M | 1 |
| Wong, NS | 1 |
| Fernando, NH | 3 |
| Honeycutt, W | 4 |
| Madoff, RD | 2 |
| Pan, SY | 1 |
| Chen, QQ | 1 |
| Gao, XP | 1 |
| Ocvirk, J | 1 |
| Music, M | 1 |
| Bracko, M | 1 |
| Edhemovic, I | 1 |
| Brecelj, E | 1 |
| Kropivnik, M | 1 |
| Omejc, M | 1 |
| Al-Niaimi, F | 1 |
| Lyon, C | 1 |
| Van Hazel, G | 5 |
| Wong, A | 4 |
| Gilberg, F | 1 |
| Latkauskas, T | 1 |
| Pauzas, H | 1 |
| Gineikiene, I | 1 |
| Janciauskiene, R | 1 |
| Juozaityte, E | 2 |
| Saladzinskas, Z | 1 |
| Tamelis, A | 1 |
| Pavalkis, D | 1 |
| Baldi, GG | 1 |
| Tuzi, A | 1 |
| Brunetti, IM | 1 |
| Ricci, S | 1 |
| Dai, ZK | 1 |
| Yang, XS | 1 |
| Yu, LM | 1 |
| Crea, F | 1 |
| Paolicchi, E | 1 |
| Farrar, WL | 1 |
| Zhang, RX | 1 |
| Narang, AK | 1 |
| Azzopardi, N | 1 |
| Ternant, D | 1 |
| Piller, F | 1 |
| Gouilleux-Gruart, V | 1 |
| Vignault-Desvignes, C | 1 |
| Watier, H | 1 |
| Paintaud, G | 1 |
| Sbitti, Y | 1 |
| Essaidi, I | 1 |
| Debbagh, A | 1 |
| Kadiri, H | 1 |
| Oukabli, M | 1 |
| Moussaid, Y | 1 |
| Slimani, K | 1 |
| Fetohi, M | 1 |
| Elkaoui, H | 1 |
| Albouzidi, A | 1 |
| Mahi, M | 1 |
| Ali, AA | 1 |
| Ichou, M | 1 |
| Errihani, H | 1 |
| Warnecke-Eberz, U | 3 |
| Grimminger, PP | 1 |
| Chen, LC | 1 |
| Wu, YH | 1 |
| Liu, IH | 1 |
| Ho, CL | 1 |
| Chang, CH | 1 |
| Lan, KL | 1 |
| Ting, G | 1 |
| Lee, TW | 1 |
| Shien, JH | 1 |
| Egashira, A | 1 |
| Toyama, T | 1 |
| Ohga, T | 1 |
| Kohakura, F | 1 |
| Higashi, H | 5 |
| Kohnoe, S | 4 |
| Engels, B | 1 |
| Tournel, K | 1 |
| Everaert, H | 1 |
| Hoorens, A | 1 |
| Sermeus, A | 1 |
| Christian, N | 1 |
| Storme, G | 1 |
| Verellen, D | 1 |
| De Ridder, M | 1 |
| Kuo, YH | 1 |
| Tien, YW | 1 |
| Hsu, C | 1 |
| Kuo, SH | 1 |
| Cheng, AL | 6 |
| Leichman, LP | 3 |
| Goldman, BH | 1 |
| Bohanes, PO | 1 |
| Billingsley, KG | 1 |
| Corless, CL | 1 |
| Gold, PJ | 1 |
| Benedetti, JK | 4 |
| Danenberg, KD | 7 |
| Bayraktar, UD | 1 |
| Bayraktar, S | 1 |
| Hosein, P | 1 |
| Chen, E | 2 |
| Koniaris, LG | 1 |
| Rocha-Lima, CM | 1 |
| Chasen, M | 2 |
| Marcus, V | 2 |
| Hickeson, M | 2 |
| Artho, G | 2 |
| Thirlwell, MP | 3 |
| Maréchal, R | 2 |
| Vos, B | 1 |
| Polus, M | 1 |
| Demetter, P | 1 |
| Demols, A | 1 |
| Franchimont, D | 1 |
| Verset, G | 1 |
| Van Houtte, P | 1 |
| Van de Stadt, J | 1 |
| Ren, JH | 1 |
| Cui, CX | 1 |
| Li, JL | 1 |
| Wang, JW | 1 |
| Balachandran, A | 1 |
| Bhosale, P | 1 |
| Abdalla, EK | 1 |
| Abbruzzese, J | 1 |
| Chopin-Laly, X | 1 |
| Charnsangavej, C | 5 |
| Devun, F | 1 |
| Bousquet, G | 1 |
| Biau, J | 1 |
| Herbette, A | 1 |
| Roulin, C | 1 |
| Berger, F | 1 |
| Sun, JS | 1 |
| Robine, S | 1 |
| Dutreix, M | 1 |
| Martínez-Monge, R | 3 |
| Moreno, M | 1 |
| Ramos, LI | 1 |
| Nuñez, J | 1 |
| Cambeiro, M | 1 |
| Gaztañaga, M | 1 |
| Abu-Ghanem, S | 1 |
| Novik, EF | 1 |
| Abu-Ghanem, Y | 1 |
| Man, S | 1 |
| Shelef, I | 1 |
| Bouchbika, Z | 1 |
| Kouto, H | 1 |
| Baruch-Hennequin, V | 1 |
| Munoz, N | 1 |
| Cojean-Zelek, I | 1 |
| Houdart, R | 1 |
| Valleur, P | 1 |
| Maylin, C | 1 |
| Hennequin, C | 2 |
| Yu, C | 1 |
| Zhu, W | 1 |
| Chung, HJ | 1 |
| Tabe, Y | 1 |
| Suto, T | 1 |
| Werner, D | 1 |
| Steinmetz, K | 1 |
| Esch, A | 1 |
| Scotté, M | 1 |
| Hamidou, H | 1 |
| Paillot, B | 2 |
| Michot, F | 1 |
| Bickenbach, KA | 1 |
| Tang, LH | 2 |
| Goodman, K | 1 |
| Brennan, MF | 3 |
| Dematteo, RP | 1 |
| Allen, PJ | 1 |
| Semrau, R | 1 |
| Herzog, SL | 1 |
| Damodaran, S | 1 |
| Bellavia, T | 1 |
| Sait, SN | 1 |
| Wang, ES | 1 |
| Wetzler, M | 1 |
| Khushalani, NI | 2 |
| Chakravarty, T | 1 |
| Briere, TM | 1 |
| Beddar, AS | 1 |
| Mok, H | 1 |
| Reed, VK | 1 |
| Xu, HD | 1 |
| Pan, SD | 1 |
| Yue, JH | 1 |
| Liu, JR | 1 |
| Wahba, HA | 1 |
| El-Hadaad, HA | 1 |
| Roshdy, S | 1 |
| Rose, MG | 1 |
| Perkal, MF | 1 |
| Chao, HH | 1 |
| Hwang, JH | 1 |
| Lim, MC | 1 |
| Seo, SS | 1 |
| Kang, S | 1 |
| Jiang, R | 1 |
| Bellot, GL | 1 |
| Tan, WH | 1 |
| Tay, LL | 1 |
| Koh, D | 1 |
| Lau, PC | 1 |
| Zheng, SF | 1 |
| Yu, SC | 1 |
| Koh, CE | 1 |
| Bu, ZD | 1 |
| Wu, AW | 1 |
| Zhang, LH | 2 |
| Zong, XL | 1 |
| Zhang, XP | 1 |
| Li, JY | 1 |
| Hu, Y | 2 |
| Abelson, JA | 1 |
| Murphy, JD | 1 |
| Minn, AY | 1 |
| Chung, M | 4 |
| Ford, JM | 4 |
| Kunz, P | 1 |
| Norton, JA | 1 |
| Visser, BC | 1 |
| Poultsides, GA | 1 |
| Shintani, Y | 1 |
| Funakoshi, Y | 1 |
| Matsumura, A | 1 |
| Ohta, M | 3 |
| Okumura, M | 1 |
| Ide, Y | 1 |
| Watayo, Y | 1 |
| Amagasa, H | 1 |
| Ganno, H | 1 |
| Fukuda, A | 1 |
| Nagahama, T | 3 |
| Okada, Y | 4 |
| Bruera, G | 1 |
| Giuliante, F | 2 |
| Nuzzo, G | 2 |
| Antonucci, A | 1 |
| Ricevuto, E | 1 |
| Kauppi, JT | 1 |
| Oksala, N | 1 |
| Salo, JA | 1 |
| Helin, H | 1 |
| Karhumäki, L | 1 |
| Kemppainen, J | 1 |
| Sihvo, EI | 1 |
| Räsänen, JV | 1 |
| Zanow, J | 1 |
| Leistner, Y | 1 |
| Ludewig, S | 1 |
| Rauchfuss, F | 1 |
| Settmacher, U | 2 |
| Heintges, T | 1 |
| Stoll, C | 1 |
| Modest, DP | 1 |
| Neumann, J | 1 |
| Kim, YW | 2 |
| Noh, SI | 1 |
| Yeh, TS | 1 |
| Button, P | 1 |
| Sirzén, F | 1 |
| Ferte, C | 1 |
| Bourgeois, V | 1 |
| Peugniez, C | 1 |
| Lindet, C | 1 |
| Ladrat, L | 1 |
| Triboulet, JP | 4 |
| Cho, YH | 1 |
| Hong Lee, M | 1 |
| Yoo, MW | 1 |
| Bang, HY | 1 |
| Yoon, SY | 2 |
| Milandri, C | 5 |
| Magli, A | 1 |
| Ben Aharon, I | 1 |
| Purim, O | 2 |
| Kundel, Y | 1 |
| Brenner, R | 1 |
| Gordon, N | 1 |
| Sulkes, A | 4 |
| Brenner, B | 3 |
| Kim, GM | 1 |
| Nam, BH | 1 |
| Inal, A | 2 |
| Kaplan, MA | 3 |
| Kucukoner, M | 2 |
| Isikdogan, A | 3 |
| Gong, L | 1 |
| Lou, JY | 1 |
| Zhang, JW | 1 |
| Peng, ZL | 1 |
| Zhang, JQ | 1 |
| Hooker, CM | 1 |
| Brock, MV | 1 |
| Shin, J | 1 |
| How, R | 1 |
| Franco, N | 1 |
| Prevas, H | 1 |
| Hulbert, A | 1 |
| Yang, SC | 2 |
| Sanguanrungsirikul, S | 1 |
| Manusirivithaya, S | 1 |
| Burtness, B | 3 |
| Mintzer, D | 2 |
| Ruth, K | 1 |
| Tuttle, H | 1 |
| Sylvester, J | 1 |
| Kim, SD | 1 |
| Lee, HY | 1 |
| Shim, JW | 1 |
| Baek, SH | 1 |
| Zabel, BA | 1 |
| Bae, YS | 1 |
| Wang, PL | 1 |
| Cheng, YB | 1 |
| Kuerban, G | 1 |
| Chang, YY | 1 |
| Vietor, NO | 1 |
| George, BJ | 1 |
| Yoon, DH | 1 |
| Wieneke, J | 1 |
| Kienle, P | 1 |
| Welzel, G | 1 |
| Brade, J | 1 |
| Horisberger, K | 2 |
| Wenz, F | 3 |
| Hofmann, WK | 1 |
| Tikidzhieva, A | 1 |
| Benner, A | 1 |
| Michel, S | 1 |
| Formentini, A | 2 |
| Dippold, W | 2 |
| von Knebel Doeberitz, M | 2 |
| Kloor, M | 1 |
| DU, JP | 1 |
| Li, SJ | 1 |
| Zhai, LP | 1 |
| Yang, XY | 1 |
| Wu, ZT | 1 |
| Martin, ST | 1 |
| Heneghan, HM | 1 |
| Gasent Blesa, JM | 1 |
| Garde Noguera, J | 1 |
| Laforga Canales, JB | 1 |
| Giner Bosch, V | 1 |
| Alberola, A | 1 |
| Soler Tortosa, M | 1 |
| Peris Godoy, M | 1 |
| Sanchez, JL | 1 |
| Provencio Pulla, M | 1 |
| Alberola Candel, V | 1 |
| Harder, J | 1 |
| Ihorst, G | 1 |
| Buechler, P | 1 |
| Kloeppel, G | 1 |
| Röcken, C | 2 |
| Endlicher, E | 1 |
| Reinacher-Schick, A | 1 |
| Schmoor, C | 1 |
| Connolly, S | 1 |
| Scott, P | 1 |
| Cochrane, D | 1 |
| Harte, R | 1 |
| Dong, B | 1 |
| Du, H | 1 |
| Yuan, P | 1 |
| Wu, A | 1 |
| Bedford, MR | 1 |
| Anathhanam, S | 1 |
| Saleh, D | 1 |
| Hickson, A | 1 |
| McGregor, AK | 1 |
| Boyle, K | 1 |
| Burke, D | 2 |
| Winkler, J | 1 |
| Zipp, L | 1 |
| Knoblich, J | 1 |
| Zimmermann, F | 1 |
| Carpenter, WR | 1 |
| Meyer, AM | 1 |
| Qaqish, B | 1 |
| Weiner, BJ | 1 |
| Kanzaki, M | 1 |
| Wada, J | 1 |
| Nakatsuka, A | 1 |
| Teshigawara, S | 1 |
| Inoue, K | 9 |
| Terami, T | 1 |
| Katayama, A | 1 |
| De Hertogh, G | 1 |
| Fieuws, S | 1 |
| Yi, JH | 1 |
| Yim, DS | 1 |
| Schönekaes, K | 2 |
| Rübe, C | 2 |
| Sulkowski, U | 2 |
| Preusser, P | 4 |
| Prott, FJ | 2 |
| Willich, N | 3 |
| Dewdney, A | 2 |
| Liu, YW | 1 |
| Qiu, F | 2 |
| Zhan, ZY | 1 |
| Feng, M | 1 |
| Yan, J | 1 |
| Zhao, JG | 1 |
| Xiong, JP | 3 |
| Mutyala, V | 1 |
| Bains, S | 1 |
| Patil, C | 1 |
| Madhavarao, B | 1 |
| Maggiulli, E | 1 |
| Broggi, S | 1 |
| Gianolini, S | 1 |
| Salvetti, C | 1 |
| Di Muzio, NG | 1 |
| Kim, KK | 1 |
| Lange, TS | 1 |
| Singh, RK | 1 |
| Brard, L | 1 |
| Moore, RG | 1 |
| Matsutani, T | 1 |
| Sasajima, K | 1 |
| Yokoyama, T | 2 |
| Matsushita, A | 1 |
| Hirakata, A | 1 |
| Takao, Y | 1 |
| Umakoshi, M | 1 |
| Hayakawa, T | 1 |
| Hosone, M | 1 |
| Uchida, E | 2 |
| Radziwon-Balicka, A | 1 |
| Medina, C | 1 |
| O'Driscoll, L | 1 |
| Treumann, A | 1 |
| Bazou, D | 1 |
| Inkielewicz-Stepniak, I | 1 |
| Radomski, A | 1 |
| Jow, H | 1 |
| Radomski, MW | 1 |
| Chang, KJ | 3 |
| Reid, T | 1 |
| Senzer, N | 1 |
| Pinto, H | 1 |
| Chak, A | 1 |
| Soetikno, R | 1 |
| Tsuji, Y | 3 |
| Nagase, M | 2 |
| Miyata, Y | 1 |
| Mizutani, N | 1 |
| Hashigaki, S | 1 |
| Short, M | 1 |
| Halkett, G | 1 |
| Reece, W | 2 |
| Borg, M | 1 |
| Zissiadis, Y | 1 |
| Márquez, E | 1 |
| Rodríguez, E | 1 |
| Pascual, J | 1 |
| Guo, M | 1 |
| Gradishar, WJ | 1 |
| Perez, EA | 3 |
| Sledge, GW | 1 |
| Utsunomiya, T | 1 |
| Utsunomiya, H | 1 |
| Peer, CJ | 1 |
| McManus, TJ | 1 |
| Petros, WP | 2 |
| Bleiberg, H | 9 |
| Vandebroek, A | 1 |
| Deleu, I | 1 |
| Vergauwe, P | 2 |
| Rezaei Kalantari, H | 1 |
| Efira, A | 1 |
| Seshimo, K | 1 |
| Ikeda, H | 6 |
| Yamamura, M | 1 |
| Kodera, M | 1 |
| Fujita, H | 5 |
| Shibagaki, K | 1 |
| Takita, K | 1 |
| Nishie, M | 1 |
| Iwakawa, K | 1 |
| Smalley, SR | 4 |
| Estes, NC | 4 |
| Goldman, B | 1 |
| Jessup, JM | 5 |
| Stemmermann, GN | 2 |
| Gómez-Martín, C | 1 |
| Gil-Martín, M | 1 |
| Núñez, JA | 1 |
| Puig, M | 1 |
| Damin, DC | 1 |
| Rosito, MA | 1 |
| Contu, PC | 1 |
| Tarta, C | 1 |
| Ferreira, PR | 1 |
| Kliemann, LM | 1 |
| Schwartsmann, G | 1 |
| Bauer, KM | 1 |
| Lambert, PA | 1 |
| Hummon, AB | 1 |
| van der Zee, JA | 1 |
| Dicheva, BM | 1 |
| Seynhaeve, AL | 1 |
| Koning, GA | 1 |
| Eggermont, AM | 2 |
| Ten Hagen, TL | 1 |
| Goyer, P | 1 |
| Benoist, S | 1 |
| Hajjam, ME | 1 |
| Penna, C | 2 |
| Nordlinger, B | 7 |
| Zafar, SF | 1 |
| Orsucci, D | 1 |
| Pizzanelli, C | 1 |
| Alì, G | 1 |
| Calabrese, R | 1 |
| Ricci, G | 1 |
| Lenzi, P | 1 |
| Petrozzi, L | 1 |
| Moretti, P | 1 |
| Siciliano, G | 1 |
| Treska, V | 1 |
| Safranek, J | 1 |
| Lysak, D | 1 |
| Mirka, H | 1 |
| Skalicky, T | 1 |
| Slauf, F | 1 |
| Hes, O | 1 |
| Shatz, M | 1 |
| Menendez, D | 1 |
| Resnick, MA | 1 |
| Phillips, BE | 1 |
| Tubbs, RR | 1 |
| Plesec, T | 1 |
| Kofoed, SC | 1 |
| Lundsgaard, M | 1 |
| Ellemann, AC | 1 |
| Svendsen, LB | 1 |
| Dellas, K | 1 |
| Richter, M | 1 |
| Park, DH | 1 |
| Lee, SK | 1 |
| Kim, MH | 1 |
| Han, DJ | 1 |
| Capitain, O | 2 |
| Asevoaia, A | 1 |
| Poirier, AL | 2 |
| Florschütz, A | 1 |
| Mantovani-Löffler, L | 1 |
| Kneba, M | 1 |
| Glanemann, M | 1 |
| Schlattmann, P | 1 |
| Gahn, B | 1 |
| Sung, EZ | 1 |
| Arasaradnam, RP | 1 |
| Jarvie, EM | 1 |
| James, S | 1 |
| Goodyear, SJ | 1 |
| Borman, RA | 1 |
| Snead, D | 1 |
| Sanger, GJ | 1 |
| Nwokolo, CU | 1 |
| Toyama, Y | 1 |
| Ushigome, T | 1 |
| Watanabe, K | 3 |
| Onda, S | 1 |
| Saito, R | 2 |
| Yoshida, S | 6 |
| Kawahara, H | 2 |
| Yanagisawa, S | 1 |
| Przyborek, M | 1 |
| Schleucher, N | 3 |
| Vanhoefer, U | 5 |
| Lu, Z | 1 |
| Rottenberg, Y | 1 |
| Kadouri, L | 1 |
| Wygoda, M | 1 |
| Rivkind, A | 1 |
| Vainer, GW | 1 |
| Peretz, T | 1 |
| Hubert, A | 1 |
| Guo, WJ | 2 |
| Wang, AY | 1 |
| Levy, A | 1 |
| Chargari, C | 1 |
| Huguet, F | 2 |
| Védrine, L | 1 |
| Deutsch, E | 1 |
| Verbeke, CS | 1 |
| Unek, T | 1 |
| Akman, T | 2 |
| Atilla, K | 1 |
| Ellidokuz, H | 1 |
| Bora, S | 1 |
| Sarioglu, S | 1 |
| Glockzin, G | 1 |
| von Breitenbuch, P | 1 |
| Lee, LK | 1 |
| Lin, TC | 4 |
| Wang, HS | 3 |
| Yen, CC | 3 |
| Liu, JH | 3 |
| Tzeng, CH | 3 |
| Krstovski, N | 1 |
| Dokmanovic, L | 1 |
| Lazic, J | 1 |
| Rodic, P | 1 |
| Paripovic, L | 1 |
| Janic, D | 1 |
| Schneider, BJ | 1 |
| Hayman, JA | 1 |
| Chang, AC | 1 |
| Orringer, MB | 5 |
| Pickens, A | 1 |
| Pan, CC | 1 |
| Urba, SG | 6 |
| Arias, F | 1 |
| del Moral-Avila, R | 1 |
| Gómez-Millán, J | 1 |
| Jiménez, E | 1 |
| Wals, A | 2 |
| Tisaire, JL | 1 |
| Alcantara, MP | 1 |
| Margolin, DA | 1 |
| Cai, F | 1 |
| Lecumberri, E | 1 |
| Clerc, A | 1 |
| Dupertuis, YM | 1 |
| Pichard, C | 1 |
| Ayez, N | 1 |
| Alberda, WJ | 1 |
| Burger, JW | 1 |
| Dwarkasing, RS | 1 |
| Willemssen, FE | 1 |
| Verhoef, C | 1 |
| Kwak, JY | 1 |
| Jang, SJ | 1 |
| Ismael, G | 1 |
| Hegg, R | 1 |
| Muehlbauer, S | 1 |
| Heinzmann, D | 1 |
| Lum, B | 1 |
| Kim, SB | 1 |
| Pienkowski, T | 1 |
| Jackisch, C | 1 |
| Iqbal, MS | 1 |
| Hardman, J | 1 |
| Ercan, S | 1 |
| Seker, M | 1 |
| Yilmaz, BE | 1 |
| Orcun, A | 1 |
| Martinez-Lapiscina, EH | 1 |
| Erro, ME | 1 |
| Cabada, T | 1 |
| Tuñón, T | 1 |
| Medeni, M | 1 |
| Ambrosy, AP | 1 |
| Kunz, PL | 1 |
| Witteles, RM | 1 |
| Flaherty, AM | 1 |
| Peddi, PF | 1 |
| Lubner, S | 1 |
| McWilliams, R | 1 |
| Picus, J | 5 |
| Sorscher, SM | 2 |
| Menias, C | 1 |
| Linehan, D | 1 |
| Rousseau, B | 1 |
| Rebours, V | 1 |
| Bengrine-Lefèvre, L | 1 |
| Lévy, P | 1 |
| Raymond, E | 6 |
| Ruszniewski, P | 2 |
| Golden, DW | 1 |
| Novak, CJ | 1 |
| Liauw, SL | 1 |
| Ryu, KW | 1 |
| Quaroni, L | 1 |
| Casson, AG | 2 |
| Kim, YB | 2 |
| Choi, JJ | 1 |
| Lee, I | 2 |
| Cho, JH | 1 |
| Niu, J | 1 |
| Mims, MP | 1 |
| Pavlidis, N | 4 |
| Gentil, J | 1 |
| Tsuruta, Y | 1 |
| Takamori, S | 1 |
| Shishikura, Y | 1 |
| Schroeder, C | 1 |
| von Weyhern, CH | 1 |
| Weinmann, M | 1 |
| Bamberg, M | 1 |
| Berger, B | 1 |
| Hoffmann, K | 4 |
| Bartsch, D | 1 |
| Klein, J | 1 |
| Mansmann, U | 2 |
| Capussotti, L | 1 |
| Kunz, R | 1 |
| Uguen, T | 1 |
| Tchoundeu, B | 1 |
| Chattopadhyay, S | 1 |
| Mondal, SK | 1 |
| Saha, A | 1 |
| Manna, A | 1 |
| Kundu, SK | 1 |
| Yoshimi, K | 1 |
| Hashimoto, T | 2 |
| Niwa, Y | 1 |
| Serikawa, T | 1 |
| Kuramoto, T | 1 |
| Cho, NY | 1 |
| Park, JG | 2 |
| Kang, GH | 1 |
| Nagashima, T | 2 |
| Niiro, M | 1 |
| Hirayama, K | 1 |
| Date, S | 1 |
| Okihara, K | 1 |
| Mukaisho, K | 1 |
| Truong, TG | 1 |
| Jones, KA | 1 |
| Dito, E | 1 |
| Ong, A | 1 |
| Nakamura, Y | 4 |
| Weinreich, J | 1 |
| Schott, TC | 1 |
| Königsrainer, I | 1 |
| Küper, M | 1 |
| Schott, H | 1 |
| Bilici, M | 1 |
| Cetin, B | 2 |
| Ekinci, AS | 1 |
| Cayir, K | 2 |
| Yetisyigit, T | 1 |
| Tekin, SB | 1 |
| Eroglu, C | 1 |
| Turhal, S | 1 |
| Salman, T | 1 |
| Schwartzman, AD | 1 |
| Sethi, R | 1 |
| Smith, R | 2 |
| Focan, C | 3 |
| Kreutz, F | 1 |
| Graas, MP | 1 |
| Longrée, L | 1 |
| Focan-Henrard, D | 1 |
| Demolin, G | 1 |
| Moeneclaey, N | 1 |
| Rostom, Y | 1 |
| Zaghloul, H | 1 |
| Khedr, G | 1 |
| El-Shazly, W | 1 |
| Abd-Allah, D | 1 |
| Clavier, JB | 1 |
| Antoni, D | 2 |
| Atlani, D | 1 |
| Schumacher, C | 1 |
| Noel, G | 1 |
| Tufan, G | 1 |
| Stevenson, L | 1 |
| Middleton, GW | 1 |
| Evans, L | 1 |
| Ford, D | 1 |
| Plummer, C | 1 |
| Blazeby, JM | 2 |
| Griffin, M | 4 |
| Eatock, MM | 2 |
| Bampton, CL | 1 |
| Strickland, AH | 3 |
| Swieboda-Sadlej, A | 1 |
| Nanayakkara, N | 1 |
| Sun, YN | 1 |
| Zhong, ZD | 1 |
| Bass, MB | 1 |
| Adewoye, AH | 1 |
| Francis, WP | 1 |
| Ho, T | 1 |
| Xuan, Y | 1 |
| Lee, G | 1 |
| Shim, W | 1 |
| Yun, J | 1 |
| Ham, IH | 1 |
| Helbling, D | 1 |
| Gautschi, O | 1 |
| Bosman, F | 1 |
| Gloor, B | 1 |
| Burkhard, R | 2 |
| Madlung, A | 1 |
| Rauch, D | 1 |
| Borner, M | 1 |
| Baertschi, D | 1 |
| Yan, P | 1 |
| Benhattar, J | 2 |
| Leibundgut, EO | 1 |
| Bougel, S | 1 |
| Markoutsaki, N | 1 |
| Roussel, H | 1 |
| Rahmi, G | 1 |
| Van der Stiegel, M | 1 |
| Palazzo, L | 1 |
| Fabre, M | 1 |
| Cuenod, CA | 1 |
| Liang, JW | 1 |
| Zhou, ZX | 1 |
| Hu, JJ | 1 |
| Zhao, P | 2 |
| Yu, DS | 1 |
| Wang, GP | 1 |
| Sana, J | 1 |
| Gombosova, J | 1 |
| Nekvindova, J | 1 |
| Radova, L | 1 |
| Martella, B | 1 |
| Cardin, F | 1 |
| Lorenzetti, R | 1 |
| Terranova, C | 1 |
| Amato, B | 1 |
| Militello, C | 1 |
| Pioche, M | 1 |
| Aguero Garcete, G | 1 |
| Lépilliez, V | 1 |
| Nozières, C | 1 |
| Lombard-Bohas, C | 1 |
| Saurin, JC | 1 |
| Hong, J | 1 |
| Cho, EK | 7 |
| Park, YH | 5 |
| Lee, WK | 3 |
| Schmutz, JL | 1 |
| Trechot, P | 1 |
| Krug, S | 1 |
| Michl, P | 1 |
| Olszewski, AJ | 1 |
| Grossbard, ML | 3 |
| Chung, MS | 1 |
| Chalasani, SB | 1 |
| Kozuch, PS | 1 |
| Hernando-Requejo, O | 1 |
| García-García, E | 1 |
| Morelli, P | 1 |
| Rubio, C | 1 |
| López-Ríos, F | 1 |
| Muro, A | 1 |
| López, U | 1 |
| Prados, S | 1 |
| Bérille, J | 1 |
| Tan, S | 1 |
| Kligerman, S | 1 |
| Feigenberg, S | 1 |
| D'Souza, WD | 1 |
| Knox, JJ | 5 |
| Bianchi, R | 1 |
| Mayr, M | 1 |
| Schulte, N | 1 |
| Belle, S | 1 |
| Krause, A | 1 |
| Schmid, RM | 1 |
| Mulcahy, M | 1 |
| Obel, J | 1 |
| Rocha-Lima, CS | 1 |
| Iwata, T | 1 |
| Hanada, S | 1 |
| Toda, M | 1 |
| Reis-Filho, JS | 1 |
| Waddell, TS | 1 |
| Noor, D | 1 |
| Stenning, S | 2 |
| Sharif, S | 1 |
| Petrelli, NJ | 6 |
| Lopa, SH | 1 |
| Wolmark, N | 7 |
| Salmenkylä, S | 1 |
| Kouri, M | 2 |
| Pukkala, E | 1 |
| Luukkonen, P | 1 |
| Hyöty, M | 1 |
| Pääkkönen, M | 1 |
| Mäkelä, J | 1 |
| Mustonen, H | 1 |
| Järvinen, HJ | 1 |
| Naito, Y | 2 |
| Fukushima, H | 1 |
| Takano, T | 1 |
| Derbel, O | 1 |
| Penet, AS | 1 |
| Stella, M | 1 |
| Méeus, P | 1 |
| Orlandini, F | 1 |
| Pérol, M | 1 |
| Murakami, N | 2 |
| Morota, M | 1 |
| Sumi, M | 2 |
| Itami, J | 1 |
| Dréanic, J | 1 |
| Mir, O | 1 |
| Boudou-Rouquette, P | 1 |
| Dhooge, M | 1 |
| Goldwasser, F | 2 |
| Lee, MA | 1 |
| Choi, IS | 2 |
| Rousseau, D | 1 |
| Denis, F | 1 |
| Girault, S | 1 |
| Paumier, A | 1 |
| Hamy, A | 1 |
| Mahé, MA | 2 |
| Mesgouez-Nebout, N | 1 |
| Smit, JK | 1 |
| Muijs, CT | 1 |
| Burgerhof, JG | 1 |
| Paardekooper, G | 1 |
| Timmer, PR | 1 |
| Muller, K | 1 |
| Woutersen, D | 1 |
| Mul, VE | 1 |
| van Dijk, BA | 1 |
| Langendijk, JA | 1 |
| Plukker, JT | 3 |
| Pasini, F | 1 |
| Zhao, E | 1 |
| Andalib, A | 1 |
| Shankaran, V | 1 |
| Mummy, D | 1 |
| Koepl, L | 1 |
| Blough, D | 1 |
| Yim, YM | 1 |
| Yu, E | 2 |
| Ramsey, S | 1 |
| Klaver, YL | 1 |
| Morris, DL | 4 |
| Huang, DZ | 1 |
| Yan, Z | 1 |
| Zhuang, ZX | 1 |
| Wan, HP | 1 |
| Deng, T | 1 |
| Zheng, RS | 1 |
| Hu, CH | 1 |
| Wang, ML | 1 |
| Meng, JC | 1 |
| Ba, Y | 1 |
| Guan, Z | 1 |
| Liang, L | 1 |
| Graves, CA | 2 |
| Camphausen, K | 2 |
| Parameswaran, R | 1 |
| Titcomb, DR | 1 |
| Blencowe, NS | 1 |
| Berrisford, RG | 1 |
| Wajed, SA | 1 |
| Streets, CG | 1 |
| Hollowood, AD | 1 |
| Krysztopik, R | 1 |
| Barham, CP | 1 |
| Anter, AH | 1 |
| Abdel-Latif, RM | 1 |
| Kilic, D | 1 |
| Yalman, D | 1 |
| Aksu, G | 1 |
| Atasoy, BM | 1 |
| Igdem, S | 1 |
| Dincbas, FO | 1 |
| Korbakis, D | 1 |
| Fragoulis, EG | 1 |
| Scorilas, A | 1 |
| Tian, YF | 1 |
| Lee, HH | 1 |
| Shiue, YL | 1 |
| Huang, HY | 1 |
| Pan, HY | 1 |
| Chen, SH | 2 |
| Pacelli, F | 1 |
| Sanchez, AM | 1 |
| Covino, M | 1 |
| Tortorelli, AP | 1 |
| Bossola, M | 1 |
| Gambacorta, MA | 3 |
| Doglietto, GB | 1 |
| Chen, YN | 1 |
| Tan, BB | 1 |
| Zhao, XF | 1 |
| Jiao, ZK | 1 |
| Zhang, ZD | 1 |
| Chang, SL | 1 |
| Shi, MM | 1 |
| Xiong, YL | 1 |
| Jia, XS | 1 |
| Wang, EH | 1 |
| Suresh, AV | 1 |
| Manikhas, G | 1 |
| Rogowski, W | 1 |
| Huang, X | 1 |
| Wu, B | 1 |
| Warner, D | 1 |
| Jain, R | 1 |
| Bossi, P | 2 |
| Perrone, F | 1 |
| Miceli, R | 1 |
| Cantù, G | 2 |
| Orlandi, E | 1 |
| Fallai, C | 1 |
| Locati, LD | 2 |
| Cortelazzi, B | 1 |
| Quattrone, P | 2 |
| Potepan, P | 1 |
| Licitra, L | 2 |
| Pilotti, S | 2 |
| Wood, MD | 1 |
| Zaki, BI | 1 |
| Gordon, SR | 1 |
| Sutton, JE | 1 |
| Gui, J | 1 |
| Bubis, JA | 1 |
| Dragnev, KH | 1 |
| Rigas, JR | 1 |
| Hwang, JA | 1 |
| Hong, SH | 1 |
| Ono, CR | 1 |
| Lynn, P | 1 |
| Grosso, F | 1 |
| Mandalà, M | 1 |
| Maglione, V | 1 |
| Berretta, L | 1 |
| Mariani, N | 1 |
| Rossi, M | 1 |
| Piovano, PL | 1 |
| Drago, D | 1 |
| Summa, M | 1 |
| Franzone, P | 1 |
| Musante, F | 1 |
| Spinoglio, G | 1 |
| Musola, M | 1 |
| Cassandrini, PA | 1 |
| Venturini, M | 1 |
| Ritchim, P | 1 |
| Charkrabandhu, T | 1 |
| Jongraksat, W | 1 |
| Pucci, F | 4 |
| Camisa, R | 2 |
| Bui, S | 1 |
| Galdy, S | 1 |
| Leonardi, F | 1 |
| Anselmi, E | 1 |
| Losardo, PL | 1 |
| Roncoroni, L | 1 |
| Dell'abate, P | 1 |
| Vigil, C | 1 |
| Yaremko, BP | 1 |
| Palma, DA | 1 |
| Erickson, AL | 1 |
| Pierce, G | 1 |
| Malthaner, RA | 1 |
| Inculet, RI | 1 |
| Dar, AR | 1 |
| Rodrigues, GB | 1 |
| Luján, J | 1 |
| García De Burgos, F | 1 |
| Jordán, A | 1 |
| García, M | 1 |
| Reyes, F | 1 |
| Espinosa, MD | 1 |
| Mirjolet, JF | 2 |
| Didelot, C | 2 |
| Barberi-Heyob, M | 3 |
| Merlin, JL | 3 |
| Truter, EJ | 1 |
| Santos, AS | 1 |
| Els, WJ | 1 |
| Hartung, G | 3 |
| Samel, S | 3 |
| Pichlmeier, U | 1 |
| Hehlmann, R | 4 |
| Queisser, W | 4 |
| Balart, J | 2 |
| Capellà, G | 1 |
| de los Inocentes, RM | 1 |
| de Andrés, J | 1 |
| Ares, C | 1 |
| Craven-Bartle, J | 1 |
| Lluís, F | 1 |
| Crucitta, E | 1 |
| De Lucia, L | 2 |
| Del Gaizo, F | 1 |
| Lannelli, A | 1 |
| Tafuto, S | 1 |
| Buzzi, F | 2 |
| De Cataldis, G | 1 |
| Eisold, S | 1 |
| Dihlmann, S | 1 |
| Linnebacher, M | 1 |
| Aulmann, M | 1 |
| Schlehofer, JR | 1 |
| Ridder, R | 1 |
| Vitoratos, N | 1 |
| Salamalekis, E | 1 |
| Makrakis, E | 1 |
| Creatsas, G | 1 |
| Iizuka, R | 1 |
| Kakihara, N | 2 |
| Matsumura, H | 1 |
| Takenaka, A | 2 |
| Gagnadoux, F | 1 |
| Roiron, C | 1 |
| Carrie, E | 1 |
| Monnier-Cholley, L | 1 |
| Lebeau, B | 2 |
| Ahn, JH | 2 |
| Bahng, H | 1 |
| Kang, WC | 1 |
| Kim, WK | 2 |
| Lee, KD | 1 |
| Liu, TW | 2 |
| Wu, CW | 2 |
| Tiu, CM | 1 |
| Liu, JM | 2 |
| Chung, TR | 2 |
| Whang-Peng, J | 2 |
| Cheeseman, SL | 1 |
| Joel, SP | 1 |
| Chester, JD | 1 |
| Wilson, G | 1 |
| Dent, JT | 1 |
| Richards, FJ | 1 |
| Pignon, JP | 4 |
| Merouche, Y | 1 |
| Berthault-Cvitkovic, F | 1 |
| Luboinski, M | 1 |
| Ezenfis, J | 1 |
| Clavero-Fabri, MC | 2 |
| McInnes, A | 1 |
| Blackie, R | 1 |
| Raby, N | 1 |
| Fullarton, GM | 1 |
| Soukop, M | 6 |
| Algar Algar, FJ | 1 |
| Alvarez Kindelán, A | 1 |
| Fuentes Vaamonde, E | 1 |
| Salvatierra Velázquez, A | 1 |
| Baamonde Laborda, C | 1 |
| López Pujol, FJ | 1 |
| Mohiuddin, M | 5 |
| Marks, G | 1 |
| Mashino, K | 1 |
| Inoue, H | 3 |
| Matsukuma, A | 2 |
| Kawaguchi, H | 1 |
| Kusumoto, H | 2 |
| Haraguchi, M | 1 |
| Bazarbashi, S | 1 |
| Rahal, M | 1 |
| Raja, MA | 1 |
| El Weshi, A | 1 |
| Pai, C | 1 |
| Ezzat, A | 2 |
| Ajarim, D | 1 |
| Memon, M | 1 |
| Al Fadda, M | 1 |
| Görgülü, S | 1 |
| Oğuz, E | 1 |
| Zor, A | 1 |
| Zor, U | 1 |
| Gürdoğan, M | 1 |
| Tezel, T | 1 |
| Price, T | 1 |
| Nehls, O | 4 |
| Klump, B | 2 |
| Arkenau, HT | 3 |
| Greschniok, A | 1 |
| Gregor, M | 2 |
| Porschen, R | 3 |
| Elomaa, I | 3 |
| Repo, H | 1 |
| Joensuu, H | 3 |
| Carraro, S | 1 |
| Roca, EL | 1 |
| Cartelli, C | 1 |
| Rafailovici, L | 1 |
| Castillo Odena, S | 1 |
| Wasserman, E | 1 |
| Gualdrini, U | 1 |
| Huertas, E | 1 |
| Barugel, M | 1 |
| Ballarino, G | 1 |
| Rodriguez, MC | 1 |
| Masciangioli, G | 1 |
| Cho, MJ | 1 |
| Song, KS | 1 |
| Yoon, WH | 1 |
| Sutter, T | 1 |
| Zühlke, H | 1 |
| Kölling-Schlebusch, K | 1 |
| Frings, S | 2 |
| Leonard, GD | 1 |
| Zhuang, SH | 1 |
| Ishio, T | 1 |
| Endo, K | 1 |
| Ikeda, Y | 1 |
| Toh, Y | 1 |
| Okamura, T | 2 |
| Tasaka, K | 1 |
| Tomofuji, Y | 1 |
| Chinzei, T | 1 |
| Takizawa, M | 1 |
| Hirano, M | 2 |
| Uno, Y | 1 |
| Kikuchi, T | 1 |
| Asaumi, Y | 1 |
| Kikkawa, H | 2 |
| Koyama, M | 2 |
| Watabe, S | 1 |
| Ohe, S | 1 |
| Kamio, Y | 1 |
| Chiba, M | 1 |
| Rassu, PC | 1 |
| Cassinelli, G | 1 |
| Ronzitti, F | 1 |
| Bronzino, P | 1 |
| Stanizzi, T | 1 |
| Casaccia, M | 1 |
| Rothenberg, ML | 3 |
| Seay, TE | 2 |
| George, CS | 1 |
| Tanaka, MS | 1 |
| Giguere, JK | 1 |
| Pruitt, BT | 1 |
| Di Martino, N | 3 |
| Orditura, M | 5 |
| Cosenza, A | 1 |
| Del Genio, A | 1 |
| Catalano, G | 12 |
| Chen, XX | 1 |
| Lai, MD | 1 |
| Zhang, YL | 1 |
| Lauria, R | 1 |
| De Laurentiis, M | 1 |
| Arpino, G | 1 |
| Massarelli, E | 1 |
| Ferrara, C | 1 |
| Vernaglia Lombardi, A | 1 |
| Costanzo, R | 1 |
| Bianco, AR | 3 |
| Shiah, HS | 1 |
| Jan, CM | 1 |
| Calvo, E | 2 |
| Cortés, J | 3 |
| González-Cao, M | 1 |
| Aramendía, JM | 1 |
| Fernández-Hidalgo, O | 2 |
| Martín-Algarra, S | 2 |
| Salgado, JE | 1 |
| de Irala, J | 2 |
| Brugarolas, A | 2 |
| Naka, T | 1 |
| Sugamura, K | 1 |
| Hylander, BL | 1 |
| Widmer, MB | 1 |
| Repasky, EA | 1 |
| Mercier, M | 1 |
| Rath, GK | 1 |
| Sharma, DN | 1 |
| Shukla, NK | 1 |
| Maraveyas, A | 1 |
| O'Boyle, C | 1 |
| Cowen, M | 1 |
| Kern, M | 1 |
| Hoepffner, N | 1 |
| Neuhaus, P | 3 |
| Sugita, M | 1 |
| Togo, S | 1 |
| Miura, Y | 2 |
| Akiyama, H | 1 |
| Kunisaki, C | 1 |
| Hatada, T | 2 |
| Mohri, T | 1 |
| Jacot, W | 1 |
| Lemanski, C | 1 |
| Senesse, P | 2 |
| Prost, P | 2 |
| Delard, R | 1 |
| Masson, B | 2 |
| Dubois, JB | 2 |
| Waters, JS | 2 |
| Lofts, F | 3 |
| Norman, A | 9 |
| Kim, WS | 6 |
| Tsavaris, N | 7 |
| Kosmas, C | 5 |
| Gennatas, K | 1 |
| Vadiaka, M | 3 |
| Skopelitis, E | 1 |
| Xila, V | 1 |
| Rokana, S | 2 |
| Margaris, E | 1 |
| Zografos, G | 1 |
| Papastratis, G | 2 |
| Kouraklis, G | 1 |
| Aquino, A | 1 |
| Prete, SP | 1 |
| Balduzzi, A | 2 |
| Fossile, E | 1 |
| Torino, F | 1 |
| Bonmassar, L | 1 |
| Di Giacomo, A | 1 |
| Cappelletti, D | 1 |
| Cardillo, A | 1 |
| Graziani, G | 1 |
| Miyanari, N | 1 |
| Mori, T | 8 |
| Yasuno, M | 1 |
| Happich, K | 1 |
| Schirner, I | 1 |
| Brueckl, WM | 2 |
| Mace, AD | 1 |
| Lale, AM | 1 |
| Capper, JW | 1 |
| Emig, M | 1 |
| Pilz, L | 2 |
| Willeke, F | 2 |
| Bex, A | 1 |
| Otto, T | 1 |
| Lümmen, G | 1 |
| Rübben, H | 1 |
| Kempin, S | 1 |
| Gutierrez, J | 2 |
| Wilson, E | 1 |
| Lowery, C | 1 |
| Diasio, R | 2 |
| Yamada, H | 2 |
| Ichikawa, W | 1 |
| Uetake, H | 1 |
| Shirota, Y | 2 |
| Nihei, Z | 1 |
| Hirayama, R | 1 |
| Rebollo, J | 1 |
| Vincent, M | 1 |
| Ho, C | 1 |
| Tomiak, A | 1 |
| Winquist, E | 1 |
| Whiston, F | 1 |
| Stitt, L | 1 |
| Kjaer, M | 1 |
| Skovsgaard, T | 1 |
| Linné, T | 2 |
| Boussard, B | 2 |
| Oulid-Aïssa, D | 1 |
| Pyrhönen, S | 3 |
| Tigaud, JM | 5 |
| Brunet, R | 6 |
| Jacob, JH | 2 |
| Levoir, D | 1 |
| Taamma, A | 1 |
| Cvitkovic, E | 5 |
| Violette, S | 1 |
| Festor, E | 1 |
| Pandrea-Vasile, I | 1 |
| Mitchell, V | 1 |
| Adida, C | 1 |
| Dussaulx, E | 1 |
| Lacorte, JM | 1 |
| Chambaz, J | 1 |
| Lacasa, M | 1 |
| Lesuffleur, T | 1 |
| Kagawa, R | 1 |
| Sakata, S | 1 |
| Tada, M | 1 |
| Saguchi, T | 1 |
| Murayama, C | 2 |
| Salman, HS | 1 |
| Cynamon, J | 1 |
| Jagust, M | 1 |
| Bakal, C | 1 |
| Rozenblit, A | 3 |
| Kaleya, R | 3 |
| Negassa, A | 1 |
| Wadler, S | 10 |
| Huguier, M | 3 |
| Ochiai, T | 5 |
| Maruyama, M | 5 |
| Ebuchi, M | 4 |
| Takashima, I | 1 |
| Natsui, S | 1 |
| Sakoma, T | 1 |
| Katsumoto, Y | 2 |
| Maruyama, K | 2 |
| Furukawa, J | 2 |
| Nagai, K | 2 |
| Maruyama, N | 2 |
| Sue, F | 1 |
| Souma, I | 1 |
| Izawa, H | 1 |
| Sakita, I | 1 |
| Kanai, T | 2 |
| Kouro, T | 1 |
| Schüll, B | 1 |
| Ulrich-Pur, H | 1 |
| Schmid, K | 1 |
| Raderer, M | 3 |
| Haider, K | 2 |
| Kwasny, W | 4 |
| Depisch, D | 7 |
| Schneeweiss, B | 2 |
| Lang, F | 1 |
| Ninomiya, S | 1 |
| Takeo, S | 1 |
| Vannozzi, F | 1 |
| Amadori, D | 3 |
| Del Tacca, M | 4 |
| Garin, L | 1 |
| Blanchot, J | 1 |
| Le Guilcher, P | 1 |
| Rodríguez-Ramírez, S | 1 |
| Hernández-Pacheco, F | 1 |
| Gutiérrez De La Barrera, M | 1 |
| Fernández, R | 2 |
| Labastida, S | 3 |
| Mehta, VK | 2 |
| Cho, C | 1 |
| Jambalos, C | 1 |
| Poen, J | 2 |
| Koong, A | 1 |
| Lin, A | 1 |
| Bastidas, JA | 1 |
| Young, H | 2 |
| Dunphy, EP | 1 |
| Fisher, G | 2 |
| Xiao, Q | 1 |
| Peng, B | 1 |
| Lai, Y | 1 |
| Akbulut, H | 2 |
| Altuntas, F | 1 |
| Akbulut, KG | 1 |
| Ozturk, G | 1 |
| Cindoruk, M | 1 |
| Unal, E | 1 |
| Icli, F | 2 |
| Jüngert, B | 1 |
| Brueckl, V | 1 |
| Hautmann, M | 1 |
| Niki, T | 1 |
| Hamano, K | 1 |
| Okutani, T | 1 |
| Hirohata, S | 1 |
| Nakashima, T | 2 |
| Yasutake, K | 1 |
| Kawaguchi, K | 1 |
| Sashikata, T | 1 |
| Kypson, AP | 1 |
| Morphew, E | 1 |
| Jones, R | 2 |
| Gottfried, MR | 2 |
| Seigler, HF | 4 |
| Yang, TS | 3 |
| Chiang, JM | 2 |
| Hsieh, PS | 2 |
| Yeh, CY | 2 |
| Changchien, CR | 2 |
| Kerr, DJ | 5 |
| McArdle, CS | 5 |
| Ledermann, J | 1 |
| Taylor, I | 3 |
| Sherlock, DJ | 1 |
| Schlag, PM | 1 |
| Buckels, J | 2 |
| Mayer, D | 1 |
| Cain, D | 1 |
| Stephens, RJ | 1 |
| Papagikos, M | 1 |
| Janjan, NA | 9 |
| Feig, B | 3 |
| Hung, A | 1 |
| Delclos, M | 2 |
| Cleary, K | 1 |
| Myerson, R | 3 |
| Zobeiri, I | 1 |
| Birnbaum, E | 1 |
| Dietz, D | 1 |
| Fleshman, J | 1 |
| Kodner, I | 1 |
| Ratkin, G | 3 |
| Terrosu, G | 1 |
| Cedolini, C | 1 |
| Bresadola, V | 1 |
| Baccarani, U | 1 |
| Uzzau, A | 1 |
| Signor, M | 1 |
| Fongione, S | 1 |
| Buffoli, A | 1 |
| Iop, A | 1 |
| Vigevani, E | 1 |
| Sacco, C | 1 |
| Cartei, G | 2 |
| Bresadola, F | 1 |
| Bar Sela, G | 1 |
| Tsalic, M | 1 |
| Gaitini, D | 1 |
| Steiner, M | 2 |
| Haim, N | 4 |
| Black, CA | 1 |
| Ensley, JF | 2 |
| Gennatas, C | 2 |
| Dardoufas, C | 1 |
| Mouratidou, D | 2 |
| Pouli, A | 1 |
| Androulakis, G | 1 |
| Philippakis, M | 1 |
| Voros, D | 1 |
| Batalis, T | 1 |
| Besbeas, S | 1 |
| Hatzistylianos, G | 1 |
| Katsos, J | 1 |
| Komporozos, V | 1 |
| Legakis, N | 1 |
| Mallas, H | 1 |
| Peros, G | 1 |
| Photopoulos, A | 1 |
| Pisiotis, C | 1 |
| Polymeneas, G | 1 |
| Retalis, G | 1 |
| Samanidis, L | 1 |
| Smyrniotis, V | 1 |
| Stamatiadis, A | 1 |
| Vasiliou, J | 1 |
| Andreadis, H | 1 |
| Papadimitriou, J | 1 |
| Bermann, A | 1 |
| Rettig, K | 2 |
| Strohmeyer, G | 1 |
| Kawashima, M | 1 |
| Nakagohri, T | 2 |
| Ogino, T | 3 |
| Maru, Y | 1 |
| Yoshino, M | 2 |
| Kaneyasu, Y | 3 |
| Okawa, T | 3 |
| Yajima, M | 1 |
| Nakabayashi, M | 1 |
| Seshimo, A | 2 |
| Kameoka, S | 2 |
| Aomi, S | 1 |
| Mitsuhashi, N | 2 |
| Loesch, DM | 1 |
| Canfield, VA | 1 |
| Parker, GA | 1 |
| Hynes, HE | 2 |
| Ellis, PG | 1 |
| Ferri, WA | 1 |
| Robert, NJ | 2 |
| Catalano, P | 1 |
| Rao, MS | 1 |
| Lin, JC | 1 |
| Jan, JS | 1 |
| Hsu, CY | 1 |
| Jiang, RS | 1 |
| Wang, WY | 1 |
| Sawada, M | 1 |
| Ono, Y | 1 |
| Fukushima, M | 5 |
| Fujito, T | 1 |
| Goda, F | 1 |
| Matsuyama, J | 1 |
| Hojo, S | 1 |
| Yano, Y | 2 |
| Endo, W | 1 |
| Maeura, Y | 1 |
| Nakagoe, T | 1 |
| Yamaguchi, E | 1 |
| Tsuji, T | 2 |
| Shibasaki, S | 1 |
| Yasutake, T | 1 |
| Ayabe, H | 2 |
| Krenn, V | 1 |
| Okabe, S | 2 |
| Tanami, H | 1 |
| Fukahara, T | 1 |
| Udagawa, M | 1 |
| Ootsukasa, S | 1 |
| Maruyama, S | 2 |
| Murase, N | 2 |
| Yamashita, H | 4 |
| Siefker-Radtke, AO | 1 |
| Gee, J | 1 |
| Daliani, D | 1 |
| Millikan, RE | 1 |
| Pisters, LL | 1 |
| Gérard, JP | 5 |
| Chapet, O | 2 |
| Nemoz, C | 1 |
| Romestaing, P | 3 |
| Coquard, R | 1 |
| Barbet, N | 2 |
| Atlan, D | 2 |
| Adeleine, P | 1 |
| Freyer, G | 3 |
| Grinev, MV | 1 |
| Beech, DJ | 1 |
| Madan, AK | 1 |
| Aliabadi-Wahle, S | 1 |
| Hays, AN | 1 |
| Long, WP | 1 |
| Carrat, F | 1 |
| Mal, F | 3 |
| Beerblock, K | 7 |
| Cady, J | 4 |
| Vaitkevicius, V | 4 |
| Langer, C | 1 |
| Jakob, C | 3 |
| Müller, D | 1 |
| Siemer, A | 1 |
| Markus, PM | 1 |
| Füzesi, L | 3 |
| Harris, EE | 1 |
| Schultz, D | 1 |
| Bertsch, H | 1 |
| Fox, K | 1 |
| Glick, J | 2 |
| Solin, LJ | 4 |
| Lorvidhaya, V | 2 |
| Chitapanarux, I | 1 |
| Sangruchi, S | 1 |
| Lertsanguansinchai, P | 1 |
| Kongthanarat, Y | 1 |
| Tangkaratt, S | 1 |
| Visetsiri, E | 1 |
| Magnin, V | 2 |
| Giovannini, MH | 1 |
| Bardou, VJ | 2 |
| Alzieu, C | 1 |
| Arora, A | 1 |
| Potter, J | 1 |
| Hosie, KB | 1 |
| Gilbert, JA | 1 |
| Downes, M | 1 |
| Lakin, G | 1 |
| Pemberton, G | 1 |
| Timms, K | 1 |
| Young, A | 1 |
| Stanley, A | 1 |
| Stein, DE | 1 |
| Mahmoud, NN | 2 |
| Rose, DG | 1 |
| Isenberg, GA | 1 |
| Goldstein, SD | 1 |
| Mitchell, E | 2 |
| Fry, RD | 2 |
| Awakura, Y | 2 |
| Nonomura, M | 2 |
| Itoh, N | 1 |
| Maeno, A | 1 |
| Fukuyama, T | 2 |
| Mo, B | 1 |
| Pater, A | 1 |
| Gutzler, F | 1 |
| Steinmann, S | 2 |
| Boehme, M | 1 |
| Raeth, U | 1 |
| Stremmel, W | 1 |
| Malik, IA | 1 |
| Aziz, Z | 1 |
| Murad, AM | 3 |
| Guimarães, RC | 2 |
| Aragão, BC | 2 |
| Rodrigues, VH | 1 |
| Scalabrini-Neto, AO | 2 |
| Padua, CA | 1 |
| Moore, FC | 1 |
| Fujii, R | 1 |
| Picozzi, VJ | 2 |
| Kozarek, RA | 1 |
| Traverso, LW | 3 |
| Yan, L | 1 |
| Mao, Y | 2 |
| Kelm, J | 1 |
| Ahlhelm, F | 1 |
| Weissenbach, P | 1 |
| Schliesing, P | 1 |
| Regitz, T | 1 |
| Deubel, G | 1 |
| Engel, C | 1 |
| Kleinberg, L | 2 |
| Knisely, JP | 2 |
| Heitmiller, R | 1 |
| Zahurak, M | 2 |
| Salem, R | 2 |
| Heath, EI | 2 |
| Forastiere, AA | 5 |
| Cohen, V | 1 |
| Panet-Raymond, V | 1 |
| Sabbaghian, N | 1 |
| Morin, I | 1 |
| Batist, G | 1 |
| Rozen, R | 1 |
| Makower, D | 1 |
| Fehn, K | 1 |
| Landau, L | 1 |
| Wissel, P | 1 |
| Versola, M | 1 |
| Mani, S | 1 |
| Bonnefoi, H | 1 |
| Biganzoli, L | 2 |
| Mauriac, L | 1 |
| Cufer, T | 1 |
| Schaefer, P | 2 |
| Atalay, G | 1 |
| Lortholary, A | 2 |
| Delozier, T | 2 |
| Monnier, A | 3 |
| Bourgeois, H | 1 |
| Bougnoux, P | 1 |
| Riffaud, JCh | 1 |
| Besson, D | 1 |
| Lotz, V | 1 |
| Yeo, CJ | 9 |
| Shibata, T | 2 |
| Noguchi, T | 3 |
| Kikuchi, R | 1 |
| Oka, Y | 2 |
| Toyoda, H | 1 |
| Okada, S | 5 |
| Saini, A | 1 |
| Jodrell, D | 1 |
| Ross, PJ | 3 |
| Denham, JW | 5 |
| Steigler, A | 1 |
| Kilmurray, J | 1 |
| Wratten, C | 1 |
| Lamb, DS | 3 |
| Delaney, G | 1 |
| Christie, D | 1 |
| Jamieson, G | 1 |
| Walpole, E | 2 |
| Gokel, Y | 1 |
| Paydas, S | 1 |
| Ishikura, S | 1 |
| Jiao, SC | 1 |
| Lu, SX | 1 |
| Duffour, J | 1 |
| Debrigode, C | 1 |
| Bressolle, F | 1 |
| Pinguet, F | 1 |
| Bading, JR | 1 |
| Yoo, PB | 1 |
| Fissekis, JD | 1 |
| Alauddin, MM | 1 |
| D'Argenio, DZ | 1 |
| Conti, PS | 1 |
| Kwiatkowski, F | 1 |
| Chevalier, V | 1 |
| Chevrier, R | 1 |
| Richard, D | 1 |
| Cure, H | 3 |
| Chollet, P | 8 |
| Chachoua, A | 1 |
| Speyer, J | 2 |
| Escalon, J | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Correale, P | 3 |
| Messinese, S | 2 |
| Marsili, S | 3 |
| Ceciarini, F | 1 |
| Pozzessere, D | 1 |
| Sabatino, M | 1 |
| Cerretani, D | 2 |
| Pellegrini, M | 1 |
| Di Palma, T | 1 |
| Neri, A | 1 |
| Calvanese, A | 1 |
| Pinto, E | 2 |
| Giorgi, G | 2 |
| Benchekroun, A | 1 |
| Nouini, Y | 1 |
| Zannoud, M | 1 |
| Kasmaoui, el H | 1 |
| Jira, H | 1 |
| el Alj, HA | 1 |
| Ghaemmaghami, F | 1 |
| Behtash, N | 1 |
| Yarandi, F | 1 |
| Moosavi, A | 1 |
| Modares, M | 1 |
| Toogeh, G | 1 |
| Khanafshar, N | 1 |
| Cocconi, G | 4 |
| Gamboni, A | 1 |
| Gasperoni, S | 4 |
| Rodinò, C | 2 |
| Porrozzi, S | 1 |
| Di Costanzo, F | 6 |
| Canaletti, R | 2 |
| Melissas, J | 1 |
| Schoretsanitis, G | 1 |
| Daskalakis, M | 1 |
| Tsiftsis, DD | 1 |
| Achille, E | 1 |
| Colbert, N | 1 |
| Boaziz, C | 1 |
| Piedbois, P | 4 |
| Boutan-Laroze, A | 1 |
| Kemeny, NE | 1 |
| Gococo, KO | 1 |
| Kardinal, CG | 3 |
| Vaishampayan, U | 3 |
| Jain, V | 2 |
| Adsay, V | 2 |
| Day, J | 1 |
| Tokunaga, T | 2 |
| Sumimura, J | 1 |
| Yoshidome, K | 1 |
| Fujita, S | 4 |
| Tsuji, K | 2 |
| Oota, F | 1 |
| Tsuboyama, N | 1 |
| Nagai, I | 1 |
| Micke, O | 2 |
| Bruns, F | 1 |
| Kurowski, R | 1 |
| Horst, E | 1 |
| Hausler, JW | 1 |
| Schäfer, U | 1 |
| Birnbaum, EH | 3 |
| Feig, BW | 3 |
| Singh, AK | 1 |
| Lin, EH | 1 |
| Fleshman, JW | 3 |
| Thames, HD | 2 |
| Kodner, IJ | 3 |
| Lockett, MA | 1 |
| Phan, T | 2 |
| Read, TE | 3 |
| Nesbitt, JC | 1 |
| Lahoti, S | 3 |
| Martin, F | 3 |
| Putnam, JB | 6 |
| Smythe, WR | 2 |
| Vaporciyan, AA | 3 |
| Walsh, GL | 3 |
| Roth, JA | 11 |
| Penna, Ch | 1 |
| Claude, L | 2 |
| Brickell, K | 1 |
| Porter, D | 1 |
| An, FS | 1 |
| Huang, JQ | 1 |
| Xie, YT | 1 |
| Rong, TH | 1 |
| Chen, ZH | 1 |
| Feng, B | 1 |
| Gunel, N | 1 |
| Onuk, E | 1 |
| Yilmaz, E | 1 |
| Bayram, O | 1 |
| Yamac, D | 1 |
| Cihan, A | 1 |
| Ucan, B | 1 |
| Yildirim, Y | 1 |
| Celenkoglu, G | 1 |
| Ozkan, S | 1 |
| Nomura, K | 1 |
| Hayashi, S | 2 |
| Oota, H | 1 |
| Kamimura, T | 1 |
| Kim, DJ | 1 |
| Suh, JH | 2 |
| Cho, YS | 1 |
| Shin, SK | 1 |
| Kang, JK | 1 |
| Cassinello, J | 2 |
| Escudero, P | 1 |
| Marcos, F | 2 |
| Pujol, E | 2 |
| Pérez-Carrión, R | 1 |
| Colmenarejo, A | 3 |
| González del Val, R | 1 |
| Valero, J | 1 |
| Oruezábal, MJ | 1 |
| Guillem, V | 1 |
| García, I | 1 |
| Arcediano, A | 2 |
| Marfà, X | 2 |
| Noh, JH | 4 |
| Jung, CW | 4 |
| Im, YH | 5 |
| Park, K | 6 |
| Park, CH | 4 |
| Günther, K | 1 |
| Dimmler, A | 1 |
| Rödel, F | 1 |
| Bittorf, BR | 1 |
| Matzel, KE | 1 |
| Papadopoulos, T | 1 |
| Gambardella, A | 1 |
| Miyake, H | 1 |
| Takamura, K | 1 |
| Tashiro, S | 2 |
| Nakazato, H | 1 |
| Koike, A | 3 |
| Baba, S | 1 |
| Mai, M | 1 |
| REITEMEIER, RJ | 14 |
| MOERTEL, CG | 34 |
| KNOCK, FE | 3 |
| BRENNAN, MJ | 1 |
| TALLEY, RW | 3 |
| DRAKE, EH | 2 |
| VAITKEVICIUS, VK | 16 |
| POZNANSKI, AK | 1 |
| BRUSH, BE | 1 |
| CHANG, WW | 1 |
| BUERGER, L | 1 |
| DESBERG, D | 1 |
| TANNO, V | 1 |
| MCBRIDE, TJ | 1 |
| NOBLE, LC | 1 |
| CARR, MA | 1 |
| HULL, K | 1 |
| OLESON, JJ | 1 |
| BLACKBURN, CM | 1 |
| SHERLOCK, P | 1 |
| CHAN, DP | 1 |
| HO, JH | 1 |
| WOO, AW | 1 |
| HART, GD | 1 |
| CENTARO, A | 1 |
| GASPARRI, F | 1 |
| MAIJNELLI, M | 1 |
| PERITI, P | 2 |
| GOLLIN, FF | 1 |
| ANSFIELD, FJ | 2 |
| VERMUND, H | 2 |
| WATSON, EC | 1 |
| HELSPER, JT | 1 |
| DEMOSS, EV | 1 |
| RIEHL, JL | 1 |
| BROWN, WJ | 1 |
| MCCAFFERY, JF | 1 |
| CAMMACK, KV | 1 |
| CHILDS, DS | 6 |
| COLBY, MY | 3 |
| HOLBROOK, MA | 7 |
| CRESSY, NL | 2 |
| SCHELL, HW | 2 |
| MCALISTER, WH | 1 |
| FLOCH, MH | 1 |
| HELLMAN, L | 1 |
| HAHN, RG | 12 |
| WILSON, WL | 1 |
| DELAGARZA, JG | 1 |
| Giannakakis, T | 1 |
| Gouveris, P | 2 |
| Dimitrakopoulos, A | 1 |
| Karadima, D | 1 |
| Papalambros, E | 2 |
| Margaris, H | 1 |
| Tsipras, H | 1 |
| O'Connell, M | 2 |
| Cooke, E | 2 |
| Jantscheff, P | 1 |
| Terracciano, L | 1 |
| Lowy, A | 2 |
| Glatz-Krieger, K | 1 |
| Grunert, F | 1 |
| Micheel, B | 1 |
| Brümmer, J | 1 |
| Laffer, U | 3 |
| Metzger, U | 2 |
| Rochlitz, C | 1 |
| Reszka, R | 1 |
| Lucas, S | 1 |
| Futamura, N | 1 |
| Matsutomo, M | 1 |
| Yasumura, M | 1 |
| Tateyama, K | 1 |
| Hu, YC | 1 |
| Komorowski, RA | 1 |
| Graewin, S | 1 |
| Hostetter, G | 1 |
| Kallioniemi, OP | 1 |
| Pitt, HA | 2 |
| Ahrendt, SA | 1 |
| Dittler, HJ | 1 |
| Helmberger, H | 1 |
| Busch, R | 5 |
| Kollmannsberger, C | 5 |
| Fink, U | 4 |
| Kawakami, K | 2 |
| Watanabe, G | 1 |
| Araneo, M | 1 |
| Frager, D | 1 |
| Marino, J | 1 |
| DeGregorio, P | 1 |
| Mortazabi, F | 1 |
| Firoozi, K | 1 |
| Jindal, K | 1 |
| Kulke, MH | 4 |
| Earle, CC | 4 |
| Stuart, K | 3 |
| Catarius, KJ | 1 |
| Winkelmann, J | 1 |
| Foo, K | 1 |
| Lim Joon, D | 2 |
| Weih, L | 1 |
| Ngan, S | 1 |
| Thomas, R | 1 |
| Mariani, G | 1 |
| Giaccon, G | 1 |
| Mastore, M | 1 |
| Goldberg, M | 2 |
| Farma, J | 1 |
| Lampert, C | 1 |
| Colarusso, P | 2 |
| Coia, L | 3 |
| Frucht, H | 1 |
| Goosenberg, E | 1 |
| Beard, M | 1 |
| Semiglazov, VF | 1 |
| Maksimov, SIa | 1 |
| Semiglazov, VV | 1 |
| Kosnikov, AG | 1 |
| Bai, YR | 1 |
| Wu, GH | 1 |
| Wu, XD | 1 |
| Zhou, RH | 1 |
| Lu, DQ | 1 |
| Maruyama, KT | 1 |
| Ishigami, H | 1 |
| Kikkawa, N | 4 |
| Iijima, S | 3 |
| Handa, R | 2 |
| Naoi, Y | 1 |
| Oshima, S | 2 |
| Kurokawa, E | 2 |
| Shimizu, J | 2 |
| Masutani, S | 3 |
| Imamura, H | 1 |
| Tatsuta, M | 2 |
| Yura, M | 1 |
| Saeki, N | 1 |
| Kitamura, S | 1 |
| Tomotsu, K | 1 |
| Takamura, M | 1 |
| Okamoto, N | 1 |
| Maruta, M | 2 |
| Masumori, K | 1 |
| Nishioka, K | 1 |
| Iwasaki, Y | 5 |
| Katayanagi, S | 2 |
| Matsumoto, H | 1 |
| Horiguchi, S | 1 |
| Balmaña, J | 1 |
| Rius, X | 1 |
| Gallen, M | 2 |
| Navarro, S | 1 |
| Arcusa, A | 1 |
| Gallardo, E | 1 |
| Brunet, J | 1 |
| Kremser, C | 2 |
| Judmaier, W | 2 |
| Hein, P | 1 |
| Griebel, J | 2 |
| Lim, JT | 2 |
| Truong, PT | 1 |
| Berthelet, E | 1 |
| Pai, H | 1 |
| Joe, H | 1 |
| Wai, E | 1 |
| Larsson, S | 1 |
| Kader, HA | 1 |
| Weinerman, B | 1 |
| Olivotto, IA | 1 |
| Sørbye, H | 5 |
| Oechsle, K | 2 |
| Honecker, F | 2 |
| Käfer, G | 1 |
| Kanz, L | 5 |
| Funakoshi, K | 1 |
| Tasaki, A | 1 |
| Inayoshi, J | 1 |
| Arai, F | 1 |
| Motoyama, H | 1 |
| Akiyama, N | 3 |
| Mezawa, S | 2 |
| Homma, H | 2 |
| Akiyama, T | 3 |
| Kogawa, K | 1 |
| Kida, M | 2 |
| Murase, K | 2 |
| Iyama, S | 3 |
| Al-Sukhun, S | 1 |
| Soulen, R | 1 |
| Weaver, D | 1 |
| Levin, K | 1 |
| Forman, JD | 1 |
| Morton, RF | 1 |
| Williamson, SK | 3 |
| Findlay, BP | 1 |
| Pitot, HC | 2 |
| Coleman, TA | 1 |
| Redger, CD | 1 |
| Hamill, RL | 1 |
| Dainer, P | 1 |
| Shibata, K | 3 |
| Kikkawa, F | 1 |
| Suzuki, Y | 4 |
| Terauchi, M | 1 |
| Kajiyama, H | 1 |
| Ino, K | 1 |
| Mizutani, S | 2 |
| Antón, A | 3 |
| Marcuello, E | 1 |
| Massutti, B | 1 |
| Fenández-Martos, C | 1 |
| Huarte, L | 1 |
| Balcells, M | 3 |
| Han, JY | 2 |
| Lee, DH | 2 |
| Kim, HY | 2 |
| Kim, EA | 1 |
| Ju, SY | 1 |
| Shin, EH | 1 |
| Sorio, C | 1 |
| Moore, PS | 1 |
| Ennas, MG | 1 |
| Tecchio, C | 1 |
| Bonora, A | 1 |
| Sartoris, S | 1 |
| Balzarini, P | 1 |
| Grigolato, P | 1 |
| Assersohn, L | 1 |
| Ward, C | 1 |
| Larsson, B | 1 |
| Sundin, A | 1 |
| Khamis, H | 1 |
| Gibson, MK | 3 |
| Abraham, SC | 1 |
| Heitmiller, RF | 2 |
| Heath, E | 1 |
| Forastiere, A | 4 |
| Samuel, J | 1 |
| Flood, TP | 1 |
| Agbemadzo, B | 1 |
| Renta, V | 1 |
| Mullai, N | 1 |
| Osafo, DC | 1 |
| Holloway, N | 1 |
| Cohen, JA | 1 |
| Tekuzman, G | 1 |
| Engin, H | 1 |
| Turker, A | 1 |
| Barista, I | 1 |
| Gullu, I | 1 |
| Guler, N | 2 |
| Ozisik, Y | 1 |
| Kars, A | 2 |
| Furusawa, J | 1 |
| Mizumati, T | 1 |
| Iizuka, K | 1 |
| Imamura, M | 5 |
| Yamaki, T | 1 |
| Yasuda, M | 3 |
| Hansson, J | 1 |
| Saenger, J | 1 |
| Leible, M | 1 |
| Seelig, MH | 1 |
| Tajima, T | 1 |
| Saitoh, T | 1 |
| Jingu, K | 1 |
| Rigatos, SK | 2 |
| Potamiannou, A | 1 |
| Tsiakopoulos, I | 1 |
| Androulakis, N | 3 |
| Jaeger, D | 1 |
| Hahnfeld, S | 1 |
| Rummel, MJ | 1 |
| Rost, A | 1 |
| Orth, J | 1 |
| Knuth, A | 4 |
| Hong, TJ | 1 |
| Cohen, DP | 1 |
| Tyler, DS | 5 |
| Anscher, MS | 4 |
| Ludwig, KA | 2 |
| Mantyh, C | 2 |
| Spector, NL | 1 |
| Ertel, PJ | 1 |
| Mangum, SG | 1 |
| Hahn, P | 1 |
| Eifel, PJ | 5 |
| Morris, M | 3 |
| Levenback, C | 1 |
| Grigsby, PW | 5 |
| Cooper, J | 3 |
| Rotman, M | 2 |
| Gershenson, D | 2 |
| Mutch, DG | 3 |
| Yumuk, PF | 1 |
| Abacioglu, U | 1 |
| Caglar, H | 1 |
| Sengoz, M | 1 |
| Turhal, NS | 1 |
| Guba, M | 1 |
| Koehl, GE | 1 |
| Doenecke, A | 1 |
| Steinbauer, M | 1 |
| Wagner, C | 1 |
| Frank, E | 1 |
| Geissler, EK | 1 |
| Ford, HE | 1 |
| Mulligan, ED | 1 |
| Dunne, B | 2 |
| Keeling, N | 2 |
| Ohta, S | 1 |
| Kawabe, S | 1 |
| Gotoh, M | 1 |
| Hirata, I | 1 |
| Katsu, K | 1 |
| Hongo, H | 1 |
| Fujita, K | 1 |
| Tsuchida, A | 2 |
| Hayashida, Y | 1 |
| Takagi, M | 1 |
| Kawakita, H | 1 |
| Kubouchi, T | 1 |
| Kinoshita, M | 1 |
| Kataba, Y | 1 |
| Mio, H | 1 |
| Sekiya, M | 1 |
| Kathou, T | 1 |
| Morishita, Y | 6 |
| Kasakura, Y | 2 |
| Yagyu, T | 2 |
| Murayama, M | 2 |
| Nakamura, E | 1 |
| Nozaki, H | 1 |
| Niida, M | 1 |
| Yasuoka, H | 1 |
| Nishimoto, Y | 1 |
| Watanabe, Y | 6 |
| Syouda, S | 1 |
| Kouno, T | 1 |
| Fukuhara, A | 1 |
| Berkey, BA | 1 |
| Gaspar, LE | 5 |
| Yeh, KH | 5 |
| Wan, JP | 1 |
| Lin, CS | 1 |
| Liu, CC | 1 |
| Tsamandas, AC | 1 |
| Ravazoula, P | 1 |
| Zolota, V | 1 |
| Salakou, S | 1 |
| Tepetes, K | 1 |
| Kalogeropoulou, C | 1 |
| Tsota, I | 1 |
| Kourelis, T | 1 |
| Karavias, D | 1 |
| Scopa, CD | 1 |
| Bonikos, DS | 1 |
| Petsas, T | 1 |
| White, JD | 1 |
| Junor, EJ | 1 |
| McGarva, J | 1 |
| McManners, J | 1 |
| Holland, IS | 1 |
| Soung, YH | 1 |
| Park, WS | 1 |
| Cho, YG | 1 |
| Kim, CJ | 1 |
| Seo, SH | 1 |
| Nam, SW | 1 |
| Yoo, NJ | 1 |
| Lee, JY | 1 |
| Clavijo, J | 1 |
| Gomez-de-Segura, IA | 1 |
| Gomez-García, L | 1 |
| Vallejo-Cremades, MT | 1 |
| Sanchez, M | 1 |
| de Miguel, E | 1 |
| Ho, HS | 1 |
| Ong, HS | 1 |
| Dzik-Jurasz, A | 1 |
| Hedley, D | 3 |
| Oza, A | 3 |
| Siu, LL | 3 |
| Pond, GR | 4 |
| Katsumata, K | 3 |
| Ichimiya, H | 1 |
| Wakana, Y | 1 |
| Whitehead, RP | 2 |
| Ardalan, B | 7 |
| Goodwin, JW | 1 |
| Balcerzak, SP | 3 |
| Samlowski, WE | 1 |
| Shore, S | 1 |
| Zumstein, L | 1 |
| Willer, A | 2 |
| Weisser, A | 1 |
| Gnad, U | 1 |
| Saussele, S | 2 |
| Kreil, S | 2 |
| El-Salhy, M | 1 |
| Milano, MT | 2 |
| Chmura, SJ | 2 |
| Garofalo, MC | 3 |
| Rash, C | 2 |
| Roeske, JC | 1 |
| Connell, PP | 1 |
| Kwon, OH | 1 |
| Jani, AB | 2 |
| Heimann, R | 2 |
| McDermott, P | 1 |
| Burmeister, J | 1 |
| Bossenberger, T | 1 |
| Fossati, R | 1 |
| Boffi, L | 1 |
| Scatizzi, M | 1 |
| Tardio, B | 1 |
| Mastrodonato, N | 1 |
| Banducci, S | 1 |
| Consani, G | 1 |
| Pancera, G | 2 |
| Wu, WC | 1 |
| Chen, SC | 2 |
| Chuang, WL | 1 |
| Chen, VM | 1 |
| Thrift, KM | 1 |
| Morel-Kopp, MC | 1 |
| Jackson, D | 1 |
| Ward, CM | 1 |
| Flower, RL | 1 |
| Walsh, G | 3 |
| Lynch, PM | 6 |
| Smythe, R | 3 |
| Vaporciyan, A | 2 |
| Faust, J | 1 |
| Cohen, DS | 2 |
| Nivers, R | 2 |
| Joh, JW | 1 |
| Park, YJ | 2 |
| Nam, HR | 1 |
| Ahn, YC | 1 |
| Suganuma, T | 1 |
| Terauchi, R | 1 |
| Shikina, A | 1 |
| Aozasa, S | 1 |
| Utsunomiya, K | 1 |
| Fujino, K | 2 |
| Hase, K | 1 |
| Hildebrandt, B | 1 |
| Wust, P | 1 |
| Dräger, J | 1 |
| Lüdemann, L | 1 |
| Sreenivasa, G | 1 |
| Tullius, SG | 1 |
| Amthauer, H | 1 |
| Felix, R | 1 |
| Ghielmini, M | 1 |
| Martinoli, S | 2 |
| Clerici, M | 1 |
| Cetta, F | 1 |
| Savelli, V | 1 |
| Guarnieri, A | 1 |
| Sai, H | 1 |
| Mitsumori, M | 1 |
| Yamauchi, C | 1 |
| Araki, N | 2 |
| Okumura, S | 1 |
| Hiraoka, M | 1 |
| Takanashi, K | 2 |
| Machida, T | 5 |
| Katsuki, S | 1 |
| Di Cosimo, S | 1 |
| Malaguti, P | 1 |
| Pellicciotta, M | 1 |
| Terzoli, E | 3 |
| Yu, ZW | 1 |
| Dong, XS | 1 |
| Yao, XQ | 1 |
| Yin, XH | 1 |
| Fu, SB | 1 |
| Ema, T | 1 |
| Sakurai, Y | 7 |
| Uraguchi, T | 1 |
| Imazu, H | 1 |
| Ochiai, M | 1 |
| Funabiki, T | 1 |
| Steffens, F | 1 |
| Bathe, OF | 1 |
| Dowden, S | 1 |
| Sutherland, F | 1 |
| Butts, C | 1 |
| Bigam, D | 1 |
| Walley, B | 1 |
| Ruether, D | 1 |
| Ernst, S | 1 |
| Janjan, N | 2 |
| Songun, I | 2 |
| Tesselaar, ME | 2 |
| Kranenbarg, EK | 1 |
| de Vries, JE | 2 |
| Wils, JA | 5 |
| van der Bijl, J | 2 |
| Shibata, SI | 1 |
| Pezner, R | 1 |
| Doroshow, JH | 7 |
| Chow, WA | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| McNamara, MV | 1 |
| Morgan, RJ | 2 |
| Raschko, JW | 1 |
| Somlo, G | 2 |
| Tetef, ML | 1 |
| Yen, Y | 1 |
| Synold, TW | 1 |
| Wagman, L | 1 |
| Vora, N | 1 |
| Carroll, M | 1 |
| Longmate, J | 1 |
| Kuehr, T | 1 |
| Rapoport, BL | 1 |
| Daniel, F | 1 |
| Jacobs, C | 1 |
| Davidson, N | 1 |
| Carmichael, J | 2 |
| Kamoshida, S | 2 |
| Shiogama, K | 1 |
| Matsuyama, A | 1 |
| Shimomura, R | 1 |
| Inada, K | 1 |
| Tsutsumi, Y | 2 |
| Zanke, C | 1 |
| Hohl, H | 1 |
| Adami, B | 1 |
| Schroeder, M | 3 |
| Klein, O | 2 |
| Höhler, T | 2 |
| Eisendrath, P | 1 |
| Legendre, H | 1 |
| Pector, JC | 3 |
| De Becker, D | 1 |
| Ishiyama, T | 2 |
| Nakamura, T | 9 |
| Inazawa, K | 1 |
| Kasai, M | 1 |
| Nozaki, T | 1 |
| Kawamura, S | 1 |
| Sawamura, N | 1 |
| Hiraga, H | 1 |
| Fukuda, Y | 4 |
| Fujio, N | 3 |
| Mayumi, K | 1 |
| Ihara, T | 3 |
| Terakura, M | 1 |
| Takatori, H | 3 |
| Tsukazaki, T | 3 |
| Tsukazaki, Y | 3 |
| Yavuzsen, T | 1 |
| Yaren, A | 2 |
| Tarhan, O | 2 |
| Sagol, O | 2 |
| Coker, A | 1 |
| Alakavuklar, M | 1 |
| Smith, RE | 2 |
| Colangelo, L | 2 |
| Wieand, HS | 14 |
| Begovic, M | 2 |
| Tamaru, N | 1 |
| Hishikawa, Y | 2 |
| Ejima, K | 1 |
| Nagasue, N | 2 |
| Muramatsu, M | 1 |
| Koji, T | 2 |
| Harada, O | 1 |
| Sasamoto, M | 1 |
| Shimaya, S | 1 |
| Sugiyama, S | 2 |
| Ishiko, T | 2 |
| Doi, K | 2 |
| Nakagawa, M | 1 |
| Morinaga, H | 2 |
| Yamane, T | 2 |
| Egami, H | 2 |
| Kanayama, T | 4 |
| Ishimaru, S | 1 |
| Voelter, V | 2 |
| Choi, N | 1 |
| Park, SD | 1 |
| Lynch, T | 1 |
| Wright, C | 2 |
| Wain, J | 1 |
| Donahue, D | 1 |
| Mathisen, D | 1 |
| Hiller, L | 1 |
| Geh, I | 1 |
| Yu, SJ | 1 |
| Joh, YH | 1 |
| Hribaschek, A | 2 |
| Pross, M | 2 |
| Ridwelski, K | 2 |
| Meyer, F | 1 |
| Fenske, A | 1 |
| Krüger, S | 1 |
| Lippert, H | 2 |
| Sasson, AR | 1 |
| Wetherington, RW | 1 |
| Ross, EA | 1 |
| Freedman, G | 3 |
| Pingpank, JF | 1 |
| Eisenberg, BL | 4 |
| Birtle, AJ | 1 |
| Newby, JC | 1 |
| Harland, SJ | 3 |
| Silva e Sousa, AH | 2 |
| Campos, FG | 3 |
| Kiss, DR | 3 |
| Taoka, H | 1 |
| Hirano, H | 1 |
| Mitsui, Y | 1 |
| Umino, W | 1 |
| Nobuoka, Y | 1 |
| Yamashita, M | 1 |
| Tanigawa, K | 1 |
| Yoshimine, S | 1 |
| Imai, T | 2 |
| Miyashita, K | 1 |
| Ikuma, H | 1 |
| Miyanishi, K | 2 |
| Takada, K | 2 |
| Oku, T | 1 |
| Ishiwatari, H | 1 |
| Kogawa, T | 1 |
| Kato, J | 5 |
| Niitsu, Y | 4 |
| Morio, A | 1 |
| Futagawa, T | 1 |
| Oh, T | 1 |
| Yamazaki, A | 1 |
| Konno, H | 2 |
| Benavides, M | 2 |
| García-Alfonso, P | 1 |
| Cobo, M | 1 |
| Muñoz-Martín, A | 1 |
| Gil-Calle, S | 1 |
| Carabantes, F | 1 |
| Villar, E | 1 |
| Graupera, J | 1 |
| Pérez-Manga, G | 3 |
| Maish, M | 1 |
| Erasmus, JJ | 1 |
| Bresalier, R | 1 |
| Munden, RF | 1 |
| Rice, D | 1 |
| Taillier, G | 1 |
| Elmiger, R | 1 |
| Gerster, JC | 1 |
| Imdahl, A | 1 |
| Schöffel, U | 1 |
| Hopf, UT | 1 |
| Elkiran, ET | 1 |
| Beyazit, Y | 1 |
| Robb, WB | 1 |
| Naughton, P | 1 |
| Walsh, TN | 2 |
| Tanimoto, K | 1 |
| Shimokuni, T | 1 |
| Ukon, K | 1 |
| Tsujimoto, H | 1 |
| Kawahara, K | 2 |
| Hiyama, K | 1 |
| Nikkuni, K | 1 |
| Nagahashi, M | 1 |
| Nishimura, A | 2 |
| Kawachi, Y | 2 |
| Arsène, D | 1 |
| Paitel, JF | 1 |
| Buecher, B | 3 |
| Kaminsky, MC | 1 |
| Milan, C | 1 |
| Anastasopoulos, D | 1 |
| Mellou, S | 1 |
| Detsi, I | 1 |
| Tsiakalos, G | 1 |
| Pateli, A | 1 |
| Klouvas, G | 2 |
| Papadimitriou, A | 1 |
| Bonnen, M | 1 |
| Rodriguez-Bigas, M | 2 |
| Pop, C | 1 |
| Nica, R | 1 |
| Vlaicu, R | 1 |
| Vinereanu, D | 1 |
| Aust, DE | 2 |
| Meyer, W | 2 |
| Schwabe, W | 1 |
| Häusler, P | 1 |
| Smirnakis, F | 1 |
| Moskovitz, DN | 1 |
| Novakovic, P | 1 |
| Yates, Z | 1 |
| Lucock, M | 1 |
| Luciani, F | 1 |
| Spada, M | 1 |
| De Milito, A | 1 |
| Molinari, A | 1 |
| Rivoltini, L | 1 |
| Montinaro, A | 1 |
| Marra, M | 1 |
| Lugini, L | 1 |
| Logozzi, M | 1 |
| Lozupone, F | 1 |
| Federici, C | 1 |
| Iessi, E | 1 |
| Parmiani, G | 1 |
| Arancia, G | 3 |
| Belardelli, F | 1 |
| Fais, S | 1 |
| Brasiūnas, V | 1 |
| Brasiūniene, B | 1 |
| Barauskas, G | 1 |
| Goto, A | 2 |
| Szanto, J | 2 |
| Padi, E | 1 |
| Bükki, J | 1 |
| Biakhov, M | 1 |
| Zuber, E | 1 |
| Jacques, C | 2 |
| Stanclift, RM | 1 |
| Gilson, SD | 1 |
| Kosaka, T | 3 |
| Imaizumi, H | 2 |
| Usami, K | 1 |
| Ueno, K | 2 |
| Fujiwara, H | 1 |
| Sonoyama, T | 1 |
| Ichikawa, D | 1 |
| Sakakura, C | 1 |
| Itoi, H | 1 |
| Otsuji, E | 2 |
| Hagiwara, A | 1 |
| Yamagishi, H | 1 |
| Mitsuishi, Y | 1 |
| Kishida, T | 1 |
| Yoshitani, S | 1 |
| Kuroda, M | 1 |
| Yokoi, M | 1 |
| Tamesa, T | 1 |
| Mori, N | 1 |
| Tangoku, A | 1 |
| Oka, M | 2 |
| Tokuuye, K | 4 |
| Al-Khatib, H | 1 |
| Burgart, L | 1 |
| Cera, PJ | 1 |
| Flynn, PJ | 4 |
| Finch, TR | 1 |
| Levitt, R | 3 |
| Windschitl, HE | 5 |
| Knost, JA | 3 |
| Tschetter, LK | 7 |
| Garay, CA | 1 |
| Gurtler, J | 1 |
| Kennedy, P | 1 |
| Brandt, DS | 1 |
| Polikoff, J | 1 |
| Wertheim, M | 1 |
| Shumaker, G | 1 |
| Hallman, D | 1 |
| Burger, B | 1 |
| Gupta, S | 3 |
| Sando, K | 1 |
| Ito, T | 4 |
| Mikata, S | 1 |
| Ide, H | 1 |
| Michiura, T | 1 |
| Kainuma, S | 2 |
| Yamanaka, H | 2 |
| Iwase, K | 2 |
| Ishibashi, S | 1 |
| Nishimura, H | 2 |
| Mizusawa, H | 1 |
| Stevens, CW | 1 |
| Yao, JC | 2 |
| Allen, PK | 1 |
| Mau-Holzmann, UA | 1 |
| Kolb, H | 1 |
| Reichenmiller, HE | 1 |
| Riess, O | 1 |
| Schömig, E | 1 |
| Lee, KE | 1 |
| Chung, CW | 1 |
| Lu, JW | 2 |
| Suardi, S | 1 |
| Lo Vullo, S | 1 |
| Oggionni, M | 1 |
| Olmi, P | 1 |
| Pierotti, MA | 1 |
| Gnad-Vogt, U | 1 |
| Presicci, PF | 1 |
| Veronesi, G | 1 |
| D'Aiuto, M | 1 |
| Spaggiari, L | 1 |
| Russo, V | 1 |
| Pasetto, L | 1 |
| Marino, F | 1 |
| Wheeler, JM | 1 |
| Dodds, E | 1 |
| Warren, BF | 2 |
| Cunningham, C | 1 |
| George, BD | 1 |
| Jones, AC | 1 |
| Mortensen, NJ | 1 |
| Repp, M | 1 |
| Kingreen, D | 1 |
| Hennesser, D | 1 |
| Micheel, S | 1 |
| Scholz, C | 1 |
| Alter, P | 1 |
| Herzum, M | 1 |
| Schaefer, JR | 1 |
| Maisch, B | 1 |
| Hirohashi, Y | 1 |
| Sumi, K | 1 |
| Matsuyama, S | 1 |
| Ikemoto, T | 1 |
| Nishioka, M | 2 |
| Yawata, Y | 1 |
| Terashima, Y | 3 |
| Ikushima, H | 1 |
| Shimada, M | 1 |
| Flandin, I | 1 |
| Kubas, A | 1 |
| Khodri, M | 1 |
| Wautot, V | 1 |
| Mazeron, R | 1 |
| Gohongi, T | 2 |
| Iida, H | 5 |
| Nakai, R | 2 |
| Gunji, N | 2 |
| Akine, Y | 2 |
| Orii, K | 3 |
| Haller, D | 3 |
| Ugai, H | 1 |
| Todoroki, T | 2 |
| Matsuzaki, Y | 2 |
| Fiorentini, G | 7 |
| Caudana, R | 4 |
| Piazza, E | 2 |
| Comella, G | 7 |
| Ceravolo, C | 3 |
| Miserocchi, L | 3 |
| Mambrini, A | 6 |
| Del Freo, A | 2 |
| Zamagni, D | 4 |
| Rabbi, C | 3 |
| Marangolo, M | 4 |
| Dinçer, M | 1 |
| Holcroft, CA | 1 |
| Kvols, LK | 6 |
| Pennucci, C | 1 |
| Sanguinetti, F | 1 |
| Lombardi, M | 2 |
| Nicoli, N | 1 |
| Liu, WB | 1 |
| Xu, XQ | 1 |
| Zhao, YR | 1 |
| Schneider, S | 1 |
| Uchida, K | 2 |
| Yochim, J | 1 |
| Salonga, D | 3 |
| Chen, P | 1 |
| Tsao-Wei, D | 1 |
| Groshen, S | 4 |
| Hoelscher, AH | 3 |
| Danenberg, PV | 6 |
| Richard, K | 1 |
| Toita, T | 3 |
| Uno, T | 3 |
| Kodaira, T | 2 |
| Shinoda, A | 1 |
| Maebayashi, K | 1 |
| Kawaguchi, A | 1 |
| Teshima, T | 2 |
| Chen, CC | 1 |
| Lee, RC | 1 |
| Kanou, Y | 1 |
| Ooshima, H | 1 |
| Kawase, J | 1 |
| Kudou, J | 2 |
| Mizuno, Y | 2 |
| Sekikawa, K | 2 |
| Ohki, S | 2 |
| Ohshima, T | 1 |
| Fukushima, T | 1 |
| Kanazawa, M | 1 |
| Takenoshita, S | 1 |
| Muneoka, K | 1 |
| Shirai, Y | 1 |
| Yokoyama, N | 3 |
| Hatakeyama, K | 2 |
| Nishida Arazawa, ST | 1 |
| Rawet, V | 1 |
| Coelho Siqueira, SA | 1 |
| Gama-Rodrigues, JJ | 1 |
| Schattner, M | 1 |
| Akhurst, T | 1 |
| Kanemitsu, K | 1 |
| Chikamoto, A | 1 |
| Nakahara, O | 1 |
| Hiraoka, T | 2 |
| Ikeda, O | 1 |
| Imuta, M | 1 |
| Feyerherd, P | 1 |
| Ludwig, K | 2 |
| Foitzik, T | 1 |
| Coward, J | 1 |
| Joshi, MB | 1 |
| Conlon, DH | 1 |
| Salonga, DS | 1 |
| Harpole, DH | 3 |
| Sumitsuzi, A | 1 |
| Kamohara, H | 1 |
| Kuwahara, N | 1 |
| Feld, R | 1 |
| Nematollahi, M | 1 |
| Mazeron, JJ | 1 |
| Knaebel, HP | 1 |
| Seiler, C | 1 |
| Lindel, K | 3 |
| Schmitz-Winnenthal, H | 1 |
| Fritz, S | 2 |
| Goldschmidt, H | 1 |
| Krempien, R | 1 |
| Diehl, V | 1 |
| Colucci, G | 6 |
| Thaler, W | 1 |
| Dejaco, H | 1 |
| Marsoner, H | 1 |
| Grones, A | 1 |
| Davis, DA | 1 |
| Fugate, SE | 1 |
| Penberthy, DR | 2 |
| Shepard, RC | 1 |
| Jones, RS | 2 |
| Manzano, H | 1 |
| Chirivella, I | 1 |
| Matano, E | 1 |
| Bianco, R | 1 |
| Infusino, S | 1 |
| Damiano, V | 1 |
| Simeone, E | 1 |
| Diadema, MR | 1 |
| Lieto, E | 2 |
| Castellano, P | 1 |
| Vironen, J | 1 |
| Juhola, M | 1 |
| Kairaluoma, M | 1 |
| Jantunen, I | 1 |
| Kellokumpu, I | 1 |
| Seule, M | 1 |
| Steiner, B | 1 |
| Bauer, I | 1 |
| Freund, M | 1 |
| Schuff-Werner, P | 1 |
| Jankilevich, G | 1 |
| Mermershtain, W | 2 |
| Gluzman, A | 1 |
| Gusakova, I | 1 |
| Walfish, S | 1 |
| Cohen, Y | 5 |
| Ariad, S | 1 |
| Park, KW | 1 |
| Veronese, ML | 1 |
| Berlin, J | 5 |
| Shults, J | 1 |
| Davis, L | 2 |
| Ismail, AS | 1 |
| Quinn, MG | 1 |
| Wright, MA | 1 |
| Ernst, A | 1 |
| Kao, V | 1 |
| Parr, A | 2 |
| Grollman, F | 3 |
| Kirsch, IR | 1 |
| Hokita, S | 1 |
| Xi, H | 2 |
| Mueller, RP | 3 |
| Dienes, HP | 3 |
| Brivio, F | 1 |
| Fumagalli, L | 1 |
| Fattori, L | 1 |
| Nespoli, L | 1 |
| Denova, M | 1 |
| Sargenti, E | 1 |
| Nespoli, A | 1 |
| Ryu, BY | 1 |
| Choi, SJ | 1 |
| Hu, MJ | 1 |
| Wu, YL | 2 |
| Qiao, MM | 1 |
| Fu, H | 1 |
| Bu, LM | 1 |
| Ji, X | 1 |
| Liu, CY | 1 |
| Fisher, R | 2 |
| Schache, D | 1 |
| Rischin, D | 2 |
| Hehr, T | 2 |
| Schleicher, J | 1 |
| Jehle, EC | 1 |
| Boehlke, I | 1 |
| Mauer, AM | 1 |
| Kraut, EH | 1 |
| Krauss, SA | 1 |
| Ansari, RH | 1 |
| Kasza, K | 1 |
| Szeto, L | 1 |
| Bazan, V | 1 |
| Agnese, V | 1 |
| Corsale, S | 1 |
| Calò, V | 1 |
| Valerio, MR | 1 |
| Latteri, MA | 1 |
| Vieni, S | 1 |
| Grassi, N | 1 |
| Dardanoni, G | 1 |
| Tomasino, RM | 1 |
| Gebbia, N | 5 |
| Russo, A | 2 |
| Wong, AA | 1 |
| Tamm, EP | 1 |
| Xiong, HQ | 1 |
| Bonetto, E | 5 |
| Oliani, C | 3 |
| Galli, L | 4 |
| Bordonaro, R | 5 |
| Passardi, A | 2 |
| Choi, EY | 1 |
| Ki Lee, W | 1 |
| Henri, M | 1 |
| Latulippe, JF | 1 |
| Heyen, F | 1 |
| Dubé, S | 1 |
| Eimermacher, A | 1 |
| Menges, M | 1 |
| Gracien, E | 1 |
| Duyster, J | 1 |
| Lersch, C | 2 |
| von Delius, S | 1 |
| Hennig, M | 1 |
| Bredenkamp, R | 1 |
| Zagon, IS | 1 |
| Jaglowski, JR | 1 |
| Verderame, MF | 1 |
| Smith, JP | 5 |
| Leure-Dupree, AE | 1 |
| McLaughlin, PJ | 1 |
| Ramnath, N | 1 |
| Intengan, ME | 1 |
| Slocum, HK | 2 |
| Smith, PF | 1 |
| Stewart, CC | 1 |
| Hoffman, JL | 1 |
| Javle, MM | 2 |
| Berdzik, J | 2 |
| Creaven, PJ | 3 |
| Shirakusa, T | 1 |
| Dong, PD | 1 |
| O'Connor, JK | 1 |
| Sause, WT | 1 |
| Hazard, LJ | 1 |
| Belnap, LP | 1 |
| Noyes, RD | 1 |
| Nudelman, IL | 1 |
| Fuko, V | 1 |
| Geller, A | 1 |
| Fenig, E | 1 |
| Lelchuk, S | 1 |
| Ooka, M | 1 |
| Okajima, S | 1 |
| Shindo, H | 1 |
| Tonouchi, A | 1 |
| Yamamori, H | 1 |
| Ashktorab, H | 1 |
| Dawkins, FW | 1 |
| Mohamed, R | 1 |
| Larbi, D | 1 |
| Smoot, DT | 1 |
| Brugge, WR | 1 |
| Sahani, D | 1 |
| Brachtel, EF | 1 |
| Dai, MS | 1 |
| Felici, A | 1 |
| Gamucci, T | 1 |
| Pollera, CF | 1 |
| Fariello, AM | 1 |
| Moscetti, L | 2 |
| Adami, E | 1 |
| Moody, JS | 1 |
| Russo, SM | 2 |
| Sung, WJ | 1 |
| Kim, TB | 1 |
| Jung, HY | 2 |
| Yu, W | 2 |
| Skopelitis, H | 1 |
| Kopterides, P | 1 |
| Kopteridis, P | 1 |
| Loukeris, D | 1 |
| Sigala, F | 1 |
| Zorbala-Sypsa, A | 1 |
| Felekouras, E | 1 |
| Panucci, MG | 2 |
| Lee, SN | 1 |
| Park, DK | 1 |
| Takezako, Y | 1 |
| Choueiri, MB | 1 |
| Tawil, AN | 1 |
| El-Hajj, II | 1 |
| El Saghir, NS | 1 |
| Dobelbower, R | 1 |
| Lipsitz, S | 2 |
| Sischy, B | 3 |
| Smith, TJ | 2 |
| Kawakami, H | 1 |
| Isobe, K | 1 |
| Aruga, T | 1 |
| Saisho, H | 2 |
| Kawata, T | 1 |
| Fulfaro, F | 1 |
| Bajardi, E | 1 |
| Intrivici, C | 1 |
| Vuolo, G | 1 |
| Carli, AF | 1 |
| Caraglia, M | 1 |
| Del Prete, S | 1 |
| Nikolic-Tomasevic, Z | 2 |
| Jelic, S | 2 |
| Filipovic-Ljeskovic, I | 1 |
| Tomasevic, Z | 2 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 3 |
| Oka, H | 1 |
| Takemiya, S | 1 |
| Nishiyama, K | 1 |
| Yamamura, T | 5 |
| Tsuchiya, S | 2 |
| Ogawa, N | 3 |
| Oman, M | 1 |
| Lundqvist, S | 1 |
| Gustavsson, B | 3 |
| Hafström, LO | 1 |
| Naredi, P | 1 |
| Okur, A | 1 |
| Kantarci, M | 1 |
| Akgun, M | 1 |
| Alper, F | 1 |
| Onbas, O | 1 |
| Bessell, JR | 1 |
| Tsai, JY | 1 |
| Iannitti, D | 1 |
| Berkenblit, A | 1 |
| Akerman, P | 2 |
| Nadeem, A | 1 |
| Rathore, R | 1 |
| Harrington, D | 1 |
| Roye, D | 1 |
| Barnett, JM | 1 |
| Maia, C | 1 |
| Kim, SR | 1 |
| Pistevou-Gompaki, K | 1 |
| Kouloulias, V | 1 |
| Papaloukas, C | 1 |
| Eleftheriadis, D | 1 |
| Andronikidis, I | 1 |
| Eleftheriadis, N | 1 |
| Bitzilekis, D | 1 |
| Schiessel, R | 3 |
| Novi, G | 1 |
| Holzer, B | 1 |
| Rosen, HR | 1 |
| Renner, K | 1 |
| Hölbling, N | 1 |
| Feil, W | 1 |
| Urban, M | 1 |
| Dimri, K | 1 |
| Balachandran, P | 1 |
| Lal, P | 1 |
| Sikora, SS | 1 |
| Rastogi, N | 1 |
| Saxena, R | 1 |
| Datta, NR | 1 |
| Ayyagari, S | 1 |
| Kapoor, VK | 1 |
| Kelley, ST | 1 |
| Bakouboula, B | 1 |
| Morel, O | 1 |
| Douchet, MP | 1 |
| Chauvin, M | 1 |
| Wakelee, HA | 1 |
| Advani, RH | 1 |
| Fodor, MB | 1 |
| Chao, Y | 5 |
| Cabral Filho, S | 1 |
| Majlis, A | 4 |
| Assadourian, S | 1 |
| Ho, WM | 1 |
| Ma, B | 1 |
| Mok, T | 1 |
| Yeo, W | 1 |
| Lai, P | 1 |
| Lim, R | 1 |
| Koh, J | 2 |
| Wong, YY | 1 |
| King, A | 1 |
| Leow, CK | 1 |
| Chan, AT | 1 |
| Bhandary, S | 1 |
| Prasad, GN | 1 |
| Shenoi, SD | 1 |
| Morgan-Meadows, S | 1 |
| Mulkerin, D | 1 |
| Berlin, JD | 4 |
| Bailey, H | 1 |
| Saphner, T | 2 |
| Jumonville, A | 1 |
| Hansen, R | 5 |
| Ahuja, H | 1 |
| McFarland, T | 1 |
| Kamoshita, N | 2 |
| Makita, F | 2 |
| Aiba, M | 1 |
| Tokiniwa, H | 1 |
| Ohwada, S | 4 |
| Rault, A | 1 |
| Béllannée, G | 1 |
| Abdel-Latif, MM | 1 |
| O'Riordan, JM | 1 |
| Kelleher, D | 1 |
| Morales Chamorro, R | 1 |
| Serrano Blanch, R | 1 |
| Méndez Vidal, MJ | 1 |
| Gómez España, MA | 1 |
| Rubio Pérez, MJ | 1 |
| de la Haba Rodríguez, JR | 1 |
| Aranda Aguilar, E | 1 |
| Mark Smithers, B | 1 |
| Smeenk, HG | 1 |
| de Castro, SM | 1 |
| Jeekel, JJ | 1 |
| Erdmann, J | 1 |
| Gouma, DJ | 2 |
| Barletta, E | 1 |
| Fiore, F | 1 |
| Daniele, B | 1 |
| D'Angelo, R | 1 |
| Ferrari, E | 1 |
| Formato, R | 1 |
| Tortoriello, A | 1 |
| Turitto, G | 1 |
| Bruni, GS | 1 |
| Pignata, S | 1 |
| Beresford, M | 1 |
| Richman, P | 1 |
| Stott, D | 1 |
| Osborne, M | 1 |
| Ashford, R | 1 |
| Grainger, J | 1 |
| Al-Jabbour, J | 1 |
| Talbot, I | 1 |
| Mitchell, IC | 2 |
| Meyrick Thomas, J | 1 |
| Livingstone, JI | 2 |
| McCue, J | 1 |
| MacDonald, P | 1 |
| Northover, JA | 1 |
| Windsor, A | 1 |
| Novell, R | 1 |
| Wallace, M | 1 |
| Harrison, RA | 2 |
| Müller, C | 3 |
| Köster, W | 1 |
| Christofferson, E | 1 |
| Le, QT | 1 |
| Ho, A | 1 |
| Greco, R | 1 |
| Norton, J | 1 |
| Yang, GP | 1 |
| Kokkinakis, DM | 1 |
| Neuner, RD | 1 |
| Maciá-Escalante, S | 1 |
| Molina-Garrido, MJ | 1 |
| Carrato-Mena, A | 1 |
| von Borstel, R | 1 |
| Szego, P | 1 |
| Parent, J | 1 |
| Mayrand, S | 1 |
| Corns, R | 1 |
| Burtin, P | 2 |
| Faria, S | 1 |
| Devic, S | 1 |
| Lin, YC | 2 |
| Chang, HK | 1 |
| Hsueh, S | 1 |
| Tsai, CS | 1 |
| Lo, YF | 1 |
| Hwang, TL | 1 |
| Chen, MF | 2 |
| McDermott, U | 1 |
| Galligan, L | 1 |
| Allen, W | 1 |
| Wilson, T | 1 |
| Nielsen, JN | 1 |
| Hoeffding, LD | 1 |
| Machiels, JP | 1 |
| Duck, L | 1 |
| Honhon, B | 1 |
| Coster, B | 1 |
| Coche, JC | 1 |
| Scalliet, P | 1 |
| Aydin, S | 1 |
| Kerger, J | 1 |
| Remouchamps, V | 1 |
| Canon, JL | 1 |
| Van Maele, P | 1 |
| Gilbeau, L | 1 |
| Kirkove, C | 1 |
| Octave-Prignot, M | 1 |
| Baurain, JF | 1 |
| Kartheuser, A | 1 |
| Ahmed, M | 1 |
| Lukyanov, AN | 1 |
| Torchilin, V | 1 |
| Tournier, H | 1 |
| Schneider, AN | 1 |
| Goldberg, SN | 1 |
| Mortensen, JP | 2 |
| Bisgaard, C | 1 |
| Hansen, JW | 1 |
| Rafaelsen, SR | 1 |
| Matsuoka, T | 3 |
| Morikage, N | 1 |
| Kuga, T | 1 |
| Wei, Q | 1 |
| Ewald, P | 3 |
| Bekesch, M | 1 |
| Sarbia, M | 2 |
| Stein, HJ | 2 |
| Vanni, B | 1 |
| Aschelter, AM | 2 |
| Zappalà, AR | 1 |
| Nisticò, C | 2 |
| Martus, P | 1 |
| Papadoupolos, T | 1 |
| Klimpfinger, M | 1 |
| Raab, R | 1 |
| Cusnir, M | 1 |
| Burdick, RK | 1 |
| Van Echo, DA | 1 |
| Moesinger, R | 1 |
| Guo, JC | 1 |
| Zhao, YP | 1 |
| Liao, Q | 2 |
| Ayav, A | 1 |
| Habib, N | 1 |
| Jiao, LR | 1 |
| Lebray, P | 1 |
| Elias, D | 8 |
| Falk, SJ | 2 |
| Hong, CW | 1 |
| Ehrsson, H | 1 |
| Baltesgard, L | 1 |
| Øgreid, D | 1 |
| Starkhammar, H | 4 |
| Wallin, I | 1 |
| Lim, JF | 1 |
| Tjandra, JJ | 2 |
| Hiscock, R | 1 |
| Chao, MW | 2 |
| Dos Santos, JG | 3 |
| Sava, C | 1 |
| Tres, A | 1 |
| Coombes, RC | 3 |
| Crivellari, D | 2 |
| Marchet, A | 3 |
| Sanchez, E | 1 |
| Bliss, JM | 2 |
| Homewood, J | 1 |
| Couvreur, ML | 4 |
| Baron, B | 3 |
| Woods, E | 1 |
| Emson, M | 1 |
| Hickey, H | 1 |
| Dunn, JA | 2 |
| Lorchel, F | 1 |
| Buffet, J | 1 |
| Bosset, M | 1 |
| Chaigneau, L | 2 |
| Servagi, S | 1 |
| Jatoi, A | 2 |
| Murphy, BR | 1 |
| Nikcevich, DA | 2 |
| Fitch, TR | 1 |
| Rowland, KM | 1 |
| Gul, M | 1 |
| Duzenli, A | 1 |
| Bircan, M | 1 |
| Cander, B | 1 |
| Kocak, S | 1 |
| Ozdemir, K | 1 |
| Innis, M | 1 |
| Sandiford, N | 1 |
| Shenoy, RK | 1 |
| Prussia, PR | 1 |
| Zbar, A | 1 |
| O'Rourke, MA | 1 |
| Frontiera, MS | 1 |
| Jackson, DV | 1 |
| Eloubeidi, MA | 1 |
| Russo, S | 2 |
| Steg, A | 2 |
| Thornton, J | 1 |
| Fiveash, J | 1 |
| Carpenter, M | 1 |
| Blanquicett, C | 2 |
| Johnson, MR | 2 |
| Bamba, T | 1 |
| Kanda, T | 1 |
| Ohashi, M | 1 |
| Hanyu, T | 1 |
| Yajima, K | 2 |
| Tanabe, T | 3 |
| Kitajima, A | 1 |
| Amano, S | 1 |
| Enomoto, K | 1 |
| Matsuo, S | 2 |
| Negishi, N | 1 |
| Oinuma, T | 1 |
| Nemoto, N | 1 |
| Shiba, Y | 1 |
| Umekita, N | 3 |
| Noda, K | 2 |
| Kitamura, M | 5 |
| Pigeau, H | 1 |
| Dupré, PF | 1 |
| Benouna, J | 1 |
| Classe, JM | 1 |
| Pioud, R | 1 |
| Dravet, F | 1 |
| Mackay, HJ | 1 |
| Billingsley, K | 1 |
| Smith, A | 1 |
| Yeung, R | 1 |
| Croitoru, M | 1 |
| Stathopoulos, JG | 1 |
| Xynotroulas, JP | 1 |
| Dimou, E | 1 |
| Watwe, V | 1 |
| Lawrence, D | 2 |
| Groth, J | 1 |
| El-Hajjar, D | 1 |
| Geradts, J | 1 |
| Dobelbower, MC | 1 |
| Raisch, KP | 1 |
| Seay, LL | 1 |
| Clemons, LK | 1 |
| Suter, S | 1 |
| Posey, J | 2 |
| Bonner, JA | 1 |
| Benatti, P | 1 |
| Gafà, R | 1 |
| Barana, D | 1 |
| Marino, M | 1 |
| Scarselli, A | 1 |
| Pedroni, M | 1 |
| Maestri, I | 1 |
| Guerzoni, L | 1 |
| Roncucci, L | 1 |
| Menigatti, M | 1 |
| Roncari, B | 1 |
| Maffei, S | 1 |
| Santini, A | 1 |
| Losi, L | 1 |
| Di Gregorio, C | 1 |
| Ponz de Leon, M | 1 |
| Lanza, G | 1 |
| Neiss, S | 1 |
| Ling, FC | 1 |
| Moenig, S | 1 |
| Cedermark, B | 2 |
| Bentzen, SM | 1 |
| Grönberg, H | 1 |
| Hultborn, R | 1 |
| Albertsson, M | 5 |
| Lee, JN | 1 |
| Aparicio, J | 1 |
| Fernandez-Martos, C | 1 |
| Vincent, JM | 1 |
| Maestu, I | 1 |
| Llorca, C | 1 |
| Busquier, I | 1 |
| Campos, JM | 1 |
| Perez-Enguix, D | 1 |
| Malani, AK | 1 |
| Gupta, C | 1 |
| Rangineni, S | 1 |
| Gupta, V | 1 |
| Taylor, JR | 2 |
| Hollis, DR | 3 |
| Sutherland, S | 2 |
| Buchsbaum, DJ | 1 |
| Eloubeidi, M | 1 |
| Vickers, SM | 1 |
| Chhieng, DC | 1 |
| Carpenter, MD | 1 |
| Sellers, JC | 1 |
| Tago, M | 1 |
| Nakamura, N | 2 |
| Shiraishi, K | 1 |
| Sasano, N | 1 |
| Ohtomo, K | 1 |
| Ambrosini-Spaltro, A | 1 |
| Salvi, F | 1 |
| Betts, CM | 1 |
| Frezza, GP | 1 |
| Piemontese, A | 1 |
| Del Prete, P | 1 |
| Baldoni, C | 1 |
| Foschini, MP | 1 |
| Viale, G | 2 |
| Horton, PJ | 1 |
| Chaudhury, PK | 1 |
| Znajda, TL | 1 |
| Martinie, JB | 1 |
| Rochon, C | 1 |
| Tzimas, GN | 1 |
| Metrakos, P | 1 |
| González Vela, JL | 1 |
| Sánchez Guillén, JM | 1 |
| Treviño Aguirre, SA | 1 |
| Hernández Barajas, D | 1 |
| Brito Villanueva, WO | 1 |
| Cárdenas Estrada, E | 1 |
| González Guerrero, JF | 1 |
| Yagüe, XH | 1 |
| Soy, E | 1 |
| Merino, BQ | 1 |
| Puig, J | 1 |
| Fabregat, MB | 1 |
| Colomer, R | 1 |
| Medarova, Z | 1 |
| Pham, W | 1 |
| Kim, Y | 1 |
| Moore, A | 2 |
| Cho, HK | 1 |
| Lee, ES | 1 |
| Shim, CK | 1 |
| Chung, SJ | 1 |
| Kim, DD | 1 |
| Marshall, J | 3 |
| Haluszka, O | 1 |
| Engstrom, P | 4 |
| Watson, JC | 1 |
| Eisenberg, D | 1 |
| McGarrity, E | 1 |
| Chiang, SS | 2 |
| Gallego-Plazas, J | 1 |
| Calvo, FA | 1 |
| García-Sabrido, JL | 1 |
| Gómez-Espí, M | 1 |
| Del Valle, E | 1 |
| Muñoz-Jiménez, F | 1 |
| Alvarez, E | 1 |
| Ohsugi, H | 1 |
| Seong, J | 1 |
| Cho, CW | 1 |
| Lee, Y | 1 |
| Han, SH | 1 |
| Zhou, ZF | 1 |
| Yin, BJ | 1 |
| Liu, DL | 1 |
| Zhu, LJ | 1 |
| Pan, LX | 1 |
| Mantyh, CR | 1 |
| Yu, D | 2 |
| Clary, BM | 4 |
| Pappas, TN | 4 |
| El-Khoueiry, AB | 1 |
| Kluger, N | 1 |
| Bessis, D | 1 |
| Guillot, B | 1 |
| Rouzbahman, M | 1 |
| Matono, S | 1 |
| Yamana, H | 1 |
| Sugiura, T | 2 |
| Mizuno, H | 1 |
| Hoki, M | 1 |
| Souma, Y | 1 |
| Ozawa, H | 1 |
| Kanou, T | 1 |
| Nakamori, Y | 1 |
| Giordano, KF | 1 |
| Stella, PJ | 1 |
| Foster, N | 1 |
| Mailliard, JA | 7 |
| Arveux, P | 1 |
| Girault, C | 1 |
| Kalykaki, A | 2 |
| Samonis, G | 1 |
| Varette, C | 6 |
| Bergenfeldt, M | 1 |
| Dongiovanni, V | 1 |
| Spinnler, MT | 1 |
| Ardine, M | 1 |
| Carneiro, BA | 1 |
| Kaminer, L | 1 |
| Eldibany, M | 1 |
| Sreekantaiah, C | 1 |
| Kaul, K | 1 |
| Locker, GY | 1 |
| Heluwaert, F | 1 |
| Santre, C | 1 |
| Martin, C | 2 |
| Hilleret, MN | 1 |
| Martin, D | 3 |
| Yau, K | 1 |
| Price, P | 1 |
| Pillai, RG | 1 |
| Aboagye, E | 1 |
| Kaur, T | 1 |
| Khanduja, KL | 1 |
| Kaushik, T | 1 |
| Kaushik, G | 1 |
| Gupta, R | 2 |
| Gupta, NM | 1 |
| Vaiphei, K | 1 |
| Beretta, E | 1 |
| Mancin, M | 1 |
| Dognini, G | 1 |
| Rades, D | 1 |
| Tribius, S | 1 |
| Yekebas, EF | 1 |
| Bahrehmand, R | 1 |
| Wildfang, I | 1 |
| Kilic, E | 1 |
| Muellerleile, U | 1 |
| Gross, E | 1 |
| Schild, SE | 2 |
| Alberti, W | 1 |
| Shuai, XM | 1 |
| Han, GX | 1 |
| Wang, GB | 1 |
| Chen, JH | 1 |
| Engles, JM | 1 |
| Quarless, SA | 1 |
| Mambo, E | 1 |
| Ishimori, T | 1 |
| Wahl, RL | 1 |
| Weissenberger, C | 1 |
| Otto, F | 1 |
| Barke, A | 1 |
| Henne, K | 1 |
| von Plehn, G | 1 |
| Rein, A | 1 |
| Bartelt, S | 1 |
| Henke, M | 1 |
| Forshaw, MJ | 2 |
| Chrystal, K | 2 |
| Cheong, K | 2 |
| Atkinson, S | 1 |
| Botha, A | 1 |
| Mason, RC | 4 |
| Vincitore, M | 1 |
| Michelini, A | 1 |
| Sheehan, S | 1 |
| Burge, ME | 1 |
| Jackson, DP | 1 |
| Anthoney, DA | 1 |
| Halstead, F | 1 |
| Hirota, T | 2 |
| Kodaira, S | 4 |
| Kassam, Z | 1 |
| Lockwood, G | 1 |
| O'brien, C | 1 |
| Brierley, J | 1 |
| Siu, L | 1 |
| Cummings, B | 3 |
| Ringash, J | 1 |
| Sengul, N | 1 |
| Woodhouse, S | 1 |
| Arrigain, S | 1 |
| Xu, M | 1 |
| Larach, JA | 1 |
| Ahn, BK | 1 |
| Weiss, EG | 1 |
| Nogueras, JJ | 1 |
| Valencia Julve, J | 1 |
| Alonso Orduña, V | 1 |
| Escó Barón, R | 1 |
| López-Mata, M | 1 |
| Méndez Villamón, A | 1 |
| Ould-Kaci, M | 1 |
| Breau, JL | 1 |
| Morvan, F | 3 |
| Serio, G | 1 |
| Pederzoli, P | 5 |
| Iacono, C | 2 |
| Pulica, C | 1 |
| Capelli, P | 1 |
| Torri, T | 3 |
| Pacetti, P | 2 |
| Pagani, M | 1 |
| Alvarez, JV | 1 |
| López, MJ | 1 |
| Segovia, F | 1 |
| Filipovich, E | 1 |
| Castro, IG | 1 |
| Mediema, BE | 1 |
| Curr, N | 1 |
| Saunders, H | 1 |
| Murugasu, A | 1 |
| Schwarz, M | 1 |
| Gin, D | 1 |
| Li, QS | 1 |
| Zhang, XQ | 1 |
| Li, DP | 1 |
| Sheng, XG | 1 |
| Du, XL | 1 |
| Song, QQ | 1 |
| Jeon, SB | 1 |
| Wöhlke, M | 1 |
| Barten, M | 2 |
| Kim, SN | 2 |
| Hong, YJ | 1 |
| Contreras, J | 1 |
| Macías, J | 1 |
| Fortes, I | 1 |
| Rivas, D | 1 |
| González, P | 1 |
| Herruzo, I | 1 |
| Moreno-Vega, AL | 1 |
| Fuentes-Pradera, J | 1 |
| Gordón-Santiago, Mdel M | 1 |
| Vargas-Machuca, JC | 1 |
| Orel, NF | 1 |
| Borisova, TA | 1 |
| Markovich, AA | 1 |
| Zaguzina, NN | 1 |
| Zhang, YS | 1 |
| Zhu, LF | 1 |
| Weng, XS | 1 |
| Corporaal, S | 1 |
| Smit, WM | 1 |
| Russel, MG | 1 |
| Legdeur, MC | 1 |
| Abraham, J | 1 |
| Brewster, A | 1 |
| Hardwick, R | 1 |
| Havard, T | 1 |
| Lewis, W | 1 |
| Askill, C | 1 |
| Manson, J | 1 |
| Williamst, GT | 1 |
| Court, J | 1 |
| Farrey, K | 1 |
| Crozier, JE | 1 |
| McKee, RF | 1 |
| Angerson, WJ | 1 |
| Anderson, JH | 2 |
| Horgan, PG | 1 |
| McMillan, DC | 1 |
| Roof, KS | 1 |
| Coen, J | 1 |
| Lynch, TJ | 2 |
| Fidias, P | 1 |
| Choi, NC | 4 |
| Melloni, G | 1 |
| Bandiera, A | 1 |
| Carretta, A | 1 |
| Ciriaco, P | 1 |
| Arrigoni, G | 1 |
| Zannini, P | 1 |
| Chateau, MC | 1 |
| Borrelly, C | 1 |
| Guida, C | 1 |
| Cascini, LG | 1 |
| Morrica, B | 1 |
| Parisi, V | 1 |
| Gebbia, V | 8 |
| Verderame, F | 2 |
| Ferraù, F | 2 |
| Callari, A | 1 |
| Caruso, M | 2 |
| Tirrito, ML | 1 |
| Valenza, R | 3 |
| Borsellino, N | 2 |
| Tralongo, P | 2 |
| Chen, JZ | 1 |
| Luo, RC | 1 |
| Skare, NG | 1 |
| Vinholes, J | 1 |
| Lago, S | 1 |
| Pecego, R | 1 |
| Carlone, N | 1 |
| Manni, A | 1 |
| Aitini, E | 3 |
| Etzel, CJ | 1 |
| Amos, CI | 1 |
| Milas, L | 2 |
| Hittelman, WN | 1 |
| Karpeh, MS | 1 |
| Coit, DG | 1 |
| Klimstra, DS | 1 |
| Bossard, N | 1 |
| Renouf, D | 1 |
| Abbrederis, K | 1 |
| Roethling, N | 2 |
| Swanson, GP | 1 |
| Faulkner, J | 1 |
| Noble, MJ | 1 |
| Stephens, RL | 5 |
| O'Rourke, TJ | 1 |
| Quick, DP | 1 |
| Thompson, IM | 1 |
| Crawford, ED | 4 |
| Thompson, JN | 1 |
| Scarffe, JH | 3 |
| Lofts, FJ | 3 |
| Smith, DB | 2 |
| Verma, M | 1 |
| Weeden, S | 1 |
| Ferrero, JM | 2 |
| Chamorey, E | 2 |
| Oudard, S | 1 |
| Dides, S | 1 |
| Lesbats, G | 2 |
| Cavaglione, G | 1 |
| Nouyrigat, P | 1 |
| Foa, C | 1 |
| Kaphan, R | 1 |
| McCoy, S | 1 |
| Patel, T | 1 |
| Cobb, PW | 2 |
| Yost, KJ | 1 |
| Spreafico, A | 1 |
| Johnson, CD | 1 |
| Tan, MT | 1 |
| Stipa, F | 1 |
| De Salvo, GL | 1 |
| Fabris, G | 1 |
| Ferraro, B | 1 |
| Bruttocao, A | 1 |
| Aurilio, G | 1 |
| Vecchione, L | 1 |
| Harashima, K | 1 |
| Nonaka, T | 1 |
| Jia, JH | 1 |
| Zhang, MX | 1 |
| Zhou, YB | 1 |
| Zhang, RM | 1 |
| Yu, XP | 1 |
| Okamoto, R | 4 |
| Kandabashi, K | 1 |
| Sasaki, E | 1 |
| Nakagawa, S | 1 |
| Yabusaki, H | 4 |
| Saigenji, K | 1 |
| Choi, W | 1 |
| Cogdell, D | 1 |
| Hamilton, SR | 1 |
| Qiu, XH | 1 |
| Zhang, SQ | 1 |
| Chen, ZM | 1 |
| Kobayashi, D | 1 |
| Honda, I | 2 |
| Kagawa, S | 1 |
| Tokunaga, N | 1 |
| Nishizaki, M | 2 |
| Teraishi, F | 1 |
| Gouchi, A | 1 |
| Matsuoka, J | 1 |
| Chujo, M | 1 |
| Kawano, Y | 2 |
| Miyawaki, M | 1 |
| Imakiire, T | 1 |
| Hayashita, Y | 1 |
| Kwon, JM | 1 |
| Park, BB | 2 |
| Han, MJ | 1 |
| Radosevic-Jelic, L | 1 |
| Daban, A | 1 |
| Gundling, F | 1 |
| Fuchs, M | 1 |
| Nowak, L | 1 |
| Hoffmann, E | 1 |
| Schepp, W | 1 |
| Zhou, AW | 1 |
| Fu, YC | 1 |
| Tripathy, D | 1 |
| Closon-Dejardin, MT | 1 |
| Untereiner, M | 1 |
| Leduc, B | 1 |
| Mackiewicz, R | 1 |
| Movsas, B | 2 |
| Diratzouian, H | 1 |
| Hanlon, A | 1 |
| Stein, J | 2 |
| Kister, D | 1 |
| Eisenberg, B | 2 |
| Kendal, WS | 1 |
| Jonker, D | 2 |
| Stern, H | 1 |
| Moyana, T | 1 |
| Blaszkowsky, L | 3 |
| Battu, S | 2 |
| Kolodziej, M | 1 |
| Rousey, SR | 1 |
| Pluenneke, RE | 1 |
| Perrine, G | 1 |
| Mull, S | 1 |
| Ilegbodu, D | 1 |
| Wang, HP | 1 |
| Lee, JM | 1 |
| Yang, CH | 1 |
| Lin, JT | 3 |
| Haraguchi, Y | 1 |
| Ueno, S | 1 |
| Sakamoto, F | 1 |
| Toyoyama, H | 1 |
| Ikeda, N | 2 |
| Kamikado, C | 1 |
| Aikou, T | 1 |
| Tsuchiya, M | 1 |
| Takita, W | 1 |
| Koshino, H | 1 |
| Kurihara, A | 1 |
| Kaneko, H | 2 |
| Teramoto, T | 2 |
| Strojan, P | 2 |
| Zakotnik, B | 1 |
| Chun, JH | 1 |
| Lisi, V | 1 |
| Peramiquel, L | 1 |
| Dalmau, J | 1 |
| Puig, L | 1 |
| Roé, E | 1 |
| Fernández-Figueras, MT | 1 |
| Alomar, A | 1 |
| Dawson, SJ | 1 |
| Biagi, J | 1 |
| Foo, KF | 1 |
| Hui, A | 1 |
| Milner, AD | 1 |
| Thomas, RJ | 1 |
| Kalra, AV | 1 |
| Campbell, RB | 1 |
| Constenla, M | 3 |
| Fodor, M | 4 |
| Voznyi, E | 3 |
| Risse, ML | 1 |
| Gotlib, V | 1 |
| Khaled, S | 1 |
| Lapko, I | 1 |
| Mar, N | 1 |
| Agelaki, S | 1 |
| Kotsakis, AP | 1 |
| Gioulbasanis, J | 1 |
| Tsetis, D | 1 |
| Sfakiotaki, G | 1 |
| Chatzidaki, D | 1 |
| Rana, V | 1 |
| Gould, MS | 1 |
| Palla, S | 1 |
| Guha, S | 1 |
| Oeda, M | 1 |
| Sanada, Y | 2 |
| Wada, Y | 6 |
| Mizuiri, H | 1 |
| Shigematsu, H | 1 |
| Cho, CH | 2 |
| Shyr, Y | 1 |
| Beauchamp, RD | 2 |
| Chakravarthy, B | 1 |
| Prenzel, KL | 1 |
| König, A | 1 |
| Schnickmann, C | 1 |
| Yokoi, K | 2 |
| Ishikawa, N | 1 |
| Seya, T | 2 |
| Horiba, K | 1 |
| Kanazawa, Y | 2 |
| Ohkawa, K | 2 |
| Kudoh, H | 2 |
| Yoshioka, M | 1 |
| Tajiri, T | 2 |
| Honma, H | 1 |
| Fukada, T | 1 |
| Yasuno, K | 1 |
| Koyama, T | 1 |
| Seike, K | 2 |
| Kametaka, H | 1 |
| Hashimoto, R | 1 |
| Hasegawa, A | 1 |
| de Geus-Oei, LF | 1 |
| Ruers, TJ | 1 |
| Leer, JW | 2 |
| Corstens, FH | 1 |
| Oyen, WJ | 1 |
| da Silva, RG | 1 |
| Demiray, M | 1 |
| Ulukaya, EE | 1 |
| Arslan, M | 1 |
| Gokgoz, S | 1 |
| Saraydaroglu, O | 1 |
| Ercan, I | 1 |
| Evrensel, T | 1 |
| Manavoglu, O | 1 |
| Minisini, AM | 1 |
| Pauletto, G | 1 |
| Bergonzi, P | 1 |
| Fasola, G | 1 |
| Sadighi, S | 1 |
| Mohagheghi, MA | 1 |
| Montazeri, A | 1 |
| Sadighi, Z | 1 |
| Schoppmeyer, K | 2 |
| Wiedmann, M | 2 |
| Liebmann, A | 1 |
| Hauss, J | 1 |
| Mossner, J | 2 |
| Caca, K | 2 |
| Witzigmann, H | 1 |
| Hildebrandt, G | 1 |
| Anderson, C | 1 |
| Nijagal, A | 1 |
| Noguchi, H | 1 |
| Kitajima, M | 4 |
| Konishi, N | 1 |
| Sato, G | 2 |
| Nagaoka, I | 1 |
| Futagawa, S | 1 |
| Rojas Llimpe, FL | 2 |
| Mutri, V | 2 |
| Giannetta, L | 1 |
| Funaioli, C | 2 |
| Berardi, R | 2 |
| Longobardi, C | 2 |
| Piana, E | 1 |
| Martoni, AA | 2 |
| Ezzeldin, H | 1 |
| Vance, K | 1 |
| Sellers, S | 1 |
| Popov, IP | 1 |
| Kecmanovic, D | 1 |
| Borojevic, N | 1 |
| Micev, MT | 1 |
| Kezic, I | 1 |
| Siefker-Radtke, A | 1 |
| González-González, JJ | 1 |
| Sanz-Alvarez, L | 1 |
| Marqués-Alvarez, L | 1 |
| Navarrete-Guijosa, F | 1 |
| Martínez-Rodríguez, E | 1 |
| Cho, BC | 2 |
| Cheong, JH | 1 |
| Kelsey, CR | 2 |
| Honda, K | 1 |
| Fukuhara, T | 2 |
| Kushihata, F | 1 |
| Abe, S | 3 |
| Okuda, T | 3 |
| Koo, DH | 1 |
| Miyake, Y | 1 |
| Oshima, K | 1 |
| Zu, Y | 1 |
| Kennedy, EP | 1 |
| Hwang, SJ | 1 |
| Lee, SD | 1 |
| Sin, CH | 1 |
| Nam, SH | 1 |
| Mottolese, M | 2 |
| Orlandi, G | 1 |
| Merola, R | 1 |
| Buglioni, S | 2 |
| Di Benedetto, A | 1 |
| Pinnarò, P | 1 |
| Perracchio, L | 1 |
| Venturo, I | 1 |
| Cianciulli, A | 1 |
| Hughes, MA | 2 |
| Frassica, DA | 2 |
| Younes, F | 1 |
| Moukadem, W | 1 |
| Nasr, F | 1 |
| Chahine, G | 1 |
| Wydmański, J | 1 |
| Poltorak, S | 1 |
| Maka, B | 1 |
| Miszczyk, L | 1 |
| Wolny, E | 1 |
| Bielaczyc, G | 1 |
| Zajusz, A | 1 |
| Fritschi, L | 1 |
| Jensen, SA | 1 |
| Vilmar, A | 2 |
| Sørensen, JB | 2 |
| Kraus-Tiefenbacher, U | 1 |
| Leitner, A | 1 |
| Grobholz, R | 1 |
| Kähler, G | 1 |
| Murakami, D | 1 |
| Tsujitani, S | 3 |
| Osaki, T | 1 |
| Katano, K | 1 |
| Tatebe, S | 1 |
| Ikeguchi, M | 2 |
| Valenti, V | 1 |
| Diaz-Gonzalez, J | 1 |
| Beunza, JJ | 1 |
| Alvarez-Cienfuegos, JA | 1 |
| Borget, I | 1 |
| Aupérin, A | 2 |
| Abbas, M | 1 |
| Mousseau, M | 2 |
| Cassan, P | 1 |
| Stremsdoerfer, N | 1 |
| Nasca, S | 2 |
| Queuniet, AM | 1 |
| Ozyiğit, T | 1 |
| Buğra, Z | 1 |
| Lahans, T | 1 |
| Kabeya, K | 1 |
| Neri, B | 3 |
| Pantaleo, P | 1 |
| Grifoni, R | 1 |
| Paoletti, C | 1 |
| Rotella, V | 1 |
| Pantalone, D | 1 |
| Taddei, A | 1 |
| Mercatelli, A | 2 |
| Tonelli, P | 1 |
| Diculescu, M | 1 |
| Hoepffner, NM | 1 |
| Sailer, V | 1 |
| Chick, J | 1 |
| Brock, K | 1 |
| Albert, D | 1 |
| Morgan, B | 1 |
| Berry, DP | 1 |
| Blanshard, K | 1 |
| Price, D | 1 |
| Bower, G | 1 |
| Steward, WP | 1 |
| Qayyum, A | 1 |
| Mujtaba, I | 1 |
| Ogino, S | 1 |
| Kawasaki, T | 6 |
| Loda, M | 1 |
| Vega-Villegas, ME | 1 |
| López-Brea, MF | 1 |
| Karanlik, H | 1 |
| Muslumanoglu, M | 1 |
| Igci, A | 1 |
| Emek, E | 1 |
| Ozmen, V | 1 |
| Kecer, M | 1 |
| Parlak, M | 1 |
| Cambray i Amenós, M | 1 |
| Navarro García, M | 1 |
| Martí Ragué, J | 1 |
| Pareja Fernández, L | 1 |
| Pera Fábregas, J | 1 |
| Grau Cat, J | 1 |
| Navarro Ferrando, JT | 1 |
| Mate Sanz, JL | 1 |
| Ribera Santasusana, JM | 1 |
| Zuccaro, G | 3 |
| Vargo, JJ | 1 |
| Dumot, JA | 1 |
| Carroll, MA | 1 |
| Saggio, G | 1 |
| Cesta, A | 1 |
| Amiconi, G | 1 |
| Blasio, AD | 1 |
| Manza, SG | 1 |
| Rusin, B | 1 |
| Ferris, AM | 1 |
| Takano, S | 1 |
| Oda, K | 1 |
| Oshima, T | 1 |
| Noda, M | 3 |
| Kuno, T | 2 |
| Hashimoto, A | 2 |
| Gega, M | 1 |
| Yagyuu, T | 1 |
| Yoshikawa, R | 3 |
| Yanagi, H | 4 |
| Minami, K | 1 |
| Kameda, A | 1 |
| Tsutani, Y | 1 |
| Miyahara, E | 2 |
| Noso, Y | 1 |
| Dolinsky, CM | 1 |
| Mick, R | 1 |
| Whittington, RW | 1 |
| Rosato, EF | 1 |
| Dupont, J | 1 |
| Seo, BG | 1 |
| Viteri, A | 1 |
| Muñoz, A | 1 |
| Rubio, I | 1 |
| Barceló, R | 2 |
| Martínez-Bueno, A | 1 |
| Carrera, S | 1 |
| López-Vivanco, G | 1 |
| Piessen, G | 1 |
| Briez, N | 1 |
| Yanagisawa, Y | 1 |
| Maruta, F | 1 |
| Iinuma, N | 1 |
| Ishizone, S | 1 |
| Koide, N | 1 |
| Nakayama, J | 1 |
| Miyagawa, S | 2 |
| Pintoffl, JP | 1 |
| Meisinger, I | 1 |
| Horger, M | 1 |
| Lim, YJ | 1 |
| Rhee, JC | 1 |
| Bae, YM | 1 |
| Chun, WJ | 1 |
| Isacoff, WH | 1 |
| Bendetti, JK | 1 |
| Barstis, JJ | 1 |
| Jazieh, AR | 1 |
| Sur, HY | 1 |
| Sung, HJ | 1 |
| Jeen, YT | 1 |
| Chun, HJ | 1 |
| Gaffney, DK | 2 |
| Miller, B | 1 |
| Ryu, J | 1 |
| Avizonis, V | 1 |
| Fromm, M | 1 |
| Greven, K | 1 |
| Enzinger, P | 1 |
| Lawrence, C | 2 |
| Norwood, AA | 1 |
| Tucci, M | 1 |
| Benghuzzi, H | 1 |
| Caron, P | 1 |
| Seiter, K | 2 |
| Malik, Z | 1 |
| Mickle, M | 1 |
| Mulcahy, MF | 1 |
| Chen, YW | 1 |
| Yen, SH | 2 |
| Chen, SY | 1 |
| Huang, PI | 1 |
| Shiau, CY | 1 |
| Liu, YM | 1 |
| Kaminski, A | 1 |
| Giuliani, F | 3 |
| Cartenì, G | 1 |
| Manzione, L | 3 |
| Romito, S | 1 |
| Tchekmedyian, S | 1 |
| Hu, E | 1 |
| Chan, D | 1 |
| Amado, RG | 1 |
| Nabhan, C | 1 |
| Ragam, A | 1 |
| Samuels, B | 1 |
| Milton, DT | 1 |
| Prasad, L | 1 |
| Hooberman, A | 1 |
| Hartsell, W | 2 |
| Anthony, A | 1 |
| Weisman, R | 1 |
| Bitran, JD | 5 |
| Anderson, SE | 1 |
| Bains, M | 1 |
| Hummer, A | 1 |
| Ostwald, C | 1 |
| Lay, GC | 1 |
| Caraul, B | 1 |
| Dessì, M | 1 |
| Orrù, S | 1 |
| Murtas, R | 1 |
| Deidda, MA | 1 |
| Farigu, R | 1 |
| Farci, D | 1 |
| Maxia, L | 1 |
| Casula, G | 1 |
| Amichetti, M | 1 |
| Feisthammel, J | 1 |
| Tampellini, M | 3 |
| Brizzi, MP | 1 |
| Bitossi, R | 1 |
| Alabiso, I | 1 |
| Sculli, CM | 1 |
| Chiusa, L | 1 |
| Papotti, M | 1 |
| Dogliotti, L | 2 |
| Kuo, LJ | 1 |
| Liu, MC | 1 |
| Jian, JJ | 1 |
| Horng, CF | 1 |
| Cheng, TI | 1 |
| Chen, CM | 1 |
| Fang, WT | 1 |
| Chung, YL | 1 |
| Nielsen, D | 1 |
| Iversen, A | 1 |
| Vejlø, C | 1 |
| Yamada, E | 2 |
| Ninomiya, M | 1 |
| Takakura, N | 2 |
| Yoshizawa, Y | 1 |
| Sasaya, S | 1 |
| Maezawa, K | 1 |
| Rodriguez-Blanco, I | 1 |
| Ginarte Val, M | 1 |
| Peteiro, C | 1 |
| Toribio, J | 1 |
| Jen, YM | 2 |
| Di Maggio, G | 1 |
| Di Cristina, L | 1 |
| Agueli, R | 1 |
| Russo, P | 1 |
| Riechelmann, RP | 1 |
| Townsley, CA | 1 |
| Chin, SN | 1 |
| Moon, YW | 2 |
| Hoshina, K | 1 |
| Kobayashi, I | 2 |
| Kurita, M | 1 |
| Shida, D | 1 |
| Shinkai, H | 1 |
| Miyashita, M | 1 |
| Paran, H | 1 |
| Edelstein, E | 1 |
| Klein, B | 1 |
| Gutman, M | 1 |
| Wang, YJ | 1 |
| Feng, JX | 1 |
| Cao, WG | 1 |
| Xi, WQ | 1 |
| Xu, HP | 1 |
| Che, JF | 1 |
| Jin, YN | 1 |
| Zhang, HG | 1 |
| Zhang, YJ | 1 |
| Song, SP | 1 |
| Chu, DT | 1 |
| Yang, ZY | 1 |
| Hong, X | 1 |
| Lu, L | 1 |
| Zhang, CH | 1 |
| Kotasek, D | 1 |
| Davies, T | 1 |
| Briasoulis, E | 1 |
| Fatouros, M | 1 |
| Roukos, DH | 1 |
| Van Krieken, HH | 1 |
| Mulder, NH | 3 |
| Carstens, H | 1 |
| Takeuchi, S | 3 |
| Hentrich, M | 1 |
| Seroneit, T | 1 |
| Marabotti, C | 1 |
| Awad, L | 3 |
| Köberle, D | 1 |
| Borner, MM | 4 |
| Rufibach, K | 1 |
| Wernli, M | 2 |
| Leslie, M | 1 |
| Maehara, S | 1 |
| Makino, I | 1 |
| Imamura, S | 1 |
| Aso, M | 1 |
| Katoh, H | 1 |
| Cobo, F | 1 |
| De Celis, G | 1 |
| Pereira, A | 1 |
| Latorre, X | 1 |
| Pujadas, J | 1 |
| Albiol, S | 1 |
| Sharma, SP | 1 |
| Choi, MY | 1 |
| Lauwers, GY | 2 |
| Hur, C | 1 |
| Chung, DC | 1 |
| Mitchell, P | 1 |
| Beale, P | 2 |
| Friedlander, M | 1 |
| White, S | 1 |
| Nishino, Y | 1 |
| Yamaura, G | 1 |
| Ohtsuka, K | 1 |
| Kakudo, Y | 1 |
| Chiba, N | 1 |
| Sakayori, M | 1 |
| Murakawa, Y | 2 |
| Shibata, H | 2 |
| Mamiya, N | 1 |
| Mamiya, K | 1 |
| Satomi, M | 1 |
| Chisato, N | 1 |
| Ebisawa, Y | 1 |
| Bartelink, H | 2 |
| Nelson, JW | 1 |
| Chino, JP | 1 |
| Clough, RW | 1 |
| Di, LJ | 1 |
| Jin, ML | 1 |
| Shi, YX | 1 |
| Mortimer, J | 2 |
| Kocha, W | 2 |
| Zhong, LX | 1 |
| Tao, QS | 1 |
| Tang, XM | 1 |
| Iyer, RV | 1 |
| Gibbs, J | 1 |
| Kuvshinoff, B | 1 |
| Kepner, J | 1 |
| Soehnlein, N | 1 |
| Stahtea, XN | 1 |
| Roussidis, AE | 1 |
| Kanakis, I | 1 |
| Tzanakakis, GN | 1 |
| Chalkiadakis, G | 1 |
| Kletsas, D | 1 |
| Karamanos, NK | 1 |
| Deeks, ED | 1 |
| Suehisa, H | 1 |
| Toyooka, S | 1 |
| Uchida, A | 1 |
| Soh, J | 1 |
| Ouchida, M | 1 |
| Date, H | 1 |
| Sanghera, P | 1 |
| Ho, K | 1 |
| Muscroft, T | 1 |
| Hartley, A | 1 |
| Wrzesinski, SH | 1 |
| McGurk, ML | 1 |
| Donovan, CT | 1 |
| Ferencz, TM | 1 |
| Desai, SP | 1 |
| Knol, JA | 1 |
| Huang, EH | 1 |
| McGinn, CJ | 1 |
| Millis, R | 1 |
| Jean, M | 1 |
| Kennedy, T | 2 |
| Marnitz, S | 1 |
| Köhler, C | 1 |
| Roth, C | 1 |
| Füller, J | 1 |
| Bischoff, A | 1 |
| Wendt, T | 1 |
| Schneider, A | 2 |
| Budach, V | 1 |
| Lee, WB | 1 |
| Sy, HM | 1 |
| Filip, DJ | 1 |
| Grossniklaus, HE | 1 |
| Thomsen Lønborg, J | 1 |
| Mård, D | 1 |
| Astrup Jensen, S | 1 |
| Allendorf, JD | 1 |
| Lauerman, M | 1 |
| Bill, A | 1 |
| DiGiorgi, M | 1 |
| Goetz, N | 1 |
| Remotti, H | 1 |
| Schrope, B | 1 |
| Sherman, W | 1 |
| Fine, RL | 1 |
| Terzi, C | 1 |
| Canda, AE | 1 |
| Atila, K | 1 |
| Sonmez, D | 1 |
| Fuzun, M | 1 |
| Gorken, IB | 1 |
| Obuz, F | 1 |
| Eigenbrod, T | 1 |
| Klebl, F | 1 |
| Ishizu, K | 1 |
| Sunose, N | 1 |
| Tsuruo, T | 5 |
| Yamori, T | 3 |
| Nikaido, T | 1 |
| Araki, H | 1 |
| Chiba, H | 1 |
| Jung, GR | 1 |
| Kim, KJ | 1 |
| Choi, CH | 1 |
| Lee, TB | 1 |
| Han, SI | 1 |
| Han, HK | 1 |
| Lim, SC | 1 |
| Suttie, SA | 1 |
| Park, KG | 1 |
| Smith, TA | 1 |
| Merlin, F | 1 |
| Prochilo, T | 1 |
| Kildani, B | 2 |
| Tucci, A | 1 |
| Ferrari, S | 1 |
| D'Adda, P | 1 |
| Kuebler, JP | 2 |
| Robinson, B | 1 |
| Hua, D | 2 |
| Huang, ZH | 2 |
| Deng, JZ | 1 |
| Katia, D | 1 |
| Zilembo, N | 1 |
| Ardizzoia, A | 1 |
| Marini, G | 1 |
| Schieppati, G | 1 |
| Pinotti, G | 1 |
| Palazzo, S | 1 |
| Fagnani, D | 1 |
| Reguzzoni, G | 1 |
| Agostana, B | 1 |
| Duro, M | 1 |
| Botta, M | 1 |
| Mozzana, R | 1 |
| Mantovani, G | 1 |
| Torres, MA | 1 |
| Jhingran, A | 1 |
| Levenback, CF | 1 |
| Bodurka, DC | 1 |
| Ramondetta, LM | 1 |
| Hirakawa, M | 1 |
| Son, HJ | 1 |
| Isaksson, B | 1 |
| Almström, M | 1 |
| Albiin, N | 1 |
| Permert, J | 1 |
| Fang, WJ | 1 |
| Zhang, XC | 1 |
| Yu, LF | 1 |
| Bao, HY | 1 |
| Shi, GM | 1 |
| Huang, S | 1 |
| Siperstein, AE | 1 |
| Ballem, N | 1 |
| Parikh, RT | 1 |
| Schippinger, W | 1 |
| Samonigg, H | 1 |
| Thödtmann, R | 1 |
| Jagoditsch, M | 1 |
| Steger, GG | 1 |
| Jakesz, R | 3 |
| Herbst, F | 1 |
| Hofbauer, F | 1 |
| Wohlmuth, P | 1 |
| Ruotsalainen, T | 1 |
| Korpela, R | 1 |
| Saxelin, M | 1 |
| Ollus, A | 1 |
| Valta, P | 1 |
| Schinzari, G | 1 |
| D'Argento, E | 1 |
| Trigila, N | 1 |
| Astone, A | 2 |
| Lim, L | 1 |
| Chao, M | 1 |
| Millar, JL | 2 |
| Kipp, D | 1 |
| Rezo, A | 1 |
| Fong, A | 1 |
| Jones, IT | 1 |
| McLaughlin, S | 1 |
| van de Schoot, L | 1 |
| Romme, EA | 1 |
| van Lijnschoten, G | 1 |
| van Driel, OJ | 1 |
| Cen, P | 1 |
| Majno, PE | 1 |
| Giostra, E | 1 |
| Terraz, S | 1 |
| Allal, AS | 1 |
| Wolfson, AH | 1 |
| Crook, W | 1 |
| Krishan, A | 1 |
| Markoe, AM | 1 |
| Lucci, JA | 1 |
| Coco, C | 5 |
| Cosimelli, M | 3 |
| Bellavita, R | 1 |
| Morganti, AG | 1 |
| La Torre, G | 1 |
| Trodella, L | 1 |
| Genovesi, D | 3 |
| Portaluri, M | 1 |
| Maurizi-Enrici, R | 1 |
| Barbera, F | 1 |
| Maranzano, E | 1 |
| Lupattelli, M | 1 |
| Ibele, AR | 1 |
| Koplin, SA | 1 |
| Slaughenhoupt, BL | 1 |
| Kryger, JV | 1 |
| Friedl, A | 1 |
| Lund, DP | 1 |
| Shin, H | 1 |
| Tudor-Smith, C | 1 |
| Raraty, M | 1 |
| Jung, EJ | 2 |
| Pinsk, I | 1 |
| Phang, PT | 1 |
| Jeffery, M | 1 |
| Schulz, J | 1 |
| Soufi-Mahjoubi, R | 1 |
| Barrueco, J | 2 |
| Muzikansky, A | 1 |
| Sujendran, V | 1 |
| Wheeler, J | 1 |
| Baron, R | 1 |
| Maynard, N | 1 |
| Ohara, T | 1 |
| Okuda, Y | 1 |
| Suzuki, N | 3 |
| Kiguchi, K | 1 |
| Ishizuka, B | 1 |
| Tavares-Bello, R | 1 |
| Law, CC | 1 |
| Fu, YT | 1 |
| Chau, KK | 1 |
| Choy, TS | 1 |
| So, PF | 1 |
| Wong, KH | 1 |
| Perez-Staub, N | 1 |
| Yang, YQ | 1 |
| Zhang, LJ | 1 |
| Dong, H | 1 |
| Jiang, CL | 1 |
| Wu, JX | 1 |
| Xiao, HS | 1 |
| Gao, HJ | 1 |
| Zhang, QH | 1 |
| Peignaux, K | 1 |
| N'guyen, TD | 1 |
| Mirabel, X | 1 |
| Marchal, C | 1 |
| Verrelle, P | 2 |
| Bai, P | 1 |
| Zhang, R | 1 |
| Li, XG | 1 |
| Ma, SK | 1 |
| Wu, LY | 1 |
| Zhang, WH | 1 |
| Han, JQ | 1 |
| Liang, RX | 1 |
| Qu, FS | 1 |
| Yan, TX | 1 |
| Li, XQ | 1 |
| Rakhit, A | 1 |
| Fettner, SH | 1 |
| Brennscheidt, U | 1 |
| Wang, HZ | 1 |
| Wang, HB | 1 |
| Gao, H | 1 |
| Kang, SP | 1 |
| Ledbetter, L | 1 |
| Johnson, M | 1 |
| McLean, SR | 1 |
| Shousha, S | 1 |
| Francis, N | 1 |
| Lim, A | 1 |
| Eccles, S | 1 |
| Nathan, M | 1 |
| Brock, CS | 1 |
| Palmieri, C | 1 |
| Mitsuno, M | 1 |
| Ide, T | 1 |
| Ohtaka, K | 1 |
| Senzaki, M | 1 |
| Ishida, S | 1 |
| Yada, A | 1 |
| Hanai, M | 1 |
| Kurakata, S | 1 |
| Min, JS | 6 |
| Fujisawa, M | 1 |
| Ono, S | 1 |
| Nitta, S | 1 |
| Shinjou, K | 1 |
| Machida, M | 1 |
| Kitabatake, T | 1 |
| Ishibiki, Y | 1 |
| Urao, M | 1 |
| Kojima, K | 2 |
| Armbrust, T | 1 |
| Sobotta, M | 1 |
| Grabbe, E | 1 |
| Ramadori, G | 1 |
| Xue, YW | 1 |
| Han, JG | 1 |
| Li, BX | 1 |
| Salvagni, S | 1 |
| Tagliaferri, P | 1 |
| Crocicchio, F | 1 |
| Mari, E | 1 |
| Kim, KS | 1 |
| Choi, JS | 1 |
| Cha, SH | 1 |
| Torrisi, R | 1 |
| Ghisini, R | 1 |
| Bottiglieri, L | 1 |
| Veronesi, P | 1 |
| Luini, A | 1 |
| Orlando, L | 1 |
| Colleoni, M | 3 |
| De Greve, J | 1 |
| Braumann, D | 2 |
| Joosens, E | 1 |
| Müller, L | 1 |
| Janssens, J | 1 |
| Reimer, P | 1 |
| Späth-Schwalbe, E | 1 |
| Wilke, HJ | 1 |
| Van Den Brande, J | 1 |
| Debois, M | 1 |
| Bethe, U | 1 |
| Caputo, G | 1 |
| Condorelli, S | 1 |
| Germano, D | 1 |
| Mattina, M | 1 |
| Amadio, P | 1 |
| Reggiardo, G | 2 |
| Tomimatsu, H | 1 |
| Akamatsu, M | 1 |
| Nakata, W | 1 |
| Ohmae, T | 1 |
| Ohata, K | 1 |
| Matsubara, S | 1 |
| Katamoto, T | 1 |
| Udaka, T | 1 |
| Jida, M | 1 |
| Waki, N | 1 |
| Kubo, M | 1 |
| Sogabe, O | 1 |
| Shirakawa, K | 1 |
| Fanti, S | 1 |
| Castellucci, P | 1 |
| Sperandi, F | 1 |
| Furuta, S | 1 |
| Sunagawa, R | 1 |
| Inaba, K | 1 |
| Isogaki, J | 1 |
| Komori, Y | 1 |
| Uyama, I | 1 |
| Zhao, AG | 1 |
| Yang, JK | 1 |
| You, SF | 1 |
| Zhao, HL | 1 |
| Tang, LD | 1 |
| Lim, T | 1 |
| Kim, KM | 1 |
| Wisinski, KB | 1 |
| Wahl, AO | 1 |
| Sencan, O | 1 |
| Buyukcelik, A | 1 |
| Boruban, MC | 1 |
| Demirkazik, A | 1 |
| Senler, FC | 1 |
| Onur, H | 1 |
| Francis, P | 1 |
| Crown, J | 2 |
| Balil, A | 1 |
| Nordenskjöld, B | 2 |
| Vorobiof, D | 1 |
| Dolci, S | 1 |
| Jamin, S | 1 |
| Bendahmane, B | 1 |
| Gelber, RD | 2 |
| Castiglione-Gertsch, M | 2 |
| Piccart-Gebhart, M | 1 |
| Horger, MS | 1 |
| Koppenhöfer, U | 1 |
| Brunner, TB | 1 |
| Rupp, A | 1 |
| Melzner, W | 1 |
| Ballardini, M | 1 |
| Orlandi, M | 1 |
| Guadagni, S | 2 |
| Fu, SY | 1 |
| Leon, R | 1 |
| Aristu, JJ | 1 |
| Riedel, ER | 1 |
| Balteskard, L | 2 |
| Tveit, K | 2 |
| Heikkilä, R | 1 |
| Garmo, H | 1 |
| Copois, V | 1 |
| Bec, N | 1 |
| Robert, B | 1 |
| Fraslon, C | 1 |
| Conseiller, E | 1 |
| Molina, F | 1 |
| Larroque, C | 1 |
| Koutras, AK | 1 |
| Gerolymos, MK | 1 |
| Kontogeorgou, E | 1 |
| Iconomou, G | 1 |
| Tsiata, E | 1 |
| Chrysanthopoulos, C | 1 |
| Tai, BC | 1 |
| Soo, RA | 1 |
| Han, HC | 1 |
| Ng, SS | 1 |
| Tan, WL | 1 |
| Zeps, N | 1 |
| Baratta, A | 1 |
| Gorin, RJ | 1 |
| Costa, R | 1 |
| Kogo, M | 1 |
| Yoneyama, K | 1 |
| Imawari, M | 1 |
| Kiuchi, Y | 1 |
| Lee, KC | 1 |
| Calzolari, F | 1 |
| Tison, C | 1 |
| Giampalma, E | 1 |
| Cecconetto, L | 1 |
| Golfieri, R | 1 |
| Yonemori, K | 1 |
| Takesako, Y | 1 |
| Rosemurgy, A | 1 |
| Luzardo, G | 1 |
| Bowers, C | 1 |
| Zervos, E | 1 |
| Al-Saadi, S | 1 |
| Carroll, R | 1 |
| Chheda, H | 1 |
| Carey, L | 1 |
| Goldin, S | 1 |
| Grundy, S | 1 |
| Kudryk, B | 1 |
| Zwiebel, B | 1 |
| Black, T | 1 |
| Briggs, J | 1 |
| Chervenick, P | 1 |
| Berdah, JF | 1 |
| Teissier, E | 1 |
| Codoul, JF | 1 |
| Badetti, JL | 1 |
| Hébert, C | 1 |
| Mari, V | 1 |
| Ogreid, D | 1 |
| Kook, MC | 1 |
| Lee, JR | 1 |
| Cho, SJ | 1 |
| Tsunoda-Shimizu, H | 1 |
| Hamaoka, T | 1 |
| Tsugawa, K | 3 |
| Yagata, H | 1 |
| Kikuchi, M | 1 |
| Kimmick, GG | 1 |
| Cirrincione, C | 1 |
| Duggan, DB | 1 |
| Bhalla, K | 2 |
| Robert, N | 1 |
| Berry, D | 1 |
| Lemke, S | 1 |
| Winer, E | 1 |
| Touboul, E | 3 |
| Tepper, J | 1 |
| Krasna, MJ | 1 |
| Reed, CE | 1 |
| Goldberg, R | 1 |
| Kiel, K | 1 |
| Willett, C | 1 |
| Sugarbaker, D | 1 |
| Ette, C | 1 |
| Kudrimoti, MR | 1 |
| Fromm, ML | 1 |
| Lieuw-a-Fa, M | 1 |
| Peringa, J | 1 |
| Leeksma, O | 1 |
| Terpstra, W | 1 |
| Seller, S | 1 |
| Santoro, L | 1 |
| Zorzino, L | 1 |
| Dell'Orto, P | 1 |
| Sonzogni, A | 1 |
| Monfardini, L | 1 |
| Milani, V | 1 |
| Pazos, M | 1 |
| Issels, RD | 2 |
| Buecklein, V | 1 |
| Tschoep, K | 1 |
| Schaffer, P | 1 |
| Duehmke, E | 1 |
| Schaffer, M | 1 |
| Paik, YH | 1 |
| Lee, DK | 1 |
| Yoon, DS | 1 |
| Gorbounova, VA | 1 |
| Biakhov, MY | 1 |
| Granov, DA | 1 |
| Hossain, AM | 1 |
| Blatter, J | 1 |
| Kaiser, C | 1 |
| Ma, D | 1 |
| Tani, M | 1 |
| Kawai, M | 1 |
| Miyazawa, M | 1 |
| Hirono, S | 1 |
| Ina, S | 1 |
| Nishioka, R | 1 |
| Uchiyama, K | 2 |
| Werbrouck, BF | 1 |
| Pauwels, WJ | 1 |
| De Bleecker, JL | 1 |
| Katoh, S | 1 |
| Ohno, T | 2 |
| Kataoka, M | 1 |
| Tanaka, E | 1 |
| Harima, Y | 1 |
| Hollerbach, S | 1 |
| Wilhelm, G | 1 |
| Derigs, HG | 1 |
| Grossmann, J | 1 |
| von Moos, R | 1 |
| Heitzmann, F | 1 |
| Terraciano, L | 1 |
| Neuweiler, J | 1 |
| Bieri, G | 1 |
| Rust, C | 1 |
| Toepfer, M | 1 |
| Li, LH | 1 |
| Zhu, JD | 1 |
| Ohaki, Y | 1 |
| Trindade, F | 1 |
| Haro, R | 1 |
| Fariña, MC | 1 |
| Requena, L | 1 |
| Kadikoylu, G | 1 |
| Yavasoglu, I | 1 |
| Barutca, S | 1 |
| Meydan, N | 1 |
| Bolaman, Z | 1 |
| Sasada, T | 1 |
| Denno, R | 4 |
| Kanai, M | 2 |
| Mizukami, Y | 1 |
| Kohno, S | 1 |
| Takabayashi, A | 2 |
| Viel, E | 2 |
| Demarchi, MF | 1 |
| Legat, C | 1 |
| Stein, U | 1 |
| Thiery-Vuillemin, A | 1 |
| Yakir, R | 1 |
| Luna, K | 1 |
| Marc, W | 1 |
| Tamar, S | 1 |
| Avraham, R | 1 |
| Ayala, H | 1 |
| Hsiao, CW | 1 |
| Jao, SW | 1 |
| Ishiyama, H | 1 |
| Hayakawa, K | 1 |
| Heudel, P | 1 |
| You, B | 1 |
| Glehen, O | 1 |
| Vie, B | 1 |
| Innominato, PF | 1 |
| Bjarnason, G | 1 |
| Coens, C | 1 |
| Tumolo, S | 1 |
| Genet, D | 1 |
| Bottomley, A | 1 |
| Giacchetti, S | 1 |
| Lévi, F | 5 |
| Laessig, D | 1 |
| Haas, M | 1 |
| Golf, A | 1 |
| Mundt, P | 1 |
| Mochmann, HC | 1 |
| Ebhardt, H | 1 |
| Zeitz, M | 1 |
| Duchmann, R | 1 |
| Pauschinger, M | 1 |
| Seung, SK | 1 |
| Smith, JW | 1 |
| Ross, HJ | 1 |
| Papadopoulos, CA | 1 |
| Wilson, H | 2 |
| Walko, CM | 1 |
| Delva, R | 4 |
| Jacob, J | 1 |
| Merrouche, Y | 3 |
| Piot, G | 3 |
| Chen, XZ | 1 |
| Gou, HF | 1 |
| Chen, ZX | 1 |
| Chen, JP | 1 |
| Kristensen, B | 1 |
| Cold, S | 1 |
| Edlund, P | 1 |
| Ewertz, M | 1 |
| Lindman, H | 1 |
| Bergh, J | 1 |
| Saadati, H | 1 |
| Bouillet, T | 2 |
| Hiro, J | 1 |
| Pennathur, A | 1 |
| Landreneau, RJ | 1 |
| Ward, J | 1 |
| Christie, NA | 1 |
| Schuchert, M | 1 |
| Cooper, K | 1 |
| Land, SR | 1 |
| Keam, B | 1 |
| Ham, HS | 1 |
| Gorgun, B | 2 |
| Goplerud, DR | 1 |
| Watne, AL | 2 |
| Thompson, JP | 1 |
| Dockerty, MB | 1 |
| Symmonds, RE | 1 |
| Hayles, AB | 1 |
| Brindley, GV | 1 |
| Bonnet, JD | 1 |
| Brocard, H | 1 |
| Akoun, G | 1 |
| Turpin, G | 1 |
| Gendre, JP | 1 |
| Rhodes, EG | 1 |
| Boesen, EA | 1 |
| Corringham, RE | 1 |
| Matthews, KB | 1 |
| Tuddenham, EG | 1 |
| Kernoff, PB | 1 |
| Steffensrud, S | 1 |
| Erichsen, H | 1 |
| Røysland, P | 1 |
| Klepp, R | 1 |
| Klepp, O | 1 |
| Wünsch, E | 1 |
| Petersen, H | 1 |
| Ahmed, NK | 1 |
| Jones, BG | 1 |
| Fielding, JW | 1 |
| Newman, CE | 1 |
| Howell, A | 1 |
| Brookes, VS | 2 |
| Wright, J | 1 |
| Abolfathi, A | 1 |
| Penman, E | 1 |
| Marks, V | 1 |
| Deppe, G | 4 |
| Cohen, CJ | 3 |
| Gazet, JC | 1 |
| Spears, CP | 5 |
| Shahinian, AH | 1 |
| Moran, RG | 1 |
| Heidelberger, C | 2 |
| Corbett, TH | 2 |
| Okazaki, H | 1 |
| Shirasaka, T | 10 |
| Fujii, S | 1 |
| Pant, KD | 1 |
| Shochat, D | 1 |
| Nelson, MO | 1 |
| Goldenberg, DM | 2 |
| Villacorte, D | 1 |
| Heck, D | 1 |
| Corbett, T | 1 |
| Habeshaw, T | 1 |
| Adam, JS | 1 |
| Kirk, J | 1 |
| Harada, T | 3 |
| Ohmura, H | 1 |
| Nishizawa, O | 1 |
| Tsuchida, S | 2 |
| Dimitriadis, K | 1 |
| Boutis, L | 1 |
| Tavantzis, J | 1 |
| Bouchoris, N | 1 |
| Koukourikos, S | 1 |
| Hatzigogos, K | 1 |
| Safarini, S | 1 |
| Houghton, JA | 17 |
| Houghton, PJ | 15 |
| Kolarić, K | 3 |
| Dujmović, I | 1 |
| Beals, SP | 1 |
| Lucas, RJ | 1 |
| Bukowski, RM | 11 |
| Schacter, LP | 1 |
| Groppe, CW | 4 |
| Hewlett, JS | 4 |
| Weick, JK | 7 |
| Togni, P | 1 |
| Sessa, C | 2 |
| Varini, M | 1 |
| Cavalli, F | 2 |
| Gahbauer, R | 2 |
| Rodriquez-Antunez, A | 1 |
| Hermann, R | 1 |
| Smith, FP | 10 |
| Rustgi, VK | 1 |
| Schertz, G | 1 |
| Woolley, PV | 11 |
| Schein, PS | 17 |
| Theodors, A | 2 |
| Waddell, WR | 2 |
| Gerner, RE | 1 |
| Reich, MP | 1 |
| Patt, YZ | 2 |
| Peters, RE | 1 |
| Chuang, VP | 1 |
| Wallace, S | 2 |
| Mavligit, G | 1 |
| Oberfield, RA | 4 |
| Karakousis, CP | 1 |
| Kauppila, A | 1 |
| Jänne, O | 1 |
| Kujansuu, E | 1 |
| Vihko, R | 1 |
| Taylor, RE | 2 |
| Smith, IE | 2 |
| Ford, HT | 1 |
| Bryant, BM | 1 |
| Casey, AJ | 1 |
| Smyth, JF | 2 |
| Miller, TP | 3 |
| McMahon, LJ | 1 |
| Karrer, K | 2 |
| Pridun, N | 2 |
| Denck, H | 1 |
| Konno, A | 1 |
| Togawa, K | 1 |
| Grozea, PN | 1 |
| Carlin, DA | 1 |
| Young, D | 2 |
| Vine, E | 1 |
| Ghanbarpour, A | 1 |
| Shani, J | 2 |
| Siemsen, JK | 1 |
| Wolf, W | 3 |
| Sordillo, PP | 2 |
| Magill, GB | 2 |
| Avni, A | 1 |
| Haikin, H | 1 |
| Feuchtwanger, MM | 1 |
| Sacks, M | 1 |
| Naggan, L | 1 |
| Sarov, B | 1 |
| Sarov, I | 1 |
| Shorthouse, AJ | 1 |
| Jones, JM | 1 |
| Steel, GG | 1 |
| Peckham, MJ | 2 |
| Schwarzenberg, L | 6 |
| Tourani, JM | 2 |
| Michalski, B | 2 |
| Hayat, M | 2 |
| Dorval, T | 6 |
| Misset, JL | 8 |
| Delouche, C | 1 |
| Brochon, D | 1 |
| Fraioli, JP | 1 |
| Jasmin, C | 2 |
| Maral, R | 2 |
| Mathe, G | 5 |
| Allegra, JC | 2 |
| Woodcock, TM | 1 |
| Richman, SP | 4 |
| Bland, KI | 1 |
| Wittliff, JL | 1 |
| Kitade, F | 1 |
| Sakuramoto, K | 1 |
| Okajima, K | 1 |
| Cedermark, BJ | 3 |
| Gunven, P | 1 |
| Hammarberg, C | 1 |
| Brooks, JL | 1 |
| Ryan, JA | 1 |
| Bauermeister, DE | 1 |
| von der Maase, H | 2 |
| Magnusson, K | 1 |
| Sveinsson, T | 1 |
| Iigo, M | 16 |
| Kuretani, K | 6 |
| Hoshi, A | 15 |
| Komatubara, S | 1 |
| Teramoto, S | 1 |
| Tatsumura, T | 2 |
| Murakami, A | 1 |
| Fujisawa, T | 1 |
| Chorba, T | 1 |
| Orenstein, JM | 1 |
| Harisiadis, L | 1 |
| Moody, T | 1 |
| Burton, T | 1 |
| Schulof, RS | 1 |
| Futatsuki, K | 3 |
| Shimada, S | 2 |
| Kanda, Y | 4 |
| Ishibashi, I | 2 |
| Sendai, H | 1 |
| Akazawa, S | 4 |
| Cunningham, J | 1 |
| Purvis, J | 1 |
| DeWys, WD | 1 |
| Begg, CB | 1 |
| Brodovsky, H | 1 |
| Creech, R | 1 |
| Khandekar, J | 1 |
| Smith, BJ | 2 |
| Ashford, RF | 2 |
| Bakowski, M | 1 |
| Hellman, K | 1 |
| Newton, K | 1 |
| Phillips, R | 1 |
| Lambert, J | 1 |
| Peters, N | 1 |
| Higgins, GA | 2 |
| Amadeo, JH | 2 |
| Smith, DE | 4 |
| Humphrey, EW | 1 |
| Keehn, RJ | 2 |
| McElhinney, J | 1 |
| McCaughan, JJ | 1 |
| Murphy, GP | 2 |
| Slack, NH | 1 |
| Mittelman, A | 7 |
| Velez-Garcia, E | 1 |
| Vogel, CL | 1 |
| Marcial, V | 1 |
| Ketcham, A | 1 |
| Bartolucci, A | 1 |
| Smalley, R | 1 |
| Lopez, M | 3 |
| Perno, CF | 1 |
| Papaldo, P | 1 |
| Presant, CA | 3 |
| Denes, AE | 1 |
| Bartolucci, AA | 4 |
| Coates, AS | 1 |
| Tattersall, MH | 4 |
| Swanson, C | 1 |
| Fox, RM | 3 |
| Raghavan, D | 1 |
| Engstrom, PF | 10 |
| MacIntyre, JM | 2 |
| Klaassen, DJ | 3 |
| Kiseleva, ES | 1 |
| Pitskhelauri, VG | 1 |
| Trakhtenberg, AKh | 1 |
| Bidiak, IP | 1 |
| Zholkiver, KI | 1 |
| Knysh, VI | 2 |
| Aliev, BM | 1 |
| Dvoĭrin, VV | 1 |
| Barsukov, IuA | 1 |
| Sparsø, BH | 1 |
| Kristensen, D | 1 |
| Christiansen, J | 1 |
| Damgaard Nielsen, SA | 1 |
| Hebjørn, M | 1 |
| Andersen, B | 1 |
| Sternberg, CN | 1 |
| Cheng, EW | 1 |
| Malcolm, A | 1 |
| Johnson, DH | 2 |
| Burnett, LS | 1 |
| Jones, HW | 1 |
| Jolivet, J | 3 |
| Giroux, L | 1 |
| Laurin, S | 1 |
| Gruber, J | 1 |
| Bettez, P | 1 |
| Band, PR | 1 |
| Schutt, AJ | 12 |
| Rubin, J | 8 |
| Creagan, ET | 1 |
| Inagaki, J | 2 |
| Horikoshi, N | 4 |
| Ezaki, K | 2 |
| Usui, N | 2 |
| Nakada, H | 4 |
| Naito, E | 1 |
| Fuse, Y | 1 |
| Yorioka, S | 1 |
| Kodama, T | 1 |
| Takino, T | 1 |
| Shimono, M | 1 |
| Shiu, MH | 2 |
| Cahan, A | 1 |
| Fogh, J | 1 |
| Fortner, JG | 2 |
| Kingsnorth, AN | 1 |
| Russell, WE | 1 |
| McCann, PP | 1 |
| Diekema, KA | 1 |
| Malt, RA | 1 |
| Bedikian, AY | 4 |
| Bodey, GP | 7 |
| Valdivieso, M | 7 |
| Burgess, MA | 2 |
| Friedman, MA | 2 |
| Carter, SK | 9 |
| Kimura, K | 1 |
| Hannigan, J | 1 |
| Wakui, A | 3 |
| Taguchi, T | 4 |
| Burk, K | 1 |
| Gropp, C | 2 |
| Rodeck, G | 1 |
| Logothetis, CJ | 5 |
| Samuels, ML | 5 |
| von Eschenbach, AC | 2 |
| Trindade, A | 3 |
| Ogden, S | 2 |
| Grant, C | 2 |
| Johnson, DE | 3 |
| Hakuta, Y | 1 |
| Ashizawa, I | 1 |
| Nakazima, K | 1 |
| Akiyama, J | 2 |
| Sagara, Y | 1 |
| Takeda, Y | 2 |
| Boulis-Wassif, S | 1 |
| Gerard, A | 3 |
| Loygue, J | 1 |
| Camelot, D | 1 |
| Duez, N | 6 |
| Sekine, S | 1 |
| Katsumi, S | 1 |
| Mukae, S | 1 |
| Furukawa, R | 1 |
| Watanabe, I | 2 |
| Panettiere, FJ | 3 |
| Haas, C | 1 |
| McDonald, B | 1 |
| Costanzi, JJ | 5 |
| Athens, J | 1 |
| Oishi, N | 5 |
| Chen, TT | 4 |
| Sampi, K | 1 |
| Fujiki, T | 1 |
| Izuno, O | 2 |
| Suda, Y | 2 |
| Urata, M | 1 |
| Yanagawa, T | 1 |
| Yura, Y | 1 |
| Nitta, T | 1 |
| Lönn, U | 4 |
| Lönn, S | 4 |
| Nosoh, Y | 1 |
| Yoshinaka, K | 1 |
| Yamaguchi, M | 2 |
| Toge, T | 3 |
| Niimoto, M | 3 |
| Hattori, T | 4 |
| Satomi, Y | 3 |
| Senga, Y | 1 |
| Fukuda, M | 1 |
| Nakahashi, M | 2 |
| Ohshima, H | 1 |
| Furuhata, A | 2 |
| Douglass, HO | 8 |
| Lavin, PT | 5 |
| Goudsmit, A | 1 |
| Paul, AR | 6 |
| Lagomarsino Caprino, MC | 1 |
| De Vecchis, L | 2 |
| Popoli, P | 1 |
| Abderhalden, RT | 1 |
| Zimmerman, SE | 1 |
| Naganuma, K | 3 |
| Kawabata, H | 3 |
| Oh-Hara, T | 1 |
| Tsukagoshi, S | 5 |
| Shlemkevich, MP | 2 |
| Shiian, DN | 4 |
| Phillips, RK | 1 |
| Quill, DS | 1 |
| Dudley, HA | 1 |
| Ibuka, T | 2 |
| Ishiwata, J | 3 |
| Satomi, T | 2 |
| Shehata, WM | 2 |
| Meyer, RL | 2 |
| Krause, RJ | 1 |
| Jazy, FK | 2 |
| Cormier, WJ | 2 |
| Kozlov, AM | 1 |
| Novikov, AM | 1 |
| Bassalyk, LS | 1 |
| Sof'ina, ZP | 1 |
| Kihara, K | 4 |
| Kusuyama, H | 1 |
| Washizuka, M | 2 |
| Vogl, SE | 1 |
| Brodovsky, HS | 2 |
| Bauer, M | 1 |
| Horton, J | 2 |
| Elson, PJ | 1 |
| Babaian, RJ | 1 |
| Carter, DC | 2 |
| Allan, SG | 1 |
| Kaye, SB | 3 |
| Sangster, G | 1 |
| Calman, KC | 2 |
| Hutcheon, AW | 1 |
| Epelbaum, R | 2 |
| Waldhorn, RE | 1 |
| Tsou, E | 1 |
| Kerwin, DM | 1 |
| Heim, ME | 2 |
| Swoboda, M | 1 |
| Pahlke, W | 1 |
| Edler, L | 3 |
| Bicker, U | 1 |
| Horner-Vallet, D | 1 |
| Cappelaere, P | 2 |
| Delobelle, A | 1 |
| Depadt, G | 2 |
| Madelain, M | 1 |
| Demaille, A | 1 |
| Droz, JP | 8 |
| Kac, J | 3 |
| Spielmann, M | 2 |
| Crespon, B | 1 |
| Ley, G | 1 |
| Zimmermann, P | 1 |
| Theodore, C | 6 |
| Chavy, A | 1 |
| Shildt, RA | 1 |
| Kennedy, PS | 1 |
| Athens, JW | 1 |
| O'Bryan, RM | 3 |
| Shapiro, CM | 3 |
| Shapiro, RA | 1 |
| Shah, A | 1 |
| MacDonald, WC | 1 |
| Tashiro, K | 1 |
| Masuda, F | 4 |
| Ohishi, Y | 1 |
| Schulz, A | 1 |
| Kracht, J | 1 |
| Brenner, HJ | 1 |
| Bibi, C | 1 |
| Chaitchik, S | 2 |
| Gerbie, MV | 1 |
| Desser, RK | 2 |
| Schifeling, D | 1 |
| Kozloff, MF | 2 |
| Robin, E | 2 |
| Recant, W | 1 |
| Michel, A | 2 |
| Rochman, H | 1 |
| Billings, AA | 2 |
| Haas, CD | 1 |
| Mansfield, CM | 1 |
| Considine, B | 1 |
| Gattoni, F | 1 |
| Mazzoni, R | 1 |
| Moro, E | 1 |
| Frontini, L | 2 |
| Uslenghi, C | 1 |
| Hoskins, RB | 1 |
| Cohen, AC | 1 |
| Kaufman, S | 2 |
| Wood, WC | 3 |
| Carey, RW | 7 |
| Khankhanian, N | 1 |
| McBride, CM | 1 |
| McMurtrey, MJ | 1 |
| Hashimoto, I | 1 |
| Sawada, Y | 1 |
| Mikami, J | 1 |
| Yoshimoto, M | 1 |
| Nishidai, H | 1 |
| Nakanishi, Y | 1 |
| Kashi, Y | 1 |
| Kuwayama, H | 1 |
| Eastwood, GL | 1 |
| Kohashi, E | 1 |
| Niederle, N | 4 |
| Kurschel, E | 2 |
| Schmidt, CG | 1 |
| Furuta, K | 2 |
| Nakazaki, S | 1 |
| Kiyomitsu, Y | 1 |
| Hori, K | 1 |
| Gnatyshak, AI | 2 |
| Bertoldi, I | 1 |
| Cavaleri, V | 1 |
| D'Avena, C | 1 |
| Mangialardi, N | 1 |
| Chirletti, P | 1 |
| Castro, JR | 1 |
| Saunders, WM | 1 |
| Quivey, JM | 1 |
| Chen, GT | 1 |
| Collier, JM | 1 |
| Woodruff, KH | 1 |
| Lyman, JT | 1 |
| Twomey, P | 2 |
| Frey, C | 2 |
| Phillips, TL | 1 |
| Yoshizawa, H | 1 |
| Kanazawa, K | 3 |
| Okamura, Y | 1 |
| Kajiwara, T | 2 |
| Anderson, JM | 1 |
| Conroy, JF | 3 |
| Roda, PI | 1 |
| Brodsky, I | 2 |
| Kahn, SB | 1 |
| Bulova, SI | 1 |
| Pequignot, E | 1 |
| Hanna, WT | 1 |
| Regester, RF | 1 |
| Murphy, WM | 1 |
| Chang, YC | 1 |
| Falkson, G | 7 |
| Tormey, DC | 6 |
| Crowley, J | 1 |
| Blokhina, NG | 3 |
| Sorokina, GA | 1 |
| Sugimori, H | 1 |
| Jimi, S | 1 |
| Watanabe, E | 1 |
| Morita, T | 2 |
| Shigyo, R | 1 |
| Toyota, Y | 1 |
| Tsukamoto, N | 1 |
| Matsuyama, T | 1 |
| Taki, I | 1 |
| Ornitz, R | 1 |
| Rogers, C | 1 |
| Chang, BK | 1 |
| Gutman, R | 1 |
| Takai, S | 1 |
| Mazzucco, G | 1 |
| Fornari, G | 1 |
| Monga, G | 1 |
| Havemann, K | 1 |
| Fukuda, O | 1 |
| Tajima, C | 1 |
| Nakayama, M | 1 |
| Maeyama, M | 1 |
| Recent, W | 1 |
| DeLuca, SA | 1 |
| Castronovo, FP | 1 |
| Rhea, JT | 1 |
| Lerner, H | 1 |
| Marcovitz, E | 1 |
| Zaren, H | 1 |
| Underwood, DA | 1 |
| Tsai, AR | 1 |
| Yiannikas, J | 1 |
| Heupler, FA | 1 |
| Narisawa, T | 2 |
| Sano, M | 3 |
| Pouillart, P | 8 |
| Bretaudeau, B | 1 |
| Palangie, T | 7 |
| Jouve, M | 5 |
| Garcia-Giralt, E | 5 |
| Asselain, B | 1 |
| Sakuramoto, T | 1 |
| Vaughn, CB | 4 |
| Maniscalco-Greb, E | 1 |
| Lockhard, C | 1 |
| Groshko, G | 2 |
| Enochs, K | 1 |
| Duffin, H | 1 |
| Demitrish, M | 1 |
| Schabel, FM | 1 |
| Skipper, HE | 1 |
| Trader, MW | 1 |
| Laster, WR | 1 |
| Griswold, DP | 1 |
| Choy, DS | 1 |
| Newman, H | 1 |
| Vieta, J | 1 |
| Jochimsen, PR | 1 |
| Brady, P | 1 |
| Chinn, BJ | 1 |
| Daversa, GC | 1 |
| Parzuchowski, JS | 1 |
| White, DR | 1 |
| Richards, F | 2 |
| Cooper, MR | 2 |
| Spurr, CL | 1 |
| Chlebowski, RT | 5 |
| Silverberg, I | 2 |
| Pajak, T | 1 |
| Weiner, J | 2 |
| Kardinal, C | 1 |
| Bateman, JR | 6 |
| Woods, RL | 2 |
| Levi, JA | 4 |
| Brodie, GN | 1 |
| Torti, FM | 1 |
| McCracken, JD | 5 |
| Ray, P | 1 |
| Saiki, JH | 2 |
| Rivkin, SE | 4 |
| Rossof, AH | 1 |
| Moore, TN | 1 |
| Keehn, R | 1 |
| Elliott, D | 1 |
| Higgins, G | 1 |
| Chapman, JL | 1 |
| Garland, M | 1 |
| Pederson, B | 1 |
| Demitrish, MM | 1 |
| Chinn, B | 2 |
| Ward, D | 2 |
| Brady, PR | 1 |
| Howell, SB | 4 |
| Wung, WE | 1 |
| Taetle, R | 1 |
| Hussain, F | 1 |
| Romine, JS | 1 |
| Hazel, JJ | 1 |
| Huggins, M | 1 |
| Maksymiuk, A | 1 |
| MacFarlane, JK | 1 |
| Wheeler, TK | 2 |
| Edelstyn, GA | 2 |
| Bates, TS | 1 |
| Brinkley, D | 2 |
| Evans, RG | 2 |
| Kitchen, G | 1 |
| MacRae, KD | 2 |
| Nicol, NT | 1 |
| Spittle, M | 1 |
| Chuang, V | 1 |
| Haynie, TP | 1 |
| Trux, F | 1 |
| Olson, M | 1 |
| Cruz, AB | 5 |
| Leichman, L | 8 |
| Helmkamp, BF | 1 |
| Beecham, JB | 1 |
| Wandtke, JC | 1 |
| Keys, H | 1 |
| Levine, AW | 1 |
| Donegan, WL | 1 |
| Irwin, M | 1 |
| Quarles, JM | 1 |
| Morris, NG | 1 |
| Leibovitz, A | 1 |
| Ausman, RK | 2 |
| Caballero, GA | 2 |
| Quebbeman, E | 3 |
| Ausman, DC | 1 |
| Smalley, RV | 3 |
| Scogna, DM | 1 |
| Malmud, LS | 1 |
| Cowen, DM | 1 |
| Siegerstetter, J | 1 |
| Janik, AC | 1 |
| Double, JA | 6 |
| Granov, AM | 1 |
| Borisov, AE | 1 |
| Plotkin, LL | 1 |
| Zemlianoĭ, VP | 1 |
| Shelukhin, AP | 1 |
| Karlin, DA | 3 |
| Stroehlein, JR | 1 |
| Bennetts, RW | 1 |
| Jones, RD | 1 |
| Heifetz, LJ | 1 |
| Mahal, PS | 1 |
| Kukleta, JF | 1 |
| Altorfer, J | 1 |
| Akovbiantz, A | 1 |
| Gasser, RW | 2 |
| Schmalzl, F | 2 |
| Campbell, TN | 1 |
| Pfeifle, C | 1 |
| House, BA | 1 |
| Calabro-Jones, PM | 1 |
| Byfield, JE | 1 |
| Ward, JF | 1 |
| Sharp, TR | 1 |
| Gota, CH | 1 |
| Chan, KK | 1 |
| Weiner, JM | 2 |
| Block, JB | 1 |
| Mughal, T | 1 |
| Goold, MA | 1 |
| Phillips, RH | 1 |
| MacKay, IS | 1 |
| Tice, AJ | 1 |
| Tampier, C | 1 |
| Zamorano, R | 1 |
| Sato, H | 2 |
| Satoh, H | 1 |
| Isono, K | 2 |
| Onoda, S | 1 |
| Okuyama, K | 1 |
| Tounosu, N | 1 |
| Chin, F | 1 |
| Kouzu, T | 1 |
| Ryu, M | 1 |
| Hirasawa, H | 1 |
| Matsumura, Y | 1 |
| Komiyama, S | 1 |
| Makishima, K | 1 |
| Hiroto, I | 1 |
| Beckley, S | 1 |
| Wajsman, Z | 2 |
| Maeso, E | 1 |
| Pontes, E | 1 |
| Murphy, G | 2 |
| Dworken, HJ | 1 |
| Botti, RE | 1 |
| Hemstreet, G | 1 |
| Hester, M | 1 |
| Revazova, ES | 1 |
| Horno Gimeno, M | 1 |
| Savrin, RA | 1 |
| Martin, EW | 1 |
| Wolberg, WH | 1 |
| Morin, J | 1 |
| Tokuzen, R | 1 |
| Aroney, RS | 2 |
| Dalley, DN | 2 |
| Chan, WK | 1 |
| Bell, DR | 1 |
| Rosi, DR | 1 |
| Nogeire, C | 1 |
| Brown, B | 1 |
| Ali, M | 1 |
| Ewer, M | 1 |
| Samuels, M | 1 |
| Halpren, J | 1 |
| Brufman, G | 1 |
| Shnider, B | 1 |
| Biran, S | 1 |
| Jacobs, AJ | 2 |
| Bruckner, H | 3 |
| Giuliani, FC | 1 |
| Zirvi, KA | 3 |
| Kaplan, NO | 1 |
| Goldin, A | 2 |
| Ando, N | 2 |
| Goldobenko, GV | 1 |
| Lycev, VA | 1 |
| Sidorcenkov, VO | 1 |
| Gapanjuk, ON | 1 |
| Aleksanjan, AZ | 1 |
| Baranec, GV | 1 |
| Schmitz, R | 6 |
| Hüper, J | 2 |
| Pichlmayr, R | 2 |
| Frytak, S | 1 |
| Weiland, LH | 1 |
| Livstone, E | 1 |
| Spiro, H | 1 |
| Knowlton, A | 1 |
| Kalser, M | 1 |
| Barkin, J | 1 |
| Lessner, H | 1 |
| Mann-Kaplan, R | 1 |
| Ramming, K | 1 |
| Douglas, HO | 2 |
| Thomas, P | 1 |
| Nave, H | 1 |
| Bateman, J | 1 |
| Lokich, J | 3 |
| Brooks, J | 2 |
| Chaffey, J | 1 |
| Corson, JM | 1 |
| Zamcheck, N | 1 |
| Novak, JW | 1 |
| Bibby, MC | 4 |
| Mughal, MA | 1 |
| Fukuda, I | 1 |
| Iwanaga, T | 4 |
| Otani, T | 1 |
| Drago, JR | 7 |
| Worgul, TJ | 1 |
| Efimov, GA | 1 |
| Ushakov, IuM | 1 |
| Amasaki, H | 1 |
| Antonelli, D | 1 |
| Beker, B | 1 |
| Barzilay, J | 1 |
| Payne, JE | 1 |
| Meyer, JH | 1 |
| Macpherson, JG | 1 |
| Nelson, DS | 1 |
| Walls, RS | 1 |
| Pheils, MT | 1 |
| Goldman, LB | 5 |
| Gershwin, ME | 6 |
| Fraile, RJ | 1 |
| Baker, LH | 6 |
| Buroker, TR | 2 |
| Horwitz, J | 1 |
| Schmitz, CA | 2 |
| Richlmayr, R | 1 |
| Remington, JH | 1 |
| Sobel, SH | 1 |
| Savlov, ED | 1 |
| Ward, A | 1 |
| Sherlock, D | 1 |
| Matsukura, N | 1 |
| Aoyagi, M | 1 |
| Kawachi, T | 1 |
| Hirashima, T | 1 |
| Takasugi, T | 1 |
| Ushio, K | 1 |
| Sugimura, T | 1 |
| Piver, MS | 4 |
| Barlow, JJ | 5 |
| Späti, B | 2 |
| Jungi, WF | 1 |
| Mayr, AC | 2 |
| Hammer, B | 1 |
| Senn, HJ | 2 |
| Lei, D | 1 |
| Castaño-Almendral, A | 1 |
| Brunner, KW | 2 |
| Martz, G | 2 |
| Obrecht, P | 1 |
| Melchert, F | 1 |
| Rhomberg, W | 1 |
| Hoth, DF | 2 |
| Levin, B | 11 |
| Echtermeyer, V | 1 |
| Benz, C | 2 |
| Schoenberg, M | 1 |
| Choti, M | 1 |
| Cadman, E | 2 |
| Smythe, T | 3 |
| Ueno, W | 3 |
| Hoth, D | 2 |
| Smith, F | 1 |
| Boiron, M | 2 |
| Gisselbrecht, C | 3 |
| Lagarde, C | 2 |
| Ichiki, AT | 1 |
| Israelsen, KL | 1 |
| Sonoda, T | 2 |
| Collmann, IR | 1 |
| Maroda, SJ | 1 |
| Phillips, JO | 1 |
| Caravella, LP | 1 |
| Burns, JA | 1 |
| Zangmeister, M | 1 |
| Schuurman, B | 1 |
| Sirovich, I | 1 |
| Heuff, G | 1 |
| van der Wilt, CL | 2 |
| Beelen, RH | 1 |
| Meyer, S | 1 |
| Neubauer, BL | 1 |
| Best, KL | 1 |
| Counts, DF | 1 |
| Goode, RL | 1 |
| Hoover, DM | 1 |
| Jones, CD | 1 |
| Sarosdy, MF | 1 |
| Shaar, CJ | 1 |
| Tanzer, LR | 1 |
| Merriman, RL | 1 |
| Yuasa, C | 1 |
| Toko, T | 1 |
| Takeda, S | 3 |
| Unemi, N | 2 |
| Kuroda, Y | 4 |
| Tsuji, M | 2 |
| Demachi, H | 2 |
| Stéphan, F | 1 |
| Etienne, MC | 1 |
| Wallays, C | 1 |
| Clergue, F | 1 |
| Bufill, JA | 1 |
| Grace, WR | 1 |
| Neff, R | 1 |
| Testa, A | 3 |
| Latteri, M | 2 |
| Bajardi, G | 1 |
| Mastrandrea, G | 1 |
| Cipolla, C | 2 |
| Pischedda, G | 1 |
| Curto, G | 2 |
| Cannata, G | 1 |
| Turrisi, AT | 1 |
| Highley, MS | 2 |
| Parnis, FX | 1 |
| Trotter, GA | 1 |
| Houston, SJ | 1 |
| Penson, RT | 1 |
| Daliani, DD | 1 |
| Eisenberg, PD | 1 |
| Weems, J | 1 |
| Lord, R | 1 |
| Fueger, R | 1 |
| Chevallier, B | 4 |
| Roche, H | 4 |
| Fumoleau, P | 3 |
| Kerbrat, P | 2 |
| Genot, JY | 1 |
| Fargeot, P | 2 |
| Olivier, JP | 2 |
| Fizames, C | 1 |
| Jacquet, P | 1 |
| Averbach, AM | 1 |
| Stephens, AD | 1 |
| Hoshima, M | 1 |
| Mugitani, T | 1 |
| Koishi, K | 1 |
| Masuyama, M | 1 |
| Miyata, K | 2 |
| Ozaki, M | 2 |
| Ooshima, I | 1 |
| Kinoshita, H | 1 |
| Takeda, A | 2 |
| Yoshimura, S | 2 |
| Shouko, T | 1 |
| Koizumi, T | 1 |
| Mori, K | 2 |
| Osaku, M | 1 |
| Watahiki, Y | 1 |
| Hojyo, M | 1 |
| Kosaka, A | 1 |
| Maruo, H | 1 |
| Hyogo, H | 1 |
| Kido, S | 1 |
| Matsuda, M | 2 |
| Matsuura, M | 2 |
| Nakajima, N | 2 |
| Maeshiro, T | 2 |
| Awane, Y | 2 |
| Terada, J | 1 |
| Mizuno, I | 2 |
| Mohri, N | 2 |
| Inagaki, H | 1 |
| Manabe, T | 2 |
| Kondo, K | 5 |
| Akiyama, S | 4 |
| Nonami, T | 1 |
| Kasai, Y | 2 |
| Hibi, K | 2 |
| Gardin, G | 1 |
| Rosso, R | 8 |
| Campora, E | 1 |
| Repetto, L | 1 |
| Naso, C | 1 |
| Canavese, G | 1 |
| Catturich, A | 1 |
| Corvò, R | 1 |
| Guenzi, M | 1 |
| Pronzato, P | 1 |
| Yudelman, I | 1 |
| Nussbaum, M | 1 |
| Beattie, E | 1 |
| Figueredo, AT | 2 |
| Fawcet, SE | 1 |
| Molloy, DW | 1 |
| Dobranowski, J | 1 |
| Paulseth, JE | 1 |
| Cleary, KR | 7 |
| Buchholz, DJ | 4 |
| Fenoglio, CJ | 3 |
| Collier, C | 1 |
| Sahmoud, T | 4 |
| Fiorentino, M | 1 |
| Stevens, J | 1 |
| Rosato, F | 2 |
| Barbot, D | 3 |
| Biermann, W | 3 |
| Cantor, R | 2 |
| Dubrow, RA | 2 |
| Meterissian, SH | 1 |
| Roubein, LD | 2 |
| Lepek, KJ | 1 |
| Murray, D | 2 |
| O'Brien, M | 5 |
| Gill, PG | 4 |
| Devitt, P | 1 |
| Yeoh, E | 4 |
| Hamilton, CS | 3 |
| Adachi, Y | 5 |
| Sakino, I | 1 |
| Konishi, J | 1 |
| Funahashi, S | 1 |
| Yo, R | 1 |
| Iso, Y | 1 |
| Ayabe, K | 1 |
| Foutzilas, G | 1 |
| Markantonakis, P | 1 |
| Mylonakis, N | 2 |
| Bacoyannis, C | 1 |
| Zisiadis, A | 1 |
| Sobolos, K | 1 |
| Kohara, N | 1 |
| Kitaoka, F | 1 |
| Komuta, K | 2 |
| Motojima, K | 1 |
| Kanematsu, T | 1 |
| Jannot, MC | 1 |
| Yeaton, P | 1 |
| Pauwels, O | 1 |
| DePrez, C | 1 |
| Astruc, J | 1 |
| Chazottes, E | 1 |
| Kruczynski, A | 1 |
| Kiss, R | 1 |
| Ryan, MB | 1 |
| Natrajan, G | 1 |
| Gould, P | 1 |
| Kimura, O | 1 |
| Kurayoshi, K | 2 |
| Sugezawa, A | 1 |
| Makino, M | 2 |
| Kaibara, N | 3 |
| Hisatomi, K | 1 |
| Nagafuchi, Y | 1 |
| Ohsato, K | 1 |
| Molina Esquivel, J | 1 |
| Vargas Sandoval, G | 1 |
| Rodríguez del Rincón, E | 1 |
| Velázquez López, J | 1 |
| Fontana, T | 1 |
| Noviello, MR | 1 |
| Egami, I | 1 |
| Onda, M | 1 |
| Tonusin, A | 1 |
| Sukthomya, W | 1 |
| Changwiwit, W | 1 |
| Nimmolrat, A | 1 |
| Loganzo, F | 1 |
| Maslak, P | 1 |
| Lai, L | 1 |
| de Oliveira, AR | 1 |
| Schwartz, GK | 3 |
| Blundell, ML | 1 |
| Altorki, NK | 1 |
| Albino, AP | 1 |
| Turk, PS | 1 |
| Belliveau, JF | 1 |
| Darnowski, JW | 1 |
| Weinberg, MC | 1 |
| Leenen, L | 1 |
| Wanebo, HJ | 1 |
| Rosen, H | 4 |
| Sebesta, C | 4 |
| Roos, G | 1 |
| Stenram, U | 3 |
| Héry, M | 1 |
| Gedouin, D | 1 |
| Goudier, MJ | 2 |
| Jacquin, JP | 1 |
| Plat, F | 2 |
| Cabarrot, E | 1 |
| Serin, D | 2 |
| Namer, M | 2 |
| Wada, K | 1 |
| Iijima, Y | 1 |
| Hirota, Y | 1 |
| Hongo, J | 1 |
| Nicolaides, C | 2 |
| Briassoulis, E | 1 |
| Sirott, M | 1 |
| Heelan, R | 2 |
| Keresztes, R | 1 |
| Kallinowski, F | 1 |
| Eble, MJ | 1 |
| Wannenmacher, M | 1 |
| Herfarth, C | 1 |
| Dorval, ED | 1 |
| Regimbeau, C | 2 |
| Picon, L | 2 |
| Bérard, H | 1 |
| Reeder, LB | 1 |
| Hoffman, PC | 2 |
| Drinkard, LC | 1 |
| Naunheim, KS | 2 |
| Petruska, PJ | 1 |
| Roy, TS | 2 |
| Schlueter, JM | 2 |
| Baue, AE | 2 |
| Sørensen, P | 1 |
| Edal, AL | 1 |
| Madsen, EL | 1 |
| Fenger, C | 1 |
| Poulsen, MR | 1 |
| Petersen, OF | 1 |
| Wiseman, CL | 1 |
| Girvin, GW | 1 |
| Matsumoto, GH | 1 |
| Bates, DM | 1 |
| Garcia, JM | 1 |
| Clyde, JC | 1 |
| Lin, PH | 1 |
| Knopf, K | 1 |
| Redei, I | 1 |
| Green, F | 1 |
| Scher, R | 3 |
| Ellis, PA | 1 |
| Talbot, DC | 2 |
| Nicolson, MC | 2 |
| Priest, K | 1 |
| Margolin, K | 5 |
| Raschko, J | 1 |
| Sorich, J | 1 |
| Akman, S | 5 |
| Vasilev, S | 1 |
| Algan, O | 1 |
| Coia, LR | 10 |
| Keller, SM | 2 |
| Schultheiss, TE | 1 |
| Hanks, GE | 2 |
| Horii, H | 1 |
| Imai, J | 1 |
| Watanabe, C | 1 |
| Ishiyama, M | 1 |
| Takada, O | 1 |
| Kawamura, T | 1 |
| Hasebe, K | 1 |
| Chari, RS | 1 |
| Russell, L | 1 |
| Hathorn, J | 1 |
| Cao, Z | 1 |
| You, Z | 1 |
| Zhou, S | 1 |
| Shinohara, K | 1 |
| Zabudkin, AF | 1 |
| Bukhteev, SV | 1 |
| Bernhard, H | 1 |
| Jäger-Arand, E | 1 |
| Bernhard, G | 1 |
| Riemann, JF | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Ajao, OG | 1 |
| Grillo, IA | 1 |
| Malatani, T | 1 |
| al Shehri, MY | 1 |
| Mochizuki, F | 2 |
| Tomioka, K | 1 |
| Sato, F | 1 |
| Yamagata, T | 1 |
| Nagakawa, Y | 1 |
| Kobari, Y | 1 |
| Iwai, S | 1 |
| Shibata, N | 3 |
| Tamai, M | 2 |
| Bolli, E | 1 |
| Saccomanno, S | 1 |
| Mondini, G | 1 |
| Guglielmi, A | 3 |
| Ligas, B | 1 |
| Connio, M | 1 |
| Mori, A | 1 |
| Espinosa, E | 2 |
| García-Girón, C | 1 |
| Chacon, I | 1 |
| Garrido, P | 1 |
| Sauter, ER | 1 |
| Cohen, AM | 11 |
| Enker, WE | 5 |
| Frankel, J | 4 |
| Kodama, S | 1 |
| Yanase, T | 1 |
| Ikarashi, H | 1 |
| Kazama, Y | 1 |
| Fried, G | 1 |
| Tsalik, M | 1 |
| Stein, M | 2 |
| Dale, J | 1 |
| Romani, R | 1 |
| Umehara, Y | 1 |
| Okubo, T | 1 |
| Sano, Y | 1 |
| Sakamoto, R | 1 |
| Tsuchiya, Y | 3 |
| Nagato, Y | 1 |
| Moriyama, R | 1 |
| Mizumoto, K | 1 |
| Furumoto, T | 1 |
| Kawamura, Y | 1 |
| Katoh, K | 1 |
| Jablonski, KA | 1 |
| Port, RE | 2 |
| Schlemmer, HP | 2 |
| Bachert, P | 2 |
| Keilholz, L | 1 |
| Dworak, O | 1 |
| Köckerling, F | 2 |
| Rexroth, G | 1 |
| Scotland, V | 1 |
| Boyce, HW | 1 |
| Nicolson, V | 3 |
| Garcia, P | 1 |
| Gravalos, C | 1 |
| Tusquets, I | 1 |
| Font, A | 1 |
| Perez, G | 1 |
| Cortés-Funes, H | 3 |
| Fabregat, X | 1 |
| Morise, K | 2 |
| Kusugami, K | 1 |
| Iwase, H | 1 |
| Horiuchi, Y | 1 |
| Kuroiwa, A | 1 |
| Suga, S | 1 |
| Kumai, K | 1 |
| Matsumoto, M | 3 |
| Kitazaki, M | 1 |
| Noma, M | 1 |
| Ota, M | 1 |
| Ban, K | 1 |
| Masuda, K | 1 |
| Shida, H | 1 |
| Shchepotin, IB | 1 |
| Shabahang, M | 1 |
| Nauta, RJ | 1 |
| Buras, RR | 1 |
| Brenner, RV | 1 |
| Evans, SR | 1 |
| Couteau, C | 1 |
| Bastit, P | 1 |
| Braly, PS | 1 |
| Blessing, JA | 3 |
| Homesley, HD | 2 |
| Averette, H | 1 |
| Fanning, J | 1 |
| Ladd, C | 1 |
| Hilgers, RD | 1 |
| Caudry, M | 3 |
| Bonnel, C | 3 |
| Floquet, A | 1 |
| Marsault, C | 1 |
| Quétin, P | 1 |
| Pujol, J | 1 |
| Maton, O | 1 |
| Dujols, JP | 1 |
| Caudry, Y | 1 |
| Skawinski, P | 1 |
| Weese, JL | 4 |
| Agarwal, P | 1 |
| Litwin, S | 4 |
| Watts, P | 2 |
| Chen, YC | 2 |
| Chen, BR | 1 |
| Lee, WJ | 2 |
| Lee, PH | 2 |
| Wang, CH | 1 |
| Wang, TH | 1 |
| Nakai, Y | 1 |
| Furuse, K | 1 |
| Asakawa, M | 2 |
| Fukuoka, M | 1 |
| Niitani, H | 2 |
| Johnson, PW | 2 |
| Hall, MR | 1 |
| Wrigley, PF | 3 |
| Slevin, ML | 4 |
| Empereur, S | 1 |
| Fagot, D | 1 |
| Forgue-Lafitte, E | 1 |
| Chastre, E | 1 |
| Zimber, A | 1 |
| Mester, J | 1 |
| Gespach, C | 1 |
| Costa, MJ | 1 |
| Stewart, G | 1 |
| Goodnight, JE | 1 |
| Kabuto, T | 3 |
| Kameyama, M | 2 |
| Hiratsuka, M | 2 |
| Kimura, F | 1 |
| Sugaya, J | 1 |
| Sejima, T | 1 |
| Takano, Y | 1 |
| Kiriyama, M | 2 |
| Tomita, F | 2 |
| Kita, I | 1 |
| Yamamoto, O | 1 |
| Sakai, S | 1 |
| Shiraishi, T | 1 |
| Hosoda, Y | 1 |
| Shirato, M | 1 |
| Seki, T | 2 |
| Hirama, K | 1 |
| Mikami, Y | 1 |
| Nishi, T | 1 |
| Konn, M | 1 |
| Satoh, Y | 1 |
| Une, Y | 2 |
| Fujisawa, J | 1 |
| Uchino, J | 2 |
| Sasson, Z | 1 |
| Morgan, CD | 1 |
| Thomas, G | 2 |
| MacKenzie, B | 1 |
| Platts, ME | 1 |
| Theodossiou, C | 1 |
| Kroog, G | 1 |
| Ettinghausen, S | 1 |
| Tolcher, A | 1 |
| Cowan, K | 1 |
| O'Shaughnessy, J | 1 |
| Chen, TB | 1 |
| Huzak, M | 1 |
| Macura, S | 1 |
| Vuk-Pavlović, S | 1 |
| Loehrer, PJ | 3 |
| Harry, D | 1 |
| Weinerman, BH | 1 |
| MacCormick, RE | 1 |
| Comande, S | 1 |
| Buccellato, C | 1 |
| Khansur, T | 1 |
| Allred, C | 1 |
| Tavassoli, M | 1 |
| Tamaki, Y | 1 |
| Touno, T | 2 |
| Shin, E | 1 |
| Wright, CD | 2 |
| Mathisen, DJ | 3 |
| Wain, JC | 3 |
| Grillo, HC | 3 |
| Hilgenberg, AD | 2 |
| Moncure, AC | 2 |
| Daly, M | 1 |
| Logan, DL | 2 |
| Mansi, J | 2 |
| Nash, A | 1 |
| Sacks, N | 1 |
| Ford, H | 1 |
| Bradley, C | 1 |
| Selby, P | 1 |
| Buswell, L | 1 |
| Recht, A | 1 |
| Clark, J | 3 |
| Ravikumar, T | 1 |
| Busse, PM | 1 |
| Coleman, CN | 1 |
| Semmler, W | 1 |
| Hohenberger, P | 2 |
| Schlag, P | 3 |
| Lorenz, WJ | 1 |
| van Kaick, G | 1 |
| Gao, Z | 1 |
| Meng, FH | 1 |
| Nakagawa, H | 3 |
| Koezuka, M | 1 |
| Miyawaki, Y | 1 |
| Tokiyoshi, K | 1 |
| Hagiwara, Y | 2 |
| Tsuruzono, K | 1 |
| Villar-Grimalt, A | 2 |
| Belón, J | 2 |
| Jimeno, JM | 1 |
| Candel, MT | 1 |
| García de Paredes, ML | 1 |
| Colajori, E | 1 |
| Carrillo Hernández, JF | 1 |
| Ernesto de Obaldía Castillo, G | 1 |
| Ramírez Ortega, C | 1 |
| Frías Mendivil, M | 1 |
| Pardo, M | 1 |
| Bernstein, M | 1 |
| Villamil, A | 1 |
| Davidson, G | 1 |
| Erlichman, C | 5 |
| Motoyama, M | 1 |
| Imaoka, T | 1 |
| Ichihara, N | 1 |
| Hirai, K | 1 |
| Ashikaga, K | 1 |
| Kimura, C | 1 |
| Kuroda, H | 2 |
| Ono, M | 2 |
| Kusano, F | 1 |
| Yamamoto, C | 1 |
| Maekawa, N | 1 |
| Sasaki, N | 1 |
| Tajiri, K | 1 |
| Tazawa, J | 1 |
| Fassas, AB | 1 |
| Gattani, AM | 1 |
| Morgello, S | 1 |
| Yit, CC | 1 |
| Das, NP | 1 |
| Krook, JE | 12 |
| Poplin, EA | 2 |
| Khanuja, PS | 1 |
| Kraut, MJ | 1 |
| Herskovic, AM | 1 |
| Lattin, PB | 1 |
| Cummings, G | 2 |
| Kinzie, JL | 1 |
| Steiger, Z | 1 |
| Shibata, J | 3 |
| Aiba, K | 1 |
| Minowa, S | 1 |
| Tsuzuki, H | 1 |
| Niki, M | 1 |
| Ueda, H | 1 |
| Takamoto, Y | 1 |
| Oohara, M | 1 |
| Igarashi, S | 4 |
| Osada, H | 1 |
| Nishimura, G | 3 |
| Kurosu, Y | 1 |
| Wakasugi, H | 2 |
| Yokota, M | 1 |
| Furukawa, M | 1 |
| Mukuta, T | 1 |
| Funakoshi, A | 1 |
| Long, HJ | 1 |
| Nelimark, RA | 1 |
| Su, JQ | 1 |
| Garneau, SC | 1 |
| Poon, MA | 4 |
| Kugler, JW | 2 |
| Blitzer, PH | 1 |
| Dosoretz, DE | 1 |
| Katin, MJ | 1 |
| Rubenstein, JH | 1 |
| Harwin, WN | 1 |
| Raymond, MG | 1 |
| Teufel, TE | 1 |
| Seidenstein, L | 1 |
| Mangano, MM | 1 |
| Salenius, SA | 1 |
| Budman, DR | 2 |
| Korzun, AH | 2 |
| Younger, J | 2 |
| Hart, RD | 1 |
| Ellerton, JA | 1 |
| Ferree, CR | 1 |
| Bélanger, K | 1 |
| Yelle, L | 1 |
| Guévin, R | 1 |
| Potvin, M | 2 |
| Wilson, J | 1 |
| Rudinskas, L | 1 |
| Latreille, J | 1 |
| Dionne, J | 1 |
| Gagné, L | 1 |
| Ucar, A | 1 |
| Reddy, R | 1 |
| Livingstone, AS | 1 |
| Markoe, A | 1 |
| Schwade, J | 1 |
| Donofrio, K | 1 |
| Weese, J | 1 |
| Solin, L | 1 |
| Weiner, L | 1 |
| Paul, A | 2 |
| Hanks, G | 1 |
| Teshima, K | 1 |
| Yamagata, S | 2 |
| Sugawa, T | 1 |
| Kubo, H | 1 |
| Sugimoto, O | 2 |
| Nakajima, H | 1 |
| Yamabe, T | 1 |
| Kaga, S | 1 |
| Kano, A | 1 |
| Saitoh, A | 1 |
| Kikuchi, H | 4 |
| Tsushima, K | 3 |
| Narita, N | 1 |
| Suematsu, T | 1 |
| Kawabata, S | 1 |
| Kodama, I | 1 |
| Koufuji, K | 1 |
| Aoyagi, K | 1 |
| Maruiwa, M | 1 |
| Ohta, J | 1 |
| Kumegawa, H | 1 |
| Egeli, R | 1 |
| Arma, S | 1 |
| Aeberhard, P | 1 |
| Barras, JP | 1 |
| Müller, W | 1 |
| Castiglione, M | 1 |
| Schroeder, R | 1 |
| Roux, FX | 5 |
| Brasnu, D | 5 |
| Devaux, B | 1 |
| Chabardes, E | 1 |
| Schwaab, G | 1 |
| Laccourreye, O | 2 |
| Menard, M | 2 |
| Janot, F | 2 |
| Bertrand, J | 1 |
| Steele, G | 3 |
| Posner, M | 3 |
| Busse, P | 2 |
| Cady, B | 2 |
| Stone, M | 2 |
| Jenkins, R | 1 |
| Osteen, R | 1 |
| Taylor, DD | 1 |
| Gerçel-Taylor, C | 1 |
| Fowler, WC | 2 |
| Okayasu, T | 2 |
| Cullinan, SA | 4 |
| McAtee, N | 3 |
| Murphy, RF | 3 |
| Hamilton, JM | 6 |
| Balis, F | 2 |
| Steinberg, S | 1 |
| Arbuck, SG | 4 |
| Setser, A | 1 |
| Jordan, E | 1 |
| Chen, A | 2 |
| Weidmann, B | 1 |
| Teipel, A | 1 |
| Ritzi, EM | 1 |
| Pyo, S | 1 |
| Swain, SM | 1 |
| Honig, SF | 1 |
| Wolf, GT | 1 |
| Esclamado, RM | 1 |
| McLaughlin, PW | 1 |
| Thornton, AF | 1 |
| Graham, RA | 2 |
| Atkins, MB | 1 |
| Karp, DD | 1 |
| Wazer, DE | 3 |
| Hackford, AW | 2 |
| Fedeli, A | 3 |
| Fuhrman, GM | 1 |
| Ota, DM | 4 |
| Furuya, Y | 2 |
| Ku, Y | 1 |
| Hamabe, Y | 1 |
| Saitoh, Y | 2 |
| Navarro-Carola, E | 1 |
| Demuynck, B | 6 |
| Soubrane, D | 2 |
| Grangé, JD | 3 |
| Krulik, M | 11 |
| Kajanti, M | 1 |
| Meyer, HJ | 1 |
| Berns, T | 3 |
| Achterrath, W | 1 |
| Knipp, H | 1 |
| Harstrick, A | 3 |
| Köhne-Wömpner, CH | 1 |
| Schöffski, P | 4 |
| Murase, M | 2 |
| Kodera, Y | 1 |
| Kiriyama, K | 1 |
| Nagata, H | 1 |
| Ohiwa, Y | 1 |
| Miwa, M | 2 |
| Inamura, Y | 1 |
| Suzumura, K | 1 |
| Kanemitsu, T | 1 |
| Naruse, T | 1 |
| Miyazaki, N | 1 |
| Ohkura, H | 2 |
| Kajimura, N | 1 |
| Okazaki, N | 4 |
| Sobrero, AF | 1 |
| Guglielmi, AP | 1 |
| Mori, AM | 1 |
| Melioli, GG | 1 |
| Bertino, JR | 6 |
| Takamura, A | 1 |
| Horio, K | 1 |
| Ohta, T | 2 |
| Yamano, M | 1 |
| Sawaguchi, Y | 1 |
| Ichiki, Y | 1 |
| Hirata, Y | 1 |
| Kanaya, S | 2 |
| Niho, Y | 4 |
| John, WJ | 3 |
| Neefe, JR | 1 |
| Cantrell, J | 1 |
| Smith, M | 1 |
| O'Reilly, SE | 1 |
| Gelmon, KA | 1 |
| Onetto, N | 1 |
| Parente, J | 1 |
| Rubinger, M | 1 |
| Page, RA | 1 |
| Plenderleith, IH | 1 |
| Ohkubo, M | 1 |
| Barbe, L | 1 |
| Lesur, G | 1 |
| Turner, L | 1 |
| Dupont, C | 1 |
| Coggia, M | 1 |
| Dupuy, P | 1 |
| Dorra, M | 1 |
| Koide, T | 1 |
| Kawai, Y | 2 |
| Takeshige, K | 1 |
| Bertheault-Cvitkovic, F | 1 |
| Soussan, S | 1 |
| Brienza, S | 2 |
| Adam, R | 1 |
| Itzhaki, M | 1 |
| Bismuth, H | 1 |
| Koyama, S | 2 |
| Tsujimoto, M | 1 |
| Kitagawa, M | 2 |
| Kagamimori, S | 1 |
| Griffon, G | 1 |
| Weber, B | 2 |
| Chen, JA | 1 |
| Garton, GR | 1 |
| Martin, JK | 4 |
| McIlrath, DC | 3 |
| Cha, SS | 2 |
| Kerr, IG | 1 |
| Doyle, N | 1 |
| Macdonald, M | 1 |
| Sone, M | 1 |
| Earle, JD | 2 |
| Foley, JF | 6 |
| McKenna, PJ | 2 |
| Twito, DI | 3 |
| Burch, PA | 2 |
| Miyoshi, H | 1 |
| Tsunoda, Y | 1 |
| Takeuchi, H | 1 |
| Ueda, K | 1 |
| Mochizuki, R | 1 |
| Miyauchi, H | 1 |
| Iwashita, R | 1 |
| Kaizer, L | 1 |
| Fine, S | 3 |
| Minsky, B | 1 |
| Cohen, A | 2 |
| Enker, W | 1 |
| Guillem, J | 3 |
| Conti, J | 1 |
| Rustamov, IR | 1 |
| Dzhulbekov, KI | 1 |
| Igarashi, T | 2 |
| Hanyu, F | 1 |
| Picciocchi, A | 2 |
| Magistrelli, P | 1 |
| Roncolini, G | 1 |
| Netri, G | 1 |
| Mattana, C | 2 |
| Cellini, N | 3 |
| De Franco, A | 1 |
| Vecchio, FM | 1 |
| Blumenstein, B | 1 |
| Saiers, JH | 2 |
| Coltman, CA | 5 |
| Hurteloup, P | 1 |
| Tomio, L | 1 |
| Zorat, PL | 1 |
| Paccagnella, A | 1 |
| Segati, R | 1 |
| Loreggian, L | 1 |
| Lora, O | 1 |
| Favaretto, A | 1 |
| Fede, A | 1 |
| Liebes, L | 1 |
| Schwartz, EL | 1 |
| Dutcher, JP | 2 |
| Wang, FS | 1 |
| Chang, YM | 2 |
| Wallace, HJ | 1 |
| Greer, BE | 1 |
| Cain, J | 1 |
| Stelzer, KJ | 1 |
| Russell, KJ | 1 |
| Tamimi, HK | 1 |
| Figge, DC | 1 |
| Russell, AH | 1 |
| Griffin, TW | 1 |
| Hoff, SJ | 1 |
| Stewart, JR | 1 |
| Sawyers, JL | 1 |
| Murray, MJ | 1 |
| Merrill, WH | 1 |
| Adkins, RB | 2 |
| Cooper, SG | 1 |
| Bonaventura, A | 1 |
| Joseph, DJ | 2 |
| Stewart, JF | 1 |
| Rustum, Y | 4 |
| Herrera, L | 5 |
| Creaven, P | 3 |
| Grison, X | 1 |
| Zittoun, J | 3 |
| Metzger, G | 3 |
| Richaud, J | 1 |
| Lotz, JP | 4 |
| Hannoun, L | 3 |
| Marquet, J | 3 |
| Morton, CL | 3 |
| Adkins, DA | 2 |
| Rahman, A | 3 |
| Kase, S | 2 |
| Kubota, T | 7 |
| Takeuchi, T | 4 |
| Furukawa, T | 4 |
| Ishibiki, K | 3 |
| Suganuma, Y | 1 |
| Oguro, A | 1 |
| Torii, T | 1 |
| Ishikawa, A | 1 |
| Ozawa, M | 1 |
| Toyama, K | 1 |
| Yeung, RS | 1 |
| Kowalyshyn, MJ | 1 |
| Tanemura, H | 5 |
| Tanaka, S | 3 |
| Oshita, H | 1 |
| Asano, M | 2 |
| Kaneda, N | 1 |
| Kumazawa, I | 1 |
| Murren, JR | 1 |
| Ganpule, S | 1 |
| Papac, R | 1 |
| Son, YH | 1 |
| Peschel, RE | 1 |
| Durivage, H | 1 |
| Buzaid, AC | 2 |
| Lamb, L | 1 |
| Makuch, R | 1 |
| Hait, WN | 1 |
| Inada, T | 4 |
| Ozawa, I | 1 |
| Hishinuma, S | 1 |
| Kotake, K | 1 |
| Najjar, TA | 1 |
| Slomiany, BL | 1 |
| Drake, J | 1 |
| Chisena, T | 1 |
| Cysyk, R | 1 |
| Kano, Y | 1 |
| Sasagawa, M | 1 |
| Laufman, LR | 4 |
| Collier, MA | 1 |
| Sullivan, BA | 1 |
| McKinnis, RA | 1 |
| Clendennin, NJ | 1 |
| Guaspari, A | 1 |
| Brenckman, WD | 3 |
| Fleming, TR | 10 |
| Taylor, SA | 1 |
| Dohden, K | 1 |
| Ohmura, K | 1 |
| Neu, IS | 2 |
| Samandas, N | 1 |
| Owen, W | 1 |
| Dussek, J | 1 |
| Barker, S | 1 |
| Darnton, SJ | 4 |
| Allen, SM | 2 |
| Edwards, CW | 1 |
| Matthews, HR | 3 |
| Xing, FY | 1 |
| Liu, WH | 1 |
| Dong, W | 1 |
| Gu, BW | 1 |
| Okazaki, K | 2 |
| Naito, H | 1 |
| Wu, JT | 1 |
| Tamura, S | 1 |
| Shiozaki, H | 1 |
| Miyata, M | 1 |
| Kido, Y | 1 |
| Pazdur, R | 7 |
| Gomez, J | 1 |
| Bready, B | 1 |
| Hudes, GR | 1 |
| Kitson, J | 1 |
| Walczak, J | 3 |
| Peddada, AV | 1 |
| Harvey, JC | 1 |
| Anderson, PJ | 1 |
| Davidson, W | 1 |
| Kagan, AR | 1 |
| Atiq, OT | 1 |
| Tong, W | 1 |
| Trochanowski, B | 1 |
| Toomasi, F | 1 |
| Fell, S | 2 |
| Haynes, H | 4 |
| Katz, HJ | 1 |
| Wiernik, PH | 5 |
| Fujita, J | 1 |
| Yamagishi, Y | 1 |
| Kubo, A | 1 |
| Takigawa, K | 1 |
| Yamaji, Y | 1 |
| Takahara, J | 1 |
| Brockmann, WP | 1 |
| Sommer, K | 1 |
| Steiner, P | 1 |
| Hübener, KH | 1 |
| Kornek, G | 4 |
| Schulz, F | 1 |
| Kimmel, DW | 2 |
| Carstensen, JM | 1 |
| Burcharth, F | 1 |
| Bobbio-Pallavicini, E | 1 |
| Porta, C | 2 |
| Moroni, M | 2 |
| Spaghi, A | 2 |
| Casagranda, I | 1 |
| Nastasi, G | 2 |
| Nozue, M | 1 |
| Koike, N | 2 |
| Kawamoto, T | 1 |
| Toko, K | 1 |
| Sindou, T | 1 |
| Kondou, T | 1 |
| Mun, Y | 1 |
| Nithou, M | 1 |
| Takiyama, W | 2 |
| Sakamoto, N | 1 |
| Ohashi, R | 1 |
| Kirihara, Y | 1 |
| Doihara, H | 1 |
| Tanada, M | 2 |
| Soga, H | 1 |
| Komatsu, T | 1 |
| Ookubo, K | 1 |
| Chan, A | 1 |
| Langevin, J | 1 |
| Khoo, R | 2 |
| Cummings, BJ | 2 |
| Keane, TJ | 2 |
| O'Sullivan, B | 2 |
| Wong, CS | 2 |
| Catton, CN | 2 |
| Schnall, S | 1 |
| Glees, J | 1 |
| Kalnicki, S | 2 |
| Dalton, J | 3 |
| Chesser, MR | 3 |
| Mandeli, J | 2 |
| Janus, C | 2 |
| Beuzeboc, P | 4 |
| Livartowski, A | 1 |
| Valone, FH | 1 |
| Gandara, DR | 2 |
| Luce, JA | 1 |
| Wall, S | 1 |
| Braham, N | 1 |
| George, M | 1 |
| Letvak, L | 1 |
| Perez-Tamayo, C | 3 |
| Snady, H | 3 |
| Lehrer, D | 1 |
| Harpaz, N | 1 |
| Suh, C | 1 |
| Park, KC | 1 |
| Kim, HT | 1 |
| Wozniak, AJ | 1 |
| Blumenstein, BA | 1 |
| Boileau, M | 1 |
| Fletcher, WS | 3 |
| Kuo, TH | 2 |
| Hoffman, RM | 1 |
| Ota, Y | 1 |
| Shirafuji, T | 1 |
| Adachi, A | 2 |
| Okugawa, T | 1 |
| Rino, Y | 1 |
| Sairenji, M | 1 |
| Motohashi, H | 1 |
| Delfau, S | 2 |
| Maisani, JE | 3 |
| Zarba, JJ | 1 |
| Basile, M | 1 |
| Mahjoubi, M | 2 |
| Benahmed, M | 1 |
| Armand, JP | 1 |
| Laurie, JA | 4 |
| Tangen, CM | 2 |
| Ungerleider, JS | 1 |
| Emerson, WA | 1 |
| Glick, JH | 1 |
| Evans, OB | 1 |
| Maddox, AM | 1 |
| Spiridonidis, CH | 1 |
| Leach, SD | 2 |
| Klostergaard, J | 1 |
| Leroux, ME | 1 |
| Hsu, HA | 1 |
| Hsi, BP | 1 |
| Siddik, ZH | 1 |
| Danhauser, LL | 1 |
| Tomasovi, SP | 1 |
| Yumoto, Y | 1 |
| Kawase, K | 1 |
| Narimatsu, A | 1 |
| Okada, O | 1 |
| Yagihashi, A | 2 |
| Yamamitsu, S | 4 |
| Colozza, M | 1 |
| Mosconi, AM | 2 |
| Anastasi, P | 2 |
| de Angelis, V | 1 |
| Giansanti, M | 1 |
| Mercati, U | 1 |
| Aristei, C | 1 |
| Latini, P | 1 |
| Tonato, M | 1 |
| Pierga, JY | 2 |
| Dieras, V | 3 |
| Paraiso, D | 1 |
| Scholl, SM | 2 |
| Bates, BA | 1 |
| Detterbeck, FC | 2 |
| Qaqish, BF | 1 |
| Cohen, H | 2 |
| Laine, L | 4 |
| Crookes, P | 3 |
| Silberman, H | 4 |
| Baranda, J | 3 |
| Garcia, Y | 1 |
| Marcell, A | 1 |
| Karall, M | 2 |
| Peterson, RF | 1 |
| Berenberg, JL | 2 |
| McClure, S | 1 |
| Chapman, RA | 2 |
| Eyre, HJ | 1 |
| Solanki, D | 1 |
| Gagliano, R | 1 |
| Fornasiero, A | 3 |
| Gignoux, M | 2 |
| de Leonardis, V | 1 |
| Romano, S | 2 |
| Andreoli, F | 2 |
| Pernice, LM | 1 |
| Bruno, L | 1 |
| Borrelli, D | 1 |
| Valeri, A | 1 |
| Fabbroni, S | 1 |
| Intini, C | 1 |
| Cini, G | 2 |
| Cwikiel, M | 1 |
| Cwikiel, W | 1 |
| Stuschke, M | 2 |
| Walz, MK | 2 |
| Molls, M | 1 |
| Fett, W | 1 |
| Makoski, HB | 1 |
| Breuer, N | 1 |
| Schmidt, U | 1 |
| Niebel, W | 1 |
| Sack, H | 1 |
| Eigler, FW | 1 |
| Seeber, S | 3 |
| Schnall, SF | 1 |
| Stryker, SJ | 1 |
| Kiel, KD | 1 |
| Shaw, JM | 1 |
| Ujiki, GT | 1 |
| Poticha, SM | 1 |
| Ikegami, H | 1 |
| Nishikawa, H | 2 |
| Yokota, S | 2 |
| Tachibana, T | 1 |
| Higashino, K | 1 |
| Tangen, C | 1 |
| Hutchins, LF | 3 |
| Natale, RB | 1 |
| Guy, JT | 1 |
| Savarese, DM | 1 |
| Gordon, J | 1 |
| Smith, TW | 1 |
| Litofsky, NS | 1 |
| Licho, R | 1 |
| Ragland, R | 1 |
| Recht, L | 1 |
| Mansi, JL | 2 |
| Glees, JP | 1 |
| Dalgleish, AG | 1 |
| Knight, MJ | 1 |
| Kung, SP | 1 |
| Hsieh, RK | 2 |
| Fan, S | 2 |
| Wei, CH | 1 |
| Carey, PD | 1 |
| Farrer, C | 1 |
| Gordon, A | 1 |
| Sommers, SS | 1 |
| Pearce, S | 1 |
| Monson, JR | 1 |
| Guillou, PJ | 2 |
| Maurer, U | 1 |
| Härle, M | 1 |
| Jungius, KP | 1 |
| Thomas, F | 1 |
| Arriagada, R | 1 |
| Mouriesse, H | 1 |
| Le Chevalier, T | 3 |
| Fontaine, F | 1 |
| Tursz, T | 1 |
| Hsu, WL | 1 |
| Shueng, PW | 1 |
| Wu, CJ | 1 |
| Liu, HS | 1 |
| Hwang, JM | 1 |
| Witham, M | 1 |
| Harnett, PR | 1 |
| Tagliaventi, M | 1 |
| Mazzocchi, B | 1 |
| Bella, M | 2 |
| Donati, D | 1 |
| Acito, L | 2 |
| Maggian, P | 1 |
| Angiona, S | 3 |
| Ahmed, FY | 1 |
| Watson, M | 4 |
| Hill, AS | 1 |
| O'Brien, ME | 1 |
| Evans, TC | 1 |
| Carducci, MA | 1 |
| Zahurak, ML | 2 |
| Grochow, LB | 3 |
| Babu, KG | 2 |
| Raud, C | 1 |
| Kumaraswamy, SV | 1 |
| Lalitha, N | 2 |
| Beitler, JJ | 2 |
| Camacho, M | 2 |
| Levine, B | 1 |
| Giannopoulos, A | 1 |
| Bacoyiannis, C | 1 |
| Papadimas, V | 1 |
| Kalahanis, N | 1 |
| Karatzas, G | 1 |
| Sakelaropoulos, N | 1 |
| Archimandritis, A | 1 |
| Papachristodoulou, A | 1 |
| Malacarne, P | 3 |
| Maestri, A | 1 |
| Takechi, T | 2 |
| Satake, H | 1 |
| Uchida, J | 1 |
| Fujioka, A | 1 |
| Karpeh, M | 1 |
| Schwartz, G | 1 |
| Gerdes, H | 1 |
| Lightdale, C | 2 |
| Botet, J | 5 |
| Lauers, G | 1 |
| Quan, V | 1 |
| Bassot, V | 2 |
| Laccourreye, L | 1 |
| Naudo, P | 1 |
| Guichard, M | 1 |
| Noonan, N | 1 |
| Hollywood, D | 1 |
| Kelly, A | 2 |
| Hennessy, TP | 1 |
| Marsh, RD | 1 |
| Chu, NM | 1 |
| Bewsher, C | 1 |
| Copeland, EM | 4 |
| Kurimoto, H | 1 |
| Ono, K | 2 |
| Fuku, A | 1 |
| Muchmore, JH | 2 |
| Preslan, JE | 1 |
| George, WJ | 1 |
| Cerottini, JP | 1 |
| Saraga, E | 1 |
| Metthez, G | 1 |
| Givel, JC | 2 |
| Ardiet, JM | 1 |
| Sentenac, I | 1 |
| Chauvet, B | 1 |
| Reynaud-Bougnoux, A | 1 |
| Le Floch, O | 1 |
| Kumagai, N | 1 |
| Serizawa, H | 1 |
| Iwabuchi, N | 1 |
| Watanabe, N | 2 |
| Hamada, Y | 1 |
| Tsuchimoto, K | 1 |
| Morinaga, S | 1 |
| Xiao, S | 1 |
| Christie, DR | 1 |
| Bull, CA | 1 |
| Langlands, AO | 1 |
| Poorter, RL | 2 |
| Bakker, PJ | 2 |
| Huizing, MT | 1 |
| Taat, CW | 2 |
| Rietbroek, RC | 1 |
| Rauws, EA | 1 |
| Veenhof, CH | 4 |
| Petrov, VP | 1 |
| Perekhodov, SN | 1 |
| Lazarev, GV | 1 |
| Cohen, L | 1 |
| Hendrickson, FR | 2 |
| Lennox, AJ | 1 |
| Kroc, TK | 1 |
| Hatcher, MA | 1 |
| Bennett, BR | 1 |
| Gleissner, B | 1 |
| Hilgenfeld, RU | 1 |
| Thiel, E | 1 |
| Magnien, F | 1 |
| Lapprand, M | 1 |
| Oddes, B | 1 |
| Nose, H | 2 |
| Nakasuka, H | 1 |
| Nakayama, H | 1 |
| Nagahama, H | 2 |
| Rasheshyam, D | 1 |
| Bouleuc, C | 1 |
| Azzouzi, K | 1 |
| See, J | 1 |
| Esteso, A | 1 |
| Avenin, D | 1 |
| Izrael, V | 3 |
| Pagani, O | 1 |
| Cummings, F | 2 |
| Browne, M | 1 |
| Akerley, W | 1 |
| Wanebo, H | 1 |
| Weitberg, A | 2 |
| Cole, B | 1 |
| Bigley, J | 1 |
| Beitz, J | 2 |
| Darnowski, J | 1 |
| Werner, A | 1 |
| Bender, E | 1 |
| Mahaffey, W | 1 |
| McKeating, J | 1 |
| Marrangoni, A | 1 |
| Katoh, A | 2 |
| Cripps, MC | 1 |
| Andersen, JS | 1 |
| Portenoy, RK | 1 |
| Green, MR | 2 |
| Tarassoff, PG | 1 |
| Brown, TD | 1 |
| Casper, ES | 2 |
| Storniolo, AM | 1 |
| Kudoh, M | 1 |
| Susaki, Y | 1 |
| Ideyama, Y | 1 |
| Nanya, T | 1 |
| Shikama, H | 1 |
| Fujikura, T | 1 |
| Fockens, P | 1 |
| Bartelsman, JF | 1 |
| Moreau, S | 2 |
| Zylberait, D | 1 |
| Majello, E | 1 |
| Pezzella, G | 1 |
| Giuseppe, S | 1 |
| Giotta, F | 1 |
| Riccardi, F | 1 |
| Fortunato, S | 1 |
| Kok, TC | 3 |
| Splinter, TA | 2 |
| Spry, NA | 1 |
| Walker, QJ | 1 |
| Stock, E | 1 |
| Orenberg, EK | 1 |
| Yu, NY | 1 |
| Kanekal, S | 1 |
| Brown, DM | 1 |
| Windsor, AC | 1 |
| Somers, SS | 1 |
| Hassan, S | 1 |
| Macadam, R | 1 |
| Sadek, SA | 1 |
| Ragnhammar, P | 1 |
| Blomgren, H | 2 |
| Gonda, T | 1 |
| Hojo, I | 1 |
| Fukunari, H | 1 |
| Grossi, F | 1 |
| Tixi, L | 2 |
| Sanchez, W | 1 |
| Alvarado, I | 1 |
| Wagener, DJ | 6 |
| Hoogenraad, WJ | 1 |
| Lusinchi, A | 4 |
| Taal, BG | 3 |
| de Graeff, A | 1 |
| Amos, EH | 1 |
| McCarty, PJ | 1 |
| Gage, JO | 1 |
| Emlet, JL | 1 |
| Lowrey, GC | 1 |
| Peterson, CA | 1 |
| Amos, WR | 1 |
| Nakaizumi, A | 1 |
| Uehara, H | 1 |
| Matayoshi, Y | 1 |
| Jacobson, J | 1 |
| Panella, TJ | 1 |
| Ron, IG | 2 |
| Lotan, A | 1 |
| Inbar, MJ | 1 |
| Rosenstein, ED | 1 |
| Kramer, N | 1 |
| Leitner, SP | 1 |
| Michaelson, RA | 1 |
| Tan, EH | 1 |
| Ang, PT | 2 |
| Bushunow, PW | 1 |
| Kirkwood, J | 1 |
| Skarlatos, J | 1 |
| Kosma, L | 1 |
| Koukourakis, M | 1 |
| Zambatis, C | 1 |
| Kapsoritakis, A | 1 |
| Mouder, N | 1 |
| Yannakakis, D | 1 |
| Kubo, Y | 1 |
| Kurita, A | 1 |
| Saeki, T | 1 |
| Goey, SH | 1 |
| Gratama, JW | 1 |
| Ward, U | 1 |
| Mertelsmann, RH | 1 |
| Osterwalder, B | 2 |
| Verweij, J | 2 |
| Stoter, G | 2 |
| Palmieri, G | 2 |
| Nicollela, D | 1 |
| Ianniello, GP | 1 |
| Montella, M | 1 |
| Frasci, G | 1 |
| Perna, M | 1 |
| Kikuyama, M | 1 |
| Murohisa, G | 1 |
| Suzuki, F | 1 |
| Tsugiki, M | 1 |
| Souda, K | 1 |
| Yoshimi, T | 1 |
| Van Laar, JA | 1 |
| Smid, K | 3 |
| Kuiper, CM | 1 |
| Pinedo, HM | 3 |
| Joffe, JK | 1 |
| Hughes, M | 1 |
| Wardley, A | 1 |
| Meehan, M | 1 |
| Rigg, A | 1 |
| Gore, M | 1 |
| Moore, H | 1 |
| Rath, U | 2 |
| Oliver, I | 1 |
| Svensson, C | 2 |
| Ravikumar, TS | 2 |
| Dixon, K | 1 |
| Ebie, N | 1 |
| Millikan, K | 1 |
| Murthy, AK | 1 |
| Griem, K | 1 |
| Recine, DC | 1 |
| Doolas, A | 1 |
| Taylor, S | 2 |
| Sporn, JR | 2 |
| Slater, D | 1 |
| Cohen, N | 1 |
| Greenberg, BR | 1 |
| Schneider, HJ | 1 |
| Sampson, SA | 1 |
| Andreyev, HJ | 2 |
| Tilsed, JV | 1 |
| Clarke, PA | 1 |
| Yamazaki, N | 1 |
| Takasaki, S | 1 |
| Masumoto, N | 2 |
| Tabata, H | 1 |
| Onodera, H | 1 |
| Nishitai, R | 1 |
| Maetani, S | 1 |
| Dimpfl, T | 1 |
| Stumpfe, M | 1 |
| Baltzer, J | 1 |
| Genz, T | 1 |
| Deeb, LS | 1 |
| Yamout, BI | 1 |
| Shamseddine, AI | 1 |
| Shabb, NS | 1 |
| Uthman, SM | 1 |
| Ohno, M | 2 |
| Moriwaki, R | 1 |
| Kohno, M | 1 |
| Tadatomo, H | 1 |
| Koyanagi, Y | 3 |
| Takayanagi, N | 1 |
| Anakura, T | 1 |
| Ostkamp, K | 1 |
| Wagner, W | 1 |
| Pötter, R | 1 |
| Moriuchi, S | 1 |
| Kaba, SE | 1 |
| Kyritsis, AP | 1 |
| Hess, K | 1 |
| Yung, WK | 1 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Jaeckle, KA | 1 |
| Levin, VA | 1 |
| Lucchi, E | 1 |
| Favre, R | 1 |
| Hyams, DM | 1 |
| Mamounas, EP | 1 |
| Petrelli, N | 2 |
| Rockette, H | 3 |
| Jones, J | 3 |
| Deutsch, M | 1 |
| Wickerham, L | 1 |
| Fisher, B | 2 |
| Kitao, Y | 1 |
| Yasuoka, R | 1 |
| Miyagaki, T | 1 |
| Ekström, K | 1 |
| Hoffman, K | 1 |
| Sjödén, PO | 1 |
| Haglund, U | 1 |
| Enander, LK | 1 |
| Sellström, H | 1 |
| Heuman, R | 1 |
| Shanahan, F | 1 |
| Qian, C | 1 |
| Kocha, WI | 4 |
| Graham, M | 2 |
| Chan, AK | 1 |
| Wong, AO | 1 |
| Langevin, JM | 1 |
| Jenken, DA | 1 |
| Heine, JA | 1 |
| Buie, WD | 1 |
| Johnson, DR | 1 |
| Yoshimori, M | 2 |
| Weiden, PL | 3 |
| Thompson, T | 2 |
| Stain, S | 2 |
| Casagrande, Y | 1 |
| Vignoud, J | 1 |
| Le Bail, N | 2 |
| Grann, A | 2 |
| Bass-Loeb, J | 1 |
| Lefranc, JP | 1 |
| Blondon, J | 1 |
| Buffat, L | 1 |
| Deniaud, E | 1 |
| Belkacémi, Y | 1 |
| Benmiloud, M | 1 |
| Huart, J | 1 |
| Laugier, A | 1 |
| Schlienger, M | 1 |
| Martino, RL | 1 |
| Morrell, LM | 2 |
| Dandekar, NP | 1 |
| Dalal, AV | 1 |
| Tongaonkar, HB | 1 |
| Kamat, MR | 1 |
| Petroni, GR | 1 |
| Vaughn, DJ | 2 |
| Holroyde, C | 1 |
| Nuamah, I | 1 |
| Armstead, B | 1 |
| Graiff, C | 1 |
| Nelli, P | 1 |
| Vicario, G | 1 |
| Sgarbossa, G | 1 |
| Pancheri, F | 1 |
| Manente, P | 1 |
| Okabo, S | 1 |
| Shimoju, K | 1 |
| Sakurazawa, K | 1 |
| Yabata, E | 1 |
| Saitoh, S | 2 |
| Tamura, Y | 2 |
| Hizawa, Y | 1 |
| Munakata, A | 2 |
| Raghunathan, K | 1 |
| Schmitz, JC | 1 |
| Priest, DG | 1 |
| Kumagai, K | 1 |
| Ueki, K | 1 |
| Inoki, C | 1 |
| Orino, I | 1 |
| Ueki, M | 2 |
| MacLeod, C | 1 |
| Moylan, E | 1 |
| Piazza, GA | 1 |
| Rahm, AK | 1 |
| Finn, TS | 1 |
| Fryer, BH | 1 |
| Stoumen, AL | 1 |
| Pamukcu, R | 1 |
| Ahnen, DJ | 1 |
| Lin, P | 1 |
| Ichikawa, A | 1 |
| Baker, P | 1 |
| Beger, H | 2 |
| Link, K | 2 |
| Büchler, M | 1 |
| Brashear, A | 1 |
| Siemers, E | 1 |
| Chung, YS | 1 |
| Nakata, B | 2 |
| Onoda, N | 2 |
| Sowa, M | 2 |
| Oikawa, I | 3 |
| Mukaiya, M | 3 |
| Hiraike, N | 1 |
| Takasaka, H | 2 |
| Katsuramaki, T | 2 |
| Yamashiro, K | 1 |
| Tomoda, H | 1 |
| Saito, T | 2 |
| Miura, M | 2 |
| Yamazaki, S | 1 |
| Ikeyama, S | 1 |
| Taki, S | 1 |
| Ishikawa, M | 1 |
| Yogita, S | 1 |
| Kamm, YL | 1 |
| Lerner-Tung, MB | 1 |
| Chang, AY | 1 |
| Ong, LS | 1 |
| Kreiser, D | 1 |
| Blijham, GH | 1 |
| Sakamoto, S | 3 |
| Iwama, T | 1 |
| Tsukada, K | 1 |
| Sagara, T | 1 |
| Murakami, S | 3 |
| Kudo, H | 2 |
| Okayasu, I | 1 |
| Jones, DR | 1 |
| Egan, TM | 1 |
| Parker, LA | 1 |
| Konovalova, NP | 1 |
| Volkova, LM | 1 |
| Tat'ianenko, LV | 1 |
| Kotel'nikova, RA | 1 |
| Iakushchenko, TN | 1 |
| Kagiia, T | 1 |
| Street, JC | 1 |
| Alfieri, AA | 1 |
| Koutcher, JA | 1 |
| Wender, DB | 1 |
| Schroeder, G | 2 |
| Ghosh, C | 1 |
| Kirschling, RJ | 1 |
| Kamthan, AG | 2 |
| Morris, JC | 1 |
| Mandeli, JP | 1 |
| Leben, D | 1 |
| Cooperman, A | 2 |
| Lu, J | 1 |
| Rakovitch, E | 1 |
| Fyles, AW | 1 |
| Pintilie, M | 1 |
| Leung, PM | 1 |
| Girinsky, T | 1 |
| Marsiglia, H | 1 |
| Dhermain, F | 1 |
| Randrianarivelo, H | 1 |
| Proulx, GM | 1 |
| Daley, W | 1 |
| Athanassiadou, P | 1 |
| Athanassiades, P | 2 |
| Petrakakou, E | 1 |
| Zerva, C | 1 |
| Mavrikakis, M | 1 |
| Murray, CL | 1 |
| Ford, WJ | 1 |
| Swenson, KK | 1 |
| Heros, D | 1 |
| Sperduto, PW | 1 |
| von Schlippe, M | 1 |
| Becker, M | 3 |
| Larto, MA | 1 |
| Kirby, TJ | 1 |
| Koka, A | 1 |
| Tefft, M | 1 |
| Irwin, JF | 1 |
| Waterfield, W | 1 |
| Poussin-Rosillo, H | 1 |
| Sardi, A | 1 |
| Hejna, MH | 1 |
| Weinlaender, G | 1 |
| Vorbeck, F | 1 |
| Fiebiger, WC | 1 |
| You, NC | 1 |
| Kim, CB | 1 |
| Fushiki, H | 1 |
| Hidaka, T | 1 |
| Fujimura, M | 1 |
| Yamakawa, Y | 1 |
| Izumi, R | 1 |
| Fujita, A | 2 |
| Takabatake, H | 1 |
| Tagaki, S | 1 |
| Sekine, K | 2 |
| Kudo, T | 2 |
| Kuwahara, H | 1 |
| Takamatsu, S | 3 |
| Sugano, N | 2 |
| Hiddemann, W | 1 |
| Sugawara, T | 1 |
| Omodei Zorini, C | 1 |
| Deffontaines, D | 1 |
| Scholl, S | 1 |
| Hara, S | 1 |
| Hashizume, S | 1 |
| Itoyanagi, N | 1 |
| Tagawa, Y | 1 |
| Tsuji, H | 2 |
| Shinguu, H | 1 |
| Tou, K | 1 |
| Tooyama, H | 1 |
| Yamazumi, K | 1 |
| Okawa, MK | 1 |
| Kokubo, N | 1 |
| Karasawa, K | 1 |
| Fukuhara, N | 1 |
| Toda, J | 1 |
| Kuroda, C | 1 |
| Matsumoto, N | 1 |
| Ueno, T | 2 |
| Liang, S | 1 |
| Koshiji, M | 1 |
| Taketani, S | 3 |
| Hioki, K | 3 |
| Ikehara, S | 4 |
| Murotani, M | 1 |
| Iihara, K | 1 |
| Takami, M | 1 |
| Kitada, M | 1 |
| Tsukahara, Y | 1 |
| Niinobu, T | 1 |
| Hanada, M | 1 |
| Nose, T | 1 |
| Yuasa, Y | 1 |
| Miki, H | 2 |
| Noguchi, S | 2 |
| Tazaki, N | 1 |
| Kida, T | 1 |
| Pace, R | 1 |
| Giunta, S | 1 |
| Gallà, DA | 1 |
| Silecchia, GF | 1 |
| Franchi, F | 3 |
| Narduzzi, C | 1 |
| Kawabata, K | 1 |
| Nio, Y | 3 |
| Padhani, A | 1 |
| Prendiville, J | 1 |
| Massey, A | 1 |
| Popescu, R | 1 |
| Pokorny, RM | 1 |
| Wrightson, WR | 1 |
| Lewis, RK | 1 |
| Paris, KJ | 1 |
| Hofmeister, A | 1 |
| LaRocca, R | 1 |
| Myers, SR | 1 |
| Ackerman, D | 1 |
| Galandiuk, S | 1 |
| O'Hagan, S | 1 |
| Diamond, T | 1 |
| Landreaneau, RJ | 1 |
| Day, R | 1 |
| Ferson, PF | 1 |
| Keenan, RJ | 1 |
| Seeger, J | 1 |
| Lembersky, B | 2 |
| Dresler, C | 1 |
| Kahn, M | 1 |
| Fitzgibbons, RJ | 3 |
| Shepherd, L | 1 |
| Vukov, AM | 1 |
| Figueredo, A | 1 |
| Konda, B | 1 |
| Look, KY | 1 |
| Valea, FA | 1 |
| McGehee, R | 1 |
| Manetta, A | 2 |
| Webster, KD | 1 |
| Andersen, WA | 1 |
| Frassineti, GL | 1 |
| Vinci, M | 1 |
| Caroti, C | 1 |
| Ciferri, E | 1 |
| Verdi, E | 1 |
| Sasahara, K | 1 |
| Kamei, M | 1 |
| Surico, N | 1 |
| Ribaldone, R | 1 |
| Warzelhan, J | 1 |
| Byram, D | 1 |
| Bell, R | 1 |
| Bond, R | 1 |
| Vaughan, S | 1 |
| McLennan, R | 1 |
| Lim-Joon, M | 1 |
| Wada, M | 1 |
| Longo, GS | 2 |
| Izzo, J | 1 |
| Tong, WP | 1 |
| Zielinski, Z | 1 |
| Gorlick, R | 2 |
| Chou, TC | 1 |
| Pfreundner, L | 2 |
| Baier, K | 1 |
| Schwab, F | 1 |
| Willner, J | 1 |
| Bratengeier, K | 2 |
| Feustel, H | 2 |
| Fuchs, KH | 1 |
| Rossi, BM | 2 |
| Nakagawa, WT | 2 |
| Novaes, PE | 1 |
| Filho, WD | 1 |
| Lopes, A | 2 |
| Ojugo, AS | 1 |
| McSheehy, PM | 2 |
| Stubbs, M | 2 |
| Alder, G | 1 |
| Bashford, CL | 1 |
| Maxwell, RJ | 1 |
| Leach, MO | 1 |
| Judson, IR | 1 |
| Griffiths, JR | 2 |
| Friedrich, M | 1 |
| Daniel, PT | 1 |
| Benter, T | 1 |
| Bauer, B | 1 |
| Dietz, R | 1 |
| Kimoto, M | 1 |
| Mure, T | 1 |
| Onuma, E | 1 |
| Iki, K | 1 |
| Tadaoka, Y | 1 |
| Majima, T | 2 |
| Kawasaki, S | 1 |
| Kubozoe, T | 1 |
| Tsunoda, T | 2 |
| Kajihara, K | 1 |
| Akama, F | 1 |
| Ninomiya, H | 1 |
| Shigeta, K | 1 |
| Sano, I | 1 |
| Iwasaki, K | 1 |
| Yokomori, T | 2 |
| Iesato, H | 2 |
| Ouya, T | 1 |
| Blumenson, LE | 1 |
| Flett, MQ | 1 |
| Propert, KJ | 1 |
| Trump, D | 1 |
| Wilding, G | 1 |
| Hudes, G | 1 |
| Burch, P | 1 |
| Keller, A | 1 |
| Loehrer, P | 1 |
| Shinohara, N | 1 |
| Demura, T | 1 |
| Toyoda, K | 1 |
| Kashiwagi, A | 1 |
| Ohmuro, H | 1 |
| Ohzono, S | 1 |
| Koyanagi, T | 1 |
| Mantini, G | 1 |
| Barbaro, B | 1 |
| Cogliandolo, S | 1 |
| Ambesi-Impiombato, F | 1 |
| Tedesco, M | 1 |
| Miles, JS | 1 |
| Fu, J | 1 |
| Banerjee, D | 1 |
| Jhanwar, S | 1 |
| Cailleux, PE | 1 |
| Alleaume, C | 1 |
| Maillet, ML | 1 |
| Sire, M | 1 |
| Person-Joly, MC | 1 |
| Maigre, M | 1 |
| Maillart, P | 1 |
| Fety, R | 1 |
| Dumesnil, Y | 1 |
| Geslin, J | 1 |
| Gesta, P | 1 |
| Danquechin-Dorval, E | 1 |
| Larra, F | 1 |
| Chen, CL | 1 |
| Marczell, A | 4 |
| Karner, J | 2 |
| Salem, G | 1 |
| Greiner, R | 1 |
| Burger, D | 1 |
| Stöger, F | 1 |
| Ritschel, J | 1 |
| Kovats, E | 1 |
| Vischer, HM | 1 |
| Donegan, J | 1 |
| Reed, C | 1 |
| Yamane, N | 1 |
| Taniguchi, T | 1 |
| Duley, JA | 1 |
| Nethersell, AB | 1 |
| Kawashima, K | 1 |
| Kamiyama, H | 1 |
| Stein, ME | 1 |
| Drumea, K | 1 |
| Yarnitsky, D | 1 |
| Benny, A | 1 |
| Tzuk-Shina, T | 1 |
| Casucci, D | 1 |
| Gulino, A | 1 |
| Frati, L | 1 |
| Sanz-Altamira, PM | 1 |
| Ferrante, K | 1 |
| Jenkins, RL | 1 |
| Lewis, WD | 1 |
| Huberman, MS | 2 |
| Stuart, KE | 1 |
| Bozec, L | 1 |
| Bierling, P | 1 |
| Fromont, P | 1 |
| Debat, P | 1 |
| Bours, V | 1 |
| Jerusalem, G | 1 |
| Fillet, G | 1 |
| Nüsslein, S | 1 |
| Katalinic, A | 1 |
| Lu, JD | 1 |
| Kim, RY | 2 |
| Iba, T | 1 |
| Yagi, Y | 1 |
| Kidokoro, A | 1 |
| Ishi, K | 1 |
| Koyatsu, J | 1 |
| Sumi, S | 2 |
| Kidouchi, K | 1 |
| Yamamoto, N | 1 |
| Deguchi, T | 1 |
| Kuriyama, M | 1 |
| Yoh, M | 1 |
| Nakano, M | 1 |
| Kawada, Y | 1 |
| Shinoda, I | 1 |
| Steyn, RS | 1 |
| Vijeyasingam, R | 1 |
| Cullen, MH | 3 |
| Burke, SJ | 1 |
| Percarpio, BA | 1 |
| Knight, DC | 1 |
| Kwasnik, EM | 1 |
| Belsanti, V | 1 |
| Marzola, M | 2 |
| Corgna, E | 1 |
| Sdrobolini, A | 3 |
| Figoli, F | 3 |
| Algeri, R | 2 |
| Ujiie, S | 1 |
| Kanamaru, R | 3 |
| Crawley, C | 1 |
| Takasaki, M | 3 |
| Takamatsu, M | 1 |
| Horimi, T | 3 |
| Takahashi, I | 3 |
| Peters, HD | 1 |
| Possinger, K | 2 |
| Hietschold, SM | 1 |
| Pincemaille, B | 1 |
| Besançon, C | 1 |
| Balme, B | 1 |
| Devaux, Y | 1 |
| Thomas, L | 1 |
| Scher, RM | 1 |
| Provins, S | 1 |
| Ho, DH | 1 |
| Covington, W | 1 |
| Brown, N | 1 |
| Huo, YY | 1 |
| Lassere, Y | 1 |
| Kuritani, J | 1 |
| de Souza, PM | 1 |
| Gansl, R | 1 |
| Sousa, AH | 1 |
| Kobayashi, A | 1 |
| Caujolle, C | 1 |
| Gastaud, P | 1 |
| Montoya, ML | 1 |
| Demarquay, JF | 1 |
| Delmont, JP | 1 |
| Kuniyasu, T | 1 |
| Tabuchi, Y | 1 |
| Mullany, S | 1 |
| Svingen, PA | 1 |
| Kaufmann, SH | 1 |
| Lozac'h, P | 1 |
| Topart, P | 1 |
| Volant, A | 1 |
| Gonzales, A | 1 |
| Lu, K | 1 |
| Harrison, LB | 1 |
| Mychalczak, B | 1 |
| Anderson, L | 1 |
| White, C | 1 |
| Fisher, BJ | 1 |
| Perera, FE | 1 |
| Bauman, GS | 1 |
| Taylor, M | 1 |
| Vincent, MD | 1 |
| Plewes, EA | 1 |
| Engel, CJ | 1 |
| Stitt, LW | 1 |
| Navarro, M | 2 |
| Herait, P | 3 |
| Aebi, S | 2 |
| Fink, D | 1 |
| Gordon, R | 1 |
| Fink, JL | 1 |
| Cheshire, PJ | 4 |
| Stewart, CF | 1 |
| Hallman, JD | 1 |
| Lutz, L | 1 |
| Luo, X | 1 |
| Park, HC | 1 |
| Yoon, HJ | 1 |
| Choi, YM | 1 |
| Cho, KS | 1 |
| Lindner, H | 1 |
| Dikken, C | 1 |
| Sitzia, J | 1 |
| Goswitz, MS | 1 |
| Raijman, I | 4 |
| Lenzi, R | 3 |
| Cripps, C | 2 |
| Goel, R | 2 |
| Oza, AM | 1 |
| Skillings, JR | 1 |
| Kerr, I | 1 |
| Germond, CJ | 1 |
| Maroun, JA | 2 |
| Franssen, E | 1 |
| Dulude, H | 1 |
| Ginsberg, R | 1 |
| Pajak, TF | 1 |
| Sheahan, DG | 1 |
| Gunderson, L | 1 |
| Estes, N | 1 |
| Okamoto, M | 1 |
| Kasetani, H | 1 |
| Kaji, R | 1 |
| Goda, H | 1 |
| Ohe, G | 1 |
| Bold, RJ | 1 |
| Takashima, T | 1 |
| Bousquet, J | 1 |
| Slim, K | 1 |
| Alexandre, M | 1 |
| Chipponi, J | 1 |
| Suwa, H | 1 |
| Hosotani, R | 2 |
| Okino, T | 1 |
| Monden, K | 1 |
| Arii, S | 1 |
| Kogire, M | 3 |
| Ohshio, G | 1 |
| Fukumoto, M | 1 |
| Ferry, DR | 2 |
| Aziz, SA | 1 |
| Tramboo, NA | 1 |
| Mohi-ud-Din, K | 1 |
| Iqbal, K | 1 |
| Jalal, S | 1 |
| Ahmad, M | 1 |
| Bavisotto, LM | 1 |
| Patel, NH | 1 |
| Althaus, SJ | 1 |
| Coldwell, DM | 1 |
| Nghiem, HV | 1 |
| Storer, B | 1 |
| Au, E | 3 |
| Seow-Choen, F | 2 |
| Soo, KC | 2 |
| Low, CH | 2 |
| Chng, HC | 1 |
| Ng, BK | 2 |
| Gil-Delgado, M | 1 |
| de Gramond, A | 1 |
| Khayat, D | 1 |
| Valencak, J | 1 |
| Weinländer, G | 1 |
| Fiebiger, W | 1 |
| Miholic, J | 1 |
| Seto, Y | 2 |
| Masamune, R | 1 |
| Kunii, Y | 1 |
| Djordjevic, B | 1 |
| Lange, CS | 1 |
| Schwartz, MS | 1 |
| Ueno, Y | 1 |
| Yoshikawa, H | 1 |
| Tanihata, H | 1 |
| Masuda, M | 1 |
| Matsuda, T | 1 |
| Mabuchi, K | 2 |
| Kitaoka, H | 1 |
| Hirata, N | 1 |
| Kitaoka, U | 1 |
| Kawabata, Y | 1 |
| Yano, S | 2 |
| Ohishi, T | 1 |
| Darut-Jouve, A | 1 |
| Coudert, B | 1 |
| Jolimoy, G | 1 |
| Belichard, C | 1 |
| Arnoud, L | 1 |
| Guerrin, J | 2 |
| Duan, C | 1 |
| Leng, A | 1 |
| Serravezza, G | 1 |
| Lelli, G | 1 |
| Nicolella, G | 1 |
| Brandi, M | 1 |
| Kimura, H | 1 |
| Corral, P | 1 |
| Rodríguez-Coria, D | 1 |
| Goldblum, J | 1 |
| Medendorp, SV | 1 |
| Pimentel, R | 1 |
| Gitlin, L | 1 |
| Sabaawy, HE | 1 |
| Farley, T | 1 |
| Ahmed, T | 2 |
| Feldman, E | 2 |
| Abraham, NG | 2 |
| Bender, H | 1 |
| Bangard, N | 1 |
| Metten, N | 1 |
| Bangard, M | 1 |
| Mezger, J | 1 |
| Schomburg, A | 1 |
| Biersack, HJ | 1 |
| Khalil, A | 2 |
| Seoud, M | 2 |
| Kahwaji, S | 2 |
| Taher, A | 1 |
| Bizri, AR | 1 |
| Medawar, W | 2 |
| Ibrahim, K | 1 |
| Habbal, Z | 1 |
| Klas, JV | 1 |
| Rothenberger, DA | 1 |
| Kissel, J | 1 |
| Zaers, J | 1 |
| Bellemann, ME | 1 |
| Strauss, LG | 1 |
| Brix, G | 2 |
| Warner, E | 1 |
| Jensen, JL | 1 |
| Khoo, KE | 1 |
| Kerr, IA | 1 |
| Fields, AL | 2 |
| Hrincu, A | 1 |
| Fushida, S | 2 |
| Taniguchi, K | 2 |
| Bando, E | 2 |
| Michiwa, Y | 1 |
| Fujimura, T | 2 |
| Yonemura, Y | 2 |
| Pegram, M | 1 |
| Hsu, S | 1 |
| Lewis, G | 1 |
| Pietras, R | 1 |
| Beryt, M | 1 |
| Sliwkowski, M | 1 |
| Coombs, D | 1 |
| Baly, D | 1 |
| Kabbinavar, F | 1 |
| Slamon, D | 1 |
| Sause, W | 1 |
| Bundy, BN | 1 |
| Malfetano, JH | 1 |
| Hannigan, EV | 1 |
| Clarke-Pearson, DL | 1 |
| Liao, SY | 1 |
| Mamounas, E | 1 |
| Wieand, S | 1 |
| Bear, HD | 2 |
| Atkins, JN | 2 |
| Song, K | 1 |
| Sabaawy, HM | 1 |
| Quan, S | 1 |
| Kancherla, R | 1 |
| Masaki, T | 1 |
| Partyka, S | 1 |
| Dumas, P | 2 |
| Baek, HJ | 1 |
| Kim, YC | 1 |
| Shim, YM | 1 |
| Kim, CM | 1 |
| Zo, JI | 1 |
| Shankar, A | 1 |
| Renaut, AJ | 1 |
| Whelan, J | 1 |
| Blot, E | 1 |
| Marie, I | 1 |
| Delastre, O | 1 |
| Cailleux, N | 1 |
| Lévesque, H | 1 |
| Courtois, H | 1 |
| Kuriyama, S | 1 |
| Mitoro, A | 1 |
| Tsujinoue, H | 1 |
| Toyokawa, Y | 1 |
| Okamoto, S | 1 |
| Fukui, H | 2 |
| Funahashi, Y | 1 |
| Koyanagi, N | 1 |
| Sonoda, J | 1 |
| Kitoh, K | 1 |
| Yoshimatsu, K | 1 |
| Imaseki, H | 1 |
| Asato, Y | 1 |
| Yoshimi, F | 1 |
| Ono, H | 1 |
| Amemiya, R | 1 |
| Miya, T | 1 |
| Goya, T | 1 |
| Ohnuma, S | 1 |
| Takenami, K | 1 |
| Hosoya, Y | 1 |
| Kitoh, Y | 1 |
| Kobayashi, E | 1 |
| Okabe, R | 1 |
| Fujimura, A | 1 |
| Arber, N | 1 |
| Beger, HG | 1 |
| Korc, M | 1 |
| Chakravarthy, A | 2 |
| Sohn, TA | 1 |
| Haulk, TL | 1 |
| Ord, S | 1 |
| Streeter, OE | 1 |
| Martz, KL | 1 |
| Delrowe, JD | 1 |
| Asbell, SO | 1 |
| Salter, MM | 1 |
| Roach, M | 1 |
| Doidy, L | 1 |
| Sabourin, JC | 1 |
| Bonvalot, S | 1 |
| Nabai, H | 1 |
| Mohindra, R | 1 |
| Mehregan, D | 1 |
| Waller, CF | 1 |
| von Lintig, F | 1 |
| Daskalakis, A | 1 |
| Musahl, V | 1 |
| Lange, W | 1 |
| Damle, S | 1 |
| Wolf, E | 1 |
| Kito, T | 1 |
| Okabayashi, K | 1 |
| Mehran, R | 1 |
| Maroun, J | 1 |
| Crepeau, A | 1 |
| Iwata, R | 1 |
| Ido, T | 1 |
| Gamo, M | 1 |
| Evrard, A | 1 |
| Cuq, P | 1 |
| Ciccolini, J | 1 |
| Vian, L | 1 |
| Cano, JP | 1 |
| Hürny, C | 2 |
| Otani, S | 1 |
| Iwagaki, H | 1 |
| Jikuhara, A | 1 |
| Tagashira, H | 1 |
| Nagao, A | 1 |
| Isozaki, H | 1 |
| Hizuta, A | 1 |
| Skradis, A | 1 |
| Kolar, C | 1 |
| Kolath, J | 1 |
| Anderson, J | 1 |
| Lawson, T | 1 |
| Talmadge, J | 1 |
| Gmeiner, WH | 1 |
| Yorozu, A | 1 |
| Dokiya, T | 2 |
| Oki, Y | 1 |
| Allen, DC | 1 |
| Fon, LJ | 1 |
| McAleer, JJ | 1 |
| Irwin, ST | 1 |
| Keizer, HJ | 1 |
| Hermans, J | 2 |
| Klementschitsch, P | 1 |
| Sakukawa, R | 1 |
| Saiki, I | 1 |
| Shapiro, JD | 1 |
| Harold, N | 1 |
| Takimoto, C | 1 |
| Vaughn, D | 1 |
| Liewehr, D | 1 |
| Monahan, B | 1 |
| Lash, A | 1 |
| Flemming, D | 1 |
| Behan, K | 1 |
| Quinn, M | 1 |
| Morrison, G | 1 |
| Yamamoto, W | 1 |
| Hanaoka, H | 1 |
| Matsukawa, M | 1 |
| Jones, SE | 1 |
| McIntyre, K | 1 |
| Mennel, R | 1 |
| Orr, D | 1 |
| Kirby, R | 1 |
| Agura, E | 1 |
| Duncan, L | 1 |
| Roque, T | 1 |
| Regan, D | 1 |
| Schuster, M | 1 |
| Dimitrov, N | 1 |
| Garrison, L | 1 |
| Lange, M | 1 |
| Fata, F | 2 |
| Viens, P | 1 |
| Janvier, M | 1 |
| Fabbro, M | 1 |
| Labat, JP | 1 |
| Linassier, C | 1 |
| Audhuy, B | 1 |
| Feuilhade, F | 1 |
| Costa, B | 1 |
| Rousseau, F | 1 |
| Guillot, A | 1 |
| Jacquemier, J | 1 |
| Oka, S | 2 |
| Kondo, A | 1 |
| Maeta, M | 1 |
| Gravina, A | 1 |
| Faranda, A | 1 |
| Comis, S | 2 |
| O'Byrne, KJ | 1 |
| Propper, DJ | 1 |
| Braybrooke, JP | 1 |
| Bates, NP | 1 |
| Taylor, MA | 1 |
| Madigan, D | 1 |
| Ganesan, TS | 1 |
| Harris, AL | 2 |
| Silva, RR | 1 |
| Martignoni, G | 1 |
| Gasparini, G | 2 |
| Baldelli, AM | 1 |
| Giuliodori, L | 1 |
| Agostinelli, R | 1 |
| Paulino, AC | 2 |
| Keppen, MD | 1 |
| Dalton, RJ | 2 |
| Gerstner, JB | 1 |
| Jancewicz, MT | 1 |
| Ebbert, LP | 1 |
| Fonck, M | 2 |
| Grogan, M | 1 |
| Melamed, I | 1 |
| Wong, FL | 1 |
| Pearcey, RG | 1 |
| Joseph, PK | 1 |
| Portelance, L | 1 |
| Crook, J | 1 |
| Jones, KD | 1 |
| Horsell, KW | 1 |
| Merten, S | 1 |
| King, DW | 1 |
| Levitt, M | 1 |
| House, A | 1 |
| Robbins, P | 2 |
| Vieceli, G | 1 |
| Marchiori, E | 1 |
| Chidel, MA | 1 |
| Kupelian, PA | 1 |
| Antonuzzo, A | 1 |
| Brunetti, I | 1 |
| Pfanner, E | 2 |
| Conte, P | 2 |
| Lutz, MP | 1 |
| Königer, M | 1 |
| Muche, R | 1 |
| Ellenrieder, V | 1 |
| Steinkamp, M | 1 |
| Gress, TM | 1 |
| Bensmaine, MA | 1 |
| Lucas, V | 1 |
| Dupont-André, G | 1 |
| Nomura, E | 1 |
| Sako, S | 1 |
| Otani, M | 1 |
| Wakahara, M | 1 |
| Ooshita, H | 1 |
| Kanno, A | 1 |
| Suhara, T | 1 |
| Nakata, T | 1 |
| Saitou, S | 1 |
| Takata, N | 1 |
| Harada, K | 1 |
| Yoshinaka, I | 1 |
| Maeda, M | 1 |
| Hargraves, K | 1 |
| Curley, S | 1 |
| Popescu, RA | 1 |
| Parikh, B | 1 |
| Tocchi, A | 1 |
| Lepre, L | 1 |
| Costa, G | 1 |
| Liotta, G | 1 |
| Mazzoni, G | 1 |
| Agostini, N | 1 |
| Miccini, M | 1 |
| Larzillière, I | 1 |
| Brandissou, S | 1 |
| Breton, P | 1 |
| Lingoungou, A | 1 |
| Ramain, JP | 1 |
| Harnois, C | 1 |
| Oyaizu, H | 1 |
| Ikebukuro, K | 2 |
| Tokunaga, R | 2 |
| Ganser, A | 1 |
| Wiese, KH | 1 |
| Rambusch, E | 1 |
| de Vries, MJ | 1 |
| Hanauske, A | 1 |
| Sasaki, J | 3 |
| Tanaka, O | 3 |
| Tsutsui, M | 1 |
| Fukuzawa, S | 1 |
| Cordel, S | 1 |
| Goupille, C | 1 |
| Hallouin, F | 1 |
| Meflah, K | 1 |
| Le Pendu, J | 1 |
| Ninomiya, Y | 1 |
| Yanagisawa, A | 1 |
| Kitagawa, T | 2 |
| Taieb, S | 1 |
| Vaillant, E | 1 |
| Pommier, P | 1 |
| Bonvoisin, S | 1 |
| Morignat, E | 1 |
| Page, C | 1 |
| Beidler, DR | 1 |
| Wicha, MS | 1 |
| Núñez, G | 1 |
| Carr, JA | 1 |
| Ajlouni, M | 1 |
| Wong, D | 2 |
| Velanovich, V | 1 |
| Danikas, D | 1 |
| Theodorou, SJ | 1 |
| Arvanitis, ML | 1 |
| Zinterhofer, LM | 1 |
| Rienzo, AA | 1 |
| Petroianu, A | 1 |
| Cabral, LO | 1 |
| Carpi, A | 2 |
| Frassoldati, A | 2 |
| Mosconi, A | 1 |
| Borrini, A | 1 |
| Buzzi, P | 1 |
| Kucuk, O | 1 |
| Pandya, KJ | 1 |
| Skeel, RT | 3 |
| Peracchia, A | 1 |
| Bonavina, L | 1 |
| Via, A | 1 |
| Incarbone, R | 1 |
| Farczádi, E | 1 |
| Kaszás, I | 1 |
| Benyó, I | 1 |
| Bodnár, Z | 1 |
| Szlobodnyik, J | 1 |
| Szende, B | 1 |
| Turnbull, AD | 1 |
| Sullivan, D | 1 |
| Stockman, J | 1 |
| Blumgart, LH | 1 |
| Klinkenbijl, JH | 1 |
| van Pel, R | 1 |
| Arnaud, JP | 3 |
| Gonzalez, DG | 1 |
| de Wit, LT | 1 |
| Hennipman, A | 1 |
| Thirion, P | 1 |
| Haddad, E | 1 |
| Gogas, H | 1 |
| Sasano, H | 1 |
| Ohi, R | 1 |
| Imaizumi, M | 2 |
| Shineha, R | 1 |
| Shibuya, D | 1 |
| Matsumoto, G | 1 |
| Ise, H | 1 |
| Müller, HH | 2 |
| Schratter-Sehn, A | 1 |
| Krauss, G | 1 |
| Locker, G | 1 |
| Ashizawa, T | 1 |
| Sumi, T | 1 |
| Murohashi, T | 1 |
| Minari, Y | 1 |
| Itakura, M | 1 |
| Yamasawa, K | 1 |
| Musha, N | 2 |
| Sando, N | 2 |
| Setu, Y | 1 |
| Setu, M | 1 |
| Oka, K | 2 |
| Hudec, WA | 1 |
| Talamini, MA | 1 |
| Kaufman, HS | 1 |
| Canto, MI | 1 |
| Topazian, M | 1 |
| Olukayode, K | 1 |
| Gambiez, L | 1 |
| Denimal, F | 1 |
| Karoui, M | 1 |
| Dewailly, V | 1 |
| Pruvot, FR | 1 |
| Quandalle, P | 1 |
| Han, Q | 1 |
| Takenoue, T | 2 |
| Koyama, K | 3 |
| Dickie, G | 1 |
| Hodge, R | 1 |
| Morton, K | 1 |
| Wilson, KS | 1 |
| Minatoya, T | 1 |
| Ajisaka, H | 1 |
| Iwatani, Y | 1 |
| Iwasaki, T | 1 |
| Sinmaru, H | 1 |
| Takeuchi, I | 2 |
| Idezuki, Y | 2 |
| Hohya, I | 1 |
| Nihei, T | 1 |
| Colonna, M | 1 |
| Bellaïche, A | 1 |
| Parc, R | 1 |
| Ukarapol, N | 1 |
| Wongsawasdi, L | 1 |
| Singhavejsakul, J | 1 |
| Alexander, EP | 1 |
| Lipman, T | 1 |
| Harmon, J | 1 |
| Wadleigh, R | 1 |
| Takeda, N | 1 |
| Ishihata, R | 1 |
| James, RD | 1 |
| Karasek, P | 1 |
| Jandik, P | 1 |
| Alakl, M | 1 |
| Gruia, G | 1 |
| Daly, JM | 1 |
| Deuffic, S | 1 |
| Pelissier, E | 1 |
| Favre, JP | 1 |
| Jaeck, D | 1 |
| Fourtanier, G | 1 |
| Grandjean, JP | 1 |
| Marre, P | 1 |
| Israel, ZH | 1 |
| Lossos, A | 1 |
| Barak, V | 1 |
| Soffer, D | 1 |
| Siegal, T | 1 |
| Arthur, DW | 1 |
| Schmidt-Ullrich, RK | 1 |
| Friedman, RB | 1 |
| Kachnic, LA | 2 |
| Amir, C | 1 |
| Hackney, MH | 1 |
| Lawrence, W | 3 |
| Levy-Piedbois, C | 1 |
| Durand-Zaleski, I | 1 |
| Juhel, H | 1 |
| Schmitt, C | 1 |
| Bellanger, A | 1 |
| Janinis, J | 1 |
| Skarlos, D | 1 |
| Papagianopoulos, P | 1 |
| Aki, Z | 1 |
| Kotiloğlu, G | 1 |
| Ozyilkan, O | 1 |
| Fan, FS | 1 |
| Toki, J | 1 |
| Bergmann-Leitner, ES | 1 |
| Abrams, SI | 1 |
| Lavrenkov, K | 1 |
| Kawahara, M | 2 |
| Takii, Y | 1 |
| Teng, HC | 1 |
| Hung, HC | 1 |
| King, KL | 1 |
| Chi, KH | 1 |
| Chang, FY | 1 |
| He, Z | 1 |
| Fei, H | 1 |
| Latona, C | 1 |
| Kawamura, K | 1 |
| Tasaki, K | 1 |
| Takenaga, K | 1 |
| Sakiyama, S | 1 |
| Tagawa, M | 1 |
| Hochmuth, K | 1 |
| Collette, M | 1 |
| Yoshimasu, T | 1 |
| Oura, S | 1 |
| Maebeya, S | 1 |
| Tanino, H | 1 |
| Bessho, T | 1 |
| Arimoto, J | 1 |
| Sakurai, T | 1 |
| Matsuyama, K | 1 |
| Suzuma, T | 1 |
| Hirai, I | 1 |
| Unno, J | 1 |
| Shirozaki, T | 1 |
| Arai, S | 2 |
| Okuyama, H | 1 |
| Hayashida, N | 1 |
| Kouda, S | 1 |
| Tadokoro, M | 1 |
| Ishikou, T | 1 |
| Touda, J | 1 |
| Kajiwara, M | 1 |
| Midgley, RS | 1 |
| Marshall, ME | 1 |
| O'Rourke, M | 2 |
| Barnett, TC | 1 |
| Olmeo, N | 1 |
| Cavicchi, F | 1 |
| Contu, A | 1 |
| Hinoshita, E | 1 |
| Uchiumi, T | 1 |
| Taguchi, K | 1 |
| Tsuneyoshi, M | 1 |
| Kuwano, M | 1 |
| Westermann, AM | 1 |
| Swart, M | 1 |
| Craanen, M | 1 |
| Gerritsen, WR | 1 |
| Wientjes, MG | 1 |
| Gan, Y | 1 |
| Au, JL | 1 |
| Ducreux, MP | 1 |
| Lacave, AJ | 1 |
| Planker, M | 1 |
| Santos, JG | 1 |
| Bodenstein, H | 1 |
| Kin, R | 1 |
| Nishimoto, N | 1 |
| Hirai, T | 1 |
| Kamata, T | 1 |
| Nakamoto, A | 1 |
| Onishi, I | 1 |
| Takeda, T | 1 |
| Koyasaki, N | 1 |
| Kanno, M | 1 |
| Shinkawa, H | 1 |
| Wada, N | 1 |
| Naka, S | 1 |
| Yasuhara, H | 1 |
| Kuroda, T | 1 |
| Nojiri, T | 1 |
| Nagao, T | 1 |
| Nagao, K | 1 |
| Kawasaki, H | 1 |
| Matsunaga, T | 1 |
| Nakagawa, N | 1 |
| Yabana, T | 1 |
| Yasojima, T | 1 |
| Furuhata, T | 1 |
| Hata, F | 1 |
| Yovine, A | 1 |
| Hsu, KC | 1 |
| Chang, TC | 1 |
| Oh, CM | 1 |
| Bleeker, WA | 1 |
| Otter, R | 1 |
| Cornalba, G | 1 |
| Smerieri, F | 1 |
| Paradiso, J | 1 |
| Kiefer, L | 1 |
| McCart, JA | 1 |
| Puhlmann, M | 1 |
| Libutti, SK | 1 |
| Bartlett, DL | 1 |
| Feng, J | 1 |
| Zheng, X | 1 |
| Dai, A | 1 |
| Alektiar, KM | 1 |
| Zelefsky, MJ | 1 |
| Powell, B | 1 |
| Grieu, F | 1 |
| Menso, L | 1 |
| Nukui, Y | 1 |
| Kwok, QS | 1 |
| Banerji, U | 1 |
| Townsend, ER | 1 |
| Homerin, M | 1 |
| Hmissi, A | 1 |
| Hendler, D | 1 |
| Haag, C | 2 |
| Lingenfelser, T | 1 |
| Baronius, W | 2 |
| Hempel, V | 2 |
| Ezekiel, G | 1 |
| Walfisch, S | 1 |
| Di Paolo, AD | 1 |
| Innocenti, F | 1 |
| Melosi, A | 1 |
| Battistoni, M | 1 |
| Barsanti, G | 1 |
| Ahmed, S | 2 |
| Du, W | 2 |
| Arlauskas, P | 1 |
| Gordon, C | 1 |
| Kellogg, C | 1 |
| Kim, CD | 1 |
| Um, SH | 1 |
| Jacobson, JL | 1 |
| Modiano, M | 1 |
| Moore, DF | 1 |
| Schroder, LE | 1 |
| Nita, ME | 1 |
| Ono-Nita, SK | 1 |
| Tsuno, N | 1 |
| Tominaga, O | 1 |
| Nakagami, K | 1 |
| Sugitani, K | 1 |
| Ohya, T | 1 |
| Fukutomi, K | 1 |
| Ohkuma, K | 1 |
| Hisano, C | 1 |
| Kaji, Y | 1 |
| McGrath, P | 1 |
| Strodel, WE | 1 |
| Suh, CO | 1 |
| Talamonti, MS | 1 |
| Harbison, SP | 1 |
| Stiller, GD | 1 |
| Henry, DH | 1 |
| Fisher, SA | 1 |
| Kikunaga, H | 1 |
| Sotome, K | 1 |
| Morisue, A | 1 |
| Matsudo, A | 1 |
| Nakai, H | 1 |
| Takao, M | 1 |
| Osakabe, Y | 1 |
| Miura, H | 1 |
| Momono, S | 1 |
| Iwata, S | 1 |
| Taki, Y | 1 |
| Waddell, BE | 1 |
| Lee, RJ | 1 |
| Weber, TK | 1 |
| András, C | 1 |
| Csiki, Z | 1 |
| Gál, I | 1 |
| Takács, I | 1 |
| Antal, L | 1 |
| Szegedi, G | 1 |
| Delauter, BJ | 1 |
| Stover, LL | 1 |
| Zuhowski, EG | 1 |
| Plunkett, W | 1 |
| Zamboni, WC | 1 |
| Noh, JK | 1 |
| Kastl, S | 1 |
| Brunner, T | 1 |
| Herrmann, O | 1 |
| Riepl, M | 1 |
| Grabenbauer, G | 1 |
| Klein, P | 1 |
| Peyrat, JP | 1 |
| Abecassis, J | 1 |
| Millon, R | 1 |
| David, JS | 1 |
| Gueugniaud, PY | 1 |
| Hepp, A | 1 |
| Gaussorgues, P | 1 |
| Petit, P | 1 |
| Hess, KR | 2 |
| Korman, LT | 1 |
| Zahurek, ML | 1 |
| O'Reilly, S | 1 |
| Hurwitz, H | 2 |
| Katoh, M | 1 |
| Koninkx, J | 1 |
| Schumacher, U | 1 |
| Hasuike, Y | 1 |
| Nishisho, I | 1 |
| Ukei, T | 1 |
| Oozato, H | 1 |
| Lammering, G | 1 |
| Hartmann, KA | 1 |
| Frenken, M | 1 |
| Aryus, B | 1 |
| Döker, R | 1 |
| Ulrich, B | 1 |
| Iwamoto, M | 1 |
| Niiya, F | 1 |
| Ikeda, S | 1 |
| Nagata, S | 1 |
| Odou, E | 1 |
| Hayabuchi, N | 1 |
| Ida, K | 1 |
| Kamiya, T | 1 |
| Gilles, V | 1 |
| Molitor, JL | 1 |
| Ratanatharathorn, V | 1 |
| Sirachainan, E | 1 |
| Jirajarus, M | 1 |
| Sirilerttrakul, S | 1 |
| Eckel, F | 1 |
| Lippl, F | 1 |
| Assmann, G | 1 |
| Schulte-Frohlinde, E | 1 |
| Rauch, DP | 1 |
| Maurer, CA | 1 |
| Pampallona, S | 1 |
| Ludwig, CU | 2 |
| Debernardis, D | 1 |
| Tunesi, G | 1 |
| Maley, F | 1 |
| Ott, MJ | 1 |
| Ryan, D | 1 |
| Benoit, R | 1 |
| Grobost, O | 1 |
| Chalmet, P | 1 |
| Knegt, PP | 1 |
| Ah-See, KW | 1 |
| vd Velden, LA | 1 |
| Kerrebijn, J | 1 |
| Rotholtz, N | 1 |
| Pisano, M | 1 |
| Kaplan, E | 1 |
| Secic, M | 1 |
| Coucke, P | 1 |
| Pikarsky, A | 1 |
| Weiss, E | 1 |
| Haie-Meder, C | 1 |
| Lhommé, C | 1 |
| de Crevoisier, R | 2 |
| Morice, P | 1 |
| Resbeut, M | 1 |
| Kamiya, N | 1 |
| Asano, S | 1 |
| Shinya, F | 1 |
| Turrisi, A | 1 |
| Iannettoni, M | 1 |
| Strawderman, M | 1 |
| Furuyama, JI | 1 |
| Hashimoto-Tamaoki, T | 1 |
| Gerhardt, P | 1 |
| Schnirer, II | 1 |
| Putnam, J | 1 |
| Feng, C | 1 |
| Paty, PP | 1 |
| Löhr, JM | 1 |
| Breslin, TM | 1 |
| Harbison, DB | 1 |
| Jean, ME | 1 |
| Dackiw, AP | 1 |
| Motegi, M | 1 |
| Sasamoto, H | 1 |
| Wada, W | 1 |
| Raina, V | 1 |
| Gujral, S | 1 |
| Matsuno, S | 1 |
| Boffi, B | 1 |
| Francesconi, D | 1 |
| Mazzanti, R | 1 |
| Medi, F | 1 |
| Siliani, L | 1 |
| Tarquini, R | 1 |
| Moretti, R | 1 |
| Gneiting, T | 1 |
| Kreczy, A | 1 |
| Pfeiffer, KP | 1 |
| Shaw, JE | 1 |
| Manning, MA | 1 |
| Lauve, AD | 1 |
| Neifeld, JP | 1 |
| Moore, MB | 1 |
| Aloia, T | 1 |
| Sporn, T | 1 |
| Linoila, I | 1 |
| Backus, HH | 1 |
| Dukers, DF | 1 |
| van Groeningen, CJ | 2 |
| Vos, W | 1 |
| Bloemena, E | 1 |
| Wouters, D | 1 |
| van Riel, JM | 1 |
| Giaccone, G | 2 |
| Siu, W | 1 |
| Kapp, DS | 1 |
| Wren, SM | 1 |
| King, C | 1 |
| Terris, MK | 1 |
| Sekikawa, T | 1 |
| Tsukui, H | 1 |
| Kina, S | 1 |
| Kawahara, T | 2 |
| Kishida, Y | 1 |
| Yakumaru, K | 1 |
| Kagami, H | 1 |
| Kamiya, K | 1 |
| Baba, M | 1 |
| Oota, M | 1 |
| Shouji, T | 1 |
| Igarashi, A | 1 |
| Eguchi, T | 1 |
| Imai, S | 1 |
| McNevin, MS | 1 |
| Gross, EK | 1 |
| Whiteford, HM | 1 |
| Lewis, JL | 1 |
| Mueller, HH | 1 |
| Mattes, E | 1 |
| Gassel, HJ | 1 |
| Schramm, H | 1 |
| Staib-Sebler, E | 1 |
| Vetter, G | 1 |
| Heinrich, S | 1 |
| Jan, YY | 1 |
| Liau, CT | 1 |
| Gibbs, JF | 1 |
| Cao, S | 1 |
| Aoki, Y | 1 |
| Tsuneki, I | 1 |
| Onaitis, MW | 1 |
| Noone, RB | 1 |
| Hartwig, M | 1 |
| Morse, M | 1 |
| Jowell, P | 1 |
| McGrath, K | 1 |
| Clary, B | 1 |
| Tyler , DS | 1 |
| Frykholm, GJ | 1 |
| Katai, H | 1 |
| Domenge, C | 1 |
| Wibault, P | 2 |
| Koscielny, S | 1 |
| Bobin, S | 1 |
| Luboinski, B | 1 |
| Eschwege, F | 2 |
| Bourhis, J | 1 |
| Kovàcs, G | 1 |
| Saghatchian, M | 1 |
| Fizazi, K | 1 |
| Borel, C | 2 |
| Ruffié, P | 2 |
| De Filippis, S | 1 |
| Rosselli, M | 1 |
| Pompili, PL | 1 |
| Koo, WH | 1 |
| Chua, EJ | 2 |
| Hoe, M | 1 |
| Petit, T | 1 |
| Ghnassia, JP | 1 |
| Rodier, JF | 1 |
| Escande, A | 1 |
| Mors, R | 1 |
| Haegelé, P | 1 |
| Mahyar-Roemer, M | 1 |
| Roemer, K | 1 |
| Schache, DJ | 1 |
| Bell, A | 1 |
| Selle, F | 1 |
| Shelton, CH | 1 |
| Minasi, JS | 1 |
| Lew, JI | 1 |
| Gooding, WE | 1 |
| Safatle-Ribeiro, AV | 1 |
| Hundt, A | 1 |
| Sturm, J | 2 |
| Knoll, MR | 1 |
| Petryk, M | 2 |
| Evans, A | 1 |
| Cooperman, AM | 1 |
| Hammerman, H | 1 |
| Siegel, J | 1 |
| Stark, B | 1 |
| Bank, S | 1 |
| Nesbitt, J | 1 |
| Martin, FD | 1 |
| Staren, ED | 1 |
| Iwamura, T | 1 |
| Appert, HE | 1 |
| Howard, JM | 2 |
| Ratkin, GA | 1 |
| Kuranaga, N | 1 |
| Shinomiya, N | 1 |
| Mochizuki, H | 1 |
| Böhm, B | 1 |
| Helfritzsch, H | 1 |
| Thiele, M | 1 |
| Altendorf-Hofmann, A | 1 |
| Scheele, J | 1 |
| Archer, VR | 1 |
| Mulholland, PJ | 1 |
| Virkkunen, P | 1 |
| Kohno, H | 1 |
| Kimoto, T | 1 |
| Dhar, DK | 1 |
| Kubota, H | 1 |
| Tachibana, M | 1 |
| Reading, DM | 1 |
| Gunn, IF | 1 |
| Green, MD | 2 |
| McLaughlin, SJ | 1 |
| Pedersen, JS | 1 |
| McGinty, J | 1 |
| Parda, D | 1 |
| Karlovits, S | 1 |
| Davis, C | 1 |
| Caushaj, P | 1 |
| D'Agnano, I | 1 |
| Vasselli, S | 1 |
| Perrone Donnorso, R | 1 |
| D'Angelo, C | 1 |
| Brenna, A | 1 |
| Benevolo, M | 1 |
| Zupi, G | 4 |
| Yamashita, A | 1 |
| Maruo, K | 1 |
| Shirota, K | 1 |
| Baz, DV | 1 |
| Bofill, JS | 1 |
| Nogueira, JA | 1 |
| Lestuzzi, C | 1 |
| Picano, E | 1 |
| Meneguzzo, N | 1 |
| Kammori, M | 1 |
| Haniuda, N | 1 |
| Takubo, K | 2 |
| Endo, H | 1 |
| Kaminishi, M | 1 |
| Sunouchi, K | 1 |
| Higuchi, Y | 1 |
| Tsurita, G | 1 |
| Zhan, M | 1 |
| Jacobson, SD | 1 |
| Shepherd, LE | 1 |
| Boz, G | 1 |
| Rossi, C | 1 |
| Tosolini, G | 1 |
| Trovò, MG | 1 |
| Pories, WJ | 1 |
| Hillard, J | 1 |
| Wiley, AL | 3 |
| Youngblood, R | 1 |
| McIntyre, DJ | 1 |
| Howe, FA | 1 |
| Rodrigues, LM | 1 |
| Wadsworth, P | 1 |
| Price, NM | 1 |
| Nicholson, G | 1 |
| Noordhuis, P | 1 |
| Mulligan, E | 2 |
| Goffre, B | 1 |
| Zerbib, F | 1 |
| Saric, J | 1 |
| Kuhn, R | 1 |
| Boltze, C | 1 |
| Allman, D | 1 |
| Boyer, M | 1 |
| Jahn, M | 1 |
| Schmiegel, WH | 1 |
| Vieitez, JM | 1 |
| Weitzel, C | 1 |
| Dencausse, Y | 1 |
| Dietzler, P | 1 |
| Bambach, M | 1 |
| Wojatschek, C | 1 |
| Lindemann, H | 1 |
| Qeisser, W | 1 |
| Heydon, K | 1 |
| Eifel, P | 1 |
| Toukairin, H | 1 |
| Kure, N | 1 |
| Tamamori, Y | 1 |
| Nishino, H | 1 |
| Nishihara, T | 1 |
| Varvarigos, N | 1 |
| Kamaradou, H | 1 |
| Kourti, A | 1 |
| Papavasiliou, ED | 1 |
| Papaioannou, H | 1 |
| Migdalis, IN | 1 |
| Galanis, C | 1 |
| Almond, J | 1 |
| Fernandez-Cruz, L | 1 |
| Pap, A | 1 |
| Spooner, D | 1 |
| Zoetmulder, FA | 1 |
| Fuwa, N | 1 |
| Kano, M | 1 |
| Shikama, N | 1 |
| Matsumoto, A | 1 |
| Kamata, M | 1 |
| Furutani, K | 1 |
| Tatibana, H | 1 |
| Raouf, A | 1 |
| Evoy, D | 1 |
| Carton, E | 1 |
| Sweeney, E | 1 |
| Cristofanilli, M | 1 |
| Buzdar, AU | 1 |
| Sneige, N | 1 |
| Smith, T | 1 |
| Wasaff, B | 1 |
| Ibrahim, N | 1 |
| Booser, D | 1 |
| Rivera, E | 1 |
| Murray, JL | 1 |
| Valero, V | 1 |
| Singletary, ES | 1 |
| Hunt, K | 1 |
| Strom, E | 1 |
| McNeese, M | 1 |
| Stelling, C | 1 |
| Hortobagyi, GN | 1 |
| Zotter, H | 1 |
| Schwinger, W | 1 |
| Kerbl, R | 1 |
| Urban, C | 1 |
| Smolle Juettner, FM | 1 |
| Hinterleitner, T | 1 |
| Wong, NA | 1 |
| Brett, L | 1 |
| Stewart, M | 1 |
| Leitch, A | 1 |
| Dunlop, MG | 1 |
| Lessells, AM | 1 |
| Jodrell, DI | 1 |
| White, RR | 1 |
| Paulson, EK | 1 |
| Baillie, J | 1 |
| Branch, MS | 1 |
| Jowell, PS | 1 |
| McGrath, KM | 1 |
| Kresl, JJ | 1 |
| Henning, GT | 1 |
| Donohue, J | 1 |
| Pitot, H | 1 |
| Nagorney, D | 1 |
| Baglan, KL | 1 |
| Frazier, RC | 1 |
| Huang, RR | 1 |
| Martinez, AA | 1 |
| Robertson, JM | 1 |
| Virik, K | 1 |
| Ryder, K | 1 |
| Cowling, M | 1 |
| Deng, Z | 1 |
| Lou, X | 1 |
| Hua, B | 1 |
| Wang, A | 1 |
| Caliò, E | 1 |
| Seminara, P | 2 |
| Aronne, T | 1 |
| Sbaffi, E | 1 |
| Pagani Guazzugli Bonaiuti, V | 1 |
| Gargano, L | 1 |
| Escourrou, J | 1 |
| Pages, P | 1 |
| Moreau, J | 1 |
| Faure, P | 1 |
| Moritani, M | 1 |
| Fujimitsu, Y | 1 |
| Shinohara, M | 1 |
| Niido, T | 1 |
| Duffaud, F | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Huang, KC | 1 |
| Cheng, YM | 1 |
| Hsu, HC | 1 |
| Wang, SM | 1 |
| Ford, J | 1 |
| Edelstein, PS | 1 |
| Vierra, M | 1 |
| Bastidas, AJ | 1 |
| de Wit, R | 1 |
| Greim, G | 1 |
| van der Born, K | 1 |
| Wanders, J | 1 |
| de Boer, RF | 1 |
| Peng, ZH | 1 |
| Xing, TH | 1 |
| Qiu, GQ | 1 |
| Tang, HM | 1 |
| Hsieh, YC | 1 |
| Miller, LL | 1 |
| Yee, LK | 2 |
| Schuler, B | 1 |
| Chen, AP | 1 |
| Chabuk, C | 1 |
| Grabenc, M | 1 |
| Takimoto, CH | 1 |
| Kouvatseas, G | 1 |
| Giannoulis, E | 1 |
| Androulakis, I | 1 |
| Rengelshausen, J | 1 |
| Hull, WE | 1 |
| Schwenger, V | 1 |
| Göggelmann, C | 1 |
| Walter-Sack, I | 1 |
| Bommer, J | 1 |
| Zeuli, M | 1 |
| Di Costanzo, E | 1 |
| Paoloni, FP | 1 |
| Cherubini, R | 1 |
| Abushullaih, S | 1 |
| Saad, ED | 1 |
| Munsell, M | 1 |
| Lim, KC | 1 |
| Dunlop, DJ | 1 |
| Koufos, C | 1 |
| Gomi, T | 1 |
| Ohtoshi, M | 1 |
| Tamaki, N | 1 |
| Momoi, H | 1 |
| Katayama, T | 1 |
| Lamont, EB | 1 |
| Lauderdale, DS | 1 |
| Schilsky, RL | 1 |
| Christakis, NA | 1 |
| Planting, A | 2 |
| Baujat, B | 1 |
| Maindrault, F | 1 |
| Nagata, T | 1 |
| Kouniavsky, G | 1 |
| Khaikin, M | 1 |
| Zvibel, I | 1 |
| Zippel, D | 1 |
| Brill, S | 1 |
| Halpern, Z | 1 |
| Papa, M | 1 |
| Honegger, H | 1 |
| Hanselmann, S | 1 |
| Müller, S | 1 |
| Wada, I | 1 |
| Craig, G | 1 |
| Nair, S | 1 |
| Law, A | 1 |
| Gallagher, J | 1 |
| Ellison, N | 1 |
| Bernath, A | 1 |
| Craipeau, C | 1 |
| Massacesi, C | 1 |
| Pistilli, B | 1 |
| Valeri, M | 1 |
| Lippe, P | 1 |
| Rocchi, MB | 1 |
| Cellerino, R | 1 |
| Piga, A | 1 |
| Jang, WI | 1 |
| Ballo, MT | 1 |
| Mason, K | 1 |
| Wong, AB | 1 |
| Nguyen, Q | 1 |
| Kouloulias, VE | 2 |
| Nikita, KS | 2 |
| Kouvaris, JR | 2 |
| Uzunoglu, NK | 2 |
| Golematis, VC | 1 |
| Papavasiliou, CG | 1 |
| Vlahos, LJ | 2 |
| Adamek, HE | 1 |
| Yachida, S | 1 |
| Fukushima, N | 1 |
| Matsuno, Y | 1 |
| Kosuge, T | 1 |
| Hirohashi, S | 1 |
| Ohsawa, T | 1 |
| Inokuma, S | 1 |
| Hoshino, T | 1 |
| Daijo, H | 1 |
| Davies, MM | 1 |
| Carnochan, P | 1 |
| Glover, C | 1 |
| Kaur, S | 1 |
| Allen-Mersh, TG | 1 |
| Shih, CH | 1 |
| Ruo, L | 1 |
| Quan, SH | 1 |
| Spott, C | 1 |
| Bozzetti, F | 1 |
| Andreola, S | 1 |
| Baratti, D | 1 |
| Stani, SC | 1 |
| Spinelli, P | 1 |
| Vaishampayan, UN | 1 |
| Levin, KJ | 1 |
| Proulx, G | 1 |
| Nava, H | 2 |
| Bodnar, L | 1 |
| Klippenstein, D | 1 |
| Smith, J | 1 |
| Nava, E | 1 |
| Smith, P | 1 |
| Greco, W | 1 |
| Douglass, H | 1 |
| Paradiso, A | 1 |
| Ranieri, G | 1 |
| Silvestris, N | 1 |
| Costa, A | 1 |
| De Lena, M | 1 |
| Leone, A | 1 |
| Vallejo, C | 1 |
| Lacava, J | 1 |
| Calvilio, J | 1 |
| Escribano, A | 1 |
| de Castro, J | 1 |
| Sánchez, ME | 1 |
| Mata, A | 1 |
| García Grande, A | 1 |
| Mateo, A | 1 |
| González Barón, M | 1 |
| Joo, HJ | 1 |
| Yi, JW | 1 |
| Kim, MW | 1 |
| Ohta, Y | 1 |
| Takemura, S | 1 |
| Kawasaki, M | 1 |
| de O Ferreira, F | 1 |
| Ferrigno, R | 1 |
| David Filho, WJ | 1 |
| Nishimoto, IN | 1 |
| Vieira, RA | 1 |
| Golematis, BC | 2 |
| Mystakidou, K | 1 |
| Bergevin, PR | 2 |
| Patwardhan, VC | 1 |
| Weissman, J | 1 |
| Lee, SM | 1 |
| Barone, RM | 1 |
| Starichkov, MS | 2 |
| Nivinskaia, MM | 1 |
| Bychkov, MB | 2 |
| Lichinitser, MR | 1 |
| Chebotareva, LI | 1 |
| Prostman, TJ | 1 |
| Lanzotti, VJ | 2 |
| Thomas, DR | 1 |
| Holoye, PY | 1 |
| Boyle, LE | 1 |
| Smith, TL | 1 |
| Israel, L | 2 |
| Depierre, A | 1 |
| Stevenson, DL | 1 |
| Mikhailidis, DP | 1 |
| Gillett, DS | 1 |
| Xynos, FP | 1 |
| Hartwich, G | 2 |
| Neidhardt, B | 2 |
| Black, K | 1 |
| Hanna, SS | 1 |
| Langer, B | 1 |
| Jirsch, DW | 1 |
| Rider, WD | 1 |
| Zeitoun, P | 2 |
| Lamy, P | 1 |
| Lamaze, R | 1 |
| Tutton, PJ | 1 |
| Barkla, DH | 1 |
| Young, RC | 1 |
| Chabner, BA | 1 |
| Hubbard, SP | 1 |
| Fisher, RI | 1 |
| Bender, RA | 1 |
| Anderson, T | 4 |
| Simon, RM | 1 |
| Canellos, GP | 1 |
| DeVita, VT | 1 |
| Pazianos, AG | 1 |
| Salzman, FA | 1 |
| Stein, TP | 1 |
| Hargrove, WC | 1 |
| Miller, EE | 1 |
| Wallace, HW | 1 |
| Buzby, GP | 1 |
| Mullen, JL | 1 |
| Friedman, M | 1 |
| Cassidy, M | 1 |
| Levine, M | 1 |
| Phillips, T | 1 |
| Spivack, S | 1 |
| Resser, KJ | 1 |
| Goffin, JC | 2 |
| Maurer, RE | 4 |
| Volm, M | 2 |
| Faufmann, M | 1 |
| MAttern, J | 2 |
| Wayss, K | 2 |
| Wasserman, TH | 1 |
| Hanley, J | 3 |
| Carbone, PP | 3 |
| Sych, F | 1 |
| Habs, M | 1 |
| Schmähl, D | 1 |
| McCaffrey, JA | 1 |
| Polio, J | 1 |
| Clouse, ME | 1 |
| Hamilton, T | 1 |
| Merrin, CE | 1 |
| Nüvemann, M | 1 |
| Fernholz, HJ | 1 |
| Frik, W | 1 |
| Bernath, AM | 1 |
| Cohen, MH | 2 |
| Ihde, DC | 2 |
| Fossieck, BE | 1 |
| Matthews, MJ | 1 |
| Minna, JD | 2 |
| Grady, ED | 1 |
| Nolan, TR | 1 |
| Crumbley, AJ | 1 |
| Rosen, AR | 1 |
| Breuel, HP | 1 |
| Douwes, F | 1 |
| Bähre, M | 1 |
| San Luis, T | 1 |
| Emrich, D | 1 |
| Seligman, M | 1 |
| Greenstreet, RL | 1 |
| Morris, D | 1 |
| Aisner, J | 3 |
| Elias, EG | 3 |
| Reynolds, RD | 1 |
| O'Dell, S | 1 |
| Möschl, P | 1 |
| Lubec, G | 1 |
| Awrich, A | 1 |
| Klotz, JH | 1 |
| Minton, JP | 1 |
| Hill, GJ | 4 |
| Aust, JB | 3 |
| Grage, TB | 2 |
| Multhauf, PM | 1 |
| Shoemaker, JP | 1 |
| Dagher, RK | 1 |
| Golubeva, VA | 1 |
| Osipov, NE | 1 |
| Bukharova, IK | 1 |
| Priestman, T | 1 |
| Baum, M | 1 |
| Jones, V | 1 |
| Forbes, J | 1 |
| Alyea, EP | 1 |
| Dees, JE | 1 |
| Glenn, JF | 1 |
| Abdallah, AM | 1 |
| Bell, G | 1 |
| Diggs, CH | 1 |
| Smyth, AC | 1 |
| Kim, PN | 2 |
| Ratanatharathron, V | 1 |
| Wojtaszak, B | 2 |
| Terz, JJ | 2 |
| Horsley, JS | 3 |
| Brown, PW | 2 |
| Romero, C | 1 |
| Tanneberger, S | 1 |
| Kingston, RD | 1 |
| Ellis, DJ | 1 |
| Powell, J | 1 |
| Waterhouse, JA | 1 |
| Hurst, MD | 1 |
| Smith, JA | 1 |
| Klahr, C | 1 |
| Smith, LF | 2 |
| Buroker, T | 3 |
| Dindogru, A | 1 |
| DeMattia, M | 1 |
| Groth, C | 1 |
| Bunn, PA | 1 |
| Nugent, JL | 1 |
| Eddy, JL | 1 |
| Groppe, C | 2 |
| McCracken, J | 2 |
| O'Bryan, R | 1 |
| Panettiere, F | 1 |
| Coltman, C | 1 |
| Bottomley, R | 1 |
| Bonnet, J | 2 |
| Thigpen, T | 1 |
| Hoogstraten, B | 2 |
| Heilbrun, L | 2 |
| Chauvergne, J | 1 |
| Berlie, J | 1 |
| Clavel, B | 1 |
| Gary-Bobo, J | 2 |
| Brulé, G | 1 |
| Klein, T | 1 |
| Pommatau, E | 1 |
| Carton, M | 1 |
| Voznyĭ, EK | 2 |
| Borisov, VI | 1 |
| Perevodchikova, NI | 2 |
| Babaian, LA | 1 |
| Vaarik, KhM | 1 |
| Woll, J | 1 |
| Carbone, P | 1 |
| Hestorff, R | 1 |
| Sardoff, L | 1 |
| Padilla, F | 1 |
| Guy, G | 1 |
| Quagliana, J | 1 |
| Belt, RJ | 1 |
| Stephens, R | 1 |
| Schaefer, J | 1 |
| Arnold, H | 1 |
| Drings, P | 1 |
| Geldmacher, J | 1 |
| Kredel, L | 1 |
| Mayer, M | 1 |
| von Oldershausen, HF | 1 |
| Rösch, W | 1 |
| Wahrendorf, J | 1 |
| Vassilopoulos, PP | 1 |
| Shingleton, WW | 1 |
| Jubert, AV | 1 |
| Moss, SE | 2 |
| Rosenoff, S | 1 |
| Rake, MO | 2 |
| Mallinson, CN | 1 |
| Cocking, JB | 1 |
| Cwynarski, MT | 1 |
| Fox, CA | 1 |
| Wass, VJ | 1 |
| Diffey, BL | 1 |
| Jackson, GA | 1 |
| Kessinger, MA | 1 |
| Lemon, HM | 2 |
| Comis, RL | 4 |
| Davy, M | 1 |
| Mossige, J | 1 |
| Johannessen, JV | 1 |
| Cooney, D | 1 |
| Eckels, DD | 2 |
| Salas, H | 1 |
| Butler, TP | 1 |
| Solomon, A | 1 |
| White, LA | 1 |
| Perry, MC | 2 |
| Kennedy, BJ | 2 |
| Weiss, RB | 1 |
| Lee, YT | 2 |
| Hartman, HA | 1 |
| Kessinger, A | 1 |
| Stone, SP | 1 |
| Eckels, D | 1 |
| Palmer, JM | 1 |
| Staab, R | 1 |
| Livingston, R | 1 |
| Wolma, FJ | 1 |
| Kelly, JP | 1 |
| Hannam, TW | 1 |
| Giles, GR | 1 |
| Soloway, MS | 2 |
| Shippel, RM | 1 |
| Ikard, M | 1 |
| Yakushiji, M | 1 |
| Ide, K | 1 |
| Rowling, J | 1 |
| West, C | 1 |
| Rózewicki, S | 1 |
| Rzepka, I | 1 |
| Górski, H | 1 |
| Cifuentes de Castro, L | 1 |
| Lee, PW | 1 |
| Tomomatsu, H | 1 |
| Morita, N | 1 |
| Nagai, T | 1 |
| Shiwaku, Y | 1 |
| Shingami, T | 1 |
| Nakao, Y | 1 |
| Shimokawahara, H | 1 |
| Hashimoto, S | 2 |
| Yunoki, K | 1 |
| Kutzner, J | 1 |
| Kempf, P | 1 |
| Brückner, R | 1 |
| Rohwedder, JJ | 1 |
| Sagastume, E | 1 |
| Khwaja, TA | 1 |
| Yokoyama, M | 1 |
| Himori, T | 1 |
| Dimitriades, M | 1 |
| Papadimitriou, GC | 1 |
| Razis, DV | 1 |
| Panopoulos, C | 1 |
| Midoulas, N | 1 |
| Buell, GV | 1 |
| Bergreen, PW | 1 |
| Krein, BM | 1 |
| Eckert, M | 1 |
| Gerassimidis, T | 1 |
| Schultess, F | 1 |
| Hammann, J | 1 |
| Beck, I | 1 |
| Hishinuma, H | 1 |
| Majima, S | 1 |
| Nakao, E | 1 |
| Morisawa, K | 1 |
| Cho, K | 1 |
| Nishioka, B | 2 |
| Fischetti, MR | 1 |
| Weitzman, SA | 1 |
| Kelley, RM | 1 |
| Sohier, WD | 1 |
| DiBenedetto, J | 1 |
| Moayeri, H | 1 |
| Evans, JT | 1 |
| Richardson, RL | 1 |
| Shulman, SF | 1 |
| Oldham, RK | 1 |
| Heppner, GH | 1 |
| Dexter, DL | 1 |
| DeNucci, T | 1 |
| Miller, FR | 1 |
| Calabresi, P | 2 |
| Davis, S | 1 |
| Buscaglia, MD | 1 |
| Brown, I | 1 |
| Ward, HW | 1 |
| Kune, GA | 1 |
| Hobbs, JB | 1 |
| Butterfield, D | 1 |
| Sali, A | 1 |
| Fichardt, T | 1 |
| Sandison, AG | 2 |
| Hillcoat, BL | 1 |
| McCulloch, PB | 1 |
| Ehsan, MH | 1 |
| Rosenfeld, JM | 1 |
| Nakamura, A | 2 |
| Bates, IS | 1 |
| Spittle, H | 1 |
| Wheeler, T | 1 |
| Serrou, B | 1 |
| Sancho-Garnier, H | 1 |
| Plagne, R | 1 |
| Metz, R | 1 |
| Pujol, H | 2 |
| Block, NL | 1 |
| Camuzzi, F | 1 |
| Stover, B | 1 |
| Claflin, A | 1 |
| Troner, M | 1 |
| Politano, VA | 1 |
| Didolkar, MS | 1 |
| van Eden, EB | 2 |
| Mittelman, JA | 1 |
| Bakemeier, RF | 1 |
| Cohen, D | 1 |
| Yron, I | 1 |
| Grover, NB | 1 |
| Weiss, DW | 1 |
| MacFadyen, BV | 1 |
| Dudrick, SJ | 3 |
| Souchon, EA | 1 |
| Watson, P | 1 |
| Nevin, JE | 2 |
| Hoffman, AA | 1 |
| Inoguchi, T | 1 |
| Yamasaki, I | 1 |
| Yazuka, K | 1 |
| Kita, T | 1 |
| Kuwano, K | 1 |
| Piver, S | 1 |
| Chung, WS | 1 |
| Lee, FT | 1 |
| Vongtama, V | 2 |
| Fugmann, RA | 1 |
| Anderson, JC | 1 |
| Stolfi, RL | 1 |
| Martin, DS | 3 |
| Grage, TD | 1 |
| Metter, GE | 2 |
| Cornell, GN | 1 |
| Strawitz, JG | 1 |
| Frelick, RW | 1 |
| Kaufman, JH | 1 |
| Franz, JL | 1 |
| Bixenman, WW | 1 |
| Nicholls, JV | 1 |
| Warwick, OH | 1 |
| Malkasian, GD | 2 |
| Decker, DG | 2 |
| Jorgensen, EO | 2 |
| Morgan, DF | 1 |
| Busuttil, RW | 1 |
| Li, MC | 1 |
| Ross, ST | 1 |
| Reuter, HJ | 1 |
| Gehan, E | 1 |
| Abisatov, KhA | 1 |
| Khan, SV | 1 |
| Murphy, S | 1 |
| Huguley, CM | 1 |
| Belpomme, D | 1 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Gautier, H | 1 |
| Laparre, C | 1 |
| Baron, A | 1 |
| Collier, D | 1 |
| Lowitz, BB | 1 |
| Kane, RD | 1 |
| Mickey, DD | 1 |
| Paulson, DF | 2 |
| Ikram, H | 1 |
| Plaude, RK | 1 |
| Osman, VI | 1 |
| Tabachnik, BI | 1 |
| Purinia, IZh | 1 |
| Gutman, EKh | 1 |
| Merrin, C | 1 |
| Etra, W | 1 |
| Baumgartner, G | 1 |
| Dowell, KE | 1 |
| Armstrong, DM | 1 |
| Ingis, DA | 1 |
| Farmer, RG | 1 |
| Kas'ianenko, IV | 1 |
| Horsley, S | 1 |
| Donaldson, M | 1 |
| Lovett, WL | 1 |
| Ruffner, BW | 1 |
| Regelson, W | 1 |
| Otis, PT | 1 |
| Armentrout, SA | 1 |
| Melnick, I | 1 |
| Baggerly, JT | 1 |
| Landes, R | 1 |
| Easley, CA | 1 |
| Lee, FJ | 1 |
| Håkansson, L | 2 |
| Dahn, I | 1 |
| Huldt, B | 1 |
| Tropé, C | 1 |
| Dencker, H | 1 |
| Seifert, P | 1 |
| Reed, ML | 2 |
| Frank, S | 1 |
| Richter, K | 1 |
| Ehrhart, H | 1 |
| Penning, W | 1 |
| Meister, P | 1 |
| Schmidt, D | 1 |
| Götz, A | 1 |
| Schimmel, DH | 1 |
| Julien, PJ | 1 |
| Gamsu, G | 1 |
| Schulman, S | 2 |
| Thorp, GW | 1 |
| Kirsner, JB | 1 |
| Rosenberg, IH | 1 |
| Nichols, M | 1 |
| Vyas, AC | 1 |
| Hamilin, R | 1 |
| Gottlieb, JA | 3 |
| Freireich, EJ | 3 |
| Delikaris, PG | 1 |
| Haritopoulos, NK | 1 |
| Setakis, NG | 1 |
| Schifeling, DJ | 1 |
| Dobelbower, RR | 3 |
| Merrick, HW | 3 |
| Bernhardt, G | 1 |
| Reile, H | 1 |
| Birnböck, H | 1 |
| Spruss, T | 1 |
| Schönenberger, H | 1 |
| Monma, K | 1 |
| Sakaki, N | 1 |
| Tabata, I | 1 |
| Gazdar, AF | 3 |
| Beck, H | 1 |
| Zunino, F | 1 |
| Capranico, G | 1 |
| Smith, FW | 1 |
| Heys, SD | 1 |
| Evans, NT | 1 |
| Roeda, D | 1 |
| Gvozdanovic, D | 1 |
| Eremin, O | 1 |
| Mallard, JR | 1 |
| Sugimoto, Y | 2 |
| Ohe, Y | 2 |
| Nishio, K | 2 |
| Ohmori, T | 2 |
| Morikage, T | 1 |
| Saijo, N | 2 |
| Wu, GR | 1 |
| Kiyabu, M | 2 |
| Chandrasoma, P | 1 |
| Miyama, T | 1 |
| Hirata, T | 1 |
| Mafune, K | 1 |
| Hiraishi, M | 1 |
| Fielding, LP | 1 |
| Hittinger, R | 1 |
| Grace, RH | 2 |
| Fry, JS | 1 |
| Paik, S | 1 |
| Koh, E | 1 |
| Garten, L | 1 |
| Gray, R | 2 |
| Byrd, DR | 3 |
| Connelly, JH | 1 |
| Ames, FC | 3 |
| Laidman, PJ | 1 |
| Gebauer, K | 1 |
| Trotter, J | 1 |
| Vering, A | 1 |
| Michel, RT | 1 |
| Mitze, M | 1 |
| Stegmüller, M | 1 |
| Bender, HG | 1 |
| Colofiore, J | 2 |
| Sawyer, R | 1 |
| Warszawski, N | 1 |
| Bohndorf, W | 1 |
| Nishikata, K | 3 |
| Daemen, T | 1 |
| Regts, J | 1 |
| Morselt, H | 1 |
| Scherphof, GL | 1 |
| Hemmingsson, A | 1 |
| Nyman, R | 1 |
| Lottsfeldt, JL | 1 |
| Fevold, KL | 1 |
| Williams, LG | 5 |
| Loftin, SK | 1 |
| Dayan, A | 1 |
| Luzi Fedeli, S | 2 |
| Klimberg, VS | 1 |
| Langston, JD | 1 |
| Maners, A | 1 |
| Gocio, JC | 1 |
| Lang, NP | 1 |
| Westbrook, KC | 1 |
| Broadwater, JR | 1 |
| Broder, LE | 1 |
| Sridhar, KS | 2 |
| Selawry, OS | 2 |
| Charyulu, KN | 1 |
| Rao, RK | 1 |
| Saldana, MJ | 1 |
| Lenz, C | 1 |
| Ray, M | 1 |
| Muggia, FM | 2 |
| Radin, R | 1 |
| Omura, K | 1 |
| Ishida, F | 1 |
| Matsu, T | 2 |
| Brinkmann, J | 1 |
| Breier, B | 1 |
| Tatsuki, Y | 1 |
| Fujimoto, I | 2 |
| Yamauchi, K | 1 |
| Hasumi, K | 2 |
| Masubuchi, K | 2 |
| Berruti, A | 1 |
| Gorzegno, G | 1 |
| Vitetta, G | 1 |
| Ober, H | 1 |
| Ebina, T | 1 |
| Hosokawa, T | 1 |
| Kaufman, DS | 1 |
| Eliseo, R | 1 |
| Convery, K | 1 |
| Pisansky, TM | 1 |
| Schaid, DJ | 1 |
| Loprinzi, CL | 1 |
| Schray, MF | 1 |
| Schomberg, PJ | 1 |
| Bonhomme, L | 1 |
| Mathieu, MC | 1 |
| Amdidouche, D | 1 |
| Faure, E | 1 |
| Guisteau, D | 1 |
| Fredj, G | 1 |
| Naveau, S | 1 |
| Pfeffel, F | 1 |
| Wiltschke, C | 1 |
| Funovics, J | 1 |
| Rosvold, E | 1 |
| Schilder, R | 1 |
| DiFino, SM | 1 |
| Banerjee, TK | 2 |
| Heim, WJ | 1 |
| Ozols, RF | 1 |
| de Mulder, PH | 1 |
| Burghouts, JT | 2 |
| Dobrowsky, W | 2 |
| Ammarguellat, H | 1 |
| Benhamed, M | 1 |
| Laplaige, P | 1 |
| Goldberg, J | 1 |
| Kunimura, T | 1 |
| Morohoshi, T | 1 |
| Taguchi, S | 1 |
| Hatta, Y | 1 |
| Saito, Y | 1 |
| Niwa, M | 1 |
| Maruyama, Y | 1 |
| Ishizuka, K | 1 |
| Hasegawa, T | 1 |
| Ogoshi, K | 1 |
| Percarpio, B | 1 |
| Bitterman, J | 1 |
| Sabbath, K | 1 |
| Alfano, F | 1 |
| Ruszkowski, R | 1 |
| Bowen, J | 1 |
| Jimeno, J | 1 |
| Cruz-Hernández, J | 1 |
| Nishiyama, T | 1 |
| Sasagawa, T | 1 |
| Tanikawa, T | 1 |
| Katayama, Y | 1 |
| Kawakami, Y | 1 |
| Terunuma, M | 1 |
| Ravaud, A | 1 |
| Bussières, E | 2 |
| Lagarde, P | 1 |
| Costa, P | 1 |
| Wiseberg, J | 1 |
| McCulloch, W | 1 |
| Petruska, P | 1 |
| Andrus, CH | 1 |
| Johnson, FE | 1 |
| Peters, T | 1 |
| Byhardt, RW | 1 |
| Order, S | 1 |
| Gallagher, MJ | 1 |
| Pederson, J | 1 |
| Wong, SW | 1 |
| Martz, K | 1 |
| al-Sarraf, M | 3 |
| Brindle, J | 1 |
| Byhardt, R | 1 |
| Emami, B | 1 |
| Gray, BN | 1 |
| Anderson, JE | 1 |
| Burton, MA | 1 |
| Codde, J | 1 |
| Morgan, C | 1 |
| Klemp, P | 1 |
| Schuricht, A | 1 |
| Zhen, YS | 1 |
| Taniki, T | 1 |
| Meadows, LM | 1 |
| Lindley, C | 1 |
| Ozer, H | 1 |
| Olweny, C | 1 |
| Carey, P | 1 |
| Wajima, T | 1 |
| Mukhopadhyay, P | 1 |
| Rausa, L | 1 |
| Ingria, F | 1 |
| Spatafora, G | 1 |
| Zerillo, G | 1 |
| Cimino, A | 1 |
| Pastorello, T | 1 |
| Ferrara, P | 1 |
| Van Ginckel, R | 1 |
| Distelmans, W | 1 |
| De Brabander, M | 1 |
| Callens, M | 1 |
| Janssens, B | 1 |
| Jagers, E | 1 |
| Wouters, L | 1 |
| De Coster, R | 1 |
| Janssen, PA | 1 |
| Hook, CC | 1 |
| Scheithauer, BW | 1 |
| Forsyth, PA | 1 |
| Rodriguez, M | 1 |
| Marks, LB | 1 |
| Halperin, EC | 1 |
| Prosnitz, LR | 1 |
| Ross, M | 1 |
| Vredenburgh, JJ | 1 |
| Rosner, GL | 1 |
| Peters, W | 1 |
| Hughes, LL | 1 |
| Luengas, J | 1 |
| Perry, DJ | 1 |
| Goutsou, M | 1 |
| Modeas, C | 1 |
| Muchmore, E | 1 |
| Rege, V | 1 |
| Chahinian, AP | 1 |
| Hirsh, V | 1 |
| Poiesz, B | 1 |
| Sbalzarini, G | 1 |
| Pandolfi, C | 1 |
| Labadini, A | 1 |
| Kao, GD | 1 |
| Altermatt, HJ | 1 |
| Gebbers, JO | 1 |
| Laissue, JA | 1 |
| Natali, M | 1 |
| Carpano, S | 1 |
| Conti, EM | 1 |
| Barranco, SC | 1 |
| Townsend, CM | 1 |
| Ho, BY | 1 |
| Reumont, KJ | 1 |
| Koester, SK | 1 |
| Ford, PJ | 1 |
| Chu, E | 1 |
| Zinn, S | 1 |
| Boarman, D | 1 |
| Denham, J | 1 |
| Jones, AM | 1 |
| Stafford, PM | 1 |
| Daniilidis, J | 1 |
| Kalogera-Fountzila, A | 1 |
| Nicolaou, A | 1 |
| Banis, K | 1 |
| Dimitriadis, A | 1 |
| Sombolos, K | 1 |
| De Besi, P | 1 |
| Busnardo, B | 1 |
| Toso, S | 1 |
| Girelli, ME | 1 |
| Nacamulli, D | 1 |
| Simioni, N | 1 |
| Casara, D | 1 |
| Zorat, P | 1 |
| Fiorentino, MV | 1 |
| Riechman, B | 1 |
| Reichman, B | 2 |
| Bromberg, J | 2 |
| Grinblatt, DL | 1 |
| Lovett, D | 1 |
| Wong, J | 1 |
| Buckley, M | 1 |
| Murray, P | 2 |
| Setanoians, A | 1 |
| Cooke, TG | 1 |
| Fleischer, AB | 1 |
| O'Keefe, EJ | 1 |
| Schaldenbrand, JD | 1 |
| Siders, DB | 1 |
| Zainea, GG | 1 |
| Thieme, ET | 1 |
| Saikawa, Y | 1 |
| Nishibori, H | 1 |
| Beretta, A | 1 |
| Cesana, B | 1 |
| Cozzaglio, L | 1 |
| Cristoni, M | 1 |
| Walker, SJ | 1 |
| Steel, A | 1 |
| Codacci-Pisanelli, G | 1 |
| Codacci-Pisanelli, M | 1 |
| Ferri, GM | 1 |
| Grieco, A | 1 |
| Pagani, V | 1 |
| Bloss, JD | 1 |
| DiSaia, PJ | 1 |
| Mannel, RS | 1 |
| Hyden, EC | 1 |
| Walker, JL | 1 |
| Berman, ML | 1 |
| Kuwa, K | 1 |
| Kasahara, N | 1 |
| Consul, S | 1 |
| Baheti, D | 1 |
| Ahmann, FR | 2 |
| Garewal, HS | 1 |
| Yin, MB | 1 |
| Miyamoto, T | 1 |
| Mochinaga, N | 1 |
| Fragu, P | 1 |
| Fabri, MC | 1 |
| Papadopoulos, S | 1 |
| Halpern, S | 1 |
| Prade, M | 1 |
| Dougherty, J | 1 |
| Casper, E | 1 |
| Vinciguerra, V | 1 |
| Rosenbluth, R | 1 |
| Jordá, E | 1 |
| Galan, A | 1 |
| Betlloch, I | 1 |
| Ramon, D | 1 |
| Revert, A | 1 |
| Torres, V | 1 |
| Lumbroso, J | 4 |
| Lasser, PH | 1 |
| Russell, SA | 1 |
| Wilkinson, MJ | 1 |
| Ostick, DG | 1 |
| Vukelja, SJ | 1 |
| Bonner, MW | 1 |
| McCollough, M | 1 |
| Gaule, DA | 1 |
| Fanucchi, PJ | 1 |
| Keeling, JH | 1 |
| Nakajima, S | 1 |
| Honda, R | 1 |
| Bonomi, P | 2 |
| Gale, M | 1 |
| Rowland, K | 2 |
| Taylor, SG | 1 |
| Purl, S | 1 |
| Phillips, A | 1 |
| Kittle, CF | 2 |
| Warren, W | 2 |
| Tsai, CM | 2 |
| Perng, RP | 2 |
| Kramer, BS | 3 |
| Piantadosi, S | 1 |
| Puts, JP | 1 |
| Herve, JP | 1 |
| Delelo, R | 1 |
| Ballet, F | 1 |
| Atabek, U | 1 |
| Gionfra, T | 1 |
| Gandolfo, G | 1 |
| Ameglio, F | 1 |
| Cornia, E | 1 |
| Bacchi, M | 2 |
| Bartolucci, R | 2 |
| McBride, C | 1 |
| Boddie, A | 1 |
| Jackson, DE | 2 |
| Roh, M | 1 |
| Hohn, D | 1 |
| Goodman, A | 1 |
| Zukerberg, LR | 1 |
| Nikrui, N | 1 |
| Scully, RE | 1 |
| Josui, K | 1 |
| Arisawa, Y | 1 |
| Suto, A | 1 |
| Abe, O | 2 |
| Satta, T | 1 |
| Azuma, S | 3 |
| Kawata, R | 3 |
| Miya, K | 1 |
| Kunieda, K | 1 |
| Takao, H | 1 |
| Kakizaki, K | 1 |
| Yamauchi, H | 1 |
| Thompson, PI | 1 |
| Deasy, NP | 1 |
| Thuraisingham, RC | 1 |
| Raber, MN | 2 |
| Faintuch, J | 2 |
| Sumrall, C | 1 |
| Frost, P | 1 |
| Sleijfer, DT | 1 |
| Grond, J | 1 |
| Verschueren, RC | 1 |
| Ellis, GK | 1 |
| Green, S | 1 |
| Rivkin, S | 1 |
| Sakanoue, Y | 1 |
| Shoji, Y | 1 |
| Utsunomiya, J | 1 |
| Balis, FM | 1 |
| Sorensen, JM | 1 |
| Sartor, O | 1 |
| Goldstein, LJ | 1 |
| Hoshino, M | 1 |
| Satou, N | 1 |
| Pastor, MC | 1 |
| Carles, J | 2 |
| Ribelles, N | 2 |
| Oller, B | 1 |
| Armengol, M | 1 |
| Salva, A | 1 |
| Ribas, M | 1 |
| Armstrong, JG | 1 |
| Ziegler, LD | 1 |
| Kroll, SS | 1 |
| Case, D | 1 |
| Brockschmidt, J | 1 |
| Schnell, FM | 1 |
| Grote, TH | 1 |
| West, JH | 1 |
| Anthony, S | 1 |
| Stanley, V | 1 |
| DeCaprio, JA | 1 |
| Gonin, R | 1 |
| Bonadonna, G | 3 |
| Valtonen, M | 1 |
| Guarnaccia, S | 1 |
| Pais, V | 1 |
| Grous, J | 1 |
| Spirito, N | 1 |
| Bach, A | 1 |
| Goodman, P | 1 |
| Cathcart-Rake, WF | 1 |
| Mowery, WE | 1 |
| Mies, C | 1 |
| Ernst, F | 1 |
| Hentschel, E | 1 |
| Kimler, BF | 1 |
| Collins, RT | 1 |
| Beart, RW | 3 |
| Kubista, TP | 1 |
| Meyers, WC | 1 |
| Bagshawe, KD | 1 |
| Sharma, K | 1 |
| Southall, PJ | 1 |
| Boden, JA | 1 |
| Boxer, GM | 1 |
| Patridge, TA | 1 |
| Antoniw, P | 1 |
| Pedley, RB | 1 |
| Falliers, CJ | 1 |
| Mutch, RS | 1 |
| Hutson, PR | 1 |
| Leigh, JE | 2 |
| Pfeifle, DM | 1 |
| Slavik, M | 1 |
| LeClair, JM | 1 |
| Falchuk, ZM | 1 |
| Bothe, A | 1 |
| Lagadec, B | 2 |
| Gonzalez-Canali, G | 2 |
| Willems, G | 1 |
| Delvaux, G | 1 |
| Moliterni, A | 1 |
| Ferrari, L | 1 |
| Solano, V | 1 |
| Pitre, J | 1 |
| Houssin, D | 1 |
| Louvel, A | 1 |
| Vigouroux, C | 1 |
| Gaudric, M | 1 |
| Chapuis, Y | 1 |
| Bromberg, C | 1 |
| Leonetti, C | 2 |
| Malorni, W | 2 |
| Greco, C | 2 |
| Formisano, G | 2 |
| Ceci, G | 1 |
| Colozza, MA | 1 |
| De Lisi, V | 1 |
| Lottici, R | 1 |
| Saito, D | 2 |
| Miyamoto, K | 1 |
| Rothman, H | 1 |
| Cantrell, JE | 1 |
| Difino, S | 1 |
| Fryer, J | 1 |
| Fonte, CE | 1 |
| Cardello, F | 1 |
| Parnes, HL | 1 |
| Abrams, JS | 1 |
| Tait, N | 1 |
| Minford, J | 1 |
| Allen, SL | 1 |
| Duggan, D | 1 |
| Berdel, WE | 2 |
| Danhauser-Riedl, S | 1 |
| Steinhauser, G | 1 |
| Rastetter, J | 1 |
| Siegmund, R | 1 |
| Illiger, HJ | 1 |
| Klee, M | 1 |
| Rieche, K | 1 |
| Mainzer, K | 1 |
| Günzl, C | 1 |
| Lewerenz, B | 1 |
| Koizumi, J | 1 |
| Shiraishi, H | 1 |
| Hori, M | 2 |
| Urba, S | 2 |
| Takasugi, BJ | 1 |
| Zupanc, D | 1 |
| Luetić, J | 1 |
| Lepage, E | 1 |
| Ishibashi, O | 1 |
| Paris, P | 1 |
| Seydel, HG | 2 |
| Stablein, DM | 1 |
| Kinzie, JJ | 1 |
| Thomas, PR | 1 |
| Szinai, I | 1 |
| Veres, Z | 1 |
| Szabolcs, A | 1 |
| De Clercq, E | 5 |
| Sakatoku, M | 1 |
| Tatsuzawa, T | 1 |
| Masuda, S | 1 |
| Kashani-Sabet, M | 1 |
| Haedicke, K | 1 |
| Scanlon, KJ | 1 |
| Gridelli, C | 1 |
| Airoma, G | 1 |
| Balestrino, M | 1 |
| Bisogno, A | 1 |
| Incoronato, P | 1 |
| Nyce, J | 1 |
| Klann, RC | 1 |
| Holbrook, CT | 1 |
| Cheson, BD | 3 |
| Moriguchi, S | 1 |
| Sznol, M | 1 |
| Reboul, F | 1 |
| Cullinan, S | 1 |
| Norris, BD | 1 |
| Barlow, JF | 1 |
| Chilvers, CE | 1 |
| Beretta, G | 1 |
| Rutten, A | 1 |
| Wickerham, DL | 1 |
| Redmond, C | 1 |
| Fisher, ER | 1 |
| Davies, RJ | 1 |
| Robidoux, A | 1 |
| Evans, WK | 2 |
| Shepherd, FA | 2 |
| Rusthoven, J | 1 |
| Stewart, DJ | 1 |
| Aitken, SE | 1 |
| Slapak, CA | 1 |
| Browne, MJ | 1 |
| Curt, G | 1 |
| Cummings, FJ | 2 |
| Wiemann, M | 1 |
| Morris, DM | 1 |
| Gross, DC | 1 |
| Edwards, J | 1 |
| Teshima, H | 2 |
| Denz, H | 1 |
| Gisin, H | 1 |
| Obrecht, JP | 1 |
| Goudie, MJ | 1 |
| Silver, R | 1 |
| Costanza, M | 1 |
| Rice, MA | 1 |
| Wood, W | 1 |
| Servis, KL | 1 |
| el-Tahtawy, A | 1 |
| Albright, MJ | 1 |
| Barker, PB | 1 |
| Ring, R | 1 |
| Atkinson, D | 1 |
| Ong, R | 1 |
| King, M | 1 |
| Porile, JL | 1 |
| Olopade, OI | 1 |
| Laudonio, N | 2 |
| Erba, E | 1 |
| D'Incalci, M | 1 |
| Delanian, S | 1 |
| Abensour, L | 1 |
| Radparvar, S | 4 |
| Germain, G | 2 |
| Pennington, J | 1 |
| Dieudonne, P | 1 |
| Dumont, MA | 1 |
| Wainer, IW | 2 |
| Jadaud, P | 1 |
| Kamiyama, T | 1 |
| Satou, Y | 1 |
| Sano, F | 1 |
| Nojima, T | 1 |
| Ryan, B | 1 |
| McMurtrey, M | 1 |
| DeCaro, L | 1 |
| Mountain, C | 1 |
| Clark, JL | 1 |
| Barcewicz, P | 1 |
| Nava, HR | 1 |
| Goodwin, PS | 1 |
| van Heerden, JA | 1 |
| Skotinkova, OI | 1 |
| Sergeeva, NS | 1 |
| Moroz, IA | 1 |
| Sviridova, IK | 1 |
| Pelevina, II | 1 |
| Prosperi Porta, R | 1 |
| Rulli, G | 1 |
| Giovagnoli, MR | 1 |
| Carenza, L | 1 |
| Goya, N | 2 |
| Yanagisawa, H | 1 |
| Nakamura, R | 2 |
| Toma, H | 2 |
| Wereldsma, JC | 1 |
| Bruggink, ED | 1 |
| Meijer, WS | 1 |
| Roukema, JA | 1 |
| van Putten, WL | 1 |
| Multhauf, P | 2 |
| Litchfield, T | 2 |
| Carr, B | 4 |
| Bertrand, M | 4 |
| Goldberg, D | 4 |
| Blayney, D | 2 |
| Barkanov, AI | 1 |
| Itin, AB | 1 |
| Wright, JC | 1 |
| Schmeck, HJ | 1 |
| Bartels, E | 1 |
| Viets, CH | 1 |
| Arnold, W | 1 |
| Yoshimoto, J | 1 |
| Ochi, J | 1 |
| Tanahashi, T | 1 |
| Nanba, K | 1 |
| Saegusa, M | 1 |
| Hara, M | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Kunitomo, K | 1 |
| Kawahito, M | 1 |
| Komi, N | 1 |
| Kerr, GR | 1 |
| Arnott, SJ | 1 |
| Gohji, K | 1 |
| Kamidono, S | 1 |
| Burke, P | 1 |
| Stulc, J | 1 |
| Emrich, LJ | 3 |
| Inoue, F | 1 |
| Takeda, I | 1 |
| Miyake, M | 1 |
| Mimura, H | 1 |
| Orita, K | 1 |
| Teder, H | 1 |
| Erichsen, C | 2 |
| Christensson, PI | 2 |
| Jönsson, PE | 2 |
| LoRusso, P | 2 |
| Tapazoglou, E | 1 |
| Kish, JA | 1 |
| Kelly, J | 1 |
| Jacobsson, B | 1 |
| Elias, L | 1 |
| Crissman, HA | 1 |
| Smith, RA | 1 |
| Stubblefield, GC | 1 |
| Reagan, MT | 1 |
| Birsic, W | 1 |
| D'Oro, L | 1 |
| Charoensiri, S | 1 |
| Lele, SB | 2 |
| Sawyer, RC | 1 |
| Derby, S | 1 |
| Salvia, B | 1 |
| Hottenrott, C | 2 |
| Pedani, F | 1 |
| Brando, V | 1 |
| Gabriele, P | 1 |
| Giordano, C | 1 |
| Everson, LK | 3 |
| Vaughn, C | 1 |
| Chapman, J | 1 |
| Maniscalco, B | 1 |
| Reznik, S | 1 |
| Piper, D | 1 |
| Kac, JL | 1 |
| Muff, NS | 2 |
| Shetabi, H | 2 |
| Stutz, FH | 2 |
| Eiesland, H | 1 |
| Mitani, K | 1 |
| Rios, AA | 1 |
| Ende, K | 1 |
| Edwards, C | 1 |
| Faintuch, JS | 2 |
| Saks, S | 1 |
| Gutterman, JU | 1 |
| Stewart, FM | 1 |
| Harkins, BJ | 1 |
| Hahn, SS | 1 |
| Daniel, TM | 1 |
| Dembo, A | 1 |
| DePetrillo, A | 1 |
| Pringle, J | 1 |
| Ackerman, I | 1 |
| Bryson, P | 1 |
| Balogh, J | 1 |
| Osborne, R | 1 |
| Rosen, B | 1 |
| Fyles, A | 1 |
| Hallissey, MT | 2 |
| Ward, LC | 1 |
| Hockey, MS | 1 |
| Arima, S | 1 |
| Futami, K | 1 |
| Shimura, H | 1 |
| Morimoto, T | 1 |
| Monden, A | 1 |
| Nylen, U | 1 |
| Winblad, G | 1 |
| Araki, E | 2 |
| Ogasawara, H | 1 |
| Itoh, T | 1 |
| Furukohri, N | 1 |
| Baba, T | 1 |
| Okudaira, N | 1 |
| Odagiri, H | 1 |
| Zanea-Wangler, E | 1 |
| Kesseler, J | 1 |
| Ploss, HJ | 1 |
| Romanini, A | 1 |
| Russello, O | 1 |
| Nicolin, A | 1 |
| Sidibe, S | 2 |
| Ishitsuka, H | 1 |
| Ohkawa, T | 1 |
| Misaki, O | 1 |
| Inglis, R | 1 |
| Kirkowa-Reimann, M | 1 |
| Otsuka, S | 1 |
| Tsubuku, Y | 1 |
| Kenmizaki, H | 1 |
| Tatekawa, I | 1 |
| Soga, K | 1 |
| Turuya, T | 1 |
| Toshima, M | 1 |
| Shibasaki, K | 1 |
| Matugi, H | 1 |
| Kawai, C | 1 |
| Asakura, H | 1 |
| Kelly, KA | 1 |
| Urata, A | 1 |
| Rubin, JR | 1 |
| Marschke, RF | 2 |
| Marquet, RL | 1 |
| Niemiec, TR | 1 |
| Senekjian, EK | 1 |
| Montag, AG | 1 |
| Weeks, A | 1 |
| Gravel, D | 1 |
| Grem, J | 1 |
| Chun, HG | 1 |
| Lupera, H | 1 |
| Lapleige, P | 1 |
| Zelkowitz, RS | 1 |
| Posner, MR | 1 |
| Weitberg, AB | 1 |
| Wang, QL | 1 |
| de Quay, N | 1 |
| Cuttat, JF | 1 |
| Tevaearai, H | 1 |
| Chapuis, G | 1 |
| Albe, X | 1 |
| Vassilakos, P | 1 |
| Rak, J | 1 |
| Kuśnierczyk, H | 1 |
| Strzadała, L | 1 |
| Kłosiewicz, S | 1 |
| Radzikowski, C | 1 |
| Christiansen, NP | 1 |
| Abdi, EA | 1 |
| Hanson, J | 1 |
| Harbora, DE | 1 |
| Young, DG | 1 |
| McPherson, TA | 1 |
| Mukaiyama, T | 1 |
| Kuraishi, Y | 1 |
| Hazelton, BJ | 1 |
| Molinaro, P | 1 |
| Lafleur, F | 1 |
| Blum, RH | 2 |
| Kanojia, MD | 2 |
| Cricca, A | 1 |
| Guaraldi, M | 1 |
| Pannuti, F | 1 |
| Kuske, RR | 1 |
| Perez, CA | 1 |
| Lovett, RD | 1 |
| Galakatos, AE | 1 |
| Camel, HM | 1 |
| Kao, MS | 1 |
| Redman, BG | 1 |
| Kinzie, J | 1 |
| Dalesio, O | 3 |
| Roussel, A | 1 |
| Samana, G | 1 |
| Michel, J | 1 |
| Bognel, C | 1 |
| Grandjouan, S | 1 |
| Obertop, H | 1 |
| Temsch, EM | 1 |
| Petzl, DH | 1 |
| Sinha, PP | 2 |
| Goudeau, P | 1 |
| Boman, BM | 1 |
| Dickinson, R | 1 |
| Presgrave, P | 1 |
| Levi, J | 1 |
| Milliken, S | 1 |
| Woods, R | 1 |
| Saiga, T | 1 |
| Kashu, I | 1 |
| Tabuchi, K | 1 |
| Midorikawa, O | 1 |
| Donadieu, S | 1 |
| Chodkiewicz, JL | 1 |
| Laccourreye, H | 2 |
| Köhler, L | 1 |
| Mennigen, R | 1 |
| Eypasch, E | 1 |
| Blöchl, H | 1 |
| Schröder, U | 1 |
| McElhinney, RS | 3 |
| McCormick, JE | 3 |
| Atassi, G | 3 |
| Pratesi, G | 3 |
| Radacic, M | 3 |
| Treat, J | 2 |
| Falchuk, SC | 1 |
| Tremblay, C | 1 |
| Spielman, M | 1 |
| Rouesse, J | 1 |
| Sevin, D | 1 |
| Hines, JD | 2 |
| Spiess, JL | 1 |
| Giroski, P | 1 |
| Carter, SG | 1 |
| Stydnicki, KA | 2 |
| Morgan, ED | 2 |
| Collier, M | 2 |
| Knick, VB | 2 |
| Duch, DS | 2 |
| Mullin, R | 2 |
| Ferone, R | 2 |
| Flanagan, B | 2 |
| Odujinrin, O | 2 |
| Ludwig, H | 1 |
| Liang, CL | 1 |
| Hsu, H | 1 |
| Wirtanen, GW | 2 |
| Stephenson, JA | 1 |
| Ramirez, G | 3 |
| Demets, D | 1 |
| Joseph, RR | 1 |
| Higashi, Y | 1 |
| Andoh, M | 1 |
| Kitahara, S | 1 |
| Horiuchi, S | 1 |
| Oshima, H | 1 |
| Tjandra, J | 1 |
| Tsukiyama, I | 1 |
| Kajiura, Y | 1 |
| Egawa, S | 1 |
| Hijikata, J | 1 |
| Pincus, M | 1 |
| Faber, LP | 1 |
| Pan, XY | 1 |
| Li, FQ | 1 |
| Yu, RJ | 1 |
| Xie, GF | 1 |
| Zhao, LY | 1 |
| Mira, JG | 1 |
| Taylor, SL | 1 |
| Madejewicz, S | 1 |
| Plager, J | 1 |
| Soloman, J | 1 |
| Huan, S | 1 |
| Singhakowinta, A | 1 |
| Samal, B | 1 |
| Lokich, JJ | 2 |
| Ahlgren, JD | 3 |
| Gullo, JJ | 1 |
| Philips, JA | 1 |
| Fryer, JG | 1 |
| Walton, LA | 1 |
| Hatch, TR | 1 |
| Fuchs, EF | 1 |
| Oster, MW | 1 |
| Panasci, L | 1 |
| Wang, GT | 1 |
| Holl, E | 1 |
| Zänker, KS | 1 |
| Lange, J | 1 |
| Malet-Martino, MC | 1 |
| Faure, F | 1 |
| Vialaneix, JP | 1 |
| Palevody, C | 1 |
| Hollande, E | 1 |
| Martino, R | 1 |
| Flippin, TA | 1 |
| Langston, HD | 1 |
| Prather, JL | 1 |
| Scott, DI | 1 |
| Monk, MR | 1 |
| Sanchez, JD | 1 |
| Phelps, CD | 1 |
| Miller, DM | 1 |
| Alberto, P | 1 |
| Mermillod, B | 1 |
| Germano, G | 1 |
| Kaplan, S | 1 |
| Weber, W | 3 |
| Joss, R | 1 |
| Ayoub, J | 1 |
| Audet-Lapointe, P | 1 |
| Méthot, Y | 1 |
| Beaulieu, R | 1 |
| Chemaly, R | 1 |
| Cormier, A | 1 |
| Déry, JP | 1 |
| Drouin, P | 1 |
| Gauthier, P | 1 |
| Kimoto, H | 1 |
| Tsunamura, Y | 1 |
| Ichihashi, T | 1 |
| Hashizume, Y | 1 |
| Sertoli, MR | 2 |
| Bruzzone, M | 2 |
| Rubagotti, A | 2 |
| Bentivoglio, G | 1 |
| Conio, A | 1 |
| Pescetto, G | 1 |
| Marymont, JV | 1 |
| Travers, H | 1 |
| Housholder, DF | 1 |
| Kido, C | 1 |
| Hayakawa, M | 1 |
| Iizuka, A | 1 |
| Inagaki, T | 1 |
| Nakura, E | 1 |
| Ohno, R | 1 |
| Tunekawa, H | 1 |
| Kikuchi, K | 2 |
| Ogata, T | 1 |
| Vance, RB | 1 |
| Weiss, GB | 1 |
| Weiss, KD | 1 |
| Torrance, PM | 3 |
| Furusaka, T | 1 |
| Kida, A | 1 |
| Yokode, Y | 1 |
| Tomita, H | 1 |
| Axelson, JA | 1 |
| Clark, RH | 1 |
| Dimitrov, NV | 2 |
| Yamanaka, A | 1 |
| Shaw, MT | 1 |
| Shaw, MK | 1 |
| La Ciura, P | 1 |
| La Grotta, G | 1 |
| Nigra, E | 1 |
| Comandone, A | 1 |
| Grecchi, G | 1 |
| Leria, G | 1 |
| Calciati, A | 1 |
| Guimaraes dos Santos, J | 1 |
| Kim, JP | 2 |
| Nadal, JC | 1 |
| Stablein, D | 1 |
| Tominaga, J | 1 |
| Kunieda, E | 1 |
| Shigematsu, N | 1 |
| Bjerkeset, T | 1 |
| Fjøsne, HE | 1 |
| Watase, M | 1 |
| Umeshita, K | 1 |
| Shimano, T | 1 |
| Monden, M | 1 |
| Okamura, J | 1 |
| Claycomb, CL | 1 |
| Berkovic, M | 1 |
| Pasterz, R | 1 |
| Savaraj, N | 1 |
| Burgess, M | 1 |
| Zhero, SV | 1 |
| Ganina, KP | 1 |
| Kitano, M | 1 |
| Shimokawa, K | 2 |
| Tsuya, H | 1 |
| Ohashi, H | 2 |
| Fieck, JM | 1 |
| Lam, WK | 2 |
| So, SY | 2 |
| Kung, TM | 1 |
| Sham, MK | 1 |
| Ip, M | 2 |
| Yashige, H | 1 |
| Inazawa, J | 1 |
| Nishigaki, H | 1 |
| Horiike, S | 1 |
| Taniwaki, M | 1 |
| Misawa, S | 1 |
| Sadamoto, Y | 1 |
| Haruma, K | 1 |
| Tokumo, K | 1 |
| Sumii, K | 1 |
| Kajiyama, G | 1 |
| Furue, H | 1 |
| Nakao, I | 1 |
| Hancock, SL | 1 |
| Goffinet, DR | 1 |
| Carlson, RW | 1 |
| Mark, JB | 1 |
| Scott, KW | 1 |
| Williams, SD | 2 |
| Nichols, CR | 1 |
| Katano, M | 1 |
| Hisatsugu, T | 1 |
| Cantor, RJ | 1 |
| Weiss, SM | 1 |
| Rosato, FE | 1 |
| Mergenthaler, HG | 1 |
| Binsack, T | 1 |
| Wilmanns, W | 1 |
| Komatsumoto, M | 1 |
| Hamada, J | 1 |
| Takeichi, N | 1 |
| Hosokawa, M | 1 |
| Onitsuka, S | 1 |
| Nakazawa, H | 1 |
| Misu, Y | 1 |
| Shikata, J | 1 |
| Kozakai, M | 1 |
| Marée, D | 1 |
| Nehashi, Y | 1 |
| Haghbin, M | 1 |
| Hinson, J | 1 |
| de Insausti, CL | 1 |
| Gutiérrez, LE | 1 |
| Hayano, K | 1 |
| Hattori, S | 1 |
| Quebbeman, EJ | 2 |
| Cantwell, BM | 1 |
| Gustavsson, BG | 3 |
| Berne, M | 2 |
| Frösing, R | 3 |
| Bernstein, L | 1 |
| Hayes, AA | 1 |
| Iosi, F | 1 |
| Kienzle, HF | 1 |
| Wilhelm, S | 1 |
| Frich, JC | 1 |
| Wilson, JF | 1 |
| Ball, AS | 1 |
| Mann, CV | 1 |
| Clifton, MA | 1 |
| Baker, WN | 1 |
| Goode, AW | 1 |
| Mehta, MP | 1 |
| Shahabi, S | 1 |
| Jacobson, G | 1 |
| Nordgren, CE | 1 |
| Shiotani, M | 1 |
| Honda, H | 1 |
| Nishi, O | 1 |
| Baumgart, J | 1 |
| Zhukovskaya, NV | 1 |
| Anisimov, VN | 1 |
| Zakem, MH | 1 |
| Mortimer, JE | 1 |
| Higano, C | 1 |
| Scholnik, AP | 1 |
| Arnold, DJ | 1 |
| Walker, WS | 1 |
| Schwenke, P | 1 |
| Suhrland, LG | 2 |
| Balcueva, EP | 1 |
| Loiseau, JP | 1 |
| Carlsson, G | 1 |
| deGraaf, SS | 1 |
| Rodman, JR | 1 |
| Elhakim, T | 1 |
| Goodman, PJ | 1 |
| Brownlee, RW | 1 |
| Laufman, L | 1 |
| Hansen, RM | 3 |
| Davis, HL | 2 |
| Zaentz, SD | 1 |
| Schiferl, EA | 1 |
| Ousley, JL | 1 |
| Pogodzinski, AE | 1 |
| Trump, DL | 1 |
| Lacave, A | 1 |
| Fabre, A | 1 |
| Chodkiewicz, JP | 1 |
| Domergue, J | 1 |
| Ismail, M | 1 |
| Astre, C | 1 |
| Saint-Aubert, B | 1 |
| Joyeux, H | 1 |
| Solassol, C | 1 |
| Roldan, GE | 1 |
| Ilstrup, DM | 1 |
| Hayashi, R | 1 |
| Kurata, A | 1 |
| Planting, AS | 1 |
| Eibl-Eibesfeldt, B | 1 |
| Storz, V | 1 |
| Kummermehr, J | 1 |
| Moynihan, T | 1 |
| Beatty, P | 1 |
| Ausman, R | 2 |
| Chitambar, C | 1 |
| Vukelich, M | 1 |
| Kita, M | 1 |
| Sethi, VK | 1 |
| Chia, KB | 1 |
| Khor, TH | 1 |
| Tan, BC | 1 |
| Tan, TM | 1 |
| Liu, LY | 1 |
| Hong, WJ | 1 |
| Hou, YJ | 1 |
| Yao, ZH | 1 |
| Wu, AR | 1 |
| Jack, A | 1 |
| McMurdo, DF | 1 |
| Blijham, G | 1 |
| Splinter, T | 1 |
| Frick, J | 1 |
| Trave, F | 2 |
| Milliron, S | 1 |
| Baroni, M | 1 |
| Krzeczowski, KA | 1 |
| Roach, R | 1 |
| Segal, M | 1 |
| Vandenbulcke, JM | 2 |
| Fourtillan, JB | 1 |
| Bacoyiannes, H | 1 |
| Kontoyiannes, D | 1 |
| Cazap, EL | 1 |
| Estevez, RA | 2 |
| Alvarez, CA | 1 |
| Hannois, A | 1 |
| Thomson, D | 1 |
| Gill, G | 1 |
| Omura, GA | 3 |
| Graham, SD | 1 |
| Walker, A | 1 |
| Cox, EB | 1 |
| Laszlo, J | 1 |
| Berry, WR | 1 |
| Cazap, E | 1 |
| Marantz, A | 1 |
| Wilcosky, T | 1 |
| Hunt, TM | 1 |
| Windle, R | 1 |
| Walach, N | 1 |
| Horn, Y | 1 |
| Welling, RE | 1 |
| Gelman, RS | 1 |
| Falkson, CI | 1 |
| Wolter, JM | 1 |
| Stark, ME | 1 |
| Dyer, MC | 1 |
| Coonley, CJ | 1 |
| Nitenberg, G | 1 |
| Reznek, RH | 1 |
| Lundell, G | 1 |
| Fallenius, A | 1 |
| Ohman, U | 1 |
| Burger, AJ | 1 |
| Mannino, S | 1 |
| Theobaldy, S | 1 |
| Hofmann-Preiss, K | 1 |
| Walter, M | 1 |
| Smith, JB | 2 |
| Ghayad, PY | 2 |
| Dhabuwala, CB | 2 |
| Drelichman, A | 2 |
| Pierce, JM | 2 |
| Galligioni, E | 1 |
| Canobbio, L | 1 |
| Fassio, T | 1 |
| Vaccher, E | 1 |
| Lo Re, G | 1 |
| Veronesi, A | 1 |
| Kavanagh, JJ | 1 |
| Copeland, L | 1 |
| Roberts, WS | 1 |
| Purvis, JD | 1 |
| Yamaizumi, Z | 1 |
| Nishimura, S | 1 |
| Richmond, J | 1 |
| Bae, Y | 1 |
| Lewis, J | 1 |
| Burdakin, J | 1 |
| Jacobsen, G | 1 |
| Wile, A | 1 |
| Smolin, M | 1 |
| Almersjö, O | 2 |
| Waldenström, J | 1 |
| Insler, MS | 1 |
| Helm, CJ | 1 |
| Quilty, PM | 1 |
| Berne, MH | 1 |
| Spears, PC | 1 |
| Gez, E | 1 |
| Yablonsky-Peretz, T | 1 |
| Weshler, Z | 1 |
| Garewal, H | 1 |
| Li, XT | 1 |
| Li, PY | 1 |
| Nishimawari, K | 1 |
| Shinde, SR | 1 |
| Shaha, PB | 1 |
| Shetty, PA | 1 |
| Henderson, A | 1 |
| Ahuja, RK | 1 |
| Simanovsky, M | 1 |
| Feldman, MI | 1 |
| Urabe, T | 1 |
| Burkes, R | 1 |
| Paul, K | 1 |
| DeBoer, G | 1 |
| Büyükünal, E | 1 |
| Berkarda, N | 1 |
| Serdengeçti, S | 1 |
| Derman, U | 1 |
| Berkarda, B | 1 |
| Kikuchi, Y | 2 |
| Kizawa, I | 1 |
| Oomori, K | 1 |
| Kasimis, BS | 1 |
| Miller, JB | 1 |
| Kaneshiro, CA | 1 |
| Forbes, KA | 1 |
| Moran, EM | 1 |
| Speyer, JL | 1 |
| Dubin, N | 1 |
| Wernz, JC | 1 |
| Roses, D | 1 |
| Sanger, J | 1 |
| Jett, JR | 1 |
| Brunk, FS | 1 |
| Brechot, JM | 1 |
| Ameille, J | 1 |
| de Fenoyl, O | 1 |
| Rochemaure, J | 1 |
| Hagin, GD | 1 |
| Sugimoto, M | 1 |
| Wakabayashi, Y | 1 |
| Vanden-Bulcke, JM | 1 |
| Glass, A | 1 |
| Aabo, K | 1 |
| Hald, I | 1 |
| Hørbov, S | 1 |
| Dombernowsky, P | 1 |
| Hansen, HH | 1 |
| Sørensen, HM | 1 |
| Lundvall, F | 1 |
| Nielsen, NC | 1 |
| Sørensen, BL | 1 |
| Swierz, J | 1 |
| Dinse, GE | 1 |
| Davis, TE | 1 |
| Creech, RH | 1 |
| Arseneau, JC | 1 |
| Greenspan, EM | 1 |
| Pagano, M | 1 |
| Aogauchi, R | 1 |
| Tsubota, N | 1 |
| Yamashita, C | 1 |
| Yoshikawa, K | 1 |
| Ishii, N | 1 |
| Hirahara, K | 1 |
| Aoki, S | 1 |
| Sekiguchi, I | 2 |
| Tamada, T | 2 |
| Nishida, M | 1 |
| Yu, DY | 1 |
| Jewell, LD | 1 |
| Murray, CJ | 1 |
| Thomson, AB | 1 |
| Abe, F | 1 |
| Shibuya, K | 1 |
| Ashizawa, J | 1 |
| Horinishi, H | 1 |
| Ishizuka, M | 1 |
| Umezawa, H | 1 |
| Pasmantier, MW | 1 |
| Coleman, M | 1 |
| Silver, RT | 1 |
| Ballard, WP | 1 |
| Asakawa, H | 1 |
| Otawa, H | 1 |
| Parker, EF | 1 |
| Marks, RD | 1 |
| Kratz, JM | 1 |
| Chaikhouni, A | 1 |
| Warren, ET | 1 |
| Bartles, DM | 1 |
| Yoshida, A | 1 |
| Noda, H | 1 |
| Kitamura, O | 1 |
| Takemori, Y | 1 |
| Fujiwara, M | 1 |
| Weber-Stadelmann, W | 1 |
| Fuller, AF | 1 |
| Krane, IM | 1 |
| Budzik, GP | 1 |
| Donahoe, PK | 1 |
| Takeshita, Y | 1 |
| Ohwada, M | 1 |
| Shiba, E | 1 |
| Terasawa, T | 1 |
| Wada, A | 1 |
| Becker, T | 1 |
| Caballero, G | 1 |
| Jenkins, D | 1 |
| Blake, D | 1 |
| Tangen, L | 1 |
| Schulte, W | 1 |
| Zimmerman, RJ | 1 |
| VanWinkle, TJ | 1 |
| Mantel, N | 1 |
| Frei, E | 2 |
| Kinami, Y | 1 |
| Miyazaki, I | 1 |
| Weatherall, TJ | 1 |
| Janaki, L | 1 |
| Boyer, C | 1 |
| August, DA | 1 |
| Ottow, RT | 1 |
| Gianola, FJ | 1 |
| Schneider, PD | 1 |
| Catton, GE | 1 |
| Wu, YF | 2 |
| Ellison, NM | 1 |
| Servi, RJ | 1 |
| Fischer, HP | 1 |
| Leone, B | 1 |
| Rabinovich, M | 1 |
| Ferrari, CR | 1 |
| Boyer, J | 1 |
| Rosso, H | 1 |
| Strauss, E | 1 |
| Zhen, ZA | 1 |
| Shao, JK | 1 |
| Zhen, HD | 1 |
| Han, ZH | 1 |
| Wood, CD | 1 |
| Ponder, BA | 1 |
| Manaka, RC | 1 |
| Cohen, JL | 2 |
| Wile, AG | 1 |
| Stemmer, EA | 1 |
| Andrews, PA | 1 |
| Murphy, MP | 1 |
| Abramson, IS | 1 |
| Kalser, MH | 1 |
| Ellenberg, SS | 1 |
| Chiuten, DF | 2 |
| Bedikian, A | 2 |
| Shepard, KV | 1 |
| Sweet, DL | 1 |
| Yap, SH | 1 |
| Wobbes, T | 1 |
| van Dam, FE | 1 |
| Hillen, HF | 1 |
| Hoogendoorn, GJ | 1 |
| Scheerder, H | 1 |
| van der Vegt, SG | 1 |
| Einhorn, LH | 1 |
| Hui, SL | 1 |
| Pennington, K | 1 |
| Nobile, MT | 1 |
| Tagarelli, G | 1 |
| Miller, A | 1 |
| Loo, TL | 1 |
| Benvenuto, JA | 1 |
| Einstein, AB | 1 |
| Rudolph, RH | 1 |
| Luce, JK | 1 |
| Sorokina, EA | 1 |
| Hellriegel, W | 1 |
| Tancini, G | 1 |
| Haslam, JB | 1 |
| Cavanaugh, PJ | 1 |
| Stroup, SL | 1 |
| Basso, A | 1 |
| Wrbka, E | 1 |
| Sandeman, TF | 1 |
| Pettavel, J | 1 |
| Morgenthaler, F | 1 |
| Fain, WR | 1 |
| Conn, JH | 1 |
| Chavez, CM | 1 |
| Navashin, SM | 1 |
| Fomina, IP | 1 |
| Osokina, LI | 1 |
| Zharikov, AA | 1 |
| Witte, S | 1 |
| Hindringer, B | 1 |
| Papaioannou, AN | 1 |
| Murray-Lyon, IM | 1 |
| Parsons, VA | 1 |
| Blendis, LM | 1 |
| Dawson, JL | 1 |
| Laws, JW | 1 |
| Williams, R | 1 |
| Limber, GK | 1 |
| King, RE | 1 |
| Silverberg, SG | 1 |
| Sakker, S | 1 |
| Ware, CC | 1 |
| Macfayden, BV | 1 |
| Burrows, JH | 1 |
| Tucker, WG | 1 |
| Dendy, PP | 1 |
| DeKernion, JB | 2 |
| Resnick, MI | 1 |
| Persky, L | 2 |
| Resnick, ML | 1 |
| Yagoda, A | 1 |
| Jato, J | 1 |
| Windheuser, JJ | 1 |
| Smith, FE | 1 |
| Lane, M | 1 |
| Hudgins, PT | 1 |
| Tashima, CK | 1 |
| Morrow, LB | 1 |
| Burrow, GN | 1 |
| Kaplan, SR | 1 |
| Mulrow, PJ | 1 |
| Kühböck, J | 1 |
| Pokorny, D | 1 |
| Steinbach, K | 1 |
| Eggerth, G | 1 |
| Rutledge, F | 4 |
| Rottenberg, VI | 1 |
| Bergsagel, DE | 1 |
| Ferguson, E | 1 |
| Obi, LJ | 1 |
| Man, B | 1 |
| Kraus, L | 1 |
| Pikielny, S | 1 |
| Korfsmeier, KH | 1 |
| Furnari, S | 1 |
| Pavone-Macaluso, M | 1 |
| Veroux, G | 1 |
| Mattea, E | 1 |
| Speckhard, ME | 1 |
| Hurley, JD | 1 |
| Fetherston, WC | 1 |
| Grueninger, AJ | 1 |
| Wharton, JT | 1 |
| Belousova, AK | 1 |
| Moskalik, KG | 1 |
| Kozlov, AP | 1 |
| Akimov, AA | 1 |
| Moertel, C | 1 |
| van der Merwe, AM | 2 |
| van Dyk, JJ | 2 |
| Falkson, HC | 2 |
| Faulkner, SL | 1 |
| Reynolds, VH | 1 |
| Hattori, N | 1 |
| Ono, T | 1 |
| Aran, M | 1 |
| Bilge, N | 1 |
| Ozman, M | 1 |
| Gailani, S | 2 |
| Leone, L | 2 |
| Sugawara, H | 1 |
| Harata, T | 1 |
| Yamaguchi, O | 1 |
| Savran, VR | 1 |
| Galt, RM | 2 |
| Oester, YT | 2 |
| Sylvester, R | 1 |
| Andrews, JT | 1 |
| Cox, KR | 1 |
| Hare, WS | 1 |
| McConchie, IH | 1 |
| Goepfert, H | 1 |
| Jesse, RH | 1 |
| Lindberg, RD | 1 |
| Grover, FL | 1 |
| Webb, MJ | 1 |
| Donovan, JF | 1 |
| Kaslow, RA | 1 |
| Wisch, N | 1 |
| Glass, JL | 1 |
| Carr, DT | 1 |
| Lee, RE | 1 |
| Holland, JF | 2 |
| Burningham, R | 1 |
| Larsen, V | 1 |
| Franksson, C | 1 |
| Bergstrand, A | 1 |
| Ljungdahl, I | 1 |
| Magnusson, G | 1 |
| Nordenstam, H | 1 |
| Larsen, RR | 1 |
| Montminy, L | 1 |
| Cerruti, FR | 1 |
| Ammon, J | 1 |
| Hermann, HJ | 1 |
| Janssen, B | 1 |
| Schmidt, L | 1 |
| Günther, W | 1 |
| Moroz, LV | 2 |
| Karev, NI | 1 |
| Nordman, E | 1 |
| Kauppinen, C | 1 |
| Skarin, AT | 1 |
| Tandon, RN | 1 |
| Bunnell, IL | 1 |
| Cooper, RG | 1 |
| Blom, J | 1 |
| Roberts, GA | 1 |
| Nagel, GA | 1 |
| Dana, M | 1 |
| Spigel, SC | 1 |
| Ellert, J | 1 |
| Creasey, WA | 1 |
| Kovach, JS | 1 |
| Tully, TE | 1 |
| Shafer, RB | 1 |
| Chawla, PL | 1 |
| Sekiya, S | 1 |
| Takamizawa, H | 1 |
| Ahmann, DL | 1 |
| Bisel, HF | 1 |
| Dines, DE | 1 |
| Burdette, WJ | 1 |
| Miller, E | 1 |
| Burns, BC | 1 |
| Soffar, S | 1 |
| Colby, M | 1 |
| Tubaro, E | 1 |
| Bulgini, MJ | 1 |
| Molina, C | 1 |
| Cheminat, JC | 1 |
| Passemard, N | 1 |
| Adam, J | 1 |
| Ermolenko, AS | 1 |
| Tarasova, GV | 1 |
| Nelson, RS | 1 |
| Lanza, FL | 1 |
| Syrkin, AB | 1 |
| Benson, J | 1 |
| Labelle, E | 1 |
| Lleander, VC | 1 |
| Goldstein, G | 1 |
| Pershin, MP | 1 |
| Chumakina, SI | 1 |
| Gunka, II | 1 |
| Pantophel, AM | 1 |
| Steklenev, NA | 1 |
| Zirin, MA | 1 |
| Grjaznova, IN | 1 |
| Shain, AA | 1 |
| Pecherskaja, BG | 1 |
| Saveliev, NP | 1 |
| Bashirova, NG | 1 |
| Kuzmin, VP | 1 |
| Budarina, EM | 1 |
| Svedencov, EP | 1 |
| Phateeva, KV | 1 |
| Iunusmetov, IR | 1 |
| Silitrin, NP | 1 |
| Shklovskii, GS | 1 |
| Balas, AN | 1 |
| Ushivceva, AE | 1 |
| Gordan, GS | 1 |
| Wessler, S | 1 |
| Avioli, LV | 1 |
| Kanzawa, F | 1 |
| Jacobs, EM | 1 |
| Reeves, WJ | 1 |
| Wood, DA | 1 |
| Pugh, R | 1 |
| Braunwald, J | 1 |
| From, P | 1 |
| Morrissey, WJ | 1 |
| Sams, J | 1 |
| Minami, T | 2 |
| Pugh, RP | 1 |
| Cassidy, FR | 1 |
| Marshall, GJ | 1 |
| Irwin, LE | 1 |
| Krant, MJ | 1 |
| Shnider, BI | 1 |
| Matias, PI | 1 |
| Baxter, D | 1 |
| Hillemand, P | 1 |
| Roux, M | 1 |
| Muller, JM | 1 |
| Bernard, HJ | 1 |
| Delavierre, P | 1 |
| Braun-Falco, O | 1 |
| Lukacs, I | 1 |
| Chevrel, B | 1 |
| Chevrel, JP | 1 |
| Sheehe, PR | 1 |
| Graham, S | 1 |
| Vinhafs, JC | 1 |
| Ferreira, AJ | 1 |
| Neyazaki, T | 1 |
| Seki, Y | 1 |
| Egawa, N | 1 |
| Suzuki, C | 1 |
| Tugarinov, OA | 1 |
| Smolianskaia, AZ | 1 |
| Klein, E | 1 |
| Konovalova, AL | 1 |
| Bengmark, S | 1 |
| Brix, M | 1 |
| Börjesson, B | 1 |
| Hafström, L | 1 |
| Olsson, A | 1 |
| Mitchell, MS | 1 |
| DeConti, RC | 1 |
| Serpick, AA | 1 |
| Edwards, AJ | 1 |
| Rowland, GF | 1 |
| Sumner, MR | 1 |
| Hurd, CM | 1 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Rowe, DS | 1 |
| Barrett, O | 2 |
| Reboul, AR | 1 |
| Lewest, G | 1 |
| Herter, FP | 1 |
| Mulcare, RJ | 1 |
| McCarthy, JG | 1 |
| Gump, FE | 1 |
| Ukai, M | 1 |
| Buckley, K | 1 |
| Wheeler, B | 1 |
| Nadler, SH | 1 |
| Abasov, IT | 1 |
| Nadzharov, AG | 1 |
| Bernard, E | 1 |
| Goolsby, CD | 1 |
| Daly, JW | 1 |
| Skinner, OD | 1 |
| Gibbs, CE | 1 |
| Kaufman, JJ | 1 |
| Kaneshiro, W | 1 |
| Roux, F | 1 |
| Chakravorty, RC | 1 |
| Sarkar, SK | 1 |
| Mukerji, B | 1 |
| Topolnicki, W | 1 |
| Lee, TC | 1 |
| Lowenfels, AN | 1 |
| Rohmans, M | 1 |
| Bourgeois, C | 1 |
| Plecha, FR | 1 |
| Clarkson, B | 1 |
| Ohkita, T | 1 |
| O'Connor, A | 1 |
| Sullivan, RD | 1 |
| Zurek, WZ | 1 |
| Traldi, A | 1 |
| Morini, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer; a Randomized Phase-II-study of the Arbeitsgemeinschaft Internistische Onkologie[NCT01503372] | Phase 2 | 75 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patient[NCT04617457] | Phase 2 | 150 participants (Anticipated) | Interventional | 2021-10-10 | Recruiting | ||
| A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer[NCT01867892] | Phase 2 | 86 participants (Anticipated) | Interventional | 2013-06-30 | Enrolling by invitation | ||
| An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers[NCT06135896] | Phase 2 | 98 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | ||
| Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma[NCT02935309] | Phase 1 | 20 participants (Actual) | Interventional | 2016-10-14 | Completed | ||
| A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Managem[NCT02008656] | Phase 2 | 358 participants (Actual) | Interventional | 2013-11-30 | Active, not recruiting | ||
| A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)[NCT04592913] | Phase 3 | 958 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | ||
| Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)[NCT04736485] | Phase 2 | 67 participants (Anticipated) | Interventional | 2021-06-28 | Active, not recruiting | ||
| Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response[NCT03033927] | 74 participants (Actual) | Observational | 2017-01-24 | Active, not recruiting | |||
| Evaluation of Exceptional Responders With Solid Tumor Cancer[NCT02555735] | 250 participants (Anticipated) | Observational | 2015-10-31 | Enrolling by invitation | |||
| Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas[NCT02839343] | Phase 2 | 126 participants (Actual) | Interventional | 2016-12-31 | Active, not recruiting | ||
| A Phase I Study of Onivyde and 5-FU in Combination With Xilonix for Advanced Pancreatic Cancer With Cachexia[NCT03207724] | Phase 1 | 16 participants (Actual) | Interventional | 2017-10-16 | Completed | ||
| A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomac[NCT01216644] | Phase 2/Phase 3 | 716 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy[NCT01362127] | Phase 2 | 181 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients With Borderline Resectable Pancreatic Cancer[NCT01661088] | Phase 2 | 25 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas[NCT03504423] | Phase 3 | 528 participants (Actual) | Interventional | 2018-11-09 | Completed | ||
| Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic[NCT02195180] | Phase 2 | 141 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers[NCT00524186] | Phase 1 | 23 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to PI left institute) | ||
| PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma[NCT02366819] | Phase 4 | 36 participants (Anticipated) | Interventional | 2014-12-11 | Recruiting | ||
| Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-08 | Completed | ||
| Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in Previously Untreated HER2 Positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma[NCT03409848] | Phase 2 | 97 participants (Actual) | Interventional | 2018-03-01 | Completed | ||
| Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma[NCT03484299] | Phase 1 | 20 participants (Anticipated) | Interventional | 2018-05-30 | Recruiting | ||
| Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases[NCT01972490] | Phase 4 | 241 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma[NCT03503630] | Phase 2 | 44 participants (Actual) | Interventional | 2018-07-20 | Active, not recruiting | ||
| TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)[NCT01362361] | Phase 2 | 54 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Prospective, Open-Label, Single-Arm and Multicentre Phase II Study to Explore the Efficacy and Safety of Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Middle and Lower Locally Advanced Rectal Cancer[NCT05792735] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-04-11 | Recruiting | ||
| Rationale and Design of a Prospective, Multicenter Phase Ⅱ Clinical Trial of Safety and Efficacy Evaluation of Long Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.[NCT04911517] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma[NCT02562716] | Phase 2 | 147 participants (Actual) | Interventional | 2016-01-06 | Completed | ||
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[NCT02545504] | Phase 3 | 432 participants (Actual) | Interventional | 2015-10-13 | Completed | ||
| Preoperative Radiochemotherapy With Concurrent Deep Regional Hyperthermia for Locally Advanced Rectal Cancer. A Prospective Phase II Trial[NCT02353858] | Phase 2 | 78 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial[NCT06050317] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-08-18 | Recruiting | ||
| Patient Reported Outcomes Following Cancer of the Rectum[NCT04936581] | 200 participants (Anticipated) | Observational | 2021-09-01 | Recruiting | |||
| A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroe[NCT03675737] | Phase 3 | 1,579 participants (Actual) | Interventional | 2018-11-08 | Active, not recruiting | ||
| A Phase II, Single-arm Clinical Trial of Administration of Cisplatin and 5- Fluorouracil With Afatinib as First-line Therapy in Patients With Inoperable Gastric or Gastroesophageal Junction Cancer[NCT01743365] | Phase 2 | 55 participants (Actual) | Interventional | 2013-02-11 | Completed | ||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer[NCT01333033] | Phase 2 | 257 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)[NCT02478931] | 10,000 participants (Anticipated) | Observational | 2013-09-05 | Recruiting | |||
| A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma[NCT05161572] | Phase 2 | 152 participants (Anticipated) | Interventional | 2021-09-28 | Recruiting | ||
| MAgnetic Resonance Imaging Guided LAteral Lymph Node Dissection in Lower REctal Cancer - A Multicenter, Prospective, Registry Study (MALAREC)[NCT04850027] | 268 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Recruiting | |||
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
| A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | ||
| Clinical Study of CT and MR in Staging and Prediction of Response in Patients With Gastric Cancer[NCT04028375] | 400 participants (Anticipated) | Observational | 2019-09-01 | Recruiting | |||
| A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615] | Phase 2 | 252 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial[NCT06121700] | Phase 2 | 55 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)[NCT04047004] | Phase 1 | 20 participants (Actual) | Interventional | 2020-03-11 | Completed | ||
| Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial.[NCT01814969] | Phase 3 | 260 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470] | Phase 3 | 1,226 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy[NCT01285557] | Phase 3 | 361 participants (Actual) | Interventional | 2011-04-14 | Terminated (stopped due to Due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in study.) | ||
| A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274] | Phase 3 | 3,397 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Induction Chemotherapy With Folfoxiri Plus Cetuximab and Maintenance With Cetuximab or Bevacizumab Therapy in Unresectable Kras Wild-type Metastatic Colorectal Cancer Patients[NCT02295930] | Phase 2 | 143 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| Resectable Pancreatic Adenocarcinoma Neo-Adjuvant FOLF(IRIN)OX-based CHEmotherapy - A Multicenter, Randomised Phase II Trial (PANACHE01-PRODIGE48 Study)[NCT02959879] | Phase 2 | 160 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma[NCT00515411] | Phase 2 | 111 participants (Actual) | Interventional | 2006-10-23 | Completed | ||
| A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy [NCT02250326] | Phase 2 | 240 participants (Actual) | Interventional | 2015-01-07 | Completed | ||
| Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST)[NCT02670746] | 44 participants (Actual) | Observational | 2015-10-01 | Terminated (stopped due to Due to slow recruitment study is being terminated.) | |||
| Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients[NCT02555813] | 317 participants (Actual) | Observational | 2015-05-08 | Completed | |||
| A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NS[NCT02027428] | Phase 3 | 427 participants (Actual) | Interventional | 2014-02-11 | Completed | ||
| Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309] | Phase 2 | 65 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally Advanced HER2-Positive Breast Cancer[NCT01940497] | Phase 3 | 240 participants (Actual) | Interventional | 2013-11-15 | Completed | ||
| S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma[NCT01959139] | Phase 1/Phase 2 | 126 participants (Actual) | Interventional | 2014-01-23 | Active, not recruiting | ||
| A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer[NCT01068327] | Phase 1 | 46 participants (Actual) | Interventional | 2007-11-05 | Completed | ||
| Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer[NCT01191697] | Phase 2 | 37 participants (Actual) | Interventional | 2011-02-28 | Active, not recruiting | ||
| A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)[NCT02979691] | Phase 2/Phase 3 | 350 participants (Anticipated) | Interventional | 2016-10-31 | Completed | ||
| Therapeutic Efficacy and Safety of Concurrent FOLFIRINOX Plus HIFU for Locally Advanced/Borderline Resectable Pancreatic Cancer: A Prospective Single-center, Single-arm, Investigator-initiated, Open-labeled, Exploratory Clinical Trial[NCT05262452] | 60 participants (Anticipated) | Interventional | 2021-08-09 | Recruiting | |||
| INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL[NCT02205047] | Phase 2 | 171 participants (Anticipated) | Interventional | 2015-07-15 | Active, not recruiting | ||
| Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease[NCT00865709] | Phase 2 | 198 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial[NCT00994864] | 235 participants (Actual) | Interventional | 2009-11-30 | Completed | |||
| REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer[NCT00824785] | Phase 3 | 574 participants (Actual) | Interventional | 2008-05-31 | Terminated (stopped due to Lack of efficacy) | ||
| A Single Arm, Open Label, Exploratory Study of Pemetrexed and S-1 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT03843853] | Phase 2 | 0 participants (Actual) | Interventional | 2019-05-01 | Withdrawn (stopped due to cooperation terminated) | ||
| A Single Arm, Open Label, Exploratory Study of Pemetrexed and TAS-102 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT04683965] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-01-01 | Active, not recruiting | ||
| Approximation to the Therapeutic Individualization in Patients With Locally Advanced Gastric and Gastroesophageal Cancer Through Modelling and Generation of Predictive Gene Signatures[NCT02454673] | 121 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| PATHOS Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.[NCT04925154] | 192 participants (Anticipated) | Observational [Patient Registry] | 2021-12-13 | Recruiting | |||
| A Phase 1 Study Of Sunitinib Malate In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer[NCT00555620] | Phase 1 | 76 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
| Phase I/II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer[NCT00889187] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to Excess toxicity was identified intraoperatively) | ||
| A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy[NCT04281511] | 238 participants (Actual) | Observational [Patient Registry] | 2019-04-03 | Completed | |||
| Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab[NCT00827671] | Phase 2 | 12 participants (Actual) | Interventional | 2009-03-31 | Terminated (stopped due to Experimental treatment not feasible due to high rate of drop out) | ||
| A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer[NCT00307736] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab as First-line Therapy in Subjects With Metastatic Colorectal Cancer.[NCT00439517] | Phase 2 | 302 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| The Outcome After Operation for Pancreatic and Periampullary Tumors in Greeland Inuit.[NCT05595811] | 2,326 participants (Actual) | Observational | 1999-01-01 | Completed | |||
| Postoperative and Long-term Survival in Relation to Life-expectancy After Pancreatic Surgery in Elderly Patients[NCT04893408] | 1,556 participants (Actual) | Observational | 2010-01-01 | Completed | |||
| Non Inferiority Multicenter Phase III Randomized Trial Comparing Preoperative Chemotherapy Only to Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Resectable Rectal Cancer (Intergroup FRENCH-GRECCAR- PRODIGE)[NCT03875781] | Phase 3 | 540 participants (Anticipated) | Interventional | 2019-06-05 | Recruiting | ||
| Early Evaluation of Chemosensitivity for Low-risk Stage II/III Rectal Cancer[NCT03666442] | Phase 2 | 61 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy[NCT04749108] | Phase 2/Phase 3 | 1,075 participants (Anticipated) | Interventional | 2021-11-26 | Recruiting | ||
| A Multicenter, Prospective, Randomized Clinical Trial to Investigate the Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.[NCT03042000] | 1,200 participants (Anticipated) | Interventional | 2017-02-28 | Not yet recruiting | |||
| FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY[NCT00002523] | Phase 3 | 1,011 participants (Actual) | Interventional | 1993-04-30 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Complete Pathologic Response Rectal Cancers EYSAC.1 Study[NCT03351959] | 1,000 participants (Anticipated) | Observational | 2018-01-01 | Recruiting | |||
| Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373] | Phase 2 | 200 participants (Anticipated) | Interventional | 2016-01-01 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase 2 Study of Neoadjuvant Modified FOLFIRINOX in Patients With Borderline Resectable Pancreas Adenocarcinoma[NCT02749136] | Phase 2 | 44 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| The Identification, Validation and Implementation of Molecular Markers to Predict Response to Fluorouracil-based Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients - Prospective Clinical Observational Study[NCT03127111] | 300 participants (Anticipated) | Observational | 2022-12-01 | Not yet recruiting | |||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811] | Phase 3 | 2,559 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab[NCT03362684] | Phase 3 | 1,808 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)[NCT02364024] | 856 participants (Actual) | Observational | 2005-11-30 | Completed | |||
| A Phase Ib/II Trial of Capeox Regimen Combined With Sintilimab and Bevacizumab in First-line Treatment for Recurrent or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma[NCT05640609] | Phase 1/Phase 2 | 57 participants (Anticipated) | Interventional | 2023-03-10 | Recruiting | ||
| A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer[NCT00548548] | Phase 3 | 774 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, an[NCT00719550] | Phase 1/Phase 2 | 130 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial[NCT00941655] | Phase 3 | 15 participants (Actual) | Interventional | 2009-07-22 | Completed | ||
| Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer[NCT00284258] | Phase 2/Phase 3 | 426 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study[NCT00343239] | Phase 2 | 59 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [NCT00477711] | Phase 2 | 41 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [NCT02870036] | Phase 1 | 243 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Strategy Phase III Intergroup Study for Chemotherapy of the Metastatic or Locally Advanced Cancers of the Stomach[NCT00374036] | Phase 3 | 416 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| PET/MR-imaging and Circulating Tumour Cells to Evaluate the Response of Chemotherapy in Patients With Gastroesophageal Junction Cancer[NCT02433301] | 23 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| 5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial[NCT01500993] | Phase 3 | 401 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| A Randomized Phase II Study of Docetaxel in Combination With Oxaliplatin With or Without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease[NCT00382720] | Phase 2 | 275 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator：A Prospective Phase 2 Trial[NCT05338866] | 58 participants (Anticipated) | Observational | 2022-01-01 | Enrolling by invitation | |||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma[NCT02812680] | 200 participants (Anticipated) | Observational | 2016-06-30 | Active, not recruiting | |||
| A Phase II Study of Erlotinib in Combination With Capecitabine as First-line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)[NCT00816868] | Phase 2 | 62 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial[NCT01145404] | Phase 2 | 76 participants (Anticipated) | Interventional | 2010-06-30 | Terminated (stopped due to Changes of SoC for third line therapy resulting in poor recruitment) | ||
| A Clinical Trial Using Electrochemotherapy With Bleomycin for the Treatment of Non-metastatic Unresectable Pancreatic Cancer[NCT03225781] | 1 participants (Actual) | Interventional | 2017-07-01 | Terminated (stopped due to Logistic reasons) | |||
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Rectal Microbiome Variability Among Rectal Cancer Cohorts Including Complete Clinical Responders, Pathologic Responders, and Early Recurrence[NCT04223102] | 40 participants (Anticipated) | Interventional | 2020-02-18 | Active, not recruiting | |||
| A Prospective Multicenter Randomized Controlled Trial of the Clinical Efficacy of Neoadjuvant Therapy Based on Organoids Drug Sensitivity Versus Empirical Neoadjuvant Therapy in the Treatment of Advanced Rectal Cancer[NCT05352165] | 192 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Timing of Rectal Cancer Response to Chemoradiation[NCT00335816] | Phase 2 | 248 participants (Anticipated) | Interventional | 2008-08-31 | Active, not recruiting | ||
| Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial[NCT03038256] | Phase 2 | 244 participants (Anticipated) | Interventional | 2018-01-31 | Recruiting | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. A Prospective Phase II Pilot Trial of the German Rectal Cancer Study Group[NCT03561142] | Phase 2 | 94 participants (Anticipated) | Interventional | 2018-06-15 | Recruiting | ||
| Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rect[NCT00349076] | Phase 3 | 1,256 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma[NCT03694262] | Phase 2 | 30 participants (Actual) | Interventional | 2019-07-19 | Completed | ||
| Phase II Study of Optimum Design of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer[NCT02938195] | Phase 2 | 50 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| [NCT02445209] | Phase 3 | 56 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer[NCT01198392] | Phase 3 | 270 participants (Anticipated) | Interventional | 2008-09-30 | Recruiting | ||
| A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.[NCT01972503] | Phase 4 | 300 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer[NCT00303771] | Phase 3 | 282 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Therapy in Rectal Cancers: Focus on Cyclomodulin-producing Escherichia Coli[NCT04103567] | 220 participants (Anticipated) | Interventional | 2020-01-14 | Recruiting | |||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212] | Phase 3 | 456 participants (Anticipated) | Interventional | 2019-10-22 | Recruiting | ||
| Phase I Study of Pre-operative Continuous 5-FU, and Sorafenib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma[NCT01376453] | Phase 1 | 18 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase I/II Study of Docetaxel, 5-Fluorouracil and Oxaliplatin (D-FOX) in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction[NCT00526110] | Phase 1/Phase 2 | 98 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Study of the Value of the PET/CT in Evaluating the Response of Distal Rectal Cancer to Neoadjuvant Chemoradiation Therapy[NCT00254683] | Phase 2 | 100 participants (Anticipated) | Interventional | 2005-09-30 | Recruiting | ||
| Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer[NCT01523457] | Phase 2 | 75 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Assessment of Cardiorespiratory Fitness and Lung Function in Lung Cancer Patients Undergoing Neoadjuvant Cancer Therapy and Role of Prehabilitation in Preventing Associated Decline[NCT05636969] | 25 participants (Anticipated) | Observational | 2023-02-01 | Not yet recruiting | |||
| A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response[NCT03515941] | Early Phase 1 | 6 participants (Actual) | Interventional | 2018-06-22 | Terminated (stopped due to The PI has decided to close the study due to the outdated study design.) | ||
| Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study[NCT03110926] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-06-19 | Active, not recruiting | ||
| Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer[NCT00381706] | Phase 2 | 245 participants (Actual) | Interventional | 2006-09-15 | Completed | ||
| A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative G[NCT01590719] | Phase 2 | 123 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer[NCT01211210] | Phase 2/Phase 3 | 495 participants (Actual) | Interventional | 2010-06-30 | Active, not recruiting | ||
| Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy of Lower Rectal Cancer With Suspected Local Lymph Node Metastasis[NCT03587480] | 250 participants (Anticipated) | Interventional | 2018-12-17 | Recruiting | |||
| A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum[NCT00145769] | Phase 3 | 326 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach[NCT01246960] | Phase 2 | 168 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Score for Measuring Bowel Dysfunction After Sphincter-preserving Surgery Among Rectal Cancer Patients[NCT03569488] | 1,100 participants (Anticipated) | Observational | 2020-01-24 | Recruiting | |||
| A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer[NCT00573131] | Phase 2 | 137 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to OncoGel did not show any impact on overall tumor response) | ||
| Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial[NCT04289792] | Phase 2 | 27 participants (Anticipated) | Interventional | 2020-05-09 | Recruiting | ||
| A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients With Metastatic HER2-Negative,[NCT01662869] | Phase 3 | 564 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy[NCT01658943] | Phase 2 | 137 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study[NCT05395910] | Phase 1 | 36 participants (Anticipated) | Interventional | 2022-10-31 | Recruiting | ||
| A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma [NCT00096278] | Phase 3 | 2,710 participants (Actual) | Interventional | 2004-09-15 | Completed | ||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Risk of Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy[NCT04941625] | 150 participants (Anticipated) | Observational | 2018-02-23 | Recruiting | |||
| A Phase I/II Study of Weekly Intravenous Oxaliplatin in Combination With Oral Daily Capecitabine and Radiation Therapy in the Neoadjuvant Treatment of Rectal Cancer[NCT00086931] | Phase 1/Phase 2 | 37 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy (SCPRT) Followed by Consolidation Chemotherapy Versus Long Course Chemoradiation for Unresectable Rectal Cancer[NCT03714490] | Phase 2 | 200 participants (Anticipated) | Interventional | 2018-10-23 | Recruiting | ||
| Resource-Sparing Curative Treatment for Rectal Cancer[NCT01459328] | Phase 3 | 350 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial[NCT00030732] | Phase 3 | 319 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial[NCT00073905] | Phase 2 | 44 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile[NCT00737373] | Phase 2 | 143 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00098982] | Phase 1 | 16 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer[NCT00953511] | 80 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)[NCT00025142] | Phase 2 | 0 participants | Interventional | 2001-07-31 | Completed | ||
| A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater[NCT00354887] | Phase 2 | 31 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. A Pan-European Prospective Multicenter Double Single Arm Cohort Study.[NCT06068023] | 400 participants (Anticipated) | Observational | 2023-07-01 | Recruiting | |||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294] | Phase 1 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.[NCT03341286] | Phase 2 | 140 participants (Anticipated) | Interventional | 2017-11-30 | Not yet recruiting | ||
| A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study)[NCT00407186] | Phase 3 | 788 participants (Actual) | Interventional | 2007-01-11 | Active, not recruiting | ||
| A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer[NCT01313416] | Phase 2 | 2 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to Drug supply issues) | ||
| Impact of Widths After Gastric Tube Reconstruction on Quality of Life for Patients With Esophagogastric Cancers[NCT01911832] | Phase 3 | 60 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study[NCT04776590] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-01-28 | Recruiting | ||
| A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial[NCT03001596] | 264 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2[NCT00274872] | Phase 2/Phase 3 | 600 participants (Anticipated) | Interventional | 2004-01-31 | Active, not recruiting | ||
| Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.[NCT01705184] | Phase 2 | 120 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)[NCT00142350] | Phase 3 | 690 participants | Interventional | 2000-11-30 | Completed | ||
| Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096] | Phase 2 | 35 participants (Anticipated) | Interventional | 2017-02-01 | Recruiting | ||
| A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer[NCT00032175] | Phase 3 | 508 participants (Anticipated) | Interventional | 2002-04-30 | Completed | ||
| Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy[NCT01383746] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Not enough inclusion) | ||
| Induction Chemotherapy, Preoperative Radiochemotherapy, Consolidation Chemotherapy, Operation and Adjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer- OIGIT 5-01 Phase II Trial[NCT01489332] | Phase 2 | 60 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer[NCT01613469] | Phase 2 | 5 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to Re-eval of patient population) | ||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212] | Phase 2 | 195 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Open-label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution Versus Best Supportive Nutritional Care in Patients With Pancreatic Cancer Receiving 2nd Line Chemotherapy[NCT01362582] | Phase 3 | 32 participants (Actual) | Interventional | 2010-03-31 | Terminated | ||
| Phase III Comparison of Adjuvant Chemoendocrine Therapy With CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients With Involved Axillary Lymph Nodes and Positive Receptors[NCT00929591] | Phase 3 | 1,558 participants (Actual) | Interventional | 1989-05-31 | Completed | ||
| A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477] | Phase 2 | 257 participants (Actual) | Interventional | 2017-10-05 | Active, not recruiting | ||
| A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.[NCT03515798] | Phase 2 | 81 participants (Anticipated) | Interventional | 2018-07-24 | Recruiting | ||
| A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients[NCT03571633] | Phase 2 | 90 participants (Anticipated) | Interventional | 2018-08-06 | Recruiting | ||
| Multicenter, Randomized, Open-label Phase II Study to Compare the Efficacy and Safety of Trastuzumab and Paclitaxel Based Regimen Plus Carboplatin or Epirubicin as Neoadjuvant Therapy in HER2-positive Breast Cancer Patients[NCT01428414] | Phase 2 | 100 participants (Anticipated) | Interventional | 2011-08-31 | Active, not recruiting | ||
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System[NCT02662348] | Phase 1 | 6 participants (Anticipated) | Interventional | 2016-02-29 | Enrolling by invitation | ||
| A Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction[NCT00193128] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer[NCT00094809] | Phase 2 | 252 participants (Actual) | Interventional | 2003-02-01 | Completed | ||
| A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer[NCT00320749] | Phase 1 | 21 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma[NCT00215644] | Phase 2 | 72 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases[NCT01095523] | Phase 2 | 0 participants (Actual) | Interventional | 2010-01-14 | Withdrawn | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer[NCT01163396] | Phase 2 | 57 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers[NCT03978078] | 200 participants (Anticipated) | Interventional | 2016-09-12 | Recruiting | |||
| Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.[NCT05687617] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-12-15 | Recruiting | ||
| A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer[NCT01041404] | Phase 3 | 584 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer[NCT02004769] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks[NCT02852096] | 600 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | |||
| Trastuzumab Plus XELOX for HER2-positive Stage III Gastric Cancer After D2 Gastrectomy：Prospective Observational Study.[NCT02250209] | Phase 2 | 40 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Retrospective Study for Evaluation of Real-world Efficacy and Safety of Ramucirumab Plus Paclitaxel in Patients With Locally-advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04192734] | 1,063 participants (Actual) | Observational | 2019-12-18 | Completed | |||
| Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System[NCT05165602] | 30 participants (Anticipated) | Observational | 2022-01-01 | Not yet recruiting | |||
| A Phase 1B/2 Study of Trastuzumab, Bevacizumab With Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)[NCT05640830] | Phase 1/Phase 2 | 47 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| Efficacy and Prognostic Factors of Trastuzumab Based Therapy in HER2 Positive Advanced Gastric Cancer: a Single Center Prospective Observational Study[NCT03024450] | 98 participants (Actual) | Observational [Patient Registry] | 2012-01-31 | Completed | |||
| Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy and Systemic Chemotherapy in Gastric Cancer With Regional Peritoneal Metastasis, a Multicenter and Single-arm Phase III Study[NCT03023436] | Phase 3 | 220 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Phase I Study of the Efficacy and Safety of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors[NCT05707910] | Phase 1 | 9 participants (Anticipated) | Interventional | 2023-02-10 | Recruiting | ||
| A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707] | Phase 2 | 55 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Prospective Study for Real-world Data (RWD) of Ramucirumab Plus Paclitaxel in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04915807] | 222 participants (Anticipated) | Observational [Patient Registry] | 2021-06-30 | Not yet recruiting | |||
| A Phase II Study of Adjuvant Chemotherapy of S-1 With Oxaliplatin in Gastric Cancer at Stage IIIB/ IV (AJCC 6th) After D2 Resection[NCT02191566] | Phase 2 | 8 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to The patient's study enrollment was too low.) | ||
| European Study Group For Pancreatic Cancer - Trial 3[NCT00058201] | Phase 3 | 1,030 participants (Anticipated) | Interventional | 2001-07-31 | Completed | ||
| A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552] | Phase 3 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn | ||
| Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER[NCT02268006] | Phase 2 | 50 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression[NCT00303758] | Phase 3 | 202 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy[NCT03734952] | 537 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer[NCT00192075] | Phase 2 | 84 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Follow up and Functional Outcome of Organ Saving Treatment in Patients With Good Response to Neo-adjuvant (Chemo)Radiation for Rectal Cancer[NCT02278653] | 100 participants (Anticipated) | Observational [Patient Registry] | 2014-03-31 | Active, not recruiting | |||
| Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer[NCT01721785] | 307 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer[NCT00100841] | Phase 2 | 66 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Preoperative Combined Radiochemotherapy for Patients With Newly Diagnosed, Primary Operable and Locally Advanced Rectal Carcinoma (cT3, Nx, M0) of the Lower and Middle Rectum[NCT00297141] | Phase 2 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma[NCT00003216] | Phase 3 | 518 participants (Anticipated) | Interventional | 1998-07-31 | Completed | ||
| Phase II Clinical Trial of Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer[NCT01022541] | Phase 2 | 47 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by Oral Fluorouracil (UFT) in Serosa-positive Gastric Cancer (JCOG9206-2)[NCT00147147] | Phase 3 | 280 participants | Interventional | 1993-01-31 | Completed | ||
| A Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms[NCT03121599] | 3 participants (Actual) | Interventional | 2017-06-11 | Terminated (stopped due to Delayed study materials, poor recruitment) | |||
| A Study of 18F-FLT Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Cases of Prefibrotic/Early Primary Myelofibrosis (PMF) and Essential Thrombocythemia (ET)[NCT03116542] | 21 participants (Anticipated) | Interventional | 2017-05-07 | Recruiting | |||
| Usefulness of Cell-free DNA Quantification With Fluorescent Assay in Response Evaluation of Palliative Chemotherapy[NCT05227950] | 100 participants (Anticipated) | Observational [Patient Registry] | 2022-01-01 | Recruiting | |||
| A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00056446] | Phase 3 | 855 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo[NCT00056459] | Phase 3 | 1,168 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) Functional CTCs Using EPIDROP[NCT05346536] | 63 participants (Anticipated) | Interventional | 2022-06-16 | Recruiting | |||
| A Phase II Study Of Paclitaxel-Based Chemoradiotherapy Regimen With Selective Surgical Salvage For Resectable Locoregionally Advanced Carcinoma Of The Esophagus[NCT00069953] | Phase 2 | 43 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer[NCT05400681] | 200 participants (Anticipated) | Observational [Patient Registry] | 2020-08-01 | Recruiting | |||
| Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients[NCT00112658] | Phase 2/Phase 3 | 342 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II[NCT03717298] | Phase 2 | 30 participants (Actual) | Interventional | 2018-10-30 | Completed | ||
| 1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081] | Phase 2 | 58 participants (Anticipated) | Interventional | 2019-12-12 | Recruiting | ||
| Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction[NCT05986890] | 16 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | |||
| Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2021-06-15 | Active, not recruiting | ||
| Phase I Study of Low Kilovoltage Intraoperative Radiation for Patients With Resectable Pancreatic Adenocarcinoma[NCT02599662] | Phase 1 | 12 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response[NCT05196334] | 88 participants (Actual) | Observational | 2021-07-01 | Active, not recruiting | |||
| A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma[NCT03610100] | Phase 2/Phase 3 | 328 participants (Anticipated) | Interventional | 2015-12-31 | Suspended (stopped due to Suspended to recruitment following TSC review on efficacy and toxicities) | ||
| An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-09-03 | Recruiting | ||
| Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers[NCT03291899] | Phase 2 | 32 participants (Anticipated) | Interventional | 2017-01-03 | Recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer: The SMART Study[NCT04276857] | 27 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Pembrolizumab Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas[NCT05132504] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-08-31 | Recruiting | ||
| A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)[NCT04787991] | Phase 1 | 45 participants (Anticipated) | Interventional | 2021-08-09 | Active, not recruiting | ||
| A Phase II Trial of Flouro-Gem as a First Line Treatment of Metastatic Adenocarcinoma of the Pancreas (GEFLUPAN)[NCT04769414] | Phase 2 | 48 participants (Actual) | Interventional | 2021-02-20 | Completed | ||
| A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer[NCT01488552] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| Clinical Efficacy of QingyiHuaji Optimized Formula Combined With Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Study[NCT05840341] | Phase 3 | 306 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma[NCT01558869] | Phase 2 | 37 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer[NCT05065801] | Phase 2 | 162 participants (Anticipated) | Interventional | 2022-01-30 | Recruiting | ||
| Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine/Nab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer[NCT04570943] | Phase 2 | 103 participants (Anticipated) | Interventional | 2020-12-15 | Recruiting | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma[NCT03943667] | Phase 3 | 211 participants (Actual) | Interventional | 2019-05-23 | Completed | ||
| A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer[NCT03167112] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-07-03 | Recruiting | ||
| Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed[NCT00070213] | Phase 3 | 460 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer[NCT03530267] | Phase 2 | 124 participants (Actual) | Interventional | 2018-09-28 | Active, not recruiting | ||
| PAXG Out in the Country[NCT04480268] | Phase 4 | 175 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG): The Heidelberg Imaging Program in Cancer of the Oesophago-gastric Junction During Neoadjuvant Treatment:[NCT01271322] | Phase 2 | 0 participants | Interventional | 2010-10-31 | Terminated | ||
| A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer[NCT00114231] | Phase 2 | 90 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| A Phase II Study of 5-Fluorouracil, Bevacizumab (Avastin), and Radiation in the Preoperative or Adjuvant Treatment of Patients With Stage II / III Rectal Cancer[NCT00308516] | Phase 2 | 66 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer[NCT00411450] | Phase 2 | 116 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150] | Phase 2/Phase 3 | 231 participants (Anticipated) | Interventional | 2020-01-05 | Recruiting | ||
| Oxaliplatin (NSC-266046) Plus Protracted Infusion 5-Fluorouracil And Radiation For Potentially Curable Esophageal Cancer: A Phase II Trial With Molecular Correlates[NCT00086996] | Phase 2 | 98 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Phase II Study of Neoadjuvant Chemotherapy With Modified FOLFOX6 Regimen and Effects of Tumor Regression in Locally Advanced Gastric Cancer[NCT02226380] | Phase 2 | 75 participants (Anticipated) | Interventional | 2013-10-31 | Recruiting | ||
| A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma[NCT00411229] | Phase 3 | 1,035 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) Who Received Radical Resecti[NCT01935778] | Phase 3 | 286 participants (Anticipated) | Interventional | 2013-10-02 | Recruiting | ||
| The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer: A Randomized Controlled Trial[NCT03607656] | Phase 2/Phase 3 | 270 participants (Actual) | Interventional | 2018-06-08 | Completed | ||
| A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery Using a Phase 3 [NCT03403296] | 640 participants (Actual) | Observational | 2016-07-13 | Completed | |||
| Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | ||
| A Randomized Phase II Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)[NCT04793932] | Phase 2 | 261 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer[NCT01739894] | Phase 2 | 20 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Phase II Study of the Combination of Cetuximab, Capecitabine, and Oxaliplatin With Out Without Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer[NCT00321100] | Phase 2 | 23 participants (Actual) | Interventional | 2006-04-12 | Terminated (stopped due to Enrollment closed 10/15/2008 based on data about KRAS.) | ||
| Total Neoadjuvant Therapy in Rectal Cancer Treatment[NCT04747951] | Phase 4 | 280 participants (Anticipated) | Interventional | 2020-10-30 | Recruiting | ||
| A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480] | Phase 2 | 0 participants | Interventional | Completed | |||
| A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer[NCT00668863] | Phase 2 | 71 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Pilot Study[NCT05396326] | Phase 1 | 20 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | ||
| Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Prospective, Phase 2, Single Arm Trial.[NCT05346874] | Phase 2 | 37 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | ||
| Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal E[NCT00865982] | Phase 2 | 50 participants (Anticipated) | Interventional | 2008-09-30 | Active, not recruiting | ||
| Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427] | Phase 2 | 101 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| A Phase III, Randomized Open-Label Study to Compare the Pharmacokinetics, Efficacy, and Safety of Subcutaneous (SC) Trastuzumab With Intravenous (IV) Trastuzumab Administered in Women With HER2-Positive Early Breast Cancer (EBC)[NCT00950300] | Phase 3 | 596 participants (Actual) | Interventional | 2009-10-16 | Completed | ||
| Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review[NCT05931042] | 1,209 participants (Actual) | Observational | 2023-06-01 | Completed | |||
| A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480] | Phase 2 | 63 participants (Actual) | Interventional | 2020-02-01 | Completed | ||
| A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres[NCT00450203] | Phase 2/Phase 3 | 1,103 participants (Anticipated) | Interventional | 2007-10-31 | Recruiting | ||
| A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junctio[NCT00583674] | Phase 2 | 171 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial[NCT00814619] | Phase 2 | 68 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Phase I Study of Capecitabine, Cisplatin and Imatinib in Patients With Unresectable or Metastatic Gastric Cancer.[NCT00601510] | Phase 1 | 38 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer[NCT01072981] | Phase 3 | 722 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer[NCT00569387] | Phase 2 | 73 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma[NCT02465736] | Phase 3 | 610 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors[NCT03863145] | Early Phase 1 | 90 participants (Anticipated) | Interventional | 2022-06-14 | Recruiting | ||
| A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma[NCT00752570] | Phase 2 | 144 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer[NCT01152710] | Phase 2 | 57 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study[NCT00842686] | Phase 2 | 60 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer[NCT00533533] | Phase 1/Phase 2 | 68 participants (Anticipated) | Interventional | 2006-01-31 | Completed | ||
| Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723] | 441 participants (Actual) | Observational | 2011-08-01 | Completed | |||
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma[NCT00004102] | Phase 2 | 0 participants | Interventional | 1999-01-31 | Completed | ||
| Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy[NCT00855946] | 46 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| MRI for Response Evaluation After Chemoradiation for Locally Advanced Rectal Cancer[NCT04790227] | 50 participants (Anticipated) | Observational | 2022-01-31 | Not yet recruiting | |||
| Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692] | 200 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594] | Phase 3 | 1,691 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT00212615] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY[NCT00002631] | Phase 3 | 298 participants (Anticipated) | Interventional | 1995-06-30 | Completed | ||
| A Clinical Trial to Evaluate Postoperative Immunotherapy and Postoperative Systemic Chemotherapy in the Management of Resectable Colon Cancer[NCT00427570] | Phase 3 | 0 participants | Interventional | 1977-09-30 | Completed | ||
| "Radical External Beam Chemoradiation in Patients With Rectal Cancer: a Wait-and-see Approach"[NCT03001362] | 48 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | |||
| Prediction of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.[NCT02439086] | 20 participants (Anticipated) | Interventional | 2015-09-30 | Not yet recruiting | |||
| Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma[NCT00009893] | Phase 2 | 42 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer[NCT00142038] | Phase 2 | 80 participants | Interventional | 2004-03-31 | Completed | ||
| Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma[NCT02289547] | Phase 3 | 184 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study[NCT00783172] | Phase 1 | 4 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Problems with IRB) | ||
| Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil[NCT00960284] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Mono-Center Phase ǀ Study on Dose Escalation of Stereotactic Body Radiotherapy (SBRT) Treating Pancreatic Cancer Patients With CyberKnife[NCT02716207] | 16 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| 3D-printing Template-assisted CT-guided I125 Seed Implantation and Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer:A Prospective Multicenter Cohort Study[NCT03964064] | 100 participants (Anticipated) | Interventional | 2019-06-11 | Recruiting | |||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Effects of Different Treatment for Anorectal Function of Patients With Rectal Cancer: a Study Protocol for a Prospective, Observational, Controlled, Multicentre Study[NCT05671809] | 402 participants (Anticipated) | Observational [Patient Registry] | 2023-01-01 | Not yet recruiting | |||
| A Phase II Study of Oxaliplatin and Capecitabine in Patients With Measurable Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia[NCT00040859] | Phase 2 | 48 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00265850] | Phase 3 | 2,334 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Phase II Study Of Docetaxel And Capecitabine In Patients With Measurable Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction[NCT00054457] | Phase 2 | 46 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Phase II Study to Assess Efficacy and Safety of Capecitabine and Irinotecan Plus Bevacizumab Followed by Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients With Metastatic Colorectal Cancer[NCT02119026] | Phase 2 | 120 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Surgery Outcome Treated by Neo-adjuvant Chemotherapy FOLFOXIRI Regimen in Colorectal Cancer With Liver-limited Synchronous Metastases[NCT05362825] | 89 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer[NCT00123851] | Phase 2 | 32 participants | Interventional | 2003-03-31 | Completed | ||
| International Registry on Cholangiocarcinoma Treatment[NCT01920503] | 40 participants (Anticipated) | Observational [Patient Registry] | 2013-07-31 | Recruiting | |||
| Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy[NCT03035071] | 26 participants (Actual) | Interventional | 2010-05-01 | Completed | |||
| Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer[NCT02572050] | Phase 2 | 87 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study[NCT05351398] | 54 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.[NCT00674167] | Phase 2 | 21 participants (Actual) | Interventional | 2007-05-31 | Active, not recruiting | ||
| A RANDOMISED, CONTROLLED TRIAL OF PRE- AND POST-OPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER[NCT00002615] | Phase 3 | 500 participants (Anticipated) | Interventional | 1994-06-30 | Completed | ||
| An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.[NCT01234324] | Phase 2 | 171 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04999332] | Phase 2 | 58 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| Prospective Observational Study of Patients With Locally Advanced Gastric Cancer Treated With Perioperative Chemotherapy and Surgery[NCT01633203] | 61 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy in R0 Gastric Cancer[NCT02640898] | 500 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| A Phase II Study of PN-401, 5-FU and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach[NCT00004233] | Phase 2 | 65 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score Through Registration[NCT02781285] | 1,500 participants (Anticipated) | Observational [Patient Registry] | 2014-12-31 | Recruiting | |||
| Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly[NCT02992886] | Phase 2 | 68 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer[NCT04301557] | Phase 2 | 25 participants (Anticipated) | Interventional | 2020-07-31 | Recruiting | ||
| Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer[NCT06114420] | 500 participants (Anticipated) | Observational | 2023-01-30 | Recruiting | |||
| Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2011-01-12 | Completed | ||
| Preoperative Radiotherapy With or Without Concurrent Chemotherapy (5-Fluorouracil and Leucovorin) in T3-4 Rectal Cancers - Randomized Trial[NCT00296608] | Phase 3 | 762 participants (Actual) | Interventional | 1993-04-30 | Completed | ||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer[NCT00026364] | Phase 1 | 22 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Study of Anti-pd-l1 Monoclonal Antibody Injection (ZKAB001) Combined Albumin Binding Paclitaxel, Cisplatin in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma.[NCT04460066] | Phase 1/Phase 2 | 70 participants (Anticipated) | Interventional | 2020-11-18 | Active, not recruiting | ||
| Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Locally Advanced Resectable Rectal Cancer: A Phase II Pilot Study[NCT00689702] | Phase 2 | 43 participants (Actual) | Interventional | 2007-02-28 | Active, not recruiting | ||
| Open Label, Randomized Multicentre Phase II/III Study of Docetaxel in Combination With Cisplatin (CDDP) or Docetaxel in Combination With 5-Fluorouracil (5-FU) and CDDP Compared to the Combination of CDDP and 5-FU in Patients With Metastatic or Locally Rec[NCT00290966] | Phase 2/Phase 3 | 610 participants | Interventional | 1998-10-31 | Completed | ||
| Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemo-radiation for Preoperative Enlarged Lateral Nodes in Advanced Low Rectal Cancer: a Phase III Randomized Controlled Trial[NCT02614157] | 51 participants (Actual) | Interventional | 2016-05-31 | Terminated (stopped due to The enrollment was too low) | |||
| Prospective Randomized Clinical Trial on Delay Phenomenon Utility in Preventing Oesophagogastric Anastomotic Dehiscence After Ivor-Lewis Esophagectomy. Pilot Study.[NCT02432794] | 44 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Coala-T-CBD Study: A Study of the Effect of Hemp-CBD on the Severity and Duration of Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy for Non-Metastatic Breast, Uterine, Pancreatic, and Colorectal Cancer and All Sta[NCT04398446] | Phase 2 | 56 participants (Actual) | Interventional | 2020-05-27 | Active, not recruiting | ||
| A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018] | Phase 2 | 54 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer[NCT00111761] | Phase 2 | 43 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Taxotere-Cisplatin-5FU (TCF) Versus Taxotere-Cisplatin (TC) Versus Epirubicin-Cisplatin-5FU (ECF) as Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial[NCT00004873] | Phase 2 | 0 participants | Interventional | 1999-08-31 | Completed | ||
| Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas[NCT01143545] | Phase 1 | 10 participants (Actual) | Interventional | 2010-12-07 | Terminated (stopped due to Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.) | ||
| Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation[NCT01049100] | 250 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | |||
| A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931] | Phase 3 | 2,472 participants (Anticipated) | Interventional | 2000-02-29 | Completed | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| The Influence of Probiotics on Vancomycin-Resistant Enterococcus[NCT00591474] | 8 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to Participant lost to followup) | |||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer[NCT02833753] | Phase 1 | 14 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Randomized Study of Adjuvant Radiochemotherapy After Surgery Versus Radiochemotherapy Alone in Patients With Locally Advanced Esophageal Cancer[NCT00416858] | Phase 3 | 40 participants (Anticipated) | Interventional | Completed | |||
| Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181] | Phase 3 | 86 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Concurrent EUS-guided Intra-tumour Injection of OncoSil (32P) With Chemotherapy in Locally Advanced Pancreatic Carcinoma.[NCT05131776] | Phase 2/Phase 3 | 20 participants (Anticipated) | Interventional | 2021-11-01 | Recruiting | ||
| Protocole de Phase II: Etude de Faisabilite de L'Oxaliplatine en Association Chimio-Radiotherapie Concomitante Dans le Traitement Des Cancers du Pancreas Localement Avances Non Resecables[NCT00275119] | Phase 2 | 0 participants | Interventional | 2003-11-30 | Active, not recruiting | ||
| A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449] | Phase 2 | 58 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer[NCT00003118] | Phase 3 | 56 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Monitoring Efficacy of Radiotherapy Based on Next Generation Sequencing Liquid Biopsy Technique in Lung Cancer and Esophageal Cancer: a Prospective Study[NCT04014465] | 150 participants (Anticipated) | Observational | 2019-02-01 | Recruiting | |||
| Different Radiation Dose of Neoadjuvant Chemoradiation Followed By Surgery in Treating Patients With Locally Advanced, Resectable Thoracic Esophageal Cancer[NCT03381651] | 144 participants (Anticipated) | Interventional | 2018-02-22 | Recruiting | |||
| Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study[NCT05028231] | 46 participants (Anticipated) | Observational | 2021-06-05 | Recruiting | |||
| Phase II Study of Adjuvant Gemcitabine Started One Week After Laparoscopic[NCT01045941] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to The study was never initiated) | |||
| A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma[NCT01553019] | Phase 2 | 2 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.[NCT00375999] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer[NCT00075556] | Phase 2 | 0 participants | Interventional | 2002-01-31 | Active, not recruiting | ||
| First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287] | Phase 3 | 554 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| FOcUs on Colorectal CAncer oUtcomes: Long-Term Study[NCT03965325] | 300 participants (Anticipated) | Observational | 2019-06-07 | Recruiting | |||
| [NCT02748772] | Phase 3 | 148 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Clinical Trial Of Safety Of Robot-assisted Thoracic Approach Verus Open Transthoracic Esophagectomy in Esophageal Cancer.[NCT04652180] | 108 participants (Anticipated) | Interventional | 2020-11-06 | Recruiting | |||
| A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors[NCT00001579] | Phase 1 | 50 participants | Interventional | 1997-06-30 | Completed | ||
| A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926] | Phase 2 | 50 participants | Interventional | 2000-06-30 | Completed | ||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase[NCT00248404] | Phase 1/Phase 2 | 155 participants (Anticipated) | Interventional | 2005-09-30 | Completed | ||
| An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)[NCT00815308] | Phase 2 | 55 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981] | Phase 2 | 136 participants (Anticipated) | Interventional | 2020-09-28 | Recruiting | ||
| Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma[NCT00226473] | Phase 4 | 200 participants | Interventional | 2001-09-30 | Recruiting | ||
| Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897] | Phase 2 | 40 participants (Actual) | Interventional | 2018-10-25 | Completed | ||
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer[NCT01137123] | Phase 3 | 301 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851] | Phase 2 | 16 participants (Actual) | Interventional | 2015-04-30 | Active, not recruiting | ||
| CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment[NCT00122772] | Phase 3 | 601 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters[NCT00603408] | Phase 2 | 5 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to Study was discontinued due to lack of accrual.) | ||
| Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA)[NCT03100409] | 137 participants (Actual) | Interventional | 2017-02-01 | Terminated (stopped due to The study was closed prematurely because the interim analysis found that subjects in the experimental group had less gastrointestinal toxicity.) | |||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon[NCT00425152] | Phase 3 | 2,151 participants (Actual) | Interventional | 1989-07-31 | Completed | ||
| A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon[NCT00427310] | Phase 3 | 1,158 participants (Actual) | Interventional | 1984-03-31 | Completed | ||
| Prediction of Benefit From Adjuvant Chemotherapy for pT1N1 Gastric Cancer: A Pilot Retrospective Multicenter Cohort Study[NCT03485105] | 1,000 participants (Anticipated) | Observational | 2017-11-01 | Active, not recruiting | |||
| MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171] | 180 participants (Anticipated) | Observational | 2022-10-25 | Recruiting | |||
| Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis[NCT02350166] | Phase 3 | 40 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
| Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial[NCT02969473] | Phase 2 | 120 participants (Anticipated) | Interventional | 2010-10-31 | Active, not recruiting | ||
| A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma[NCT04844385] | Phase 2 | 83 participants (Anticipated) | Interventional | 2021-02-20 | Recruiting | ||
| Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658] | 200 participants (Anticipated) | Observational | 2010-11-30 | Recruiting | |||
| A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma[NCT00052962] | Phase 3 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| A Phase II Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, Panitumumab and External Beam Radiation, in Patients With Localized, Non-Metastatic Pancreatic Adenocarcinoma[NCT01130701] | Phase 2 | 0 participants (Actual) | Interventional | 2010-05-31 | Withdrawn (stopped due to Study never went beyond FDA application for an IND #. FDAA required institutional DSMC which this institution then lacked.) | ||
| Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer[NCT01856322] | Phase 2 | 3 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to The trial was prematurely closed due to lack of accrual.) | ||
| Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients[NCT02579980] | 32 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Evaluation of Antibody-dependent Cell Cytotoxicity (ADCC) Against Gastric Cancer Cells[NCT02078362] | 30 participants (Anticipated) | Observational | 2013-09-30 | Recruiting | |||
| A Randomized Phase III Trial of Postoperative Chemotherapy or Chemo-radiotherapy for Locally Advanced Gastric Cancer After D2 Resection[NCT03601988] | Phase 3 | 408 participants (Anticipated) | Interventional | 2018-07-28 | Recruiting | ||
| Comparative Study on the Efficacy of Lobaplatin and Paclitaxel in the Treatment of Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT04808466] | Phase 2 | 231 participants (Anticipated) | Interventional | 2021-09-18 | Recruiting | ||
| Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer[NCT04942899] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-08-30 | Not yet recruiting | ||
| A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628] | 10 participants (Anticipated) | Interventional | 2012-01-31 | Not yet recruiting | |||
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.[NCT03534713] | Phase 3 | 310 participants (Anticipated) | Interventional | 2020-07-17 | Recruiting | ||
| A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma[NCT00901836] | 2 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Study closed due to feasability) | |||
| A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer[NCT00212589] | Phase 3 | 60 participants | Interventional | 2002-12-31 | Completed | ||
| A Phase I-II Study of Capecitabine and Oxaliplatin in Chemotherapy-Naive and Thymidylate Synthase Inhibitor Pretreated Advanced or Metastatic Colorectal Cancer[NCT00004187] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-06-30 | Completed | ||
| Phase II Study of High-dose （86 Gy）Intensity Modulated Radiotherapy and Concurrent Paclitaxel and Cisplatin in Locoregionally Advanced Esophageal Cancer[NCT03535207] | 50 participants (Anticipated) | Interventional | 2018-04-01 | Recruiting | |||
| Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Cisplatin and Paclitaxel in Patients With Esophageal Cancer[NCT03082586] | 31 participants (Actual) | Interventional | 2016-11-20 | Completed | |||
| A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer[NCT00001338] | Phase 3 | 65 participants | Interventional | 1993-06-30 | Completed | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer[NCT00001428] | Phase 2 | 65 participants | Interventional | 1995-02-28 | Completed | ||
| A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer[NCT02311361] | Phase 1/Phase 2 | 65 participants (Actual) | Interventional | 2015-03-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as time from randomization to the first documentation of event where events considered are 1) disease progression, per RECIST, prior to surgery, 2) surgery with R2 resection, 3) recurrent disease following surgery, or 4) death due to any cause. Will be estimated using the method of Kaplan-Meier in each arm and compared between treatment groups using the log-rank test. The correlation between pathologic complete response (pCR) status and event-free survival time will be assessed by Cox model with landmark approach. (NCT02839343)
Timeframe: 4 years and 7 months
| Intervention | Months (Median) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 15.0 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 10.2 |
Overall adverse event rates will be compared between treatment groups using Chi-square test (or Fisher's exact test if the data in contingency table is sparse). (NCT02839343)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 66 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 55 |
Defined as the percentage of patients who are alive at 18 months after randomization divided by the total number of evaluable patients in each arm. An evaluable patient is defined as any patient who signed informed consent, deemed eligible by central review and received any protocol-defined treatment. 95% confidence interval will be estimated based on standard method. Chi-squared test (or Fisher's exact test if the data in contingency table is sparse) will be used to compare 18 month OS rates among treatment arms. OS within each arm will be summarized by Kaplan-Meier method. Median, 1-year and 2-year rates will be estimated based on Kaplan-Meier curves. (NCT02839343)
Timeframe: 18 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 64.6 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 47.3 |
Defined as the percentage of patients in whom a pCR was confirmed by histopathologic review of the surgical specimen. Chi-square test (or Fisher's exact test if the data in contingency table is sparse) will be used to compare pCR resection rate between two treatment arms. Sensitivity analysis will be conducted among patients in cohort 1) and cohort 2). The association between pCR rate and OS/progression free survival (PFS) will be assessed by log-rank test and Cox model. (NCT02839343)
Timeframe: 24 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 0 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 11 |
Defined as the percentage of patients in whom an achieved R0 resection was achieved during surgery. (NCT02839343)
Timeframe: 24 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1 (mFOLFIRINOX + Surgery + FOLFOX) | 49 |
| Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx) | 35 |
Chireac tumour regression grade (NCT01362127)
Timeframe: Therapy followed in 14-16 weeks before surgery. After surgery the patients will be followed until 60 weeks after completed therapy.
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 22 |
| Chemotherapy | 7 |
Safety profile of carrying out radical surgery after respective neoadjuvant therapy. (NCT01362127)
Timeframe: Five years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Radiochemotherapy | 79 |
| Chemotherapy | 81 |
The European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and disease specific questionnaires (QLQ-OES24/OG25). All items included in the questionnaires are analysed and also separate analysis of dysphagia questionnaires for oesophageal cancer were used, both clinically and psychometrically validated. All questions have four response alternatives (1, not at all; 2:a little, 3: quite a bit, 4: very much), except global scales which comprise seven response alternatives from poor to excellent. Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 according to the EORTC scoring manual. A higher score indicates either more symotoms or better function, depending on the question. (NCT01362127)
Timeframe: Entry study up to Five years follow up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Mean global QoL | Dysphagia score all | |
| Chemotherapy | 69 | 31 |
| Radiochemotherapy | 67 | 27 |
To estimate overall survival as a function of time from study enrollment. (NCT01661088)
Timeframe: up to 2 years
| Intervention | months (Median) |
|---|---|
| Study Treatment | 24.4 |
To estimate progression-free survival as a function of time from study enrollment. Progression is defined as at least a 20% increase in the LD (longest diameter) of the primary lesion or the appearance of one or more new lesions (NCT01661088)
Timeframe: up to 2 years
| Intervention | months (Median) |
|---|---|
| Study Treatment | 13.1 |
To determine the frequency of achieving an R0 resection using a neoadjuvant regimen of FOLFIRINOX followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine in patients with borderline resectable pancreatic cancer. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed. (NCT01661088)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Study Treatment | 52 |
Defined as the rate of Complete Response (CR) plus Partial Response (PR): Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least 30% decrease in the sum of diameters of target lesions; (NCT03504423)
Timeframe: 38 months
| Intervention | Participants (Count of Participants) |
|---|---|
| CPI-613, mFolfirinox | 104 |
| Folfirinox | 90 |
Defined as the duration from the date of randomization to the date of death from any cause (NCT03504423)
Timeframe: 38 months
| Intervention | months (Median) |
|---|---|
| CPI-613, mFolfirinox | 11.10 |
| Folfirinox | 11.73 |
"Defined as the duration from the date of randomization to the date of progressive disease or death from any cause.~Progressive Disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression." (NCT03504423)
Timeframe: 38 months
| Intervention | months (Median) |
|---|---|
| CPI-613, mFolfirinox | 7.82 |
| Folfirinox | 7.98 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 33 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 5.8 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 10.5 |
"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 25 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 15.5 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 19.6 |
Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.4 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.8 |
Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.9 |
(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Febrile neutropenia | Anal Fistula | Diarrhea | Hematemesis | Nausea | Peripheral ischemia | Vomiting | Fatigue | Laparoscopy surgery | Pain | Sepsis | Lung infection | Pneumonia | Hypernatremia | Neutrophil count decreased | Platelet count decreased | Anorexia | Dehydration | Hypokalemia | Back pain | Peripheral sensory neuropathy | Syncope | Dyspnea | Pleural embolism | Skin infection | Thromboembolic event | Abdominal pain | Enterocolitis | Hemorrhoids | G-tube infection | Neutropenic entercolitis | Alkaline phosphatase increased | |
| Arm A: FOLFIRINOX (HER2-negative) | 1 | 2 | 1 | 4 | 1 | 2 | 1 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 19 | 3 | 3 | 4 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Disease-free survival (DFS) is calculated for patients who undergo surgical resection (R0/R1). DFS will be measured from the date of surgical resection to date of first documentation of recurrence (loco-regional or distant) or death due to any cause. Patients last known to be alive and free of disease will be censored at date of last contact. (NCT02562716)
Timeframe: Up to 4 years
| Intervention | Months (Median) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 10.9 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 14.2 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02562716)
Timeframe: Up to 6 months post registration (and within 2 to 4 weeks after the last dose of Cycle 3 preoperative chemotherapy.).
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 5 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 10 |
R0 resection classification is defined as macroscopically complete tumor removal with negative microscopic surgical margins (bile duct, pancreatic parenchyma, and superior mesenteric artery margins). (NCT02562716)
Timeframe: Up to 8 months post registration (and within 4 to 8 weeks after the last dose of Cycle 3 preoperative chemotherapy).
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 34 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 28 |
(NCT02562716)
Timeframe: Up to 8 months post registration (and within 4 to 8 weeks after the last dose of Cycle 3 preoperative chemotherapy).
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 40 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 33 |
OS is the length of time between protocol registration and patient death (NCT02562716)
Timeframe: Up to 4 years for the estimates of median overall survival. Up to 2 years for Statistical Analysis 1 and 2, comparing the observed 2-year overall survival (OS) to the null hypothesis of 40%, in each arm.
| Intervention | Months (Median) |
|---|---|
| mFOLFIRINOX ->Surg ->mFOLFIRINOX | 23.2 |
| Gem/Nab-P ->Surg ->Gem/Nab-P | 23.6 |
Only adverse events that are possibly, probably or definitely related to preoperative and postoperative chemotherapy are reported. (NCT02562716)
Timeframe: Duration of treatment and follow up until death or 4 years post registration.
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal infection | Acute kidney injury | Alanine aminotransferase increased | Allergic reaction | Anemia | Anorexia | Aspartate aminotransferase increased | Biliary tract infection | Blood bilirubin increased | Colonic perforation | Constipation | Dehydration | Diarrhea | Dysesthesia | Dyspnea | Fall | Fatigue | Febrile neutropenia | Hepatobiliary disorders - Other, specify | Hyperglycemia | Hypertension | Hypoalbuminemia | Hypoglycemia | Hypokalemia | Hypomagnesemia | Hyponatremia | Infections and infestations - Other, specify | Infusion related reaction | Insomnia | Leukocytosis | Lung infection | Lymphocyte count decreased | Mucositis oral | Myocardial infarction | Nausea | Neutrophil count decreased | Non-cardiac chest pain | Pancreatitis | Papulopustular rash | Peripheral motor neuropathy | Peripheral sensory neuropathy | Platelet count decreased | Pneumonitis | Rectal hemorrhage | Respiratory failure | Sepsis | Skin infection | Thromboembolic event | Vomiting | Weight loss | White blood cell decreased | |
| Gem/Nab-P->Surg->Gem/Nab-P | 0 | 1 | 2 | 0 | 4 | 0 | 1 | 1 | 3 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 3 | 2 | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 1 | 0 | 2 | 2 | 1 | 0 | 1 | 17 | 1 | 0 | 1 | 0 | 3 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 6 |
| mFOLFIRINOX->Surg->mFOLFIRINOX | 1 | 0 | 3 | 1 | 4 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 8 | 1 | 0 | 1 | 4 | 0 | 1 | 2 | 0 | 0 | 0 | 3 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 3 | 11 | 0 | 1 | 0 | 1 | 5 | 3 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 1 |
ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT02545504)
Timeframe: Up to 135.4 weeks at the time of final analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Andecaliximab + mFOLFOX6 | 50.5 |
| Placebo + mFOLFOX6 | 41.1 |
OS was defined as the time interval from the date of randomization to death from any cause. (NCT02545504)
Timeframe: Andecaliximab + mFOLFOX6 median follow-up at the time of final analysis: 19.43 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 19.45 months
| Intervention | months (Median) |
|---|---|
| Andecaliximab + mFOLFOX6 | 12.52 |
| Placebo + mFOLFOX6 | 11.76 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events in a given study period that meet any of the following criteria: Any AE with onset date of on or after andecalizimab/placebo start date and no later than 30 days after permanent discontinuation of all study treatment (andecaliximab/placebo and chemotherapy) or Any AEs with onset date of on or after the andecaliximab/placebo start date and no later than 55 days after permanent discontinuation of andecaliximab/placebo or AEs leading to discontinuation of andecaliximab/placebo. (NCT02545504)
Timeframe: First dose date up to the last dose date (maximum:161.7 weeks) plus 30 to 55 days
| Intervention | percentage of participants (Number) |
|---|---|
| Andecaliximab + mFOLFOX6 | 99.1 |
| Placebo + mFOLFOX6 | 99.5 |
PFS was defined as the interval of time from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause. (NCT02545504)
Timeframe: Andecaliximab + mFOLFOX6 median follow-up at the time of the final analysis: 18.64 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 18.74 months
| Intervention | months (Median) |
|---|---|
| Andecaliximab + mFOLFOX6 | 7.46 |
| Placebo + mFOLFOX6 | 7.06 |
Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to 30 days after the last dose of all study treatment, or 55 days after the last dose of andecaliximab/placebo for participants who permanently discontinued all study treatments. If the relevant baseline laboratory value is missing, then any abnormality of at least Grade 1 was considered treatment-emergent. (NCT02545504)
Timeframe: First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Hematology | Serum Chemistry | Coagulation | |
| Andecaliximab + mFOLFOX6 | 94.4 | 91.7 | 7.4 |
| Placebo + mFOLFOX6 | 89.5 | 92.9 | 3.3 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.0 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.7 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.3 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 10.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.8 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented. (NCT03675737)
Timeframe: Up to 33.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 257 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 204 |
An AE was defined as any untoward medical occurrence, in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE is presented. (NCT03675737)
Timeframe: Up to 36.7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 776 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 771 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 51.3 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.0 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 52.1 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 42.6 |
ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 60.6 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 43.0 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 12.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.5 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 13.0 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.4 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 15.7 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 11.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 6.9 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 8.1 |
| Placebo + Chemotherapy (FP or CAPOX Regimen) | 5.6 |
The primary endpoint of this study is the percentage of PET/CT non-responders within each induction treatment group reporting a pCR. A pCR is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor. (NCT01333033)
Timeframe: Up to 5 years
| Intervention | percentage of participants with a pCR (Number) |
|---|---|
| FOLFOX Non-Responder | 17.95 |
| CP Non-Responder | 20 |
"A Complete Pathological Response (pCR) is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor. A non-responder was defined as having a PET/CT SUV (standard uptake value) decrease of less than 35% after induction.>~>>>~>~>>> Among the patients who completed induction therapy and did not respond, the percentage of patients reporting a pCR in each arm were compared." (NCT01333033)
Timeframe: Up to 5 years
| Intervention | percentage of participants with a pCR (Number) |
|---|---|
| FOLFOX Regimen Non-Responders | 17.95 |
| CP (Carboplatin + Paclitaxel + Radiation) Non-Responders | 20 |
"A PET/CT response to induction therapy is defined as metabolic activity of the tumor decreasing by >=35%, as>~>>~>>~>> measured by maximum standardized uptake value (SUVmax). A pCR is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor." (NCT01333033)
Timeframe: Up to 5 years
| Intervention | percentage of participants with a pCR (Number) |
|---|---|
| FOLFOX Responder | 40.28 |
| CP (Carboplatin + Paclitaxel + Radiation) Responder | 14.06 |
A PET/CT response to induction therapy is defined as metabolic activity of the tumor decreasing by >=35%, as measured by maximum standardized uptake value (SUVmax). (NCT01333033)
Timeframe: Up to 5 years
| Intervention | percentage of patients with a response (Number) |
|---|---|
| FOLFOX Regimen | 64.86 |
| CP (Carboplatin + Paclitaxel + Radiation) | 56.14 |
"A non-responder was defined as having a PET/CT SUV (standard uptake value) decrease of less than 35% after induction.~Among the patients who completed induction therapy and did not respond, the progression free survival in each arm were compared. PFS will be measured from study entry until documented progression or death from any cause. PFS will be estimated using the method of Kaplan and Meier." (NCT01333033)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| FOLFOX Regimen Non-Responder | NA |
| CP Non-Responder | 33.4 |
"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/FOLFIRI | 11.1 |
| Aflibercept/FOLFIRI | 19.8 |
"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 12.06 |
| Aflibercept/FOLFIRI | 13.50 |
"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 4.67 |
| Aflibercept/FOLFIRI | 6.90 |
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
| Intervention | participants (Number) | |
|---|---|---|
| At least one positive sample in the ADA assay | At least one positive sample in the NAb assay | |
| Aflibercept/FOLFIRI | 8 | 1 |
| Placebo/FOLFIRI | 18 | 2 |
"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Treatment-Emergent Adverse Event (TEAE) | Serious TEAE | TEAE leading to Death | TEAE causing permanent treatment discontinuation | |
| Aflibercept/FOLFIRI | 606 | 294 | 37 | 164 |
| Placebo/FOLFIRI | 592 | 198 | 29 | 73 |
Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 5.1 |
| 5FU+Cisplatin | 4.2 |
An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| S-1+Cisplatin | 157 |
| 5FU+Cisplatin | 78 |
ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | percentage of participants (Number) |
|---|---|
| S-1+Cisplatin | 34.7 |
| 5FU+Cisplatin | 19.8 |
OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From the date of randomization until disease progression or death, cut-off date: 15 August 2014 (approximately 40 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 7.5 |
| 5FU+Cisplatin | 6.6 |
PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of randomization until disease progression or death, cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 4.4 |
| 5FU+Cisplatin | 3.9 |
TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment. (NCT01285557)
Timeframe: From date of randomization until disease progression, cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 4.2 |
| 5FU+Cisplatin | 3.8 |
TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 1.8 |
| 5FU+Cisplatin | 1.9 |
AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAE | TESAE | |
| 5FU+Cisplatin | 111 | 31 |
| S-1+Cisplatin | 214 | 63 |
"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 67.1 |
| Mutant KRAS Arm D | 65.0 |
"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 74.6 |
| Wild-type KRAS Arm D | 71.5 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 87.9 |
| Mutant KRAS Arm D | 82.7 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 87.3 |
| Wild-type KRAS Arm D | 85.6 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Mutant KRAS Arm A | 55.6 |
| Mutant KRAS Arm D | 72.3 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Wild-type KRAS Arm A | 51.1 |
| Wild-type KRAS Arm D | 73.3 |
"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as accurate and appropriate" (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
| Intervention | percentage of paticipants (Mean) |
|---|---|
| Arm A, - Modified DCF | 63 |
| ARM B - Parent DCF With G-CSF | 53 |
| Arm C - Modified DCF+ Trastuzumab | 73 |
Overall survival measured in months (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months
| Intervention | months (Median) |
|---|---|
| Arm A, - Modified DCF | 18.8 |
| ARM B - Parent DCF With G-CSF | 12.6 |
| Arm C - Modified DCF+ Trastuzumab | 24.9 |
Dose intensity was the cumulative dose divided by the dosing period in weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/ week (Mean) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 716.66 |
Dose intensity was the cumulative dose divided by the dosing period in weeks). (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/week (Mean) |
|---|---|
| Nab-Paclitaxel + Durvalumab Combination Arm | 279.96 |
Dose intensity was the cumulative dose divided by the dosing period in weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | mg/m^2/week (Mean) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 54.73 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 57.18 |
| Nab-Paclitaxel Alone | 58.61 |
Overall survival was defined as the time in months between randomization/treatment assignment and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; participants were followed for overall survival up to 30 months
| Intervention | Months (Median) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 8.1 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 10.1 |
| Nab-Paclitaxel Alone | 17.0 |
Progression-free survival was defined as the time in months from the date of randomization/assignment to the date of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria documented by computed tomography (CT) scan, not including symptomatic deterioration, or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. Participants who did not have disease progression and had not died, regardless of whether they were discontinued from treatment, were censored at the date of last tumor assessment, on or prior to the clinical cut-off date that the participant was progression free. Progressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions from nadir. (NCT02250326)
Timeframe: From date of first dose of IP to DP; up to data cut-off date of 30 August (Aug) 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 December (Dec) 2017 for Durva + nab-paclitaxel; participants were followed for PFS for up to 18 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 3.2 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 4.5 |
| Nab-Paclitaxel Alone | 4.2 |
Overall Response was defined as percentage of participants who achieved a radiologic confirmed complete response or partial response according to RECIST V 1.1 criteria and compared with baseline among all tumor assessments, where baseline was the last CT obtained prior to or on Day 1 of treatment. Per RECIST V 1.1 criteria, a CR is defined as a disappearance of all target lesions; a PR is defined as having at least a 30% decrease in the sum of diameters of target lesions from baseline. Responses were evaluated every 6 weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 13.6 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 27.8 |
| Nab-Paclitaxel Alone | 16.3 |
"Disease control rate was defined as the percentage of participants who had a CR, PR or SD during the course of the study, according to RECIST version 1.1 criteria, as evaluated by the investigator. RECIST Version 1.1 criteria is defined as follows:~Complete Response is the disappearance of all target lesions;~Partial Response is at least a 30% decrease in the sum of diameters of target lesions from baseline;~Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. Responses were evaluated every 6 weeks." (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 65.4 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 70.9 |
| Nab-Paclitaxel Alone | 67.5 |
The discontinuation rate was defined as the percentage of participants who had study drug discontinued and was assessed throughout the conduct of the study. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + CC-486 Combination Arm | 100.0 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 80.8 |
| Nab-Paclitaxel Alone | 96.2 |
TEAEs were defined as any adverse event or serious adverse event that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP for Arms A and C or up to 90 days after the last dose for Arm B, and those SAEs made known to the investigator at any time thereafter that are suspected of being related to IP. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild l intervention/therapy required Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. (NCT02250326)
Timeframe: TEAEs were collected up to 4 weeks after receiving last dose of IP for nab-paclitaxel and CC-486 + nab-paclitaxel, and up to 90 days after the last IP dose for Durva + nab-paclitaxel; TEAEs were collected up to 86.1 weeks
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Grade (GR) 3/4 TEAE | Grade 3 or Higher | Treatment Related TEAE | Treatment Related Serious TEAE | Treatment Related GR 3 or Higher TEAE | TEAE With Action to Reduce/Interrupt IP | Treatment-Related to Reduce or Interrupt IP | TEAE with Action Taken to Withdraw IP | TEAE with Fatal Outcome | Treatment Related TEAE with Fatal Outcome | |
| Nab-Paclitaxel + CC-486 Combination Arm | 79 | 30 | 48 | 49 | 74 | 11 | 32 | 49 | 36 | 8 | 4 | 0 |
| Nab-Paclitaxel + Durvalumab Combination Arm | 78 | 37 | 53 | 55 | 71 | 17 | 32 | 57 | 32 | 9 | 12 | 4 |
| Nab-Paclitaxel Alone | 78 | 29 | 47 | 47 | 68 | 5 | 25 | 38 | 27 | 8 | 3 | 1 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) |
|---|---|
| Nab-Paclitaxel | |
| Nab-Paclitaxel Alone | 10.1 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Nab-Paclitaxel | CC-486 | |
| Nab-Paclitaxel + CC-486 Combination Arm | 10.1 | 20.3 |
A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Nab-Paclitaxel | Durvalumab (Reductions Not Allowed per Protocol) | |
| Nab-Paclitaxel + Durvalumab Combination Arm | 14.1 | 0.0 |
Duration of overall response was measured from the time criteria were first met for CR/PR until the first date the recurrent or progressive disease (PD) was radiologically documented. Participants who did not have PD after the response were censored on the date of last tumor assessment. If a participant died before PD, the participant was censored on the date of death. (NCT02027428)
Timeframe: Between Day 1 of the Induction Period through to the date of disease progression or death; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study.
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 5.95 |
| BSC: Induction + Maintenance | 4.60 |
Overall survival was defined as the duration in months between randomization and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off (01 August 2019 whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive. (NCT02027428)
Timeframe: From the date of randomization to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + Best Supportive Care (BSC) | 17.61 |
| Best Supportive Care (BSC) | 12.16 |
Overall survival was defined as the time in months from Day 1 of treatment for the Induction part to death from any cause. Subjects who were alive at the time of analysis had their OS censored at the date or last contact of 01 August 2019, whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive. (NCT02027428)
Timeframe: Between Day 1 of treatment in the Induction Part to death from any cause; up to 01 August 2019; survival follow up was 55.89 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 20.57 |
| BSC: Induction + Maintenance | 15.05 |
Progression-free survival is defined as the time in months from the date of randomization to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by computerized axial tomography [CT scan], not including symptomatic deterioration) or death (any cause) on or prior to 01 Aug 2019. RECIST 1.1 Definition: - Complete response (CR) -disappearance of all target lesions; - Partial response (PR) -at least a 30% decrease in the sum of diameters of target lesions from baseline - Stable disease (SD) -neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase of lesions to qualify for progressive disease (PD) - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir, and/or the appearance of new lesions. (NCT02027428)
Timeframe: From the date of randomization to the date of disease progression or death of any cause; up to data cut off date of 15 September 2017; up to 27.6 months
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + Best Supportive Care (BSC) | 3.12 |
| Best Supportive Care (BSC) | 2.60 |
PFS was defined as the time in months from Day 1 of treatment for the Induction part to the date of disease progression according to RECIST 1.1 criteria (documented by CT-scan, not including symptomatic deterioration) or death (any cause) on or prior to 01 August 2019, whichever occurred earlier. RECIST 1.1 Definition: - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progression. (NCT02027428)
Timeframe: Between Day 1 of the Induction Part through to the date of disease progression or death; up to 01 August 2019; the maximum treatment duration was 234.1 weeks for entire study
| Intervention | months (Median) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 6.47 |
| BSC: Induction + Maintenance | 5.55 |
Overall response in the maintenance period was defined as the percentage of participants who showed an improvement in best overall response from stable disease (SD) or partial response (PR) during Induction to a Complete Response (CR) or PR during Maintenance according to RECIST 1.1 criteria and confirmed in no less than 28 days. Evaluation takes as reference the lesion measurement or status at the last tumor assessment before randomization to Maintenance. The 95% CI was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. - Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. (NCT02027428)
Timeframe: For the induction period the maximum treatment was 19 weeks for the maintenance period the maximum treatment was 150 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 9.6 |
| BSC: Induction + Maintenance | 3.0 |
Overall response was defined as the percentage of participants with a confirmed assessment of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and confirmed in no less than 28 days. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to < 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. (NCT02027428)
Timeframe: Day 1 of treatment in the induction period and subsequent anticancer therapy, death or discontinuation up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | percentage of participants (Number) |
|---|---|
| Nab-Paclitaxel + BSC: Induction + Maintenance | 69.1 |
| BSC: Induction + Maintenance | 57.6 |
Disease control rate was defined as the percentage of participants who had radiologic CR, PR or SD for >= 6 weeks according to RECIST 1.1 criteria as determined by the investigator. Only participants with a confirmed CR/PR are included in this summary. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. RECIST 1.1 Definition: - CR- disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to < 10 mm. - PR- at least a 30% decrease in the sum of diameters of target lesions from baseline; - SD- neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The 95% CI was calculated using Clopper-Pearson method. (NCT02027428)
Timeframe: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 induction through maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants - Induction | 47.9 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 99.3 |
| BSC: Induction + Maintenance | 100.0 |
Time to confirmed complete or partial response (CR/PR) is defined as the time from day 1 of treatment in Induction to the first occurrence of confirmed CR/PR. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. Only participants with a confirmed CR or PR are included in this summary. (NCT02027428)
Timeframe: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 Induction through Maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study
| Intervention | months (Median) |
|---|---|
| All Participants - Induction | 1.446 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 1.478 |
| BSC: Induction + Maintenance | 1.413 |
TEAE in the Induction part is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and on or before the day of randomization for subjects who entered into the Maintenance part, or, for subjects who did not enter into the Maintenance part, before the treatment discontinuation date plus 28 days or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate Grade, 3 = Severe Grade, 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator. (NCT02027428)
Timeframe: Day 1 of Induction up to Week 23 (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severity Grade 3/4 TEAE | Severity Grade 3 or higher TEAE | Treatment-related (trt-related) TEAE | Trt-related serious TEAE | TEAE-study drug dose reduced or interrupted | Trt-related TEAE-dose reduced or interrupted | TEAE-study drug withdrawn | Trt-related TEAE-study drug withdrawn | TEAE-outcome of death | Trt-related TEAE-outcome of death | |
| All Participants - Induction | 419 | 177 | 337 | 340 | 408 | 82 | 341 | 301 | 55 | 35 | 32 | 7 |
| TEAE Specific to Carboplatin | NA | NA | NA | NA | 394 | 73 | 291 | 236 | 53 | 29 | NA | 6 |
| TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 407 | 80 | 340 | 292 | 55 | 34 | NA | 7 |
TEAE over entire study is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and before the treatment discontinuation date plus 28 days, or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator. (NCT02027428)
Timeframe: From Day 1 up to 01 August 2019; (maximum treatment length plus 28 days); the maximum treatment duration was 234.1 weeks for entire study
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAE | Serious TEAE | Severity Grade 3/4 TEAE | Severity Grade 3 or higher TEAE | Treatment-related (trt-related) TEAE | Trt-related serious TEAE | TEAE-study drug dose reduced or interrupted | Trt-related TEAE-dose reduced or interrupted | TEAE-study drug withdrawn | Trt-related TEAE- study drug withdrawn | TEAE-outcome of death | Trt-related TEAE-outcome of death | |
| BSC: Induction + Maintenance | 62 | 21 | 48 | 48 | 61 | 8 | 52 | 45 | 0 | 1 | 2 | 0 |
| BSC: TEAE Specific to BSC | NA | NA | NA | NA | 1 | 0 | 1 | 0 | 0 | 0 | NA | 0 |
| BSC: TEAE Specific to Carboplatin | NA | NA | NA | NA | 58 | 7 | 45 | 37 | 1 | 0 | NA | 0 |
| BSC: TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 61 | 8 | 52 | 45 | 1 | 0 | NA | 0 |
| Nab-Paclitaxel + BSC: Induction + Maintenance | 130 | 54 | 108 | 109 | 129 | 22 | 115 | 107 | 22 | 18 | 4 | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to BSC | NA | NA | NA | NA | 18 | 1 | 17 | 0 | 20 | 2 | NA | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to Carboplatin | NA | NA | NA | NA | 123 | 16 | 95 | 85 | 1 | 1 | NA | 0 |
| Nab-Paclitaxel + BSC: TEAE Specific to Nab-Paclitaxel | NA | NA | NA | NA | 129 | 22 | 113 | 104 | 22 | 18 | NA | 0 |
Actual dose (mg) administered = (sum over all cycles of actual dose received [mg] divided by number of cycles). Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up last dose of trastuzumab (up to approximately 1 year)
| Intervention | mg (Mean) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 599.7 |
| Trastuzumab (Vial): Neoadjuvant | 600.00 |
| Trastuzumab (SID): Adjuvant | 593.3 |
| Trastuzumab (SID): Neoadjuvant | 595.9 |
DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
| Intervention | Months (Median) |
|---|---|
| Trastuzumab (Vial): Adjuvant | NA |
| Trastuzumab (Vial): Neoadjuvant | NA |
| Trastuzumab (SID): Adjuvant | NA |
| Trastuzumab (SID): Neoadjuvant | NA |
Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up last dose of trastuzumab (up to approximately 1 year)
| Intervention | days (Mean) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 346 |
| Trastuzumab (Vial): Neoadjuvant | 352.2 |
| Trastuzumab (SID): Adjuvant | 340.1 |
| Trastuzumab (SID): Neoadjuvant | 351.9 |
Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to death due to any cause (up to approximately 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab (Vial): Adjuvant | NA |
| Trastuzumab (Vial): Neoadjuvant | NA |
| Trastuzumab (SID): Adjuvant | NA |
| Trastuzumab (SID): Neoadjuvant | NA |
Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to death due to any cause (up to approximately 4.5 years)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 5.2 |
| Trastuzumab (Vial): Neoadjuvant | 4.5 |
| Trastuzumab (SID): Adjuvant | 0.0 |
| Trastuzumab (SID): Neoadjuvant | 5.26 |
(NCT01940497)
Timeframe: Screening (Day -28 to -1) up to 2.5 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial) | 100 |
| Trastuzumab (SID) | 100 |
A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 18.5 |
| Trastuzumab (Vial): Neoadjuvant | 33.3 |
| Trastuzumab (SID): Adjuvant | 6.6 |
| Trastuzumab (SID): Neoadjuvant | 11.1 |
In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to 24 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial): Neoadjuvant | 40.9 |
| Trastuzumab (SID): Neoadjuvant | 15.8 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Trastuzumab (Vial): Adjuvant | 98.9 |
| Trastuzumab (Vial): Neoadjuvant | 100.0 |
| Trastuzumab (SID): Adjuvant | 89.1 |
| Trastuzumab (SID): Neoadjuvant | 95.2 |
Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions. (NCT01940497)
Timeframe: After at least 4 participants completed 5 cycles of adjuvant treatment (1 cycle = 21 days; maximum up to 1 year)
| Intervention | Percentage of HCPs (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialization: Oncologist | Specialization: Specialist nurse | Specialization: Other | Specialization: Missing | Personally administered/supervised: Always | Personally administered/supervised: Sometimes | Personally administered/supervised: Never | If 'Never', who administered: Specialist nurse | Syringe prepared at: Pharmacy | Syringe prepared at: Oncology ward | Syringe prepared at: Missing | Time to fill syringe: less than (<) 5 minutes | Time to fill syringe: 6-10 minutes | Time to fill syringe: 11-15 minutes | Time to fill syringe: Unknown | Total time for vial administration: <3 minutes | Total time for vial administration: <5 minutes | Total time for vial administration: 6-15 minutes | Time to prepare SID: <5 minutes | Time to prepare SID: 6-10 minutes | Time to prepare SID: 11-15 minutes | Time to prepare SID: 16-20 minutes | Time to prepare SID: >20 minutes | Total time for SID administration: <3 minutes | Total time for SID administration: <5 minutes | Total time for SID administration: 6-15 minutes | Injection site: Irritation: A lot | Injection site: Irritation: A few | Injection site: Irritation: None | Injection site: Bruising: A few | Injection site: Bruising: None | Injection site: Infection: None | Fever,shivering,flu-like,rash,swelling:A few | Fever,shivering,flu-like,rash,swelling:None | Time at hospital for administration: <2 hours | Time at hospital for administration: >2, <3 hours | Time at hospital for administration: >3, <4 hours | Time at hospital for administration: >4 hours | Time at hospital for administration: Missing | Anxiety to participants: None | Anxiety to participants: A fair amount | Ease of vial administration: None | Ease of vial administration: A fair amount | Ease of vial administration: A lot | Subcutaneous route may simplify management: Yes | Subcutaneous route may simplify management: No | Would recommend SID to intravenous route: Yes | Would recommend SID to intravenous route: No | Would recommend subcutaneous route to medics: Yes | Would recommend subcutaneous route to medics: No | Would recommend subcutaneous to medics:Missing | Convenience of using SID by participants: Yes | Convenience of using SID by participants: No | Convenience of using SID by participants: Missing | |
| HCPs: Trastuzumab (SID) | 16.0 | 76.0 | 8.0 | 0.0 | 48.0 | 48.0 | 4.0 | 4.0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 72.0 | 14.0 | 4.0 | 2.0 | 8.0 | 26.0 | 30.0 | 44.0 | 4.0 | 36.0 | 60.0 | 10.0 | 90.0 | 100.0 | 14.0 | 86.0 | 44.0 | 34.0 | 12.0 | 10.0 | 0.0 | 90.0 | 10.0 | NA | NA | NA | 100.0 | 0.0 | 96.0 | 4.0 | 90.0 | 8.0 | 2.0 | 96.0 | 4.0 | 0.0 |
| HCPs: Trastuzumab (Vial) | 17.3 | 69.2 | 11.5 | 1.9 | 40.4 | 51.9 | 7.7 | 7.7 | 55.8 | 40.4 | 3.8 | 67.3 | 13.5 | 5.8 | 13.5 | 1.9 | 59.6 | 38.5 | NA | NA | NA | NA | NA | NA | NA | NA | 1.9 | 46.2 | 51.9 | 7.7 | 92.3 | 100.0 | 15.4 | 84.6 | 44.2 | 23.1 | 23.1 | 7.7 | 1.9 | 82.7 | 17.3 | 5.8 | 38.5 | 55.8 | 94.2 | 5.8 | 96.2 | 3.8 | 100.0 | 0.0 | 0.0 | 94.2 | 0.0 | 5.8 |
"Participants were asked the following 5 questions: (1) Following the first injection given by the physician/nurse and training on how to use the SID, I felt comfortable injecting the study drug by myself; (2) The SID was convenient and easy to use; (3) I am confident giving myself an injection in the thigh with the SID; (4) Taking all things into account, I find self-administration using the SID satisfactory; (5) If given the opportunity, I would choose to continue self-injecting the study drug using the SID at home. Response to each question was recorded as either of the following options: Unknown, Strongly Disagree, Disagree, Unsure, Agree, Strongly Agree. Percentage of participants who provided responses to above questions was reported. Data for this outcome measure were analyzed and reported only for Trastuzumab (SID) arm." (NCT01940497)
Timeframe: After at least 14 cycles (1 cycle = 21 days; maximum up to 1 year)
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Comfortable: Unknown | Comfortable: Strongly Disagree | Comfortable: Disagree | Comfortable: Unsure | Comfortable: Agree | Comfortable: Strongly Agree | Convenient: Unknown | Convenient: Strongly Disagree | Convenient: Disagree | Convenient: Unsure | Convenient: Agree | Convenient: Strongly Agree | Confident: Unknown | Confident: Strongly Disagree | Confident: Disagree | Confident: Unsure | Confident: Agree | Confident: Strongly Agree | Satisfactory: Unknown | Satisfactory: Strongly Disagree | Satisfactory: Disagree | Satisfactory: Unsure | Satisfactory: Agree | Satisfactory: Strongly Agree | Would continue: Unknown | Would continue: Strongly Disagree | Would continue: Disagree | Would continue: Unsure | Would continue: Agree | Would continue: Strongly Agree | |
| Trastuzumab (SID) | 0.0 | 0.0 | 0.0 | 6.7 | 40 | 53.3 | 0.0 | 0.0 | 0.0 | 6.7 | 33.3 | 60 | 0.0 | 0.0 | 0.0 | 6.7 | 40.0 | 53.3 | 0.0 | 0.0 | 0.0 | 6.7 | 33.3 | 60 | 0.0 | 0.0 | 13.3 | 6.7 | 20 | 60 |
"Objective tumor response rate (complete response, unconfirmed complete response, partial response, unconfirmed partial response) in patients with measurable disease were assessed in each arm and compared between arms using Chi-squared test.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions" (NCT01959139)
Timeframe: Up to 3 years
| Intervention | percent of participants (Number) |
|---|---|
| Phase II: mFOLFIRINOX | 45 |
| Phase II: mFOLFIRINOX + PEGPH20 | 33 |
"Assess safety of mFOLFIRINOX in combination with PEGPH20 and select the optimal dose of PEGPH20 for the Phase II portion.~MTD of PEGPH20 in combination with mFOLFORINOX was evaluated by testing decreasing doses of PEGPH20 from 3mcg/kg on Day 1 and Day 3/4, to 3mcg/kg on Day 1 only and to 1.6 mcg/kg on Day 1 only.~MTD reflects the highest dose that had a dose-limiting toxicity (DLT) rate of ≤ 17%. DLTs were defined as treatment regimen related: grade ≥ 3 non-hematologic toxicity; grade 4 absolute neutrophil count (ANC) anemia or thrombocytopenia; grade 4 ANC lasting > 7 days; grade ≥ 3 febrile neutropenia; grade ≥ 3 elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT), total bilirubin, and creatinine; delay in starting the 2nd cycle of mFOLFIRINOX by > 2 weeks due to drug related toxicity.~DLT were graded using the NCI CTCAE version 4. Note: the third and lowest dose level was not reached." (NCT01959139)
Timeframe: 2 cycles of 14 days
| Intervention | ug/kg (Number) |
|---|---|
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/4 | 0 |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 | 3 |
| All Phase 1 Participants | 3 |
"Time from date of registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact.~Assessed using the logrank test." (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years
| Intervention | months (Median) |
|---|---|
| Phase II: mFOLFIRINOX | 14.4 |
| Phase II: mFOLFIRINOX + PEGPH20 | 7.7 |
Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause. Participants last known to be alive without report of progression are censored at date of last contact. (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years
| Intervention | months (Median) |
|---|---|
| Phase II: mFOLFIRINOX | 6.2 |
| Phase II: mFOLFIRINOX + PEGPH20 | 4.3 |
"Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.~Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living e.g. bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.~Grade 4: Life-threatening consequences; urgent intervention indicated.~Grade 5: Death related to adverse event" (NCT01959139)
Timeframe: Duration of treatment and follow up until death or 3 years post registration
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain | Acute kidney injury | Alanine aminotransferase increased | Alkaline phosphatase increased | Anemia | Anorexia | Arthralgia | Ascites | Aspartate aminotransferase increased | Blood bilirubin increased | Creatinine increased | Dehydration | Depression | Diarrhea | Esophagitis | Fatigue | Febrile neutropenia | Gallbladder obstruction | Gastrointestinal disorders - Other, specify | General disorders and admin site conditions- Other | Generalized muscle weakness | Hyperglycemia | Hypertension | Hypokalemia | Hyponatremia | Hypophosphatemia | Hypotension | Infections and infestations - Other, specify | Infusion related reaction | Leukocytosis | Lung infection | Lymphocyte count decreased | Mucositis oral | Myalgia | Nausea | Neutrophil count decreased | Pain | Paresthesia | Peripheral motor neuropathy | Peripheral sensory neuropathy | Peritoneal infection | Platelet count decreased | Portal vein thrombosis | Pulmonary hypertension | Resp, thoracic and mediastinal disorders - Other | Sepsis | Skin infection | Small intestine infection | Spasticity | Thromboembolic event | Ventricular tachycardia | Vomiting | Weight loss | White blood cell decreased | |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/4 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 Only | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Phase II: mFOLFIRINOX | 1 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 1 | 7 | 1 | 10 | 0 | 6 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 8 | 4 | 1 | 1 | 1 | 2 | 0 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 8 | 1 | 2 |
| Phase II: PEGPH20 + mFOLFIRINOX | 3 | 0 | 3 | 2 | 2 | 3 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 12 | 1 | 11 | 0 | 0 | 1 | 0 | 3 | 1 | 0 | 4 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 4 | 4 | 2 | 12 | 3 | 0 | 0 | 1 | 5 | 1 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 0 | 10 | 0 | 2 |
DOR is defined as the time from date of first documented confirmed objective response to date of first documented progressive disease (PD). Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 14.9 |
Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 23.2 |
PFS is defined as the duration of time from study entry to documented disease progression (PD) requiring removal from the study or death. Participants alive without PD were censored at the earliest of the date of the last disease evaluation or start of new anticancer therapy. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow up of 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | months (Median) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 14.0 |
ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow-up of 23.2 months (IQR: 11.0 - 46.9 months ).
| Intervention | percentage of patients (Number) |
|---|---|
| Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine | 81 |
Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) was first documented or to the date of death, whichever occurred first according to Response Evaluation Criteria in Solid Tumors (RECIST). Subjects still having CR or PR and alive at the time of analysis were censored at their last date of tumor evaluation. CR was defined as disappearance of tumor lesions, PR as a decrease of at least 30% and PD as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks
| Intervention | months (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 7.5 |
| Matching Placebo + mFOLFOX6 | 6.7 |
Overall response of a subject was defined as the best tumor response (Complete Response (CR) or Partial Response (PR)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 45 |
| Matching Placebo + mFOLFOX6 | 61 |
Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00865709)
Timeframe: From randomization of the first subject until 33 months later.
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 535 |
| Matching Placebo + mFOLFOX6 | 552 |
Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression or death due to any cause, whichever occurred first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | Months (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 9.1 |
| Matching Placebo + mFOLFOX6 | 8.7 |
Time to progression (TTP) was defined as the time from date of randomization to disease progression. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | Months (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 9.2 |
| Matching Placebo + mFOLFOX6 | 9.0 |
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 6.5 |
| 5-FU/Cisplatin | 5.8 |
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 8.6 |
| 5-FU/Cisplatin | 7.9 |
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).
| Intervention | Percentage of patients in each group (Number) |
|---|---|
| S-1/Cisplatin | 29.1 |
| 5-FU/Cisplatin | 31.9 |
The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 4.8 |
| 5-FU/Cisplatin | 5.5 |
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 3.8 |
| 5-FU/Cisplatin | 3.8 |
DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. (NCT00555620)
Timeframe: Baseline up to Month 15
| Intervention | months (Median) |
|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | 14.1 |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | 6.3 |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 10.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 5.9 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 6.3 |
Any DLT event in Cycle 1: Grade (GR) 3/4 nausea, vomiting, or diarrhea despite anti-emetics, anti-diarrheals; GR 3 nonhematological toxicity for greater than or equal to (≥)7 days (except alopecia, skin or hair discoloration, hyperamylasemia, or hyperlipasemia without other clinical evidence of pancreatitis and asymptomatic hyperuricemia); GR 4 nonhematological toxicity; GR 4 neutropenia ≥7 days or thrombocytopenia; GR ≥3 febrile neutropenia or neutropenic infection; GR 3 thrombocytopenia ≥7 days; any treatment-related toxicity having >3 consecutive CAP or SU missed doses per cycle; delayed toxicity recovery >14 days. (NCT00555620)
Timeframe: Baseline up to Day 21
| Intervention | participants (Number) |
|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | 1 |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | 0 |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 3 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 2 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0 |
Percentage of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as ≥30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00555620)
Timeframe: Baseline, Day 21 of every even-numbered cycle up to 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | 16.7 |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | 42.9 |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 46.7 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 43.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 45.5 |
PFS defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. (NCT00555620)
Timeframe: Baseline up to Month 15
| Intervention | months (Median) |
|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | 3.2 |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | 6.6 |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 6.4 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 8.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 2.8 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 5.5 |
Area under the plasma concentration-time curve from time 0 to 24 hours postdose (0-24), also considered the AUC between doses at steady state. (NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
| Intervention | nanogram hours per milliliter (ng*hr/mL) (Mean) | ||
|---|---|---|---|
| AUC (0-24) SU011248 | AUC (0-24) SU012662 | AUC (0-24) total drug (SU011248+SU012662) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 844 | 321 | 1163 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 902 | 327 | 1230 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 1420 | 524 | 1944 |
AUC (12) = Area under the plasma concentration versus time curve from time zero (predose) to the extrapolated time 12 hours postdose. It is obtained from AUC (0 - last) plus AUC (last - 12) (NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng*hr/mL (Mean) | |||
|---|---|---|---|---|
| CAP (n = 1, 4, 9) | 5'DFCR (n = 1, 7, 10) | 5'DFUR (n = 1, 6, 10) | 5-FU (n = 1, 5, 10) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 25435 | 15522 | 15522 | 1299 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8865 | 10091 | 10291 | 842 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2663 | 7087 | 4822 | 353 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng*hr/mL (Mean) | |||
|---|---|---|---|---|
| CAP (n = 1, 4, 10) | 5'DFCR (n = 1, 7, 10) | 5'DFUR (n = 1, 6, 10) | 5-FU (n = 1, 5, 9) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 7480 | 9200 | 7770 | 386 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8069 | 11467 | 9099 | 489 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2828 | 8853 | 5703 | 285 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
| Intervention | ng*hr/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 7555 | 13532 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 7373 | 8213 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2899 | 3157 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
| Intervention | ng*hr/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 355 | 688 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 506 | 854 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 291 | 350 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
| Intervention | ng*hr/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 12815 | 8614 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 11229 | 9776 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 8028 | 6464 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
| Intervention | ng*hr/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 8855 | 8500 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8951 | 10017 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 5658 | 4829 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 176 | 552 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 495 | 866 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 165 | 153 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4800 | 5500 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8017 | 8036 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 3352 | 2267 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4010 | 6259 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 7166 | 10082 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2891 | 2074 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 7000 | 20491 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 11681 | 16276 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2051 | 1989 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.0 | 0.0 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.8 | 0.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 0.0 | 0.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 11.1 | 50.5 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 55.60 | 0.00 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 13.0 | 0.00 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.0 | 33.5 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 34.4 | 0.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.4 | 0.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 24.8 | 32.0 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.0 | 0.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 0.0 | 0.0 |
(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
| Intervention | nanograms per milliliter (ng/mL) (Mean) | ||
|---|---|---|---|
| Cmax SU011248 | Cmax SU012662 | Cmax total drug (SU011248+SU012662) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 40.1 | 14.0 | 53.9 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 46.5 | 16.6 | 62.4 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 69.7 | 23.7 | 93.0 |
(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Cmin SU011248 | Cmin SU012662 | Cmin total drug (SU011248+SU012662) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 29.0 | 11.9 | 41.6 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 30.2 | 11.1 | 41.8 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 49.2 | 18.7 | 68.5 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.8 | 0.6 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.6 | 0.6 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 1.2 | 1.1 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.7 | 0.7 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.8 | 0.8 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 1.0 | 1.1 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.7 | 0.6 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.7 | 0.7 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 1.0 | 1.0 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Mean) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 0.3 | 0.4 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.4 | 0.4 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 0.3 | 0.5 |
(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
| Intervention | hour (hr) (Median) | ||
|---|---|---|---|
| Tmax SU011248 | Tmax SU012662 | Tmax total drug (SU011248+SU012662) | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.0 | 9.0 | 4.0 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 8.0 | 6.0 | 6.0 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 8.0 | 8.0 | 8.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Median) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.5 | 0.4 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.6 | 0.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.0 | 3.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Median) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.3 | 0.4 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.6 | 0.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.0 | 3.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Median) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.5 | 0.4 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.8 | 0.5 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.0 | 3.0 |
(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
| Intervention | hr (Median) | |
|---|---|---|
| Cycle 1, Day 1 | Cycle 1, Day 14 | |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | 4.3 | 0.3 |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | 0.5 | 0.4 |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | 2.0 | 2.0 |
DLT occurring within 3 weeks of the start of chemoradiation therapy was defined as: Grade 3 non-hematologic or hematologic toxicity requiring interruption of >7 days (d) of chemo or >3d chemoradiation; Grade 4 non-hematologic; Grade 4 neutropenia or thrombocytopenia; Treatment-related death; Delays in surgery >3 weeks due to treatment-related toxicity. A 30% increase in any surgical complication rate beyond those previously established rates (readmission rate: 16%; pancreatic fistula/intra-abdominal abscess/infection rate: 27%, major intra-abdominal bleeding requiring return to OR: 1.6%, delayed gastric emptying: 4.4%, and superficial wound infection rate: 8%) was also considered a DLT. (NCT00889187)
Timeframe: within 3 weeks of the start of chemoradiation therapy
| Intervention | patients with DLT (Number) |
|---|---|
| Phase 1 Cohort 1: Photon Rad (30 Gy/12 Days)+Capecitabine | 0 |
| Phase I Cohort 2: Photon Rad (25 Gy/11 Days)+Capecitabine | 0 |
| Phase I Cohort 3: Photon Rad (25 Gy/5 Days)+Capecitabine | 0 |
Neoadjuvant short-course photon radiation therapy MTD in combination with capecitabine 825 mg/m2 orally BID for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy is determined by the number of patients who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If none of 3 initial patients or only 1 of 6 patients have a DLT on dose level 3 then 6 additional patients are treated at this dose. If during this expansion, the rate of DLT exceeds 30% then the next lower dose level is declared the MTD. If no DLTs are observed, the MTD is not reached. (NCT00889187)
Timeframe: within 3 weeks of the start of chemoradiation therapy
| Intervention | Gy per fraction (Number) |
|---|---|
| All Phase I: Photon Rad+Capecitabine | NA |
MTD of Erlotinib was determined using a traditional 3 + 3 dose escalation scheme of three dose levels (50,100,150mg). Successive cohorts of 3-6 patients were enrolled into dose escalation cohorts for 14 day cycles. MTD reflects the highest dose of Erlotinib that had ≤1 out of 6 patients with Dose-Limiting Toxicity (DLT) at the highest dose level below the maximally administered dose. The maximally administered dose is the first dose that causes DLT in >33% of patients. DLT was defined as: Any grade 4 neutropenia, Any grade 3 thrombocytopenia, or Any ≥ grade 3 non-hematologic toxicity that results in greater than 7 days interruption in therapy. (NCT00307736)
Timeframe: 3 years
| Intervention | mg (Number) |
|---|---|
| 5-FU, Bevacizumab, Erlotinib and Radiation | 100 |
The number of subjects who achieved a pathologic complete response as determine by pathologist, following completion of the study therapy. Pathologic complete response represents the absence of residual invasive disease in the rectum and in the regional lymph nodes. (NCT00307736)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Completed Study Therapy | 9 |
| Underwent Resection | 10 |
| Treated at MTD | 7 |
Summary of disease free survival at 1, 2, and 3 years. Disease free survival is the length of time after primary treatment for cancer ends that the participant survives without any clinical signs or symptoms of that cancer. The data is shown of the percentage of participants still in disease free survival at one, two, and three years. (NCT00307736)
Timeframe: 1, 2, 3 years
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 Year | 2 Years | 3 Years | |
| 5-fluorocuracil, Bevacizumab, Erlotinib and Radiation | 93.4 | 83.4 | 75.5 |
Surgical morbidity following R0 resection with one of the following procedures: abdominal perineal resection, low anterior resection, and low anterior resection with coloanal anastomosis. (NCT00307736)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| anastomotic leaks | intra-abdominal infection | wound infections | pulmonary embolus | small bowel obstruction | urinary obstruction/retention | fever | |
| Surgery, 5-fluorocuracil, Bevacizumab, Erlotinib and Radiation | 4 | 2 | 2 | 1 | 1 | 5 | 1 |
"Summary of grade 3 or greater toxicity by grade and type. All adverse events were evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.~Grade 3: Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.~Grade 4 Life-threatening consequences; urgent intervention indicated." (NCT00307736)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphopenia | Diarrhea w/o prior colostomy | Hypophosphatemia | Rash: acne/acneiform | ALT-SGPT | AST-SGOT | Cardiac-ischemia | Colitis | Dehydration | Fatigue | Febrile neutropenia | Hypertension | Hyperuricemia | Hypokalemia | Hyponatremia | Muco/stomatitis (symptom) oral cavity | Muco/stomatitis by exam-oral cavity | Proteinuria | Radiation dermatitis | Rash/desquamation | Rectum-pain | |
| Grade 3 | 16 | 6 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Grade 4 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"BOR defined as percentage of subjects, whose BOR was either (confirmed) complete response (CR) or partial response (PR), relative to the number of subjects belonging to the study population of interest. CR defined as Disappearance of all target lesions plus disappearance of all non-target lesions & without appearance of any new lesions; confirmed minimum 4 weeks later. PR defined as At least 30% reduction in the SOLD of target lesions plus no significant change in non-target lesions to qualify for either CR or PD without appearance of new lesions; confirmed minimum 4 weeks later" (NCT00439517)
Timeframe: Evaluations were performed every 8 weeks until disease progression, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
| Intervention | percentage of participants (Number) |
|---|---|
| UFOX + Cetuximab | 37.5 |
| FOLFOX4 + Cetuximab | 51.3 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00439517)
Timeframe: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
| Intervention | months (Median) |
|---|---|
| UFOX + Cetuximab | 12.9 |
| FOLFOX4 + Cetuximab | 15.5 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00439517)
Timeframe: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 31 Aug 2011
| Intervention | months (Median) |
|---|---|
| UFOX + Cetuximab | 16.8 |
| FOLFOX4 + Cetuximab | 18.4 |
Duration from randomization until progression or death due to any cause. Only deaths within 12 weeks of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. Response and progression were assessed by the Investigators using response evaluation criteria in solid tumors (RECIST) 1.0 criteria (NCT00439517)
Timeframe: Time from randomization to disease progression, death, or last tumor assessment reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
| Intervention | months (Median) |
|---|---|
| UFOX + Cetuximab | 6.6 |
| FOLFOX4 + Cetuximab | 8.2 |
Please refer to Adverse Events section for details of individual serious adverse events and other adverse events (NCT00439517)
Timeframe: Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
| Intervention | participants (Number) |
|---|---|
| UFOX + Cetuximab | 151 |
| FOLFOX4 + Cetuximab | 149 |
The EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QOL. (NCT00439517)
Timeframe: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Baseline | Cycle 3 | Cycle 6 | |
| FOLFOX4 + Cetuximab | 0.734 | 0.758 | 0.771 |
| UFOX + Cetuximab | 0.747 | 0.782 | 0.758 |
TPQ was used to investigate which features of chemotherapy treatment are the most relevant in ensuring patient satisfaction. The most essential characteristics of a cancer medication are shown at baseline and at cycle 3, along with percentage of subjects selecting that characteristic. (NCT00439517)
Timeframe: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline: Does not increase your risk of infection | Baseline: Does not interfere with daily activities | Baseline: Does not make you vomit | Baseline: Does not give you diarrhea | Cycle 3: Does not increase your risk of infection | Cycle 3: Does not interfere with daily activities | Cycle 3: Does not make you vomit | Cycle 3: Does not give you diarrhea | |
| FOLFOX4 + Cetuximab | 16 | 15 | 14 | 5 | 15 | 11 | 10 | 4 |
| UFOX + Cetuximab | 18 | 17 | 4 | 9 | 15 | 10 | 4 | 15 |
"All of the single-item measures of the FACT-C are assessed on ordinal response categories ranging from 0=Not at all to 4=Very much. For scoring purposes the response scores are reversed on negatively phrased questions. The principle for scoring the sub-scales is the same in all cases: subscale score = (Sum of items × Number of items in the subscale) / numbers of items answered. The lowest possible total score is 0 and the highest is 136. A high scale score represents a high QOL." (NCT00439517)
Timeframe: At baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. Cycles were 4 weeks long unless dosing delays
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Baseline | Cycle 3 | Cycle 6 | |
| FOLFOX4 + Cetuximab | 96.45 | 95.89 | 94.70 |
| UFOX + Cetuximab | 98.22 | 95.41 | 94.75 |
Non-protocol medical care visits and consultations (NCT00439517)
Timeframe: From randomisation until final visit, reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009
| Intervention | visits or consultations (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Emergency room visit | Hospital oupatient clinic visit | Practice visit | Home visit | General Practitioner consultation | Specialist consultation | Nurse consultation | Other consultation | |
| FOLFOX4 + Cetuximab | 26 | 35 | 159 | 130 | 124 | 84 | 123 | 18 |
| UFOX + Cetuximab | 34 | 40 | 71 | 15 | 65 | 62 | 15 | 19 |
Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only be calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow up for progression of disease during first line therapy. Median duration of response was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization to the end of study, up to 26 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 7.1 |
| Placebo | 5.8 |
The primary efficacy endpoint for this study was overall survival (time to death), defined as the time between randomization and the date of death irrespective of the cause of death. Patients for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive. Median survival was estimated by the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until death, up to 26 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 12.1 |
| Placebo | 10.1 |
Progression-free survival (PFS) is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first. Patients who neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow up for progression of disease. Median PFS was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until disease progression or death, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 6.7 |
| Placebo | 5.3 |
Progression-free survival (PFS) during first-line therapy is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first and only if it occurs no later than 28 days after last confirmed intake of any study medication and only if it occurs before the start of non-study antineoplastic treatment. Participants who did not progress or die in this interval or were lost to follow-up were censored at the date of the last tumor assessment within this time window. Median PFS was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until 28-days after the last study treatment was administered, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 6.9 |
| Placebo | 5.4 |
Time to progression is defined as the time from randomization to the first occurrence of progressive disease (PD). PD was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Patients with no PD at study completion (including those who died before PD) were censored at the date of the last tumor assessment. Median time to PD was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until disease progression; assessed every 6 weeks for the first year and every 12 weeks thereafter, up to 26 months.
| Intervention | months (Median) |
|---|---|
| Bevacizumab | 7.0 |
| Placebo | 5.6 |
Best overall response during first-line therapy is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response, as determined by the RECIST criteria. CR is defined as the disappearance of all target and non-target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions and no new or progression of non-target lesions, or the disappearance of all target lesions and persistence of one or more non-target lesion(s). (NCT00548548)
Timeframe: From randomization until the end of study, up to 26 months.
| Intervention | participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Bevacizumab | 143 | 168 |
| Placebo | 111 | 186 |
The intensity of Adverse Events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 on a five-point scale from Grade 1 (Mild) to Grade 5 (Death). A serious AE (SAE) was defined as any event that is fatal, life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. (NCT00548548)
Timeframe: From randomization until 3 months after last dose (up to 26 months)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any Adverse event | Serious AE | Grade 3/4/5 AE | Grade 5 AE | Deaths not due to Progression | |
| Bevacizumab | 380 | 134 | 293 | 18 | 31 |
| Placebo | 377 | 137 | 294 | 25 | 29 |
Disease control for participants with measurable disease was defined as a complete response (CR), partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the RECIST criteria. For participants without measurable disease, disease control was defined as no disease progression for ≥ 6 weeks. (NCT00548548)
Timeframe: From randomization until the end of study, up to 26 months.
| Intervention | participants (Number) | |
|---|---|---|
| Participants with Disease Control | Participants without Disease Control | |
| Bevacizumab | 300 | 87 |
| Placebo | 271 | 116 |
Participants who were alive and disease free at 12 months. DFS was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was disappearance of all target lesions. Partial response was at least a 30% decrease in target lesions. Progression was at least a 20% increase in target lesions and stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00941655)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 2 |
| Systemic Chemotherapy Alone | 0 |
Blood loss during surgery is related to complexity of the operation and via that to the stage of disease (more tumor to be cytoreduced, more blood loss). (NCT00941655)
Timeframe: Day 1
| Intervention | ml (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 650 |
Time it takes to perform this complex surgery and HIPEC to reduce tumor burden overall in this disease. (NCT00941655)
Timeframe: up to 12 hours
| Intervention | hours (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 10.1 |
Recuperation period following complex surgery for this disease. (NCT00941655)
Timeframe: 1-10 weeks
| Intervention | Days (Median) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 17 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00941655)
Timeframe: Date treatment consent signed to date off study, approximately, 40.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Surgery + HIPEC + Systemic Chemotherapy | 8 |
| Systemic Chemotherapy Alone | 5 |
CCR is assessed by Sugarbaker's criteria. CCR-0 is no residual tumor. CCR-1 is no residual nodules greater than 2.5 mm in diameter, CCR-2 is no residual nodules greater than 25 mm, and CCR-3 is residual nodules greater than 25 mm. (NCT00941655)
Timeframe: Day 1
| Intervention | Scores on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
Gillys stage measures the completeness of the cytoreduction and is recorded before and after surgery. It is used to classify disease burden and determine prognosis. Stage 0 is no macroscopic signs of disease, stage 1 is nodules >5mm in one part of the abdomen, stage 2 is nodules >5 mm throughout the abdomen, stage 3 is nodules 5mm to 2 cm, and stage 4 is nodules < 2 cm. (NCT00941655)
Timeframe: Day 1
| Intervention | Stage (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 Before Surgery | Patient 1 After Surgery | Patient 2 Before Surgery | Patient 2 After Surgery | Patient 3 Before Surgery | Patient 3 After Surgery | Patient 4 Before Surgery | Patient 4 After Surgery | Patient 5 Before Surgery | Patient 5 After Surgery | Patient 6 Before Surgery | Patient 6 After Surgery | Patient 7 Before Surgery | Patient 7 After Surgery | Patient 8 Before Surgery | Paitent 8 After Surgery | |
| Surgery + HIPEC + Systemic Chemotherapy | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 |
Time between the first day of treatment and the date of death. (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient #1 | Patient #2 | Patient #4 | Patient #6 | Patient #7 | Patient #9 | Patient #11 | Patient #15 | |
| Surgery + HIPEC + Systemic Chemotherapy | 19 | 11 | 11 | 4 | 14 | 5 | 12 | 0 |
Time between the first day of treatment and the date of death (NCT00941655)
Timeframe: 12 weeks up to 3 years
| Intervention | Months (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Patient #3 | Patient #5 | Patient #8 | Patient #10 | Patient #12 | Patient #13 | Patient #14 | |
| Systemic Chemotherapy Alone | 17 | 6 | 10 | 0 | 0 | 8 | 0 |
"Percentage of partial and complete responses, according to WHO criteria:~Complete Response: Disappearance of all known disease, determined by 2 observations not less than 4 weeks apart.~Partial Response: Decrease by at least 50% of the diameters of all measurable lesions, determined by 2 observations not less than 4 weeks apart." (NCT00382720)
Timeframe: every 8 weeks up to a maximum of 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| (TE) Taxotere and Eloxatin | 23.1 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 46.6 |
| (TEX) Taxotere, Eloxatin and Xeloda | 25.6 |
The number of months measured from the date of randomization to the date of death due to any cause. (NCT00382720)
Timeframe: up to a maximum of 36 months
| Intervention | months (Median) |
|---|---|
| (TE) Taxotere and Eloxatin | 8.97 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 14.59 |
| (TEX) Taxotere, Eloxatin and Xeloda | 11.30 |
"The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause.~WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion." (NCT00382720)
Timeframe: every 8 weeks up to a maximum of 36 months
| Intervention | Months (Median) |
|---|---|
| (TE) Taxotere and Eloxatin | 4.50 |
| (TEF) Taxotere, Eloxatin and 5-fluorouracil | 7.66 |
| (TEX) Taxotere, Eloxatin and Xeloda | 5.55 |
MTD is the highest dose at which 1 or fewer dose limiting toxicities (DLT's) are observed in 6 patients. DLT defined as any non-hematologic grade III/IV or neutropenia-associated (infection or fever treated in the hospital) toxicity attributable to this therapy. Response evaluated after two 14-day treatments of Docetaxel, 5-Fluorouracil and Oxaliplatin (One cycle = 28 days). (NCT00526110)
Timeframe: 28 days
| Intervention | mg/m^2 (Number) |
|---|---|
| Phase I | 50 |
Overall survival was defined as the time from the start of treatment until death or last follow-up. Kaplan-Meier curve was used to estimate overall survival. (NCT00526110)
Timeframe: Up to 30 months
| Intervention | months (Median) |
|---|---|
| Phase II | 11.1 |
Progression Free Survival (PFS) defined as the time from the first study drug administration until the first day of radiological and/or symptomatic disease progression is documented, or the start of further anticancer therapy or death from any cause, whichever occurs first. Kaplan-Meier curve was used to estimate PFS. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesion. (NCT00526110)
Timeframe: Assessed from baseline to 30 months
| Intervention | months (Median) |
|---|---|
| Phase II | 6.5 |
Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1 by independent radiology review) at 8 week intervals in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 35.1 |
| LAPC Modified FOLFIRINOX | 17.2 |
Overall survival will be determined in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 81 |
| LAPC Modified FOLFIRINOX | 100 |
The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of FOLFIRINOX. Tumour response was determined according to RECIST 1.1 by independent radiology review. (NCT01523457)
Timeframe: 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| MPC Modified FOLFIRINOX | 54 |
| LAPC Modified FOLFIRINOX | 97 |
The rate of surgical resection in the cohort of patients with locally advanced disease will be determined. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total | Unresectable | Borderline | |
| LAPC Modified FOLFIRINOX | 13 | 6 | 7 |
Toxicities will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0. Rates of grade 3 and 4 toxicities will be compared to historical controls. MPC and LAPC are combined because they were given the exact same medication. The study aimed to compare this dosage with historical dosage, so this comparison is the most appropriate. (NCT01523457)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | Febrile neutropenia | Diarrhea | Fatigue | Alanine aminotransferase (ALT) increased | Thromboembolic event | Peripheral sensory neuropathy | Vomiting | |
| LAPC Modified FOLFIRINOX | 5 | 2 | 2 | 2 | 4 | 4 | 0 | 0 | 0 | 1 |
| MPC Modified FOLFIRINOX | 4 | 5 | 2 | 1 | 8 | 5 | 3 | 3 | 2 | 1 |
Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure
| Intervention | months (Median) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | NA |
| Arm 2: Adjuvant Chemoradiation | NA |
The number of patients who complete the recommended therapy will be counted for each arm. (NCT03515941)
Timeframe: From date of assigned therapy up to 17 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Adjuvant Chemotherapy | 3 |
| Arm 2: Adjuvant Chemoradiation | 2 |
Overall survival (OS) was defined as the time from study entry to death of any cause. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 11.6 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 8.6 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 11.8 |
Progression free survival (PFS) was defined as the time from study entry to progression or death of any cause. The median PFS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 7.1 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 4.9 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 6.8 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with adenocarcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 61 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 45 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 54 |
Time to treatment failure (TTF) was measured from study entry until documented progression, death resulting from any cause, or end of protocol therapy because of unacceptable toxicity. The median TTF with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: Adenocarcinoma (ECF + Cetuximab) | 5.6 |
| Arm B: Adenocarcinoma (IC + Cetuximab) | 4.3 |
| Arm C: Adenocarcinoma (FOLFOX + Cetuximab) | 6.7 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with squamous cell carcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Squamous Cell Carcinoma (ECF + Cetuximab) | 67 |
| Arm B: Squamous Cell Carcinoma (IC + Cetuximab) | 13 |
| Arm C: Squamous Cell Carcinoma (FOLFOX + Cetuximab) | 60 |
Duration of response was defined using RECIST v. 1.1 criteria as the time from the date criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death from any cause. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants who were not known to have died and who did not have PD were censored at the date of the last tumor assessment prior to the date of any subsequent systemic anticancer therapy. (NCT01246960)
Timeframe: Time of first response to measured PD (up to Month 23.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 7.4 |
| Placebo and mFOLFOX6 | 5.8 |
Participants with treatment-emergent anti-ramucirumab antibodies were participants with a 4-fold increase (2 dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). (NCT01246960)
Timeframe: Months 1, 2, 4, 6, and 8
| Intervention | participants (Number) |
|---|---|
| Ramucirumab and mFOLFOX6 | 0 |
| Placebo and mFOLFOX6 | 1 |
OS was defined as the time from randomization to death due to any cause. OS was censored at the date of the last follow-up visit for participants who were alive or lost to follow-up. (NCT01246960)
Timeframe: Randomization to date of death from any cause (up to Month 28.3)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 11.7 |
| Placebo and mFOLFOX6 | 11.5 |
The percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) is reported. Response was defined using RECIST, v. 1.1 criteria. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. The percentage of participants with objective response=(number of participants whose best overall response achieved was CR or PR/number of participants treated)*100. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 23.0)
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab and mFOLFOX6 | 45.2 |
| Placebo and mFOLFOX6 | 46.4 |
PFS was defined using Response Evaluation Criteria in Solid Tumors [RECIST version (v.) 1.1] as the time from randomization to the first observation of progressive disease (PD) or death due to any cause, whichever came first. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 millimeters (mm); the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. If a participant did not have a baseline disease assessment, PFS time was censored at the randomization date, regardless of whether or not PD or death was observed. Participants not known to have died or have objective PD were censored at the last post-baseline radiological assessment date. (NCT01246960)
Timeframe: Randomization to measured PD or date of death from any cause (up to Month 25.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 6.4 |
| Placebo and mFOLFOX6 | 6.7 |
TTP was defined using RECIST v. 1.1 as the time from study randomization to the first date of PD. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. TTP was censored at the date of last adequate tumor assessment if death was due to causes other than PD. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 25.0)
| Intervention | months (Median) |
|---|---|
| Ramucirumab and mFOLFOX6 | 8.7 |
| Placebo and mFOLFOX6 | 7.1 |
Reported are the number of participants who had ramucirumab/placebo-related: AEs, serious AEs (SAEs), AEs based on common terminology criteria for adverse events (CTCAE) ≥Grade 3, AEs = CTCAE Grade 5, as well as, AEs leading to treatment discontinuation and AEs resulting in death. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module. (NCT01246960)
Timeframe: Baseline through study completion (up to Month 28.3)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any Ramucirumab/Placebo-Related AE | Any Ramucirumab/Placebo-Related SAE | Any Ramucirumab/Placebo-Related ≥Grade 3 AE | Any Ramucirumab/Placebo-Related Grade 5 AE | Any AE Leading to Treatment Discontinuation | Any AE with Outcome of Death | |
| Placebo and mFOLFOX6 | 64 | 12 | 33 | 3 | 5 | 2 |
| Ramucirumab and mFOLFOX6 | 64 | 10 | 36 | 0 | 18 | 5 |
"Per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and by Spiral CT assessment:~Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR" (NCT00573131)
Timeframe: Screening and Week 12
| Intervention | percentage of patients (Number) |
|---|---|
| Group 1 | 12.5 |
| Group 2 | 20.0 |
From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT01658943)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| mFOLFOX | 6.7 |
| MK2206 and Selumetinib | 3.9 |
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact. (NCT01658943)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| mFOLFOX | 2.0 |
| MK2206 and Selumetinib | 1.9 |
Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT01658943)
Timeframe: Up to 3 years
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain | Alanine aminotransferase increased | Alkaline phosphatase increased | Anemia | Anorexia | Aspartate aminotransferase increased | Blood bilirubin increased | Cognitive disturbance | Dehydration | Device related infection | Diarrhea | Edema face | Encephalopathy | Erythema multiforme | Erythroderma | Fatigue | Generalized muscle weakness | Hepatic failure | Hyperglycemia | Hypertension | Hypokalemia | Hypomagnesemia | Hyponatremia | Hypophosphatemia | Hypotension | Hypoxia | Left ventricular systolic dysfunction | Lung infection | Lymphocyte count decreased | Mucositis oral | Multi-organ failure | Nausea | Neoplasms benign, malignant and unspecified | Neutrophil count decreased | Platelet count decreased | Rash acneiform | Rash maculo-papular | Skin infection | Soft tissue infection | Stevens-Johnson syndrome | Syncope | Vomiting | Weight loss | White blood cell decreased | |
| mFOLFOX | 1 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 8 | 1 | 0 | 3 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 2 |
| MK2206 and Selumetinib | 0 | 4 | 2 | 3 | 1 | 3 | 0 | 1 | 6 | 0 | 4 | 1 | 1 | 1 | 1 | 7 | 1 | 1 | 7 | 5 | 1 | 0 | 4 | 1 | 1 | 1 | 1 | 1 | 0 | 4 | 1 | 0 | 2 | 0 | 0 | 5 | 7 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
Confirmed response (CR) is two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. Partial response (PR) is two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration. Unconfirmed CR is one objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR is one objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR. (NCT01658943)
Timeframe: Up to 3 years
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Partial Response | Unconfirmed Partial Response | Stable/No response | Increasing disease | Symptomatic Deterioration | Assessment Inadequate | |
| mFOLFOX | 4 | 1 | 14 | 29 | 3 | 6 |
| MK2206 and Selumetinib | 0 | 1 | 12 | 34 | 2 | 6 |
Where events are defined as recurrence, second primary cancer, or death from any cause (NCT00096278)
Timeframe: 3 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil | 75.5 |
| Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | 77.4 |
Percentage of patients who did not experience an event where events are defined as death from any cause. (NCT00096278)
Timeframe: 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (mFOLFOX6) | 77.6 |
| Arm II (Bevacizumab, mFOLFOX6) | 78.7 |
Overall response rate defined as Complete Response (CR), disappearance of all target lesions; or Partial Response (PR), at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. In addition to a baseline scan, confirmatory scans for those deemed to have achieved a PR or CR. (NCT00354887)
Timeframe: Every 9 weeks from treatment initiation and confirmatory images 6 weeks or more after initial responses
| Intervention | participants (Number) | |
|---|---|---|
| Participants with CR | Participants with PR | |
| Oxaliplatin + Capecitabine | 3 | 12 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
Defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death from any cause. (NCT00193128)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 16.3 |
Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00193128)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 24.1 |
The absence of any residual tumor cells in a histologic evaluation of a tumor specimen following surgery is defined as a complete pathologic response (NCT00193128)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2) | 24 |
Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 2 |
| Placebo | 8 |
Dose delay or reduction in chemotherapy doses due to neutropenia (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 5 |
| Placebo | 26 |
Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 41 |
| Placebo | 53 |
Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC < 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 3 |
| Placebo | 10 |
Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) < 1 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 16 |
| Placebo | 51 |
Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) <0.5 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 13 |
| Placebo | 17 |
Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of neutropenia (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 7 |
| Placebo | 9 |
Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 34 |
| Placebo | 37 |
Kaplan-Meier estimate of the median time to disease progression or death (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Days (Median) |
|---|---|
| Pegfilgrastim (Neulasta) | 318 |
| Placebo | 322 |
Death from any cause through the end of the follow-up period (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 47 |
| Placebo | 49 |
The NCI Common Terminology Criteria for Adverse Events version 3.0 was used for adverse event reporting and toxicity grading. (NCT00320749)
Timeframe: Weekly up to 24 weeks
| Intervention | percent of patients (Number) | ||
|---|---|---|---|
| leukopenia | neutropenia | fatigue | |
| Capecitabine, Docetaxel, Gemcitabine | 29 | 29 | 25 |
MTD will be the dose at which 1 or fewer patients (≤ 1/6) experiences a DLT during the first or second cycle with the next higher dose having at least 2/3 or 2/6 patients experiencing Dose Limiting Toxicities (DLT). (NCT00320749)
Timeframe: Weekly up to 24 weeks
| Intervention | mg/m^2 (Number) | ||
|---|---|---|---|
| docetaxel | gemcitabine | capecitabine | |
| Capecitabine, Docetaxel, Gemcitabine | 36 | 750 | 625 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00320749)
Timeframe: every 8 weeks, up to 24 weeks
| Intervention | percent of patients (Number) | ||
|---|---|---|---|
| Partial Response | Complete Response | Stable Disease | |
| Capecitabine, Docetaxel, Gemcitabine | 11 | 0 | 72 |
Objective response was defined as having a CR or a PR. Response assessment was performed using modified WHO criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: >50% decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. Duration of objective response was defined as time from first appearance of CR or PR to time of PD (PD: >25% increase in one or more lesions, or appearance new lesions) or death. Duration of objective response was to be assessed using Kaplan-Meier analysis. (NCT00215644)
Timeframe: From first documented objective response to PD or death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | NA |
| ECX Only | NA |
OS was defined as the duration from randomization to death (due to any cause). OS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline until death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 9.4 |
| ECX Only | 12.2 |
Objective response was defined as having a complete response (CR) or a partial response (PR). Response assessment was performed using modified World Health Organization (WHO) criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: greater than (>) 50 percent (%) decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 31 |
| ECX Only | 58 |
PFS was defined as the time from randomization to the first documentation of PD or to death due to any cause, whichever occurred first. PD: >25% increase in one or more lesions, or appearance new lesions. PFS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 4.8 |
| ECX Only | 7.1 |
EORTC QLQ-C30 included GHS/QoL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from EORTC QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL was linearly transformed and ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). EORTC QLQ-C30 GHS/QoL score at baseline and best overall change from baseline (throughout study) are reported. (NCT00215644)
Timeframe: Baseline (Day 1), Post Baseline (Up to 3 Years)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Post-Baseline | |
| ECX Only | 67.9 | -10.0 |
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab | 53.3 | 0.0 |
(NCT01041404)
Timeframe: BL
| Intervention | kg (Median) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 60 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 61 |
The median time, in months, of the duration of response. Participants were censored at the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | months (Median) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 4.8 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 6.9 |
Duration of response was defined for responders as the time from the date on which the CR or PR was first recorded to the date on which PD is first noted. Participants were censored on the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 80.0 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 71.9 |
The median time, in months, from the date of randomization to the date of an OS event. Participants were censored at the last date tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | months (Median) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 11.1 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 13.8 |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 62.8 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 56.8 |
Clinical benefit was defined as stable disease (SD), CR, or PR for 6 weeks or longer as determined by RECIST. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as a reference the smallest SLD recorded since treatment had started. For NTLs, SD was defined as a persistence of one or more NTLs and/or maintenance of tumor marker levels above the normal limits. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 69.3 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 78.9 |
For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 34.5 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 47.3 |
The median time, in months, from the date of randomization to the date of a PFS event. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | months (Median) |
|---|---|
| Fluoropyrimidine, Cisplatin | 5.5 |
| Trastuzumab, Fluoropyrimidine, Cisplatin | 6.7 |
PFS was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or date of death, whichever occurs first. For target lesions (TL), PD was defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD) of TLs, taking as a reference the smallest SLD recorded since the treatment started, or the appearance of one or more lesions. For non-target lesions (NTL), PD was defined as an unequivocal progression of existing NTLs. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 81.0 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 76.9 |
Individual steady state predicted exposure, as assessed by median AUC (measured as mg multiplied by [*] day per liter [L]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. Individual steady state AUC was calculated using all available PK samples from all timepoints. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
| Intervention | mg*day/L (Median) |
|---|---|
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 1030 |
The median time, in months, from the date of randomized to the date of a TTP event. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | months (Median) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 5.6 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 7.1 |
TTP was defined as the time from the date of randomization and the date of the first occurrence of PD. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) |
|---|---|
| Fluoropyrimidine/Cisplatin (FP) | 74.1 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 70.7 |
Median Cmax (measured as mg/L) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
| Intervention | mg/L (Median) |
|---|---|
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 128 |
Median Cmin (measured as milligrams per liter [mg/L]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
| Intervention | mg/L (Median) |
|---|---|
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 23.0 |
The QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | scores on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dysphagia Scale: BL (n=276,287) | Dysphagia Scale: Week 4 (n=234,250) | Dysphagia Scale: Week 7 (n=181,220) | Dysphagia Scale: Week 10 (n=176,203) | Dysphagia Scale: Week 13 (n=152,183) | Dysphagia Scale: Week 16 (n=120,165) | Dysphagia Scale: Week 19 (n=114,143) | Dysphagia Scale: Week 22 (n=79,143) | Dysphagia Scale: Week 25 (n=64,124) | Dysphagia Scale: Week 28 (n=47,111) | Dysphagia Scale: Week 31 (n=45,95) | Dysphagia Scale: Week 34 (n=37,87) | Dysphagia Scale: Week 37 (n=29,64) | Dysphagia Scale: Week 40 (n=24,55) | Dysphagia Scale: Week 43 (n=12,43) | Dysphagia Scale: Week 46 (n=14,42) | Dysphagia Scale: Week 49 (n=10,36) | Dysphagia Scale: Week 52 (n=8,30) | Dysphagia Scale: Week 55 (n=6,24) | Dysphagia Scale: Week 58 (n=6,21) | Dysphagia Scale: Week 61 (n=4,17) | Dysphagia Scale: Week 64 (n=3,20) | Dysphagia Scale: Week 67 (n=4,16) | Dysphagia Scale: Week 70 (n=3,14) | Dysphagia Scale: Week 73 (n=3,12) | Dysphagia Scale: Week 76 (n=3,8) | Dysphagia Scale: Week 79 (n=3,9) | Dysphagia Scale: Week 82 (n=2,6) | Dysphagia Scale: Week 85 (n=2,6) | Dysphagia Scale: Week 88 (n=2,6) | Dysphagia Scale: Week 91 (n=2,4) | Dysphagia Scale: Week 94 (n=2,6) | Dysphagia Scale: Week 97 (n=1,5) | Dysphagia Scale: Week 100 (n=1,4) | Dysphagia Scale: Week 103 (n=1,4) | Dysphagia Scale: Week 106 (n=1,4) | Dysphagia Scale: Week 109 (n=1,4) | Dysphagia Scale: Week 112 (n=1,5) | Dysphagia Scale: Week 115 (n=1,4) | Dysphagia Scale: Week 118 (n=1,5) | Dysphagia Scale: Week 121 (n=1,5) | Dysphagia Scale: Week 124 (n=1,5) | Dysphagia Scale: Week 127 (n=1,3) | Dysphagia Scale: Week 130 (n=0,3) | Dysphagia Scale: Week 133 (n=1,3) | Dysphagia Scale: Week 136 (n=0,2) | Dysphagia Scale: Week 139 (n=0,2) | Dysphagia Scale: Week 142 (n=0,2) | Dysphagia Scale: Week 145 (n=0,1) | Dysphagia Scale: Final Visit (n=157,159 | Pain Scale: BL (n=276,287) | Pain Scale: Week 4 (n=234,250) | Pain Scale: Week 7 (n=181,219) | Pain Scale: Week 10 (n=176,203) | Pain Scale: Week 13 (n=152,183) | Pain Scale: Week 16 (n=120,165) | Pain Scale: Week 19 (n=114,143) | Pain Scale: Week 22 (n=79,143) | Pain Scale: Week 25 (n=64,124) | Pain Scale: Week 28 (n=47,111) | Pain Scale: Week 31 (n=45,95) | Pain Scale: Week 34 (n=37,87) | Pain Scale: Week 37 (n=29,64) | Pain Scale: Week 40 (n=24,55) | Pain Scale: Week 43 (n=12,43) | Pain Scale: Week 46 (n=14,42) | Pain Scale: Week 49 (n=10,36) | Pain Scale: Week 52 (n=8,30) | Pain Scale: Week 55 (n=6,24) | Pain Scale: Week 58 (n=6,21) | Pain Scale: Week 61 (n=4,17) | Pain Scale: Week 64 (n=3,20) | Pain Scale: Week 67 (n=4,16) | Pain Scale: Week 70 (n=3,14) | Pain Scale: Week 73 (n=3,12) | Pain Scale: Week 76 (n=3,8) | Pain Scale: Week 79 (n=3,9) | Pain Scale: Week 82 (n=2,6) | Pain Scale: Week 85 (n=2,6) | Pain Scale: Week 88 (n=2,6) | Pain Scale: Week 91 (n=2,6) | Pain Scale: Week 94 (n=2,6) | Pain Scale: Week 97 (n=1,5) | Pain Scale: Week 100 (n=1,4) | Pain Scale: Week 103 (n=1,4) | Pain Scale: Week 106 (n=1,4) | Pain Scale: Week 109 (n=1,4) | Pain Scale: Week 112 (n=1,5) | Pain Scale: Week 115 (n=1,4) | Pain Scale: Week 118 (n=1,5) | Pain Scale: Week 121 (n=1,5) | Pain Scale: Week 124 (n=1,5) | Pain Scale: Week 127 (n=1,3) | Pain Scale: Week 130 (n=0,3) | Pain Scale: Week 133 (n=1,3) | Pain Scale: Week 136 (n=0,2) | Pain Scale: Week 139 (n=0,2) | Pain Scale: Week 142 (n=0,2) | Pain Scale: Week 145 (n=0,1) | Pain Scale: Final Visit (n=157,160) | Reflux Symptoms Scale: BL (n=275,287) | Reflux Symptoms Scale: Week 4 (n=234,250) | Reflux Symptoms Scale: Week 7 (n=180,220) | Reflux Symptoms Scale: Week 10 (n=176,203) | Reflux Symptoms Scale: Week 13 (n=152,182) | Reflux Symptoms Scale: Week 16 (n=120,165) | Reflux Symptoms Scale: Week 19 (n=114,165) | Reflux Symptoms Scale: Week 22 (n=79,143) | Reflux Symptoms Scale: Week 25 (n=64,124) | Reflux Symptoms Scale: Week 28 (n=47,111) | Reflux Symptoms Scale: Week 31 (n=45,95) | Reflux Symptoms Scale: Week 34 (n=45,95) | Reflux Symptoms Scale: Week 37 (n=29,64) | Reflux Symptoms Scale: Week 40 (n=24,55) | Reflux Symptoms Scale: Week 43 (n=12,42) | Reflux Symptoms Scale: Week 46 (n=14,42) | Reflux Symptoms Scale: Week 49 (n=10,36) | Reflux Symptoms Scale: Week 52 (n=8,30) | Reflux Symptoms Scale: Week 55 (n=6,24) | Reflux Symptoms Scale: Week 58 (n=6,21) | Reflux Symptoms Scale: Week 61 (n=4,17) | Reflux Symptoms Scale: Week 64 (n=3,20) | Reflux Symptoms Scale: Week 67 (n=4,16) | Reflux Symptoms Scale: Week 70 (n=3,13) | Reflux Symptoms Scale: Week 73 (n=3,12) | Reflux Symptoms Scale: Week 76 (n=3,8) | Reflux Symptoms Scale: Week 79 (n=3,9) | Reflux Symptoms Scale: Week 82 (n=2,6) | Reflux Symptoms Scale: Week 85 (n=2,6) | Reflux Symptoms Scale: Week 88 (n=2,6) | Reflux Symptoms Scale: Week 91 (n=2,4) | Reflux Symptoms Scale: Week 94 (n=2,6) | Reflux Symptoms Scale: Week 97 (n=1,5) | Reflux Symptoms Scale: Week 100 (n=1,4) | Reflux Symptoms Scale: Week 103 (n=1,4) | Reflux Symptoms Scale: Week 106 (n=1,4) | Reflux Symptoms Scale: Week 109 (n=1,4) | Reflux Symptoms Scale: Week 112 (n=1,5) | Reflux Symptoms Scale: Week 115 (n=1,4) | Reflux Symptoms Scale: Week 118 (n=1,5) | Reflux Symptoms Scale: Week 121 (n=1,5) | Reflux Symptoms Scale: Week 124 (n=1,5) | Reflux Symptoms Scale: Week 127 (n=1,3) | Reflux Symptoms Scale: Week 130 (n=0,3) | Reflux Symptoms Scale: Week 133 (n=1,3) | Reflux Symptoms Scale: Week 136 (n=0,2) | Reflux Symptoms Scale: Week 139 (n=0,2) | Reflux Symptoms Scale: Week 142 (n=0,2) | Reflux Symptoms Scale: Week 145 (n=0,1) | Reflux Symptoms Scale: Final Visit (n=1,5) | Eating Restrictions (ER) Scale: BL (n=276,287) | ER Scale: Week 4 (n=234,250) | ER Scale: Week 7 (n=181,220) | ER Scale: Week 10 (n=176,203) | ER Scale: Week 13 (n=152,183) | ER Scale: Week 16 (n=120,165) | ER Scale: Week 19 (n=114,143) | ER Scale: Week 22 (n=79,143) | ER Scale: Week 25 (n=64,124) | ER Scale: Week 28 (n=47,111) | ER Scale: Week 31 (n=45,95) | ER Scale: Week 34 (n=37,87) | ER Scale: Week 37 (n=29,64) | ER Scale: Week 40 (n=24,55) | ER Scale: Week 43 (n=12,43) | ER Scale: Week 46 (n=14,42) | ER Scale: Week 49 (n=10,36) | ER Scale: Week 52 (n=8,30) | ER Scale: Week 55 (n=6,24) | ER Scale: Week 58 (n=6,21) | ER Scale: Week 61 (n=4,17) | ER Scale: Week 64 (n=3,20) | ER Scale: Week 67 (n=4,16) | ER Scale: Week 70 (n=3,14) | ER Scale: Week 73 (n=3,12) | ER Scale: Week 76 (n=3,8) | ER Scale: Week 79 (n=3,9) | ER Scale: Week 82 (n=2,6) | ER Scale: Week 85 (n=2,6) | ER Scale: Week 88 (n=2,6) | ER Scale: Week 91 (n=2,4) | ER Scale: Week 94 (n=2,6) | ER Scale: Week 97 (n=1,5) | ER Scale: Week 100 (n=1,4) | ER Scale: Week 103 (n=1,4) | ER Scale: Week 106 (n=1,4) | ER Scale: Week 109 (n=1,4) | ER Scale: Week 112 (n=1,5) | ER Scale: Week 115 (n=1,4) | ER Scale: Week 118 (n=1,5) | ER Scale: Week 121 (n=1,5) | ER Scale: Week 124 (n=1,5) | ER Scale: Week 127 (n=1,3) | ER Scale: Week 130 (n=0,3) | ER Scale: Week 133 (n=1,3) | ER Scale: Week 136 (n=0,2) | ER Scale: Week 139 (n=0,2) | ER Scale: Week 142 (n=0,2) | ER Scale: Week 145 (n=0,1) | ER Scale: Final Visit (n=157,160) | Anxiety Scale: BL (n=276,287) | Anxiety Scale: Week 4 (n=234,250) | Anxiety Scale: Week 7 (n=181,220) | Anxiety Scale: Week 10 (n=176,203) | Anxiety Scale: Week 13 (n=152,183) | Anxiety Scale: Week 16 (n=120,165) | Anxiety Scale: Week 19 (n=114,143) | Anxiety Scale: Week 22 (n=79,143) | Anxiety Scale: Week 25 (n=64,124) | Anxiety Scale: Week 28 (n=47,111) | Anxiety Scale: Week 31 (n=45,95) | Anxiety Scale: Week 34 (n=37,87) | Anxiety Scale: Week 37 (n=29,64) | Anxiety Scale: Week 40 (n=24,55) | Anxiety Scale: Week 43 (n=12,43) | Anxiety Scale: Week 46 (n=14,42) | Anxiety Scale: Week 49 (n=14,42) | Anxiety Scale: Week 52 (n=8,30) | Anxiety Scale: Week 55 (n=6,24) | Anxiety Scale: Week 58 (n=6,21) | Anxiety Scale: Week 61 (n=4,17) | Anxiety Scale: Week 64 (n=3,20) | Anxiety Scale: Week 67 (n=4,16) | Anxiety Scale: Week 70 (n=3,14) | Anxiety Scale: Week 73 (n=3,12) | Anxiety Scale: Week 76 (n=3,8) | Anxiety Scale: Week 79 (n=3,9) | Anxiety Scale: Week 82 (n=2,6) | Anxiety Scale: Week 85 (n=2,6) | Anxiety Scale: Week 88 (n=2,6) | Anxiety Scale: Week 91 (n=2,4) | Anxiety Scale: Week 94 (n=2,6) | Anxiety Scale: Week 97 (n=1,5) | Anxiety Scale: Week 100 (n=1,4) | Anxiety Scale: Week 103 (n=1,4) | Anxiety Scale: Week 106 (n=1,4) | Anxiety Scale: Week 109 (n=1,4) | Anxiety Scale: Week 112 (n=1,5) | Anxiety Scale: Week 115 (n=1,4) | Anxiety Scale: Week 118 (n=1,5) | Anxiety Scale: Week 121 (n=1,5) | Anxiety Scale: Week 124 (n=1,5) | Anxiety Scale: Week 127 (n=1,3) | Anxiety Scale: Week 130 (n=0,3) | Anxiety Scale: Week 133 (n=1,3) | Anxiety Scale: Week 136 (n=0,2) | Anxiety Scale: Week 139 (n=0,2) | Anxiety Scale: Week 142 (n=0,2) | Anxiety Scale: Week 145 (n=0,2) | Anxiety Scale: Final Visit (n=157,160) | Dry Mouth: BL (n=274,287) | Dry Mouth: Week 4 (n=232,249) | Dry Mouth: Week 7 (n=180,219) | Dry Mouth: Week 10 (n=176,203) | Dry Mouth: Week 13 (n=152,183) | Dry Mouth: Week 16 (n=120,165) | Dry Mouth: Week 19 (n=113,143) | Dry Mouth: Week 22 (n=79,143) | Dry Mouth: Week 25 (n=64,124) | Dry Mouth: Week 28 (n=47,111) | Dry Mouth: Week 31 (n=45,95) | Dry Mouth: Week 34 (n=37,87) | Dry Mouth: Week 37 (n=29,64) | Dry Mouth: Week 40 (n=23,55) | Dry Mouth: Week 43 (n=12,43) | Dry Mouth: Week 46 (n=14,42) | Dry Mouth: Week 49 (n=10,36) | Dry Mouth: Week 52 (n=8,30) | Dry Mouth: Week 55 (n=6,24) | Dry Mouth: Week 58 (n=6,21) | Dry Mouth: Week 61 (n=4,17) | Dry Mouth: Week 64 (n=3,20) | Dry Mouth: Week 67 (n=4,16) | Dry Mouth: Week 70 (n=3,14) | Dry Mouth: Week 73 (n=3,12) | Dry Mouth: Week 76 (n=3,8) | Dry Mouth: Week 79 (n=3,9) | Dry Mouth: Week 82 (n=2,6) | Dry Mouth: Week 85 (n=2,6) | Dry Mouth: Week 88 (n=2,6) | Dry Mouth: Week 91 (n=2,4) | Dry Mouth: Week 94 (n=2,6) | Dry Mouth: Week 97 (n=1,5) | Dry Mouth: Week 100 (n=1,4) | Dry Mouth: Week 103 (n=1,4) | Dry Mouth: Week 106 (n=1,4) | Dry Mouth: Week 109 (n=1,4) | Dry Mouth: Week 112 (n=1,5) | Dry Mouth: Week 115 (n=1,4) | Dry Mouth: Week 118 (n=1,5) | Dry Mouth: Week 121 (n=1,5) | Dry Mouth: Week 124 (n=1,5) | Dry Mouth: Week 127 (n=1,3) | Dry Mouth: Week 130 (n=0,3) | Dry Mouth: Week 133 (n=1,3) | Dry Mouth: Week 136 (n=0,2) | Dry Mouth: Week 139 (n=0,2) | Dry Mouth: Week 142 (n=0,2) | Dry Mouth: Week 145 (n=0,1) | Dry Mouth: Final Visit (n=157,157) | Taste: BL (n=275,286) | Taste: Week 4 (n=234,249) | Taste: Week 7 (n=179,217) | Taste: Week 10 (n=176,200) | Taste: Week 13 (n=151,181) | Taste: Week 16 (n=119,165) | Taste: Week 19 (n=113,143) | Taste: Week 22 (n=79,143) | Taste: Week 25 (n=64,124) | Taste: Week 28 (n=47,111) | Taste: Week 31 (n=45,95) | Taste: Week 34 (n=37,87) | Taste: Week 37 (n=28,64) | Taste: Week 40 (n=24,55) | Taste: Week 43 (n=12,43) | Taste: Week 46 (n=14,42) | Taste: Week 49 (n=9,36) | Taste: Week 52 (n=8,30) | Taste: Week 55 (n=6,24) | Taste: Week 58 (n=6,21) | Taste: Week 61 (n=4,17) | Taste: Week 64 (n=3,20) | Taste: Week 67 (n=4,16) | Taste: Week 70 (n=3,14) | Taste: Week 73 (n=3,12) | Taste: Week 76 (n=3,8) | Taste: Week 79 (n=3,9) | Taste: Week 82 (n=2,6) | Taste: Week 85 (n=2, 6) | Taste: Week 88 (n=2,6) | Taste: Week 91 (n=2,4) | Taste: Week 94 (n=2,6) | Taste: Week 97 (n=1,5) | Taste: Week 100 (n=1,4) | Taste: Week 103 (n=1,4) | Taste: Week 106 (n=1,4) | Taste: Week 109 (n=1,4) | Taste: Week 112 (n=1,5) | Taste: Week 115 (n=1,4) | Taste: Week 118 (n=1,5) | Taste: Week 121 (n=1,5) | Taste: Week 124 (n=1,5) | Taste: Week 127 (n=1,3) | Taste: Week 130 (n=0,3) | Taste: Week 133 (n=1,3) | Taste: Week 136 (n=0,2) | Taste: Week 139 (n=0,2) | Taste: Week 142 (n=0,2) | Taste: Week 145 (n=0,1) | Taste: Final Visit (n=157,158) | Body Image: BL (n=272,286) | Body Image: Week 4 (n=233,249) | Body Image: Week 7 (n=180,219) | Body Image: Week 10 (n=175,203) | Body Image: Week 13 (n=152,182) | Body Image: Week 16 (n=119,165) | Body Image: Week 19 (n=114,140) | Body Image: Week 22 (n=79,143) | Body Image: Week 25 (n=64,124) | Body Image: Week 28 (n=47,111) | Body Image: Week 31 (n=45,95) | Body Image: Week 34 (n=37,87) | Body Image: Week 37 (n=29,64) | Body Image: Week 40 (n=24,55) | Body Image: Week 43 (n=12,43) | Body Image: Week 46 (n=14,42) | Body Image: Week 49 (n=10,36) | Body Image: Week 52 (n=8,30) | Body Image: Week 55 (n=6,24) | Body Image: Week 58 (n=6,21) | Body Image: Week 61 (n=4,17) | Body Image: Week 64 (n=3,20) | Body Image: Week 67 (n=4,16) | Body Image: Week 70 (n=4,14) | Body Image: Week 73 (n=3,12) | Body Image: Week 76 (n=3,8) | Body Image: Week 79 (n=3,9) | Body Image: Week 82 (n=2,6) | Body Image: Week 85 (n=2,6) | Body Image: Week 88 (n=2,5) | Body Image: Week 91 (n=2,4) | Body Image: Week 94 (n=2,6) | Body Image: Week 97 (n=1,5) | Body Image: Week 100 (n=1,4) | Body Image: Week 103 (n=1,4) | Body Image: Week 106 (n=1,4) | Body Image: Week 109 (n=1,4) | Body Image: Week 112 (n=1,5) | Body Image: Week 115 (n=1,4) | Body Image: Week 118 (n=1,5) | Body Image: Week 121 (n=1,5) | Body Image: Week 124 (n=1,5) | Body Image: Week 127 (n=1,3) | Body Image: Week 130 (n=0,3) | Body Image: Week 133 (n=1,3) | Body Image: Week 136 (n=0,2) | Body Image: Week 139 (n=0,2) | Body Image: Week 142 (n=0,2) | Body Image: Week 145 (n=0,1) | Body Image: Final Visit (n=157,159) | Hair Loss: BL (n=64,76) | Hair Loss: Week 4 (n=68,71) | Hair Loss: Week 7 (n=65,82) | Hair Loss: Week 10 (n=75,78) | Hair Loss: Week 13 (n=66,80) | Hair Loss: Week 16 (n=53,72) | Hair Loss: Week 19 (n=50,56) | Hair Loss: Week 22 (n=38,54) | Hair Loss: Week 25 (n=24,49) | Hair Loss: Week 28 (n=20,39) | Hair Loss: Week 31 (n=17,26) | Hair Loss: Week 34 (n=13,24) | Hair Loss: Week 37 (n=12,16) | Hair Loss: Week 40 (n=11,13) | Hair Loss: Week 43 (n=5,9) | Hair Loss: Week 46 (n=5,13) | Hair Loss: Week 49 (n=4,7) | Hair Loss: Week 52 (n=3,4) | Hair Loss: Week 55 (n=2,6) | Hair Loss: Week 58 (n=2,3) | Hair Loss: Week 61 (n=1,2) | Hair Loss: Week 64 (n=1,4) | Hair Loss: Week 67 (n=1,4) | Hair Loss: Week 70 (n=1,2) | Hair Loss: Week 73 (n=1,5) | Hair Loss: Week 76 (n=1,3) | Hair Loss: Week 79 (n=1,4) | Hair Loss: Week 82 (n=1,1) | Hair Loss: Week 85 (n=1,1) | Hair Loss: Week 88 (n=1,2) | Hair Loss: Week 91 (n=1,1) | Hair Loss: Week 94 (n=1,2) | Hair Loss: Week 97 (n=1,2) | Hair Loss: Week 100 (n=1,2) | Hair Loss: Week 103 (n=1,1) | Hair Loss: Week 106 (n=1,1) | Hair Loss: Week 109 (n=0,2) | Hair Loss: Week 112 (n=1,3) | Hair Loss: Week 115 (n=1,2) | Hair Loss: Week 118 (n=1,3) | Hair Loss: Week 121 (n=1,2) | Hair Loss: Week 124 (n=1,2) | Hair Loss: Week 127 (n=1,1) | Hair Loss: Week 130 (n=0,1) | Hair Loss: Week 133 (n=1,1) | Hair Loss: Final Visit (n=61,60) | |
| Fluoropyrimidine/Cisplatin (FP) | 18.7 | 11.8 | 10.9 | 8.5 | 8.8 | 10.2 | 9.5 | 10.0 | 6.9 | 6.6 | 6.4 | 3.9 | 5.4 | 3.7 | 4.6 | 2.4 | 4.4 | 1.4 | 0.0 | 3.7 | 2.8 | 0.0 | 2.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 15.4 | 29.7 | 21.6 | 19.4 | 17.0 | 16.0 | 17.0 | 19.2 | 15.8 | 11.3 | 11.2 | 12.6 | 12.2 | 13.8 | 14.9 | 13.0 | 15.5 | 11.7 | 9.4 | 9.7 | 5.6 | 4.2 | 2.8 | 4.2 | 2.8 | 0.0 | 5.6 | 2.8 | 0.0 | 4.2 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 24.7 | 18.3 | 14.8 | 12.8 | 12.6 | 12.8 | 12.0 | 11.3 | 9.0 | 5.6 | 6.6 | 7.4 | 7.2 | 6.1 | 7.9 | 7.4 | 4.8 | 2.2 | 2.8 | 5.6 | 0.0 | 2.8 | 3.7 | 2.8 | 3.7 | 0.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 15.3 | 27.4 | 20.6 | 18.8 | 17.5 | 16.0 | 17.8 | 20.8 | 15.5 | 11.6 | 13.9 | 13.4 | 10.6 | 12.5 | 13.5 | 9.7 | 10.9 | 11.7 | 5.2 | 8.3 | 9.7 | 4.2 | 0.0 | 8.3 | 2.8 | 5.6 | 2.8 | 5.6 | 4.2 | 4.2 | 4.2 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 23.8 | 47.5 | 42.0 | 40.6 | 38.2 | 35.7 | 32.9 | 35.8 | 31.7 | 25.2 | 27.4 | 29.1 | 23.1 | 27.2 | 29.6 | 30.6 | 26.2 | 20.0 | 23.6 | 31.5 | 20.4 | 8.3 | 5.6 | 11.1 | 3.7 | 7.4 | 0.0 | 11.1 | 11.1 | 11.1 | 11.1 | 11.1 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 41.5 | 24.5 | 24.0 | 24.6 | 23.5 | 23.2 | 23.9 | 22.4 | 19.0 | 16.1 | 10.6 | 12.6 | 9.9 | 12.6 | 8.7 | 11.1 | 9.5 | 16.7 | 12.5 | 5.6 | 11.1 | 8.3 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 24.0 | 17.2 | 20.7 | 20.1 | 21.8 | 19.9 | 20.4 | 24.5 | 19.0 | 10.9 | 12.1 | 8.1 | 6.3 | 8.3 | 8.3 | 5.6 | 4.8 | 7.4 | 4.2 | 11.1 | 11.1 | 8.3 | 11.1 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 25.3 | 30.9 | 32.6 | 30.7 | 30.1 | 28.9 | 29.1 | 30.7 | 28.7 | 22.4 | 23.4 | 25.2 | 18.9 | 23.0 | 20.8 | 27.8 | 21.4 | 16.7 | 16.7 | 16.7 | 11.1 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 31.0 | 15.1 | 20.1 | 25.1 | 21.8 | 22.2 | 28.3 | 23.3 | 20.2 | 13.9 | 26.7 | 15.7 | 7.7 | 8.3 | 12.1 | 6.7 | 26.7 | 0.0 | 11.1 | 16.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | 23.0 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 16.6 | 12.5 | 12.8 | 10.6 | 9.0 | 9.1 | 8.8 | 7.8 | 6.8 | 5.3 | 6.8 | 7.5 | 7.3 | 6.5 | 5.2 | 2.9 | 2.2 | 4.4 | 3.7 | 3.2 | 0.7 | 3.3 | 2.8 | 3.2 | 4.6 | 2.8 | 2.5 | 3.7 | 1.9 | 1.9 | 0.0 | 1.9 | 2.2 | 2.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.6 | 5.6 | 0.0 | 17.0 | 27.0 | 21.8 | 20.1 | 17.5 | 16.2 | 15.9 | 16.3 | 15.1 | 14.4 | 14.0 | 14.6 | 12.5 | 13.8 | 11.8 | 9.7 | 10.1 | 9.5 | 8.6 | 4.5 | 6.3 | 5.4 | 9.6 | 8.3 | 6.5 | 9.7 | 5.2 | 7.4 | 6.9 | 5.6 | 5.6 | 2.1 | 5.6 | 8.3 | 6.3 | 8.3 | 6.3 | 4.2 | 10.0 | 4.2 | 8.3 | 10.0 | 8.3 | 8.3 | 11.1 | 13.9 | 12.5 | 8.3 | 8.3 | 0.0 | 26.8 | 16.9 | 16.0 | 15.4 | 13.5 | 12.9 | 14.4 | 10.6 | 10.6 | 9.7 | 9.6 | 10.1 | 9.3 | 10.9 | 9.3 | 9.0 | 6.6 | 6.5 | 8.1 | 6.5 | 5.3 | 2.6 | 3.9 | 6.3 | 4.3 | 7.9 | 1.4 | 3.7 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.8 | 0.0 | 0.0 | 0.0 | 4.4 | 0.0 | 6.7 | 7.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 18.3 | 23.9 | 21.1 | 19.0 | 17.4 | 17.0 | 15.1 | 15.5 | 13.6 | 12.9 | 11.3 | 12.5 | 10.9 | 9.5 | 9.5 | 7.0 | 6.0 | 8.1 | 9.3 | 5.2 | 6.0 | 5.4 | 8.3 | 10.4 | 6.5 | 9.0 | 5.2 | 5.6 | 2.8 | 4.2 | 4.2 | 4.2 | 4.2 | 6.7 | 6.3 | 6.3 | 4.2 | 4.2 | 3.3 | 4.2 | 6.7 | 5.0 | 1.7 | 0.0 | 8.3 | 5.6 | 0.0 | 4.2 | 0.0 | 0.0 | 22.8 | 48.2 | 43.8 | 39.3 | 38.2 | 37.5 | 37.1 | 34.9 | 32.8 | 29.2 | 26.9 | 28.4 | 27.8 | 28.2 | 26.3 | 25.1 | 23.3 | 25.9 | 27.4 | 28.2 | 21.7 | 25.5 | 23.9 | 18.8 | 27.0 | 28.7 | 27.8 | 33.3 | 25.9 | 24.1 | 14.8 | 22.2 | 22.2 | 31.1 | 16.7 | 22.2 | 19.4 | 16.7 | 22.2 | 19.4 | 20.0 | 15.6 | 17.8 | 22.2 | 18.5 | 18.5 | 16.7 | 11.1 | 16.7 | 0.0 | 40.9 | 23.9 | 23.3 | 26.9 | 25.0 | 21.1 | 23.4 | 20.5 | 16.3 | 12.1 | 10.8 | 11.2 | 9.6 | 9.4 | 7.3 | 6.2 | 4.8 | 6.5 | 10.0 | 8.3 | 14.3 | 11.8 | 6.7 | 8.3 | 11.9 | 13.9 | 20.8 | 11.1 | 5.6 | 0.0 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 23.6 | 17.9 | 24.8 | 24.0 | 25.3 | 25.2 | 23.8 | 22.6 | 19.6 | 15.9 | 14.7 | 13.0 | 9.6 | 7.8 | 7.9 | 7.0 | 7.9 | 4.6 | 7.8 | 4.2 | 4.8 | 0.0 | 1.7 | 4.2 | 0.0 | 2.8 | 0.0 | 0.0 | 5.6 | 0.0 | 5.6 | 0.0 | 5.6 | 6.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.3 | 31.9 | 31.7 | 27.9 | 28.4 | 28.2 | 28.1 | 25.0 | 22.4 | 22.6 | 20.1 | 19.3 | 18.0 | 18.2 | 19.4 | 15.5 | 15.9 | 13.9 | 16.7 | 16.7 | 15.9 | 13.7 | 18.3 | 14.6 | 16.7 | 27.8 | 37.5 | 25.9 | 16.7 | 11.1 | 6.7 | 16.7 | 16.7 | 13.3 | 8.3 | 8.3 | 16.7 | 8.3 | 6.7 | 16.7 | 6.7 | 6.7 | 6.67 | 11.1 | 0.0 | 11.1 | 16.7 | 0.0 | 16.7 | 0.0 | 30.4 | 25.0 | 16.4 | 19.1 | 20.1 | 20.4 | 23.6 | 21.4 | 22.2 | 18.4 | 14.5 | 10.3 | 16.7 | 12.5 | 12.8 | 3.7 | 5.1 | 9.5 | 8.3 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 | 0.0 | 6.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 19.4 |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score equals (=) better level of functioning or greater degree of symptoms. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | scores on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: BL (n=274,287) | Global Health Status: Week 4 (n=235,249) | Global Health Status: Week 7 (n=180,220) | Global Health Status: Week 10 (n=176,202) | Global Health Status: Week 13 (n=152,182) | Global Health Status: Week 16 (n=121,165) | Global Health Status: Week 19 (n=114,143) | Global Health Status: Week 22 (n=78,143) | Global Health Status: Week 25 (n=64,124) | Global Health Status: Week 28 (n=47,111) | Global Health Status: Week 31 (n=45,95) | Global Health Status: Week 34 (n=36,87) | Global Health Status: Week 37 (n=29,64) | Global Health Status: Week 40 (n=23,55) | Global Health Status: Week 43 (n=12,43) | Global Health Status: Week 46 (n=13,42) | Global Health Status: Week 49 (n=9,36) | Global Health Status: Week 52 (n=7,29) | Global Health Status: Week 55 (n=5,24) | Global Health Status: Week 58 (n=5,21) | Global Health Status: Week 61 (n=4,17) | Global Health Status: Week 64 (n=3,20) | Global Health Status: Week 67 (n=4,17) | Global Health Status: Week 70 (n=3,14) | Global Health Status: Week 73 (n=3,12) | Global Health Status: Week 76 (n=3,8) | Global Health Status: Week 79 (n=3,9) | Global Health Status: Week 82 (n=2,5) | Global Health Status: Week 85 (n=2,6) | Global Health Status: Week 88 (n=2,6) | Global Health Status: Week 91 (n=2,4) | Global Health Status: Week 94 (n=2,6) | Global Health Status: Week 97 (n=1,5) | Global Health Status: Week 100 (n=1,4) | Global Health Status: Week 103 (n=1,3) | Global Health Status: Week 106 (n=1,4) | Global Health Status: Week 109 (n=1,4) | Global Health Status: Week 112 (n=1,5) | Global Health Status: Week 115 (n=1,4) | Global Health Status: Week 118 (n=1,5) | Global Health Status: Week 121 (n=1,5) | Global Health Status: Week 124 (n=1,5) | Global Health Status: Week 127 (n=1,3) | Global Health Status: Week 130 (n=0,3) | Global Health Status: Week 133 (n=1,3) | Global Health Status: Week 136 (n=0,2) | Global Health Status: Week 139 (n=0,2) | Global Health Status: Week 142 (n=0,2) | Global Health Status: Week 145 (n=0,1) | Global Health Status: Final Visit (n=158,160) | Physical Functioning: BL (n=276,287) | Physical Functioning: Week 4 (n=235,250) | Physical Functioning: Week 7 (n=181,220) | Physical Functioning: Week 10 (n=174,201) | Physical Functioning: Week 13 (n=151,183) | Physical Functioning: Week 16 (n=121,165) | Physical Functioning: Week 19 (n=114,143) | Physical Functioning: Week 22 (n=79,143) | Physical Functioning: Week 25 (n=64,124) | Physical Functioning: Week 28 (n=47,110) | Physical Functioning: Week 31 (n=45,95) | Physical Functioning: Week 34 (n=37,87) | Physical Functioning: Week 37 (n=29,64) | Physical Functioning: Week 40 (n=24,55) | Physical Functioning: Week 43 (n=12,43) | Physical Functioning: Week 46 (n=14,42) | Physical Functioning: Week 49 (n=10,36) | Physical Functioning: Week 52 (n=8,30) | Physical Functioning: Week 55 (n=6,24) | Physical Functioning: Week 58 (n=6,21) | Physical Functioning: Week 61 (n=4,17) | Physical Functioning: Week 64 (n=3,20) | Physical Functioning: Week 67 (n=4,17) | Physical Functioning: Week 70 (n=3,14) | Physical Functioning: Week 73 (n=3,12) | Physical Functioning: Week 76 (n=3,8) | Physical Functioning: Week 79 (n=3,9) | Physical Functioning: Week 82 (n=2,6) | Physical Functioning: Week 85 (n=2,6) | Physical Functioning: Week 88 (n=2,6) | Physical Functioning: Week 91 (n=2,4) | Physical Functioning: Week 94 (n=2,6) | Physical Functioning: Week 97 (n=1,5) | Physical Functioning: Week 100 (n=1,4) | Physical Functioning: Week 103 (n=1,4) | Physical Functioning: Week 106 (n=1,4) | Physical Functioning: Week 109 (n=1,4) | Physical Functioning: Week 112 (n=1,5) | Physical Functioning: Week 115 (n=1,4) | Physical Functioning: Week 118 (n=1,5) | Physical Functioning: Week 121 (n=1,5) | Physical Functioning: Week 124 (n=1,5) | Physical Functioning: Week 127 (n=1,3) | Physical Functioning: Week 130 (n=0,3) | Physical Functioning: Week 133 (n=1,3) | Physical Functioning: Week 136 (n=0,2) | Physical Functioning: Week 139 (n=0,2) | Physical Functioning: Week 142 (n=0,2) | Physical Functioning: Week 145 (n=0,1) | Physical Functioning: Final Visit (n=158,161) | Role Functioning: BL (n=276,287) | Role Functioning: Week 4 (n=234,250) | Role Functioning: Week 7 (n=181,220) | Role Functioning: Week 10 (n=176,202) | Role Functioning: Week 13 (n=152,182) | Role Functioning: Week 16 (n=121,165) | Role Functioning: Week 19 (n=114,143) | Role Functioning: Week 22 (n=79,142) | Role Functioning: Week 25 (n=64,124) | Role Functioning: Week 28 (n=47,110) | Role Functioning: Week 31 (n=45,95) | Role Functioning: Week 34 (n=37,87) | Role Functioning: Week 37 (n=29,64) | Role Functioning: Week 40 (n=24,55) | Role Functioning: Week 43 (n=12,43) | Role Functioning: Week 46 (n=14,42) | Role Functioning: Week 49 (n=10,36) | Role Functioning: Week 52 (n=8,30) | Role Functioning: Week 55 (n=6,24) | Role Functioning: Week 58 (n=6,21) | Role Functioning: Week 61 (n=4,17) | Role Functioning: Week 64 (n=3,20) | Role Functioning: Week 67 (n=4,17) | Role Functioning: Week 70 (n=3,14) | Role Functioning: Week 73 (n=3,12) | Role Functioning: Week 76 (n=3,8) | Role Functioning: Week 79 (n=3,9) | Role Functioning: Week 82 (n=2,6) | Role Functioning: Week 85 (n=2,6) | Role Functioning: Week 88 (n=2,6) | Role Functioning: Week 91 (n=2,4) | Role Functioning: Week 94 (n=2,6) | Role Functioning: Week 97 (n=1,5) | Role Functioning: Week 100 (n=1,4) | Role Functioning: Week 103 (n=1,4) | Role Functioning: Week 106 (n=1,4) | Role Functioning: Week 109 (n=1,4) | Role Functioning: Week 112 (n=1,5) | Role Functioning: Week 115 (n=1,4) | Role Functioning: Week 118 (n=1,5) | Role Functioning: Week 121 (n=1,5) | Role Functioning: Week 124 (n=1,5) | Role Functioning: Week 127 (n=1,3) | Role Functioning: Week 130 (n=0,3) | Role Functioning: Week 133 (n=1,3) | Role Functioning: Week 136 (n=0,2) | Role Functioning: Week 139 (n=0,2) | Role Functioning: Week 142 (n=0,2) | Role Functioning: Week 145 (n=0,1) | Role Functioning: Final Visit (n=158,161) | Emotional Functioning: BL (n=276,287) | Emotional Functioning: Week 4 (n=235,250) | Emotional Functioning: Week 7 (n=180,220) | Emotional Functioning: Week 10 (n=176,202) | Emotional Functioning: Week 13 (n=152,183) | Emotional Functioning: Week 16 (n=121,165) | Emotional Functioning: Week 19 (n=114,143) | Emotional Functioning: Week 22 (n=79,143) | Emotional Functioning: Week 25 (n=64,124) | Emotional Functioning: Week 28 (n=47,111) | Emotional Functioning: Week 31 (n=45,95) | Emotional Functioning: Week 34 (n=37,87) | Emotional Functioning: Week 37 (n=29,64) | Emotional Functioning: Week 40 (n=24,55) | Emotional Functioning: Week 43 (n=12,43) | Emotional Functioning: Week 46 (n=14,42) | Emotional Functioning: Week 49 (n=10,36) | Emotional Functioning: Week 52 (n=8,29) | Emotional Functioning: Week 55 (n=6,24) | Emotional Functioning: Week 58 (n=6,21) | Emotional Functioning: Week 61 (n=4,17) | Emotional Functioning: Week 64 (n=3,20) | Emotional Functioning: Week 67 (n=4,17) | Emotional Functioning: Week 70 (n=3,14) | Emotional Functioning: Week 73 (n=3,12) | Emotional Functioning: Week 76 (n=3,8) | Emotional Functioning: Week 79 (n=3,9) | Emotional Functioning: Week 82 (n=2,6) | Emotional Functioning: Week 85 (n=2,6) | Emotional Functioning: Week 88 (n=2,6) | Emotional Functioning: Week 91 (n=2,4) | Emotional Functioning: Week 94 (n=2,6) | Emotional Functioning: Week 97 (n=1,5) | Emotional Functioning: Week 100 (n=1,4) | Emotional Functioning: Week 103 (n=1,4) | Emotional Functioning: Week 106 (n=1,4) | Emotional Functioning: Week 109 (n=1,4) | Emotional Functioning: Week 112 (n=1,5) | Emotional Functioning: Week 115 (n=1,4) | Emotional Functioning: Week 118 (n=1,5) | Emotional Functioning: Week 121 (n=1,5) | Emotional Functioning: Week 124 (n=1,5) | Emotional Functioning: Week 127 (n=1,3) | Emotional Functioning: Week 130 (n=0,3) | Emotional Functioning: Week 133 (n=1,3) | Emotional Functioning: Week 136 (n=0,2) | Emotional Functioning: Week 139 (n=0,2) | Emotional Functioning: Week 142 (n=0,2) | Emotional Functioning: Week 145 (n=0,1) | Emotional Functioning: Final Visit (n=158,161) | Cognitive Functioning: BL (n=276,287) | Cognitive Functioning: Week 4 (n=235,250) | Cognitive Functioning: Week 7 (n=180,220) | Cognitive Functioning: Week 10 (n=176,202) | Cognitive Functioning: Week 13 (n=152,183) | Cognitive Functioning: Week 16 (n=121,165) | Cognitive Functioning: Week 19 (n=114,143) | Cognitive Functioning: Week 22 (n=79,143) | Cognitive Functioning: Week 25 (n=64,124) | Cognitive Functioning: Week 28 (n=47,111) | Cognitive Functioning: Week 31 (n=45,95) | Cognitive Functioning: Week 34 (n=37,87) | Cognitive Functioning: Week 37 (n=29,64) | Cognitive Functioning: Week 40 (n=24,55) | Cognitive Functioning: Week 43 (n=12,43) | Cognitive Functioning: Week 46 (n=14,42) | Cognitive Functioning: Week 49 (n=10,36) | Cognitive Functioning: Week 52 (n=8,29) | Cognitive Functioning: Week 55 (n=6,24) | Cognitive Functioning: Week 58 (n=6,21) | Cognitive Functioning: Week 61 (n=4,17) | Cognitive Functioning: Week 64 (n=3,20) | Cognitive Functioning: Week 67 (n=4,17) | Cognitive Functioning: Week 70 (n=3,14) | Cognitive Functioning: Week 73 (n=3,12) | Cognitive Functioning: Week 76 (n=3,8) | Cognitive Functioning: Week 79 (n=3,9) | Cognitive Functioning: Week 82 (n=2,6) | Cognitive Functioning: Week 85 (n=2,6) | Cognitive Functioning: Week 88 (n=2,6) | Cognitive Functioning: Week 91 (n=2,4) | Cognitive Functioning: Week 94 (n=2,6) | Cognitive Functioning: Week 97 (n=1,5) | Cognitive Functioning: Week 100 (n=1,4) | Cognitive Functioning: Week 103 (n=1,4) | Cognitive Functioning: Week 106 (n=1,4) | Cognitive Functioning: Week 109 (n=1,4) | Cognitive Functioning: Week 112 (n=1,5) | Cognitive Functioning: Week 115 (n=1,4) | Cognitive Functioning: Week 118 (n=1,5) | Cognitive Functioning: Week 121 (n=1,5) | Cognitive Functioning: Week 124 (n=1,5) | Cognitive Functioning: Week 127 (n=1,3) | Cognitive Functioning: Week 130 (n=0,3) | Cognitive Functioning: Week 133 (n=1,3) | Cognitive Functioning: Week 136 (n=0,2) | Cognitive Functioning: Week 139 (n=0,2) | Cognitive Functioning: Week 142 (n=0,2) | Cognitive Functioning: Week 145 (n=0,1) | Cognitive Functioning: Final Visit (n=158,161) | Social Functioning: BL (n=276,286) | Social Functioning: Week 4 (n=235,250) | Social Functioning: Week 7 (n=179,220) | Social Functioning: Week 10 (n=176,202) | Social Functioning: Week 13 (n=152,183) | Social Functioning: Week 16 (n=180,165) | Social Functioning: Week 19 (n=114,143) | Social Functioning: Week 22 (n=79,143) | Social Functioning: Week 25 (n=64,124) | Social Functioning: Week 28 (n=47,111) | Social Functioning: Week 31 (n=45,95) | Social Functioning: Week 34 (n=37,87) | Social Functioning: Week 37 (n=29,64) | Social Functioning: Week 40 (n=24,55) | Social Functioning: Week 43 (n=12,43) | Social Functioning: Week 46 (n=14,42) | Social Functioning: Week 49 (n=10,36) | Social Functioning: Week 52 (n=8,29) | Social Functioning: Week 55 (n=6,24) | Social Functioning: Week 58 (n=6,21) | Social Functioning: Week 61 (n=4,17) | Social Functioning: Week 64 (n=3,20) | Social Functioning: Week 67 (n=4,17) | Social Functioning: Week 70 (n=3,14) | Social Functioning: Week 73 (n=3,12) | Social Functioning: Week 76 (n=3,8) | Social Functioning: Week 79 (n=3,9) | Social Functioning: Wek 82 (n=2,6) | Social Functioning: Week 85 (n=2,6) | Social Functioning: Week 88 (n=2,6) | Social Functioning: Week 91 (n=2,4) | Social Functioning: Week 94 (n=2,6) | Social Functioning: Week 97 (n=1,5) | Social Functioning: Week 100 (n=1,4) | Social Functioning: Week 103 (n=1,4) | Social Functioning: Week 106 (n=1,4) | Social Functioning: Week 109 (n=1,4) | Social Functioning: Week 112 (n=1,5) | Social Functioning: Week 115 (n=1,4) | Social Functioning: Week 118 (n=1,5) | Social Functioning: Week 121 (n=1,5) | Social Functioning: Week 124 (n=1,5) | Social Functioning: Week 127 (n=1,3) | Social Functioning: Week 130 (n=0,3) | Social Functioning: Week 133 (n=1,3) | Social Functioning: Week 136 (n=0,2) | Social Functioning: Week 139 (n=0,2) | Social Functioning: Week 142 (n=0,2) | Social Functioning: Week 145 (n=0,1) | Social Functioning: Final Visit (n=158,161) | Fatigue: BL (n=276,287) | Fatigue: Week 4 (n=235,250) | Fatigue: Week 7 (n=181,220) | Fatigue: Week 10 (n=176,201) | Fatigue: Week 13 (n=152,183) | Fatigue: Week 16 (n=121,165) | Fatigue: Week 19 (n=114,143) | Fatigue: Week 22 (n=79,143) | Fatigue: Week 25 (n=64,124) | Fatigue: Week 28 (n=47,110) | Fatigue: Week 31 (n=45,95) | Fatigue: Week 34 (n=37,87) | Fatigue: Week 37 (n=29,64) | Fatigue: Week 40 (n=24,55) | Fatigue: Week 43 (n=12,43) | Fatigue: Week 46 (n=14,42) | Fatigue: Week 49 (n=10,36) | Fatigue: Week 52 (n=8,30) | Fatigue: Week 55 (n=6,24) | Fatigue: Week 58 (n=6,21) | Fatigue: Week 61 (n=4,17) | Fatigue: Week 64 (n=3,20) | Fatigue: Week 67 (n=4,17) | Fatigue: Week 70 (n=3,14) | Fatigue: Week 73 (n=3,12) | Fatigue: Week 76 (n=3,8) | Fatigue: Week 79 (n=3,9) | Fatigue: Week 82 (n=2,6) | Fatigue: Week 85 (n=2,6) | Fatigue: Week 88 (n=2,6) | Fatigue: Week 91 (n=2,4) | Fatigue: Week 94 (n=2,6) | Fatigue: Week 97 (n=1,5) | Fatigue: Week 100 (n=1,4) | Fatigue: Week 103 (n=1,4) | Fatigue: Week 106 (n=1,4) | Fatigue: Week 109 (n=1,4) | Fatigue: Week 112 (n=1,5) | Fatigue: Week 115 (n=1,4) | Fatigue: Week 118 (n=1,5) | Fatigue: Week 121 (n=1,5) | Fatigue: Week 124 (n=1,5) | Fatigue: Week 127 (n=1,3) | Fatigue: Week 130 (n=0,3) | Fatigue: Week 133 (n=1,3) | Fatigue: Week 136 (n=0,2) | Fatigue: Week 139 (n=0,2) | Fatigue: Week 142 (n=0,2) | Fatigue: Week 145 (n=0,1) | Fatigue: Final Visit (n=158,160) | Nausea & Vomiting: BL (n=276,287) | Nausea & Vomiting: Week 4 (n=235,250) | Nausea & Vomiting: Week 7 (n=181,220) | Nausea & Vomiting: Week 10 (n=176,201) | Nausea & Vomiting: Week 13 (n=121,183) | Nausea & Vomiting: Week 16 (n=121,165) | Nausea & Vomiting: Week 19 (n=114,143) | Nausea & Vomiting: Week 22 (n=79,143) | Nausea & Vomiting: Week 25 (n=64,124) | Nausea & Vomiting: Week 28 (n=47,110) | Nausea & Vomiting: Week 31 (n=45,95) | Nausea & Vomiting: Week 34 (n=37,87) | Nausea & Vomiting: Week 37 (n=29,64) | Nausea & Vomiting: Week 40 (n=24,55) | Nausea & Vomiting: Week 43 (n=12,43) | Nausea & Vomiting: Week 46 (n=14,42) | Nausea & Vomiting: Week 49 (n=10,36) | Nausea & Vomiting: Week 52 (n=8,30) | Nausea & Vomiting: Week 55 (n=6,24) | Nausea & Vomiting: Week 58 (n=6,21) | Nausea & Vomiting: Week 61 (n=4,17) | Nausea & Vomiting: Week 64 (n=3,20) | Nausea & Vomiting: Week 67 (n=4,17) | Nausea & Vomiting: Week 70 (n=3,14) | Nausea & Vomiting: Week 73 (n=3,12) | Nausea & Vomiting: Week 76 (n=3,8) | Nausea & Vomiting: Week 79 (n=3,9) | Nausea & Vomiting: Week 82 (n=2,6) | Nausea & Vomiting: Week 85 (n=2,6) | Nausea & Vomiting: Week 88 (n=2,6) | Nausea & Vomiting: Week 91 (n=2,4) | Nausea & Vomiting: Week 94 (n=2,6) | Nausea & Vomiting: Week 97 (n=1,5) | Nausea & Vomiting: Week 100 (n=1,4) | Nausea & Vomiting: Week 103 (n=1,4) | Nausea & Vomiting: Week 106 (n=1,4) | Nausea & Vomiting: Week 109 (n=1,4) | Nausea & Vomiting: Week 112 (n=1,5) | Nausea & Vomiting: Week 115 (n=1,4) | Nausea & Vomiting: Week 118 (n=1,5) | Nausea & Vomiting: Week 121 (n=1,5) | Nausea & Vomiting: Week 124 (n=1,5) | Nausea & Vomiting: Week 127 (n=1,3) | Nausea & Vomiting: Week 130 (n=0,3) | Nausea & Vomiting: Week 133 (n=1,3) | Nausea & Vomiting: Week 136 (n=0,2) | Nausea & Vomiting: Week 139 (n=0,2) | Nausea & Vomiting: Week 142 (n=0,2) | Nausea & Vomiting: Week 145 (n=0,1) | Nausea & Vomiting: Final Visit (n=158,161) | Pain: BL (n=276,287) | Pain: Week 4 (n=235,250) | Pain: Week 7 (n=181,220) | Pain: Week 10 (n=176,202) | Pain: Week 13 (n=152,183) | Pain: Week 16 (n=121,165) | Pain: Week 19 (n=114,143) | Pain: Week 22 (n=79,143) | Pain: Week 25 (n=64,124) | Pain: Week 28 (n=47,111) | Pain: Week 31 (n=45,95) | Pain: Week 34 (n=37,87) | Pain: Week 37 (n=29,64) | Pain: Week 40 (n=24,55) | Pain: Week 43 (n=12,43) | Pain: Week 46 (n=14,42) | Pain: Week 49 (n=10,36) | Pain: Week 52 (n=8,30) | Pain: Week 55 (n=6,24) | Pain: Week 58 (n=6,21) | Pain: Week 61 (n=4,17) | Pain: Week 64 (n=3,20) | Pain: Week 67 (n=4,17) | Pain: Week 70 (n=3,14) | Pain: Week 73 (n=3,12) | Pain: Week 76 (n=3,8) | Pain: Week 79 (n=3,9) | Pain: Week 82 (n=2,6) | Pain: Week 85 (n=2,6) | Pain: Week 88 (n=2,6) | Pain: Week 91 (n=2,4) | Pain: Week 94 (n=2,6) | Pain: Week 97 (n=1,5) | Pain: Week 100 (n=1,4) | Pain: Week 103 (n=1,4) | Pain: Week 106 (n=1,4) | Pain: Week 109 (n=1,4) | Pain: Week 112 (n=1,5) | Pain: Week 115 (n=1,4) | Pain: Week 118 (n=1,5) | Pain: Week 121 (n=1,5) | Pain: Week 124 (n=1,5) | Pain: Week 127 (n=1,3) | Pain: Week 130 (n=0,3) | Pain: Week 133 (n=1,3) | Pain: Week 136 (n=0,2) | Pain: Week 139 (n=0,2) | Pain: Week 142 (n=0,2) | Pain: Week 145 (n=0,1) | Pain: Final Visit (n=158,161) | Dyspnoea: BL (n=274,281) | Dyspnoea: Week 4 (n=232,249) | Dyspnoea: Week 7 (n=181,217) | Dyspnoea: Week 10 (n=176,198) | Dyspnoea: Week 13 (n=151,182) | Dyspnoea: Week 16 (n=121,165) | Dyspnoea: Week 19 (n=113,143) | Dyspnoea: Week 22 (n=79,143) | Dyspnoea: Week 25 (n=63,124) | Dyspnoea: Week 28 (n=47,110) | Dyspnoea: Week 31 (n=45,95) | Dyspnoea: Week 34 (n=36,87) | Dyspnoea: Week 37 (n=29,64) | Dyspnoea: Week 40 (n=24,55) | Dyspnoea: Week 43 (n=12,43) | Dyspnoea: Week 46 (n=14,42) | Dyspnoea: Week 49 (n=10,36) | Dyspnoea: Week 52 (n=8,30) | Dyspnoea: Week 55 (n=6,24) | Dyspnoea: Week 58 (n=6,21) | Dyspnoea: Week 61 (n=4,17) | Dyspnoea: Week 64 (n=3,20) | Dyspnoea: Week 67 (n=4,17) | Dyspnoea: Week 70 (n=3,14) | Dyspnoea: Week 73 (n=3,12) | Dyspnoea: Week 76 (n=3,8) | Dyspnoea: Week 79 (n=3,9) | Dyspnoea: Week 82 (n=2,6) | Dyspnoea: Week 85 (n=180,6) | Dyspnoea: Week 88 (n=2,6) | Dyspnoea: Week 91 (n=2,4) | Dyspnoea: Week 94 (n=2,6) | Dyspnoea: Week 97 (n=1,5) | Dyspnoea: Week 100 (n=1,4) | Dyspnoea: Week 103 (n=1,4) | Dyspnoea: Week 106 (n=1,4) | Dyspnoea: Week 109 (n=1,4) | Dyspnoea: Week 112 (n=1,5) | Dyspnoea: Week 115 (n=1,4) | Dyspnoea: Week 118 (n=1,5) | Dyspnoea: Week 121 (n=1,5) | Dyspnoea: Week 124 (n=1,5) | Dyspnoea: Week 127 (n=1,3) | Dyspnoea: Week 130 (n=0,3) | Dyspnoea: Week 133 (n=1,3) | Dyspnoea: Week 136 (n=0,2) | Dyspnoea: Week 139 (n=0,2) | Dyspnoea: Week 142 (n=0,2) | Dyspnoea: Week 145 (n=0,1) | Dyspnoea: Final Visit (n=157,160) | Insomnia: BL (n=276,285) | Insomnia: Week 4 (n=234,248) | Insomnia: Week 7 (n=181,219) | Insomnia: Week 10 (n=175,200) | Insomnia: Week 13 (n=152,183) | Insomnia: Week 16 (n=120,164) | Insomnia: Week 19 (n=113,143) | Insomnia: Week 22 (n=79,143) | Insomnia: Week 25 (n=64,124) | Insomnia: Week 28 (n=47,110) | Insomnia: Week 31 (n=45,94) | Insomnia: Week 34 (n=37,87) | Insomnia: Week 37 (n=29,63) | Insomnia: Week 40 (n=24,55) | Insomnia: Week 43 (n=12,43) | Insomnia: Week 46 (n=13,42) | Insomnia: Week 49 (n=10,36) | Insomnia: Week 52 (n=8,30) | Insomnia: Week 55 (n=6,24) | Insomnia: Week 58 (n=6,21) | Insomnia: Week 61 (n=4,17) | Insomnia: Week 64 (n=3,20) | Insomnia: Week 67 (n=4,17) | Insomnia: Week 70 (n=3,14) | Insomnia: Week 73 (n=3,12) | Insomnia: Week 76 (n=3,8) | Insomnia: Week 79 (n=3,9) | Insomnia: Week 82 (n=2,6) | Insomnia: Week 85 (n=2,6) | Insomnia: Week 88 (n=2,6) | Insomnia: Week 91 (n=2,4) | Insomnia: Week 94 (n=2,6) | Insomnia: Week 97 (n=1,5) | Insomnia: Week 100 (n=1,4) | Insomnia: Week 103 (n=1,4) | Insomnia: Week 106 (n=1,4) | Insomnia: Week 109 (n=1,4) | Insomnia: Week 112 (n=1,5) | Insomnia: Week 115 (n=1,4) | Insomnia: Week 118 (n=1,5) | Insomnia: Week 121 (n=1,5) | Insomnia: Week 124 (n=1,5) | Insomnia: Week 127 (n=1,3) | Insomnia: Week 130 (n=0,3) | Insomnia: Week 133 (n=1,3) | Insomnia: Week 136 (n=0,2) | Insomnia: Week 139 (n=0,2) | Insomnia: Week 142 (n=0,2) | Insomnia: Week 145 (n=0,1) | Insomnia: Final Visit (n=157,160) | Appetite Loss: BL (n=275,286) | Appetite Loss: Week 4 (n=235,250) | Appetite Loss: Week 7 (n=180,216) | Appetite Loss: Week 10 (n=176,201) | Appetite Loss: Week 13 (n=151,183) | Appetite Loss: Week 16 (n=121,165) | Appetite Loss: Week 19 (n=114,141) | Appetite Loss: Week 22 (n=79,143) | Appetite Loss: Week 25 (n=64,124) | Appetite Loss: Week 28 (n=47,109) | Appetite Loss: Week 31 (n=45,95) | Appetite Loss: Week 34 (n=37,87) | Appetite Loss: Week 37 (n=29,64) | Appetite Loss: Week 40 (n=24,55) | Appetite Loss: Week 43 (n=12,43) | Appetite Loss: Week 46 (n=14,42) | Appetite Loss: Week 49 (n=9,36) | Appetite Loss: Week 52 (n=8,30) | Appetite Loss: Week 55 (n=6,24) | Appetite Loss: Week 58 (n=6,21) | Appetite Loss: Week 61 (n=4,17) | Appetite Loss: Week 64 (n=3,20) | Appetite Loss: Week 67 (n=4,17) | Appetite Loss: Week 70 (n=3,14) | Appetite Loss: Week 73 (n=3,12) | Appetite Loss: Week 76 (n=3,8) | Appetite Loss: Week 79 (n=3,9) | Appetite Loss: Week 82 (n=2,6) | Appetite Loss: Week 85 (n=2,6) | Appetite Loss: Week 88 (n=2,6) | Appetite Loss: Week 91 (n=2,4) | Appetite Loss: Week 94 (n=2,6) | Appetite Loss: Week 97 (n=1,5) | Appetite Loss: Week 100 (n=1,4) | Appetite Loss: Week 103 (n=1,4) | Appetite Loss: Week 106 (n=1,4) | Appetite Loss: Week 109 (n=1,4) | Appetite Loss: Week 112 (n=1,5) | Appetite Loss: Week 115 (n=1,4) | Appetite Loss: Week 118 (n=1,5) | Appetite Loss: Week 121 (n=1,5) | Appetite Loss: Week 124 (n=1,5) | Appetite Loss: Week 127 (n=1,3) | Appetite Loss: Week 130 (n=0,3) | Appetite Loss: Week 133 (n=1,3) | Appetite Loss: Week 136 (n=0,2) | Appetite Loss: Week 139 (n=0,2) | Appetite Loss: Week 142 (n=0,2) | Appetite Loss: Week 145 (n=0,1) | Appetite Loss: Week Final Visit (n=156,161) | Constipation: BL (n=276,285) | Constipation: Week 4 (n=235,247) | Constipation: Week 7 (n=179,220) | Constipation: Week 10 (n=175,203) | Constipation: Week 13 (n=152,183) | Constipation: Week 16 (n=121,165) | Constipation: Week 19 (n=114,143) | Constipation: Week 22 (n=78,143) | Constipation: Week 25 (n=64,124) | Constipation: Week 28 (n=47,111) | Constipation: Week 31 (n=45,95) | Constipation: Week 34 (n=37,86) | Constipation: Week 37 (n=29,64) | Constipation: Week 40 (n=24,55) | Constipation: Week 43 (n=12,43) | Constipation: Week 46 (n=14,42) | Constipation: Week 49 (n=10,36) | Constipation: Week 52 (n=8,29) | Constipation: Week 55 (n=6,24) | Constipation: Week 58 (n=6,21) | Constipation: Week 61 (n=4,17) | Constipation: Week 64 (n=3,20) | Constipation: Week 67 (n=4,17) | Constipation: Week 70 (n=3,14) | Constipation: Week 73 (n=3,12) | Constipation: Week 76 (n=3,8) | Constipation: Week 79 (n=3,9) | Constipation: Week 82 (n=2,6) | Constipation: Week 85 (n=2,6) | Constipation: Week 88 (n=2,6) | Constipation: Week 91 (n=2,4) | Constipation: Week 94 (n=2,6) | Constipation: Week 97 (n=1,5) | Constipation: Week 100 (n=1,4) | Constipation: Week 103 (n=1,4) | Constipation: Week 106 (n=1,4) | Constipation: Week 109 (n=1,4) | Constipation: Week 112 (n=1,5) | Constipation: Week 115 (n=1,4) | Constipation: Week 118 (n=1,5) | Constipation: Week 121 (n=1,5) | Constipation: Week 124 (n=1,5) | Constipation: Week 127 (n=1,3) | Constipation: Week 130 (n=0,3) | Constipation: Week 133 (n=1,3) | Constipation: Week 136 (n=0,2) | Constipation: Week 139 (n=0,2) | Constipation: Week 142 (n=0,2) | Constipation: Week 145 (n=0,1) | Constipation: Final Visit (n=158,160) | Diarrhoea: BL (n=276,283) | Diarrhoea: Week 4 (n=234,246) | Diarrhoea: Week 7 (n=180,220) | Diarrhoea: Week 10 (n=174,202) | Diarrhoea: Week 13 (n=152,183) | Diarrhoea: Week 16 (n=120,165) | Diarrhoea: Week 19 (n=114,143) | Diarrhoea: Week 22 (n=78,143) | Diarrhoea: Week 25 (n=64,124) | Diarrhoea: Week 28 (n=47,111) | Diarrhoea: Week 31 (n=45,95) | Diarrhoea: Week 34 (n=37,87) | Diarrhoea: Week 37 (n=29,64) | Diarrhoea: Week 40 (n=24,55) | Diarrhoea: Week 43 (n=12,42) | Diarrhoea: Week 46 (n=14,42) | Diarrhoea: Week 49 (n=10,36) | Diarrhoea: Week 52 (n=8,29) | Diarrhoea: Week 55 (n=6,24) | Diarrhoea: Week 58 (n=6,21) | Diarrhoea: Week 61 (n=4,17) | Diarrhoea: Week 64 (n=3,20) | Diarrhoea: Week 67 (n=4,17) | Diarrhoea: Week 70 (n=3,14) | Diarrhoea: Week 73 (n=3,12) | Diarrhoea: Week 76 (n=3,8) | Diarrhoea: Week 79 (n=3,9) | Diarrhoea: Week 82 (n=2,6) | Diarrhoea: Week 85 (n=2,6) | Diarrhoea: Week 88 (n=2,6) | Diarrhoea: Week 91 (n=2,4) | Diarrhoea: Week 94 (n=2,6) | Diarrhoea: Week 97 (n=1,5) | Diarrhoea: Week 100 (n=1,4) | Diarrhoea: Week 103 (n=1,4) | Diarrhoea: Week 106 (n=1,4) | Diarrhoea: Week 109 (n=1,4) | Diarrhoea: Week 112 (n=1,5) | Diarrhoea: Week 115 (n=1,4) | Diarrhoea: Week 118 (n=1,5) | Diarrhoea: Week 121 (n=1,5) | Diarrhoea: Week 124 (n=1,5) | Diarrhoea: Week 127 (n=1,3) | Diarrhoea: Week 130 (n=0,3) | Diarrhoea: Week 133 (n=1,3) | Diarrhoea: Week 136 (n=0,2) | Diarrhoea: Week 139 (n=0,2) | Diarrhoea: Week 142 (n=0,2) | Diarrhoea: Week 145 (n=0,1) | Diarrhoea: Final Visit (n=157,160) | Financial Difficulties: BL (n=274,286) | Financial Difficulties: Week 4 (n=234,249) | Financial Difficulties: Week 7 (n=178,220) | Financial Difficulties: Week 10 (n=175,202) | Financial Difficulties: Week 13 (n=151,181) | Financial Difficulties: Week 16 (n=120,165) | Financial Difficulties: Week 19 (n=113,143) | Financial Difficulties: Week 22 (n=78,142) | Financial Difficulties: Week 25 (n=63,124) | Financial Difficulties: Week 28 (n=45,111) | Financial Difficulties: Week 31 (n=45,94) | Financial Difficulties: Week 34 (n=36,87) | Financial Difficulties: Week 37 (n=29,64) | Financial Difficulties: Week 40 (n=24,55) | Financial Difficulties: Week 43 (n=12,43) | Financial Difficulties: Week 46 (n=14,42) | Financial Difficulties: Week 49 (n=10,35) | Financial Difficulties: Week 52 (n=8,29) | Financial Difficulties: Week 55 (n=6,24) | Financial Difficulties: Week 58 (n=6,21) | Financial Difficulties: Week 61 (n=4,17) | Financial Difficulties: Week 64 (n=3,20) | Financial Difficulties: Week 67 (n=4,17) | Financial Difficulties: Week 70 (n=3,14) | Financial Difficulties: Week 73 (n=3,12) | Financial Difficulties: Week 76 (n=3,8) | Financial Difficulties: Week 79 (n=3,9) | Financial Difficulties: Week 82 (n=2,6) | Financial Difficulties: Week 85 (n=2,6) | Financial Difficulties: Week 88 (n=2,6) | Financial Difficulties: Week 91 (n=2,4) | Financial Difficulties: Week 94 (n=2,6) | Financial Difficulties: Week 97 (n=1,5) | Financial Difficulties: Week 100 (n=1,4) | Financial Difficulties: Week 103 (n=1,4) | Financial Difficulties: Week 106 (n=1,4) | Financial Difficulties: Week 109 (n=1,4) | Financial Difficulties: Week 112 (n=1,5) | Financial Difficulties: Week 115 (n=1,4) | Financial Difficulties: Week 118 (n=1,5) | Financial Difficulties: Week 121 (n=1,5) | Financial Difficulties: Week 124 (n=1,5) | Financial Difficulties: Week 127 (n=1,3) | Financial Difficulties: Week 130 (n=0,3) | Financial Difficulties: Week 133 (n=1,3) | Financial Difficulties: Week 136 (n=0,2) | Financial Difficulties: Week 139 (n=0,2) | Financial Difficulties: Week 142 (n=0,2) | Financial Difficulties: Week 145 (n=0,1) | Financial Difficulties: Final Visit (n=158,160) | |
| Fluoropyrimidine/Cisplatin (FP) | 55.3 | 61.0 | 60.9 | 62.3 | 63.8 | 60.8 | 61.0 | 65.1 | 68.0 | 72.0 | 69.6 | 70.8 | 66.1 | 62.0 | 72.9 | 75.0 | 68.5 | 72.6 | 76.7 | 76.7 | 79.2 | 77.8 | 75.0 | 77.8 | 80.6 | 77.8 | 77.8 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | 83.3 | NA | 83.3 | NA | NA | NA | NA | 53.2 | 78.9 | 76.0 | 79.3 | 78.2 | 80.2 | 79.8 | 78.8 | 80.7 | 85.8 | 86.2 | 85.6 | 86.3 | 85.7 | 84.4 | 85.6 | 87.6 | 88.7 | 88.3 | 85.6 | 86.7 | 91.7 | 95.6 | 93.3 | 97.8 | 97.8 | 95.6 | 95.6 | 93.3 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 93.3 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 72.1 | 73.2 | 67.4 | 70.9 | 70.2 | 73.4 | 72.0 | 71.1 | 74.7 | 81.3 | 80.5 | 82.2 | 83.3 | 81.6 | 79.9 | 80.6 | 82.1 | 81.7 | 85.4 | 80.6 | 77.8 | 83.3 | 83.3 | 83.3 | 88.9 | 88.9 | 83.3 | 83.3 | 91.7 | 100.0 | 91.7 | 91.7 | 100.0 | 83.3 | 83.3 | 100.0 | 100.0 | 100.0 | 83.3 | 100.0 | 100.0 | 83.3 | 83.3 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 63.5 | 75.4 | 80.5 | 81.3 | 82.9 | 82.6 | 83.1 | 82.2 | 85.9 | 88.2 | 86.0 | 85.7 | 88.5 | 83.9 | 83.6 | 81.9 | 82.1 | 88.3 | 86.5 | 76.4 | 85.6 | 95.8 | 100 | 95.8 | 97.2 | 94.4 | 100.0 | 97.2 | 95.8 | 95.8 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 75.1 | 86.9 | 86.0 | 85.7 | 85.6 | 88.2 | 82.8 | 84.2 | 85.9 | 85.9 | 86.5 | 87.0 | 88.3 | 88.5 | 83.3 | 88.9 | 89.3 | 85.0 | 91.7 | 94.4 | 91.7 | 91.7 | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 79.5 | 72.4 | 72.1 | 73.1 | 74.5 | 72.7 | 72.7 | 74.4 | 79.3 | 83.3 | 83.0 | 81.5 | 84.7 | 85.1 | 85.4 | 87.5 | 86.9 | 85.0 | 87.5 | 86.1 | 88.9 | 91.7 | 94.4 | 95.8 | 94.4 | 100.0 | 94.4 | 94.4 | 100.0 | 91.7 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | NA | 100.0 | NA | NA | NA | NA | 68.1 | 36.3 | 37.1 | 34.4 | 35.3 | 32.9 | 33.0 | 33.1 | 30.0 | 22.2 | 24.1 | 22.0 | 22.8 | 21.8 | 23.6 | 19.4 | 20.6 | 19.4 | 16.7 | 18.5 | 16.7 | 8.3 | 7.4 | 13.9 | 11.1 | 7.4 | 7.4 | 7.4 | 0.0 | 5.6 | 0.0 | 0.0 | 0.0 | 11.1 | 0.0 | 0.0 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 40.4 | 15.0 | 16.6 | 16.9 | 16.4 | 12.8 | 14.2 | 14.2 | 10.3 | 8.6 | 3.5 | 3.7 | 4.5 | 2.9 | 4.2 | 2.8 | 1.2 | 3.3 | 2.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 14.9 | 24.9 | 17.8 | 14.5 | 13.4 | 12.0 | 13.6 | 14.2 | 15.0 | 10.7 | 8.2 | 12.2 | 12.2 | 11.5 | 18.8 | 16.7 | 13.1 | 13.3 | 6.3 | 2.8 | 8.3 | 0.0 | 5.6 | 0.0 | 0.0 | 5.6 | 5.6 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 27.4 | 12.4 | 12.1 | 12.7 | 14.6 | 11.3 | 15.4 | 15.3 | 13.9 | 12.7 | 9.2 | 10.4 | 10.2 | 10.3 | 9.7 | 19.4 | 11.9 | 6.7 | 12.5 | 5.6 | 5.6 | 16.7 | 0.0 | 8.3 | 0.0 | 0.0 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 20.0 | 27.2 | 22.1 | 21.9 | 19.8 | 14.7 | 15.3 | 17.1 | 14.8 | 15.1 | 9.9 | 10.4 | 9.0 | 8.0 | 13.9 | 13.9 | 7.7 | 10.0 | 12.5 | 16.7 | 11.1 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 21.9 | 35.2 | 31.5 | 27.2 | 26.7 | 24.7 | 24.5 | 26.9 | 19.0 | 12.0 | 14.2 | 11.1 | 11.7 | 12.6 | 13.9 | 5.6 | 4.8 | 3.7 | 0.0 | 0.0 | 5.6 | 8.3 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 35.3 | 22.9 | 20.6 | 19.0 | 19.2 | 16.7 | 14.6 | 13.5 | 12.0 | 7.3 | 7.8 | 10.4 | 5.4 | 11.5 | 8.3 | 8.3 | 4.8 | 3.3 | 4.2 | 5.6 | 11.1 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 19.0 | 10.9 | 9.1 | 8.7 | 10.5 | 6.6 | 8.1 | 7.3 | 6.0 | 7.3 | 5.7 | 5.9 | 5.4 | 5.7 | 6.9 | 8.3 | 4.8 | 10.0 | 8.3 | 11.1 | 11.1 | 16.7 | 11.1 | 16.7 | 11.1 | 11.1 | 22.2 | 11.1 | 0.0 | 0.0 | 0.0 | 16.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 10.0 | 27.3 | 23.6 | 23.6 | 21.5 | 22.5 | 23.1 | 20.6 | 19.7 | 16.4 | 17.0 | 15.6 | 10.2 | 13.8 | 22.2 | 16.7 | 16.7 | 16.7 | 8.3 | 16.7 | 11.1 | 16.7 | 11.1 | 16.7 | 11.1 | 11.1 | 11.1 | 11.1 | 16.7 | 16.7 | 16.7 | 16.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 26.6 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 54.9 | 60.9 | 60.5 | 61.9 | 63.6 | 61.9 | 63.8 | 64.9 | 67.8 | 68.5 | 70.0 | 72.0 | 70.6 | 70.6 | 73.6 | 73.8 | 76.6 | 71.3 | 73.8 | 73.8 | 72.5 | 70.0 | 72.5 | 68.5 | 68.1 | 67.7 | 69.4 | 60.0 | 79.2 | 73.6 | 79.2 | 79.2 | 78.3 | 85.4 | 75.0 | 77.1 | 77.1 | 75.0 | 72.9 | 75.0 | 75.0 | 81.7 | 72.2 | 72.2 | 72.2 | 66.7 | 66.7 | 66.7 | 66.7 | 53.1 | 79.6 | 79.5 | 79.3 | 80.2 | 80.5 | 80.7 | 81.5 | 83.6 | 84.8 | 83.7 | 85.4 | 85.1 | 85.8 | 88.2 | 89.9 | 91.9 | 92.0 | 89.2 | 93.1 | 91.4 | 91.0 | 91.0 | 93.3 | 92.9 | 91.1 | 90.0 | 92.6 | 90.0 | 95.6 | 95.6 | 98.3 | 97.8 | 97.3 | 96.7 | 96.7 | 98.3 | 95.0 | 97.3 | 93.3 | 96.0 | 94.7 | 96.0 | 93.3 | 93.3 | 95.6 | 93.3 | 93.3 | 93.3 | 100.0 | 73.8 | 73.9 | 76.1 | 73.3 | 74.3 | 75.1 | 74.6 | 75.8 | 79.7 | 82.4 | 79.7 | 81.1 | 82.2 | 81.5 | 82.1 | 86.8 | 86.5 | 88.0 | 84.4 | 88.2 | 89.7 | 87.3 | 87.5 | 90.2 | 86.9 | 80.6 | 81.3 | 81.5 | 80.6 | 91.7 | 94.4 | 91.7 | 100.0 | 90.0 | 100.0 | 100.0 | 100.0 | 95.8 | 93.3 | 83.3 | 86.7 | 90.0 | 90.0 | 88.9 | 88.9 | 88.9 | 83.3 | 83.3 | 83.3 | 100.0 | 68.7 | 73.1 | 77.9 | 80.2 | 81.2 | 80.5 | 81.9 | 82.4 | 84.0 | 84.8 | 85.5 | 85.7 | 85.4 | 86.3 | 86.7 | 87.8 | 87.5 | 91.4 | 88.2 | 88.5 | 88.9 | 90.7 | 86.3 | 89.2 | 89.3 | 82.9 | 87.5 | 84.3 | 83.3 | 91.7 | 90.3 | 95.8 | 88.9 | 91.7 | 87.5 | 87.5 | 89.6 | 91.7 | 95.0 | 93.8 | 90.0 | 95.0 | 90.0 | 100.0 | 88.9 | 91.7 | 95.8 | 95.8 | 95.8 | 100.0 | 74.3 | 85.7 | 86.3 | 86.5 | 86.8 | 85.7 | 86.8 | 87.6 | 87.4 | 87.4 | 88.0 | 90.0 | 88.7 | 91.4 | 91.5 | 91.5 | 91.7 | 92.6 | 89.7 | 91.0 | 90.5 | 91.2 | 93.3 | 91.2 | 91.7 | 83.3 | 83.3 | 81.5 | 88.9 | 91.7 | 94.4 | 95.8 | 94.4 | 90.0 | 95.8 | 91.7 | 95.8 | 95.8 | 93.3 | 95.8 | 96.7 | 96.7 | 96.7 | 100.0 | 88.9 | 94.4 | 100.0 | 100.0 | 100.0 | 100.0 | 80.0 | 72.0 | 74.1 | 75.1 | 76.7 | 76.3 | 77.5 | 79.5 | 80.1 | 80.2 | 80.2 | 78.9 | 80.7 | 81.8 | 82.7 | 84.1 | 86.9 | 84.7 | 82.2 | 85.4 | 87.3 | 90.2 | 85.8 | 85.3 | 86.9 | 80.6 | 81.3 | 85.2 | 80.6 | 88.9 | 88.9 | 91.7 | 91.7 | 90.0 | 95.8 | 100.0 | 91.7 | 95.8 | 96.7 | 95.8 | 96.7 | 100.0 | 96.7 | 83.3 | 94.4 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 71.4 | 34.2 | 34.5 | 34.1 | 33.2 | 33.7 | 32.8 | 29.4 | 26.7 | 25.1 | 23.2 | 22.2 | 19.7 | 19.8 | 18.6 | 17.1 | 13.8 | 14.5 | 17.2 | 14.4 | 16.4 | 14.4 | 17.2 | 15.0 | 16.7 | 16.7 | 18.1 | 18.5 | 29.6 | 11.1 | 9.3 | 11.1 | 7.4 | 11.1 | 11.1 | 19.4 | 13.9 | 16.7 | 17.8 | 25.0 | 17.8 | 17.8 | 13.3 | 14.8 | 18.5 | 14.8 | 22.2 | 22.2 | 22.2 | 11.1 | 37.6 | 15.7 | 19.7 | 18.9 | 16.4 | 14.7 | 14.5 | 13.9 | 12.2 | 8.2 | 6.5 | 8.8 | 7.5 | 6.8 | 4.8 | 1.2 | 2.8 | 0.9 | 5.0 | 2.1 | 3.2 | 0.0 | 4.2 | 2.9 | 2.4 | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 19.8 | 25.1 | 17.9 | 16.1 | 14.4 | 13.3 | 12.4 | 12.8 | 13.2 | 12.2 | 12.0 | 11.8 | 11.3 | 12.2 | 10.3 | 8.9 | 6.7 | 6.5 | 10.0 | 8.3 | 7.1 | 4.9 | 6.7 | 4.9 | 4.8 | 9.7 | 8.3 | 9.3 | 2.8 | 0.0 | 2.8 | 4.2 | 0.0 | 3.3 | 8.3 | 0.0 | 0.0 | 0.0 | 3.3 | 0.0 | 3.3 | 3.3 | 0.0 | 0.0 | 5.6 | 5.6 | 0.0 | 0.0 | 0.0 | 0.0 | 25.4 | 13.4 | 11.8 | 10.8 | 11.3 | 13.7 | 13.5 | 11.9 | 12.1 | 9.4 | 10.3 | 9.1 | 9.6 | 10.4 | 4.8 | 6.2 | 5.6 | 4.6 | 5.6 | 8.3 | 6.3 | 3.9 | 8.3 | 5.9 | 7.1 | 8.3 | 8.3 | 7.4 | 16.7 | 5.6 | 5.6 | 8.3 | 5.6 | 0.0 | 0.0 | 8.3 | 8.3 | 8.3 | 6.7 | 8.3 | 6.7 | 6.7 | 6.7 | 11.1 | 11.1 | 11.1 | 16.7 | 16.7 | 16.7 | 33.3 | 18.3 | 23.6 | 23.3 | 20.4 | 18.0 | 18.9 | 17.7 | 20.0 | 17.0 | 15.9 | 13.3 | 14.9 | 13.4 | 11.1 | 10.3 | 9.3 | 9.5 | 7.4 | 7.8 | 8.3 | 9.5 | 7.8 | 10.0 | 9.8 | 9.5 | 11.1 | 8.3 | 11.1 | 11.1 | 11.1 | 5.6 | 0.0 | 5.6 | 6.7 | 8.3 | 0.0 | 0.0 | 0.0 | 6.7 | 0.0 | 6.7 | 6.7 | 0.0 | 0.0 | 11.1 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 24.6 | 33.8 | 33.6 | 31.3 | 29.4 | 28.4 | 27.9 | 25.1 | 20.7 | 16.7 | 11.6 | 13.0 | 9.6 | 10.9 | 9.7 | 7.0 | 5.6 | 6.5 | 10.0 | 10.0 | 4.8 | 0.0 | 8.3 | 5.9 | 7.1 | 5.6 | 4.2 | 0.0 | 5.6 | 5.6 | 11.1 | 0.0 | 5.6 | 0.0 | 0.0 | 8.3 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11.1 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 33.5 | 21.5 | 20.2 | 17.6 | 15.1 | 15.8 | 15.4 | 14.5 | 10.0 | 10.2 | 9.6 | 6.3 | 4.7 | 10.4 | 7.9 | 7.0 | 7.1 | 5.6 | 10.3 | 6.9 | 6.3 | 5.9 | 5.0 | 5.9 | 4.8 | 11.1 | 4.2 | 3.7 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 20.0 | 10.7 | 12.2 | 14.2 | 11.9 | 12.0 | 12.9 | 10.3 | 9.6 | 6.2 | 4.8 | 4.9 | 5.7 | 4.2 | 3.0 | 2.4 | 1.6 | 3.7 | 2.3 | 4.2 | 4.8 | 0.0 | 3.3 | 2.0 | 3.3 | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.7 | 0.0 | 0.0 | 0.0 | 6.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 29.3 | 27.7 | 23.9 | 23.3 | 22.7 | 24.4 | 22.4 | 24.9 | 22.3 | 21.6 | 23.4 | 24.5 | 23.4 | 23.6 | 19.4 | 18.3 | 20.0 | 20.7 | 18.1 | 22.2 | 23.5 | 16.7 | 17.6 | 19.0 | 19.4 | 25.0 | 25.9 | 22.2 | 16.7 | 16.7 | 25.0 | 16.7 | 20.0 | 16.7 | 8.3 | 16.7 | 16.7 | 13.3 | 16.7 | 13.3 | 13.3 | 13.3 | 11.1 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 27.9 |
"The participant assessed their pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as no pain and the right-hand extreme equals 100 mm as unbearable pain. A negative change indicated improvement." (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | mm (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BL (n=275,284) | Week 4 (n=234,249) | Week 7 (n=181,219) | Week 10 (n=174, 202) | Week 13 (n=152,181) | Week 16 (n=121,165) | Week 19 (n=114,142) | Week 22 (n=79,141) | Week 25 (n=64,124) | Week 28 (n=47,111) | Week 31 (n=45,95) | Week 34 (n=37,86) | Week 37 (n=29,64) | Week 40 (n=24,54) | Week 43 (n=12,43) | Week 46 (n=14,41) | Week 49 (n=10,36) | Week 52 (n=8,30) | Week 55 (n=6,24) | Week 58 (n=6,20) | Week 61 (n=4,17) | Week 64 (n=3,20) | Week 67 (n=4,17) | Week 70 (n=3,13) | Week 73 (n=3,10) | Week 76 (n=3,8) | Week 79 (n=3,9) | Week 82 (n=2,6) | Week 85 (n=2,6) | Week 88 (n=2,6) | Week 91 (n=2,4) | Week 94 (n=2,6) | Week 97 (n=1,5) | Week 100 (n=1,4) | Week 103 (n=1,4) | Week 106 (n=1,4) | Week 109 (n=1,4) | Week 112 (n=1,5) | Week 115 (n=1,4) | Week 118 (n=1,5) | Week 121 (n=1,5) | Week 124 (n=1,4) | Week 127 (n=1,3) | Week 130 (n=0,3) | Week 133 (n=1,3) | Week 136 (n=0,2) | Week 139 (n=0,2) | Week 142 (n=0,2) | Week 145 (n=0,1) | Final visit/withdrawal (n=157,161) | |
| Fluoropyrimidine/Cisplatin (FP) | 21.1 | 14.6 | 11.1 | 14.5 | 11.3 | 14.0 | 15.4 | 13.3 | 12.7 | 8.6 | 8.7 | 9.4 | 15.5 | 16.4 | 12.6 | 16.1 | 7.2 | 5.8 | 2.3 | 4.7 | 5.3 | 2.0 | 1.5 | 1.3 | 1.0 | 1.7 | 1.0 | 0.0 | 1.0 | 0.5 | 0.5 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | 0.0 | NA | NA | NA | NA | 23.8 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 17.9 | 13.3 | 13.8 | 12.9 | 12.2 | 12.8 | 12.0 | 15.1 | 11.0 | 12.3 | 12.5 | 10.7 | 10.9 | 8.8 | 7.2 | 7.4 | 6.5 | 6.9 | 3.3 | 3.8 | 7.2 | 6.8 | 8.9 | 1.3 | 16.5 | 12.9 | 5.9 | 4.8 | 6.3 | 5.7 | 7.5 | 5.8 | 0.2 | 0.3 | 6.5 | 7.8 | 7.3 | 4.2 | 5.8 | 3.8 | 3.2 | 4.5 | 6.3 | 5.7 | 5.0 | 6.0 | 8.0 | 7.5 | 15.0 | 21.9 |
Analgesic medications were recorded throughout the study until disease progression. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Taking any analgesic medication | Discontinued at least 1 medication | Decreased dose of at least 1 medication | No change in any medication | Increased dose or added at least 1 medication | |
| Fluoropyrimidine/Cisplatin (FP) | 29.0 | 5.9 | 0.3 | 5.5 | 17.2 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 29.3 | 1.7 | 0.3 | 7.1 | 20.1 |
Change in body weight was categorized as an increase of greater than (>)5 percent (%), no change (plus or minus [±]5%), decrease of >5-10%, or a decrease of >10% from BL to the end of study. Time windows were applied in order to assign visits to weight measurements, and the lowest post-screening value recorded was used for the analysis. The percentage change in weight from screening was summarized over time. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Increase >5% | No change (±5%) | Decrease >5-10% | Decrease >10% | |
| Fluoropyrimidine/Cisplatin (FP) | 1.5 | 51.6 | 28.2 | 18.7 |
| Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H) | 1.1 | 50.5 | 27.2 | 21.2 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 12.7 |
| A + FOLFOX 4 | 7.9 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A + FOLFOX 4 - Avastin Subgroup | 5.2 |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. (NCT00192075)
Timeframe: randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 20.6 |
| A + FOLFOX 4 | 19.7 |
Defined as the time from randomization to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 8.6 |
| A + FOLFOX 4 | 9.5 |
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG - Avastin Subgroup | 13.7 |
| A + FOLFOX 4 - Avastin Subgroup | 11.5 |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 8.6 |
| A + FOLFOX 4 | 9.7 |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG - Avastin Subgroup | 13.7 |
| A + FOLFOX 4 - Avastin Subgroup | 13.8 |
Percentage of participants who were alive at 12 months and 24 months. (NCT00192075)
Timeframe: randomization to the date of death from any cause (up to 24 months)
| Intervention | percentage of participants alive (Number) | |
|---|---|---|
| 12-Month Survival | 24-Month Survival | |
| A + FOLFOX 4 - Avastin Subgroup | 83.3 | 66.7 |
| A+FFG - Avastin Subgroup | 75.6 | 50.4 |
Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either >=1 Grade 4 or >=2 Grade 3 adverse events (NCT00192075)
Timeframe: every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia (Grade 3) | Neutropenia (Grade 4) | Thrombocytopenia (Grade 3) | Thrombocytopenia (Grade 4) | Leukopenia (Grade 3) | Leukopenia (Grade 4) | Anemia (Grade 3) | Anemia (Grade 4) | Febrile neutropenia (Grade 3) | Febrile neutropenia (Grade 4) | Diarrhea (Grade 3) | Diarrhea (Grade 4) | Small intestinal obstruction (Grade 3) | Small intestinal obstruction (Grade 4) | Fatigue (Grade 3) | Fatigue (Grade 4) | Cerebral infarction (Grade 3) | Cerebral infarction (Grade 4) | Hyperglycemia (Grade 3) | Hyperglycemia (Grade 4) | Dehydration (Grade 3) | Dehydration (Grade 4) | Deep vein thrombosis (Grade 3) | Deep vein thrombosis (Grade 4) | Myocardial infarction (Grade 3) | Myocardial infarction (Grade 4) | Subdural hematoma (Grade 3) | Subdural hematoma (Grade 4) | Perirectal abscess (Grade 3) | Perirectal abscess (Grade 4) | Hypoxia (Grade 3) | Hypoxia (Grade 4) | |
| A + FOLFOX 4 - Avastin Subgroup | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| A+FFG - Avastin Subgrouup | 3 | 5 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Overall Response Rate (CR+PR) | Stable Disease (SD) | Disease Control Rate (CR+PR+SD) | Progressive Disease | Unknown | |
| A + FOLFOX 4 - Avastin Subgroup | 1 | 8 | 9 | 8 | 17 | 1 | 0 |
| A+FFG - Avastin Subgroup | 0 | 0 | 0 | 11 | 11 | 6 | 1 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Overall Response Rate (CR+PR) | Stable Disease (SD) | Disease Control Rate (CR+PR+SD) | Progressive Disease | Unknown | |
| A + FOLFOX 4 | 2 | 15 | 17 | 16 | 33 | 7 | 2 |
| A+FFG | 1 | 3 | 4 | 21 | 25 | 14 | 3 |
(NCT00100841)
Timeframe: From randomization to the first documented disease progression
| Intervention | months (Median) |
|---|---|
| Treatment (Combination Chemotherapy) | 9.6 |
The primary objective is to evaluate safety in all treated patients specifically the rate of serious adverse events which were defined as grade 5 events, grade 4 hemorrhage or thrombosis or bowel perforation (NCT00100841)
Timeframe: The duration of the study
| Intervention | participants (Number) | |
|---|---|---|
| Grade 5 Death | Grade 4 venous thrombosis | |
| Treatment (Combination Chemotherapy) | 2 | 2 |
One-year survival estimate is reported. Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. This analysis was planned to occur when all patients had been potentially followed for 1 year. On the basis of a 1-year survival rate of 60% from the Radiation Therapy Oncology Group (RTOG) esophageal database, 38 analyzable patients with a 1-year survival rate of 77.5% or better was needed for this trial to be deemed promising enough for development of a Phase III protocol (type I error of 0.05 and type II error of 0.20). (NCT00069953)
Timeframe: From registration to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 1 year.
| Intervention | percentage of participants (Number) |
|---|---|
| ChemoRT and Selective Surgery | 71 |
The primary endpoint was 3-year disease-free survival (DFS). Evidence of local recurrence, distant metastasis, or death from any cause within 3 years counted as events in the time-to-event Kaplan-Meier analysis of disease-free survival. (NCT00114231)
Timeframe: Up to 3 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 88.2 |
The local recurrence rate (percentage) is defined as the percentage of patients who had local recurrence as initial sites of failure at the end of follow-up. (NCT00114231)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 4 |
The rate (percentage) of patients with negative resection margins after undergoing local excision is reported below. (NCT00114231)
Timeframe: At time of surgery
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 98.7 |
The rate (percentage) of patients with pathologic complete response (pCR) is reported below. Pathologic response will be determined by comparing tumor width and stage in the surgical specimen with the same parameters as determined by pre-CRT ERUS: PATHOLOGIC COMPLETE RESPONSE (pCR): no residual tumor. (NCT00114231)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 44 |
Morbidity and mortality after neoadjuvant cheoradiotherapy and local excision. (NCT00114231)
Timeframe: Up to 30 days
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Mortality | Morbidity | |
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 6 | 10 |
The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment (NCT00308516)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Preoperative 5FU/Radiation/Bevacizumab | 85 |
| Postoperative 5FU/Radiation/Bevacizumab | 97 |
Overall Survival (OS) is defined ad the Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00308516)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Preoperative 5FU/Radiation/Bevacizumab | NA |
| Postoperative 5FU/Radiation/Bevacizumab | NA |
"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response based on investigator review of scans using modified RECIST criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no post-baseline radiographic tumor assessment(s) were considered non-responders.~CR: disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or PD and no new lesions." (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 23 |
| Mutant KRAS | 16 |
Duration of response is defined as the time from the date of first response to the date of first progression of disease during second-line treatment (as evaluated by the investigator) or death (if the death was due to disease progression but not detected earlier) in the subset of participants who responded (CR or PR, as evaluated by the investigator). Duration of response was analyzed using Kaplan-Meier methods; participants who responded but did not progress while on study were censored at the date of last tumor assessment. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 29 |
| Mutant KRAS | 23 |
Overall survival is defined as as the number of days from Study Day 1 to the date of death due to any cause. Overall survival was analyzed using the Kaplan-Meier method; participants who were lost to follow-up or who had not died at the end of the study (52 weeks after the last participant was enrolled) were censored at the date of last contact. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 50 |
| Mutant KRAS | 31 |
Progression-free survival time was defined as the time from Study Day 1 to the date of disease progression (based on investigator assessment) or the date of death due to any cause. Participants who terminated from the study early (eg, prior to disease progression due to fully withdrawn informed consent) were censored at their last tumor assessment. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 26 |
| Mutant KRAS | 19 |
Time to progression is defined as the time from study Day 1 to the date of observed disease progression. Time to progression was analyzed using Kaplan-Meier methods; participants who did not have disease progression were censored at the date of last evaluable tumor assessment. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 26 |
| Mutant KRAS | 17 |
Time to response of second-line treatment is defined as the time from study Day 1 to the date of first documentation of CR or PR, calculated for those participants with an objective tumor response of CR or PR. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 9.1 |
| Mutant KRAS | 9.3 |
Time to failure of second-line treatment is defined as the time from study Day 1 to the date of the earliest of the following events: end of second-line therapy due to any reason except for complete response and curative surgery; progressive disease; or death due to any cause. Time to treatment failure was analyzed using Kaplan-Meier methods; participants who did not discontinue second-line treatment or discontinue due to complete response or curative surgery, who were still alive, and who did not have disease progression were censored at the date of the last contact. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 19 |
| Mutant KRAS | 15 |
The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST criteria as assessed by the investigator. Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline. (NCT00411450)
Timeframe: Week 17 and Week 25
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 17 | Week 25 | |
| Mutant KRAS | 58 | 58 |
| Wild-type KRAS | 64 | 64 |
The immunogenicity of panitumumab was evaluated using 2 different screening immunoassays for the detection of anti-panitumumab antibodies: an acid dissociation bridging enzyme-linked immunosorbent assay (ELISA; detecting high-affinity antibodies) and a Biacore® biosensor immunoassay (detecting both high and low-affinity antibodies). When either of the 2 screening assays yielded a positive result, that particular sample was subjected to an in vitro bioassay for the detection of neutralizing antibodies. (NCT00411450)
Timeframe: Prior to first dose and 28 days after the last dose of second-line treatment
| Intervention | participants (Number) | |
|---|---|---|
| Binding antibody positive | Neutralizing antibody positive | |
| Panitumumab Plus FOLFIRI | 1 | 0 |
The severity of adverse events (AEs) was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, except for panitumumab related skin toxicities, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The relationship of each adverse event to the panitumumab and/or FOLFIRI regimen was assessed by the investigator. A serious adverse event was defined as an adverse event that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. (NCT00411450)
Timeframe: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Grade 3 or higher adverse event | Panitumumab-related adverse events | Chemotherapy-related adverse events | ≥ grade 3 panitumumab-related adverse events | ≥ grade 3 chemotherapy-related adverse events | Serious adverse events | Serious panitumumab-related adverse events | Serious chemotherapy-related adverse events | Life-threatening adverse events | Ended second-line treatment due to adverse events | Ended panitumumab due to adverse events | Ended FOLFIRI due to adverse events | Death due to adverse events | Panitumumab infusion reactions | Deaths during study | |
| Panitumumab Plus FOLFIRI | 115 | 94 | 107 | 112 | 56 | 65 | 46 | 15 | 24 | 18 | 18 | 20 | 28 | 8 | 2 | 71 |
Laboratory toxicities were graded according to CTCAE version 3. (NCT00411450)
Timeframe: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Anemia | Neutropenia | Hypomagnesaemia | Hypokalemia | Hypocalcaemia | Hyperbilirubinaemia | |
| Panitumumab Plus FOLFIRI | 1 | 4 | 8 | 1 | 3 | 1 |
Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no radiographic tumor assessment(s) at Week 17 or 25 were considered non-responders. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions. (NCT00411450)
Timeframe: Week 17 and Week 25
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 17 | Week 25 | |
| Mutant KRAS | 14 | 14 |
| Wild-type KRAS | 20 | 22 |
"The progression-free survival rate is defined as the Kaplan-Meier (KM) estimator of progression-free survival at Week 17 and Week 25 reported as the probability of being event (disease progression or death)-free. Tumor assessments were evaluated by the investigator according to modified RECIST criteria.~PD: At least a 20% increase in the size of target lesions since the treatment started or at least a 25% increase in the size of non-target lesions and the lesion(s) measure ≥ 10 mm, or the appearance of any new lesions. Participants who withdraw from the study prior to completion of Week 17 or 25 radiographic tumor assessments were censored at the last evaluable tumor assessment." (NCT00411450)
Timeframe: Week 17 and Week 25
| Intervention | percent probability (Number) | |
|---|---|---|
| Week 17 | Week 25 | |
| Mutant KRAS | 55 | 41 |
| Wild-type KRAS | 67 | 52 |
Measured from time of registration to death, or last contact date (NCT00086996)
Timeframe: 0-5 years
| Intervention | months (Median) |
|---|---|
| Chemo Plus RT, Surgery, Chemo | 28.3 |
Complete pathologic response assessed after chemoradiotherapy and surgery, defined as no evidence of residual disease on path review. Patients who did not receive surgery are assumed to have not responded. (NCT00086996)
Timeframe: 10-16 weeks after beginning study treatment
| Intervention | participants (Number) |
|---|---|
| Chemo Plus RT, Surgery, Chemo | 26 |
measured from date of registration to time of first documentation of progression by Response Evaluation Criteria in Solid Tumors (RECIST), death, or last contact date. (NCT00086996)
Timeframe: 0-3 years
| Intervention | months (Median) |
|---|---|
| Chemo Plus RT, Surgery, Chemo | 19.7 |
Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00086996)
Timeframe: Up to 3 years
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adult respiratory distress syndrome (ARDS) | Anorexia | CNS cerebrovascular ischemia | Calcium, serum-low (hypocalcemia) | Cardiac troponin T (cTnT) | Cardiac-ischemia/infarction | Chyle or lymph leakage | Confusion | Cough | Creatinine | Dehydration | Diarrhea | Distention/bloating, abdominal | Dysphagia (difficulty swallowing) | Dyspnea (shortness of breath) | Esophagitis | Fatigue (asthenia, lethargy, malaise) | Febrile neutropenia | Fever in absence of neutropenia, ANC lt1.0x10e9/L | Fistula, GI - Oral cavity | Gastrointestinal-Other (Specify) | Glucose, serum-high (hyperglycemia) | Heartburn/dyspepsia | Hemoglobin | Hypotension | Hypoxia | Inf (clin/microbio) w/Gr 3-4 neuts - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - Blood | Inf w/normal ANC or Gr 1-2 neutrophils - Lung | Inf w/normal ANC or Gr 1-2 neutrophils - Perit cav | Inf w/normal ANC or Gr 1-2 neutrophils - Wound | Infection with unknown ANC - Blood | Infection with unknown ANC - Lung (pneumonia) | Infection with unknown ANC - Wound | Leak (including anastomotic), GI - Esophagus | Leukocytes (total WBC) | Lymphopenia | Mood alteration - anxiety | Mucositis/stomatitis (clinical exam) - Esophagus | Mucositis/stomatitis (clinical exam) - Oral cavity | Mucositis/stomatitis (functional/symp) - Esophagus | Mucositis/stomatitis (functional/symp) - Oral cav | Muscle weakness, not d/t neuropathy - body/general | Nausea | Necrosis, GI - Stomach | Neutrophils/granulocytes (ANC/AGC) | Obstruction, GI - Esophagus | Pain - Abdomen NOS | Pain - Pain NOS | Pericardial effusion (non-malignant) | Platelets | Pleural effusion (non-malignant) | Pneumonitis/pulmonary infiltrates | Potassium, serum-low (hypokalemia) | Pulmonary/Upper Respiratory-Other (Specify) | Renal failure | SVT and nodal arrhythmia - Atrial fibrillation | SVT and nodal arrhythmia - Sinus tachycardia | Skin breakdown/decubitus ulcer | Sodium, serum-low (hyponatremia) | Stricture/stenosis (incl anastomotic), Esophagus | Syncope (fainting) | Thrombosis/thrombus/embolism | Typhlitis (cecal inflammation) | Vomiting | Weight loss | Wound complication, non-infectious | |
| Chemo Plus RT, Surgery, Chemo | 4 | 15 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 12 | 1 | 4 | 3 | 3 | 14 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 1 | 6 | 1 | 2 | 3 | 1 | 4 | 1 | 2 | 1 | 1 | 2 | 10 | 1 | 1 | 4 | 5 | 2 | 1 | 11 | 1 | 1 | 1 | 1 | 1 | 4 | 2 | 3 | 3 | 4 | 3 | 1 | 2 | 1 | 1 | 5 | 2 | 1 | 2 | 1 | 7 | 13 | 1 |
Follow-up for survival to be done at 3 month intervals for 2 years, then 6 month intervals for up to 5 years from study registration (NCT00321100)
Timeframe: From dose of first study drug to last timepoint known to be alive (median follow-up for all patients was 25.9 months)
| Intervention | months (Median) |
|---|---|
| Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab | 18 |
| Cetuximab, Oxaliplatin, Capecitabine | 42.5 |
"Per Response Evaluation Criteria In Solid Tumors (RECISTv1.0) assessed by CT, MRI, x-ray scan:~Complete response (CR): Disappearance of all lesions Partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions (SoL); from baseline SoL Stable disease (SD): Neither PR, PD, or CR Progressive disease (PD): >=20% increase in the SoL; from smallest SoL. Or appearance of new lesion" (NCT00321100)
Timeframe: every 6-9 weeks; from dose of first study drug to event
| Intervention | months (Median) |
|---|---|
| Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab | 8.7 |
| Cetuximab, Oxaliplatin, Capecitabine | 14.4 |
"Objective response rate calculated by the proportion of overall response: CR+PR. Patients were categorized by one of the following (1-4 per RECISTv1.0 criteria on CT, MRI, x-ray; 4-9 considered failure to respond/disease progression):~complete response (CR): Disappearance of all lesions~partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions (SoL); from baseline SoL~stable disease (SD): Neither PR, PD, or CR~progressive disease (PD): >=20% increase in the SoL; from smallest SoL. Or appearance of new lesion~early death from malignant disease~early death from toxicity~early death from other cause~9) unknown (not assessable, insufficient data)" (NCT00321100)
Timeframe: every 6-9 weeks; from date of first study drug dose until off treatment date (median of 8 cycles; range <1-19)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Overall response | Complete response | Partial response | Stable disease | |
| Cetuximab, Oxaliplatin, Capecitabine | 8 | 1 | 7 | 3 |
| Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab | 4 | 1 | 3 | 7 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L/hour (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 32.9 |
CL is calculated as dose divided by AUC 0-∞ (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L/hour (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 23.0 |
DR is defined as the time from the first objective documentation of complete or partial response that is subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurs first. The definition of censorship is the same as PFS. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | weeks (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 28.3 |
ORR is defined as the percentage of participants with best overall response of either a confirmed complete (CR) or partial response (PR) relative to the number of participants in FAS. Based on the response evaluation criteria in solid tumors (RECIST), CR is defined as the disappearance of all target lesions and PR is defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesion. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | percentage of participants (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 36.6 |
Concentration at 22 hour post start of 5-FU infusion were to be used as Css if 5-FU concentrations suggested steady state at 22 hours time point. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 650 |
"PFS is defined as the time from the date of enrollment to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first.~PFS data was censored on the day following the date of the last tumor assessment documenting absence of progressive disease for patients who 1) were given anti-tumor treatment other than the study treatment prior to observing objective tumor progression; 2) were removed from the study prior to documentation of objective tumor progression; and 3) were ongoing at the time of the analysis." (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | weeks (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 28.9 |
Terminal phase half-life of irinotecan was calculated as ln 2/ kel. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 5.36 |
Vss was calculated using following equation: CL x mean residence time (MRT), where MRT = the area under the first moment curve from zero time to infinity (AUMC 0-∞)/AUC 0-∞- (infusion time/2), AUMC 0-∞ = the area under the first moment curve from zero time to time t (AUMC t)+ ((t x Ct*)/ kel) + (Ct* / kel^2), AUMC t is calculated using the linear trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 160 |
AUC 0-24 was determined using the Linear/Log trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng.h/mL (Mean) | ||
|---|---|---|---|
| Sunitinib AUC 0-24 | SU012662 AUC 0-24 | Total (sunitinib + SU0122662) AUC 0-24 | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 1161 | 346 | 1507 |
"AUC last of irinotecan and its metabolite SN-38 were calculated using the Linear/Log trapezoidal method.~AUC∞ of irinotecan was calculated using following equation; AUC last+(C*t/kel), where Ct* is the estimated concentration at the time of the last quantifiable concentration, kel is terminal phase rate constant that is estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile." (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng.h/mL (Mean) | ||
|---|---|---|---|
| Irinotecan AUC last | Irinotecan AUC ∞ | SN-38 AUC last | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 13100 | 13800 | 274 |
Plasma concentrations were assessed at predose, 2, 4, 6, 8, and 24 hours postdose and Cmax and Ctrough of sunitinib, its metabolite SU012662, and the total (sunitinib + SU0122662) were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Sunitinib Cmax | Sunitinib Ctrough | SU012662 Cmax | SU012662 Ctrough | Total (sunitinib + SU0122662) Cmax | Total (sunitinib + SU0122662) Ctrough | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 54.3 | 41.8 | 15.8 | 11.3 | 70.0 | 53.1 |
Plasma samples were assessed at prior to initiation of irinotecan (and l-leucovorin) infusion, 1, 2 (predose for 5-FU bolus), 4, 8, and 24 hours after initiation of irinotecan infusion, and Cmax of irinotecan and its metabolite SN-38 were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Irinotecan Cmax | SN-38 Cmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 1963 | 25.1 |
Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Treatment emergent adverse events | Serious adverse events | CTCAE grade 3 or 4 adverse events | CTCAE grade 5 adverse events | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 71 | 32 | 70 | 1 |
(NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) | |
|---|---|---|
| Irinotecan tmax | SN-38 tmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 2 | 4 |
(NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) | ||
|---|---|---|---|
| Sunitinib Tmax | SU012662 Tmax | Total (sunitinib + SU0122662) Tmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 6 | 4 | 6 |
PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d*μg/mL). (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
| Intervention | d*μg/mL (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 2056 |
| Herceptin SC + Chemotherapy | 2268 |
PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d*μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
| Intervention | d*μg/mL (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 2179 |
| Herceptin SC + Chemotherapy | 2610 |
PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
| Intervention | μg/mL (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 230 |
| Herceptin SC + Chemotherapy | 166 |
Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event. (NCT00950300)
Timeframe: Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
| Intervention | months (Median) |
|---|---|
| Herceptin IV + Chemotherapy | NA |
| Herceptin SC + Chemotherapy | NA |
PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
| Intervention | μg/mL (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 221 |
| Herceptin SC + Chemotherapy | 149 |
Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough >20 μg/mL was reported. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
| Intervention | participants (Number) |
|---|---|
| Herceptin IV + Chemotherapy | 216 |
| Herceptin SC + Chemotherapy | 227 |
Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough >20 μg/mL was reported. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
| Intervention | participants (Number) |
|---|---|
| Herceptin IV + Chemotherapy | 232 |
| Herceptin SC + Chemotherapy | 227 |
Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
| Intervention | μg/mL (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 62.1 |
| Herceptin SC + Chemotherapy | 90.4 |
Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL). (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
| Intervention | μg/mL (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 57.8 |
| Herceptin SC + Chemotherapy | 78.7 |
OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause. (NCT00950300)
Timeframe: Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
| Intervention | months (Median) |
|---|---|
| Herceptin IV + Chemotherapy | NA |
| Herceptin SC + Chemotherapy | NA |
The percentage of participants who died at any time during the study was reported. (NCT00950300)
Timeframe: Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
| Intervention | percentage of participants (Number) |
|---|---|
| Herceptin IV + Chemotherapy | 14.5 |
| Herceptin SC + Chemotherapy | 13.6 |
Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported. (NCT00950300)
Timeframe: Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
| Intervention | percentage of participants (Number) |
|---|---|
| Herceptin IV + Chemotherapy | 33.3 |
| Herceptin SC + Chemotherapy | 32.7 |
Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (≥) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method. (NCT00950300)
Timeframe: Tumor assessments at Baseline; on Day 1 of Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months overall)
| Intervention | percentage of participants (Number) |
|---|---|
| Herceptin IV + Chemotherapy | 88.8 |
| Herceptin SC + Chemotherapy | 87.2 |
Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method. (NCT00950300)
Timeframe: After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
| Intervention | percentage of participants (Number) |
|---|---|
| Herceptin IV + Chemotherapy | 40.7 |
| Herceptin SC + Chemotherapy | 45.4 |
Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method. (NCT00950300)
Timeframe: After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
| Intervention | percentage of participants (Number) |
|---|---|
| Herceptin IV + Chemotherapy | 34.2 |
| Herceptin SC + Chemotherapy | 39.2 |
Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
| Intervention | μg/mL (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 51.7 |
| Herceptin SC + Chemotherapy | 80.6 |
Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
| Intervention | μg/mL (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 51.4 |
| Herceptin SC + Chemotherapy | 80.3 |
PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
| Intervention | days (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 0.05 |
| Herceptin SC + Chemotherapy | 4.12 |
Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to <10 mm with no prior assessment of PD. PR was defined as ≥30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR. (NCT00950300)
Timeframe: Tumor assessments at Baseline; on Day 1 Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of chemotherapy (approximately 6 months overall)
| Intervention | weeks (Median) |
|---|---|
| Herceptin IV + Chemotherapy | 6.14 |
| Herceptin SC + Chemotherapy | 6.14 |
PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
| Intervention | days (Mean) |
|---|---|
| Herceptin IV + Chemotherapy | 0.06 |
| Herceptin SC + Chemotherapy | 4.08 |
"Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with Treatment-induced ADAs and Treatment-enhanced ADA against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer)." (NCT00950300)
Timeframe: Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
| Intervention | participants (Number) | |
|---|---|---|
| Treatment-induced ADA | Treatment-enhanced ADA | |
| Herceptin SC + Chemotherapy | 49 | 13 |
"Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with Treatment-induced ADAs and Treatment-enhanced ADA against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer)." (NCT00950300)
Timeframe: Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
| Intervention | participants (Number) | |
|---|---|---|
| Treatment-induced ADAs | Treatment-enhanced ADA | |
| Herceptin IV + Chemotherapy | 28 | 2 |
| Herceptin SC + Chemotherapy | 46 | 1 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method. Overall Survival (OS) will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFOX or FOLFIRI + Bevacizumab | 29.0 |
| Arm B: FOLFOX or FOLFIRI + Cetuximab | 30.0 |
PFS will be measured from study entry until first documented progression or death from any cause. Time to event distributions will be estimated using the Kaplan-Meier method. PFS will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFOX or FOLFIRI + Bevacizumab | 10.6 |
| Arm B: FOLFOX or FOLFIRI + Cetuximab | 10.5 |
"Duration of overall response was measured from the time that measurement criteria are met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the onset of progression. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date).~Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 244.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 315 |
The primary variable was duration of disease control (DDC) and was defined as the sum of progression free survival intervals during first line and second line treatment (= time from the beginning of first line treatment until onset of progression during second line treatment). Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). (NCT02119026)
Timeframe: screening, every 8 to 9 weeks until progression, at end of treatment (other than progression), every 3 months until progression, death or up to 24 months (whatever comes first)
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 373.00 |
| B: XELOX + BEV Followed by XELIRI + BEV | 370.00 |
The first line PFS was defined as the progression free survival interval during first line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. (NCT02119026)
Timeframe: at progression of disease (PD) in first line therapy or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 241 |
| B: XELOX + BEV Followed by XELIRI + BEV | 280 |
The rate of overall response was measured as the response rate from randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | Participants (Count of Participants) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 32 |
| B: XELOX + BEV Followed by XELIRI + BEV | 36 |
Overall survival was measured as the time from the randomization date to the date of death. Patients without death date were censored at the date of the last tumor assessment (exception: availability of validated information about a later exitus date or a prolonged survival - in such a case the date of the follow-up assessment was either defined as the exitus date or replaced the last tumor assessment date) or the date of refusal. (NCT02119026)
Timeframe: date of death or date of last tumor assessment (28d safety f-u) in patients without death
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 593.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 643 |
"The second line PFS was defined as the progression free survival interval during second line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at progression of disease (PD) in second line therapy or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 129 |
| B: XELOX + BEV Followed by XELIRI + BEV | 155 |
Time to overall response was measured from the time of randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). Patients without response were censored at the date of the last tumor assessment, the date of death or the date of refusal. (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 185.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 178.0 |
Best response in first line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | Partial Response (PR) | Complete Response (CR) | |
| A: XELIRI + BEV Followed by XELOX + BEV | 4 | 21 | 26 | 2 |
| B: XELOX + BEV Followed by XELIRI + BEV | 1 | 23 | 30 | 0 |
Best response in second line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | Partial Response (PR) | Complete Response (CR) | Not available (NA) | |
| A: XELIRI + BEV Followed by XELOX + BEV | 7 | 11 | 6 | 0 | 8 |
| B: XELOX + BEV Followed by XELIRI + BEV | 8 | 13 | 2 | 0 | 1 |
The number of participants in Part 2 who died during the study. (NCT00111761)
Timeframe: From enrollment until last contact. Maximum follow-up was 16 months.
| Intervention | participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 6 |
Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 8 |
The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With IFL | 11 |
The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 6 |
Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With IFL | 9 |
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 24.3 |
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With FOLFIRI | 41.1 |
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 73.1 |
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 73.1 |
Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 35.0 |
Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until death or diease progression. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With FOLFIRI | 47.3 |
Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 5.9 |
Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Weeks (Median) |
|---|---|
| Panitumumab With IFL | 24.3 |
(NCT00375999)
Timeframe: One year
| Intervention | month (Median) |
|---|---|
| Treatment Group | 13.4 |
DNA was extracted from tumor specimens.Screened for the presence of KRAS codon 12 and 13 mutations using a PCR clamping and melting curve technique. PCR amplification of the wild-type KRAS sequence was suppressed in this process by the incorporation in the reaction mix of a locked nucleic-acid oligomer16 spanning codons 12 and 13 of the KRAS gene. Post-PCR hybridization and melting curve analysis using fluorescently tagged oligonucleotides incorporated in the original PCR reaction permitted the identification and discrimination of distinct KRAS codon 12 and 13 missense mutations. (NCT00815308)
Timeframe: 07/29/2010-09/30/2010
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 53 |
The overall response rate was defined as the numbers of patients with a complete response (CR) or partial response (PR). CR was defined as no target lesion at follow-up computed tomography scan and barium swallow examination 3-6 weeks after completion of chemo-radiation. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT00815308)
Timeframe: 1 to 3 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 44 |
All patients were regularly monitored for possible adverse events, which were graded according to National Cancer Institute Common Toxicity Criteria version 3.0. (NCT00815308)
Timeframe: Every week during treatment and 1 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 55 |
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting. All detailed information regarding serious and other adverse events are listed in the Adverse Event module of these results. (NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 5 |
(NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 0 |
OS = Time from registration until death from any cause (NCT00603408)
Timeframe: Until study was terminated (23.5 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 100 |
"Complete response: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level~Partial response: at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD~Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started,~Progressive disease: at least a 20% increase in the sum of the LD of the target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one more new lesions, or unequivocal progression of existing non-target lesions." (NCT00603408)
Timeframe: At the time of surgery (week 13)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Cisplatin + Radiation + Recommended Surgery | 2 | 3 | 0 | 0 |
Here is the number of participants with an adverse event. For a detailed list of adverse events see the adverse event module. (NCT00052962)
Timeframe: 2003-2008
| Intervention | Participants (Number) |
|---|---|
| Arm 1 Surgery + Post op Chemotherapy | 7 |
| Arm 2 Surgery + CHPP | 6 |
Local failure will be assessed radiographically using endoscopy with biopsy, CT scan, and a positron emission computed tomography-CT scan. which was defined as persistence /recurrence of the tumor in the radiation therapy field. (NCT03082586)
Timeframe: 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Radiochemotherapy 1 | 0 |
| Arm 2: Radiochemotherapy 2 | 1 |
| Arm 3: Radiochemotherapy 3 | 1 |
| Arm 4: Radiochemotherapy 4 | 0 |
| Arm 5: Radiochemotherapy 5 | 0 |
| Arm 6: Radiochemotherapy 6 | 0 |
The DLTs were defined as grade >/=4 esophatitis, any other grade >/=3 nonhematological toxicity (except nausea and vomiting), or grade >/=4 hematological toxicity lasting more than 7 days, which are possibly, probably, or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. (NCT03082586)
Timeframe: 15 months
| Intervention | dose limiting toxicity (Number) |
|---|---|
| Arm 1: Radiochemotherapy 1 | 0 |
| Arm 2: Radiochemotherapy 2 | 0 |
| Arm 3：Radiochemotherapy 3 | 0 |
| Arm 4: Radiochemotherapy 4 | 1 |
| Arm 5: Radiochemotherapy 5 | 0 |
| Arm 6: Radiochemotherapy 6 | 2 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02311361)
Timeframe: Date treatment consent signed to date off study, approximately 18 months and 4 days for Cohort 1/Dose Level A1, 23 months and 29 days for Cohort 2/Dose Level A2, 32 months and 19 days for Cohort C/Dose Level C1, and 44 months and 18 days for Cohort C/Dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Durvalumab + 8 Gray (Gy) in 1 Fraction | 14 |
| Durvalumab +5 Gy in 5 Fractions | 10 |
| Durvalumab +Tremelimumab + 8 Gy in 1 Fraction | 19 |
| Durvalumab +Tremelimumab +5 Gy in 5 Fractions | 20 |
Amount of time participants survived after therapy. (NCT02311361)
Timeframe: From study entry to death or date of last contact, whichever occurs first, up to 2 years of follow-up
| Intervention | Months (Median) |
|---|---|
| Cohort A Dose Level A1 | 3.3 |
| Cohort A Dose Level A2 | 9.0 |
| Cohort C Dose Level C1 | 2.1 |
| Cohort C Dose Level C2 | 4.2 |
Participants who survived at least 6 months after therapy. (NCT02311361)
Timeframe: 6 month
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A Dose Level A1 | 26 |
| Cohort A Dose Level A2 | 58 |
| Cohort C Dose Level C1 | 12 |
| Cohort C Dose Level C2 | 40 |
PFS is the defined as the median amount of time subject survives without disease progression after treatment. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). NOTE: While RECIST Progressive Disease (PD) will be noted and recorded the immune-related (IR) RECIST criteria will be applied to determine discontinuation of study treatment. For modified Immune-Related Response Criteria (irRC), only target and measurable lesions are taken into account. (NCT02311361)
Timeframe: From study entry to disease progression, death or date of last contact, whichever occurs first, an average of 6 months
| Intervention | Months (Median) |
|---|---|
| Cohort A Dose Level A1 | 1.7 |
| Cohort A Dose Level A2 | 2.5 |
| Cohort C Dose Level C1 | 0.9 |
| Cohort C Dose Level C2 | 2.3 |
Adverse Events (AEs) are reported by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade 1=Mild, Grade 2= Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Fatal. (NCT02311361)
Timeframe: Participants were assessed from the start of study treatment at Cycle 1 then after every cycle (1 cycle = 28 days) of protocol treatment until 30 days after they were taken off treatment, approximately 4.0 months.
| Intervention | Adverse events (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 Abdominal pain | Grade 1 Alanine aminotransferase increased | Grade 1 Alkaline Phosphatase increased | Grade 1 Anemia | Grade 1 Anorexia | Grade 1 Atrial fibrillation | Grade 1 Aspartate aminotransferase increased | Grade 1 Back pain | Grade 1 Blood bilirubin increased | Grade 1 Cough | Grade 1 Creatinine increased | Grade 1 Diarrhea | Grade 1 Dizziness | Grade 1 Dry mouth | Grade 1 Dysgeusia | Grade 1 Endocrine disorders,Other, Elevated T3, T4 | Grade 1 Eye disorders - decr. in near vision,bilat | Grade 1 - Fatigue | Grade 1 Fever | Grade 1 Headache | Grade 1 Hemorrhoidal hemorrhage | Grade 1 Hoarseness | Grade 1 Hyperglycemia | Grade 1 - Hyperkalemia | Grade 1 Hyperuricemia | Grade 1 Hypoalbuminemia | Grade 1 Hypocalcemia | Grade 1 - Hyponatremia | Grade 1 Hypothyroidism | Grade 1 Infusion related reaction | Grade 1 Lymphocyte count decreased | Grade 1 Mucositis | Grade 1 Musculoskeletal & connective tissue | Grade 1 Nausea | Grade 1 Neutrophil count decreased | Grade 1 Pain | Grade 1 Platelet count decreased | Grade 1 Pruritis | Grade 1 Rash maculo-papular | Grade 1 Serum amylase increased | Grade 1 - Skin/subc tissue disorder - Night sweats | Grade 1 Skin/subc tissue disorder - Rash | Grade 1 Skin/subc tissue - Psoriasis | Grade 1 Skin/subc tissue disorder - Itching | Grade 1 Skin/subc tissue disorder-Skinpeeling hand | Grade 1 Vertigo | Grade 1 Vomiting | Grade 1 Weight loss | Grade 1 White blood cell decreased | Grade 2 Abdominal pain | Grade 2 Anemia | Grade 2 Anorexia | Grade 2 Autoimmune disorder | Grade 2 Diarrhea | Grade 2 Dysgeusia | Grade 2 Endocrine disorders - TSH elev-Hypothyroid | Grade 2 Fatigue | Grade 2 Fecal incontinence | Grade 2 Fever | Grade 2 Gastroesophageal reflux disease | Grade 2 Hyperglycemia | Grade 2 Hypoalbuminemia | Grade 2 Hypothyroidism | Grade 2 Hypophosphatemia | Grade 2 Infusion related reaction | Grade 2 Lymphocyte count decreased | Grade 2 Malaise | Grade 2 Nausea | Grade 2 Neutrophil count decreased | Grade 2 Platelet count decreased | Grade 2 Rash maculo-papular | Grade 2 Weight loss | Grade 2 White blood cell count | Grade 3 Anemia | Grade 3 Anorexia | Grade 3 Colitis | Grade 3 Dehydration | Grade 3 Diarrhea | Grade 3 Fatigue | Grade 3 Hyperthyroidism | Grade 3 Lymphocyte count decreased | Grade 3 Nausea | Grade 3 Serum amylase increased | Grade 3 Vomiting | Grade 4 Lymphocyte count decreased | |
| Cohort A Dose Level A1 | 0 | 1 | 0 | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 15 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Cohort A Dose Level A2 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 4 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 |
| Cohort C Dose Level C1 | 0 | 0 | 0 | 9 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 17 | 0 | 0 | 3 | 0 | 0 | 7 | 2 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 9 | 0 | 0 | 2 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 15 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 6 | 0 | 1 | 0 | 2 |
| Cohort C Dose Level C2 | 1 | 5 | 2 | 9 | 3 | 1 | 6 | 1 | 1 | 1 | 1 | 7 | 1 | 0 | 0 | 0 | 0 | 7 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | 1 | 4 | 1 | 2 | 26 | 1 | 0 | 2 | 1 | 1 | 13 | 3 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 7 | 1 | 10 | 2 | 1 | 4 | 1 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 30 | 2 | 3 | 1 | 2 | 1 | 2 | 0 | 3 | 1 | 2 | 3 | 3 | 1 | 1 | 18 | 2 | 0 | 2 | 2 |
Progressive disease (PD): >=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): >=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD. (NCT02311361)
Timeframe: At screening then every 8 weeks until disease progression or patient is taken off the trial, whichever comes first, approximately 6 months.
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | |
| Cohort A Dose Level A1 | 0 | 1 | 3 | 4 |
| Cohort A Dose Level A2 | 0 | 0 | 4 | 4 |
| Cohort C Dose Level C1 | 0 | 0 | 2 | 6 |
| Cohort C Dose Level C2 | 0 | 1 | 5 | 10 |
283 reviews available for fluorouracil and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Female; Fluorouracil | 2022 |
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro | 2022 |
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2022 |
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Chemotherapy, Adjuvan | 2022 |
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Eso | 2023 |
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2023 |
Missed Gastric Cancer Metastasis to the Appendix: Case Report and Literature Review.
Topics: Adenocarcinoma; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Appendiceal | 2020 |
Chemotherapy for patients with unresectable or metastatic small bowel adenocarcinoma: a systematic review.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; | 2020 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA Topoisomerases, Type I; Fluorouracil; Humans; Irinotecan; | 2020 |
Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Colon; Femal | 2020 |
Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Proto | 2021 |
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C | 2021 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorou | 2017 |
The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2017 |
Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil | 2017 |
A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Disease | 2017 |
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Adenocarcinoma located at a Meckel's Diverticulum: A case report and literature review.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colonoscopy; Fema | 2017 |
Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoradiotherapy; Do | 2019 |
Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Hum | 2018 |
Pancreaticoduodenectomy with Replaced Common Hepatic Artery and Portal Vein Reconstruction in Primary Carcinoma Duodenum: a Case Report and Literature Review.
Topics: Adenocarcinoma; Aged; Angioplasty; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2019 |
Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug C | 2018 |
Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Electroporation; | 2018 |
Non-α-fetoprotein-producing adrenal hepatoid adenocarcinoma: A case report and literature review.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenal Glands; alpha-Fetoproteins; Antineoplastic Combined | 2018 |
Metastatic Urachus Neoplasia: A Case Report and Review of the Current Literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cystectomy; Fatal Outcome; Fl | 2019 |
Neoadjuvant Treatment for Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct | 2019 |
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and | 2019 |
Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: a case report and literature review.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Cr | 2019 |
Role of Nuclear Factor Erythroid 2-Related Factor 2 (NRF-2) Mediated Antioxidant Response on the Synergistic Antitumor Effect of L-Arginine and 5-Fluro Uracil (5FU) in Breast Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antioxidants; Arginine; Breast Neoplasms; Fluorouracil; Humans; NF-E2-Relat | 2019 |
Small intestinal adenocarcinoma: rarely considered, often missed?
Topics: Adenocarcinoma; Aged; Capsule Endoscopy; Celiac Disease; Chemotherapy, Adjuvant; Cystic Fibrosis; Do | 2013 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Tri | 2013 |
Second-line therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2013 |
Adenocarcinoma of the colon in children: case series and mini-review of the literature.
Topics: Abdomen; Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Barium Sulfate; | 2013 |
Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2013 |
Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathies; Colorectal Neoplasm | 2013 |
[A case of early colorectal cancer with synchronous multiple liver metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2013 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2014 |
Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Tri | 2014 |
Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Clinical Trials | 2014 |
Disseminated intravascular coagulation as clinical manifestation of colorectal cancer: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; De | 2014 |
[Penile metastasis from rectal carcinoma: a case report and literature review].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2014 |
Adenocarcinoma of the ampulla of Vater: what treatment options are available?
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2015 |
Role of solute carrier transporters in pancreatic cancer: a review.
Topics: Adenocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Membran | 2014 |
[Disappearance of a gastric lesion following modified FOLFOX6 chemotherapy in a patient with metastatic colorectal cancer: a case report and literature review].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Ma | 2014 |
Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease- | 2015 |
[Molecular pathology of colorectal cancer].
Topics: Adenocarcinoma; Algorithms; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Colorectal | 2015 |
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluor | 2015 |
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
Topics: Adenocarcinoma; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials | 2015 |
Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2015 |
Resection of a Submucosal Tumor-Like Superficial Carcinoma in Middle Thoracic Esophagus Concomitant with Mucosal Adenocarcinoma and Submucosal Squamous Cell Carcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
[A CASE OF SOLITARY ADRENAL TUMOR METASTASIZED FROM RECTAL CANCER].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy P | 2015 |
[A Case of Pathologically Complete Response of a Rectal Cancer after Preoperative Treatment with mFOLFOX6 and Radiation Therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2015 |
[A Case of Sigmoid Colon Cancer with Metastasis to the Uterus].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2015 |
[A Case of Descending Colon Adenocarcinoma with Neuroendocrine Differentiation Successfully Treated with FOLFIRI plus Bevacizumab].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothe | 2016 |
Borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreatect | 2016 |
Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical | 2016 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pa | 2016 |
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; | 2016 |
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, T | 2016 |
Small bowel adenocarcinoma of the jejunum: a case report and literature review.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Delay | 2016 |
Unresectable liver metastases in colorectal cancer: review of current strategies.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2016 |
FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2008 |
Capecitabine-induced oromandibular dystonia: a case report and literature review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Asian People; Brain Stem; Capecitabine; Deoxycytidi | 2008 |
[A case of alpha-fetoprotein-producing gastric cancer with hepatic metastasis successfully treated with combination chemotherapy].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2008 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Ca | 2008 |
[Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Crohn Disease; Fluorouracil; Humans; | 2009 |
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2009 |
The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2008 |
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Tri | 2009 |
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2009 |
Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2009 |
The spectrum of 5-fluorouracil cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arr | 2009 |
Small bowel adenocarcinoma.
Topics: Adenocarcinoma; Age of Onset; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Fema | 2008 |
[Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adju | 2008 |
Medical management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabe | 2009 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Chemoth | 2009 |
[Therapy in gastric cancer. From an oncological perspective].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2009 |
Diagnosis and management of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Chemotherapy, Adjuvant; Cholangiog | 2009 |
[Neoadjuvant chemotherapy and pancreatoduodenectomy for locally advanced colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Flu | 2009 |
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature.
Topics: Acidosis, Renal Tubular; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2010 |
Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Intestinal Neoplasms; | 2010 |
[A case of poorly differentiated adenocarcinoma of the rectum with disseminated carcinomatosis of the bone marrow successfully treated with mFOLFOX-6/bevacizumab].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
[Recent developments of pharmacogenomics in the treatment of colorectal cancers].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Biotr | 2010 |
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
Topics: Adenocarcinoma; Age Factors; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Cap | 2011 |
[Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2011 |
[A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antimetabolites, Antineoplastic; Antin | 2010 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic | 2011 |
[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2011 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; C | 2011 |
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cap | 2011 |
[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].
Topics: Adenocarcinoma; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; | 2011 |
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2011 |
[Chemotherapy and rectal cancer].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2011 |
[Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choice Behav | 2012 |
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cap | 2012 |
Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia | 2012 |
Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
New biomarkers and targets in pancreatic cancer and their application to treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, Pan | 2012 |
Addisonian crisis secondary to bilateral adrenal metastases in rectal carcinoma: report of a rare case and literature review.
Topics: Addison Disease; Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Capecitab | 2013 |
Management of diabetes and pancreatic cancer.
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2012 |
Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Duodenal Neoplasms; Fe | 2013 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Du | 2012 |
Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2013 |
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Top | 2013 |
Combined-modality therapy for rectal cancer using irinotecan.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Top | 2002 |
[Primary adenocarcinoma of the appendix. Case report and review of the literature].
Topics: Adenocarcinoma; Adult; Appendectomy; Appendiceal Neoplasms; Appendicitis; Cecal Neoplasms; Chemother | 2002 |
[Gemcitabine and pancreatic cancer].
Topics: Adenocarcinoma; Analgesia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2002 |
Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bone Morphogenetic Protein 2; Bone Morphogen | 2003 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabin | 2002 |
Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2003 |
Developments in the systemic therapy of pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2003 |
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Older patients with colon cancer: is adjuvant chemotherapy safe and effective?
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Leuco | 2003 |
Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical T | 2003 |
Sigmoidoduodenal fistula as a rare complication of colonic carcinoma: report of a case.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Duodenal Diseases; Fluorouracil; Hu | 2003 |
[Chemoradiation in pancreatic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M | 2003 |
Pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2003 |
Focus on gastric cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadheri | 2004 |
The development and application of functional nuclear magnetic resonance to in vivo therapeutic anticancer research: 2002 Sir Godfrey Hounsfield lecture delivered at the President's Day, Manchester.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract; Biomarkers; Fluorouracil; Forecastin | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplat | 2004 |
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2004 |
Neoadjuvant treatment of oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2004 |
[Chemoradiation for pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2004 |
Colonic rupture in a patient on combination chemotherapy for metastasized carcinoma of the esophagogastric junction. Case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cecal Diseases; Cisplatin; Colonic D | 2005 |
[Clinical role of interleukin-2 in the surgical treatment of liver metastasis due to colon adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Combined | 2004 |
Role of post-operative chemoradiation in resected gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2005 |
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2004 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2005 |
[Molecular biology in clinical cancer research: the example of digestive cancers].
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2005 |
Role of adjuvant therapy in the management of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Can | 2005 |
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Radiation and chemoradiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2005 |
[Management of rectal cancer in pregnant women].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Case Management; Cesarean Section; Chemotherapy, Adjuv | 2005 |
The role of bevacizumab as first-line therapy for colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2005 |
Adjuvant therapy of resected gastric cancer is necessary.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil | 2005 |
Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe?
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Col | 2006 |
Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; DNA; DNA Topoiso | 2006 |
Current state of adjuvant therapy in resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2006 |
Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcium; Cisplatin; Combined Modalit | 2006 |
Capecitabine in carcinoma of the pancreas.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2006 |
Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine | 2007 |
Molecular markers for gastric adenocarcinoma: an update.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2006 |
Urachal carcinoma: surgical and chemotherapeutic options.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cispla | 2006 |
[Complications of surgical resection of esophageal cancer].
Topics: Adenocarcinoma; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Endosc | 2006 |
The case for routine use of adjuvant therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemotherapy, Adjuv | 2007 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2007 |
Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Flu | 2007 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 2007 |
Adjuvant therapy for pancreatic cancer: to treat or not to treat?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Flu | 2007 |
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Tria | 2007 |
Docetaxel: in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do | 2007 |
Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2008 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2007 |
Neoadjuvant and adjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidin | 2008 |
Total mesorectal excision and management of rectal cancer.
Topics: Adenocarcinoma; Anastomosis, Surgical; Antineoplastic Agents; Combined Modality Therapy; Disease Man | 2007 |
Adjuvant therapy in pancreatic cancer: a critical appraisal.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Che | 2007 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Ad | 2008 |
The chemotherapy of prostatic adenocarcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclop | 1980 |
Possibilities and limitations of the cytostatic treatment of gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Es | 1982 |
Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; | 1994 |
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bilirubin; Combined Modality Therapy; Fatal Outcome; Fe | 1995 |
Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1994 |
Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy.
Topics: Adenocarcinoma; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; BCG Vacci | 1995 |
Cerebral demyelination with 5-fluorouracil and levamisole.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorec | 1994 |
Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Adjuvant; | 1994 |
Current approaches to multimodality management of advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri | 1993 |
Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1993 |
The use of mitomycin in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1993 |
Mitomycin therapy in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1993 |
Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Protocols; Clinical Trials a | 1995 |
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1996 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Horm | 1996 |
[Cancer of the anal canal].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1990 |
Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluor | 1996 |
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1995 |
[Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; | 1996 |
[Sequential methotrexate and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1996 |
[A case of alpha-fetoprotein-producing pancreatic carcinoma--review of 41 cases reported in Japan].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1996 |
Isolated liver perfusion for liver metastases: pharmacokinetic advantage?
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 1996 |
[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Sch | 1997 |
Meningeal carcinomatosis as the presenting manifestation of gastric adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 1997 |
Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.
Topics: Adenocarcinoma; Aged; Antidotes; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease | 1997 |
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla | 1997 |
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1997 |
Clinical experience with gemcitabine in pancreatic carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Evalu | 1997 |
Chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 1998 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancr | 1998 |
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 1998 |
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothec | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Practical recommendations for the management of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Ther | 1999 |
Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo | 1999 |
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
External beam radiotherapy for pelvic node recurrence after curative resection of colon cancer: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colectomy; Colonic Neopla | 1999 |
Colorectal cancer in adolescents.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon; Colore | 1999 |
[Adenocarcinoma of the exocrine pancreas: management and therapeutic hopes].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Case-Control Studies; Chemotherapy, Adjuvant; Clini | 1999 |
Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Fluorour | 1999 |
In situ standardised AgNOR analysis: a simplified method for routine use to determine prognosis and chemotherapy efficiency in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Nuclear | 2000 |
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1999 |
Adenocarcinoma at the esophageal gastric junction arising in an 11-year-old girl.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Child; Cisplatin; Esophagectomy; Esophagogastric Ju | 1999 |
[Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
[Adjuvant intra-arterial chemotherapy after curative resection of liver metastasis from colorectal cancer. Results of a pilot study in 30 patients].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; F | 1999 |
Colonic carcinoma: a case report in a child and review literature.
Topics: Abdominal Pain; Adenocarcinoma; Biopsy, Needle; Child; Colectomy; Colonic Neoplasms; Fluorouracil; F | 2000 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal | 2000 |
Adjuvant therapy of colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, | 2000 |
Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Flu | 2000 |
Clinical update of gemcitabine in pancreas cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Com | 2000 |
The treatment of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Pancreatic Ductal; Chemotherapy, | 2000 |
[Concomitant radiochemotherapy in cancer of the cervix uteri: modifications of the standards].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2000 |
[Palliative therapy of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Ge | 2001 |
Neoadjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo | 2001 |
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phyto | 2001 |
Irinotecan-induced dysarthria.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
[A case of gastric cancer with multiple liver metastases that were completely responsive to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirub | 2001 |
[A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug | 2001 |
Early appendiceal adenocarcinoma. A review of the literature with special reference to optimal surgical procedures.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Appendiceal Neoplasms; Fluorouracil; Humans; Japan; | 2002 |
Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic | 2002 |
Chemotherapy options for gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2002 |
[Chemotherapy for the patients with esophageal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Ce | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow D | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2002 |
Progress report. Cytotoxic therapy for gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Carcinoma, | 1976 |
An aggressive approach to prostatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Castration; Cortisone; Cyclophosphamide; Diethylstilbes | 1977 |
Individual cell biology: basis and prospects for a rational cancer chemotherapy.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Chromosome Aberrations; Cyclophospham | 1977 |
Chemotherapy of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fluorour | 1979 |
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Female; F | 1975 |
[Systemic chemotherapy in metastatic colorectal adenocarcinomas].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fem | 1992 |
The value of adjuvant therapy after radical surgery for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 1992 |
Treatment of gastrointestinal and renal adenocarcinomas with interferon-alpha.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Inter | 1992 |
Aggressive therapy for cancer of the pancreas. Does it help?
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Care; Palliative Car | 1990 |
Skin reactions to radiotherapy--a spectrum resembling erythema multiforme: case report and review of the literature.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Erythema Multiforme; Female; Flu | 1992 |
Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Drug Eruptions; Fluorouracil; Humans; Infusions, Intravenous; Male; Photosensi | 1991 |
Vaginal adenosis and clear cell carcinoma after 5-fluorouracil treatment for condylomas.
Topics: Adenocarcinoma; Adult; Condylomata Acuminata; Female; Fluorouracil; Humans; Vaginal Diseases; Vagina | 1991 |
Levamisole in the adjuvant treatment of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1991 |
Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1990 |
Clinical trial with 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; | 1990 |
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Clinical; Colonic Neoplas | 1990 |
[Combination radiotherapy and chemotherapy in cancer of the pancreas. Review of the literature and prospects].
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Pancreatic Neoplasms; Prognosis; Ra | 1990 |
Management of colorectal cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hu | 1990 |
Update in cancer chemotherapy, Part III: Lung cancer, Part 1.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Carcinoma; C | 1985 |
Pancreatic cancer in 1988. Possibilities and probabilities.
Topics: Adenocarcinoma; Combined Modality Therapy; Diagnosis, Differential; Fluorouracil; Humans; Lymphatic | 1988 |
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dru | 1989 |
[5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; | 1989 |
Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Transplantation; Thymidyl | 1989 |
Phase I/II study of definitive radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) for advanced or recurrent gynecologic malignancies. Preliminary report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C | 1989 |
Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1989 |
[Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma. Preliminary results].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 1989 |
In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; Femal | 1988 |
Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasm | 1988 |
[Current views of the treatment of non-microcellular carcinoma of the lungs].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyc | 1985 |
Chemotherapy in advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Cystadenocarcinoma; Cystadeno | 1973 |
Genitourinary-tract problems of the aged male.
Topics: Adenocarcinoma; Age Factors; Aged; Cyclophosphamide; Cyproterone; Diethylstilbestrol; Fluorouracil; | 1974 |
The role of chemotherapy in the treatment of lung cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Bleomycin; Carcinoma, Small Cell; Carcinom | 1974 |
The chemical therapy of breast cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; | 1974 |
Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aniline Compounds; Bone Neoplasms; Cyclophosphamide; Evaluation St | 1973 |
A review of chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Chlorambucil; Chromomycins; Cyclophosphamide; Cyt | 1974 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclo | 1971 |
[Molecular basis of the relation between the cytotoxic effect of antineoplastic compounds and the cell cycle phase].
Topics: Adenocarcinoma; Adrenocorticotropic Hormone; Alkylating Agents; Androgens; Animals; Antibiotics, Ant | 1972 |
[Use of optical quantum generators (lasers) in oncology].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Basal Cell; Carcinom | 1972 |
Obstacles to the improvement of radiotherapy of rectal cancer.
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Fluorouracil; Humans; Laparotomy; Lymphography; Methods; | 1973 |
Nonhormonal chemotherapy of endometrial adenocarcinoma: a review.
Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Drug Evaluation; Drug Therapy | 1974 |
Recent advances in pancreatic cancer.
Topics: Adenocarcinoma; Angiography; Antigens, Neoplasm; Biopsy; Carcinoembryonic Antigen; Endoscopy; Evalua | 1974 |
Current progress in the management of cancer. A collective review.
Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem | 1969 |
The metabolism and pharmacology of 5-fluorouracil.
Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber | 1971 |
Chemotherapy of ovarian cancer with melphalan.
Topics: Adenocarcinoma; Ascites; Carcinoma; Cyclophosphamide; Female; Fluorouracil; Humans; Injections, Intr | 1968 |
1532 trials available for fluorouracil and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Fema | 2022 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Femal | 2021 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2021 |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Hum | 2022 |
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Granulocyte | 2022 |
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
Topics: Adenocarcinoma; Capecitabine; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm | 2022 |
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorour | 2022 |
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dis | 2022 |
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; D | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Flu | 2022 |
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2022 |
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2023 |
Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Do | 2022 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2023 |
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Fluorouracil; Human | 2023 |
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Appendiceal Neoplasms; Colorectal | 2023 |
Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th | 2023 |
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPL
Topics: Adenocarcinoma; Clinical Trials, Phase II as Topic; Esophagogastric Junction; Fluorouracil; Humans; | 2023 |
Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2019 |
Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adj | 2019 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiothe | 2020 |
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Female; Flu | 2019 |
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemoth | 2019 |
Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2020 |
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2020 |
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 2020 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia | 2020 |
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2020 |
Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal Cancer: A Dilemma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2019 |
Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Co | 2020 |
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2020 |
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neo | 2020 |
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-U | 2020 |
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2020 |
Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2020 |
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne | 2020 |
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pr | 2020 |
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2020 |
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Moda | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2020 |
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 P | 2020 |
The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Double-B | 2020 |
Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycyti | 2020 |
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine | 2020 |
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal | 2020 |
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antin | 2020 |
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2021 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2021 |
Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2021 |
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil | 2021 |
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2021 |
Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial.
Topics: Adenocarcinoma; Chemoradiotherapy; Fluorouracil; Humans; Hyperthermia; Neoadjuvant Therapy; Neoplasm | 2021 |
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2021 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap | 2021 |
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2021 |
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherap | 2017 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Dose Fr | 2017 |
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-F | 2017 |
A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2017 |
Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colectomy | 2017 |
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combin | 2018 |
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2017 |
Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2017 |
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2018 |
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2018 |
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizum | 2018 |
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2018 |
Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Sur | 2018 |
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2018 |
Preoperative radiotherapy and local excision of rectal cancer: Long-term results of a randomised study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Mo | 2018 |
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Fre | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2018 |
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Antineoplastic Agents; Antineoplastic Combined C | 2018 |
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che | 2019 |
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2019 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Di | 2019 |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2018 |
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F | 2019 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F | 2019 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F | 2019 |
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F | 2019 |
FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Diffusion kurtosis imaging and conventional diffusion weighted imaging to assess electrochemotherapy response in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidi | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2019 |
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2019 |
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2019 |
Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2019 |
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2019 |
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doub | 2019 |
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, S | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Ag | 2019 |
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2019 |
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2019 |
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre | 2014 |
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2013 |
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2013 |
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2013 |
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colo
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxyc | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2013 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2013 |
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antin | 2013 |
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com | 2013 |
A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Agents; Antineoplastic Combined Chemot | 2013 |
Evaluation of Outcomes in Patients With Carcinoma of the Cervix Treated With Concurrent Radiation and Cisplatin Versus Cisplatin/5-FU Compared With Radiation Alone.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2015 |
Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2013 |
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2013 |
Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2013 |
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidin | 2014 |
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Blood Vessels; Capecitabine; Chemoradiotherap | 2013 |
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Rea | 2014 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2013 |
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2015 |
Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv | 2014 |
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2014 |
Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2014 |
Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Che | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docet | 2014 |
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; De | 2014 |
Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2014 |
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2014 |
Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2014 |
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotti | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; | 2014 |
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2014 |
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2014 |
Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2014 |
Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycyt | 2014 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2015 |
S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Combinati | 2014 |
Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Deoxycytidine; F | 2014 |
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Biomarkers, Tumor; Ca | 2014 |
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2017 |
A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesoph
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2014 |
Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2014 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati | 2014 |
Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Disea | 2014 |
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2015 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2014 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2014 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2014 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2014 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2015 |
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 2014 |
Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chem | 2015 |
Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma | 2014 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China | 2015 |
Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2015 |
Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD8-Positi | 2015 |
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2015 |
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2015 |
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2015 |
Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplas | 2015 |
Phase I dose escalation trial of nitroglycerin in addition to 5-fluorouracil and radiation therapy for neoadjuvant treatment of operable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2015 |
[Immediate results of combined therapy for local recurrences of rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2015 |
The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2016 |
Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2015 |
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2015 |
Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; | 2016 |
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoem | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Fre | 2015 |
Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; | 2016 |
Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2015 |
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Dis | 2015 |
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2015 |
Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chem | 2016 |
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2016 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2016 |
FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2016 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2018 |
A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi | 2015 |
A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2016 |
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape | 2016 |
A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2016 |
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Chemoradiotherapy; Deoxycytidine; Female; F | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; | 2016 |
Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fracti | 2016 |
A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogast | 2018 |
Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Consolidation Chemotherapy; Double-B | 2016 |
Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2016 |
Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorouraci | 2016 |
Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
Topics: Adenocarcinoma; Aged; Anal Canal; Antimetabolites, Antineoplastic; Chemoradiotherapy; Fecal Incontin | 2016 |
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Fr | 2017 |
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2016 |
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2016 |
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Femal | 2016 |
A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2016 |
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabi | 2016 |
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cel | 2018 |
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2016 |
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Co | 2016 |
Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Digestive S | 2016 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04).
Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Chemoradiotherapy; Colectomy; Disease-Free Survival; Do | 2017 |
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cam | 2016 |
EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2017 |
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2017 |
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazo | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers | 2017 |
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemotherapy | 2017 |
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2017 |
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2017 |
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant | 2017 |
Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dr | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Pr | 2008 |
Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy | 2008 |
Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; | 2008 |
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2008 |
Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2008 |
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Ch | 2008 |
A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2008 |
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2008 |
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2009 |
Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2008 |
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2008 |
Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2008 |
[Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherap | 2008 |
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acid | 2009 |
Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2008 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C | 2009 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2008 |
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2009 |
Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo | 2008 |
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2008 |
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2008 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility | 2008 |
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2008 |
A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2009 |
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2009 |
Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2008 |
Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2009 |
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2009 |
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2009 |
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2009 |
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2009 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 8 | 2009 |
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop | 2009 |
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2009 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine | 2009 |
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2008 |
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Squamous C | 2009 |
Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Antirheumatic Agents; Chemotherapy, | 2009 |
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chemotherapy | 2009 |
Second-line therapy in refractory pancreatic cancer. results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2009 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2009 |
Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2009 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deo | 2009 |
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2009 |
Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2009 |
Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2009 |
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; D | 2010 |
Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2009 |
A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapR
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 2009 |
Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Feasibility | 2009 |
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabin | 2009 |
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2009 |
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Antineoplastic Combined Chemotherapy Protocols; Ax | 2010 |
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2010 |
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 2010 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2010 |
Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2009 |
Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2009 |
Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma | 2010 |
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies | 2010 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2010 |
A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
Association between histological type of tumour growth and patient survival in t2-t3 lymph node-negative rectal cancer treated with sphincter-preserving total mesorectal excision.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2009 |
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2010 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2010 |
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2009 |
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2009 |
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2009 |
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2009 |
[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2009 |
Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Monitori | 2010 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2009 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2009 |
CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Cell Cycle; Cisplatin; Cyclin D1; DNA R | 2009 |
A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2010 |
Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2009 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomis
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxy | 2009 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 2010 |
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2010 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
Endoscopic chemotherapy with 5-fluorouracil in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Endoscopy, Digestive System; Fluorou | 2010 |
An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinica
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Fluorouracil; | 2009 |
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2009 |
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Resp | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2010 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Ca | 2010 |
Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast | 2010 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2010 |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2011 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
[Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2010 |
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; | 2010 |
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2010 |
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2010 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2010 |
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2010 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; | 2011 |
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fl | 2010 |
Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Grou
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy | 2011 |
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2011 |
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy | 2010 |
Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Emboliza | 2010 |
Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2010 |
[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2010 |
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Feasibility study of sentinel lymph node biopsy in esophageal cancer with conservative lymphadenectomy.
Topics: Adenocarcinoma; Aged; Antimony; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2012 |
Treatment of colorectal cancer with and without bevacizumab: a phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2010 |
No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2011 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Pro | 2010 |
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; | 2010 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; | 2010 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; | 2010 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; | 2010 |
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Diagnostic | 2011 |
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2012 |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2010 |
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2011 |
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2010 |
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacolog | 2010 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2011 |
[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; D | 2010 |
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2010 |
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclon | 2010 |
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplas | 2012 |
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 2011 |
Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Cont | 2011 |
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2012 |
Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2012 |
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2011 |
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group tri
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2011 |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Drug Re | 2011 |
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2011 |
Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Adenosq | 2011 |
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che | 2011 |
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che | 2011 |
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho | 2011 |
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad | 2011 |
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad | 2011 |
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad | 2011 |
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Moda | 2011 |
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2011 |
A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort St | 2011 |
T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
Preoperative radiotherapy combined with capecitabine chemotherapy in Chinese patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv | 2011 |
Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2011 |
Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dise | 2011 |
Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy | 2012 |
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2011 |
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2011 |
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2011 |
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2011 |
[Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2011 |
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2012 |
Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Drug Administrat | 2012 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorect | 2012 |
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2011 |
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2011 |
Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Disease-Free Survival; Dose Fract | 2012 |
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2011 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2012 |
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2012 |
Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2011 |
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2011 |
Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease | 2012 |
Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi | 2012 |
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2012 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P | 2011 |
Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Fr | 2012 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2012 |
The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2012 |
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2012 |
High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Feas | 2012 |
Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Drug R | 2012 |
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarke | 2012 |
Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape | 2012 |
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetax | 2012 |
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2012 |
A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2012 |
Characterisation of rectal motion during neo-adjuvant radiochemotherapy for rectal cancer with image-guided tomotherapy: implications for adaptive dose escalation strategies.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2012 |
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothe | 2012 |
Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Fema | 2013 |
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Ch | 2012 |
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; | 2012 |
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studi | 2013 |
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Ant | 2013 |
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2012 |
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2012 |
Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2012 |
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti | 2013 |
Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chem | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2012 |
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxy | 2013 |
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2012 |
Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Proto | 2012 |
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisp | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2013 |
Effect of portal vein chemotherapy on liver metastasis after surgical resection of colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasms; Fluoro | 2012 |
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycyti | 2013 |
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2013 |
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabin | 2012 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc | 2013 |
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi | 2013 |
Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Co | 2012 |
Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Dose Fractionation, | 2013 |
Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidi | 2013 |
Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Enzyme-Linked I | 2012 |
Assessment and comparison of recovery after open and minimally invasive esophagectomy for cancer: an exploratory study in two centers.
Topics: Activities of Daily Living; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemoth | 2013 |
The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2013 |
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasm | 2013 |
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camp | 2013 |
Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-F | 2013 |
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dise | 2013 |
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2002 |
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptot | 2002 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 2002 |
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2002 |
A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2002 |
Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2002 |
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Female; Fluor | 2002 |
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle | 2002 |
Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2002 |
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Drug | 2002 |
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Nee | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2002 |
Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2003 |
Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2003 |
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch | 2003 |
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotecti | 2002 |
Preoperative chemoradiotherapy in cancer of the thoracic esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 2002 |
Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-alpha2b.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2003 |
Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2003 |
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea | 2003 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Doc | 2003 |
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp | 2002 |
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2003 |
Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2003 |
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2003 |
Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Female; Fluorouracil; Gallbladder Neoplasms; Humans | 2003 |
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2003 |
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigen | 2003 |
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2003 |
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2003 |
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms | 2003 |
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2003 |
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2003 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Squar | 2003 |
First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2003 |
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence I | 2003 |
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-S | 2003 |
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin | 2003 |
Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; CA-19-9 Antige | 2003 |
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2003 |
Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2003 |
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Postoperative chemoradiotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Follow | 2003 |
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2003 |
Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Antimetabolites, Antineoplastic; | 2004 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2003 |
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin | 2003 |
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2003 |
Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2003 |
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
[The modern organ- and function-sparing surgical treatment in oncology].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fea | 2003 |
Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2003 |
Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2003 |
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2003 |
Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caff | 2003 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
Usefulness of preoperative chemoradiation in locally advanced cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2004 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2003 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2004 |
Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chi-Square Distribution; Colectomy; Colonic Neoplasms; | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 2004 |
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2004 |
Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2003 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Circadian Rhythm; Colorectal Neoplasms; Fluorouracil; Humans; | 2004 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 2004 |
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dose-Res | 2004 |
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Dox | 2004 |
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti | 2004 |
Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas | 2004 |
Regional pelvic hyperthermia as an adjunct to chemotherapy (oxaliplatin, folinic acid, 5-fluorouracil) in pre-irradiated patients with locally recurrent rectal cancer: a pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combine | 2004 |
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2004 |
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 2004 |
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of | 2004 |
Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2004 |
Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2004 |
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2004 |
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2004 |
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2004 |
Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2004 |
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasm | 2005 |
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2004 |
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; Drug Ad | 2004 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2005 |
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2004 |
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2004 |
Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2004 |
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2005 |
Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2004 |
Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, | 2004 |
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2004 |
Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Duodenal Neoplas | 2005 |
Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2005 |
How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
[Trial of outpatient anti-cancer chemotherapy with infusion of 5-FU and cisplatin for advanced gastric and colorectal cancers].
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 2005 |
5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2005 |
Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Clinic | 2005 |
Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; D | 2005 |
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Color | 2005 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carbo | 2005 |
Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dose Fractionation, Radia | 2005 |
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2005 |
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2005 |
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagog | 2005 |
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2005 |
Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA, Neoplasm; Drug Administrati | 2005 |
Treatment of rectal cancer by chemoradiation followed by surgery: analysis and early clinical outcome in 66 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Endosonography; Fem | 2005 |
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2006 |
Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic A | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2005 |
Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2005 |
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2005 |
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2005 |
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2005 |
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2005 |
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2005 |
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2005 |
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2005 |
Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2006 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic A | 2006 |
Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distributi | 2005 |
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2006 |
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemot | 2005 |
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deox | 2005 |
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bio | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2006 |
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2005 |
Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2006 |
FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Age | 2005 |
[Effectiveness of 5-fluoruracil and vinorelbine in patients who had received multi-treatments for metastatic breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Flu | 2005 |
Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Creatini | 2006 |
Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2006 |
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2006 |
A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2006 |
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2006 |
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2005 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2006 |
A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
Topics: Adenocarcinoma; Alkylating Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic | 2006 |
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Fe | 2006 |
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2006 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
[Study on efficacy and toxicity of new combined regimen "taxoter + cisplatin + 5-fluorouracil" in disseminated and locally-spread stomach cancer. Comparative analysis of tolerance and efficacy in patients younger and older than 65 years].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2006 |
Pilot study of preoperative combined modality treatment for locally advanced operable oesophageal carcinoma: toxicities and long-term outcome.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplas | 2006 |
Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2006 |
Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2006 |
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2006 |
Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2006 |
Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary | 2003 |
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2003 |
A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2006 |
Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2006 |
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Anemia; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin | 2007 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2006 |
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
Topics: Acetates; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2006 |
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; D | 2006 |
The synchronization of chemotherapy to circadian rhythms and irradiation in pre-operative chemoradiation therapy with hyperthermia for local advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Combined Modality Therapy; Fem | 2006 |
A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2006 |
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 2006 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2007 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2006 |
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2006 |
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2006 |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres | 2007 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma | 2006 |
A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2006 |
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy; | 2007 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2006 |
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy | 2007 |
Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Do | 2006 |
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 2006 |
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine | 2007 |
Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality | 2007 |
Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; F | 2007 |
FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2007 |
The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Gastrectomy; Hum | 2007 |
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2006 |
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorec | 2007 |
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract | 2007 |
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austral | 2007 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2008 |
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-1 | 2007 |
Preoperative radio-chemotherapy (RT-CT) in rectal cancer. Prospective study with postoperative RT-CT control group.
Topics: Adenocarcinoma; Amputation, Surgical; Antimetabolites, Antineoplastic; Colostomy; Combined Modality | 2007 |
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Dis | 2007 |
A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Denmark; | 2007 |
A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; D | 2007 |
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2007 |
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipy | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2007 |
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2007 |
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2007 |
Combined modality chemoradiation in elderly oesophageal cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2007 |
Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Camptothecin; Female; F | 2007 |
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2007 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2007 |
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disea | 2007 |
Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2007 |
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2007 |
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution | 2007 |
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution | 2007 |
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2007 |
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2007 |
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2007 |
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E | 2007 |
A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2007 |
A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2007 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct N | 2007 |
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam | 2007 |
Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2007 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin | 2007 |
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Diseases; Colonic Neop | 2007 |
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Female; Fluor | 2007 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2006 |
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2008 |
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2008 |
A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Colorectal Neopl | 2007 |
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2007 |
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2007 |
A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2008 |
Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial.
Topics: Adenocarcinoma; Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2008 |
Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2008 |
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2007 |
Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Ch | 2007 |
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud | 2007 |
Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Digestive System Surgical Procedures; Disease | 2007 |
Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2007 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2008 |
[Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2007 |
Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cel | 2007 |
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; E | 2008 |
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neo | 2008 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemot | 2008 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |
Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2008 |
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2008 |
Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2008 |
Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2008 |
[Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2007 |
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2008 |
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagea | 2007 |
Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemothera | 2007 |
32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phospho | 2008 |
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2008 |
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2008 |
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2009 |
Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Dr | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2007 |
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplast | 2007 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2008 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin | 2008 |
A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2008 |
Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2008 |
Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2007 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2008 |
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Colorec | 2008 |
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2008 |
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2008 |
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
Topics: 3' Untranslated Regions; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer. A pilot study.
Topics: Adenocarcinoma; Aged; Alanine Transaminase; Alkaline Phosphatase; Amylases; Antineoplastic Combined | 1984 |
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up | 1982 |
[Chemotherapy of the non-small cell bronchogenic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; | 1983 |
The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 1984 |
Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi).
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Therapy | 1980 |
Combined irradiation and three-drug chemotherapy in inoperable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug | 1982 |
A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response.
Topics: Acid Phosphatase; Adenocarcinoma; Clinical Trials as Topic; Doxorubicin; Fluorouracil; Humans; Male; | 1983 |
A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Drug Administration Schedu | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Fluorouracil; Gastrectomy | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1984 |
Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Cisplatin; Clinical Tria | 1983 |
Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as | 1983 |
5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine | 1984 |
Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Female; Fluorour | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
[Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1984 |
[Effectiveness of combined and complex treatment of patients with operable cancer of the rectum].
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cobalt Radioisotopes; Combined Modality Thera | 1984 |
Complications following postoperative combined radiation and chemotherapy in adenocarcinoma of the rectum and rectosigmoid. A randomized trial that failed.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M | 1984 |
MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxo | 1984 |
Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California Oncology Group and the Japanese Gastric Cancer Chemotherapy Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; California; Clinical Tr | 1983 |
Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubici | 1984 |
Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastroint
Topics: Adenocarcinoma; Clinical Trials as Topic; Colectomy; Combined Modality Therapy; Fluorouracil; Follow | 1984 |
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1984 |
An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1984 |
Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Ne | 1984 |
Chemotherapy of pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combinat | 1981 |
Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fluoroura | 1983 |
[Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers].
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Herpes Labialis; Humans; Hypotension | 1984 |
Treatment of advanced gastric cancer with 5-fluorouracil versus mitomycin C.
Topics: Adenocarcinoma; Adult; Clinical Trials as Topic; Female; Fluorouracil; Humans; Male; Middle Aged; Mi | 1982 |
[Antiblastic therapy of nonadvanced colorectal cancer: preliminary results of a randomized therapeutic trial].
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo | 1982 |
Clinical problems in radiotherapy of carcinoma of the pancreas.
Topics: Adenocarcinoma; Alpha Particles; Clinical Trials as Topic; Fluorouracil; Helium; Humans; Liver Neopl | 1982 |
[Clinical trial of cisplatin in the treatment of ovarian carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cystadenocarcino | 1982 |
Combination chemotherapy in advanced gastrointestinal malignancy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combinat | 1980 |
Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide | 1980 |
Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Diarrhea; Drug Therap | 1980 |
Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Cyclop | 1980 |
The chemotherapy of prostatic adenocarcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclop | 1980 |
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Aged; Agranulocytosis; Anorexia; Antineoplastic Agents; Clinical Trials as Topic; Do | 1980 |
Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combinat | 1981 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dru | 1981 |
Modulation of 5-fluorouracil toxicity by allopurinol in man.
Topics: Adenocarcinoma; Allopurinol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorouraci | 1981 |
Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up | 1981 |
Adjuvant chemotherapy with four drugs for stage 2 breast cancer.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Co | 1980 |
Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; L | 1982 |
Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug A | 1982 |
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
Topics: Adenocarcinoma; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug T | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].
Topics: Adenocarcinoma; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxypr | 1980 |
The activity of paclitaxel in gastrointestinal tumors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 1995 |
Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epir | 1994 |
Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1995 |
Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1994 |
The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Disease Progression; Fluorouracil; Humans; Interferon-alpha; Male; Prospective | 1995 |
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1995 |
[Hepatic arterial infusion therapy for gastric liver metastasis using implanted reservoir].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluoroura | 1995 |
[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1995 |
[Outcomes of effective treatment of cases of metastatic liver tumors by intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1995 |
Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1995 |
Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 1995 |
Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Hu | 1995 |
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aust | 1995 |
Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; H | 1995 |
[Is radiotherapy necessary in the control of colorectal cancer?].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Cobalt Radioisotopes; Colectomy; Colonic | 1995 |
Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1995 |
Induction chemotherapy and irradiation in advanced carcinoma of the cervix.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined M | 1995 |
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1993 |
Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
[Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer].
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluo | 1995 |
Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1994 |
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Intraoperative radiotherapy for primary and recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 1995 |
[Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study].
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Diarrhe | 1995 |
Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil.
Topics: Adenocarcinoma; Colonic Neoplasms; Fatty Liver; Female; Fluorouracil; Humans; Interferon alpha-2; In | 1995 |
Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy.
Topics: Adenocarcinoma; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; BCG Vacci | 1995 |
Treating esophageal cancer with a combination of chemotherapy, radiation, and excision.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intestine, Small; Leucovorin; Neopl | 1995 |
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran | 1994 |
A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 1995 |
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; CA-125 Antigen; Drug Therapy, Combination; Female; F | 1995 |
Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1995 |
[Biochemically modulated chemotherapy with high-dose L-leucovorin and 5-fluorouracil for multiple liver metastasis from colorectal cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Live | 1995 |
Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case | 1995 |
[Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report].
Topics: Adenocarcinoma; Adult; Aged; Animals; Catheterization; Endometrial Neoplasms; Female; Fluorouracil; | 1995 |
Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1995 |
5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1995 |
Preoperative high-dose radiation and chemotherapy in adenocarcinoma of the esophagus and esophagogastric junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eso | 1994 |
Efficacy of postoperative 5-FU, high-dose leucovorin, and sequential radiation therapy for clinically resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1995 |
Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1995 |
5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1995 |
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea | 1995 |
[Preoperative radiochemotherapy in primary non-resectable rectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Chemotherapy, Adjuvant; Female; Fluorouracil; | 1995 |
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1995 |
Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1995 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration | 1995 |
Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1995 |
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm | 1994 |
Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 1994 |
Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Mod | 1994 |
[Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Administration Sch | 1994 |
5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1994 |
A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Female; Fluorouracil; Humans; Leucovorin; Male; Midd | 1994 |
Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1994 |
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi- | 1994 |
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Phase II study with iododoxorubicin in measurable advanced colorectal adenocarcinoma. Effective rescue using weekly high-dose 5-fluorouracil (WFU). Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD), Work Group of SEOM (Spanish Medical Onc
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle | 1994 |
[The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1994 |
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Therapy, Combination | 1994 |
Effectiveness of chemotherapy for advanced adenocarcinoma of the pancreas in combined modality therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Autonomic Nerve Block; Celiac Plexus; Combined Modal | 1994 |
Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Respons | 1994 |
Radiation and chemotherapy. Treatment of localized pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 1994 |
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 1994 |
The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administratio | 1994 |
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modali | 1994 |
Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1994 |
[Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1994 |
[Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1994 |
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluo | 1994 |
Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Drug Administration Schedule; Female; Fluorouracil; Ga | 1994 |
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1994 |
Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi | 1994 |
5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
[Concomitant arterial infusion chemotherapy with tamoxifen therapy for hepatic metastases from pancreatic adenocarcinoma--a preliminary report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Inject | 1993 |
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Colonic Neoplasms; Drug Admin | 1993 |
Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1993 |
Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical.
Topics: Adenocarcinoma; Administration, Inhalation; Aerosols; Aged; Animals; Bronchial Neoplasms; Carcinoma, | 1993 |
[Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea | 1993 |
High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Int | 1993 |
Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian R | 1993 |
Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Evaluation Studies as Top | 1994 |
A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; I | 1993 |
Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Brachytherapy; Combined Modality Therapy; Drug Administration Schedule; | 1994 |
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1993 |
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1993 |
Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1993 |
Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 1993 |
Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; | 1993 |
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1993 |
5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Duodenal Neoplasms; | 1993 |
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1993 |
A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1993 |
A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Femal | 1993 |
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 1993 |
High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Dr | 1993 |
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; F | 1993 |
Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1993 |
Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1993 |
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 1993 |
Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fema | 1993 |
Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1993 |
The use of mitomycin in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1993 |
Mitomycin in anal canal carcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anu | 1993 |
Mitomycin therapy in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1993 |
Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Flu | 1993 |
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1993 |
Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 1993 |
Survival after combined modality therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1993 |
Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy P | 1993 |
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 1993 |
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 1995 |
Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1996 |
Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati | 1996 |
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati | 1996 |
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati | 1996 |
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati | 1996 |
Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Col | 1995 |
Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 1995 |
Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; | 1995 |
Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 1996 |
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1996 |
A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcino | 1996 |
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Infusions, Intrave | 1995 |
A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 1996 |
Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 1996 |
Concurrent 5-fluorouracil, daily low-dose cisplatin, and radiotherapy in stage IIIB cervical cancer. A phase II prospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squa | 1996 |
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1996 |
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1996 |
Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |
Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 1996 |
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Regional chemotherapy for inoperable pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Infusi | 1996 |
[ACNU and methyl-CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chin | 1996 |
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Fluorour | 1996 |
Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1996 |
Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop | 1996 |
Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1996 |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Pr | 1996 |
Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Respons | 1996 |
Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1996 |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
[Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG)
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1996 |
[Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Ad | 1996 |
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1996 |
Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1996 |
Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1996 |
Advanced colorectal carcinoma: redefining the role of oral ftorafur.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1996 |
5-Fluorouracil continuous infusion in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal N | 1996 |
Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modalit | 1996 |
[Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female | 1996 |
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Age | 1996 |
Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Syner | 1996 |
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C | 1997 |
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplati | 1997 |
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1996 |
Integration of surgery in multimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1997 |
Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 1997 |
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla | 1997 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1997 |
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1997 |
A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluo | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci | 1997 |
Progress in treating esophageal adenocarcinoma.
Topics: Adenocarcinoma; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Pr | 1997 |
A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 1997 |
Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro | 1997 |
Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1997 |
Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1997 |
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1997 |
Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1997 |
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil; | 1996 |
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, An | 1997 |
A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Antimetaboli | 1997 |
Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt | 1997 |
[A randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP 5-FU and dl-leucovorin for colorectal cancer].
Topics: Adenocarcinoma; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
[The influence on prognosis of intraoperative chemotherapy for adenocarcinoma of gastric cardia].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cardia; Female; Fluorouracil; Humans; Intraop | 1996 |
Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Clinical Protocols; Combined | 1997 |
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergi | 1997 |
[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 1997 |
The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1996 |
The French experience with infusional 5-FU in gastric and pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bio | 1996 |
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1997 |
Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 1997 |
Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1997 |
[Preoperative intraluminal 5-FU osmosis chemotherapy as an adjuvant to radical resection for rectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy | 1996 |
A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1997 |
Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 1997 |
Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Flu | 1997 |
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1997 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent cervical cancer with or without radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 1997 |
A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Re | 1997 |
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cath | 1997 |
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1997 |
Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1997 |
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin | 1998 |
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin | 1998 |
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin | 1998 |
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin | 1998 |
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
Topics: Adenocarcinoma; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Endonucleases; Female; F | 1998 |
Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1997 |
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1998 |
Postoperative adjuvant radiotherapy and 5-fluorouracil chemotherapy for rectal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hu | 1998 |
[Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female | 1998 |
Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1998 |
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; H | 1998 |
5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy | 1998 |
Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colon | 1998 |
High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug | 1998 |
Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neopla | 1998 |
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1998 |
Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diterpenes; Epirubicin; | 1998 |
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca | 1998 |
Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 1998 |
A phase II trial of cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 1998 |
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1998 |
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Infusions, Int | 1998 |
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1998 |
Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Prot | 1998 |
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phy | 1998 |
OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-F | 1998 |
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; | 1998 |
Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1998 |
A phase II trial of preoperative mitomycin, cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1998 |
Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1999 |
5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Colorectal Neopl | 1998 |
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antidotes; Antineoplastic Combined Chemotherapy P | 1999 |
[Biochemical modulation of 5-FU--effect of low dose CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin | 1999 |
Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility St | 1999 |
The relation between erythropoietin, hematocrit and hemoglobin in breast cancer patients on non-nephrotoxic chemotherapy.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, | 1998 |
The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1998 |
Local excision of rectal carcinoma: a safe alternative for more advanced tumors?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1999 |
Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C | 1999 |
[No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 1999 |
Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1999 |
[Influence of preoperative on gastric cancer tissues and cells].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1997 |
[Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
[Treatment for advanced colorectal carcinoma with 5-fluorouracil plus low-dose leucovorin].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone | 1999 |
Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?
Topics: Adenocarcinoma; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Black Pe | 1999 |
Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1999 |
Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1999 |
Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Ant | 1999 |
The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colorectal | 1999 |
Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK)
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1999 |
Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1999 |
A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G | 1999 |
Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1999 |
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marro | 1999 |
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 1999 |
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Esop | 1999 |
Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1999 |
A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Fluorou | 1999 |
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
[Neoadjuvant treatment of operable esophageal cancers].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic | 1999 |
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1999 |
Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl | 1999 |
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 1999 |
Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1999 |
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2000 |
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2000 |
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2000 |
Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality T | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Di | 2000 |
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2000 |
Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch | 2000 |
Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2000 |
Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2000 |
Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardia; Doxorubicin; Dr | 2000 |
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the Europe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 2000 |
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2000 |
[The clinical effect of low-dose FP (5-FU + low-dose CDDP) in patients with far advanced gastric cancer, and their quality of life].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2000 |
[Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2000 |
The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2000 |
Intra-arterial chemotherapy for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2000 |
Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2000 |
Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2000 |
Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 2000 |
[Adjuvant therapy of colon cancer stage C MAC. Adverse effects and efficacy in the Department of Oncology, Soroka Medical Center in the years 1991-1994].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 1999 |
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo | 2000 |
Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2000 |
A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etop | 2000 |
The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival | 2000 |
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deo | 2000 |
Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2000 |
A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disea | 2000 |
Neoadjuvant radio-chemotherapy in advanced primarilynon-resectable carcinomas of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Radiation; Fluor | 2000 |
[Short-term hypofractionated radiotherapy followed by total mesorectal excision].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2000 |
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2000 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2000 |
Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Femal | 2000 |
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb | 2001 |
Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma.
Topics: Adenocarcinoma; Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free | 2001 |
Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease Pr | 2001 |
Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2001 |
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2001 |
Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous | 2001 |
Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2001 |
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2001 |
Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid | 2001 |
Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2001 |
Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
[Percutaneous radiotherapy plus brachytherapy and concurrent chemotherapy for patients with localized esophageal carcinoma--Radiation Oncology Group Study 9207].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma, Squamous Cell; Combined M | 2001 |
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Differe | 2001 |
Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembr | 2001 |
Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease- | 2001 |
A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Chemotherapy, Adjuvant; Chronotherapy; Combined Modality Therapy; | 2001 |
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 2001 |
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2001 |
A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Combined | 2001 |
Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fracti | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Response shift in the perception of health for utility evaluation. an explorative investigation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Attitude to Health; | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of high-dose 5-fluorouracil and folinic acid: evaluation of feasibility.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2001 |
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality The | 2001 |
Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2001 |
Alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: a preliminary report of phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2001 |
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2001 |
[Clinical study on treatment of rectal carcinoma with Chinese herbal medicine and high dose fluorouracil emulsion via rectal infusion].
Topics: Adenocarcinoma; Administration, Rectal; Adult; Antimetabolites, Antineoplastic; CD4-CD8 Ratio; Drug | 1999 |
[Clinical study on treatment of mid-late stage gastric carcinoma by composite xiansu capsule combined with chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caps | 1999 |
P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell D | 2002 |
Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Endosonography; Fem | 2001 |
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2002 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2001 |
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2002 |
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2001 |
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil | 2002 |
Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progressio | 2001 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2002 |
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2002 |
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combin | 2002 |
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility Studie | 2001 |
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2002 |
Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2002 |
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2002 |
Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas | 2002 |
Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe?
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2002 |
Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2002 |
[Chemotherapy of non-microcellular disseminated bronchial cancer (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, Squam | 1979 |
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Administrati | 1978 |
Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases.
Topics: Adenocarcinoma; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Cli | 1979 |
Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combina | 1977 |
Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; N | 1979 |
[The combined treatment of bronchial carcinoma (author's transl)].
Topics: Adenocarcinoma; Aged; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical | 1975 |
Combination modality therapy in lung cancer: a survival study showing beneficial results of AMCOF (adriamycin, methotrexate, cyclophosphamide, oncovin and 5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Carcinoma, S | 1978 |
Chemotherapy for adenocarcinoma and large cell anaplastic carcinoma of the lung with ftorafur, adriamycin, and cis-dichlorodiammineplatinum(II).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin | 1978 |
Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclo | 1977 |
A controlled study of 5-fluorouracil versus 5-fluorouracil and methyl-CCNU in advanced gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorourac | 1977 |
Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorourac | 1978 |
Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Eval | 1978 |
The West Midlands gastric carcinoma chemotherapy trial: planning and results.
Topics: Adenocarcinoma; Aged; Carcinoma; Clinical Trials as Topic; Disability Evaluation; Evaluation Studies | 1978 |
Phase II trial of 5-fluorouracil plus melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinat | 1978 |
Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Blood Cell Count; Clinical Trials as Topic; Colonic Neoplasms; Doxorubi | 1978 |
Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Ther | 1978 |
5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Eval | 1978 |
5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Huma | 1978 |
Chemotherapy of advanced breast cancer. Results of a controlled trial comparing two three-drug regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cycl | 1978 |
Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1978 |
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Digestive System; Dox | 1978 |
[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)].
Topics: Adenocarcinoma; Carmustine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestinal Neoplasms; | 1979 |
Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study.
Topics: Adenocarcinoma; Catheterization; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; | 1979 |
Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1979 |
Chemotherapy of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fluorour | 1979 |
Adriamycin, mitomycin C, and 5-fluorouracil in combination for advanced colorectal adenocarcinoma previously treated with 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Dru | 1979 |
Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Fluorouracil; Humans; Middle Aged; Panc | 1979 |
Gastric cancer: current status of treatment.
Topics: Adenocarcinoma; Aged; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ther | 1977 |
A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; | 1979 |
Adjuvant cytotoxic liver perfusion for colorectal cancer.
Topics: Adenocarcinoma; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; England; Female; | 1979 |
Four drug combination cytotoxic chemotherapy following surgery for breast cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Administration Sched | 1978 |
Results of a randomized trial of prophylactic chemotherapy in T3-T4 breast cancer patients previously treated by radiotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Drug Adminis | 1978 |
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms; | 1976 |
A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazin | 1976 |
Sequential and combination chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedul | 1976 |
Primary treatment of advanced ovarian adenocarcinoma, stages III and IV.
Topics: Adenocarcinoma; Alkylating Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug Therapy, Combi | 1975 |
Adjuvant chemotherapy with 5-fluorouracil after surgical resection of colorectal carcinoma (COG protocol 7041). A preliminary report.
Topics: Adenocarcinoma; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Prospective Studies; Rectal N | 1977 |
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem | 1977 |
Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms | 1976 |
Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Adminis | 1976 |
A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studie | 1975 |
[Use of ftorafur for the treatment of 3d-4th stage].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Femal | 1975 |
[Sequential chemotherapy based on the hypothesis of a circadian rhythm of tumor proliferation].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Circadian R | 1975 |
Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
Topics: Adenocarcinoma; Aged; Alopecia; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evalua | 1976 |
Chemotherapy as an adjuvant to surgery for colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Postoperative Care; P | 1975 |
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administratio | 1975 |
Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Hepar | 1992 |
A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 1992 |
A phase II clinical trial evaluating the use of two sequential, four-drug combination chemotherapy regimens in ambulatory bronchogenic adenocarcinoma patients.
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchog | 1992 |
Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1992 |
Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female | 1992 |
A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluor | 1992 |
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1992 |
Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluor | 1992 |
Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; | 1992 |
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; F | 1992 |
A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1992 |
High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801).
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil | 1992 |
The value of adjuvant therapy after radical surgery for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
Treatment of adenocarcinoma of the cardia with synchronous chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 1990 |
Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer. A retrospective analysis of 39 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; | 1991 |
Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; | 1992 |
Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug | 1992 |
A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intra | 1992 |
Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer).
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 1991 |
A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1991 |
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caffeine; Carboplatin; | 1991 |
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results.
Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Femal | 1991 |
Preliminary report of high dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1991 |
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1991 |
Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1991 |
Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1991 |
Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1991 |
High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Evaluation; Fluorouracil; Humans; Infusions, In | 1991 |
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 1991 |
Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1991 |
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 1991 |
Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Levamisole in the adjuvant treatment of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1991 |
A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1991 |
Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorec | 1991 |
Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group).
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1991 |
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1991 |
Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl | 1991 |
An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla | 1991 |
Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 1991 |
Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society.
Topics: Adenocarcinoma; Adult; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule | 1990 |
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusion Pump | 1990 |
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Proto | 1990 |
A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Mo | 1990 |
Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; In | 1990 |
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1990 |
Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1990 |
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venou | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
[Can the occurrence of extrahepatic metastases in regional chemotherapy of the liver be prevented by adding systemic chemotherapy? A randomized multicenter study].
Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps | 1989 |
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dru | 1989 |
Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemother | 1989 |
A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 1989 |
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 1989 |
Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy | 1989 |
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Costs and | 1985 |
Combination chemotherapy with etoposide and 5-fluorouracil in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combinat | 1989 |
Adjuvant chemoimmuno- and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: a 7-year follow-up analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical T | 1989 |
A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Epirubicin; Fluorouracil; Humans; Neoplasm Metastasis; Ran | 1989 |
High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood; Clinical Trials as Topic; Col | 1989 |
A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 1989 |
Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Human | 1989 |
Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study.
Topics: Adenocarcinoma; Blood Chemical Analysis; Colorectal Neoplasms; Combined Modality Therapy; Female; Fl | 1989 |
[Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer--results of a randomized trial].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; | 1988 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle A | 1985 |
Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M | 1988 |
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1989 |
Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1986 |
Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin | 1986 |
A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Female; Floxurid | 1988 |
Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
[Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Ca | 1985 |
Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cl | 1986 |
5-Methyltetrahydrofolic acid (MFH4): an effective folate for the treatment of advanced colorectal cancer with 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; | 1988 |
Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
Immunochemosurgery as a new approach to reasonable treatment of advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials | 1988 |
The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal | 1988 |
Clinical experience with CF-FUra.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cl | 1988 |
Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum.
Topics: Actuarial Analysis; Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid | 1986 |
5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin | 1987 |
Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To | 1988 |
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine | 1988 |
Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1988 |
An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer.
Topics: Adenocarcinoma; Biological Availability; Colonic Neoplasms; Fluorouracil; Hematopoiesis; Humans; Inf | 1987 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1986 |
Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1986 |
Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 1986 |
Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Tr | 1986 |
Treatment of gastrointestinal cancer: the Southeastern Cancer Study Group experience, 1979 to 1983.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Evalu | 1986 |
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosp | 1986 |
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1987 |
FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1987 |
Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Sched | 1987 |
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 1985 |
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fema | 1985 |
Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma.
Topics: Adenocarcinoma; Aged; Body Weight; Clinical Trials as Topic; Cyclophosphamide; Drug Administration S | 1985 |
A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical Tria | 1985 |
A randomized comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosp | 1985 |
The need for pilot studies and surgery-only controls in adjuvant therapy trials for large-bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1985 |
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestin | 1969 |
Adrenal function in patients treated with testosterone and fluorinated pyrimidines.
Topics: 17-Ketosteroids; Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormon | 1968 |
Advanced lung cancer: A clinical trial of radiotherapy plus two drug combination regimens.
Topics: Adenocarcinoma; Amides; Antineoplastic Agents; Carcinoma; Carcinoma, Small Cell; Carcinoma, Squamous | 1973 |
Current therapy approaches of the Division of Cancer Treatment with emphasis on pancreatic carcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topi | 1974 |
Effect of concomitant drug treatment on toxic and therapeutic activity of 5-fluorouracil (5-FU; NSC-19893).
Topics: Adenocarcinoma; Antiemetics; Clinical Trials as Topic; Drug Antagonism; Drug Synergism; Fluorouracil | 1972 |
A comparison of 5-fluorouracil administered by slow infusion and rapid injection.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Infusions, Parenteral; Injections, I | 1972 |
Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug | 1974 |
Cancer of the gastrointestinal tract. Radiation therapy.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurr | 1974 |
Radiotherapy plus 5-FU compared to radiotherapy alone for inoperable and unresectable bronchogenic carcinoma.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Top | 1972 |
Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cytarabine; Diabetic Ketoacidosis; Diar | 1972 |
A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
Topics: Adenocarcinoma; Alopecia; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Diseases; Huma | 1974 |
[Oxytetracycline, vehicle for therapeutic drugs, fluorouracil and nitrogen mustard, in the treatment of gastrointestinal tumors].
Topics: Adenocarcinoma; Adult; Bile Duct Neoplasms; Clinical Trials as Topic; Drug Combinations; Esophagus; | 1970 |
Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation.
Topics: Adenocarcinoma; Adult; Aged; Cobalt Isotopes; Female; Fluorouracil; Humans; Injections, Intravenous; | 1968 |
Comparison of antimetabolites in the treatment of breast and colon cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites; Breast Neoplasms; Child; Clinical Trials a | 1967 |
3130 other studies available for fluorouracil and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
Topics: Acetates; Adenocarcinoma; Animals; Chemical Phenomena; Chemistry; Chlorine; Colonic Neoplasms; Hydro | 1989 |
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug R | 2011 |
Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2021 |
A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fluoroura | 2022 |
Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Hum | 2021 |
Antitumor Activity of Zinc Nanoparticles Synthesized with Berberine on Human Epithelial Colorectal Adenocarcinoma (Caco-2) Cells through Acting on Cox-2/NF-kB and p53 Pathways.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-2-Associated X Protein; Berberine; Caco-2 Cells; Caspase 3; | 2022 |
Results of the observational prospective RealFLOT study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2021 |
Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Frozen Sections; Human | 2022 |
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2022 |
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcin | 2022 |
[A Case of Metastatic Pancreatic Ductal Adenocarcinoma Successfully Treated with Modified FOLFIRINOX and Concurrent Radiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Hu | 2021 |
Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Fluorouracil; Humans; Pancreatic Neoplasms; Radiation, Ionizing; R | 2022 |
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Esophageal Neoplasms | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
Bias and Pancreatic Cancer Reporting.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Fluorouracil; Humans; Irinotec | 2022 |
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort | 2022 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinom | 2022 |
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2022 |
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
Topics: Ablation Techniques; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2022 |
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Mi | 2022 |
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Fluorouracil; Humans; In | 2022 |
Response in
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Pancreatic | 2022 |
Robotic low anterior resection of rectal metastasis from small bowel adenocarcinoma: A case report.
Topics: Adenocarcinoma; Aged; Duodenal Neoplasms; Female; Fluorouracil; Humans; Keratin-20; Keratin-7; Leuco | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flu | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; | 2022 |
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2022 |
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasm | 2023 |
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2022 |
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2022 |
Development and validation of a cancer-associated fibroblast-derived lncRNA signature for predicting clinical outcomes in colorectal cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Cancer-Associated Fibroblasts; Colorectal Neoplasms; Female; Fluor | 2022 |
FKBP4 regulates 5-fluorouracil sensitivity in colon cancer by controlling mitochondrial respiration.
Topics: Adenocarcinoma; Carrier Proteins; Colonic Neoplasms; Copper; Electron Transport Complex IV; Fluorour | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2022 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Femal | 2023 |
Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Carbohydrates; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Neoadjuvant Thera | 2022 |
The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Deferoxamine; | 2022 |
Surprising efficacy twist of two established cytostatics revealed by a-la-carte 3D cell spheroid preparation protocol.
Topics: Adenocarcinoma; Cell Line, Tumor; Colonic Neoplasms; Cytostatic Agents; Fluorouracil; Humans; Irinot | 2022 |
New Oxazolo[5,4-
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Prolifera | 2022 |
Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2023 |
Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Eso | 2023 |
Expression pattern of secretory-cell-related transcriptional signatures in colon adenocarcinomas defines tumor microenvironment characteristics and correlates with clinical outcomes.
Topics: Adenocarcinoma; Cluster Analysis; Colonic Neoplasms; Fluorouracil; Humans; Tumor Microenvironment | 2023 |
Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2023 |
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms | 2023 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; | 2022 |
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2022 |
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Diseas | 2023 |
Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Eso | 2023 |
Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drugs, Chinese Herbal; Fluorouracil; Humans; JNK Mitogen | 2023 |
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinote | 2023 |
Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2023 |
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorourac | 2023 |
FOXM1/NCAPH activates glycolysis to promote colon adenocarcinoma stemness and 5-FU resistance.
Topics: Adenocarcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluoro | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient | 2023 |
Ferroptosis-associated gene CISD2 suppresses colon cancer development by regulating tumor immune microenvironment.
Topics: Adenocarcinoma; Cell Cycle; Colonic Neoplasms; Ferroptosis; Fluorouracil; Humans; Tumor Microenviron | 2023 |
A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fem | 2023 |
Clinical implications and chemo-sensitivity of adjuvant chemotherapy in patients with poorly cohesive cells-gastric cancer.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Oxaliplatin | 2023 |
Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fluorour | 2023 |
In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; bcl-2-Associated X Protein; Caspases; Colorectal Neo | 2023 |
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; | 2023 |
TRIM69: a marker of metastasis and potential sensitizer to 5-Fluorouracil and PD-1 blockers in colon adenocarcinoma.
Topics: Adenocarcinoma; Algorithms; Colonic Neoplasms; Fluorouracil; Humans; Programmed Cell Death 1 Recepto | 2023 |
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic | 2023 |
Customizing Therapy for Esophageal Cancer: CROSS vs. FLOT.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2024 |
Colorectal Adenocarcinoma: Imaging using 5-Fluoracil Nanoparticles Labeled with Technetium 99 Metastable.
Topics: Adenocarcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Nanoparticles; Radiopharmaceuticals; Tec | 2019 |
Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Mystery of neck lump: an uncommon presentation of urachal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Diagnosis, | 2019 |
Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Colorecta | 2019 |
Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cause o | 2019 |
Port-site metastasis of pancreatic adenocarcinoma following 'successful' completion of neoadjuvant chemoradiation using FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2020 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2020 |
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Fem | 2019 |
Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo | 2019 |
DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2019 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; C | 2019 |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumo | 2020 |
PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2020 |
LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a/PDCD4 axis in colorectal cancer.
Topics: Adenocarcinoma; Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colorectal Neoplasms; Drug | 2020 |
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D | 2020 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2020 |
Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 2020 |
Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2019 |
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combin | 2020 |
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; | 2020 |
Perioperative chemotherapy for gastric cancer in FLOT4.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox | 2020 |
Perioperative chemotherapy for gastric cancer in FLOT4.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox | 2020 |
iASPP-Mediated ROS Inhibition Drives 5-Fu Resistance Dependent on Nrf2 Antioxidative Signaling Pathway in Gastric Adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Drug Re | 2020 |
Metabolic response assessment and PET-guided treatment of esophageal cancer.
Topics: Adenocarcinoma; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Positron-Emission | 2020 |
shRNA-mediated inhibition of PhosphoGlycerate Kinase 1 (PGK1) enhances cytotoxicity of intraperitoneal chemotherapy in peritoneal metastasis of gastric origin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorou | 2020 |
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2021 |
Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Beclin-1; | 2020 |
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Deoxycytid | 2020 |
Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2020 |
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2020 |
Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2020 |
Segmental Polyposis.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colec | 2020 |
The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Biomarkers; Cetuximab; Colonic | 2020 |
Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Mellitus; Female; Flu | 2020 |
Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2020 |
What is causing this patient's severe pruritus?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; | 2020 |
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Binding Si | 2020 |
Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2020 |
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemor | 2021 |
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cel | 2020 |
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidi | 2020 |
Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2020 |
FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2020 |
Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotec | 2021 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2020 |
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2020 |
Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
Topics: Acneiform Eruptions; Adenocarcinoma; Administration, Topical; Aloe; Antineoplastic Agents; Antineopl | 2021 |
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bi | 2020 |
Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antin | 2020 |
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2020 |
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Checkpoint Kinase 2; | 2020 |
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2020 |
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case | 2020 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcita | 2021 |
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinot | 2021 |
Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Sectional Stu | 2020 |
Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Intravenous; Adolescent; Adult; Aged; Aged | 2020 |
Comments on "Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma".
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Ele | 2020 |
Even a partial pathological response is associated with lower relapse rates in patients with operable rectal cancer undergoing neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase | 2021 |
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2020 |
Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels.
Topics: Adenocarcinoma; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Antineoplasti | 2021 |
Organ Preservation in the Treatment of Stage II and III Rectal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colectomy; | 2020 |
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2021 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2021 |
A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Contraindications, Drug; Dihydropyrimidine Dehydrog | 2020 |
Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2021 |
Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri | 2021 |
[A Case of Advanced Rectal Cancer Successfully Treated with Preoperative Radiochemotherapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2020 |
The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2021 |
Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci | 2021 |
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer.
Topics: Adenocarcinoma; Adenosylhomocysteinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherap | 2021 |
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Stud | 2021 |
Risk factors for sexual dysfunction after rectal cancer surgery in 948 consecutive patients: A prospective cohort study.
Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch | 2021 |
Chemotherapy of metastatic colon cancer in France: A population-based study.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocol | 2021 |
AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagogastric | 2021 |
Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report.
Topics: Adenocarcinoma; Aged; Bevacizumab; Colorectal Neoplasms; Drug Therapy; Fluorouracil; Humans; Japan; | 2021 |
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Real-world Patterns of Adjuvant Chemotherapy Following Neoadjuvant Chemoradiation for Patients With Resected Rectal Adenocarcinoma.
Topics: Adenocarcinoma; Alberta; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fem | 2021 |
Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Follow-Up Studies; Hum | 2021 |
Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem | 2021 |
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Cohort Studies; Disease-Free Surviva | 2021 |
Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2021 |
A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Gastrointestinal | 2022 |
Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Female; Fluorouracil; Huma | 2021 |
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Color | 2021 |
The "Dextran-Magnetic Layered Double Hydroxide-Fluorouracil" Drug Delivery System Exerts Its Anti-tumor Effect by Inducing Lysosomal Membrane Permeability in the Process of Cell Death.
Topics: Adenocarcinoma; Antineoplastic Agents; Azure Stains; Blotting, Western; Cell Death; Cell Line, Tumor | 2021 |
Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Luteolin; Q | 2022 |
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2021 |
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pro | 2021 |
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; | 2021 |
Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; CD24 Antigen; Colorectal Neoplasms; Drug Resistance, | 2021 |
Union is strength: Textbook outcome with perioperative chemotherapy compliance decreases the risk of death in advanced gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2022 |
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc | 2021 |
A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; | 2017 |
Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Circ | 2017 |
Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Colectomy; Female; Fluorouracil; | 2017 |
Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 2017 |
5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer.
Topics: Acetylation; Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chromatin; Colorect | 2017 |
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2017 |
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagogastri | 2017 |
Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Hum | 2017 |
Revealing chemical processes and kinetics of drug action within single living cells via plasmonic Raman probes.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Chemical Phenomena; Cisplatin | 2017 |
Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Benzothiazo | 2017 |
Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Capecit | 2017 |
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Tumour growth increased following antiangiogenic interruption: the challenge of tumour evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; F | 2017 |
Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2017 |
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2017 |
Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2018 |
[Good remission under HER2 blockade in an advanced carcinoma of the oesophagogastric junction with only focal HER2 overexpression].
Topics: Adenocarcinoma; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2017 |
Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Fluorouracil; Hum | 2017 |
Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro.
Topics: Adenocarcinoma; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Melatonin | 2018 |
Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemo | 2018 |
Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxal | 2018 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitab | 2017 |
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Line, T | 2017 |
Metastatic primary seminal vesicle adenocarcinoma: management of a rare tumour with multiagent chemotherapy and hormonal therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Genital Neoplasms, Mal | 2017 |
Early small bowel perforation due to aflibercept.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2017 |
Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carbopla | 2017 |
Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
Topics: Adenocarcinoma; Adult; Biomarkers; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colec | 2017 |
Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Disseminated Intravascular Co | 2017 |
Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemother | 2018 |
Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Female; Fluorouracil; Humans; Magnetic | 2018 |
Metastasis in the mandibular condyle: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 2017 |
Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2018 |
Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Colorectal Neopl | 2018 |
Metaplastic Cells in the Stomach Arise, Independently of Stem Cells, via Dedifferentiation or Transdifferentiation of Chief Cells.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Cell Lineage; Cell Proliferation; Cell Transdifferentiat | 2018 |
5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Endog | 2017 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Cutaneous drug Reactions: Chemotherapy-induced hyperpigmentation.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2017 |
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2018 |
Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2018 |
High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extra | 2018 |
Efficacy of low-dose 5-fluorouracil/cisplatin therapy for invasive extramammary Paget's disease.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2018 |
Could early tumour volume changes assessed on morphological MRI predict the response to chemoradiation therapy in locally-advanced rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2018 |
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetax | 2018 |
Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Comb | 2018 |
Targeting PRPK Function Blocks Colon Cancer Metastasis.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic N | 2018 |
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antin | 2018 |
Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.
Topics: Adenocarcinoma; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diag | 2018 |
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colec | 2018 |
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2018 |
Tumor response after long interval comparing 5x5Gy radiation therapy with chemoradiation therapy in rectal cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Carcinoma, Signet Ring | 2018 |
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2018 |
Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Topics: Adenocarcinoma; Aged; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Coh | 2018 |
Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: An Updated Analysis of Long-Term Follow-Up from Single Institution.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, | 2018 |
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adj | 2018 |
Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2018 |
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2018 |
Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
Topics: Adenocarcinoma; Allografts; Animals; Antineoplastic Combined Chemotherapy Protocols; Autografts; Car | 2018 |
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2018 |
Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neopla | 2018 |
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; | 2018 |
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2018 |
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2018 |
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; | 2018 |
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2018 |
Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2018 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease | 2019 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamo | 2018 |
C-Reactive Protein Level Predicts Survival Outcomes in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; C-Reactive Pr | 2018 |
Trans-Frontal Five-Fluorouracil (TraFFF): a novel technique for the application of adjuvant topical chemotherapeutic agents in sinonasal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Topical; Adult; Ambulatory Care; Antimetabolites, Antineoplastic; Ch | 2018 |
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotox | 2019 |
The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuv | 2018 |
Neoadjuvant Capecitabine Results in Similar Total Lymph Node Harvests as 5-Fluorouracil but an Increased Number of Lymph Nodes Containing Adenocarcinoma on Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal | 2018 |
E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Agents; Cadherins; Colonic Neoplasms; Drug Resistance, | 2019 |
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2019 |
Laparoscopic repair of bevacizumab-induced vesicovaginal fistula in metastatic colon cancer - a video vignette.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neo | 2019 |
Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Ca | 2018 |
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplasti | 2018 |
Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Arthr | 2019 |
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2019 |
An Organoid-Based Preclinical Model of Human Gastric Cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Proliferation; Epirubicin; Epithelium; Fluorour | 2019 |
High-dose versus standard-dose radiation therapy for cervical esophageal cancer: Retrospective single-institution study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2019 |
[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Campt | 2018 |
[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2018 |
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2019 |
Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Combined Modal | 2019 |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2019 |
[COMPLETE RESECTION OF URACHAL CARCINOMA WITH SIGMOID COLON INVASION AFTER FOLFOX CHEMOTHERAPY: A CASE REPORT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colon, Sigmoid; Combined | 2018 |
[A Case of Recurrent Colon Cancer with Long-Term Complete Response Treated with FOLFOX Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Flu | 2018 |
Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2019 |
Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; F | 2019 |
A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents, Immunological; An | 2019 |
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio | 2019 |
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2018 |
Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2018 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deo | 2018 |
Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Hu | 2019 |
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Caco-2 Cells; Cell Line, | 2019 |
XRCC4, which is inhibited by PFDA, regulates DNA damage repair and cell chemosensitivity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cisplatin; Decanoic Acids; DNA Breaks, Do | 2019 |
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N | 2019 |
Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biological Availability; Cell Survival; Colorectal | 2019 |
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dih | 2019 |
Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2019 |
Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem | 2021 |
Perioperative FLOT: new standard for gastric cancer?
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox | 2019 |
Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro | 2019 |
FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dise | 2019 |
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2019 |
Perioperative FLOT superior to ECF/X.
Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox | 2019 |
Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studie | 2019 |
Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; | 2019 |
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2019 |
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant | 2019 |
Metastatic gastric adenocarcinoma of the tongue with initial symptoms of glossodynia.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastric Mucosa | 2019 |
Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2019 |
Combined treatment for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcita | 2019 |
Optimal duration of adjuvant therapy for stage III colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chem | 2019 |
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; C | 2019 |
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
[Intussusception Caused by Colon Cancer in Pregnancy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonoscop | 2019 |
Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Atypical PRES with diffusion restriction or neurotoxicity- ? part of same spectrum-after oxaliplatin (FOLFOX-4 regimen) for colonic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluoroura | 2019 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Card | 2013 |
Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Agents; Biomarke | 2013 |
Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; beta Catenin; Biomarkers, Tumor; CD8 Antigens | 2013 |
Advancements in the management of pancreatic cancer: 2013.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2013 |
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Commo | 2013 |
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
[Panitumumab-induced trichomegaly].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2013 |
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, | 2013 |
Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 2013 |
Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2013 |
5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Color | 2013 |
Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Ring-enhancing lesion associated with radiation-induced liver disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2015 |
Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; | 2013 |
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Belgium; Chemotherapy, Adjuvant; Col | 2013 |
Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cel | 2013 |
Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2014 |
Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2015 |
[Secondary necrotizing fasciitis associated with panitumumab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Causal | 2013 |
Semi-IPN chitosan/polyvinylpyrrolidone microspheres and films: sustained release and property optimisation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line; Chitosan; Delayed-Acti | 2013 |
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Do | 2013 |
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bayes Theorem; Biomarkers, Tumor; Cell Line, Tumor; Clu | 2013 |
[Immediate results of complex treatment of resectable rectal neoplasms of distal localization].
Topics: Adenocarcinoma; Antineoplastic Agents; Case-Control Studies; Disease-Free Survival; Female; Fluorour | 2013 |
Histopathological regression grading matches excellently with local and regional spread after neoadjuvant therapy of rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Chi-Square Distributio | 2013 |
Neoadjuvant-intensified treatment for rectal cancer: time to change?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Jun | 2014 |
Cytotoxic withanolides from the leaves of Moroccan Withania frutescens.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Chromatography, High P | 2013 |
Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Coculture Techniques; Colonic Neoplasms; Cytotoxic | 2013 |
Treatment of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2013 |
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2014 |
[Results of combined treatment of patients with metastatic gastric cancer. Case study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2013 |
Evolving role of neoadjuvant therapy in rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com | 2013 |
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2013 |
Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2013 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter | 2013 |
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2013 |
[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Diseas | 2013 |
Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Impact of postoperative chemoradiotherapy and chemoradiotherapy alone for esophageal cancer in North-West Iran.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Expanding the Lauren classification: a new gastric cancer subtype?
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Fluorouracil; Gene Expression Regulation, | 2013 |
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cell Proli | 2014 |
The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy | 2013 |
Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case | 2013 |
Pretreatment patient comorbidity and tobacco use increase cost and risk of postoperative complications after esophagectomy at a high-volume cancer center.
Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cance | 2013 |
ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Endonuclease | 2013 |
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Adolescent; Adult; Aged; Aged, 80 and over; Anti | 2014 |
Topical henna ameliorated capecitabine-induced hand-foot syndrome.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; | 2014 |
Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2014 |
Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Anastomosis, Surgical; Anastomotic Leak; | 2013 |
Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.
Topics: Acute Disease; Adenocarcinoma; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protoco | 2013 |
γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line | 2013 |
Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2013 |
Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2013 |
Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Bridged-Ring Compounds; Chemoradiotherapy; Combined Mo | 2013 |
Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2013 |
Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.
Topics: Adenocarcinoma; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Carcinoma, Squ | 2013 |
Crohn's disease with worsening symptoms.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Combined Mo | 2013 |
Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviv | 2014 |
Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Paraneoplastic optic neuropathy and retinopathy associated with colon adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonoscopy; Comb | 2013 |
A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2014 |
Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy; Colonoscop | 2014 |
Multiagent chemotherapy for metastatic adenocarcinoma of the seminal vesicle.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Genital Neoplasms, Mal | 2014 |
The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2014 |
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tr | 2013 |
Autocrine extra-pancreatic trypsin 3 secretion promotes cell proliferation and survival in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Apoptosis; Autocrine Communication; Barrett Esophagus; Cell Line, Tumor; Cell Membra | 2013 |
Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetax | 2013 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Campto | 2013 |
The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell L | 2014 |
Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma?
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine | 2013 |
Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Drug Res | 2013 |
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2013 |
Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2013 |
Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.
Topics: Adenocarcinoma; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2014 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemothera | 2014 |
Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio | 2014 |
[Impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Signet Ring Cel | 2013 |
Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Immunoh | 2015 |
Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2014 |
Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy.
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Caspase 3; | 2014 |
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj | 2014 |
The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergis | 2013 |
[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin | 2013 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; D | 2014 |
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Colonic N | 2014 |
[A case of multiple skin metastases from cancer of the descending colon responding to FOLFIRI/cetuximab therapy].
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Ch | 2014 |
[A case of advanced colon cancer successfully treated with combination therapy of cetuximab and oxaliplatin, leucovorin, and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
[A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovor | 2013 |
ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferatio | 2014 |
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Sq | 2014 |
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biological Transport; Cell Survival; Colonic Neopla | 2015 |
Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi | 2014 |
Dermatomyositis associated with capecitabine in the setting of malignancy.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy, Needle; Capecit | 2014 |
Laparoscopic abdominosacral resection for locally advanced primary rectal cancer after treatment with mFOLFOX6 plus bevacizumab, followed by preoperative chemoradiotherapy.
Topics: Abdomen; Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2014 |
Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; | 2014 |
Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Colon carcinoma treated with oxaliplatin and capecitabine in a 12-year-old child.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Colonic Neoplas | 2014 |
Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Ce | 2014 |
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Ampulla of Vater; Animals; Antimetabolites, Antineoplastic | 2014 |
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cispl | 2014 |
[Hyperammonemic encephalopathy in a patient treated with 5-fluorouracil].
Topics: Adenocarcinoma; Antimetabolites; Fluorouracil; Humans; Hyperammonemia; Lung Neoplasms; Male; Middle | 2014 |
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplati | 2016 |
Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferati | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colo | 2014 |
Cetuximab-induced esophageal ulcer: the first report in literature.
Topics: Abdomen, Acute; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemothe | 2014 |
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Calcium Signaling; Cell | 2014 |
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Syn | 2014 |
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Mono | 2014 |
Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2014 |
Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Are we systematically under-dosing patients with fluorouracil?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy | 2015 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cam | 2014 |
Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dise | 2013 |
Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neopla | 2014 |
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
Diterpenoid C of Radix Curcumae: an inhibitor of proliferation and inducer of apoptosis in human colon adenocarcinoma cells acting via inhibiting MAPK signaling pathway.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cel | 2014 |
Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cap | 2014 |
A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil | 2014 |
Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget's disease.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2015 |
Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; | 2014 |
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Ind | 2014 |
Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment.
Topics: Aberrant Crypt Foci; Adenocarcinoma; Adenoma; Administration, Oral; Animals; Antimetabolites, Antine | 2014 |
Patterns of recurrence after trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemot | 2014 |
Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2014 |
[A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Duodena | 2014 |
[Bevacizumab-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antihypertensive Agents; A | 2014 |
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2014 |
The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Chemoradiot | 2014 |
Late complications after proctectomy in rectal cancer patients who underwent radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Agents; Case-C | 2014 |
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2014 |
Overcoming the challenges of primary tumor management in patients with metastatic colorectal cancer unresectable for cure and an asymptomatic primary tumor.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Colonos | 2014 |
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic | 2014 |
Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined | 2015 |
The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer:
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pr | 2014 |
Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; Biopsy; Chemoradiotherapy; Combined Modality Therapy | 2014 |
Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecit | 2014 |
In reply to Ren et al.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura | 2014 |
IMRT with capecitabine in advanced pancreatic cancer. In regard to Passoni et al.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura | 2014 |
Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Bindin | 2014 |
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blot | 2014 |
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b | 2014 |
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2014 |
Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoro | 2014 |
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2014 |
Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; | 2014 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2014 |
[A case of pathological complete response of advanced rectal cancer with liver metastasis accompanied by tumor thrombus following treatment with bevacizumab/FOLFOX4 chemotherapy].
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
[The combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj | 2014 |
Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Prolife | 2014 |
The wide gulf between stage III and stage IV colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer.
Topics: Adenocarcinoma; Cell Division; Cell Hypoxia; Cell Line, Tumor; Cell Shape; Cobalt; Colonic Neoplasms | 2014 |
Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Anastomotic Leak; Antimetabolites, Anti | 2014 |
Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diseas | 2014 |
Capecitabine induced colitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; | 2014 |
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell | 2015 |
An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; | 2014 |
The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell | 2014 |
Impact of liver-directed therapy in colorectal cancer liver metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheter Ablation; Colorec | 2014 |
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2014 |
Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineopl | 2014 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2015 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2015 |
Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Chr | 2014 |
SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Wester | 2014 |
Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cis | 2014 |
Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2014 |
Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2014 |
Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carbamoyl-Phosphate Syntha | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Duct | 2014 |
[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2014 |
Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreat | 2014 |
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2014 |
Laser-induced drug release for local tumor control--a proof of concept.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; beta-Cyclodextrins; Bromodeoxyuridine; Cel | 2014 |
Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Car | 2014 |
Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2014 |
Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Ce | 2014 |
Adjuvant chemotherapy by FOLFOX for gastric hepatoid adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2014 |
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2015 |
Transanal endoscopic microsurgery with entrance into the peritoneal cavity: is it safe?
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Blood Loss, Su | 2014 |
Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 2014 |
Overcoming 5-Fu resistance of colon cells through inhibition of Glut1 by the specific inhibitor WZB117.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Resi | 2014 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Comparison of 2-dimensional and 3-dimensional conformal treatment plans in gastric cancer radiotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Fluorouracil; Gastrect | 2014 |
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C | 2014 |
Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Intussusception due to rectal adenocarcinoma in a young adult: a case report.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2014 |
Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Pro | 2014 |
ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, | 2015 |
IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2015 |
[Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv | 2014 |
Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response | 2014 |
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
[Long-term survival of a patient with sigmoid colon cancer showing multiple liver metastases treated by performing partial hepatectomy, five years after achieving a complete response via hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Fluorouracil; Hepatectomy; Humans; Infusions, | 2014 |
A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2015 |
MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor | 2014 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fema | 2015 |
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2017 |
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2014 |
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Chemoradiot | 2014 |
FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2014 |
MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; | 2015 |
Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2015 |
Facial adenocarcinoma treated with intra-arterial chemotherapy.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Facial Neoplasms; Female; Fluoro | 2015 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine | 2015 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colecto | 2015 |
The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Enzyme Activation; | 2014 |
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Proto | 2014 |
MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.
Topics: Adenocarcinoma; Anoikis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferati | 2014 |
[Combined treatment of patients with locally advanced rectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatectomy; Hum | 2015 |
Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo | 2015 |
Neoadjuvant therapy for localized pancreatic cancer: support is growing?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; | 2015 |
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2015 |
Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2015 |
Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
Topics: Adenocarcinoma; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antimetabolites, Antin | 2015 |
Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas.
Topics: Adenocarcinoma; Animals; Aptamers, Nucleotide; Chitosan; CHO Cells; Colorectal Neoplasms; Cricetinae | 2015 |
[After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; | 2015 |
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2015 |
Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Campt | 2015 |
[Efficiency of pre-operative chemoradiotherapy in treating a case of advanced rectal cancer].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; | 2014 |
[Surgical resection after chemotherapy for advanced rectal cancer - report of a case].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
[Irradiation with carbon ions for locally recurrent rectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Heavy Io | 2014 |
[A case of metastatic gastric cancer originating from transverse colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Col | 2014 |
[A case report of hepatectomy for liver metastasis of colon cancer after heavy particle radiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Ther | 2014 |
[A case of advanced gastric cancer with liver metastasis involving curative surgery after neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2014 |
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2015 |
Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 2015 |
Use of extracorporeal membrane oxygenation for mechanical circulatory support in a patient with 5-fluorouracil induced acute heart failure.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colorectal Neoplasms; Extrac | 2015 |
Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiothera | 2017 |
[A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2015 |
High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2015 |
A rare cause of esophagitis with crystal deposition.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crystallization; Esoph | 2015 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur L | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Capecitabine; Colecto | 2015 |
Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Duodenal Neoplasms; Female; F | 2015 |
Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer.
Topics: Adenocarcinoma; Chemoradiotherapy; Female; Fluorouracil; Gene Expression Profiling; Gene Expression | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Long-Term Survival of Patient with Epstein-Barr Virus-Positive Gastric Cancer Treated with Chemotherapy: Case Report.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Cell Prolif | 2015 |
Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2015 |
Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2015 |
[Individualized therapy of synchronous ovarian and colon cancers with lymph].
Topics: Abdominal Pain; Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; | 2015 |
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease-Free Su | 2015 |
Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; | 2015 |
Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Chemotherapy, Adjuv | 2015 |
Role of Adjuvant Chemotherapy in ypT0-2N0 Patients Treated with Preoperative Chemoradiation Therapy and Radical Resection for Rectal Cancer.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chem | 2015 |
Development of lattice-inserted 5-Fluorouracil-hydroxyapatite nanoparticles as a chemotherapeutic delivery system.
Topics: 3T3 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antimetabolites, Antineoplastic; Cell Li | 2015 |
Chemotherapeutic treatment of colorectal cancer in pregnancy: case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2015 |
Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2016 |
Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Neoadjuvant therapy does not affect lymph node ratio in rectal cancer.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; I | 2016 |
Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2014 |
Organizing pneumonia with fatal outcome after adjuvant chemotherapy with FOLFOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas | 2017 |
Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2015 |
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2015 |
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2015 |
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Baculoviral IAP Rep | 2015 |
Metabolic alteration--Overcoming therapy resistance in gastric cancer via PGK-1 inhibition in a combined therapy with standard chemotherapeutics.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug | 2015 |
A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2015 |
Infection by Cx43 adenovirus increased chemotherapy sensitivity in human gastric cancer BGC-823 cells: not involving in induction of cell apoptosis.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, | 2015 |
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cross-Sectional | 2015 |
Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancr | 2015 |
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2015 |
Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Biomarke | 2016 |
Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Che | 2016 |
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
Topics: Adenocarcinoma; Adenosine Triphosphate; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Anti | 2016 |
Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fem | 2015 |
Pneumatosis intestinalis due to 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Primary Adenocarcinoma with Focal Choriocarcinomatous Differentiation in the Sigmoid Colon.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2015 |
[Para-Aortic Lymphadenectomy and Subsequent Chemotherapy after Resection of the Primary Lesion for Poorly Differentiated Adenocarcinoma of the Sigmoid Colon - A Case Report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; | 2015 |
[Septic shock and Tissierella praeacuta].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cholecystitis | 2016 |
Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Col | 2015 |
[mFOLFOX6 chemotherapy enabling curative resection in a patient with locally advanced duodenal adenocarcinoma and lymph node metastases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Duo | 2015 |
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2016 |
A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dialysis Solutions; Esoph | 2016 |
Lin28A enhances chemosensitivity of colon cancer cells to 5-FU by promoting apoptosis in a let-7 independent manner.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; DNA Repa | 2016 |
Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit | 2016 |
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Topics: Adenocarcinoma; Aged; Case-Control Studies; Chemoradiotherapy, Adjuvant; Colostomy; Disease-Free Sur | 2016 |
Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case | 2016 |
Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2015 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neo | 2015 |
[Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; | 2015 |
[Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Stud | 2016 |
Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Stu | 2015 |
Integration of in silico modeling, prediction by binding energy and experimental approach to study the amorphous chitin nanocarriers for cancer drug delivery.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitin; Curcumin; Docetaxel; | 2016 |
Synergistic anticancer properties of docosahexaenoic acid and 5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, T | 2016 |
Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Adhesion | 2016 |
Sequential boost in neoadjuvant irradiation for T3N0-1 rectal cancer: long-term results from a single-center experience.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Dig | 2016 |
Impact of multicellular tumor spheroids as an in vivo‑like tumor model on anticancer drug response.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorour | 2016 |
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Camptothecin; Cetuximab; Colorecta | 2016 |
[Analysis of clinical predictive factors of pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer].
Topics: Adenocarcinoma; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Radiotherapy, Intensit | 2016 |
Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2016 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; | 2016 |
The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anaerobic Threshold; Antineoplastic Combined Chemotherapy Protocols; Cardiores | 2016 |
Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer.
Topics: Adenocarcinoma; Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Ce | 2016 |
Potent in vivo anticancer activity and stability of liposomes encapsulated with semi-purified Job's tear (Coix lacryma-jobi Linn.) extracts on human colon adenocarcinoma (HT-29) xenografted mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Coix; Colon; Colonic Neoplasms; Dr | 2016 |
Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2016 |
[A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil | 2016 |
[Surgical Resection and Adjuvant Chemotherapy with FOLFOX6 for Primary Duodenal Adenocarcinoma and Nodal Metastasis Resulted in Complete Remission].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Duodenal Neo | 2016 |
Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothec | 2017 |
Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Resista | 2016 |
Colonic perforation following endoscopic mucosal resection in a patient on bevacizumab treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2016 |
Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Diffusion Magnet | 2016 |
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2016 |
Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; C | 2016 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2017 |
Transient global ventricular dysfunction in an adolescent affected by pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Male; Pancreatic | 2016 |
Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi | 2016 |
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Tumor; Chemoradiother | 2016 |
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasm | 2017 |
miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Culture Techniques; Disease Models, A | 2016 |
Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; F | 2016 |
Outcomes of Preoperative Chemoradiotherapy and Combined Chemotherapy with Radiotherapy Without Surgery for Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2016 |
Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemot | 2016 |
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2016 |
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2016 |
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dige | 2016 |
Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Chemotherapy, A | 2017 |
Usefulness of chemoradiotherapy for inoperable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2017 |
The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
AFP-producing adenocarcinoma of the esophagogastric junction: report of a case with atypical immunohistochemical findings responding to palliative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regime).
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esoph | 2016 |
Radiation field size and dose determine oncologic outcome in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2018 |
Interstitial lung disease caused by oxaliplatin. An uncommon but not unknown complication.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2017 |
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; B7-H1 Antigen; Barrett Esophagus; Biopsy; Cell Line | 2016 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorecta | 2017 |
Management of rectal cancer: the 2016 French guidelines.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Chemoradiotherap | 2017 |
Antitumor efficacy of combined gene and radiotherapy in animals.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Combi | 2016 |
Adenocarcinoma mimicking appendicular lump: a diagnostic dilemma-a case report.
Topics: Abdominal Abscess; Adenocarcinoma; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Appe | 2016 |
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemo | 2016 |
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm | 2017 |
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2017 |
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2017 |
A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.
Topics: Abdominal Pain; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; C | 2016 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxy | 2017 |
Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disseminated | 2017 |
"
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal | 2016 |
When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2017 |
[A Case of Small Bowel Adenocarcinoma That Was Diagnosed and Treated using Laparoscopic Surgery].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, A | 2016 |
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2016 |
[A Case of Advanced Rectal Cancer Resulting in a Pathologically Complete Response after Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deo | 2016 |
A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Catheter Ablation | 2017 |
Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; b | 2017 |
Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluo | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxyc | 2017 |
Assessment of anti-cancerous potential of 6-gingerol (Tongling White Ginger) and its synergy with drugs on human cervical adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspase 3; Catechols; Cell Cycle Checkpoints; Cell | 2017 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dise | 2017 |
The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2017 |
The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2017 |
Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2017 |
The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cis | 2017 |
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2017 |
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA2 Protein; Carci | 2017 |
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2017 |
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survi | 2008 |
Giant eccrine adenocarcinoma with skin and lymph node metastases: favourable response to chemotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2009 |
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Age Factors; Aged; Chemotherapy, Adjuvant; Cohort Studies; Colectomy; Female; Fluoro | 2009 |
Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti | 2008 |
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti | 2008 |
Granulocyte-colony stimulating factor producing rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colectomy; Fatal Outcome; | 2008 |
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, An | 2008 |
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Cel | 2008 |
Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Female | 2009 |
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Stud | 2008 |
Docetaxel: new indication. Metastatic gastric cancer: keep using fluorouracil-based chemotherapy. No tangible progress.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Drug Approval; Europe; Fluorouracil; Humans; Neoplasm Metast | 2008 |
Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antioxidants; Cannabinoid Receptor Antagonists; Can | 2009 |
[Rectal adenocarcinoma metastasis to the facial skin--case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Facial Neopl | 2008 |
Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; DNA, Neoplasm; Female; Fl | 2008 |
FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2008 |
[Case of gastric cancer with isolated brain metastasis successfully managed by gamma knife radiotherapy and chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined | 2008 |
[5-Fluorouracil-induced reticular hyperpigmentation].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2009 |
Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms | 2008 |
Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; F | 2008 |
Novel opportunities for thymidylate metabolism as a therapeutic target.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Computational Biology; DN | 2008 |
Early clinical results from chemoradiation with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohor | 2008 |
[FOLFOX versus PLF regimen in treatment of advanced gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2008 |
Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis | 2009 |
Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female | 2008 |
The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Combined Mod | 2008 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2008 |
A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2008 |
The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion; Cell Proliferation; Colla | 2008 |
[Postoperative radio-chemotherapy in locally advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl | 2008 |
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy | 2008 |
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrogra | 2008 |
Is surgical debridement and topical 5 fluorouracil the optimum treatment for woodworkers' adenocarcinoma of the ethmoid sinuses? A case-controlled study of a 20-year experience.
Topics: Adenocarcinoma; Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; C | 2008 |
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2009 |
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2009 |
The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
[A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Fluorourac | 2008 |
Fatal pneumonitis induced by oxaliplatin.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc | 2008 |
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dihydrouracil Dehyd | 2009 |
Epidermal growth factor receptor as a predictor of tumor response to preoperative chemoradiation in locally advanced gastric carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2008 |
[Sinusoidal obstruction syndrome induced by FOLFOX adjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2008 |
Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri | 2008 |
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2009 |
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Black or African American; Capecitabine; Deox | 2008 |
In vitro antiproliferative characteristics of flavonoids and diazepam on SNU-C4 colorectal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Cell Line, Tumor; Cell Pro | 2009 |
Neo-adjuvant chemoradiotherapy in advanced rectal carcinoma: a note of caution.
Topics: Adenocarcinoma; Fatal Outcome; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Rectal | 2008 |
Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose Fractionation, Radiati | 2009 |
A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2008 |
Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2009 |
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P | 2009 |
Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Hypoxia; Cell Proliferation; Coloni | 2009 |
[Analysis of the diagnosis and treatment of cervical minimal deviation adenocarcinoma].
Topics: Actins; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryoni | 2008 |
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2009 |
Coexistence Hodgkin's lymphoma and colonic adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Colonic | 2010 |
Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
[A case of primary orbital adenocarcinoma responding to chemoradiation].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality | 2009 |
[A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2009 |
Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2009 |
Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2009 |
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2009 |
Severe hiccups during chemotherapy: corticosteroids the likely culprit.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Antidotes; Antiemetics; Antimetabolites, Antineoplas | 2009 |
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colo | 2009 |
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined C | 2009 |
Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carc | 2009 |
A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Female; Fluorouracil; Heart Failure; Humans; Middle | 2009 |
Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Doxorubici | 2009 |
Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High | 2009 |
Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2009 |
Synchronous isolated adrenal metastasis from rectum adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Female; Flu | 2009 |
Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Human | 2010 |
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Inf | 2009 |
Lymph node harvest after proctectomy for invasive rectal adenocarcinoma following neoadjuvant therapy: does the same standard apply?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2009 |
Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fl | 2009 |
High-dose rate brachytherapy using inverse planning simulated annealing for locoregionally advanced cervical cancer: a clinical report with 2-year follow-up.
Topics: Adenocarcinoma; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2009 |
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2009 |
Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fas-Associated Death Dom | 2010 |
Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; ErbB Recep | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex | 2009 |
SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Colon; Colonic Neoplasms; Drug Resist | 2009 |
Decreased expression of microRNA-143 and -145 in human gastric cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blotting, Western; Cell Pr | 2009 |
Interstitial lung disease associated with oxaliplatin: description of two cases.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemot | 2009 |
Capecitabine-induced acute myeloid leukaemia.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Hu | 2009 |
Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca | 2009 |
Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Prolife | 2009 |
Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Combi | 2009 |
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2009 |
Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Do | 2010 |
The application of poly (glycerol-sebacate) as biodegradable drug carrier.
Topics: Absorbable Implants; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cel | 2009 |
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2009 |
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2009 |
Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2009 |
Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Duodenal Neoplasms; Fluoroura | 2009 |
Current role of bevacizumab in colorectal cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2009 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Cell Division; Cell Line, | 2010 |
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemothe | 2009 |
Intestinal permeability, vitamin A absorption, alpha-tocopherol, and neopterin in patients with rectal carcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Aged; alpha-Tocopherol; Antimetabolites, Antineoplastic; Antioxidants; Carbohydrates | 2010 |
A case of 5-fluorouracil-induced acute psychosis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hum | 2009 |
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
Postoperative morbidity with diversion after low anterior resection in the era of neoadjuvant therapy: a single institution experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, | 2009 |
Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer.
Topics: Actins; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Squamous Cell | 2009 |
Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxy | 2009 |
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Capec | 2009 |
Rectal angiosarcoma after adjuvant chemoradiotherapy for adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fatal Outcome; Fluorouracil | 2009 |
Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomark | 2009 |
Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dih | 2009 |
Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
[Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic An | 2009 |
[Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-1 | 2009 |
[Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Ant | 2009 |
[Metachronous metastasis from rectal adenocarcinoma to the penis--case report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; bcl-2-Associated X | 2010 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2009 |
Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2010 |
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2010 |
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2010 |
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2010 |
[A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2009 |
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2010 |
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; | 2010 |
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea | 2010 |
Treatment of gastric cancer in Asia: the missing link.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2009 |
Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; | 2010 |
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, | 2010 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2010 |
Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Apoptosis; | 2010 |
[Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2009 |
[A case of primary adenocarcinoma of small intestine with multiple liver metastases successfully treated with mFOLFOX6].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; DNA-Binding Proteins; Drug Synergism; Elli | 2009 |
Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2010 |
Bilateral phrenic nerve paralysis as a manifestation of paraneoplastic syndrome.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
Topics: Adenocarcinoma; Adenoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2009 |
The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Count; Cell Cycle; Cell Survival; C | 2010 |
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Ad | 2010 |
A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.
Topics: Adenocarcinoma; Aged; Apoptosis; Cell Division; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 2010 |
APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistan | 2009 |
Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Sickle cell crisis in a patient receiving capecitabine chemotherapy.
Topics: Adenocarcinoma; Anemia, Sickle Cell; Antineoplastic Agents, Phytogenic; Capecitabine; Colonic Neopla | 2010 |
Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blood Volume; Dose-Response Relationship, | 2009 |
HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; | 2010 |
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2010 |
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
[A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antimetabolites, Antineoplast | 2009 |
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents | 2010 |
Pancreatic cancer: progress made.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemo | 2010 |
CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Che | 2010 |
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
[A prospective study of FOLFOX7 scheme as neoadjuvant chemotherapy for stage III gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
[Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2010 |
A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neopl | 2010 |
Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bezafibrate; Capecitabine; Cecum; Deoxycytidine; Fluorouracil | 2010 |
Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy | 2010 |
Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Combined Modality Therapy; | 2010 |
Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplat | 2010 |
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Ma | 2010 |
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che | 2010 |
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Dru | 2010 |
[Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy].
Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoth | 2010 |
[Herpes simplex virus bronchopneumonitis in patient with acute respiratory failure after surgery].
Topics: Acute Disease; Acyclovir; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antiviral Agents; B | 2010 |
Management of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2010 |
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
Topics: Adenocarcinoma; Aged; Antimetabolites; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylase | 2010 |
Time to move to targeted drugs in biliary tract cancer?
Topics: Adenocarcinoma; Ampulla of Vater; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2010 |
Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy.
Topics: Adenocarcinoma; Biopsy; Carcinoma in Situ; DNA, Viral; Female; Fluorouracil; Histocytochemistry; Hum | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
[Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report].
Topics: Adenocarcinoma; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic | 2010 |
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2010 |
Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot | 2010 |
[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junctio | 2009 |
Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Pharmacological; DNA-Binding Proteins; Fluorourac | 2010 |
Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti | 2010 |
[A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; An | 2010 |
Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2010 |
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line; Cell L | 2010 |
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2010 |
DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cisplatin; DNA Damage; | 2010 |
Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free S | 2010 |
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv | 2011 |
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin | 2010 |
Metastatic urachal cancer responding to FOLFOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cystectom | 2010 |
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemothera | 2011 |
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; C | 2010 |
[Pathologically complete response of multiple liver metastases from rectal cancer treated with mFOLFOX6 plus bevacizumab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2010 |
Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
Anal function and intersphincteric resection.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; | 2010 |
A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); | 2011 |
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids.
Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chemical Precipitation; Drug Resistan | 2010 |
High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2010 |
The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coculture Techniques; | 2010 |
Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2010 |
Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Su | 2011 |
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2011 |
Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Lin | 2010 |
Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy.
Topics: Acute Disease; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2010 |
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2010 |
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv | 2011 |
Chemoradiation for esophageal cancer: institutional experience with three different regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2011 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato | 2011 |
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2010 |
High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, M | 2010 |
A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2010 |
Low dosage 5-fluorouracil increases the transfection efficiency of Ad/VEGF-A in mouse lung carcinoma cell line LA795 and inhibits tumor growth.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proli | 2010 |
Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2010 |
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2010 |
Chemotherapy-induced myelotoxicity and incidence of lung metastasis in an animal model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cisplatin; Colonic Ne | 2011 |
[Selection of anticancer drug for poorly-differentiated adenocarcinoma of colorectum from the level of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase activities in cancer tissue].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cell Differentiation; Colorectal Neoplasms; Dihydrourac | 2010 |
Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Mod | 2010 |
Primary site resection is superior for incurable metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2010 |
Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydropyrimidine Dehydrog | 2010 |
Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape | 2011 |
[A case of locally invasive obstructive jejunal cancer with curative resection after stenting and chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Endoscopy | 2010 |
Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Endome | 2010 |
Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; | 2010 |
Multi-modality therapy for metastatic colorectal cancer-ready for prime time?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Colectomy; Colonoscopy | 2010 |
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cros | 2010 |
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract | 2011 |
Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoth | 2011 |
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biop | 2010 |
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal | 2010 |
Suppressed protein expression of the death-associated protein kinase enhances 5-fluorouracil-sensitivity but not etoposide-sensitivity in human endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis Regula | 2010 |
Interleukin-10 and -12 predict chemotherapy-associated toxicity in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisp | 2010 |
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine; | 2010 |
Two cases of coronary vasospasm induced by 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Cecal Neoplasms; Coron | 2010 |
Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorouraci | 2011 |
Metastatic lymph node targeted chemosensitivity test for gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; An | 2011 |
[Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorou | 2010 |
Criteria for three-dimensional anorectal ultrasound assessment of response to chemoradiotherapy in rectal cancer patients.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, | 2011 |
Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2010 |
L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Biopsy; Cell Membrane; Fluorouracil; Humans; Hyperthermia, Induced; Lar | 2010 |
Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Neuroendocr | 2010 |
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Outcomes from chemoradiotherapy for patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
[mFOLFOX6 for treatment of anal canal cancer with disseminated carcinomatosis of bone marrow--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow Ne | 2010 |
A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumor.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cecum; Cell Proliferation; Colonic Neoplas | 2011 |
Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2010 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2010 |
Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose Fractionation, Radiation | 2011 |
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2011 |
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 2011 |
Hepar lobatum carcinomatosum associated with metastatic rectal carcinoma: an unusual cause of liver dysmorphy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Liver; Liver Neoplasms; Male; | 2011 |
[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case].
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Female; Flu | 2010 |
Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bariatric Surgery; Deglutition | 2011 |
Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2010 |
X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2012 |
Perforated mixed carcinoid-adenocarcinoma in transverse colon and at gastroenterostomy site: case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Colon, Transverse; | 2010 |
Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antioxidants; Capecitabine; Cricetinae; De | 2011 |
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma | 2010 |
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma | 2010 |
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma | 2010 |
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma | 2010 |
Laparoscopic proctectomy after neoadjuvant therapy: safety and long-term follow-up.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Digestive System Surgi | 2011 |
Adjuvant 5-fluorouracil-induced colitis necessitating completion colectomy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colitis; Fluorou | 2011 |
Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis.
Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary Angiogra | 2012 |
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2010 |
Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, P | 2011 |
Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2011 |
[Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; F | 2010 |
[A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2010 |
[A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phyto | 2010 |
[A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
[A case report of advanced rectal cancer showing a pathological complete response by neo-adjuvant FOLFOX chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovor | 2010 |
[A case report of primary adenocarcinoma of small intestine].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecit | 2011 |
miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Carrier Proteins; Cell Line, Tumor; Colorectal Neoplasms; Dru | 2011 |
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2011 |
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Topics: Adenocarcinoma; Anti-Allergic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies | 2011 |
Capecitabine-induced, nonneutropenic enterocolitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cecal Neoplasms; Chemotherapy, Adjuva | 2011 |
Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Su | 2011 |
Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antin | 2011 |
5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Capecitabine; Deoxycytidine; | 2011 |
Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemorad | 2012 |
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Squamous Cell; | 2011 |
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2010 |
Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II | 2011 |
Scan? Cure? Sure!
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic | 2011 |
A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplati | 2010 |
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Combined Chemother | 2012 |
Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Fluorouracil; Hepatic Ar | 2012 |
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2011 |
Mediastinal infusion with tracheal necrosis: an unusual complication of Port-a-cath devices.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2011 |
[Mixed carcinoid-adenocarcinoma in transverse colon].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoid Tumor; Colon, Transverse; Colonic N | 2010 |
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 2011 |
An evaluation of whether neoadjuvant therapy delays closure of defunctioning loop ileostomy following anterior resection for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, Antineoplast | 2011 |
Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis.
Topics: Adenocarcinoma; Animals; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Drug Resistan | 2011 |
Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb | 2011 |
The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema | 2012 |
Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer : prognostic significance of tumor regression.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcin | 2011 |
Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2011 |
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema | 2011 |
Synchronous colonic adenocarcinoma and pelvic schwannoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carcinoembryoni | 2011 |
Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2011 |
Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2011 |
MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxy | 2011 |
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2011 |
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2011 |
HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2011 |
[Isolation and identification of side population cells in human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; ATP-Binding Cassette Transporters; Cell Cycle; Cell | 2011 |
[Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2011 |
Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Topics: Adenocarcinoma; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2011 |
Short-course versus standard chemoradiation in T3 rectal cancer.
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Radiation | 2011 |
Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight; | 2012 |
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Va | 2011 |
CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, | 2012 |
Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2012 |
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2011 |
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; CD | 2011 |
[Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamil | 2011 |
Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adj | 2012 |
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2011 |
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2011 |
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptotic Protease- | 2012 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined M | 2011 |
Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACH
Topics: Adenocarcinoma; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antimetabolites, | 2011 |
[Therapeutic adherence to oral cancer therapy and interdisciplinary management].
Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protoco | 2011 |
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2011 |
Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; | 2011 |
Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2011 |
[Successful chemotherapy of carcinomatosis of the bone marrow with disseminated intravascular coagulation from a rectal carcinoma found by eosinophilia].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcino | 2011 |
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2011 |
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Ce | 2011 |
Clinical outcomes of mild hyperthermia for locally advanced rectal cancer treated with preoperative radiochemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adj | 2011 |
Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2011 |
Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2011 |
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2011 |
Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemot | 2012 |
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2011 |
Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci | 2011 |
Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonoscopy; Endosonography; | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2011 |
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Topics: Adenocarcinoma; Adenoviruses, Human; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival | 2011 |
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2012 |
The prognostic value of grade of regression and oncocytic change in rectal adenocarcinoma treated with neo-adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Nonsurgical management of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; | 2011 |
Resolving actinic keratoses: an expected side-effect of capecitabine therapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2012 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
[Anticancer effect of 5-fluorouracil combined with extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma].
Topics: Adenocarcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; F | 2011 |
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Chemoradiot | 2011 |
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2011 |
Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Colonic Neoplasms; Fluorourac | 2012 |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin | 2011 |
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2012 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecit | 2012 |
Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tu | 2012 |
Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dia | 2011 |
Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem | 2012 |
Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura | 2011 |
Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2011 |
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2012 |
Radiotherapy: the importance of local control in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; M | 2011 |
Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2012 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che | 2012 |
Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer.
Topics: Abnormal Karyotype; Adenocarcinoma; Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II a | 2012 |
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2012 |
Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2012 |
Pathologic complete response after FOLFOX7 in a locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 2012 |
Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Com | 2012 |
Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2012 |
Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; F | 2012 |
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; De | 2012 |
Low dihydropyrimidine dehydrogenase correlates with prolonged survival in patients with lung adenocarcinoma treated with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouraci | 2011 |
[Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node].
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecita | 2011 |
[A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucov | 2011 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
Unusual course of an abdominal aortic aneurysm in a patient treated with chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Aortogra | 2012 |
Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 2012 |
Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cel | 2012 |
A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Antineoplastic Agents; Apoptosis; Cancer Vaccines; | 2012 |
The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2012 |
Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl | 2012 |
[HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Octarepeat peptides of prion are essential for multidrug resistance in gastric cancer cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cisplatin; Doxorubici | 2012 |
A case report of 5-fluorouracil-induced coronary artery vasospasm.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Coronary Vasospasm; Coronary Vessels; Fluorou | 2010 |
Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apop | 2012 |
Response of glutathione S-transferase Pi (GSTP1) to neoadjuvant therapy in rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; F | 2012 |
Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2012 |
Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycy | 2012 |
Postoperative chemoradiotherapy for gallbladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemoradiotherapy; Female; Fluorouracil; Gallbladder Neoplasms; Humans; | 2012 |
Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Chemoradiotherapy, Adjuvant; Colonic Neo | 2012 |
A case of type 2 diabetes and metastatic liver cancer exhibiting hypercholesterolemia with abnormal lipoproteins.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure | 2012 |
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
Topics: Adenocarcinoma; Aged; Anastomotic Leak; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant | 2012 |
[Combined radiochemotherapy of an irresectable carcinoma of the pancreas].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cholangiopancreat | 1998 |
Bilateral acute ptosis leading to the diagnosis of a presumed metastatic gastric adenocarcinoma.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capec | 2012 |
[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bl | 2012 |
[A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Ce | 2012 |
Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blood Platelets; Caco-2 Cells; Cell Cycle; Cell Pr | 2012 |
Inadvertent severe acute kidney injury and oxaliplatin.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorecta | 2013 |
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, A | 2012 |
Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Calcium-C | 2012 |
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
[A case of primary adenocarcinoma of small intestine responding to XELOX chemotherapy and leading to a partial metabolic response].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorou | 2012 |
Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, | 2012 |
Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antioxidants; Cell Adhesion; Cell Line, Tumor; Chro | 2012 |
Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; B | 2012 |
Complete calcification of colorectal liver metastases on imaging after chemotherapy does not indicate sterilization of disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Colo | 2012 |
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiomyopathies; Colo | 2012 |
A complex oncosurgical approach to increasing the resectability of colorectal cancer metastases - a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Emboliza | 2014 |
The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Cell Line; Cytokines; DNA Damage; DNA, Neoplasm; D | 2012 |
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabi | 2012 |
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.
Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2012 |
Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2012 |
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2012 |
[Expression of Bcl-w protein in human small intestinal adenocarcinoma and effect of Bcl-w siRNA on apoptosis in intestinal adenocarcinoma HuTu-80 cells].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line | 2012 |
FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase | 2012 |
Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Capecitabine; Deoxycytid | 2012 |
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, epirubicin and cisplatin (modified ECF) as adjuvant chemotherapy in resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Disease-Free | 2012 |
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Colon carcinoma in a child treated with oxaliplatin and antiangiogenic treatment regimens.
Topics: Adenocarcinoma; Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Self-assessment quiz: answers, critiques, and references.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 2012 |
Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Lin | 2013 |
Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; De | 2013 |
Oncologically safe distal resection margins in rectal cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2012 |
5-Fluorouracil induced hyperammonemic encephalophathy: etiopathologic correlation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Brain Neoplasms; Diffusion Magnetic Resonance Imagi | 2012 |
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2012 |
Capecitabine-induced chest pain relieved by diltiazem.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Cap | 2012 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy | 2012 |
Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines.
Topics: Adenocarcinoma; Animals; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription F | 2012 |
Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy, | 2012 |
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Topics: Adenocarcinoma; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluoroura | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
[A case of adenocarcinoma occurring at colostomy site 7 years after abdominoperineal resection for rectal cancer resected after preoperative mFOLFOX6 chemotherapy].
Topics: Abdominal Wall; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colost | 2012 |
Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2012 |
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Primary carcinoma of jejunum--a case report.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antimetabolites, Antineoplastic; Capecitabine; Chemothe | 2012 |
Use of a chemically induced-colon carcinogenesis-prone Apc-mutant rat in a chemotherapeutic bioassay.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Animals; Antimetabolites, Antineoplastic; Azoxym | 2012 |
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2013 |
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplasti | 2012 |
Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 2013 |
Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
Topics: Adenocarcinoma; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, | 2012 |
Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free | 2013 |
Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Blotting, Western; | 2013 |
Double pancreatic and gastric adenocarcinomas: a rare association.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; | 2013 |
[Clinicopathological features and prognosis of primary appendiceal adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Combi | 2012 |
Local recurrence of gastric cancer after total gastrectomy: an unusual presentation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2012 |
Macroscopic and histologic regression of duodenal polyposis with FOLFOX4 chemotherapy for an ileal pouch adenocarcinoma in a patient with familial adenomatous polyposis.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
[Resolution of actinic keratosis with capecetabin].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorou | 2012 |
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamou | 2013 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers | 2012 |
Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
Topics: Adenocarcinoma; Aged; Anal Canal; Brazil; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Mic | 2013 |
Solitary bulky mediastinal lymph node metastasis from colon cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Differentiation; Chemother | 2013 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Proto | 2013 |
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytid | 2012 |
Cervical extravasation of bevacizumab.
Topics: Adenocarcinoma; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antin | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brid | 2013 |
[Esophageal cancer: outcome according to therapeutic strategy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2013 |
Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2013 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Impact of adjuvant chemoradiotherapy for rectal cancer on the long-term quality of life and late side effects: a multicentric clinical evaluation by the Turkish Oncology Group.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2012 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Re | 2013 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 2013 |
Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antine | 2013 |
Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, We | 2013 |
Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Cis | 2013 |
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2013 |
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chi- | 2013 |
Neoadjuvant therapy and mini-invasive total mesorectal excision for rectal cancer: feasibility and outcome analysis from a single institution prospectively collected data base.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Irinotecan during pregnancy in metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl | 2012 |
Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; F | 2012 |
Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherap | 2013 |
[Angina related to 5-Fluorouracil].
Topics: Adenocarcinoma; Aged; Angina, Unstable; Antimetabolites, Antineoplastic; Chest Pain; Electrocardiogr | 2002 |
G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antimetabolites; Antimetabolites, Antineoplastic; Breast Neoplasms; Bromodeoxyuridin | 2002 |
Correlation between cell survival, clonogenic activity and micronuclei induction in DMBA-OC-1R cells treated with immunospecific albumin microspheres containing cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell | 2002 |
Treatment with 5-fluorouracil enhances radiosensitivity of the human pancreatic cancer cell line MiaPaCa-2.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Survival; Combined Modality Therapy; Fluoroura | 2002 |
Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2.
Topics: Adenocarcinoma; Adenovirus Infections, Human; Animals; Antimetabolites, Antineoplastic; Cell Divisio | 2002 |
Sigmoid colon cancer during pregnancy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Female; Flu | 2002 |
[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Ascitic Fluid; Drug Combinati | 2002 |
Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2002 |
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin.
Topics: Adenocarcinoma; Afferent Loop Syndrome; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2002 |
Advanced pancreatic cancer--5 years on.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; | 2002 |
[Simultaneaous bilateral pulmonary metastasectomy of carcinoma of the sweat glands].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Axilla; Chemotherapy, Adjuva | 2002 |
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2002 |
Long-term results of reirradiation for patients with recurrent rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Color | 2002 |
[A case of recurrent gallbladder cancer responding to low-dose 5-FU and CDDP therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2002 |
A case of myocardial ischaemia induced by 5-fluorouracil.
Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Electrocardiogr | 2002 |
Chronomodulated chemotherapy in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Clinical Trials as To | 2002 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2002 |
Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
[A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2002 |
[Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combine | 2002 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2002 |
[A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 2002 |
Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2002 |
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regula | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2002 |
Surgical resection with and without chemotherapy in oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
[A case of gastric cancer with multiple liver metastases responding to combined hepatic arterial and aortic infusion chemotherapy with cisplatinum, 5-fluorouracil, and levofolinate calcium].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2002 |
[A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sc | 2002 |
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 2002 |
Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Thera | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres | 2002 |
Adenocarcinoma of the ethmoid sinuses: a case of two primary tumours.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Ethmoid Sinus; Fluoro | 2002 |
Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colonic Diseases; D | 2002 |
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorourac | 2001 |
Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2002 |
Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Northern; Ca | 2003 |
[Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2002 |
[A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Col | 2002 |
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2002 |
[Chemotherapy in adenocarcinomas of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2002 |
[A case report of intra-hepatic arterial infusion of mitomycin C with degradable starch microspheres for liver metastases of sigmoid colon carcinoma].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biodegradation, Enviro | 2002 |
[A case of metastatic vaginal tumor of rectal cancer].
Topics: Adenocarcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; Hysterectomy; Middle Aged; | 2002 |
[A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Co | 2002 |
Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcin | 2002 |
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuva | 2002 |
Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Female; Fluor | 2002 |
Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antimetabolites, Antineoplastic; Col | 2003 |
[Clinical comparison between intraoperative local arterial infusion chemotherapy and systemic venous chemotherapy of gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxo | 2001 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxy | 2003 |
[A case of advanced gastric adenocarcinoma with mild elevation of serum SCC that responded remarkably to adjuvant chemotherapy of ADM, CDDP, ETP and 5-FU (ACVF)].
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2003 |
Chemoradiation for adenocarcinoma of the anus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Sq | 2003 |
Hormone-refractory prostate cancer responding to capecitabine.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Antineoplastic Agents, | 2003 |
Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; | 2003 |
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[A case of advanced colon cancer responding to treatment with levofolinate combined with 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Admini | 2003 |
[A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi | 2003 |
Distal intramural spread is an independent prognostic factor for distant metastasis and poor outcome in patients with rectal cancer: a multivariate analysis.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluoroura | 2003 |
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; | 2003 |
[Cytoreductive surgery as an alternative to palliative operations in oncology (the model of treatment of stage IV colorectal cancer)].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 2002 |
Synchronous occurrence of glioblastoma multiforme and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplat | 2003 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
[Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2003 |
A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel carrier solution.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Co | 2003 |
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Ch | 2003 |
Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2003 |
Apoptosis, 5-fluorouracil sensitivity and expression of apoptotic proteins in a human ectocervical cell carcinogenesis model using different media.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Transforme | 2003 |
Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Cell Division; Co | 2003 |
Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cis | 2003 |
[Study on the chemosensitivity test of human gastric cancer using the MTT assay].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Screening Assays, Antitumor; Fem | 2001 |
Physical training during intrahepatic chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Exercise Therapy; Fluorouracil; Forced Expiratory V | 2003 |
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deo | 2003 |
The recent past and future of adjuvant therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri | 2003 |
[A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Colo | 2003 |
Relapse patterns after chemo-radiation for carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2003 |
Chronic myeloid leukemia in a patient with colon adenocarcinoma.
Topics: Adenocarcinoma; Cisplatin; Colonic Neoplasms; Fluorouracil; Humans; Leukemia, Myelogenous, Chronic, | 2002 |
[The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells].
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Drug Interactions; Esophageal Neoplasms; Etoposide | 2003 |
Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
Topics: Adenocarcinoma; Animals; Colorectal Neoplasms; Disease Models, Animal; Female; Fluorine Radioisotope | 2003 |
[First-line metastatic cancer of the colon].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio | 2003 |
[Modeling 5-FU clearance during a chronomodulated infusion].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chronothe | 2003 |
[Ureteral adenocarcinoma in men: a case report].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality | 2003 |
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2003 |
[A case report of complete remission of liver metastases from colorectal cancer treated with continuous hepatic arterial infusion].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal | 2003 |
The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.
Topics: Academic Medical Centers; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Chemotherapy, | 2003 |
[Cancer of the gastric antrum].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Combined Modality Therapy; Fluorourac | 2003 |
Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Breast | 2003 |
[Effect of the change of caspase-3 activity on the neoadjuvant chemotherapy-induced apoptosis of large-intestinal carcinoma cells].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin | 2003 |
Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl | 2003 |
[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; | 2003 |
P27 does not predict histopathological response to radiochemotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins | 2003 |
Arterial infusion chemotherapy for the patient of unresectable pancreatic carcinoma with multiple liver metastases: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fatal Outcome; Fluo | 2003 |
Comparison of rapid and slow intravenous administration of 5-fluorouracil in treating patients with advanced carcinoma of the large intestine.
Topics: Adenocarcinoma; Administration, Intravenous; Colonic Diseases; Fluorouracil; Humans; Intestinal Neop | 1962 |
COORDINATED SURGICAL-CHEMICAL THERAPY OF CANCER.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; DNA; DNA, Neoplasm; Fluorouracil; | 1963 |
5-FLUOROURACIL TREATMENT OF LIVER METASTASES BY CONTINUOUS HEPATIC ARTERY INFUSION VIA COURNAND CATHETER: RESULTS AND SUITABILITY FOR INTENSIVE POSTSURGICAL ADJUVANT CHEMOTHERAPY.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Gast | 1963 |
DISSEMINATED GEOTRICHOSIS; CASE REPORT.
Topics: Adenocarcinoma; Aged; Colitis; Colonic Neoplasms; Fluorouracil; Geotrichosis; Humans; Mycoses; Patho | 1964 |
ADENOCARCINOMA OF THE RETE TESTIS.
Topics: Adenocarcinoma; Fluorouracil; Geriatrics; Humans; Male; Radiotherapy; Rete Testis; Surgical Procedur | 1964 |
CHEMOTHERAPEUTIC STUDIES WITH OSTEOGENIC SARCOMA HE10734.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Fl | 1964 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
ACUTE GASTRITIS RESULTING FROM REGIONAL INFUSION OF AN ANTIMETABOLITE.
Topics: Adenocarcinoma; Angiography; Antimetabolites; Chemotherapy, Cancer, Regional Perfusion; Diagnosis, D | 1963 |
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N | 1964 |
PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
Topics: Adenocarcinoma; Ascites; Deglutition Disorders; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms | 1964 |
[PRESENT POSSIBILITIES OF CHEMOPROPHYLAXIS, COMPLEMENTARY AND PALLIATIVE CHEMOTHERAPY IN ASSOCIATION WITH SURGERY IN THE TREATMENT OF UTERINE NEOPLASMS].
Topics: Adenocarcinoma; Antineoplastic Agents; Aziridines; Chemoprevention; Female; Fluorouracil; Humans; Mi | 1964 |
CLINICAL STUDIES OF COMBINED CHEMOTHERAPY AND IRRADIATION IN INOPERABLE BRONCHOGENIC CARCINOMA.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluo | 1964 |
5-FLUOURACIL IN THE TREATMENT OF DISSEMINATED COLON AND RECTAL CARCINOMA.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Geriatrics; Neoplasm Metastasis; Pharmacology; Rect | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
CLINICAL EXPERIENCE WITH PALLIATION OF METASTATIC ADENOCARCINOMA WITH 5-FLUOROURACIL CHEMOTHERAPY.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Dextropropoxyphene; Fluorouraci | 1964 |
COMBINED 5-FLUOROURACIL AND SUPERVOLTAGE RADIATION THERAPY IN THE PALLIATIVE MANAGEMENT OF ADVANCED GASTROINTESTINAL CANCER: A PILOT STUDY.
Topics: Adenocarcinoma; Biomedical Research; Cobalt Isotopes; Drug Therapy; Fluorouracil; Gastrointestinal N | 1964 |
EFFECTIVENESS AND TOXICITY OF PROLONGED INFUSIONS OF 5-FLUOROURACIL IN THE TREATMENT OF CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma; Carcinoma, Sq | 1965 |
COMPARISON OF THE EFFECTS OF CHEMOTHERAPY AND LOCAL IRRADIATION ON THE VASCULARITY OF A TRANSPLANTED MOUSE MAMMARY ADENOCARCINOMA AND A PLEOMORPHIC SARCOMA.
Topics: Adenocarcinoma; Angiography; Animals; Blood Vessels; Fluorouracil; Mammary Neoplasms, Animal; Mammar | 1965 |
RECTAL MUCOSAL BIOPSY IN THE EVALUATION OF CANCER CHEMOTHERAPY.
Topics: Adenocarcinoma; Biopsy; Cecal Neoplasms; Drug Therapy; Fluorouracil; Humans; Mucous Membrane; Neopla | 1965 |
TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
Topics: Adenocarcinoma; Colonic Neoplasms; Double-Blind Method; Drug Therapy; Fluorouracil; Humans; Neoplasm | 1965 |
COMPARISON OF 5-FLUOROURACIL (NSC-19893) AND 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) IN TREATMENT OF PATIENTS WITH ADVANCED ADENOCARCINOMA OF COLON OR RECTUM.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Deoxyuridine; Drug Therapy; Fluorouracil; | 1965 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
Clinical studies with 5-fluorouracil in 47 patients.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma; Carcinoma, Squamous Cell; Fluorourac | 1962 |
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance.
Topics: Adenocarcinoma; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineo | 2003 |
[Liposome encapsulation of cystostatic drugs and starch microspheres improve tumor targeting in locoregional therapy. An animal experiment study of CC 531 liver tumor].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Delivery System | 1998 |
[A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 2003 |
Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; | 2003 |
Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm | 2003 |
Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy.
Topics: Acute Disease; Adenocarcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Coronary Angiography; Coro | 2003 |
[A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colo | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2003 |
[A case of spinal infarction related to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothec | 2003 |
[A case of locally extended rectal carcinoma quickly responding to local intraarterial infusion therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinom | 2003 |
Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Combi | 2003 |
Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic | 2003 |
[A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; | 2003 |
Rectal adenocarcinoma with germ-cell differentiation: report of a case.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 2003 |
A novel cell line and xenograft model of ampulla of Vater adenocarcinoma.
Topics: Adenocarcinoma; Ampulla of Vater; Animals; Cell Adhesion; Common Bile Duct Neoplasms; Deoxycytidine; | 2004 |
Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. an autoradiographic study in the rat.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Autoradiography; Colonic Neoplasms; Female | 2004 |
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Aged; bcl-2-Associated X Protein; Cisplatin; Combined Modality Therapy; Disease-Free | 2003 |
Complete pathologic responses to preoperative chemoradiation in two patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2004 |
Choroidal metastasis from adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Choroid Neoplasms | 2003 |
Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2003 |
[A case of parotid carcinoma with hepatic metastasis that responded remarkably to combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr | 2003 |
[A case of advanced gastric cancer with multiple liver metastases responding completely to hepatic arterial infusion and systemic chemotherapies].
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 2003 |
Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2004 |
[A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female | 2004 |
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2003 |
Outcome of rectal and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colectomy; Combined Modality Therap | 2003 |
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Aorta, Thoracic; Colonic Neoplasms; Deoxyr | 2004 |
Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis | 2004 |
[A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated I | 2004 |
[A case of gastric cancer with a synchronous hepatic metastasis responding to postoperative oral administration of UFT and intermittent intrahepatic arterial chemotherapy of 5-FU].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adm | 2004 |
[A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Colonic Neoplasms; | 2004 |
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dru | 2004 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Coloni | 2004 |
Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2004 |
Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Calorimet | 2004 |
The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
Adenocarcinoma of the salivary gland? A chemo-sensitive disease.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorouracil; | 2004 |
Inactivating mutation of the pro-apoptotic gene BID in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carr | 2004 |
Growth hormone protects the intestines but not the tumour from 5-fluorouracil toxicity in the short term in the rat.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Bacterial Translocation; Body W | 2004 |
Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chem | 2004 |
A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex).
Topics: Adenocarcinoma; Aged; Alloys; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2004 |
[Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2004 |
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Pro | 2004 |
Comparison between triple therapy with octreotide, galanin and serotonin, 5-fluorouracil/leucovorin, and sequential treatment with both, on human colon cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; C | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents | 2004 |
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2004 |
[A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colo | 2004 |
Sustained complete remission of metastatic oesophageal adenocarcinoma using long-term therapy with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Doxorubicin; Esophageal Neoplasms; Fluorourac | 2004 |
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cam | 2004 |
Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2004 |
Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeuti | 2004 |
Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells.
Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Sub | 2004 |
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2004 |
Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
Topics: Adenocarcinoma; Animals; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Drug Therapy, Combination; F | 2004 |
[Mitomycin-induced hemolytic uremia syndrome].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Do | 2004 |
A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Digestive System Surg | 2004 |
Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2004 |
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci | 2004 |
[A case of advanced colon cancer responding to l-LV+5-FU as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; C | 2004 |
[Successful treatment of 5-FU intraarterial infusion on the third postoperative day for a patient with multiple liver metastases from colon cancer and high risk of liver failure].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Benzimidazoles; Colectomy; Colonic Neoplasms; | 2004 |
[A case of advanced descending colon cancer with peritoneal dissemination responding to weekly high-dose l-leucovorin/5-fluorouracil combination therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respon | 2004 |
Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer.
Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Lin | 2004 |
[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2004 |
[A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colon, Sigm | 2004 |
[Long-term control of rectal liver metastases by hepatic arterial infusion chemotherapy of 5-fluorouracil and l-leucovorin--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2004 |
Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dise | 2004 |
ECF in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorou | 2004 |
[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2004 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox | 2003 |
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; E | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2004 |
[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheters, Indwe | 2004 |
[Bilateral shoulder-hand syndrome revealing hypothyroidism and colon carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Diagnosi | 2004 |
[Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2004 |
Fluorouracil-induced neurotoxicity presenting with generalized tonic-clonic seizure.
Topics: Adenocarcinoma; Anticonvulsants; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Male; Middle | 2004 |
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Sq | 2004 |
[A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
Guillain-Barré syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Guillain-Barre Syndrome; Hum | 2004 |
Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2004 |
Vasospastic angina caused by 5-fluorouracil. A case report.
Topics: Adenocarcinoma; Aged; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary | 2003 |
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; D | 2004 |
Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Division; Cell Survival; Colonic Neoplasms; Do | 2004 |
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Antineoplastic Agents; Benzimidazo | 2004 |
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fem | 2004 |
Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Dogs; Female; Fluorouracil; Gastrointesti | 2004 |
[A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; | 2004 |
[A case of unresectable multiple liver metastases from colon cancer successfully treated by hepatic arterial infusion chemotherapy and systemic immunotherapy (IFNANK) followed by hepatic resection].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2004 |
[A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic | 2004 |
[Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2004 |
[A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colostomy; | 2004 |
5-FU-induced acute leukoencephalopathy.
Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Brain Diseases; Colonic Neoplasms; F | 2004 |
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemot | 2004 |
Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cecal Neoplasms; Dihydropyrimidine Dehydrogenase Defic | 2004 |
[Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2004 |
Long-term survival after salvage surgery for colorectal lung metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2005 |
Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square | 2004 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
Coronary artery spasm induced by 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coronary Angiograph | 2005 |
[Two cases of gastric cancer with multiple liver metastases responding to TS-1 with hepatic arterial infusion of CDDP following low-dose 5-FU and CDDP chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relat | 2005 |
[A case of advanced rectal cancer responding to 5-fluorouracil based preoperative chemoradiation therapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administratio | 2005 |
Concurrent proton beam radiotherapy and systemic chemotherapy for the metastatic liver tumor of gastric carcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2005 |
Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Dose-Response Relatio | 2005 |
Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration.
Topics: Adenocarcinoma; Adenoviridae; Animals; Female; Fluorouracil; Gallbladder Neoplasms; Genetic Therapy; | 2005 |
Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Coronary Vasospasm | 2005 |
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola | 2005 |
[Influence of chemotherapy on Th1/Th2 cytokine switching in stomach cancer patients].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 2004 |
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2005 |
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 2005 |
[A case of liver metastases from cecal cancer successfully treated with fluorouracil and folinic acid (UFT/LV)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Chemotherapy, | 2005 |
[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2005 |
Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2005 |
An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoro | 2005 |
The effects of capecitabine in Raynaud's disease: a case report.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Capecitabine; Deoxycytidine; Fluorouracil; Follow-Up Studie | 2005 |
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
[A case of bilateral multiple liver metastases with distant lymph node metastases due to rectal cancer successfully treated with hepatic arterial infusion (HAI) of levofolinate (l-LV)/5-fluorouracil (5-FU) and radiotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2005 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy.
Topics: Adenocarcinoma; Anticoagulants; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Synergism; | 2005 |
Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C | 2005 |
Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2005 |
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl | 2005 |
Therapy for colorectal cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms | 2005 |
Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma. Results of 8-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Dose Fractionat | 2005 |
Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2005 |
Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice.
Topics: Adenocarcinoma; Alkaloids; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogen | 2005 |
Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line.
Topics: Adenocarcinoma; Andrographis; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Mu | 2005 |
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2005 |
Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2005 |
Complete pathologic response after chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hu | 2005 |
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line, | 2005 |
[Expression of metabolic enzymes of fluoropyrimidines in primary colorectal cancer and its clinical significance].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorec | 2005 |
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Chemotherapy, Adjuvant; Combined M | 2005 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu | 2005 |
[A case of metastatic submandibular lymphnode treated successfully with palliative oral (5-FU + PSK) chemotherapy in the elderly].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2005 |
Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Cell Line, Tu | 2005 |
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Deoxycyt | 2005 |
Early occurrence of chylothorax related to thoracic irradiation and concomitant chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chylothorax; Cispl | 2005 |
Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Neuroendocrin | 2005 |
Combined-modality neoadjuvant therapy for rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; | 2005 |
Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
Inflammatory breast cancer in a male.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cyclophospha | 2005 |
Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Back Pa | 2005 |
Unbiased estimation of tumor regression rates during chemoradiotherapy for esophageal carcinoma using CT and stereology.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2005 |
Neoadjuvant chemoradiotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Is adjuvant therapy with three-dimensional conformal irradiation combined with capecitabine (Xeloda) for gastric cancer effective?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; | 2005 |
Technique and long-term results of intersphincteric resection for low rectal cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Disease-Free Survival; Female; Fluorouracil; Hemoglobins; Human | 2006 |
An audit of postoperative radiotherapy after non-curative resection for cancer of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality The | 2005 |
Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Caspase 8; Caspases; F | 2005 |
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluoro | 2005 |
[Reversible cardiogenic shock under 5-fluorouracil treatment].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 2005 |
Serpentine supravenous streaks induced by 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Hyperpigmentation; Inf | 2005 |
[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2005 |
Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Algorithms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Fluorourac | 2005 |
Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 2005 |
Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clostridioides difficile; Dihydropyrimidine Dehydro | 2005 |
Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; | 2005 |
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil: a first step to neoadjuvant treatment?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Digestive System Surgical Pro | 2005 |
The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fe | 2005 |
Predicting recurrence risk for synchronous primary colon cancers.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cecal N | 2004 |
Current and future strategies for treating metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2004 |
Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blotting, Wester | 2005 |
Patient with angina secondary to capecitabine.
Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothera | 2005 |
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
Topics: Acetates; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2006 |
The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2005 |
Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neopla | 2005 |
Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunohisto | 2005 |
Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2005 |
Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bra | 2006 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation.
Topics: 3' Untranslated Regions; Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; | 2006 |
Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Calm | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bac | 2003 |
[Establishment, characterization, and biological analysis of pancreatic adenocarcinoma cell strain SW1990/FU].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Drug Resista | 2005 |
Portal hypertension secondary to 90Yttrium microspheres: an unknown complication.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2005 |
Combination chemotherapy in advanced small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemothera | 2005 |
[A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cecal | 2005 |
Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecit | 2006 |
Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Female; Fluorouracil; Follow-U | 2006 |
Cardiotoxicity resembling myocardial infarction that occurs during chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Chest Pain; Colonic Neoplasms; Diagnosis, Differential; Electrocardiography; | 2005 |
Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Par | 2005 |
[Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Drug Therapy, | 2005 |
[A case of breast cancer detected by MRI mammography after Hollywood syndrome].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Implants; Breast Neoplasms; C | 2005 |
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined | 2005 |
Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Cohort Studies; Combined Modal | 2005 |
Microsatellite instability and colorectal cancer prognosis.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Ant | 2005 |
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squa | 2005 |
Thyroid metastasis from colorectal cancer: role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2005 |
Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Esophageal Ne | 2006 |
Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Transformation, Neopl | 2006 |
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2006 |
Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chemothera | 2005 |
Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase | 2006 |
In vivo imaging of tumor response to therapy using a dual-modality imaging strategy.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers; Female; Fl | 2006 |
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; Femal | 2005 |
Pharmacogenetics in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Esophage | 2005 |
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2006 |
[A case of advanced rectal cancer responding to l-Leucovorin (LV)/5-fluorouracil( 5-FU) therapy as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 2006 |
Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2006 |
[Chronomodulated chemotherapy of oxaliplatin, 5-fluorouracil and folinic acid for advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Drug Adm | 2005 |
Chronic cutaneous lupus flare induced by systemic 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Fluorouracil; Humans; Lup | 2006 |
Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Fe | 2006 |
Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.
Topics: Abdomen; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Ci | 2006 |
[A case of postoperative liver metastasis from bile duct carcinoma responding to transarterial chemoembolization].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoembo | 2006 |
Feasibility of 5-Fluorouracil resumption in a patient experiencing drug-induced acute Prinzmetal angina.
Topics: Adenocarcinoma; Angina Pectoris, Variant; Electrocardiography; Fluorouracil; Humans; Male; Middle Ag | 2006 |
Oxaliplatin-related acute myelogenous leukemia.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2006 |
[Coma following chemotherapy: is 5FU implicated? Discussion about on case-report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cecal Neoplasms; Cecum; Coma; Fluorouracil; Humans; | 2006 |
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
Topics: Adenocarcinoma; Biological Transport, Active; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Ne | 2006 |
P53, COX-2, iNOS protein expression changes and their relationship with anti-oxidant enzymes in surgically and multi-modality treated esophageal carcinoma patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western | 2006 |
Capecitabine chemoradiation for rectal cancer after curative surgery.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2006 |
Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemoreceptor Cells; Ci | 2006 |
Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubici | 2006 |
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2006 |
Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 2006 |
Effects of radiotherapy on different histopathological types of rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2006 |
Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, | 2006 |
Multiple periungual pyogenic granulomas following systemic 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Diagnosis, Differential; Fluorouracil; Granul | 2006 |
[Neoadjuvant chemotherapy before radiotherapy in treatment of patients with cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.
Topics: Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ca | 2006 |
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dihydropyrimidine De | 2006 |
Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2006 |
Intraventricular metastases from rectal-sigmoid adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiac Tamponad | 2006 |
[Clinical observation on treatment of gastric cancer with zhijing granules: a report of 148 cases].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Dru | 2006 |
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 2006 |
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Chemotherapy, Adjuvant; C | 2006 |
Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemother | 2006 |
[Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Female; Fluoroura | 2006 |
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2006 |
Capecitabine-induced cerebellar toxicity.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cecal Neoplasms; Cerebellar Ata | 2006 |
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Huma | 2006 |
[Concurrent low-dose cisplatin/5-FU chemotherapy and radiation for the recurrent gastric carcinoma--case reports].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2006 |
On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancr | 2006 |
A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2006 |
[Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; DNA Pr | 2004 |
Comparative proteomics of apoptosis initiation induced by 5-fluorouracil in human gastric cancer.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Fluorouracil; Humans; Proteomics; Stomach Neoplasms | 2006 |
[Clinicopathological characteristics of gastric cancer in elderly patients].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[A case of advanced gastric cancer responding remarkably to paclitaxel + low-dose FP therapy in a neoadjuvant setting].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2006 |
Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway.
Topics: Adenocarcinoma; Carboxylesterase; Cell Line, Tumor; Chromatin; Colonic Neoplasms; Consensus Sequence | 2006 |
[A case of advanced gastric cancer with peritoneal metastasis that responded to paclitaxel plus 5-FU therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2006 |
[A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardi | 2006 |
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dihydrouracil Dehydrogenas | 2006 |
["Iatrogenic acute coronary syndrome"--59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Chemotherapy, Adjuvant; Colon, Ascending; Colonic Neoplasms; Fluoro | 2006 |
Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferati | 2006 |
Acute proctocolitis with commencement of neoadjuvant chemoradiation for rectal cancer.
Topics: Acute Disease; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; | 2006 |
[A case of effective multidisciplinary treatment with hepatic resection for synchronous multiple liver metastases from rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubic | 2006 |
[Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemoth
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2006 |
Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin | 2006 |
Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blood Vessels; Cell Di | 2006 |
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2006 |
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2006 |
The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dihydrou | 2006 |
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
[Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenas | 2006 |
[Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chronother | 2006 |
[A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2006 |
FDG-PET in colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinic | 2006 |
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neopl | 2006 |
Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Drug | 2007 |
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
Topics: Adenocarcinoma; Aged; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP) | 2007 |
Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort St | 2006 |
Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2007 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2006 |
[Anaphylactic reaction to oxaliplatin--a case of colon cancer].
Topics: Adenocarcinoma; Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2006 |
Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases].
Topics: Adenocarcinoma; Cecal Neoplasms; Chemotherapy, Adjuvant; Colectomy; Fluorouracil; Hepatectomy; Human | 2006 |
Hypoxia-inducible factor-1alpha suppressing apoptosis and increasing tolerance of lung cancer cells to chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfam | 2006 |
Inhibitory effect of pulmonary carcinoma by adenovirus-mediated CD/UPRT gene.
Topics: Adenocarcinoma; Adenoviridae; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; | 2006 |
Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Fluor | 2006 |
Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
Topics: Adenocarcinoma; Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2007 |
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti | 2007 |
Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2007 |
Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2006 |
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA- | 2007 |
Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2007 |
Analysis of early postoperative morbidity among patients with rectal cancer treated with and without neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; Combined Modality Therapy; Female | 2007 |
Left ventricular thrombus in a patient with esophageal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Diagnosis, Differential; Esophageal Neoplasms; Fluo | 2007 |
Integrating Chinese and conventional medicine in colorectal cancer treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidin | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2007 |
Effects of chemotherapy on patients with unresectable or metastatic adenocarcinoma of gallbladder.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fem | 2007 |
Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Duodenal Neopl | 2007 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluoro | 2007 |
[Acute promyelocytic leukemia in a patient with colon adenocarcinoma treated with fluorouracil].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Leukemia, | 2007 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop | 2007 |
[Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[A long survival case of sigmoid colon cancer patient with initially unresectable hepatic metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluoroura | 2007 |
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female | 2007 |
Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2007 |
Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2007 |
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemo | 2007 |
Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apo | 2007 |
A comparison of 5-fluorouracil and natural chemotherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzoquinones; Catechin; Cell Proliferation; Cell Survival; C | 2007 |
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; H | 2007 |
Bevacizumab in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2007 |
The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Liver resection after FOLFOX with bevacizumab.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2007 |
Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2007 |
Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; | 2007 |
Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; | 2007 |
Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 2007 |
Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2007 |
Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedul | 2007 |
[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 2007 |
Multiple atypical naevi after systemic 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Back; Biopsy; Diagnosis, Differential; Fluorouracil; Humans; Male; Nevus, Pigm | 2007 |
Images in clinical medicine. Diffuse chemoradiotherapy-related enterocolitis.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Colon; Combined Modality Therapy | 2007 |
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2007 |
[A case of metastatic colon cancer to paraaortic lymph nodes and liver treated successfully with oxaliplatin combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 2007 |
Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transport | 2007 |
Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; | 2007 |
[Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2007 |
[Establishment of a multi drug-resistant human lung adenocarcinoma cell line and biological characteristics there of].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxy | 2007 |
The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2007 |
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2007 |
Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progress | 2007 |
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Peopl | 2007 |
Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antidotes; Antimetabolites, Antineoplastic; Antineopl | 2007 |
Capecitabine and irinotecan in advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycyt | 2007 |
Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Microsatellite Instabilit | 2007 |
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2007 |
A renewed call for equipoise.
Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethi | 2007 |
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2007 |
[A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 2007 |
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2007 |
Analysis of anal sphincter preservation rate according to tumor level and neoadjuvant chemoradiotherapy in rectal cancer patients.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2007 |
Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apo | 2007 |
Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; ErbB R | 2007 |
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Trans | 2007 |
Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Drug Hyper | 2007 |
Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever.
Topics: Adenocarcinoma; Amyloidosis, Familial; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryo | 2007 |
Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinom | 2007 |
Metastatic esophageal adenocarcinoma presenting in the iris.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deo | 2007 |
Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Cont | 2007 |
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Digestive Syst | 2008 |
Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2006 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2007 |
Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
Topics: Adenocarcinoma; Amyotrophic Lateral Sclerosis; Antineoplastic Combined Chemotherapy Protocols; Campt | 2007 |
Effect of betulinic acid on anticancer drug-resistant colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-2-Associated X Protein; bcl-Associated Death Protein; Bet | 2007 |
[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Surviva | 2007 |
[A case of resection of synchronous multiple liver metastases from colorectal cancer after hepatic infusion chemotherapy and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined | 2007 |
Therapeutic efficacy of DNA-loaded PLGA microspheres in tumor-bearing mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therap | 2007 |
Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2007 |
Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Female; Fluorourac | 2007 |
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2008 |
Colonic adenocarcinoma in a 13-year-old with cystic fibrosis.
Topics: Adenocarcinoma; Adolescent; Air; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protoco | 2007 |
Preoperative chemoradiation followed by transanal excision for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2007 |
Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; | 2007 |
Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2007 |
Upregulated expression of S100A6 in human gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Dox | 2007 |
[Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
[Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Comb | 2007 |
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydroura | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Densi | 2007 |
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin | 2008 |
[A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2007 |
Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Colon; Colonic Polyps; Colonoscopy; Colorectal | 2007 |
[Reversal effect and mechanism of arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901].
Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporte | 2007 |
Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2007 |
[Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2007 |
[A patient with recurrent sigmoid colon cancer in whom pleural effusion and ascites resolved after FOLFOX 4 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Fluorouracil; Humans; Leuco | 2007 |
[Two cases of advanced low rectal cancer, preoperative chemo-radiation therapy leading to complete histological response].
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Humans; Lymph Node Excision; M | 2007 |
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Female; F | 2007 |
[Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Ce | 2007 |
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Chem | 2008 |
Inoperable pancreatic cancer: standard of care.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Com | 2007 |
The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2008 |
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2008 |
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; C | 2008 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2008 |
Sister Mary Joseph nodule: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Mo | 2007 |
Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2008 |
Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2008 |
FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; C-Reactive Pro | 2007 |
Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
Topics: Adenocarcinoma; Female; Fluorouracil; Gene Expression; Humans; Ki-67 Antigen; Male; Middle Aged; Neo | 2008 |
Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2008 |
Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil | 2008 |
Sepsis from liver abscesses in metastatic colorectal carcinoma after chemoimmunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; D | 2008 |
Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Confidence I | 2008 |
Sphincter-preserving operations following preoperative chemoradiation: an alternative to abdominoperineal resection for lower rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Colectomy; Female | 2008 |
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Combi | 2009 |
A case of 5-fluorouracil-induced peripheral neuropathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electromyography; Female; Fluorouracil; Humans; Low | 2008 |
Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2008 |
Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Ch | 2008 |
Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm | 2008 |
Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine.
Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Capecitabine; Deoxycytidine; Dose-Response Rel | 2008 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; De | 2008 |
Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2008 |
The toxicity and outcomes of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected high-risk gastric cancer: results of a single institute.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Rectal prolapse as initial clinical manifestation of colon cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2008 |
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2008 |
Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluor | 2007 |
Capecitabine-associated coronary vasospasm: a case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytid | 2008 |
Will we ever be ready for blood level-guided therapy?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Drug Admin | 2008 |
Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Drug C | 2008 |
Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; F | 2008 |
Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2008 |
Mechanism of resistance to chemoradiation in p53 mutant human colon cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Blotting, Western; Colonic Neoplasms; Combined Moda | 2008 |
Intra-arterial chemotherapy in advanced pelvic tumors.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Injections, Int | 1967 |
Ovarian and parovarian tumors in infants and children.
Topics: Adenocarcinoma; Adolescent; Child; Child, Preschool; Dysgerminoma; Female; Fluorouracil; Histocytoch | 1967 |
Bronchial adenoma and the carcinoid syndrome.
Topics: Adenocarcinoma; Adenoma; Adrenal Cortex Hormones; Bronchial Neoplasms; Carcinoid Tumor; Chlorpromazi | 1967 |
[Attack treatment of broncho-pleuro-pulmonary cancer by polychemotherapy under the protection of phytohemagglutinin].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betametha | 1967 |
Disappearance of antibodies to Factor VIII in a patient with acquired haemophilia and carcinoma of the pancreas during cytotoxic therapy with fluorouracil and CCNU.
Topics: Adenocarcinoma; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Factor VIII; Femal | 1984 |
Enzymes of the de novo and salvage pathways for pyrimidine biosynthesis in normal colon, colon carcinoma, and xenografts.
Topics: Adenocarcinoma; Animals; Carboxy-Lyases; Colon; Colonic Neoplasms; Fluorouracil; Humans; Intestinal | 1984 |
Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C.
Topics: Adenocarcinoma; Adult; Anemia, Macrocytic; Brain Edema; Disseminated Intravascular Coagulation; Fema | 1980 |
Pancreatic somatostatinoma presenting with hypoglycaemia.
Topics: Adenocarcinoma; Adult; Chlorothiazide; Diazoxide; Female; Fluorouracil; Humans; Hypoglycemia; Pancre | 1980 |
Combination chemotherapy for advanced endometrial adenocarcinoma.
Topics: Adenocarcinoma; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxyprogesterone; | 1980 |
Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, I | 1980 |
In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Resistance; Fluorodeoxyuridylate; Fluorouracil; Inj | 1982 |
Metabolism of 5-fluorouracil in various human normal and tumor tissues.
Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Squamous Cell; Digestive System; Fluorouracil; Ga | 1981 |
Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Antigens, Neoplasm; Carcinoembryonic Antigen; Colonic Neoplasms; Epitopes; | 1982 |
Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Resistance; Fluorouracil; Leukemia P388; Mice; Neop | 1982 |
Weekly large fraction radiotherapy and 5 fluorouracil as a palliative treatment for large bowel carcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Diarrhea; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; | 1982 |
Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract.
Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Carcinoma, Transitional Cell; Charcoal; Doxorubicin; Female; | 1982 |
Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma.
Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Female; Fluorouracil; Humans; Hypoxanthines | 1983 |
Management of high bile duct carcinoma.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Aged; Bile Duct Neoplasms; Bile Ducts; Combined Modality Therapy | 1984 |
Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1982 |
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu | 1982 |
Mixed beam radiotherapy and combination chemotherapy in localized pancreatic adenocarcinoma-preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Elementary Particles; | 1982 |
Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Hematopoi | 1982 |
Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineop | 1982 |
Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Cyclophosphamide; Drug Therapy, Combination; | 1983 |
Effective retreatment of patients with colorectal cancer and liver metastases.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Resistan | 1983 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality | 1983 |
The abdominoinguinal incision in limb salvage and resection of pelvic tumors.
Topics: Abdominal Muscles; Abdominal Neoplasms; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy P | 1984 |
Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fem | 1980 |
Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Com | 1980 |
[Combined chemotherapy of bronchial carcinomas (author's transl)].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, | 1980 |
Analysis of the results of our combined therapy for maxillary cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell | 1980 |
Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Drug Administration Sched | 1982 |
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular | 1982 |
Phase II trial of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin (MOF-Strep) in patients with disseminated pancreatic carcinoma.
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Female | 1982 |
Antibody pattern to human cytomegalovirus in patients with adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Viral; Colonic Neoplasms; Cytomegalovirus; Fluorouracil; He | 1981 |
Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 1982 |
[Treatment of rectocolic and gastric adenocarcinomas with 5-fluorouracil associated with high doses of folinic acid. Results of an experimental study].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leu | 1982 |
A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Drug Therapy, | 1982 |
Clinical evaluation of preoperative combined chemotherapy with neocarzinostatin (NCS) and 5-Fluorouracil (combined NF therapy) against gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antibiotics, Antin | 1981 |
Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Drug Th | 1983 |
Prognostic significance of hormone receptors in early recurrence of breast cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1983 |
Potentiation of the chemotherapeutic effect of 5-fluorouracil by combination with guanosine 5'-monophosphate.
Topics: Adenocarcinoma; Animals; Drug Therapy, Combination; Fluorouracil; Guanine Nucleotides; Guanosine Mon | 1983 |
Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Estrogens | 1983 |
[Pre- and intra-operative chemotherapy using FT-207 suppositories--with special reference to lung cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Fluorouracil | 1982 |
[New chemotherapeutic method for the treatment of tracheal and bronchial cancers--nebulization chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, | 1983 |
[Transfer factor immunochemotherapy for primary lung cancer--evaluation of histologic types].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1983 |
An atypical endocrine tumor of the lung responsive to radiation therapy and 5-fluorouracil-streptozotocin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bombesin; Carcinoma, | 1984 |
[Clinical trial on the effect of tegafur (SF-SP)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Capsules; Carcinoma, Intraductal, Noninfiltrating | 1984 |
5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Ga | 1984 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome.
Topics: Adenocarcinoma; Adult; Anemia, Hemolytic; Drug Therapy, Combination; Female; Fluorouracil; Humans; K | 1983 |
Phase II study of ftorafur in previously untreated and treated patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1983 |
[Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur].
Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1983 |
[Case of Borrmann III stomach cancer effectively treated by UFT therapy (co-administration of uracil and futraful)].
Topics: Adenocarcinoma; Administration, Oral; Aged; Drug Therapy, Combination; Fluorouracil; Humans; Male; S | 1983 |
Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cisplatin; Fluorouracil; Hot Temperature; | 1983 |
Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line; Cell Survival; Eflornithine; Fluoroura | 1983 |
Phase I evaluation of oral tegafur.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio | 1983 |
[Analysis of factors affecting clinical cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Fluorouraci | 1983 |
[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1983 |
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev | 1983 |
[A gastric cancer patient who underwent curative resection by angiotension-induced hypertension cancer chemotherapy].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxo | 1984 |
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra | 1984 |
[The case studies on oral administration of tegafur encapsulated with slow releasing granule (SF-SP) for three rectal patients].
Topics: Adenocarcinoma; Administration, Oral; Aged; Capsules; Delayed-Action Preparations; Female; Fluoroura | 1984 |
[Combination chemotherapy of CIS-diamminedichloroplatinum (II) and fluoropyrimidine derivatives for advanced gastric cancer: a preliminary report].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1984 |
Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line; C | 1984 |
Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Aphidicolin; Cell Line; Colonic Neoplasms; Diterpenes; | 1984 |
[Experimental chemotherapy of human gastrointestinal and breast cancers in nude mice and its correlation to clinical effect].
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1984 |
[Increased cytotoxic effects of various anticancer drugs by alpha-interferon (HLBI) on human tumor xenografts in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Syner | 1984 |
[Chemotherapy of renal cell carcinoma. 3. Single-agent therapy with FT-207 or vinblastine].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Huma | 1984 |
On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice.
Topics: Adenocarcinoma; Animals; Cell Survival; Colonic Neoplasms; Female; Floxuridine; Fluorodeoxyuridylate | 1980 |
Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Nausea | 1980 |
Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; Lymphatic Met | 1984 |
[5-Fluorouracil treatment combined with ascorbic acid in patients with disseminated stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Ascorbic Acid; Carcinoma; Combined Modality Therapy; Female; Fluorourac | 1984 |
Experimental colon neoplasia enhanced by extract of sperm (protamine).
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Colonic Polyps; Dimethylhydrazines; Female; Fluorouracil | 1984 |
[Low-dose methotrexate and sequential 5-FU treatment in advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1984 |
Postoperative adjuvant irradiation and 5-fluorouracil for adenocarcinoma of the cecum. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Cecal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Human | 1984 |
[Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents].
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Female; Fluorouracil; Gangliosides; Lung Neoplasms; Mamma | 1984 |
[Chemotherapy of metastatic urothelial carcinoma. cis-Diamminedichloroplatinum combination chemotherapy for patients with decreased renal function].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; | 1984 |
Cisplatin, doxorubicin, and 5-FU in combination for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1984 |
Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorourac | 1984 |
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Doxorubicin; Estro | 1984 |
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; D | 1984 |
Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1984 |
Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin | 1984 |
Treatment of autochthonous rat colonic adenocarcinomas with a thioether-lysophospholipid derivative in mono- and combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot | 1984 |
[5 years' results of a CMF protocol (methotrexate, cyclophosphamide, fluorouracil) of adjuvant chemotherapy in breast cancers].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mo | 1984 |
[Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluo | 1983 |
Remission of metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Humans; Intestinal Poly | 1983 |
[A clinical study (phase II) of a combination of 5-fluorouracil, vincristine and methyl CCNU in patients with advanced carcinoma of the large intestine].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; | 1983 |
Chemotherapy of advanced gastric cancer with 72-hour continuous intravenous 5-fluorouracil infusion at 2-week intervals.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, | 1983 |
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco | 1983 |
First histologic findings in metastases of colorectal carcinoma following isolated liver perfusion with cytostatics.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Humans; L | 1983 |
Adjuvant therapy for Dukes C adenocarcinoma of colon.
Topics: Abdomen; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle | 1983 |
Malignant tumors of the vagina. Classification and approach to treatment.
Topics: Adenocarcinoma; Adolescent; Adult; Carcinoma in Situ; Carcinoma, Squamous Cell; Child; Diethylstilbe | 1983 |
Multimodality therapy of stage III adenocarcinoma of the breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1983 |
Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Therapy, Co | 1983 |
[A case of primary duodenal cancer. Diagnostic and therapeutic considerations].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug | 1983 |
Combined modality treatment of gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Doxorubicin; Drug Therap | 1983 |
The natural history of gastric cancer and prognostic factors influencing survival.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic M | 1984 |
[5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Humans; M | 1984 |
Endoscopic local injection of early gastric carcinoma with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Follow-Up Studies; Gastroscopy; Humans; Injections; Male | 1984 |
[A case of advanced gastric cancer which disappeared histopathologically after short-time chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyt | 1984 |
Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors.
Topics: Adenocarcinoma; Age Factors; Animals; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Fluorou | 1984 |
[Results of combined treatment of cancer of the stomach taking into consideration tumor sensitivity to 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies | 1984 |
Chemoradiotherapeutic prevention of local recurrence after stapled anastomoses in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Follow-Up Studies; Humans; | 1981 |
Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy.
Topics: Adenocarcinoma; Colonic Neoplasms; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; | 1981 |
Renal disease after mitomycin C therapy.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Blood Pressure; Blood Urea Nitrogen; Creatinine; F | 1981 |
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; | 1981 |
[Conservative treatment of primary and recurrent malignant stomach neoplasms].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male | 1981 |
[Long-term chemotherapy with FT-207 for ovarian cancer (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorourac | 1981 |
Fast neutron irradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Colitis; Cost-Benefit Analysis; Energy Transfer; Esophagitis; Evaluation Studies as | 1981 |
Chemotherapy of pancreatic adenocarcinoma: initial report on two transplantable models in the Syrian hamster.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cricetinae; Cyclophosphamide; Disease Models, Animal | 1982 |
[Chemotherapy of renal cell carcinoma. 1. MFC therapy].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Drug Therapy, Combination; Eva | 1982 |
Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cytarabine; Fluorescent Antibody Technique; Fluorouraci | 1982 |
[Chemotherapy of stomach cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cisplatin; Doxorubicin; Drug Administration Sched | 1982 |
[Renal cell carcinoma].
Topics: Adenocarcinoma; Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; Kidney Neoplasms; Lung | 1982 |
[Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer].
Topics: Adenocarcinoma; Azirines; Carbazilquinone; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1982 |
[Clinical evaluation of Tegafur suppository in the treatment of uterine cancer--with special reference to the drug concentration in the blood, secretion from the pelvic dead space, and tissues of female genital organs].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Genita | 1982 |
Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; | 1983 |
The effects of chemotherapy on bony metastases as measured by quantitative skeletal imaging.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Colonic Neoplasms; Diphosphon | 1983 |
Gastric cancer-survival at the Pennsylvania Hospital with and without adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Gas | 1983 |
[Co-administration of adriamycin and 5-fluorouracil for the treatment of advanced stomach cancer].
Topics: Adenocarcinoma; Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mi | 1983 |
Coronary insufficiency and 5-fluorouracil therapy. A case report, review, and suggestion regarding mechanism.
Topics: Adenocarcinoma; Angina Pectoris; Fluorouracil; Humans; Male; Middle Aged; Sigmoid Neoplasms | 1983 |
[Pulmonary metastasis of renal cell carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; | 1983 |
Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Indomethacin; M | 1983 |
[Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug T | 1982 |
[Chemotherapy of metastatic urothelial carcinoma].
Topics: Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Therapy, Combinatio | 1982 |
VP-16 and adriamycin in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1982 |
Concepts for controlling drug-resistant tumor cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Burden; Cisplatin; Cyclophosphamide; Dactinomyc | 1980 |
Chemotherapy in gastric and oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combinat | 1982 |
Rectal adenocarcinoma treated with intra-arterial 5-fluorouracil. Prolonged remission.
Topics: Adenocarcinoma; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neop | 1982 |
Subacute vincristine toxicity following five consecutive daily doses.
Topics: Adenocarcinoma; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; H | 1982 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Gastrointesti | 1982 |
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
Topics: Adenocarcinoma; Bone Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Lung N | 1982 |
Radiation therapy combined with intra-arterial 5-FU chemotherapy for treatment of localized adenocarcinoma of the pancreas: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Cobalt Radioisotopes; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male; | 1982 |
Spontaneous pneumothorax in gynecologic malignancies.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drainage; Drug Therapy, | 1982 |
Adenocarcinoma of the colon with hepatic metastases. Fifteen-year survival.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Prognosis; | 1982 |
Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Hu | 1982 |
Ex vivo hemodialysis culture system for assessing the activity of cancer chemotherapeutic agents.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dogs; Drug Eval | 1982 |
Long-term, ambulatory, continuous intravenous infusion of 5-fluorouracil for the treatment of metastatic adenocarcinoma in the liver.
Topics: Adenocarcinoma; Aged; Ambulatory Care; Cecal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; | 1982 |
Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Dox | 1982 |
The assessment of response of murine transplantable colon tumors to combination chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Cell Line; Colonic Neoplasms; Dimethylhy | 1982 |
[Vascular isolation and perfusion of the liver in clinical practice].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Colonic Neop | 1982 |
Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch | 1982 |
[Juvenile carcinoma of the duodenum in two brothers (author's transl)].
Topics: Adenocarcinoma; Adult; Duodenal Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Male | 1982 |
[Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)].
Topics: Adenocarcinoma; Alopecia; Candidiasis, Oral; Diarrhea; Female; Fluorouracil; Hepatomegaly; Humans; M | 1982 |
[Autoradiographic studies on nucleic acid synthesis of human gastric cancer cells. II. Effects of 5-fluorouracil on nucleic acid synthesis of cancer cells (author's transl)].
Topics: Adenocarcinoma; Aged; Cell Survival; Cells, Cultured; Female; Fluorouracil; Humans; Male; Middle Age | 1982 |
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule.
Topics: Adenocarcinoma; Aged; Allopurinol; Brain Diseases; Drug Administration Schedule; Drug Evaluation; Dr | 1982 |
Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro.
Topics: Adenocarcinoma; Cell Line; Cell Survival; Clone Cells; Colonic Neoplasms; Dose-Response Relationship | 1982 |
Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Kinetic | 1982 |
Nasal cartilage necrosis following high-dose 5-FU: a case report.
Topics: Adenocarcinoma; Cartilage; Female; Fluorouracil; Humans; Middle Aged; Necrosis; Nose; Pelvic Neoplas | 1982 |
The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Methotr | 1982 |
[Combined therapy of advanced gastric cancer].
Topics: Adenocarcinoma; Female; Fluorouracil; Gastrectomy; Humans; Methotrexate; Middle Aged; Stomach Neopla | 1982 |
Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965--1979.
Topics: Adenocarcinoma; Aged; Cyclophosphamide; Diaphragm; Doxorubicin; Female; Fluorouracil; Humans; Male; | 1982 |
[Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; F | 1982 |
[Antitumor effect of UFT against malignant tumors of maxillary sinus--clinical and biochemical study].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1982 |
Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Drug Therapy, Combination; Estra | 1981 |
Angina and anemia with marked valvular stenosis.
Topics: Adenocarcinoma; Aged; Anemia, Hypochromic; Angina Pectoris; Aortic Valve Stenosis; Colon; Colonic Ne | 1982 |
[Effect of chemotherapy on the growth of human gastrointestinal tumor strains].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms, Experimental; Mic | 1980 |
[Experimental chemotherapy. II: Study of the cytomorphologic effects of radiation and antitumor chemotherapy on neoplastic tissue].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chick Embryo; Culture Techniques; Cyclophosphamide; | 1980 |
The relationship of the possible hepatic toxicity of chemotherapeutic drugs and carcinoembryonic antigen elevation.
Topics: Adenocarcinoma; Biopsy; Carcinoembryonic Antigen; Chemical and Drug Induced Liver Injury; Fluorourac | 1981 |
Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations.
Topics: Adenocarcinoma; Colon; Colonic Neoplasms; Deoxyuracil Nucleotides; Dose-Response Relationship, Drug; | 1981 |
Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorouracil; | 1980 |
Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1981 |
5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; F | 1981 |
Vinblastine, cyclophosphamide and 5-fluorouracil (VEF) combination chemotherapy for metastatic hypernephroma.
Topics: Adenocarcinoma; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mal | 1981 |
Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate.
Topics: Adenocarcinoma; Age Factors; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Com | 1981 |
Chemotherapy of human colorectal tumor xenografts in athymic mice with clinically active drugs: 5-fluorouracil and 1-3-bis-(-2-chloroethyl)-1-nitrosourea (BCNU). Comparison with doxorubicin derivatives: 4'deoxydoxorubicin and 4'-O-methyldoxorubicin.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Doxorubicin; Fluorouracil; Humans; Mice; Mic | 1981 |
Antitumor activity of 1-alkoxycarbonylalkylcarbamoyl-5-fluorouracil derivatives by oral administration.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Fema | 1981 |
[Analysis of radiobiological parameters of radiation therapy of local rectum carcinomas after preceding synchronization of the tumour cell cycle (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Cell Cycle; Fluorouracil; Humans; Middle Aged; Rectal Neoplasms | 1981 |
Studies in an animal model on the effectiveness of adjuvant chemotherapy with 5-FU and BCNU in cases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluoroura | 1981 |
Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
Topics: Adenocarcinoma; Animals; Cell Survival; Drug Therapy, Combination; Female; Fluorouracil; Lethal Dose | 1981 |
Long-term survivors with nonresectable advanced carcinoma of the rectum.
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Prognosis; Recta | 1981 |
Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
Topics: Adenocarcinoma; Animals; Carmustine; Cyclophosphamide; Doxorubicin; Drug Combinations; Drug Therapy, | 1981 |
[Remote results of the treatment of colon cancer].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Mal | 1981 |
Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil.
Topics: Adenocarcinoma; Female; Fluorouracil; Gastroenteritis; Humans; Leukopenia; Melphalan; Middle Aged; P | 1981 |
[Effect of 5-fluorouracil (5 Fu) on growth and morphology of human ovarian clear cell carcinoma transplanted into nude mice (author's transl)].
Topics: Adenocarcinoma; Adult; Animals; Female; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplanta | 1981 |
[Early cardiotoxicity of 5-fluorouracil].
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Myocarditis; Pericarditi | 1981 |
The value of lymphocyte transformation in carcinoma of the colon and rectum.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Lymphocyte Activa | 1980 |
Evaluation of nonhormonal cytotoxic chemotherapy in the Nb rat prostate adenocarcinoma: autonomous tumor (18-Pr and 13-Pr).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Ev | 1980 |
Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.
Topics: Adenocarcinoma; Administration, Oral; Bone Marrow; Fluorouracil; Humans; Infusions, Parenteral; Inje | 1980 |
Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; In Vitro Techniques | 1980 |
Adjuvant chemotherapy of human colorectal adenocarcinoma after growth on mice with congenital thymic dysplasia ("nude"). 2. Tumor remission following treatment with 5-FU and VCR of xenotransplanted primary human colorectal adenocarcinomas.
Topics: Adenocarcinoma; Animals; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mice; Mice, | 1980 |
Treatment of carcinoma of the rectum and squamous carcinoma of the anus by combination chemotherapy, radiotherapy and operation.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; | 1980 |
Long term survival following chemotherapy for carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Pancreatic Neoplasms; Razoxane | 1980 |
Chemotherapeutic study on canine gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine.
Topics: Adenocarcinoma; Animals; Dogs; Fluorouracil; Humans; Male; Methylnitronitrosoguanidine; Stomach Neop | 1980 |
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medr | 1980 |
[Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas].
Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; | 1980 |
5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Sche | 1980 |
[Adjuvant chemotherapy of human colorectal adenocarcinoma after growth on mice with congenital thymic dysplasia ("nude"). 1. Experiments to test the feasibility of combined chemotherapy with VCR and 5-FU (author's transl)].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Mice; M | 1980 |
Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma; Cell Line; Colonic Neoplasms; Drug Administration Sched | 1980 |
5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1980 |
Sequential carcinoembryonic antigen levels. A predictor of response and relapse in combination chemotherapy of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil | 1981 |
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; M | 1981 |
Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; Me | 1981 |
Punctal-canalicular stenosis related to systemic fluorouracil therapy.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Female; Fluorouracil; Humans; Intestinal Neoplasms; Lacrima | 1981 |
The combination 5-fluorouracil/levamisole induces enhanced rat Kupffer cell-mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Analysis of Variance; Animals; Cell Separation; Cells, Cultu | 1995 |
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Dis | 1995 |
[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopla | 1995 |
[A case of gastric cancer responding well to MTX/5-FU (methotrexate/5-fluorouracil) and PMUE (CDDP, MMC, UFT, etoposide) therapies upon lymphnode recurrence].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 1995 |
Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Brain Diseases; Cecal Neoplasms; Dihydrourac | 1995 |
Cancer recurrence following laparoscopic colectomy. Report of two patients treated with heated intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Laparosco | 1995 |
[Intra-arterial infusion chemotherapy for advanced liver metastases from lung cancer via implantable vascular access: report of six cases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplat | 1995 |
[A case of intrahepatic infusion chemotherapy with angiotensin II human for liver metastasis from early gastric cancer].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure | 1995 |
[Sclerosing cholangitis-induced biliary cyst formation: complication of hepatic artery infusion chemotherapy].
Topics: Adenocarcinoma; Biliary Tract Diseases; Cholangitis, Sclerosing; Cysts; Fluorouracil; Hepatic Artery | 1995 |
[A case of advanced gastric cancer treated effectively with neo-adjuvant chemotherapy using l-leucovorin and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 1995 |
[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1995 |
Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1995 |
Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Chemoth | 1995 |
Preoperative infusional chemoradiation therapy for stage T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Administration Sched | 1995 |
5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Cycle; Cell Division; Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; R | 1995 |
[Advanced gastric carcinoma with extensive lymph node metastases successfully treated by sequential methotrexate/5-fluorouracil therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoro | 1995 |
A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1995 |
Effective treatment of liver metastases from colon cancer with a combination of gamma-interferon and cisplatin chemotherapy: report of a case.
Topics: Adenocarcinoma; Administration, Oral; Cisplatin; Colectomy; Drug Therapy, Combination; Fluorouracil; | 1995 |
Chemotherapy-induced nuclear alterations of morphologic and genomic characteristics in a human colon cancer grafted onto nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Cell Nucleus; Chromatin; Colonic Neopl | 1995 |
Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1995 |
A 10-year survivor with unresectable hepatic metastases from sigmoid colon carcinoma treated with regional chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans | 1995 |
[A case of liver metastasis of gastric cancer with portal vein tumor thrombosis responding to chemotherapy with 5-FU and epirubicin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Huma | 1995 |
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line; Cisplatin; DNA Damage; Esophageal Neop | 1995 |
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 1993 |
Relation between the incorporation of 5-fluorouracil into liver carcinoma and normal tissue RNA at hepatic arterial administration in the rat is altered by overnight starvation.
Topics: Adenocarcinoma; Animals; Fluorouracil; Hepatic Artery; Infusions, Intra-Arterial; Liver Neoplasms, E | 1993 |
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Multimodality therapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1995 |
[Effects of 5-fluorouracil in shrinking residual gastric cancer: a case report].
Topics: Adenocarcinoma; Aged; Fluorouracil; Gastrectomy; Humans; Male; Neoplasm, Residual; Remission Inducti | 1995 |
[Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac | 1994 |
[Home therapy approach in cancer patients-chemotherapy (case 2-1)].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac | 1994 |
[Home therapy approach in cancer patients-chemotherapy (case 2-3)--intra-arterial infusion cancer chemotherapy for hepatic metastasis of colorectal cancer--case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic | 1994 |
New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Fatal | 1995 |
[The use of endolymphatic chemotherapy in patients with metastatic stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
Colo-rectal carcinoma in a tropical African population: an overview report.
Topics: Adenocarcinoma; Administration, Rectal; Adolescent; Adult; Aged; Anus Neoplasms; Ascites; Colonic Ne | 1994 |
[Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1995 |
[Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci | 1995 |
FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 1994 |
[A case of meningeal carcinomatosis which occurred after treatment for recurrence of the cervical carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combine | 1995 |
SMS 201.995 (Sandostatin) enhances in-vitro effects of 5-fluorouracil in colorectal cancer.
Topics: Adenocarcinoma; Carcinoma; Colonic Neoplasms; Colorimetry; Drug Synergism; Fluorouracil; Humans; Oct | 1995 |
[A case of advanced gastric remnant carcinoma with Virchow's metastasis treated with neoadjuvant chemotherapy (low dose CDDP + 5-FU) followed by surgical resection].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; E | 1995 |
[A case report: postoperative recurrence of peritoneal dissemination of gastric cancer responding to sequential methotrexate and 5-FU (5-fluorouracil)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 1995 |
Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Data Interpretation, Statistical; Female; Fluorou | 1994 |
[Cardiac toxicity of 5-fluorouracil].
Topics: Adenocarcinoma; Angina Pectoris; Cardiomyopathies; Cecal Neoplasms; Colonic Neoplasms; Death, Sudden | 1994 |
Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells.
Topics: Adenocarcinoma; Biological Transport; Colonic Neoplasms; Drug Administration Schedule; Drug Synergis | 1995 |
[A case of multiple liver metastasis from remnant gastric cancer responding to leucovorin.5-FU+UFT therapy].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adm | 1995 |
Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Combined Modality Therap | 1994 |
[Chemotherapy in the treatment of brain metastases of breast cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; C | 1994 |
A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgi | 1993 |
Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1994 |
The arotinoid Ro 40-8757 has antiproliferative effects in drug-resistant human colon and breast cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Division; Colonic Neoplasms; Doxorubic | 1994 |
Fine-needle aspiration cytology in locally advanced breast adenocarcinoma: a case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas | 1994 |
[A long-survival case of unresectable liver metastasis of colon cancer by hepatic arterial intermittent multidrug infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxoru | 1994 |
[A case of fistula-cancer response to arterial chemoembolization].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoembolization, T | 1994 |
[A case of gastric cancer with Borrmann type 4 responding to 5-FU-MMC combined chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluoro | 1994 |
[A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cy | 1994 |
5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.
Topics: Acute Disease; Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lip Ne | 1994 |
Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cer | 1994 |
Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids.
Topics: Adenocarcinoma; Amino Acid Sequence; Cell Cycle; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug | 1994 |
5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Esophageal | 1994 |
[A case of advanced gastric cancer successfully treated with resection after FEP (5-FU, epirubicin, CDDP) combined chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D | 1994 |
Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 1994 |
Management of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1994 |
Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; H | 1994 |
[Effect of fagopyrum cymosum rootin on clonal formation of four human tumor cells].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drugs, Chinese Herbal; | 1993 |
[Chemotherapy for metastatic brain tumors with CDDP and other agents: correlation between chemotherapeutic effects and the results of in vitro chemosensitivity tests using collagen gel-embedded culture combined with computerized image analysis in metastat
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla | 1994 |
Gastric carcinoma: curative resection and adjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Chemot | 1994 |
Necrosis in a meningioma following systemic chemotherapy. Case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Embolizat | 1994 |
[Effect of BOF-A2 on experimental and spontaneous metastasis model of mouse colon 26].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Chemotherapy, Adjuvant; Colonic Neoplas | 1994 |
[A case of advanced gastric cancer with multiple liver metastases showing marked response to new combination chemotherapy using 5-FU, THP and MMC (FTM)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administrati | 1994 |
Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation.
Topics: Adenocarcinoma; Cell Division; Chalcone; Chalcones; Colonic Neoplasms; Flavonoids; Fluorouracil; Hum | 1994 |
Chemoradiotherapy of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
[Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells].
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Resistance; Fluorouracil; Humans; Polymerase Chain Reaction; | 1994 |
[Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with multiple liver metastases].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1994 |
[A case of gastric cancer completely responding to sequential methotrexate and 5-fluorouracil therapy].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Admini | 1994 |
[Neoadjuvant chemotherapy for elderly advanced gastric cancer: a case report of MTX/5-FU sequential therapy followed by radical gastrectomy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug A | 1994 |
[Complete response in a case of unresectable gastric cancer treated by combined chemoimmunotherapy of MMC, 5-FU and OK-432].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 1994 |
Ethmoid sinus carcinomas: results and prognosis after neoadjuvant chemotherapy and combined surgery--a 10-year experience.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Che | 1994 |
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Humans; Inf | 1993 |
Enhancement of antitumor effects of combined chemoimmunotherapy.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; CD4-Positive T-Lymphocytes; Chemotherapy, Adjuvant; | 1993 |
Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung; Lung Neoplasms; | 1994 |
The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy.
Topics: Adenocarcinoma; Angina Pectoris; Electrocardiography; Female; Fluorouracil; Heart; Heart Diseases; H | 1994 |
Levels of viral glycoprotein reflect enhanced effectiveness of combined drug treatments.
Topics: Adenocarcinoma; Animals; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; Cel | 1994 |
Mitoxantrone, 5-FU, and leucovorin in breast cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Adm | 1994 |
Local excision of rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1994 |
Laparoscopic intestinal stomas.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Colonic Diseases; Colostomy; | 1994 |
[Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports].
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Circadian Rhythm; Drug Administration Schedule; Eso | 1994 |
[Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1993 |
[The clinical effect of chemotherapy with 5-FU and low-dose CDDP in patients with advanced gastric cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
[Efficacy of the treatment of gastric cancer as neo-adjuvant chemotherapy of 48 hour continuous intravenous infusion of 5-fluorouracil (5-FU) with leucovorin (LV)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluo | 1993 |
Semiautomated 14C-thymidine incorporation assay for in vitro screening of anticancer drug.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Radioisotopes; Carcinoma, Signet Ring Cell; Cell Divis | 1993 |
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Cycle; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug S | 1993 |
[A case of pulmonary metastasis from colon cancer successfully treated by 5-FU combined with leucovorin and interferon alpha-2a].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluoroura | 1993 |
Changes of 31P-MR spectroscopy in experimental tumors following radiotherapy combined with 5-fluorouracil compound (UFT).
Topics: Adenocarcinoma; Animals; Cell Division; Combined Modality Therapy; Flow Cytometry; Fluorouracil; Mag | 1993 |
[Cardiac toxicity of 5 fluoro-uracil: a case of atrioventricular conduction disorders].
Topics: Adenocarcinoma; Fluorouracil; Heart Block; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1993 |
[Weekly hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouraci | 1993 |
[Efficacy of 48-hour infusion of 5-fluorouracil for gall bladder cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 1993 |
Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Circadian Rhythm; Diarrhea; Dose-Response Relationship, Drug; Female; F | 1993 |
Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cis | 1993 |
Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1994 |
[A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 1994 |
[Local use of a drug combination consisting of fluorouracil, cyclophosphamide and silicone sorbent in patients with colonic cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Topical; Antineoplastic Combined Chemother | 1993 |
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Fema | 1994 |
Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 1994 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance.
Topics: Adenocarcinoma; Base Sequence; Colonic Neoplasms; DNA, Neoplasm; Drug Resistance; Fluorouracil; Huma | 1993 |
Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines.
Topics: Adenocarcinoma; Adult; Aged; Carboplatin; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid | 1993 |
Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1993 |
Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diar | 1993 |
Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells.
Topics: Adenocarcinoma; Cell Survival; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug Synergism; Fluorou | 1993 |
The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, | 1993 |
[A case of complete response by intermittent intra-arterial injection of 5-fluorouracil and carboplatin for liver metastases due to pancreatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluorouracil; H | 1993 |
[Advanced breast cancer with onset of multi-organ metastases successfully treated with combined loco-regional therapies: a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Ch | 1993 |
[A case of postoperative pulmonary metastasis of colon cancer which responded to treatment with leucovorin and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1993 |
A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Animals; Colonic Neoplasms; Fluorouracil; Gastrectomy; Humans; | 1993 |
Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Doxorubicin; Female; | 1993 |
Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions.
Topics: Adenocarcinoma; Female; Fluorouracil; Gastritis; Humans; Infusions, Parenteral; Middle Aged; Stomach | 1993 |
Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues.
Topics: Adenocarcinoma; Colorectal Neoplasms; Culture Techniques; Fluorouracil; Folic Acid; Humans; Leucovor | 1993 |
Multifocal inflammatory leukencephalopathy caused by adjuvant therapy with 5-fluorouracil and levamisole after resection for an adenocarcinoma of the colon.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop | 1993 |
Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1993 |
[Alternative combination chemotherapy with mitomycin C, vincristine, methotrexate, 5-fluorouracil, cis-platinum and adriamycin for adenocarcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do | 1993 |
[Effect of preoperative FPL (5-fluorouracil, cisplatin, leucovorin) therapy on patients with primary unresectable advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1993 |
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols | 1993 |
High dose rate intraluminal radiation in a combined modality treatment plan for carcinoma of the esophagus.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous C | 1993 |
Respiratory failure due to pulmonary lymphangitis carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorouracil; | 1993 |
Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hum | 1993 |
[Metachronous liver metastases treated with repeated liver resections and chemotherapy].
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neop | 1993 |
Dependence of the thymidylate synthase inhibition rate on the interval after the last administration of tegafur in sigmoid colon cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colon, Sigmoid; Combined Modality Therapy; Drug Admi | 1993 |
[A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1993 |
[A case of advance colon cancer responding to sequential methotrexate and 5-fluorouracil therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 1993 |
Combined modality therapy increasing local control of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1993 |
Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1993 |
Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Combined Modali | 1993 |
[A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoro | 1993 |
[A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1993 |
High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1993 |
Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Staging; Pancreatic Neoplasms | 1995 |
Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro.
Topics: Adenocarcinoma; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbop | 1996 |
[FAM as a palliative chemotherapy for gastric cancer with bone metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated Intrava | 1996 |
[Three cases of uterine cervical adenocarcinoma successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1996 |
[Study of serum CDDP concentrations in patients with advanced or recurrent adeno-or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1996 |
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; In | 1996 |
Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1995 |
Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1996 |
Preoperative "chemoradiation" for stages II and III rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1996 |
Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Brain Diseases; Colonic Neoplasms; Demyelinati | 1996 |
Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fema | 1995 |
[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Fatal Outcome; Female; Flu | 1996 |
Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A | 1995 |
Adenocarcinoma of the duodenum with liver metastases. Complete remission and long-term survival with 5-fluorouracil chemotherapy--a case report.
Topics: Adenocarcinoma; Adult; Duodenal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Remission | 1996 |
Carcinoma colon with mandible and liver metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1996 |
Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dr | 1996 |
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 1996 |
Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 1996 |
The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1996 |
Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antimetabolites, Antineoplastic; Cohort Studies; Combined M | 1996 |
[A case of advanced gastric cancer with lung and liver metastasis treated by CDDP and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 1996 |
p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo | 1996 |
[Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases].
Topics: Actuarial Analysis; Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplast | 1990 |
[A case of carcinomatous peritonitis for which combination therapy of 5-FU, leucovorin and cisplatin was effective].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Fl | 1996 |
Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 1995 |
Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1995 |
[Regression of 4th-stage cancer of the rectum].
Topics: Adenocarcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Rectal Neoplas | 1996 |
Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adju | 1996 |
[Severe myalgias: an unusual undesirable effect of levamisole combined with 5-fluorouracil].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined | 1996 |
Canities--reversal with chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm | 1995 |
Two cases of neurotoxicity possibly related to 5-fluorouracil and FA administration.
Topics: Adenocarcinoma; Central Nervous System Diseases; Colonic Neoplasms; Drug Interactions; Female; Fluor | 1996 |
Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineopl | 1996 |
Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell.
Topics: Adenocarcinoma; Aromatase Inhibitors; Breast Neoplasms; Cell Division; DNA; Enzyme Inhibitors; Estra | 1996 |
5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Drug Therapy, Combination; | 1996 |
Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations | 1995 |
Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
[A case of Borrmann type 4 gastric cancer successfully treated with MTX and 5-FU therapy through the hepatic artery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 1996 |
Modified clearing technique to identify lymph node metastases in post-irradiated surgical specimens from rectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Ly | 1996 |
Preoperative radiotherapy for rectal cancer: benefits and controversies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neopl | 1996 |
Postoperative radiotherapy for locally advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 1996 |
Exacerbation of rheumatoid arthritis after termination of chemotherapy for breast carcinoma.
Topics: Adenocarcinoma; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Breast Neoplasms; Cyclophosphamid | 1996 |
Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.
Topics: Adenocarcinoma; Animals; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 1996 |
Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemot | 1997 |
[A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colectomy; Colonic Neop | 1997 |
The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1997 |
Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5-fluorouracil sequential therapy: report of a case.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1997 |
[Results of adjuvant chemotherapy of operated high risk cervix carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1996 |
[Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chem | 1997 |
[A case of advanced colon cancer with marked response to combination chemotherapy with 5-FU, low dose CDDP, and leucovorin].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1997 |
[A two-year asymptomatic case with postoperative lung metastasis of sigmoid colon cancer responding to sequential methotrexate and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Drug Administr | 1997 |
"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 1997 |
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin | 1997 |
Adenocarcinoma of bladder.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; C | 1997 |
[Two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil, cisplatin and cytarabine].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Administ | 1997 |
Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Diet; Drug Synergism; Fluor | 1997 |
Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous | 1997 |
Carcinoma of the esophagus treated with radical chemoradiation 19 years after irradiation for recurrent breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamou | 1997 |
Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Topics: 16,16-Dimethylprostaglandin E2; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; | 1997 |
Effect of preoperative 5-fluorouracil on apoptosis of advanced gastric cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Flow Cytometry; Fluorouracil; Humans; In | 1997 |
Focal dystonia after chemotherapy: a case series.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Dyst | 1997 |
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Flo | 1997 |
[Secondary hepatic resections in a case of sigmoid colon cancer with multiple liver metastasis (H3) after successful continuous hepatic artery infusion chemotherapy oriented by in vitro chemosensitivity test].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug | 1997 |
Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as | 1997 |
Pharmacokinetics of intrapericardial administration of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Bre | 1997 |
Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Differentiatio | 1997 |
Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1997 |
[Inhibitory effect of the radiosensitizer AK-2123 on experimental liver metastasis and active transport of calcium ions].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Calcium Channel Blockers; Female; Fluorour | 1997 |
In vivo and ex vivo study of metabolic and cellular effects of 5-fluorouracil chemotherapy in a mouse mammary carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Cycle; Ethanolamines; Fluorouracil; Magnetic Re | 1997 |
Combined modality therapy for stage II and stage III pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1997 |
Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas | 1997 |
Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1997 |
Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Appendiceal Neoplas | 1997 |
Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; ATP Binding Cassette | 1997 |
Multifocal inflammatory leukoencephalopathy after fluorouracil and levamisole therapy for colon cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Brain; Chemotherapy, Adjuva | 1997 |
Multimodality treatment in the management of esophageal cancer: neoadjuvant chemoradiotherapy followed by transhiatal esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera | 1997 |
Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1997 |
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Ca | 1997 |
[Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 1997 |
[Cisplatin/5-fluorouracil intraperitoneal administration superior to intravenous administration for liver metastases of colonic carcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1997 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac | 1997 |
Synergistic effects of hyperthermia in preoperative radiochemotherapy for rectal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Evaluatio | 1997 |
First line protracted venous infusion fluorouracil with CisDDP or carboplatine in advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; | 1997 |
[A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Co | 1997 |
[A case report of preoperative intra-arterial infusion chemotherapy for pancreatic head carcinoma].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1997 |
[Liver abscess caused by hepatic artery infusion chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; Fluorouracil; Hepatec | 1997 |
[A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasm | 1997 |
[Percutanous trans-catheter intervention for the diagnosis and treatment of malignant pericardial effusion, with a report of 50 cases].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Catheteriz | 1996 |
Mechanisms underlying apoptosis induced by combination of 5-fluorouracil and interferon-gamma.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Caspase 1; Colonic Neoplasms; Cysteine Endope | 1997 |
[Preoperative chemoradiation therapy for advanced rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1997 |
[Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1997 |
[A case of stage IVb gastric cancer effectively treated by neoadjuvant chemotherapy and total gastrectomy with no residual tumor (R0)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1997 |
[Long-term complete response in two cases of liver metastases from rectal and gastric cancer treated with intra-arterial infusion chemotherapy of leucovorin and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1997 |
5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1997 |
Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer.
Topics: Adenocarcinoma; Administration, Rectal; Animals; Antibiotics, Antineoplastic; Chromatography, High P | 1997 |
Cutaneous metastasis as a complication of hepatic intra-arterial chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac | 1997 |
[A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, | 1998 |
Topical treatment of vaginal recurrence of endometrial carcinoma with 5-fluorouracil: case-report.
Topics: Adenocarcinoma; Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; B | 1997 |
[Penetrating duodenal ulcer as a complication of a hepatic artery port catheter in hepatic metastasis of sigmoid carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Duodena | 1997 |
Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Colonic Neoplasms; Dose- | 1998 |
[3D-Ct-planned interstitial HDR brachytherapy + percutaneous irradiation and chemotherapy in inoperable pancreatic carcinoma. Methods and clinical outcome].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Brachytherapy; | 1998 |
Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial.
Topics: Abdomen; Adenocarcinoma; Adjuvants, Immunologic; Anal Canal; Antidotes; Antimetabolites, Antineoplas | 1998 |
Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells.
Topics: Adenocarcinoma; Animals; Biological Transport; Carbon Radioisotopes; Carbonyl Cyanide p-Trifluoromet | 1998 |
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electrocardiography; Female; Fluorouracil; Heart; H | 1998 |
[A case of advanced gastric cancer with virchow's metastasis responding remarkably to combination chemotherapy of low-dose CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant; | 1998 |
[A case of multiple liver metastasis of gastric cancer responding to hepatic arterial infusion chronotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Ad | 1998 |
Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro | 1998 |
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Colo | 1998 |
[p53 and Bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Apo | 1998 |
[Enhanced induction of apoptosis of human colorectal cancer cells after preoperative treatment with 5-fluorouracil its relationship to DNA ploidy pattern].
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Female; Flow Cytometry; Flu | 1998 |
Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Creatinine; Dihydrouracil Dehydrogenase (NADP | 1998 |
[Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1998 |
A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Demyelinating Diseases; Female; | 1998 |
Irinotecan-induced immune thrombocytopenia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B | 1998 |
[How I treat colorectal cancer. I. Prevention and adjuvant treatment].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antimeta | 1998 |
[Proliferation and apoptosis before and after preoperative simultaneous radiochemotherapy of rectal carcinomas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Biopsy; Cell Division | 1998 |
[The intratumoral levels of thymidylate synthetase and folate in gastric and colon cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Fluoro | 1998 |
[A case of gastric cancer with decreased dihydropyrimidine dehydrogenase activity].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Female; F | 1998 |
[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1998 |
Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 1998 |
Advanced pancreatic cancer successfully treated with continuous infusion of 5-fluorouracil and low-dose cisplatin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; | 1998 |
Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1998 |
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino | 1998 |
[Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 1998 |
[Membranous lipodystrophy caused by chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas | 1998 |
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1998 |
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo | 1998 |
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo | 1998 |
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo | 1998 |
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo | 1998 |
[Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug | 1998 |
[Probable choroid metastasis of an esophageal adenocarcinoma that regressed with chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Choroid Neoplasms; Cisplatin; | 1998 |
Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies; Antimetabolites, Antineoplastic; Carcino | 1998 |
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Survi | 1998 |
[Adenocarcinoma of the Barrett esophagus. Apropos of 44 resected cases].
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; | 1997 |
Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Drug Resistanc | 1998 |
High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Carcinom | 1998 |
Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 1998 |
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Pr | 1997 |
Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Animals; Cell Division; Colonic Neoplasms; Combined Modality Therapy; Female; Fluoro | 1995 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 1996 |
[How toxic and effective is simultaneous radiochemotherapy with hydroxyurea, 5-FU and cisplatin in cervix carcinoma?].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1998 |
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di | 1998 |
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fractionatio | 1998 |
cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro.
Topics: Adenocarcinoma; Animals; Antibodies; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplat | 1998 |
Biochemical modulation therapy for pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplati | 1998 |
[Does neoadjuvant radiochemotherapy augment the resectability of pancreatic cancers?].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 1998 |
[Nursing situation in outpatient chemotherapy following surgery for gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1998 |
Detection of multiple hepatic micrometastases in pancreatic adenocarcinoma with a solitary liver metastasis by direct sequencing of the K-ras gene: a case report.
Topics: Adenocarcinoma; Aged; Base Sequence; Combined Modality Therapy; Dose Fractionation, Radiation; Femal | 1999 |
Supraventricular arrhythmia: a complication of 5-fluorouracil therapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atr | 1998 |
Adjuvant chemotherapy for patients with resected Dukes' C and high-risk B2 colon cancer with fluorouracil and levamisole.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; | 1998 |
Effect of 5-fluorouracil on gastrointestinal carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinogens; Carcinoma, Squamous Cell; Flu | 1999 |
[A case of unresectable pancreatic cancer responding to MTX/5-FU sequential therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1999 |
Rationale of the so-called extended resection for pancreatic invasive ductal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Femal | 1999 |
Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasms; Cyclooxygenase In | 1998 |
[Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Colonic Ne | 1999 |
[A case of multiple liver metastases showing good response by administration of carmofur alone in an aged patient with colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neopla | 1999 |
[A case of advanced gallbladder cancer responding to neoadjuvant intra-arterial chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1999 |
[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, | 1999 |
[Neoplasm-inhibiting effect and sensitivity-promoting effect of indomethacin in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Co | 1997 |
Inguinal lymph node metastases from rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colostomy; Combined Mod | 1999 |
Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1999 |
Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Colonic Neoplasms | 1999 |
Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Aorta; Colorectal Neoplasms; Female; Fluorine Ra | 1999 |
[A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 1999 |
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal | 1999 |
Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer.
Topics: 3T3 Cells; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Northern; | 1999 |
[Thrombotic microangiopathy associated with cancer is an oncologic emergency: a case report].
Topics: Adenocarcinoma; Adult; Anticoagulants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 1999 |
Electrochemotherapy against colorectal carcinoma: comparison of in vitro cytotoxicity of 5-fluorouracil, cisplatin and bleomycin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bleomycin; Cell Membrane Permeability; Cisplatin; Co | 1999 |
Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic | 1999 |
Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cispla | 1999 |
[A case of type 4 gastric cancer with peritoneal dissemination treated with intra-aortic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female | 1999 |
Combination effects of tamoxifen plus 5-fluorouracil on gastric cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cell Di | 1999 |
Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.
Topics: Adenocarcinoma; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Induction; Floxuridine; Fluorouracil; G | 1999 |
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 | 1999 |
[Total pelvic exenteration and rectal cancer. Apropos of 20 cases].
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 1999 |
Selective inflammatory effect of systemic fluorouracil in actinic keratosis.
Topics: Adenocarcinoma; Administration, Topical; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; F | 1999 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1999. Neurologic disorder in a 65-year-old man after treatment of colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Cogniti | 1999 |
Neoadjuvant chemotherapy before surgery for resectable carcinoma of the lower esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 1999 |
FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, | 1999 |
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Survival; Cloning, Molecular; Colorectal Neoplasms; DNA, | 1999 |
[A case of local recurrence of rectal cancer responding to local intraarterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Huma | 1999 |
Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biotransformation; Body Weight; Chromatogr | 1999 |
High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 1999 |
Pathology of rectal adenocarcinoma following preoperative adjuvant radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Female; Fibrosis; | 1999 |
Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Be | 1999 |
Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; C | 1999 |
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female | 1999 |
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 1999 |
Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 1999 |
[Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo | 1999 |
The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma, | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
Pre-operative chemoradiotherapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, Antineoplast | 1999 |
Preoperative combined radiotherapy and chemotherapy for rectal cancer does not affect early postoperative morbidity and mortality in low anterior resection.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Case-Control St | 1999 |
Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
[Chemotherapy and surgery compared to surgery alone in localized cancer of the esophagus].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1999 |
Advanced gallbladder carcinoma with liver metastasis showing a favorable response after intra-arterial infusion chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; | 1999 |
Gemcitabine and cancer of the pancreas: new preparation. Helpful or not?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Fluorourac | 1999 |
[Long partial response (PR) in a case of multiple liver metastasis from colon cancer effectively treated by continuous hepatic intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1999 |
[A long-survival case of gastric cancer with multiple liver metastasis: usefulness of intraoperative multimodality therapy and post-operative intra-arterial chemotherapy for liver lesions].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Sche | 1999 |
Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis | 1999 |
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1999 |
Rectal cancer and inguinal metastases: prognostic role and therapeutic indications.
Topics: Abdominal Neoplasms; Adenocarcinoma; Aged; Aged, 80 and over; Biopsy; Female; Fluorouracil; Follow-U | 1999 |
Anaphylactic reaction to oxaliplatin: a case report.
Topics: Adenocarcinoma; Anaphylaxis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1999 |
Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase 3 and caspase 8.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, | 1999 |
Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Huma | 1999 |
[A case of advanced gastric cancer with abdominal para-aortic lymph node metastasis successfully treated with FLP therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Carcinoma, S | 1999 |
Intra-arterial infusion of 5-fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Cisp | 1999 |
Role for alpha1,2-fucosyltransferase and histo-blood group antigen H type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dru | 2000 |
Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Comb | 1999 |
[Curative treatment of non-metastatic esophageal cancer: concomitant chemoradiotherapy and high-dose-rate endoluminal curietherapy boost].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1999 |
Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Drug Resistance, | 1999 |
Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival--a ten-year experience.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Life | 1999 |
Malar metastasis from rectal carcinoma: a case report.
Topics: Adenocarcinoma; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fatal Outcome; Female | 1999 |
Current trends in the surgical treatment of esophageal and cardia adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cardia; Chemother | 1999 |
Changes in apoptotic and mitotic activity in rectal carcinoma after short-term cytostatic therapy as possible predictive factors.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Carcinoembryonic Antigen; Female; | 1999 |
[A case of stage IV (A3) cervical and upper thoracic esophageal adenocarcinoma successfully treated with concurrent chemoradiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1999 |
[Two cases of recurrent gastric cancer for which combination chemotherapy with pirarubicin, cis-platinum and 5-fluorouracil were markedly effective].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2000 |
[A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2000 |
[Long-term complete response in a case of unresectable rectal cancer following chemoradiation].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2000 |
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; A | 2000 |
[Prognosis and adjuvant chemotherapy of axillary node-negative breast cancer patients].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, | 1997 |
Cisplatin-5-fluorouracil therapy with remarkable effect and 5-year survival for paraaortic lymph node metastases of rectal carcinoma in females: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Female; Fluo | 1999 |
Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2000 |
Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2000 |
[A case of stage IVb (H2P0N4T4) gastric cancer successfully treated with neoadjuvant chemotherapy (PMFE therapy)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorour | 2000 |
[A case of gastric cancer with liver metastasis responding to low-dose CDDP/5-FU combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Admi | 2000 |
[A case of diffusely infiltrating carcinoma of the sigmoid colon associated with lymphangitis carcinomatosa effectively treated with sequential MTX.5-FU and 5'-DFUR].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2000 |
[Complete remission in a case of sigmoid colon cancer with multiple liver metastases-treatment with arterial chemotherapy and percutaneous microwave coagulation therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 2000 |
Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
[Staging laparoscopy for a patient with advanced gastric cancer whose serum CA 19-9 level decreased remarkably after 2 courses of F/P therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Drug Adm | 2000 |
Intraperitoneal chemotherapy: biologic implications for clinical outcome.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Infusions, | 2000 |
Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dementia, Vascula | 2000 |
Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; | 1999 |
A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin.
Topics: Adenocarcinoma; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Drug Interactions; Drug Ther | 2000 |
Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
Topics: Adenocarcinoma; Age Factors; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoembryonic | 2000 |
Morphological change, loss of deltapsi(m) and activation of caspases upon apoptosis of colorectal adenocarcinoma induced by 5-FU.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Nucleus; Colorectal Neopl | 2000 |
Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunolog | 2000 |
[A patient with advanced gastric cancer who obtained downstaging and underwent radical surgery by neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2000 |
[Chemosensitivity test for 170 human breast carcinoma samples].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1998 |
Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro | 2000 |
Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity.
Topics: Adenocarcinoma; Animals; Cell Survival; Colonic Neoplasms; Escherichia coli; Fluorouracil; Lymphoma; | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpret | 2000 |
[Role of radiotherapy in the multidisciplinary approach to pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; In | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non- | 2000 |
[A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2000 |
[A case study of alpha feto protein (AFP)-producing gastric carcinoma with multiple liver metastases, in which chemotherapy was effective enough to once save a life in rapid decline].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluor | 2000 |
Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouraci | 1996 |
Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
Topics: Adenocarcinoma; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; | 2000 |
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic | 2000 |
[A case of gastric cancer with multiple liver metastasis responding to combined chemotherapy with low-dose cisplatin and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2000 |
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Pr | 2000 |
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; | 2000 |
Colon carcinoma with synchronous ovarian metastasis--report and discussion of five cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring | 2000 |
Perfusion of the oesophagus and stomach during hepatic artery chemotherapy via an aberrant gastric artery.
Topics: Adenocarcinoma; Angiography; Antimetabolites, Antineoplastic; Catheterization; Colonic Neoplasms; Em | 1999 |
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cytosine Deaminase; Dose-Response Relationship, Drug; Dr | 2000 |
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 1998 |
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Colonic Neopla | 2000 |
Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; | 2000 |
Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Colonic Neoplasms; Drug I | 2000 |
[Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin | 2000 |
[A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aorta; Fluorouracil; Gastrectomy; Humans; Lymph Nod | 2000 |
[A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2000 |
[A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 2000 |
[A case of colonic cancer with multiple liver metastases effectively treated by intra-arterial chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Femal | 2000 |
Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Co | 2000 |
Absorbable mesh sling prevents radiation-induced bowel injury during "sandwich" chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Case-Control Studies; Chemotherapy, Adjuvant; Dose-Response Relationshi | 2000 |
Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chr | 2000 |
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma; Cell Cycle; Dose | 2000 |
Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Critical Care; Drug Monitoring; Drug Therapy, | 2000 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.
Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluoroura | 2000 |
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.
Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluoroura | 2000 |
[Postoperative simultaneous radiochemotherapy improves survival in patients with cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Aden | 2000 |
[Cancer of the ethmoid sinus].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2000 |
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2000 |
Heat shock protein expression in human tumours grown in severe combined immunodeficient mice.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Femal | 2000 |
[Case report--efficacy of short-term intraarterial 5-fluorouracil for liver metastasis from colorectal cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Dr | 2000 |
[Intra-arterial infusion therapy for unresectable liver metastasis of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neop | 2000 |
[A case of pulmonary metastases of breast cancer responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Ad | 2000 |
[Induced hypertensive chemotherapy with angiotensin II found effective for mediastinal lymph node metastases of unknown origin].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxo | 2000 |
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2000 |
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; D | 2001 |
[Anaphylactoid shock due to folinic acid during treatment of metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anaphylaxis; Antimetabolites, Antineoplastic; Colorectal Ne | 2000 |
Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment.
Topics: Adenocarcinoma; Administration, Topical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineopla | 2001 |
Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Aged; Anal Canal; Antimetabolites, Antineoplastic; Case-Control Studies; Female; Flu | 2001 |
[A case of advanced gastric cancer with Virchow's and paraaortic lymph node metastases successfully resected after combined chemotherapy of low-dose CDDP and 5-FU].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administratio | 2001 |
[Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2001 |
Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2001 |
Options for investigative postsurgical therapy for gastric cancer, and case report of using the option for combined immunotherapy and chemotherapy.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Combin | 2001 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytid | 2001 |
[Long-term survival of a patient with postoperative liver metastasis of stage IVa gallbladder cancer responding to hepatic arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2001 |
Undifferentiated leukemia following treatment of gastric cancer with 5 fluorouracil, doxorubicin, mitomycin C chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; | 2000 |
Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouraci | 2001 |
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Bindin | 2001 |
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomark | 2001 |
External beam radiotherapy for synchronous rectal and prostatic tumors.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Humans; Male; Neoplas | 2001 |
Gastric cancer with Virchow's and multiple lung metastases showing a remarkable response to preoperative chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2001 |
[Effective combination chemotherapy for a recurrent case of carcinoma of the remnant stomach].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 2001 |
[Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2001 |
Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm | 2001 |
Image analysis for quantitation of solid tumor drug sensitivity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dose-Response Relations | 1999 |
Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Node-positive mucosal gastric cancer: a follow-up study.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Female; Fluorourac | 2001 |
Adjuvant postoperative 5-fluorouracil chemotherapy combined with pelvic radiation for rectal cancer: results from an Asian population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antimetabolites, Antineoplastic; Ch | 2001 |
Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monocl | 2001 |
p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents.
Topics: Adenocarcinoma; Alleles; Amino Acid Chloromethyl Ketones; Anticarcinogenic Agents; Antineoplastic Ag | 2001 |
Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2001 |
A pilot study of preoperative chemoradiotherapy for resectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Feasibility Studies; Female; Fluorouracil; Gast | 2001 |
Long-term follow-up of twenty patients with adenocarcinoma of the pancreas: resection following combined modality therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2001 |
Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineopla | 2001 |
Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study.
Topics: Adenocarcinoma; Antineoplastic Agents; Carrier Proteins; Cell Division; Cisplatin; Clone Cells; Colo | 2001 |
[Therapy results of locoregional recurrences in rectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2001 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2001 |
Expression of metallothionein in colorectal cancers and synchronous liver metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2001 |
Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2001 |
p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cell Nucleus; Chemotherapy, Adjuvant; Colorectal Neopla | 2001 |
Experimental chemotherapy against canine mammary cancer xenograft in SCID mice and its prediction of clinical effect.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2001 |
A case of bone metastasis from gastric carcinoma after a nine-year disease-free interval.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined | 2001 |
Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dr | 1999 |
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carb | 2001 |
A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2001 |
Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Agents; Colon; Combin | 2001 |
Prophylaxis of peritoneal carcinomatosis in experimental investigations.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Fluorouracil; Infusions, Parenteral; Male | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
[Adjuvant short-term continuous hepatoarterial infusion of 5-FU for advanced colorectal cancer using a removable hepatoarterial catheter].
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Catheterization; Chemotherapy, Adjuv | 2001 |
Cardiac tamponade as the first manifestation of gastric cancer and remission after chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cisplatin; | 2001 |
Spontaneous and inducible apoptosis in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Combined | 2001 |
Management of a 16-year-old boy with adenocarcinoma at the esophageal gastric junction.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Di | 2001 |
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Nucleus; Co | 2001 |
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas: great logic, grim reality.
Topics: Adenocarcinoma; Fluorouracil; Humans; Immunosuppressive Agents; Neoadjuvant Therapy; Neoplasm Stagin | 2001 |
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2001 |
Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Female; Fluorouraci | 2002 |
The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.
Topics: Acute Disease; Adenocarcinoma; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Modal | 2002 |
Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcin | 2001 |
In vitro models of a three-drug regimen (epirubicin, cisplatin and fluorouracil) for the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cisplatin; Colonic Neopl | 2001 |
[Prognosis of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combin | 2001 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
Relationship between Fas/FasL expression and apoptosis of colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2001 |
N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran | 2001 |
[The effect of blood-pancreatic juice barrier on 5-fluorouracil in post-pancreatoduodenectomy patients].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Th | 1999 |
Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colonic Neoplasms; | 2002 |
[Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2002 |
Construct validity of medicare chemotherapy claims: the case of 5FU.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chi-Square Distribution; Colonic Neoplasms; D | 2002 |
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasms; Combined | 2002 |
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clin | 2002 |
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Pr | 2002 |
Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2002 |
Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chil | 2002 |
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; | 2002 |
[Value of postoperative radiochemotherapy with 5-fluorouracil plus leucovorin in stage IB-IV M0 stomach carcinoma].
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans | 2002 |
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
[A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug C | 2002 |
Basic fibroblast growth factor infusion increases tumour vascularity, blood flow and chemotherapy uptake.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blood Flow Velocity; Fibroblast Growth Fac | 2002 |
Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Comorbidity; Femal | 2002 |
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, S | 2002 |
mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Femal | 2002 |
Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transport | 2002 |
[A case of unresectable gastric cancer complicated by a serious hepatic disorder and Virchow lymph node metastasis in which FP therapy and TS-1 administration were effective].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemot | 2002 |
Letter: Neurotoxicity of 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Male; Parkin | 1975 |
Treatment of carcinoma of the pancreas with radon seed implantation and intra-arterial infusion of 5-FUDR.
Topics: Adenocarcinoma; Adult; Aged; Fluorouracil; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplas | 1975 |
[Chemoradiation therapy of inoperable lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Fl | 1975 |
Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; | 1976 |
[Recent personal results in advanced bronchial cancer. Palliative immuno-chemotherapy. 63 cases].
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamou | 1976 |
Cardiotoxicity of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Angina Pectoris; Cecal Neoplasms; Female; Fluorouracil; Humans | 1977 |
Enhancement of the cancer chemotherapeutic effect by anticancer agents in the form of fat emulsion.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carcinoma, | 1977 |
Adriamycin alone or in combination in 100 patients with carcinoma of the cervix or vagina.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Dactin | 1978 |
[Chemotherapy of colorectal carcinomas].
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Palli | 1978 |
Management of carcinoma of the extrahepatic bile ducts.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Child; Commo | 1978 |
[Therapeutic advances in digestive oncology. III. Chemotherapy of digestive system cancers].
Topics: Adenocarcinoma; Digestive System Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplas | 1979 |
Cell proliferation in dimethylhydrazine-induced colonic adenocarcinomata following cytotoxic drug treatment.
Topics: 5,7-Dihydroxytryptamine; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cimetidine; | 1978 |
Effect of nutritional status and 5-fluorouracil on protein synthesis in parenterally alimented LEW/Mai rats.
Topics: Adenocarcinoma; Animals; Fluorouracil; Neoplasm Proteins; Neoplasms, Experimental; Nutritional Physi | 1979 |
Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1979 |
Adjuvant therapy of gastric cancer: the 40742 clinical trial of the EORTC Gastro-intestinal Tract Cooperative Group.
Topics: Adenocarcinoma; Drug Administration Schedule; Fluorouracil; Humans; Radiotherapy, High-Energy; Stoma | 1979 |
Immunobiology and therapeutic manipulation of heterotransplanted Nb rat prostatic adenocarcinoma. Chemotherapy of autonomous tumor, 102 Pr, heterotransplanted into congenitally athymic (nude) mice and syngeneic Nb rats.
Topics: Adenocarcinoma; Animals; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, | 1979 |
Sensitivity tests of tumors to cytostatic agents. I. Comparative investigations on transplanted tumors in vivo and in vitro.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cell Division; Cricetinae; Da | 1975 |
The chemotherapy of urologic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co | 1975 |
Chemotherapy studies in autochthonous rat tumors intestinal cancer.
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Dimethylhydrazines; Dimethylnitrosamine; Doxorubicin; Dru | 1978 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusi | 1979 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
[Determination of individual sensitivity of gastric cancer to 5-fluorouracil by tumor tissue respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Fluorouracil; Glycol | 1975 |
Chemotherapy of urogenital cancer.
Topics: Adenocarcinoma; Adult; Child; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; Fluorouracil; Hum | 1976 |
[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Car | 1976 |
Combination chemotherapy with methyl-CCNU, 5-fluorouracil, and vincristine in adenocarcinoma and large cell carcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Drug Therapy, Combination; Female; Fluorouracil; | 1976 |
Internal radiation therapy of liver cancer (90-Yttrium resin spheres intra-arterially) to supplement external radiation therapy, local and systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Female; Fluorourac | 1977 |
Case report: Liver scintigraphy in the follow-up of a patient on cytotoxic therapy.
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Fluorouracil; Humans; | 1976 |
Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Carcinoid | 1977 |
Mastectomy as an adjunct to combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Int | 1978 |
[5-fluorouracil inhibits the collagenolytic activity of invasive colonic adenocarcinomas in vitro].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Microbial Colla | 1978 |
5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230.
Topics: Adenocarcinoma; Adenoma, Islet Cell; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; | 1979 |
Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate.
Topics: Adenocarcinoma; Animals; Chloroquine; Drug Therapy, Combination; Female; Fluorouracil; Hypothyroidis | 1979 |
[Therapeutic effect of ftorafur].
Topics: Adenocarcinoma; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Fluorouracil; Mammary Gland | 1977 |
Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1977 |
[Comparative assessment of the effectiveness of the preparations CCNU, 5-fluorouracil, ftorafur and their combinations in inoperable stomach cancer].
Topics: Adenocarcinoma; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Nitrosourea Compounds; S | 1978 |
Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Central Nervous System; Colonic Neoplasms; Drug Evaluation; Female; Flu | 1979 |
Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Colonic Neoplasms; Digestive System; Drug Evaluation; Drug | 1979 |
A phase II trial of ftorafur: adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Marrow; Central Nervous System; Digestive S | 1979 |
Heterologous growth of human ovarian cancer. A new in vivo testing system.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Humans; Injections, Intramuscular; Injections, Intrap | 1977 |
Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Drug Resistance; Fluorodeoxyuridylate; Fluorouracil; Huma | 1979 |
Chemotherapy of Nb rat adenocarcinoma of the prostate heterotransplanted into congenitally athymic (nude) mice: report of 5-fluorouracil and cyclophosphamide.
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Disease Models, Animal; Fluorouracil; Male; Mice; Mice, N | 1979 |
[Nonsurgical treatments of colonic cancers: chemotherapy, immunotherapy, radiotherapy].
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Human | 1979 |
5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Administration Schedule; Drug | 1979 |
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gas | 1979 |
Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
Topics: Adenocarcinoma; Colonic Neoplasms; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; | 1979 |
Effect of preoperative intralesional BCG and postoperative 5-FU chemotherapy in three adenocarcinoma lines in rats.
Topics: Adenocarcinoma; Animals; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Male; Mammary Neoplas | 1979 |
5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Bone Marrow; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1979 |
Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infus | 1979 |
Basal cell nevus syndrome and adenocarcinoma of the colon. Response to systemic fluorouracil.
Topics: Adenocarcinoma; Adult; Carcinoma, Basal Cell; Colonic Neoplasms; Female; Fluorouracil; Humans; Nevus | 1979 |
The effect of 5-fluorouracil and adriamycin on heterotransplantation of Noble rat prostatic tumors in congenitally athymic (nude) mice.
Topics: Adenocarcinoma; Animals; Doxorubicin; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation | 1979 |
Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC).
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cyclophospham | 1979 |
Combination chemotherapy for advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fem | 1979 |
The cytocidal action of metronidazole in combination with other antineoplastic agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Colonic Neoplasms; D | 1979 |
Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Evaluation Studies as | 1979 |
Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Drug The | 1979 |
Transplantation of experimental ovarian tumors and their sensitivity to carcinostatics.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Granulosa Cell Tumor; Humans; Male; Mitomycins; Neopl | 1979 |
Improved combination chemotherapy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Female; Fluorouraci | 1979 |
Prostate adenocarcinoma model: Nb rat chemotherapy.
Topics: Adenocarcinoma; Animals; Castration; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Doxorub | 1979 |
[Early results of polychemotherapy in advanced ovarian tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Carcinoma, Papillary; Cyclophosphamide; Cyst | 1979 |
[Combined drug therapy in transplanted colonic mice tumors].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation, Preclinical; Drug The | 1979 |
[A case with gastric cancer by OK-MF'C therapy (author's transl)].
Topics: Adenocarcinoma; Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; | 1979 |
[Preoperative irradiation of rectal carcinoma wit 5-fluorouracil].
Topics: Adenocarcinoma; Cobalt Radioisotopes; Fluorouracil; Humans; Infusions, Parenteral; Preoperative Care | 1978 |
Heparin and polychemotherapy for treatment of lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1977 |
Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma.
Topics: Adenocarcinoma; Animals; BCG Vaccine; Drug Administration Schedule; Drug Therapy, Combination; Femal | 1977 |
Combination chemotherapy for solid tumors using 5-fluorouracil, chromomycin-A, and prednisolone.
Topics: Adenocarcinoma; Breast Neoplasms; Chromomycins; Colonic Neoplasms; Drug Therapy, Combination; Evalua | 1977 |
Chemotherapy of ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Fe | 1978 |
Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hu | 1978 |
Sequential 5-fluorouracil and hydroxyurea therapy for metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Hydroxyurea; Neoplasm Metastasis; Rectal Ne | 1978 |
Evaluation of chemotherapeutic effects on gastric cancer in relation to the histological pattern.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Cytarabine; Drug Therapy, Combination; Fluorouracil; Huma | 1978 |
[The primary appendix carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Appendiceal Neoplasms; Colostomy; Cyclophosphamide; Female; Fluorouraci | 1978 |
[Evaluation of radiation therapy and chemotherapy combined with nephrectomy for renal cell carcinoma (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Cytarabine; Drug Therapy, Combination; Evaluation Studies as Topic; Fem | 1978 |
Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer.
Topics: Adenocarcinoma; Administration, Oral; Carcinoma; Emulsions; Fluorouracil; Humans; Lymph Nodes; Lymph | 1978 |
Treatment of advanced colorectal cancer with a combination of 5-fluorouracil and methyl-CCNU.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Nitrosourea Comp | 1978 |
Phase II study of melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1978 |
Combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cyclophosphamide; Drug Resistance; Fluoro | 1978 |
Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Doxorubicin; Drug Therapy, Com | 1978 |
Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; DNA, Neoplasm; Fluorodeoxyuridy | 1978 |
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.
Topics: Adenocarcinoma; Animals; Drug Interactions; Drug Therapy, Combination; Female; Fluorouracil; Mammary | 1978 |
Cancer of the pancreas in young adults.
Topics: Adenocarcinoma; Adult; Biopsy, Needle; Female; Fluorouracil; Humans; Laparotomy; Liver Neoplasms; Ne | 1978 |
Management of urinary bladder cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fem | 1978 |
Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Pare | 1978 |
Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Fluorouracil; Leukemia, Ex | 1978 |
Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Dactinomycin; Doxoru | 1978 |
Chemoimmunotherapy of syngeneic mouse mammary carcinomas employing methanol extraction residue.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; BCG Vaccine; Cyclophosphamide; Female; Fluorouracil; | 1976 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Body Weight; Cachexia; Evaluation Studies as Topic; Fe | 1975 |
Intravenous hyperalimentation as an adjunct to cancer chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Digestive System; Fluorouracil; Humans; Male; Neoplasms; | 1975 |
Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Sc | 1975 |
[Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)].
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regi | 1976 |
Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluo | 1977 |
The treatment of gastric cancer with combined surgical resection and chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Prognosis | 1977 |
Oculomotor disturbances associated with 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Adult; Brain Stem; Cerebellar Diseases; Colonic Neoplasms; Eye Movements; Female; Fl | 1977 |
Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate.
Topics: Adenocarcinoma; Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil | 1977 |
Chemotherapy of carcinoma of the cervix.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Squamous Cel | 1977 |
Primary adenocarcinoma of the small intestine.
Topics: Adenocarcinoma; Adult; Aged; BCG Vaccine; Female; Fluorouracil; Follow-Up Studies; Humans; Intestina | 1977 |
Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study.
Topics: Adenocarcinoma; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxyprogesterone; | 1977 |
Chemoprophylaxis for patients with colorectal cancer. Prospective study with five-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Follow-Up Stu | 1976 |
[Multifactorial immunological treatment of cancer in urology].
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Cobalt Radioisotopes; Female; Fluorouracil; Humans; | 1976 |
[Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)].
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Follow-Up Studi | 1976 |
[Combination chemotherapy in the treatment of polymetastic breast cancer. Comparison of therapeutic effects of 2 methods of sequential drug administration. Role of adriamycin in these combinations].
Topics: Adenocarcinoma; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drug Tol | 1976 |
Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; | 1976 |
Phase II trial of 5-fluorouracil (NSC-19893), adriamycin (NSC-123127), and methotrexate (NSC-740) in lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; | 1976 |
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
Topics: Acid Phosphatase; Adenocarcinoma; Carcinoembryonic Antigen; Drug Therapy, Combination; Fluorouracil; | 1976 |
Acute cardiac pain and electrocardiographic changes following cytotoxic treatment for metastatic carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Coronary Disease; Cyclophosphamide; | 1976 |
Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors.
Topics: Adenocarcinoma; Administration, Oral; Animals; Ascites; Carcinoma, Ehrlich Tumor; Female; Fluorourac | 1976 |
Systemic chemotherapy of advanced head and neck malignancies.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor | 1975 |
Adenocarcinoma of the bile ducts. Relationship of anatomic location to clinical features.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Bile Duct Neoplasms; Bile Ducts; Bile Ducts, Intr | 1975 |
[Conservative treatment of lung cancer].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combination; Drug-Related | 1975 |
Combination chemotherapy in metastatic carcinoma of the breast. Results with a three-drug combination.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Ethylnit | 1975 |
Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fluorou | 1975 |
Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laparotomy, and radiation therapy.
Topics: Adenocarcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Laparotomy; Melp | 1975 |
The effect of cytostatic drugs on the synthesis of DNA in adenocarcinomas of the stomach. An in vitro study.
Topics: Adenocarcinoma; Antineoplastic Agents; Cells, Cultured; Depression, Chemical; DNA, Neoplasm; Fluorou | 1975 |
Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Fluorouracil; Humans; Melphala | 1975 |
[1st report on programmed chemotherapy of ovarian carcinoma].
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Cystadenocarcinoma; Cystadenoma; Drug Thera | 1975 |
Resolution of pulmonary lymphangitic carcinoma of the breast.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Castration; Female; Fluorouracil; Humans; Lung Neoplasms; L | 1976 |
The gasteointestinal oncology clinic. A multidisciplinary approach to cancer diagnosis and management at a University Medical Center.
Topics: Adenocarcinoma; Colitis, Ulcerative; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; | 1976 |
Neurotoxicity from 5-fluorouracil (NSC-19893) administration reproduced by mitomycin C (NSC-26980).
Topics: Adenocarcinoma; Aged; Ataxia; Blood-Brain Barrier; Cerebellar Ataxia; Colonic Neoplasms; Fluorouraci | 1976 |
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise | 1976 |
Current thoughts on the surgical treatment of rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; | 1976 |
Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Combined Modality Therapy; Fe | 1992 |
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ce | 1992 |
[Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1992 |
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Camptothecin; Carcino | 1992 |
Pattern of 2-deoxy-2-[18F]-fluro-D-glucose accumulation in liver tumours: primary, metastatic and after chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; | 1992 |
Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.
Topics: Adenocarcinoma; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Damage; Drug Re | 1992 |
[Preoperative regional radiofrequency thermochemotherapy of colorectal cancer: clinical and pathological studies].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diathermy; F | 1992 |
Effects of preoperative chemotherapy on gastric adenocarcinomas. A morphologic study of 25 cases.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1992 |
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta | 1992 |
Activities of thymidylate synthetase and thymidine kinase in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Linear | 1992 |
Overexpression of erbB-2 protein in gastric adenocarcinoma--a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adj | 1992 |
Intraportal 5-fluorouracil for colorectal cancer: the AXIS trial.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans | 1992 |
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Cancer Care Facilities; Chemotherapy, Adjuvant; Combined Modality Thera | 1992 |
5-Fluorouracil-induced pseudoporphyria.
Topics: Adenocarcinoma; Diagnosis, Differential; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Mid | 1992 |
Influence of chemotherapy on hormone receptor concentration in a xenotransplanted endometrial cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bleomycin; Carboplatin; Cyclophosphamide; Endometria | 1992 |
Combined isodose curves of high-dose rate interstitial brachytherapy with external-beam radiation therapy in pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvan | 1992 |
In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Cell Div | 1992 |
The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells: evidence of macrophage activation.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adenocarcinoma; Animals; Colonic Neoplasms; Cytotoxicity, Immunol | 1992 |
Nonresectable adenocarcinoma of the rectum assessed by MR imaging before and after chemotherapy and irradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1992 |
Identification and characterization of osteoclast progenitors by clonal analysis of hematopoietic cells.
Topics: Adenocarcinoma; Animals; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Culture Med | 1992 |
Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour | 1992 |
Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination.
Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1992 |
Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: a study in reference to thymidylate synthetase activity inhibition.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Res | 1992 |
Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid | 1992 |
Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Com | 1992 |
[Case report of a successful stage reduction of gastric carcinoma preoperatively treated by combined chemotherapy of 5-FU(UFT) and cisplatin].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fem | 1992 |
[Hypertrichosis lanuginosa acquisita in ulcerative colitis with colon cancer].
Topics: Adenocarcinoma; Adult; Biopsy; Cecal Neoplasms; Chemotherapy, Adjuvant; Colectomy; Colitis, Ulcerati | 1992 |
[Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1992 |
Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Mo | 1992 |
[Multifocal leukoencephalopathy following adjuvant therapy with fluorouracil and levamisole].
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Leukoenceph | 1992 |
Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 1992 |
Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate.
Topics: Abdominal Neoplasms; Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 1992 |
The pre-operative treatment of oesophageal carcinoma with synchronously administered chemotherapy and radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
[Chemotherapy-associated hemolytic uremic syndrome--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1992 |
Adjuvant postoperative radiation therapy for rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Fol | 1992 |
Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combi | 1992 |
Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles.
Topics: Adenocarcinoma; Adsorption; Animals; Charcoal; Female; Fluorouracil; Mammary Neoplasms, Experimental | 1992 |
Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorodeoxy | 1992 |
Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1992 |
[Histological evaluation of intra-arterial infusion and systemic chemotherapy of pancreatic carcinomas].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 1992 |
[Borrmann 4 gastric cancer treated with l-LV and 5-FU combination--a case report].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 1992 |
Combined modality preoperative therapy for unresectable rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem | 1992 |
[Adjuvant treatment of rectal carcinoma: also a step forward?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal | 1992 |
[Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1992 |
Preoperative chemotherapy and radiotherapy for esophageal carcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Com | 1992 |
[CT guided direct intervention chemotherapy of lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
[A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion | 1992 |
Regression of liver metastases following treatment with yttrium-90 microspheres.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Chemotherapy, Cancer, Regional Perfusion; Col | 1992 |
Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined | 1992 |
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; DNA Replic | 1992 |
Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery .
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1992 |
Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide: feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1992 |
Possible interactions between warfarin and 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Drug Interactions; Fluorouracil; Humans; Male; Warfarin | 1992 |
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
Levamisole plus 5-fluorouracil inhibits the growth of human colorectal xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour | 1992 |
Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Biopsy; Brain; Chemoth | 1992 |
Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1992 |
Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: effects on cell survival, DNA repair, and cell recovery.
Topics: Adenocarcinoma; Cell Survival; Cesium Radioisotopes; Colonic Neoplasms; DNA Repair; Dose-Response Re | 1992 |
[Platelet aggregation during adjuvant chemotherapy with CMF].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1991 |
Chemotherapy for pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1991 |
Heavy water enhances the antineoplastic effect of 5-fluoro-uracil and bleomycin in nude mice bearing human carcinoma.
Topics: Adenocarcinoma; Animals; Bleomycin; Carcinoma, Squamous Cell; Colonic Neoplasms; Deuterium; Drug Syn | 1990 |
5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Epirubicin; | 1990 |
Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Survival; Doxorubicin; Drug Admin | 1990 |
Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; DNA; Drug Interactions; Drug Resistance; Fluorodeo | 1990 |
Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1991 |
Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethas | 1991 |
Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1992 |
Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; | 1992 |
Response of pancreatic carcinoma to 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovo | 1992 |
Preoperative radiation therapy for locally advanced carcinoma of the rectum. Clinicopathologic correlative review.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Stag | 1992 |
Increased drug resistance of cultured human cancer cell lines in three-dimensional cellular growth assay using collagen gel matrix.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Collagen; Colonic Neoplasms; Culture Media; Doxoru | 1992 |
A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dox | 1991 |
5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA, Neoplasm; | 1991 |
Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1991 |
Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Eva | 1991 |
Choroidal metastases as a presenting sign after 24 years of a primary breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Choroid Neoplasms; | 1991 |
Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; DNA; DNA Damage; Dose-Response Relationship, Drug; | 1991 |
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neop | 1991 |
In vivo drug intracellular localisation by analytical ion microscopy: preliminary study in gastric adenocarcinomas treated with 5-fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Humans; Microscopy, Electron; Stomach Neoplasms | 1991 |
Painful, red hands. A side effect of 5-fluorouracil by continuous perfusion.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans; Mi | 1991 |
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hep | 1991 |
MMAF for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; | 1991 |
[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1991 |
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carc | 1991 |
Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; | 1991 |
Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy.
Topics: Adenocarcinoma; Animals; Azoxymethane; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dise | 1991 |
Preoperative chemoradiotherapy for adenocarcinoma of the pancreas. Rationale and technique.
Topics: Adenocarcinoma; Adult; Biopsy, Needle; Clinical Protocols; Combined Modality Therapy; Decision Trees | 1991 |
Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Survival; Colonic Neoplasms; Drug Synergism; Fluorouracil; Folic Acid; Interfer | 1991 |
Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1991 |
In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Do | 1991 |
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1991 |
Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Enzyme Activation; Flu | 1991 |
Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Fluorouracil; Huma | 1991 |
[A long-term survival case of advanced gastric cancer undergoing radical gastrectomy by second-look operation after successful chemotherapy (CDDP, MMC, 5-FU)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1991 |
[Long-term arterial infusion chemotherapy combined with external irradiation therapy for unresectable pancreatic cancer--a case report].
Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 1991 |
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Fluorouracil; Gastrointestinal Neoplasms; Leucovorin; Lymphatic Metastasis; Neoplasm | 1991 |
Disappearance of hyperplastic polyposis after resection of rectal cancer. Report of two cases.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Brachytherapy; Colonic Neoplasms; Colonoscopy; Combined | 1991 |
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 1991 |
[Hepatic arterial infusion of farmorubicin (FARM) and 5-fluorouracil (5-FU) in a patient with massive hepatic metastasis from gastric cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorourac | 1991 |
Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: results of a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1991 |
Extrahepatic biliary system cancer: an update of a combined modality approach.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Brach | 1991 |
Primary breast cancer after prophylactic mastectomy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mod | 1991 |
Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxo | 1990 |
Doxorubicin/methotrexate/fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1990 |
Adenocarcinoma of the urachus associated with elevated levels of CA 125.
Topics: Adenocarcinoma; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy | 1991 |
Intrapericardial infusion of 5-fluorouracil. An unusual complication of a Hickman catheter.
Topics: Adenocarcinoma; Arrhythmias, Cardiac; Catheterization, Central Venous; Colonic Neoplasms; Female; Fl | 1991 |
Sphincter preservation in rectal cancer by local excision and postoperative radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Brachytherapy; Combined Modality Therapy; Female; Fluoroura | 1991 |
5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorour | 1991 |
Combined-modality therapy for rectal carcinoma--the time has come.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal | 1991 |
Selective uptake of toxic nucleoside (125IUdR) by resistant cancer.
Topics: Adenocarcinoma; Animals; Cell Line; Choriocarcinoma; Colon; Colonic Neoplasms; Cytarabine; Drug Resi | 1991 |
Cancer chemotherapy: hormonal changes and recurring asthma.
Topics: Adenocarcinoma; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asthma; Breast Ne | 1991 |
Adenocarcinoma of the pancreas: current management of resectable and locally advanced disease.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Pancreatic N | 1991 |
A pilot study of sphincter-sparing management of adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Combined Modality Therapy; Female; Fluorouracil; Humans; Ma | 1991 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1991 |
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili | 1991 |
[Ectasing cholangitis and secondary biliary cirrhosis following intra-arterial hepatic chemotherapy. Treatment by liver transplantation].
Topics: Adenocarcinoma; Adult; Cholangitis, Sclerosing; Female; Fluorouracil; Humans; Infusions, Intra-Arter | 1991 |
A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1991 |
Different effects of sequential combinations of N-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 1991 |
[Chemotherapy in cancers of the gallbladder and bile ducts].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cytarabine; | 1991 |
Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1991 |
Chest pain in a cancer patient on chemotherapy.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Fluorouracil; Humans; Male; Myocardial Infarction; Strepto | 1991 |
Stimulation of clonal growth of human colorectal tumor cells by IL-3 and GM-CSF. Modulation of 5-FU cytotoxicity by GM-CSF.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colorectal Neoplasms; Combined Modality The | 1990 |
[Myocardial infarcts within the scope of 5-fluorouracil therapy].
Topics: Adenocarcinoma; Adult; Electrocardiography; Fluorouracil; Humans; Infusions, Intravenous; Liver Neop | 1990 |
Carmofur-induced organic mental disorders.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Electroencephalography; Female; Fluorouracil; Follow-U | 1990 |
Open phase II with 5-fluorouracil, 4-epi-doxorubicin and mitomycin C (FEM) in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1990 |
Acute non-lymphocytic leukemia following FAM combination adjuvant chemotherapy for gastric and lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherap | 1990 |
[Successful treatment of advanced gastric cancer with multiple liver metastasis by combination chemotherapy using mitomycin C, 5-fluorouracil, and high-dose leucovorin: a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 1990 |
Treatment of experimental liver metastases in the rat by continuous intraportal infusion of 5-fluorouracil and heparin: a pilot study.
Topics: Adenocarcinoma; Animals; Anticoagulants; Drug Therapy, Combination; Fluorouracil; Heparin; Humans; I | 1990 |
Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1990 |
Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Interactions; Floxuridine; Fluorouracil; Humans; Ki | 1990 |
[A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum].
Topics: Adenocarcinoma; Administration, Oral; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Lymph | 1990 |
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; | 1990 |
Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antiviral Agents; Bromodeoxyuridine; Colonic Neoplas | 1990 |
Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells.
Topics: Adenocarcinoma; Carbon Radioisotopes; Colonic Neoplasms; Dehydroepiandrosterone; Fluorouracil; Human | 1990 |
Appendiceal adenocarcinoid with ovarian metastasis.
Topics: Adenocarcinoma; Adult; Appendiceal Neoplasms; Female; Fluorouracil; Humans; Ovarian Neoplasms; Strep | 1990 |
Clinical trials referral resource. Adjuvant therapy for colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colo | 1990 |
Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas.
Topics: Adenocarcinoma; Carbon-Nitrogen Ligases; Carcinoma, Squamous Cell; DCMP Deaminase; DNA-Directed DNA | 1990 |
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Squamous Cell; Cell Line; Dose-Respo | 1990 |
A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1990 |
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1990 |
Preoperative chemotherapy is beneficial for geriatric patients with locally advanced and metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1990 |
[Effective continuous intraarterial chemotherapy for a patient with FIGO stage IIIb cervical adenocarcinoma invasing the bladder wall].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Hum | 1990 |
5-fluorouracil (5-FU) plus high dose folinic acid (FA): a modified scheme with reduced toxicity.
Topics: Adenocarcinoma; Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Leucovorin; Male; Middle | 1990 |
Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic N | 1990 |
Gastric adenocarcinoma presenting with soft tissue masses.
Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Male; Soft Tissue Neoplasms; Stomach Neoplasms; Thigh | 1990 |
Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Colonic Neoplasm | 1990 |
[Combination radiotherapy and chemotherapy in the treatment of locally advanced adenocarcinoma of the pancreas. Experiences of the Gustave Roussy Institute].
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cis | 1990 |
Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; Cytosol; Fluorouracil; Humans; Kinetics; Thymidine | 1990 |
Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 1990 |
[Reversible cardiogenic shock due to 5FU. Apropos of a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Fluorouracil; | 1990 |
Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; | 1990 |
[A case of non-functioning adrenocortical tumor].
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Combined Modality Therapy; Female | 1990 |
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1990 |
Adjuvant 5-FU and MeCCNU improves survival following curative gastrectomy for adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemot | 1990 |
[Assessment of individual sensitivity to chemotherapy of human pulmonary tumors transplanted to subrenal capsule of CBA mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamid | 1990 |
Chemosensitivity and DNA content as prognostic factors in ovarian cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Colony-Forming Units Assay; Doxorubicin; Female; Fluorouracil; Folic Acid; Hum | 1990 |
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1990 |
[5-Fluorouracil (5-FU) concentration in prostatic tissue of rats and in prostatic cancer patients after oral administration of 5-FU].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Animals; Fluorouracil; Humans; Linear | 1990 |
[Chemoradiation treatment of pancreatic cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1985 |
[Intraductal chemotherapy of bile duct cancer with 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Cancer, Regional | 1986 |
[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Drug A | 1987 |
[Combination therapy with lentinan, mitomycin c, 5-fluorouracil and radiation--a case of long-term survival of pancreas cancer after palliative surgery].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 1987 |
External beam radiotherapy for rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 1987 |
Establishment of a human urachal adenocarcinoma cell line (KO-BT-1) and its chemosensitivity.
Topics: Adenocarcinoma; Adult; Animals; Cell Line; Fluorouracil; Humans; Interferons; Male; Mice; Mice, Inbr | 1987 |
Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1987 |
[Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1988 |
5-Fluorouracil incorporation into RNA of a rat liver adenocarcinoma after hepatic artery injection together with degradable starch microspheres.
Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Female; Fluorouracil; Injections, Intra-Arterial; Liver | 1987 |
Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1988 |
Effects of dosage and infusion time on the incorporation of 5-fluorouracil into DNA and RNA of normal tissues and an adenocarcinoma transplanted to rat liver.
Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Fluorouracil; | 1988 |
Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Division; Drug Synergism; Floxuridine; Fluorou | 1988 |
Effective palliation of metastatic adenocarcinoma to the liver: a case report.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, | 1988 |
The combined effect of interferon and 5-FU on tumor-cell metastasis in the nude mouse.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluor | 1989 |
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1989 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, A | 1989 |
Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1989 |
Postoperative adjuvant chemotherapy and radiotherapy for cancer of the large bowel and rectum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cecal Neoplasms; Colonic Neop | 1989 |
[The concentration of 5-fluorouracil in blood and tissues of the patients with carcinoma of the cervix after administration of UFT and 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neop | 1989 |
Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
Concurrent radiation and chemotherapy in vulvar carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1989 |
Distributions of tegafur in tissues of gastric adenocarcinoma patients: tissue uptakes and concentrations in plasma after oral and rectal administrations.
Topics: Adenocarcinoma; Administration, Oral; Administration, Rectal; Adult; Aged; Female; Fluorouracil; Hum | 1989 |
Adjuvant therapy for colon carcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Interfer | 1989 |
Preoperative irradiation with and without chemotherapy (MFL) in the treatment of primarily non-resectable adenocarcinoma of the rectum. Results from two consecutive studies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1989 |
[Effects of chemo-endocrine therapy on DMBA-induced rat mammary carcinoma].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Drug Evaluation; Drug Therapy, Combinatio | 1989 |
5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole.
Topics: Adenocarcinoma; Colonic Neoplasms; Dipyridamole; DNA; DNA Damage; Floxuridine; Fluorouracil; Humans; | 1989 |
Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Chrom | 1989 |
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 1989 |
Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bromodeoxyuridine; Chromatography, High Pressure Liq | 1989 |
MTX-5-FU combination therapy compared to FUDR monotherapy in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; | 1989 |
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Un | 1989 |
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery | 1989 |
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Colonic Neoplasms; Combined Modality Th | 1989 |
[In vitro studies of 5-FU sensitivity on uterine cervical cancer cell lines--comparison between squamous cell carcinoma and adenocarcinoma].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Survival; DNA, Neoplasm; Drug Screening Assays, Antit | 1989 |
Clinical trials referral resource. Adjuvant therapy of breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; | 1989 |
[Effect of human epidermal factor (hEGF) on antitumor activity of 5-fluorouracil (5-FU) in human gastric cancer cell lines].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Cell Division; Cell Line; Cell Survival; Drug Screening As | 1989 |
[Metastatic liver cancer from the stomach successfully treated by combined immunochemotherapy and transarterial embolization].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabin | 1989 |
[Two cases of digestive cancer demonstrated remarkable regression by hyperthermia with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic N | 1989 |
Clinical trials referral resource. Adjuvant treatment of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; | 1989 |
[Current status in the treatment of inoperable non-small cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Ca | 1985 |
Combined effect of 5-fluorouracil and interferon on experimental liver metastases of rat colon carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour | 1985 |
Adenocarcinoma of the small intestine presenting as an ovarian mass. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Femal | 1989 |
Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluatio | 1989 |
Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug E | 1989 |
A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1989 |
[Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1989 |
[Synchronous hepatic metastases of colorectal adenocarcinoma: what is the course? Apropos of 36 cases].
Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, In | 1989 |
[120-hour continuous 5-FU infusion and cisplatin in the treatment of advanced esophageal carcinoma--clinical analysis of 19 cases].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1989 |
Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 1989 |
Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study.
Topics: Activities of Daily Living; Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemothe | 1989 |
Application of a new radiometric system for identification of potentially useful drug combinations for treatment of human gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Screenin | 1989 |
Radiation therapy with/without simultaneous weekly 5 F.U. in locally recurrent carcinoma of the recto-sigmoid.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal | 1989 |
Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1989 |
Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 1989 |
Increased contraenvironmental-pressure cell division capability: a decisive force in metastasis and invasion of mouse lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Clone Cells; Fluorouracil; Lung Neoplasms; Mice; | 1989 |
Adenocarcinoma of the ethmoid sinuses. Results of a new protocol based on inductive chemotherapy combined with surgery. Four years experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1989 |
Treatment with 5-FU, VCR and BCNU in tumor bearing nude mice.
Topics: Adenocarcinoma; Animals; Carmustine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Mice; Mice, | 1989 |
Human-alpha-interferon on xenotransplanted human colonic adenocarcinomas in nude mice.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Interferon Typ | 1989 |
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms; Dr | 1989 |
Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1989 |
Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1989 |
Clinical experience with leucovorin and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1989 |
Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Fluorouracil; Humans; Infu | 1989 |
Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced-stage colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1989 |
Treatment of metastatic colorectal adenocarcinoma with fluorouracil and high-dose leucovorin: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 1989 |
Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Art | 1989 |
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemical Phenomena; Chemistry; Colonic Neo | 1989 |
Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil.
Topics: Adenocarcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps; Leucovorin | 1989 |
[Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Human | 1989 |
Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Carcinoembryonic Antigen; | 1987 |
Perianal Paget's disease. Report of three cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anus Neoplasms; Female; Fluorouracil; Humans; Male; Neoplas | 1988 |
Radiation therapy for advanced gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; | 1988 |
Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1988 |
[Experimental chemotherapy of human gastric cancer cell lines in vitro and in nude mice].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Allyl Compounds; Animals; Antibiotics, Antineoplastic; Cel | 1988 |
Simultaneous chemotherapy-radiotherapy with prophylactic cranial irradiation for inoperable adeno and large cell lung carcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin | 1988 |
Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1989 |
Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cycloph | 1989 |
Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; | 1989 |
Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder.
Topics: Adenocarcinoma; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Middle Age | 1989 |
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Combinations; Drug Evaluation, Preclinical; Fluorou | 1989 |
[Observation on the curative effect postoperatively of late gastric cancer by the fu zheng anti-cancer method combined with chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Medicine | 1985 |
On the differential affinities of two anticancer analogues to their target.
Topics: Adenocarcinoma; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Floxuridine; Fluoro | 1985 |
Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma.
Topics: Adenocarcinoma; Cells, Cultured; Colonic Neoplasms; Floxuridine; Fluorine; Fluorouracil; Humans; Mac | 1986 |
Adjuvant therapy for breast cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1987 |
Myocardial ischemia with fluorouracil and floxuridine therapy.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Coronary Disease; Electrocardiography; Floxuridine; Fluorou | 1987 |
[Locoregional chemotherapy of hepatic metastases of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Infusion Pumps; I | 1987 |
Increased levels of DNA lesions induced by leucovorin-5-fluoropyrimidine in human colon adenocarcinoma.
Topics: Adenocarcinoma; Aphidicolin; Cell Line; Cell Survival; Colonic Neoplasms; Diterpenes; DNA; DNA Damag | 1988 |
[Status of estrogen receptors in breast cancer and prediction of chemotherapy sensitivity].
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouraci | 1988 |
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arteritis; Carcinoma, Hepatocellular; Cholecystitis; Ch | 1985 |
[Low-dose intermittent intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dox | 1985 |
[Sequential chemotherapy with low-dose methotrexate and 5-fluorouracil in advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1985 |
[Postoperative chemotherapy of pathological stage I non-small cell carcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1986 |
Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.
Topics: Adenocarcinoma; Adenosine Monophosphate; Animals; Cell Line; Colonic Neoplasms; Deoxyuracil Nucleoti | 1986 |
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1986 |
Combination chemotherapy with CDDP and 5-FU in head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cyst | 1986 |
cis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 1987 |
[UFT in the treatment of primary lung cancer--5-FU concentration in the tissue and side effects].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; | 1987 |
Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than is well differentiated carcinoma.
Topics: Aclarubicin; Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Age | 1987 |
5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; | 1987 |
[Combined effects of radiation and 5-FU derivatives].
Topics: Adenocarcinoma; Animals; Cell Division; Fluorouracil; Male; Mice; Radiotherapy Dosage; Tegafur | 1986 |
Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 1986 |
[A case of multiple liver metastases from sigmoid carcinoma treated successfully with arterial infusion chemotherapy].
Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Dru | 1986 |
Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon Radioisotopes; Cyste | 1986 |
Microangiopathic hemolytic anemia, noncardiac pulmonary edema, and renal failure after treatment of metastatic adenocarcinoma of the colon with 5-fluorouracil and mitomycin-C: report of a case.
Topics: Adenocarcinoma; Anemia, Hemolytic; Colonic Neoplasms; Female; Fluorouracil; Humans; Kidney Failure, | 1986 |
[Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment].
Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Eval | 1986 |
Prognostic factors in metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1986 |
[Determination of the individual sensitivity of human stomach cancer cells to fluoropyrimidines by the cytomorphological criteria of heterotransplants in diffusion chambers].
Topics: Adenocarcinoma; Animals; Carcinoma; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Fe | 1986 |
[A model for the sensitivity determination of anticancer agents against human cancer using nude mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Line; Cisplatin; Colonic Neoplas | 1987 |
[Successful treatment of advanced gastric cancer by combined cisplatinum, mitomycin C and 5-FU administration. A case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Gas | 1987 |
Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Pancreatic N | 1987 |
[Improved quality of life in a patient with Borrmann type 4 gastric cancer treated with combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Methot | 1987 |
[Advanced gastric cancer with DIC and multiple bone metastasis treated with surgical resection and chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Co | 1987 |
[FO-152].
Topics: Absorption; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Dogs; Drug Evaluation; Female | 1987 |
Esophageal carcinoma: modest benefits from combined modality therapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1987 |
Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cysteine | 1987 |
Successful treatment of multiple liver metastases by liver perfusion.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Heparin; | 1987 |
[A case of gastric cancer with multiple liver metastases responding to combination therapy of recombinant interferon-gamma (KW-2202) and 5-FU].
Topics: Adenocarcinoma; Aged; Drug Therapy, Combination; Fluorouracil; Humans; Interferon-gamma; Liver Neopl | 1987 |
[A case of recurrent sigmoid colon cancer successfully treated with 5-FU and UFT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Lympha | 1988 |
[Inhibitory effect of UFT on postoperative lung metastasis of mammary adenocarcinoma in SHR rats].
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Flu | 1988 |
Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac | 1988 |
Effect of endocrine treatment on prostatic blood flow in patients with prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Combined Modality Therap | 1988 |
[A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Int | 1988 |
5-Fluorouracil, high-dose folinic acid, and mitomycin C combination chemotherapy in advanced gastrointestinal adenocarcinomas. A pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1988 |
[Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion | 1988 |
Combined modality preoperative therapy in poor prognostic rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1988 |
[Hemolytic-uremic syndrome caused by mitomycin C].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hemolytic-Uremic Syndr | 1988 |
[A case of variant angina induced by 5-fluorouracil and Tegafur].
Topics: Adenocarcinoma; Angina Pectoris, Variant; Coronary Vasospasm; Electrocardiography; Fluorouracil; Hum | 1988 |
[Three cases of renal failure associated with microangiopathic hemolytic anemia after mitomycin C therapy].
Topics: Adenocarcinoma; Aged; Anemia, Hemolytic; Breast Neoplasms; Female; Fluorouracil; Glomerulonephritis, | 1988 |
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil | 1985 |
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluo | 1988 |
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Deoxyuracil Nucleotides; Drug Resistance; Fluor | 1988 |
Modulation of the cytotoxic effect of 5-fluorouracil by N-methylformamide on a human colon carcinoma cell line.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neoplasms; Cy | 1988 |
[Portable infusion pump for ambulatory cytostatic therapy in inoperable liver metastases].
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Infusion Pumps; Live | 1988 |
Postoperative radiation therapy with weekly 5 fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Hum | 1988 |
Phase I-II study of prophylactic hepatic irradiation with local irradiation and systemic chemotherapy for adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Humans; Liver Neoplasms; Middl | 1988 |
Regional injection of 5-fluorouracil and starch microspheres in colorectal cancer.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fluorouracil; Humans | 1988 |
Treatment of probable subclinical liver metastases and gross pancreatic carcinoma with hepatic artery 5-fluorouracil infusion and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Hepatic Artery; Humans | 1988 |
Duodenal carcinoma--a curable disease.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Duodenal Neoplasms; Female; Fluorouracil; Fo | 1988 |
[Intraarterial infusion of oncostasis in patients with advanced cervical adenocarcinoma--two case reports].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci | 1988 |
Carcinogenesis and aging. VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4-benzoquinone-guanylhydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats.
Topics: Adenocarcinoma; Aging; Animals; Antineoplastic Agents; Cell Division; Female; Fluorouracil; Leukemia | 1988 |
Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 1988 |
Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1988 |
High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo | 1988 |
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1988 |
Pharmacodynamics of 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Animals; Bone Marrow; Colonic Neoplasms; Deoxyuracil Nucleotides; Fluorodeoxyuridyla | 1988 |
Selectivity of CF and 5-fluorouracil: critical role of polyglutamylation.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Fluorouracil; Folic Acid; Humans; Leucovorin; | 1988 |
[Ethmoidal adenocarcinoma surgically treated in one stage by transfacial and subfrontal approach after inductive chemotherapy. Preliminary results of a new therapeutic approach].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Transplantation; Ethmoid Sinus; | 1987 |
Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eso | 1988 |
Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients.
Topics: Adenocarcinoma; Adult; Age Factors; Colonic Neoplasms; Female; Fluorouracil; France; Humans; Male; R | 1988 |
External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Hum | 1988 |
[A case of dermatomyositis associated with breast cancer].
Topics: Adenocarcinoma; Breast Neoplasms; Combined Modality Therapy; Dermatomyositis; Doxorubicin; Female; F | 1988 |
Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Chromato | 1988 |
Effective treatment for adenocarcinoma of the stomach when surgery is contraindicated.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Female; Fluorouracil; Humans; Stomach Neoplasms | 1988 |
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1988 |
Basic investigations on interaction of 5-fluorouracil and tumor ischemia in the treatment of liver malignancies.
Topics: Adenocarcinoma; Animals; Combined Modality Therapy; Female; Fluorouracil; Humans; Ischemia; Liver Ne | 1988 |
Continuous 5-fluorouracil infusion in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; | 1988 |
[Clinical evaluation of implantable drug delivery system (Port-A-Cath) in cancer chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1988 |
Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma; Colonic Neoplasms; Co | 1987 |
[Treatment of 63 advanced ovarian carcinomas].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1987 |
The 6 day subrenal capsule assay is of no value with primary surgical explants from gastric cancer.
Topics: Adenocarcinoma; Animals; Cisplatin; Doxorubicin; Drug Evaluation, Preclinical; Epirubicin; Fluoroura | 1986 |
An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Epirub | 1987 |
Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fema | 1986 |
Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1987 |
A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.
Topics: Adenocarcinoma; Bone Marrow Diseases; Diarrhea; Drug Evaluation; Erythema; Fluorouracil; Humans; Inj | 1987 |
Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1987 |
Biologic modulation of 5-fluorouracil with high-dose leucovorin and combination chemotherapy of 5-fluorouracil and cisplatin in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Dose-R | 1987 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Gas | 1987 |
Cannulation of the portal vein for cytotoxic liver perfusion in colorectal carcinomas: an alternative approach.
Topics: Adenocarcinoma; Antineoplastic Agents; Catheterization; Colonic Neoplasms; Fluorouracil; Humans; Liv | 1987 |
Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluo | 1987 |
Regional adjuvant irradiation for adenocarcinoma of the cecum.
Topics: Adenocarcinoma; Cecal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrenc | 1987 |
Determination of thymidylate synthase activity in colon tumor tissues after treatment with 5-fluorouracil.
Topics: Adenocarcinoma; Charcoal; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; Thymidylate | 1987 |
Fatal acute tumor lysis syndrome with metastatic breast carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Breast Neoplasms; Cyclophos | 1987 |
Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases--a pilot study.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Inf | 1987 |
5-Fluorouracil-induced coronary vasospasm.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Coronary Vasospas | 1987 |
Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 1987 |
[Chemotherapy of metastatic gastric cancer--x-ray follow-up].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Follow-Up | 1987 |
Effects of cyclophosphamide alone and scheduled methotrexate-5-fluorouracil combination chemotherapy on transplantable R-3327 prostatic adenocarcinoma in F1 hybrid male rat.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fluoroura | 1987 |
Adjuvant chemotherapy in gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality | 1987 |
Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1987 |
Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; D | 1987 |
Phase II trial of sequential chemotherapy and low-dose radiotherapy in advanced gastric adenocarcinoma. A Southwest Oncology Group Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carm | 1987 |
Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Drug Synergi | 1987 |
Comparison of three treatment strategies for esophageal cancer within a single institution.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1987 |
Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Fe | 1987 |
Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2'-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver.
Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; Female; Fluorodeox | 1987 |
Ankyloblepharon associated with systemic 5-fluorouracil treatment.
Topics: Adenocarcinoma; Blepharitis; Eyelid Diseases; Fluorouracil; Humans; Male; Middle Aged; Skin Ulcer; S | 1987 |
Urachal carcinoma: a response to chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Middle A | 1987 |
Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; Drug Interactions; Female; Fluo | 1986 |
Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 1986 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
[Comparison of in vitro assays for the cytotoxic effect of anticancer drugs].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Line; Colony-Forming Units Assay; Diterpenes | 1986 |
[Cytostatic treatment of gastrointestinal tumors].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Moda | 1986 |
5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1986 |
[Experimental and clinical studies on a sensitivity test of anticancer agents by 3H-thymidine autoradiography using a human malignant tumor transplanted to nude mice].
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Autoradiography; Cyclophosphamide; Drug Evalua | 1986 |
Cardiac tamponade as the only initial feature of malignancy: a case report and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Common Col | 1986 |
Chemotherapy improves pulmonary function in a patient with gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Hum | 1986 |
125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree.
Topics: Adenocarcinoma; Aged; Bile Duct Neoplasms; Brachytherapy; Female; Fluorouracil; Humans; Male; Middle | 1986 |
Adenocarcinoma of the cecum. Analysis of 106 cases.
Topics: Adenocarcinoma; Cecal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Prognosis; Retrosp | 1986 |
[Sequential dose of methotrexate and 5-fluorouracil in advanced gastric cancer--response, survival time and toxicity].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 1986 |
5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin | 1986 |
Chemotherapy in colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1986 |
Adjuvant effects of calmodulin antagonists to 5-fluorouracil on tumor cell proliferation and the mechanisms.
Topics: Adenocarcinoma; Calmodulin; Cell Division; Cell Line; Female; Fluorouracil; Humans; Ovarian Neoplasm | 1987 |
Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage.
Topics: Adenocarcinoma; Animals; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Isoenzym | 1987 |
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1985 |
[Chemotherapy of bronchopulmonary and pleural adenocarcinoma. Apropos of 31 cases].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophospha | 1985 |
Gastric cancer: complete chemotherapy response in an elderly woman: current status of treatment.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fema | 1985 |
The effects of cyclophosphamide, ketoconazole, aclacinomycin-A, methotrexate, and scheduled methotrexate-5-fluorouracil combination chemotherapy on the transplantable R-3327 prostatic adenocarcinoma in the F1 hybrid male rat.
Topics: Aclarubicin; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1985 |
[Chronic myelogenous leukemia following therapy of early gastric cancer].
Topics: Adenocarcinoma; Fluorouracil; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Multiple Prim | 1985 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl | 1985 |
[Clinical study on the permeability of FT-207 and 5-FU in primary lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cell Membrane Permeability; Female; Fluoroura | 1985 |
[A case of complete regression of gastric carcinoma and liver metastases by treatment with tegafur].
Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Liver Neoplasms; Male; Stomach Neoplasms; Tegafur | 1985 |
[Phase II study of sustained released granules of tegafur (SF-SP) on inoperable or recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Delayed-Action Preparations; Drug Administration Schedule; Drug Evaluat | 1985 |
[Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug | 1985 |
Cyclic combination chemotherapy in advanced adenocarcinoma of the lung: comparison of two FAM schedules.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl | 1985 |
Erosive gastroduodenitis with marked epithelial atypia after hepatic arterial infusion chemotherapy.
Topics: Adenocarcinoma; Aluminum; Cimetidine; Colonic Neoplasms; Fluorouracil; Gastric Mucosa; Humans; Infus | 1985 |
Enhancement of antitumor effect of cytotoxic agents by bestatin.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic Neop | 1985 |
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Topics: Adenocarcinoma; Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1985 |
[Evaluation of combined radiotherapy of gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1985 |
[A long survival case of carcinoma of the colon with hepatic metastasis following intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Colonic Neoplasms; Fluor | 1985 |
Chemoradiation therapy and resection for carcinoma of the esophagus: short-term results.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1985 |
[A case of advanced male breast cancer treated effectively with estrogen].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Combined Modality The | 1985 |
[A case of advanced gastric cancer showing complete cure by immunochemotherapy with FT-207 and OK-432 confirmed by thorough histologic examination of total gastrectomy matter].
Topics: Adenocarcinoma; Biological Products; Female; Fluorouracil; Gastrectomy; Humans; Injections, Intrader | 1985 |
Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin | 1985 |
[Clinical application of local hyperthermia combined with antineoplastic agents].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents; Body Temperature; Cis | 1985 |
[Level of 5-FU in uterine cervical cancer tissue after oral administration of UFT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cervix Ute | 1985 |
[A case of long-term survival of liver metastasis of breast cancer successfully treated with chemotherapy and endocrine therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cy | 1985 |
Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Colonic Neoplasms; Female; Fluorouracil; Humans; Infus | 1985 |
5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; | 1986 |
The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil.
Topics: Adenocarcinoma; Cell Division; Cell Survival; Cells, Cultured; Colonic Neoplasms; DNA, Neoplasm; Dru | 1986 |
[Distribution of 1-hexycarbamoyl-5-fluorouracil in rats and human patients, and clinical results in patients with colorectal cancer].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Mal | 1986 |
Mechanism of potentiation of antitumor activity of 5-fluorouracil against adenocarcinoma 755 by L-cysteine.
Topics: Adenocarcinoma; Animals; Cysteine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; | 1986 |
Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1985 |
Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Combined Modal | 1985 |
Adjuvant chemotherapy of gastric carcinoma: a pilot study of oral administration of injectable 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Female; Fluorouracil; Humans; Liver; Male; Middle | 1985 |
Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic N | 1985 |
[Therapy-induced tumor regression. Morphological findings in malignant primary and secondary liver tumors following intensive regional cytostatic treatment].
Topics: Adenocarcinoma; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Doxoru | 1985 |
Cardiotoxicity as a result of 5-fluorouracil therapy.
Topics: Adenocarcinoma; Adult; Fluorouracil; Heart; Humans; Male; Myocardial Infarction; Sigmoid Neoplasms; | 1985 |
Histopathologic effect of preoperative chemotherapy using 5-Fu fat emulsion in gastric cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Stomach Neoplasms | 1985 |
[Experimental studies with the use of metastatic clones isolated from mouse tumors].
Topics: Adenocarcinoma; Animals; Clone Cells; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; | 1985 |
Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evalu | 1985 |
Comparative radiopharmacokinetics of 18F-5-fluorouracil administered i.v. to rats bearing a mammary tumor.
Topics: Adenocarcinoma; Animals; Female; Fluorine; Fluorouracil; Injections, Intravenous; Kinetics; Mammary | 1985 |
Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Chromatography, | 1985 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic | 1985 |
Treatment of metastatic colorectal carcinoma with cisplatin and 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1985 |
Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; | 1985 |
A pilot study to determine clinical tolerability of intensive combined modality therapy for locally unresectable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Female; Fluorouracil; Humans; Lomustine; Male; Middle Aged | 1985 |
Immunochemosurgery for gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modali | 1985 |
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1985 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom | 1985 |
Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1985 |
Cerebellar ataxia with weekly 5-fluorouracil administration.
Topics: Adenocarcinoma; Cerebellar Ataxia; Colonic Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Neo | 1971 |
[Combined treatment of patients with inoperable stomach cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorourac | 1970 |
[Esophageal tumors--therapeutic problems].
Topics: Adenocarcinoma; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Esophageal Neoplasm | 1972 |
Chemotherapy and hormone therapy in gynecologic cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Choriocarcinoma; Dactinomycin; F | 1973 |
Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan.
Topics: Adenocarcinoma; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Doxorubicin; Fluoroura | 1973 |
Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Cobalt Radioisotopes; Evaluation Studies as Topic; Female; Fluorouracil | 1973 |
[Three years of experience in the polychemotherapy of inoperable bronchial carcinoma].
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Austria; Br | 1974 |
The roles of radiotherapy and cytotoxic drugs in the management of carcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplas | 1973 |
The treatment of hepatic metastases by long-term chemotherapeutic infusions.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Evaluation Studies as Topic; Female; | 1970 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
[Study of the action of antitumor compounds on primary explants from human tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; An | 1967 |
[Method and results of experimental chemotherapy of a human colonic carcinoma (H.Ad.No. 1) in the cheek pouch of the golden hamster].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aziridines; Cheek; Colonic Neoplasms; Cricetinae; Cy | 1969 |
5-Fluorouracil and radiotherapy for gastrointestinal cancer.
Topics: Adenocarcinoma; Esophagogastric Junction; Fluorouracil; Humans; Male; Stomach Neoplasms | 1970 |
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs.
Topics: Adenocarcinoma; Aged; Angiography; Aortography; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perf | 1970 |
Chemotherapy for lung cancer at the Institute of Experimental and Clinical Oncology, Academy of Medical Sciences, USSR.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcino | 1973 |
Pseudomyxoma peritonaei: a report of ten cases.
Topics: Adenocarcinoma; Adult; Aged; Appendectomy; Appendiceal Neoplasms; Castration; Cystadenoma; Female; F | 1973 |
Carcinoma of the duodenum: comparison of surgery, radiotherapy, and chemotherapy.
Topics: Adenocarcinoma; Age Factors; Aged; Barium Sulfate; Duodenal Neoplasms; Female; Fluorouracil; Humans; | 1973 |
Intravenous hyperalimentation in cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Body Weight; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Ne | 1974 |
Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver.
Topics: Adenocarcinoma; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arte | 1967 |
Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamid | 1968 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Growth inhibition by chemotherapeutic agents on stilbestrol-induced hamster kidney tumor.
Topics: Adenocarcinoma; Animals; Cricetinae; Cyclophosphamide; Dactinomycin; Diethylstilbestrol; Fluorouraci | 1971 |
Effect of resection of the primary neoplasm on responsiveness to chemotherapy of patients with large bowel cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Nitrosourea Compounds; Rectal | 1972 |
The response of the stilbestrol-induced renal tumor to chemotherapeutic agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cricetinae; Cyclophosphamide; Dactinomycin; Diethyls | 1973 |
5-Fluorouracil and derivatives in cancer chemotherapy. 3. In vivo enhancement of antitumor activity of 5-fluorouracil (FU) and 5-fluoro-2'-deoxyuridine (FUDR).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chromatography, Thin Layer; Deoxycytidine; Deoxyurid | 1973 |
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine | 1974 |
Conservative management of malignant pericardial effusion.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cardiomegaly; Female; Fluorouracil; Follow-Up Studies | 1974 |
Hypercalcemia in cancer: response to therapy.
Topics: Adenocarcinoma; Adult; Allopurinol; Antineoplastic Agents; Calcium; Cyclophosphamide; Fluorouracil; | 1974 |
Infusion chemotherapy in hepatoma and metastatic liver tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; | 1967 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Fibrosarcoma; Fluorouraci | 1969 |
[Polychemotherapy of malignant tumors and hemoblastoses].
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Bronchial Neoplasms; Carcinom | 1968 |
Chemotherapy in the treatment of cancer of the ovary.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Cyclophosphamide; Cystadenocarcinoma; Dactinomycin; Female | 1970 |
[Pathologic anatomy of rectal cancer treated by intra-arterial administration of 5-fluoruracil].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; | 1970 |
Carcinoma of the colon and rectum in patients up to 25 years of age.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Age Factors; Colonic Neoplasms; Female; | 1971 |
Catheterization of the umbilical vein and its use for hepatography.
Topics: Adenocarcinoma; Adult; Aged; Angiography; Breast Neoplasms; Catheterization; Diatrizoate; Female; Fl | 1971 |
[Effect of 5-fluorouracil on protein metabolism of tumors and normal tissues in culture].
Topics: Adenocarcinoma; Animals; Autoradiography; Carcinoma, Basal Cell; Cell Line; Cell Transformation, Neo | 1970 |
Cancer chemotherapy in urology.
Topics: Adenocarcinoma; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Chlorambucil; Cobal | 1971 |
Integrated therapy in the treatment of ovarian cancer with surgery, radiation and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Ascites; Chlorambucil; Cobalt Isotopes; Cyclophosphamide; | 1972 |
Chemotherapy of ovarian cancer. New approaches to treatment.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents; Cyclophosphamide; Cystadenocarcinom | 1972 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro | 1973 |
[Determination of the individual sensitivity of gastric cancerous tumors to 5-fluorouracil according to respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Drug Evaluation, Pre | 1974 |
Chemotherapy for adenocarcinoma and alveolar cell carcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Female; Fluorouracil; Follow-Up Studies; | 1974 |
[Treatment of liver cancer with oral administration of N-(2'-furanidyl)-5 fluorouracil (FT207) (author's transl)].
Topics: Adenocarcinoma; Administration, Oral; Aged; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver N | 1974 |
[5-Fluorouracil in the treatment of gastrointestinal tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1973 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Diagnosis, treatment and prognosis of renal cell carcinoma.
Topics: Adenocarcinoma; Angiography; Blood Sedimentation; Chromomycins; Female; Fluorouracil; Humans; Kidney | 1974 |
[Determination of the sensitivity of cancerous tumors of the stomach to 5-fluorouracil in vitro].
Topics: Adenocarcinoma; Aged; Drug Evaluation, Preclinical; Female; Fluorouracil; Humans; In Vitro Technique | 1974 |
In vitro estimate of sensitivity of individual human tumors to antitumor agents.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenicals; Benzoates; Breast Neoplasms; Carbon Radi | 1974 |
Endometrial cancer: approach to development of effective chemotherapy.
Topics: Acrylates; Adenocarcinoma; Adolescent; Adult; Aged; Alkylating Agents; Cyclophosphamide; Doxorubicin | 1974 |
Liver scanning for the detection of metastases following colo-rectal cancer surgery.
Topics: Adenocarcinoma; Adult; Celiac Artery; Colonic Neoplasms; Female; Fluorouracil; Gold Isotopes; Hepate | 1973 |
Arterial infusion and radiation therapy in the treatment of advanced cancer of the nasal cavity and paranasal sinuses.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Carotid Artery, External; Carotid Artery, Internal; Chemot | 1973 |
The gallbladder as a conduit between the liver and intestine.
Topics: Adenocarcinoma; Adolescent; Adult; Bile Ducts; Carcinoma; Cholangiography; Common Bile Duct; Drainag | 1973 |
Acute leukemia following cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Methotrexate; Ovarian | 1972 |
Renal carcinoma (hypernephroma) occurring in 5 siblings.
Topics: Adenocarcinoma; Adult; Biopsy; Female; Fluorouracil; Humans; Kidney; Kidney Neoplasms; Male; Middle | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
[Polychemotherapy of broncho-pulmonary cancer: report of clinical research].
Topics: Adenocarcinoma; Adult; Aged; Bronchial Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Hu | 1972 |
[Principles, technic and clinical performance of synchronized radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Androstanols; Bone Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, S | 1972 |
[Preliminary results of the use of 5-fluoruracil to prevent recurrences and metastases following radical surgery for stomach cancer].
Topics: Adenocarcinoma; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; N | 1972 |
Treatment of the patient with adenocarcinoma of unknown origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Autopsy; Carmustine; Female; Fluorouracil; Human | 1972 |
The value of megavolt therapy in carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Cardia; Cell Division; Cobalt Isotopes; Female; Fluorouracil | 1972 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
The treatment of metastatic carcinoma of the liver by the percutaneous selective hepatic artery infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Injections, Intra-Arter | 1973 |
Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma.
Topics: Adenocarcinoma; Adrenalectomy; Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Huma | 1973 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
FIVB--a new combination of drugs in the treatment of cancer.
Topics: Adenocarcinoma; Aged; Amides; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Imi | 1973 |
[Cytostatic therapy of metastazing rectal carcinoma].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Fluorouracil; Humans; Injections, Intra | 1973 |
Radiotherapy for bronchogenic carcinoma: actual difficulties and plans for the future.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide | 1973 |
Disseminated breast carcinoma. Treatment with combination chemotherapy.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fem | 1973 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |
Timing of administration of 5-fluorouracil in combination with irradiation in the treatment of advanced adenocarcinoma. Comparison of methods used to assess radiological response to the treatment of pulmonary metastases.
Topics: Adenocarcinoma; Cobalt Radioisotopes; Fluorouracil; Humans; Lung Neoplasms; Male; Methods; Middle Ag | 1973 |
The administration of 5-fluorouracil by mouth.
Topics: Adenocarcinoma; Administration, Oral; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart | 1974 |
Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; | 1974 |
Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
Topics: Adenocarcinoma; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Mal | 1974 |
Serial liver scanning. Metastatic disease.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injectio | 1974 |
Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis-(2 chloretjyl)-1-nitrosourea (BCNU).
Topics: Adenocarcinoma; Adult; Aged; Biopsy; Carmustine; Drug Therapy, Combination; Evaluation Studies as To | 1974 |
The effects of hormones and chemotherapeutic agents on rat uterine adenocarcinoma cells in tissue culture.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chromomycins; Clone Cells; Culture Media; Culture Te | 1974 |
The effects of cytostatic drugs on transplanted tumours. An investigation of the correlation between in vivo and in vitro results.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Cytarabine; Dauno | 1974 |
Systemic chemotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fema | 1967 |
Cytotoxic and antifungal agents: their body distribution and tissue affinity.
Topics: Adenocarcinoma; Animals; Antifungal Agents; Antineoplastic Agents; Autoradiography; Bacillus cereus; | 1968 |
[Our experiences with polychemotherapy of malignant endothoracic tumors (103 cases)].
Topics: Adenocarcinoma; Adult; Androgens; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; C | 1968 |
[Clinico-morphologic analysis of the results of long-term intra-arterial chemotherapy of the far advanced stages of rectal cancer].
Topics: Adenocarcinoma; Adult; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluoroura | 1968 |
Gastroscopic color photography in cancer chemotherapy.
Topics: Adenocarcinoma; Color; Cyclophosphamide; Fluorouracil; Follow-Up Studies; Gastroscopy; Humans; Lymph | 1970 |
[Time factor in evaluating antineoplastic agents].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Dactinomycin; Fluorouracil; M | 1972 |
Enhancement of tumor growth and immunosuppression in mice with 5-fluorouracil.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Immunosuppression Therapy; Mammary Neoplasms, Experim | 1972 |
Chemotherapy in the management of metastatic cancer of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho | 1972 |
Treatment with 5-fluorouracil in prophylaxis of relapses and metastases of stomach cancer.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Injections, Intravenous; Mal | 1972 |
Calusterone in the therapy for advanced breast cancer.
Topics: Adenocarcinoma; Axilla; Bone Neoplasms; Breast Neoplasms; Castration; Drug Synergism; Female; Fluoro | 1972 |
Antitumor activity of cyclocytidine in a variety of tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Line; Cyclization; Cy | 1972 |
Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal D | 1971 |
[Lung cancer].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Cobalt Isotopes; Cyclop | 1971 |
Circulating cancer cells: pre- and post-chemotherapy observations.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Female; Filtration; Fluorouracil; Humans; Male; | 1971 |
[Continuous intra-arterial perfusion of renal tumors with chemotherapeutic agents].
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Humans; Injections, Intra-Arterial; Kidney Neoplasms; Ma | 1971 |
5-fluorouracil given once weekly: comparison of intravenous and oral administration.
Topics: Adenocarcinoma; Administration, Oral; Biliary Tract Diseases; Breast Neoplasms; Female; Fluorouracil | 1971 |
Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Fluorouracil; Human | 1971 |
[Villous tumors of the jejunum and ileum].
Topics: Adenocarcinoma; Cell Transformation, Neoplastic; Female; Fluorouracil; Humans; Ileum; Intestinal Neo | 1971 |
Lack of effect of warfarin (NSC-59813) alone or in combination with 5-fluorouracil (NSC-19893) on primary and metastatic L1210 leukemia and adenocarcinoma 755.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Leukemia L1210; Mice; Neoplasm Metastasis; Neoplasm T | 1971 |
[Hypernephroma metastases of the skin and therapeutic possiblities].
Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Nose Neopla | 1971 |
[Gallbladder cancer].
Topics: Adenocarcinoma; Adenoma; Carcinoma; Cholelithiasis; Fluorouracil; Gallbladder Neoplasms; Humans; Mel | 1971 |
Association of cancer of the breast and acute myelocytic leukemia.
Topics: Adenocarcinoma; Adult; Aged; Anti-Bacterial Agents; Breast Neoplasms; Carcinoma; Female; Fluorouraci | 1967 |
[5-Fluorouracil(5-FU) in the treatment of adenocarcinomas of the digestive tract (apropos of 13 cases)].
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged | 1967 |
Bronchial artery infusion therapy for lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Bronchial Arteries; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cath | 1969 |
[Distribution of 5-fluorouracil in the bodies of mice with tumors of different sensitivities to the drug].
Topics: Adenocarcinoma; Animals; Fluorouracil; Kidney; Liver; Mammary Neoplasms, Experimental; Melanoma; Mic | 1970 |
Local chemotherapy of cutaneous neoplasms.
Topics: Adenocarcinoma; Allergy and Immunology; Antineoplastic Agents; Carcinoma, Squamous Cell; Dactinomyci | 1970 |
[Submicroscopic changes in the cells of mammary gland adenocarcinoma in mice caused by 5-fluorouracil].
Topics: Adenocarcinoma; Animals; Cell Nucleolus; Cell Nucleus; Endoplasmic Reticulum; Fluorouracil; Mammary | 1970 |
Preferential attack on cancer by selected SH inhibitors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Ascites; Breast Neoplasms; Carcinoma, Ehrlich Tumor; | 1970 |
Treatment of hepatic tumours.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Hepatic Artery; Humans; Laparotomy; Lei | 1970 |
Immunosuppression by 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antigens; Blood Bactericidal Activity; Blood Platel | 1970 |
An evaluation of combination chemotherapy with procarbazine (NSC-77213) and 5-fluorouracil (NSC-19893) in advanced carcinoma of the lung.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Benzoates; Blood Cell Count; Carcinoma; Carcinoma, Bro | 1970 |
Differential effects of anti-tumour drugs on human tumour and spleen DNA synthesis in vitro.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Culture Techniques; Disease Model | 1971 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
[Internal cancer therapy: cooperative clinical studies. Principles, organization and first results of the Swiss chemotherapy group].
Topics: Adenocarcinoma; Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Car | 1967 |
Carcinoma of the colon and rectum.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic | 1968 |
Liver regeneration after major hepatectomy. Effect of chemotherapy on growth and function--case report.
Topics: Adenocarcinoma; Female; Fluorouracil; Gallbladder Neoplasms; Gold Isotopes; Hepatectomy; Humans; Liv | 1968 |
[Modalities and results of anticancer polychemotherapy in 73 cases of advanced broncho-pleuro-pulmonary cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms | 1968 |
A radioisotopic method for determining optimum non-surgical therapy for advanced cancer. II. Clinical experience.
Topics: Adenocarcinoma; Breast Neoplasms; Diethylstilbestrol; Female; Fluorouracil; Fluoxymesterone; Gastroi | 1968 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |
5-fluorouracil therapy for cancer of the stomaach.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; S | 1968 |
[218 cases of prolonged polychemotherapy in advanced cancer (especially bronchopulmonary). Modalities and results].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neop | 1968 |
Combination of 5-fluorouracil and radiation as primary therapy of carcinoma of the cervix.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Female; Fluorouracil; Humans; Mesonephrom | 1968 |
Further studies on human bladder and kidney tumors transplanted to the hamster cheek pouch.
Topics: Adenocarcinoma; Animals; Computers; Cricetinae; Female; Fluorouracil; Humans; Kidney Neoplasms; Male | 1969 |
The use of parenteral 5-fluorouracil in solid tumours. A preliminary report.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal Neoplasms; Genital | 1969 |
Response of recurrent carcinoma of the colon to combined deep x-ray therapy and chemotherapy with 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans | 1969 |
Local injection of fluorouracil in skin cancer.
Topics: Adenocarcinoma; Fluorouracil; Humans; Injections; Male; Middle Aged; Neoplasm Recurrence, Local; Per | 1969 |
Fluorouracil toxicity following gastrointestinal surgery.
Topics: Adenocarcinoma; Colitis, Ulcerative; Colostomy; Fluorouracil; Humans; Intestinal Mucosa; Intestinal | 1965 |
Kinetics of proliferation of cancer cells in neoplastic effusions in man.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Cell Division; DNA, Neoplasm; Exudates and T | 1965 |
Chemotherapy for liver cancer by protracted ambulatory infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans | 1965 |
[The use of 5-fluorouracil in the therapy of some epithelial tumors].
Topics: Adenocarcinoma; Breast Neoplasms; Carcinosarcoma; Fluorouracil; Humans; Intestinal Neoplasms; Lung N | 1966 |